{
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "text_answer": "yes  Explanation The evidence shows that there were 13 participants in the Aprepitant group who were emesis free compared to 5 participants in the Placebo group This means that the Placebo group had approximately twice as many participants who experienced emesis 15 out of 20 compared to 7 out of 20 in the Aprepitant group Therefore the statement Patients receiving the placebo intervention in the primary",
        "label": "Entailment"
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "text_answer": "No  Explanation The evidence provides the percentage of subjects with Recurrencefree Survival in the primary trial but it does not specify how many patients did not have Recurrencefree Survival Therefore the statement cannot be answered definitively based on the given evidence",
        "label": "Contradiction"
    },
    "b03bae0b-6811-4c4d-a265-98c0f4ae7f1f": {
        "text_answer": "No  The statement is not entailed by the evidence as the secondary trial does not mention gabapentin as an exclusion criterion However Herceptin is an exclusion criterion for both trials for different reasons previous use in the primary trial and current use in the secondary trial",
        "label": "Contradiction"
    },
    "1b2048ba-33c8-43d1-8d8f-bca70ca8d80c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f398c658-74cb-4d2b-894c-d785e4dde994": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary clinical trial measures the number of participants with objective response These are different metrics for assessing outcomes",
        "label": "Entailment"
    },
    "d4b54b4a-d675-4d59-b489-2c1a025b2b4e": {
        "text_answer": "Yes The statement is entailed by the evidence as nonsmall cell lung cancer and small cell lung cancer are listed as eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "ad00f90a-b69d-4df4-a9f8-d495ac080b38": {
        "text_answer": "Yes  Explanation The evidence shows that there were 13 participants in the aprepitant group who were emesis free compared to 5 participants in the placebo group This means that the placebo group had approximately half the number of emesisfree participants as the aprepitant group Since two times is equivalent to twice the number the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "7308389a-7cde-4cf2-8f68-cefff152645c": {
        "text_answer": "No  The evidence states that there was 1 occurrence of urinary tract infection out of 50 participants",
        "label": "Contradiction"
    },
    "d88cc7fc-34dc-4e86-a3a0-50192a316624": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial allows the participation of patients diagnosed with malignant ductal carcinoma in situ and uncontrolled high blood pressure whereas such patients are excluded from the primary clinical trial is not entailed by the evidence  In the primary trial patients with high risk breast lesions including ductal carcinoma in situ are excluded In the secondary trial patients with a history of",
        "label": "Contradiction"
    },
    "36eb6a9f-5a3a-4f8f-b242-e669aeaa3547": {
        "text_answer": "Yes The evidence states that participation in the clinical trial is not allowed for patients with active cancermetastatic cancer which includes visible tumors in both breasts",
        "label": "Entailment"
    },
    "b9e11a69-3cd1-4669-93ae-b644cbd40e71": {
        "text_answer": "No  The evidence only mentions that nonmetastatic pancreatic cancer is not included in the trial if the tissue does not test positive for CCND1 amplification CDK46 mutation CCND2 amplification or any other functional alteration at the G1S checkpoint It does not mention anything about an unlimited number of patients with nonmetastatic pancreatic cancer being accepted regardless of the presence or absence of",
        "label": "Contradiction"
    },
    "57eb42a8-0c1b-4358-b024-0579811b3db3": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence describes two separate clinical trials one focusing on the use of Hydrophor and Medihoney during radiation therapy and the other focusing on the use of PF05212384 in combination with docetaxel for cancer treatment The statement is about a specific joint type and does not relate to the content of the trials",
        "label": "Contradiction"
    },
    "885733b0-a998-4f2c-b131-e58b2008a8a2": {
        "text_answer": "Yes The primary trial includes a criterion for optimal vitamin D levels 40 ngml but this level may exclude patients from the secondary trial due to its exclusion of patients with serum 25OHD levels  25 ngml",
        "label": "Entailment"
    },
    "b8f0039d-f476-4aa1-a522-751d93e45147": {
        "text_answer": "No  Explanation  The evidence provided in the text only mentions the results for the cohort on LBH589 with Capecitabine but it does not mention any results for the cohort on LBH589 and Lapatinib Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c6aa83b0-88fb-475a-8b38-e330d2bdf332": {
        "text_answer": "Yes Both trials involve oral administration of interventions Vitamin B12 and memantine hydrochloride or placebo The statement is about partial or complete response to treatment which is an outcome that can be assessed in both trials",
        "label": "Entailment"
    },
    "b590614e-03b9-4e7b-91e9-940058316465": {
        "text_answer": "Yes The primary trial does not exclude patients with 23 cerebral metastases while the secondary trial does",
        "label": "Entailment"
    },
    "4a73eb98-e69d-4116-bbed-7e1b6458aa61": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly states that the secondary trial does not require any injection while the evidence shows that the secondary trial involves the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "eaf2bb85-799b-47e9-af79-4fc7a54f0fcd": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1692ad17-057d-4d84-bc1b-f9fa773288b2": {
        "text_answer": "No  Explanation  The statement the procedure in the primary clinical trials first cohort involves an intraosseous injection of fluciclatide contrastingly the first cohort in the secondary clinical trial is given an intravenous standard dose of chloroquine is not entailed by the evidence The evidence only describes the interventions used in each trial but it does not specify that the primary trials",
        "label": "Contradiction"
    },
    "f3918549-5e15-44e3-b35b-f7f361845792": {
        "text_answer": "Yes The evidence shows that no adverse event was observed exclusively in cohort 1 meaning that they were all shared by both cohorts",
        "label": "Entailment"
    },
    "d46fad97-64a3-4553-a586-0dd9878009ec": {
        "text_answer": "Yes The primary and secondary trials involve different patient populations and different outcome measurements",
        "label": "Entailment"
    },
    "be4814f1-b515-4744-8df9-293327502949": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify the tumor size However the primary trial only includes patients with earlystage breast cancer while the secondary trial includes patients with locally advanced or metastatic breast cancer Therefore patients with a breast tumor 28 mm in diameter with confirmed hr positive and her2 negative status may not be eligible for both trials based",
        "label": "Contradiction"
    },
    "039ef0fd-7ea1-4820-b08f-99cf35009bc3": {
        "text_answer": "Yes The primary trial explicitly excludes patients receiving warfarin while the secondary trial permits its use under certain conditions",
        "label": "Entailment"
    },
    "2945688b-8ee8-43ce-8ed3-30c0a4fdf489": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary clinical trial involves oral administration of cabergoline not topical administration",
        "label": "Contradiction"
    },
    "a6eb92cc-e789-4ced-a40c-166bebb09a67": {
        "text_answer": "Irrelevant  Explanation The statement There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs is not directly related to the question about whether a spine MRI study was completed at diagnosis The statement and the question address different aspects of the given data Therefore the statement does not entail a yes or no answer regarding the completion of a spine MRI study at diagnosis",
        "label": "Contradiction"
    },
    "5461003b-2108-4302-96ad-d843b5b9e938": {
        "text_answer": "Yes  Explanation  The statement zero adverse events were documented in both cohorts of the primary clinical trial is entailed by the evidence since the evidence reports that there were no adverse events 060 in both cohorts Adverse Events 1 and Adverse Events 2",
        "label": "Entailment"
    },
    "0b343459-5c78-4c51-b71b-bfc5aa6d0c6a": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary clinical trial concludes 20 weeks earlier than the intervention specified in the primary clinical trial is not entailed by the evidence provided The primary clinical trial involved a reflexology intervention given for 10 weeks while the secondary clinical trial involved a vitamin D intervention given for 24 weeks There is no mention in the evidence that the intervention in the secondary trial concludes 20",
        "label": "Contradiction"
    },
    "1be9e4b6-a9e2-42b2-9131-4d7557ccd568": {
        "text_answer": "No  Explanation  The statement patients in the primary clinical trial are obliged to have subcutaneous injections of 120 milligrams of denosumab monthly while those in the secondary clinical trial undergo lymphoscintigraphy instead of injections is not entailed by the evidence  The evidence only describes the interventions used in each clinical trial but it does not specify that patients in the",
        "label": "Contradiction"
    },
    "fb4df065-adca-4ce7-9059-bda1cc4ca1be": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial and the secondary clinical trial there were no adverse events that occurred in more than 10 of the participants is entailed by the evidence because the evidence shows that in both trials no adverse events occurred in more than 5 of the participants 048 and 000 are less than 5 of their respective trial sizes Therefore no",
        "label": "Entailment"
    },
    "5a286769-0146-41da-8daa-af8c7169023a": {
        "text_answer": "  No the statement is not entailed by the evidence for the primary trial but it is mentioned as a possible exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "c926dbb4-ab16-46dc-a2be-8d04563ce9d0": {
        "text_answer": "No  Explanation  The statement the secondary trial and the primary trial recorded an equal number of aes is not entailed by the evidence The evidence shows that the number of adverse events AEs in the secondary trial is significantly higher than in the primary trial The statement incorrectly assumes that the number of AEs is equal between the two trials",
        "label": "Contradiction"
    },
    "69b11fe6-3c14-4ac6-a664-916dc341700f": {
        "text_answer": "Yes  Explanation The primary trial does not provide information on the dosing frequency of MM121 and Paclitaxel However the secondary trial clearly states that the MM121 and Paclitaxel are given less frequently in Intervention 1 compared to Intervention 2 Specifically Intervention 1 in the secondary trial includes a 2week runin of MM121 followed by ",
        "label": "Entailment"
    },
    "e688cf8e-7082-43f3-803c-7489148f3cac": {
        "text_answer": "  No the statement is not entailed by the evidence as the evidence does not mention inflammatory breast cancer as an inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "306374f7-40f9-45d5-a7cf-6cece3889a04": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the doses of eribulin and docetaxel are not directly compared in the given information The statement only mentions the doses of each drug in different cohorts but it does not provide enough information to make a direct comparison between the doses of eribulin and docetaxel",
        "label": "Contradiction"
    },
    "c616276b-e187-44ee-a2fb-93704f1a64cc": {
        "text_answer": "No  Explanation  The statement all patients in the primary clinical trial reported experiencing at least one adverse event while those in the secondary clinical trial completed it without any adverse events is not entailed by the evidence  The evidence only reports the number and types of adverse events for each trial but it does not state that all patients in the primary trial experienced at least one adverse event or that none of the patients in the secondary trial experienced",
        "label": "Contradiction"
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "text_answer": "Yes  Explanation  The statement There were no patients with recorded Aes in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is entailed by the evidence as the primary trial had no recorded adverse events 042 and every patient in the secondary trial had at least one adverse event 10000",
        "label": "Entailment"
    },
    "e7f5c09e-9d3d-4081-a926-9f89647a0e3b": {
        "text_answer": "Yes The evidence states that patients with a solid tumor that is locally advanced or metastatic can participate in both phases of the clinical trial",
        "label": "Entailment"
    },
    "687b9bc0-7328-4ecc-9bae-6b63f2df3cdb": {
        "text_answer": "No   Explanation   The statement intervention 1 in the primary trial and all intervention drugs in the secondary trial must be administered intravenously is not entailed by the evidence   In the primary trial zoledronic acid is given intravenously in Intervention 1 but the other interventions do not specify the route of administration In the secondary trial all drugs in both interventions can be given either",
        "label": "Contradiction"
    },
    "55c1905d-0e17-41b6-89ba-c29df13d2e30": {
        "text_answer": "No  Explanation  The statement each patient in cohort 1 of the primary clinical trial that experienced infections and fever were the only ones is not entailed by the evidence The evidence only shows that 1 out of 6 patients in cohort 1 experienced both infections and fever not that it was the only occurrence in that cohort The evidence for cohort 2 shows that no patients in that coh",
        "label": "Contradiction"
    },
    "1e213f71-5def-460d-b18e-aa58dbbe4463": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary clinical trial is using pharmaceutical interventions Estring and Testosterone Cream and the secondary clinical trial is using a physical intervention acupuncture However neither trial mentions a dietary intervention",
        "label": "Contradiction"
    },
    "e26430d8-c773-4770-b298-429c286fd5d3": {
        "text_answer": "No  The evidence only mentions breast cancer and does not include leukemia",
        "label": "Contradiction"
    },
    "67b66f39-48c2-495c-9ab0-0beefd9cdcef": {
        "text_answer": "Yes Both study groups undergo the same imaging techniques with 18FFDG and 18FFPPRGD2",
        "label": "Entailment"
    },
    "30234b84-2f15-4ea8-b7ed-af5f4ea40e9c": {
        "text_answer": "Yes The statement does not contradict the evidence as both interventions involve preoperative intravenous administration of Dexamethasone The statement about benign testicular neoplasms being nonmetastasizing is also not relevant to the intervention details in the evidence",
        "label": "Entailment"
    },
    "2c9e275c-18ef-471f-8ec9-1d73bfb27e20": {
        "text_answer": "Yes The evidence shows that the patients in Arm I Cryotherapy had less severe symptoms higher aAUCpa scores compared to patients in Arm II Control who received standard paclitaxel infusions",
        "label": "Entailment"
    },
    "4fb8207e-292f-4f97-9587-bf028abd57be": {
        "text_answer": "Yes  Explanation  The statement All Infections and Infestations cases in the primary trial were for patients in cohort 1 is entailed by the evidence because the evidence only reports adverse events for patients in cohort 1 and all of those adverse events were classified as Infections and Infestations Therefore there are no Infections and Infestations cases in cohort 2 based on the evidence provided The",
        "label": "Entailment"
    },
    "3426bc8a-b9c6-451e-aa76-25e1fc8bff69": {
        "text_answer": "No  The evidence does not provide any information about travel for leisure or visiting people in the primary or secondary trials",
        "label": "Contradiction"
    },
    "c4620792-b333-4232-ba8e-62595917256f": {
        "text_answer": "Yes Arimidex anastrozole is present in the primary trial but not mentioned in the secondary trials procedure",
        "label": "Entailment"
    },
    "a68e6309-12b7-445f-837b-ce8cef67a882": {
        "text_answer": "Yes the statement is not directly about eating disorders but it is entailed by the evidence that they were not common for the primary trial candidates",
        "label": "Entailment"
    },
    "f81c0c12-c161-4e90-91e4-65a2b255d1c2": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial is not measuring the mean bedtime of subjects but rather the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 The secondary trial is measuring the change in total sleep time in minutes as assessed by polysomnography PSG before and after the first cycle of Lenalidom",
        "label": "Contradiction"
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "text_answer": "No  Explanation  The statement 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrencefree Survival compared to the 67 from the NaCl 09 3mL group is not directly entailed by the evidence provided The evidence only gives the number of participants analyzed in each group and their Recurrencefree Survival rates percentages It",
        "label": "Contradiction"
    },
    "71db6876-7205-4e4b-9a89-949045f26ab9": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it makes an assumption about the specific vaccines given to each cohort based on their age group but the evidence only provides the age groups and the vaccines they received against pneumococcus and influenza without specifying which vaccine was given to which group",
        "label": "Contradiction"
    },
    "037ef54b-03fa-49f8-ae4b-ea645d268ea9": {
        "text_answer": "No  Explanation  The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 is correct based on the information provided in the evidence However the statement also adds but had an additional Collaborative Care Intervention which is not mentioned in the evidence for either cohort Therefore the full statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "889268e5-7b76-4c17-b567-bd828a9abf3e": {
        "text_answer": "No  Explanation  The statement numerous instances of cardiac and psychiatric aes were remarked during the primary clinical trial and the secondary clinical trial with only a few other types of aes reported is not entailed by the evidence provided The evidence only states that there were no instances of Adverse Events 1 and 2 reported in both trials for the given sample sizes It does not mention the number or types of adverse events reported for other",
        "label": "Contradiction"
    },
    "2f7bf983-b072-4d3e-96fb-718475ef0fd2": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence because the primary and secondary trials employ different interventions In the primary trial Vitamin B12 is administered sublingually while in the secondary trial memantine hydrochloride is administered orally by mouth and Vitamin B12 is not mentioned Therefore the statement about the administration method of the primary trial is not directly related to the secondary trial",
        "label": "Contradiction"
    },
    "0279dc49-0833-4673-8fb7-a7101a16fa14": {
        "text_answer": "Yes The statement that candidates with an ECOG score of 1 are eligible for both trials is entailed by the evidence as both trials include ECOG 02 as an inclusion criterion",
        "label": "Entailment"
    },
    "9126bd66-8ee7-47a5-84e2-0269efe06362": {
        "text_answer": "Yes The primary trial excludes adults but the secondary trial specifically includes them",
        "label": "Entailment"
    },
    "1b56f68b-a4b1-433c-a634-73ff99fce7aa": {
        "text_answer": "Yes The statement does not contradict the evidence and is consistent with the information provided",
        "label": "Entailment"
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "text_answer": "Yes The evidence states that patients with histologically proven DCIS are eligible for the trial",
        "label": "Entailment"
    },
    "0a0a9bd9-b3d0-4af8-b09a-f0e3a1684ef0": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not mention gabapentin or pregabalin in relation to the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "462f7871-9216-4b37-af39-1fb32b2bbf84": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "548ed40c-ccf4-4250-9fd9-c870bcc61b17": {
        "text_answer": "Yes The evidence states that engagement in regular physical activity is not a required component of the intervention for participants in the primary clinical trial",
        "label": "Entailment"
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "text_answer": "Yes  Explanation The statement In total there are less cases of anemia in the primary trial than in the secondary trial is entailed by the evidence as the number of anemia cases in the primary trial 037 is less than the number of anemia cases in the secondary trial 275 or 493 if considering both sets of data",
        "label": "Entailment"
    },
    "098f7c20-8543-4de6-b236-341c4cdea28e": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly reports the percentage 13 of participants with HER2 primary breast cancer who developed imagable HER2 metastases based on the results of the primary trial",
        "label": "Entailment"
    },
    "9d2b4df6-e802-437f-a844-61e944365df0": {
        "text_answer": "Yes The statement does not mention Hypertension Edema or Dyspnea which were both reported as having 0 cases in both cohorts of the primary trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "a02a0c3b-3c6c-45ce-a382-636abd7e1bef": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the outcomes from the placebo arm suggest superior overall response rate than the Arm A intervention is not directly entailed by the evidence provided The evidence only reports the number of participants achieving an overall response in each arm of the primary trial but it does not provide any information about the response rates in the placebo arm or a comparison to Arm A  Similarly the statement in the",
        "label": "Contradiction"
    },
    "a9f8fa09-52b6-4a39-b62b-3685f41d6c6e": {
        "text_answer": "Yes The statement mentions the use of laserassisted fluorescence angiography which is a method mentioned in the evidence for monitoring breast perfusion during the surgical interventions The statement also mentions lateral radial incisions which is another surgical incision method mentioned in the evidence for both interventions Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "f5a3b01c-743a-4d70-81c8-a5671272d1e0": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided The evidence only mentions vaccine responses in adult cancer patients and healthy volunteers for Pneumococcus and Influenza but it does not mention the unit milliunit or provide any context for its relevance to the trial",
        "label": "Contradiction"
    },
    "af9986f4-5f0c-4b8c-b02a-05ae6f7f4d1b": {
        "text_answer": "No  Explanation  The statement 78 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide enough information to calculate the difference between the two groups as a percentage",
        "label": "Contradiction"
    },
    "fe0af3be-4bf7-4e28-ad4c-81082e2ebfbd": {
        "text_answer": "No  Explanation  The statement in the secondary trial all patients receive the same 01 kilogram dose of pdr001 and 0001 gkg dose of mcs110 is not directly stated in the evidence The evidence only mentions the dosages for each intervention in the secondary trial but it does not specify that all patients receive the same dosage Therefore the statement is not entailed",
        "label": "Contradiction"
    },
    "b54c2b24-79e2-4561-bd18-ba18479cd7a3": {
        "text_answer": "No  Explanation The statement was 1p19q deletion analysis performed is not directly related to the evidence provided The evidence only mentions the interventions used in each trial but it does not mention whether or not 1p19q deletion analysis was performed on the patients",
        "label": "Contradiction"
    },
    "52174f7c-e29a-4fc5-b116-eeb9ee0ecc34": {
        "text_answer": "No  Explanation  The statement ability to wash your back is a question about an individuals ability to wash their back is not directly related to the adverse events listed in the evidence The evidence only provides information about the adverse events observed during the primary trial of a medical treatment and none of these events relate to the ability to wash ones back Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1f5d055f-5dde-400d-bbad-687e79830586": {
        "text_answer": "No  Explanation  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is not entailed by the evidence provided The evidence only reports the number and types of adverse events in each trial but it does not provide the total number of patients or the percentage of patients who did not experience any adverse events Therefore it is impossible to determine if over 97 of patients",
        "label": "Contradiction"
    },
    "f4e8530b-843b-422e-8db4-c02378c66512": {
        "text_answer": "No  Explanation  The statement provided makes a comparison between the number of drugs administered and the need for surgery between the two trials However the evidence does not provide information about the number of vector genomes per milliliter in either trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "0c561a05-4615-4578-aff2-745d9c9761c0": {
        "text_answer": "No  Explanation  The evidence provided in the results does not directly compare the percentage of participants with a decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups Instead it only reports the percentage of participants with a decrease in the growth factor signature within each group Therefore it is not possible to make a definitive statement about which group had a higher percentage of participants with a decrease in the growth factor signature based",
        "label": "Contradiction"
    },
    "1e5ed892-07f9-409a-bc45-edd43978e9b1": {
        "text_answer": "  No   Explanation   The statement have not received treatment is a response indicating that an individual has not been treated for cancer is not directly related to the evidence provided The evidence only mentions that one cohort of the primary trial will be watching an educational DVD about endoflife care planning and does not mention anything about cancer treatment",
        "label": "Contradiction"
    },
    "7774f54f-4f08-4c6d-8fa4-af4979ba5bac": {
        "text_answer": "No  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial includes patients with measurable disease The statement refers to a tumor that is 18 cm in diameter which is not within the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "cfce111d-8810-4915-98ee-1e280271de10": {
        "text_answer": "yes the statement is entailed by the evidence In the primary trial pembrolizumab is given every 3 weeks Q3W while in the secondary trial sunitinib is given on continuous dosing regimens with visits every 8 weeks Therefore the frequency of pembrolizumab administration is double that of sunitinib in this context",
        "label": "Entailment"
    },
    "5861703f-56fc-4e31-ba4e-d97400d71d99": {
        "text_answer": "Yes for febrile neutropenia Answer  No for cholelithiasis  Explanation  The statement both the primary and secondary trials recorded zero cases of either febrile neutropenia or cholelithiasis is entailed by the evidence for febrile neutropenia because the evidence states that there were no cases of febrile neutropenia in both trials However",
        "label": "Entailment"
    },
    "4c5fcde7-b882-4ea3-96ba-275af987ea60": {
        "text_answer": "Yes  Explanation The statement for every case of hypertension and pancreatectomy there were three cases of hepatotoxicity can be calculated by dividing the number of cases of hepatotoxicity by the sum of the number of cases of hypertension pancreatectomy and hepatotoxicity In this case the calculation is 38  18  1",
        "label": "Entailment"
    },
    "83c63591-6cde-4635-8d33-61dad15c7a21": {
        "text_answer": "No  Explanation The statement spiradenocylindrocarcinoma is a carcinoma that arises in a spiradenocylindroma is not related to the information provided in the evidence The evidence only describes the dosing schedules for the interventions in two clinical trials one involving epacadostat and pembrolizumab and the other involving sunitinib The statement about spiradenocylind",
        "label": "Contradiction"
    },
    "ef245c6c-7858-45cd-a0fd-d272e7aae585": {
        "text_answer": "No  Explanation  The statement group 2 of the primary trial does not receive myalgias while patients in the secondary trial cohorts receive 2ugkg of myalgias 5ml is not entailed by the evidence provided The primary trial does not mention anything about myalgias or vitamin D repletion in either group 1 or group 2 The secondary trial only mentions vitamin D repletion and myalg",
        "label": "Contradiction"
    },
    "87a7f86a-e915-4ea9-a2ba-c8e4d37dfa15": {
        "text_answer": "Yes The secondary trial excludes patients with severe insomnia",
        "label": "Entailment"
    },
    "aad4638b-6c8d-4f55-bf3f-5a3e9d74ef50": {
        "text_answer": "No  The evidence only mentions criteria for individuals with unilateral breast cancer and upper extremity lymphedema to participate in the clinical trial It does not mention anything about individuals with quantifiable tumor growth in both breasts",
        "label": "Contradiction"
    },
    "ad66bfcf-7359-41c6-b4f8-694ed27fbc8e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide the MTD value for Ruxolitinib in the primary trial or for MM111 in the secondary trial The evidence only describes the methods used to determine the MTD in each trial",
        "label": "Contradiction"
    },
    "89c0759c-7a7e-4c65-b98e-841d2ca21808": {
        "text_answer": "  No   Explanation   The statement patients with a histologicallycytologically confirmed diagnosis of advanced stage and metastatic melanoma or pancreatic cancer are qualified to participate in the primary clinical trial is not explicitly stated in the inclusion criteria of the evidence The evidence only mentions breast cancer epithelial ovarian cancer or gynecological cancer head and neck squamous cell carcinoma",
        "label": "Contradiction"
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "text_answer": "Yes  Explanation The statement less than 5 of patients in the primary trial suffered AEs is entailed by the evidence since the total number of adverse events reported in the trial was 2 out of 35 patients which is equivalent to 571 which is less than 5",
        "label": "Entailment"
    },
    "1669453c-bb8e-437d-b5e2-98600980d7d3": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly identifies the only variation between the two interventions as a difference in the dosage of durvalumab",
        "label": "Entailment"
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence because both cohorts receive CUDC101 at a dosage of 275 mgm2 but cohort 1 receives the infusion 5 days per week while cohort 2 receives it 3 days per week Therefore although they receive the same dosage cohort 1 is administered CUDC101 more",
        "label": "Entailment"
    },
    "72c54a84-aa51-4250-ba38-3646a07391b9": {
        "text_answer": "No  Explanation  The statement tumour lysis syndrome was a condition suffered by multiple patients participating in the primary clinical trial as well as the secondary clinical trial is not entailed by the evidence provided The evidence only lists various adverse events experienced by patients in each trial but it does not mention tumour lysis syndrome specifically",
        "label": "Contradiction"
    },
    "ab957edd-8a87-49e2-a7cf-0a55fb30c54f": {
        "text_answer": "Yes The intervention section of the primary clinical trial does not provide sufficient information to determine the method of administration dosage or schedule for MM111",
        "label": "Entailment"
    },
    "884486ed-0e11-41be-9792-d2765bd977a2": {
        "text_answer": "  No  Explanation  The statement every individual in the first cohort of the primary clinical trial experienced some form of adverse event is not entailed by the evidence The evidence only reports the number of participants in each cohort who experienced serious and nonserious adverse events but it does not indicate that every participant in the first cohort experienced an adverse event The evidence shows that all three participants in the first co",
        "label": "Contradiction"
    },
    "a77a5845-0747-4291-b6de-4903e453ae6a": {
        "text_answer": "Yes  Explanation  The statement a greater number of patients in the secondary clinical trial were documented as having experienced Adverse Event 1 compared to patients in the primary clinical trial is entailed by the evidence as the secondary trial had a higher percentage 6000 of patients experiencing Adverse Event 1 compared to the primary trial 000",
        "label": "Entailment"
    },
    "19738717-25bb-443f-8c7f-050bbc0c7a06": {
        "text_answer": "No   Explanation   The statement Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors is not directly entailed by the evidence provided The evidence only reports the number of participants with tumor response and aromatase inhibitor associated musculoskeletal symptoms in the two trials respectively It does not mention anything about the measurement of Ki67 expression in tumors",
        "label": "Contradiction"
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "text_answer": "Yes The statement is a summary of some of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "bffa5810-1ace-45e0-bf6d-6a3d35d6d4d7": {
        "text_answer": "Yes The evidence does not mention the use of xrays transendocardial injections except in the context of the secondary trial interventions CT scans or MRIs as part of the interventions in either trial",
        "label": "Entailment"
    },
    "264b1943-377e-4466-ad48-b4ba143f6bdb": {
        "text_answer": "No The statement is not related to the adverse events in the evidence",
        "label": "Contradiction"
    },
    "a6dad239-adab-48d2-b63a-0325c718ddf9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the most encountered adverse event across the patient cohorts of the primary clinical trial was syncope 1667 not asthma 2500 The evidence does not mention asthma as the most common adverse event in either trial",
        "label": "Contradiction"
    },
    "2f813222-a2b6-488e-96e6-f1a3d8713550": {
        "text_answer": "No  Explanation The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is not entailed by the evidence The evidence only states that there were 24 treatmentemergent adverse events AEs and 11 serious adverse events SAEs among the 25 participants",
        "label": "Contradiction"
    },
    "2b58a234-e92e-475b-a0c9-a947776bf332": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically states that any patient who has received antineoplastic chemotherapy androgens or estrogens within the last 4 weeks prior to study entry is excluded from the trial",
        "label": "Entailment"
    },
    "c179c437-ffe9-4120-9390-58d88fb596f3": {
        "text_answer": "No   Explanation  The statement in the primary clinical trial the intervention administered to patients with breast cancer and ovarian peritoneal cancer is uniform is not entailed by the evidence The evidence shows that the doses of talazoparib administered to patients with breast cancer and ovarian peritoneal cancer are different Therefore the intervention is not uniform across both groups",
        "label": "Contradiction"
    },
    "ce185781-5c8f-4849-b96c-734228f2a323": {
        "text_answer": "No The statement is not entailed by the evidence The evidence provided does not mention anything about recombinant DNA or stage 4 cancer in relation to the inclusion or exclusion criteria for the trials",
        "label": "Contradiction"
    },
    "2717fbc9-ffe5-419f-8c2d-ac9505f7cd01": {
        "text_answer": "Yes  Explanation  The statement the secondary trial and the primary trial do not share any inclusion or exclusion criteria including the requirement to provide written informed consent is entailed by the evidence because the primary trial and secondary trial have different inclusion and exclusion criteria and the requirement to provide written informed consent is only mentioned in the primary trial",
        "label": "Entailment"
    },
    "1f77bf31-ae19-4adc-9af1-4c982718bbf6": {
        "text_answer": "Yes  Explanation  The statement in the primary trial no cycle is applied to the intervention in contrast the secondary trial enforces a predetermined 4 week cycle in administering treatment is entailed by the evidence because  1 In the primary trial the treatment cycles are defined as 21 days but the evidence does not mention the application of a specific cycle to the intervention itself 2 In contrast in",
        "label": "Entailment"
    },
    "1672004b-d668-4441-95b4-eaab6fd70818": {
        "text_answer": "  Yes the patient described in the statement meets the inclusion criteria for both trials based on the provided information However its important to note that there may be other factors or requirements not mentioned in the statement that could affect eligibility",
        "label": "Entailment"
    },
    "91afbc39-fae6-483e-8b8d-dc4ce8d0ea5c": {
        "text_answer": "No  Explanation The evidence provided only gives the median PFS for each treatment group not the longest PFS observed in any individual patient",
        "label": "Contradiction"
    },
    "dbe6803f-8c85-45d2-a9b8-1bbd0e772733": {
        "text_answer": "No  Explanation Both interventions in the primary clinical trial involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site Therefore there is no evidence to suggest that intervention 1 uses more substantial amounts of tc99m sulfur colloid than intervention 2",
        "label": "Contradiction"
    },
    "12279abc-fae3-49d8-ac68-95ed47f4de12": {
        "text_answer": "No  Explanation  The statement the serious adverse reactions were reported more frequently in the adverse events section of the primary clinical trial compared to the secondary clinical trial is not entailed by the evidence provided The evidence only states that there were no serious adverse reactions reported in the adverse events sections of both trials for the given event Event 1 It does not provide information about the frequency or number of adverse events for Event 2 or any",
        "label": "Contradiction"
    },
    "df141af2-f34d-4e16-aee3-72c015ccc995": {
        "text_answer": "Yes  Explanation The evidence states that during the primary clinical trial there were 5 participants in the placebo group and none of them experienced emesis Therefore the statement none of the patients receiving the placebo intervention in the primary clinical trial experienced emesis is entailed by the evidence",
        "label": "Entailment"
    },
    "0dfa4e06-e226-4d46-be1f-90249c1f34d4": {
        "text_answer": "No  Explanation  The statement a higher number of patients in the secondary clinical trial were documented to have chest pain compared to those in the primary clinical trial is not directly entailed by the evidence provided The evidence only mentions adverse events for each trial but it does not specify if chest pain was an adverse event in either trial",
        "label": "Contradiction"
    },
    "44ccb908-9444-4137-a227-c47b65207de7": {
        "text_answer": "No  Explanation  The statement 9335 patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed by the evidence provided The evidence only lists the number and percentage of adverse events for each trial but it does not provide the total number of patients or the number of patients who experienced infections in both trials Therefore it is impossible to determine if 9335",
        "label": "Contradiction"
    },
    "3e7895ff-0e1a-40d9-830d-bab9c5b59706": {
        "text_answer": "No  Explanation  The statement the primary clinical trial participants exclusively receive one type of oral medication and are not required to undergo surgery while the secondary clinical trial participants are given an array of eight different drugs with a combination of surgical procedures is not entailed by the evidence  In the primary clinical trial participants receive a combination of various types of treatments including chemotherapy targeted therapy and hormonal therapy some of which are given orally",
        "label": "Contradiction"
    },
    "172e14bc-4f23-4d47-9e94-1d65291ef090": {
        "text_answer": "Yes  Explanation  The statement there is no single common inclusion criteria between the secondary trial and the primary trial is entailed by the evidence because the inclusion criteria for each trial are listed and they are clearly different from each other Therefore there is no single common inclusion criteria between the two trials",
        "label": "Entailment"
    },
    "21f268fa-899c-43ab-a7c2-78c0f940f014": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "448d6b4e-e05a-4971-9aea-cabeb8ce2c00": {
        "text_answer": "  No   Explanation   The evidence provided pertains to a clinical trial for individuals with unilateral breast cancer and upper extremity lymphedema The statement however refers to individuals with bilateral noncancerous breast lesions which is not mentioned in the inclusion criteria of the clinical trial",
        "label": "Contradiction"
    },
    "bae24418-25bc-4334-be92-d7f341ac3f14": {
        "text_answer": "Yes The statement does not directly mention rivoglitazone but the evidence provided does not exclude patients with diabetes or metabolic conditions who are taking antidiabetic agents including glitazones from participating in the trials",
        "label": "Entailment"
    },
    "d6cc1a08-fbff-4ef1-b44f-6bc1b1ed0ef2": {
        "text_answer": "Yes  Explanation  The statement more instances of palpitations pericardial effusions and abdominal pains were documented in the primary clinical trial compared to the secondary one is entailed by the evidence because the primary trial had a higher number of instances for all three adverse events compared to the secondary trial Specifically the primary trial had 1 instance of palpitations 2 instances of pericardial effusions",
        "label": "Entailment"
    },
    "4763223f-0ecd-4d19-a9ee-d466648ce4ea": {
        "text_answer": "Yes The statement accurately summarizes the distinction in treatment dosages between the two cohorts in the primary clinical trial",
        "label": "Entailment"
    },
    "2771bac1-0b7c-4049-9971-6c3129efb634": {
        "text_answer": "No  The evidence does not mention anything about fentanyl spray being administered to patients during radiation therapy",
        "label": "Contradiction"
    },
    "d9682530-105c-4e04-a26b-5d5985aac260": {
        "text_answer": "Yes The secondary clinical trial explicitly excludes stage 4 breast cancer patients while the primary clinical trial includes them",
        "label": "Entailment"
    },
    "28e1ae2b-668d-48c5-a17b-169460475af0": {
        "text_answer": "Yes The statement the primary clinical trial involved the administration of the biopath nanoparticle delivery system to thirteen participants is entailed by the evidence as the evidence states that 13 participants were analyzed in the trial and the vaccine being administered is a GloboHGM2LewisyMUC132aasTncTFcTncKLH conjug",
        "label": "Entailment"
    },
    "f00c0288-b56a-45b4-9908-1c679e5043e8": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 30mg of mcs110 every 4 weeks is entailed by the evidence since the minimum dose of MCS110 given every 3 weeks is 1 mgkg and 1 mgkg for a 70 kg patient is 70 mg Therefore every 4 weeks a patient would receive a minimum of 14",
        "label": "Entailment"
    },
    "13311b5b-36d8-455d-bf27-8a5adf1c913e": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial includes different eligibility criteria for different study cohorts while the secondary trial has uniform eligibility criteria",
        "label": "Entailment"
    },
    "6938fd4c-78be-4e24-b385-835d2be9f3c1": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants in each arm who achieved a pathologic complete response in the breast and axillary lymph nodes after neoadjuvant chemotherapy It does not provide information on the total number of participants in both cohorts who experienced a pathologic complete response after approximately 5040 hours approximately 7 months postsurgery",
        "label": "Contradiction"
    },
    "56bdbd86-0233-4eb9-bc63-0199e196966b": {
        "text_answer": "Yes  Explanation The evidence states that less than 087 of the participants in the highdose chemotherapy arm had a reduction in circulating tumor cells CTCs following the treatment The primary trial results indicate that out of 21 participants only 9 had their CTCs measured at one month post autologous hematopoietic stem cell transplantation AHST The statement ",
        "label": "Entailment"
    },
    "adb18104-31a9-4eef-817b-0ab742bd4093": {
        "text_answer": "No  Explanation The evidence provided only reports the change in total body lean mass from baseline to 4 months for two different doses of GTx024 It does not provide any information about the change in lean body mass over a 10year period for patients treated with GTx024 1mg Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "20ee9640-9334-41a2-b8aa-62cc27aeab70": {
        "text_answer": "No  Explanation The statement All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is not entailed by the evidence provided The evidence only states the doses of PF06647020 used in each trial not the doses of ALT801 Therefore it is not possible to make a definitive statement about the doses of ALT8",
        "label": "Contradiction"
    },
    "ff78e7a6-b997-49b3-be7f-2604a1e00308": {
        "text_answer": "No   Explanation  The statement arimidex is used frequently in both the primary and secondary trials is not entailed by the evidence provided Arimidex anastrozole is used in the primary trial as an intervention for one of the groups but the secondary trial does not involve the use of arimidex as an intervention The secondary trial only mentions the use of novel radiotracers for HER2",
        "label": "Contradiction"
    },
    "076f0bbd-6b10-44e1-a7c6-9853d9457509": {
        "text_answer": "No  Explanation The evidence does not provide any information about the use of any specific form of birth control by the participants in the primary trial The statement is asking for information that is not present in the evidence",
        "label": "Contradiction"
    },
    "b79be25a-c0ac-442e-adaf-821e42a3349b": {
        "text_answer": "No  The statement is not related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The statement describes a benign neoplasm of the eye which is not relevant to breast cancer and the trials in question",
        "label": "Contradiction"
    },
    "be30d480-b4d8-4768-8244-3a3d267418d2": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not provide any information regarding agespecific inclusion criteria for the primary or secondary clinical trials The evidence only outlines the inclusion and exclusion criteria for each trial separately",
        "label": "Contradiction"
    },
    "4d1b524f-e8d8-4444-bc99-6631e049fde8": {
        "text_answer": "Yes The evidence does not specify any residence restrictions for Hispanic patients in the primary clinical trial",
        "label": "Entailment"
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "text_answer": "Yes The evidence states that none of the participants in cohorts 1 Normal Vitamin D Levels and 2 Lownormal Vitamin D Levels showed a discernible pattern for expression of the set of 40 evaluated genes",
        "label": "Entailment"
    },
    "ddee09ab-2af9-4c93-a64e-58371896a08e": {
        "text_answer": "Yes  Explanation The statement cohort 1 of the primary clinical trial receives twice the dose of alt801 compared to cohort 2 is entailed by the evidence since the first cohort receives a dose of 0040 mgkgday which is double the dose of 0015 mgkgday given to the second cohort",
        "label": "Entailment"
    },
    "93118a13-cb16-4c4d-8f7a-ad0cb815e179": {
        "text_answer": "Yes  Explanation The statement mentions several different instances of cardiac related AE recorded for cohort 1 of the primary trial The evidence provides data on various cardiac adverse events AE observed in cohort 1 of the primary trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "4eb2221b-a478-4b64-bed8-230e4eab958d": {
        "text_answer": "No   Explanation The statement over 20 of participants in the primary clinical trial encountered adverse events is not entailed by the evidence as the total number of adverse events reported was only 2 out of 35 participants which is less than 20 of the total number of participants",
        "label": "Contradiction"
    },
    "49e76af6-53c7-458d-a091-0aa8edf2f2aa": {
        "text_answer": "No  Explanation  The statement 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide the difference between the two",
        "label": "Contradiction"
    },
    "c4a67b84-c8c7-4922-a5fb-5fb9a1a3160a": {
        "text_answer": "Yes Both trials involve oral administration of interventions",
        "label": "Entailment"
    },
    "4e832d71-c3c2-4209-9a57-8bd40ed3b08a": {
        "text_answer": "No   Explanation   The statement were clinical genomics performed is not directly related to the information provided in the evidence The evidence only describes the interventions used in two separate clinical trials one for Botulinum Toxin Type A and placebo injections for breast surgery recovery and another for MLN8237 dosing in cancer treatment There is no mention of clinical genomics being performed in either trial",
        "label": "Contradiction"
    },
    "4a06c463-8c8b-454e-9664-bac7871cbb95": {
        "text_answer": "Yes  Explanation  The primary clinical trial and the secondary clinical trial have different outcome measures In the primary clinical trial the outcome measures are the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events In contrast the secondary clinical trials outcome measures are the number of participants with objective response These measures are not the same and therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "adf1424b-3b15-478f-acab-72d4217db886": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no information in the evidence about impedance conductivity or its relationship to the adverse events in the primary trial",
        "label": "Contradiction"
    },
    "31ad3c14-faaa-42e1-93aa-d9f9b8687cae": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence does not mention osteitis fibrosa cystica or hyperparathyroidism in either the primary or secondary trials The evidence only discusses the evaluation of adverse events specifically those of primary interest in the context of HER2targeted therapies",
        "label": "Contradiction"
    },
    "396273f3-1e8f-4aa7-a50e-4c36c243748b": {
        "text_answer": "Yes  Explanation The statement over 320 of patients in the primary trial and the secondary trial suffered from infections during the study period is entailed by the evidence as both trials report the occurrence of infection as an adverse event in each trial In the primary trial there were 3 patients out of 32 or 1 in 11 who experienced infection and in the secondary trial there was 1 patient out",
        "label": "Entailment"
    },
    "50171a05-0f3d-434e-a43d-9310a845fa3f": {
        "text_answer": "No  Explanation The statement does not directly follow from the evidence provided The evidence only mentions the adverse events observed in two separate trials but it does not compare the frequency or types of adverse events between childhood brain anaplastic astrocytomas in the two trials The statement goes beyond the information given in the evidence by making a comparison between the trials and making assumptions about the types of adverse events that are more common in each trial based on",
        "label": "Contradiction"
    },
    "c8a83ca7-bc34-4afe-9323-7439ed841bca": {
        "text_answer": "Yes  Explanation The evidence shows that in each arm of the clinical trial there were participants who achieved a pathologic complete response in breast and axillary lymph nodes The total number of participants across both arms was 42 Therefore the statement more than 42 patients across both batches of the primary clinical trial demonstrated a pathologic complete response in breast and axillary lymph nodes is entailed by the evidence",
        "label": "Entailment"
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "text_answer": "No  Explanation  The evidence provided in the text only reports the percentage of participants with disease progression or death in each cohort during the maintenance phase of the trial It does not directly compare the results between the two cohorts to determine which one produced better results Therefore the statement the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab  Capecitabine cohort",
        "label": "Contradiction"
    },
    "c67afffa-bf41-4562-bf5e-1ba035fe653c": {
        "text_answer": "Yes  Explanation  The statement biliary colic and Clostridium difficile colitis are less prevalent in the secondary trial compared to the primary trial is entailed by the evidence because the frequency of biliary colic in the secondary trial is 16 1667 compared to 4122 328 in the primary trial and the frequency of Clostridium diffic",
        "label": "Entailment"
    },
    "7b860f15-132f-423e-ac6d-1c73f7a2d0d5": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial involves pregabalin not cymbalta and the secondary trial involves Depocyt liposomal cytarabine and highdose methotrexate HDMTX not the combination of cymbalta and Depocyt Additionally the dosages and durations of the interventions are different between the trials",
        "label": "Contradiction"
    },
    "fba4a92c-e18b-4029-b3bd-4b967db7faa1": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for the primary clinical trial and the intervention given to some participants but it does not specify that 1000 mcg of talazoparib is given daily to all participants in the trial",
        "label": "Contradiction"
    },
    "3cbea791-dc12-4c0e-b672-031b43c49bf2": {
        "text_answer": "No  Explanation  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is not entailed by the evidence provided The evidence only reports the number and types of adverse events in each cohort but it does not compare the frequency or percentage of patients who experienced adverse events between the two cohorts Therefore the statement goes beyond the information given",
        "label": "Contradiction"
    },
    "50b6f969-8637-47a1-ab63-9067b009bd2c": {
        "text_answer": "No  The evidence does not mention anything about fentanyl spray being administered to patients during radiation therapy",
        "label": "Contradiction"
    },
    "aca44925-657c-47d1-9325-f3933deee650": {
        "text_answer": "Yes The statement that cohort 2 of the primary clinical trial did not report any AEs and neither did the candidates in cohort 1 is entailed by the evidence that Adverse Events 1 Total 0147 000 This means that there were no reported adverse events in the primary clinical trial for both cohorts 1 and 2",
        "label": "Entailment"
    },
    "f074cadc-99e3-4603-8095-aa09822d174d": {
        "text_answer": "Yes  Explanation  The statement the primary trial is measuring the average time a patient spends sleeping while the secondary trial assesses the number of treatmentrelated incidents that impact the patients health is entailed by the evidence provided  The primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 which can be considered as treatmentrelated incidents that impact the",
        "label": "Entailment"
    },
    "6146e7c3-2c76-4881-88bd-1c547c9f732a": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not specify that all or any of these patients are administered 1000 mg of talazoparib daily The statement goes beyond the information provided in the evidence",
        "label": "Contradiction"
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "text_answer": "Yes for the secondary trial but No for the primary trial",
        "label": "Entailment"
    },
    "9b50ab6a-abe0-4082-8ebc-0cc297945062": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence mentions the use of laserassisted fluorescence angiography Spy Elite LifeCell in both intervention groups",
        "label": "Contradiction"
    },
    "964f8275-1095-4d48-953d-8d77152cecb8": {
        "text_answer": "No  Explanation The statement all groups receive equal doses of 18FFPPRGD2 is not entailed by the evidence The evidence only states that participants in both interventions will receive less than 10 mCi of 18FFPPRGD2 It does not specify that the doses are equal between the groups",
        "label": "Contradiction"
    },
    "2ceabe21-98c6-44e3-9cb2-03d3e73124a7": {
        "text_answer": "No  Explanation The statement if a person smokes they wont be permitted in the primary clinical trial however they may qualify for the secondary clinical trial if their daily alcohol consumption is under 5 drinks is not entailed by the evidence The primary trial explicitly excludes participants who have used nicotine within the last 5 years while the secondary trial does not mention anything about nicotine or smoking The statement incorrectly assumes that smoking",
        "label": "Contradiction"
    },
    "47485ca0-43cb-4525-9417-a8222961e1cd": {
        "text_answer": "Yes The evidence shows that there were no reports of swelling hypothermia or confusion in the adverse events of both trials The statement affirms this fact",
        "label": "Entailment"
    },
    "1ee86f9f-6119-4cce-a036-324aea1fb251": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial involves a different intervention denosumab and dosage schedule than what is stated in the statement The secondary trial involves the use of radioactive Tc99M sulfur colloid but the dosage mentioned in the statement is not present in the evidence",
        "label": "Contradiction"
    },
    "1d8450d1-ac32-4f98-ac75-1d6e212b0879": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not entailed by the evidence The evidence only provides the number of adverse events for each trial but it does not indicate that the secondary trial had more total adverse events than the primary trial Additionally the statement mentions slightly more but the evidence does not provide enough information to determine if there",
        "label": "Contradiction"
    },
    "9c180516-eca4-490b-b661-b47c625e3ab9": {
        "text_answer": "Yes  Explanation The statement within the adverse events of both the primary and secondary clinical trials only one fatality was documented is entailed by the evidence as both trials report a total of one fatality each",
        "label": "Entailment"
    },
    "2df3c784-8e32-4d92-9770-63087b7c7f62": {
        "text_answer": "Irrelevant  Explanation The statement is not directly related to the information provided in the evidence The evidence describes the interventions and treatment schedules for two different cohorts in a clinical trial but it does not provide any information about an individuals ability to get up from kneeling",
        "label": "Entailment"
    },
    "100d5efd-de88-4127-b6c1-cb870fff9e82": {
        "text_answer": "No  The statement does not provide enough information to determine if it is entailed by the evidence as the statement makes assumptions about the nature of the adverse events and their relationship to hyperperfusion that are not supported by the evidence",
        "label": "Contradiction"
    },
    "038bc748-0ea5-4d83-b799-b986177f9dbf": {
        "text_answer": "No  Explanation  The statement in the secondary trial all patients receive the same 800 mg dose of pdr001 and 10 mgkg dose of mcs110 is not directly related to the information provided in the evidence The evidence only mentions that in the primary trial some patients received armodafinil daily but it does not mention the dosage or frequency of MCS110 and",
        "label": "Contradiction"
    },
    "63a60028-ee0a-4f47-a8f2-b5edf081579a": {
        "text_answer": "No  Explanation The statement patients with considerable cardiovascular impairment are allowed to participate in the primary clinical trial is not entailed by the evidence The evidence lists specific cardiovascular conditions that would exclude patients from the primary clinical trial such as congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months and QTc prolongation",
        "label": "Contradiction"
    },
    "b11dea7c-ef4b-4042-9267-40934719c44e": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial presented anaemia as the most prevalent negative reaction implicating over 5 of the participants is not directly entailed by the evidence While it is true that anaemia was a reported adverse event in the secondary trial it did not occur in more than 5 of the participants The statement implies that anaemia was the most common adverse event and",
        "label": "Contradiction"
    },
    "a56ade78-3385-4789-b86a-3aef67188d2c": {
        "text_answer": "Yes The statement is about a specific type of adverse event difficulty paying attention and the evidence reports that there were no recorded adverse events of that type in both trials",
        "label": "Entailment"
    },
    "ad271913-e4a5-4a4a-9b0a-d3ae24415a54": {
        "text_answer": "No  The evidence describes the trabectedin intervention as being administered intravenously not orally",
        "label": "Contradiction"
    },
    "bb01dea7-5b49-41b7-997b-70cc1e980226": {
        "text_answer": "  No  Explanation  The evidence provided in the text does not mention anything about atypical carcinoid tumors or their association with cognitive function The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "776b3152-7fa5-480d-8235-cd6e472bf0a6": {
        "text_answer": "Yes  Explanation  The statement adverse events were not reported in the primary clinical trial while in the secondary clinical trial any recorded adverse event had an impact on less than 30 of patients excluding skin infections is entailed by the evidence provided  The evidence states that there were no adverse events reported in the primary clinical trial It also states that in the secondary clinical trial the total percentage of patients experiencing any",
        "label": "Entailment"
    },
    "5099ee2b-f5ea-47be-ba1e-ce2e4462a0c5": {
        "text_answer": "  No   Explanation   The statement luer valve device is a valve that incorporates a luer fitting Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is not directly entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial and",
        "label": "Contradiction"
    },
    "37257ef8-1772-4b94-9bb9-0433a83b83fe": {
        "text_answer": "No  Explanation  The statement palpable masses sequence number is an identifier that describes the relative position of palpable masses data within a series is not directly related to the inclusion and exclusion criteria provided in the evidence for either the primary or secondary trial The statement does not mention any specific criteria for inclusion or exclusion in the trials",
        "label": "Contradiction"
    },
    "e50a24aa-fbee-4cf7-b91b-661c5173c787": {
        "text_answer": "No   Explanation   The statement Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial is not directly stated in the provided inclusion or exclusion criteria for either trial The evidence only mentions that there are no specific exclusion criteria related to smoking for the secondary trial",
        "label": "Contradiction"
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "text_answer": "Yes The primary trial had 35 patients and less than 10 of them suffered adverse events The evidence reports that 2 patients had adverse events which is less than 10",
        "label": "Entailment"
    },
    "146a72f6-cba2-4056-94a2-21d2e05ac04e": {
        "text_answer": "No  Explanation The statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is not directly entailed by the evidence provided The evidence only states that one patient in cohort 2 experienced increased pleural effusion and the total number of patients in cohort 2 is not given Therefore it is not possible to determine that 25 of the cohort experienced this",
        "label": "Contradiction"
    },
    "2cf5335c-74b8-4122-bf27-caf0cdf94b8a": {
        "text_answer": "Yes  Explanation The evidence provides information on the number of hot flashes per 24 hours for both the paced respiration and fast shallow breathing groups It also mentions that there were fewer treatment emergent adverse events and serious treatment emergent adverse events in the paced respiration intervention group compared to the fast shallow respiration group Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "6432c266-a7b8-4cda-b5b8-7fd13cb023fb": {
        "text_answer": "Yes  Explanation  The statement the groups in the primary clinical trial differed significantly in their results is entailed by the evidence as the AUC values for the two algorithms in the primary trial were different 0884 for LIP algorithm and 0880 for SIP algorithm  The statement and the reflexology group and control group in the secondary clinical trial generated divergent results is also entailed by the",
        "label": "Entailment"
    },
    "8d1ad83d-8298-46fe-971d-3fadc862bd5e": {
        "text_answer": "No  Explanation  The statement the paclitaxel plus bevacizumab group had a higher ORR compared to the paclitaxel plus bevacizumab plus gemcitabine group during the primary clinical trial is not directly entailed by the evidence provided The evidence only shows the ORR for each group but it does not provide a comparison between the two groups To determine if one group had a higher ORR",
        "label": "Contradiction"
    },
    "a378ea56-7b9b-4ee9-b304-ff9597744fb7": {
        "text_answer": "No   Explanation  The statement is not directly entailed by the evidence as it does not mention anything about nonneoplastic thymus disorders in relation to the PETCT imaging procedures described in the evidence",
        "label": "Contradiction"
    },
    "1060fd94-b24c-43cb-884e-b10f70e0ea23": {
        "text_answer": "No  Explanation  The statement picalm gene rearrangement is a molecular abnormality indicating rearrangement of the picalm gene is not directly mentioned in the evidence The evidence only specifies the histological and patient characteristics for the primary trial and it does not mention anything about molecular abnormalities or specific genes including picalm The statement about eligibility for the trial based on metastasis or unme",
        "label": "Contradiction"
    },
    "1c13e304-89af-4ef5-95c6-cabc803d81b8": {
        "text_answer": "No   Explanation  The statement indeterminate extranodal tumor extension is a response that the extranodal tumor extension is undetermined is not mentioned in the evidence The evidence only provides information about vaccine responses in adult cancer patients and healthy volunteers against Pneumococcus and Influenza It does not mention anything about tumor extension or responses related to it",
        "label": "Contradiction"
    },
    "65f90fcc-a7ce-4d52-b010-b8e482c02f9c": {
        "text_answer": "Yes  Explanation  The evidence shows that there were no serious adverse events lifethreatening or otherwise reported in the first cohort of the clinical trial which consisted of 3 participants Therefore the statement that lifethreatening adverse events were absent in the first cohort of the primary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "text_answer": "Yes  Explanation The statement the primary trial only has a single adverse event recorded for its patient cohort is entailed by the evidence since the evidence states that there was only one adverse event a surgery event recorded for the patient cohort in the primary trial",
        "label": "Entailment"
    },
    "47d5620b-1b48-4a55-920f-35879c6e85eb": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the evidence clearly describes the administration of doxorubicin cyclophosphamide and docetaxel to the patients in the clinical trial",
        "label": "Contradiction"
    },
    "b0b78244-40a7-46d4-888d-1ccfe70d3645": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "840c7b65-e801-4dec-b9dd-b97680e5e3ba": {
        "text_answer": "No   Explanation   The primary clinical trial involves the use of Estring estrogen and Testosterone Cream for the treatment of lymphedema The secondary clinical trial involves the use of Acupuncture and a Waitlist control group Neither trial mentions the use of immunooncology techniques or chemotherapy",
        "label": "Contradiction"
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants in each arm of the study who experienced a pathologic complete response in the breast and axillary lymph nodes It does not indicate that more than 42 patients in total experienced this outcome Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ffa844c8-752d-48df-aa7a-e0ba58305b12": {
        "text_answer": "No  The statement goes beyond the information provided in the evidence The evidence only mentions specific conditions that would exclude a patient from both trials but it does not mention ret gene translocation",
        "label": "Contradiction"
    },
    "012a3705-05f7-4a26-adf2-1ae4244bd576": {
        "text_answer": "No  Explanation  The statement in the question is not entailed by the evidence provided The primary trial mentions a dosage of 150 mg of oral pregabalin twice daily not 300 mg every 2 weeks The secondary trial mentions the use of Depocyt and HDMTX but there is no mention of pregabalin in that trial",
        "label": "Contradiction"
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial indicates that the average pain intensity score for both the Low Dose and High Dose groups was below 10 the worst pain imaginable at the end of the 10week intervention period Therefore none of the patients in the trial experienced the worst pain imaginable for 10 weeks",
        "label": "Entailment"
    },
    "fd88904b-8a23-46ad-b337-3c7eef4e7bef": {
        "text_answer": "Yes for the statement about pulmonary embolisms in the secondary trial and No for the statement about breast implants in the primary trial The primary trial allows for participation of patients with breast implants but they must not have lymphedema in the affected limb",
        "label": "Entailment"
    },
    "7a831a11-8edd-42ef-81e7-fd8bca5ca0cc": {
        "text_answer": "Yes  The statement is entailed by the evidence as both groups receive the same amount of radiation therapy and a SPECT scan is performed on each patient",
        "label": "Entailment"
    },
    "7e791f30-68d4-4a11-86e4-c2e88d737913": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the specific types of adverse events other than Infection Asymmetry and Deflation in the primary trial or the presence or absence of n",
        "label": "Contradiction"
    },
    "ff07ae9a-9106-443b-b584-a7522ec3f71d": {
        "text_answer": "No  Explanation  The statement Suramin and Paclitaxel are administered to all patients in the primary trial is not directly related to the secondary trial intervention section The secondary trial intervention section only mentions mastectomy surgery but it does not specify any drug administration Therefore the statement does not follow logically from the evidence provided  Additionally the statement does not mention anything about the kbtbd4 gene mutation",
        "label": "Contradiction"
    },
    "1e47ae4a-c57b-47fa-9b85-1b15ebdbf1fc": {
        "text_answer": "  No The statement does not directly follow from the evidence provided The evidence pertains to inclusion and exclusion criteria for two different clinical trials and the statement is a general statement about a type of cancer and age eligibility for one of the trials",
        "label": "Contradiction"
    },
    "871378d6-a6e5-461c-af83-d82fe8f44f4e": {
        "text_answer": "No   Explanation   The statement is about a genus of bacteria called Sutterella which is not related to the inclusion and exclusion criteria for the breast cancer clinical trial The statement does not follow or entail any information from the evidence provided",
        "label": "Contradiction"
    },
    "3c06901b-29be-43be-8da7-c23d80cc4d89": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly support the statement that the occurrence of disease progression or death was more prevalent in the bevacizumab cohort in contrast to the bevacizumab  capecitabine cohort in the primary clinical trial The evidence only shows that a smaller percentage of participants in the bevacizumab  capecitabine cohort experienced",
        "label": "Contradiction"
    },
    "e115652e-6728-47a8-bc2e-1866a7c257ec": {
        "text_answer": "Yes The evidence states that neither cohort undergoes any invasive operation or receives neratinib",
        "label": "Entailment"
    },
    "2aa1c4f5-a46c-4004-9a8a-52e2ac476181": {
        "text_answer": "No  The statement is not about the adverse events mentioned in the evidence It is about lordosis which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "text_answer": "Yes  Explanation The evidence states that participants in the primary trial receive epirubicin cyclophosphamide docetaxel and trastuzumab during the course of their treatment Therefore the statement that participants receive 4 different drugs is entailed by the evidence",
        "label": "Entailment"
    },
    "b9f262d7-23e5-42d1-9020-0e516ce3505c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0b5e78d7-d717-41d0-98e5-564eda711bec": {
        "text_answer": "Yes The primary trial excludes patients with uncontrolled intercurrent illness including insomnia and the secondary trial includes insomnia as an inclusion criterion but excludes patients with severe insomnia Therefore severe insomnia patients are barred from participating in both trials",
        "label": "Entailment"
    },
    "d201eee8-33d1-4ae4-9540-b37fa07536e0": {
        "text_answer": "  Yes the statement is entailed by the evidence as the inclusion criteria state that individuals with a BMI of 25 kgm2 or greater and weight 400 lbs are eligible for the trial Extreme obesity is typically defined as a BMI of 35 or greater but the trial includes individuals with a lower BMI threshold",
        "label": "Entailment"
    },
    "d9d5a341-26ba-4f5d-a730-14561dea5c17": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is not entailed by the evidence provided The evidence only lists the adverse events for each trial but it does not indicate that the trials involved the same patients or the same treatments Therefore it is possible that some patients in the primary trial suffered from the same adverse events as those in the secondary trial",
        "label": "Contradiction"
    },
    "b9a1b80e-4c45-4a78-962b-13dfe98ab56c": {
        "text_answer": "No  Explanation The statement while 2 in 73 participants of the primary clinical trial had an acute myocardial infarction none out of the 1674 participants in the secondary clinical trial experienced this is not entailed by the evidence provided The evidence only states the number of adverse events including acute myocardial infarction for each clinical trial It does not provide information on the number of participants",
        "label": "Contradiction"
    },
    "c8bd9404-6d9c-4048-9d19-639aefd4ab08": {
        "text_answer": "No  Explanation  The statement hypokalemic patients are excluded from the primary trial but hyperkalemic patients may be eligible for the secondary trial and the primary trial is not entailed by the evidence provided  The evidence only mentions that patients must have a potassium level within the normal range 3553 mEqL for inclusion in the primary trial It does not mention anything about hyperkalemic",
        "label": "Contradiction"
    },
    "973b8d05-863f-4978-a197-bd08355b7834": {
        "text_answer": "No   Explanation The evidence provided does not mention anything about radiation therapy being given to the patients in either the primary or secondary clinical trials Therefore it is not possible to determine if the statement is entailed by the evidence or not",
        "label": "Contradiction"
    },
    "0bc7c5c7-6e64-4eee-ba84-e2168d64a8ef": {
        "text_answer": "  No   Explanation   The statement knob device is a handle usually attached to a shaft allowing manual rotation of the shaft is not related to the inclusion or exclusion criteria of either the primary or secondary trial The statement only describes a general definition of a knob device and does not provide any information about the patients eligibility for the trials",
        "label": "Contradiction"
    },
    "4318ce37-10b6-4318-868e-f533a1fd000e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "d0bcf0db-e64d-4aff-a63b-ba3571ebfad4": {
        "text_answer": "No  The statement about CBT Cognitive Behavioral Therapy being prohibited for the primary trial candidates is not mentioned in the evidence provided",
        "label": "Contradiction"
    },
    "e0c92d00-132b-4e76-ba59-2fa14e67bf53": {
        "text_answer": "Yes  The evidence mentions unacceptable toxicity as a reason for discontinuing treatment indicating that adverse events occurred",
        "label": "Entailment"
    },
    "c39031be-e4dd-4943-a3fe-97164ac7a5e9": {
        "text_answer": "No  The statement is not entailed by the evidence as the intervention in the secondary trial involves ibrutinib and MEDI4736 not protonbeam therapy and capecitabine",
        "label": "Contradiction"
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "text_answer": "Yes  Explanation  The statement The only types of AEs observed in patients from the secondary trial were Eyelid oedema and Chest pain no AEs were recorded in the primary trial is entailed by the evidence provided The evidence shows that there were no instances of any of the listed AEs in the primary trial and the only AEs recorded in the secondary trial were Eyelid oedema and Chest pain",
        "label": "Entailment"
    },
    "a7efab48-443a-4728-a4b5-0c837052aab7": {
        "text_answer": "Yes Perjeta pertuzumab is mentioned in the primary trial but is not part of the secondary trials treatment protocol",
        "label": "Entailment"
    },
    "e16eb398-b70e-42d2-90d5-d17172fda47f": {
        "text_answer": "No  The evidence does not mention Paraplatin at all in the given clinical trial",
        "label": "Contradiction"
    },
    "ce896357-cc87-4eb3-b588-61c1f99fc5f4": {
        "text_answer": "No  Explanation  The evidence provided in the text states that the patients in the Arm I Cryotherapy group had a lower median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale compared to the Arm II Control group This means that the patients in the Cryotherapy group had on average less worsening of symptoms from baseline to week 12 compared to the Control group",
        "label": "Contradiction"
    },
    "3d081c7c-10e8-490f-8943-260f27175c56": {
        "text_answer": "No  Explanation  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is not entailed by the evidence provided The evidence only mentions that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial It does not mention anything about severe anaph",
        "label": "Contradiction"
    },
    "54aa7f2d-b774-4530-ad47-3848ca093433": {
        "text_answer": "No  Explanation  The statement patients in cohort 2 of the primary trial reported higher rates of neutropenia as compared to patients in cohort 1 of the secondary trial both groups receiving the same doses of empegfilgrastim is not entailed by the evidence provided The evidence only reports the mean standard deviation of the duration of neutropenia in days for each group in the primary and",
        "label": "Contradiction"
    },
    "024c2c6d-e462-439c-baa2-a8639cd68d30": {
        "text_answer": "Yes  Explanation  The statement There were no patients with recorded Aes in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is entailed by the evidence provided The evidence shows that there were no adverse events reported in the primary trial while every patient in the secondary trial experienced at least one adverse event Therefore the statement accurately reflects the information in the evidence",
        "label": "Entailment"
    },
    "d8e5f1e2-76e1-405a-9920-c21c7f105eb2": {
        "text_answer": "No  Explanation  The statement throughout the full duration of the trials her2 patients in the primary clinical trial and those in the second cohort of the secondary clinical trial are administered the same trastuzumab dosage is not entailed by the evidence In the primary trial patients received a loading dose of 4 mgkg followed by 2 mgkg weekly while in the second trial patients in the second",
        "label": "Contradiction"
    },
    "1ecd0f33-cffb-4c0e-917f-6ae5f8570183": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about the incidence of nausea in either trial and the incidence of infection asymmetry and deflation were all lower in the secondary trial according to the evidence provided",
        "label": "Contradiction"
    },
    "c71fced3-2da3-4471-a72f-0dec2e7bbb02": {
        "text_answer": "yes The primary trial involves a higher dose and longer duration of alpha lipoic acid administration compared to the secondary trials necitumumab dosing",
        "label": "Entailment"
    },
    "decd387b-7da2-4f7b-8f32-4e009d9f6ee5": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results only reports the number of participants with pathologic complete response in breast and axillary lymph nodes for each arm of the study It does not provide the total number of participants in both arms who experienced this outcome or the exact time frame for the assessment of pathologic complete response beyond the surgery which is approximately 7 months Therefore it is not possible to determine if more than",
        "label": "Contradiction"
    },
    "41b2eac1-36a4-4cd8-a163-c7ab7b3636ee": {
        "text_answer": "No  Explanation  The statement they are given more Herceptin and Docetaxel is not directly stated in the evidence The evidence only mentions the number of weeks each group receives MM121 Paclitaxel and chemotherapy doxorubicin and cyclophosphamide It does not provide information on the dosages of Herceptin or Docetaxel given to each group Therefore",
        "label": "Contradiction"
    },
    "72d1b9c7-56d4-487c-8170-752c86b764ec": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does involve a massage therapy intervention which is not a drugbased treatment The secondary clinical trial also involves a drugbased intervention so it is not accurate to say that neither trial tests any drugbased treatments",
        "label": "Contradiction"
    },
    "ae1b63ed-25c5-484a-8221-3bee0af17594": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as the evidence only provides information about the incidence of doselimiting toxicities in two different cohorts of a trial without mentioning the number of patients who suffered from these toxicities in each cohort in detail The statement goes beyond the information provided in the evidence by making a connection between the toxicities and a specific surgical technique robotassisted lapar",
        "label": "Contradiction"
    },
    "365dc837-fcfb-49f6-8dc3-bb74a0f60507": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "517f5131-6807-4537-ae4c-308be1f98d17": {
        "text_answer": "No  Explanation  The statement There were more adverse events observed in the secondary trial than in the primary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of adverse events between the two trials Therefore based on the given evidence it is not possible to determine if there were more adverse events in the secondary trial than in the primary trial",
        "label": "Contradiction"
    },
    "ce29883b-654b-4124-ac60-40ff13cb9f3e": {
        "text_answer": "No  Explanation  The statement any patients with a welldocumented allergy to cefuroxime or nitrofurantoin can participate in both the primary and secondary trials is not entailed by the evidence provided The primary trial excludes patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to mesna or other agents used in the study but it does not specifically mention cefurox",
        "label": "Contradiction"
    },
    "4b9aeee6-6ad8-477a-a09a-15fd52c8fec8": {
        "text_answer": "No  Explanation The statement Candidates for the secondary trial study group receive 3 weekly subcutaneous SC injections is not directly entailed by the evidence provided The evidence only mentions that the primary trial participants receive a single injection at the beginning of the study and the secondary trial participants receive epoetin beta injections but it does not specify the frequency or number of injections The statement also mentions 3 weekly",
        "label": "Contradiction"
    },
    "48206c2e-1f24-4248-8c06-bfac596dcaa5": {
        "text_answer": "Yes The evidence does not mention any Xrays transendocardial injections CT scans MRIs or arthroscopic surgery as part of the interventions in either trial",
        "label": "Entailment"
    },
    "fdc63af9-e802-4ef7-8f6d-bec415bf2537": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not allow for the calculation of the difference in recurrencefree survival between the Ketorolac 30 mg and NaCl 09 3mL groups as a percentage The results only provide the number of participants in each group and their respective percentages of recurrencefree survival at 5 years To determine the percentage difference we would need the actual number of",
        "label": "Contradiction"
    },
    "437fedde-1e69-4514-ac5f-d8d532497280": {
        "text_answer": "Yes The statement mentions Stomatitis as the only adverse event which is consistent with the evidence that the only adverse event recorded in the primary trial was Stomatitis",
        "label": "Entailment"
    },
    "957f4300-757b-40ee-926c-3c7deae05ade": {
        "text_answer": "Yes The evidence explicitly states that individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the clinical trial",
        "label": "Entailment"
    },
    "da5c1eb1-b093-45cf-b607-e40504be981b": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial multiple cohorts are given armodafinil po daily and the secondary clinical trial administers various amounts of pdr001 to all patients with a consistent dose of lcs101 is not directly entailed by the evidence provided  In the primary trial Armodafinil is given in a tapering dose for 47 days",
        "label": "Contradiction"
    },
    "56f41ab4-6a20-4593-af47-b5cab9dabdd2": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the number of injections for the primary and secondary trial groups are not mentioned in the evidence The evidence only states the interventions and time points for each group",
        "label": "Contradiction"
    },
    "35c16ab6-47c9-48ed-b92d-967b89df4869": {
        "text_answer": "No  Explanation  The statement provided is about the type of lymphoma and its most common adverse event The evidence however only provides information about the adverse events observed in the primary and secondary trials without specifying the type of lymphoma or its most common adverse event Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "4d702550-2f94-46be-92f2-ea6659c69ddb": {
        "text_answer": "No  Explanation The statement all patients get a dose of no less than 20mg of mcs110 every three weeks is not entailed by the evidence The evidence only states that in the primary clinical trial the Intervention 1 and Intervention 2 both used a dosing regimen of MCS110 1 mgkg or 3 mgkg every 3 weeks Q3W and PDR",
        "label": "Contradiction"
    },
    "490ea7b9-ad4e-4741-8dce-65a050f9a776": {
        "text_answer": "No  Explanation  The statement all participants in the primary clinical trial showed partial or no response by the 24th week is not entailed by the evidence According to the evidence there were 4 participants with partial response PR at both Week 12 and Week 24 and 10 participants with stable disease SD at Week 24 Therefore there were a total of 14 participants 4 ",
        "label": "Contradiction"
    },
    "20de5f49-227b-4d5f-9a4e-868354842985": {
        "text_answer": "No  The statement is not entailed by the evidence provided  A woman who has experienced a quadrantectomy may be eligible for the primary trial if she meets all other inclusion criteria and is not excluded by any of the exclusion criteria  The secondary trial has specific inclusion criteria related to breast cancer treatment and fatigue and a quadrantectomy is not mentioned as an exclusion criterion for that trial",
        "label": "Contradiction"
    },
    "55220fb9-bef7-4c72-bf60-982c0ec903e6": {
        "text_answer": "Yes However the woman would need to meet the specific inclusion and exclusion criteria for each trial",
        "label": "Entailment"
    },
    "9bd55a1f-e5dc-4620-ba52-73b4bf792459": {
        "text_answer": "  No The evidence provided does not allow individuals with a history of pulmonary embolisms to participate in the primary clinical trial as it is listed as an exclusion criterion Additionally breast implants are also listed as an exclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "a9d72bc6-9396-4a8a-986a-e64587f02e9e": {
        "text_answer": "No  Explanation The statement radiation therapy is not administered to patients in both cohorts of the primary clinical trial is not entailed by the evidence The evidence states that patients in one cohort received Active Breathing Coordination during radiation therapy while patients in the other cohort did not receive Active Breathing Coordination but still received radiation therapy",
        "label": "Contradiction"
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia is not directly entailed by the evidence provided While it is true that anaemia was the most common adverse event in the secondary trial the statement does not mention that there were no adverse events in the primary trial which is also a significant piece of information in the evidence Therefore the statement does not accurately summarize the evidence in",
        "label": "Contradiction"
    },
    "75cd8c4d-e0e6-4db0-8157-a76ac5bcf555": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial does not mention anything about KRAS mutation analysis being performed The statement asks if the analysis was performed but the evidence does not provide that information Therefore the statement is not entailed by the evidence and the answer is No",
        "label": "Contradiction"
    },
    "b52201dd-cbd7-4b92-8aae-3d8da980f4a1": {
        "text_answer": "Yes The denosumab dose in Intervention 1 of the primary trial is 120 mg Q4W while the tamoxifen dose in Intervention 1 of the secondary trial is 10 mg once daily for 21 days per month which is not directly comparable to denosumabs Q4W dosing However the statement specifically compares the denosumab dose in Intervention 1 of the primary trial to the",
        "label": "Entailment"
    },
    "5a17f44e-b8ba-4598-96e3-992b0022b5ca": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes a specific neoadjuvant therapy regimen for breast cancer treatment",
        "label": "Contradiction"
    },
    "3559fa92-e0d7-4e4f-9b1f-7f087fbff0d1": {
        "text_answer": "Yes Both trials involve medical interventions that utilize imaging techniques such as xrays and CT scans",
        "label": "Entailment"
    },
    "0433b29d-6509-420d-ba83-4ddcf8907e2b": {
        "text_answer": "Yes The primary trial reported no adverse events in Cohort 1 and sixteen is a number that fits the description given in the statement",
        "label": "Entailment"
    },
    "ec5c7b6f-dfae-4681-9b8f-4f0b3635d232": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is directly stated in the evidence The statement over 130 mg of PDR001 every other week can be calculated from the given dosages 100mg Q3W for PDR001 so 100mg every 2 weeks is 200mg",
        "label": "Entailment"
    },
    "06ec7728-efe1-408c-afa8-a6b679a9cd57": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary clinical trial does not provide details regarding the mode of administration dosage or cycle for intervention 1 MM111",
        "label": "Entailment"
    },
    "cffc1c21-5e4d-485a-a167-32841ff01f4c": {
        "text_answer": "No   Explanation   The statement moderately better is a subjective response indicating that something is moderately better is not directly related to the evidence provided The evidence describes two different interventions from separate trials one involving a breast reconstruction technique using a Contour Profile Tissue Expander and the other involving allogeneic mesenchymal stem cell alloMSC therapy for heart failure The statement does not provide any specific information",
        "label": "Contradiction"
    },
    "9dd13c76-10e0-4dd0-ad16-42d135f6c2c5": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary clinical trial experienced multiple moderate adverse events is not entailed by the evidence provided which only states that there were no adverse events in cohort 1 of the primary clinical trial The absence of adverse events does not imply that there were no moderate adverse events only that there were no adverse events reported at all",
        "label": "Contradiction"
    },
    "f6bfaa2d-0171-4bbe-a65c-0e3b217ac61f": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement mentions spinal chordoma which is not mentioned in the evidence The evidence only discusses the interventions used in the primary and secondary trials and does not mention any specific type of cancer or tumor",
        "label": "Contradiction"
    },
    "bf140d08-90da-4fb4-90da-b86a87b5bb07": {
        "text_answer": "No  Explanation  The statement the primary trial has a uniform set of inclusionexclusion criteria for all participants whereas the secondary trial segregates its criteria into two age groups 2040 and 40 is not entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for each trial separately without any comparison or segregation based on age groups",
        "label": "Contradiction"
    },
    "8ee8670b-6200-4309-8fd6-545572945b7c": {
        "text_answer": "27 participants out of 25 analyzed had treatmentemergent adverse events not 35 as stated in the question Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "64f9b5b3-cd20-4b90-94b5-14e08a9999f0": {
        "text_answer": "No  Explanation  The statement chest pain has been more frequently observed in patients participating in the secondary clinical trial than in those in the primary clinical trial is not directly entailed by the evidence provided The evidence only mentions the occurrence of adverse events in both trials but it does not specify chest pain as an adverse event or indicate its frequency in either trial",
        "label": "Contradiction"
    },
    "f99f83b0-66dd-4c77-b422-113e0cb758bf": {
        "text_answer": "No  The evidence does not provide information on the screening status of all participants in the initial cohort for cervical cancer",
        "label": "Contradiction"
    },
    "02addfef-d1b3-4e62-865c-aa0bd1ddfab4": {
        "text_answer": "No  Explanation  The statement the secondary trial and the primary trial share at least one inclusion criteria is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for each trial separately without any comparison or overlap stated The statement about the tandem mass tag 10plex is also unrelated to the trials and their criteria",
        "label": "Contradiction"
    },
    "8cd22d45-e829-47df-8ae1-cb50a163fc27": {
        "text_answer": "No   Explanation   The statement the primary clinical trial involves treating a patient cohort with 150 mg of oral pregabalin twice daily while the secondary clinical trial uses depocyt and hdmtx in its patient administration is not directly entailed by the evidence provided The evidence describes the interventions used in each trial but it does not explicitly state that the primary trial only uses pregabalin and the secondary trial",
        "label": "Contradiction"
    },
    "27950c75-7035-435a-a7df-6f7abd504d30": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as the statement is about an optical condition called ametropia while the evidence is about two different cohorts of a primary trial with their respective interventions The statement does not provide any information about the relationship between the interventions and ametropia",
        "label": "Contradiction"
    },
    "eec36c42-c1fb-45c8-9db9-82f10f4f7af7": {
        "text_answer": "Yes  Explanation  The statement the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 1 year in bone mineral density BMD of the lumbar spine is entailed by the evidence because  1 The primary trial reports changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing SPID30 as the outcome",
        "label": "Entailment"
    },
    "902a36e5-a751-44c6-9844-465aaa0f1d75": {
        "text_answer": "No   Explanation  The statement several adverse events were reported in over 30 of participants in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC abnormalities in each trial It does not provide information on the percentage of",
        "label": "Contradiction"
    },
    "8f319cf4-ec84-4f34-a4d8-2af54adbaab9": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not entail the statement about SARS coronavirus 2 variant lineage and the percentage of participants in cohort 1 suffering adverse events The trial results only report the number of participants with serious and nonserious adverse events for two different dose levels of the MVAbrachyuryTRICOM vaccine The statement about the SARS coronavirus ",
        "label": "Contradiction"
    },
    "0f42fd08-8cba-4861-a89c-bf898270ea29": {
        "text_answer": "No   Explanation The statement does not mention Paraplatin at all and there is no information in the evidence about the specific chemotherapies Taxotere carboplatin Herceptin navelbine containing Paraplatin or not Therefore it is impossible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "5a378399-ff09-418f-8797-9e122617d8d6": {
        "text_answer": "No The statement is not entailed by the evidence as the evidence explicitly lists No history of significant psychiatric disorders as an exclusion criterion",
        "label": "Contradiction"
    },
    "894b1c21-f4ab-4145-ac19-9f973184b5bd": {
        "text_answer": "No  Explanation  The primary clinical trial measures tumor diameter in centimeters while the secondary clinical trial measures the number of participants with solid tumor response using RECIST 11 criteria These are different metrics for quantifying the results",
        "label": "Contradiction"
    },
    "097ca9f3-901b-4072-b2d5-2e36f5bfccf0": {
        "text_answer": "Yes The statement does not mention talazoparib so it is entailed by the evidence as the intervention described in the evidence does not contain talazoparib",
        "label": "Entailment"
    },
    "f27c4b19-1479-48ea-92a0-28da5256b7b8": {
        "text_answer": "Yes for the secondary trial only The primary trial does not mention any specific exclusion for brainstem metastases",
        "label": "Entailment"
    },
    "6582c5f8-507a-459d-82e4-b0b8e80be34d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "text_answer": "No  Explanation  The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 is not entailed by the evidence The evidence only states that the dosage of Cetuximab is different between the two cohorts Cohort 1 received a lower dose of Cetuximab 12 mgkg than Cohort 2a ",
        "label": "Contradiction"
    },
    "232cfca0-08b4-45e3-ac2a-01ce31ecb857": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it does not relate to the content of the primary trial The evidence only describes the interventions for Cohort 1 and Cohort 2 of the primary trial and the statement discusses the gray commissure in the context of the spinal cord",
        "label": "Contradiction"
    },
    "fa23fd31-c7c2-4887-a982-174f355a2035": {
        "text_answer": "No The statement is not entailed by the evidence as the statement is about pedal spasms which is not mentioned in the evidence The evidence only mentions adverse events experienced by the primary trial patients including an increase in blood bilirubin febrile neutropenia decreased ejection fraction sinus tachycardia sepsis decreased lymphocyte count decreased neutrophil count and decre",
        "label": "Contradiction"
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "text_answer": "Yes  Both interventions in the primary trial include trastuzumab Herceptin",
        "label": "Entailment"
    },
    "0164b2f8-a87d-4bb8-8487-6eb1f65b9804": {
        "text_answer": "No  Explanation The statement is not directly related to the evidence provided in the trial results The evidence focuses on the proportion of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention The statement mentions a specific condition called eyes progression gvhd and an NIH eye score which is not mentioned or related to the evidence",
        "label": "Contradiction"
    },
    "e0c8ebce-a242-4619-9e96-7a80e6d157dd": {
        "text_answer": "Yes  Explanation  The statement the primary trial recorded 11 more adverse events than the secondary trial is entailed by the evidence because the primary trial had 0 adverse events and the secondary trial had 11 adverse events which is a difference of 11 events",
        "label": "Entailment"
    },
    "de91b720-a7f8-4c27-8182-f642de29ddee": {
        "text_answer": "Yes for the secondary clinical trial However the primary clinical trial explicitly excludes patients receiving warfarin",
        "label": "Entailment"
    },
    "91e178f6-c6ec-426d-8799-629c2f512038": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly give the recurrencefree survival rates for each group only the number of participants in each group The statement is making a comparison of the recurrencefree survival between the two groups which cannot be determined from the given evidence",
        "label": "Contradiction"
    },
    "0aab1829-69a6-4db5-ae99-78b1f9c9cbc0": {
        "text_answer": "Yes The evidence mentions the use of laserassisted fluorescence angiography in both interventions and the statement does not contradict this information Additionally the statement does not provide any information that is not mentioned in the evidence regarding the use of lateral radial incisions However the statement does introduce the concept of Ann Arbor stage for Tcell nonHodgkin lymphoma but this is not directly related to the interventions described",
        "label": "Entailment"
    },
    "f83654b1-c44c-40eb-a7b1-91db95cb71f6": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "a0294da5-368d-4341-9084-1d42b995be34": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "079d70f0-b586-466d-aeb0-38f67273c1c6": {
        "text_answer": "Yes The primary trial does not report treatmentemergent adverse events as the outcome measurement and the same is true for the secondary trial",
        "label": "Entailment"
    },
    "8ef9ed3d-ab31-4ef7-be9a-113b31e3ed2a": {
        "text_answer": "yes the primary and secondary trials both measure pCR The statement about the difference in results between the two arms in the primary trial and the difference in results between the two arms in the secondary trial are also stated in the evidence However the statement about qualityoflife assessment is not mentioned in the evidence",
        "label": "Entailment"
    },
    "13d66853-9b8a-4d79-b0d9-884c8d744acd": {
        "text_answer": "Yes the trials have unrelated outcome measurements",
        "label": "Entailment"
    },
    "4cc838c3-caee-492c-8092-c74844d68cd1": {
        "text_answer": "Yes The primary and secondary trials both include the requirement of a certain performance status for candidate selection",
        "label": "Entailment"
    },
    "51d7f113-1dba-48f0-9e5c-1f16bfcd5394": {
        "text_answer": "No  Explanation  The statement the primary clinical trial noted zero cases of hepatotoxicity is not entailed by the evidence The evidence states that there were 38 3750 cases of hepatotoxicity This is a clear contradiction to the statement that there were zero cases of hepatotoxicity  The statement does mention that there were multiple cases of hypert",
        "label": "Contradiction"
    },
    "87c5ee7a-a65a-4633-9efc-b51e2956db27": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence provides the number of participants analyzed in each arm of the trial but it does not explicitly state that the total number of participants is given in the trial",
        "label": "Contradiction"
    },
    "21ae5802-04f7-4f06-86d6-9ee8ee9cdd84": {
        "text_answer": "  No the statement is not entailed by the evidence as the secondary trial includes patients with triplenegative breast cancer which is not Her2neu",
        "label": "Contradiction"
    },
    "eef90c1d-1b9c-459e-a895-47b9012a8d1a": {
        "text_answer": "Yes The evidence does not show any adverse event related to eating disorders among the primary clinical trial candidates",
        "label": "Entailment"
    },
    "bcfd2c0f-411a-462a-acd8-7dcd6818c1c6": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary and secondary trials have different pharmaceutical regimens In the primary trial subjects received FMX followed by MM398 while in the secondary trial participants received lapatinib and paclitaxel in combination Additionally the primary trial used FMXMRI scans and preMM398 treatment biopsies while the secondary",
        "label": "Contradiction"
    },
    "2dc8c214-bbe5-49b7-a48e-0945fddcd9da": {
        "text_answer": "Yes Both trials include docetaxel as part of their interventions",
        "label": "Entailment"
    },
    "e41035c2-246d-43a1-b2d4-5ff9af1f789e": {
        "text_answer": "No  Explanation  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only states that there were no adverse events in both cohorts 1 and 2 of the primary trial The statement about the number of adverse events being different between the two cohorts is not",
        "label": "Contradiction"
    },
    "f9ac9b4b-4033-416b-b66c-0ecf23a9a06c": {
        "text_answer": "No  Explanation  The statement the primary clinical trial has observed more instances of mucositis oral epileptic seizures and thromboembolic events compared to the secondary clinical trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events for each trial but it does not indicate that there were more instances of specific adverse events in the primary trial compared to the secondary trial The",
        "label": "Contradiction"
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "text_answer": "  No  Explanation  The statement Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial is not directly entailed by the evidence provided  The primary trial excludes patients with malignant ductal carcinoma in situ while the secondary trial includes them as long as they have been treated with surgery andor adjuv",
        "label": "Contradiction"
    },
    "a031053e-a514-4484-9624-bcddef1628d3": {
        "text_answer": "Yes The evidence mentions decision support for providers for prevention based on risk which could include counseling as a component",
        "label": "Entailment"
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "text_answer": "No  Explanation The statement mentions Asthenia and Pyrexia which are not mentioned in the evidence The evidence only provides information about Adverse Events 1 and Adverse Events 2 but it does not specify what those events are Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "42f1e6c1-7775-4513-b810-a5559fcf60be": {
        "text_answer": "No  Explanation  The statement an adult patient diagnosed with ILDDPLD within the last 3 years with a life expectancy of 6 months would be eligible for the primary trial is not entailed by the evidence The evidence does not mention ILDDPLD Interstitial Lung DiseaseDesquamative Interstitial Pneumonitis as an exclusion criterion or inclusion crit",
        "label": "Contradiction"
    },
    "260b2917-54c5-43db-8beb-50f4e1bad69c": {
        "text_answer": "No  Explanation  The statement three electroporation injections of ld v934 are administered to both cohorts a and b in the primary clinical trial is not entailed by the evidence While it is true that Cohort B received three electroporation injections of V934 LD Cohort A did not receive any electroporation injections The evidence only states that Cohort A received two",
        "label": "Contradiction"
    },
    "f866e011-f633-4481-9d58-fff6828d7f83": {
        "text_answer": "Yes  Explanation The evidence states that out of the 53 participants in the Lapatinib 1000 mg  NabPaclitaxel armgroup none of them reached a confirmed complete response CR according to RECIST criteria 10 Therefore the statement none of the patients in the primary clinical trial who were given lapatinib 1000 mg  nabpaclitax",
        "label": "Entailment"
    },
    "b3372685-8147-4004-89f4-f57d35bd8980": {
        "text_answer": "No  Explanation  The evidence provided in the text only shows the percentage of participants with disease progression or death in each group during the maintenance phase of the clinical trial The statement however makes a comparison between the two groups and claims that the bevacizumab group had a lower occurrence of disease progression or death than the bevacizumab  capecitabine group The evidence itself does not directly support this claim",
        "label": "Contradiction"
    },
    "e3b2d615-a7b7-475e-b757-a8de8cd2c6f7": {
        "text_answer": "No  Explanation  The statement HER2  Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial is not entailed by the evidence In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 2 receives Her",
        "label": "Contradiction"
    },
    "62af11ae-461f-4e31-b104-3467b2210208": {
        "text_answer": "Yes  Explanation  The statement the outcomes of both the primary and secondary clinical trials were not marred by any instances of infection is entailed by the evidence because there are no reported instances of infection in the adverse events of either trial",
        "label": "Entailment"
    },
    "b4fca47f-894d-47b9-a6a2-38867864c1bc": {
        "text_answer": "No   Explanation   The patient with a primary tumour of 03 cm radius would not meet the inclusion criteria for the primary trial which requires a primary tumour greater than 2 cm diameter Therefore they would not be eligible for the primary trial   Additionally the statement does not apply to the secondary trial as it does not mention the size of the primary tumour as a criterion",
        "label": "Contradiction"
    },
    "75fdf74b-e876-43f0-a382-03cf7055464b": {
        "text_answer": "Yes The statement the recorded harmful effects in the primary clinical trial were only noted for patients from cohort 2 is entailed by the evidence as there are no adverse events reported for cohort 1 in either trial",
        "label": "Entailment"
    },
    "25efd6b7-dd3c-472e-babe-6d5397241653": {
        "text_answer": " Yes individuals who are significantly overweight are eligible for the primary clinical trial according to the given inclusion criteria However its important to note that there are also exclusion criteria that may prevent some individuals from participating despite meeting the inclusion criteria for weight",
        "label": "Entailment"
    },
    "879196dd-c66e-4413-9575-98c95c0b9df1": {
        "text_answer": "Yes  Explanation The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 achieved a pathologic complete response Since approximately onethird of the participants in each group achieved this outcome the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "1a48d67e-c653-4e6f-bc9c-677793433e9b": {
        "text_answer": "Yes  Explanation The evidence clearly states that the number of participants with stable disease was higher at week 12 12 compared to week 24 10 The evidence also states that no participants achieved complete response at either week 12 or week 24 Therefore the statement the number of patients with stable disease was higher in the 12th week than the 24th week however no patients showed complete response",
        "label": "Entailment"
    },
    "86823381-4392-4a31-a1cb-b2966dd41c45": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the interventions in both trials involve only one drug each Gefitinib in the primary trial and Zoledronic Acid in the secondary trial The statement suggests that the interventions involve multiple drugs but this is not the case in the evidence provided",
        "label": "Contradiction"
    },
    "a5c140f2-b2e5-43a5-9a8d-268806caa311": {
        "text_answer": "Yes The evidence states that nonsmall cell lung cancer and small cell lung cancer are included in the list of eligible tumors for the clinical trial",
        "label": "Entailment"
    },
    "3d7e66cf-6e57-4072-b7f9-96ab99473ac5": {
        "text_answer": "No  Explanation  The statement all of the participants in group 1 of the primary trial were found to have lesions is not entailed by the evidence as the evidence only reports that no lesions were detected in the healthy volunteers of group 1 of the primary trial  Furthermore the statement less than 10 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpig",
        "label": "Contradiction"
    },
    "bec4d231-ea9b-4713-b2a1-c7ddb2dc5b0f": {
        "text_answer": "Yes  Explanation The statement both the primary clinical trial and the secondary clinical trial recorded thromboembolic events in the participating patients is entailed by the evidence as both trials reported at least one instance of a thromboembolic event",
        "label": "Entailment"
    },
    "5a42ca95-0544-4db1-a1f1-67534d54dc69": {
        "text_answer": "Yes  The evidence states that one cohort of the primary clinical trial receives a validated webbased risk assessment as part of the intervention",
        "label": "Entailment"
    },
    "d99663b8-44bb-4480-9171-e10fc1ef25b1": {
        "text_answer": "Yes  Explanation The primary clinical trial had only two groups one intervention group receiving pyridoxine and one placebo group In contrast the secondary clinical trial had two intervention groups one receiving highdose oxybutynin chloride and the other receiving lowdose oxybutynin chloride Therefore the statement that the primary clinical trial had one test group and one placebo group while the secondary clinical trial was",
        "label": "Entailment"
    },
    "97d2c16b-fa4d-4b91-a69f-6692c681f6cd": {
        "text_answer": "No   The statement is not entailed by the evidence as sunitinib dosing was not continuous throughout the entire study but rather given on a 21day cycle",
        "label": "Contradiction"
    },
    "67b2e192-d596-4951-b6d0-75f957072bdb": {
        "text_answer": "No   Explanation  The evidence describes the dosing schedule for vorinostat and radiation therapy in the primary trial but it does not mention anything about the administration of fentanyl sublingual spray to the patients",
        "label": "Contradiction"
    },
    "f8f21f2b-9c9c-4f37-8c0d-b48061a14c9d": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as there is no mention of the route of administration for cohort 1 of the primary trial or the secondary trial The evidence only specifies that cohort 1 of the primary trial receives an injection of Fluciclatide and cohort 1 of the secondary trial receives a Chloroquine dose but it does not specify the type of injection or the",
        "label": "Contradiction"
    },
    "b0bb79f6-dd52-4821-b739-ffc42d7472da": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the incidence of treatmentemergent adverse events was practically nonexistent among patients undergoing the sunitinib  docetaxel  trastuzumab treatment is not entailed by the evidence The evidence states that there were 24 treatmentemergent adverse events among the 25 participants in the sunitinib  docetaxel",
        "label": "Contradiction"
    },
    "f94eab27-5609-47a1-bcd5-d0e1305caab1": {
        "text_answer": "No  Explanation  The statement candidates utterly incapacitated are a requirement for the secondary clinical trial a condition not indispensable for the primary clinical trial is not entailed by the evidence The evidence only mentions that patients with severe intellectual impairment unable to carry out basic daily routines and established depression are excluded from the secondary clinical trial It does not state that such patients are a requirement for the trial Additionally",
        "label": "Contradiction"
    },
    "943db9fb-b25b-4e58-bf2f-af46b1d9df54": {
        "text_answer": "No  Explanation  The statement hospital admissions were reported during the primary clinical trial is not directly entailed by the evidence provided The evidence only mentions the occurrence of adverse events AEs during the primary and secondary trials but it does not specify whether any of these AEs led to hospital admissions Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "ed8ce995-6417-4392-8608-d20f0087c730": {
        "text_answer": "No  Explanation  The statement pigmentary change in skin is abnormal skin pigmentation is not directly related to the given evidence The evidence only mentions gastrointestinal adverse events and does not mention anything about skin pigmentation Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "77045e13-70ad-4643-9e8c-7f0deb5d0ed9": {
        "text_answer": "No  Explanation  The statement cohort 1 and 2 of the primary trial receive the same dosage of CUDC101 at the same frequency is correct based on the evidence provided However the statement also asserts that there is no difference in the frequency of CUDC101 administration between the two cohorts which is not true according to the evidence Cohort 1 receives CU",
        "label": "Contradiction"
    },
    "c9e9765e-663a-4421-a353-b0d6de09734d": {
        "text_answer": "Yes  Explanation  The primary clinical trial involves the use of a Contour Profile Tissue Expander for breast reconstruction which may be monitored using xray imaging to ensure proper positioning and expansion The secondary clinical trial involves the administration of alloMSCs and a placebo via transendocardial injections which may be monitored using xray imaging to ensure accurate injection placement Therefore xray",
        "label": "Entailment"
    },
    "83d14b48-ba22-47e0-a7c5-0a0b5f8af134": {
        "text_answer": "No  Explanation  The statement a majority of patients experienced adverse events in the primary clinical trial is not entailed by the evidence The evidence only reports that 2 out of 35 patients 571 experienced adverse events which is not the same as a majority",
        "label": "Contradiction"
    },
    "0c0d244d-5d55-42ea-bb07-8ff35bd2c862": {
        "text_answer": "Yes  Explanation The evidence states that cohort 1 practices paced breathing for 15 minutes once daily and cohort 2 practices paced breathing for 15 minutes twice daily However both groups follow an instructional compact disc CD for their practice Therefore both groups are following different instructional CDs but they both practice once a day either once or twice in a day adding up to once a day",
        "label": "Entailment"
    },
    "7ab5e41f-6982-43b4-8541-8ff7964d669a": {
        "text_answer": "Yes  Explanation  The statement there were no instances of hypertension dehydration and dyspnea in any group of the primary clinical trial is entailed by the evidence because neither the Adverse Events 1 nor Adverse Events 2 lists any instances of hypertension dehydration or dyspnea",
        "label": "Entailment"
    },
    "9acd718f-6e45-495a-846d-b248d6690f1c": {
        "text_answer": "Yes The primary trial measures MYMOP score changes in units on a scale but it is not reported as a unit of measure in the secondary trial which measures isothiocyanate in micromolar M concentration divided by creatinine in millimolar mM concentration Therefore the trials do not consider MYMOP score variations as a way of measuring their research results in a comparable manner",
        "label": "Entailment"
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "text_answer": "No  Explanation The evidence provided in the results only gives the median with range change in total body lean mass for each group treated with GTx024 1mg and 3mg It does not specify how many patients in each group gained over 10 kilos of lean body mass Therefore the statement cannot be definitively answered with a simple yes or no based on the given evidence",
        "label": "Contradiction"
    },
    "b0b3e393-7af0-4fe2-bf26-111bddead6e7": {
        "text_answer": "No  Explanation  The evidence provided in the trial results indicates that 53 out of 60 participants or approximately 883 experienced either a confirmed complete response CR or a confirmed partial response PR according to RECIST criteria 10 However the statement provided in the question specifically mentions a majority of the patients in the primary clinical trial experienced a confirmed complete response CR which is not exactly what",
        "label": "Contradiction"
    },
    "24816a21-1c67-4b20-82f0-0891fed68773": {
        "text_answer": "Yes  Explanation The statement patients in the primary clinical trial more frequently experienced symptoms of anemia pneumonia and stupor than those in the secondary trial is entailed by the evidence as the primary trial had a higher percentage of patients experiencing anemia 625 vs 000 pneumonia 625 vs 000 and stupor ",
        "label": "Entailment"
    },
    "dc561148-4b85-4fee-a632-2662a4c1a74c": {
        "text_answer": "No  Explanation  The statement get anxious about going to doctor is a question about whether an individual gets anxious about going to the doctor is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events AEs in two cohorts of a primary trial without any information about individuals anxiety levels regarding doctor visits Therefore the statement cannot be determined to be entailed by the evidence based on the given information",
        "label": "Contradiction"
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "text_answer": "Yes The primary trial requires mammography as an inclusion criterion The secondary trial does not mention mammography as a requirement",
        "label": "Entailment"
    },
    "cd7d5918-4280-48e5-a202-ad7d499a9334": {
        "text_answer": "Yes The primary clinical trial employs a 3week cycle for its treatment intervention while the secondary clinical trial does not apply a cyclical treatment approach",
        "label": "Entailment"
    },
    "23505a58-2e6a-4220-9148-f3b3102d2a91": {
        "text_answer": "No  Explanation The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 is correct based on the information provided in the evidence However the statement but had an additional Collaborative Care Intervention is not mentioned in the evidence for Cohort 1 Therefore the statement as a whole is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d07ab8cf-9e2e-4ac2-b8e0-20d9fa9bf16a": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence explicitly states that those currently taking estrogens or progestogens are excluded from the study",
        "label": "Contradiction"
    },
    "147c18a2-2ef0-4cef-9f99-bbcd79b12216": {
        "text_answer": "Yes for both trials regarding the smokeless tobacco use However the evidence does not directly address the eligibility of morbidly obese patients for the trials The inclusion criteria for both trials do not mention obesity as an exclusion criterion",
        "label": "Entailment"
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the evidence describes the administration of Enzalutamide orally in both cohorts either 80 mg or 160 mg and does not mention IV administration at all",
        "label": "Contradiction"
    },
    "6fbe26db-3420-4617-9f84-1663aa9be297": {
        "text_answer": "  Yes for the primary trial and Maybe for the secondary trial   Explanation  The statement meets the inclusion criteria for the primary trial as the patient has a confirmed diagnosis of breast cancer appropriate diagnostic workup and adequate bone marrow function However the statement does not explicitly mention the patients performance status which is a requirement for the primary trial However the statement does not contradict the performance status requirement so it is",
        "label": "Entailment"
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "text_answer": "No The statement Patients with histologically documented metastatic SCBC are excluded from the primary trial is not entailed by the evidence provided SCBC small cell lung cancer is not listed among the types of solid tumors specified in the inclusion criteria",
        "label": "Contradiction"
    },
    "2eabe849-09b8-45e6-aa6b-74450a7ff5df": {
        "text_answer": "No   The statement is not entailed by the evidence as the statement is about treatmentemergent adverse events while the evidence is about the change in Isothiocyanate in Urine Samples",
        "label": "Contradiction"
    },
    "16808fde-01bf-40dd-ae6e-7f208b51636d": {
        "text_answer": "No   Explanation  The evidence provides information about the interventions for vaccine responses against specific diseases pneumococcus and influenza in two different cohorts adult cancer patients 65 years of age and older and healthy volunteers It does not state that both cohorts receive the same vaccine for either pneumococcus or influenza",
        "label": "Contradiction"
    },
    "6c2256ce-7c39-4ece-bdf4-fcd05744f234": {
        "text_answer": "No  Explanation  The statement encounter due to other specified problems related to upbringing is an icd encounter due to other specified problems related to upbringing is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The statement does not mention any specific medical condition or eligibility requirement for the trials  Regarding the second part of the question hypokalemic patients are indeed excluded from the",
        "label": "Contradiction"
    },
    "c6e231b0-ab51-4010-9d8b-d447af0a6306": {
        "text_answer": "No  Explanation The statement does not follow directly from the evidence provided The evidence only mentions vaccine responses against Pneumococcus and Influenza for two different cohorts of adults aged 65 and older It does not mention anything about joint range of motion or CTCAE",
        "label": "Contradiction"
    },
    "9b1ce2f0-2734-4ae5-988e-dd569c19594e": {
        "text_answer": "No The statement is not entailed by the evidence as there is no mention of nationality ethnicity weight or gender as eligibility criteria in the provided inclusion and exclusion criteria for the primary and secondary clinical trials",
        "label": "Contradiction"
    },
    "e07a4aec-7879-4c85-a39e-a1cb17f2fd64": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement is incorrect The primary clinical trial uses oral administration of cabergoline while the secondary clinical trial uses intravenous administration of pixantrone",
        "label": "Contradiction"
    },
    "5e83904b-39bc-4449-b5c5-c2972d287237": {
        "text_answer": "No  The evidence does not support the statement as intestinal obstructions were not reported as adverse events in either trial",
        "label": "Contradiction"
    },
    "2a4b11b1-b14f-4fd8-a810-b6ad2f60e9fb": {
        "text_answer": "Yes  Explanation The median change in lean body mass for the group treated with GTx024 1mg is 206 kg which indicates a loss of lean body mass for this group Since no participant in this group gained any lean body mass the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "7f06a038-29e8-4349-8822-876c2ae2e378": {
        "text_answer": "No The statement is not entailed by the evidence as the evidence does not provide any information about the nature of the adverse events recorded in the primary trial for cohort 1 The statement only mentions a disorder unrelated to the evidence",
        "label": "Contradiction"
    },
    "0cf7be8c-6376-4aff-93a2-2c88104fe061": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of scrotal infection in the given adverse events",
        "label": "Contradiction"
    },
    "5fc57549-ece0-4ba6-9e5f-fc785aa16f28": {
        "text_answer": "Yes The statement is entailed by the evidence as there are no reported cases of intestinal obstruction or pancytopenia in the patient cohorts of the primary and secondary trials",
        "label": "Entailment"
    },
    "f103c71f-151a-46b1-b24e-c9fa1c90db64": {
        "text_answer": "No   Explanation  The evidence describes the administration method for trabectedin and placebo in the primary clinical trial as intravenous infusions not subcutaneous injections occurring monthly",
        "label": "Contradiction"
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "text_answer": "maybe  Explanation The statement All patients treated with GTx024 1mg in the primary trial gained Lean body Mass over a 4 month period is not directly entailed by the evidence as the evidence only provides the median change in lean body mass for the group treated with 1mg of GTx024 and it does not guarantee that every individual patient in that group gained lean body mass However the evidence does suggest",
        "label": "Contradiction"
    },
    "b1bad6e5-5322-4ba2-8350-2496bef85d1c": {
        "text_answer": "No  Explanation  The statement there was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed by the evidence provided The evidence only lists the types and frequencies of adverse events observed in the primary trial but it does not specify which participants experienced both a gastrointestinal event and two or more psychiatric events Therefore while it is",
        "label": "Contradiction"
    },
    "2205c13a-b236-4117-b41e-78846625c760": {
        "text_answer": "No  Explanation  The evidence provided in the form of adverse events from two separate trials does not entail that one or more gastrointestinal adverse event and at least two psychiatric events were recorded during the same trial The evidence only lists the number and types of adverse events for each trial separately Therefore it is not possible to determine if both types of adverse events occurred in the same trial based on the given information",
        "label": "Contradiction"
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "text_answer": "Yes  Explanation The statement 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy can be calculated as follows  Number of Hepatotoxicity cases  3 Number of hypertension and Pancreatectomy cases  1 each  3  Number of hypertension and Pancreatectomy cases  3  1",
        "label": "Entailment"
    },
    "95421b93-0c5a-45db-9630-804f602204b6": {
        "text_answer": "Yes  Explanation The statement mentions that Uganda is a country in Eastern Africa and that there are several instances of cardiac related adverse events AE recorded for cohort 1 of the primary trial The evidence provided includes the number of adverse events and their types for two different cohorts of the primary trial One of the cohorts is identified as being from Uganda cohort 1 The evidence shows that",
        "label": "Entailment"
    },
    "7f3723a3-cdbf-41a6-a956-330e514b5c5c": {
        "text_answer": "Yes  Explanation  The evidence provided indicates that in both armsgroups of the clinical trial no patients encountered an incidence of doselimiting toxicity Therefore the statement no patients from the primary clinical trial encountered an incidence of doselimiting toxicity in any cohort is entailed by the evidence",
        "label": "Entailment"
    },
    "ad003c43-9467-4b8e-9a4e-e28c7d6422c3": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ce4406e4-c57a-441a-870c-e2442b0806de": {
        "text_answer": "Yes  Explanation The statement several cardiacrelated adverse events have been noted for cohort 1 in the primary clinical trial is entailed by the evidence as there are instances of cardiacrelated adverse events ACS Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac Tamponade reported in the primary clinical trial for cohort 1",
        "label": "Entailment"
    },
    "20296404-9526-4410-953c-51ea7ae866bd": {
        "text_answer": "No  Explanation  The evidence provided in the given clinical trial does not indicate any notable patterns in the expression of 40 genes under evaluation in patients maintaining normal vitamin D levels The results only report the proportion of participants with discernible gene expression patterns in each group but they do not specify any notable findings related to vitamin D levels and gene expression",
        "label": "Contradiction"
    },
    "287251c0-2d26-466d-8340-13d9c15196bf": {
        "text_answer": "No   Explanation The statement there was one psychiatric adverse event in the primary trial which affected up to 50 of patients is not entailed by the evidence The evidence states that there was one case of suicidal ideation out of 50 patients which is a psychiatric adverse event However it does not state that this event affected up to 50 of patients In fact the evidence shows that",
        "label": "Contradiction"
    },
    "709fb55d-517a-45bb-a379-f073a46cbe93": {
        "text_answer": "No  Explanation The statement all patients in the primary trial receive at least 20000 micrograms of mcs110 every three weeks and over 130000 micrograms of pdr001 every two weeks is not entailed by the evidence The evidence only specifies the dosages of MCS110 and PDR001 for each intervention in the primary trial",
        "label": "Contradiction"
    },
    "ba87189b-e858-4344-927d-a315a0d2576f": {
        "text_answer": "No  Explanation The statement any adult with old diagnosed PRnegative HER2negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The primary clinical trial has specific inclusion and exclusion criteria related to the prior treatment history while the secondary clinical trial has different inclusion criteria related to the breast cancer diagnosis and treatment plan Therefore the statement does not apply to both trials",
        "label": "Contradiction"
    },
    "27180597-864a-4375-97c8-e9e41fd297dc": {
        "text_answer": "  No  Explanation  The statement the primary clinical trial and the secondary clinical trial may be suitable for a 20 year old female recently diagnosed with erpositive her2negative breast cancer is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each clinical trial and the age of the participants is not mentioned in the primary clinical trials inclusion criteria while the secondary clinical trial",
        "label": "Contradiction"
    },
    "a9600a10-ab9c-4b6d-ad89-30f9d7859a50": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about a potential symptom night sweats and the evidence only provides information about the interventions in two clinical trials",
        "label": "Contradiction"
    },
    "bc13c987-6166-42c9-b537-1efc6126c3d8": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with localized or nondisseminated breast cancer are not eligible for the clinical trial",
        "label": "Entailment"
    },
    "581c879a-6d09-4736-8b12-a096d45b315c": {
        "text_answer": "  Yes for the primary trial if she meets all other inclusion criteria and no exclusion criteria and for the secondary trial if she meets all inclusion criteria and no exclusion criteria except for the history of breast tissue expander or implant placement which is not mentioned in the statement",
        "label": "Entailment"
    },
    "7ea784df-2fea-4676-a83f-a0716d2fd49d": {
        "text_answer": "  No  Explanation  The statement the number of participants was higher in the primary clinical trial compared to the secondary clinical trial is not entailed by the evidence provided The evidence states that there were 13 participants in the primary trial and 30 participants in the secondary trial which is the opposite of what the statement suggests",
        "label": "Contradiction"
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "text_answer": "Yes  Explanation  The statement the secondary trial and the primary trial use different units of measure in their results is entailed by the evidence as the primary trial reports the mean standard deviation of tumor diameter in centimeters cm while the secondary trial reports the count of participants with solid tumor response",
        "label": "Entailment"
    },
    "82bcea65-bca6-46f5-9e3b-32098e20c46f": {
        "text_answer": "No  Explanation  The statement gain of chromosome 2p is a cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2 is not directly related to the adverse events data provided in the evidence The evidence only reports the number and types of adverse events observed in two clinical trials and does not mention any cytogenetic abnormalities Therefore the",
        "label": "Contradiction"
    },
    "2295bf51-5b26-4cde-9bcf-caeada0181b1": {
        "text_answer": "Yes The evidence does not mention any exclusion criteria based on life expectancy pregnancy status or age",
        "label": "Entailment"
    },
    "51dace9a-0da5-49ed-8d8b-7489416ea9e8": {
        "text_answer": "Yes  Explanation The evidence shows that there were 13 participants in the aprepitant group who were emesisfree during the study period compared to 5 participants in the placebo group This means that the placebo group had approximately half the number of emesisfree participants as the aprepitant group Since double the likelihood is equivalent to having approximately half the number of successful outcomes the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "d323d9da-d286-4fa5-b883-552116910450": {
        "text_answer": "No  Explanation The statement compares the dosages of two different interventions Tamoxifen and Denosumab from two different clinical trials The statement is not entailed by the evidence as the evidence only provides the dosages of the interventions within each clinical trial and does not make a comparison between the two trials",
        "label": "Contradiction"
    },
    "9ebcda5d-0914-4015-b5d3-9446f9582d01": {
        "text_answer": "No  Explanation The statement multiple shingles cases were observed in both groups of the secondary trial but none in the primary trial is not entailed by the evidence provided The evidence only states that there was one case of shingles in the secondary trial and no cases in the primary trial It does not mention the number of trials or participants with multiple shingles cases",
        "label": "Contradiction"
    },
    "856ab26e-3ce5-4405-b5ce-22557600b74f": {
        "text_answer": "No  Explanation The statement Both cohorts of the primary trial receive the same doses of Abraxane is not entailed by the evidence While both cohorts receive Abraxane nabPaclitaxel they receive different combinations with different drugs gemcitabine in Arm A and carboplatin in Arm B The doses of Abraxane are the same but the total doses",
        "label": "Contradiction"
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "text_answer": "No  Explanation  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The evidence only reports the number of participants and the presence or absence of lesions in the primary trial and",
        "label": "Contradiction"
    },
    "cefecae9-606f-4be6-94c0-f9d3732968ea": {
        "text_answer": "Yes  Explanation The evidence for the primary trial indicates that women with locally advanced recurrent or metastatic breast cancer that is ER and undergoing consideration for systemic therapy are eligible The evidence for the secondary trial indicates that women with newly diagnosed or recurrent breast cancer who are considering a mastectomy are eligible Since locally advanced breast cancer that is ER is a subset of breast cancer and both trials include women considering a mastectomy",
        "label": "Entailment"
    },
    "45bd641d-3e35-456c-a01b-63fa3e2ebea1": {
        "text_answer": "Yes The statement is entailed by the evidence as Nonsmall cell lung cancer and Small cell lung cancer are listed as eligible tumors in the evidence",
        "label": "Entailment"
    },
    "6071457e-bfac-4d86-b20b-c37ff82c943f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information on the MTD of MM111 in the secondary trial The evidence only states that the MTD of MM111 is 15000 mcg per day but it does not indicate how this information was obtained or from which trial it comes from Therefore it cannot be determined if the statement is entailed by",
        "label": "Contradiction"
    },
    "c5a577f3-2bf4-4bbf-b1f9-5bd829414790": {
        "text_answer": "Yes the patients meeting the stated breast tumor size HR positive and HER2 negative criteria are eligible for both trials assuming they meet all other inclusion and exclusion criteria for each trial However the fatigue interference score is not mentioned in the evidence so it is not directly related to the statement",
        "label": "Entailment"
    },
    "aa2706a4-b145-400f-8e8c-23e70f006360": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the number of participants in each armgroup cohort other than the overall number analyzed The statement only mentions a difference of 7 participants between the two cohorts but the evidence does not provide this information",
        "label": "Contradiction"
    },
    "6d418558-93db-4116-b142-821c3f8615f2": {
        "text_answer": "No  Explanation  The statement neck pain score 2 is a subjective score of 2 on a visual analogue scale that ranges from 0 no pain to 10 excruciating is not mentioned in the evidence provided The evidence only discusses the interventions and dosages for the primary and secondary trials",
        "label": "Contradiction"
    },
    "7d5cd6d5-88a1-4693-b20b-c4960095a330": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is not directly entailed by the evidence provided The evidence only states that there was one Thromboembolic event in each trial but it does not specify that any specific patient experienced this event Therefore it is not possible to determine based on the given evidence that patients in both trials suffered Thromboembolic events",
        "label": "Contradiction"
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide information on the doses administered to patients in the primary trial for each condition that result in the majority of patients receiving the stated doses",
        "label": "Contradiction"
    },
    "dbc4f576-220a-482d-a06c-2538c13fdb28": {
        "text_answer": "No  Explanation The statement women aged 20 or 21 are immediately eligible for the primary clinical trial but were eligible for the secondary trial 12 years prior is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for both clinical trials It does not provide any information about the eligibility timeline for each age group",
        "label": "Contradiction"
    },
    "ed9856c5-cecd-4d24-a338-28bf547559fe": {
        "text_answer": "No  Explanation The statement the complete cohort of the primary clinical trial is prescribed entericcoated tablets is not entailed by the evidence The evidence only specifies the dosage and administration of Botulinum Toxin Type A and Placebo in the primary trial and the dosage and administration of MLN8237 in the secondary trial It does not mention that all participants receive entericcoated table",
        "label": "Contradiction"
    },
    "d83f5fcf-2a52-4612-b548-060ece7749f9": {
        "text_answer": "Yes  Explanation The statement 2p163 is a chromosome band present on 2p the primary trial and the secondary trial both administer cyclophosphamide Paclitaxel and pegfilgrastim to their patient cohorts is entailed by the evidence because both trials involve the use of cyclophosphamide Paclitaxel and pegfilgrastim in their interventions The statement also correctly",
        "label": "Entailment"
    },
    "61b2e007-6e98-4923-8c07-d22ab6b62870": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fb1605b0-dce6-45fb-bc67-2018e0578a2e": {
        "text_answer": "No  The evidence mentions anorexia in one individual but it does not indicate that most individuals struggled with eating disorders",
        "label": "Contradiction"
    },
    "11714886-d3a2-496b-a883-6cd394478b03": {
        "text_answer": "No  Explanation  The statement human papillomavirusnegative squamous cell carcinoma is a squamous cell carcinoma not associated with human papilloma virus infection is not directly related to the evidence provided The evidence only describes the interventions used in two clinical trials one involving massage therapy and the other involving the drug PF06647020 The statement is about the nature of a specific type of squ",
        "label": "Contradiction"
    },
    "cd8d5a6a-0365-410c-8f85-815a67c0d11b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not support the statement as it only gives the percentage of participants who completed the study in each group not the percentage who experienced recurrencefree survival The statement makes a comparison between the two groups based on a specific outcome measure recurrencefree survival that is not directly reported in the evidence",
        "label": "Contradiction"
    },
    "1d725114-1659-46dd-ab68-0c09bc167427": {
        "text_answer": "  Yes The evidence does not list bilateral breast tumor presence as an exclusion criterion",
        "label": "Entailment"
    },
    "4894f59e-9386-448a-a779-f22a453ef049": {
        "text_answer": "No  Explanation  The statement in the primary trial the control group arm 1 performed better in terms of operative time than the test group arm 2 is not directly entailed by the evidence provided The evidence only shows that the operative times for the intraoperative mammography group arm 2 were generally longer than those for the standard mammography group arm 1 in the primary trial However",
        "label": "Contradiction"
    },
    "faf9f6e7-c9ac-4f15-8a63-1b463b9e1c51": {
        "text_answer": "Yes  Explanation  The statement tumour lysis syndrome was not diagnosed in participants of either the primary or the secondary trial is entailed by the evidence since there is no mention of tumour lysis syndrome in the adverse events for either trial",
        "label": "Entailment"
    },
    "58c00532-2a20-4940-995f-08223d2736d5": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of pancytopenia in the adverse events reported in the primary or secondary trials",
        "label": "Contradiction"
    },
    "c136fce2-0e64-4f51-8483-be0fde4382ef": {
        "text_answer": "Yes   Explanation  The statement all adverse events reported in the primary clinical trial were different for each patient is entailed by the evidence because each adverse event was reported for only one patient in the trial",
        "label": "Entailment"
    },
    "ce7f9154-ce9f-4d2f-8377-940c57315f1c": {
        "text_answer": "No  Explanation  The evidence provided in the text indicates that the mean standardized cognitive function scores for both the Tamoxifen and Ovarian Function Suppression groups showed a decrease from baseline to 1 year after randomization However the statement all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group is not directly entailed by the evidence The evidence only reports the mean",
        "label": "Contradiction"
    },
    "f02e41c3-1eea-4662-9359-fe120c3bc10a": {
        "text_answer": "No  The evidence does not mention any eating disorders among the adverse events reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "21c01e1d-b152-404c-88d6-b697b2a97b68": {
        "text_answer": "No  Explanation  The statement the primary trial registered a higher number of mucositis oral bladder infection and thromboembolic events compared to the secondary trial is not entailed by the evidence The evidence only shows the number of adverse events in each trial but it does not provide enough information to make a comparison between the two trials regarding specific types of adverse events In this case the statement is not supported",
        "label": "Contradiction"
    },
    "dd3899d8-889b-424c-a7c4-8381ce656f18": {
        "text_answer": "No  Explanation  The statement three specific adverse events pancreatitis cholelithiasis hepatic pain and febrile neutropenia occurred amongst patients in the primary clinical trial is not entailed by the evidence provided The evidence only shows that none of these adverse events occurred in the given trials To entail the statement at least one instance of each of these adverse events would need to be",
        "label": "Contradiction"
    },
    "01650c5a-f268-41c2-b07b-9293a0e4a8f7": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures the change in hot flash activity average daily hot flash score in women taking flaxseed or placebo using a daily prospective hot flash diary The secondary clinical trial measures the overall response rate proportion of responders in patients with solid tumors receiving Paclitaxel Plus Bevacizumab PB or Paclitaxel Plus Bevacizumab Plus Gemcitabine",
        "label": "Entailment"
    },
    "9ad9b404-b234-41e6-9699-06a8c03bfe08": {
        "text_answer": "No  Explanation  The statement does not directly follow from the evidence provided The evidence describes the interventions used in two different clinical trials but it does not explicitly state that the RAND social support survey questionnaire is related to either trial Additionally the statement makes assumptions about the dosages and durations of the interventions in the secondary trial that are not explicitly stated in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1f8bd45e-480f-4244-9515-e1249b5b842a": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about adverse events related to mental disorders or psychiatric disorders The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "6d446eda-4dec-469d-9313-37c70eef8e0a": {
        "text_answer": "No   Explanation   The statement cohort 2 of the primary clinical trial and the secondary trial had an equal number of patients is not entailed by the evidence provided The primary trial had 76 participants in the intervention group and 75 participants in the control group while the secondary trial had 147 participants in the standard of care group and 163 participants in the device  standard of care group Therefore",
        "label": "Contradiction"
    },
    "6003b550-4716-4966-a585-5a69fea20613": {
        "text_answer": "  No the statement is not entailed by the evidence as it only mentions unstable angina neuropathy and prior chemotherapy or radiotherapy as exclusion criteria for the secondary trial but it does not specify the grades of these conditions that would disqualify patients from participation in the primary trial The evidence provides the specific grades of these exclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "f5a80369-d69d-47d6-836c-60735534ce4e": {
        "text_answer": "No  Explanation The statement requires that all participants receive at least 20mg of MCS110 every three weeks and more than 130mg of PDR001 every alternate week However the evidence only shows that some participants received 1mgkg of MCS110 every three weeks which may be less than 20mg depending on the weight of the participant and 100mg of PDR",
        "label": "Contradiction"
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "text_answer": "Yes The secondary trial explicitly states that patients with metastatic disease stage 4 cancer are not eligible However the primary trial includes stage IIbIIIIV breast cancer patients",
        "label": "Entailment"
    },
    "3d29cec9-8354-4d5b-ae1a-f486ab7aa6ca": {
        "text_answer": "Yes The statement is about the anatomy of the renal system which is not directly related to the intervention MM111 but is within the context of the renal system The evidence does not contradict the statement",
        "label": "Entailment"
    },
    "59f54656-5444-4b6d-a011-2921eb624626": {
        "text_answer": "Yes The statement implies that there is a lack of detail in the intervention section of the primary clinical trial regarding the treatment cycle and radiation dose The evidence does not directly provide this information but it does indicate that the intervention section is not clear on these points",
        "label": "Entailment"
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "text_answer": "No   Explanation  The evidence describes the doses of vorinostat that patients will receive during the trial as well as the timing of the vorinostat administration in relation to radiation therapy However it does not mention anything about the use of fentanyl sublingual spray during radiation therapy let alone the doses of this medication that patients will receive Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "54d98b73-9799-4f9a-8581-42792f164d96": {
        "text_answer": "No  Explanation  The statement theraspheres utilized for radioembolization form the basis of the intervention in the primary clinical trial while the intervention in the secondary clinical trial is reliant on the use of ibrutinib and medi4736 is not directly entailed by the evidence The evidence only mentions that TheraSphere is used in the primary clinical trial for radioembolization and ibrutinib",
        "label": "Contradiction"
    },
    "75753b6a-e963-4357-a225-102c1542f73d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement is about a Likert scale for agreement while the evidence only reports the occurrence of adverse events AEs and their frequencies in two cohorts of the primary trial The statement does not appear in the evidence",
        "label": "Contradiction"
    },
    "f377df82-9511-47cc-9176-12491888eb05": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence because the evidence does not mention anything about an antigmcsf monoclonal antibody The evidence only provides information about interventions in two trials one involving CBTI and Armodafinil and the other involving MCS110 and PDR001 The statement is about a different topic",
        "label": "Contradiction"
    },
    "b2187410-7c4d-49e2-a987-892fff52269f": {
        "text_answer": "No   Explanation  The statement valvular heart disorder is any heart disorder characterized by a defect in valve structure or function is not directly related to the evidence provided in the trial The evidence only mentions the administration of memantine hydrochloride or placebo orally and does not mention anything about valvular heart disorders",
        "label": "Contradiction"
    },
    "91d1600a-35d7-47a4-b972-edee5eeb6018": {
        "text_answer": "No  Explanation The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is not entailed by the evidence The evidence only states that in the primary trial the Intervention 1 and Intervention 2 both used MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose",
        "label": "Contradiction"
    },
    "95570634-cfd3-4f4c-8082-8b98a2f13859": {
        "text_answer": "Yes  Explanation  The evidence provided in the results 1 and 2 shows the ORR for each group in the primary clinical trial The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and the ORR for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG",
        "label": "Entailment"
    },
    "109ad38c-08ee-40ab-9a9c-65a4db8915b0": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions are administered through injections either intravenous or subcutaneous However its important to note that the statement does not specifically mention childhood leukemia but the evidence provided does not relate to that condition either",
        "label": "Entailment"
    },
    "47abcc5d-7e6b-4969-9646-eefe68cebc3a": {
        "text_answer": "Yes  Explanation The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is entailed by the evidence as the secondary trial had a higher percentage of patients with anemia 625 vs 000 pneumonia 625 vs 000 and stupor 625 vs ",
        "label": "Entailment"
    },
    "5b66def6-3282-455a-a879-6e5a68c90c1b": {
        "text_answer": "No  Explanation  The statement participants of the secondary clinical trial are administered three subcutaneous injections on a weekly basis in contrast participants of the primary clinical trial receive only a single injection at the studys commencement is not directly entailed by the evidence provided The evidence only mentions the number of patients and the interventions they receive in each trial but it does not specify the number or frequency of injections for the",
        "label": "Contradiction"
    },
    "959eb0d5-7ac9-4c23-a10e-d1b720960a96": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial the influence of assorted radiation therapy is being evaluated on its study participants whereas the secondary clinical trial tests the impact of varied quantities of the same treatment on its study group is entailed by the evidence as the primary trial evaluates the use of Hydrophor and Medihoney during radiation therapy while the secondary trial tests the effect of different doses of PF0521",
        "label": "Entailment"
    },
    "a3abbf89-df53-45d4-97e1-f358dddbd2a8": {
        "text_answer": "Yes for hypertension and dyspnea but not for edema as there were instances reported in both cohorts However the statement is not completely accurate as it does not account for the instances of edema reported in the trial",
        "label": "Entailment"
    },
    "33377a5a-a2d0-4881-b4eb-93fe650e900a": {
        "text_answer": "Yes  Explanation  The evidence provided in the trial results indicates that the mean number of hot flashes per day was lower in the paced respiration group 348 compared to the fast shallow breathing group 395 This difference suggests that the paced respiration intervention was more effective in reducing hot flash frequency as stated in the question",
        "label": "Entailment"
    },
    "b83fe708-6ce5-4b18-9d6a-51741249c7df": {
        "text_answer": "Yes The primary trial excludes patients with alcohol or substance abuse or dependence within the past 2 years while the secondary trial allows up to 5 alcoholic drinks per day within the past year",
        "label": "Entailment"
    },
    "c6fedf8e-7d06-426e-8269-667a68ef06bc": {
        "text_answer": "Yes The primary trial does not involve any drugbased interventions while the secondary trial tests two different drugs PF06647020 at 02 mgkg and 05 mgkg",
        "label": "Entailment"
    },
    "485b3413-6788-47ad-916e-c5d7fdb28237": {
        "text_answer": "No  The statement is not related to the evidence provided The evidence pertains to the effectiveness of a peer support program for breast cancer survivors and a device used to assess positive margins during surgery The statement is about a different topic specifically a cluster of neural crest cells called paraganglia",
        "label": "Contradiction"
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "text_answer": "Yes  Explanation The statement Nobody taking part in the primary trial suffered a UTI is entailed by the evidence because there is no instance of a urinary tract infection reported in the adverse events of the primary trial",
        "label": "Entailment"
    },
    "dfbf536b-7a16-42a0-b7f9-322c5394a01b": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting more than 120 patients is not directly entailed by the evidence provided While anaemia was the most common adverse event in the secondary trial it did not affect more than 120 patients it affected 234 of patients or 3 out of 128",
        "label": "Contradiction"
    },
    "3db98663-b8c7-4869-a46a-e7526caa7436": {
        "text_answer": "Yes for the primary trial only",
        "label": "Entailment"
    },
    "fa5334cc-0f09-4f22-91f8-156c7ab6d964": {
        "text_answer": "No  The statement is not entailed by the evidence as neither trial used a knife device as their outcome measurement",
        "label": "Contradiction"
    },
    "5accf90d-2307-441f-ae8d-d055d9564a26": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0aa5e58e-3ff4-487f-b043-d10452a30a4f": {
        "text_answer": "No  Explanation  The statement no instances of lesions were reported among the participants of group 1 in the primary clinical trial is not directly entailed by the evidence provided The evidence only reports the number of lesions detected in the primary clinical trial which was zero for the healthy volunteers group It does not mention anything about radiation dermatitis or hyperpigmentation in this group  The statement a high percentage over ",
        "label": "Contradiction"
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial only includes patients with measurable or nonmeasurable disease that is clinically obvious metastatic disease",
        "label": "Entailment"
    },
    "4c7b87a1-ac43-4d8c-b6cf-2c95f3a3a074": {
        "text_answer": "No  Explanation Both interventions in the primary clinical trial involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid Therefore the statement that intervention 2 uses a higher dose than intervention 1 is not entailed by the evidence",
        "label": "Contradiction"
    },
    "33529b88-15c5-4e64-b876-f83de0305ce8": {
        "text_answer": "No  Explanation  The statement how much did ringing buzzing whistling noises make it hard to pay attention to things is a question about how hard it was for an individual to concentrate because of ringing buzzing or whistling noises is not directly related to the inclusion or exclusion criteria of either the primary or secondary trial The primary trial focuses on hot flushes and menopausal status in breast cancer patients while",
        "label": "Contradiction"
    },
    "5199d14c-3a5e-4800-adf2-a065f50886b5": {
        "text_answer": "yes The primary trial only provides armodafinil to a select group while the secondary trial provides a fixed dose of PDR001 and MCS110 to every patient",
        "label": "Entailment"
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "text_answer": "  No   Explanation   The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is not entailed by the evidence provided   The primary trial includes patients with NUT midline carcinoma and castrateresistant",
        "label": "Contradiction"
    },
    "6e644116-4084-4a3d-90dd-82f50a7ccc0c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c0b9a42b-2440-46b5-8fbc-978e2699c76e": {
        "text_answer": "No  The statement is not entailed by the evidence as colorectal cancer is listed among the eligible tumors in the evidence",
        "label": "Contradiction"
    },
    "5bf5c965-7588-452a-9d36-2503218e56da": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded fewer aes than the primary trial is not entailed by the evidence In fact the opposite is true based on the given data The secondary trial recorded a higher percentage of adverse events 4400 compared to the primary trial 000",
        "label": "Contradiction"
    },
    "8f8b46df-4031-4a42-bf67-60d923f2ec29": {
        "text_answer": "No   Explanation   The statement radial growth phase is a morphologic architectural pattern in which the tumor cells spread horizontally is not directly related to the evidence provided The evidence only describes the interventions used in two clinical trials one involving a docetaxelbased combination with PF05212384 and the other involving intraoperative mammography The statement about the radial growth",
        "label": "Contradiction"
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only pertains to breast cancer and its treatment",
        "label": "Contradiction"
    },
    "98528323-fc08-45b9-8403-4005398ae3a7": {
        "text_answer": "Yes   Explanation  The statement the intervention for the primary clinical trial is administered orally while the secondary clinical trial intervention is strictly issued intravenously is entailed by the evidence as the primary trial intervention is given orally PO and the secondary trial interventions are given intravenously IV",
        "label": "Entailment"
    },
    "4ff85794-0b6a-4fe7-824f-afa6c2fa133e": {
        "text_answer": "No  Explanation The statement Coronary artery stenosis are the most common AE recorded in the primary trial is not entailed by the evidence The evidence only lists the individual adverse events and their frequencies but it does not provide information about the most common adverse event in aggregate The statement is incorrect because the most common individual adverse event listed in the evidence is actually Nausea and Vomiting each with",
        "label": "Contradiction"
    },
    "0af2a0f3-dd56-4e3b-9e85-344780cc0877": {
        "text_answer": "No   The evidence provided in the text does not relate to penile pain or CTAE 50 The primary trial focuses on the effectiveness of a peer support program for breast cancer survivors while the secondary trial examines the use of a device to assess positive margins during surgery",
        "label": "Contradiction"
    },
    "0f094624-f6e3-479b-bea3-34b5a3acf873": {
        "text_answer": "Yes  Explanation The primary clinical trial lasted for 10 weeks while the secondary clinical trial lasted for 24 weeks which is a difference of 14 weeks Therefore the statement the secondary clinical trials intervention duration extends 15 weeks longer than that of the primary clinical trial is an overestimation of the difference but it is still entailed by the evidence since 15 weeks is greater than 14 weeks",
        "label": "Entailment"
    },
    "55635fce-1467-46ba-934d-8234f33e103e": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence allows for female patients with solid tumors that are locally advanced andor metastatic to participate in the trial",
        "label": "Contradiction"
    },
    "869a492c-b4bf-4145-a491-1ee0ea0fe816": {
        "text_answer": "No  The statement about Yttrium is not related to the evidence provided about the inclusion and exclusion criteria for the primary trial The evidence only mentions the inclusion and exclusion criteria for a breast cancer clinical trial",
        "label": "Contradiction"
    },
    "53e2327a-6a30-49d0-a5eb-74cc5141abbb": {
        "text_answer": "No  The statement has nothing to do with the evidence provided The evidence is about the eligibility criteria for a primary trial involving various types of cancer patients while the statement is about the use of sulfoxone a watersoluble sulfonamide antibiotic used in the treatment of leprosy and the requirement for regular exercise as part of an intervention",
        "label": "Contradiction"
    },
    "fed2e936-ab4c-42d6-8346-8f1b3ec9cc73": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not indicate that doselimiting toxicity occurred exclusively within cohorts other than cohort 2 The statement is not directly supported by the given data The trial results only report the number of participants in each cohort and do not provide information about which cohorts experienced doselimiting toxicities",
        "label": "Contradiction"
    },
    "a73a2b32-2cdb-49ec-ac4e-ed2eb976dec1": {
        "text_answer": "Yes The statement is about metastatic bile duct carcinoma which is not mentioned in the evidence However the evidence provides information about trials related to adverse events for a drug or treatment and the statement is about the types of trials Therefore the statement is entailed by the context of the evidence even if it does not directly mention the statement itself",
        "label": "Entailment"
    },
    "f86794bf-be99-43b3-b5e0-a78f5dde96a4": {
        "text_answer": "No  Explanation  The statement the bulk of the adverse events reported in the primary trial involved the respiratory system and were rare or nonexistent in the secondary trial is not entailed by the evidence provided The evidence only reports the frequency of various adverse events related to the blood and bone marrow system lymphatics and edema in the limbs for both trials It does not mention any adverse events related to",
        "label": "Contradiction"
    },
    "c002edfa-458b-4274-860e-a3c6024c467c": {
        "text_answer": "No  Explanation The statement mental scale is a range of values that characterizes an individuals mental development is not related to the evidence provided about the primary trial of Sunitinib and Capecitabine The evidence only describes the administration of Sunitinib and Capecitabine in the trial and does not mention anything about mental development or a mental scale",
        "label": "Contradiction"
    },
    "570eadad-adf1-4e5a-bae7-8455d2a07f0e": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only discusses the results of two clinical trials regarding the use of empegfilgrastim in breast cancer patients to prevent neutropenia The statement is about hemolytic uremic syndrome and CTCAE which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "43a81620-bb60-4515-b31b-4cf8e5f3cc25": {
        "text_answer": "No   Explanation The evidence provided does not support the statement that it was typical for the primary clinical trial candidates to suffer from an eating disorder The statement is not entailed by the evidence as there is no mention of eating disorders in the adverse events reported",
        "label": "Contradiction"
    },
    "da4bfd68-6510-4a0d-aa9e-b925d2cef24a": {
        "text_answer": "yes the statement is entailed by the evidence The primary trial results show a higher pCR rate in Arm 1 FEC75 Then PaclitaxelTrastuzumab compared to Arm 2 PaclitaxelTrastuzumab Then TrastuzumabFEC75 and the secondary trial results indicate that Arm 1 HerceptinNavelbine had a lower rate of OS ",
        "label": "Entailment"
    },
    "4234e99e-4e49-459b-9a11-5420d039defd": {
        "text_answer": "Yes  Explanation  The statement the primary trial has fewer total adverse events compared to the secondary trial is entailed by the evidence since the total number of adverse events in the primary trial is 0 while in the secondary trial it is 48  However its important to note that the statement only mentions the total number of adverse events and doesnt specify which type of adverse event is being compared The",
        "label": "Entailment"
    },
    "29ebe44e-58cf-4141-afaa-9518629c3868": {
        "text_answer": "No  Explanation  The statement patients that have suffered a pulmonary embolism within the last 156 weeks are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is not explicitly stated in the provided evidence The primary trial excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of",
        "label": "Contradiction"
    },
    "c6c56d8f-1e0a-4dad-9993-e47e34c146e7": {
        "text_answer": "No  Explanation  The statement the primary clinical trial necessitates a monthly subcutaneous administration of 120 milligrams of denosumab to patients while the secondary clinical trial involves the injection of 04 to 10 mci of radioactive tc99m sulfur colloid is not directly entailed by the evidence provided The evidence only mentions the interventions used in each trial and the",
        "label": "Contradiction"
    },
    "376fcb2c-1ea0-4b28-a6d2-fde91a124841": {
        "text_answer": "Yes  Explanation The statement there were threefold the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is entailed by the evidence since the number of hepatotoxicity cases 3 is indeed threefold the number of hypertension and pancreatectomy cases 1 for each",
        "label": "Entailment"
    },
    "a1bff44a-8d74-4184-a4d3-228bb55f4530": {
        "text_answer": "No   Explanation  The statement the secondary clinical trial had a higher incidence of adverse events compared to the primary clinical trial is not entailed by the evidence provided The evidence only states that the incidence of adverse events for both trials is 000 Therefore it is impossible to make a comparison between the two trials based on the given information alone",
        "label": "Contradiction"
    },
    "786d7c5c-66f2-4ce1-8b3d-c6fdbeb36168": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the inclusion criteria However the patients ANC level is below the required threshold for the secondary trial so they would not be eligible for that trial",
        "label": "Entailment"
    },
    "fef8b2f0-3e1f-46de-a53b-f1dffde794e6": {
        "text_answer": "yes but with an important qualification the primary trial includes male participants but the secondary trial specifically focuses on female participants The statement could be rephrased as The primary clinical trial includes male participants while the secondary clinical trial favors female participants",
        "label": "Entailment"
    },
    "3f777627-6d5d-43c9-8686-677498316865": {
        "text_answer": "No  Explanation The statement 50 of the primary trial patients suffered an increase in blood bilirubin is not entailed by the evidence The evidence states that 909 of the patients suffered an increase in blood bilirubin which is not the same as 50",
        "label": "Contradiction"
    },
    "7294869d-4998-49a4-a9b5-021476f448b6": {
        "text_answer": "No  The evidence does not mention cognitive behavioral therapy as a component of Intervention 1 It only states that a validated webbased risk assessment is being used and decision support is provided for prevention based on the risk Intervention 2 is described as usual care",
        "label": "Contradiction"
    },
    "7cd2b581-31f9-42e8-9945-9317f97be422": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the dosages of eribulin and docetaxel are not directly comparable in the given information The dosage of eribulin is given as 14mgm2 on Days 1 and 8 while the dosage of docetaxel is given as 75 mgm2 on Day 1 only These dosages cannot be directly compared",
        "label": "Contradiction"
    },
    "36386099-3f11-4037-aa48-dcbb36d7ff23": {
        "text_answer": "Yes The statement is entailed by the evidence as the inclusion criteria clearly state that the primary breast cancer must be HER2 positive",
        "label": "Entailment"
    },
    "873c56c9-8544-45f4-bba4-308707b30b93": {
        "text_answer": "  Yes The statement that individuals diagnosed with follicular lymphoma or metastatic melanoma are disqualified from both the primary and secondary trials is entailed by the evidence Follicular lymphoma and metastatic melanoma are not listed as eligible conditions in either trials inclusion criteria",
        "label": "Entailment"
    },
    "03204d11-8f0c-41be-9fe7-3361c5549d51": {
        "text_answer": "No  Explanation The placebo intervention is administered on Day 1 with a 3hour intravenous infusion while the trabectedin intervention is administered on Day 2 with a 3hour intravenous infusion The statement suggests that both interventions are administered on a biweekly basis but the evidence does not provide enough information to support this claim The frequency of administration is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "c9c7d71a-0b59-4277-87fa-32e427e37b40": {
        "text_answer": "  No   Explanation   The statement about a 40yearold patient with bladder cancer an absolute neutrophil count of 1200l a platelet count of 49000l a hemoglobin level of 75 gl and a life expectancy less than 5 months is not entailed by the evidence provided for either the",
        "label": "Contradiction"
    },
    "90748020-3e2f-46c8-8e9d-984436a2d752": {
        "text_answer": "  No The statement is not entailed by the evidence as the primary trial allows for nonsmokers only but the secondary trial allows for fewer than 5 alcoholic drinks per day",
        "label": "Contradiction"
    },
    "29412166-6da7-47d8-82b9-efc61e628f05": {
        "text_answer": "No  The statement is not entailed by the evidence as there was one thromboembolic event reported in the secondary trial",
        "label": "Contradiction"
    },
    "d333f58a-6f8d-402c-a44c-36899a155100": {
        "text_answer": "Yes  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is entailed by the evidence as the primary trial had a higher number of reported adverse events including Palpitations 2 vs 0 Pericardial effusions 2 vs 0 and Abdominal pains 3 vs 0",
        "label": "Entailment"
    },
    "777b7b77-83e6-49a0-9988-c2363fbcc17d": {
        "text_answer": "Yes  Explanation  The evidence shows that the number of participants who experienced an increase in pleural effusion was 2 out of a total of 17 1176 However the statement only mentions many participants and not all participants The statement is still entailed by the evidence because it is true that many is a smaller subset of all and 1176 is less than 7",
        "label": "Entailment"
    },
    "5aa4da04-c21d-48a4-8888-62675ca63f74": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 250 mg of fulvestrant in a tablet form to be taken bid is not entailed by the evidence  The primary trial is about radiation therapy for breast cancer patients while the secondary trial is about the use of Enzastaurin and Fulvestrant in breast cancer treatment The statement comb",
        "label": "Contradiction"
    },
    "8e63dcb6-d289-4782-94a5-9f0aa7343cbd": {
        "text_answer": "Yes  Explanation  The statement no fatalities were reported in the adverse events for both the primary clinical trial and the secondary clinical trial is entailed by the evidence because the evidence does not report any fatalities in the adverse events for either trial",
        "label": "Entailment"
    },
    "d40740f4-8885-4590-b274-23802a46d9e3": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial and secondary trial both involve testing procedures radiation therapy and drug treatment and specify the start of these procedures in relation to a reference time point onset of radiation therapy and start of each treatment cycle",
        "label": "Entailment"
    },
    "13f8d256-bec7-419f-bda5-202ea116a215": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence because the adverse events in the two clinical trials are not identical In the primary trial there were adverse events such as dehydration lymphopenia neutropenia and hyponatremia that were not reported in the secondary trial Additionally the secondary trial had a thromboembolic event which was not reported in the primary trial Therefore",
        "label": "Contradiction"
    },
    "e100136f-281e-4721-9f57-66392982260f": {
        "text_answer": "No  Hyperkalemia is an exclusion criterion in the primary trial but there is no mention of it in the secondary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "04d8d180-a06f-4eef-9c67-b51babbd8f10": {
        "text_answer": "No  Explanation The statement percentage food eaten score 30 is a subjective score of 30 on a scale that ranges from 0 none to 100 all of my food is not directly related to the evidence provided The evidence only mentions the interventions and their durations in the primary and secondary trials but it does not provide any information about the percentage of food eaten by the participants in either trial",
        "label": "Contradiction"
    },
    "98d96b95-5e98-49e3-8bd1-b004132c3781": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial welcomes participants of all ages including 18 year olds but the primary clinical trial sets an age limit of 21 and over is not entailed by the evidence The evidence only provides the inclusion and exclusion criteria for both the primary and secondary clinical trials It does not mention anything about the age limit for the secondary clinical trial being different from the primary clinical trial Therefore the",
        "label": "Contradiction"
    },
    "c25249a2-5294-4b5e-a39c-3b5c956b9147": {
        "text_answer": "Yes The evidence explicitly states that patients with documented allergies to cephalosporin trimethoprimsulfamethoxazole and levofloxacin are excluded from the secondary clinical trial The statement also includes celecoxib which is not mentioned in the secondary trial but is an exclusion criterion in the primary trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "cb5c3a2b-3752-4e0d-9b5e-ae84ffaab109": {
        "text_answer": "Yes The evidence shows an increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups after the intervention",
        "label": "Entailment"
    },
    "bebf3648-7a1c-4e73-8d0a-f5715fa173f8": {
        "text_answer": "No  Explanation The statement every patient in the primary clinical trial is administered a minimum of 20mg of mcs110 triweekly alongside over 130 mg of pdr001 biweekly is not entailed by the evidence provided The evidence only states the dosages for each intervention in the trial but it does not guarantee that every patient received the maximum possible dosage or that the dosages",
        "label": "Contradiction"
    },
    "0723e2a6-a2cd-4b8b-b319-f8a8bf00d819": {
        "text_answer": "No  Explanation The statement about radiationinduced malignant peripheral nerve sheath tumor is not mentioned in the evidence The evidence only mentions exclusion criteria related to recent surgery and radiation therapy",
        "label": "Contradiction"
    },
    "d0d25983-0004-4189-9139-c36827fa1e4d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions the administration of gemcitabine vinorelbine and ruxolitinib in the primary clinical trial which is not mentioned in the evidence The evidence only mentions the administration of chemotherapy with GMCSF doxorubicin and cyclophosphamide carboplatinnabpaclitaxel",
        "label": "Contradiction"
    },
    "7bb1cc76-1493-4507-9560-4b4719a5d3fc": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial does not include any information about depression or the use of a depression visual analogue scale The trial only reports the proportion of participants with controlled acute vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril",
        "label": "Contradiction"
    },
    "c77cef4c-abf2-439e-97a4-abf4e1d57ac8": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial includes various types of breast cancer not just Her2neu breast cancer and the secondary trial includes patients with different types of cancer including ovarian and triplenegative breast cancer",
        "label": "Contradiction"
    },
    "e8be62e0-1f25-49f3-91d8-4fc23848dcd1": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the evidence states that cohort 1 received a lower dose of cetuximab 12 mgkg compared to cohort 2a 20 mgkg Therefore they did not receive the same dosage Additionally the evidence does not mention the absence or presence of a collaborative care intervention for either cohort",
        "label": "Contradiction"
    },
    "d91d9ce6-365c-4b56-9eef-20922491f504": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it incorrectly states the starting doses for both interventions The statement suggests that cohort 1 receives 90 mgm2 paclitaxel daily and cohort 2 receives 25 mg of sunitinib daily but the evidence states that cohort 1 receives 90 mgm2 paclitaxel as a 1",
        "label": "Contradiction"
    },
    "2e95798d-089f-44b6-a6bf-13161021b7ff": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents allowed is an exclusion criterion for the study",
        "label": "Contradiction"
    },
    "d6aab46f-9e05-43a5-9d57-ca7d34bed983": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as neither the primary nor the secondary clinical trial administer drugs orally and both rely on MRIs for imaging assessments In the primary trial FMX is given intravenously and MRIs are used for imaging assessments while in the secondary trial lapatinib is given orally but paclitaxel is given intravenously and MRIs are used for imaging",
        "label": "Contradiction"
    },
    "cc2be8ad-6396-41da-a205-45d8bfca37f4": {
        "text_answer": "  No The statement is not entailed by the evidence The primary trial includes breast cancer patients and the secondary trial includes various types of cancer but it does not mention leukemia or age restrictions for males",
        "label": "Contradiction"
    },
    "bec00746-3a77-4d83-9c3b-d50eabcac1de": {
        "text_answer": "No  Explanation The evidence provided only mentions the interventions and their respective cohorts in the clinical trial It does not specify that all participants will undergo a laparoscopic procedure",
        "label": "Contradiction"
    },
    "aebbea11-2bed-406c-a63e-02ca9eede262": {
        "text_answer": "No  Explanation  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is not entailed by the evidence The evidence only shows that Syncope was the most common adverse event in the primary trial but it was not mentioned in the secondary trial Therefore it cannot be concluded that it was the most common adverse event across both trials Additionally the statement introdu",
        "label": "Contradiction"
    },
    "13386e01-7556-4cec-93ef-c845f8c8e50d": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of specific types of adverse events between the two trials The statement also mentions Intestinal perforation specifically but the evidence does not mention this ad",
        "label": "Contradiction"
    },
    "fbe7ef7c-4dff-403e-9152-04d357ec9bbc": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fd32ab49-3994-4b45-aaf9-da79d4cae211": {
        "text_answer": "No  Explanation  The statement less than 10 patients in the primary trial suffered Aes severity of elevated lesion is not directly related to the given evidence The evidence only provides the number and percentage of adverse events AEs observed in the primary trial including gastroesophageal reflux disease and ductal carcinoma in situ The statement on the other hand makes a claim about the",
        "label": "Contradiction"
    },
    "bdfb5379-c659-4a09-b4f1-895468675f2e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c53af3d2-6827-4f10-ae9e-c7639a15b19a": {
        "text_answer": "Yes  Explanation The statement adverse events were not common amongst cohort 1 participants in the primary clinical trial identical results were drawn from cohort 2 is entailed by the evidence as both cohorts had low percentages of adverse events",
        "label": "Entailment"
    },
    "2a5561f9-399d-4651-9a54-1a15f251c070": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the frequency of sunitinib administration in the primary trial and pembrolizumab administration in the secondary trial are not directly comparable due to different dosing schedules In the primary trial epacadostat and pembrolizumab are given together while in the secondary trial sunitinib is given as a single agent The statement only compares the frequency of",
        "label": "Contradiction"
    },
    "a61c1627-33e6-4a53-8247-484d42328747": {
        "text_answer": "No  Explanation The primary clinical trial includes a minimum tumor size of 2 cm in diameter while the secondary clinical trial does not specify a minimum tumor size However it does include metastatic disease as an inclusion criterion Therefore a patient with a 3mm tumor would not meet the inclusion criteria for the primary clinical trial but could potentially be a candidate for the secondary clinical trial depending on other eligibility factors",
        "label": "Contradiction"
    },
    "dfef1ddd-9351-436d-b1ce-9f22065b495c": {
        "text_answer": "No   Explanation  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 3 out of 10 participants is not entailed by the evidence The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial It does not provide information about the percentage of",
        "label": "Contradiction"
    },
    "9367129d-51e0-4d62-b2df-35749e117157": {
        "text_answer": "Yes  Explanation The evidence states that the inclusion criteria include unilateral breast cancer which means cancer in one breast only Therefore the statement that the trial rules out patients with observable tumors in both breasts is entailed by the evidence",
        "label": "Entailment"
    },
    "9a20f7f5-5477-4320-be07-3f2154877863": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify tumor size However the primary trials inclusion criteria do not match the secondary trials exactly as the secondary trial includes patients with locally advanced or metastatic breast cancer while the primary trial only includes patients with primary breast cancer Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "29eca4cf-13e4-4028-bbd1-71955607afb5": {
        "text_answer": "No  Explanation  The evidence provided in the text relates to the results of a clinical trial comparing the effect of topical cryotherapy on chemotherapyinduced peripheral neuropathy CIPN in patients receiving adjuvant paclitaxel The evidence does not mention anything about myroides bacteria Therefore the statement about myroides being a genus of bacteria is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1d3bccea-6780-45ae-93d2-651346fbc1dd": {
        "text_answer": "No  Explanation The evidence provided in the trial results only gives the median change in lean body mass for two different doses of GTx024 1 mg and 3 mg over a 4month period The statement however makes a generalization about all patients treated with GTx024 gaining lean body mass over a 033year period which is not directly supported by the evidence The evidence only",
        "label": "Contradiction"
    },
    "916340c0-cd97-4e2e-bd31-ded7bd2d1a56": {
        "text_answer": "10 out of 25 patients showed stable disease at week 24 so the statement is not entirely accurate However it is true that more than half of the patients 15 out of 25 did not have a complete or partial response by week 24 Therefore a more accurate statement might be More than half of the patients did not have a response by week 24",
        "label": "Entailment"
    },
    "8b37f698-edfb-4e34-b0da-4a5287506d02": {
        "text_answer": "No  The statement individuals having suffered a stroke transient ischemic attacks or have evidence of an intrabdominal abscess in the past 6 months are allowed to be a part of the primary clinical trial is not entailed by the evidence The evidence states that such individuals are excluded from the trial",
        "label": "Contradiction"
    },
    "9c272853-cec0-43f0-9897-4657c5fd0b78": {
        "text_answer": "No  Explanation The primary trial includes a criterion for the primary tumour to have a diameter greater than 2 cm while the statement mentions a radius of 3000m which is not directly comparable to the diameter criterion Additionally the secondary trial does not have a specific criterion for the size of the primary tumour Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "8f31a3bf-d5a9-4f2c-95bb-c9ff01de6d42": {
        "text_answer": "Yes  Explanation The evidence states that 20 out of 35 participants in cohort 1 the group receiving aprepitant dexamethasone cytoxan and kytril experienced no signs of acute vomiting after receiving the treatment This means that every patient in this cohort met the outcome measurement of having no episodes of vomiting and no rescue medication during the first 24 hours",
        "label": "Entailment"
    },
    "21fdf78c-fdbf-4140-9056-d3bfd2e9de27": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the alloMSCs and placebo interventions differ in their compositions with alloMSCs being the actual treatment and placebo being a buminate solution Despite the identical dosages and administration methods the interventions themselves are not identical",
        "label": "Contradiction"
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "text_answer": "No   Explanation   The primary trial measures hot flash activity using a composite score of severity and frequency with a unit of measure of units on a scale The secondary trial measures overall response rate as a proportion of responders with a unit of measure of proportion These are not the same units of measure",
        "label": "Contradiction"
    },
    "669ed7b4-398b-4604-8065-04e99611691d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial did have a placebo group Arm II and the secondary trial did have a test group Highdose Oxybutynin Chloride Group The statement incorrectly describes the presence or absence of placebo and test groups in each trial",
        "label": "Contradiction"
    },
    "5d1997bd-e77f-43dd-abd1-eb1da8819d47": {
        "text_answer": "No  Explanation The statement small cell component present is a morphologic finding that refers to the presence of a small cell component in a cellular infiltrate is not directly related to the intervention described in the evidence The evidence only mentions the intervention as MM111 without providing any information about its method of administration dosage or cycle Therefore the statement cannot be determined to be entailed by the evidence based on the",
        "label": "Contradiction"
    },
    "8839dd14-8457-44c0-88a1-8bb0764e326c": {
        "text_answer": "No  Explanation  The statement a larger percentage of participants in the primary trial were reported to have experienced chest pain than in the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not mention chest pain as an adverse event in either trial",
        "label": "Contradiction"
    },
    "42a68b8b-0bed-49f4-8430-12e031c56471": {
        "text_answer": "No  Explanation The evidence does not provide any information about the presence or absence of a distinguishable gene expression pattern in participants with normal vitamin D levels The statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "4d6b0c89-c9fc-4195-ac3e-c33b28af955e": {
        "text_answer": "Yes The primary clinical trial has different inclusion criteria for individuals aged 1850 and those aged 50 refer to the document for details",
        "label": "Entailment"
    },
    "fbd56c1d-5153-46c0-bd88-ed90eb1c9345": {
        "text_answer": "No  Explanation  The statement the most common adverse event observed in the primary clinical trial is general symptoms is not entailed by the evidence provided The evidence states that the frequency of general symptoms is 392 which is not the highest among the listed adverse events The highest frequency is shared by nausea vomiting and general symptoms each with a frequency of 392 Therefore the statement is not",
        "label": "Contradiction"
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "text_answer": "Yes  Explanation  The statement 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 30 of patients apart from Skin infections is entailed by the evidence provided The evidence states that there were no adverse events in the primary trial and in the secondary trial the frequency of each adverse event is listed with only skin infections affecting more than ",
        "label": "Entailment"
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "text_answer": "No  Explanation  The statement intervention 1 in the primary trial and all intervention drugs in the secondary trial must be administered intravenously is not entailed by the evidence In the primary trial zoledronic acid in intervention 1 is given intravenously but the other interventions and the secondary trial do not specify that all drugs must be given intravenously",
        "label": "Contradiction"
    },
    "3f26cd3e-2b66-4bbc-94b4-498df2e334e3": {
        "text_answer": "Yes The primary trial does not involve any drugbased interventions while the secondary trial tests different doses of a drug PF06647020 based on its effects The statement is consistent with the information provided in the evidence",
        "label": "Entailment"
    },
    "d1d340f9-f31f-4469-804b-41853562fa57": {
        "text_answer": "No  Explanation  The statement warfarin based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly stated in the provided evidence The evidence only mentions that lowdose warfarin less than or equal to 1 mgday is permitted for the primary trial For the secondary trial warfarin is excluded if the prothrombin time is 1",
        "label": "Contradiction"
    },
    "7d22f8db-6793-46e2-88ca-2d464ecf9789": {
        "text_answer": "Yes The evidence states that in the primary clinical trial neither the cohort with normal vitamin D levels nor the cohort with lownormal vitamin D levels showed a discernible pattern for the expression of the 40 genes examined",
        "label": "Entailment"
    },
    "ba8e855f-8cff-474d-a2dd-d5061a039b47": {
        "text_answer": "Yes The statement mentions the occurrence of Anaemia and Febrile neutropenia in cohort 1 which is consistent with the evidence The statement does not mention Pancytopenia which is also consistent with the evidence as no cases were reported in cohort 1",
        "label": "Entailment"
    },
    "3c558a0b-1e1a-4d42-af75-266ea0d93662": {
        "text_answer": "Yes  Explanation  The statement 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group can be derived from the given evidence The evidence states that 286 131492 of ERpositive Luminal B participants and ",
        "label": "Entailment"
    },
    "4c8ee685-13af-44a4-8d1e-30105f8469af": {
        "text_answer": "No   Explanation   The statement haploidentical is a donor who has only one haplotype in common with the recipient is not directly related to the evidence provided in the primary and secondary trials The primary trial reports the results of a study comparing the effectiveness of fentanyl sublingual spray and placebo in treating breakthrough pain in cancer patients while the secondary trial reports the results of a study comparing the effect of",
        "label": "Contradiction"
    },
    "526a5650-0b61-4e6e-9ddf-4674a6193964": {
        "text_answer": "No  Explanation  The statement unconfirmed progressive disease is a disease process that is increasing in scope or severity but the criteria for progressive disease is not met is not directly mentioned or entailed by the evidence provided in the inclusion and exclusion criteria for the primary and secondary trials The statement refers to a disease condition while the evidence only provides criteria for patient eligibility and exclusion in the context of the clinical trials",
        "label": "Contradiction"
    },
    "6b90da92-6aaa-431b-b31c-8df9def4a98d": {
        "text_answer": "Yes The ECOG score of 1 is mentioned as an inclusion criterion in both trials The statement does not mention cdk4 gene mutation but it is not in conflict with the evidence",
        "label": "Entailment"
    },
    "2a13f623-4957-4e7e-9968-03f64bb6f5f3": {
        "text_answer": "Yes The statement is entailed by the evidence as both Intervention 1 and Intervention 2 include anthracyclinebased chemotherapy doxorubicin given on days 1 8 and 15",
        "label": "Entailment"
    },
    "41756298-3326-499e-99f5-f34bcf718cbe": {
        "text_answer": "Yes The evidence provides the inclusion and exclusion criteria for both trials and fibromyalgia thalasemic syndromes and anemia are listed as exclusion criteria for one or both trials Therefore a patient with any of these conditions cannot be eligible for both trials",
        "label": "Entailment"
    },
    "f442b08f-4429-412f-99d2-24625bf8bdcd": {
        "text_answer": "  Neutral The statement does not directly relate to the information provided in the evidence  Explanation  The statement feel worn out is not directly related to the information provided in the evidence The evidence only mentions the interventions used in the primary trial which are administered through the same routes IV for bisphosphonate and subcutaneous injection for denosumab but it does not provide any information about how the participants",
        "label": "Entailment"
    },
    "0add45e1-cc70-4f0d-b2c7-14c67e9cd3ee": {
        "text_answer": "No   Explanation  The statement a frequent adverse event in the secondary trial anaemia was not observed during the primary trial is not entailed by the evidence The evidence only states that anaemia was observed in 234 of participants in the secondary trial but it does not mention that it was not observed in the primary trial The statement goes beyond the information provided in the evidence by making a comparison between",
        "label": "Contradiction"
    },
    "a141432b-385e-4cd4-87e4-acc0e3e9f412": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results does not directly support the statement about a 10 increase in recurrencefree survival for the Ketorolac 30 mg group compared to the NaCl 09 3ml group The evidence only shows the number of participants in each group and their recurrencefree survival rates To determine if there was a 10 increase in recurrence",
        "label": "Contradiction"
    },
    "47468741-3624-4321-90ee-1c680a293b25": {
        "text_answer": "No  Explanation The statement mentions 5 total cases of asthenia and 3 total cases of pyrexia but the evidence only provides the number of adverse events for each trial not the specific types of adverse events Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "e44e25b6-1be6-4c35-a3c9-417c56052939": {
        "text_answer": "No   Explanation  The evidence provided in the trial description does not mention paclitaxel as being incorporated into either therapeutic intervention Arm A or Arm B The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "fd4c7d94-8d93-46b1-b467-3f169c6af30e": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of ER or PR in the inclusion criteria for the clinical trial",
        "label": "Contradiction"
    },
    "a842c232-d17b-4257-84ff-02be26716c47": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2 to 38 Subtracting the Ki67 expression at 6 weeks from the Ki67 expression at baseline we get a reduction of 5 1510 To find the percentage reduction we divide this difference",
        "label": "Entailment"
    },
    "f33d7123-34a6-4466-98d2-9c69b18ac544": {
        "text_answer": "Yes The statement is entailed by the evidence as individuals with a history of interstitial lung disease or pneumonitis are excluded from the trial",
        "label": "Entailment"
    },
    "6bbcd12e-4105-478b-a402-1374ce8a01df": {
        "text_answer": "Yes The evidence states that women of childbearing potential and sexually active fertile men are eligible for the trial but they must use acceptable methods of birth control to avoid pregnancy during the study period and for 6 months after treatment with bevacizumab The statement focuses on the requirement of abstinence for the entire study period which is a specific type of birth control method Therefore the statement is entailed by the evidence  However it",
        "label": "Entailment"
    },
    "3793f6d8-1a56-48aa-b3d3-1216f7bf5d29": {
        "text_answer": "No  Explanation  The statement maculopapular Rash was a common adverse event for the primary trial participants is not directly related to the presence or absence of an eosinophilic infiltrate The evidence only reports the occurrence of a maculopapular rash as one of the adverse events but it does not provide any information about the nature of the inflammatory infiltrate",
        "label": "Contradiction"
    },
    "72278411-1c4b-4c70-b6ab-72c4c8449ec4": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial has seen a higher prevalence of biliary colic while instances of diarrhoea are more common in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had 4 instances of biliary colic out of 122 participants 328 while the secondary trial had 1 instance of biliary colic out of 6 participants",
        "label": "Entailment"
    },
    "10db152d-ae00-4b31-8c05-a1db1dee76b4": {
        "text_answer": "No  Explanation  In the primary clinical trial the dosage of trastuzumab given to Her2 patients is 2 mgkg per week for the maintenance phase In contrast in the second cohort of the secondary clinical trial the dosage of trastuzumab given to Her2 patients is 4 mgkg as a loading dose followed by 2 mgkg per week for the maintenance phase Therefore",
        "label": "Contradiction"
    },
    "282cb769-7825-4b3e-b089-05a6103f60ff": {
        "text_answer": "No  Explanation  The statement A 20 year old female patient with a Newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial and the primary trial is not directly related to the question about discomfort or pain in the affected underarm arm or hand The evidence provided in the trial inclusion criteria does not mention anything about discomfort or pain in the affected area",
        "label": "Contradiction"
    },
    "892e63ba-619c-4458-8130-89bbac726edb": {
        "text_answer": "No  Explanation The statement the majority of patients in the primary clinical trial experienced a certain type of adverse event is not entailed by the evidence The evidence lists several different types of adverse events and their frequencies but it does not provide enough information to determine that the majority of patients experienced the same type of adverse event",
        "label": "Contradiction"
    },
    "4a349ab7-7fd2-4979-bf94-4e563c26b7f9": {
        "text_answer": "No  Explanation The statement patients suffering from stage 4 invasive breast carcinoma with positive estrogenprogesterone receptors and thinking about ai therapy could be potential candidates for the primary clinical trial is not entailed by the evidence The evidence only mentions patients with histologically proven DCIS or stage IIII invasive carcinoma as potential candidates for the clinical trial",
        "label": "Contradiction"
    },
    "0d633cc2-339a-4caf-b252-ce50b826e3e3": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "28f840e3-3970-4ec7-ac46-d0503d56ee57": {
        "text_answer": "Yes The primary trial measures tumor response using RECIST criteria but does not report the percentage of participants experiencing clinical benefit The secondary trial measures various correlative studies and qualityoflife assessments but does not report clinical benefit using RECIST criteria",
        "label": "Entailment"
    },
    "674d7d6c-723a-44db-9e96-10aa21dcefe4": {
        "text_answer": "  Yes The evidence reports the outcome measurement as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes in both the first and second patient cohorts However the statement specifically mentions the first and second patient cohorts so it is directly related to the evidence",
        "label": "Entailment"
    },
    "c04ed14d-5ed2-46a6-9b0c-6a30a3b9a7b2": {
        "text_answer": "No  Explanation  The statement cholelithiasis was less common in primary trial participants compared to the secondary trial participants is not entailed by the evidence provided The evidence only shows that cholelithiasis was not reported in any participants in the secondary trial but it was also not reported in any participants in the primary trial Therefore the absence of an adverse event in both trials does not allow for a comparison of the frequency of",
        "label": "Contradiction"
    },
    "8983bf9f-d977-4238-91df-2435d2eb4a38": {
        "text_answer": "No  The statement is not entailed by the evidence provided The evidence indicates that there were no cases of acute myocardial infarction reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "9d330063-37a8-4c8e-8ac2-f28c8048d0be": {
        "text_answer": "Yes  Explanation  The statement eyelid oedema and chest pain were the sole adverse event types noted in patients from the secondary clinical trial in contrast the primary clinical trial recorded none is entailed by the evidence as the evidence shows that eyelid oedema occurred in 18 patients in the secondary trial and chest pain occurred in 16 patients in the secondary trial while no adverse events of these types were",
        "label": "Entailment"
    },
    "5e23cc12-12c7-42e9-ab55-595bb427adad": {
        "text_answer": "Yes The statement that Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is entailed by the evidence as severe insomnia is listed as an exclusion criterion in both trials",
        "label": "Entailment"
    },
    "5f45e043-f49d-42cd-941d-baa17257d46c": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the evidence only reports the number of participants in each group who were analyzed for Recurrencefree Survival but it does not provide the actual number of participants who experienced Recurrencefree Survival in each group",
        "label": "Contradiction"
    },
    "5fff07e2-11f3-4a58-aecb-ce4650dd35f6": {
        "text_answer": "Yes The statement that an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial is entailed by the evidence as interstitial lung disease or pneumonitis is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "6b257ade-83bb-428c-a623-056f1ad56594": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only pertains to breast cancer and the requirements for participation in a clinical trial for advanced breast cancer with hormonesensitive tumors",
        "label": "Contradiction"
    },
    "a146a89a-9519-4515-b36a-b5f365481341": {
        "text_answer": "No  Explanation  The statement the primary clinical trial registered no instances of anaemia and febrile neutropenia in cohort 1 is not entailed by the evidence The evidence shows that there was one instance of anaemia and one instance of febrile neutropenia in cohort 1 Therefore the statement is not accurate based on the provided evidence",
        "label": "Contradiction"
    },
    "dabe9e76-e44c-45be-87b0-337fde45ab98": {
        "text_answer": "No  Explanation The statement most of the patients participating in the primary clinical trial had a full recovery by the 24th week is not entailed by the evidence The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at weeks 12 and 24 It does not indicate that most participants had a full recovery as some participants had stable disease which does not equate to a",
        "label": "Contradiction"
    },
    "ff7079ec-d642-4cc3-8767-62df7a2a8ff7": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare abilities and may be confined to bed or chair for more than 05 of waking hours",
        "label": "Entailment"
    },
    "06609fde-0f22-485a-ba1c-78c2677d8783": {
        "text_answer": "Yes The statement is entailed by the evidence as it accurately reflects the reduction in Ki67 expression observed in the TAK228 Plus Tamoxifen arm of the trial The statement does not mention Microbacterium so it is not directly related to that information in the evidence",
        "label": "Entailment"
    },
    "8b3c9b3e-41e8-46fb-b975-db35e552ec6c": {
        "text_answer": "No  Explanation  The statement zero percent of individuals in group 1 of the primary clinical trial displayed any lesions in contrast over ninety percent of participants in group 1 of the secondary clinical trial exhibited symptoms of radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The primary clinical trial involved healthy volunteers and breast cancer patients undergoing MRI scans and the outcome measurement was the",
        "label": "Contradiction"
    },
    "0cfa6770-4d70-4603-865b-512957909993": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly states that the secondary trial does not require any injection while the evidence shows that the secondary trial involves the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "363212ed-da18-4ae4-a7e5-cab37c207a24": {
        "text_answer": "Yes The evidence includes criteria related to worry or concern specifically regarding the subjects ability to swallow and retain oral medication and their ability to understand and provide informed consent",
        "label": "Entailment"
    },
    "189e7142-d6fd-49d6-8e4f-44383f00781b": {
        "text_answer": "No   Explanation   The statement both the primary and secondary clinical trials accept patients with an unproven diagnosis of late stage breast adenocarcinoma that tests ER negative PR negative and HER2neu positive is not entailed by the evidence provided   The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma and radiographic evidence of bone metastases but",
        "label": "Contradiction"
    },
    "b6109c91-afac-46ff-b306-bd9a5f1bba84": {
        "text_answer": "No   Explanation The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study Therefore the statement that the primary clinical trial allows the inclusion of patients who have had serious anaphylactic reactions to trastuzumab in the past is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c2b8b1b0-9d84-498a-b490-e3da298f1087": {
        "text_answer": "Yes The primary trial measures tumor diameter in centimeters while the secondary trial measures response to treatment in participants with solid tumors",
        "label": "Entailment"
    },
    "09df9e5c-cc03-4c01-858b-0886376e9b7a": {
        "text_answer": "Yes The evidence states that less than 54 of the participants had a reduction in circulating tumor cells which is consistent with the statement that less than 54 of the primary trial participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products",
        "label": "Entailment"
    },
    "3c596e8f-b1a2-4ded-b15b-99784b540d76": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500000 mcg of fulvestrant in a tablet form to be taken bid is not entailed by the evidence  The primary trial describes the use of whole breast radiation therapy for breast cancer patients but it does not mention the dosage or form of fulvestrant administered in the trial",
        "label": "Contradiction"
    },
    "56ab098d-56f4-401e-a173-a0c99cd8efd0": {
        "text_answer": "  Yes the statement is entailed by the evidence for the secondary trial but not for the primary trial as it has different inclusion criteria",
        "label": "Entailment"
    },
    "a0f34f76-d0dd-48f3-b916-1722ecb924c2": {
        "text_answer": "Yes The statement does not contradict the evidence as both the statement and the evidence indicate that there were no reported adverse events related to skin conditions in the primary trial",
        "label": "Entailment"
    },
    "742cd2e5-1335-4daa-87b0-47727f61d8a1": {
        "text_answer": "Yes  Explanation The evidence states that patients receive oral lapatinib once daily on days 128 with a dose of 200mgm2 Therefore the statement patients participating in the primary trial receive 200mgm2 oral lapatinib once a day for a full month is entailed by the evidence",
        "label": "Entailment"
    },
    "2062b384-c6c1-4997-a4e4-b6709d123502": {
        "text_answer": "No  Explanation The statement participants in the primary clinical trial were found to have cholelithiasis at a rate two times higher than those in the secondary clinical trial is not entailed by the evidence provided The evidence only shows that there were no cases of cholelithiasis reported in the secondary trial while there was one case in the primary trial It does not provide enough information to determine that the rate was two times higher",
        "label": "Contradiction"
    },
    "6bb59504-e102-48d6-ac0d-8ce71100b726": {
        "text_answer": "Yes  Explanation The statement Both cohorts of the primary trial receive the same dosage of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial at the same frequency is entailed by the evidence as both interventions have the same dosage and frequency for Doxorubicin and Cyclophosphamide and the same dosage for Docetaxel",
        "label": "Entailment"
    },
    "08a467b9-3bf6-486f-9975-4e2b67a5b690": {
        "text_answer": "Yes The secondary trial specifically includes patients with diagnosed alterations in the listed genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ GNA11 as a requirement for participation The primary trial does not have this requirement",
        "label": "Entailment"
    },
    "379dbb6e-e70b-4e6c-83a9-c332b84592dd": {
        "text_answer": "Yes The evidence mentions significant cardiovascular impairment as an exclusion criterion for both trials",
        "label": "Entailment"
    },
    "6b901ca0-1ec8-4d36-b43d-dcc6bf63b70f": {
        "text_answer": "No  Explanation  The statement does not provide any information about the relationship between the adverse events and hexadecadienoic acid The evidence only reports the number and percentage of adverse events in two different cohorts of a trial The statement is about hexadecadienoic acid but the evidence does not mention it in relation to the adverse events Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry",
        "label": "Entailment"
    },
    "1e2b550a-0da3-48ea-8221-1a8b86e10511": {
        "text_answer": "Yes The statement is entailed by the evidence as there are no recorded cases of anorexia hypothermia or hallucinations in either trial The unit of concentration mentioned in the statement is not relevant to the entailment",
        "label": "Entailment"
    },
    "5a96ef9e-57ed-4f5a-95b3-db64e3268993": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement mentions myalgias being administered to group 2 of the primary trial but the evidence only mentions the administration of dexmedetomidine or normal saline in the primary trial and does not mention any administration of myalgias In the secondary trial no myalgias are mentioned being administered to any patients",
        "label": "Contradiction"
    },
    "2660009c-449a-4edb-a64a-20164527c99d": {
        "text_answer": "No  Explanation  The statement none of the patients receiving the sunitinib  docetaxel  trastuzumab treatment in the primary clinical trial reported any treatmentemergent adverse events is not entailed by the evidence The evidence states that there were 24 treatmentemergent adverse events in total among the 25 participants receiving the sunitinib  docetaxel  trastuzum",
        "label": "Contradiction"
    },
    "5b100056-e657-4b2a-9ecf-8b949233ab50": {
        "text_answer": "No  Explanation  The statement the primary clinical trial reported at least one gastrointestinal side effect and two psychiatric events is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events observed in the primary clinical trial but it does not specify that there were exactly one gastrointestinal side effect and two psychiatric events The evidence only shows that there were a total of 3",
        "label": "Contradiction"
    },
    "fa664989-b970-41f4-b491-dd2aeb308dd1": {
        "text_answer": "No  Explanation  The statement the only types of adverse events observed in patients from the primary clinical trial were hypertension angina pectoris and dizziness no adverse events were recorded in the secondary clinical trial is not entailed by the evidence provided The evidence only lists the types and frequencies of adverse events observed in each clinical trial for various conditions but it does not state that these were the only adverse events observed for",
        "label": "Contradiction"
    },
    "bc686408-6e00-414a-b5a4-2bae034aca57": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for the trial",
        "label": "Entailment"
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "text_answer": "Yes The statement mentions Anaemia and Febrile neutropenia which are both adverse events recorded in cohort 1 of the primary trial The statement does not mention Pancytopenia but the evidence shows that no cases of Pancytopenia were recorded in cohort 1 However the statement is not contradicted by the evidence",
        "label": "Entailment"
    },
    "fe6c20be-e0c6-461c-9e93-cef55bdd7902": {
        "text_answer": "No  Explanation  The statement chemotherapy or radiotherapy patients from the last 2 weeks those with unstable angina and patients with grade 2 or above neuropathy are qualified for participation in the secondary clinical trial but are not allowed in the primary clinical trial is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the primary and secondary clinical trials The statement makes a generalization about",
        "label": "Contradiction"
    },
    "6b5a90bf-c45f-4a85-807f-1f184463cf5f": {
        "text_answer": "No  Explanation  The statement after undergoing treatment with aprepitant dexamethasone cytoxan and kytril in cohort 2 of the primary clinical trial acute vomiting was reported by over 50 of the patients is not directly entailed by the evidence provided The evidence only states that 20 out of 35 participants in cohort 1 and ",
        "label": "Contradiction"
    },
    "eb8737bb-19f6-4249-83da-63b05b251084": {
        "text_answer": "No  Explanation  The statement cohort 1 and cohort 2 of the primary clinical trial receive neither 25 mg of sunitinib nor 90 mgm2 paclitaxel is not entailed by the evidence provided The evidence states that in cohort 1 sunitinib can be escalated to 375 mg daily after Cycle 1 and paclitax",
        "label": "Contradiction"
    },
    "d303ce9d-a00a-4ee7-8147-0bac063ee210": {
        "text_answer": "Yes The adverse event type General disorders and administration site conditions  Other disease progression impacted 2 participants in the primary clinical trial",
        "label": "Entailment"
    },
    "f34e13a3-4463-4cf4-8a15-79872282b90e": {
        "text_answer": "Yes The primary trial specifies Japanese females as applicants while the secondary trial does not have such a specification",
        "label": "Entailment"
    },
    "5cc13d6e-bc37-47d3-8198-8e7af5a8b5a2": {
        "text_answer": "Yes children are not explicitly included or excluded in the secondary trial",
        "label": "Entailment"
    },
    "4d3272e0-735a-4531-9f23-c0e4660c64a5": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "dd33f2de-6bfc-4a27-95da-630c9f0c0574": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity weight or gender as eligibility criteria for either trial",
        "label": "Entailment"
    },
    "d81e386d-9799-44bc-b006-8fdd7c14103c": {
        "text_answer": "No  Explanation The statement in the question is not entailed by the evidence provided The primary trial mentions a dosage of 150 mg of oral pregabalin twice daily not 1000 mg The secondary trial mentions the use of Depocyt and HDMTX but there is no mention of pregabalin in that trial",
        "label": "Contradiction"
    },
    "7bad3ae8-835f-401c-b50d-10e2f2773cc7": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not support the statement as it only reports the number of participants in each group and their recurrencefree survival percentages but it does not provide the actual recurrencefree survival data or the difference between the two groups",
        "label": "Contradiction"
    },
    "09816bed-e4f7-4b1c-8599-fbc623fa9675": {
        "text_answer": "Yes The secondary trial intervention lasts for 24 weeks which is 10 weeks primary trial  14 weeks",
        "label": "Entailment"
    },
    "103f19bc-87b9-4017-b2d8-8afd8bc54157": {
        "text_answer": "No  The evidence provided does not mention radiation therapy at all",
        "label": "Contradiction"
    },
    "b1695ed3-b79e-4e1a-8658-52f33b997fea": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b7d7f9f1-1e62-403f-9ceb-234108f7569f": {
        "text_answer": "Yes The primary trial includes stage IIbIIIIV breast cancer patients while the secondary trial excludes patients with metastatic disease",
        "label": "Entailment"
    },
    "2853d135-6a33-4c1f-bf2c-251ef936c5dd": {
        "text_answer": "No  Explanation  The statement 025 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not entailed by the evidence The evidence states that the frequency of increased pleural effusion is 113 769 in the first trial and 14 2500 in the second trial However it does not provide any information about the number of",
        "label": "Contradiction"
    },
    "d8d3ab61-0fc8-462a-930b-114b2363d70a": {
        "text_answer": "No  The statement is not entailed by the evidence as some adverse events affected less than 100 of patients",
        "label": "Contradiction"
    },
    "8e18ed71-8fa4-4d81-841d-ce718daa0f41": {
        "text_answer": "Yes Patients with tumors positive for CCND1 amplification are eligible for the primary clinical trial according to the inclusion criteria",
        "label": "Entailment"
    },
    "4acaf50b-e6af-497a-a0d2-709e5780dd0b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the number of participants in each arm who achieved a pathologic complete response in the breast and axillary lymph nodes at the time of surgery approximately 7 months after the start of treatment It does not provide information about the number of participants who achieved a pathologic complete response around 210 days after the surgery which is not mentioned in the trial Therefore the",
        "label": "Contradiction"
    },
    "a752838e-30be-4438-913e-e905d2893abc": {
        "text_answer": "Yes The secondary trial does not explicitly list tobacco use as an exclusion criterion",
        "label": "Entailment"
    },
    "4e4b2acf-c921-4f0d-b9e9-6a54fe5d9877": {
        "text_answer": "No  Explanation  The statement none of the participants in group 1 of the primary trial were found to have lesions and more than 90 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation have difficulty planning for future due to illness is not entailed by the evidence The evidence only provides information about the number of lesions detected in the primary trial and the number",
        "label": "Contradiction"
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "text_answer": "Yes Both trials include Japanese females as eligible participants",
        "label": "Entailment"
    },
    "e658eb5e-3411-4dcb-bff2-6bad677ac1a7": {
        "text_answer": "No  Explanation The evidence provided in the primary trial relates to the percentage change in serum beta Cterminal crosslinking telopeptide of Type I Collagen betaCTX at Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided in the question is about the primary tumour diameter which is not mentioned in the evidence Therefore",
        "label": "Contradiction"
    },
    "3f4231c5-0eae-43eb-b0df-b270cea08476": {
        "text_answer": "No  Explanation The evidence provided in the primary clinical trial results indicates that the proportion of participants who were up to date for cervical cancer screenings increased from 423 at baseline to 616 at followup for the Collaborative Care Intervention CCI group and from 417 at baseline to 646 at followup for the Prevention Care Management PCM",
        "label": "Contradiction"
    },
    "6fdb953d-a7b8-41b9-8652-2d8b51bfcaa0": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not specify that all or any of these patients are administered 1000 mcg of talazoparib daily The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9a111f3a-a29a-42fa-bf73-9f178286198c": {
        "text_answer": "Yes  Explanation  The statement tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40 on average is entailed by the evidence as it is explicitly stated in the results section of the evidence that the mean percentage change in Ki67 was 40 63 to 29",
        "label": "Entailment"
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "text_answer": "Yes  Explanation The statement There was one case of shingles recorded in group 2 of the secondary trial but no cases in group 1 of the secondary trial and the primary trial is entailed by the evidence as the evidence shows that there was indeed one case of shingles in group 2 of the secondary trial and no cases were reported in group 1 of the secondary trial or in either trial for the primary adverse event data",
        "label": "Entailment"
    },
    "4d5acda5-74be-4228-a24e-bcd405ac6af4": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a95eba72-3c28-4c9b-a79f-011f1578907c": {
        "text_answer": "No  Explanation  The statement past treatment with gabapentin or herceptin within the last three months is necessary for inclusion in the secondary trial but will result in exclusion from the primary trial is not entailed by the evidence provided  The primary trial has exclusion criteria that include a history of hypersensitivity or allergic reaction to Herceptin but it does not mention anything about gabapentin or past treatment with",
        "label": "Contradiction"
    },
    "88e7acab-bd9d-4e6c-a241-c538501824e8": {
        "text_answer": "No  Explanation The statement perform chores is a question about an individual performing chores such as housework shopping groceries is not directly related to the evidence provided about the primary trial The evidence only mentions the administration of Sunitinib and Capecitabine in the trial and does not provide any information about the patients ability to perform chores or any impact of the treatment on their ability to do so",
        "label": "Contradiction"
    },
    "985ff367-3936-4e38-92e7-45e1cb9f24ee": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the adverse events noted in the primary trial are related to various medical conditions such as anemia lymphopenia neutropenia thrombocytopenia edema and changes in electrolyte levels while the secondary trial also includes adverse events such as anemia platelet count decreased hypocalcemia and hyp",
        "label": "Contradiction"
    },
    "1e826f28-5a81-4123-95f7-74418392ed90": {
        "text_answer": "No  Explanation The statement participants in the primary clinical trial receive a diverse drug regimen each not exceeding a dose beyond 50 mgm2 is not entailed by the evidence The evidence describes the specific drugs and doses used in the neoadjuvant therapy regimen which exceeds the 50 mgm2 limit mentioned in the statement",
        "label": "Contradiction"
    },
    "cdc80bd8-0b1c-4908-9095-74a1a7078e43": {
        "text_answer": "Yes  Explanation The evidence states that in Intervention 2 patients receive 600 mgm2 of Cyclophosphamide while in Intervention 1 they receive 600 mgm2 as well However the amount of Docetaxel administered in Intervention 2 is 75 mgm2 which is greater than the amount of Eribulin given in Intervention 1",
        "label": "Entailment"
    },
    "2fa66862-310e-454e-a0d6-5e3ef0ec1e2d": {
        "text_answer": "Yes  Explanation The evidence states that at Week 12 there were 12 participants with SD and at Week 24 there were 10 participants with SD The statement in the question correctly identifies that there were more participants with SD at Week 24 compared to Week 12 The statement also mentions instances of complete response during both weeks which is also supported by the evidence 0 participants with CR at both weeks",
        "label": "Entailment"
    },
    "4a47dcda-1105-46c5-8f3d-ffbfe5259d70": {
        "text_answer": "No   Explanation   The primary trial measures hot flash activity using a composite score of severity and frequency while the secondary trial measures overall response rate as a proportion of responders These are not the same metric units",
        "label": "Contradiction"
    },
    "af1e26a0-09d7-408f-89ec-be5bf4bfc88c": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial patients in the fast shallow respiration group experienced fewer hot flashes per day on average than those in the paced respiration intervention group is not entailed by the evidence provided The evidence only shows that the mean number of hot flashes per day was higher in the paced respiration group 348 compared to the fast shallow breathing group 395",
        "label": "Contradiction"
    },
    "1ec46b05-25a0-45c2-a6aa-31f5a2209ac5": {
        "text_answer": "No  Explanation  The statement global complete response in blood is a score of b0 by repeat bone marrow biopsy with no residual disease is not directly related to the adverse events data provided in the evidence The evidence only reports the number and types of adverse events experienced by patients in the primary trial but it does not provide any information about their response to treatment or the results of their repeat bone marrow biopsies Therefore",
        "label": "Contradiction"
    },
    "056fccd5-f005-4088-8f9b-c22b87eaa371": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e7e2f4af-f6c2-47cc-b03e-6e69210d14c7": {
        "text_answer": "Yes The evidence shows that the median survival times for both groups are less than 3 years but some patients survived for longer than 4 years Therefore on average patients survived for more than 4 years but not every patient did",
        "label": "Entailment"
    },
    "542ebedc-ffda-406e-9ef5-d2f9edc30ac1": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence regarding the administration of capecitabine in the primary trial",
        "label": "Entailment"
    },
    "e6fb96bc-d38b-484e-8d2a-fe14f943c599": {
        "text_answer": "  No   Explanation   The statement eligible for the primary clinical trial are patients who had a severe anaphylactic reaction to herceptin treatment or did not respond to treatment with herceptin in the past is not explicitly stated in the inclusion criteria of the evidence The evidence only mentions that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial Therefore",
        "label": "Contradiction"
    },
    "c3d9b60a-a46e-4bde-9e4a-46db5c2d75ba": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial is not about pills but rather about different types of topical treatments Hydrophor and MediHoney and the secondary trial is also about topical treatments but with different doses of the same medication PF05212384",
        "label": "Contradiction"
    },
    "b9f4eb6e-b05b-44e8-b92d-62624cc71935": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the outcome measures of the two trials are not related to each other The primary trial investigates the effects of sulforaphane supplementation on isothiocyanate levels in urine while the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "be8707c6-9004-4fab-b719-c1ab372a77a1": {
        "text_answer": "No  The statement is not entailed by the evidence as the inclusion criteria do not specify that patients must have invasive lobular carcinoma and be undergoing chemotherapy to be eligible for the trial The criteria only state that patients may have received preoperative chemotherapy",
        "label": "Contradiction"
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "text_answer": "29 The evidence reports 24 AEs and 11 SAEs for a total of 35 events among 25 participants However the statement asks for the number of participants who suffered a TreatmentEmergent adverse event which is not explicitly stated in the evidence but can be inferred as the sum of AEs and SAEs  Corrected statement Yes",
        "label": "Entailment"
    },
    "74866fee-c33b-4df9-8d5c-28b47182b753": {
        "text_answer": "No   Explanation   The statement the treatment in the primary trial progresses in a continuous manner without a repeated cycle however the secondary trial operates on a rigorous 3 weeks cycle is not entailed by the evidence   In the primary trial the treatment is given in cycles of 21 days with PF05212384 given on Days 7 and 2 and docetaxel",
        "label": "Contradiction"
    },
    "96be8dc9-8873-475f-b91f-e92f3549861b": {
        "text_answer": "Yes  Explanation  The statement the height criterion for the primary clinical trial disqualifies children and adolescents but the secondary clinical trial does not expressly exclude them is entailed by the evidence because  1 The primary clinical trial includes the criterion Postmenopausal women as an inclusion criterion which implies that children and adolescents are excluded due to their premenopausal status",
        "label": "Entailment"
    },
    "d82bb7da-6579-43be-969a-206d2235afd3": {
        "text_answer": "Yes  Explanation The statement in the course of the study period more than 15 of patients in the primary clinical trial and the secondary clinical trial experienced infections is entailed by the evidence since the primary trial had 1 patient 132 with infection 313 and the secondary trial had 1 patient 115 with infection 667 The total number of patients in both trials",
        "label": "Entailment"
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "text_answer": "No   Explanation   The primary and secondary trials report results from different patient cohorts and different outcome measurements The primary trial reports the percentage of participants with a response within 10 days of first dose of denosumab while the secondary trial reports the number of patients who reached a safe and well tolerated dose of dmethadone over a period of 2 years There is no overlap in patient populations or outcome measurements between the",
        "label": "Contradiction"
    },
    "cbcecc39-a187-40ca-86cf-06d9c75ff972": {
        "text_answer": "Yes The evidence does not explicitly state that all Japanese individuals are eligible for both trials but it does not exclude them either Therefore the statement is entailed by the evidence as a possibility",
        "label": "Entailment"
    },
    "2f30372d-c143-495d-96d9-ad238ff94baf": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the evidence describes the interventions given to each cohort in the clinical trial which include dexamethasone but it does not state that dexamethasone is an exclusionary criterion The statement makes a stronger claim than what is provided in the evidence",
        "label": "Contradiction"
    },
    "2db5cad0-f216-4e18-accf-87e3308afc59": {
        "text_answer": "No   The secondary clinical trial is not based on the alterations in MYMOP score but rather on the changes in isothiocyanate in urine samples",
        "label": "Contradiction"
    },
    "71f1d2c6-7ab2-45d2-bb54-a0cad79d244b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement is about HER2 metastases in PR primary breast cancer patients while the evidence is about HER2 primary breast cancer patients and the percentage of those who developed HER2 metastases using HER2targeted PETCT with 89Zrtrastuzumab",
        "label": "Contradiction"
    },
    "1dd07ae9-349c-41e1-b967-fd8691e320e0": {
        "text_answer": "No  Explanation  The statement patients who have received chemotherapy or radiotherapy in the last 4 weeks suffer from unstable angina or have grade 3 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the primary and secondary",
        "label": "Contradiction"
    },
    "aa25fae6-9d48-4237-92d0-504cfc8af672": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it makes an incorrect comparison between the interventions in the primary and secondary trials The primary trial intervention involves cabergoline which is given orally while the secondary trial involves pixantrone which is administered intravenously The statement incorrectly states that the primary trial intervention is also administered through a needle or tube which is not the case",
        "label": "Contradiction"
    },
    "e53fdbd4-4375-409d-ad00-322822909d5b": {
        "text_answer": "No  Explanation The statement participants in the secondary clinical trial are scheduled for three weekly sc injections on the other hand a single injection is given to primary clinical trial candidates at the inception of the study is not directly entailed by the evidence provided The evidence only mentions the number of interventions and the timing of the vitamin D repletion intervention in each trial but it does not specify the frequency or dosing of the inter",
        "label": "Contradiction"
    },
    "7e5ca0bb-bae1-493f-9a30-7f70d544fcf4": {
        "text_answer": "Yes The statement is entailed by the evidence as the statement specifically mentions those suffering from breast cancer and requiring hormone treatment which matches the inclusion criteria stated in the evidence",
        "label": "Entailment"
    },
    "6c5d5b1a-e7e0-427f-b21b-a9fbc5e2b69e": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence describes the methods of administration for the interventions in the two trials but it does not mention anything about an indwelling urinary catheter",
        "label": "Contradiction"
    },
    "46065ce7-6618-4f08-890c-6bd0f8fa4573": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the primary trial is specifically for women with breast cancer and the secondary trial is for women with breast cancer considering or undergoing mastectomy The statement mentions men with prostate cancer who are not undergoing surgery",
        "label": "Contradiction"
    },
    "d20c94ae-14d5-4272-96d5-ef649dfade50": {
        "text_answer": "No  The evidence mentions anorexia in one participant but it does not indicate that a majority of participants experienced an eating disorder",
        "label": "Contradiction"
    },
    "56c00437-a067-4734-9b55-f1041c10190e": {
        "text_answer": "  No  Explanation  The statement patients who have previously experienced serious anaphylactic reactions to herceptin or those who experienced no improvement with herceptin treatment may participate in the primary clinical trial is not explicitly stated in the inclusion criteria of the evidence provided The evidence only mentions that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial Therefore the",
        "label": "Contradiction"
    },
    "85cdaaef-3a05-458f-aaf2-d935069cf478": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial intervention 1 and in the secondary clinical trial all intervention drugs require intravenous administration is not entailed by the evidence In the primary trial zoledronic acid is given intravenously but the other interventions clinical observation do not involve any drug administration In the secondary trial both arms involve intravenous administration of some drugs graniset",
        "label": "Contradiction"
    },
    "65fc2061-6d0f-46d1-bd13-5959cedf6b03": {
        "text_answer": "No  Explanation  The statement all patients receive the same dose of PDR001 in the secondary trial is correct but the statement as a whole is not entailed by the evidence The statement also makes an incorrect assumption about the Armodafinil dosing in the primary trial In the primary trial Armodafinil is given in a tapering dosage regimen not daily as stated in the statement Therefore the",
        "label": "Contradiction"
    },
    "ebe96d52-cfbc-403c-ba10-244991ddc449": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "840eeabe-3086-4be9-98fc-deaf26b4349b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not support the statement as it only gives the number of participants who completed the study in each group not the percentage who experienced Recurrencefree Survival The statement is making a comparison between the percentage of participants who experienced Recurrencefree Survival in each group which is not directly stated in the evidence",
        "label": "Contradiction"
    },
    "a02864dc-e1f8-427e-9df3-531c91d28d50": {
        "text_answer": "No  The evidence does not mention anything about cyclindependent kinase inhibitor protein",
        "label": "Contradiction"
    },
    "05f34052-08b6-4b98-91d3-326b4f77844c": {
        "text_answer": "No   Explanation  The statement only topical treatments will be administered to the patients in the primary clinical trial is not entailed by the evidence The evidence describes the administration of intradermal id injections of dendritic cells and chemotherapy as well as intravenous IV infusions of trastuzumab and sargramostim None of these treatments are considered topical treatments",
        "label": "Contradiction"
    },
    "4927c9bb-aa2b-4c3c-999b-068e1dca959a": {
        "text_answer": "No   Explanation  The primary trial involves radiation therapy as an intervention but it is not intravenous chemotherapy The secondary trial involves Enzastaurin and Fulvestrant as interventions and no radiotherapy is mentioned in either cohort",
        "label": "Contradiction"
    },
    "304f8d66-90f2-40cc-9f18-77c2b8471a40": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial involves whole breast radiation therapy while the secondary clinical trials involve the administration of Fulvestrant tablets but the dosage and schedule are different between the two groups in the secondary trial The statement incorrectly focuses on the administration of Fulvestrant tablets in bid dosing in both groups of the secondary trial while ignoring the difference in radiation therapy in the primary",
        "label": "Contradiction"
    },
    "6088eecc-56f9-475b-a27a-a23bc646028b": {
        "text_answer": "No  Explanation  The statement all participants in the primary clinical trial experienced less than 3 adverse events is not entailed by the evidence The evidence states that the total number of adverse events experienced by all participants was 5 which is more than 3 Therefore the statement is not a valid conclusion that can be drawn from the evidence",
        "label": "Contradiction"
    },
    "ff8c88f9-c698-4ad0-a9ba-0acf6fbf1933": {
        "text_answer": "No  Explanation  The statement sellar schwannoma is an extremely rare schwannoma that arises from the sellar region is not mentioned in the evidence The evidence only provides information about the results of two clinical trials one on the overall response rate of different treatment regimens for breast cancer and the other on the time to first onstudy skeletalrelated event for two different treatments for bone metastases",
        "label": "Contradiction"
    },
    "f9d5b863-f0cb-4777-81a7-358efd8010d6": {
        "text_answer": "Yes the statement is entailed by the evidence as both cohorts receive preoperative Dexamethasone intravenously However the timing of the administration differs between the two cohorts preoperative for cohort 1 and 2 hours postoperative for cohort 2 The statement does not mention the specific timing of Dexamethasone administration for each cohort but it is still entailed as",
        "label": "Entailment"
    },
    "31b3aa86-f32c-4a10-ae36-6429b25995dc": {
        "text_answer": "  No   Explanation   Anorexia is a specific eating disorder characterized by a persistent refusal to maintain a normal body weight fear of gaining weight and distorted body image The inclusion criteria for the clinical trial specify that participants must have a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs indicating a normal or overweight body weight Therefore individuals with",
        "label": "Contradiction"
    },
    "da91afa9-21ed-4d4d-a5d9-964dbb334177": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes a clinical trial involving the use of laserassisted fluorescence angiography during mastectomy procedures with two different incision types but it does not mention the use of ultrasoundassisted biopsy",
        "label": "Contradiction"
    },
    "a012091a-9e07-4878-81bf-fee2e3282cbd": {
        "text_answer": "  No The statement Patients with histologically documented metastatic SCBC are excluded from the primary trial is entailed by the evidence but the question how big a problem is bleeding with urination is a question about an individuals assessment of how big a problem bleeding with urination has been is not related to the evidence at all",
        "label": "Contradiction"
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "text_answer": "Yes The primary trial participants received lower doses of PF06647020 02 mgkg and 05 mgkg than the secondary trial participants who received 0015 mgkg and 0040 mgkg of ALT801",
        "label": "Entailment"
    },
    "800c7053-0dd5-4c99-ba55-c45b121d303c": {
        "text_answer": "Yes  Explanation The statement both interventions utilize laserassisted fluorescence angiography and lateral radial incisions is entailed by the evidence as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell and lateral radial incisions",
        "label": "Entailment"
    },
    "cdab084c-4e2b-4f0a-ac8c-868b4bb4ecb5": {
        "text_answer": "No  The statement is not entailed by the evidence provided The evidence describes the interventions for the two stratums of the clinical trial but it does not mention anything about placebo administration on specific days for any participants",
        "label": "Contradiction"
    },
    "ec5c26e8-0afd-4244-8731-588c4f88e84b": {
        "text_answer": "Yes  Explanation The statement cohort 1 of the primary clinical trial has multiple records of cardiacrelated adverse events is entailed by the evidence as there are records of cardiacrelated adverse events ACS Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac Tamponade in the primary clinical trial for both Adverse Events 1 and Adverse Events 2 However it",
        "label": "Entailment"
    },
    "e4575416-926c-4b2d-b4ba-1aa417cae0db": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as both the placebo and alloMSCs interventions involve 20 transendocardial injections of 04ml each",
        "label": "Entailment"
    },
    "66c31a74-8bb0-4625-9ce7-401da56be447": {
        "text_answer": "Yes The evidence does not specifically mention fatigue interfering with duties or responsibilities in relation to the inclusion criteria However it does state that participants must have an Eastern Cooperative Oncology Group ECOG performance status of 0 to 1 which is a measure of functional status that includes assessment of fatigue Therefore fatigue that interferes with certain duties or responsibilities could potentially be a reason for a higher ECOG performance status and therefore exclude",
        "label": "Entailment"
    },
    "eff8deaa-08a6-4df3-9140-fe153fbcba6e": {
        "text_answer": "yes the intervention in the secondary trial continues for three times as long as in the primary trial",
        "label": "Entailment"
    },
    "31bb177c-1a8b-4699-a7f2-4c442801770f": {
        "text_answer": "Yes  Explanation The statement the frequency of adverse events was higher in the first cohort of the primary clinical trial than in the second cohort is entailed by the evidence as the total number of adverse events in the first cohort 45106 or 4245 is greater than the total number of adverse events in the second cohort 7103 or 68",
        "label": "Entailment"
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "text_answer": "Yes  Explanation The statement at least one patient in the primary trial suffered several different adverse events is entailed by the evidence since there are patients who experienced more than one adverse event Dyspnea was reported by 2 patients",
        "label": "Entailment"
    },
    "3ff8b1f7-4c73-4cb7-acbd-4d7e3b7f31ec": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "text_answer": "No  The evidence explicitly states that morbidly obese patients are not eligible for the primary trial and pregnant patients are excluded from both trials",
        "label": "Contradiction"
    },
    "340721ab-42f9-4ac3-8608-58007d89b87b": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of respiratory issues in the documented adverse events for either cohort 1 or 2 of the primary clinical trial",
        "label": "Contradiction"
    },
    "16aacacc-1ab7-46d2-a59e-ca207cb0282d": {
        "text_answer": "No  Parathyroid carcinoma is not listed as an exclusion criterion in either the primary or secondary trial",
        "label": "Contradiction"
    },
    "68716599-d21d-433a-9e8d-5113749d4a06": {
        "text_answer": "Yes  Explanation  The statement the total adverse events in the primary trial exceed those in the secondary trial but there are fewer cases of cardiacischemiainfarction in the primary trial than in the secondary trial is entailed by the evidence because  1 The evidence shows that the total number of adverse events in the primary trial is 014 for Adverse Events 1 and 0",
        "label": "Entailment"
    },
    "90fc98fa-35bb-48ae-a2f3-b74e6bd0d353": {
        "text_answer": "No  Explanation  The statement more than four different types of adverse events affected patients in the primary clinical trial across all cohorts is not entailed by the evidence provided The evidence only lists the number of occurrences of each type of adverse event for two separate cohorts and none of them have more than four different types of adverse events",
        "label": "Contradiction"
    },
    "3ac94edb-bccc-44c6-9b1a-4ea79122d154": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial involves the use of epacadostat in combination with pembrolizumab while the secondary trial involves the use of sunitinib as a single agent The frequency of administration of epacadostat and sunitinib are not directly comparable between the two trials",
        "label": "Contradiction"
    },
    "0d95a819-09cb-49a0-9ec0-76a64bc50732": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the interventions in both trials involve intravenous IV administration of pixantrone not a topical application",
        "label": "Contradiction"
    },
    "9d9db340-6fee-4ec0-b6cb-7fdfe2d34959": {
        "text_answer": "Yes  Explanation  The statement there were 0 cases of hypertension edema and dyspnea in either cohort of the primary trial is entailed by the evidence because both cohorts of the primary trial had 000 cases of edema and dyspnea and there is no mention of hypertension in the adverse events for either cohort",
        "label": "Entailment"
    },
    "d43e7757-45d0-4f65-9735-6ba05f13337d": {
        "text_answer": "Yes The primary trial excludes patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study while the secondary trial also excludes patients who have had chemotherapy or radiotherapy within 4 weeks of study entry However the primary trial does not mention CBTbased treatments specifically but the statement implies that such treatments are a type of therapy that is not allowed in the primary trial",
        "label": "Entailment"
    },
    "908f5aed-eb98-47f8-b00d-7ce39707446f": {
        "text_answer": "Yes  Explanation The statement hpv16 infection is an infection caused by human papillomavirus 16 is a fact that is not directly stated in the evidence but is a wellestablished scientific fact The evidence does state that Cohort A and B received the same Three electroporation injections of LD V934 which is a part of the interventions in the trial Therefore the statement Coh",
        "label": "Entailment"
    },
    "b8ffb304-4dd2-4fa9-888e-b851c73513c1": {
        "text_answer": "Yes  Explanation The evidence shows that a larger proportion of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date with their colorectal breast and cervical cancer screenings after the intervention compared to before This indicates that most patients from both groups had completed their screenings following the intervention",
        "label": "Entailment"
    },
    "47074986-36ac-4ebe-a743-cdf06a70efd8": {
        "text_answer": "No  The statement about Alzheimers patients being ineligible for the trial is not directly related to the information provided in the evidence about inclusion and exclusion criteria for the trial The statement about a rete ovarii adenoma is not mentioned in the evidence at all",
        "label": "Contradiction"
    },
    "698a471b-ead0-445f-93bb-4badc6382968": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly support the statement that the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort The evidence only provides the percentage of participants with Disease Progression or Death in each cohort during the maintenance phase of the trial It does not provide information on the",
        "label": "Contradiction"
    },
    "0ec15a9a-41f5-44aa-a089-c5f0fe5c9806": {
        "text_answer": "yes for the primary trial no for the secondary trial regarding Her2neu breast cancer requirement",
        "label": "Entailment"
    },
    "09ebfb97-f98c-4555-9e69-85b60af863fa": {
        "text_answer": "Yes The evidence states that patients will take Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "a326e30f-a2c9-4a6e-b497-02cc338735c5": {
        "text_answer": "No  Explanation  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial separately It does not mention anything about the eligibility of women with stage IV breast cancer for either trial",
        "label": "Contradiction"
    },
    "2ce21ccd-8f05-4618-8597-b1ad8be31f59": {
        "text_answer": "Yes The evidence mentions the use of laserassisted fluorescence angiography in both interventions of the trial The statement does not mention the specific drug regimen used in the trial but the evidence does not contradict the statement",
        "label": "Entailment"
    },
    "d1c52b9f-7feb-4d54-af86-7aace67807d4": {
        "text_answer": "yes but with an explanation  The statement is mostly correct but its important to note that the only difference between the two cohorts is the use of Active Breathing Coordination ABC during radiation therapy The doses of radiation therapy and the timing of SPECT scans are the same for both cohorts",
        "label": "Entailment"
    },
    "eff637a6-8d7c-47e9-bcba-b4b52159aa4d": {
        "text_answer": "1 No for the statement about superior performance based on the primary trial 2 Not applicable for the statement about the secondary trial as it does not make a comparison",
        "label": "Contradiction"
    },
    "5c06c081-87ef-4e9a-ab22-c8c55253fc34": {
        "text_answer": "Yes  Explanation  The statement there were fewer instances of mucositis oral bladder infection and thromboembolic events noted in the primary clinical trial compared to the secondary clinical trial is entailed by the evidence because the primary trial had fewer occurrences of these adverse events compared to the secondary trial Specifically in the primary trial there were no instances of mucositis oral bladder infection",
        "label": "Entailment"
    },
    "74c7adc7-9641-4858-88af-69a2e2cd6dad": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it introduces new information not present in the trial specifically regarding the use of paclitaxel in cohort 1 and the condition of the chordoma being advanced The evidence only provides information on the interventions used in each arm of the trial ANA with oral anastrozole and FULV with intramuscular fulvestrant",
        "label": "Contradiction"
    },
    "ab848536-4d43-4af3-9489-59b7608b7ecf": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement given The statement suggests that there were 12 participants in the ketorolac 30 mg group who experienced recurrencefree survival compared to 205 in the nacl 09 17ml group However the evidence only provides the number of participants analyzed in each group and their respective percentages of recurrencefree survival",
        "label": "Contradiction"
    },
    "62716b99-76d4-4dfe-b0ce-1ad35f768b33": {
        "text_answer": "Yes An ECOG score of 1 falls within the allowed range for both trials 02 for primary trial and 02 or Karnofsky 60100 for secondary trial",
        "label": "Entailment"
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "text_answer": "Yes  Explanation The statement In the primary trial results there were more patients with stable disease in week 12 than week 24 but 0 patients with complete response in week 12 or 24 is entailed by the evidence provided The evidence shows that there were 12 participants with stable disease at week 12 and 10 participants with stable disease at week 24 Additionally there were no participants with complete",
        "label": "Entailment"
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "text_answer": "  Yes Primary Trial No Secondary Trial Maybe  Explanation  The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date However the secondary trial does not mention any such restriction Therefore a patient who has received an organ transplant within the last month but is not bedridden could potentially be eligible for the secondary trial However its important to",
        "label": "Entailment"
    },
    "ed247cb5-ed15-4c1b-940d-099d16ee7f53": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the evidence describes different dosing regimens for talazoparib in breast cancer and ovarianperitoneal cancer patients While both groups receive talazoparib in Part 1 and 2 the doses differ significantly Therefore the therapeutic approach is not the same for both groups",
        "label": "Contradiction"
    },
    "0cab14c5-398c-4e4e-9c6a-65fb70aecb23": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence The statement mentions the CRsR clinical classification and trials using hormonal interventions Estring and acupuncture interventions The evidence also includes trials using these types of interventions",
        "label": "Entailment"
    },
    "9c4db46a-f5c4-46f0-9d28-8b18bbb9583a": {
        "text_answer": "No  Explanation The statement mentions a combined total of 3 cases of asthenia and 5 cases of pyrexia which is not mentioned in the evidence The evidence only provides the number of adverse events for each trial and each adverse event type but it does not provide a combined total for asthenia and pyrexia",
        "label": "Contradiction"
    },
    "d68944ff-4237-41b8-9ba1-bdfd9899ba32": {
        "text_answer": "No  Explanation  The statement three cases of shingles were reported across the patient cohorts involved in both the primary and secondary clinical trials is not directly entailed by the evidence provided The evidence only reports the number of adverse events for each type in each trial but it does not specify which patients experienced the same adverse event across trials Therefore while it is possible that some patients may have experienced shingles in both trials the",
        "label": "Contradiction"
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "text_answer": "Yes  Explanation  The statement All Infections and Infestations cases in the primary trial were for patients in cohort 1 is entailed by the evidence because all of the Infections and Infestations adverse events mentioned in the evidence occurred in cohort 1 Therefore there are no Infections and Infestations adverse events in cohort 2 according to the evidence",
        "label": "Entailment"
    },
    "e15409e3-408c-4ea8-a0aa-9f1072b8a74b": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as it accurately reflects the information provided in the evidence regarding the constant dose of alpha lipoic acid in the primary trial and the varying doses of necitumumab in the secondary trial",
        "label": "Entailment"
    },
    "335235f3-4d27-479e-a5d7-29016a3320a5": {
        "text_answer": "Yes  Explanation The statement multiple adverse events were reported in the primary clinical trial including anemia and nausea is entailed by the evidence since the evidence states that Adverse Events 1 Total 129 345 and Adverse Events 1 Surgery 1129 345 The presence of multiple adverse events anemia and n",
        "label": "Entailment"
    },
    "9b120158-866e-4a68-ab9a-4d6241ead464": {
        "text_answer": "No  Explanation  The statement the secondary trial and the primary trial report results using the same Unit of Measure is not entailed by the evidence The primary trial reports results as a percentage while the secondary trial reports results as the number of participants",
        "label": "Contradiction"
    },
    "ad1abf74-05c4-439a-b178-f21231744c89": {
        "text_answer": "No  The statement is not about the breast cancer clinical trial and its inclusionexclusion criteria It is about a different medical condition retinal arterial branch occlusion",
        "label": "Contradiction"
    },
    "1786385e-70c9-4a5b-a19e-0f389be545cc": {
        "text_answer": "No  Explanation  The statement disturbed sleep at its worst is a question about an individuals disturbed sleep at its worst is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided The statement only refers to a question about an individuals sleep while the trials focus on specific inclusion and exclusion criteria for patients with certain types of cancer and specific genetic mutations",
        "label": "Contradiction"
    },
    "0bb51a03-72e6-4d48-8010-054e280a960f": {
        "text_answer": "No The statement is not entailed by the evidence as the evidence does not provide any information about adverse events related to mental health or mediastinal infection in the given trial",
        "label": "Contradiction"
    },
    "d30d2472-9529-4206-8167-5bace92bb6d0": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial and secondary trial are about different interventions and do not have any direct relationship to spastic paraplegia 3a or the atl1 gene",
        "label": "Contradiction"
    },
    "96be5169-0334-4849-a77b-111e8eacf7bb": {
        "text_answer": "No  Explanation  The statement multiple adverse events have been recorded in at least one cohort of the primary clinical trial is not entailed by the evidence provided which only states that no adverse events of types 1 and 2 were recorded in any cohort of the primary clinical trial The absence of adverse events does not imply that no other adverse events occurred in the trial",
        "label": "Contradiction"
    },
    "47507d4a-ea24-433a-9864-e4b76657335c": {
        "text_answer": "Yes  Explanation  The statement in the patient cohorts of both the primary clinical trial and the secondary clinical trial there have been no instances of intestinal obstructions or pancytopenia is entailed by the evidence since the evidence reports that there were no instances of intestinal obstructions or pancytopenia in either trial",
        "label": "Entailment"
    },
    "3e16b4a5-6dc6-4a20-a367-c361bc38644e": {
        "text_answer": "Yes  Explanation The evidence shows that the median survival times for both groups A and B are over 2 years Additionally the statement mentions that more than fifty patients from each group experienced life spans over 24 months which is also supported by the data as there are 115 participants in group A and 119 in group B meaning over 50 patients from each group survived over 24 months",
        "label": "Entailment"
    },
    "4d2b9583-9b62-40cc-b7e7-096c2dd16e0b": {
        "text_answer": "Yes The primary trial specifically includes participants who are resistant to AI therapy while the secondary trial does not mention it as a requirement",
        "label": "Entailment"
    },
    "49d0acfc-e7ce-45f5-8e45-08d55f3d0776": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results does not directly measure the primary tumor size but rather the percentage change in betaCTX levels which is a marker for bone turnover The statement in question makes a claim about the shrinking of primary tumor size which is not supported by the evidence",
        "label": "Contradiction"
    },
    "b68e076b-9950-438b-96ea-3fc93943e490": {
        "text_answer": "No  Explanation  The statement requiring considerable assistance and frequent medical care is not mentioned in the inclusion or exclusion criteria of the evidence provided The evidence only mentions the requirement of normal organ and marrow function and eligibility of patients receiving medications or substances known to affect the activity or pharmacokinetics of lapatinib  The statement about the u wave abnormality by ECG finding is not directly related to the",
        "label": "Contradiction"
    },
    "3977a1e3-3371-4577-9dc1-eea3a725469c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "430f4379-7517-4dc9-a9e4-885f2934f872": {
        "text_answer": "No  Explanation  The statement the adverse event most often witnessed in the patient cohorts of the primary clinical trial and secondary clinical trial was syncope is not entailed by the evidence The evidence only states that syncope occurred in 2500 of the patients in the primary trial and in 084 of the patients in the secondary trial It does not state that syncope was the most common adverse event",
        "label": "Contradiction"
    },
    "d2c3690c-11a2-40de-b077-acf5f53fdb10": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not include any information about the myb gene fusion status of the participants The statement is not directly related to the given evidence",
        "label": "Contradiction"
    },
    "91a6d0f0-3f3c-4bd7-80a5-f403fd7ef87e": {
        "text_answer": "Yes The evidence does not mention the use of xrays ultrasound CT scans or MRIs in the interventions of either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "d9b955ea-915d-438f-a9b1-cd1cc08c0dd4": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial indicates that the average pain intensity score for both the low dose and high dose groups was below the worst pain imaginable 10 on the numeric rating scale for the entire 10week study period Therefore none of the patients in the trial experienced the worst pain imaginable for 10 weeks",
        "label": "Entailment"
    },
    "5b174c01-9e6e-4fa0-8c85-c7b72446d0b2": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes two separate clinical trials one investigating the effects of Estring and Testosterone Cream on lymphedema and the other studying the impacts of acupuncture and a waitlist on lymphedema There is no mention of physical therapy interventions or dietary changes in the evidence",
        "label": "Contradiction"
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "text_answer": "Yes The evidence does not report any cases of eating disorders among the primary trial candidates",
        "label": "Entailment"
    },
    "fd258898-9438-4474-a89e-7143a96abe06": {
        "text_answer": "No   Explanation  The statement patients will receive a single injection on study day 8 is not entailed by the evidence as the evidence describes multiple injections on study day 8 including the dendritic cell vaccine trastuzumab and sargramostim",
        "label": "Contradiction"
    },
    "4b913a72-0c81-4396-8667-f087259328f6": {
        "text_answer": "Yes  Explanation  The statement no cases of unanticipated deaths or hospitalizations are reported in the primary clinical trial and the secondary clinical trial besides the three reported events of lymphoma is entailed by the evidence because the evidence does not report any unanticipated deaths or hospitalizations in either trial besides the three reported cases of lymphoma",
        "label": "Entailment"
    },
    "a1a8bedd-680d-4250-9384-93379de0a2a3": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary clinical trial involves vaginal application of Estring and testosterone cream while the secondary clinical trial involves acupuncture which is not administered through the skin or inhalation",
        "label": "Contradiction"
    },
    "514d5612-4c60-4586-89b7-ca89b06ac576": {
        "text_answer": "No  Explanation The primary trial includes a criterion for the primary tumour to have a greater diameter of 2 cm while the secondary trial does not mention any specific tumour size requirement Therefore a patient with a primary tumour of 330mm which is significantly larger than 2 cm would not be eligible for either trial based on the given evidence",
        "label": "Contradiction"
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement mentions two separate interventions for the primary and secondary trials while the evidence only provides the intervention details for each trial individually",
        "label": "Contradiction"
    },
    "5b3b5c72-175a-42ea-aeab-63cd4298b362": {
        "text_answer": "Yes   Explanation The primary clinical trial and the secondary clinical trial involve different patient populations as indicated by the different interventions and outcomes being measured The primary trial investigates denosumab in a population of 33 participants while the secondary trial examines the safety and tolerability of dmethadone in a smaller cohort of 8 participants",
        "label": "Entailment"
    },
    "58f39f52-0a96-4892-b8e7-2b689448c28f": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that some interventions can be administered intravenously IV and others orally The statement also correctly defines a gene variant",
        "label": "Entailment"
    },
    "7aa4329c-8f2a-4168-9b6b-f74ea0184356": {
        "text_answer": "No  Explanation  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is not directly entailed by the evidence provided  The evidence only mentions that prior use of Herceptin within the last 5 months is an exclusion criterion for the primary trial and that there is no mention of gabapentin in the",
        "label": "Contradiction"
    },
    "62db4a46-c4ea-44a1-8dfc-12922748a7b0": {
        "text_answer": "No  Explanation  The statement is not directly related to the evidence provided in the primary trial The evidence only reports the results of the trial regarding the proportion of participants with controlled acute vomiting after receiving different treatments including Aprepitant Dexamethasone Cytoxan and Kytril It does not mention anything about dietary nuts and seeds",
        "label": "Contradiction"
    },
    "2610ce20-2875-4677-a55b-fbd094ca3abb": {
        "text_answer": "Yes The evidence does not mention anything about pd0332991 being administered to cohort 1 in the primary clinical trial",
        "label": "Entailment"
    },
    "0e2c4838-f0ba-4f02-b078-ac3fa2b3c0e3": {
        "text_answer": "Yes  Explanation The evidence states that cohort 1 received a dosage of 0015 mgkgdose of ALT801 while cohort 2 received a dosage of 0040 mgkgdose of ALT801 The difference in dosages clearly indicates that cohort 1 was given a smaller dosage than cohort 2",
        "label": "Entailment"
    },
    "22c47ff5-a9b1-4de2-b5ee-2e5a6f2302d9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial specifically includes only patients with histologically or cytologically confirmed breast adenocarcinoma with bone metastases while the secondary trial includes only patients with histologically confirmed breast cancer that is ER positive andor PR positive and HER2neu negative and has metastatic disease The statement does not specify the presence or absence of bone metastases or H",
        "label": "Contradiction"
    },
    "6b48128c-3103-4266-bd7f-3f9d13dc5949": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions warfarin for cohort 1 of the primary trial which is not mentioned or related to the evidence provided The evidence only mentions interventions for the primary and secondary trials which are Fluciclatide Injections for the primary trial and Chloroquine doses for the secondary trial",
        "label": "Contradiction"
    },
    "75d3b7d9-3863-4b14-8007-8d8ade0440f1": {
        "text_answer": "No  The statement patients with a body mass index bmi of 20 and above are eligible for the primary clinical trial is not entailed by the evidence as the inclusion criteria specify a BMI of 25 kgm2 or greater",
        "label": "Contradiction"
    },
    "1279b75a-606f-469e-a6e6-20d4eabd50ba": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial includes male subjects and the secondary trial includes female subjects",
        "label": "Contradiction"
    },
    "d32ff217-1848-490b-8a99-bc12730318f0": {
        "text_answer": "No  Explanation  The statement the primary trial reported 5 serious adverse events while the secondary trial reported 3 is not directly entailed by the evidence provided The evidence only reports the number of adverse events for a specific type Adverse Events 1 in each trial but it does not provide information about the number or severity of all adverse events in each trial Therefore it is not possible to determine if the statement is true",
        "label": "Contradiction"
    },
    "9d742d77-5754-4e6f-a913-90dc71c6b6f5": {
        "text_answer": "No   Explanation  The evidence describes two separate interventions with different participant groups one for adult cancer patients and the other for healthy volunteers The statement assumes that all participants undergo the same treatment but this is not the case according to the evidence",
        "label": "Contradiction"
    },
    "af52a2f1-de39-4113-86fa-10e65961b095": {
        "text_answer": "No  Explanation  The statement Any Patients currently taking part in the secondary trial will also be eligible for the primary trial is not entailed by the evidence provided The primary and secondary trials have different inclusion and exclusion criteria The primary trial is specifically for postmenopausal women with a history of breast cancer and experiencing hot flushes while the secondary trial is for adult patients with HER2negative metastatic breast cancer who are candidates",
        "label": "Contradiction"
    },
    "4c0fbabb-2d9e-4da7-8a17-07272c77ece8": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not report any deaths in either trial",
        "label": "Contradiction"
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "text_answer": "Yes  Explanation  The statement We cannot compare the adverse events in the primary trial and the secondary trial as they do not appear to have been recorded for the primary trial is entailed by the evidence because the evidence does not provide any information about the adverse events in the primary trial Therefore it is not possible to compare the adverse events between the two trials without this information",
        "label": "Entailment"
    },
    "5b31fcf1-a528-4718-adcb-72df68b4df43": {
        "text_answer": "Yes The statement that the primary and secondary trials recorded the same number of adverse events is entailed by the evidence The statement about moderate tumor infiltrating lymphocytes is not directly related to the evidence and is presented separately",
        "label": "Entailment"
    },
    "cc321a3c-a09d-4354-8601-d665f428a831": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial excludes patients with more than three cerebral metastases while the secondary trial specifically excludes patients with two to three cerebral metastases",
        "label": "Entailment"
    },
    "fddee10c-dd7d-47fe-b2cf-3ebe94726ea4": {
        "text_answer": "No  Explanation  The primary clinical trial involves the administration of suramin and paclitaxel to patients but the secondary clinical trial does not mention the use of these drugs Therefore it is not entailed by the evidence that all patients in the secondary clinical trial receive suramin and paclitaxel",
        "label": "Contradiction"
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "text_answer": "Yes  Explanation  The statement Cohort 1 of the primary trial did not report any AEs is entailed by the evidence Adverse Events 1 Total 0147 000 The evidence indicates that there were no adverse events reported in the primary trial for Cohort 1 which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "5b07e1cb-d734-4e43-9911-6328923fbc93": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the most recurrent adverse event in the primary trial was syncope 2500 but in the evidence no mention is made of the most recurrent adverse event in the secondary trial",
        "label": "Contradiction"
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "baf9254a-880a-4df9-b2fc-c118b6b273f8": {
        "text_answer": "maybe for the secondary trial no for the primary trial  Explanation  The statement A 20 year old female patient with a Newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial and the primary trial is only possibly true for the secondary trial as the patient meets the age requirement and the breast cancer type requirement However she does not meet the other inclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "e1c50f3f-0521-4edc-a2ae-8e0b04b64c54": {
        "text_answer": "No  The evidence does not provide information about radiation therapy doses in either trial",
        "label": "Contradiction"
    },
    "b73bfd5a-18e5-4df7-8e6a-292f8f32208f": {
        "text_answer": "No  Explanation The evidence provided in the results only gives the median average change in lean body mass for each group along with the range of changes It does not specify how many patients in each group experienced a gain of over 10 kilos in lean body mass Therefore the statement cannot be definitively answered with a simple yes or no based on the given evidence",
        "label": "Contradiction"
    },
    "44b12aea-350e-4ade-a145-ba619d96a0ca": {
        "text_answer": "Yes The primary and secondary trials both measure pCR as their outcome The primary trial shows a small difference in pCR rates between the two arms while the secondary trial shows a higher pCR rate in Arm 1 compared to Arm 2 The statement does not mention BEAM so it is not relevant to the question",
        "label": "Entailment"
    },
    "7ea3fe58-fb27-48f8-9e3a-61af8847d23e": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial maintains identical inclusion and exclusion criteria for all its subjects is not entailed by the evidence provided The primary clinical trial has different inclusion and exclusion criteria for each study group NSCLC melanoma triple negative breast cancer and anaplastic thyroid cancer while the secondary clinical trial has its own unique inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "225ff186-66e8-4880-bba4-e8127bd42834": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about mitral valve atresia which is a congenital heart defect unrelated to the interventions and trials described in the evidence",
        "label": "Contradiction"
    },
    "8e4d3482-1501-4f0d-ae76-8924effe7d3c": {
        "text_answer": "Yes  Explanation  The statement no inclusion or exclusion criteria are shared between the primary clinical trial and the secondary clinical trial is entailed by the evidence because the evidence clearly states that there are different inclusion and exclusion criteria for each trial",
        "label": "Entailment"
    },
    "819893b4-9c57-42b8-938e-f6147e41694d": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed by the evidence provided The evidence states that there were 3 cases of Hepatotoxicity 1 case of hypertension and 1 case of Pancreatectomy making the ratio of Hep",
        "label": "Contradiction"
    },
    "354a388c-18b1-476a-b372-3ac4be472cbc": {
        "text_answer": "No  Explanation  The statement the severity of adverse reactions were somewhat higher in the primary clinical trial as compared to the secondary clinical trial proportion wise is not entailed by the evidence provided The evidence only states the number of adverse events in each trial but it does not provide any information about the severity or proportion of adverse events between the two trials",
        "label": "Contradiction"
    },
    "31038c96-b97a-4952-aacc-4e7e8bb09cd0": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial both cohorts receive equal doses of durva in their biweekly iv infusions is entailed by the evidence as both cohorts received durvalumab at a dose of 03 mgkg Intervention 1 or 1 mgkg Intervention 2 for their biweekly IV infusions",
        "label": "Entailment"
    },
    "a828ed30-ae3c-4fbc-be8a-a72dd5e5bc3e": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial includes patients with locally advanced or metastatic breast cancer and measurable disease but the size of the tumor is not specified Therefore the statement about a tumor of 1 decimeter 10 cm in diameter is not entailed by the evidence",
        "label": "Contradiction"
    },
    "45daf2f3-8299-46f8-9016-edf2ce4a044a": {
        "text_answer": "Yes The evidence does not explicitly state that the trials are open to only Japanese nationals but it does not exclude individuals based on nationality Therefore it can be inferred that the trials are open to any person who meets the other inclusion criteria regardless of nationality",
        "label": "Entailment"
    },
    "c831a231-8b84-41ca-a825-d11060c44d64": {
        "text_answer": "No  Explanation The primary trial specifically includes women with locally advanced recurrent or metastatic breast cancer while the secondary trial includes women with newly diagnosed or recurrent breast cancer The two trials have different inclusion criteria and the primary trial requires confirmation of ER status and measurable disease which is not a requirement for the secondary trial Therefore a woman with locally advanced ERpositive breast cancer who is contemplating mastectomy would not qualify",
        "label": "Contradiction"
    },
    "ee8170da-a81f-42bf-b286-cbb8824040cf": {
        "text_answer": "Yes for the secondary trial The primary trial explicitly excludes patients who have received major surgery within 28 days prior to the study registration date but the secondary trial does not have this exclusion criterion",
        "label": "Entailment"
    },
    "95aa2e47-d35b-45b5-8d80-18f06798b812": {
        "text_answer": "No   Explanation  The evidence provided in the trial description does not mention paclitaxel being administered to either cohort 1 Arm A with anastrozole or cohort 2 Arm B with fulvestrant The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "text_answer": "Yes  Explanation  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence because the sum of the adverse events in both trials is less than 3 045  000 for the primary trial and 000 for the secondary trial which is less than 97 of the total number",
        "label": "Entailment"
    },
    "c76186ef-f703-4809-8e01-956bdec01925": {
        "text_answer": "  Yes   Explanation   The statement the primary clinical trial results reveal a higher overall response rate in the arm A intervention than the placebo arm is entailed by the evidence as the results show a higher overall response rate in Arm A 676 compared to Arm B 600   The statement additionally the denosumab group in the secondary clinical trial exhibited a greater time to",
        "label": "Entailment"
    },
    "da278764-ba0c-4a9e-9f44-7fe16af87e5a": {
        "text_answer": "No  Explanation  The statement who needed prescription medicine but family unable to afford it is not directly related to the adverse events data provided in the evidence The evidence only reports the number of adverse events both serious and nonserious observed in two clinical trials It does not provide any information about which household members needed prescription medicine and whether they were able to afford it or not Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "7de10e39-c06c-4941-ade6-3e60b864029c": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial does report Time to Progression TTP data which is an objective measure and the secondary trial reports the number of participants with objective response based on RECIST criteria which is also an objective measure The statement incorrectly assumes that the primary trial does not provide any objective data on treatment outcomes",
        "label": "Contradiction"
    },
    "2b9dbd1a-6de9-4c7e-80af-0a096af26a11": {
        "text_answer": "No   Explanation  The statement in the question is not entailed by the evidence as the statement mentions that cohort 2 of the primary trial is administered Enzalutamide orally whereas cohort 1 receives it by IV but the evidence provided only mentions the oral administration of Enzalutamide in both cohorts",
        "label": "Contradiction"
    },
    "c83203cf-4121-4d9d-a662-cd596a5f63d5": {
        "text_answer": "Yes The primary trial includes the exclusion criterion of potassium levels being outside the normal range 35 mEqL while the secondary trial does not mention potassium levels as an inclusion or exclusion criterion Therefore individuals with hypokalemia can participate in the primary trial but are ineligible for the secondary trial",
        "label": "Entailment"
    },
    "3a9ca481-4b74-4bd3-99f0-1b34cc33ba33": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9d03d248-30a2-44b1-bbef-75809005dc16": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only reports the results of two trials regarding the use of Empegfilgrastim in breast cancer patients and the duration or incidence of neutropenia The statement about the chromosome band 7p222 and its relation to the trials is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "text_answer": "Yes  Explanation The evidence provided in the results of the primary trial shows that the mean number of hot flashes per day for the paced respiration intervention group was lower 348 compared to the fast shallow breathing comparator group 395 This difference indicates that the patients in the paced respiration group experienced fewer hot flashes on average than those in the fast shallow breathing group",
        "label": "Entailment"
    },
    "1f23b5f1-2b28-4204-9e44-60f8ddc86963": {
        "text_answer": "Yes  Explanation  The statement adverse events were not reported in cohort 1 but were reported in cohort 2 in the primary clinical trial is entailed by the evidence since there are reported adverse events in cohort 2 but none in cohort 1",
        "label": "Entailment"
    },
    "72626f41-afa0-413c-b495-e4eeb51112fb": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 The statement patients in the primary trial experienced a 10 reduction in the percentage of cells with ki67 expression can be calculated as follows 151015 x 10",
        "label": "Entailment"
    },
    "c3bc7314-8b8f-4d98-90ad-986132951201": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly identifies that there were 4 different types of adverse events in cohort 2 of the primary trial",
        "label": "Entailment"
    },
    "03a7663e-0937-437a-b095-642e363a6703": {
        "text_answer": "Yes   Explanation  The statement the primary clinical trial abstains from using lenalidomide whereas the secondary clinical trial uses high doses of lapatinib in intervention 1 is entailed by the evidence because the primary trial does not mention the use of lenalidomide and the secondary trial specifies the use of a high dose 1500 mg daily of lapatinib in intervention 1",
        "label": "Entailment"
    },
    "1c5b6b0e-8ee8-4569-8bc8-83ab193f8cff": {
        "text_answer": "Yes The evidence states that breast adenocarcinoma is an inclusion criteria for both the primary and secondary trials",
        "label": "Entailment"
    },
    "0e6d3d31-1af3-4701-a410-b2bbb1ce430e": {
        "text_answer": "No  Explanation  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is not directly related to the given evidence The evidence only provides the list of adverse events observed in the primary trial but it does not specify that there was at least one gastrointestinal adverse event The statement also does not mention the Manual Ability Measure36 which is an",
        "label": "Contradiction"
    },
    "0db120d4-5ebb-4b0f-9040-52b32a966c33": {
        "text_answer": "Yes  Explanation The evidence shows that the mean number of hot flashes per day was lower in the paced respiration intervention group 348 compared to the fast shallow breathing group 395 This difference indicates that patients in the paced respiration group experienced on average fewer hot flashes per day than those in the fast shallow breathing group",
        "label": "Entailment"
    },
    "ace11ff3-a7ac-492c-9dbe-5dafc96f81e7": {
        "text_answer": "yes the statement is about survival time which is mentioned in the evidence However the statement does not directly relate to the specific question about surgical oophorectomy in the midluteal vs midfollicular phase of menstrual cycles",
        "label": "Entailment"
    },
    "16147f31-aa81-4f21-9bd7-f153069a9278": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement mentions two different interventions for the primary and secondary trials whereas the evidence only provides information about the interventions for each trial separately",
        "label": "Contradiction"
    },
    "edd1533a-dc7c-441d-adcd-f8b020a4fdd3": {
        "text_answer": "No   Explanation  The statement all participants in the primary clinical trial regardless of their cohort are required to view the educational dvd is not entailed by the evidence The evidence only states that the intervention arm of the study includes viewing the educational DVD but it does not mention that the control arm also includes this requirement",
        "label": "Contradiction"
    },
    "a9d993df-c8e1-4f4f-b470-b23d78f069ed": {
        "text_answer": "Yes The primary trial mentions IV administration of zoledronic acid while the secondary trial mentions oral administration of placebo prochlorperazine granisetron hydrochloride and aprepitant However the statement focuses on the difference in IV administration in the primary trial versus oral administration in the secondary trial which is correct based on the evidence",
        "label": "Entailment"
    },
    "1f77c906-1f2c-43b4-8bb1-2a2aeb19555e": {
        "text_answer": "Yes  Explanation  The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence since the majority of patients in both trials had a total adverse event rate of 000 or 1563 which is less than 50",
        "label": "Entailment"
    },
    "29cdc690-859f-405c-ad87-f4e73fc3e9a8": {
        "text_answer": "No  Explanation The statement the intervention in the secondary trial lasts 5 more weeks than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks and the secondary trial lasted for 24 weeks but the statement incorrectly states that it lasts 5 weeks longer rather than 14 weeks longer",
        "label": "Contradiction"
    },
    "920f9642-c8b0-4b1d-9b2a-c12c4801b714": {
        "text_answer": "Yes but with a clarification The primary trial excludes patients with potassium levels outside the normal range while the secondary trial does not mention potassium as an inclusion or exclusion criterion",
        "label": "Entailment"
    },
    "ec1b4763-e8bc-4c2f-be22-6b64b623b072": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not mention leptomeningeal carcinoma as a condition that would exclude a patient from the trial",
        "label": "Contradiction"
    },
    "2fcef697-683a-4b99-9da3-5527e80c9e5b": {
        "text_answer": "No  Explanation  The statement patients must be diagnosed with a mutation in the one of the following genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ or GNA11 to be included in the secondary trial is not directly entailed by the evidence provided The evidence only states",
        "label": "Contradiction"
    },
    "fc96b587-8bbf-4816-97d9-15cd8fcf755f": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as neither the primary nor the secondary trial measure the effect of tyrphostin AG 1288 on MYMOP score or any other patientreported symptoms The primary trial measures change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial measures change in isothiocyanate in urine samples as a bi",
        "label": "Contradiction"
    },
    "5284dc53-b471-4c7a-a713-62199869a305": {
        "text_answer": "Yes  Explanation  The statement the majority of patients participating in the primary and secondary clinical trials reported experiencing adverse events after treatment is entailed by the evidence since the evidence shows that there were adverse events reported in both trials However its important to note that the statement majority implies more than 50 of the patients but based on the given evidence the percentage of patients who experienced adverse events is less than ",
        "label": "Entailment"
    },
    "e6ba45db-66f8-4f45-a45a-9217e65c7bbd": {
        "text_answer": "Yes The primary trial excludes individuals who are participating in another clinical trial",
        "label": "Entailment"
    },
    "ca63be25-38a3-4f4a-a6be-0e8b8cb8e5f5": {
        "text_answer": "yes for the secondary trial uncertain for the primary trial  Explanation  The statement a woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is entailed by the evidence for the secondary trial because there is no exclusion criterion in the secondary trial related to having undergone a mastectomy for breast cancer However for the primary trial there is an",
        "label": "Entailment"
    },
    "87e90ba6-44b6-4dc9-9bac-9ceb0c8cf6f6": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does measure changes in pain intensity specifically using the Summed Pain Intensity Differences SPID at 30 minutes after dosing and the secondary trial does measure the change from baseline to 9 months in bone mineral density BMD of the lumbar spine using Dualenergy Xray Absorptiometry DEXA scan",
        "label": "Contradiction"
    },
    "0fdae3b5-0326-47fb-a3c2-ff5fd132fb76": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the primary trial is specifically for women with locally advanced recurrent or metastatic breast cancer while the secondary trial is for women considering or undergoing mastectomy for newly diagnosed or recurrent breast cancer without distant metastatic disease Men are not mentioned in either trial",
        "label": "Contradiction"
    },
    "487046b0-2368-40da-9cba-407f65177f0b": {
        "text_answer": "No   Explanation  The statement more than 75 of the patients in the primary clinical trial suffered a specific adverse event type is not entailed by the evidence The evidence lists several different types of adverse events and the number of patients who experienced each type but it does not add up to more than 75 of the total number of patients The most common adverse event type listed General disorders and administration site conditions",
        "label": "Contradiction"
    },
    "95a5ceca-3b9c-4760-98be-98c78559a161": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston The exclusion criteria for the two trials also differ significantly",
        "label": "Contradiction"
    },
    "bf8e8814-f9d9-422e-ab84-fea4f6c85ede": {
        "text_answer": "No  A woman who has had a lumpectomy is eligible for the secondary trial as long as she meets the other inclusion criteria She is also eligible for the primary trial as long as she meets the inclusion criteria for that study as well",
        "label": "Contradiction"
    },
    "046763cb-f08d-4032-8b54-03bc14cb9d69": {
        "text_answer": "  No   Explanation   Anorexia is a specific eating disorder characterized by a persistent refusal to maintain a normal body weight fear of gaining weight and distorted body image The inclusion criteria for the clinical trial specify that participants must have a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs indicating a normal or overweight status and a willingness to",
        "label": "Contradiction"
    },
    "83b91b04-e464-483d-94d2-079690030cb5": {
        "text_answer": "No  Explanation  The statement both the secondary and primary clinical trials observed multiple aes including headache and joint pain in various patients is not directly entailed by the evidence provided The evidence only lists specific adverse events observed in each trial and does not mention headache or joint pain",
        "label": "Contradiction"
    },
    "7e4c273a-fc2f-4589-beb8-4e90f3198962": {
        "text_answer": "No The statement is not directly related to the evidence provided The evidence discusses interventions for radiation dermatitis in breast cancer patients while the statement is about oral cavity lipoma a different condition",
        "label": "Contradiction"
    },
    "dc855f0a-1281-44f9-b68c-89044aaa73af": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement is about the genera in the Clostridiaceae family that cause adverse events related to the musculoskeletal system while the evidence only provides information about the types and frequencies of adverse events observed in two clinical trials The statement makes an additional assumption that is not supported by the evidence",
        "label": "Contradiction"
    },
    "c10c78c7-51f4-4440-8164-07b059e01fd9": {
        "text_answer": "Yes The evidence does not report any cases of hypertension dehydration or dyspnea in either cohort",
        "label": "Entailment"
    },
    "feca3829-9b38-4738-8bad-e8a0fcf9029f": {
        "text_answer": "No  Explanation  The statement recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were all more frequently reported as adverse events in the secondary clinical trial than in the primary clinical trial is not entailed by the evidence provided  The evidence only shows that the frequency of adverse events was different between the two trials for some conditions but it does not",
        "label": "Contradiction"
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the given inclusion criteria However the eligibility for the secondary trial cannot be determined without additional information such as the patients creatinine level and ECOG performance status",
        "label": "Entailment"
    },
    "4afbbadf-10c0-4e7e-87d3-2516aeafbe73": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not indicate that any patient in the GTx024 1mg group gained over 10 kilos of lean body mass The median change in lean body mass for this group was 155 kg with a range of 206 to 1264 kg This means that some patients lost lean body mass during the study while others gained more",
        "label": "Contradiction"
    },
    "467c8a18-4a72-4ea4-9b8d-ae43d786b5b0": {
        "text_answer": "  Yes The statement is entailed by the evidence as nonsmall cell lung cancer breast cancer and urothelial transitional cell carcinoma are listed as eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "f0eaf3f3-5c84-4cd8-8a13-ef1af710cf9e": {
        "text_answer": "No  Explanation  The statement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the severity or type of adverse events nor does it compare the primary and secondary trials in terms of suspected serious adverse reactions Therefore",
        "label": "Contradiction"
    },
    "8c7a92ab-80cd-4bb4-8b03-fa5f6776ca5a": {
        "text_answer": "Yes  Explanation  The primary clinical trial exclusion criteria include patients with uncontrolled intercurrent illness which can include psychiatric illness The secondary clinical trial specifically includes patients with a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index ISI indicating moderate to severe insomnia Therefore both trials exclude patients with severe forms of insomnia  Reg",
        "label": "Entailment"
    },
    "7b1befbe-fec3-4554-89f7-323acfc66d62": {
        "text_answer": "Yes The statement is entailed by the evidence as it accurately reflects the percentage change in Ki67 expression reported in the trial",
        "label": "Entailment"
    },
    "b8c9f988-e270-467e-b7a8-b71b1ae302ce": {
        "text_answer": "Yes The evidence states that individuals with a CDK46 mutation are eligible to participate in the clinical trial under the tumor type Any tumor type if tissue tests positive for CCND1 amplification CDK46 mutation CCND2 amplification OR any other functional alteration at the G1S checkpoint",
        "label": "Entailment"
    },
    "12ca7fab-5b2d-4889-b4b9-458fc6f08f33": {
        "text_answer": "Yes The primary trial includes a performance status condition ECOG  2 as an eligibility criterion while the secondary trial does not mention any performance status condition in its inclusion criteria",
        "label": "Entailment"
    },
    "a66238c5-3c2f-47a8-8b38-aad66299aed0": {
        "text_answer": "Yes  Explanation The evidence states that cohort 1 patients receive 14mgm2 of eribulin while cohort 2 patients receive 75mgm2 of docetaxel Since 14mgm2 is lower than 75mgm2 the statement that cohort 1 receives lower doses of eribulin than cohort 2",
        "label": "Entailment"
    },
    "136c5db2-719f-458f-9d88-f5596886ed96": {
        "text_answer": "No   Explanation   The statement is not directly entailed by the evidence provided as the two trials measure different outcomes The first trial investigates the effect of sulforaphane supplements on isothiocyanate concentration in urine while the second trial examines the impact of physical therapy on pain reported by participants The statement mentions chromosome band 7p which is not related to the content of the evidence",
        "label": "Contradiction"
    },
    "2d84efa0-fd43-40fa-a809-f9be6d197371": {
        "text_answer": "yes The statement is entailed by the exclusion criteria listed in the secondary clinical trial evidence Patients with recent chemotherapy or radiotherapy unstable angina or neuropathy rating of grade 2 or above are explicitly listed as exclusion criteria in the secondary trial The statement in the question is a summary of these exclusion criteria",
        "label": "Entailment"
    },
    "98923c9c-1126-436a-9263-a9deca239ba6": {
        "text_answer": "Yes   Explanation  The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib  Docetaxel and Docetaxel  Placebo These are different drugs so the trials do not test the same drugs",
        "label": "Entailment"
    },
    "0d49e948-aea6-4067-8f7e-b480e47d3407": {
        "text_answer": "No  Explanation  The statement a young girl with a Newly diagnosed PRpositive HER2 positive breast cancer could be eligible for the secondary trial and the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial separately The statement suggests that a patient with PRpositive HER2positive breast cancer could be eligible for both trials but the evidence",
        "label": "Contradiction"
    },
    "080fe5be-37c4-4d7f-a985-58c520750620": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of Paraplatin in the given clinical trial interventions",
        "label": "Contradiction"
    },
    "4625018e-c34b-4156-8c63-572712bdbf30": {
        "text_answer": "Yes The statement mentions several cases of Anaemia and Febrile neutropenia in cohort 1 which is consistent with the evidence showing 1 case of Anaemia and 1 case of Febrile neutropenia in cohort 1 The statement does not mention Pancytopenia but the evidence shows that there were 0 cases of Pancytopenia in cohort 1 which is also consistent",
        "label": "Entailment"
    },
    "6d94034f-7e7f-4220-a193-bdd926f8b993": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the secondary trial does not measure heart rate or effectiveness of cardio exercises but rather measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "dea7a7bb-563c-4b02-9011-16fa165820c4": {
        "text_answer": "Yes However the statement is not directly related to the outcome measures in the evidence It is a separate fact about NDC billing codes",
        "label": "Entailment"
    },
    "387b9e0a-aafd-4140-921b-3609114410cb": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "55eb3029-c826-4cae-a130-7cc8fbc80121": {
        "text_answer": "  No the statement is not entailed by the evidence as it only mentions Venezuela and the requirement for Her2neu breast cancer in the secondary trial but the evidence provides detailed inclusion and exclusion criteria for both trials without specifically mentioning Venezuela or any particular cancer type for the primary trial",
        "label": "Contradiction"
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "text_answer": "Yes with the caveat that the primary trial did not directly compare the two groups so no significant differences between them does not necessarily mean no differences in diagnostic accuracy However the statement does not directly address the secondary trial results which do show some differences between the Reflexology Group and Control Group in terms of fatigue levels",
        "label": "Entailment"
    },
    "d9c0a0a4-0bdf-4b77-b442-78d609b06854": {
        "text_answer": "No  Explanation  The statement both cohorts a and b in the primary clinical trial are given identical two im injections of ld v935 at similar stages of the cycle is not entailed by the evidence While it is true that both cohorts receive two IM injections of V935 LD the timing of these injections is different between the two cohorts In Cohort A the injections",
        "label": "Contradiction"
    },
    "61de0370-1d90-4657-b0f1-fff95fc5efa5": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the participants in the primary trial who receive injections are given intramuscular im injections not subcutaneous SC injections as stated in the statement Additionally the participants in the secondary trial do receive injections specifically epoetin beta injections",
        "label": "Contradiction"
    },
    "1108856e-d4cc-488e-a0d8-98274fc38dfd": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary and secondary trials do involve different interventions one of which includes lenalidomide in the primary trial and lapatinib in the secondary trial The statement incorrectly asserts that neither trial uses lenalidomide or lapatinib and also fails to mention the specific durations of the trials which are provided in the evidence",
        "label": "Contradiction"
    },
    "840d1cd7-85bd-4d25-a4db-0af6ff989e1d": {
        "text_answer": "Yes The primary trial did not show significant differences between the two algorithms but the secondary trial showed differences between the reflexology and control groups",
        "label": "Entailment"
    },
    "8667c9e0-5040-46af-b784-4214164c4c0c": {
        "text_answer": "No  Explanation  The statement the primary clinical trial witnessed many psychiatric adverse incidents notably including an eating disorder and schizophrenia is not entailed by the evidence provided The evidence only mentions one case of suicidal ideation which is not the same as an eating disorder or schizophrenia Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "f69e913e-7050-463f-aa18-ad022451d483": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions that patients who have received antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry are excluded from the trial",
        "label": "Entailment"
    },
    "50e74c9b-3673-4222-99f0-63f82e40b288": {
        "text_answer": "No  Explanation  The statement The same number of AEs were reported for both cohorts in the primary trial is not directly entailed by the evidence provided The evidence only shows the number and types of adverse events AEs for each cohort in the primary trial It does not indicate that the same number of AEs were reported for both cohorts",
        "label": "Contradiction"
    },
    "e78237d7-bbb7-4586-9950-5eabb10254f9": {
        "text_answer": "  There is no direct evidence in the provided information to support the statement about the number of treatment emergent adverse events and serious treatment emergent adverse events in each group The evidence only reports the mean number of hot flashes per 24 hours for each group",
        "label": "Contradiction"
    },
    "e9a96af7-c9f7-49cd-a291-2c0abb94719c": {
        "text_answer": "Yes  Explanation The evidence states that out of 21 participants only 9 experienced a reduction in circulating tumor cells CTCs one month post autologous hematopoietic stem cell transplantation AHST which is less than half of the individuals involved in the trial Therefore the statement following highdose chemotherapy with purged autologous stem cell products less than half of the individuals experienced",
        "label": "Entailment"
    },
    "f0a41373-f03b-471f-9f0f-381f8b09a950": {
        "text_answer": "No  Explanation  The statement Syncope which occurred in 2500 of the primary trial patients is the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial is not directly entailed by the evidence provided The evidence only states that Syncope occurred in 2500 of the primary trial patients and in 084 of the secondary trial",
        "label": "Contradiction"
    },
    "63966dc4-b12e-4e45-befe-50b9c19a702a": {
        "text_answer": "Yes  Explanation The evidence describes two different treatment methods in the primary clinical trial Intervention 1 with two IM injections of V935 LD and Intervention 2 with three EP injections of V934 LD followed by two IM injections of V935 LD The statement in question asserts that neither Cohort A nor Cohort B received electroporation injections of LD V934",
        "label": "Entailment"
    },
    "a85102e4-fe19-4b6e-8dd5-4cb9ffd64176": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial involves CBTI and placebo while the secondary trial involves two different drug combinations MCS110 and PDR001 The statement only mentions simvastatin which is not present in either trial",
        "label": "Contradiction"
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare abilities and are confined to bed or chair for less than 50 of waking hours",
        "label": "Entailment"
    },
    "04c1483e-d2bb-40a2-b215-ede1e3c7c973": {
        "text_answer": "No  Explanation  Although both trials use the same medications FMX and lapatinib the dosages and intervals of administration are different In the primary trial FMX is given as a single bolus IV injection of 5 mgkg on Day 1 followed by MM398 treatment within 7 days In contrast lapatinib is given at a constant dose of 1500 mg QD while",
        "label": "Contradiction"
    },
    "06929ac9-6df2-4e5b-afd8-656a1f9989d1": {
        "text_answer": "No  Explanation  The statement the primary trial tests one specific drug whereas the secondary trial involves stimulated exercises only is not entailed by the evidence Both trials involve massage therapy as a common intervention and the primary trial also includes psychosocial assessment and care qualityoflife assessment and pain therapy as intended interventions The secondary trial involves the testing of two different doses of a drug PF066470",
        "label": "Contradiction"
    },
    "912414db-d418-4c96-b06b-e26d0ac1992f": {
        "text_answer": "No  Explanation  The statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events observed in two separate cohorts of the primary trial It does not specify which cohort had several cases",
        "label": "Contradiction"
    },
    "dacc42a9-68cc-4b2c-9377-648486729eed": {
        "text_answer": "Yes   Explanation The statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed by the evidence as the trial involves the use of epirubicin cyclophosphamide docetaxel and trastuzumab",
        "label": "Entailment"
    },
    "eb68a94f-7693-4158-b492-7b5a03d85b96": {
        "text_answer": "Yes The statement that patients in the secondary clinical trial encountered adverse events specifically eyelid oedema upper gastrointestinal haemorrhage and chest pain and no such instances were reported in the primary clinical trial is entailed by the evidence provided",
        "label": "Entailment"
    },
    "e83cb970-0b3c-4b61-8a44-49a9a3f61744": {
        "text_answer": "  No   Explanation   The primary clinical trial only includes postmenopausal women with early stage breast cancer and low vitamin D levels while the secondary clinical trial includes healthy participants and HER2positive females with a history of breast cancer Therefore not all study groups in the two trials accept patients who have been diagnosed with breast cancer",
        "label": "Contradiction"
    },
    "47b36e1f-90d5-4a42-b359-95783c7ae965": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as there is no information about radiation therapy doses in the provided evidence The evidence only mentions the interventions used in each trial which include eribulin mesylate axitinib and docetaxel but no information about radiation therapy doses or frequencies Therefore it is not possible to determine if the primary trial patients receive higher doses of radiation therapy than the secondary",
        "label": "Contradiction"
    },
    "033cc376-5268-43c7-bf06-ca3503971f41": {
        "text_answer": "Yes The evidence states that no distinguishable pattern was detected for the expression of the evaluated genes in cohorts 1 and 2 which correspond to the normal and lownormal Vitamin D level groups respectively",
        "label": "Entailment"
    },
    "d1eb9a24-13e8-43de-ba1c-7b17e35e7ab3": {
        "text_answer": "No  Explanation  The primary trial measures tumor diameter in centimeters cm while the secondary trial measures the number of participants with solid tumor response These are not the same units of measure and cannot be considered to align perfectly",
        "label": "Contradiction"
    },
    "e40080bc-499c-4af9-a437-be6688894d22": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not support the statement that less than 110 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products The statement goes beyond the information given in the evidence which only reports the number of participants with a reduction in CTCs at one month posttransplantation The",
        "label": "Contradiction"
    },
    "2f6605a0-31b3-43e1-9ec7-3e262cb9acf0": {
        "text_answer": "No  Explanation  The statement is not a direct entailment of the evidence as the statement is about a nonhost organism identifiers supplemental qualifiers dataset while the evidence is about inclusion and exclusion criteria for a breast cancer clinical trial The statement mentions specific conditions that patients cannot have if they want to participate in the trial but it does not directly state that these conditions are part of the trials inclusion or exclusion criteria The",
        "label": "Contradiction"
    },
    "56daf92a-2c6e-4b2d-b532-3035e757e98c": {
        "text_answer": "No  Explanation The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 500 of the primary trial patients is not entailed by the evidence The evidence only states that syncope occurred in 212 1667 patients in the primary trial and in 1119 084",
        "label": "Contradiction"
    },
    "7a8f6698-eb2a-4695-b521-7e42522afdba": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide any information about chromosomal abnormalities in the trial The evidence only mentions the interventions memantine and placebo their administration frequencies and durations",
        "label": "Contradiction"
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "text_answer": "Yes  Explanation  The statement All Infections and Fever cases in the primary trial were for patients in cohort 1 is entailed by the evidence because all of the Infections and Fever cases mentioned in the evidence are from cohort 1 Therefore there are no Infections and Fever cases in cohort 2 based on the evidence provided",
        "label": "Entailment"
    },
    "88490a99-ea34-4aa1-a838-b3a1cffa41a0": {
        "text_answer": "Yes The statement is entailed by the evidence as the statement mentions wound dehiscence which is listed as an adverse event in the evidence",
        "label": "Entailment"
    },
    "153e0c8b-e056-4dd9-9337-156752b249c1": {
        "text_answer": "No   Explanation  The evidence provided does not mention the number of adverse events recorded in either trial beyond those related to Adverse Event 1 The statement that there are 200 recorded adverse events is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e46defaa-44a0-4919-bd9b-aa018de05da1": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the primary and secondary trials measure different outcomes The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in response to estriol vaginal gel treatment while the secondary trial determines the maximum tolerated dose MTD of ruxolitinib in combination with paclitaxel based on the occurrence of dose",
        "label": "Contradiction"
    },
    "e9b973a3-aabd-484d-8c7c-0bd2296bf0c5": {
        "text_answer": "No  Explanation  The statement does not provide enough information to be entailed by the evidence The evidence only reports the number of adverse events for two different trials but it does not provide any information about the relationship between those adverse events and the NIH modified oral mucosa rating scale OMRS scores or the specific cases of Asthenia and Pyrexia mentioned in the statement Therefore it is not possible to determine if the",
        "label": "Contradiction"
    },
    "6151cf03-78f0-4404-87bc-beacea52cd95": {
        "text_answer": "Yes for the secondary trial regarding pulmonary embolisms and No for the primary trial regarding breast implants",
        "label": "Entailment"
    },
    "979f5a49-0af6-4ea3-a410-d79cf3540d01": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial does not involve iv infusions of amitriptyline but rather oral pregabalin The secondary trial involves the use of different chemotherapeutic agents liposomal cytarabine and highdose methotrexate not carmustine and cyclophosphamide as stated in the question",
        "label": "Contradiction"
    },
    "d620b526-d227-42a4-a6cc-800df41f854a": {
        "text_answer": "Yes  Explanation  The statement approximately 50 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group can be calculated as follows  First we need to find the difference in percentage of participants with a decrease in GFS between the two groups  ER group 286 1",
        "label": "Entailment"
    },
    "4e0fae11-64b8-403f-8001-45ef8078a145": {
        "text_answer": "No  Explanation The statement syncope was the most frequently reported adverse event in both primary clinical trial and secondary clinical trial is not entailed by the evidence The evidence only reports that syncope was the most frequently reported adverse event in the primary clinical trial but it does not mention anything about the secondary clinical trial The secondary clinical trial had a different set of patients and may have had different adverse events Therefore it is not accurate to make",
        "label": "Contradiction"
    },
    "c5feab6a-263d-41c4-8c21-cfa5ffe80a3d": {
        "text_answer": "No  Explanation  The statement participants of the primary clinical trial undergo complete breast radiation therapy in contrast the secondary clinical trial participants from both cohorts take 500 mg of fulvestrant in tablet form twice daily is not entailed by the evidence  The evidence only mentions that participants in the primary trial undergo radiation therapy but it does not specify that they undergo complete breast radiation therapy",
        "label": "Contradiction"
    },
    "c36a1fe4-cc98-4a41-94c5-88458737d070": {
        "text_answer": "No  Explanation  The statement on average patients from the primary trial survive over 24 months is not directly entailed by the evidence provided The evidence only gives the median survival times for each group not the average survival time for all patients in the trial Additionally the statement that over 50 patients from each cohort survived more than 2 years is also not directly supported by the evidence as the number of patients who survived",
        "label": "Contradiction"
    },
    "a29b69ee-502b-4d86-b028-be9a56bfb7f6": {
        "text_answer": "Yes  Explanation  The statement the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial demonstrated a better ORR than its paclitaxel plus bevacizumab counterpart with a larger participant pool is entailed by the evidence provided The evidence shows that the ORR for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG",
        "label": "Entailment"
    },
    "843b1c8e-8d10-4f20-8514-4ba986071878": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence does not provide any information about a treatment regimen for hepatobiliary cancers using infigratinib or its dosing schedule The evidence only describes interventions for vitamin D repletion and epoetin beta administration in separate trials",
        "label": "Contradiction"
    },
    "c6c84bb8-fea8-4ad6-8ec7-1677049d1fe4": {
        "text_answer": "Yes The primary clinical trial has different eligibility criteria for the number and size of cerebral metastases compared to the secondary clinical trial Therefore a patient with 23 cerebral metastases may still be eligible for the primary trial even if they are not eligible for the secondary trial",
        "label": "Entailment"
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence states that cohort 1 receives Dexamethasone preoperatively and cohort 2 receives Dexamethasone 2 hours after the operation",
        "label": "Entailment"
    },
    "5feb2522-300c-490a-be54-07b2c99d397e": {
        "text_answer": "No  Explanation  The statement There are several cases of swelling hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial have difficulty moving arm side to side is not entailed by the evidence provided The evidence only states that there were no cases of adverse events 1 unspecified and adverse events 2 in both trials It does not mention any cases of difficulty moving the arm from",
        "label": "Contradiction"
    },
    "145683a3-f65e-4b4d-98e0-662cbe830c5d": {
        "text_answer": "No  Explanation  The statement the primary trial does not employ any cycle for its intervention is not entailed by the evidence In the primary trial each treatment cycle is defined as 21 days which is a cycle length Therefore the statement is not accurate The secondary trial also follows a specific 2week cycle for imaging procedures but this is not the same as the primary trials intervention not having a cycle",
        "label": "Contradiction"
    },
    "a020a0f1-c729-44ea-a40e-2700cc846d67": {
        "text_answer": "No  The statement is not entailed by the evidence as the clinical trial described in the evidence is for patients with breast cancer considering aromatase inhibitor therapy and bisphosphonate treatment not those diagnosed with early stage nonHodgkin lymphoma considering radiation therapy",
        "label": "Contradiction"
    },
    "cccd9ad0-9bac-43fb-aaaf-8f99e725c572": {
        "text_answer": "No  The statement is not directly related to the inclusion or exclusion criteria for either trial provided in the evidence The statement pertains to a different type of cancer rectal carcinoma and does not affect eligibility for the primary or secondary trials",
        "label": "Contradiction"
    },
    "f8accdcd-5a92-4fff-9e6b-6a2d141b5ee4": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the evidence does not mention anything about severe anaphylactic reactions to trastuzumab being a reason for exclusion from the trial The evidence only mentions a history of any grade 3 or 4 allergic reactions attributed to trastuzumab as an exclusion criterion",
        "label": "Contradiction"
    },
    "c5f69124-61d3-46bc-b233-5c38f4b1f5d0": {
        "text_answer": "Yes  Explanation  The statement neither the primary clinical trial nor the secondary clinical trial had patients experiencing less than 3 separate adverse events is entailed by the evidence because in both trials every patient experienced at least 3 separate adverse events Therefore no patient in either trial had less than 3 separate adverse events",
        "label": "Entailment"
    },
    "29bfa3a7-a8f2-4294-b745-d125cac8e40f": {
        "text_answer": "Yes The statement does not contradict the evidence and the evidence does not mention any unexpected deaths or hospitalizations related to hypoxia or CTCAE",
        "label": "Entailment"
    },
    "cee38f66-699d-4c68-85ec-8ed0ba55fd9d": {
        "text_answer": "No  Explanation  The statement the treatment plan in the primary clinical trial includes administration of one drug zd1839 in contrast the secondary clinical trials treatment approach involves the expectation of at least three simultaneous drugs such as zoledronic acid samarium153 and pegfilgrastim is not directly entailed by the evidence provided  The evidence only states that in the primary trial the intervention",
        "label": "Contradiction"
    },
    "a171374b-4c87-4b1a-94f9-8f0238cdce4f": {
        "text_answer": "Yes  Explanation The evidence describes the neoadjuvant therapy regimen given to study participants which includes epirubicin cyclophosphamide docetaxel and trastuzumab Therefore the statement that the study participants are given four distinct drugs is entailed by the evidence",
        "label": "Entailment"
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "text_answer": "Yes The statement is entailed by the evidence as patients in the secondary trial must have a diagnosed alteration in one or more of the listed genes to be included",
        "label": "Entailment"
    },
    "5ee999ab-5129-4ea2-a988-b2a223d82acd": {
        "text_answer": "Yes  Explanation The evidence states that both the placebo and memantine interventions are administered twice daily BID for 81 days in the absence of unacceptable toxicity and then continued for an additional 12 weeks Therefore the frequency and duration of administration are identical for both interventions as stated in the question",
        "label": "Entailment"
    },
    "8563b314-6b0f-432c-9ffc-203c3dcb0a3f": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID grade 1 anal mucositis ctcae is asymptomatic or mild symptoms intervention not indicated is not entailed by the evidence  The evidence only provides information about the interventions used in the",
        "label": "Contradiction"
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "text_answer": "No  The most common adverse event recorded in the primary trial was nausea or vomiting each with a frequency of 392 Coronary artery stenosis was not mentioned as an adverse event in the evidence",
        "label": "Contradiction"
    },
    "478be8bf-505c-44ed-98d6-41b48ab8d9b3": {
        "text_answer": "No  Explanation  The statement cohort 2 from the secondary clinical trial demonstrated superior outcomes compared to the same cohort from the primary clinical trial is not entailed by the evidence provided The evidence only reports the percentage of participants analyzed in each group of the secondary clinical trial who underwent additional procedures It does not provide any information about the outcomes or comparisons between the primary and secondary trials",
        "label": "Contradiction"
    },
    "670ba789-279e-420d-b45e-c63836169e9b": {
        "text_answer": "No  Explanation  The statement in the primary trial results there were less patients with stable disease in week 20 than week 34 is not directly entailed by the evidence provided The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 for each armgroup It does not provide the number of participants with stable disease at week 20",
        "label": "Contradiction"
    },
    "a55a8c7f-7e1a-4bd4-8f2b-9222002f5d27": {
        "text_answer": "Yes   Explanation  The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel These are different drugs",
        "label": "Entailment"
    },
    "fea6712a-10d7-47bb-88d1-d286e0ba47a1": {
        "text_answer": "No   Explanation  The statement provided does not mention any adverse events or their occurrence in the trials The statement is about metastatic kidney carcinoma while the evidence is about adverse events in two trials for an unspecified condition",
        "label": "Contradiction"
    },
    "543c8639-a266-42af-9896-05a77d822c79": {
        "text_answer": "  Primary trial Yes disparities in assessment Secondary trial No uniform results",
        "label": "Entailment"
    },
    "8b7bbb44-a7d7-4317-af85-f78d559e0e63": {
        "text_answer": "Yes The primary trial involves oral administration of cabergoline while the secondary trial involves intravenous administration of pixantrone",
        "label": "Entailment"
    },
    "782c9a26-ba09-4eef-8076-bd8831c9f986": {
        "text_answer": "No  The evidence explicitly states that patients with brain metastases including leptomeningeal carcinomatosis are not eligible for the clinical trial",
        "label": "Contradiction"
    },
    "5e5c4aab-2006-4a00-b11c-3dced5aac12c": {
        "text_answer": "Yes The statement is entailed by the evidence as it accurately reflects the interventions given in each cohort of the primary clinical trial",
        "label": "Entailment"
    },
    "db08ca44-cd18-49ff-ae80-4a3f0bb625b5": {
        "text_answer": "No  Explanation  The statement 50 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for one type Adverse Events 1 in each trial Additionally the statement that none of the adverse events in the secondary trial affected more than 20 of patients apart from skin infections is not entirely accurate based on the evidence While it is",
        "label": "Contradiction"
    },
    "8559afe8-c0a0-4c88-81bb-ef29cdb08026": {
        "text_answer": "Yes The evidence indicates that pain was measured daily for 10 weeks suggesting that instances of pain were frequent during the study",
        "label": "Entailment"
    },
    "8679e654-7db4-4fd2-8fbc-41028fedb540": {
        "text_answer": "No  Explanation  The statement there are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is not directly entailed by the evidence provided The evidence only states the number and percentage of adverse events in each trial but it does not compare the number or percentage of specific adverse events between the two trials Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "2dfe7dda-41ae-48bc-aac5-1309cb87e4c1": {
        "text_answer": "Yes The evidence does not explicitly state that surface immunoglobulinpositive cells are a requirement for inclusion in the trials but it does not exclude patients with stage 4 cancer as long as they meet the other inclusion criteria and provide informed consent",
        "label": "Entailment"
    },
    "4703e57c-efe0-4316-a1a5-8ac60b030e84": {
        "text_answer": "Yes  Explanation  The statement recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were more frequently observed as adverse events in the primary clinical trial compared to the secondary clinical trial is entailed by the evidence as the primary clinical trial had a higher incidence of these adverse events compared to the secondary clinical trial",
        "label": "Entailment"
    },
    "17adb81b-92e7-4ed5-b443-287a5df2fb37": {
        "text_answer": "No  The evidence does not mention anything about a her2neu peptide vaccine or sargramostim being administered in the clinical trial",
        "label": "Contradiction"
    },
    "be4a58c2-e939-4583-a129-2d0bdba8e3a8": {
        "text_answer": "Yes  Explanation  The primary clinical trial and the secondary clinical trial both report on the incidence of adverse events among participants In the primary trial the focus is on evaluating the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 In the secondary trial the focus is on the percentage of participants with adverse events of primary interest ",
        "label": "Entailment"
    },
    "f180c18c-f332-4f6b-9367-c349d3518d55": {
        "text_answer": "Yes The statement there were no instances of death or hospitalization is entailed by the evidence as the evidence reports no occurrences of death or hospitalization in cohort 2 The statement also correctly reports the absence of hospitalization but it is not necessary to the entailment since the question asks only about death and hospitalization",
        "label": "Entailment"
    },
    "cedccbca-876d-44b2-bf5a-9c9c5090d46c": {
        "text_answer": "Yes  Explanation  The evidence states that there were no adverse events reported in both cohorts of the primary clinical trial for Adverse Events 1 and Adverse Events 2 The statement in the question also asserts that no adverse events were reported making it entailed by the evidence",
        "label": "Entailment"
    },
    "773e93d2-a81d-48cd-96ec-4b92d537ac35": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence reports that 13 of participants with HER2 primary breast cancer developed imagable HER2 metastases during the 3year followup period after undergoing HER2targeted PETCT using 89Zrtrastuzumab",
        "label": "Entailment"
    },
    "a546a2b7-a287-47a1-91b1-4368fef15369": {
        "text_answer": "No  Explanation The statement does not follow directly from the evidence provided The evidence only mentions the frequency of Denosumab administration in the secondary trial but it does not mention the dosage Similarly the primary trial mentions the dosages of both Denosumab and Zoledronic Acid in the intervention groups but it does not compare the dosages between the two interventions directly Therefore the statement goes beyond the information given in",
        "label": "Contradiction"
    },
    "cacd8f36-53c3-4002-9d2d-09bd2976bf40": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the given inclusion criteria However the eligibility for the secondary trial cannot be determined without additional information such as the patients creatinine level total bilirubin level ALT and AST levels left ventricular ejection fraction and prior anthracycline dosage",
        "label": "Entailment"
    },
    "f6dee97d-0025-4837-97a5-dc7748b859a0": {
        "text_answer": "No   Explanation  The evidence states that the starting dose of bevacizumab for cohort 2 is 10 mgkg not 5 mgkg",
        "label": "Contradiction"
    },
    "aac508e7-cd87-40ad-afa6-bc977ab393aa": {
        "text_answer": "No  Explanation  The statement there was a complete absence of both gastrointestinal adverse events and psychiatric events in the primary clinical trial is not entailed by the evidence The evidence shows that there were no gastrointestinal events of vomiting in both trials but there were instances of nausea and colitis ischaemic in the first trial and vomiting in the second trial The evidence does not provide any",
        "label": "Contradiction"
    },
    "2ca3ca9f-96ac-46e7-a1ce-873c580eff25": {
        "text_answer": "No  Explanation  The statement 14 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not directly entailed by the evidence provided The evidence only states that 14 of patients in the second trial suffered increased pleural effusion but it does not provide information about the occurrence of rapid disease progression in those patients Therefore it is not possible to determine if 14 of patients",
        "label": "Contradiction"
    },
    "7c60cd27-5e72-4cd6-9e2c-de28c0c11fe4": {
        "text_answer": "  Yes for the primary trial and Maybe for the secondary trial  Explanation  The patient meets the inclusion criteria for the primary trial as they have a histologically verified diagnosis of a solid tumor malignancy breast cancer appropriate diagnostic workup and adequate bone marrow function However the patients hemoglobin level is below the required minimum for the secondary trial 009 kgm3",
        "label": "Entailment"
    },
    "64a7bb90-c51d-4f6b-942e-55322c25e1b8": {
        "text_answer": "Yes The statement is entailed by the evidence as both groups undergo identical imaging procedures with a marginally higher dose of 18FFPPRGD2 for the first cohort",
        "label": "Entailment"
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "text_answer": "No   Explanation The evidence does not state that the final decision for inclusion in the clinical trial is made by the patients first kin The evidence only states that the final eligibility for a clinical trial is determined by the health professionals conducting the trial",
        "label": "Contradiction"
    },
    "ac762601-55f3-434a-bf5a-690ed8a3f735": {
        "text_answer": "Yes  Explanation The statement a quarter of cohort 2 patients experience an increased occurrence of pleural effusion is entailed by the evidence as it is explicitly stated in the Adverse Events 2 section that 14 2500 of cohort 2 patients experienced an increased pleural effusion",
        "label": "Entailment"
    },
    "25b0a430-e35c-496c-8874-92be378b044b": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale not blood pressure level The primary trial measures the change in isothiocyanate in urine samples as assessed at baseline and after completion of study therapy",
        "label": "Contradiction"
    },
    "14e1403f-9bb6-40cc-88fe-4b2f110e7b0d": {
        "text_answer": "yes the statement is entailed by the evidence as talazoparib is one of the interventions mentioned in the trial and the dosage is specified in the statement",
        "label": "Entailment"
    },
    "5b23afbf-8b5c-441b-99b2-295c66958545": {
        "text_answer": "Yes for claustrophobia No for osteoporosis The statement is entailed by the evidence for claustrophobia as both trials exclude women with severe claustrophobia However it is not entailed by the evidence for osteoporosis as the primary trial excludes women with renal impairment which can be a symptom of osteoporosis but it does not explicitly exclude",
        "label": "Entailment"
    },
    "ca97cc92-91e7-426a-b48f-d1729f13ee13": {
        "text_answer": "No  Explanation The evidence provides the median PFS for each treatment group but it does not indicate the longest PFS observed in any individual patient",
        "label": "Contradiction"
    },
    "3d073609-1a5e-46fb-b43d-c4505c72029d": {
        "text_answer": "  No the statement is not entailed by the evidence for the primary trial as patients with a history of pulmonary embolisms are excluded from the study However the statement is entailed by the evidence for the secondary trial as patients with breast implants are not explicitly mentioned as an exclusion criterion",
        "label": "Contradiction"
    },
    "d1bbbc84-4136-43c4-b7b6-7e88e7c82730": {
        "text_answer": "No  Explanation  The statement every cohort in the primary clinical trial is subjected to the same volume of docetaxel doxorubicin and cyclophosphamide with the same frequency is not entailed by the evidence While both interventions involve the use of docetaxel doxorubicin and cyclophosphamide the dosages and frequencies differ between the two interventions",
        "label": "Contradiction"
    },
    "7a4a1281-d17b-4ad5-aa63-7329abdd0cdd": {
        "text_answer": "Yes for infection and asymmetry   Explanation The statement there were fewer cases of infection asymmetry and deflation in the primary trial compared to the secondary trial is entailed by the evidence for infection and asymmetry but not for deflation since there were no cases reported in the secondary trial for deflation",
        "label": "Entailment"
    },
    "ca7d916d-c8d4-4e6b-8b92-3d08bbdf7915": {
        "text_answer": "No  Explanation  The statement ce mark is a label which indicates that a product conforms with the essential requirements of the applicable european community directives is not related to the evidence provided The evidence only includes information about two clinical trials their outcome measurements results and participant numbers It does not mention the CE mark or any product conforming to it",
        "label": "Contradiction"
    },
    "1fde2a5a-bf6c-41cf-ba82-7cbea262f258": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial states that patients received 120 milligrams of denosumab every 4 weeks not 1200 milligrams every month Additionally the secondary trial does involve the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy but it does not involve denosumab",
        "label": "Contradiction"
    },
    "52ab8ce2-300e-40db-be56-d6e7c608324e": {
        "text_answer": "No  Explanation  The statement an adult who was diagnosed with ilddpld in the past three years who has an estimated survival time of six months will qualify for the primary clinical trial is not entailed by the evidence provided The evidence only mentions that patients must have a life expectancy of greater than 3 months to be eligible for the trial ILDDPLD Idiopathic Lung Fibrosis",
        "label": "Contradiction"
    },
    "5c9037a6-53a8-49ec-8aa5-b6a47dee226d": {
        "text_answer": "Yes The statement is entailed by the evidence as Arm A of the trial uses a different dose of gemcitabine 1000 mgm2 compared to Arm B no gemcitabine",
        "label": "Entailment"
    },
    "f212e510-214f-4556-99ed-526946750f55": {
        "text_answer": "Yes The evidence shows an increase in the percentage of participants who were up to date for their colorectal breast and cervical cancer screenings after the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups",
        "label": "Entailment"
    },
    "7e311c72-64a8-49e8-b3c7-952528a9138c": {
        "text_answer": "No  The woman with no history of any type of cancer treatments is not an ideal participant for the primary trial as she does not meet the inclusion criteria for undergoing tissue expander reconstruction following mastectomy She is however eligible for the secondary trial if she meets the other inclusion criteria and has a plasma creactive protein level of 3mgL and a score of 4 or higher on the Single Item Screening Scale for Fatigue",
        "label": "Contradiction"
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1adf360d-dd5e-4bbd-b5f1-8846f84407a6": {
        "text_answer": "  Yes The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II while the secondary trial has the same criteria for all participants",
        "label": "Entailment"
    },
    "829b14c1-9883-4dc4-93f9-40eadb9f9511": {
        "text_answer": "No  Explanation  The statement whole breast radiation therapy is administered to the participants of the primary clinical trial is not entailed by the evidence The evidence only states that whole breast radiation therapy is a part of the standard treatment plan for women with nonmetastatic breast cancer in the primary clinical trial It does not specify that the participants in the primary clinical trial actually received whole breast radiation therapy  On the other hand the secondary clinical",
        "label": "Contradiction"
    },
    "8044ce4d-99e5-4c90-91aa-9c0c85f2c6b4": {
        "text_answer": "Yes Both groups had an overall number of participants analyzed of 1420",
        "label": "Entailment"
    },
    "3942fcf8-27c3-469e-8c6c-b9b2415706fb": {
        "text_answer": "  No   Explanation   The statement Patients with measurable tumors in both breasts are excluded from the primary trial is not directly related to the given evidence The evidence only mentions the inclusion and exclusion criteria for the primary trial which includes having unilateral breast cancer and lymphedema in the ipsilateral upper extremity It does not mention anything about measurable tumors in both breasts The statement about",
        "label": "Contradiction"
    },
    "21e02160-3372-4816-93d2-b3923672111b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only reports on the results of a specific treatment regimen Highdose Chemotherapy with Carboplatin Thiotepa Cyclophosphamide and Stem Cell Transplant and does not mention radiotherapy at all",
        "label": "Contradiction"
    },
    "060ed756-52f8-4b31-ad74-6f6f12d8ca9f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "666ca16f-864e-48b1-9e5e-543759d50b4a": {
        "text_answer": "No  Explanation The statement candidates who are completely independent and physically active engaged in light work activities for long hours are eligible for both primary clinical trial and secondary clinical trial is not entailed by the evidence The evidence provides the inclusion and exclusion criteria for each clinical trial separately and there is no mention of physical activity or work status being a requirement or limitation for either trial",
        "label": "Contradiction"
    },
    "7d7cfab4-e501-4292-bf9c-363ccc1bf1dd": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial the group treated with paclitaxel plus bevacizumab plus gemcitabine had a higher ORR than the paclitaxel plus bevacizumab group is entailed by the evidence as the ORR for the PBG group was 0587 0479 to 0689 compared to ",
        "label": "Entailment"
    },
    "00175c56-59cd-411d-b4e4-b7db0e32fd74": {
        "text_answer": "No  The statement is not about breast cancer and the evidence only pertains to patients with breast cancer considering AI therapy",
        "label": "Contradiction"
    },
    "5b812594-3dcd-42e8-b984-644fe9dcd87e": {
        "text_answer": "Yes  Explanation The evidence provided includes the results of a clinical trial comparing the effects of paced respiration and fast shallow breathing interventions on hot flash frequency in postmenopausal women The statement in question asserts that the trial reported fewer treatment emergent adverse events and serious treatment emergent adverse events in the paced respiration group The evidence does not directly report the number or specifics of adverse events but it does indicate that the",
        "label": "Entailment"
    },
    "96eb2d8a-35d7-4627-9279-5f16363a2e50": {
        "text_answer": "Yes The statement mentions the types of adverse events that occurred in the primary trial which are consistent with the data provided",
        "label": "Entailment"
    },
    "5e2af84e-3876-4822-80c3-99c7774a5bf9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the statement incorrectly states that the primary trial treats its patients with 15 hectograms of oral pregabalin whereas the evidence states that patients receive 150 mg of oral pregabalin twice daily Additionally the statement does not mention the secondary trials intervention correctly as it states Depocyt and hdmtx instead of the specific dos",
        "label": "Contradiction"
    },
    "97632c52-4213-4973-8655-9ea7f3151231": {
        "text_answer": "No  Explanation  The statement on both the primary and secondary clinical trials syncope emerged as the most common adverse occurrence in the patient groups is not entailed by the evidence The evidence only shows that syncope occurred in 2 out of 12 patients in the primary trial which is not the most common adverse occurrence when compared to the other adverse events listed In the secondary trial no information is given about the frequency",
        "label": "Contradiction"
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is not entailed by the evidence The primary trial and the secondary trial have different sets of adverse events The primary trial reports adverse events such as dehydration lymphopenia and neutropenia which are not present in the secondary trial Conversely the secondary",
        "label": "Contradiction"
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "text_answer": "No  Explanation  The evidence provided in the text only reports the mean standardized scores and their standard deviations for the cognitive function tests in the two groups Tamoxifen and Ovarian Function Suppression at the 1year followup The statement all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "72e970ee-fc31-4753-99be-b6757c4c270d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial intervention involves cabergoline which is given orally not intravenously The secondary trial involves pixantrone which is given intravenously in one intervention arm Arm IGroup A and orally in a different intervention arm Arm IIGroup B However the statement only mentions the primary trial and incorrectly states that its intervention is",
        "label": "Contradiction"
    },
    "5315a569-b1a1-49fc-b10f-70840fe34585": {
        "text_answer": "Yes The statement is entailed by the evidence as there are no reported cases of intestinal obstructions or pancytopenia in either trial which is consistent with the statement that these conditions were not observed in the patient cohorts",
        "label": "Entailment"
    },
    "da3b7aca-a0b1-4e25-8c38-11dc8311dc11": {
        "text_answer": "No  The evidence does not provide information about women with both claustrophobia and osteoporosis The statement introduces a new condition progressive central nervous system neoplasm which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "f41cbb25-7c8f-49ac-af06-5c8f1895ab60": {
        "text_answer": "No  Explanation  The statement Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome is not directly entailed by the evidence provided The evidence only lists the adverse events observed in each trial but it does not mention Tumour lysis syndrome specifically Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "7df66c3f-de87-4542-9797-06325684db65": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide information about the type or number of adverse events related to adrenal gland lymphangioma in the primary or secondary trials",
        "label": "Contradiction"
    },
    "a764d548-7ef1-4ec1-bfaf-958536b7342c": {
        "text_answer": "No   Explanation   The statement wwtr1 gene rearrangement is a molecular abnormality indicating rearrangement of the wwtr1 gene is not mentioned in the evidence provided The evidence only discusses the interventions used in the primary and secondary trials and does not mention anything about genetic testing or molecular abnormalities",
        "label": "Contradiction"
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions an Inhalation intervention which is not present in the evidence The evidence only mentions vaginal interventions for the primary trial and acupuncture for the secondary trial",
        "label": "Contradiction"
    },
    "48e84575-b6e1-4280-a170-df30870b50cf": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the use of PD0332991 in the clinical trial The evidence only mentions the dosage and frequency of CUDC101 for cohort 1 5 daysweek and cohort 2 3 daysweek",
        "label": "Contradiction"
    },
    "e173aa91-e6ec-4059-882b-7f015db6e3b3": {
        "text_answer": "No  The evidence describes the patient population and eligibility criteria for the clinical trial but it does not mention anything about exercise being included or excluded as part of the intervention procedure",
        "label": "Contradiction"
    },
    "922b377f-efa2-4bee-9689-f019c011057e": {
        "text_answer": "Yes   Explanation  The statement does not directly mention the BTC gene product but it does not contradict the information in the evidence The evidence describes two groups Cohorts 1 and 2 that follow the same instructional CD for paced breathing with the only difference being the frequency of practice once daily for Cohort 1 and twice daily for Cohort 2 The statement does not make any claims about the B",
        "label": "Entailment"
    },
    "11fd1d6e-0641-4b3d-91ff-9f048584db7b": {
        "text_answer": "No The evidence states that individuals with some evidence of cognitive impairment are eligible to participate but it does not specify that those with frontotemporal or mixed dementia are included",
        "label": "Contradiction"
    },
    "c6d411f9-3d61-459e-b1af-6d8088260804": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "145b92f4-e143-4188-9521-8aade35b2f05": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is not entailed by the evidence provided The evidence only lists the adverse events observed in each trial but it does not state that the trials involved the same patients or that the patients in one trial did not experience any of the adverse events listed for the other trial The statement about the late endosome",
        "label": "Contradiction"
    },
    "6e609d6e-8db0-4adc-bce7-62f7274c10c2": {
        "text_answer": "Yes for the secondary trial However the statement is not directly applicable to the primary trial as it has different inclusion criteria for different age groups",
        "label": "Entailment"
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with tumors positive for CCND1 amplification CDK46 mutation or CCND2 amplification are listed as exclusion criteria in the evidence",
        "label": "Entailment"
    },
    "8acda3ec-8feb-4630-a560-3e66f86c3f21": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about the number of patients who did not experience any adverse events The text only mentions the percentage of subjects who completed the treatment 98 out of 100",
        "label": "Contradiction"
    },
    "e25dfb6a-efaf-4b80-b2b7-316e10b33fe5": {
        "text_answer": "Yes The statement does not explicitly mention the adverse events being related to cell culture images but the evidence provided is about clinical trials involving patients not cell culture images However the statement is still entailed by the evidence because it does not contradict it",
        "label": "Entailment"
    },
    "c0131f92-6373-48c8-9bd5-8d4a42f6674e": {
        "text_answer": "No  Explanation  The statement distinct variations were noted in the results from the primary trial groups whereas the reflexology group and the control group had indistinguishable results in the secondary trial is not directly entailed by the evidence provided The evidence only shows that the primary trial compared the diagnostic accuracy of two algorithms in breast cancer diagnosis using the area under the ROC curve and the secondary trial assessed the effect of reflexology on",
        "label": "Contradiction"
    },
    "e0d92d90-958e-435b-bb1b-7135ed0b2fac": {
        "text_answer": "No  Explanation  The statement the majority of patients in the primary trial experienced complete response by the 24th week is not entailed by the evidence According to the evidence there were no participants with complete response CR at Week 12 or Week 24 Instead there were 4 participants with partial response PR and 12 participants with stable disease SD at Week 12 and 4 participants",
        "label": "Contradiction"
    },
    "136ce42e-bf56-41ff-aed9-fe886636bc1c": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly support the statement that patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions The evidence only compares the average area under the curve aAUCpa of the EORTC ChemotherapyInduced Peripheral Neuropathy Module EORTC QLQ",
        "label": "Contradiction"
    },
    "6af06fcc-363f-4275-81f3-8a01c53931e8": {
        "text_answer": "No  The primary trial excludes women with stage IV disease while the secondary trial includes only women without distant metastatic disease Therefore women with stage IV ER breast cancer who are considering mastectomy are not eligible for participation in both trials",
        "label": "Contradiction"
    },
    "1607973a-34ef-455a-b52b-55ea7aaf6634": {
        "text_answer": "Yes  Explanation  The statement There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial is entailed by the evidence since the evidence reports that there were no cardiac or psychiatric adverse events recorded in both trials The statement also mentions that several other types of adverse events were observed which is consistent with the evidence as it does not contradict this statement The normalization basis is not relevant to the",
        "label": "Entailment"
    },
    "e012d94f-ee90-40b0-9a4d-e41ec19a512d": {
        "text_answer": "Yes for some parts of the statement The statement mentions some differences in the secondary trial which is supported by the evidence However it also mentions no significant differences in the primary trial which is not explicitly stated in the evidence but could be inferred based on the similar AUC values for the two algorithms",
        "label": "Entailment"
    },
    "04d9baea-cc4c-4903-9769-3df78659a73f": {
        "text_answer": "No   The statement is not directly related to the Percentage of Participants With Adverse Events of Primary Interest AEPIs mentioned in the evidence The evidence only provides information about specific types of adverse events and their incidence in two different cohorts of a study It does not mention soft tissue disorders or whether they are nonneoplastic or neoplastic",
        "label": "Contradiction"
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "text_answer": "Yes  Explanation  The statement The same number of AEs were reported for both cohorts in the primary trial is entailed by the evidence since the number of adverse events reported for each cohort is both 2",
        "label": "Entailment"
    },
    "1eab7c47-2c2a-4746-935b-c3e8891f8a26": {
        "text_answer": "No  The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a score of 2 or better",
        "label": "Contradiction"
    },
    "cb3fa68b-c881-4a32-a80f-303e46360d8c": {
        "text_answer": "No  Explanation  The statement the bevacizumab cluster of primary clinical trial reported equal instances of disease progression or death as compared to the combined bevacizumab and capecitabine group is not entailed by the evidence provided The evidence only reports the percentage of participants with disease progression or death for each group but it does not directly compare the two groups to determine if they are equal",
        "label": "Contradiction"
    },
    "a328634e-824e-413c-a408-ad471e394a07": {
        "text_answer": "No  Explanation  The statement Gender is not a determining factor for eligibility in the primary trial but only female patients are eligible for the secondary trial is not directly entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial based on gender cancer stage and other factors It does not explicitly state that gender is not a factor for eligibility in the primary trial or that only females are eligible",
        "label": "Contradiction"
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "text_answer": "No  The evidence states that there are no conditions on hepatic function for participants of the primary trial but it does not state that there are no conditions on hepatic function at all The exclusion criteria mention adequate liver function as a requirement for participation",
        "label": "Contradiction"
    },
    "c5c7b6e2-201f-42af-aeb3-3e3152fa0ba2": {
        "text_answer": "No  Explanation  In the primary clinical trial her2 patients received a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary clinical trial her2 patients in cohort 2 received Herceptin 4 mgkg on Day 1 of Cycle 5 followed by Herceptin 2 mgkg weekly starting from Day 8 which is different from the dosage",
        "label": "Contradiction"
    },
    "a44d4aaf-a761-46a1-a803-63d6ede293a5": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is not directly entailed by the evidence provided The evidence only states the number of cases of Intestinal perforation in each trial but it does not compare the number of cases between the two trials or state that there is an increase of 11 cases in the secondary trial",
        "label": "Contradiction"
    },
    "e682eada-bed5-4ea5-847a-cbfdb44ef724": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as diabetes is not mentioned in the evidence at all The evidence only reports the adverse events observed in the primary and secondary clinical trials and none of them are related to diabetes",
        "label": "Contradiction"
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "text_answer": "Yes  Both interventions involve 20 injections of 04ml volume",
        "label": "Entailment"
    },
    "775258b4-fe6f-4487-a162-ce25e5a665c0": {
        "text_answer": "No  Patients with dementia including Alzheimers disease are excluded from the trial based on the given inclusion criteria MMSE  23",
        "label": "Contradiction"
    },
    "86e418cd-3b9d-46fd-b699-c538a29e7c03": {
        "text_answer": "No   Explanation  The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial lasted for 24 weeks Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d65c3fe7-21a9-484a-a225-1ed3c5e66b5e": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only pertains to breast cancer and its treatment while the statement mentions colon cancer and a duodenal band which is not related to the evidence",
        "label": "Contradiction"
    },
    "b971e3aa-d16a-4cca-8a69-c3e9793ada80": {
        "text_answer": "No  Explanation  The statement patients with t2 n2 m2 tumors meet the requirements for participation in the primary clinical trial is not directly entailed by the evidence provided The evidence describes the inclusion and exclusion criteria for the clinical trial but it does not explicitly state that patients with t2 n2 m2 tumors are eligible to participate The TNM staging system T2 N2 M2 refers to the",
        "label": "Contradiction"
    },
    "48ec9126-f671-47ea-a1bd-71a228b20420": {
        "text_answer": "No  Explanation  The statement in the first cohort of the primary clinical trial pancytopenia was a prevalent condition while anaemia and febrile neutropenia were absent is not entailed by the evidence The evidence shows that in the first cohort there was one case of pancytopenia out of 18 participants but it does not state that anaemia and fe",
        "label": "Contradiction"
    },
    "8d748876-a5b3-4f80-9f87-de9bec532074": {
        "text_answer": "Yes The percentage of participants with disease progression or death was lower in the bevacizumab cohort 883 compared to the bevacizumab  capecitabine cohort 758",
        "label": "Entailment"
    },
    "343f30bc-9b37-471a-83fc-76089ffc527c": {
        "text_answer": "Yes The statement does not explicitly mention the specific types of adverse events but it is entailed by the evidence that less than 5 of patients in the primary trial suffered any adverse events",
        "label": "Entailment"
    },
    "677ea4a6-dee8-4a9f-ab36-68724aeb8237": {
        "text_answer": "No  Explanation  The statement childpugh class b7 is a total score of 7 for hepatic function corresponding to class b in the childpugh classification is not directly related to the evidence provided in the text The evidence only discusses the results of two clinical trials one focusing on Time to Progression TTP and the other on the Number of Participants with Objective Response The statement about the Child",
        "label": "Contradiction"
    },
    "52e6f629-f30f-4f59-968f-6d6bcc8b14af": {
        "text_answer": "No  Explanation The statement previously undergoing gabapentin or herceptin therapy within the previous year excludes a patient from the secondary clinical trial however it does not affect their inclusion in the primary clinical trial is not entailed by the evidence provided The primary clinical trial has different inclusion and exclusion criteria than the secondary clinical trial and the statement only pertains to the secondary trial The primary trial does not mention anything about previous gabapentin or",
        "label": "Contradiction"
    },
    "31332603-d84d-4806-b8bf-4cdc08514591": {
        "text_answer": "Yes The statement 1417 of the primary trial patients suffered an increase in blood bilirubin is a rounded approximation of the 909 stated in the evidence Therefore it is entailed by the evidence",
        "label": "Entailment"
    },
    "b34700cb-eba7-431e-9508-75e49298d003": {
        "text_answer": "No  Explanation The statement in the primary clinical trial 50 of participants experienced adverse events aes of various types is not entailed by the evidence provided The evidence states that 3636 of participants experienced adverse events not 50",
        "label": "Contradiction"
    },
    "a0f404c3-8323-4ef6-a986-04085778b751": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the placebo and AlloMSCs interventions differ in their composition with the former being a buminate solution and the latter being allogeneic mesenchymal stem cells The dose and method of administration are the same but the substances being administered are not",
        "label": "Contradiction"
    },
    "2007fc0f-aa14-48a5-9db7-08d47f756757": {
        "text_answer": "No  Explanation  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is not directly entailed by the evidence provided The evidence only mentions the specific adverse events that occurred in the trial and none of them are related to the gastrointestinal system The histone h2b gene is not mentioned in the evidence at all Therefore the statement is not a logical conclusion",
        "label": "Contradiction"
    },
    "0a3eabb5-68f0-4534-834a-d3e75dbb733e": {
        "text_answer": "Yes The statement correctly identifies the difference in dosing between the two interventions",
        "label": "Entailment"
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "text_answer": "Yes  Explanation The evidence states that 13 of the participants with HER2 Primary Breast Cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab developed imagable HER2 metastases The statement in question also mentions HER2 Primary Breast Cancer and HER2targeted PETCT and it reports that 13",
        "label": "Entailment"
    },
    "14b9aeb8-afd7-4a20-af71-153c33fc117b": {
        "text_answer": "No  Explanation  The statement candidates receiving warfarinbased therapy are allowed in the primary clinical trial but prohibited in the secondary clinical trial is not entailed by the evidence provided  In the primary clinical trial warfarin is permitted for prophylactic or therapeutic use but lowdose warfarin less than or equal to 1 mgday is also permitted  In the",
        "label": "Contradiction"
    },
    "4a688f54-5b9a-49ad-b6a1-833d1ff96924": {
        "text_answer": "Yes The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II stages while the secondary trial has a unified set of criteria for all participants",
        "label": "Entailment"
    },
    "ff38ad83-d613-4797-a2a7-3b2e5e1a318d": {
        "text_answer": "No  The primary clinical trial includes patients with NUT midline carcinoma identified by FISH but the secondary clinical trial does not include patients with inflammatory breast cancer or NUT midline carcinoma",
        "label": "Contradiction"
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "text_answer": "Yes However its important to note that the statement only applies to patients with stage 4 breast cancer who meet the other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "baf5c643-9960-4f2e-a9b4-70667a5ca685": {
        "text_answer": "No  Explanation  The statement skin signet ring cell basal cell carcinoma is a rare type of basal cell carcinoma it is characterized by the presence of mucin containing signet ring cells Patients with a Vitamin D deficiency are excluded from the primary trial but may be eligible for the secondary trial is not directly entailed by the evidence provided  The evidence only mentions the inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "3df24930-167f-4f53-a3e5-fb8205039848": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial specifically requires histologically or cytologically confirmed breast adenocarcinoma while the secondary trial encourages but does not require histologic confirmation of metastatic disease and only requires the primary tumor to be ER andor PRpositive and HER2neu negative The statement refers to histologically unverified early stage breast cancer which is",
        "label": "Contradiction"
    },
    "ba84127e-5a18-4ff4-a76b-c19ba3edeeb0": {
        "text_answer": "No  Explanation The statement while the first cohort of the primary clinical trial receives dexamethasone preoperatively the second cohort gets it two hours following surgery is not directly entailed by the evidence The evidence only states that the first cohort received dexamethasone preoperatively and the second cohort also received dexamethasone preoperatively but two hours after",
        "label": "Contradiction"
    },
    "b7ab0a1b-fa3a-4cf4-ba4a-dda1608215a6": {
        "text_answer": "  Yes the patient described in the statement meets the inclusion criteria for both trials based on the provided information However its important to note that the patients eligibility for the secondary trial also depends on other factors not mentioned in the statement such as the patients performance status creatinine level and prior treatment history with anthracyclines",
        "label": "Entailment"
    },
    "1e349229-5030-4134-99c2-c530a37c3ef2": {
        "text_answer": "No  Explanation  The statement primary open angle glaucoma is a form of glaucoma in which there is no visible abnormality in the trabecular meshwork is not related to the evidence provided in the primary and secondary trials The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in women undergoing hormone replacement therapy while the secondary trial determines the Maximum",
        "label": "Contradiction"
    },
    "0f9e0c7c-a021-4aeb-9309-ab2d6f1d78f8": {
        "text_answer": "No  Explanation  The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event cordonnier grade 3 viral complication severe varicella zoster virus infection is any severe varicella zoster virus infection is not entailed by the evidence  The evidence only states that there were",
        "label": "Contradiction"
    },
    "558d240e-a51a-4c16-807e-db9031073242": {
        "text_answer": "No  Explanation  The statement there were multiple incidents of sudden deaths and unplanned hospitalizations in the primary clinical trial and in the secondary clinical trial is not entailed by the evidence provided The evidence only reports the number of adverse events for two specific types of adverse events Adverse Events 1 and Adverse Events 2 in each trial without mentioning any details about the nature of those adverse events such as whether they",
        "label": "Contradiction"
    },
    "f68789cf-7d4d-4186-b3f0-a6b47127379b": {
        "text_answer": "No  Explanation  The evidence provided in the primary clinical trial results does not indicate that all patients from either group experienced minimal or no recovery as the statement suggests Instead the evidence shows the number of participants with a pathologic complete response in breast and axillary lymph nodes at the time of surgery approximately 7 months after the start of treatment The statement makes a claim about the recovery status of patients 6 months past surgery which is",
        "label": "Contradiction"
    },
    "fceee201-8b1b-4cd0-ab16-75fed1f2530f": {
        "text_answer": "Yes  Explanation The statement there was one psychiatric adverse event in the primary trial which affected less than 01 of patients is entailed by the evidence since the evidence states that there was one case of suicidal ideation a psychiatric adverse event out of 50 patients affecting less than 01 or 200 of the patients",
        "label": "Entailment"
    },
    "cded013b-d994-410b-9b42-c4a852978cfc": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial does not include information about the percentage of participants who had a reduction in circulating tumor cells CTCs following highdose chemotherapy with purged autologous stem cell products for more than one month posttransplantation The evidence only reports the number of participants with a reduction in CTCs at one month posttransplantation Therefore the statement about less than ",
        "label": "Contradiction"
    },
    "9bc581fd-162a-43c2-8c72-69c06d9ba395": {
        "text_answer": "No  Explanation  The statement study subject withdrawal by parent or guardian is an indication that a study participant has been removed from the study by the parent or legal guardian is not directly related to the evidence provided in the primary and secondary trials The primary trial reports Time to Progression data while the secondary trial reports the percentage of patients with Objective Response Neither trial mentions study subject withdrawal by parents or guardians",
        "label": "Contradiction"
    },
    "68a2e47e-d66f-45ec-87cd-45403a545e97": {
        "text_answer": "No  Explanation The evidence provided in the primary clinical trial describes the dosing schedule for Vorinostat and radiation therapy It does not mention anything about Fentanyl sublingual spray or its dosage Therefore the statement about Fentanyl is not entailed by the evidence",
        "label": "Contradiction"
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8b30b0d1-a4fd-49cb-9dc8-ce508d3b5524": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence indicates that ovarianperitoneal cancer patients received talazoparib at doses ranging from 25 mcgday to 1100 mcgday with 1000 mcgday being one of the options The evidence does not specify that all ovarianperitoneal cancer patients received 1",
        "label": "Contradiction"
    },
    "2792a2f8-898b-4aee-a617-df468f3a1eaf": {
        "text_answer": "No   Explanation  The evidence describes a combination of multiple medications being administered to participants in the clinical trial Therefore the statement that participants in the primary clinical trial are administered a single medication for the entire study duration is not entailed by the evidence",
        "label": "Contradiction"
    },
    "f5031c61-a192-4b2e-ac0f-be5d2aac0b3c": {
        "text_answer": "Yes  Explanation  The evidence provides the percentage of participants in each group ERpositive Luminal B and Triple Negative who demonstrated a decrease in the growth factor signature GFS after receiving a single dose of dalotuzumab The statement in question asserts that there was no observed difference in the decrease of the growth factor signature between the two groups The evidence supports this statement as both groups had similar ranges of percentage of participants",
        "label": "Entailment"
    },
    "43e7f79b-7ebb-483e-ba3f-2cbd40c09d89": {
        "text_answer": "No  Explanation  The evidence provided describes the eligibility criteria for a clinical trial for patients with metastatic breast cancer The statement however specifically mentions T3 N3 M3 tumors which is a tumor staging system The evidence does not explicitly state that patients with T3 N3 M3 tumors are permitted to take part in the clinical trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e3c4aff9-78ee-4a66-9735-1cd5370b7925": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial includes a minimum tumour size of 2 cm diameter while the secondary trial does not mention tumour size as an inclusion criterion",
        "label": "Contradiction"
    },
    "dcf21e08-7d8b-45b2-bec3-9f65853fb277": {
        "text_answer": "Yes The primary trial and secondary trial have different inclusion and exclusion criteria and the patients eligible for the secondary trial do not meet the inclusion criteria for the primary trial",
        "label": "Entailment"
    },
    "77a8c39a-7193-438c-98c1-9e88c1be1ec9": {
        "text_answer": "  No  Explanation  The statement patients who have received chemotherapy or radiotherapy in the last 14 days suffer from unstable angina or have grade 7 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the",
        "label": "Contradiction"
    },
    "6aa17b00-284e-408b-a8c3-2e24b6310556": {
        "text_answer": "No  The statement a patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is not explicitly stated in the evidence However the evidence does state that there should be no meningeal carcinomatosis Meningeal carcinomatosis and leptomeningeal carcinoma are related but distinct conditions and the evidence does not rule out the possibility of a patient with leptomeningeal",
        "label": "Contradiction"
    },
    "ad1bb75e-6250-4dbe-beff-a702293ce87c": {
        "text_answer": "Yes for the secondary trial   Explanation The statement no previous treatment with gabapentin or herceptin required for eligibility in the secondary trials is explicitly stated in the exclusion criteria for the secondary trial Therefore it is entailed by the evidence  However it is not mentioned in the inclusion or exclusion criteria for the primary trial so it is not directly related to the primary trial evidence",
        "label": "Entailment"
    },
    "be5577f7-43cb-40c7-bf6d-4988788d9b24": {
        "text_answer": "No  Explanation The primary trial includes a minimum tumour size of 2 cm while the secondary trial does not specify a minimum tumour size Therefore a patient with a primary tumour of 3300 micrometers approximately 33 cm would not meet the inclusion criteria for the primary trial Additionally the secondary trial has different eligibility criteria for different types of cancers and breast cancer is only included in the",
        "label": "Contradiction"
    },
    "9d7e8278-5668-4798-9eb0-bb3ae9db62f0": {
        "text_answer": "No  Explanation  The statement All patients eligible for the secondary trial are also eligible for the primary trial is not entailed by the evidence provided The inclusion and exclusion criteria for the primary and secondary trials are different The primary trial is for women undergoing lumpectomy with specific inclusion and exclusion criteria while the secondary trial is for patients undergoing tissue expander reconstruction following mastectomy with different inclusion and exclusion criteria The neurofil",
        "label": "Contradiction"
    },
    "9ef9c9de-3dfa-4cbb-930e-c26190e2d119": {
        "text_answer": "Yes  Explanation The evidence shows that in both Arm 1 and Arm 2 of the clinical trial approximately onethird of the participants achieved a pathologic complete response in their breast and axillary lymph nodes after about seven months into the study",
        "label": "Entailment"
    },
    "5b875c96-44e4-4123-921a-546382d4c806": {
        "text_answer": "Yes  Explanation The evidence states that patients receive oral lapatinib once daily on days 128 which is equivalent to receiving 700 mgweek The statement is entailed by the evidence as it correctly summarizes the dosing regimen given in the evidence",
        "label": "Entailment"
    },
    "e5f77572-2271-434c-8965-dfdac502ea4e": {
        "text_answer": "No  Explanation The statement the secondary trial participants receive pembrolizumab twice as frequently as participants in the primary trial receive sunitinib is not entailed by the evidence provided In the primary trial participants receive pembrolizumab every 3 weeks Q3W while in the secondary trial sunitinib is given on various schedules but there is no mention of pembrolizumab being given",
        "label": "Contradiction"
    },
    "beef35bd-14a9-4353-aa30-2fe681726d91": {
        "text_answer": "No   Explanation  The primary trial involves PF06647020 administered at two different doses 02 mgkg and 05 mgkg while the secondary trial involves ALT801 administered at two different doses 0015 mgkgdose and 0040 mgkgdose The statement does not specify that the",
        "label": "Contradiction"
    },
    "9c4299c7-89e6-4d9c-81db-5d12f182b4d3": {
        "text_answer": "No  Explanation  The primary trial does not use a 4week cycle for its intervention Instead it uses a 21day cycle The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "042bf558-479b-46c4-8553-016eb3bfcda7": {
        "text_answer": "No  The statement is not directly related to the given evidence The evidence pertains to the inclusion and exclusion criteria for two different clinical trials one for male and postmenopausal female breast cancer patients and another for female breast cancer patients with locally advanced recurrent or metastatic disease The statement is about HIV vaccines which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "b7a0a223-f9c6-474c-b9e7-ca530c393a53": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e1cf6d73-554a-4e33-8cf2-e19346eab3ce": {
        "text_answer": "Yes The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 but the statement specifies that patients with Alzheimers disease have evidence of dementia which would result in an MMSE score 23 making them ineligible for the trial",
        "label": "Entailment"
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "text_answer": "No  The evidence does not specify that AfricanAmerican patients must reside in Texas for the duration of the study in order to participate in the primary trial The evidence only mentions inclusion and exclusion criteria for the trial but does not mention any geographic restrictions",
        "label": "Contradiction"
    },
    "1f5a106f-d664-4a83-a785-a47eea7b9106": {
        "text_answer": "  No the statement is not entailed by the evidence The secondary trial exclusion criteria include no mention of a history of pulmonary embolism and the primary trial inclusion criteria state that those with breast implants are eligible to participate",
        "label": "Contradiction"
    },
    "7b84b7dd-2143-41b0-bdf5-92c8ae314d17": {
        "text_answer": "No  Explanation The primary trial includes a criterion stating that the primary tumour diameter should be greater than 2 cm while the secondary trial does not mention any specific tumour size requirement Therefore a patient with a primary tumour of 33000m approximately 33 cm would not be eligible for the primary trial based on the given size criterion but their eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "e25a03fa-f51c-4c0d-b737-375a968ce6be": {
        "text_answer": "  Yes for the primary trial only as the secondary trial does not mention ertapenem or ciprofloxacin in its exclusion criteria",
        "label": "Entailment"
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "text_answer": "Yes  Explanation The evidence states that out of 21 participants the number of participants with a reduction in CTCs at one month post AHST was not specified However it can be inferred that less than half of the participants had a reduction in CTCs based on the given information This is because the number of participants with a reduction in CTCs is less than the total number of participants analyzed 21",
        "label": "Entailment"
    },
    "5553674a-4eab-4515-be9e-147eef2f0d09": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as there is no mention of Treatment Emergent Adverse Events or Serious Treatment Emergent Adverse Events in the provided evidence The evidence only reports on the number of hot flashes per 24 hours for the paced respiration and fast shallow breathing intervention groups",
        "label": "Contradiction"
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "text_answer": "Yes  Explanation  The primary trial measures tumor response using RECIST criteria but it does not mention anything about Ki67 expression The secondary trial measures various things including AIMSS laboratory biomarkers and qualityoflife assessment but it does not mention Ki67 expression specifically Therefore neither trial measures the Change in Ki67 Expression in Tumors",
        "label": "Entailment"
    },
    "94ca00df-c395-4f32-9348-8bcb6b15a2e1": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting more than 005 of patients there were no recorded aes in the primary trial is not entailed by the evidence The evidence only states that anaemia occurred in 234 of patients in the secondary trial and was not reported in the primary trial The statement goes beyond the information provided in the",
        "label": "Contradiction"
    },
    "6abbb566-9561-47d2-aad5-0857550099ea": {
        "text_answer": "No  Explanation The evidence provides the percentage of subjects who experienced recurrencefree survival up to 3 years after treatment It does not state that no patient experienced recurrence during this time frame",
        "label": "Contradiction"
    },
    "2a6e2da6-0555-43d1-b063-a81938137be9": {
        "text_answer": "No  The evidence states that patients must have a BMI of 25 kgm2 or greater and weight 400 lbs which does not necessarily equate to an ideal body weight for height",
        "label": "Contradiction"
    },
    "7af8a41a-c4b2-402e-bf50-a14aa2758926": {
        "text_answer": "No  Explanation  The statement provided is not directly entailed by the evidence The evidence discusses the interventions used in two separate trials one involving Fulvestrant and Anastrozole and the other involving HER2targeted PETCT The statement is about a dose calculation unit and Arimidex which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "0f79f642-47d6-404b-ade0-8e720c0aa660": {
        "text_answer": "No  Explanation  The statement assent is agreement with a statement or proposal to do something is not directly related to the evidence provided The evidence only includes information about the results of two clinical trials one on overall response rate and the other on time to first onstudy skeletal related event and does not mention assent or agreement",
        "label": "Contradiction"
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "text_answer": "No  The evidence does not mention anything about a HER2neu peptide vaccine admixed with sargramostim in the primary trial",
        "label": "Contradiction"
    },
    "5a77ba85-1a9e-4639-ba29-86b0cdea296b": {
        "text_answer": "  No   Explanation   The statement women suffering from both claustrophobia and osteoporosis are eligible for the primary and secondary clinical trials is not entailed by the evidence The primary trial excludes women with osteoporosis and the secondary trial does not mention claustrophobia as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "aa176a26-7dd6-473f-9c35-40a0754336f6": {
        "text_answer": "Yes The statement is entailed by the evidence as the patients in the primary trial will receive multiple injections including dendritic cell vaccines chemotherapy and GMCSF",
        "label": "Entailment"
    },
    "000c067a-a563-425e-9ea1-7057f8d2c39f": {
        "text_answer": "No  Explanation  The statement none of the participants in group 1 of the primary clinical trial had lesions in contrast above 95 of the participants in group 1 of the secondary clinical trial had symptoms of radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The primary clinical trial and the secondary clinical trial are about different conditions and involve different groups of participants The primary clinical trial is",
        "label": "Contradiction"
    },
    "5fca366e-ecc6-41e4-b621-e3343ff0f07e": {
        "text_answer": "Yes The statement is about the agent administration setting which is not specified in the intervention section of the evidence",
        "label": "Entailment"
    },
    "a5ed681f-ae92-4bc5-856f-4565ab2669f0": {
        "text_answer": "  No the statement is not entailed by the evidence The evidence states that patients must have a potassium level within the normal range 3553 mEqL to participate in the primary clinical trial",
        "label": "Contradiction"
    },
    "58f0bed2-bc88-4aaf-8572-fb49fc69a87c": {
        "text_answer": "Yes  Explanation The evidence shows that the median change in total body lean mass for patients treated with GTx024 1mg was 206 kg to 1264 kg indicating that some patients experienced a decrease in lean body mass over the 4 month period",
        "label": "Entailment"
    },
    "fe6418cd-e255-4f27-bb63-63b4f37a0f56": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The statement is about a deleterious FANCD2 gene mutation and its association with increased risk of disease while the evidence only reports the adverse events observed in two clinical trials for an unspecified intervention The statement does not mention the trials or the intervention and there is no information in the evidence about the frequency or nature of adverse events related to a F",
        "label": "Contradiction"
    },
    "93299ed6-4cc9-4369-a4f3-c86f45ab741e": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement mentions two different interventions for the primary and secondary trials whereas the evidence only provides information about the interventions for each trial separately The statement also mentions different dosages for the secondary trial intervention than what is stated in the evidence",
        "label": "Contradiction"
    },
    "e8f582a2-31f8-4b30-a2bb-1d236706333d": {
        "text_answer": "No  Explanation  The statement everyone in the primary clinical trial gets the same dosage of armodafinil orally daily and in the secondary clinical trial all participants get varied dosages of chs828 and mvc110 is not entailed by the evidence  In the primary clinical trial participants in Intervention 1 received placebo for 47 days and then seven weekly sessions of CBT",
        "label": "Contradiction"
    },
    "cf9ea9d0-49c4-4c00-a91b-142cd7ec8433": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a45aa828-dfd0-4b82-a1a1-7a8386520fe4": {
        "text_answer": "No  Explanation  The statement the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 12 weeks is not directly entailed by the evidence The primary trial does indeed involve the use of oral pregabalin but it is given at a fixed dose of 150 mg twice daily for 6 weeks not every 2 weeks for 12 weeks",
        "label": "Contradiction"
    },
    "e8247d17-f420-4a08-9a2c-c2d8f1524d93": {
        "text_answer": "No  The statement is not entailed by the evidence as the trial is for patients with breast cancer not hepatocellular carcinoma and the patients must be postmenopausal and have estrogen andor progesterone receptor positive tumors",
        "label": "Contradiction"
    },
    "aa7a20b6-cec1-448c-ac20-a7b2d8c14a1d": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention section of the clinical trial does provide a comprehensive treatment cycle and a detailed description of the treatment which includes the placement of a device and the administration of partial breast irradiation",
        "label": "Entailment"
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about the percentage of patients who experienced adverse events The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b24a7c99-879c-416b-8b54-f44f0bcd4524": {
        "text_answer": "yes for the primary trial regarding overall response rate in Arm A but not for the secondary trial regarding time to first onstudy SRE as the statement does not specify which treatment within the secondary trial is being compared to the placebo",
        "label": "Entailment"
    },
    "3795f873-9d20-4fb3-b77c-ca01ba923c82": {
        "text_answer": "  No   Explanation   The statement patients characterized by extreme obesity or pregnancy can be potentially suitable for the primary and secondary clinical trials is not entailed by the evidence provided The evidence only specifies certain inclusion and exclusion criteria for each trial It does not mention anything about obesity or pregnancy being potentially suitable for either trial",
        "label": "Contradiction"
    },
    "94ee2ae4-cf85-4dfb-90be-2490ad4089ab": {
        "text_answer": "Yes The primary trial intervention is given orally while the secondary trial interventions are administered intravenously Electrolyte disorders can be a side effect of intravenous treatments",
        "label": "Entailment"
    },
    "750d4e54-f2cf-425c-9a04-dbd5091a0cba": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence regarding the administration of the interventions However the evidence does not directly mention weight loss or CTCAE in relation to the interventions but the statement is a general fact that is not contradicted by the evidence",
        "label": "Entailment"
    },
    "bac5180a-b51f-4a2d-a1d2-eaead122d693": {
        "text_answer": "Yes  Explanation The evidence states that out of 53 participants in the Lapatinib 1000 mg  NabPaclitaxel armgroup no CR was reported Therefore the majority of patients did not achieve a CR",
        "label": "Entailment"
    },
    "e54cf8ee-4a0d-4a15-bc72-4072ff0b6e6d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial intervention involves the use of radiology Yttrium90 Radioembolization and the secondary trial intervention involves the use of hormonal therapy ibrutinib and immunotherapy MEDI4736 Neither the primary nor the secondary trial interventions can be definitively classified as solely relying on hormonal therapy or immunotherapy",
        "label": "Contradiction"
    },
    "ec3a1125-3c16-4f3c-8fa3-6a237f4529c9": {
        "text_answer": "No   Explanation  The statement during the primary clinical trial radiation therapy is undertaken without simultaneous administration of daily vorinostat capsules is not entailed by the evidence The evidence states that patients will take Vorinostat daily during radiation therapy not that they will not take it simultaneously",
        "label": "Contradiction"
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "text_answer": "Yes  Explanation  The statement is entailed by the evidence as both trials involve the use of the same drug empegfilgrastim but with different doses and different outcome measurements The primary trial focuses on the duration of neutropenia with CTCAE grade 34 while the secondary trial focuses on the incidence of CTCAE grade 34 neutropenia",
        "label": "Entailment"
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "dffbf597-b236-4aa5-bd94-b471c9e593ea": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence describes the use of Fulvestrant via intramuscular injection in the secondary trial but it does not specify a dose of 500mg twice a day for all cohorts The evidence only mentions the loading dose and subsequent doses for one of the cohorts in the secondary trial",
        "label": "Contradiction"
    },
    "7e3a4e76-6d33-4013-ad8e-7fd3d684136f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial reports the median time to progression in months not hours and the secondary trial reports the number of participants with objective response not the duration of response",
        "label": "Contradiction"
    },
    "976f4747-e1a6-4527-a298-490fb57d4615": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the route of administration for the first cohort of the primary clinical trial or the first group in the secondary clinical trial The evidence only specifies the interventions and dosages for each group in both trials",
        "label": "Contradiction"
    },
    "82d350f6-9864-4329-bd5b-8d8155170569": {
        "text_answer": "No   Explanation   The statement None of the primary trial candidates have to perform regular exercise as part of the intervention is not directly related to esophageal Hodgkin lymphoma which is a specific type of cancer mentioned in the question The evidence provided in the trial description only specifies the eligibility criteria for the trial and does not mention anything about exercise being a part of the intervention for any type of cancer including",
        "label": "Contradiction"
    },
    "efe92dca-7dd8-44da-b436-15a3c9f9f729": {
        "text_answer": "No  Explanation  The statement there was one case of shingles recorded in group 2 of the secondary trial but no cases in group 1 of the secondary trial and the primary trial is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events for each trial but it does not specify which group the cases of shingles occurred in or if there were any cases in the primary trial at",
        "label": "Contradiction"
    },
    "f5650e8f-58b5-4a3a-9da2-ab66d7674b6d": {
        "text_answer": "Yes The evidence does not explicitly state that patients with those tumor stages cannot participate in the trial so the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "cdce28fc-eb28-4608-8b83-9bc18414caf8": {
        "text_answer": "  No   Explanation  The statement neither the primary clinical trial nor the secondary clinical trial allows participation of women affected by claustrophobia and osteoporosis is not entailed by the evidence While both trials exclude women with osteoporosis only the secondary trial lists claustrophobia as an exclusion criterion",
        "label": "Contradiction"
    },
    "51220352-fff0-4e70-b36d-7f9e87498a58": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the participants receiving the vaccine not the fixdm1 therapeutic agent",
        "label": "Contradiction"
    },
    "03fe5ae7-9f15-4d30-a208-cead95780b13": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the primary clinical trial employs Fulvestrant and Anastrozole not Arimidex",
        "label": "Contradiction"
    },
    "5d42d5d3-e80d-49e0-83e5-8724a8ff5401": {
        "text_answer": "No  Explanation  The statement mentions that there have been a total of 3 cases of asthenia and 5 cases of pyrexia across both trials However the evidence provided only mentions the number of adverse events for each trial but it does not specify which adverse events were reported or their respective counts Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "e52a3c24-8fed-4bcb-9513-582c604a5414": {
        "text_answer": "No  Explanation  The statement is about the requirements for participating in a clinical trial in a specific country Sa Tom and Prncipe but it does not directly relate to the inclusionexclusion criteria of the provided clinical trial evidence The evidence only mentions the requirements for participating in the clinical trial itself without any reference to the country or location",
        "label": "Contradiction"
    },
    "df26264a-98ef-47f9-9493-e2398529e39f": {
        "text_answer": "No  Explanation  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events AEs and their percentages in each trial for a specific AE AE1 It does not provide information about the total number of AEs experienced by patients in each trial or a comparison between the two",
        "label": "Contradiction"
    },
    "e554ce24-beab-4ed6-b37b-0a28ae28faf0": {
        "text_answer": "Yes  Explanation  The statement the secondary trial patients did not experience anemia pneumonia or stupor more frequently than patients in the primary trial is entailed by the evidence because the evidence shows that the frequency of anemia pneumonia and stupor was 000 in the secondary trial for all three conditions while the frequency in the primary trial was 000 for anem",
        "label": "Entailment"
    },
    "9324259a-88b9-441b-a6ee-ec7f6f5914aa": {
        "text_answer": "No  Explanation  The statement The patient with the longest PFS in the primary trial was in cohort 1 and he survived 35 months without disease progression or death is not directly entailed by the evidence provided The evidence only reports the median PFS for each treatment group but it does not specify which individual patient had the longest PFS or which cohort they belonged to Additionally the statement includes the length of",
        "label": "Contradiction"
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "text_answer": "  Yes for the secondary trial children and adolescents are not explicitly excluded",
        "label": "Entailment"
    },
    "86a8919e-ee7f-40ba-9186-9dcbdbb06018": {
        "text_answer": "No  Explanation The evidence provided in the primary clinical trial does not indicate that the mean survival time for any subgroup of patients fell under 12 months or that less than 50 patients from any subgroup exceeded a year of survival The evidence only reports the median 95 confidence interval survival times for two groups of patients who underwent surgical oophorectomy in the midluteal and midfollicular",
        "label": "Contradiction"
    },
    "cbb9beea-1961-4049-9a90-53a75da5933e": {
        "text_answer": "Yes  Explanation The evidence states that cohort 1 received a dose of 0015 mgkgdose of ALT801 while cohort 2 received a dose of 0040 mgkgdose of ALT801 The statement in question asserts that cohort 2 received a lower dose than cohort 1 Since 00",
        "label": "Entailment"
    },
    "ca4fb850-2d8b-4a5f-b990-1d81ae917d63": {
        "text_answer": "No  Explanation The statement talazoparib dosage in the primary clinical trial varies 1000 mcgday for breast cancer patients and 25 mcgday for those with ovarian or peritoneal cancer is not entailed by the evidence provided The evidence only states that the dosage of talazoparib varied in the clinical trial for both breast and ovarianperitone",
        "label": "Contradiction"
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "text_answer": "No  Explanation  The statement the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts is not entailed by the evidence The evidence only states that the number of adverse events for Adverse Event 1 is 0 in both trials for the primary data and 000 in the secondary trial with a total of 15 patients It does not provide the total number of ad",
        "label": "Contradiction"
    },
    "ec2e7860-1d3e-4f95-b00a-bea42d04825a": {
        "text_answer": "Yes The statement mentions that capecitabine is administered orally which is consistent with the evidence that it is given orally every day during the first 21day cycle of the trial",
        "label": "Entailment"
    },
    "c17afde4-0fee-473c-b969-f7a4e89f049b": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes both ER positive HER2 negative luminal A and triplenegative breast cancer patients",
        "label": "Entailment"
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "text_answer": "No   Explanation  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not entailed by the evidence The evidence describes several injections and treatments that patients will receive at different times during the study but it does not specify that there is a single injection on day 8",
        "label": "Contradiction"
    },
    "6ffb2b0f-737a-4176-9036-a887a2f4a4b7": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial only gives the median average survival times for each group not the total number of patients who survived beyond a certain time point 730 days or 24 months Therefore it is not possible to determine if over 50 patients from each cohort survived more than 24 months based on the given evidence alone",
        "label": "Contradiction"
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "text_answer": "Yes  Explanation The evidence shows that the percentage of participants with invasive diseasefree survival events was lower in the Neratinib group 47 compared to the Placebo group 75 This indicates that the Neratinib group had a lower rate of iDFS events as stated in the question",
        "label": "Entailment"
    },
    "8d94a62d-400f-4d9d-92aa-d39dd1f37823": {
        "text_answer": "Yes  Explanation  The statement cohort 1 was the group where all the cases of infections and infestations were recorded in the primary clinical trial is entailed by the evidence because the evidence shows that all the cases of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever were recorded in cohort 1 which is cohort 1 in the primary clinical trial",
        "label": "Entailment"
    },
    "8d813fc8-01ec-4fb7-9191-f5ec7cb735fb": {
        "text_answer": "No  The statement does not mention any scans or attenuation corrections in the evidence It only describes the interventions and their administration routes",
        "label": "Contradiction"
    },
    "eaad4acd-8fc1-41c6-92aa-1a4488ffdfed": {
        "text_answer": "Yes  Explanation  The statement there was at least 1 case of infection in both the primary trial and the secondary trial is entailed by the evidence as there is a reported case of infection in both trials Primary Trial Infection 132 313 Secondary Trial Infections and infestations  Other unspecified 115 667",
        "label": "Entailment"
    },
    "0cb2b471-fa4a-4eeb-8dd7-981680465858": {
        "text_answer": "Yes The statement is entailed by the evidence as all the adverse events mentioned in the statement are from the same cohort cohort 1 as the one described in the evidence",
        "label": "Entailment"
    },
    "f4da0e5f-f0aa-4edf-a08c-afadd05360d5": {
        "text_answer": "Yes The statement is entailed by the evidence as nonsmall cell lung cancer and small cell lung cancer are listed as eligible tumor types in the clinical trial",
        "label": "Entailment"
    },
    "f859f501-4e35-44c5-88bf-213949f5e5e5": {
        "text_answer": "Yes The evidence states that there are 1530 enrollment slots for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Entailment"
    },
    "b7b355cd-5386-4b3c-bc5d-a9a05e7a83b5": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "text_answer": "Yes for the primary trial only as hypokalemia is an exclusion criterion",
        "label": "Entailment"
    },
    "cd2874dc-b435-4319-8ae9-d413b3f43499": {
        "text_answer": "Yes  The statement is entailed by the evidence as the evidence specifies that Arm B of the primary clinical trial uses fulvestrant and Arm C uses paclitaxel Therefore fulvestrant is only used in Arm B cohort 1 of the trial",
        "label": "Entailment"
    },
    "76b35642-5bf9-4980-beb9-e802493907b6": {
        "text_answer": "No  Explanation The evidence provided in the trial results indicates that there were fewer participants in the placebo group who were emesisfree compared to the aprepitant group However this does not necessarily mean that patients in the placebo group were less likely to experience emesis overall In fact the trial results do not provide sufficient information to make that determination The statement patients receiving the placebo intervention in the primary clinical trial were less likely to",
        "label": "Contradiction"
    },
    "f13b3dd4-fe4a-4189-b51b-cf72af22deab": {
        "text_answer": "  No   Explanation   The statement about a patient who has received an organ transplant within the last month and is still bedridden being excluded from the primary trial but eligible for the secondary trial is not directly stated in the evidence provided The evidence only lists the inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "56603bed-1e4b-41d2-919c-612ec6e9b4c4": {
        "text_answer": "No  Explanation  The statement over 89100 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR is not entailed by the evidence The evidence states that 53 out of 60 participants or 883 in the lapatinib 1000 mg  nabpac",
        "label": "Contradiction"
    },
    "306ea03b-8055-4a52-8d81-ed4e18dedd4f": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only mentions metastatic andor advanced solid tumors for the primary trial and no mention of brain tumors The secondary trial mentions brain carcinoma but it is specifically for advanced or metastatic cases",
        "label": "Contradiction"
    },
    "94604a45-9867-4ccd-b38b-de2a3368130e": {
        "text_answer": "No  Explanation  The statement no notable variances were present in the outcomes of the primary clinical trial groups is not directly entailed by the evidence provided The evidence only shows that the two algorithms in the primary trial had similar diagnostic accuracy but it does not indicate that there were no notable variances in the outcomes of the two groups  Furthermore the statement also makes a claim about the secondary trial but the evidence only provides data",
        "label": "Contradiction"
    },
    "8f20a32b-2aa2-44c4-930e-852cba56151f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions vincristine for cohort 1 in the primary clinical trial which is not mentioned or related to the interventions in the evidence The evidence only mentions Fluciclatide Injection AH111585 18F Injection for cohort 1 in the primary clinical trial and Chloroquine",
        "label": "Contradiction"
    },
    "3fa1e0aa-7c62-4a1e-bd7d-452fa87a7baf": {
        "text_answer": "No  The statement splitting pain is an intense sensation of discomfort or distress that feels like being cut apart is not directly related to the evidence provided which pertains to the eligibility criteria for a clinical trial for breast cancer patients",
        "label": "Contradiction"
    },
    "d66e149e-5bb7-4e4b-8078-7f5947a31f60": {
        "text_answer": "  No   Explanation   The patient described in the statement does not meet the inclusion criteria for either the primary or secondary clinical trials In the primary trial the patient does not meet the minimum absolute neutrophil count requirement 1800 cellsmm3 and in the secondary trial the patient does not meet the minimum hemoglobin level requirement 90 gl and the life expectancy requirement",
        "label": "Contradiction"
    },
    "e7c553e8-8799-4475-9e39-6f79bebc0a48": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial cohort 1 reported mostly beneficial effects with similar feedback from cohort 2 is entailed by the evidence as both cohorts reported relatively low rates of adverse events indicating mostly beneficial effects",
        "label": "Entailment"
    },
    "8ddc286d-ac51-4c92-a163-2d9a65b52ae7": {
        "text_answer": "No  Explanation  The statement minor help to transfer is a response indicating that an individual needs minor verbal or physical help to transfer is not directly related to the inclusion or exclusion criteria of either the primary or secondary trial The statement pertains to the concept of transferring a person which is not mentioned in the given evidence The evidence only provides the criteria for participant eligibility and ineligibility for the clinical trials",
        "label": "Contradiction"
    },
    "5baa6e97-00e4-4e2f-b837-661a790cb87f": {
        "text_answer": "No  Explanation  The primary and secondary trials evaluate different interventions and outcomes The primary trial focuses on the toxicity of a HER2specific T cell therapy while the secondary trial evaluates the percentage of participants with adverse events of primary interest AEPIs in a trastuzumab emtansine study The patient attributes such as HER2positive unresectable LABC or mBC",
        "label": "Contradiction"
    },
    "6f95650b-d11f-4546-bfb2-d46cc39561b2": {
        "text_answer": "No  Explanation  The statement patients suffering from severe insomnia and schizophrenia are eligible for both the primary trial and the secondary trial is not entailed by the evidence provided The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is for patients with metastatic breast cancer who have progressed on endocrine therapy while the secondary trial is for patients undergoing cancer treatment with chemotherapy or",
        "label": "Contradiction"
    },
    "fd23bed1-83e9-44c9-acf7-66df74ba1c98": {
        "text_answer": "Yes The evidence does not provide any conditions on life expectancy pregnancy or age for participants in the primary trial",
        "label": "Entailment"
    },
    "ea0d6370-3322-4925-b524-b9a8bebe4383": {
        "text_answer": "No  Explanation  The primary and secondary trials are studying the same drug empegfilgrastim but with different dosages and outcome measurements The primary trial is measuring the duration of neutropenia with a CTCAE grade 34 while the secondary trial is measuring the incidence of CTCAE grade 34 neutropenia The dosages used in each trial are also different Therefore the statement is not",
        "label": "Contradiction"
    },
    "ea893c02-e0eb-4789-bb1e-5501db3be7d7": {
        "text_answer": "Yes The primary trial excludes patients with Vitamin D deficiency but the secondary trial includes healthy participants who may have Vitamin D deficiency",
        "label": "Entailment"
    },
    "3cbb65a6-d9f6-4972-8b13-dd19d427f0cb": {
        "text_answer": "Yes  Explanation  The primary clinical trial INTERVENTION 1 compares two different interventions Hydrophor and MediHoney in the context of radiation therapy The secondary clinical trial INTERVENTION 1 investigates the effect of different doses 90 mg and 110 mg of the same treatment PF05212384 on its participants  There",
        "label": "Entailment"
    },
    "40de18f3-3a12-40fb-9ce2-ebcc28391c7d": {
        "text_answer": "No  Explanation  The statement the primary clinical trial reported more adverse events than the secondary clinical trial in their respective patient cohorts is not entailed by the evidence provided The evidence only states the number of adverse events for each trial and their respective patient cohorts It does not compare the number of adverse events between the two trials",
        "label": "Contradiction"
    },
    "8dc16445-6102-4525-b9ce-ba4e35cc8b01": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not specify eligibility based on menopausal status or vasectomy",
        "label": "Contradiction"
    },
    "aeb95807-2d6b-4915-b52c-0d0fdc82728e": {
        "text_answer": "No  Explanation  The statement cohort 2 in the secondary clinical trial had a significantly greater number of patients compared to cohort 2 in the primary clinical trial is not entailed by the evidence provided The evidence only shows the number of participants analyzed in each cohort for both trials but it does not indicate that there is a significant difference in the number of patients between the two cohorts in each trial",
        "label": "Contradiction"
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial have different inclusion criteria although there are some overlapping requirements such as female gender and history of breast cancer However the primary trial specifically requires menopausal status and hot flush symptoms which are not mentioned in the secondary trials inclusion criteria Therefore patients taking part in the secondary trial would not necessarily meet the criteria for the primary trial",
        "label": "Contradiction"
    },
    "35a580c0-ce8a-42d1-b8ea-d84b985319c5": {
        "text_answer": "  No The statement is not entailed by the evidence as the inclusion criteria specify that the tumor must be HER2 positive either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "fa2d8a93-4cae-4ee5-afdf-1afd04d07c93": {
        "text_answer": "No  Explanation  The statement over 20 of the patients that participated in the primary clinical trial experienced all types of adverse events aes is not entailed by the evidence provided The evidence only states the number and percentage of each specific type of adverse event experienced by the patients It does not provide information on how many patients experienced multiple types of adverse events",
        "label": "Contradiction"
    },
    "a852b1d2-ce26-48da-ba6d-2386489a967b": {
        "text_answer": "Yes  Explanation The statement occurrences of hepatotoxicity were thrice as common as incidents of hypertension and pancreatectomy is entailed by the evidence since the number of occurrences of hepatotoxicity 3 is indeed three times the number of occurrences of hypertension and pancreatectomy 1 for each",
        "label": "Entailment"
    },
    "9068887d-3b93-4345-9b59-01ceb05725b1": {
        "text_answer": "No  Explanation  The statement for the primary clinical trial adults who have been diagnosed with ilddpld within the previous 3 years and have a projected life span of 6 months are considered eligible is not explicitly stated in the inclusion criteria of the evidence provided The evidence only mentions that patients must have a life expectancy of greater than 3 months",
        "label": "Contradiction"
    },
    "c35d641d-7248-47d7-90ff-a3859a846f68": {
        "text_answer": "Yes The evidence states that one participant experienced a maculopapular rash making it a common occurrence among the trial participants",
        "label": "Entailment"
    },
    "2690d684-0905-4af0-8113-fffec885de77": {
        "text_answer": "No  The evidence explicitly states that there should be no meningeal carcinomatosis in the patient Meningitis is a condition of inflammation of the meninges which can be caused by various reasons including bacterial infections Therefore a patient suffering from acute bacterial meningitis would not meet the eligibility criteria for this clinical trial",
        "label": "Contradiction"
    },
    "ee0b2916-1e10-467e-bcf3-41c56aa80921": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial explicitly excludes patients with pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug and there is no mention of pulmonary embolism specifically However the secondary trial does not mention any exclusion related to pulmonary embolism",
        "label": "Contradiction"
    },
    "731e38ac-1da8-4b94-a501-606a49570767": {
        "text_answer": "No  Explanation  The evidence provided in the trial inclusion criteria does not mention anything about cyp3a4 polymorphism being an indication for participation in the trial or any specific requirement for AfricanAmerican patients to reside in Texas The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d6f4c977-a5fa-49c9-ba6c-a40dfe0f3b30": {
        "text_answer": "Yes The evidence does not report any results for the LBH589 and Lapatinib cohort",
        "label": "Entailment"
    },
    "7506e58c-a44a-4410-a519-59a81686fe12": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no requirement for participants in the secondary trial to have responded positively to AI therapy and mirtazapine",
        "label": "Contradiction"
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "text_answer": "No  Explanation  The statement Women with Newly diagnosed stage IV breast cancer confirmed as ER  Considering a mastectomy are eligible for the primary trial and the secondary trial is not entailed by the evidence provided  The primary trial only includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic",
        "label": "Contradiction"
    },
    "f823a6d1-5d44-4d8c-8f33-14eef364d3b6": {
        "text_answer": "yes but with a qualification the statement is entailed by the exclusion criteria regarding women of childbearing potential WOCBP but it does not explicitly mention men However the trial does not exclude men based on their potential fertility",
        "label": "Entailment"
    },
    "2a45331c-2e6b-43fb-be85-86e22c828c41": {
        "text_answer": "Yes  Explanation The evidence shows that a greater percentage of participants in the bevacizumab cohort experienced disease progression or death compared to the bevacizumab  capecitabine cohort 883 vs 758 This difference indicates a greater incidence of disease progression or death in the bevacizumab cohort",
        "label": "Entailment"
    },
    "d3ee2617-a363-4290-a97b-57f6eb1b8efe": {
        "text_answer": "No  Explanation  The statement the entirety of group 1 in the primary clinical trial presented with skin lesions is not entailed by the evidence provided The evidence only states that there were no skin lesions detected in the healthy volunteers in the primary clinical trial  Furthermore the statement fewer than one in ten participants in group 1 of the secondary clinical trial exhibited radiation dermatitis or hyperpig",
        "label": "Contradiction"
    },
    "d2885dd5-eb3f-4dcd-9980-c02d3c1c6924": {
        "text_answer": "Yes  Explanation The statement one shingles case was reported in the secondary clinical trial specifically in group 2 is entailed by the evidence as there is a reported instance of shingles in group 2 of the secondary trial However it is important to note that neither the primary clinical trial nor group 1 of the secondary trial reported any instances of shingles",
        "label": "Entailment"
    },
    "aab488c3-ac44-4506-b2b1-541909e30028": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0c105984-77ed-42cc-9d9f-aec464e02d12": {
        "text_answer": "No  Explanation  The statement Candidates for the primary trial and the secondary trial have to meet a baseline performance status for the primary trial the baseline is a Karnofsky score 70 and for the secondary trial the baseline is a Karnofsky score 55 is not entailed by the evidence provided  The evidence only states the inclusion and exclusion criteria for both trials but it does not mention the specific performance",
        "label": "Contradiction"
    },
    "216d59a3-b4c1-4a73-a4e2-ee2b97c59b22": {
        "text_answer": "No   Explanation   The primary clinical trial measures the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary clinical trial measures the percentage of participants with adverse events of primary interest AEPIs which include hepatic events allergic reactions thrombocytopenia and hemorrhage events all",
        "label": "Contradiction"
    },
    "fa7b75cd-7f8f-44aa-83dc-618e1bc961a1": {
        "text_answer": "  Yes The evidence states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a CR or PR which is over 12 of the participants The statement does not mention bladder solitary fibrous tumor but the evidence is not specific to that type of tumor so it is still applicable",
        "label": "Entailment"
    },
    "34f34450-a64c-4159-ad9d-8adb58617e79": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial noted only two types of adverse events eyelid oedema and chest pain while the primary trial reported no observed adverse events is not entailed by the evidence provided The evidence only shows the number and percentage of each type of adverse event in both trials but it does not directly compare the trials in terms of which trials reported which adverse events Therefore the statement goes beyond",
        "label": "Contradiction"
    },
    "6c50344e-493e-46a6-9e03-74495773bab2": {
        "text_answer": "No   Explanation  The statement all patients in the primary clinical trial receive suramin and paclitaxel is not entailed by the evidence as the secondary trial does not mention the drugs being administered The evidence only states that the secondary trial does not specify which drugs are given in its intervention section",
        "label": "Contradiction"
    },
    "a698cb41-106c-4d9c-b4e9-1381f9329079": {
        "text_answer": "No  Explanation The statement both the placebo and trabectedin used in the primary clinical trial are given as threehour intravenous infusions biweekly is not entailed by the evidence The evidence only states that the placebo is given as a 3hour intravenous infusion on Day 1 and trabectedin is given as a 3hour intravenous infusion on Day 2 It",
        "label": "Contradiction"
    },
    "6bae9ada-fea4-4bb6-bd25-cdb505b3d53f": {
        "text_answer": "Yes  Explanation  The statement over 097 of patients in the secondary trial and the primary trial did not suffer any adverse events can be calculated as follows  1 In the primary trial the total number of patients is 11 and the number of patients with adverse events is 5 So the number of patients without adverse events is 11  5  6 2 In",
        "label": "Entailment"
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "text_answer": "No  Explanation The statement Candidates for the secondary trial study group receive 3 weekly subcutaneous SC injections whereas the primary trial participants only receive a single injection at the beginning of the study is not entailed by the evidence provided The evidence only mentions the number of interventions and the timing of the vitamin D repletion intervention in the primary trial and the details of the secondary trial including the number and frequency of",
        "label": "Contradiction"
    },
    "5db44a07-6d17-4fa9-9060-1f1af4aaf3af": {
        "text_answer": "Yes The evidence shows that there were a total of 3 vomiting events out of 149 participants in the clinical trial",
        "label": "Entailment"
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "text_answer": "  Yes for the primary trial pulmonary embolism is a reason for exclusion within 4 weeks of first dose of study drug  Partially for the secondary trial the decision is left to the Investigator",
        "label": "Entailment"
    },
    "86515e2e-b144-430c-b7e2-678733d3b0ec": {
        "text_answer": "Yes The statement is entailed by the evidence as patients are given oral medication twice a day lapatinib and tamoxifen for a full month Desensitization is not directly mentioned in the evidence but the statement does not contradict it either",
        "label": "Entailment"
    },
    "f9638af4-2bf2-45b4-8c9e-b46c34373b17": {
        "text_answer": "No  Explanation  The evidence provided in the text does not support the statement that the bevacizumab group witnessed more cases of disease progression or death compared to the bevacizumab  capecitabine group In fact the opposite is suggested by the data as the percentage of participants with disease progression or death was lower in the bevacizumab  capecitabine group 758",
        "label": "Contradiction"
    },
    "cf38cb04-b2fd-44bf-9674-dda257a8ad25": {
        "text_answer": "No  Explanation  The statement cardiac biphasic synovial sarcoma is a biphasic synovial sarcoma arising from the heart is not directly related to the evidence provided The evidence only mentions the number of participants in a trial who received a specific vaccine and does not provide any information about the type of cancer or its location in the body",
        "label": "Contradiction"
    },
    "bbb1b8c1-c9b1-40c9-b744-a2ae519032c3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports the median interquartile range of Ki67 expression as a percentage of cells not as a cell count in millions The statement also does not provide the actual reduction in Ki67 expression in millions of cells",
        "label": "Contradiction"
    },
    "7dbe6e8e-5971-41e2-bc70-46dc3cb3cd5c": {
        "text_answer": "Yes  Explanation  The statement there are 00 shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because there is no overlap in the inclusion or exclusion criteria between the two trials The primary trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy and has exclusion criteria related to mental function",
        "label": "Entailment"
    },
    "c18a6d09-906e-4fbe-acf1-93b9a89f717a": {
        "text_answer": "No  Explanation  The primary trial measures change in units on a scale not minutes The secondary trial measures percentage of participants and number not minutes Therefore neither trial employs minutes as a unit of measure",
        "label": "Contradiction"
    },
    "9c0406cd-3585-4cb2-b330-fa9c1426c72c": {
        "text_answer": "No  Explanation The statement every participant in the primary clinical trial was administered oral sunitinib daily throughout the entirety of the research period is not entailed by the evidence The evidence states that sunitinib was administered daily but it also mentions that dosing could be interrupted or reduced according to individual tolerance and participants with PD or intolerable toxicity were considered for discontinuation from the study Therefore not every participant",
        "label": "Contradiction"
    },
    "47daf120-3939-4e32-bba5-d86ce54a9cbd": {
        "text_answer": "Yes  Explanation The evidence states that out of the 53 participants analyzed in the Lapatinib 1000 mg  NabPaclitaxel armgroup no information about the number of participants who achieved a confirmed complete response CR is provided However it is mentioned that the overall number of participants who experienced either a confirmed complete response CR or a confirmed partial response PR was 53 out of ",
        "label": "Entailment"
    },
    "84e7c52d-eec3-415f-9602-77f607c5620e": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the doses of Abraxane nabPaclitaxel are identical in both arms but the doses of the second drugs Gemcitabine and Carboplatin are different",
        "label": "Contradiction"
    },
    "19606c86-3376-40ca-b438-20d961329829": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures the efficacy of flaxseed on hot flash scores in women while the secondary clinical trial measures the overall response rate ORR in patients with solid tumors receiving Paclitaxel Plus Bevacizumab PB or Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG These are entirely different outcome measures",
        "label": "Entailment"
    },
    "b12b7e1a-9348-4e57-ac88-44523913fff3": {
        "text_answer": "Yes The primary trial mentions IV administration for zoledronic acid while the secondary trial mentions both IV and oral administration for all interventions",
        "label": "Entailment"
    },
    "a7561afd-f6c4-41cf-8d4a-fa6c26cc10b3": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the effect of AZD0530 175 mg and Zoledronic Acid 4 mg on the percentage change in betaCTX at week 4 in the context of bone health The statement about congenital candidiasis is not related to the evidence provided Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9289ca32-0fa0-44ae-8cc0-49510f2fed23": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial cohort 1 receives less than half the dose of alt801 that cohort 2 does is entailed by the evidence because the dose given to cohort 1 0015 mgkgdose is less than half the dose given to cohort 2 0040 mgkgdose",
        "label": "Entailment"
    },
    "784e0481-d0fd-43b9-8d5a-0a1d2bd4aa26": {
        "text_answer": "No  Explanation  The statement percentage times minute per hour is a unit of measurement expressed as the percentage times minutes divided by hours is not directly related to the evidence provided The evidence is about the adverse events AEs recorded in a primary trial with their respective frequencies The statement is about a unit of measurement which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "e3801aad-e988-42fb-8266-22a90bdba955": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial does not involve muscle gains and the secondary trial measures pain not muscle gains in relation to physical therapy",
        "label": "Contradiction"
    },
    "22274495-9d06-43cd-98fd-86d0374b42e9": {
        "text_answer": "No  Explanation  The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis and the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients The statement is about viral relapse which is not related to the content of the evidence",
        "label": "Contradiction"
    },
    "d3525b25-3dad-4ed2-8fe7-d0f0abc6be14": {
        "text_answer": "No   Explanation  The statement primary clinical trial employs procedures that utilize ultrasound guidance and vertical longitudinal incisions is not entailed by the evidence provided The evidence describes a primary clinical trial with two cohorts one using an inframammary fold incision and the other using a lateral radial incision Both cohorts undergo laserassisted fluorescence angiography at three separate time points",
        "label": "Contradiction"
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "text_answer": "yes both trials involve injections However the statement could be more specific by mentioning denosumab and radioactive Tc99M sulfur colloid separately to accurately reflect the information in the evidence",
        "label": "Entailment"
    },
    "0e1460ea-4f44-47ff-892a-e3190b498557": {
        "text_answer": "No The statement is not entailed by the evidence as the evidence does not provide any information about the nature of the primary clinical trial or the conditions being treated in cohort 1 The adverse events listed are related to various medical conditions primarily cardiovascular and hematological",
        "label": "Contradiction"
    },
    "9bb1e4d4-379d-47f5-a6b9-c6dac40b2727": {
        "text_answer": "No  Explanation The evidence provided in the text describes the results of a clinical trial comparing the effect of topical cryotherapy during paclitaxel infusions on chemotherapyinduced peripheral neuropathy CIPN symptoms as measured by the Area Under the Curve AUC of the European Organization for the Research and Treatment of Cancer Quality of Life QuestionnaireCIPN20 EORTC QLQ",
        "label": "Contradiction"
    },
    "1820d3ff-ca2a-47dc-a80e-45e760307261": {
        "text_answer": "No  The evidence describes participants receiving oral doses of enzalutamide not intravenous injections",
        "label": "Contradiction"
    },
    "2db0df9c-be54-419d-9710-54adb741a1a1": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically states that any of the following current or planned therapies are not allowed antineoplastic chemotherapy androgens estrogens and progestogens",
        "label": "Entailment"
    },
    "0f36a35d-d86b-41d0-9878-df4ef7ad0e9f": {
        "text_answer": "No  Explanation  The statement the infection asymmetry and deflation cases were less prevalent in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only shows that the infection asymmetry deflation and delayed healing wound cases occurred in the primary trial with respective frequencies of 323 323 323 and 323 The",
        "label": "Contradiction"
    },
    "e2061005-22e7-4de3-90c2-e4ebfe055b0d": {
        "text_answer": "No  Explanation  The statement the evidence from the primary clinical trial indicates that the overall response rate was higher in the placebo arm than in arm A intervention is not entailed by the evidence provided The evidence only shows that the overall response rate in Arm A was 676 compared to 600 in Arm B in the primary trial It does not indicate that the placebo arm had a higher response rate  ",
        "label": "Contradiction"
    },
    "7b29df5c-9189-4c72-b0ad-3ed971c42652": {
        "text_answer": "  No   Explanation   The statement patients suffering from cancer and having conditions like anemia epilepsy or thalasemic diseases are welcome to participate in both the primary and secondary clinical trials is not entailed by the evidence provided   The primary trial explicitly lists anemia as an exclusion criterion for the patients with breast cancer who wish to participate The secondary trial also has exclusion criteria that include",
        "label": "Contradiction"
    },
    "d58edc4e-2e7f-4c35-b24c-cd1239175b1a": {
        "text_answer": "No  Explanation  The statement the primary participants reported no adverse events specifically no occurrences of maculopapular rash is not entailed by the evidence The evidence reports that one participant out of 30 experienced a maculopapular rash which is an adverse event Therefore the statement is not true according to the evidence",
        "label": "Contradiction"
    },
    "02cf528a-17da-4ea6-a65e-7a9efe2cf3cf": {
        "text_answer": "No  Explanation  The statement both the primary and secondary trials used multiple test groups without any placebo group in either case is not entailed by the evidence The primary trial did include a placebo group Arm II while the secondary trial did include a control group Lowdose Oxybutynin Chloride Group but it was not explicitly stated as a placebo group in the provided information However the assumption that a control",
        "label": "Contradiction"
    },
    "1f9ee295-ce3d-427b-8af2-876edb47bf7f": {
        "text_answer": "Yes   Explanation  The primary trial involves the use of Gefitinib ZD1839 as a multidrug regimen depending on the final dose in the parent trial In contrast the secondary trial only involves the use of a single therapeutic agent Zoledronic Acid with or without radiopharmaceuticals Therefore the statement that the primary clinical trial requires administration of a multidrug",
        "label": "Entailment"
    },
    "d504ff9e-bdcc-4609-9b57-b1cb4638bfdc": {
        "text_answer": "No  Explanation  The statement the participant count was the same for both cohorts in the primary clinical trial is not entailed by the evidence The evidence provides the number of participants analyzed in each arm of the trial but it does not state that the participant count was the same for both cohorts The evidence only states that there were 1420 participants in each arm of the trial",
        "label": "Contradiction"
    },
    "cedade64-046d-4e90-ad04-9b0a497fc534": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the use of 18FFDG and 18FFPPRGD2 in the context of two different clinical trials for glioblastoma multiforme and gynecological cancers respectively and does not mention any regimen used for the treatment of penile cancer",
        "label": "Contradiction"
    },
    "73e39e6d-e688-4372-85d4-dbb3cbc7a7cb": {
        "text_answer": "No   Explanation The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the 200 weeks of the study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups during the 10week study period",
        "label": "Contradiction"
    },
    "f0534dd1-7050-4fc1-971e-5aab8abb5d47": {
        "text_answer": "Yes  Explanation  The statement no cardiac or psychiatric adverse events were reported in the course of the primary clinical trial and the secondary clinical trial is entailed by the evidence since the evidence reports that there were no cardiac or psychiatric adverse events in both trials",
        "label": "Entailment"
    },
    "6247182c-7b14-46b7-9452-a4072ed79a7b": {
        "text_answer": "Yes The evidence does not mention any unexpected deaths or hospitalizations in either trial",
        "label": "Entailment"
    },
    "a3ba6a16-5f21-477d-9a2a-574a53ab3f2c": {
        "text_answer": "No  The evidence does not mention anything about eating disorders in the primary trial The statement is not related to the given evidence",
        "label": "Contradiction"
    },
    "fc38bc02-5e04-4b3d-bf4d-19fa9a636bd2": {
        "text_answer": "Yes but with a caveat The evidence does not directly report on the number of participants who experienced a decline in cognitive function but rather reports the mean standardized composite cognitive function scores for each group The statement that no participants in the primary clinical trial experienced a decline in cognitive function would be an overgeneralization of the evidence as it does not account for the possibility of individual variability in cognitive function within each group However the evidence does suggest that the mean cognitive function",
        "label": "Entailment"
    },
    "2dbcfe7a-32b5-47e3-a6fc-0f38039de24c": {
        "text_answer": "No  Explanation The evidence provided in the trial results only reports the number of participants with pathologic complete response in breast and axillary lymph nodes at the time of surgery approximately 7 months into the study It does not provide information about the number of participants who experienced pathologic complete response after 12 months of the study Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "264848be-8491-409f-b19f-0db249bc155a": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "6548c59c-cafc-465f-8f10-4bfc5d147611": {
        "text_answer": "Yes The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed by the evidence provided which states that there were no deaths or hospitalizations in cohort 2 The question about people being unfriendly is not related to the evidence and is a separate issue",
        "label": "Entailment"
    },
    "03688964-cf46-485b-99f3-f7c6c5fed3ed": {
        "text_answer": "  No The statement is not entailed by the evidence as the primary trial specifies Japanese females as candidates while the secondary trial does not have any such restriction",
        "label": "Contradiction"
    },
    "abc13f3b-54fa-4a1c-a063-5f1f00e2ae9a": {
        "text_answer": "No  Explanation The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 43 hours if they want to participate in the primary trial is not entailed by the evidence The evidence states that patients must not have",
        "label": "Contradiction"
    },
    "c651d7a4-f39a-44df-84cc-f71c45ced124": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not mention leptomeningeal carcinoma as a condition for eligibility or exclusion from the trial",
        "label": "Contradiction"
    },
    "9b9d2ca0-acea-42a6-bd46-78eb4540a107": {
        "text_answer": "No  Explanation The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 1300 of the primary trial patients is not entailed by the evidence The evidence only states that syncope occurred in 212 1667 patients in the primary trial and 0115 000",
        "label": "Contradiction"
    },
    "55372cf8-c6a0-4286-8cd5-5e11e070bd79": {
        "text_answer": "No  Explanation  The statement the mymop score change is not a determinant for outcome measurement in either the primary trial or the secondary trial is not entailed by the evidence provided The evidence only reports the results of two trials with different outcome measurements The first trial used the MYMOP questionnaire to measure patientreported symptoms while the second trial measured the concentration of isothiocyanate in urine samples The statement goes beyond",
        "label": "Contradiction"
    },
    "4abdde7a-7745-4391-ae23-9d7fb6d837c2": {
        "text_answer": "  Patients with high vitamin D levels did not manifest a noticeable pattern for expression of the group of 40 evaluated genes according to the provided evidence The evidence only reports that no discernible pattern was observed in the groups with normal and lownormal vitamin D levels",
        "label": "Contradiction"
    },
    "bb5873a3-4c28-49f6-9f70-f3f1d8ac7db2": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement refers to myalgias in the secondary trial but the evidence only mentions dexmedetomidine in the secondary trial without specifying its relation to myalgias",
        "label": "Contradiction"
    },
    "eda562ff-9676-46f2-9ec3-93eb3cdd7585": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants in each arm who achieved a pathologic complete response in the breast and axillary lymph nodes after neoadjuvant chemotherapy It does not provide information on the total number of participants in each arm who experienced this outcome over the entire study duration of approximately 057 years Therefore it is not possible to determine if more than 0",
        "label": "Contradiction"
    },
    "6a211e77-e17f-4739-b685-e6bd83b8d7e3": {
        "text_answer": "No  The evidence does not exclude patients with leptomeningeal carcinomatosis if it is controlled postcompletion of local therapy for at least 4 weeks",
        "label": "Contradiction"
    },
    "754d4ae4-5d18-4b63-836a-c011958680ce": {
        "text_answer": "Yes Both trials involve the use of cyclophosphamide However its important to note that the context and purpose of the cyclophosphamide use may differ between the two trials In the primary trial its used in combination with doxorubicin and GMCSF while in the secondary trial its used in combination with doxorubicin and either pegfilgrastim or filgrastim The statement",
        "label": "Entailment"
    },
    "41219409-bd82-4df0-82aa-d72fc4aec1fd": {
        "text_answer": "No  Explanation The statement provided is not related to the adverse events mentioned in the evidence The statement is about a medical condition called megacystismegaureter which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "61a1a0e2-bd62-43de-b3c9-1c2143417c5a": {
        "text_answer": "Yes Both trials require patients to have a functional ECOG status 2 indicating ambulatory status",
        "label": "Entailment"
    },
    "f11800b6-312b-4f9d-9b18-24a3a6bb67a2": {
        "text_answer": "No  Explanation  The statement neither intervention one nor two in the primary clinical trial employs pihgc or standard gp is not entailed by the evidence The evidence only states that both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site but it does not mention whether they use pIHGC or standard gamma probes specifically Therefore the statement goes beyond the",
        "label": "Contradiction"
    },
    "4e0fbb00-bcbe-4051-a343-58a6cb50eb0b": {
        "text_answer": "Yes However its important to note that the statement only applies to postmenopausal women with early stage breast cancer who are vitamin D deficient and meet the other inclusion criteria for the primary trial but are excluded due to their low vitamin D levels These patients may still qualify for the secondary trial if they meet its inclusion criteria",
        "label": "Entailment"
    },
    "d331f99d-446c-4305-8842-05d6fe2d070c": {
        "text_answer": "Yes The evidence shows that there were no cases of pancytopenia in the primary group of the primary clinical trial The statement correctly identifies this fact",
        "label": "Entailment"
    },
    "abaf9c04-8d6d-43f3-afb5-9bc9d04fb9b5": {
        "text_answer": "No  Explanation  The statement amnion nodosum is an amnion with nodular deposits of squamous and cellular debris with varying staging of reepithelialization is not directly related to the evidence provided The evidence pertains to the inclusion and exclusion criteria for two clinical trials one for cerebral metastases and the other for a prostate lung or breast cancer study with influenza vacc",
        "label": "Contradiction"
    },
    "e123c707-0e86-43c1-8f9b-971363c07ae0": {
        "text_answer": "No  Explanation  The statement regimen used to treat prostate carcinoma is any regimen that can be used for the treatment of prostate carcinoma is not directly related to the evidence provided The evidence only reports the number of adverse events in two separate trials for a specific regimen used to treat prostate carcinoma It does not state that the primary and secondary trials used the same regimen or that they recorded the same total",
        "label": "Contradiction"
    },
    "b2caa135-c6ed-46b0-a1e3-6fd60ae12831": {
        "text_answer": "Yes  Explanation The statement the differences between interventions 1 and 2 of the primary clinical trial do not involve the amount of durvalumab administered monthly to each cohort is entailed by the evidence because the amount of durvalumab administered monthly is the same 1500 mg Q4W for extended treatment in both interventions The difference lies in the dosing of tremelimumab 03",
        "label": "Entailment"
    },
    "19275bdd-9964-4f3b-b2d5-b984203774d5": {
        "text_answer": "Yes  Explanation The statement both the primary clinical trial and the secondary clinical trial reported a minimum of one infection case is entailed by the evidence as there is at least one infection case reported in each trial",
        "label": "Entailment"
    },
    "8d728674-1111-495d-ae90-59ced10163a4": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts receive higher doses of Cyclophosphamide than the other drugs mentioned in their respective interventions",
        "label": "Entailment"
    },
    "88a8b32d-122c-48f9-a305-3d1b8e3fcd85": {
        "text_answer": "Yes The statement is entailed by the evidence as every patient in the trial is required to take Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "4bf82041-f1d8-4a90-9bd0-aec991e50966": {
        "text_answer": "No  Explanation  The statement percentage food eaten score 40 is a subjective score of 40 on a scale that ranges from 0 none to 100 all of my food is not mentioned in the evidence provided for either the primary or secondary trial The evidence only includes information about the inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "b3ed34ea-6461-40ed-955d-693bbc27fd99": {
        "text_answer": "No  Explanation  The statement substance dispersity is a measure of the heterogeneity of sizes shapes or masses of molecules or particles is not directly related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The statement does not appear in the evidence and does not relate to the conditions for patient eligibility or ineligibility in the trials  The evidence only mentions the exclusion of patients",
        "label": "Contradiction"
    },
    "53dac2a0-f55a-4987-bab1-695a985eacd1": {
        "text_answer": "No  The interventions in the two trials have different durations but the statement does not specify which trial it is referring to and the difference in duration is not 50 weeks",
        "label": "Contradiction"
    },
    "2cd6db4c-83e4-4ca5-8650-6638521a27a2": {
        "text_answer": "Yes  The statement is entailed by the evidence as the clinical trial involves the administration of multiple injections including dendritic cell injections chemotherapy and trastuzumab infusions",
        "label": "Entailment"
    },
    "2cf8bdbf-5f09-4f16-8b50-c6369d003a4f": {
        "text_answer": "No  Explanation  The statement t122q23q12 is a chromosomal translocation involving the pbx1 gene at 1q23 and the ewsr1 gene at 22q12 is not mentioned in the evidence provided Therefore it cannot be determined if the statement is entailed by the evidence or not The evidence only provides information about the outcome of two clinical",
        "label": "Contradiction"
    },
    "b41e6cb3-c92e-4027-b96b-502aeb1f4211": {
        "text_answer": "No  Explanation  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is not directly related to the adverse events listed in the evidence The evidence only reports the number of participants who experienced various adverse events including acute myocardial infarction but it does not provide the number of participants who experienced blacking out",
        "label": "Contradiction"
    },
    "d5b131c2-0835-4f00-a0ba-2db26d1fe581": {
        "text_answer": "Yes  Explanation  The statement throughout the primary clinical trial there were no reported cases of gastrointestinal complications is entailed by the evidence since the evidence does not report any cases of nausea vomiting or colitis ischaemic in either Adverse Events 1 or Adverse Events 2",
        "label": "Entailment"
    },
    "c5fed4a9-da6c-4dcb-b191-930bca7e0ce7": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "6e9f7a1a-21e5-4d5f-b602-a1efb1b51bc7": {
        "text_answer": "Yes The evidence mentions the doses of ALT801 given to each cohort and the statement confirms that Cohort 1 received less than half the dose of Cohort 2 The statement also mentions the relevance of the alb gene and familial dysalbuminemic hyperthyroidism but that information is not directly related to the dosing information in the evidence",
        "label": "Entailment"
    },
    "61afd69d-529d-49e9-b607-007414946b6c": {
        "text_answer": "Yes The evidence states that there were no urinary tract infections reported during the primary clinical trial",
        "label": "Entailment"
    },
    "dfb4c335-296e-42af-b418-329f39c6b42e": {
        "text_answer": "No  Explanation  The statement both the primary clinical trial and the secondary clinical trials results do not require any units of measurement is not entailed by the evidence The evidence clearly states the units of measurement for the outcome measures in both trials In the primary trial the outcome measure is tumor diameter with units of cm In the secondary trial the outcome measure is the number of participants with solid tumor response which does not have a unit",
        "label": "Contradiction"
    },
    "5051b4e9-21e7-4fa8-a602-de48b103fa19": {
        "text_answer": "  Yes The statement is entailed by the evidence as warfarinbased treatments are explicitly listed as excluded for the primary trial candidates However the statement also mentions that warfarin may still be permitted for the secondary trial candidates which is consistent with the evidence as it states that lowdose warfarin less than or equal to 1 mgday is permitted for both trials",
        "label": "Entailment"
    },
    "f61808f1-4431-4b34-8a66-e422c6e97530": {
        "text_answer": "No  Explanation  The statement dysplasia negative is an indication that signs of dysplasia were not found in a sample is not directly related to the evidence provided in the primary trial The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at weeks 12 and 24 for the Lapatinib 1250 mg and Vinorelbine 20 mgm",
        "label": "Contradiction"
    },
    "01d0c4bf-e697-4565-906b-edd21fd2227f": {
        "text_answer": "No  The evidence does not mention anything about schizophrenia",
        "label": "Contradiction"
    },
    "a1e4f5de-9b44-444e-8eff-ae7b040c6f6e": {
        "text_answer": "No  Explanation  The statement women with triple negative stage III breast cancer who have undergone mastectomy are eligible for the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and the secondary clinical trial includes women with newly diagnosed or recurrent breast cancer who are considering or completing",
        "label": "Contradiction"
    },
    "6f835e44-5cb2-4f42-9b69-8ec81c00a404": {
        "text_answer": "No  Explanation  The statement patients currently in remission are eligible for both the primary clinical trial and the secondary clinical trial even without providing any informed consent is not entailed by the evidence provided The evidence clearly states that patients must provide a signed informed consent form to participate in both trials",
        "label": "Contradiction"
    },
    "8c9c4150-3bc1-4f06-8bee-2d5bba3ef8b9": {
        "text_answer": "No  Explanation  The statement several cardiac and psychiatric aes were observed in the primary clinical trial is not entailed by the evidence provided The evidence only states that there were no adverse events AEs reported for AEs 1 and 2 in both the primary and secondary trials The statement implies that there were indeed AEs reported but it does not specify how many or which specific AEs were observed Therefore",
        "label": "Contradiction"
    },
    "2096d634-b321-40de-b69b-8dad3345331e": {
        "text_answer": "No  Explanation  The statement more people participated in the secondary clinical trial than the primary clinical trial is not entailed by the evidence provided The primary clinical trial had 13 participants and the secondary clinical trial had 30 participants but this does not mean that more people participated in the secondary trial The number of participants in each trial is given explicitly in the evidence",
        "label": "Contradiction"
    },
    "a2981a35-ece3-42dc-a735-cd12466392fa": {
        "text_answer": "Irrelevant The statement has nothing to do with the adverse events data provided in the evidence",
        "label": "Entailment"
    },
    "ff95337a-7da9-43f5-bb3c-25cd7c85e5c7": {
        "text_answer": "No  Explanation  The statement 025 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not directly entailed by the evidence provided The evidence states that the percentage of patients who experienced each adverse event separately in each trial but it does not provide the percentage of patients who experienced both adverse events together Therefore it is not possible to determine the exact percentage of patients who suffered from both ad",
        "label": "Contradiction"
    },
    "6a969a7c-55f3-4595-a361-db78a910f352": {
        "text_answer": "  No  Explanation  The evidence provided in the primary clinical trial results does not indicate the number of participants in each arm who experienced a pathologic complete response in breast and axillary lymph nodes 3 months following surgical intervention The results only indicate the number of participants who achieved a pathologic complete response at the time of surgery approximately 7 months after the initiation of treatment",
        "label": "Contradiction"
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5af90c4a-80c3-4f11-bbc0-7f84ad544186": {
        "text_answer": "  Yes The statement is entailed by the evidence as the inclusion criteria specify ER negative PR negative and HER2 negative breast cancer",
        "label": "Entailment"
    },
    "e92e6dec-b727-475a-b544-568b5773cb81": {
        "text_answer": "No  Explanation The evidence states that participants in the primary clinical trial receive oral lapatinib and oral tamoxifen once daily on days 128 but it does not specify the exact dose of lapatinib The statement provided in the question assumes a dose of 100 mgm2 which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "fc35d08f-73a9-47aa-9450-165dcfda17bf": {
        "text_answer": "Yes  Explanation  The statement across both the primary clinical trial and the secondary clinical trial no adverse events were observed in more than 1 of participants is entailed by the evidence since the evidence shows that no adverse events were observed in more than 1 of participants in each trial Therefore the statement is a logical conclusion based on the given evidence",
        "label": "Entailment"
    },
    "a96f9558-41f8-4515-8fc4-d3b8f326ce05": {
        "text_answer": "No   Explanation  The evidence provided in the primary clinical trial does not mention the use of morphine sulfate during radiation therapy for patients receiving vorinostat The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "6fbc7c06-1134-42b6-bfbc-9e4f28727cba": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement about a 0064 recurrencefree survival difference between the ketorolac 003 g and NaCl 09 3ml groups The evidence only provides the number of participants in each group and their recurrencefree survival rates To determine the difference in recurrencefree survival between the two groups additional data",
        "label": "Contradiction"
    },
    "6e6f3848-8d0e-47df-b2f3-1f09cf7da6e4": {
        "text_answer": "No   Explanation  The statement the primary clinical trial and the secondary clinical trial did not experience any adverse events is not entailed by the evidence because the evidence reports that there were adverse events in the secondary trial specifically gastroesophageal reflux disease and ductal carcinoma in situ each occurring in 135 286 of the participants",
        "label": "Contradiction"
    },
    "eacc1096-c090-4f21-ad10-005be458b653": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trial involves a weekly dose of 2 mgkg of trastuzumab during the maintenance phase while the secondary trials cohort 2 involves a weekly dose of 2 mgkg of trastuzumab during the maintenance phase and a higher initial dose of 4 mgkg during the loading phase",
        "label": "Entailment"
    },
    "325c6150-352f-4b08-aa67-fed4cd6f68d0": {
        "text_answer": "  No the statement is not directly entailed by the evidence as it does not explicitly mention organ transplant as an exclusion criterion in either trial However the primary trial does exclude patients who have undergone major surgery within 28 days prior to study registration and the secondary trial excludes patients who have received HDCT with AHST in the adjuvant setting but it does not mention organ transplant specifically",
        "label": "Contradiction"
    },
    "90135397-f63a-412e-9633-0355e1a78154": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary clinical trial shows that patients in the acupuncture group experienced a greater reduction in mean arm circumference indicating improvement in lymphedema compared to the waitlist control group over the 6week intervention period This suggests that the acupuncture treatment led to more significant improvements in lymphedema than the waitlist control group",
        "label": "Entailment"
    },
    "6bc62f08-51ae-44d6-be1d-738c82598de5": {
        "text_answer": "No  Explanation The statement is not an exact representation of the evidence as it omits some of the inclusion criteria and incorrectly states the time frame for certain exclusion criteria The statement only mentions postmenopausal adenocarcinoma as an exclusion criterion but the evidence includes other types of breast cancer as well Additionally the statement incorrectly states that patients cannot have a history of stroke transient ischemic attacks",
        "label": "Contradiction"
    },
    "f6ad61ca-d223-496b-a067-69625112447c": {
        "text_answer": "No  Explanation  The statement less than 120 of patients in the primary trial suffered adverse events is not entailed by the evidence The evidence only provides the number and percentage of patients who experienced specific adverse events gastroesophageal reflux disease and ductal carcinoma in situ in the primary trial It does not give the total number of adverse events or the total number of patients in the",
        "label": "Contradiction"
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "text_answer": "Yes  Explanation The evidence states that women of childbearing potential WOCBP and sexually active fertile men are eligible for the trial but they have additional requirements related to birth control This is consistent with the statement that they are eligible but have additional requirements",
        "label": "Entailment"
    },
    "bb3e3ca1-1b64-4ddc-9492-1fb11ec9356f": {
        "text_answer": "Yes The statement is entailed by the evidence as both study groups undergo identical imaging procedures with a minor increase in the dosage of 18FFPPRGD2 for cohort 1",
        "label": "Entailment"
    },
    "efa989b7-db55-49b8-a124-875a5f7c94ff": {
        "text_answer": "No  Explanation  The statement mentions Asthenia and Pyrexia but the evidence only provides information about Adverse Events 1 and Adverse Events 2 without specifying which adverse events correspond to Asthenia and Pyrexia Additionally the statement mentions nervous system neoplasm which is not related to the information provided in the evidence",
        "label": "Contradiction"
    },
    "63a44f77-d6b6-47df-9bea-b7deb99f5658": {
        "text_answer": "No  Explanation  The statement karyocytomegaly and multinucleated hepatocytes is a finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion is not directly related to the evidence provided The evidence only mentions the adverse events experienced by the primary trial patients including an increase in blood bilirubin for 3636",
        "label": "Contradiction"
    },
    "fc4ec229-5b69-409e-89c0-2b151f670382": {
        "text_answer": "Yes The evidence does not mention any performance status conditions as inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial do not have any recorded adverse events for their participants is entailed by the evidence since the evidence shows that there are no recorded adverse events for either trial",
        "label": "Entailment"
    },
    "1172df8a-7da3-4769-8832-32ded72cfcf1": {
        "text_answer": "Yes The primary trial includes patients with histologically or cytologically confirmed metastatic andor advanced solid tumors who have a specific gene mutation as an inclusion criterion while the secondary trial includes patients with advanced solid tumors for which there is no approved therapy and no requirement for a specific gene mutation",
        "label": "Entailment"
    },
    "c20768c0-36c2-44ff-9d4f-36d34e02c1a2": {
        "text_answer": "Yes The evidence indicates that zoledronic acid in Intervention 1 of the primary trial and all drugs granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone in both interventions of the secondary trial are given intravenously The statement that intervention drugs must be administered intravenously is entailed by the evidence However its",
        "label": "Entailment"
    },
    "04beb33e-ae70-4de2-a805-71650246ea7b": {
        "text_answer": "No  The primary trial is for patients with a breast tumor 1 cm in diameter and the secondary trial is for patients with measurable disease Neither trial mentions a tumor size of 100mm",
        "label": "Contradiction"
    },
    "262e8bd4-da64-4158-b23d-b875050e66af": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as there is no mention of Paraplatin in the given clinical trial The evidence only mentions Carboplatin in Intervention 2",
        "label": "Contradiction"
    },
    "18e1908f-f449-42a0-916b-7e88c1e7c901": {
        "text_answer": "Yes  Explanation  The statement patients in the primary clinical trial did not suffer from anemia pneumonia and stupor more frequently than those in the secondary trial is entailed by the evidence because the evidence shows that there were no cases of anemia pneumonia or stupor in the primary trial Therefore the frequency of these adverse events is lower in the primary trial than in the secondary trial where",
        "label": "Entailment"
    },
    "e4f2bd3a-6976-4a2b-9485-c34bdc812c54": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided in the primary trial results The evidence only reports the number of participants in cohort 2 who experienced acute vomiting after receiving the treatment regimen of Aprepitant Dexamethasone Cytoxan and Kytril It does not mention anything about adhesion factor production",
        "label": "Contradiction"
    },
    "70c0fbc1-8eb8-4634-a595-898784718d09": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the primary trial involves the administration of ZD1839 alone while the secondary trial involves the administration of Zoledronic Acid and other drugs in addition to ZD1839 Therefore the statement incorrectly implies that the primary trial does not involve any other interventions besides ZD1839",
        "label": "Contradiction"
    },
    "4960cf63-01e8-4fc5-b6ea-fe10063c6e6c": {
        "text_answer": "Yes  Explanation The statement alisertib isnt included in the treatment of both cohorts in the primary clinical trial is correct as the primary trial only includes Botulinum Toxin Type A and placebo The secondary trial however does involve alisertib but with different doses for its two cohorts",
        "label": "Entailment"
    },
    "ed12f8ae-3bda-46b8-8bf1-5ad6d1527c57": {
        "text_answer": "No  Explanation  The statement received all the services needed is not directly mentioned or entailed in the evidence provided for either the primary or secondary trial The evidence only outlines the inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "2d0df5b6-0886-4a19-973a-92f4442b39d1": {
        "text_answer": "No   Explanation  The statement corneal deposits were less commonly identified amongst the patients in the secondary trial is not entailed by the evidence provided The evidence only states that corneal deposits were not identified in any of the patients in the secondary trial The absence of an adverse event does not necessarily mean that it is less common than another adverse event",
        "label": "Contradiction"
    },
    "f9dfbdb7-3248-450e-a7d4-782f2e68e057": {
        "text_answer": "No  Explanation The statement intravascular ultrasound and transverse radial incisions form the backbone of the surgical procedures in the primary clinical trial is not entailed by the evidence The evidence only mentions the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points during the surgical procedures but it does not mention intravascular ultras",
        "label": "Contradiction"
    },
    "1c7d5749-bf28-4ae8-8408-ccda3f13a18a": {
        "text_answer": "Yes  Explanation  Both the primary and secondary clinical trials mentioned in the evidence provide information on the determination of the Maximum Tolerated Dose MTD of interventions specifically ruxolitinib in combination with paclitaxel in the primary trial and MM111 in the secondary trial Therefore the statement that the primary and secondary clinical trials provide information on the MTD of various interventions is entailed by the",
        "label": "Entailment"
    },
    "586b08dc-8323-46ff-873f-5d262f7eae35": {
        "text_answer": "No  Explanation  The statement 90 of the adverse events in the secondary trial affected more than 95 of patients is not entailed by the evidence The evidence only provides the number and percentage of adverse events in the secondary trial but it does not indicate that more than 95 of patients experienced any specific adverse event",
        "label": "Contradiction"
    },
    "74452fe6-e38e-4f1d-a666-765c464ca765": {
        "text_answer": "Yes The statement is entailed by the evidence as the dosage of eribulin in Intervention 1 is higher 14mgm2 compared to the dosage of docetaxel in Intervention 2 75 mgm2",
        "label": "Entailment"
    },
    "c81fad5d-aa52-4147-a724-984e7d9c4cc3": {
        "text_answer": "No  Explanation  The statement adverse events that are a result of the secondary clinical trial do not occur in patients from the primary clinical trial is not entailed by the evidence The evidence only reports the occurrence of adverse events in each clinical trial but it does not provide information about whether the same types of adverse events occurred in both trials or not The statement makes a stronger claim than what is supported by the evidence",
        "label": "Contradiction"
    },
    "b3909182-2942-44c1-96e8-5650e48401df": {
        "text_answer": "No  Explanation  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is not directly entailed by the evidence provided The evidence only shows the frequency of specific adverse events in each trial but it does not provide enough information to make a definitive statement about the majority of adverse events in each trial being blood and bone marrow related or not",
        "label": "Contradiction"
    },
    "2d61f68b-3907-4337-bc4c-20f219a1c678": {
        "text_answer": "133 based on the given data the statement does not directly entail that all patients remained metastasisfree but rather that 133 of the patients did not develop imagable HER2 metastases during the 3year followup",
        "label": "Entailment"
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "text_answer": "Yes The evidence does not include any conditions related to life expectancy pregnancy or age as exclusion criteria",
        "label": "Entailment"
    },
    "2a9b88b7-4d4f-47d5-808b-df5a328935ae": {
        "text_answer": "Yes  Explanation  The statement the secondary clinical trial reported significantly less total adverse incidents in its patient cohorts than the primary clinical trial is entailed by the evidence since the evidence shows that the number of adverse events in the secondary trial was 015 000 which is less than the total number of adverse events in the primary trial which was 00 undefined percentage",
        "label": "Entailment"
    },
    "20a73393-6e4f-4096-8025-45d8fbe228b7": {
        "text_answer": "No  Explanation The evidence provided in the form of the primary clinical trial interventions does not entail that some patients receive no MCS110 at all and over 130 mg of PDR001 every other week The statement goes beyond the information given in the evidence The evidence only states the dosages of MCS110 and PDR001 for each intervention in the clinical trial It does not provide information about which",
        "label": "Contradiction"
    },
    "1a9f1afc-af2c-4dca-b701-2a04033f47b4": {
        "text_answer": "No  Explanation  The statement a prerequisite for both the primary and the secondary clinical trials is the attainment of a baseline performance level the primary clinical trial necessitates a karnofsky score of over 70 whereas the secondary clinical trial requires a score exceeding 55 is not directly entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each clinical trial but it does not",
        "label": "Contradiction"
    },
    "b4db304d-9445-44e0-9f0a-a4df38c1301b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not mention any information about Treatment Emergent Adverse Events or Serious Treatment Emergent Adverse Events for the paced respiration or fast shallow breathing groups The statement about covid19associated acute hemorrhagic necrotizing encephalitis is also unrelated to the trial results",
        "label": "Contradiction"
    },
    "197c5300-0475-46e0-aa97-cfb145da896d": {
        "text_answer": "No  Explanation  The statement every participant in group 1 of the primary trial were found to have lesions is not entailed by the evidence In the primary trial there were no participants with lesions in group 1 Healthy Volunteers The evidence only states that no lesions were detected in the 10 healthy volunteers scanned in the first year and 30 healthy volunteers scanned in the second year  Add",
        "label": "Contradiction"
    },
    "a3f8233e-3af4-41f5-a4f4-7676251de646": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial involves multiple types of treatments including chemotherapy targeted therapy and hormonal therapy as well as surgical treatment The secondary trial also involves multiple types of treatments specifically two targeted therapies everolimus and exemestane Therefore the statement is not accurate as it only mentions one type of treatment in the primary trial and surgery in the secondary trial while",
        "label": "Contradiction"
    },
    "a3e78ee7-57e9-47e4-a85f-e61451207043": {
        "text_answer": "Yes The statement does not explicitly mention the doses of ALT801 in the cohorts but the evidence states that cohort 1 receives less than half the dose of cohort 2 Therefore the statement about the different doses implies that there are two groups in the trial and one group cohort 1 is receiving a lower dose than the other cohort 2 The statement also mentions a cytogen",
        "label": "Entailment"
    },
    "87840288-7db7-4532-b5a9-ce95221cf918": {
        "text_answer": "Yes  Neither trial includes women with severe claustrophobia IBS Irritable Bowel Syndrome is not mentioned in the exclusion criteria for either trial",
        "label": "Entailment"
    },
    "c9077c20-07f8-4137-b88a-9ef599052884": {
        "text_answer": "No  Explanation The statement provided is not entailed by the evidence as the evidence reports a percentage change in Ki67 expression not an increase in Ki67 expression in terms of absolute value The evidence shows that the percentage change in Ki67 expression is approximately 40 63 to 29 indicating a decrease rather than an increase",
        "label": "Contradiction"
    },
    "290508ed-616c-4d7e-b83b-49a2fa895a44": {
        "text_answer": "Yes  Explanation The statement blood and bone marrow related issues predominantly accounted for reported adverse events in the primary clinical trial as opposed to the secondary clinical trial is entailed by the evidence as the primary clinical trial had a higher percentage of adverse events related to blood and bone marrow compared to the secondary clinical trial",
        "label": "Entailment"
    },
    "171ca8d1-c986-4446-8ee3-8b8635f4d234": {
        "text_answer": "Yes The statement that patients with CCND1 amplification CDK46 mutation or CCND2 amplification are excluded from the primary trial is explicitly stated in the inclusion criteria of the evidence",
        "label": "Entailment"
    },
    "7cd38d1e-009b-40f6-a8f8-1352ae821aa4": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial is assessing the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial is evaluating the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment The two trials are addressing different outcome",
        "label": "Contradiction"
    },
    "42c07819-8022-4275-8484-6ed9db10115c": {
        "text_answer": "Yes  Explanation The primary clinical trial is comparing the use of two different gels Hydrophor and MediHoney between two study groups Group A and Group B The secondary clinical trial on the other hand is investigating the effects of two different doses 90 mg and 110 mg of the same treatment PF05212384 on a single study group Therefore the",
        "label": "Entailment"
    },
    "d735322f-f5fc-489d-bb28-e40451860571": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial involves intravenous IV administration of zoledronic acid not oral pills The secondary trial involves intravenous IV and oral administration of granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone There is no mention of inhalation in the evidence",
        "label": "Contradiction"
    },
    "063a0207-f4fc-43c1-849e-6d3fc64b009b": {
        "text_answer": "Yes  The evidence does not report any observed thromboembolic events in either trial",
        "label": "Entailment"
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "text_answer": "Yes  Explanation  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed by the evidence provided The evidence shows that the incidence of ascites was higher in the primary trial 2223 or 090 compared to the secondary trial 090 or 1",
        "label": "Entailment"
    },
    "a63d1b8c-8ac5-4b17-a8c8-690dae246d1f": {
        "text_answer": "No   Explanation The statement is not related to the evidence provided as it discusses porcelain veneers which are a dental restoration while the evidence pertains to different drugbased interventions for cancer treatment",
        "label": "Contradiction"
    },
    "698866bd-4a77-4b0a-9e79-6fb9984692b7": {
        "text_answer": "No  Explanation  The statement arm 1s operative time was less than that of arm 2 in the primary clinical trial indicating the superior performance of standard mammography over intraoperative mammography is not entailed by the evidence The evidence only shows that the median operative time was shorter for the intraoperative mammography group compared to the standard mammography group in the primary trial It does not directly indicate the",
        "label": "Contradiction"
    },
    "144b54f3-eb81-4c83-a94c-2c01847b9299": {
        "text_answer": "Yes  Explanation  The statement the weekly intake of mm121 and paclitaxel is higher for the primary trial participants than for the cohort 1 in the secondary trial is entailed by the evidence In the primary trial patients undergo mastectomy surgery and are not specified to receive any particular drug regimen However in the secondary trial the HR subgroup in Intervention 1 receives a",
        "label": "Entailment"
    },
    "b00e3d3a-3046-4996-a028-35e45ce682be": {
        "text_answer": "Yes The statement is entailed by the evidence as diffuse parenchymal lung disease is a type of interstitial lung disease which is an exclusion criterion in the evidence",
        "label": "Entailment"
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "text_answer": "  No   Explanation   The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for the primary trial is not exactly entailed by the evidence The evidence only specifies ER positive and HER2 negative for Group 1 and triplenegative for Group 2 Progesterone receptor status is not mentioned in the inclusion criteria Therefore the statement",
        "label": "Contradiction"
    },
    "bce464d0-a0f9-4d17-9caa-6bd247cfdce3": {
        "text_answer": "No  Explanation  The statement device migration problem identified is a device that has moved from its original location due to external forces eg stent or lead movement is not directly related to the adverse events data provided in the evidence The evidence only reports the number of adverse events in each trial without specifying the cause or nature of those events Therefore it is not possible to determine if the statement is entailed by the evidence based on",
        "label": "Contradiction"
    },
    "bd828bb3-e2b2-46e0-a1fb-635d6aade839": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "71e83f04-ecd5-4d79-8062-42bcb68d6f29": {
        "text_answer": "No  Explanation The statement nearly all patients in both the primary and secondary clinical trials specifically over 97 did not report any negative outcomes is not entailed by the evidence The evidence only reports the number and percentage of patients who experienced specific adverse events in each trial but it does not provide information on the total number of patients or the percentage of patients who did not experience any adverse events The statement makes a generalization about all patients",
        "label": "Contradiction"
    },
    "6943a60c-a7c2-46c5-9238-c88db6a2b725": {
        "text_answer": "  No  Explanation  The statement cancer patients diagnosed with either fibromyalgia thalasemic syndromes or anemia are allowed to participate in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary trial excludes participants with a diagnosis of fibromyalgia and the secondary trial excludes participants with a diagnosis of thalasemic syndromes or",
        "label": "Contradiction"
    },
    "3fbecafb-c5f7-4a19-b265-1840a379f81f": {
        "text_answer": "Yes The primary trial measures pCR and the secondary trial measures pCR after preoperative therapy The statement acknowledges this difference and notes that the results for the two trials are distinct with a significant difference between the cohorts in the primary trial but similar performances in the secondary trial",
        "label": "Entailment"
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "text_answer": "Yes The statement is entailed by the evidence as both groups undergo the same imaging procedures with a slight difference in the dose of 18FFPPRGD2 for cohort 1",
        "label": "Entailment"
    },
    "bdc8ed3c-63bd-4f71-bcbd-83d11575603d": {
        "text_answer": "Yes Both trials require a certain performance status for participation",
        "label": "Entailment"
    },
    "574ab11b-3216-4b4b-a4aa-cf035483fe05": {
        "text_answer": "No  Explanation The evidence provided in the primary trial indicates that the median overall survival for patients undergoing midluteal surgery was 214 years 153 to 267 and for those undergoing midfollicular surgery was 200 years 161 to 231 Neither median survival is less than 1 year The statement that on average patients from the",
        "label": "Contradiction"
    },
    "90eff3be-13fe-4f5d-82f1-534ae1fe4a81": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided The evidence describes interventions in two clinical trials but it does not mention the tuberculum sellae or its relationship to the sella turcica or chiasmatic sulcus",
        "label": "Contradiction"
    },
    "617d4baf-29bc-4a82-a0b0-c8d2c0590599": {
        "text_answer": "Yes The statement candidates Capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial is not explicitly stated in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have a limited level of selfcare and are not completely confined to bed or chair but their performance status is still good enough to",
        "label": "Entailment"
    },
    "7ddde4b4-4070-4aff-b971-53bbd0ec9437": {
        "text_answer": "No   Explanation  The statement prefer to hear as many details as possible is not directly related to the evidence provided The evidence only describes the interventions and dosages used in two trials it does not provide any information about a persons preference for hearing details",
        "label": "Contradiction"
    },
    "1bc50379-9721-419f-959a-560b3747b8ec": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial have 00 recorded adverse events is entailed by the evidence since the evidence reports that there were no adverse events in both trials",
        "label": "Entailment"
    },
    "603ee9e3-5213-4121-97d8-4369641e9b00": {
        "text_answer": "No  Explanation The evidence provided in the primary trial relates to the percentage change in serum betaCTX levels for the AZD0530 175 mg and Zoledronic Acid 4 mg groups It does not provide information about the primary tumour diameter or the reduction in tumour diameter for each group Therefore the statement about a greater reduction in primary tumour diameter for the AZD0530 1",
        "label": "Contradiction"
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the secondary trial intervention section does describe an intervention it just does not mention the specific drugs being used The primary trial intervention section is not directly related to the secondary trial so it does not provide any information about the drugs being used in the secondary trial",
        "label": "Contradiction"
    },
    "0fd90f9b-bf76-4c3c-9964-dc635138217c": {
        "text_answer": "No  Explanation  The statement General symptoms are the most common AE recorded in the primary trial is not directly entailed by the evidence provided The evidence lists the number of occurrences for each type of adverse event but it does not indicate which type is the most common overall The statement makes a generalization about all adverse events in the trial while the evidence only provides specific information about the number of occurrences for each type",
        "label": "Contradiction"
    },
    "632b415b-ebc1-4898-8676-1ef38eecb128": {
        "text_answer": "No   Explanation The statement is not directly related to the evidence provided in the trial interventions The evidence only mentions the administration routes of the interventions IV for bisphosphonate and subcutaneous injection for denosumab while the statement is about a piga gene mutation which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "914bc3a7-1468-46df-8d13-f271220b5c84": {
        "text_answer": "Yes Both trials include candidates with an ECOG score of 1",
        "label": "Entailment"
    },
    "c6f2c906-4b0a-4b93-99ee-2152df2af3e4": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence pertains to breast cancer and hormonal therapy while the statement is about colorectal cancer and immunotherapy",
        "label": "Contradiction"
    },
    "f6a1bd73-7581-4284-b039-705aeb0236bf": {
        "text_answer": "Yes  Explanation  The statement a comparison between adverse events in the primary clinical trial and the secondary clinical trial is challenging given the apparent absence of such events from the records of the primary clinical trial is entailed by the evidence because the evidence shows that there were no reported adverse events in the primary clinical trial while there were several adverse events reported in the secondary clinical trial This makes it challenging to compare the adverse events between the two trials",
        "label": "Entailment"
    },
    "fcedf2b8-b97d-4a57-8ccc-e77c53900b3c": {
        "text_answer": "Yes  Explanation  The statement the incidence of recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were lesser in the adverse events profile of the secondary clinical trial than in the primary clinical trial is entailed by the evidence as the incidence of these adverse events is lower in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "text_answer": "Yes  Explanation The statement The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group is entailed by the evidence as the geometric mean percentage change in betaCTX for the AZD0530 175 mg group 711 759 to",
        "label": "Entailment"
    },
    "6fd90164-4ae9-4296-88d8-e6eab3811c8a": {
        "text_answer": "No  Explanation  The statement intermediate lipomatous neoplasm is a lipomatous neoplasm characterized by a high risk of local recurrence and no risk of metastasis is not mentioned in the evidence provided The evidence only mentions that the primary trial includes patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Contradiction"
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "text_answer": "Yes   Explanation The primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using the Response Evaluation Criteria In Solid Tumors RECIST criteria These are two distinct outcome measures",
        "label": "Entailment"
    },
    "cbd414d3-c3c6-4d3a-8a7a-67832757ae03": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence because in the primary trial armodafinil is given daily to one cohort Intervention 2 while in the secondary trial MCS110 dosages vary Intervention 1 and Intervention 2 but PDR001 is given at the same dosage to each patient",
        "label": "Entailment"
    },
    "78dd81db-dbc1-427a-9a3d-09f3e339ac99": {
        "text_answer": "No  Explanation  The statement concern about finances is a question about whether an individual has or had concerns about finances is not directly related to the provided evidence The evidence only reports the occurrence of adverse events in two clinical trials and there is no mention of any concerns about finances",
        "label": "Contradiction"
    },
    "8cd9c9e7-ff02-4e49-893d-a4e2837bf18f": {
        "text_answer": "No  The statement does not mention the primary trial or the intervention being given in that trial The statement only mentions alisertib which is not a part of the interventions in the primary trial",
        "label": "Contradiction"
    },
    "9b9256a3-3f1b-4f43-90da-f8ae79096bd5": {
        "text_answer": "No  The primary trial and secondary trial have different inclusion and exclusion criteria  Some patients may meet the criteria for the secondary trial but not the primary trial and vice versa",
        "label": "Contradiction"
    },
    "26731a57-6d43-4738-817a-74da5c372da2": {
        "text_answer": "yes for breast adenocarcinoma in the primary trial and for breast carcinoma in the secondary trial  Explanation The statement patients with Histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial is entailed by the evidence since breast adenocarcinoma is listed as an eligible cancer type for",
        "label": "Entailment"
    },
    "2fde518b-d7c2-4e66-bab7-0cdff22d5ffe": {
        "text_answer": "No  Explanation The evidence provided in the clinical trial description does not entail the statement that the trial welcomes Alzheimers patients for inclusion The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment is allowed However Alzheimers disease is a progressive neurodegenerative disorder characterized by a decline in cognitive function and memory imp",
        "label": "Contradiction"
    },
    "d19b920a-add8-4be3-8e09-96889800fe00": {
        "text_answer": "Yes  Explanation  The primary clinical trial and the secondary clinical trial share the requirement for the ability to give written informed consent as an eligibility criterion Therefore the statement the ability to give written informed consent is the sole common eligibility criterium between the primary clinical trial and the secondary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "37aab021-5b76-4b95-88b6-1050e9252803": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions involve preoperative intravenous administration of dexamethasone to different cohorts with the first cohort receiving it before surgery and the second cohort receiving it two hours postsurgery",
        "label": "Entailment"
    },
    "2c0f27c0-642c-4669-8f38-3304bd2fdaf3": {
        "text_answer": "Yes  Explanation The statement hepatotoxicity cases were triple the combined count of hypertension and pancreatectomy incidents is entailed by the evidence since the number of hepatotoxicity cases 3 is indeed three times the combined number of hypertension and pancreatectomy cases 1 for each",
        "label": "Entailment"
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "text_answer": "No  Explanation The primary trial includes a minimum tumour size of 2 cm while the secondary trial does not mention a minimum tumour size Therefore a patient with a primary tumour of 3 mm would not meet the inclusion criteria for the primary trial Additionally the statement does not address the other inclusion and exclusion criteria for both trials which are essential for determining eligibility",
        "label": "Contradiction"
    },
    "2f606d1d-7dd5-4d18-8ae6-7899efe85487": {
        "text_answer": " No   Explanation  The statement the secondary clinical trial accepts females who are living with IBS and claustrophobia is not entailed by the evidence provided The secondary trials exclusion criteria include severe claustrophobia but it does not mention IBS as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "51811b25-079e-44e0-a38a-b9e0735ded90": {
        "text_answer": "Yes  Explanation The statement repetitive adverse events were reported among different patients particularly in the primary clinical trial is entailed by the evidence as the adverse events were reported for multiple patients and occurred repeatedly",
        "label": "Entailment"
    },
    "f2640a7c-0890-40e2-a2dc-1dcdeefcd3bf": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes oral medication administration not injectable",
        "label": "Contradiction"
    },
    "4a9efa5a-6bb1-4b34-a2a7-dfa40fdd29b4": {
        "text_answer": "Yes  Explanation The evidence states that 1 out of 4 participants in the second cohort experienced an increased pleural effusion The statement 25 of the second cohort have experienced a rise in pleural effusion is a correct representation of this data",
        "label": "Entailment"
    },
    "207602e0-9ba8-437e-a8c2-deb34b3eaef9": {
        "text_answer": "yes The primary trial involves multiple interventions including drugs given via different routes and surgery while the secondary trial involves the use of only two specific drugs",
        "label": "Entailment"
    },
    "e7451698-de0f-49c5-b287-a419652d62e0": {
        "text_answer": "Yes  Explanation The evidence states that 13 of participants with HER2primary breast cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab developed imagable HER2 metastases The statement is consistent with this finding as it also refers to participants with HER2primary breast cancer who developed HER2 metastases after undergoing HER2",
        "label": "Entailment"
    },
    "ca09a15d-86a6-4a7e-9dfb-ff195702e0d4": {
        "text_answer": "25 the number of participants analyzed in the trial is not the same as 35 the number of patients in the statement Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "68461786-a85c-4370-8935-cb6680a3c5cb": {
        "text_answer": "No  Explanation The statement individuals with uncontrolled cardiovascular conditions can join the secondary clinical trial is not entailed by the evidence provided in the secondary trials inclusion and exclusion criteria The secondary trial explicitly excludes individuals with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months",
        "label": "Contradiction"
    },
    "e945ad07-11b2-48f7-8022-40f0af7883af": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8f74daa8-19d7-4b51-9296-9b61e885690c": {
        "text_answer": "Yes The primary trial excludes patients with alcohol abuse or dependence within the past 2 years while the secondary trial allows patients with fewer than 5 alcoholic drinks per day within the past year",
        "label": "Entailment"
    },
    "9a6bed06-19da-4284-b5fd-e68ddad563c3": {
        "text_answer": "Yes   Explanation  The evidence describes two interventions each with a specific method of administration IV bisphosphonate Q4W and subcutaneous denosumab Q12W The statement that the primary clinical trial does not provide interventions through various methods implies that there is only one method of administration used in the trial Given that the evidence only describes two interventions with distinct methods of administration the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "39ac8702-7670-4a8e-851a-49e41a77c836": {
        "text_answer": "No  Explanation  The statement diarrhea was uncommon among the primary trial participants compared to the secondary trial participants is not entailed by the evidence The evidence shows that the frequency of diarrhea was higher in the primary trial 2333 compared to the secondary trial 000 Therefore the statement is not supported by the evidence",
        "label": "Contradiction"
    },
    "e5b93c15-0c68-4b2f-bceb-a905f7116ef3": {
        "text_answer": "No  The statement is not entailed by the evidence as mirtazapine is not mentioned in the inclusion or exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "25602467-131a-44d1-a3d9-5a4a61a0ea0a": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria listed in the evidence Patients with a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks or intrabdominal abscess within the last six months are excluded from the trial",
        "label": "Entailment"
    },
    "c634ebf6-2577-4cc6-9e2d-e14da660629d": {
        "text_answer": "No  Explanation The statement is not directly related to the information provided in the evidence The evidence only mentions the doses of Eribulin Cyclophosphamide Docetaxel for each intervention group but it does not mention anything about the lesser trochanter or the attachment of the iliopsoas muscle",
        "label": "Contradiction"
    },
    "a714b4d6-d9d7-4dc7-8efe-50c92616d027": {
        "text_answer": "Yes  Explanation The evidence states that out of 25 participants treated with Sunitinib  Docetaxel  Trastuzumab 24 experienced treatmentemergent adverse events and 11 of these were serious Therefore the statement that all but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent ad",
        "label": "Entailment"
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "text_answer": "423 The statement is not exactly entailed by the evidence but it is related to the baseline data for cervical cancer screenings in cohort 1 which is 423",
        "label": "Entailment"
    },
    "0f3d96aa-a8ea-430a-ab6a-fe5e41f8b9fb": {
        "text_answer": "Yes  The statement is entailed by the evidence as both intervention groups received Dexamethasone which is a type of corticosteroid similar to Prednisone preoperatively",
        "label": "Entailment"
    },
    "606dc2e9-a1a7-400a-8971-bfb2d3a3f3ab": {
        "text_answer": "No  Explanation  The statement the primary clinical trial has a higher incidence of bronchopneumonia and physical health decline compared to the secondary clinical trial is not entailed by the evidence The evidence only provides the incidence of adverse events for each trial but it does not directly compare the incidence of bronchopneumonia and physical health decline between the two trials The statement makes a comparison that is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is not directly entailed by the evidence provided While it is true that anemia was the most common adverse event in the secondary trial the statement also asserts that there were no recorded adverse events in the primary trial which is not supported",
        "label": "Contradiction"
    },
    "32e81a4f-0434-46d3-8da4-04037c77a56b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as it contains incorrect information The statement mentions helcococcus which is not mentioned in the evidence at all Additionally the statement incorrectly states that cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide but the evidence states that it is an intravenous injection The secondary trial also does not involve intr",
        "label": "Contradiction"
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "text_answer": "No  Explanation  The statement Cohort 1 of the primary trial did not report any AEs however almost all of cohort 2 candidates suffered at least one ae is not directly entailed by the evidence provided The evidence only states that there were no AEs reported in Cohort 1 and the total number of AEs in Cohort 2 It does not provide information about the percentage of candidates in Coh",
        "label": "Contradiction"
    },
    "796ae946-899b-475c-ab4c-88ba6af1e881": {
        "text_answer": "Yes  Explanation  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is entailed by the evidence as both cohorts Adverse Events 1 and Adverse Events 2 had a total of 0 cases for each of these conditions",
        "label": "Entailment"
    },
    "eb9c708d-26e5-40a1-a0d3-6b80f689f540": {
        "text_answer": "No  Explanation  The statement hop62 is an adenocarcinoma cell line established from lung carcinoma tissue removed from a 60 year old female The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain no aes were recorded in the primary trial is not directly entailed by the evidence provided  The evidence only reports the occurrence of",
        "label": "Contradiction"
    },
    "ac12ebab-2165-42ac-bd15-a155dd895e00": {
        "text_answer": "No  Explanation  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE bothered by genital itching andor irritation is not directly related to the adverse events listed in the evidence The evidence only reports the occurrence or nonoccurrence of specific adverse events such as anemia febrile neutropenia leukoc",
        "label": "Contradiction"
    },
    "c6b00d4d-2940-484b-b305-baaf3c5ccff4": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial is not concerned with hours of sleep but rather the number of participants with treatmentemergent adverse events at the end of Cycle 1 The secondary trial on the other hand is evaluating the change in total sleep time measured in minutes using polysomnography",
        "label": "Contradiction"
    },
    "cc97aa0a-365f-459a-a65a-557dd1d930cf": {
        "text_answer": "No  Explanation  The statement unknown use of menopausal hormone therapy is a response indicating unknown use of menopausal hormonal therapy is not directly related to the exclusion criteria provided in the evidence The evidence does not mention anything about menopausal hormone therapy being a reason for exclusion  However the statement History of interstitial lung disease or pneumonitis is a reason for exclusion",
        "label": "Contradiction"
    },
    "e028bf17-f183-4afa-b470-f7741f04e41b": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases Therefore it is entailed that some participants with HER2 primary breast cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab developed HER2 metastases The statement specifies that this occurred in 61 of participants which",
        "label": "Entailment"
    },
    "604c0ae1-7d51-4238-adb7-1a0b1da1b466": {
        "text_answer": "Yes  Explanation The statement a number of cardiacaffiliated adverse instances were logged for the first cohort of the primary clinical trial is entailed by the evidence as there are instances of adverse events related to cardiac conditions ACUTE CORONARY SYNDROME ANGINA PECTORIS CARDIAC ARREST CARDIAC FAILURE and CARDIAC TAMPON",
        "label": "Entailment"
    },
    "3ae463ca-9747-4796-805c-b4b56c0be8e9": {
        "text_answer": "No  The statement have trouble communicating thoughts is not related to the evidence provided The evidence only discusses interventions for breast cancer treatment",
        "label": "Contradiction"
    },
    "3d85fd79-27cc-4e06-b4e0-88348ab9ac0a": {
        "text_answer": "Yes  Explanation  The statement there is no overlap in the inclusion and exclusion criteria for the primary and secondary clinical trials is entailed by the evidence because there are no common inclusion criteria and no common exclusion criteria between the two trials The primary trial has specific inclusion and exclusion criteria related to cancer patients while the secondary trial has inclusion criteria related to patients undergoing large core breast biopsy and no explicit exclusion criteria mentioned in the provided evidence",
        "label": "Entailment"
    },
    "9aed7121-8548-40e9-a960-618bf0173df8": {
        "text_answer": "Yes  Explanation The statement the primary clinical trials intervention section includes comprehensive descriptions regarding method of administration dose and scheduling is entailed by the evidence INTERVENTION 1 MM111 All participants because the intervention section of a clinical trial is where such information is typically provided The evidence itself does not explicitly state that the section includes comprehensive descriptions but it is a reasonable assumption based on standard clinical trial reporting practices",
        "label": "Entailment"
    },
    "8ecb562c-3169-4c07-bb44-d6e716873c08": {
        "text_answer": "  Yes the statement is entailed by the evidence as benign renal pelvis neoplasms including urothelial papillomas are not considered advanced or metastatic solid tumors and do not meet the inclusion criteria for the primary trial",
        "label": "Entailment"
    },
    "454e1858-76b2-4952-9ac0-820d81dbf966": {
        "text_answer": "No  Explanation  The statement the primary clinical trial demands that patients take a biweekly dose of decitabine whilst the secondary clinical trial requires no medication is not entailed by the evidence The primary clinical trial involves the use of Abl Cells IV and Cyclophosphamide while the secondary clinical trial involves the use of DMCHOCPEN Decitabine is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "58161b30-e890-45e5-822d-3172f884ed40": {
        "text_answer": "Yes  Explanation The evidence mentions the use of CT scans and MRIs in the primary trial for assessing the breast reconstruction process using the Contour Profile Tissue Expander In the secondary trial there is no explicit mention of CT scans or MRIs in the given interventions However imaging studies such as CT scans or MRIs are commonly used in clinical trials for monitoring the progression of the disease or the therapeutic response",
        "label": "Entailment"
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "text_answer": "Yes The evidence states that smokers are excluded from the secondary trial It does not explicitly state it for the primary trial but the primary trial also excludes smokers as per the given criteria",
        "label": "Entailment"
    },
    "630dd8d6-eff4-48f9-ac35-c1731b6c4a79": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions a meditation intervention which is not present in the evidence The primary clinical trial examines Estring and Testosterone Cream interventions and the secondary clinical trial assesses Acupuncture and a waitlist control group",
        "label": "Contradiction"
    },
    "fc38a4bc-7c69-4ae2-9dad-f089f15e4d5e": {
        "text_answer": "Yes  Explanation The statement in the context of the primary clinical trial 0035 mg less of the drug alt801 is administered to the first cohort compared to the second cohort is entailed by the evidence because the first cohort received a dose of 0015 mgkgdose and the second cohort received a dose of 0040 mgkg",
        "label": "Entailment"
    },
    "804580d2-f170-45ed-bf39-28dc33921b6d": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the statement reports a reduction in tumor sizes while the evidence reports a change in Ki67 expression which is a biomarker for cell proliferation The two are related but not the same thing Additionally the statement reports a different dosage of tamoxifen 32 mg and time frame not specified than what was used in the clinical trial",
        "label": "Contradiction"
    },
    "014e2dc7-251b-4615-a8fc-38aed023b053": {
        "text_answer": "Yes The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed by the evidence as the evidence states that there were 0 deaths and 0 hospitalizations in cohort 2 The statement about Atrial fibrillation is not directly related to the statement being evaluated",
        "label": "Entailment"
    },
    "3d82f108-1f18-426e-a49f-f7fedcb82a7c": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it does not relate to the information provided in the primary trial regarding the dosage of talazoparib for breast cancer and ovarianperitoneal cancer patients The statement is about Nocardia a different genus of bacteria and does not mention talazoparib or the primary trial at all",
        "label": "Contradiction"
    },
    "7f90773c-288c-4b5d-bc82-81d7189e6c5d": {
        "text_answer": "No  The statement does not mention carboplatin specifically and the evidence does not provide information about the dosage of paraplatin which is not the same as carboplatin",
        "label": "Contradiction"
    },
    "1f3d7969-35e1-4880-8ae5-b97c53c1e536": {
        "text_answer": "Yes  Explanation  The statement several patients in the secondary trial experienced only one adverse event is entailed by the evidence because there are patients in the secondary trial who experienced only one adverse event eg Constipation Vomiting Dehydration Infection with grade 3 or 4 neutrophils",
        "label": "Entailment"
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0b958f19-d411-426c-8144-162c6c15d9d2": {
        "text_answer": "No  Explanation  The statement the number of patients undergoing adverse events was four more in the first cohort than in the second cohort of the primary clinical trial is not entailed by the evidence provided The evidence states that there were no adverse events in the first and second cohorts of the primary clinical trial with a total of 60 patients in each cohort Therefore the statement that there were four more",
        "label": "Contradiction"
    },
    "2493d396-14df-4cf7-b2b4-3e84d4363a0f": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement describes two different interventions while the evidence describes the interventions for two separate trials The primary trial intervention is radioembolization using Yttrium90 glass microspheres and TheraSphere while the secondary trial intervention is a combination of ibrutinib and MEDI4736 with specific dosages",
        "label": "Contradiction"
    },
    "ccce8199-a89f-40b4-9c27-755f2d99c98d": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial a single type of adverse event was noticed in more than one patient is entailed by the evidence since there are two patients who experienced Other disease progression and one patient each who experienced Ileus General disorders and administration site conditions  Other disease progression Infections and infestations  Other pneumonia and Acute kidney injury",
        "label": "Entailment"
    },
    "417ed12e-5ae1-4024-9d97-ef152b78f64c": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only reports the number of participants who had a reduction in circulating tumor cells CTCs one month after highdose chemotherapy with purged autologous stem cell products It does not mention the percentage of participants who had a reduction in CTCs or any information about columnar mucosa indicators",
        "label": "Contradiction"
    },
    "5647bdb4-a763-46c0-a7f4-3d69cbc7aa95": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the participants with breast cancer and ovarianperitoneal cancer received different doses of talazoparib in the primary clinical trial",
        "label": "Contradiction"
    },
    "0f5d87e7-c78c-4579-a111-3f61640c6206": {
        "text_answer": "No  Explanation  The statement syncope was the most prevalent adverse event in both the primary and secondary clinical trials patient cohorts is not entailed by the evidence The evidence only shows that syncope was the second most common adverse event in the primary trial with a frequency of 1667 In the secondary trial no information about the prevalence of syncope was provided Therefore it cannot be concluded that syn",
        "label": "Contradiction"
    },
    "dfd39b75-1119-400a-a9af-588d7e63b867": {
        "text_answer": "No   Explanation The evidence provided in the adverse events data for both trials does not indicate that there were 10 or more deaths recorded as adverse incidents in either trial The data shows that there was one death recorded in the primary trial and none in the secondary trial",
        "label": "Contradiction"
    },
    "2fc3e471-39c1-4f8a-804f-6b2ad5f711c9": {
        "text_answer": "No  Explanation The statement in the primary clinical trial GTx024 of 1mg dosage resulted in lean body mass gain in every patient over a span of 4 months is not entailed by the evidence The evidence only provides the median change in lean body mass for the group receiving the 1mg dosage which ranges from a loss of 206 kg to a gain of 1264",
        "label": "Contradiction"
    },
    "57dec3a3-0bce-48c3-972d-e08f32ea9b15": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial had several recorded deaths in the adverse events but the primary trial had no such incident is not entailed by the evidence provided The evidence only states the number of adverse events including deaths and pain for each trial It does not specify that there were several recorded deaths in the secondary trial",
        "label": "Contradiction"
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial intervention is given orally PO not topically The secondary trial interventions are given intravenously IV but the statement does not mention the secondary trial",
        "label": "Contradiction"
    },
    "926177b8-d70d-48d4-95c9-4d74de46d9d0": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary clinical trial results indicates that out of the total number of participants analyzed in each arm no participants achieved a pathologic complete response in the breast and axillary lymph nodes Therefore the statement no pathologic complete response in breast and axillary lymph nodes was reported in patients involved in the primary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "4d8b9c01-83b6-4590-9aaf-9389b998ebff": {
        "text_answer": "Yes  The statement is entailed by the evidence as both the placebo and trabectedin are administered intravenously over a 3hour infusion but on different days",
        "label": "Entailment"
    },
    "4bda5405-4218-460a-a8b4-c958dddedfa1": {
        "text_answer": "Yes  Explanation The statement every participant in the secondary clinical trial experienced at least one adverse event is entailed by the evidence as all participants in the secondary trial had at least one adverse event recorded for them The statement while there were no recorded adverse events among the patients in the primary clinical trial is also true according to the evidence as no adverse events were recorded in the primary trial However the statement itself is not explicitly mentioned",
        "label": "Entailment"
    },
    "5484288d-bc10-458f-a516-d0019792d765": {
        "text_answer": "No  Explanation The primary clinical trial includes candidates with a Karnofsky score of 70 or better while the secondary clinical trial includes candidates with a Karnofsky score of 2 or better Therefore the statement that candidates for the primary clinical trial are acceptable with any performance status which would include a Karnofsky score of 50 or better and those for the secondary clinical trial must have a Karnofsky score less than ",
        "label": "Contradiction"
    },
    "8aef748c-257f-4a74-a391-3cdbdc839c79": {
        "text_answer": "  No the statement is not directly entailed by the evidence as the evidence does not mention 11p12p112 specifically in relation to the trials inclusion or exclusion criteria However the statement is not contradictory to the evidence either",
        "label": "Contradiction"
    },
    "a1043895-ce9b-4370-94c8-6ce3078e3bbb": {
        "text_answer": "No  Explanation  The statement all negative occurrences experienced during the primary clinical trial concerned the musculoskeletal system a situation not seen in the secondary clinical trial is not entailed by the evidence provided The evidence only mentions the occurrence of adverse events related to the bloodbone marrow and lymphatics systems in both trials without specifying that these were the only negative occurrences or that there were",
        "label": "Contradiction"
    },
    "99b10330-04b5-4aa1-bc04-9378fa54c994": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as it introduces new requirements CT scan and blood tests that are not mentioned in the inclusion or exclusion criteria for either trial The evidence only specifies mammography as a requirement for the primary trial",
        "label": "Contradiction"
    },
    "be07b8e7-1858-4182-b37f-56681f56c273": {
        "text_answer": "Yes The evidence does not provide any information about Ki67 expression in the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "9b75f8dd-3667-47be-a7d3-2cca26ae5fbe": {
        "text_answer": "No   Explanation   The statement Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial is not directly entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial and there is no mention of IBS Irritable Bowel Syndrome or any connection between claustrophobia and elig",
        "label": "Contradiction"
    },
    "f086fa4c-a302-455d-82e7-faf8b78fc2f4": {
        "text_answer": "No  The statement is not entailed by the evidence as the placebo is administered as a 3hour infusion and trabectedin is administered as a 3hour infusion on different days There is no information provided about the frequency or duration of the infusions beyond the initial dosing",
        "label": "Contradiction"
    },
    "4805b27b-471f-4571-8de9-a7a77f1bd1a4": {
        "text_answer": "No  Explanation The statement not a single ae was reported for either cohort in the primary clinical trial is not entailed by the evidence While it is true that no febrile neutropenia anaemia vertigo nausea stomatitis upper gastrointestinal haemorrhage mucosal inflammation fatigue pyrexia or gastroenteritis",
        "label": "Contradiction"
    },
    "e7505665-3677-4d18-87ec-8483dc002bd1": {
        "text_answer": "No  Explanation The statement does not directly address the interventions being compared in the primary trial The statement mentions cohort 1 and 2 but does not specify which intervention belongs to which cohort in the given evidence Additionally the statement introduces malignant pylorus neoplasm which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "b21d4a81-e82a-4bd7-ac88-5fcc046aafdf": {
        "text_answer": "Yes  Explanation  The statement there were no reported infections in the primary clinical trial nor the secondary clinical trial is entailed by the evidence because there is no mention of any infection adverse events in either trial In the primary trial there were a total of 24 adverse events reported out of 32 participants but none of them were infections Similarly in the secondary trial there were a total of 6 adverse events",
        "label": "Entailment"
    },
    "8e881af0-4e26-43c9-93e8-5e3397f857e1": {
        "text_answer": "  Yes morbidly obese patients are eligible for the primary trial as per the inclusion criteria stated in the evidence However the statement gist grade cannot be assessed is not directly related to the eligibility criteria and is not addressed in the evidence",
        "label": "Entailment"
    },
    "ea1eb143-4c11-4e40-9511-46f4e17b9e1d": {
        "text_answer": "No  Explanation The statement regardless of having cancer or not all participants in the primary clinical trial are subjected to the same intervention is not entailed by the evidence The evidence only states that there are two interventions in the primary clinical trial one for adult cancer patients 65 years of age and older and another for healthy volunteers 65 years of age and older It does not state that both interventions are the same",
        "label": "Contradiction"
    },
    "7a699c4d-46d7-48a0-915d-43b8c3a1f1f5": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of specific types of adverse events between the two trials Therefore it is not possible to determine from the evidence alone whether there were 11 more cases of Intest",
        "label": "Contradiction"
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts use the same instructional CD for paced breathing However its important to note that cohort 2 practices paced breathing twice a day while also receiving weekly chemotherapy",
        "label": "Entailment"
    },
    "d48955a5-78eb-4a53-9495-1a363c7b8e05": {
        "text_answer": "No  Explanation The evidence provides the median PFS for each treatment group but it does not indicate that any individual patient in either group survived for 6 months without disease progression or death",
        "label": "Contradiction"
    },
    "3b25e9e8-6fe5-40a3-b302-7a32f651b464": {
        "text_answer": "Yes The evidence includes Karnofsky score as an inclusion criterion with a minimum score of 80",
        "label": "Entailment"
    },
    "ccd3d27f-e743-4adf-8135-3488117f1178": {
        "text_answer": "Yes  Explanation  The statement cyclophosphamide paclitaxel and pegfilgrastim are administered to the patients in both the primary and secondary clinical trials is entailed by the evidence because both trials include the use of cyclophosphamide and paclitaxel and the secondary trial specifically mentions the use of pegfilgrastim",
        "label": "Entailment"
    },
    "cbe2e1d0-bb9b-43a2-b965-732f43d9af05": {
        "text_answer": "Yes The statement is entailed by the evidence as some patients with an ECOG score of 1 are eligible for both trials However its important to note that the combination route of administration is not mentioned in the evidence",
        "label": "Entailment"
    },
    "626fbbe0-8d56-40bf-8809-0e5d1d587a4d": {
        "text_answer": "No  The statement is not entailed by the evidence as the secondary trial includes women as well as men",
        "label": "Contradiction"
    },
    "cf935264-ef24-4f3a-b60f-1c4cc9d36a54": {
        "text_answer": "No  Explanation The statement one specific adverse event type affected more than half of the patient cohort is not entailed by the evidence The evidence only reports that the total adverse events affected 5 out of 14 patients 3571 No single adverse event type affected more than half of the patient cohort",
        "label": "Contradiction"
    },
    "60a1579f-8115-4fec-bdba-fd3031f64e19": {
        "text_answer": "No  Explanation  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is not directly entailed by the evidence provided The evidence only states the number and types of adverse events in each trial but it does not compare the number of each specific adverse event between the two trials Therefore it is not possible to make a definitive statement about which",
        "label": "Contradiction"
    },
    "7f22f322-c4fb-4001-875b-fe5baefbdc64": {
        "text_answer": "No  Explanation  The statement There was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is not directly related to the statement about Veillonella being a genus of bacteria The evidence provided only mentions the number and types of adverse events observed in the trials but it does not mention anything about Veillonella or any other specific bacterium being present or causing shingles",
        "label": "Contradiction"
    },
    "d942324e-c945-4703-b88e-905c073cfcd5": {
        "text_answer": "Yes  Explanation  The statement there were zero cases of hypertension edema and dyspnea in either cohort of the primary trial is entailed by the evidence because both cohorts Adverse Events 1 and Adverse Events 2 had a total of zero cases for each of these adverse events",
        "label": "Entailment"
    },
    "0a56f64e-6747-4fc7-a05d-6024e7b52cf6": {
        "text_answer": "No   Explanation   The statement the primary trial and the secondary trial do not use the same drugs dosages or frequency of administration in their interventions is correct based on the provided evidence However the statement consumer safety officer is an official of the food and drug administration who coordinates the review process of sponsor applications is not related to the evidence and therefore cannot be answered with a simple yes or no",
        "label": "Contradiction"
    },
    "494a6e1b-2bac-4777-9a12-077106690f16": {
        "text_answer": "Yes  Explanation  The statement there are no records of swelling hypothermia or confusion in the aes of the primary clinical trial and the secondary clinical trial is entailed by the evidence because the evidence shows that there were no records of these adverse events in both trials",
        "label": "Entailment"
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "text_answer": "No  Explanation The statement does not specify which vaccine each cohort receives against Pneumococcus or Influenza The evidence only states that one cohort receives the Pneumococcus vaccine and the other receives the Influenza vaccine but it does not mention which vaccine each cohort specifically receives against Pneumococcus or Influenza Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "327cfcfa-5534-4b9c-ab06-57fe595cb887": {
        "text_answer": "Yes  Explanation The statement there were 11 more adverse events reported in the secondary clinical trial than in the primary clinical trial is entailed by the evidence as the evidence shows that there were 11 additional adverse events in the secondary trial compared to the primary trial 0 in the primary trial vs 11 in the secondary trial",
        "label": "Entailment"
    },
    "73ac48a2-08b0-4ee5-8651-f65c88c08101": {
        "text_answer": "Yes The primary trial requires participants to be unresponsive to AI therapy but there is no such requirement mentioned in the secondary trial",
        "label": "Entailment"
    },
    "d42f5cb0-e70b-4c8b-ae2e-297254b1d95a": {
        "text_answer": "Yes Both primary and secondary trials investigate the use of Eribulin Mesylate or Axitinib as a medicinal substance",
        "label": "Entailment"
    },
    "bae680f2-9b93-494d-b2e7-65a99400af85": {
        "text_answer": "No  The statement is not entailed by the evidence as the clinical trial only includes female participants with breast cancer",
        "label": "Contradiction"
    },
    "66fb10cd-ce81-4c54-aa97-b7167d3115d8": {
        "text_answer": "No  Explanation The statement the presence of 1 cerebral metastasis located within the frontal lobe does not hinder participation in the secondary clinical trial is not directly stated or entailed by the evidence provided The evidence only mentions that those with cerebral metastases are disqualified from the primary clinical trial but it does not specify which size location or number of metastases are not allowed The secondary clinical trial",
        "label": "Contradiction"
    },
    "5cf29cab-a9e9-4385-a342-1684d424ecd8": {
        "text_answer": "No  Explanation  The statement group 1 of the primary clinical trial did not have any participants with lesions however it was observed that above 95 of group 1 participants in the secondary clinical trial suffered from radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The primary clinical trial and the secondary clinical trial are two separate studies with different outcomes and different participant groups The primary clinical",
        "label": "Contradiction"
    },
    "eaa12be4-b2f0-493a-9ce4-c70f874db211": {
        "text_answer": "No  The statement is not entailed by the evidence as coronary artery stenosis is not listed as an adverse event in the evidence provided",
        "label": "Contradiction"
    },
    "d4fb8105-81af-42ca-a829-1b77694ce0f1": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the primary and secondary trials use different outcome measurements The primary trial measures the change in severity of vaginal symptoms using the Vaginal Symptom Measure VSM while the secondary trial measures the objective response rate of HER2negative metastatic breast cancer using RECIST v10 criteria and FISH testing There is no mention of Objective",
        "label": "Contradiction"
    },
    "1efbc2a0-c0fc-4849-96d7-689fcfb3c4d1": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the preoperative intravenous administration of Dexamethasone in both cohorts and it does not provide any information about the dosing unit being a caplet or the dosage being different for caplets",
        "label": "Contradiction"
    },
    "fca1de92-2c1b-4c41-b49f-e07553b6aa83": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial general symptoms are the most frequently noted adverse event is not entailed by the evidence The evidence states that the number of general symptoms reported is equal to the number of nausea vomiting and headache reported which is 2 each However the statement implies that general symptoms are more frequent than all other adverse events combined which is not the case based on the evidence",
        "label": "Contradiction"
    },
    "935d23d4-0d67-4d42-8546-db1bab3f4a3d": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the primary trial does not mention the use of semesters or cycles and the secondary trial uses time frames of 12 weeks for the primary outcome measurement and 18 months for the secondary outcome measurement but it does not mention semesters or use age as a unit of measure",
        "label": "Contradiction"
    },
    "81e4cf84-ba33-46ce-ba44-e7edae2a2788": {
        "text_answer": "No  Explanation  The statement all individuals in group 1 of the primary clinical trial showed signs of cutaneous lesions is not entailed by the evidence provided The evidence only states that there were no lesions detected in the healthy volunteers in the primary clinical trial  Furthermore the statement less than 10 of participants in the first group of the secondary clinical trial had radiation dermatitis or hyperpigment",
        "label": "Contradiction"
    },
    "9a78f293-8ab9-4b2d-9224-3f4ae8fc45d5": {
        "text_answer": "  No   Explanation   The evidence provided describes the inclusion and exclusion criteria for a clinical trial specifically for individuals with unilateral breast cancer and secondary upper extremity lymphedema The statement however refers to participants with quantifiable bilateral breast cancer which is not explicitly mentioned in the given criteria Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "19ae1506-7a41-406e-8f43-8c32df24392b": {
        "text_answer": "No  Explanation The evidence provided in the trial results only gives the median change in lean body mass for each group treated with GTx024 at 1 mg and 3 mg It does not specify that all patients in the 1 mg group gained lean body mass over the 17 week period The range of change in lean body mass for the 1 mg group includes a loss of lean body mass for some patients Therefore the statement is",
        "label": "Contradiction"
    },
    "9dc3d717-d3b6-4002-b7f7-26e17d2cabc2": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens therapy in the last 4 weeks  28 days before study entry The statement extends this exclusion period to 24 months",
        "label": "Entailment"
    },
    "87c5a93d-fcef-46ca-8267-3d928c13c6f7": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial reported no deaths or hospitalizations except for a solitary case of atrial fibrillation is not directly entailed by the evidence provided The evidence only states that there were no deaths or hospitalizations reported in cohort 2 of the secondary clinical trial but it does not mention atrial fibrillation Therefore the statement goes beyond the information given",
        "label": "Contradiction"
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the dosage of CUDC101 is the same in both cohorts but the frequency is different The statement incorrectly states that the frequency is also the same with the only difference being the addition of PD0332991 in cohort 1",
        "label": "Contradiction"
    },
    "58f223d4-6f38-4ea3-a6fc-5ed8599df2be": {
        "text_answer": "Yes The evidence shows a median reduction of Ki67 expression from 15 to 10 after 6 weeks of TAK228 and tamoxifen therapy",
        "label": "Entailment"
    },
    "f37f99e0-a9eb-450f-850e-7bd96547bab1": {
        "text_answer": "Yes The statement does not directly mention intellectual wellbeing in the evidence but it does not contradict the statement either The evidence only describes the differences in dosages of durvalumab between the two interventions Intellectual wellbeing is not mentioned in the evidence but it is not affected by the differences in dosages described in the evidence Therefore the statement is entailed by the evidence because the statement does not contradict the evidence and the evidence does not contrad",
        "label": "Entailment"
    },
    "aa3c3321-c4f3-43b4-9821-767903e333c6": {
        "text_answer": "Yes for the secondary trial  Explanation The secondary trial excludes patients who have received any experimental agents within 4 weeks prior to the study registration date but it does not specifically mention organ transplant as an exclusion criterion However it does mention a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders as an exclusion criterion and an organ transplant within the past 30 days could potentially increase the",
        "label": "Entailment"
    },
    "959883cf-50ff-42e8-8da9-9ad0be3e18b6": {
        "text_answer": "Yes The statement does not directly mention the adverse event but it is not in conflict with the evidence The evidence only provides information about the adverse events observed in the primary trial and the statement is about the type of breast carcinoma being studied",
        "label": "Entailment"
    },
    "0e4f4030-9d92-4885-905e-3599e26db71a": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence only mentions the use of a device and partial breast irradiation but it does not specify any chemotherapy regimens in the intervention section",
        "label": "Contradiction"
    },
    "0cece9f2-8d43-4d06-97bd-fb800bd3e71a": {
        "text_answer": "  No   The primary trial utilizes the visual analog scale VAS to assess pain intensity while the secondary trial measures bone mineral density using DEXA scan There is no mention of the Hamilton Depression Rating Scale HDRS or triglyceride levels in the provided evidence",
        "label": "Contradiction"
    },
    "91439ad2-cb81-49e5-a783-ebbc2e04d64a": {
        "text_answer": "No  Explanation  The statement anaemia was encountered as a frequent adverse incident in the secondary trial affecting more than 5 of patients however no such incidents have been identified in the primary trial is not entailed by the evidence The evidence states that anaemia occurred in 234 of patients in the secondary trial which is less than 5 Therefore the statement is not accurate based on the given evidence",
        "label": "Contradiction"
    },
    "bc864ba6-4d2b-431b-9b34-7b668eb5c468": {
        "text_answer": "Yes  Explanation  The evidence shows that the percentage of participants with invasive diseasefree survival events in the Neratinib group was 47 while in the Placebo group it was 75 A lower percentage of events indicates a higher rate of invasive diseasefree survival Therefore the statement the neratinib group of the primary clinical trial had a higher rate of idfs than the placebo group is entailed",
        "label": "Entailment"
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "text_answer": "Yes  Explanation The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is entailed by the evidence since the percentage of patients with adverse events in both cohorts is 5000 in the first cohort and 4000 in the second cohort which is not a statistically significant difference",
        "label": "Entailment"
    },
    "ff3d1bb2-393e-4798-a128-090e7308f5b1": {
        "text_answer": "Yes but with a caveat The statement ezh2 gene mutation negative is not explicitly mentioned in the inclusion criteria but the patients eligibility is not excluded based on ezh2 gene mutation status Therefore the statement is not directly entailed by the evidence but the absence of ezh2 gene mutation does not disqualify a patient from participating in the trial",
        "label": "Entailment"
    },
    "34250dad-ad53-42bb-a8d3-80866141d548": {
        "text_answer": "No  Explanation  The statement worse than expected is a subjective response indicating something was worse than expected is not directly related to the evidence provided The evidence describes two separate clinical trials with their respective interventions and groups The statement is a general definition of a subjective response but it does not specifically relate to the trials or their interventions",
        "label": "Contradiction"
    },
    "d98e6c4a-c899-405d-b26e-e3a2e0cb3494": {
        "text_answer": "  No  Explanation  The statement Sexually active men and women who are not willing or not able to commit to abstinence for the duration of the study are eligible for the primary clinical trial is not explicitly stated in the inclusion or exclusion criteria provided in the evidence However the evidence does state that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study",
        "label": "Contradiction"
    },
    "b44a3eb6-01b7-488d-b18a-b3077937cc97": {
        "text_answer": "Yes  Explanation  The statement the recorded adverse events in the primary trial allow for a comprehensive comparison with the secondary trials data is entailed by the evidence because the evidence provides the number of adverse events in both the primary and secondary trials allowing for a direct comparison between the two",
        "label": "Entailment"
    },
    "a1ae68b1-c14f-44b5-bc43-8966858fbf14": {
        "text_answer": "No   Explanation   The statement provided is not directly entailed by the evidence The evidence only mentions the dosing regimens for Alpha Lipoic Acid in the primary trial and Necitumumab in the secondary trial but it does not mention anything about the country of origin of these biologic entities",
        "label": "Contradiction"
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly combines information from the two trials without specifying which trial each intervention belongs to The first trial involves oral pregabalin while the second trial involves intrathecal Liposomal Cytarabine Depocyt and intravenous Highdose Methotrexate HDMTX The statement does not make this distinction",
        "label": "Contradiction"
    },
    "98e66236-2140-45a7-8bea-e2d17f373def": {
        "text_answer": "No   Explanation  The statement is not directly related to the adverse events listed in the evidence The statement is about a specific type of tumor while the evidence is about various adverse events experienced by patients in a trial",
        "label": "Contradiction"
    },
    "07e27cba-9e03-4644-a6f3-d05b61b5e4e2": {
        "text_answer": "No  Explanation The statement less than 10 patients in the primary trial suffered Aes mixer device is a mechanical or electronic device is not entailed by the evidence The evidence only provides information about the number and types of adverse events observed in the primary trial but it does not mention anything about a device called Aes mixer or the number of patients who experienced issues related to it Therefore it is impossible to determine",
        "label": "Contradiction"
    },
    "117067e9-9bde-4d49-a4d2-51e9ac9886f6": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the statement incorrectly combines information from the two trials The primary trial treats patients with oral pregabalin while the secondary trial treats patients with a combination of intravenous and intrathecal chemotherapy HDMTX and Depocyt The statement does not accurately reflect the interventions in each trial",
        "label": "Contradiction"
    },
    "8320c826-7a88-43e8-ae24-069d0f6ff886": {
        "text_answer": "Yes  Explanation The statement compared to the secondary clinical trial the primary clinical trial shows more instances of bronchopneumonia and general health decline is entailed by the evidence as the secondary trial has one instance of bronchopneumonia and general health decline each while the primary trial has no instances reported for these adverse events",
        "label": "Entailment"
    },
    "354bc4da-42d7-452f-82bb-43e270a24c2f": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about mental health adverse events in the clinical trial",
        "label": "Contradiction"
    },
    "c472d895-f7f4-474f-8664-b7af887b1339": {
        "text_answer": "Yes  Explanation  The statement cohort b reported significantly lower adverse events compared to cohort a in the primary clinical trial is entailed by the evidence since the adverse event rate in cohort b 4000 is lower than that in cohort a 5000",
        "label": "Entailment"
    },
    "a7960e8d-c8a2-4d32-93ff-bb5902051344": {
        "text_answer": "No  The statement about being stopped in a car for a few minutes in traffic is not related to the inclusion or exclusion criteria in the evidence",
        "label": "Contradiction"
    },
    "b67a2d20-b35d-45b7-a594-8946f1f160ab": {
        "text_answer": "Yes The evidence mentions radiotherapy as part of Intervention 1",
        "label": "Entailment"
    },
    "7f7c84c5-cc6b-4d4f-a47c-4d41454fd6d0": {
        "text_answer": "Yes  Explanation The primary clinical trial states that zoledronic acid is given intravenously in Arm I of the study The secondary clinical trial states that all intervention drugs granisetron hydrochloride prochlorperazine dexamethasone palonosetron hydrochloride can be given intravenously in Arms II and III of the study Therefore the statement that intravenous administration",
        "label": "Entailment"
    },
    "4e9a0d19-c8b1-4ea4-9c73-2cf93b46f6a4": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants with pathologic complete response in breast and axillary lymph nodes for each arm of the trial Arm 1 and Arm 2 The statement however makes a claim about the total number of patients in both cohorts experiencing pathologic complete response which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "44241e4d-31dc-487e-b42c-e8c47e3e82cf": {
        "text_answer": "No  Explanation The statement primary trial candidates receive weekly subcutaneous sc infusions whereas secondary trial participants are not given any injections is not entailed by the evidence The primary trial involves patients receiving vitamin D repletion but the evidence does not specify whether this is given as an injection or not Similarly the secondary trial involves the use of epoetin beta which is given as a subcutaneous injection but this",
        "label": "Contradiction"
    },
    "a7ff54ef-32cc-4cda-b4a2-39d5f6e1559c": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 The statement that patients in the primary trial noted a 10 decrease in the percentage of cells with ki67 expression after a month of undergoing TAK228 plus tamoxifen treatment can be derived",
        "label": "Entailment"
    },
    "73052d5e-1a3a-4479-9ada-e69963c84b77": {
        "text_answer": "Yes The evidence states that there were two participants in cohort 2 who experienced doselimiting toxicities",
        "label": "Entailment"
    },
    "f2796825-a4d9-4484-8958-851d99294e3c": {
        "text_answer": "No   Explanation The primary clinical trial uses units on a scale for hot flash activity and the secondary clinical trial uses proportion of responders for overall response rate Neither trial uses seconds or minutes as units of measure",
        "label": "Contradiction"
    },
    "a5c24bc4-6444-46bb-9da4-fca0d9d6f521": {
        "text_answer": "No  Explanation  The primary clinical trial reports the determination of the Ruxolitinib Maximum Tolerated Dose MTD in combination with paclitaxel but it does not directly report the MTD value itself Instead it describes the method used to identify the MTD based on the number of patients who experience doselimiting toxicity DLT in each cohort  Similarly the secondary clinical",
        "label": "Contradiction"
    },
    "aed670bb-54a4-4769-86de-65f566bafebe": {
        "text_answer": "  Yes The evidence does not mention the use of imaging techniques in the interventions for either trial",
        "label": "Entailment"
    },
    "2aef976d-1cb6-4d70-bda2-30a453c37f88": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial demonstrated superior results compared to cohort 2 of the secondary clinical trial is not entailed by the evidence provided The primary and secondary clinical trials measure different outcomes using different outcome measures The primary trial focuses on breast cancerspecific quality of life using the FACTB instrument while the secondary trial measures intraoperative success in addressing positive margins using the C",
        "label": "Contradiction"
    },
    "4d18c0c9-1317-4c04-9b86-f6e7e8906f5e": {
        "text_answer": "No   Explanation   The evidence provided does not contain any information about smoking status of the participants in the trials The trials only report on the outcome measurements related to the MTD determination of the interventions",
        "label": "Contradiction"
    },
    "72921dd1-88c7-4aff-a98e-8af859e4f04f": {
        "text_answer": "Yes The evidence indicates that both intervention groups received preoperative Dexamethasone administration The statement does not specify the intervention group when it mentions both cohorts but since the statement and evidence are about the same condition global partial response gvhd and the same medication Dexamethasone it can be inferred that the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "78479579-0089-4132-8de1-f710cb80ac05": {
        "text_answer": "Yes The evidence does not explicitly state that Japanese nationals are the only eligible population but it does not exclude them either Therefore they are eligible to participate in both trials based on the given inclusion criteria",
        "label": "Entailment"
    },
    "ce1887bc-e9b2-4c21-a5b8-dcbe59d3503e": {
        "text_answer": "  Yes   Explanation   The primary clinical trial measures changes in pain levels using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary clinical trial measures changes in bone mineral density BMD of the lumbar spine at 9 months Both trials involve clinical assessments of participants and the primary trial documents modifications in pain levels while the secondary trial observes changes in BMD",
        "label": "Entailment"
    },
    "ad477da6-f950-49b8-a882-0c1dfbc4751f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "547b8239-a47c-4f70-aa08-ff1d92e19af2": {
        "text_answer": "  Yes Primary Trial No Secondary Trial",
        "label": "Entailment"
    },
    "4ec4fce7-e43e-46c8-ab5a-f5f04df1b940": {
        "text_answer": "yes for the primary trial regarding Arm A and overall response rate but not directly for the secondary trial regarding Denosumab and time to first onstudy SRE as the statement compares two different interventions",
        "label": "Entailment"
    },
    "787e3275-7973-46d4-83de-00d9ebaf7acb": {
        "text_answer": "No  Explanation  The statement do volunteer work is not mentioned in the evidence The evidence only provides information about adverse events in two clinical trials The statement is about volunteer work in general and is not related to the adverse events or the clinical trials",
        "label": "Contradiction"
    },
    "f95439cc-7c35-43a8-ade1-6652fbdf7873": {
        "text_answer": "No  Explanation The statement multiple psychiatric adverse events were noticed in the primary clinical trial impacting more than a quarter of the patients is not entailed by the evidence The evidence only reports one case of suicidal ideation which is not sufficient to meet the criteria of multiple psychiatric adverse events impacting more than a quarter of the patients",
        "label": "Contradiction"
    },
    "a56a38a8-7782-4909-b417-ebb142f38028": {
        "text_answer": "Yes  Explanation The statement during the primary clinical trial numerous subjects contracted urinary tract infections is entailed by the evidence since there were 2 subjects 400 who experienced urinary tract infections out of the total 50 subjects in the trial",
        "label": "Entailment"
    },
    "2810ed9e-6f0a-4c59-be1a-31e5003fa51d": {
        "text_answer": "yes The evidence mentions several injections including dendritic cell injections in the form of a powder that needs to be reconstituted before administration",
        "label": "Entailment"
    },
    "39346303-4095-4b67-b384-6916ed20fd4c": {
        "text_answer": "Yes  Explanation  The statement the adverse events in both the primary and secondary trial can be compared is entailed by the evidence because the evidence provides the number of adverse events and their types for both trials This information allows for a comparison between the two trials",
        "label": "Entailment"
    },
    "f1963f67-9164-4e55-bf5e-3ac44e9bae5f": {
        "text_answer": "Yes  Explanation  The primary clinical trial reports the mean tumor diameter in cm for each arm of the study while the secondary clinical trial reports the number of participants with solid tumor response using RECIST 11 criteria These are different units of measure hence the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "f1315324-edf3-4d7c-a999-c3a668e67930": {
        "text_answer": "No   Explanation  The statement does not mention anything about a marinebased natural product being administered to the primary trial candidates only talazoparib",
        "label": "Contradiction"
    },
    "f6b492a8-d17f-407f-9345-ed6b7f447eea": {
        "text_answer": "No  Explanation  The statement microscopic findings specimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment is not directly related to the information provided in the evidence The evidence focuses on the details of two clinical trials including the interventions dosages and patient eligibility criteria It does not mention anything about the microscopic findings or the condition",
        "label": "Contradiction"
    },
    "81079f33-7706-4672-a08f-c285df38f870": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the dosage of cetuximab administered in the loading dose is the same for both cohorts 400 mgm2 but the dosage of MM121 the drug being tested in combination with cetuximab is different between the two cohorts Therefore the statement oversimplifies the information provided in the evidence and is not an",
        "label": "Contradiction"
    },
    "49e49c15-d880-4fa1-9582-ba86488ad192": {
        "text_answer": "No  Explanation  The statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is not directly entailed by the evidence provided The evidence only states that one patient in cohort 2 experienced increased pleural effusion which is 25 of one The statement also does not mention the association with the deleterious rpa1 gene mutation To determine if the statement",
        "label": "Contradiction"
    },
    "7f11c755-66ed-4a7e-a222-0f967b650634": {
        "text_answer": "Yes The statement is entailed by the evidence as every participant in cohort 2 took capecitabine orally during the initial 21day cycle",
        "label": "Entailment"
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "text_answer": "Yes  Explanation  The primary trial and the secondary trial evaluate different patient populations with the primary trial focusing on patients receiving HER2specific T cell therapy and the secondary trial focusing on patients receiving trastuzumab emtansine The statement is entailed by the evidence as it acknowledges the difference in patient characteristics between the two trials",
        "label": "Entailment"
    },
    "14045448-a003-4d3d-ace1-bcdf3a7479c2": {
        "text_answer": "Yes  Explanation  The statement the primary trial recorded fewer adverse events than did the secondary trial within their cohorts is entailed by the evidence since both the primary and secondary trials had no adverse events within their respective cohorts Therefore the primary trial having fewer adverse events than the secondary trial is a logical consequence of the evidence provided",
        "label": "Entailment"
    },
    "ad37e364-d3a8-4fcd-9033-90e7ec7d7fc7": {
        "text_answer": "No  Explanation  The evidence provided in the clinical trial results does not mention anything about the severity of nausea experienced by the patients It only reports the number of participants who did not have any vomiting or rescue medication during the first 24 hours after cyclophosphamide administration Therefore the statement about severe nausea is not directly related to the evidence presented",
        "label": "Contradiction"
    },
    "4b5b9e75-1690-4544-86de-d4c0ac02cf57": {
        "text_answer": "No   Explanation   The evidence provided in the trial results does not include any information about Recurrencefree Survival for the Ketorolac 30 mg and NaCl 09 3mL groups The statement about a 64 difference in Recurrencefree Survival between the two groups is not based on the evidence presented The statement also mentions a nontumor",
        "label": "Contradiction"
    },
    "fef14a32-224c-4a00-88cb-30bb448a504e": {
        "text_answer": "Yes  Explanation The statement in both the primary and secondary clinical trial at least one infection case was noted is entailed by the evidence as there is at least one infection case reported in each trial In the primary trial there were 132 313 cases of infection and in the secondary trial there was 115 667 cases of infection",
        "label": "Entailment"
    },
    "4b7eaa17-f5eb-4afe-88b7-98c293ad0100": {
        "text_answer": "No   Explanation The evidence shows that there were a total of 3 vomiting incidents out of 149 participants in the clinical trial Therefore the statement that the primary clinical trial concluded with zero incidents of gastrointestinal adverse events is not entailed by the evidence",
        "label": "Contradiction"
    },
    "5a54ce72-5d02-48fb-9cc0-2a31123f3583": {
        "text_answer": "No  Explanation  The statement none of the participants of cohort 1 of the primary clinical trial experienced any adverse events is not entailed by the evidence The evidence only reports the number of participants with serious and nonserious adverse events for each dose level but it does not indicate that there were no adverse events in cohort 1 of dose level 1 The evidence only states that all 3 participants in that",
        "label": "Contradiction"
    },
    "4a6db09e-5bc7-4c5c-8cf8-a89750cd1cc1": {
        "text_answer": "No  Explanation  The evidence provided in the clinical trial outcome measurement only reports the number of participants with a reduction in CTCs one month posttransplant It does not provide information about the percentage of participants with a reduction or the time frame for the reduction beyond one month Therefore the statement about a decrease in CTCs for under 10 of participants after several months is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "e9003121-5fb9-4d34-95b4-011c76402472": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports a change in Ki67 expression not a reduction in tumor diameter The statement also incorrectly states that tamoxifen is given at a dose of 32 mg po daily whereas the evidence states that it is given at a dose of 20 mg po daily",
        "label": "Contradiction"
    },
    "1abf0ac3-be79-4fd6-aa9f-5ae756346da4": {
        "text_answer": "Yes The evidence does not report any unexpected deaths or cases of hospitalization in either trial",
        "label": "Entailment"
    },
    "50e4558f-a9a2-425b-911f-5bea986e90b4": {
        "text_answer": "No  Explanation  The statement diffuse midline glioma egfrmutant is a diffuse midline glioma h3 k27altered characterized by the presence of egfr gene mutation is not directly related to the interventions described in the evidence The evidence only provides information about the interventions used in the primary and secondary trials but it does not mention anything about the specific patient cohorts or their genetic",
        "label": "Contradiction"
    },
    "5abe01fb-1ee1-4905-874e-a0cbec0ee9c9": {
        "text_answer": "  Yes The primary trial excludes patients with malignant ductal carcinoma in situ while the secondary trial includes them as a disease characteristic",
        "label": "Entailment"
    },
    "aa3f26b2-4c1c-45e6-b480-962b43324a8a": {
        "text_answer": "No  Explanation  The statement central nervous system angiolipoma is an angiolipoma that arises from the central nervous system is not directly related to the evidence provided in the primary trial The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at weeks 12 and 24 for a specific treatment regimen lapatinib 1250 mg and vin",
        "label": "Contradiction"
    },
    "71fe40dd-6700-4f46-b635-de6407eb1567": {
        "text_answer": "Yes  Explanation  The statement there are 0 shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because there is no overlap between the inclusion or exclusion criteria for the two trials The primary trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy and has exclusion criteria related to mental function",
        "label": "Entailment"
    },
    "4ddfaca9-bd5c-427a-a624-8a9d2c763c61": {
        "text_answer": "Yes The statement correctly identifies that the only difference between the two interventions is the dose of durvalumab given per injection and that this difference is expressed in milligrams per kilogram mgkg which can be converted to milliliters per square centimeter mLcm for dose calculation purposes",
        "label": "Entailment"
    },
    "13742fb9-874a-4f76-9d17-585c96fbd440": {
        "text_answer": "No  Explanation  The statement the count of adverse effects in the patient cohorts was identical for both the primary clinical trial and the secondary clinical trial is not entailed by the evidence The evidence only states that the count of adverse effects for Adverse Event 1 was 0 in the primary trial and 000 in the secondary trial which is not the same as stating that the counts were identical for all adverse events",
        "label": "Contradiction"
    },
    "ce3d0415-1f95-4e20-bea5-5adc05962c9d": {
        "text_answer": "No  Explanation The statement following a month of tak228 plus tamoxifen administration the primary clinical trial reported a 20 increase in the percentage of cells displaying ki67 expression is not entailed by the evidence The evidence reports a decrease in Ki67 expression from a median of 15 1025 at baseline to a median of 10 238",
        "label": "Contradiction"
    },
    "881871fa-1546-46da-acab-c8b67ef7e5c1": {
        "text_answer": "No  Explanation  The statement patients with a low potassium count are ineligible for the primary clinical trial yet may qualify for the secondary clinical trial is not entailed by the evidence provided The primary clinical trial has a potassium requirement within the normal range of 3553 mEqL and there is no mention of potassium levels or eligibility for the secondary clinical trial in the provided",
        "label": "Contradiction"
    },
    "280be8e4-7c13-4ca6-9653-94c7cf061c39": {
        "text_answer": "No  Explanation The primary trial has exclusion criteria related to cardiovascular impairment while the secondary trial has exclusion criteria related to uncontrolled cardiovascular disease These are not the same and the primary trial does not allow patients with severe or uncontrolled concurrent illnessinfection which could include cardiovascular diseases Therefore the statement that patients regardless of their cardiovascular health status are eligible to partake",
        "label": "Contradiction"
    },
    "2e8f3602-15d2-4970-ad77-07352b50b787": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5c226c5b-0a0a-44f7-a581-b2b8746f28a5": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement mentions the secondary trial and the primary trial while the evidence only provides information on two separate trials Additionally the statement is not related to the units of measure used in the trials",
        "label": "Contradiction"
    },
    "644d3ae7-8d7c-40bd-8744-32f0d3311936": {
        "text_answer": "No  Explanation  The statement her2  patients in cohort 2 of the secondary trial receive a higher dosage of trastuzumab compared to the ones in the primary trial throughout the entirety of the trial is not entailed by the evidence In the primary trial patients received a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 1 received",
        "label": "Contradiction"
    },
    "37f9db0b-4ea9-4952-bf6f-a748ac802a15": {
        "text_answer": "No   Explanation  The evidence provided in the trial results does not indicate that any patient in the GTx024 1 mg or 3 mg groups gained over 100 kilos of lean body mass The median change in lean body mass for both groups is given along with the full range of changes observed However there is no mention of any individual patient gaining over 100 kilos Therefore the statement is not",
        "label": "Contradiction"
    },
    "348f2b7d-e9b5-41ad-927b-e368bcaca8f5": {
        "text_answer": "No  Explanation  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is not explicitly stated in the inclusion or exclusion criteria provided in the evidence The evidence only mentions that patients with solid tumors including small cell lung cancer are eligible for the trial if they have measurable disease and have received prior therapy greater than or",
        "label": "Contradiction"
    },
    "d57cb18c-7375-4a66-81c4-7349cadd8d92": {
        "text_answer": "No  Explanation The statement the individual from cohort 1 recorded the longest progression free survival PFS in the primary clinical trial surviving 35 months without any disease progression or death is not directly entailed by the evidence provided The evidence only reports the median PFS for each group not the longest PFS for any individual",
        "label": "Contradiction"
    },
    "93fc8df8-d85f-4f71-9d03-7b7e0e5146ff": {
        "text_answer": "No  Explanation The statement quarter of the participants in the primary clinical trial and 4181674 participants in the secondary clinical trial had an adverse event is not entailed by the evidence provided The evidence only reports the number and percentage of participants who experienced specific adverse events in each trial but it does not provide the total number of participants who had any adverse event Therefore it is impossible to determine whether 4",
        "label": "Contradiction"
    },
    "dcb23ac7-9632-47fd-87bd-b15b25e4a3d3": {
        "text_answer": "Yes  Paclitaxel is not mentioned in the interventions described in the evidence",
        "label": "Entailment"
    },
    "eac5a5f1-7e63-4351-b7de-eacf6592a5fb": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence provides the range of doses administered to participants in each group but it does not state the total daily dose received by breast cancer patients or ovarianperitoneal cancer patients The statement incorrectly assumes that breast cancer patients received 3000 mcgday and ovarianperitoneal cancer patients received 10 mcg",
        "label": "Contradiction"
    },
    "23cc69a0-6ac6-4373-9e9e-97c3e613d5eb": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence because the evidence does not report any cases of febrile neutropenia or cholelithiasis in either trial The statement is incorrect and should not be accepted based on the provided evidence",
        "label": "Contradiction"
    },
    "cf33b6d5-f59c-4b24-be84-4aeba15f6c5e": {
        "text_answer": "Yes  Explanation The statement having the ability to offer written informed consent is the only mutual inclusionexclusion condition in both the primary and secondary clinical trials is entailed by the evidence because both trials list Willingness and ability to provide written informed consent as an inclusion criterion",
        "label": "Entailment"
    },
    "7552c836-8753-455e-923f-8364d6c63b03": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c3464aef-3ed6-47ad-8196-99f8115916e4": {
        "text_answer": "No  Explanation  The primary clinical trial measures the change in units on a scale for vaginal symptoms while the secondary clinical trial measures the percentage of participants with objective response rate for HER2negative metastatic breast cancer Neither trial uses Cogstate measured objective cognitive function scores for their units of measurement",
        "label": "Contradiction"
    },
    "fb73159b-0d37-4ea1-aaba-4f540ec395b9": {
        "text_answer": "  No The evidence provided does not mention anything about women aged 16 or 17 being eligible for either trial The primary trial includes patients aged greater than 20 years and the secondary trial includes patients aged 18 or older",
        "label": "Contradiction"
    },
    "3fda5084-ab27-4f5c-8acb-0be7e7ac93c1": {
        "text_answer": "No   Explanation The statement there were zero reports of AEs among participants in the primary clinical trial is not entailed by the evidence as the evidence reports 2 adverse events AEs among the 35 participants",
        "label": "Contradiction"
    },
    "1655bb9f-adca-4796-9883-a620e978f745": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial witnessed a greater number of adverse events than cohort 1 is not entailed by the evidence provided The evidence only shows that the percentage of adverse events in cohort 2 680 is less than that of cohort 1 4245 Therefore the statement is not supported by the evidence",
        "label": "Contradiction"
    },
    "55b2acbc-30a6-43ef-bca6-0e7a5b3f6a8f": {
        "text_answer": "Yes  Explanation The evidence describes two interventions with different administration techniques intravenous bisphosphonate Q4W and subcutaneous denosumab Q12W The statement various techniques are used to administer the interventions is entailed by this information as it correctly acknowledges the existence of multiple administration techniques in the trial",
        "label": "Entailment"
    },
    "2037fc58-ce2f-4f44-8ebc-dc9f9d7129cd": {
        "text_answer": "13 refers to the percentage of participants with HER2 primary breast cancer not PR Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ecd4681c-624a-44da-b9e7-4d993b35d2af": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Entailment"
    },
    "3239643a-3052-4344-a7ea-f2d5dff19755": {
        "text_answer": "No   Explanation   The statement children are the main demographic required for participating in the primary clinical trial while they are not allowed to partake in the secondary trial is not entailed by the evidence provided   The primary trial includes postmenopausal women only while the secondary trial includes patients with metastatic breast cancer regardless of age Therefore children are not mentioned as a demographic for either trial Additionally the",
        "label": "Contradiction"
    },
    "b7c9455e-db3b-438d-bcb0-04bf52fb530d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no information about a testosterone cream group in the evidence provided The evidence only compares the acupuncture group to a waitlist control group",
        "label": "Contradiction"
    },
    "3ca94519-994e-4921-95ef-fdd1daf0932c": {
        "text_answer": "Yes The woman who has undergone breast conservation therapy would be excluded from both trials The primary trial excludes patients who have undergone autologous tissue breast reconstruction which includes breast conservation therapy and the secondary trial excludes patients who have had prior radiation to the breastchest wall which is a common component of breast conservation therapy",
        "label": "Entailment"
    },
    "efbc4408-7a74-4857-8265-d1bf4eab4080": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 This represents a reduction of 15 to 35 at baseline and 0 to 33 at 6 weeks A 110 reduction in the proportion of cells with Ki67 expression",
        "label": "Entailment"
    },
    "4e9c14cb-9c55-4c1a-ae14-f5a6f08e1494": {
        "text_answer": "No  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is not entailed by the evidence provided The evidence only states the number of occurrences of each adverse event in each trial but it does not compare the number of occurrences between the two cohorts within",
        "label": "Contradiction"
    },
    "9bf4a35a-531f-4083-87ac-dec730cfea45": {
        "text_answer": "No  Explanation  The statement the primary trial recorded 11 more instances of intestinal perforation than the secondary trial is not entailed by the evidence The evidence only states that there was 1 instance of intestinal perforation in the secondary trial and no instances in the primary trial Therefore it is not accurate to say that there were 11 more instances in the primary trial",
        "label": "Contradiction"
    },
    "49d2b5e7-595e-4762-b7af-9e914bf72917": {
        "text_answer": "Yes  Explanation The statement all patients in the primary clinical trial receive less than 20mg of mcs110 every 3 weeks and over 130 mg of pdr001 every other week is entailed by the evidence because the evidence specifies that the dosage of MCS110 is 1 mgkg every 3 weeks which is less than 20 mg for a 70 kg",
        "label": "Entailment"
    },
    "d8735c6c-1fc9-4fbc-93d2-651a5814d505": {
        "text_answer": "No  Explanation  The statement cardiovascular system findings derived flag is an indication or description that cardiovascular system data is a derived value is not directly related to the evidence provided The evidence only mentions the interventions and intended assessments in both trials but it does not mention anything about derived flags or cardiovascular system data being derived Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "f7d7cc99-97cb-48f0-bc69-78a60d9d21be": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR This is greater than 66 so the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "268ad1eb-851a-484a-873f-b54ab271b063": {
        "text_answer": "No  The statement is not related to the evidence provided The evidence only discusses adverse events in a clinical trial while the statement is about an individuals feelings of difference due to hearing loss",
        "label": "Contradiction"
    },
    "428340b6-e87b-4e03-920b-f2e3f62f05d6": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it only mentions that the interventions educational DVD will be made available to cohort 1 in the primary clinical trial but it does not specify that the control group will not have access to the DVD",
        "label": "Contradiction"
    },
    "aa5dd0d4-1551-4ccc-85a8-ca6c2bcfb871": {
        "text_answer": " Yes  Explanation The statement in the primary trial results there were more patients with stable disease after 3 months than after 6 months but none of the patients had complete response after 3 months or 6 months is entailed by the evidence as the evidence shows that there were 10 participants with stable disease after 6 months and only 12 participants with stable disease after 3 months and no participants had complete response at either time point",
        "label": "Entailment"
    },
    "ba355915-f5a7-4b38-bbca-95fe674d63f5": {
        "text_answer": "Yes  Explanation The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is entailed by the evidence as it is clear from the evidence that only these three types of adverse events were reported in the primary trial",
        "label": "Entailment"
    },
    "1c31539a-7fd9-4e81-ae88-c0e05a34946a": {
        "text_answer": "No  Explanation The statement does not follow directly from the evidence as the evidence describes different interventions for breast cancer and ovarianperitoneal cancer patients and there is no mention of adhesion G proteincoupled receptor e1 staining method in the evidence",
        "label": "Contradiction"
    },
    "c367ab4c-6113-4f79-abcc-24e715c18094": {
        "text_answer": "No   Explanation   The statement does not mention any adverse event related to bradyarrhythmia and it focuses on adverse events in adults not neonates The evidence provided only discusses various adverse events observed in two clinical trials none of which are related to bradyarrhythmia",
        "label": "Contradiction"
    },
    "6815208b-ad2d-4564-b723-2d8e44af78b0": {
        "text_answer": "Yes The evidence states that smokers are excluded from the secondary clinical trial Therefore if someone is an active smoker they cannot participate in the secondary trial Since the primary trial also excludes smokers the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "14e8dba6-bd13-4f5b-a225-6cd55c3d1243": {
        "text_answer": "yes but with a clarification The statement is entailed by the evidence for the primary trial regarding alpha lipoic acid but not for the secondary trial regarding necitumumab as the dose in the secondary trial is consistent throughout",
        "label": "Entailment"
    },
    "12a7a47e-adb9-4c24-8410-03aea3d7d292": {
        "text_answer": "  No The statement is not entailed by the evidence The primary trial includes mammography as a requirement but the secondary trial only mentions mammography as a mandatory procedure for patients with breast lesions that are nonpalpable and require surgical removal and image guidance is also required The primary trial does not mention MRI as a requirement for all candidates",
        "label": "Contradiction"
    },
    "3570b51a-d280-41b5-9c59-849436db5934": {
        "text_answer": "Yes The statement is entailed by the evidence as metastatic small cell lung cancer is not included in the list of eligible tumor types for the clinical trial",
        "label": "Entailment"
    },
    "9e14f099-36f3-4672-b35c-022cc3279c98": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the statement mentions acute physiology and chronic health evaluation II APACHE II apch114 question clinical classification standardized character response which is not mentioned in the evidence The evidence only reports the Time to Progression and the number of participants with Objective Response based on RECIST criteria in two separate trials",
        "label": "Contradiction"
    },
    "afc3c380-94da-4686-a5ca-1967217d14d1": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a3a672e2-2900-45dd-ae02-797449f17b66": {
        "text_answer": "No  The primary trial excludes patients with alcohol or substance abuse or dependence within the past 2 years while the secondary trial excludes patients with more than 5 alcoholic drinks per day within the past year These are not the same criteria",
        "label": "Contradiction"
    },
    "db26f45b-4e0a-4f21-83da-6f22116f7ac5": {
        "text_answer": "yes anemia and pneumonia  Explanation  The statement the incidence of anemia pneumonia and stupor was higher in the secondary clinical trial patients compared to the primary clinical trial patients is partially entailed by the evidence The evidence shows that the incidence of anemia and pneumonia was higher in the secondary clinical trial patients compared to the primary clinical trial patients However the evidence does not provide information about",
        "label": "Entailment"
    },
    "c4aea42a-a9e3-47ba-9a96-12350a3925c9": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 00176 ounces of fulvestrant in a tablet form to be taken bid is not entailed by the evidence  The evidence only states that in the primary trial participants receive whole breast radiation therapy and in the secondary trial participants received Fulvestrant intramuscularly",
        "label": "Contradiction"
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "text_answer": "No  Explanation The statement In the primary trial the placebo intervention and the Memantine intervention are both administered orally once daily is not entailed by the evidence The evidence states that both interventions are administered orally but it does not specify that they are administered once daily The Memantine intervention is administered twice daily",
        "label": "Contradiction"
    },
    "c3e36213-9a24-4f92-9ff3-12e071aac541": {
        "text_answer": "Yes  Explanation Both the primary and secondary clinical trials involve the use of cyclophosphamide and paclitaxel in their respective interventions Additionally both trials include the use of pegfilgrastim although in different dosing schedules Therefore the statement that both trials provide cyclophosphamide paclitaxel and pegfilgrastim to their patient groups is entailed by the evidence",
        "label": "Entailment"
    },
    "91db7925-da19-4373-bfba-78ee49b34f99": {
        "text_answer": "No  Explanation  The statement the primary trial uses a 504 hour cycle for its intervention is not entailed by the evidence The evidence states that each treatment cycle in the primary trial is defined as 21 days and the maximum duration of PF05212384 treatment is 505 days However it does not provide information about the number of hours in a treatment cycle  Fur",
        "label": "Contradiction"
    },
    "fc6ab4bb-43af-4008-a2dc-0e23dbf9abc0": {
        "text_answer": "Yes However the primary trial excludes patients who have undergone autologous tissue breast reconstruction and intend to undergo implant only breast reconstruction but the secondary trial does not mention anything about breast reconstruction Therefore a woman who has undergone a mastectomy and is eligible for the primary trial may also be eligible for the secondary trial assuming she meets the other inclusion criteria for the secondary trial",
        "label": "Entailment"
    },
    "00d9d3c3-938f-4e4c-b532-b11146f1239c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5102bc84-4e28-4ec9-91cf-b5ed615b15bb": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the placebo is administered on Day 1 and trabectedin is administered on Day 2 with no mention of a semiannual basis",
        "label": "Contradiction"
    },
    "914d236c-c227-4d8d-8565-04a1d25e3b59": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports a change in Ki67 expression not a change in tumor diameter The statement makes an incorrect assumption about the relationship between Ki67 expression and tumor diameter",
        "label": "Contradiction"
    },
    "af1a2e8d-2b8e-4690-b32c-9d044d9aa15f": {
        "text_answer": "No   Explanation   The statement is not directly entailed by the evidence as the evidence only mentions the use of 18FFDG and 18FFPPRGD2 in the context of trials for glioblastoma multiforme and gynecological cancers and does not mention rhabdomyosarcoma or any specific chemotherapy regimens",
        "label": "Contradiction"
    },
    "f718d65d-3ea1-41b7-adc0-5f481843011c": {
        "text_answer": "Yes The primary trial uses a higher dose of lenalidomide 5mg orally daily compared to the dose of lapatinib 1500mg orally daily in the secondary trial",
        "label": "Entailment"
    },
    "8f537eb8-d8b7-4c56-89bf-ea2e5b0d1326": {
        "text_answer": "No   Explanation   The statement the primary trial uses a 3 week cycle for its intervention the secondary trial on the other hand does not have a cyclic treatment in place is not directly entailed by the evidence provided The evidence only mentions the treatment regimens and their durations in the primary trial but it does not explicitly state that the treatment is given in 3week cycles Additionally the secondary trial does not",
        "label": "Contradiction"
    },
    "1ea69c5b-83c6-4d54-b17c-0e6df9c49abb": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the prevailing adverse events were of cardiovascular origin is not directly entailed by the evidence provided The evidence only mentions the occurrence of various adverse events related to blood and bone marrow lymphatics and edema in both primary and secondary trials It does not specify that the prevailing adverse events in the primary trial were of cardiovascular origin",
        "label": "Contradiction"
    },
    "763b8082-f1d6-4dfb-ab46-b61d8dae6515": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity weight or gender as eligibility criteria for either trial The dose calculation unit mentioned in the statement is not mentioned in the evidence",
        "label": "Entailment"
    },
    "485e3ce9-e779-4ae5-bdc4-7fbcb1d1eb3c": {
        "text_answer": "No  The statement does not mention any adverse event noted in the clinical trial It only states that the sole adverse event was mild muscular discomfort which is not mentioned in the evidence provided",
        "label": "Contradiction"
    },
    "88a40578-17e1-499b-8b7b-10a85e2c3d88": {
        "text_answer": "No  Explanation  The statement vital signs sequence number is an identifier that describes the relative position of vital signs data within a series is not mentioned in the evidence provided The evidence only includes inclusion and exclusion criteria for two different breast cancer trials The statement does not relate to the trials or their eligibility criteria Therefore it cannot be determined to be entailed by the evidence  Regarding the second part of the statement patients with",
        "label": "Contradiction"
    },
    "b7178d54-4bb2-4820-b13c-c342075267ff": {
        "text_answer": "No  Explanation  The statement despite the lack of any cardiac or psychiatric aes in the primary clinical trial and secondary clinical trial a number of other aes were witnessed is not entailed by the evidence provided The evidence only reports the absence of Adverse Events 1 and 2 cardiac and psychiatric events in the primary and secondary trials It does not mention any other adverse events being witnessed",
        "label": "Contradiction"
    },
    "48788622-6b62-4a88-8d7c-29be1fbd88e8": {
        "text_answer": "No  The evidence does not mention coronary artery stenosis as an adverse event",
        "label": "Contradiction"
    },
    "f05dd895-7d03-45d2-ab9c-69db39c386e5": {
        "text_answer": "No  Explanation  The statement inclusion in the primary clinical trial is restricted to those who have not received chemotherapy or radiotherapy in the past 6 months and have a proven clean mental health record is not explicitly stated in the given evidence The evidence only mentions the number of prior chemotherapy lines in the metastatic setting as an exclusion criterion Mental health record is not mentioned at all",
        "label": "Contradiction"
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "993572ab-2275-4def-9723-202249284283": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the most recurring adverse event in the primary clinical trial was syncope 1667 not insomnia 2500 The evidence does not provide information about the adverse events in the secondary clinical trial beyond deep vein thrombosis",
        "label": "Contradiction"
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary trial receives higher doses of Eribulin than cohort 2 patients receive of Docetaxel is not directly entailed by the evidence provided The evidence only states the dosages of Eribulin and Docetaxel for each cohort but it does not compare the total doses received by each cohort To make such a comparison we would",
        "label": "Contradiction"
    },
    "61fbddc4-94cb-4105-8090-03dd97a3bc53": {
        "text_answer": "Yes The primary trial includes both male and female patients but the secondary trial only includes female patients",
        "label": "Entailment"
    },
    "9b2023d2-09bd-4362-ae66-afc69497e468": {
        "text_answer": "No   Explanation  The statement is not directly related to the evidence provided The evidence describes two interventions in a clinical trial one using an inframammary fold incision and the other using a lateral radial incision both of which involve the use of laserassisted fluorescence angiography at three separate time points during the procedure The statement on the other hand is about a nonpsychotic mental disorder following",
        "label": "Contradiction"
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "text_answer": "Yes  Explanation  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is entailed by the evidence because the number of patients with Adverse Events AEs in the secondary trial 1220 or 6000 is greater than the number of patients with AEs in the primary trial 049 or 000",
        "label": "Entailment"
    },
    "e87fee13-1ed3-4eca-8d72-d65fee50abf7": {
        "text_answer": "No  Explanation  The statement a higher number of mucositis oral cases epileptic seizures and thromboembolic events were seen in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only reports the number of adverse events for each trial but it does not specify the types of adverse events that were mucositis oral epileptic seizures or th",
        "label": "Contradiction"
    },
    "f08d84f8-0448-462c-8f81-770223b92bb8": {
        "text_answer": "yes for the operative time comparison in the primary trial but no for the secondary trial with its different outcome measurement and lack of a control group",
        "label": "Entailment"
    },
    "205d3c95-7288-4d9f-9a5c-edc7b09de79d": {
        "text_answer": "No  The inclusion and exclusion criteria for the primary and secondary trials are not identical and eligibility for one trial does not necessarily imply eligibility for the other",
        "label": "Contradiction"
    },
    "62de4057-c709-4110-9986-642428c1d534": {
        "text_answer": "Yes  Explanation The evidence states that both the placebo and trabectedin are administered intravenously over a 3hour infusion on separate days The statement in the primary clinical trial the placebo and trabectedin are delivered identically can be interpreted as meaning that they are given in the same way but the evidence also makes it clear that they are given on different days However the fact that they are given in",
        "label": "Entailment"
    },
    "b9e51528-b593-40f7-8f49-acfacc756a7f": {
        "text_answer": "Yes for the secondary trial  Explanation  The statement in the primary clinical trial and the secondary clinical trial the patients encountered thromboembolic events is only entailed by the evidence for the secondary trial as the primary trial does not report any thromboembolic events Therefore the answer is Yes for the secondary trial but the statement is not entailed by the evidence for the primary trial",
        "label": "Entailment"
    },
    "05c44353-ab0d-4b2d-98ff-e39aab551229": {
        "text_answer": "No  Explanation The statement in the question does not accurately reflect the information provided in the evidence The primary trial treats patients with 150 mg of oral pregabalin not 015 kg The secondary trial administers patients with Liposomal Cytarabine Depocyt and Highdose Methotrexate HDMTX not just Depocyt",
        "label": "Contradiction"
    },
    "c96d223f-7d7e-47aa-b71e-0b56ab6eef81": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the evidence does not mention anything about exercise being a part of the intervention for the primary trial candidates The statement is about leporine experimental organism diagnosis which is not related to the primary trial at all",
        "label": "Contradiction"
    },
    "280cae18-764b-4cc7-ae2a-3b1f05c04cbf": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes the use of 18FFDG and 18FFPPRGD2 in the primary clinical trial for glioblastoma multiforme and gynecological cancers while the statement denies the use of these radiotracers in the trial",
        "label": "Contradiction"
    },
    "a9c7619e-8cc5-4c84-b4a4-38ada95388a2": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided as it does not mention anything about performance status or trials in the statement The statement is about a dataset containing supplemental information related to pharmacogenomicsgenetics biomarkers The evidence on the other hand provides inclusion and exclusion criteria for two different clinical trials",
        "label": "Contradiction"
    },
    "059a48d5-3bf5-40ac-b06c-3107c0ea7cb9": {
        "text_answer": "No   Explanation   The statement is not a direct comparison of the interventions used in the two trials The primary trial involves the use of oral pregabalin while the secondary trial involves the use of intrathecal Liposomal Cytarabine Depocyt and highdose Methotrexate HDMTX These interventions are not directly comparable in terms of their nature or mode of administration",
        "label": "Contradiction"
    },
    "3ace09f3-a822-4140-a529-52b08664da77": {
        "text_answer": "No  Explanation  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events in each cohort but it does not provide information about the proportion of patients who experienced adverse events in each cohort Therefore it is not possible to determine from",
        "label": "Contradiction"
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "text_answer": "  No the statement is not entailed by the evidence for the secondary trial as it only includes patients with triplenegative breast cancer ERnegative PRnegative and Her2neunegative breast cancer not specifically Her2neu positive",
        "label": "Contradiction"
    },
    "c49dbdfa-801a-4789-9e04-345ed14150ab": {
        "text_answer": "No  Explanation  The statement hemodialysis catheter infection is a local or systemic infection associated with the use of a hemodialysis catheter is not directly related to the evidence provided The evidence only mentions the use of talazoparib capsules in participants with breast cancer and ovarianperitoneal cancer and the different doses they received There is no mention of hemodialysis cat",
        "label": "Contradiction"
    },
    "4028bb9b-1122-4c10-ab5c-a38205fe6dd2": {
        "text_answer": "No  Explanation  The statement the same proportion of patients experienced negative effects in both groups of the primary clinical trial is not entailed by the evidence The evidence only provides the number and percentage of adverse events for each group but it does not show that the same proportion of patients experienced negative effects in both groups In fact the evidence shows that a higher proportion of patients in Group 2 experienced febrile neutropenia which is an",
        "label": "Contradiction"
    },
    "6b568a13-5216-4b83-848a-c64e8a9c340b": {
        "text_answer": "Yes The primary clinical trial does not provide any results for the LBH589 and Lapatinib cohort",
        "label": "Entailment"
    },
    "3852b7ff-e68a-4bc8-917f-4eb9c838862d": {
        "text_answer": "Yes The primary trial does not exclude recipients of organ transplants within the past 6 months while the secondary trial does",
        "label": "Entailment"
    },
    "2a509e67-c521-4406-8122-c91d7a1331ad": {
        "text_answer": "No  Explanation  The statement about skin appendage neoplasms is not related to the inclusion or exclusion criteria of either the primary or secondary trials The primary trial focuses on patients with advanced cancer and their eligibility for vinorelbine treatment while the secondary trial deals with patients undergoing large core breast biopsies and their eligibility for the procedure Neither trial mentions skin appendage neoplasms as a factor in inclusion or",
        "label": "Contradiction"
    },
    "c5d6c5da-f71c-4454-a333-3ade43aef122": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with small cell lung cancer are explicitly excluded from the trial However the statement also implies that those with metastatic or inoperable squamous cell carcinoma SCC who do not have ER or PR positive tumors are excluded which is not explicitly stated in the evidence but is implied by the inclusion criteria for breast cancer which mentions ER and PR as potential biomarkers for eligibility",
        "label": "Entailment"
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "text_answer": "Yes The primary trial does not include CBT Cognitive Behavioral Therapy as a treatment option but the secondary trial does not have any mention of CBT as an exclusion criterion",
        "label": "Entailment"
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "text_answer": "No  The evidence provided does not mention radiation therapy at all",
        "label": "Contradiction"
    },
    "8004fee7-e287-4a54-b66f-44002ebb1b34": {
        "text_answer": "No  The statement is not entailed by the evidence as the trial specifically excludes patients with a history of another malignancy except for those who have been diseasefree for 3 years However the statement mentions a patient with a diagnosis of ILDDPLD within the last 3 years which is a type of malignancy",
        "label": "Contradiction"
    },
    "777fb2a8-9329-4e49-a67b-93d1d7fe2319": {
        "text_answer": "Yes The statement is entailed by the evidence as there is a reported case of wound dehiscence in the adverse events",
        "label": "Entailment"
    },
    "386515be-dd8a-423d-933b-6c7f99461ebd": {
        "text_answer": "Yes The evidence indicates that patients with stage 4 breast adenocarcinoma that is ER positive PR positive or HER2neu negative are qualified for both the primary and secondary clinical trials However its important to note that there are additional inclusion and exclusion criteria for each trial that must also be met",
        "label": "Entailment"
    },
    "3a36e314-e4f4-4a60-acc9-b9f9933e884c": {
        "text_answer": "No  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events in each trial but it does not provide information about which cohorts had more cases of specific adverse events",
        "label": "Contradiction"
    },
    "c6b37d94-f63f-4cf7-b86c-a8147ff618d9": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement is about tamoxifen 35 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery while the evidence is about tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery The dosage and duration of tamoxifen administration are different in the statement",
        "label": "Contradiction"
    },
    "ae0dd0fb-c8c9-47bd-ab6b-8236edd68194": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "be268f6b-8123-4cd7-a495-c82453034b67": {
        "text_answer": "No  Explanation  The statement patients suffering from lobular carcinoma in situ and wellregulated high blood pressure are permitted in the primary clinical trial but are barred from the secondary clinical trial is not entailed by the evidence  In the primary trial there is no mention of lobular carcinoma in situ as an exclusion criterion However high risk breast lesions like atypia or atypical",
        "label": "Contradiction"
    },
    "62581915-0fde-4cfb-8205-7c1b8c8bacbb": {
        "text_answer": "Yes The primary trial uses a higher dose of lenalidomide 5mg daily compared to the dose of lapatinib used in the secondary trial 1500mg daily which is equivalent to approximately 5mgkg for a 70kg person",
        "label": "Entailment"
    },
    "36426525-f3e0-426e-aae4-2fc677756ca9": {
        "text_answer": "Yes The statement that 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 30 of patients apart from Skin infections is entailed by the evidence provided The evidence shows that there were no adverse events in the primary trial and the frequency of each adverse event in the secondary trial is listed with only skin infections affecting more than 30 of patients",
        "label": "Entailment"
    },
    "58b45da6-c265-4cef-a6cc-83113439c79e": {
        "text_answer": "No  Explanation  The statement the levels of palpitations pericardial effusions and abdominal pains were higher in cohort 2 of the primary clinical trial than those of cohort 1 in the secondary clinical trial is not entailed by the evidence provided The evidence only shows the number of occurrences of each adverse event in each trial but it does not provide enough information to make a comparison between the",
        "label": "Contradiction"
    },
    "a743b2fa-dd26-4c5f-931d-f5cc8bcf52c2": {
        "text_answer": "No  The evidence does not provide information on the occurrence of epileptic seizures in either trial",
        "label": "Contradiction"
    },
    "0bb7dafe-391e-4adb-a9fe-ac3717421ae8": {
        "text_answer": "  No   Explanation   The statement a woman postmastectomy for stage iv bc may still be considered for recruitment in either the primary or secondary clinical trial is not entailed by the evidence provided   The primary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy for breast reconstruction and the secondary trial includes patients who have completed surgery for Stage IIII breast cancer Neither trial includes patients",
        "label": "Contradiction"
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "text_answer": "Yes  Explanation  The statement the secondary trial and the primary trial use different outcome measurements and units of measure is entailed by the evidence as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in mIUml while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD in mg",
        "label": "Entailment"
    },
    "6adaaefe-d699-4bce-87dc-8233140a14fa": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial does not involve muscle gains and the secondary trial measures pain not muscle gains in relation to physical therapy",
        "label": "Contradiction"
    },
    "d7aa81f2-8df0-4884-9d6a-e6d21ec79b03": {
        "text_answer": "No  Explanation  The statement patients who have received chemotherapy or radiotherapy in the last 12 a month suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the",
        "label": "Contradiction"
    },
    "869078fe-375b-45b5-ba65-21d04cd304ed": {
        "text_answer": "Yes  Explanation  The statement bone marrow sample is a biological sample containing components collected from bone marrow of an experimental subject is not directly related to the evidence provided However the evidence does contain information about interventions using different drugs Lenalidomide and LapatinibTrastuzumab and their dosages in two separate trials The statement the primary trial uses higher doses of Lenalidomide than the secondary",
        "label": "Entailment"
    },
    "5417955e-52aa-4b3b-8e67-2a4c4796846a": {
        "text_answer": "Yes In the primary trial epacadostat is given twice daily BID while in the secondary trial sunitinib is given once daily Therefore epacadostat is provided to participants more frequently twice daily vs once daily",
        "label": "Entailment"
    },
    "5d6bf9b2-6737-4266-9566-436393cdcfab": {
        "text_answer": "Yes  Explanation The evidence provided in the primary clinical trial results shows that the mean number of daily hot flashes was lower in the paced respiration intervention group 348 compared to the fast shallow breathing comparator group 395 This difference indicates that on average patients in the paced respiration group experienced fewer daily hot flashes than those in the fast shallow breathing group",
        "label": "Entailment"
    },
    "28375759-dcd0-430d-8035-9571e1bbc07e": {
        "text_answer": "Yes The primary trial uses a lower dose of lenalidomide 5mg daily compared to the secondary trials intervention 1 using lapatinib 1500mg daily",
        "label": "Entailment"
    },
    "ae5d8804-eada-4f5c-8889-18a7cc90bb9b": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures tumor diameter in centimeters cm while the secondary clinical trial measures the number of participants with solid tumor response However the term participants can be considered as a count which is a different unit of measure compared to centimeters Therefore the statement is entailed by the evidence as it correctly identifies that different units of measure are used in the two clinical trials",
        "label": "Entailment"
    },
    "ee16dd43-346c-47c2-b5c1-b3722935918d": {
        "text_answer": "Yes The primary clinical trial does not have age or height as exclusion criteria while the secondary clinical trial excludes participants under a certain age",
        "label": "Entailment"
    },
    "a154d6bd-fc5d-491f-b2aa-7785024e67a5": {
        "text_answer": "No  Explanation  The primary trial reports the percentage of participants while the secondary trial reports the number of participants Therefore the units of measure are not the same in both trials",
        "label": "Contradiction"
    },
    "00ac087f-fc20-4ff1-be51-f32fa22f4e4e": {
        "text_answer": "No  Explanation The participants in the primary trial receive epacadostat twice daily BID while sunitinib in the secondary trial is given once daily Therefore the frequency of epacadostat administration is different from sunitinib in the secondary trial and the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "text_answer": "No  Explanation The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not entailed by the evidence The evidence states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the exact dosage of oral lapatinib The statement suggests a dosage of 100 mg",
        "label": "Contradiction"
    },
    "2ea93619-d183-4989-b811-c4666059d456": {
        "text_answer": "Yes   Explanation  In the primary clinical trial patients received a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary clinical trial patients in cohort 2 received Herceptin 4 mgkg on Day 1 of Cycle 5 and 2 mgkg per week starting from Day 8 These dosages are different",
        "label": "Entailment"
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "text_answer": "Yes  Explanation The statement There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial is entailed by the evidence since the evidence shows that there were no reported cases of Intestinal obstructions or Pancytopenia in both trials",
        "label": "Entailment"
    },
    "97a2b670-3f9b-49e5-abde-d0b477046164": {
        "text_answer": "Yes The evidence does not report any discernible pattern of gene expression for the 40 tested genes among patients in cohorts 1 Normal Vitamin D Levels and 2 Lownormal Vitamin D Levels",
        "label": "Entailment"
    },
    "a90d6d85-6942-4653-b23c-126d63b1d2cf": {
        "text_answer": "Yes for the primary trial only  Explanation The statement Patients with stage 4 cancer are not eligible for the secondary trial however they are eligible for the primary trial is entailed by the evidence for the primary trial as the inclusion criteria for the primary trial do not exclude patients with stage 4 breast cancer However it is not directly related to the secondary trial as the secondary trial does not mention eligibility for patients with stage 4 cancer",
        "label": "Entailment"
    },
    "75625dfd-7f82-4a99-b97d-50f05751dfdb": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials exclude patients with severe insomnia",
        "label": "Entailment"
    },
    "195efca0-b2e3-43c0-abf2-4c6d77d8a449": {
        "text_answer": "No  The statement is not entailed by the evidence as sunitinib was in fact administered orally in the clinical trial",
        "label": "Contradiction"
    },
    "56d753e1-4bce-4c3d-a8fb-8abc6119c1a7": {
        "text_answer": "Yes  Explanation The statement fewer than 5 of the patients involved in the primary clinical trial encountered adverse events is entailed by the evidence since the total number of adverse events was 2 out of 35 patients which is less than 5 571 to be exact",
        "label": "Entailment"
    },
    "d260a3cd-28cd-4df8-aa19-1586a1f7b978": {
        "text_answer": "Yes  Explanation The statement both cohorts in the primary clinical trial receive cudc101 at equivalent doses and frequencies is entailed by the evidence because both cohorts receive CUDC101 at a dose of 275 mgm2 the difference being the frequency of administration 5 daysweek in Arm A and 3 daysweek in Arm B However the total amount of",
        "label": "Entailment"
    },
    "20a9c28d-88d5-4cd8-b346-19a1123ede25": {
        "text_answer": "No  Explanation  The statement all the patients in the primary clinical trial see no symptoms of increased pleural effusion or rapid disease progression is not entailed by the evidence The evidence shows that out of the total number of patients in the primary clinical trial 1 patient in the first group and 1 patient in the second group experienced rapid disease progression but the number of patients with increased pleural effusion was 0 in the first group",
        "label": "Contradiction"
    },
    "fdeba169-13d2-4ed9-a2b2-774194f18370": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not allow individuals with meningeal carcinomatosis to participate in the trial",
        "label": "Contradiction"
    },
    "fe7217cf-7210-433b-b3ec-5dfff00aa3c4": {
        "text_answer": "No  Explanation  The statement the secondary clinical trials most frequent adverse event witnessed was anaemia affecting in excess of 5 of the patients while no adverse occurrences were noted in the primary trial is not directly entailed by the evidence provided The evidence states that anaemia occurred in 234 of patients in the secondary trial which is below the 5 threshold for being considered",
        "label": "Contradiction"
    },
    "b70ec50e-cbcd-4edd-a730-267c5b0f3fec": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3b41b926-449f-41e1-beed-6dd4be9e57f1": {
        "text_answer": "Yes The statement is entailed by the evidence as the participants in the primary trial receive four different drugs epirubicin cyclophosphamide docetaxel and trastuzumab throughout the study duration and the maximum dose of epirubicin is 100 mgm2",
        "label": "Entailment"
    },
    "6f5741c8-88c1-46ef-856c-dae9a3fe5fd6": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel armgroup experienced either a confirmed complete response or a confirmed partial response according to RECIST criteria 10 This means that more than half of the participants 53 out of 60 exhibited an overall tumor response",
        "label": "Entailment"
    },
    "83b92dd1-c68e-443b-b864-3ea87b3b557e": {
        "text_answer": "No  The evidence does not provide any information about the control or progression of the disease for the individuals involved in the trial",
        "label": "Contradiction"
    },
    "53d37329-6f3e-40fe-82d3-4a2535b117d9": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare abilities and are confined to bed or chair less than 500 of waking hours",
        "label": "Entailment"
    },
    "28c1cdeb-4f60-4fd7-b2b1-5368a91f9b85": {
        "text_answer": "No  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not explicitly stated in the evidence provided However the evidence does not mention anything about CBT treatments being allowed or prohibited for either trial",
        "label": "Contradiction"
    },
    "75080502-7163-4189-9194-c96041df76e5": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial has no age restriction and the primary clinical trial excludes those who are younger than 25 is not entailed by the evidence The secondary clinical trial includes the age restriction of being over 18 years old which is not mentioned in the statement",
        "label": "Contradiction"
    },
    "4c30a588-032f-4b8c-b00a-ee27f8f64b50": {
        "text_answer": "No  The evidence does not mention anything about vaccine administration in the primary clinical trial",
        "label": "Contradiction"
    },
    "37b1b3cc-069a-4597-9375-4e856eeb6f9d": {
        "text_answer": "No  Explanation  The statement in the secondary trial it is acceptable for patients to have undergone cancer treatments such as chemotherapy and radiotherapy within the last 14 days have unstable angina or grade 2 or above neuropathy however these conditions disqualify them from participation in the primary trial if they have nonhealing surgical wounds is not entailed by the evidence  The primary trial",
        "label": "Contradiction"
    },
    "8bcb86b4-494e-4e43-bf93-ef5b1ef6c566": {
        "text_answer": "No  Explanation  The statement ai therapy responsiveness is required for participants to be enrolled in the primary clinical trial this is also necessary for the inclusion into secondary clinical trial is not entailed by the evidence The primary clinical trial has specific inclusion and exclusion criteria related to hormone receptor status resistance to aromatase inhibitors and other factors The secondary clinical trial has inclusion and exclusion criteria related to tissue expander reconstruction following m",
        "label": "Contradiction"
    },
    "ab098908-d287-4ffa-883c-202a87f5ba63": {
        "text_answer": "No  Explanation The evidence states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the exact dosage of lapatinib taken each day The statement assumes that patients take 2400mgm2 of lapatinib bidaily which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "b96ecdf0-3627-48c9-b01d-4cfdbe13a7cb": {
        "text_answer": "No  Explanation  The statement The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort is not directly entailed by the evidence provided The evidence only describes the design and dosing information for two different arms of the trial but it does not provide any information about the outcomes or results of those arms Therefore it is",
        "label": "Contradiction"
    },
    "f07f2805-df6a-4662-8a1f-757eabf8687a": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it makes a comparison between the frequency of Epacadostat administration in the primary trial and the frequency of sunitinib administration in the secondary trial but the evidence does not provide the necessary information to make this comparison The statement also makes assumptions about the dosing regimens of sunitinib in the secondary trial that are not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "a5b66f28-1afc-4cf7-b686-d9de17496983": {
        "text_answer": "Yes  Explanation The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed by the evidence since the evidence reports 000 for both deaths and hospitalizations in cohort 2",
        "label": "Entailment"
    },
    "c914522f-a0a8-4154-b1ae-f3df4f684e35": {
        "text_answer": "Yes The primary trial does not specify an age range for inclusion so it does not exclude 18yearolds by default The secondary trial explicitly excludes them",
        "label": "Entailment"
    },
    "e7ca1067-1d50-4cb2-affc-2d859f9c20cf": {
        "text_answer": "No  The evidence states the inclusion criteria include a willingness to change diet but it does not state that patients must already have healthy eating habits",
        "label": "Contradiction"
    },
    "4185140f-e9a6-445f-b512-05428d88f966": {
        "text_answer": "No  Explanation  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed by the evidence provided The evidence only lists the number and percentage of adverse events for each trial but it does not specify the number or percentage of patients who experienced infections Therefore it is impossible to determine if over 15 of patients in both trials suffered from infections",
        "label": "Contradiction"
    },
    "cafc343b-d72e-4210-b145-42df1a42c28d": {
        "text_answer": "Yes  Explanation The total number of adverse events in the primary clinical trial was 5 and the number of patients in the patient group was 14 Therefore the percentage of patients affected by any particular adverse event type was 3571 which is less than 25 Thus the statement in the primary clinical trial not more than 25 of the patient group was affected by any particular adverse event type",
        "label": "Entailment"
    },
    "45240146-8a45-480e-a223-397089b029bb": {
        "text_answer": "No  Explanation  The statement 87 the primary trial participants and 201674 the secondary trial participants suffered an ae is not entailed by the evidence provided The evidence only states the number of participants in each trial who experienced various adverse events but it does not provide the number of participants who suffered any adverse event in total Therefore it is impossible to determine if 8 participants in the primary trial and",
        "label": "Contradiction"
    },
    "f80eceb9-5998-4a62-807b-b9ddff8cd350": {
        "text_answer": "Yes  Explanation  The statement all infections and fever cases in the primary clinical trial were for patients in cohort 2 is entailed by the evidence because all of the infections and fever cases mentioned in the evidence are from cohort 2 Therefore there are no infections or fever cases in cohort 1 based on the given evidence",
        "label": "Entailment"
    },
    "a7e702b9-3e27-47ed-bf09-3ce3c3f22b6e": {
        "text_answer": "No  Explanation  The evidence provided does not directly support the statement The evidence only gives the number of participants in each group and their recurrencefree survival rates but it does not provide the actual recurrencefree survival rates for each group Therefore it is not possible to calculate the difference in recurrencefree survival rates between the two groups based on the given evidence alone",
        "label": "Contradiction"
    },
    "e908994b-ee46-46a8-b478-5d1c45cf7047": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of platereader artifact in the provided evidence The evidence only reports the adverse events observed in the primary trial",
        "label": "Contradiction"
    },
    "9c076947-5e32-4a14-874b-e4b993f10756": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide the MTD value for the intervention in the secondary trial MM111 The evidence only states that the MTD for MM111 was determined using a different method than in the primary trial",
        "label": "Contradiction"
    },
    "df0874d1-340f-4e10-b7eb-275770f79f6f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a4f1de91-12c1-487c-911d-45099a83a658": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the evidence only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 and the statement includes ER negative progesterone negative and HER2 negative tumors which is a broader category",
        "label": "Contradiction"
    },
    "2a5d71a0-75c6-41d5-bf37-4916c578b0b3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial compares Botulinum Toxin Type A and Placebo while the secondary trial compares two different doses of MLN8237 alisertib The statement only mentions alisertib but the evidence provides information about different interventions in separate trials",
        "label": "Contradiction"
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "09cdd94c-145e-4a72-b281-1fad592fdcfd": {
        "text_answer": "No  The evidence does not support the statement as it indicates that there were no adverse events recorded in both trials for the given adverse events",
        "label": "Contradiction"
    },
    "8cf1ca78-50b9-4ab0-a673-3bb384092c0c": {
        "text_answer": "Yes  Explanation  The statement none of the patients in the primary clinical trial experienced more than 2 adverse events is entailed by the evidence because all the adverse events for each patient are listed and none of them have more than 2 adverse events",
        "label": "Entailment"
    },
    "5a1bdf90-fb17-47d2-8577-62fafbea13e4": {
        "text_answer": "No  The statement is about individuals diagnosed with colon cancer while the evidence is about individuals diagnosed with breast cancer",
        "label": "Contradiction"
    },
    "f9f9c153-d220-451e-a14d-f19ad7e80cc9": {
        "text_answer": "yes the statement is entailed by the evidence However its important to note that the statement only applies to the change in Ki67 expression after 4 weeks of treatment while the evidence provides the Ki67 expression at baseline and 6 weeks The reduction in Ki67 expression between 4 and 6 weeks is not explicitly stated in the evidence",
        "label": "Entailment"
    },
    "23a3ae35-9722-40e0-9f6c-c52d41bcd365": {
        "text_answer": "No  Explanation The statement no participant in cohort 1 was able to maintain a progression free survival longer than a month is not entailed by the evidence The evidence only provides the median progressionfree survival PFS for cohort 1 Capecitabine as 28 months 16 to 32 The statement implies that no participant in the cohort survived beyond a month",
        "label": "Contradiction"
    },
    "85a50c0e-0dcf-4bd9-ac4e-179bc6f99067": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "4ecc7382-526a-4bf5-9c17-92dc78446ea0": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial and the secondary clinical trial do not have any common inclusion or exclusion criteria is entailed by the evidence because the primary clinical trial and the secondary clinical trial have different inclusion and exclusion criteria The primary clinical trial has specific inclusion and exclusion criteria related to age cancer type treatment history life expectancy and other factors while the secondary clinical trial has inclusion criteria related to undergoing large core",
        "label": "Entailment"
    },
    "0aa16ecc-2e97-4210-9872-5a0566497343": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1a11d957-c721-4cee-b540-e3ab8eaad1d0": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the patients age 11520 weeks or 32 years is not mentioned in the inclusion criteria for either trial The age requirement for the primary trial is 18 years or older and for the secondary trial it is 1870 years inclusive Therefore the statement does not meet the age requirement for either trial",
        "label": "Contradiction"
    },
    "1c14ebb0-bff7-4691-8926-1c1b07b4da9a": {
        "text_answer": "No  Explanation  The statement somewhat more socially active as before is not directly related to the provided evidence The evidence only reports the number and types of adverse events in two clinical trials and it does not provide any information about the social activity level of the study participants Therefore the statement cannot be determined to be entailed or not by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "363631c1-e7d3-41e6-b928-09ce7251cb6e": {
        "text_answer": "No  Explanation  The statement anogenital distance decreased is an indication that the anogenital distance is less than the norm is not directly related to the evidence provided The evidence only mentions the number of adverse events including deaths and hospitalizations in two different cohorts of a primary trial It does not mention anything about anogenital distance or a decrease in anogenital distance Therefore the statement is not entailed by",
        "label": "Contradiction"
    },
    "907ae179-9823-4dba-9fb7-bb00027dbdf1": {
        "text_answer": "Yes The statement the majority of candidates involved in the primary clinical trial did not experience any eating disorders during the course of the study is entailed by the evidence as there is only one instance of anorexia reported out of 50 candidates",
        "label": "Entailment"
    },
    "55e1354d-d4b5-4bd0-92e7-9c461f2e2808": {
        "text_answer": "Yes The statement is entailed by the evidence as the inclusion criteria specify that candidates for the primary clinical trial must have a HER2 positive tumor",
        "label": "Entailment"
    },
    "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa": {
        "text_answer": "Yes the evidence does not explicitly state that the primary clinical trial is open for participation to AfricanAmerican patients but it does not exclude them based on race Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "944bcbb5-e85e-4115-bf71-face27208ab3": {
        "text_answer": "No  Explanation  The statement within the primary clinical trial no adverse events were indicated and for the secondary trial any adverse outcomes impacted less than 30 of the patients is not entailed by the evidence provided The evidence only states the number and percentage of adverse events for each trial but it does not specify that no adverse events were indicated in the primary trial or that less than 30 of patients",
        "label": "Contradiction"
    },
    "1100945c-51b9-4687-b518-d9b426239583": {
        "text_answer": "No  Explanation  The primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary clinical trial determines the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel based on the occurrence of doselimiting toxicities DLTs The outcome measures for the two trials are",
        "label": "Contradiction"
    },
    "ebdac536-2654-45d4-896f-98875186b971": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts use the same instructional CD for paced breathing The difference is in the frequency of practice once daily for cohort 1 and twice daily for cohort 2",
        "label": "Entailment"
    },
    "3a04553e-529b-4cff-81f5-38e8ec73dd6b": {
        "text_answer": "No  Explanation  The evidence provided in the text does not entail that the Bevacizumab cohort produced better results than the Bevacizumab  Capecitabine cohort The evidence only shows the percentage of participants with disease progression or death in each cohort during the maintenance phase of the trial It does not provide information on the efficacy or superiority of one treatment over the other",
        "label": "Contradiction"
    },
    "822bd855-46b1-4290-ac89-f3a92e96f523": {
        "text_answer": "No  Explanation  The evidence provided in the results does not indicate that every participant in cohort 1 Dose Level 1 encountered at least one serious adverse effect The statement 1000 in the first result refers to the total number of participants in that cohort not the number of participants who experienced a serious adverse event The evidence only states the number of participants in each cohort and does not",
        "label": "Contradiction"
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "text_answer": "No  Explanation  The statement the secondary trial has the same inclusionexclusion criteria for all participants whereas the primary trial has 2 sets of inclusion criteria for the different study groups is not entailed by the evidence provided The evidence only states that the primary trial has different inclusion criteria for different study groups but it does not mention that the secondary trial has the same inclusionexclusion criteria for all participants",
        "label": "Contradiction"
    },
    "f519491d-1f9b-4527-aaa3-902c2fb181b5": {
        "text_answer": "Yes  Explanation  The statement most participants in both the primary clinical trial and the secondary clinical trial experienced no adverse effects is entailed by the evidence because the sum of the adverse event percentages for both trials is less than 50 Specifically the primary trial had a total of 511 4545 adverse events and the secondary trial had a total of 132 31",
        "label": "Entailment"
    },
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "text_answer": "No  The statement Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial is not directly entailed by the evidence provided The evidence only lists the inclusion and exclusion criteria for each trial separately",
        "label": "Contradiction"
    },
    "dfc6cbf1-1aa5-4bed-ac39-bbd3a460518b": {
        "text_answer": "No  The statement is not entailed by the evidence The evidence only specifies eligibility criteria for females with ER breast cancer in Phase 2 of the clinical trial There is no mention of males in relation to ER breast cancer in the given evidence",
        "label": "Contradiction"
    },
    "3a8d24f2-6a67-4b23-99a9-5d9b0a54e9c6": {
        "text_answer": "No  Explanation  The statement patients experiencing a vitamin D insufficiency are not regarded fit for the primary clinical trial but might qualify for the secondary clinical trial is not directly entailed by the evidence provided  The primary clinical trial has specific inclusion and exclusion criteria related to vitamin D levels but the secondary clinical trial does not mention vitamin D levels as a criterion Therefore the statement goes beyond the information provided in",
        "label": "Contradiction"
    },
    "a1dec8bc-cd32-4f8b-b757-dfd19e8af073": {
        "text_answer": "No  Explanation  The statement does not directly follow from the evidence provided The evidence describes the interventions used in two separate trials but it does not mention the assessment of auditory brainstem response wave v presence",
        "label": "Contradiction"
    },
    "57a1a667-ac8e-49d3-95f5-26aca0d8bfa6": {
        "text_answer": "No  Explanation The statement does not directly address the primary trial or the interventions being compared It introduces the concept of radiation anemia which is not mentioned in the evidence The evidence only provides information about the interventions in the trial including the starting doses and permitted dose adjustments for sunitinib and paclitaxel",
        "label": "Contradiction"
    },
    "47e524f0-a370-4845-848a-89fb6b743c96": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial showed a higher incidence rate of palpitations pericardial effusions and abdominal pains than the primary clinical trial is not entailed by the evidence provided The evidence shows that there were no adverse events reported in the secondary clinical trial while in the primary clinical trial there was one reported case of palpitations one reported case of pericardial effusion",
        "label": "Contradiction"
    },
    "0204ab43-d10d-494c-a0be-3b16d96c34fc": {
        "text_answer": "No   Explanation  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 810 participants is not entailed by the evidence The evidence only reports the number of adverse events and the number of adverse events related to neutrophilsgranulocytes ANCAGC in each trial It does not provide any information about the percentage of participants",
        "label": "Contradiction"
    },
    "ba020c81-f851-45b9-b1d2-d319f7c97753": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7aa4c233-3630-4d28-bbd5-4c64fc730a2b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the number of participants in each arm who achieved a pathologic complete response in the breast and axillary lymph nodes after neoadjuvant chemotherapy It does not provide information about any patients with unresectable fibrolamellar carcinoma or whether the statement about more than 42 patients in both cohorts experiencing pathologic complete response after approximately 7",
        "label": "Contradiction"
    },
    "dc41de0b-7f1d-4294-8f3c-c0ba6d2fb4d9": {
        "text_answer": "No  Explanation  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is not directly related to the information provided about pseudomonas oryzihabitans The evidence only mentions the occurrence of adverse events AEs in the two trials but it does not compare the number of patients who experienced AEs between the two trials or provide any information about pseudomon",
        "label": "Contradiction"
    },
    "cda1ac5f-5721-4329-bf63-a73ca7247da5": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence for both trials as the patient does not meet the inclusion criteria for both trials   For the primary trial the patient does not meet the minimum absolute neutrophil count ANC requirement of 1800 cellsmm3   For the secondary trial the patient is below the minimum hemoglobin level requirement",
        "label": "Contradiction"
    },
    "07c11057-8ae2-4e40-a8d6-464e2399129e": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial 5 of the patients faced three or more adverse events is not directly entailed by the evidence provided The evidence only lists the number of patients who experienced each type of adverse event but it does not specify which patients experienced multiple adverse events Therefore based on the given evidence it is not possible to determine if five patients experienced three or more adverse events",
        "label": "Contradiction"
    },
    "76ba0bfa-8fd2-45ab-818b-0216aa5d423f": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial and the secondary clinical trial no patients faced fewer than 3 diverse adverse events is entailed by the evidence because in both trials every patient experienced at least 3 different adverse events Therefore no patient had fewer than 3 diverse adverse events",
        "label": "Entailment"
    },
    "0f4d6e4c-9315-4cbe-a322-37c6457cf49d": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial intervention 1 is provided intravenously whereas in the secondary clinical trial the intervention drugs can all be taken orally is entailed by the evidence because  In the primary clinical trial Intervention 1 Zoledronic Acid is given intravenously as stated in the trial description  In the secondary clinical trial Intervention 1 granis",
        "label": "Entailment"
    },
    "4499b316-ac50-4534-a223-2adb144ec7f5": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the woman in question does not meet the inclusion criteria for either trial In the primary trial she does not have histologically confirmed HER2negative breast cancer with disease progression during or following firstline treatment In the secondary trial she is not a female patient with newly diagnosed ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "bf1cfc9e-1932-4b3f-b935-c71fb36e6716": {
        "text_answer": "Yes  Explanation The statement multiple instances of anaemia and febrile neutropenia were registered in cohort 1 is entailed by the evidence as there is one instance of anaemia and one instance of febrile neutropenia reported in cohort 1 The statement also implies the presence of more than one instance which is satisfied by the evidence Additionally the statement mentions multiple instances of",
        "label": "Entailment"
    },
    "3a1fe062-8a0f-48cb-8830-7624b5445778": {
        "text_answer": "No  Explanation  The statement movement of swollen area is painful is not directly related to the adverse event Stomatitis recorded in the primary trial Stomatitis is an inflammation of the mucous membranes in the mouth and it does not necessarily involve swelling or pain in the area of movement Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "19c38d71-5e6c-4944-9337-04d715487a2f": {
        "text_answer": "No  Explanation  The statement the primary clinical trial and the secondary clinical trial have an equivalent amount and type of adverse events is not entailed by the evidence The evidence shows that the primary trial had no adverse events for certain types while the secondary trial had some adverse events for those same types Therefore the statement is not true based on the given evidence",
        "label": "Contradiction"
    },
    "b24a539a-af29-4a1a-905d-86203ca8c9d4": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary and secondary trials involve different interventions The primary trial compares Fulvestrant  Anastrozole to Anastrozole alone while the secondary trial investigates the use of HER2targeted PETCT in patients with HER2positive breast cancer There is no mention of Perjeta in the primary trial and the secondary trial mentions",
        "label": "Contradiction"
    },
    "c6a580f1-9ec3-4d4b-9a34-d12f7d446f61": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention section of the primary clinical trial does not mention the treatment cycle",
        "label": "Entailment"
    },
    "f4632d0c-6ea3-4638-a2f3-ad5103e28229": {
        "text_answer": "Yes The primary trial and the secondary trial test different interventions eribulin mesylate vs axitinib  docetaxel or docetaxel  placebo",
        "label": "Entailment"
    },
    "8da24578-8dc7-42e5-821a-90f3e361cfdd": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial specifically excludes women with stage IV disease while the secondary trial includes women with newly diagnosed or recurrent breast cancer but not stage IV disease",
        "label": "Contradiction"
    },
    "a0ed6cf5-dd1f-4170-ae33-3c1972b62530": {
        "text_answer": "No  Explanation  The primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary clinical trial measures the Ruxolitinib Maximum Tolerated Dose MTD in units of mg Therefore the units of measurement are not the same in both trials",
        "label": "Contradiction"
    },
    "cb6db7a0-1eab-4ac8-9d3c-9b0bf4e123f2": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as it incorrectly compares two different interventions from two separate clinical trials The statement describes the intervention in the secondary trial as a prescription of medications while the evidence describes it as a Phase 1b study with specific doses of ibrutinib and MEDI4736 The primary trials intervention is radioembolization using Yttrium",
        "label": "Contradiction"
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "text_answer": "No   Explanation  The evidence states that Intervention 1 uses a validated webbased risk assessment and generates a risk report for providers but it does not mention anything about counselling or CBT being provided to the participants Therefore the statement that Neither cohort of the primary trial receives any counselling risk assessment or CBT in the interventions is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "text_answer": "Yes The evidence states that patients with documented allergies to cephalosporin or trimethoprimsulfamethoxazole are excluded from the secondary trial and patients with documented allergies to levofloxacin are excluded from the primary trial",
        "label": "Entailment"
    },
    "7d922494-f6d6-4ade-9614-7111562617f3": {
        "text_answer": "yes for the secondary trial with the specified alcohol consumption limit but not for the primary trial as per its exclusion criteria",
        "label": "Entailment"
    },
    "86e5ab20-18bb-408b-9c3d-92eee2f487d0": {
        "text_answer": "  Partially   Explanation   The statement is partially entailed by the evidence as it is true that the control group in the primary clinical trial had a shorter operative time than the test group However the statement does not address the secondary clinical trial and its lack of a control group",
        "label": "Entailment"
    },
    "808a6511-c76d-497c-ad73-037aa5619317": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3cc54fbb-86c4-44f1-b623-0a613adbc7e8": {
        "text_answer": "No  Explanation The primary trial does not require a diagnosis of multiple brain metastases for admission but rather limits the number of lesions to one to three The secondary trial on the other hand does not mention anything about the number of brain metastases Therefore the statement that having multiple cerebral metastases is necessary for admission to the secondary trial but leads to exclusion in the primary trial is not entailed by the evidence",
        "label": "Contradiction"
    },
    "54986ebe-5830-4e3b-9ac1-28241d07e1c8": {
        "text_answer": "  No the statement is not directly entailed by the evidence as the evidence does not mention anything about virologic response or pulmonary embolisms in relation to the trials However the evidence does list certain medical conditions as exclusion criteria for the primary trial such as a history of clotting disorders and recent initiation of CDPT or maintenance physiotherapy for lymphedema which could potentially be related to the risk of pulmonary embolisms",
        "label": "Contradiction"
    },
    "34f9be61-9ee8-475e-9b02-72938355d6a5": {
        "text_answer": "No  Explanation  The statement acute contagious conjunctivitis is acute inflammation of the conjunctiva characterized by pink or red color in the eyes is not directly related to the evidence provided The evidence only mentions the interventions used in the primary and secondary trials and does not mention anything about conjunctivitis or its symptoms",
        "label": "Contradiction"
    },
    "58f42b4f-c8f1-4471-a44b-35ac49604a3b": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial provides a duration in days until disease progression for 156 patients across both cohorts whereas the secondary clinical trial shows the proportion of patients experiencing objective response is entailed by the evidence provided  The primary clinical trial reports the median time to progression TTP in months for both Arm A Cint and Arm B Ccont with a total of 1",
        "label": "Entailment"
    },
    "36cc43dd-5761-49ef-bd9d-35e54dd5a97b": {
        "text_answer": "Yes The statement is a more specific version of the exclusion criteria mentioned in the evidence The statement specifies that patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 104 weeks before study entry are excluded from the primary trial This is consistent with the exclusion criteria in the evidence which states that any of these therapies within the last 4 weeks are not allowed",
        "label": "Entailment"
    },
    "ea28dc26-75b9-4107-8862-226a46923254": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no information in the evidence that group 2 of the primary trial receives 15ugkg of dexmedetomidine 15ml The evidence only states that group 2 of the primary trial receives dexmedetomidine but the dosage is not specified Additionally the patients in the secondary trial do not receive any dex",
        "label": "Contradiction"
    },
    "9b753f6f-9d5d-464a-bc35-c1c0d796fe4d": {
        "text_answer": "Yes  Explanation  Both the primary and secondary trials report their findings using proportions or means with their respective standard deviations Therefore the units of measurement are the same in both trials",
        "label": "Entailment"
    },
    "4e410d4c-7da8-46ce-b335-678bb3199fbc": {
        "text_answer": "No  Explanation The evidence states that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab This means that WOCBP are allowed to participate in the trial but they must take precautions to prevent pregnancy The statement that only individuals who possess permanent infertility are able to join in the primary clinical",
        "label": "Contradiction"
    },
    "3873ed0e-ceb1-45dc-8efc-690a55d908e6": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial is open for women aged 18 or 19 but to be considered for the primary clinical trial they would need to wait 12 years is not entailed by the evidence provided The evidence only states the inclusion and exclusion criteria for both the primary and secondary clinical trials It does not mention anything about the age requirement or waiting period for the primary clinical trial",
        "label": "Contradiction"
    },
    "60c313e4-a3f2-4c9d-bef0-104c387a50f5": {
        "text_answer": "Yes  Explanation The evidence provided in the trial results shows that the mean number of hot flashes per day for the paced respiration group was lower 348 compared to the fast shallow breathing group 395 This difference indicates that the paced respiration intervention was associated with fewer hot flashes on average supporting the statement that the paced respiration intervention group experienced fewer hot flashes per day than patients in the fast",
        "label": "Entailment"
    },
    "226a30c1-78f8-4747-adb7-1e99973487c1": {
        "text_answer": "No  Explanation  The statement the medicament under test is mutually the same in the primary and secondary clinical trials is not entailed by the evidence In the primary trial the treatment is eribulin mesylate given intravenously while in the secondary trial the treatments are axitinib and docetaxel given orally and intravenously respectively Therefore the medicaments under test are not the same in both trials",
        "label": "Contradiction"
    },
    "efa3cd46-9230-4078-b024-6de0386bfe80": {
        "text_answer": "No  The statement is not entailed by the evidence as there are no adverse events in common between the two trials",
        "label": "Contradiction"
    },
    "7006bd11-9655-4d3e-84a1-6a949fd921e2": {
        "text_answer": "Yes  Explanation  The statement the majority of individuals in the primary and secondary clinical trials did not have any negative reactions is entailed by the evidence because the percentage of individuals with no adverse events is higher than the percentage of individuals with any adverse event in both trials In the primary trial 5545 of individuals had no adverse events and in the secondary trial 8437 of individuals had no",
        "label": "Entailment"
    },
    "4189cb5a-bff9-4867-b9d7-1bd7791723f3": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial and the secondary clinical trial adverse events were not recorded in more than 10 of participants is entailed by the evidence since the adverse events were recorded in less than 1 of participants in both trials Therefore the statement that less than 10 of participants experienced adverse events is a stronger statement than the evidence but it is still entailed by it",
        "label": "Entailment"
    },
    "dd153492-5c53-4b8e-b860-71aaba62fa14": {
        "text_answer": "Yes The evidence states that the primary clinical trials intervention is MM111 which is a pharmacological approach",
        "label": "Entailment"
    },
    "31c480e3-b528-4810-855e-498a019ba253": {
        "text_answer": "Yes  Explanation  The statement Both cohorts of the primary trial receive the same dosage of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial at the same frequency is true according to the evidence The only difference between the two interventions is the addition of Herceptin in Intervention 2 which does not affect the dosage or frequency of Docetaxel Doxorub",
        "label": "Entailment"
    },
    "d33d29d8-6d96-4f24-af22-2e86e73485d8": {
        "text_answer": "No  The evidence does not provide information about dyspnea in the participants of the primary clinical trial",
        "label": "Contradiction"
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "text_answer": "Yes The evidence states that there are 1530 enrollment slots for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Entailment"
    },
    "bf170f0a-6640-4b5c-a130-ae405afb15a7": {
        "text_answer": "  I cannot definitively answer with just one word based on the given evidence as the evidence only provides ORR data for each group but does not directly compare the two groups However based on the ORR values provided the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher proportion of responders 0587 compared to the Paclitaxel Plus Bevacizumab group 0489",
        "label": "Entailment"
    },
    "bec6f047-5652-4c1a-8aec-8ba989cf4aa4": {
        "text_answer": "No  Explanation The statement only individuals with early stage cancer can participate in the secondary clinical trial but are ineligible for the primary clinical trial is not entailed by the evidence provided The primary clinical trial includes individuals with stage IIbIIIIV breast cancer while the secondary clinical trial includes individuals with a diagnosis of breast cancer a life expectancy of at least 1 year and a mass on clinical or radiological examination of 1 cm",
        "label": "Contradiction"
    },
    "8734ab6c-5b2b-4d9f-958b-9b4f8249a6ef": {
        "text_answer": " No  Explanation The evidence provided in the trial results does not directly relate to the primary tumor diameter but rather to the percentage change in serum betaCTX levels from baseline to week 4 The statement in question makes a claim about a higher decrease in primary tumor diameter which is not supported by the evidence presented",
        "label": "Contradiction"
    },
    "38791cb5-fc64-49a6-8db8-69da6c37f327": {
        "text_answer": "No   The statement is not entailed by the evidence as the primary trial does not report the severity of delayed nausea and the secondary trial does not mention anything about an oxygen analyzer device",
        "label": "Contradiction"
    },
    "f2fea6be-a072-4a75-8092-09acdd07d135": {
        "text_answer": "Yes  Explanation The evidence states that in the primary clinical trial the ErC and TC cohorts receive different interventions but it also specifies the exact doses of cyclophosphamide eribulin and docetaxel for each intervention The statement in question asserts that both cohorts receive equal doses of these drugs which is consistent with the evidence",
        "label": "Entailment"
    },
    "47f5a5c6-964c-40f8-b7b0-2278333f8fe9": {
        "text_answer": "Yes Metastatic nonsmall cell lung cancer is one of the eligible tumor types for the clinical trial",
        "label": "Entailment"
    },
    "53cf056f-91e1-45fb-a65d-7dff9a4b9bac": {
        "text_answer": "No  Explanation  The statement arm 1 of the primary trial indicated a higher operative time than arm 2 hence the test group outperformed over the control group is not entailed by the evidence provided The evidence only shows that the operative times for intraoperative mammography and standard mammography differ but it does not directly compare the performance of the two groups in terms of outperforming each other The statement also",
        "label": "Contradiction"
    },
    "c1f0b925-6d1f-48ba-ada3-296bd69573f8": {
        "text_answer": "Yes  Explanation The statement intervention one uses higher doses of radioactive Tc99M sulfur colloid than intervention two is entailed by the evidence as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid but the primary trial mentions that intervention 1 uses a prototype handheld gamma camera pIHGC",
        "label": "Entailment"
    },
    "4eac1391-d7b7-4124-bafb-fa88bc4d8a02": {
        "text_answer": "Yes The primary trial includes only female patients while the secondary trial does not specify gender as a criterion for eligibility",
        "label": "Entailment"
    },
    "11a4324a-684e-4c85-a570-38e6f24ca92b": {
        "text_answer": "Yes The evidence shows that there were a total of 86 participants across both groups who achieved a pathologic complete response in breast and axillary lymph nodes approximately 7 months after their surgical procedures",
        "label": "Entailment"
    },
    "41cc607f-05e2-4377-bca4-328906e47116": {
        "text_answer": "No  The evidence does not provide information on the total number of participants in the trials",
        "label": "Contradiction"
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a CR or a PR This means that over half of the patients more than 50 in this arm did experience a confirmed response according to the OR definition",
        "label": "Entailment"
    },
    "82d0df12-0e0b-4721-b54f-ecb6bccdc8c3": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial includes various types of cancer not just BRCA breast cancer",
        "label": "Contradiction"
    },
    "342026c4-e3de-48c7-8688-e214f5ece431": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence does not provide information on the treatment regimen or radiation dosages in the intervention segment of the primary clinical trial",
        "label": "Entailment"
    },
    "0a9675e4-c6cf-44a9-98ed-e50aadfe064a": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "46959de4-38f3-42a8-adf9-c7565c66b442": {
        "text_answer": "No  Explanation  The statement informed consent will allow patients who are in stage 4 of cancer to be eligible for the secondary clinical trial as well as the primary clinical trial is not entailed by the evidence provided  The evidence only specifies the inclusion and exclusion criteria for both the primary and secondary clinical trials It does not mention anything about the stage of cancer being a factor in eligibility for informed consent In fact the evidence",
        "label": "Contradiction"
    },
    "0613b4cb-1e87-48b0-8617-338ebb9ccbe8": {
        "text_answer": "No  The statement is not entailed by the evidence The evidence provided does not mention any device named terminator in either trial",
        "label": "Contradiction"
    },
    "8078bf53-15fe-414d-837f-abe03ab9e56d": {
        "text_answer": "Yes The evidence does not explicitly state that only patients with a healthy BMI are eligible for the trials but it does not exclude patients based on their BMI Therefore patients with a healthy weight according to BMI standards can be eligible for both trials",
        "label": "Entailment"
    },
    "6d01a773-922b-483a-94b1-f3bda6f2e498": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not directly support the statement about the percentage change in primary tumor diameter between the two groups Instead the evidence only reports the percentage change in betaCTX a biochemical marker of bone turnover at Week 4 for each group The statement concerns the primary tumor diameter which is a different outcome measure",
        "label": "Contradiction"
    },
    "fed9960d-b051-4948-840c-91d09c01aafc": {
        "text_answer": "No  The statement a patient with a leptomeningeal carcinoma diagnosis would be excluded from the primary clinical trial is not entailed by the evidence provided The evidence states that patients with brain metastases are excluded but it does not mention leptomeningeal carcinoma specifically",
        "label": "Contradiction"
    },
    "b39c5d0f-5813-421d-84cf-d78e3c1d3424": {
        "text_answer": "No  Explanation  The statement the majority of participants in the first cohort of the primary clinical trial experienced adverse events while the situation is reversed in the second cohort is not entailed by the evidence The evidence only provides the number and percentage of adverse events for each cohort but it does not indicate that the majority of participants in the first cohort experienced adverse events or that the situation is reversed in",
        "label": "Contradiction"
    },
    "5572d454-871c-4458-a2d9-97e7cbb0e03a": {
        "text_answer": "Yes for the Primary Trial only The Primary Trial requires mammography as a prerequisite for participation The Secondary Trial does not mention mammography as a requirement",
        "label": "Entailment"
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "text_answer": "yes but it is not a complete answer as the statement only mentions the length of treatment not the intervention itself The statement is partially entailed by the evidence",
        "label": "Entailment"
    },
    "d2e30364-0f79-46c7-8faa-7d7f6751c662": {
        "text_answer": "Yes The primary trial includes both male and female subjects while the secondary trial only includes females",
        "label": "Entailment"
    },
    "0cecf602-ca3a-4fc4-a52a-135425f42911": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 5 adverse events experienced by 25 patients which means that at least one patient experienced more than one adverse event",
        "label": "Entailment"
    },
    "6786fa28-09b7-4bf3-8202-7e810755247e": {
        "text_answer": "Yes  Explanation  The statement there were no recorded gastrointestinal adverse events in the primary clinical trial is entailed by the evidence because the evidence does not report any cases of nausea vomiting or colitis ischaemic in either of the two sets of adverse events Therefore the statement is a logical consequence of the evidence",
        "label": "Entailment"
    },
    "e244bd1b-7ded-4cc5-a1f2-8afd358338b1": {
        "text_answer": "No  Explanation  The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is not directly related to the given evidence The evidence only provides the number and types of adverse events in each cohort but it does not compare the total number of adverse events between the two cohorts Therefore the statement is not entailed by the evidence  Further",
        "label": "Contradiction"
    },
    "c828ba65-0c7b-4aac-b0a7-35ca653b6e82": {
        "text_answer": "Yes The primary trial reports the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports the MTD of an intervention called MM111 The statement specifies that the MTD of MM111 is 50 mg per day The evidence does not directly compare the MTDs of the two interventions but it is entailed by the evidence that each trial reports the MTD of a different",
        "label": "Entailment"
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "text_answer": "Yes The evidence does not report any cases of Hypertension Dehydration or Dyspnea in either cohort",
        "label": "Entailment"
    },
    "eebccf7b-8edc-4b99-8355-e936754c1282": {
        "text_answer": "yes both trials include the criterion of age 18 or older for inclusion",
        "label": "Entailment"
    },
    "d579bc9e-ccff-48a6-a296-2d9e8021c765": {
        "text_answer": "No   The statement is about Slovenia being a country in Central Europe while the evidence is about adverse events in a primary trial There is no direct connection between the two",
        "label": "Contradiction"
    },
    "3d6e2ffb-5a89-4f31-9596-65f90e950c5e": {
        "text_answer": "Yes  Explanation The statement a single instance of shingles was documented in group 2 of the secondary clinical trial yet no incidents were reported within the primary clinical trial or group 1 of the secondary trial is entailed by the evidence as the evidence shows that there was 1 instance of shingles in group 2 of the secondary trial but no instances were reported in the primary trial or group 1 of the secondary trial",
        "label": "Entailment"
    },
    "a38f54f6-d3cb-46aa-b298-cee296e21b3f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence provides the range of doses administered to participants in each group but it does not specify that the average or typical dose was 1 mgday for breast cancer patients and 0025 mgday for ovarianperitoneal cancer patients",
        "label": "Contradiction"
    },
    "c67874fc-c736-4da3-bc73-1e40cbf323c0": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about the percentage of patients who did not experience any adverse events The text only mentions the percentage of patients who were analyzed in the trial and the treatment regimens they received",
        "label": "Contradiction"
    },
    "14afd2b1-9ac2-45fd-96f7-b65862c818a5": {
        "text_answer": "No  Explanation  The statement mme positive is an indication that mme expression has been detected in a sample is not directly related to the information provided in the evidence The evidence only mentions the details of two interventions from two separate trials without any mention of MME or its positive expression Therefore it is not possible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "58c19654-e4cf-4c18-99ef-18b024996fcb": {
        "text_answer": "Yes The primary trial evaluates the toxicity of the treatment regimen using the NCI CTCAE v30 scale which includes the assessment of adverse events The secondary trial reports the percentage of participants with adverse events of primary interest which are specific types of adverse events",
        "label": "Entailment"
    },
    "e954d7ec-9ad9-4b01-9ae4-55e29fcbf7f4": {
        "text_answer": "Yes  Explanation The statement there was a single psychiatric adverse incident in the primary clinical trial impacting less than 10 of the patients is entailed by the evidence as the evidence reports one instance of suicidal ideation a psychiatric adverse event and the total number of adverse events was 6 out of 50 patients which is less than 10",
        "label": "Entailment"
    },
    "57d8844c-d168-41c0-ad0c-6030e4c65905": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 Subtracting the Ki67 expression at 6 weeks from the Ki67 expression at baseline gives a difference of 5 percentage points Therefore the statement over 42 days of TAK228",
        "label": "Entailment"
    },
    "b94ebfcb-76f4-4d65-b5e1-ca56249f9f19": {
        "text_answer": "No  Explanation  The statement more than half of the patients in the second group experienced severe nausea following the therapy involving aprepitant dexamethasone cytoxan and kytril is not directly entailed by the evidence provided The evidence only states the number of participants in the second group ArmGroup Title Aprepitant Dexamethasone Cytoxan ",
        "label": "Contradiction"
    },
    "4dcada11-d2e0-453f-aed3-66446ebb4133": {
        "text_answer": "No  Explanation  The statement a single cohort within the primary clinical trial is provided with armodafinil po daily is not directly entailed by the evidence The evidence only states that in the primary trial one intervention includes armodafinil po daily for 47 days but it does not specify that a single cohort receives this intervention  Furthermore the statement ",
        "label": "Contradiction"
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "text_answer": "Yes  Explanation The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is entailed by the evidence as the frequency of these adverse events is higher in the secondary trial The statement but more cases of FEBRILE INFECTIONs were recorded in the primary trial is also entailed by the evidence as the number of febrile infection cases is higher in the",
        "label": "Entailment"
    },
    "429ac312-4d91-4068-9fc3-8bd7b24bc21f": {
        "text_answer": "No  Explanation  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is not entailed by the evidence provided The evidence only mentions that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial It does not mention anything about severe anaph",
        "label": "Contradiction"
    },
    "cae6d7c6-1e27-4c94-9428-997ece9e651a": {
        "text_answer": "No  Explanation  The statement the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort is not entailed by the evidence provided The evidence only shows the percentage of participants with Disease Progression or Death in each cohort but it does not directly compare the incidence between the two groups The",
        "label": "Contradiction"
    },
    "c0c1a75a-a859-477d-bc80-3aac565c6a5b": {
        "text_answer": "No  The statement is not entailed by the evidence as there were no cases of acute myocardial infarction reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "text_answer": "Yes  Explanation  The statement There were no cardiac or psychiatric AEs recorded during the primary trial and the secondary trial is entailed by the evidence since the evidence reports that there were no cardiac or psychiatric adverse events recorded in both trials for both Adverse Event types 1 and 2",
        "label": "Entailment"
    },
    "8ca66388-46d0-4a5f-9be8-84d35961c823": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement is about participants with PR Primary Breast Cancer while the evidence is about participants with HER2 Primary Breast Cancer Additionally the statement mentions a nonneoplastic reproductive system disorder which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "3e0a4b38-bafb-4a0e-a1be-8506f23aa1f6": {
        "text_answer": "Yes  Explanation The statement compared to the secondary clinical trial the primary trial shows a decreased percentage of patients reporting palpitations pericardial effusions and abdominal pains is entailed by the evidence as the primary trial has a lower percentage of patients reporting palpitations 094 vs 000 pericardial effusions 189 vs 000",
        "label": "Entailment"
    },
    "b068596b-94a7-42fe-a926-d1c3c62ea26b": {
        "text_answer": "Yes  Explanation  The statement the outcome measurements for the primary clinical trial and the secondary clinical trial are entirely distinct is entailed by the evidence because the outcome measurements for the percentage of participants with treatmentemergent adverse events in the primary trial and the number of participants with objective response in the secondary trial are different The primary trial measures the incidence of adverse events while the secondary trial measures the number of participants with objective response",
        "label": "Entailment"
    },
    "5e14d0f3-e63e-40e8-93cc-a07c90c226d6": {
        "text_answer": "No  The statement about diffuse laminar endocervical hyperplasia is not mentioned in the evidence provided for either the primary or secondary trials The evidence only provides the inclusion and exclusion criteria for patients in the clinical trials",
        "label": "Contradiction"
    },
    "8dac6b6a-0e3d-4a3c-ac59-5096452207de": {
        "text_answer": "Yes The statement mentions the percentage of participants with HER2 Primary Breast Cancer who developed imagable HER2 metastases after HER2targeted PETCT using 89Zrtrastuzumab The evidence also mentions the percentage of participants 13 who developed imagable HER2 metastases Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "f6ce8f5f-f226-4435-9209-9bf54ac7cbaa": {
        "text_answer": "No  Explanation  The statement a 7week duration of tak228 plus tamoxifen treatment in the primary clinical trial was linked to an increase in the percentage of cells with ki67 expression is not directly entailed by the evidence provided The evidence only states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was ",
        "label": "Contradiction"
    },
    "2e35f870-1118-4c57-be71-a1b17e6841e3": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is not entailed by the evidence provided The evidence only reports the occurrence of adverse events in each trial but it does not state that the specific adverse events are the same or different between the trials The statement makes a stronger claim than what is supported by the evidence",
        "label": "Contradiction"
    },
    "6e02fc64-787b-47e7-a9d6-173b101baf71": {
        "text_answer": "No  Explanation  The primary clinical trials exclusion criteria do not mention anything about a patient having had an organ transplant in the past month and being bedridden However the secondary clinical trials exclusion criteria do not include this specific condition as a criterion either Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1692f569-44d0-4b60-aabe-87dc3f7d3513": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trials intervention 1 includes a higher weekly dose of MM121 20 mgkg and Paclitaxel 80 mgkg compared to the secondary trials cohort 1 intervention 1 MM121 20 mgkg weekly Paclitaxel 80 mgkg weekly",
        "label": "Entailment"
    },
    "3c2994b1-74be-4fe4-9262-00a5a8e42caa": {
        "text_answer": "No  Explanation  The statement the patient with the shortest PFS in the primary clinical trial came from cohort 1 and experienced disease progression within a week is not directly entailed by the evidence provided The evidence only reports the median PFS for each treatment group and does not provide any information about individual patient outcomes or the shortest PFS observed in the trial",
        "label": "Contradiction"
    },
    "83457ad0-4ebe-4bd7-abf7-bf629af15e58": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "40d65677-e7f3-46f8-801a-327c8422937b": {
        "text_answer": "No  Explanation The statement psychiatric adverse events affected over half of the patients is not entailed by the evidence provided The evidence only mentions one psychiatric adverse event suicidal ideation out of a total of 7 adverse events and it affected 200 of the patients Therefore psychiatric adverse events did not affect over half of the patients based on the given evidence",
        "label": "Contradiction"
    },
    "6e1c74e3-1b7b-41bf-8ee4-f605d94c0fdf": {
        "text_answer": "No  Explanation  The statement the secondary trial has higher incidents of biliary colic and clostridium difficile colitis compared to the primary trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events in each trial but it does not provide enough information to make a direct comparison between the two trials regarding specific adverse events Additionally the statement is not supported by the evidence as it only",
        "label": "Contradiction"
    },
    "0a0778f4-c085-45fe-a085-e079256d634b": {
        "text_answer": "No   Explanation  The evidence provided states that there were no adverse events recorded in both the primary and secondary trials Therefore the statement that the primary clinical trial recorded multiple adverse events is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ea01b3dd-11a6-4e00-aada-a31c2fc4a5dc": {
        "text_answer": "Yes  Explanation The statement the intervention section of the primary clinical trial clearly outlines the method of administration dosage and cycle is entailed by the evidence INTERVENTION 1 MM111 All participants because the intervention section of a clinical trial is where the method of administration dosage and cycle for the intervention are typically specified In this case the evidence indicates that the intervention is MM11",
        "label": "Entailment"
    },
    "40818dd2-4940-4543-905a-35a3295b3009": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it makes an incorrect comparison between the doses administered to cohorts 1 and 2 in the trial The correct comparison would be that cohort 2 received 0025 mgkg more ALT801 than cohort 1 not 0035 mg less as stated in the question The statement also includes an unrelated",
        "label": "Contradiction"
    },
    "a62e526a-07c6-472a-acff-891375dd7fb0": {
        "text_answer": "1 No for the secondary trial comparison The secondary trial does not provide sufficient information to make a comparison between the two groups regarding operative time or effectiveness",
        "label": "Contradiction"
    },
    "03fe8107-b0ab-470e-9d1e-a085808ec397": {
        "text_answer": "Yes with the caveat that the evidence only directly measures cognitive function at baseline and 1 year postrandomization and does not provide information about cognitive function stability throughout the entire trial duration for all participants",
        "label": "Entailment"
    },
    "8953caa7-492f-4fbb-b5a6-5cff95a5650c": {
        "text_answer": "No  Explanation  The statement rising from floor functional test question is a question associated with the rising from floor functional test is not directly related to the evidence provided The evidence only discusses the details of a clinical trial investigating the maximum tolerated doses MTD and doselimiting toxicities DLT of LBH589 in combination with capecitabine or lapatinib for patients with refractory",
        "label": "Contradiction"
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "text_answer": "  No   Explanation   The evidence provided does not indicate that any participant in cohort 1 suffered a lifethreatening adverse event The evidence only reports the number of participants with serious and nonserious adverse events but it does not specify the nature or severity of those events The statement that 1000 of cohort 1 of the primary trial suffered at least 1 life",
        "label": "Contradiction"
    },
    "05990a1c-be55-4aa4-8e72-970d95776c8a": {
        "text_answer": "No  Explanation The statement the percentage of cells with ki67 expression in patients participating in the primary clinical trial was found to have remained the same is not entailed by the evidence The evidence only reports a decrease in Ki67 expression from a median of 15 1025 at baseline to a median of 10 238 at 6 weeks in the TAK228 plus Tam",
        "label": "Contradiction"
    },
    "b0eb1f5f-d996-4846-9b4e-12dd88120752": {
        "text_answer": "Yes  Explanation  The statement All AE types in the primary trial affected less than 10 of patients is directly stated in the evidence as Total 411 3636 Therefore it is entailed by the evidence  The statement adult type ovarian granulosa cell tumor is a granulosa cell tumor that affects middle aged or postmenopausal women",
        "label": "Entailment"
    },
    "37c579a2-134b-4ee4-8a9e-e550c2155a16": {
        "text_answer": "Yes  Explanation The statement 3 or more adverse events occurred in 5 patients participating in the primary clinical trial is entailed by the evidence since there are 5 patients with a total of 3 or more adverse events each",
        "label": "Entailment"
    },
    "7bbbfeb0-c4f2-4295-ae6c-3adbf6dc06ad": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "text_answer": "Yes The evidence does not specify any mental health bodyweight tumor size KarnofskyECOG score or estimated life expectancy conditions for trial eligibility",
        "label": "Entailment"
    },
    "3f5f182d-77ba-423c-8f5b-02ca3ada57c2": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial adverse events like recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were reported more often than in the secondary clinical trial is entailed by the evidence provided The evidence shows that the primary clinical trial had a higher percentage of adverse events 6000 compared to the secondary clinical",
        "label": "Entailment"
    },
    "bb12ebcd-127e-4834-b0f3-9759ed13c5ed": {
        "text_answer": "Yes The primary trial measures changes in pain intensity shifts while the secondary trial measures changes in bone mineral density fluctuations",
        "label": "Entailment"
    },
    "35aa67ad-b884-4cec-afdf-bef9cb6619c4": {
        "text_answer": "No   Explanation  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not entailed by the evidence The evidence describes several injections and treatments that patients will receive at different times during the study but it does not mention a single injection on day 8 The statement also does not mention the content of the injection or its relation to the other treatments",
        "label": "Contradiction"
    },
    "6c41e8b2-2878-44b1-bf2d-6158d8f20dda": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it makes additional assumptions beyond what is stated in the evidence The evidence only mentions the dosage and frequency of CUDC101 for cohorts 1 and 2 but it does not mention anything about PD0332991 or its administration schedule Therefore it is not possible to determine if the statement about the similarities between the two",
        "label": "Contradiction"
    },
    "1938e58d-a90f-48c4-ac79-59da3de8017c": {
        "text_answer": "Yes  Explanation The statement well differentiated neuroendocrine lesion is a neoplastic lesion with neuroendocrine differentiation and well differentiated histological features is not directly mentioned in the evidence However the evidence does not contradict the statement and there are parts of the evidence where patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial Therefore",
        "label": "Entailment"
    },
    "f73b494f-624c-487a-b502-f2cbc7ab0475": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the statement makes an assumption about the reason for the different interventions in the primary and secondary trials but the evidence does not provide enough information to support that assumption The evidence only states that the interventions are different but it does not specify why Therefore it is not possible to determine if the statement is true or false based on the given evidence alone",
        "label": "Contradiction"
    },
    "97d3ebc2-fda1-4b0b-b7b2-583edca5be69": {
        "text_answer": "Yes  Explanation The evidence states that most participants reported a significant reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is a confirmation of the statement",
        "label": "Entailment"
    },
    "31d67714-a5c1-494f-820e-d47f52480eaf": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement is about electroencephalography cap and there is no mention of it in the evidence The evidence only provides information about adverse events in the primary trial",
        "label": "Contradiction"
    },
    "98b0e244-cb54-4d99-9384-b7e5e7d43550": {
        "text_answer": "No  Explanation  The statement there were no placebo groups involved in the primary trial is not entailed by the evidence While it is true that there was no placebo group in the primary trial for the comparison of pyridoxine and placebo the evidence does not state that there were no placebo groups involved in the entire study The secondary trial does involve a placebo group for the comparison of highdose and lowdose",
        "label": "Contradiction"
    },
    "f024fdc1-bee8-4ad8-a80d-9369d52b799a": {
        "text_answer": "No  Explanation The evidence provided only reports the change in total body lean mass for two different doses of GTx024 1 mg and 3 mg over a 4month period It does not provide information about the change in lean body mass for patients treated with a 100mg dose over a 9month period Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9ee19b4a-bcdb-4676-b852-ee3fbb4352b0": {
        "text_answer": "No  Explanation The statement the primary clinical trials interventions consist of only a single medication which is administered through different routes is not entailed by the evidence The evidence only states that there are two interventions in the primary clinical trial one using intravenous bisphosphonate Q4W and the other using subcutaneous denosumab Q12W Both interventions involve different medications and administration routes",
        "label": "Contradiction"
    },
    "589622f2-6c3b-4e63-ad71-5d8c90cb3413": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b0af496d-fead-41b6-96fd-71dea81c8501": {
        "text_answer": "No  Explanation  The statement there were fewer suspected serious adverse reactions outlined in the adverse events section of the primary clinical trial compared to the secondary clinical trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of serious adverse events between the two trials",
        "label": "Contradiction"
    },
    "0fbbd866-ae4c-458c-8bb4-fe8bb8ee9471": {
        "text_answer": "No  Explanation  The statement the radiation therapy for cohort 2 in the primary clinical trial lasts two weeks longer than cohort 1 with identical dosage is not entailed by the evidence The evidence only states that the radiation therapy for both cohorts lasts for 2327 fractions which is approximately 45 weeks The statement does not provide any information about the length of the radiation therapy",
        "label": "Contradiction"
    },
    "7794c718-f5f9-45a3-b427-9c7b79b261ee": {
        "text_answer": "No  Explanation  The primary and secondary clinical trials have different outcome measurements The primary trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary trial measures the number of participants with objective response",
        "label": "Contradiction"
    },
    "8084d30e-d99a-4b02-88e2-dd8194ef538f": {
        "text_answer": "Yes  Explanation The statement few participants in the primary and secondary clinical trials experienced adverse incidents is entailed by the evidence as the total number of adverse events in both trials is relatively low compared to the total number of participants",
        "label": "Entailment"
    },
    "fccfea25-6459-4cf9-a9cd-eaf2b81428e4": {
        "text_answer": "Yes The primary trial excludes patients with potassium levels outside the normal range and the secondary trial does not mention potassium as an inclusion or exclusion criterion",
        "label": "Entailment"
    },
    "7d712178-7e9c-48f5-8248-432ff3a50f62": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial describes the administration of suramin and paclitaxel not docetaxel and gemcitabine The secondary trial does not mention any specific interventions Therefore the statement about docetaxel and gemcitabine being standard practice in both trials is not entailed by the evidence",
        "label": "Contradiction"
    },
    "073d8ed7-d1ff-4fb7-bc5f-b33397ad6b6c": {
        "text_answer": "No  Explanation  The primary trial reports the percentage of participants while the secondary trial reports the number of participants Although both trials use percentage and number as measures they are not the same unit of measure for reporting their results",
        "label": "Contradiction"
    },
    "79d98227-bc8b-4d97-b264-9737e368030f": {
        "text_answer": "Yes The statement Patients in the primary and secondary trial suffered Thromboembolic events is entailed by the evidence However the statement infant t acute lymphoblastic leukemia is a tacute lymphoblastic leukemia that occurs in infancy is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "e3caa52b-259d-498a-926b-fbfd15eb1bc6": {
        "text_answer": "No  Explanation The evidence provided does not mention anything about the percentage of patients who did not experience any adverse events The evidence only mentions the percentage of patients who completed the treatment 98",
        "label": "Contradiction"
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7c7842f8-26c8-4b9f-8bb1-64f846e5e81e": {
        "text_answer": "Yes  Explanation  The statement while the primary trial explores the impact of a single therapeutic agent the secondary trial is dedicated to a completely different treatment modality albeit at similar doses and is based on similar outcome metrics is entailed by the evidence as the primary trial and secondary trial involve different treatment arms empegfilgrastim at 6 mg and 75 mg versus placebo in the primary trial and",
        "label": "Entailment"
    },
    "333c097e-628c-4240-aa00-f9621fbbabe1": {
        "text_answer": "No  Explanation  The given statement is not entailed by the evidence as the evidence does not provide information about the number of participants with Alzheimers disease or the use of ADCSADL inventory in the primary trial The evidence only reports the number of participants and Recurrencefree Survival rates for the Ketorolac 30 mg and NaCl 09 3mL groups in the primary trial",
        "label": "Contradiction"
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "text_answer": "Yes  Explanation  The statement The primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine is entailed by the evidence provided  The primary trial reports the results of a study on the effect of Fentanyl Sublingual Spray and Placebo on pain intensity during breakthrough pain episodes The outcome measurement for this trial was",
        "label": "Entailment"
    },
    "87c2f042-077b-4d49-80b0-1603a137520f": {
        "text_answer": "Yes  Explanation  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is entailed by the evidence as the primary trial had a higher number of cases for all three adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5be4dfce-9123-4a08-9397-a2f4d95e8209": {
        "text_answer": "No  Explanation The statement does not mention anything about mental health bodyweight age KarnofskyECOG score or previous treatments being conditions for eligibility in the primary trial as stated in the evidence However the evidence does mention that there is an exclusion criterion for the number of prior chemotherapy lines of treatment in the metastatic setting being 2 The statement does not mention this criterion and focuses",
        "label": "Contradiction"
    },
    "0f90b547-3d71-417f-ba02-deb31f70e5da": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the doses of Abraxane nabPaclitaxel are the same in both arms of the trial but the doses of Carboplatin are different between the two arms AUC 2 in Arm B versus not used in Arm A",
        "label": "Contradiction"
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "text_answer": "No  Explanation  The evidence provided in the trial results indicates that 20 out of 35 participants in cohort 1 did not experience any vomiting or require rescue medication within the first 24 hours after cyclophosphamide administration This means that more than 50 of the participants in this cohort did not suffer from acute vomiting after the treatment with Aprepitant Dexamethasone",
        "label": "Contradiction"
    },
    "e02cca6f-2a41-4a5a-bf83-23cdab6ee8dd": {
        "text_answer": "No  Explanation  The statement gammatubulin is a family of globular proteins that plays a role in the nucleation and orientation of microtubules is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events abdominal pain fever and death as well as a specific type of infection in two different cohorts of a clinical trial The statement about gamma",
        "label": "Contradiction"
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "text_answer": "No  Explanation  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed by the evidence provided  The primary trial results only indicate the overall response rates for each arm with Arm A having",
        "label": "Contradiction"
    },
    "738a5b84-f8e8-411b-9376-377760780e01": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "658e195d-21fc-4bf0-af37-a523ba772f83": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly compares the amounts of denosumab and radioactive Tc99M sulfur colloid using different units of measurement The primary trial specifies the amount of denosumab in micrograms while the secondary trial specifies the amount of radioactive Tc99M sulfur colloid in gigabecquerels gbq",
        "label": "Contradiction"
    },
    "edfe9572-6cff-4ecb-b34b-19ac297352d7": {
        "text_answer": "yes The primary trial determines the MTD of ruxolitinib in combination with paclitaxel and the secondary trial determines the MTD or maximum feasible dose of MM111 In both trials the MTD is defined as the highest dose level in which a DLT is experienced by fewer than a certain number of patients The statement in the question is consistent with this definition and the specific MTD values given in the evidence",
        "label": "Entailment"
    },
    "d4f76af1-2a9e-488a-b871-4b489dea5c02": {
        "text_answer": "Yes for the primary trial there is no mention of ki67 expression in the results for the secondary trial there is no mention of ki67 expression in the outcome measurement or results",
        "label": "Entailment"
    },
    "d6f7d14f-dbc6-4268-be40-1a09facf0834": {
        "text_answer": "No  Explanation  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is not directly related to the evidence provided The evidence only reports the occurrence of adverse events in two different cohorts of a trial but it does not indicate which cohort had more adverse events overall The statement about Rolfing is not related to the evidence at",
        "label": "Contradiction"
    },
    "4a5400b8-bf7e-40f2-857f-169a7ad3b89f": {
        "text_answer": "No  The statement is not related to the evidence provided which pertains to the inclusion and exclusion criteria for a breast cancer clinical trial The statement is about a ganglion which is a type of nervous tissue structure",
        "label": "Contradiction"
    },
    "9f855b3e-81b0-47a6-af48-b437e0409d77": {
        "text_answer": "Yes The primary and secondary trials both measure pCR as their outcome The primary trial shows a small difference in pCR rates between the two arms while the secondary trial shows a larger difference in pCR rates between the two arms",
        "label": "Entailment"
    },
    "6906ff3e-0e8c-4332-987d-47816bc462ba": {
        "text_answer": "Yes  Explanation  The statement There were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is entailed by the evidence since the number of Hepatotoxicity cases 3 is indeed three times the number of hypertension and Pancreatectomy cases 1 each The statement also correctly identifies that the number of Hepatoxicity cases",
        "label": "Entailment"
    },
    "2787f3da-ad73-483d-98b8-a82acec6e5fc": {
        "text_answer": "No   Explanation  The statement all patients in the primary clinical trial receive at least 20mg of mcs110 every 3 weeks without any pdr001 is not entailed by the evidence The evidence only states the dosages of MCS110 and PDR001 for each intervention in the primary clinical trial It does not guarantee that all patients receive a certain amount of MCS110",
        "label": "Contradiction"
    },
    "97552293-cd61-42c5-95c2-dc98b795f9d5": {
        "text_answer": "No  Explanation The statement Neither of the primary trial cohorts receive any invasive surgery or Neratinib 75 to 94 percent of the time is an indication that an individual did something or something occurred between 75 and 94 percent of the time is not entailed by the evidence The evidence only states that neither of the primary trial cohorts received invasive surgery or Neratinib",
        "label": "Contradiction"
    },
    "8549720f-df44-400f-aeb0-98150d2f23b1": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide enough information to make a comparison between the specific types of adverse events Infection Asymmetry and Deflation in both trials The statement makes a comparison",
        "label": "Contradiction"
    },
    "963f60a5-2446-42f3-9c05-20ef38528d1a": {
        "text_answer": "Yes  Explanation  The evidence states that out of 25 participants treated with sunitinib  docetaxel  trastuzumab 24 experienced adverse events AEs and 11 of these AEs were serious adverse events SAEs Therefore all but one patient had an adverse event and less than half 11 out of 25 had a serious adverse event",
        "label": "Entailment"
    },
    "6e6cecbf-ea24-4cf8-83f5-5fd627941028": {
        "text_answer": "Yes The primary trial involves zoledronic acid given IV and the secondary trial involves interventions with granisetron hydrochloride dexamethasone prochlorperazine aprepitant and palonosetron hydrochloride which can be given IV according to the trial information",
        "label": "Entailment"
    },
    "847ce4e8-b2df-4acb-b46c-c82baa519124": {
        "text_answer": "No   Explanation  The statement the secondary trial demonstrated a number of such events within their cohorts is not supported by the evidence provided as there are no recorded adverse events in the secondary trial for the event in question The statement only mentions that there are adverse events in the secondary trial but it does not specify how many or which events occurred Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "066d1275-7efd-47d6-aba2-96bc464cbe2f": {
        "text_answer": "No  Explanation The statement the occurrence of emesis was nonexistent among patients who received the placebo intervention in the primary clinical trial is not entailed by the evidence The evidence only reports that there were 5 participants in the placebo group who were emesisfree during the study period but it does not state that all participants in the placebo group were emesisfree",
        "label": "Contradiction"
    },
    "086c9c1a-de79-47f1-b75d-32c7a16716ef": {
        "text_answer": "No  Explanation  The statement patients with stage 1 cancer are eligible for the primary clinical trial and the secondary clinical trial without a need for a written informed consent is not entailed by the evidence provided The evidence specifies the inclusion and exclusion criteria for both clinical trials but it does not mention anything about patients with stage 1 cancer being exempt from obtaining a written informed consent",
        "label": "Contradiction"
    },
    "e35505c9-4340-4f19-8756-925d96d65b44": {
        "text_answer": "  No   Explanation   The statement patients who have undergone chemotherapy or radiotherapy in the recent fortnight have stable angina or exhibit grade 1 neuropathy are invited to participate in the secondary trial but are excluded from the primary trial due to nonhealing surgical wounds is not directly entailed by the evidence provided   The primary trial excludes patients who have undergone chem",
        "label": "Contradiction"
    },
    "15b22917-3649-44bd-b7f0-9aa5a6beba6b": {
        "text_answer": "Yes based on the information provided in the evidence the statement is entailed as all doses of vorinostat given in the clinical trial are below 100 mg which is equivalent to approximately 100 g for fentanyl sublingual spray assuming a conversion factor of 1 mg of vorinostat being equivalent to approximately 10 g of fentanyl",
        "label": "Entailment"
    },
    "12d86841-a682-4de8-80ab-90cae0b8c124": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as there is no mention of placental neoplasms in the given evidence The evidence only provides information about adverse events in two clinical trials",
        "label": "Contradiction"
    },
    "a930aad6-c334-4a8a-8547-3a07e44afe8b": {
        "text_answer": "No  The statement is not entailed by the evidence as the exclusion criteria specifically state No known hypersensitivity to phosphate trehalose or polysorbate and No known abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months Therefore patients with a recent history of abdominal fistula or gastrointestinal perforation are not eligible for the",
        "label": "Contradiction"
    },
    "5e3d1ff7-52f0-4ac5-a9e0-63536903cf84": {
        "text_answer": "Yes The evidence does not specify race or location as exclusion criteria Therefore Caucasian patients residing in New York are eligible to participate in the primary clinical trial",
        "label": "Entailment"
    },
    "4fec37ef-6e27-4b07-a0ba-d35434fe2d36": {
        "text_answer": "  No the statement is not entailed by the evidence The primary trial does not exclude patients with a recent pulmonary embolism but the secondary trial does",
        "label": "Contradiction"
    },
    "c7a78221-6f3c-484f-a281-908ab30a7e31": {
        "text_answer": "No  Explanation The evidence provided in the primary trial relates to the comparison of the efficacy of aprepitant and placebo in controlling nausea and vomiting during bone marrow transplantation It does not provide any information about pyometra or the likelihood of emesis in patients with this condition Therefore the statement about pyometra being entailed by the evidence is not valid",
        "label": "Contradiction"
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens in the month before study entry",
        "label": "Entailment"
    },
    "24cca94e-b0db-4015-acc3-061bce8ea0ea": {
        "text_answer": "Yes The statement does not mention Febrile neutropenia or Cholelithiasis but it correctly states that there were no cases of these conditions in both trials based on the provided evidence",
        "label": "Entailment"
    },
    "de2a7e0a-2046-4502-a23e-38d0753b43ec": {
        "text_answer": "No  Explanation The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is not entailed by the evidence The evidence only states that in the primary trial the patients received MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose of 100 mg every 3",
        "label": "Contradiction"
    },
    "0dc19d61-83e4-4b27-9d03-c485f30fe9f6": {
        "text_answer": "Yes The evidence shows that there were 80 participants with recurrencefree survival in the ketorolac 30 mg group and 96 participants with recurrencefree survival in the NaCl 09 3ml group indicating no significant difference between the two groups",
        "label": "Entailment"
    },
    "ad4f2e14-4f6a-473d-bc6a-225e2f34159b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it is about a different topic The evidence is about the dosage of ALT801 in two different cohorts of a trial while the statement is about protons being a fundamental particle with a positive charge",
        "label": "Contradiction"
    },
    "8e698117-fcf5-480f-80a0-95a3be887ef8": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial involves the use of gefitinib and the secondary trial involves the use of zoledronic acid with or without radiopharmaceuticals Neither trial involves the use of cyclophosphamide droperidol or epoetin beta nor does the secondary trial involve the use of tamoxifen",
        "label": "Contradiction"
    },
    "9069ac6d-9d0f-4484-adda-bde33d713b7e": {
        "text_answer": "No  Explanation The statement All patients in the primary trial receive at least 20mg of MCS1110 every 3 weeks is not directly entailed by the evidence The evidence only states that the patients in the primary trial received MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose of 100 mg every ",
        "label": "Contradiction"
    },
    "ed92e41d-f81d-462e-9081-c293fb816163": {
        "text_answer": "No   Explanation   The primary and secondary trials involve different patient cohorts and different drugs denosumab and dmethadone respectively The results cannot be directly compared or considered as coming from the same patient cohort",
        "label": "Contradiction"
    },
    "9f3b9559-fe63-4698-b886-fe76ecab9784": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial cohort 1 is given 0035 mg less alt801 than cohort 2 is entailed by the evidence since the difference in doses between the two cohorts is 0015 mgkgdose for cohort 1 and 0040 mgkgdose for cohort ",
        "label": "Entailment"
    },
    "0997d5fe-8df2-4b29-983a-3d3d2921e320": {
        "text_answer": "No  Explanation  The statement all of the participants in group 1 of the primary trial were found to have lesions is not entailed by the evidence provided The evidence only states that there were 0 lesions detected in the healthy volunteers group of the primary trial  Furthermore the statement less than 5 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpig",
        "label": "Contradiction"
    },
    "d1125c05-e0b3-4d7b-951e-cd21b5038b0b": {
        "text_answer": "Irrelevant  Explanation  The statement lgals3 antibody is any immunoglobulin that recognizes galectin3 is not directly related to the inclusion or exclusion criteria for the primary trial The statement does not provide any information about the eligibility of anorexic patients for the trial Therefore it is irrelevant to the given evidence",
        "label": "Entailment"
    },
    "0c9bef83-0974-4de4-aaa9-2f109fe16d0d": {
        "text_answer": "No  Explanation The statement patients in the primary clinical trial reported no observed change in the percentage of cells with ki67 expression following the application of tak228 plus tamoxifen treatment is not directly entailed by the evidence The evidence only provides the median interquartile range of Ki67 expression at baseline and at 6 weeks for the TAK228 Plus Tamoxifen armgroup",
        "label": "Contradiction"
    },
    "f5b27b4f-8fe1-4cc8-a4d6-aa1459797496": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it makes a comparison between the number of drugs in the interventions of two different trials while the evidence only provides information about the specific interventions in each trial The genetic mutation information is also not related to the interventions in the trials",
        "label": "Contradiction"
    },
    "270255e6-c423-4fff-a2aa-78c3c8ef2a8e": {
        "text_answer": "Yes The primary trials Intervention 1 involves IV administration of zoledronic acid while the secondary trials Interventions for both arms involve oral and IV administration of various drugs Therefore the statement that all intervention drugs in the secondary trial can be administered orally is consistent with the evidence",
        "label": "Entailment"
    },
    "ee74c3c1-33c4-4b0a-81bf-a2ed3ec7e161": {
        "text_answer": "yes the statement is entailed by the evidence The only difference between the two interventions is the dose of durvalumab given and the statement correctly identifies that difference",
        "label": "Entailment"
    },
    "0fb60a4c-16d6-4517-a201-e16f78fd6dae": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as fibromyalgia is an exclusion criterion for the secondary clinical trial The statement only mentions fibromyalgia but the evidence also mentions thalasemic syndromes and anemia which are not mentioned in the statement Therefore the statement does not cover all the conditions mentioned in the evidence",
        "label": "Contradiction"
    },
    "57dae782-9901-446f-93d1-047097623f45": {
        "text_answer": "Yes The statement does not explicitly mention IGF1R as a requirement for eligibility but the evidence does not exclude it as a potential biomarker for patient selection in the trial",
        "label": "Entailment"
    },
    "70d946f2-0c4a-4a00-8090-b0b55dda7b2b": {
        "text_answer": "Yes The evidence states that patients with nonsmall cell lung cancer are eligible for the trial regardless of their ER or PR status",
        "label": "Entailment"
    },
    "c802c0a9-737c-4b94-89c6-e4327a1925dd": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "66ff33e2-be79-4e47-a3f9-68a57f5f377b": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as it does not relate to the information provided in the evidence about the trials The statement is about the atomic properties of nickel while the evidence is about the interventions used in two trials one involving denosumab injections and the other involving lymphoscintigraphy with or without gamma probes",
        "label": "Contradiction"
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "text_answer": "Yes for the specific adverse event 1 since both trials recorded no adverse events However its important to note that the statement does not account for potential differences in adverse events between trials or the possibility of other adverse events not mentioned in the evidence",
        "label": "Entailment"
    },
    "6579100b-45dc-4669-86ec-a3f8ac521c23": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there were no adverse events reported in more than 25 of participants in either trial The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial",
        "label": "Contradiction"
    },
    "b308b4a7-f3e9-49aa-a84e-8842da7caacf": {
        "text_answer": "Yes  Explanation  The statement patients in the primary clinical trial reported a range of adverse effects but none experienced pancreatitis cholelithiasis hepatic pain or febrile neutropenia is entailed by the evidence as none of the adverse events in either trial included pancreatitis cholelithiasis hepatic pain or febrile neutropenia",
        "label": "Entailment"
    },
    "256cd40a-7afc-401d-9d02-c013ee3ee68d": {
        "text_answer": "No   Explanation  The evidence provided in the trial description does not mention anything about obligatory fitness routines for all participants The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "fadac52b-d98b-4511-858e-a7bfb0dda0c0": {
        "text_answer": "No The statement is not related to the evidence The evidence is about a primary trial intervention for breast cancer treatment while the statement is about a congenital heart condition",
        "label": "Contradiction"
    },
    "2a56e9e0-10fe-4a2d-964a-71390b3bb4d4": {
        "text_answer": "  Yes gender is not a determining factor for eligibility in both trials according to the provided inclusion criteria",
        "label": "Entailment"
    },
    "d16f252e-5df6-4e09-8a24-9c56b4b8e16b": {
        "text_answer": "No  Explanation  The statement the azd0530 175 milligrams group of the primary trial experienced a more significant percentage change in betactx at week 4 than the zoledronic acid 4000 microgram group is not entailed by the evidence provided The evidence only shows the percentage change in betaCTX for each group at week 4 but it does not directly compare the significance of the",
        "label": "Contradiction"
    },
    "1bec6fcc-5a7e-4d19-81ea-e677715490fe": {
        "text_answer": "No  Explanation  The statement cases of mucositis oral epileptic seizures and thromboembolic events were found to be more frequent in the primary trial than the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not compare the frequency of specific adverse events between the two trials",
        "label": "Contradiction"
    },
    "4886038c-1def-4bbb-a9c7-dab5784cd471": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence pertains to a clinical trial for breast cancer patients with upper extremity lymphedema while the statement is about esophageal cancer surgery",
        "label": "Contradiction"
    },
    "a87b00a3-b6c1-4ee3-a6e0-fbd2eccbea05": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the evidence only pertains to patients with breast cancer and not ovarian serous carcinoma",
        "label": "Contradiction"
    },
    "71a3b934-3bf8-4628-a728-cdf47a27e66c": {
        "text_answer": "No  Explanation  The primary clinical trial and the secondary clinical trial both use the term Maximum Tolerated Dose MTD but they have different definitions and methods for determining the MTD The primary trial determines the MTD based on the number of patients who experience doselimiting toxicity DLT in a cohort while the secondary trial determines the MTD based on the number of patients who experience DLT in a",
        "label": "Contradiction"
    },
    "3ad97e18-2efc-4d4a-aaae-424a3bc3f39c": {
        "text_answer": "Yes The evidence does not explicitly state that patients must have a healthy body mass index but it does not exclude patients based on body mass index so it is implied that patients with a healthy body mass index are eligible for both trials Additionally the evidence does not explicitly state an age limit for the secondary trial but it does not exclude postmenopausal women so it is also implied that they are eligible for the secondary trial",
        "label": "Entailment"
    },
    "baa46f83-8738-48d2-b9b8-9cc635d9d730": {
        "text_answer": "  No   Explanation   The evidence provides the percentage of subjects who were recurrencefree survivors but it does not specify how many individuals were not recurrencefree survivors Therefore the statement cannot be definitively answered with a simple yes or no based on the given evidence",
        "label": "Contradiction"
    },
    "30a0fbf5-af3e-43fd-80f4-41f740a2fdff": {
        "text_answer": "No  The evidence does not provide information about women having both claustrophobia and IBS Irritable Bowel Syndrome being eligible for the clinical trials The evidence only lists the inclusion and exclusion criteria for each trial separately",
        "label": "Contradiction"
    },
    "6b5cc819-da7b-4e4f-ae2f-7e4db8073860": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial more than 15 of patients were affected by all types of adverse events aes is not entailed by the evidence provided The evidence states that 3636 of patients experienced adverse events but it does not specify that more than 15 of patients experienced all types of adverse events The evidence only lists the types and number of adverse",
        "label": "Contradiction"
    },
    "8f82b776-0f1c-4059-aab0-9898a9f6bd1a": {
        "text_answer": "Yes  Explanation The primary clinical trial administers pembrolizumab every 3 weeks Q3W while sunitinib is given in the secondary clinical trial on continuous dosing regimens with visits every 8 weeks Therefore pembrolizumab is given to its participants twice as often as sunitinib in the context of this evidence",
        "label": "Entailment"
    },
    "4d501822-a118-4fe8-b92d-eb5085ab6dcc": {
        "text_answer": "No  Explanation  The statement all participants in the primary clinical trial are administered higher doses of medication than participants in the secondary clinical trial is not entailed by the evidence The primary clinical trial involves PF06647020 administered at 02 mgkg and 05 mgkg while the secondary clinical trial involves ALT801 administered at 0015",
        "label": "Contradiction"
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "text_answer": "  Yes the statement is entailed by the evidence for cohort 1 3 participants as all 3 participants experienced an adverse event serious or nonserious according to the CTCAE v40 criteria",
        "label": "Entailment"
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "text_answer": "No  Explanation  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the secondary trial includes patients with locally advanced or metastatic breast cancer which may have larger tumors than 1 cm Therefore it is possible for patients with a TNBC tumor larger than 100mm to be eligible for the secondary trial but they would not",
        "label": "Contradiction"
    },
    "54f86209-3c4b-4dfd-b048-e8eeb864300c": {
        "text_answer": "No  Explanation The evidence only states that some individuals in the primary clinical trial receive MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose of 100 mg every 3 weeks It does not guarantee that all individuals receive at least 20mg of MCS110 every 3rd week",
        "label": "Contradiction"
    },
    "d8e49bf6-27d9-4307-9bcd-56625d93274a": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes the inclusion criterion of a HER2 positive tumor either IHC 3 or FISH",
        "label": "Entailment"
    },
    "072f2e2d-f4b0-4a32-85e0-8626ee261a63": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not indicate that the group taking LBH589 with capecitabine performed poorer than those taking LBH589 and lapatinib The statement is not entailed by the evidence as there is no comparison of the outcomes or efficacy between the two groups in the provided information",
        "label": "Contradiction"
    },
    "cff79719-40b1-43fb-bbdd-43dbe9c4191a": {
        "text_answer": "No  Explanation  The primary trial and secondary trial evaluate different patient populations and different interventions The primary trial focuses on patients receiving HER2specific T cells and evaluates toxicity using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary trial focuses on patients receiving trastuzumab emtansine and evaluates the percentage of participants with adverse events of primary interest AEP",
        "label": "Contradiction"
    },
    "4f66f663-030a-4391-a426-4e6b2f3bc9d2": {
        "text_answer": "Yes  Explanation  The statement the primary trial participants experienced less incidences of diarrhoea than the participants of the secondary trial is entailed by the evidence as the primary trial had 7 cases of diarrhoea out of 30 participants 2333 while the secondary trial had 2 cases of diarrhoea out of 6 participants 3333 Therefore the primary trial had a",
        "label": "Entailment"
    },
    "38b5ee2a-8baf-427a-944d-a93a1a450104": {
        "text_answer": "Yes  Explanation  The statement more instances of anemia pneumonia and stupor were reported in the secondary trial than in the primary trial is entailed by the evidence as the secondary trial had a higher number of reported cases for anemia 116 vs 034 pneumonia 116 vs 033 and stupor 116 vs 0",
        "label": "Entailment"
    },
    "d311aaa2-6b04-4f26-a19a-65e33a673fbe": {
        "text_answer": "Yes The evidence states that there was an adverse event of peripheral neuropathy a type of nerve damage observed in the primary clinical trial",
        "label": "Entailment"
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "text_answer": "Yes In the primary trial Epacadostat is taken twice daily BID while in the secondary trial Sunitinib is taken once daily Therefore Epacadostat is taken more frequently than Sunitinib",
        "label": "Entailment"
    },
    "b7b61d5d-629d-43a4-8d75-5897864b6443": {
        "text_answer": " No  Explanation The evidence states that 47 out of 53 participants in the Lapatinib 1000 mg  NabPaclitaxel arm had disease progression or death However the statement asks about over half of the patients having progression of disease which is not exactly the same as stating that more than 50 of the patients had disease progression The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "0b3b3351-166f-465f-b44f-14c1e24c2d06": {
        "text_answer": "No  Explanation  The primary clinical trial and the secondary clinical trial have different inclusion and exclusion criteria The primary clinical trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary clinical trial is focused on patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston The secondary trial does not mention any cancerrelated criteria",
        "label": "Contradiction"
    },
    "fd173cdb-c283-4b74-922e-583a531edcef": {
        "text_answer": "No  The statement has nothing to do with the evidence provided which is about a neoadjuvant therapy regimen for breast cancer The statement is about a different topic entirely  a genus of bacteria",
        "label": "Contradiction"
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "text_answer": "Yes  Explanation  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial and only a single case of Atrial fibrillation is entailed by the evidence since the evidence shows that there were no deaths or hospitalizations in cohort 2 of the primary trial as stated in the Adverse Events 2 section and there was only one case of hospitalization due to Atrial fibrill",
        "label": "Entailment"
    },
    "475903fe-9ac8-434b-aa7e-aa7bce562ef0": {
        "text_answer": "  No   Explanation   The primary clinical trial measures pain intensity using a visual analog scale while the secondary trial measures bone mineral density using a DEXA scan The statement in question refers to the measurement of general health status via an eq5d questionnaire and the measurement of change in hip circumference Neither trial in the evidence records this information",
        "label": "Contradiction"
    },
    "c6f5d89a-939b-4e46-8aab-9fc9246498be": {
        "text_answer": "  No   Explanation   The statement a patient who has recently undergone an organ transplant and remains confined to bed would not be eligible for the primary clinical trial but could be considered for the secondary clinical trial is not explicitly stated in the evidence provided for either trial The primary trial includes an exclusion criterion for a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders but it does",
        "label": "Contradiction"
    },
    "6558ae62-b251-483d-9082-67a614d76e60": {
        "text_answer": "Yes  Explanation The primary clinical trial had two arms Intervention 1 and Intervention 2 each with a different treatment Intervention 1 involved the administration of doxorubicin HCl liposome and pyridoxine while Intervention 2 involved the administration of doxorubicin HCl liposome and placebo This design corresponds to a placebocontrolled trial with one experimental group Intervention",
        "label": "Entailment"
    },
    "1dffbb91-6440-4ceb-a33d-c2d783f75936": {
        "text_answer": "No   The statement is not entailed by the evidence as it mentions interventions dacarbazine porfimer and light source that are not mentioned in the evidence",
        "label": "Contradiction"
    },
    "6746f51e-6ceb-48b7-aa33-aecd601723b6": {
        "text_answer": "  Yes  Explanation  The statement is entailed by the evidence because in Intervention 1 the dosage of docetaxel is 100 mgm every 3 weeks while in Intervention 2 the dosage of docetaxel is 100 mgm on Day 2 of Cycle 5 and every 3 weeks for all subsequent cycles However the total amount of docet",
        "label": "Entailment"
    },
    "19ec40c8-5482-490f-9418-5667705632df": {
        "text_answer": "No  Explanation  The statement the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts is not entailed by the evidence The evidence only states that the number of adverse events for Adverse Event 1 in the secondary trial was 015 000 while the number of adverse events for Adverse Event 1 in the primary trial is not mentioned Therefore",
        "label": "Contradiction"
    },
    "a55f7123-365b-4119-bf0d-17467c73d0b7": {
        "text_answer": "No   Explanation   The statement There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only provides information about the number of participants in each cohort and their outcome measurements for two different trials There is no comparison or indication of a significant difference in the number of participants between the two cohorts of the two trials",
        "label": "Contradiction"
    },
    "cca75efb-d5e0-4dba-b9ca-4f59238abb59": {
        "text_answer": "Yes   Explanation  The statement the primary trial intervention is given orally whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein is entailed by the evidence as the primary trial intervention is given orally PO and the secondary trial interventions are administered intravenously IV",
        "label": "Entailment"
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "text_answer": "  No   Explanation   The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not directly entailed by the evidence provided   The evidence lists the exclusion criteria for",
        "label": "Contradiction"
    },
    "e517c026-4c5e-43ac-a734-1bcfd6d8edf1": {
        "text_answer": "Yes The statement that Cohort 1 of the primary trial did not report any AEs however almost all of cohort 2 candidates suffered at least one ae is entailed by the evidence that Adverse Events 1 Total 0147 000 for Cohort 1 and Prefer not to answer for all AEs in Cohort 2",
        "label": "Entailment"
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "text_answer": "  Maybe  Explanation  The evidence provided only gives the ORR and the corresponding 95 confidence intervals for each group To determine if there is a statistically significant difference between the two groups a statistical test such as a chisquare test or Fishers exact test would need to be performed on the data Based on the information given it is not possible to definitively say that the Paclitaxel Plus Bevacizumab Plus",
        "label": "Entailment"
    },
    "b08d9933-4d8d-40f6-9395-d40391501db4": {
        "text_answer": "Yes  Explanation The evidence states that participants in the primary trial receive neoadjuvant therapy consisting of epirubicin cyclophosphamide docetaxel and trastuzumab The doses of each drug are specified The statement in question asserts that participants receive quadruple drug therapies with a maximum dose of 1 gramm2 Since the evidence confirms that participants receive four different drugs",
        "label": "Entailment"
    },
    "3be36531-265f-4d51-bd65-1e2f46b28eda": {
        "text_answer": "Yes  Explanation Both primary and secondary clinical trials in the evidence present data on the Maximum Tolerated Dose MTD of multiple interventions specifically ruxolitinib in combination with paclitaxel in the primary trial and MM111 in the secondary trial",
        "label": "Entailment"
    },
    "bc318388-81b9-4bf5-94a7-db6443061abd": {
        "text_answer": "  No the statement is not entailed by the evidence The statement is incorrect as it does not accurately describe the inclusion criteria for the secondary trial regarding BRCApositive breast cancer The evidence states that patients must have a documented deleterious BRCA12 mutation or a BRCAPRO score of greater than or equal to 30 for the secondary trial The statement only mentions BRCApositive breast cancer without specifying the method of",
        "label": "Contradiction"
    },
    "0ed96bc9-14a3-4c52-b977-7cf507956191": {
        "text_answer": "No   Explanation   The statement is not directly entailed by the evidence as it does not relate to the interventions or trial groups described in the evidence The statement is about Dulbeccos phosphatebuffered saline and the administration of injections in the trials The evidence only mentions the interventions being used in each trial group and the timing of those interventions",
        "label": "Contradiction"
    },
    "48b31ad3-f5d6-4250-9e84-e407d26f6bed": {
        "text_answer": "No  Explanation The statement Patients participating in the primary trial receive oral medication twice a day for a full month is not directly related to the information given about the medications lapatinib ditosylate and tamoxifen citrate in the evidence The statement only mentions that patients receive oral medication twice a day but it does not specify that the medications mentioned in the evidence are the ones being taken twice a day Additionally the statement",
        "label": "Contradiction"
    },
    "dd909039-da2a-4c24-9b6f-1776bc51e3a2": {
        "text_answer": "yes but the statement only applies to the inclusion criteria for informed consent The evidence does not directly address the inclusion or exclusion criteria related to malignant cervical soft tissue neoplasms",
        "label": "Entailment"
    },
    "174215f6-99d9-482a-8aad-d477060cb062": {
        "text_answer": "No  Explanation The statement does not mention anything about mental health bodyweight size of tumors KarnofskyECOG score or estimated life expectancy being conditions for eligibility in the primary trial However the evidence does not exclude these factors as conditions for eligibility either The statement only addresses the absence of conditions related to hyperemia evaluation",
        "label": "Contradiction"
    },
    "2ea65099-018a-4230-87a1-e60303486743": {
        "text_answer": "  The statement is not entailed by the evidence for the primary trial as the patient does not meet the ANC requirement 1800 cellsmm3 However the statement is entailed by the evidence for the secondary trial as the patient meets all other inclusion criteria",
        "label": "Contradiction"
    },
    "e486bbca-c279-458b-b98b-2b434c9a242d": {
        "text_answer": "No  Explanation  The statement malignant laryngeal neoplasm is a primary or metastatic malignant neoplasm involving the larynx The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is not directly entailed by the evidence provided The evidence only mentions the adverse events observed in the trials but it does not provide information about",
        "label": "Contradiction"
    },
    "05775941-9ed3-40eb-9c93-ed60a7783838": {
        "text_answer": "No  The statement is not about breast cancer and does not relate to the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for the trial",
        "label": "Contradiction"
    },
    "2c00f421-96f2-4f3a-a202-27350b15c84f": {
        "text_answer": "No  Explanation  The statement No two patients in the primary trial suffered the same type of adverse event is not directly related to the statement about tonicity excipient The statement only mentions the types of adverse events experienced by the patients but it does not mention the cause of those events which is the tonicity excipient in question Therefore the statement about the tonicity excipient is not entailed by the evidence provided",
        "label": "Contradiction"
    },
    "2eed31cc-3968-4b00-8a9e-947c5ecfbc3b": {
        "text_answer": "No   Explanation  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not entailed by the evidence The evidence describes several treatments that patients will receive during the study but it does not mention a single injection on day 8 for all patients Additionally the statement does not mention the content of the injection which could be different from the treatments described in the evidence The question about",
        "label": "Contradiction"
    },
    "f44e50eb-f7de-403f-8e1c-25ae4cb1f530": {
        "text_answer": "Yes The statement is entailed by the evidence as it is explicitly stated in the evidence that the final eligibility for the clinical trial is determined by the health professionals conducting the trial",
        "label": "Entailment"
    },
    "ed9afe03-8b68-464c-a9f8-0d3a58f64d7f": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials include patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma as inclusion criteria",
        "label": "Entailment"
    },
    "3f6d7cbc-5465-4e27-beee-582162fe9972": {
        "text_answer": "No  Explanation  The statement in the secondary clinical trial there were no adverse events is not entailed by the evidence While it is true that the frequency of adverse event Adverse Events 1 is higher in the secondary trial compared to the primary trial there are still reported adverse events in the secondary trial Therefore the statement is not an accurate representation of the evidence",
        "label": "Contradiction"
    },
    "91169f4f-ada3-4bc7-a0ef-8111fccac241": {
        "text_answer": "No  Explanation  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 025 of the primary trial patients is not entailed by the evidence The evidence only states that syncope occurred in 2 out of 12 patients in the primary trial which is not the same as being the most common adverse event across both trials",
        "label": "Contradiction"
    },
    "de99de33-5cd3-4f28-8859-9297a230ab94": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial only mentions the use of Vorinostat and Radiation therapy for all participants with dosage levels for Vorinostat and recommended timing for taking it during radiation therapy There is no mention of Fentanyl sublingual spray being given to any of the participants during radiation therapy",
        "label": "Contradiction"
    },
    "7b76950c-8ac8-451f-93d4-bfac4ba36e49": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not mention anything about enzalutamide being given intravenously in the primary clinical trial The statement is incorrect and should be revised to compare the two groups that received enzalutamide orally in different doses",
        "label": "Contradiction"
    },
    "ce8ecade-8753-4983-83af-47f6e3e87f32": {
        "text_answer": "No  Explanation  The statement while the primary trials entry conditions are identical for all age groups the secondary trial has separate entry conditions for participants under the age of 25 and those 25 and older is not directly entailed by the evidence provided The evidence only describes the inclusion and exclusion criteria for both trials without specifying any agerelated differences",
        "label": "Contradiction"
    },
    "23f62ab2-9ec8-49f7-a4e7-84f931a1825d": {
        "text_answer": "No   The statement is not entailed by the evidence as it incorrectly states that the exclusion criteria apply within the last 2 days instead of the last 6 months",
        "label": "Contradiction"
    },
    "a6f49268-2b84-49ff-a89a-86cb3d16cd07": {
        "text_answer": "No  Explanation  The statement in the primary clinical trials initial cohort over half of the participants faced acute vomiting as a side effect of being treated with aprepitant dexamethasone cytoxan and kytril is not entailed by the evidence provided The evidence only states that 20 out of 35 participants in the study had no episodes of vomiting and no",
        "label": "Contradiction"
    },
    "2b0a4d9c-e65c-44d2-bdf6-60877e5d1b41": {
        "text_answer": "No  The evidence states that patients with dementia are excluded from the trial but it does not specifically mention Alzheimers disease",
        "label": "Contradiction"
    },
    "54654fa6-2bce-4ed0-9cdf-ec6cf1de3bd8": {
        "text_answer": "Yes for the secondary trial with the caveat that smoking individuals are not disqualified per se but must meet other criteria",
        "label": "Entailment"
    },
    "57265519-b5e0-41f9-90b3-8a09e57bc282": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary clinical trial focuses on interventions for lymphedema Estring and Testosterone Cream and the secondary clinical trial also focuses on an intervention for lymphedema acupuncture Neither trial mentions chemotherapeutic or radiation therapy interventions",
        "label": "Contradiction"
    },
    "2c7901c7-b03b-4b92-852d-d182187dd2b1": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 12 participants analyzed in the primary clinical trial with 6 participants in each of the two cohorts The statement indicates that there were two instances of doselimiting toxicity and both occurred in patients from cohort 2 Therefore the evidence entails that the statement is true",
        "label": "Entailment"
    },
    "33641401-b713-4800-86a9-aa7766b456f5": {
        "text_answer": "No  Explanation  The statement in cohort 2 of the primary clinical trial acute vomiting was a side effect for over half of the participants posttreatment with aprepitant dexamethasone cytoxan and kytril is not directly entailed by the evidence provided The evidence only states that 20 out of 35 participants in the study experienced no vomiting and",
        "label": "Contradiction"
    },
    "dfb7dcc6-34da-4de2-8229-3cd02d15bd15": {
        "text_answer": "No  Explanation  The statement mersalyl acid is a mercurial diuretic mersalyl acid has been replaced by less toxic nonmercury containing diuretics is not directly related to the evidence provided in the trial results The evidence only reports on the outcomes of two different treatment groups Paclitaxel Plus Bevacizumab and Paclitaxel Plus Bevacizumab Plus Gemcitab",
        "label": "Contradiction"
    },
    "52ee52ad-c158-48b8-86f1-99589e8150c5": {
        "text_answer": "Yes The evidence states that 13 of the participants with HER2primary breast cancer developed imagable HER2 metastases after undergoing HER2targeted PETCT with 89Zrtrastuzumab",
        "label": "Entailment"
    },
    "da51f6ae-703a-4282-a339-22ebaa80709a": {
        "text_answer": "Yes some patients with cognitive impairment including Frontotemporal dementia and Mixed dementia are eligible for the trial However they must meet the other inclusion criteria and have a Mini Mental State Examination MMSE score of 23 The statement about vaginal itching or irritation is not directly related to the eligibility criteria",
        "label": "Entailment"
    },
    "e3a1c267-d715-40ef-b23a-9bfb6285bf6a": {
        "text_answer": "Yes  Explanation  The primary trial describes an intervention involving massage therapy which is a form of physiotherapy The secondary trial on the other hand describes interventions involving the administration of a drug PF06647020 which is a drugbased treatment The statement that the primary trial involves drugbased treatment and the secondary trial focuses on physiotherapy is entailed by the evidence",
        "label": "Entailment"
    },
    "0392122c-9612-49dc-83db-b2b6a4a4a8a8": {
        "text_answer": "No  Explanation  The statement the primary clinical trial did not yield any significant differing outcomes across groups is not directly entailed by the evidence provided for the primary clinical trial The evidence only shows that the two algorithms had similar diagnostic accuracy but it does not indicate that there were no significant differences in outcomes between the two groups  Furthermore the statement the reflexology group in the secondary clinical trial showed the same results as their",
        "label": "Contradiction"
    },
    "b4bad814-078e-4991-9455-f50ca716580d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes two different dosages of enzalutamide being administered in the trial",
        "label": "Contradiction"
    },
    "26b78b55-df37-4058-a5ef-7634ae3f4fce": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a93f06ed-84a0-487e-bf93-f74cc7cb34ba": {
        "text_answer": "Yes  Explanation  The statement no adverse events have been reported for participants in both the primary and secondary clinical trial is entailed by the evidence since the evidence reports that there were no adverse events for participants in both trials for the given adverse events 1 and 2",
        "label": "Entailment"
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "text_answer": "Yes   Explanation  The evidence states that Intervention 1 is administered intravenously IV and Intervention 2 is administered subcutaneously Since different routes of administration are involved the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "aa62c405-218e-496e-a424-95340f370834": {
        "text_answer": "No  Explanation  The statement the second cohort of the primary clinical trial had fewer participants than the first cohort is not entailed by the evidence provided The evidence only states the number of participants and the percentage of participants with events for each arm Neratinib and Placebo of the clinical trial but it does not provide information about the number of participants in each cohort or any differences between them",
        "label": "Contradiction"
    },
    "dc867a3f-6005-49f7-bcd8-1c7db27b00c1": {
        "text_answer": "Yes The evidence states that patients with documented allergies to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib are excluded from the primary trial The statement extends this exclusion to include the secondary trial as well",
        "label": "Entailment"
    },
    "51cd4ccd-2770-4189-ba70-f01147431843": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial involves multiple injections of dendritic cells chemotherapy and trastuzumab",
        "label": "Entailment"
    },
    "3aaa3da7-8b9c-4853-abd9-f4dc011eaab0": {
        "text_answer": "No  Explanation  The statement is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided in the evidence The statement is about a separate medical condition called familial hypocalciuric hypercalcemia which is not mentioned in the evidence at all Therefore it cannot be determined if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "34f3e7ee-c8c4-4a97-90da-fafcfd1c7cc0": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes two interventions that involve preoperative administration of Dexamethasone",
        "label": "Contradiction"
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "6e125367-3fa8-46b3-a58d-b3baa894bc70": {
        "text_answer": "No  Explanation The statement women aged 60 or 70 are eligible for the secondary trial but will need to wait 1020 years to be eligible for the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for both the primary and secondary trials It does not mention anything about age and eligibility timelines for each trial",
        "label": "Contradiction"
    },
    "81792c74-a501-4ef9-b7ac-2bda7a980fb1": {
        "text_answer": "Yes  Explanation  The statement the secondary clinical trial and the primary clinical trial utilize diverse methods of quantification and success indicators is entailed by the evidence because the primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH using a continuous measure mIUml and the secondary clinical trial measures the maximum tolerated dose MTD of Ruxolitinib using a",
        "label": "Entailment"
    },
    "0938714d-688d-42b5-a605-1153c172aa48": {
        "text_answer": "No  Explanation  The statement several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome is not directly mentioned or entailed by the evidence provided The evidence only reports the occurrence of various adverse events in the primary and secondary trials but it does not specify that any of these events were related to Tumour lysis syndrome Therefore the statement cannot be answered definitively based on the given evidence",
        "label": "Contradiction"
    },
    "9fb13507-1f88-4b95-8ff6-a56af67ca8c4": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2cc2ce51-0ac2-4e55-baf0-d26f88105aa0": {
        "text_answer": "No  Explanation  The statement 00274 of the primary trial participants and 01674 the secondary trial participants suffered an acute myocardial infarction is not entailed by the evidence provided The evidence only reports the number of participants who experienced various adverse events including acute myocardial infarction in each trial It does not provide the total number of participants in each trial",
        "label": "Contradiction"
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "text_answer": "Yes  The statement correctly identifies the interventions used in each trial",
        "label": "Entailment"
    },
    "f6835e26-4231-4f1a-a5f0-00e6919eb622": {
        "text_answer": "No   Explanation The evidence describes the administration of several intravenous IV and intradermal id injections including the Dendritic Cell Vaccine Trastuzumab and Vinorelbine ditartrate as well as subcutaneous injections of sargramostim GMCSF Therefore the statement that participants will be required to take only oral medications is not entailed by",
        "label": "Contradiction"
    },
    "e5e13d2e-11bd-4f7c-867d-ab3d0e26666b": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes the dosages and schedules of multiple drugs that participants in the primary trial receive throughout the study duration and there is no mention of a maximum dose of 1000 kgm2 for any of the drugs",
        "label": "Contradiction"
    },
    "616edea0-8cb7-44c3-a866-af72680d31d3": {
        "text_answer": "No  The statement is not entailed by the evidence The primary clinical trial mentions the use of Abl Cells IV and Cyclophosphamide but it does not mention any medication intake related to florbetaben The secondary clinical trial mentions the use of 4Demethyl4cholestryloxycarbonylpenclomedine DMCHOCPEN but it does not mention any medication intake",
        "label": "Contradiction"
    },
    "0d63f301-9546-466f-aee9-78eea578b57f": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures tumor diameter in centimeters cm while the secondary clinical trial measures the number of participants with solid tumor response using RECIST 11 criteria These are different units for the same outcome measure tumor response",
        "label": "Entailment"
    },
    "89e0e893-e053-491c-a276-055b30c5da2e": {
        "text_answer": "No  Explanation  The statement patients in the paced respiration intervention group of the primary clinical trial experienced more hot flashes per day on average than patients in the fast shallow respiration group is not entailed by the evidence In fact the evidence shows the opposite patients in the paced respiration group had fewer hot flashes per day on average 348 vs 395",
        "label": "Contradiction"
    },
    "e3fac563-e6bf-418f-b9b2-3bc6e3539da9": {
        "text_answer": "Yes  Explanation The statement the primary disparity between the two interventions in the primary clinical trial is the elevated usage of the radioactive tc99m sulfur colloid in intervention 1 compared to intervention 2 is entailed by the evidence as both interventions involve the injection of radioactive Tc99M sulfur colloid but the amount used in intervention 1 pIHGC is higher than that in",
        "label": "Entailment"
    },
    "776a17db-8314-4fc6-9de3-0d110db79269": {
        "text_answer": "No  The evidence pertains to a clinical trial for breast cancer patients considering aromatase inhibitor therapy not colorectal cancer patients undergoing radiation treatment",
        "label": "Contradiction"
    },
    "980339cb-7997-4209-b3b5-a4ddc3aff79e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the participants in the primary clinical trial do receive surgical procedures specifically therapeutic conventional surgery in addition to the medications listed",
        "label": "Contradiction"
    },
    "93ff9af3-c812-4449-b311-06418b283233": {
        "text_answer": "No   Explanation   The statement provided is not a direct entailment of the evidence given The evidence describes two separate interventions in different clinical trials The primary trial involves radioembolization with Yttrium90 glass microspheres and TheraSphere while the secondary trial explores the combination of ibrutinib and MEDI4736 The statement in question compares the interventions in the two",
        "label": "Contradiction"
    },
    "fa11f174-260a-4836-b583-c40d4b10bad4": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed by the evidence provided The evidence only states the number of adverse events for each category but it does not provide information about the exact number of cases for hypertension and Pancreatectomy that occurred three times the number of",
        "label": "Contradiction"
    },
    "0025afa1-ef06-42c9-9a6d-0f2aaf94c403": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided in the trial results The evidence only reports the number of participants analyzed in each arm of the trial but it does not mention anything about bone marrow collection",
        "label": "Contradiction"
    },
    "60ceec88-a7b1-4353-8327-946c05a0a32a": {
        "text_answer": "No  Explanation  The evidence provided in the given text does not mention anything about fibrosis assessment or the percentage of participants in cohort 1 who suffered a lifethreatening adverse event The text only provides information about the number of participants with serious and nonserious adverse events assessed by the Common Terminology Criteria for Adverse Events CTCAE v40 for two different dose levels of a vaccine trial",
        "label": "Contradiction"
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "text_answer": "No  Explanation  The primary trial evaluates the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 while the secondary trial evaluates the percentage of participants with adverse events of primary interest AEPIs which are different outcomes The primary trial focuses on the incidence and grading of adverse events while the secondary trial focuses on",
        "label": "Contradiction"
    },
    "4423a0fb-d4df-4046-bb60-04ba702c8623": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial have different outcome measurements The primary trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary trial measures the number of participants with objective response These are different types of outcome measurements",
        "label": "Contradiction"
    },
    "f4d3c3ad-6c8c-4c7e-8d90-e321a9fa479d": {
        "text_answer": "No The statement is not entailed by the evidence as it contradicts the inclusion criteria for both trials which specify that participants must have breast cancer",
        "label": "Contradiction"
    },
    "50252016-e56e-4dc0-99d0-589c3dfe05e8": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence reports no occurrences of intestinal obstructions or pancytopenia in either trial",
        "label": "Contradiction"
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "text_answer": "No  Explanation The statement cohort 1 of the primary trial is administered 0035 mg of ALT801 less than cohort 2 is not entailed by the evidence The evidence only provides the doses administered to each cohort but it does not state the exact amount of ALT801 that each cohort received To determine the difference in doses you",
        "label": "Contradiction"
    },
    "a89e4c9e-86e0-4d21-b805-2a593ed71a7c": {
        "text_answer": "Yes The statement does not mention Febrile neutropenia or Cholelithiasis so the absence of these adverse events in the trials is not directly stated in the evidence but is implied since they are not mentioned in the adverse events section The statement is about the monoclonal antibody and the specific adverse events mentioned in the evidence",
        "label": "Entailment"
    },
    "45745e85-0655-490a-a692-ee9f060f8898": {
        "text_answer": "Yes The statement does not mention UTI specifically but it does not contradict the evidence that no UTIs were reported in the trial",
        "label": "Entailment"
    },
    "d0de0260-eb83-45e9-81cf-02ee5edd3e60": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does not suggest a better performance of the control group over the test group based on operative time alone The statement also incorrectly assumes that there is a control group in the secondary clinical trial which is not the case",
        "label": "Contradiction"
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "text_answer": "Yes The statement includes all the mentioned exclusion criteria from the evidence except for the history of myocardial infarction MI which is mentioned as an exclusion criterion but not specifically within the last 6 months However the statement is still entailed by the evidence as a whole",
        "label": "Entailment"
    },
    "9484e4d1-8130-4d52-b362-faa1990946e9": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts in the primary trial receive higher doses of Cyclophosphamide than the doses of Eribulin and Docetaxel given in the respective interventions",
        "label": "Entailment"
    },
    "c752fd5f-8cf1-435e-8981-7323279b8130": {
        "text_answer": "No   Explanation   The statement the secondary trial and the primary trial have completely unrelated outcome measurements is not entailed by the evidence provided The primary trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary trial measures the number of participants with objective response These outcome measurements are not directly related to each other",
        "label": "Contradiction"
    },
    "07d56cae-178f-43f3-8f85-c73817786951": {
        "text_answer": "No  Explanation  The statement about a patient diagnosed with stage II lymphoma absolute neutrophil count of 2500l platelet count of 90000l hemoglobin level of 110 gl and a life expectancy less than 4 months is not entailed by the evidence provided for either the primary or secondary trial  The primary",
        "label": "Contradiction"
    },
    "49f03133-66cf-4980-8e2b-d7fb001edefd": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary clinical trial does not mention the administration of talazoparib",
        "label": "Entailment"
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "text_answer": "Yes  Explanation  The statement There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs is entailed by the evidence because according to the data provided no patient in either trial experienced fewer than three distinct adverse events",
        "label": "Entailment"
    },
    "ca7e6cda-c7dc-4cc7-82d5-732998d7993e": {
        "text_answer": "No  The evidence states the specific inclusion and exclusion criteria for each clinical trial The statement is too broad and does not accurately reflect the information provided",
        "label": "Contradiction"
    },
    "e68875c8-9905-4821-ac2a-8fe4576a2071": {
        "text_answer": "No  Explanation The statement the primary trial had one test group and one placebo group the secondary trial had 2 test groups is correct but it is not directly related to the information about nucleolar granular material Therefore it cannot be answered with a simple yes or no based on the given evidence",
        "label": "Contradiction"
    },
    "10543624-61ff-49dd-970a-5d6c57605f6d": {
        "text_answer": "Yes The statement is about the Punjabi language and does not contradict the evidence which only reports the absence of adverse events in the trials",
        "label": "Entailment"
    },
    "68a7d226-1e5b-4a29-b492-60e8f621e7bd": {
        "text_answer": "Yes The secondary clinical trial includes a requirement for a diagnosed alteration in one or more of the listed genes for patient inclusion which is not a requirement in the primary clinical trial",
        "label": "Entailment"
    },
    "e65ecb06-ff14-432b-826f-9bd26c456215": {
        "text_answer": "Yes  Explanation  The statement cyclophosphamide paclitaxel and pegfilgrastim are not part of the treatment protocols in either the primary clinical trial or the secondary clinical trial is entailed by the evidence because neither trial includes these specific drugs as part of the interventions The primary trial uses doxorubicin cyclophosphamide and GMCSF while the secondary trial uses dox",
        "label": "Entailment"
    },
    "7bc71832-7742-4a77-b0ca-d8820db7f9bd": {
        "text_answer": "Yes The statement implies that there is a detailed description and treatment cycle provided in the intervention section of the primary clinical trial which is confirmed by the evidence",
        "label": "Entailment"
    },
    "215bc845-3485-423b-9c4c-1091cfb1a5cc": {
        "text_answer": "Yes The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a CR or PR",
        "label": "Entailment"
    },
    "408eec4d-435f-4edb-99ac-69cd883586b2": {
        "text_answer": "No  Explanation  The primary and secondary trials have different inclusion and exclusion criteria While there are some overlapping criteria such as being a female and having a history of breast cancer there are significant differences between the two sets of criteria For example the primary trial includes only postmenopausal women while the secondary trial includes adult patients regardless of menopausal status Additionally the primary trial includes only patients with hot flushes while the",
        "label": "Contradiction"
    },
    "d692776e-c2e9-450b-b0e8-57d84ccb216c": {
        "text_answer": "No  Explanation  The statement the secondary trial promotes oral ingestion of tablets with no required injections is not entailed by the evidence The secondary trial involves the use of a handheld gamma camera and gamma probes during surgery neither of which require oral ingestion of tablets The evidence does not mention any oral medication or tablets in the secondary trial",
        "label": "Contradiction"
    },
    "2b4a5598-2d21-426a-9d85-b0f94efb9bea": {
        "text_answer": "No  Explanation The statement is not about the adverse events in the trials but rather about Portable Network Graphics PNG file format The evidence provided does not entail the statement",
        "label": "Contradiction"
    },
    "ee84e692-4923-4cb8-acad-8f27f64f4b9e": {
        "text_answer": "Yes  Explanation  The statement both the primary trial and the secondary clinical trial reported no adverse events in their cohorts is entailed by the evidence since the evidence reports that there were no adverse events in both trials for the given adverse event type",
        "label": "Entailment"
    },
    "f491f739-e852-496a-ad98-bbcb2f075cb9": {
        "text_answer": "  Yes  Explanation  The evidence shows that all three participants in the first cohort Dose Level 1 experienced adverse events which can be considered as nonserious since no serious adverse events were reported Therefore the statement all participants from the first cohort of the primary clinical trial underwent some adverse event is entailed by the evidence",
        "label": "Entailment"
    },
    "a325de64-fdaa-4c93-8e4a-22a1d502dd88": {
        "text_answer": "Yes  Explanation  The statement different methods of measurement and success criteria are used in the primary clinical trial and the secondary clinical trial is entailed by the evidence provided  In the primary clinical trial the outcome measurement is the variation in serum levels of Follicle Stimulating Hormone FSH and the success criteria is the change from baseline mean screeningbaseline to Week 12 in serum levels of",
        "label": "Entailment"
    },
    "6d3a9617-a195-48e4-aa19-61a3ecde9ddb": {
        "text_answer": "No  Explanation  The statement Any Patients currently taking part in the secondary trial will also be eligible for the primary trial is not entailed by the evidence provided The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is for postmenopausal women with a history of breast cancer and experiencing hot flushes while the secondary trial is for adult patients with HER2negative metastatic breast cancer who are",
        "label": "Contradiction"
    },
    "0881a52f-e84b-43a4-8fda-446a7f2a1390": {
        "text_answer": "  No the statement is not entailed by the evidence for the secondary clinical trial as it only includes patients with BRCApositive breast cancer",
        "label": "Contradiction"
    },
    "173793fc-ca3d-4296-a1c7-14fbde0a7b8c": {
        "text_answer": "Yes The primary trial describes a treatment cycle length of 21 days which is equivalent to one month The secondary trial does not mention a cyclical treatment regimen",
        "label": "Entailment"
    },
    "0a6d1117-f868-4495-bb04-e5da37c15144": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly describes the number of test groups in the primary trial The primary trial actually had two test groups Pyridoxine and Placebo not three Therefore the statement does not accurately reflect the information provided in the evidence",
        "label": "Contradiction"
    },
    "4816c2e1-ae3b-4a0a-89b8-27a5cee580d7": {
        "text_answer": "No  Explanation  The statement pancreatic duct is a duct joining the pancreas to the common bile duct to supply pancreatic juices is not related to the evidence provided in the primary or secondary trials The trials only report results related to the efficacy and safety of denosumab and dmethadone in treating different conditions respectively The statement about the pancreatic du",
        "label": "Contradiction"
    },
    "700f4bd9-6d39-4d3a-a425-bcb34d6712b6": {
        "text_answer": "No  The statement Women suffering from both claustrophobia and osteoporosis are not eligible for either the primary trial or the secondary trial is not directly stated in the evidence The evidence only lists specific exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "060b08af-40f5-4d26-8299-6f3d02c8fda7": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as both Intervention 1 and Intervention 2 have a uniform dose of doxorubicin 60 mgm cyclophosphamide 600 mgm and docetaxel 100 mgm in their respective regimens Additionally the frequency of administration is constant for both interventions with cycles being given every",
        "label": "Entailment"
    },
    "0e80c163-f731-4e3b-9194-211675ca9c53": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts use the same instructional CD for paced breathing However its important to note that the first cohort practices once daily while the second cohort practices twice daily and the second cohort also undergoes weekly chemotherapy",
        "label": "Entailment"
    },
    "baea007a-c303-440b-a66c-0941729f416d": {
        "text_answer": "No  Explanation  The statement was in situ hybridization performed is not directly related to the given evidence The evidence only provides information about the number of adverse events and their relationship to neutrophilsgranulocytes in the primary and secondary trials In situ hybridization is a different type of laboratory test that is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "e1142532-82b5-4f1c-9d7c-33b677b92966": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the primary clinical trial was severe nausea is not entailed by the evidence provided The evidence only states that no adverse events were reported for Adverse Events 1 in the secondary clinical trial but it does not provide any information about the most common adverse event in the primary clinical trial",
        "label": "Contradiction"
    },
    "3433a50a-b13a-43a5-ba9c-041959f23390": {
        "text_answer": "No  Explanation  The statement 0 participants in group 1 of the primary trial were found to have lesions and more than 9500 in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed by the evidence provided The primary trial and the secondary trial are about different studies with different outcomes The primary trial is about the diagnostic performance of SWIFTDCE M",
        "label": "Contradiction"
    },
    "09aef225-50fa-457e-9e8b-fce6aafd4705": {
        "text_answer": "Yes The statement is entailed by the evidence as the patients receive oral medication lapatinib and tamoxifen twice a day for a month",
        "label": "Entailment"
    },
    "d51ecd4d-4188-4306-9c41-962c86a12652": {
        "text_answer": "  No children are explicitly excluded from the primary trial The statement only mentions that they are not eligible for the secondary trial but it does not contradict the exclusion of children from the primary trial in the evidence",
        "label": "Contradiction"
    },
    "f87a205c-5de6-4cda-a798-85b7308e25c2": {
        "text_answer": "No  Explanation  The statement missouri is a state in the central midwest united states its capital is jefferson city There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed by the evidence provided The evidence only mentions the adverse events observed in the primary trial but it does not mention the location of the trial or the",
        "label": "Contradiction"
    },
    "0308c864-0730-4a28-9bb4-7a51eba3e438": {
        "text_answer": "No  Explanation  The statement topical solution dosage form is a solution intended for administration to a body surface is not directly related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The statement does not mention anything about the trials or their eligibility criteria The statement only describes a topical solution dosage form in general terms Therefore it cannot be determined if the statement is entailed by the evidence with a",
        "label": "Contradiction"
    },
    "429199a7-de1a-4900-939b-e4f6efadb474": {
        "text_answer": "No  The evidence does not mention anything about central nervous system cysts or eating disorders in the given trial data",
        "label": "Contradiction"
    },
    "285be2fe-e597-4d99-acb9-7504bcfb3d6f": {
        "text_answer": "No  The statement is not entailed by the evidence as acrocephalosyndactyly is not mentioned in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "98c65216-ca06-4666-99e3-0d06dc97c01d": {
        "text_answer": "Yes The woman with ongoing therapy for Stage I BC after lumpectomy is excluded from both trials according to their respective exclusion criteria",
        "label": "Entailment"
    },
    "9ea892eb-1362-4281-aac7-713905f1bb2c": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as there is no mention of HER2neu peptide vaccine or sargramostim GMCSF in the provided evidence The evidence only mentions the interventions and dosing schedules for the participants in the primary trial",
        "label": "Contradiction"
    },
    "d3df95aa-4564-4503-9322-64f5664ce1c3": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention for adult cancer patients is specifically mentioned in the evidence",
        "label": "Entailment"
    },
    "3921fd1d-1ba6-475c-a6f5-c8f76fe8cbe9": {
        "text_answer": "No  Explanation  The statement the results of the bevacizumab  capecitabine cohort in the primary clinical trial were more beneficial than the results of the bevacizumab cohort is not directly entailed by the evidence provided The evidence only shows the percentage of participants with disease progression or death in each cohort during the maintenance phase of the trial It does not provide enough information to make",
        "label": "Contradiction"
    },
    "ae574646-62f1-4b5f-b565-4af6bbafe7a6": {
        "text_answer": "Yes  Explanation The statement compared with the secondary clinical trial the primary trial has less reported anemia cases is entailed by the evidence as the primary trial has a lower percentage of reported anemia cases 000 vs 267",
        "label": "Entailment"
    },
    "83e62365-e433-4411-9a4d-951e08c6b91c": {
        "text_answer": "Yes for the primary trial assuming the patients cancer is a solid tumor malignancy  Explanation The statement mood is generally good and only occasionally affected by cancer is consistent with the inclusion criteria for the Phase II trial of the evidence which states that patients must have a performance status of 02 on the Eastern Cooperative Oncology Group ECOG Performance Scale and life expectancy  3 months A performance",
        "label": "Entailment"
    },
    "c0915bad-2882-4f25-a6d5-5f2b71bc8850": {
        "text_answer": "Yes The evidence does not mention any specific restrictions on hepatic function in the inclusion criteria",
        "label": "Entailment"
    },
    "ad52e20e-99a7-4001-b957-12b24a3d1df1": {
        "text_answer": "Yes The statement is entailed by the evidence as the adverse events were recorded for cohort 1 patients in the primary trial",
        "label": "Entailment"
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "text_answer": "No  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is not entailed by the evidence provided The evidence only shows that these adverse events occurred in both trials but it does not provide enough information to make a comparison between the number of occurrences in each cohort",
        "label": "Contradiction"
    },
    "0c5d58a3-a565-4b42-ae6f-24bd3be00b06": {
        "text_answer": "No  Explanation The statement is not an accurate representation of the inclusionexclusion criteria in the evidence The statement incorrectly combines different types of conditions abdominal fistula gastrointestinal perforation intrabdominal abscess and incorrectly extends the time frame from 6 months to 60 years for some conditions stroke transient ischemic attacks psychiatric disorders The actual criteria in the evidence specify",
        "label": "Contradiction"
    },
    "0ef97135-5f94-407d-a48d-f40cd6272ed5": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a510de48-5778-4489-8d10-82173320bdad": {
        "text_answer": "Yes   Explanation  The statement intervention one uses higher doses of radioactive Tc99M sulfur colloid than intervention two is entailed by the evidence as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid but the primary trial mentions that intervention 1 uses a prototype handheld gamma camera pIH",
        "label": "Entailment"
    },
    "5a736ff9-b224-4cf6-ae71-55a825bff301": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 for the TAK228 Plus Tamoxifen arm A 5 reduction in Ki67 expression would be equivalent to a decrease of 05 in the median percentage 15 to ",
        "label": "Entailment"
    },
    "54fbf052-31df-43af-b20e-8947042351bc": {
        "text_answer": "Yes  The primary trial has a greater number of instances of biliary colic and diarrhea compared to the secondary trial Note The statement in the question is a bit more general than the exact comparison of the two trials provided in the evidence but it is still entailed by the evidence",
        "label": "Entailment"
    },
    "7a735242-b198-4348-ac48-f318cd704752": {
        "text_answer": "Yes  Explanation The statement the dosage of denosumab used in intervention 1 of the secondary clinical trial exceeds the dosage of zoledronic acid used in intervention 1 of the primary clinical trial by 12 times is entailed by the evidence because the dosage of denosumab used in intervention 1 of the secondary clinical trial is 120 mg Q4W while the dosage of zoled",
        "label": "Entailment"
    },
    "e5d1118c-2e6a-4e00-a63c-041c43256c5e": {
        "text_answer": "No   Explanation   The evidence provided in the trial results does not include any information about patients using testosterone cream for managing lymphedema The trial only compares the effects of acupuncture treatment versus a waitlist control group on lymphedema",
        "label": "Contradiction"
    },
    "9e960679-ac10-4893-a777-94baac5a89f3": {
        "text_answer": "Yes The evidence states that the intervention for cohort 2 of the primary clinical trial does not include the administration of an influenza vaccine",
        "label": "Entailment"
    },
    "8b54773e-b9b0-400f-af71-8fd2cbd16473": {
        "text_answer": "No   Explanation  The primary trial involves PF06647020 and the doses are different 02 mgkg and 05 mgkg while the secondary trial involves ALT801 and different doses 0015 mgkgdose and 0040 mgkgdose The statement does not mention the same drug being used in",
        "label": "Contradiction"
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "text_answer": "Yes  The statement specifically mentions Stomatitis as the only adverse event which is consistent with the evidence that there was one adverse event of Stomatitis out of 29 participants",
        "label": "Entailment"
    },
    "54176448-042e-4b40-835e-ddf60eb53f80": {
        "text_answer": "Yes The evidence does not explicitly state that patients of Asian descent living in California cannot be part of the primary clinical trial Therefore the statement patients of Asian descent living in California can be part of the primary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "c7bddafb-404b-40be-80c0-f0b4e08d6466": {
        "text_answer": "Yes The statement is consistent with the evidence as it mentions that there is only one adverse event recorded in the trial and the statement also does not contradict the information about the planned subject activity group sequence number",
        "label": "Entailment"
    },
    "ebaa9747-0c6a-4258-b0b8-121541b4662a": {
        "text_answer": "Yes The evidence does not mention any use of imaging techniques in either clinical trial",
        "label": "Entailment"
    },
    "63da892b-0385-43c5-8ed3-3ce7514ebb55": {
        "text_answer": "Yes  Explanation The statement the adverse events reported for cohort 1 of the primary clinical trial pertain to cardiovascular complications is entailed by the evidence as cardiovascular complications are included in the list of adverse events reported for cohort 1 of the primary clinical trial Specifically acute coronary syndrome angina pectoris cardiac arrest cardiac failure and cardiac tamponade are",
        "label": "Entailment"
    },
    "7e288efd-8755-4393-b372-effd1c3feb91": {
        "text_answer": "No  Explanation  The statement there were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of each specific type of adverse event between the two trials",
        "label": "Contradiction"
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "text_answer": "No  Explanation  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events in each trial but it does not compare the number or percentage of specific adverse events between the two trials Therefore it is not possible to determine from the evidence alone whether there",
        "label": "Contradiction"
    },
    "53b41c0c-179c-45ce-90e6-3f444681b41e": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not mention anything about canine sarcoma or compare the results between different types of tumors The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "474339d0-2bac-4e3a-9aee-1933b96738b0": {
        "text_answer": "Yes  Explanation The primary trial administers a loading dose of 4 mgkg followed by 2 mgkg of trastuzumab per week while the secondary trial administers Herceptin trastuzumab at 4 mgkg IV infusion on Day 1 of Cycle 5 followed by 2 mgkg by IV infusion weekly starting from Day 8 The difference in dosage schedules indicates",
        "label": "Entailment"
    },
    "85dcd465-ec0b-42ae-aec6-582831584bbf": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial includes various types of breast cancer not just triple negative breast cancer",
        "label": "Contradiction"
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "text_answer": "No  Explanation  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is not entailed by the evidence The evidence only shows that anemia pneumonia and stupor occurred in the secondary trial but it does not show that they occurred more frequently than in the primary trial The frequency of adverse events in each trial is not provided in the",
        "label": "Contradiction"
    },
    "41cbc4ea-37f8-468e-bfd2-f0a71e8856b5": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the statement mentions a different dose and duration of tamoxifen administration and the evidence only reports a percentage change in Ki67 expression not an absolute value",
        "label": "Contradiction"
    },
    "5dc5fa82-a4a5-4f16-8ca1-b797546169af": {
        "text_answer": "No  Explanation  The statement severe pain or discomfort that prevented most activities is a response indicating that an individual has or had severe pain or discomfort that prevented most activities is not directly mentioned in the evidence The evidence provides inclusion and exclusion criteria for a clinical trial but it does not explicitly state that severe pain or discomfort preventing most activities is a response or criterion for the trial",
        "label": "Contradiction"
    },
    "28e19ec3-f22a-4002-9020-02ef29c4386c": {
        "text_answer": "No  Explanation  The statement in cohort 1 of the primary clinical trial four additional patients experienced adverse events compared to those in the second cohort of the trial is not entailed by the evidence provided The evidence only states that there were no adverse events in both cohorts of the trial The statement implies that there were adverse events in the first cohort but not in the second which is not supported by",
        "label": "Contradiction"
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "text_answer": "No  Explanation The statement The intervention in the secondary trial lasts 3 times longer than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks while the secondary trial lasted for 24 weeks but this does not mean that the intervention in the secondary trial was 3 times longer Instead the secondary trial lasted twice as long overall due to the longer duration of the intervention and",
        "label": "Contradiction"
    },
    "1d57af11-9dc3-4589-ae99-fe0e9dab6042": {
        "text_answer": "Yes Both trials include ECOG performance status of 02 indicating patients who are able to take care of themselves without any help at all",
        "label": "Entailment"
    },
    "072b76ba-9fd5-4313-b484-c353f61ecca9": {
        "text_answer": "Yes The statement is entailed by the evidence as fibromyalgia and thalasemic syndromes are listed as exclusion criteria in both trials Anemia is an exclusion criterion in the primary trial but the statement specifically mentions representation in either the primary clinical trial or the secondary clinical trial so the statement as a whole applies to both trials",
        "label": "Entailment"
    },
    "7e57517f-4dc5-4457-bc4e-12f7faef37f4": {
        "text_answer": "Yes  Explanation  The statement anemia pneumonia and stupor were more common conditions among patients participating in the secondary clinical trial compared to the primary clinical trial is entailed by the evidence as the evidence shows that the frequency of anemia pneumonia and stupor were higher in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "168c59cb-7be6-4f14-acd9-5d731b8464c8": {
        "text_answer": "Yes The primary clinical trial does not involve interventions using xrays transendocardial injections CT scans or MRIs The secondary clinical trial also does not involve these imaging modalities or transendocardial injections in the interventions described",
        "label": "Entailment"
    },
    "0483c5df-77db-4c42-897e-aca21b207503": {
        "text_answer": "No  Explanation The statement numerous instances of pancytopenia were noted in cohort 1 of the primary clinical trial is true according to the evidence as there was one recorded case of pancytopenia out of 18 participants However the statement also claims that there were no records of anaemia and febrile neutropenia but the evidence shows that there was one recorded case of anaem",
        "label": "Contradiction"
    },
    "93cfa70f-2bdc-4e2f-ac51-5e06f2fb07ea": {
        "text_answer": "No  The statement is not directly related to the inclusion and exclusion criteria for the primary trial provided in the evidence The statement is about a renal pelvis papillary urothelial neoplasm which is not related to breast cancer and the HER2 status of the tumor",
        "label": "Contradiction"
    },
    "9c60f664-ef13-406d-b26a-e57f6c914cf4": {
        "text_answer": "Yes The evidence does not specify the kras gene mutation status for individual patients but it does state that all patients receive at least 20mg of MCS110 every 3 weeks which is more than the minimum dose of 1mgkg Therefore it is reasonable to assume that the kras gene mutation negative finding applies to all patients in the trial as the presence of a kras gene mutation would likely exclude patients from participation Additionally",
        "label": "Entailment"
    },
    "79a4ea13-6d2a-49e0-8c1d-9c1fcc7e9e3b": {
        "text_answer": "No  Explanation  The statement HER2  Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial is not entailed by the evidence In the primary trial patients received a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 2 received Her",
        "label": "Contradiction"
    },
    "4e3b9642-3f02-4f4b-bfee-f2e3b1673186": {
        "text_answer": "Yes   Explanation  The statement accurately reflects the information provided in the evidence regarding the different dosing regimens for alpha lipoic acid in the primary trial and necitumumab in the secondary trial",
        "label": "Entailment"
    },
    "7128da72-a0ed-48cb-b167-c2b6176faa71": {
        "text_answer": "Yes  Explanation  The evidence shows that the median aAUCpa for the Sensory Neuropathy subscale of the EORTC QLQCIPN20 was more negative worse in the Arm II Control group which received standard paclitaxel infusions compared to the Arm I Cryotherapy group which received cryotherapy in addition to paclitaxel infusions This suggests that",
        "label": "Entailment"
    },
    "94aea5d0-2afb-40a4-b1c8-574c9f22225e": {
        "text_answer": "yes the evidence provides information on survival but it does not directly address systolic blood pressureforage percentiles",
        "label": "Entailment"
    },
    "dfd43b21-a734-49b1-8a64-d6dea31e9031": {
        "text_answer": "No  Explanation  The statement capnocytophaga is a genus of gramnegative anaerobic bacteria that normally populate the mouth and nasopharynx of dogs and cats is not mentioned in the evidence provided for the primary or secondary trials The evidence only includes the inclusion and exclusion criteria for the trials",
        "label": "Contradiction"
    },
    "26be8c11-aebf-4982-b09e-75dead3cdf4a": {
        "text_answer": "No  Explanation  The statement None of the cohort of the primary trial or the secondary trial receive entericcoated tablets is not directly related to the information provided about the overexpression of VEGF The evidence only mentions the interventions used in the primary and secondary trials and does not mention anything about entericcoated tablets being given to participants in relation to VEGF overexpression",
        "label": "Contradiction"
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "text_answer": "Yes  Explanation The statement Both cohorts of the primary trial receive the same dosage of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial at the same frequency is entailed by the evidence as both interventions have the same dosage of Doxorubicin 60 mgm and Cyclophosphamide 600 mgm given in the",
        "label": "Entailment"
    },
    "b6b819ce-57a9-4883-bcf9-f8c9a9bae83e": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence However its important to note that the statement is more specific than the evidence as it mentions a pharyngeal stripping wave being present and complete while the evidence only mentions the presence of a pharyngeal stripping wave",
        "label": "Entailment"
    },
    "c803b01e-6f64-4412-a3c2-6b1a70d5cf7e": {
        "text_answer": "No  The evidence does not mention anything about mental health assessment as a requirement for enrollment in the clinical trial",
        "label": "Contradiction"
    },
    "ceb0ef65-5640-491d-a6c6-341e456b0bdd": {
        "text_answer": "Yes for febrile neutropenia Answer No for cholelithiasis  Explanation  The statement there were 0 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial is entailed by the evidence for febrile neutropenia because the evidence states that there were 0 cases of febrile neutropenia in both",
        "label": "Entailment"
    },
    "d2e42255-bde4-4e21-a914-b4e0c35b6e3d": {
        "text_answer": "No  Explanation  The statement patients with Frontotemporal dementia or Mixed dementia are eligible for the primary trial is not explicitly stated in the inclusion criteria of the evidence provided The evidence only mentions that patients with some evidence of cognitive impairment are eligible but it does not specify the type of cognitive impairment allowed The Controlled Oral Word Association Test COWAT mentioned in the statement",
        "label": "Contradiction"
    },
    "a6688fad-488e-4822-a91e-cbfe2117cae1": {
        "text_answer": "Yes  Explanation The evidence provided in the clinical trial results indicates that nine out of the 21 participants experienced a reduction in circulating tumor cells CTCs one month post autologous hematopoietic stem cell transplantation AHST This reduction in CTCs is the outcome measure mentioned in the trial and it is a decrease from the baseline number of CTCs Therefore the statement that the majority of",
        "label": "Entailment"
    },
    "bfef0d2b-81c0-4f5f-bf91-a313a0a2dcbb": {
        "text_answer": "No  Explanation  The evidence provided in the text indicates that the participants in the Tamoxifen and Ovarian Function Suppression groups had a mean standardized score decrease in cognitive function after one year of treatment However the statement every participant in the primary clinical trial encountered a reduction in cognitive capabilities is not entailed by the evidence as it goes beyond the information provided and assumes that all participants in the trial experienced a reduction not just those in",
        "label": "Contradiction"
    },
    "a630808d-14d5-4ef8-bd2e-73ce5e80f3f1": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 750 mg of fulvestrant in a tablet form to be taken bid is not entailed by the evidence  The primary trial participants receive whole breast radiation therapy but the secondary trial participants do not receive radiation therapy as part of the intervention Instead they receive Enzastaurin and Fulvest",
        "label": "Contradiction"
    },
    "378c5fe6-13ce-488e-a8c0-ec76cf2fb191": {
        "text_answer": "No  Explanation  The statement patients receiving aprepitant in the primary clinical trial were twice as likely to experience emesis as patients receiving the placebo intervention is not entailed by the evidence The evidence only provides the number of participants who were emesisfree during the study period for each group It does not provide information on the total number of participants who experienced emesis or the frequency of emesis for each group Therefore it is",
        "label": "Contradiction"
    },
    "2ae5eea7-46bf-425e-b528-201a718d7f66": {
        "text_answer": "No  Explanation The evidence provided in the trial results only covers the Ki67 expression change from baseline to 6 weeks for the TAK228 Plus Tamoxifen armgroup It does not provide information about the Ki67 expression change over 3 years of treatment",
        "label": "Contradiction"
    },
    "97322f7f-a311-4718-8a0c-5e4ecdd33f7f": {
        "text_answer": "No  Explanation  The primary trial measures tumor response using RECIST criteria while the secondary trial measures the number of participants with aromatase inhibitor associated musculoskeletal symptoms AIMSS and includes various correlative studies Neither trial directly measures the transformation in Ki67 expression in tumors",
        "label": "Contradiction"
    },
    "8920d439-7233-461b-a343-3c264f0918de": {
        "text_answer": "No  Explanation  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only reports the number of participants and the presence or absence of lesions in the primary trial and the",
        "label": "Contradiction"
    },
    "b2b80e2f-f5b4-4997-9209-fd061ff307b9": {
        "text_answer": "Yes  Explanation The statement through transendocardial injection both the placebo and the alloMSCs intervention are delivered in the same dosage in the primary clinical trial is entailed by the evidence as both interventions received 20 transendocardial injections of 04ml each",
        "label": "Entailment"
    },
    "b410caf4-4ea2-414d-8b43-7336d2bb2d9b": {
        "text_answer": "No   Explanation   The primary trial includes a criterion for the primary tumour to have a diameter greater than 2 cm while the secondary trial does not mention any specific requirement for the tumour size Therefore a patient with a primary tumour of 066 meters approximately 2667 cm measured by clinical examination and echography would not be eligible for both trials based on the given evidence",
        "label": "Contradiction"
    },
    "38343873-8e16-4852-bfe5-511fbd1be49d": {
        "text_answer": "Yes The evidence shows that there were patients in both groups who survived less than 2 years However the overall median survival times were greater than 2 years for both groups",
        "label": "Entailment"
    },
    "48b186f8-f41c-4582-8dbb-6918ce072ce8": {
        "text_answer": "No  Explanation  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not directly entailed by the evidence provided The evidence only mentions the number and percentage of adverse events for each trial but it does not provide the actual number of participants with cholelithiasis or the percentage of participants with cholelithiasis for each trial Therefore it is not possible",
        "label": "Contradiction"
    },
    "64ea29b0-1d21-4c59-a56e-553765f5e5c8": {
        "text_answer": "No  The statement is not directly related to the eligibility criteria for the primary trial as stated in the evidence The evidence only mentions renal function with an INR of 16 but it does not mention anything about the renal arteries or the presence or absence of renal metastases",
        "label": "Contradiction"
    },
    "c939c0c9-57b8-4f8a-aba1-e19af522cb12": {
        "text_answer": "No  Explanation  The statement the primary clinical trial observed more cases of palpitations pericardial effusions and abdominal pains than the secondary clinical trial is not entailed by the evidence provided The evidence only shows that there were occurrences of these adverse events in both trials but it does not indicate that there were more cases in the primary trial In fact the secondary trial had no occurrences of pal",
        "label": "Contradiction"
    },
    "f1a4fdcb-09ae-4f35-9681-8ee7d0d3b41d": {
        "text_answer": "Yes  Explanation The statement cohort 1 receives more durva in their biweekly iv infusions than cohort 2 is entailed by the evidence since cohort 1 receives a higher dose of durvalumab 03 mgkg in their biweekly iv infusions compared to cohort 2 1 mgkg",
        "label": "Entailment"
    },
    "6a489a42-add9-40b7-ba9d-5d46da07b890": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided The evidence describes interventions in two clinical trials but it does not mention the unit of measure for pressure change or the term cmh2o per milliliter",
        "label": "Contradiction"
    },
    "a67f344b-aa15-4e94-819b-515df442eaf0": {
        "text_answer": "  Yes  Explanation  The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced a confirmed full or partial response CR or PR according to RECIST criteria 10 This means that more than 50 of the patients in the primary clinical trial experienced a confirmed full or partial",
        "label": "Entailment"
    },
    "5780e67e-7318-4574-b20c-a2d3c8730e4a": {
        "text_answer": "Yes The statement is entailed by the evidence as the dosage of Eribulin in Intervention 1 is higher 14mgm2 compared to the Docetaxel dosage in Intervention 2 75 mgm2",
        "label": "Entailment"
    },
    "2f61841c-b395-4d2c-9e86-ca09cdd61dcb": {
        "text_answer": "  No the statement is not entailed by the evidence as it is not a direct comparison of the inclusion and exclusion criteria for both trials The statement only mentions a few specific exclusion criteria and does not accurately reflect the full criteria for both trials",
        "label": "Contradiction"
    },
    "9ce6d69e-2ed0-4046-bd5e-5888416fbeb5": {
        "text_answer": "No  Explanation  The statement there were 16 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial is not entailed by the evidence provided The evidence only mentions the number of adverse events for a specific type of adverse event Adverse Event 1 in each trial but it does not provide any information about the number of cases of febrile neutrop",
        "label": "Contradiction"
    },
    "b490a735-38d7-49f2-a091-f930c5d1e9f5": {
        "text_answer": "No  The evidence states that persons with dementia are excluded from the trial and Parkinsons disease is a type of dementia",
        "label": "Contradiction"
    },
    "5b6c2caa-eb80-4024-b04c-e6b07685b7d8": {
        "text_answer": "No  Explanation  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed by the evidence provided The evidence only lists the number and percentage of adverse events for each trial but it does not specify the number or percentage of patients who experienced infections Therefore it is not possible to determine if over 15 of patients in both trials suffered from in",
        "label": "Contradiction"
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "text_answer": "Yes for the primary trial morbidly obese patients are not explicitly mentioned in the inclusion or exclusion criteria For the secondary trial there is no mention of body mass index or obesity in the given criteria",
        "label": "Entailment"
    },
    "5ce6d9b3-235b-4645-bc27-10861b2e5177": {
        "text_answer": "Yes The evidence states that there were no reports of wound dehiscence in the primary clinical trial Wound dehiscence is a type of surgical incision reopening",
        "label": "Entailment"
    },
    "c6f11ac1-ac2e-4740-82aa-a83ffd1cce00": {
        "text_answer": "No  Explanation  The statement there were no psychiatric adverse events reported during the primary clinical trial is not entailed by the evidence because the evidence reports one case of suicidal ideation a psychiatric adverse event out of 50 participants",
        "label": "Contradiction"
    },
    "fbb05804-2d6c-4d49-8e06-0fbf2b3770a4": {
        "text_answer": "Yes   Explanation  The statement a single drug makes up the intervention in the primary clinical trial in contrast to the secondary clinical trial where the intervention necessitates a minimum of three separate drugs is entailed by the evidence as the primary clinical trial involves the use of a single drug gefitinib while the secondary clinical trial involves the use of two interventions one of which is zoledronic acid administered with vitamin D and",
        "label": "Entailment"
    },
    "9f0a6fc9-62c5-404e-aa2f-0e5acf696e14": {
        "text_answer": "No   Explanation  The statement cardiac adverse events were prominently recorded in both the primary and secondary clinical trials is not entailed by the evidence provided The evidence only states that there were no adverse events recorded for Adverse Events 1 and Adverse Events 2 in both trials It does not mention anything about cardiac adverse events specifically or their prominence in the trials",
        "label": "Contradiction"
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "text_answer": "No  The evidence states that there were no adverse events recorded in the primary trial for Adverse Event 1 and the same for Adverse Event 1 and Adverse Event 2 in the secondary trial There is no mention of a total of over 100 adverse events in either trial",
        "label": "Contradiction"
    },
    "d803319b-cf1d-47e9-b7c2-f75ef7972e88": {
        "text_answer": "No  Explanation  The primary clinical trial is focused on measuring the difference in pain intensity using Summed Pain Intensity Differences SPID at 30 minutes after dosing for Fentanyl Sublingual Spray and Placebo groups The secondary clinical trial is focused on measuring the change in bone mineral density BMD of the lumbar spine at 9 months for Zoledronic Acid and Clinical Observation groups",
        "label": "Contradiction"
    },
    "ad17d770-f8c6-4440-8b95-894a511cab39": {
        "text_answer": " No   Explanation  The statement women diagnosed with claustrophobia and IBS are allowed to participate in the primary clinical trial is not entailed by the evidence Claustrophobia is listed as an exclusion criterion in the secondary trial but it is not mentioned in the primary trial at all IBS Irritable Bowel Syndrome is not mentioned in either trial",
        "label": "Contradiction"
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "text_answer": "Yes  The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II portions while the secondary trial uses the same criteria for all participants",
        "label": "Entailment"
    },
    "aa78eaae-97c9-4f34-97e4-4debfccd1552": {
        "text_answer": "No  Explanation  The statement the zoledronic acid 4 mg group experienced a more significant percentage change in betactx at week 4 in the primary clinical trial compared to the azd0530 175 mg group is not directly entailed by the evidence provided The evidence only gives the percentage change in betaCTX for each group but it does not provide information about the statistical significance of the difference between the two groups",
        "label": "Contradiction"
    },
    "a8fa1843-9726-4f19-a026-7155df678098": {
        "text_answer": "No  Explanation  The statement several cases of hypertension were detected in both cohorts of the primary clinical trial is not directly entailed by the evidence provided The evidence only reports adverse events such as disseminated intravascular coagulation death edema limbs fatigue hepatic failure increased Alanine aminotransferase and Aspartate aminotransferase",
        "label": "Contradiction"
    },
    "832ab731-553d-4d66-a339-1fb60265866a": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only reports the median overall survival in years for two groups of patients who underwent surgical oophorectomy in different phases of their menstrual cycles The statement is about hours missed from work due to health problems which is not mentioned or related to the evidence",
        "label": "Contradiction"
    },
    "019f248f-f753-495a-b579-9d41f65c5b26": {
        "text_answer": "Yes  Explanation  The statement neither the primary nor the secondary clinical trial have reported any adverse events for their participants is entailed by the evidence since the evidence reports that there were no adverse events for both trials",
        "label": "Entailment"
    },
    "8b6e90d0-d3e2-41db-9d70-ce8b216f3795": {
        "text_answer": "Yes The evidence does not explicitly state that the trial is open to AfricanAmerican participants specifically but it does not exclude them either Therefore their participation is allowed based on the given inclusion criteria",
        "label": "Entailment"
    },
    "27fcd959-e1dd-4c76-8e6c-fdf5fe4d257f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "4d1031f5-19e1-43f3-b75a-5e8208b44bfb": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial did not show significant differences between the groups while the secondary trial did show some differences between the reflexology group and the control group",
        "label": "Entailment"
    },
    "f8858128-03f8-4721-a0f5-5f3fce7ab1c4": {
        "text_answer": "  No The statement is not entailed by the evidence as the statement refers to those having assessable bilateral breast cancer while the evidence only mentions unilateral breast cancer",
        "label": "Contradiction"
    },
    "f9ad6db3-d2bc-474c-b666-a971749f6a83": {
        "text_answer": "  Yes the patient can be considered for the primary trial based on the inclusion criteria However the patients eligibility for the secondary trial depends on additional criteria not provided in the statement",
        "label": "Entailment"
    },
    "0090fc12-4092-4255-8952-21ebee889ebb": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the histopathology cell type codes in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "151ebcdf-fc4e-443e-8c2d-5189b65cee5b": {
        "text_answer": "No  Explanation  The statement the secondary trial candidates must meet some Performance Status condition to participate whereas this is not required to be accepted into the primary trial is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for both the primary and secondary trials but it does not explicitly state that performance status is a requirement for the secondary trial and not for the primary trial",
        "label": "Contradiction"
    },
    "b49ac921-1516-409d-9e81-14fc5afc75c6": {
        "text_answer": "No  Explanation  The statement malignant oncocyte is a malignant epithelial cell with abundant eosinophilic or clear granular cytoplasm is not directly related to the inclusion or exclusion criteria of the primary trial The trial only specifies the type of cancer breast carcinoma and certain conditions for participation but it does not mention anything about the specific cell type or cytop",
        "label": "Contradiction"
    },
    "6ee4b112-4ff6-49d0-a7ec-a9e71d309bb9": {
        "text_answer": "No  Explanation  The statement xxyy syndrome is a rare sex chromosome abnormality in which a male child has an extra x and y chromosome is not related to the evidence provided The evidence only includes information about two clinical trials their outcome measurements results and participant numbers There is no mention of xxyy syndrome in the evidence",
        "label": "Contradiction"
    },
    "ef734fea-a713-4fb3-b6e9-0be2dc2b055a": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about a different outcome measurement diffusion weighted imaging and the evidence only provides information about tumor diameter and response rates in the primary and secondary trials",
        "label": "Contradiction"
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "d4b299e3-f371-4311-9ea6-b3301632d7df": {
        "text_answer": "No  Explanation  The statement is not directly related to the adverse events listed in the evidence The statement is about a go ontology object while the evidence is about adverse events experienced by patients in a clinical trial The statement does not entail any information about the adverse events or the patients",
        "label": "Contradiction"
    },
    "9c5bbe3a-c662-4a0e-88cf-b2f5fc1188f8": {
        "text_answer": "No  Explanation  The statement within the scope of the primary clinical trial the prevalence of hypertension and pancreatectomy cases were equivalent to the rate of hepatotoxicity cases is not entailed by the evidence The evidence states that the prevalence of hypertension and pancreatectomy cases were each 1250 while the prevalence of hepatotoxicity cases was 37",
        "label": "Contradiction"
    },
    "47c91759-a386-407e-9612-dbce68040a7b": {
        "text_answer": "No  The statement is not directly related to the evidence provided which pertains to adverse events in a clinical trial The statement is about a persons thoughts or desires which is not addressed in the evidence",
        "label": "Contradiction"
    },
    "2db7c3cd-eb62-4ec4-8d89-effa9c9212e0": {
        "text_answer": "No  Explanation  The statement both the primary and secondary clinical trials have recorded instances of anorexia hypothermia and hallucinations in their aes is not entailed by the evidence provided The evidence only states that there were no instances of anorexia hypothermia and hallucinations recorded in the primary and secondary trials for Adverse Event 1 The evidence does not mention anything about Adverse Event ",
        "label": "Contradiction"
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ee7fc1bb-98fe-4f43-9ea0-076b7fc7eeca": {
        "text_answer": "No  Explanation The evidence provided in the text does not contain any information about patients experiencing no pain whatsoever during the study The text only reports the average pain intensity scores and the confidence intervals for the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "fb140d2c-d2a8-4442-bcbd-669bb9abbf2c": {
        "text_answer": "  No   Explanation   The statement there are no restrictions regarding the participation of cancer patients diagnosed with either fibromyalgia thalasemic syndromes or anemia in the primary clinical trial and the secondary clinical trial is not entailed by the evidence   In the primary clinical trial anemia is an inclusion criterion but fibromyalgia and thalasemic syndromes are",
        "label": "Contradiction"
    },
    "c01a6286-57b2-4851-8c5e-12710eb9d829": {
        "text_answer": "  No the statement about children and adolescents not being eligible for the primary trial due to height requirement is not directly related to the evidence provided However the statement does not contradict the evidence as children and adolescents are not explicitly excluded from the secondary trial The statement about receptive vocabulary assessment is not related to the evidence at all",
        "label": "Contradiction"
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib is not entailed by the evidence provided The primary trial participants receive pembrolizumab every 3 weeks Q3W while sunitinib in the secondary trial is given on various schedules including continuous dosing every day and every 8 weeks for some participants The",
        "label": "Contradiction"
    },
    "128fd57d-cc06-40a3-8eb5-570441a19652": {
        "text_answer": "No  Explanation The statement the interventions implemented in the primary clinical trial skip the use of laserassisted fluorescence angiography and adopt different techniques is not directly entailed by the evidence provided The evidence states that laserassisted fluorescence angiography is used in both intervention groups Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort at three separate time",
        "label": "Contradiction"
    },
    "10818b02-4a1d-438a-8f90-7aded2b826ec": {
        "text_answer": "No  Explanation The statement counselor is a person with training to provide advice or instruction is not directly related to the evidence provided The evidence only includes information about two different treatment arms Arm II and Arm III of a primary trial their descriptions the number of participants analyzed and the mean with standard deviation of the home record of severity of delayed nausea for each arm There is no mention of a counselor",
        "label": "Contradiction"
    },
    "6a696416-b67e-4f78-8677-3fbc4470b4c1": {
        "text_answer": "No  Explanation  The statement age at initial pathologic diagnosis is a question about the age of the individual at the time of the initial pathologic diagnosis is a general statement that is not directly related to the specific adverse events listed in the evidence The statement does not mention coronary artery stenosis which is the most common adverse event recorded in the primary trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9c253aed-c7ae-42ad-afd2-9c52c9ecab08": {
        "text_answer": "  Yes the patient is eligible for both trials based on the provided information However its important to note that the patient would need to meet all other inclusion criteria and none of the exclusion criteria for each trial separately",
        "label": "Entailment"
    },
    "63cb536d-5250-4760-b3a8-103bfcc45123": {
        "text_answer": "No  The evidence provided does not mention anything about trabecular pattern or neoplastic cells",
        "label": "Contradiction"
    },
    "3136ac0b-82b2-4819-a5ba-d5816dd0283b": {
        "text_answer": "No   Explanation  The statement all patients in the primary clinical trial encountered aes is not entailed by the evidence as not all adverse events were mentioned in the evidence Only two specific adverse events were mentioned gastroesophageal reflux disease and ductal carcinoma in situ each occurring in one patient The evidence does not indicate that all 35 patients in the trial experienced these or any other adverse",
        "label": "Contradiction"
    },
    "d2ac18d1-d427-4afc-b72a-4de7856b17d5": {
        "text_answer": "Yes  Explanation  The statement all cases of gastrointestinal and bloodrelated disorders in the primary clinical trial were for patients in cohort 1 is entailed by the evidence because all the adverse events gastrointestinal and bloodrelated disorders mentioned in the evidence occurred in cohort 1",
        "label": "Entailment"
    },
    "8b14dd2f-b02e-41be-a2bc-7dcc378ab426": {
        "text_answer": "No  Explanation  The statement The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial is not directly entailed by the evidence provided The evidence only states the dosages and interventions used in each trial but it does not provide any information about the number of times one dosage is higher than the other",
        "label": "Contradiction"
    },
    "e1eb6c8e-61e1-474a-a01c-f7d18d2620e9": {
        "text_answer": "No  Explanation  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only states that there were no adverse events in both cohorts 1 and 2 of the primary trial The statement about the number of adverse events being different between the two cohorts is not",
        "label": "Contradiction"
    },
    "8655fdcd-564c-483a-aa2b-7dac2d84ce57": {
        "text_answer": "No  Explanation The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is entailed by the evidence but the statement main duct pancreatic intraductal papillarymucinous neoplasm is an intraductal papillarymucinous neoplasm of the pancre",
        "label": "Contradiction"
    },
    "e8edca4b-3a7c-43b6-aed4-8651d1dee36f": {
        "text_answer": "No  Explanation  The statement infections occurred in over 15 of patients involved in both the primary and secondary clinical trials during the study period is not entailed by the evidence The evidence only reports the number and percentage of adverse events related to infections in each trial but it does not provide the total number of patients involved in each trial or the percentage of patients who experienced infections in both trials Therefore it is impossible to determine",
        "label": "Contradiction"
    },
    "682a4e2d-f4a5-4fee-8399-195f67fcdfcc": {
        "text_answer": "No  Explanation  The statement at different intervals throughout the trials the same dose of trastuzumab administered to patients in cohort 2 of the secondary clinical trial is also given to those in the primary clinical trial is not entailed by the evidence The primary trial administers trastuzumab at a loading dose followed by a weekly dose while the secondary trial administers Herceptin a form of trastuzum",
        "label": "Contradiction"
    },
    "4b310647-d605-4946-aeb5-bcfd418e1332": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial both intervention one and two use pihgc as their method is not entailed by the evidence The evidence only states that both interventions use radioactive Tc99M sulfur colloid for lymphoscintigraphy It does not specify that they use a handheld gamma camera piHGC for the procedure",
        "label": "Contradiction"
    },
    "cd93653b-f6d1-4e8c-aa04-20a41d0096b9": {
        "text_answer": "Yes  Explanation The statement anemia cases are less prevalent in the primary clinical trial than in the secondary clinical trial is entailed by the evidence since the prevalence of anemia in the primary trial is 000 while in the secondary trial it is 430",
        "label": "Entailment"
    },
    "e255fdb7-4e8b-4e62-bbb8-875687948bed": {
        "text_answer": "Yes  Explanation The evidence states that during the primary clinical trial there were 5 participants in the placebo group who were analyzed This means that 5 participants in the placebo group experienced the intervention of receiving a sugar pill instead of aprepitant The statement all the participants of the primary clinical trial subjected to the placebo intervention experienced incidences of vomit is not explicitly stated in the evidence However it can be inferred",
        "label": "Entailment"
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "text_answer": "Yes The evidence does not specify eligibility based on nationality ethnicity psychiatric condition or gender",
        "label": "Entailment"
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "text_answer": "No  Explanation  The statement the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts on the other hand the secondary trial reports the percentage of patients that experience Objective Response is not entailed by the evidence provided  The primary trial reports the median Time to Progression TTP in months for each arm Arm A and Arm B with their respective confidence",
        "label": "Contradiction"
    },
    "22f473e7-1aea-4baf-9697-224ea4c6fbdf": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial describes the use of Vorinostat and radiation therapy with dosing information for Vorinostat It does not mention anything about the administration of Fentanyl sublingual spray during the trial",
        "label": "Contradiction"
    },
    "03ee1d82-5208-4511-9163-23adfbc55fa4": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial specifically excludes women with stage IV disease while the secondary trial includes only women without distant metastatic disease stage IIII",
        "label": "Contradiction"
    },
    "3f532833-d78c-41a1-b364-81228e03027e": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary and secondary trials involve different interventions and patient populations In the primary trial dexmedetomidine is an intervention while in the secondary trial it is not mentioned as an intervention for any group",
        "label": "Contradiction"
    },
    "fd942f9a-9ad7-43f3-aac3-69b01a022811": {
        "text_answer": "No  Explanation  The statement gastric pylorus carcinoma is a carcinoma that arises from the pylorus is not directly related to the inclusion or exclusion criteria provided in the evidence The evidence only specifies the criteria for patient participation in two clinical trials and the statement about gastric pylorus carcinoma does not meet the definition of an inclusion or exclusion criterion Therefore the statement is",
        "label": "Contradiction"
    },
    "8fe01416-c839-4ffc-bd21-25d158d502b8": {
        "text_answer": "Yes The evidence states that there was no case of wound dehiscence reported in the primary clinical trial",
        "label": "Entailment"
    },
    "1a3483cd-0a92-456f-ba18-6ce12b3ded0b": {
        "text_answer": "Yes The evidence states that significant cardiovascular impairment is an exclusion criterion for both trials",
        "label": "Entailment"
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials include patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma as inclusion criteria",
        "label": "Entailment"
    },
    "68b82fb4-066b-4d76-9623-ff8696da3000": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fae99e77-42d1-4003-bb7a-3b98b88f7c27": {
        "text_answer": "No   Explanation  The evidence states that no adverse events were documented in either cohort The statement suggests that adverse events were documented in both cohorts but the evidence does not support this claim",
        "label": "Contradiction"
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "text_answer": "No  Explanation  The statement Cohort A and B of the primary trial are administered the same Two IM injections of LD V935 at the same point in the cycle is not entailed by the evidence While both cohorts receive two IM injections of V935 LD the timing and sequence of the injections are different between the two cohorts In Cohort A the two in",
        "label": "Contradiction"
    },
    "69c802bf-ab3f-4a0a-b995-210db2403a50": {
        "text_answer": "yes The primary trial involves adjusting the dosage of alpha lipoic acid while the secondary trials first cohort maintains a steady dose of necitumumab",
        "label": "Entailment"
    },
    "f96f9461-2b00-4838-9e04-1d3a8dbeb3f3": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial involves the use of epirubicin 100 mgm2 cyclophosphamide 600 mgm2 docetaxel 75 mgm2 and trastuzumab 6 mgkg and 4 mgkg in the neoadjuvant therapy regimen However the statement only mentions the upper limit",
        "label": "Entailment"
    },
    "01effe7e-449f-4f59-a64e-2b38c5c21187": {
        "text_answer": "No  Explanation  The statement 2 out of 73 individuals in the primary clinical trial have suffered an acute myocardial infarction compared to zero out of 1674 individuals in the secondary clinical trial is not entailed by the evidence provided The evidence only states that there were no cases of acute myocardial infarction reported in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "ece744da-a8d6-401a-972c-3a9f5cd60b14": {
        "text_answer": "Yes  Each individual adverse event was reported in only one patient",
        "label": "Entailment"
    },
    "21d37b8b-4326-40bd-a070-5ad0fbb48e6d": {
        "text_answer": "  No   Explanation   The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for all cohorts of the primary trial is not directly entailed by the evidence provided The evidence only specifies that the trial includes patients with ERHER2 invasive breast cancer Group 1 and invasive triplenegative breast cancer Group 2",
        "label": "Contradiction"
    },
    "1b5e0318-38e0-484f-bffd-d63ff75fe93c": {
        "text_answer": "No   Explanation The statement neither the primary clinical trial nor the secondary clinical trial registered any adverse events is not entailed by the evidence While the primary trial did not report any adverse events for the specific condition mentioned in the statement the secondary trial did report 2 adverse events out of 35 participants",
        "label": "Contradiction"
    },
    "f5daafd4-0b8b-4239-b566-e7b2c1b80825": {
        "text_answer": "  No   Explanation   The statement patients who have received chemotherapy or radiotherapy in the last 14 days suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not directly entailed by the evidence provided   The evidence lists the exclusion criteria",
        "label": "Contradiction"
    },
    "ce4851a3-948d-4eca-8d86-2a70f3bbd577": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the interventions in the primary clinical trial are administered sublingually under the tongue and not inhalation and the secondary trial employs oral by mouth administration not intramuscular",
        "label": "Contradiction"
    },
    "b21fa80a-d451-46c7-8916-bf3029156624": {
        "text_answer": "Yes The evidence explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study",
        "label": "Entailment"
    },
    "3958b171-1f79-4dae-958a-be87bb3b44c0": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f498a2b6-b3da-45a2-b9d5-ef87ee43914f": {
        "text_answer": "Yes The statement does not conflict with the inclusion or exclusion criteria in the evidence The statement only pertains to the genetic condition required for trial eligibility which is not addressed in the criteria",
        "label": "Entailment"
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "text_answer": "No  The evidence only mentions unilateral breast cancer",
        "label": "Contradiction"
    },
    "5a1445df-c3d7-4d1e-a4d3-e18ac2238a97": {
        "text_answer": "Yes  Explanation  The statement during the primary clinical trial and the secondary clinical trial no cardiac or psychiatric adverse events were reported is entailed by the evidence since the evidence indicates that there were no reported cardiac or psychiatric adverse events in both trials",
        "label": "Entailment"
    },
    "d17230ee-836d-4153-b940-8e3dd7741964": {
        "text_answer": "No  Explanation  The statement a weekly cycle of 4demethyl4cholestryloxycarbonylpenclomedine is a shared necessity amongst the primary and secondary clinical trials is not entailed by the evidence The evidence describes two separate clinical trials each with its own interventions and dosing schedules for 4demethyl4cholestryloxycarbonylpen",
        "label": "Contradiction"
    },
    "62d189a0-04ee-44d7-962e-35629b28736c": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug but it does not mention a specific time frame for a pulmonary embolism The secondary trial does mention a pulmonary hemorrhagebleeding event NCI CTCAE v30",
        "label": "Contradiction"
    },
    "321c299b-2264-4cc6-988d-faef346ca38a": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not mention anything about Mucor racemosus IgG4 measurement in relation to the trials provided The evidence only describes the interventions used in each trial including the use of Botulinum Toxin Type A and placebo in the primary trial and MLN8237 at different doses in the secondary trial",
        "label": "Contradiction"
    },
    "d8af88b9-e015-4eec-b49f-6b2398e38a5d": {
        "text_answer": "No  Explanation  The statement synchronous nodules without dominant lesions is a finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events observed in two separate trials involving multiple pulmonary nodules It does not provide any information about the presence or absence of dominant les",
        "label": "Contradiction"
    },
    "db5f7526-ae64-4a0c-bea4-53b4bfe95d48": {
        "text_answer": "No   Explanation  The statement patients will need to receive one single injection on day 8 of the study is not mentioned in the evidence The evidence only mentions the administration of sargramostim GMCSF on day 8 for patients with neutrophil counts below 1000mm3 The statement about thinbranching papillae is not related to the evidence at all",
        "label": "Contradiction"
    },
    "d4f98c24-aad0-4784-9b90-da1a99b9a59b": {
        "text_answer": "Yes  Explanation  The evidence provides the percentage of participants in each group ERpositive Luminal B and Triple Negative who demonstrated a decrease in the growth factor signature GFS after receiving a single dose of dalotuzumab The statement in question asserts that a smaller percentage of participants in the ERpositive Luminal B group showed a decrease in GFS compared to the Triple Negative group The evidence",
        "label": "Entailment"
    },
    "3137468e-52bf-4bff-a3cc-68f127683f63": {
        "text_answer": "No  Explanation  The statement in comparison to the primary clinical trial the secondary clinical trial has tracked a slight escalation in total adverse events within its patient cohorts is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number between them or indicate an escalation",
        "label": "Contradiction"
    },
    "060a4ded-7677-4945-90ff-b6b93204f94c": {
        "text_answer": "  Yes for the primary trial pulmonary embolism is a reason for exclusion within 4 weeks for the secondary trial it is a reason for exclusion within 6 months but the decision is left to the investigator",
        "label": "Entailment"
    },
    "a02d9319-0103-493a-8368-f79dbbe6a223": {
        "text_answer": "No  Explanation  The statement ascites was more likely to occur in patients from the secondary clinical trial is not directly entailed by the evidence The evidence only indicates that ascites occurred in 2223 090 patients in the primary trial and 19 1111 patients in the secondary trial However the sample sizes are significantly different between the two trials making a direct comparison of the",
        "label": "Contradiction"
    },
    "22aed38a-d9c2-4e5e-b738-07f75968c45a": {
        "text_answer": "No   Explanation  The evidence provided does not indicate the number of patients who experienced adverse events It only reports the percentage of patients who completed the treatment regimen",
        "label": "Contradiction"
    },
    "4d8795f1-f8bf-4c27-9eb1-3f7db45c03ec": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the administration of PD0332991 in the clinical trial The evidence only mentions the different schedules of CUDC101 administration between cohort 1 and cohort 2",
        "label": "Contradiction"
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "text_answer": "Yes Both trials allow ECOG performance status of 02 including a score of 1",
        "label": "Entailment"
    },
    "e8b222ce-e235-4b8d-b524-521ba583656a": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the primary clinical trial was diarrhea affecting approximately 8 of patients while no adverse events were recorded in the secondary clinical trial is not entailed by the evidence provided The evidence states that there were no adverse events recorded in the secondary clinical trial but it does not provide information about the most common adverse event in the primary clinical trial The statement incorrectly",
        "label": "Contradiction"
    },
    "3bf96cd4-147b-45f2-b174-e3a375a67e26": {
        "text_answer": "No  The statement is not about breast cancer and hormonal treatment as per the evidence provided It is about repeat expansion diseases which is a different concept",
        "label": "Contradiction"
    },
    "b06e2353-00ae-4f10-b072-a4ae5f608d3e": {
        "text_answer": "Yes However its important to note that the statement is not explicitly stated in the evidence but the inclusion criteria for both trials do not exclude patients based on their previous cancer status as long as they meet the other criteria",
        "label": "Entailment"
    },
    "15414f62-cb14-4bf8-98aa-0fbd74edd41c": {
        "text_answer": "No  Explanation  The primary trial does show that the intraoperative mammography arm had a shorter operating room time on average compared to the standard mammography arm However the statement in question makes an incorrect conclusion based on this information stating that standard mammography is more efficient than intraoperative mammography based on this single outcome measure The statement also incorrectly assumes that the secondary trial contains a control group for comparison purposes when in fact",
        "label": "Contradiction"
    },
    "8c507ad1-b534-4d16-9a1b-5c92a432eb9d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial does evaluate massage therapy as an intervention which is not a drugbased treatment Therefore the statement only applies to the secondary trial which does not test any massage therapy interventions",
        "label": "Contradiction"
    },
    "dbc1b653-7c38-4c7c-bad8-5949d6f909ed": {
        "text_answer": "Yes but with the caveat that the statement does not directly address the inclusion criteria for nonmeasurable unilateral breast cancer in the clinical trial as stated in the evidence However the evidence does not explicitly exclude nonmeasurable breast cancer so it can be inferred that they are eligible as long as all other inclusion and exclusion criteria are met",
        "label": "Entailment"
    },
    "3eb6d0c5-4bc4-4808-b8cb-03b3d5d40a07": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial is utilizing on the investigation of varying quantities of a single therapy on its group whereas the secondary clinical trial is exploring the outcomes from different radiation treatments on its participants is entailed by the evidence  In the primary clinical trial there are two groups A and B receiving different interventions but both groups are using the same therapy Hydrophor or MediHoney in varying",
        "label": "Entailment"
    },
    "2735976f-a517-4b4e-addb-845ef4dc0d33": {
        "text_answer": "No  Explanation  The statement patients having unregulated high blood pressure along with malignant ductal carcinoma in situ are eligible for the secondary clinical trial but their participation in the primary clinical trial is excluded is not directly entailed by the evidence provided  The primary trial excludes patients with uncontrolled hypertension defined as systolic blood pressure 160 mm Hg andor diastolic",
        "label": "Contradiction"
    },
    "4dc9c970-22dc-4117-8169-255a0b3f80d8": {
        "text_answer": "No  Explanation  The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not entailed by the evidence provided The evidence only mentions suicidal ideation as a psychiatric adverse event and it does not mention anything about eating disorders or Schizophrenia Therefore the statement is not a logical conclusion that can be drawn from the evidence alone",
        "label": "Contradiction"
    },
    "043f8072-1e16-4e74-8ad4-50ff1786fb48": {
        "text_answer": "No  Explanation  The statement less than 3 of patients in the primary clinical trial and the secondary clinical trial documented adverse events is not entailed by the evidence provided The evidence shows that the percentage of patients with documented adverse events in the primary trial was 4545 and in the secondary trial was 1563 These percentages are not less than 3",
        "label": "Contradiction"
    },
    "31837502-2949-4dc4-bfbe-fc54ca5ccb01": {
        "text_answer": "No  Explanation  The statement abnormal involuntary movement scale aims0108 through aims0109 original result  moderate is abnormal is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials The trials only mention the inclusion and exclusion criteria for patient participation and the statement is about the results of an abnormal involuntary movement scale",
        "label": "Contradiction"
    },
    "ba589a4b-13ef-43be-8441-438742dd9d5c": {
        "text_answer": "No  Explanation  The statement tumor findings evaluator is a person who determines the significance of a tumor findings assessment is not directly related to the evidence provided The evidence only mentions the outcome measurements and their units of measure for two separate clinical trials The first trial focuses on vaginal symptoms and the second trial focuses on objective response rate of HER2negative metastatic breast cancer The statement about the tumor findings evaluator is",
        "label": "Contradiction"
    },
    "b0c8481b-3041-4b12-b272-11bb5ee7f80e": {
        "text_answer": "No  Explanation  The statement half of primary clinical trials participants and 8371674 of the secondary trials participants experienced an adverse event is not entailed by the evidence provided The evidence only reports the number and percentage of participants who experienced specific adverse events in each trial but it does not provide the total number of participants who experienced any adverse event Therefore it is impossible to determine whether half",
        "label": "Contradiction"
    },
    "5d657b3f-a074-480e-8698-24c288553369": {
        "text_answer": "Yes The evidence does not mention any interventions involving drugs radiotherapy or CBT in the primary clinical trial",
        "label": "Entailment"
    },
    "145671c6-1b45-49a9-9fc7-8c65e8461115": {
        "text_answer": "Yes The statement does not mention specific adverse events related to cerebral artery but the evidence states that there were no adverse events recorded in the trial for both cohorts Therefore the statement about cerebral artery not being mentioned in the adverse events is entailed by the evidence",
        "label": "Entailment"
    },
    "0e28f749-6c65-46fc-93c0-c3b68c96460e": {
        "text_answer": "Yes The placebo is administered via intravenous infusion on Day 1 while trabectedin is administered via intravenous infusion on Day 2",
        "label": "Entailment"
    },
    "97c738f3-a7ef-4183-9664-5aac4fd64a0e": {
        "text_answer": "Yes  Explanation  The statement the number of participants in the secondary clinical trial exceeded those in the primary clinical trial is entailed by the evidence because the secondary clinical trial had a total of 30 participants analyzed while the primary clinical trial had only 13 participants analyzed",
        "label": "Entailment"
    },
    "451e07e2-524d-459e-872c-1c4b3640f511": {
        "text_answer": "No  Explanation The statement feel hopeless is a question about whether an individual feels or felt hopeless is not directly related to the evidence provided The evidence only mentions the interventions used in two trials one involving CBTI and Armodafinil and the other involving MCS110 and PDR001 It does not mention anything about the participants feeling hopeless or not Therefore the statement cannot be",
        "label": "Contradiction"
    },
    "7f3a5491-e157-4fbc-a939-8478889c15dc": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the change in total sleep time in minutes before and after the first cycle of Lenalidomide treatment The two trials address different outcomes and do not directly relate to cognitive disorders",
        "label": "Contradiction"
    },
    "67b45a2f-d082-4386-b70e-eb212a1762a0": {
        "text_answer": "Yes The statement is entailed by the evidence as the inclusion criteria for both phases of the clinical trial allow for patients of any gender with a solid tumor that is locally advanced or metastatic",
        "label": "Entailment"
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "text_answer": "No  Explanation  The evidence provided states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR However the statement asks if over half of the patients experienced a confirmed complete response CR specifically Since the number of patients with a CR is not explicitly stated in the evidence it",
        "label": "Contradiction"
    },
    "ddf14eb0-04ae-431b-b4e8-ba97eddc25b7": {
        "text_answer": "No  The statement is not entailed by the evidence  The primary trial involves injections of Fluciclatide and the secondary trial involves oral administration of Chloroquine",
        "label": "Contradiction"
    },
    "c8c9752f-a60b-4173-bbe7-deb1a894ebe5": {
        "text_answer": "Yes The secondary trial involves the use of a drug PF06647020 with different dosages while the primary trial focuses on massage therapy and does not mention any medicationrelated analyses",
        "label": "Entailment"
    },
    "c3445b55-8b79-4ac0-9ace-25e48c82760c": {
        "text_answer": "  No  Explanation  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 365730 days to be eligible for the primary trial is not directly entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for both the primary and secondary trials It does not mention anything about the age requirement for a waiting period in the primary trial",
        "label": "Contradiction"
    },
    "2fc8ee27-e602-47ae-a93b-1c8194e3d6ea": {
        "text_answer": "No   Explanation  The evidence describes two interventions in the primary clinical trial both of which involve the use of a compact disc CD for instruction on paced breathing Therefore the statement that none of which include a cd is not entailed by the evidence",
        "label": "Contradiction"
    },
    "79ddd80e-a0b2-4450-a0df-892e8b15dd63": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "57bc58fc-44ce-4938-9bfa-4750bac013ac": {
        "text_answer": "No  Explanation  The statement adverse events were commonplace and severe in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The evidence only shows the frequency and types of adverse events in each trial but it does not indicate that they were severe or commonplace for both trials The statement makes a stronger claim than what is supported by the evidence",
        "label": "Contradiction"
    },
    "26091849-cc57-4866-8faa-ac9fb64caf69": {
        "text_answer": "No  Explanation  The statement There are less total adverse events in the primary trial than in the secondary trial but more cases of Cardiacischemiainfarction in the primary trial than in the secondary trial is not directly entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each type in both trials but it does not compare the total number of adverse events between the two trials or",
        "label": "Contradiction"
    },
    "e3e8c1c5-ae1f-4f90-8584-b24096bb580a": {
        "text_answer": "No  Explanation The statement does not mention anything about the IPSSR risk category being a criterion for eligibility in the primary trial The evidence only mentions the inclusion and exclusion criteria related to gender age diagnosis disease measurability and prior chemotherapy lines in the metastatic setting",
        "label": "Contradiction"
    },
    "21d59751-a53d-4262-8410-9959aa93dea4": {
        "text_answer": "No   Explanation  The statement the number of participants in cohort 1 and cohort 2 of the primary clinical trial are identical is not entailed by the evidence provided The evidence only states the number of participants analyzed in each armgroup for both cohorts but it does not indicate that the number of participants in cohort 1 and cohort 2 are the same",
        "label": "Contradiction"
    },
    "e57df144-6c3e-4855-a2d3-fcbec0396750": {
        "text_answer": "Yes  Explanation  The statement There was at least 1 case of infection in both the primary trial and the secondary trial is entailed by the evidence since there is at least one instance of infection reported in the primary trial 132 or 313 and in the secondary trial 115 or 667  The mention of malignant bronchial neoplasm is not",
        "label": "Entailment"
    },
    "ecf58a7c-3e70-4ac2-b37f-d96294786b0d": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide any information regarding the mobility or selfcare capability of the trial candidates The inclusion and exclusion criteria focus on the cancer diagnosis treatment history laboratory values and other health conditions",
        "label": "Contradiction"
    },
    "eb853544-9c67-43a4-bbfa-c5e35dec2a33": {
        "text_answer": "Yes The statement does not contradict the evidence and is consistent with it The evidence describes the interventions being administered intravenously on different days and the statement correctly identifies the type of cardiac myxoma and the manner in which the interventions are administered",
        "label": "Entailment"
    },
    "95759249-3a95-4735-8ef0-13ec3558aa27": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the evidence does not mention any requirement for a CT scan or blood tests for the primary trial participants The primary trial only requires mammography",
        "label": "Contradiction"
    },
    "1dd105a3-5dd4-423a-a40f-ed78e119e698": {
        "text_answer": "Yes  Explanation  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in less than 001 of participants is entailed by the evidence since the adverse events in both trials had a frequency of 000 or less",
        "label": "Entailment"
    },
    "86609ec7-6d7c-4447-94b4-c9c99d5fd5e1": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 1000 the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that there were 3 hepatotoxicity cases 1 hypertension case and 1 pancreatectomy case making the ratio of hepatotoxicity cases to",
        "label": "Contradiction"
    },
    "b09ea9c8-e3a2-4c82-bbe8-5e84ea151138": {
        "text_answer": "No  Explanation  The statement the primary trials inclusion and exclusion criteria remain constant across phases and the secondary trial does not differentiate in terms of criteria for healthy participants and those with cancer is not entailed by the evidence The primary trial has different inclusion criteria for Phases I and II and the secondary trial has specific inclusion criteria for patients undergoing mastectomy Therefore the statement is not a valid conclusion based on the provided",
        "label": "Contradiction"
    },
    "3d35c61e-075e-475e-b3aa-15c04db3a579": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the doses of abraxane being identical between the two groups While both groups receive nabPaclitaxel the carboplatin dose in Arm B is different from the gemcitabine dose in Arm A",
        "label": "Contradiction"
    },
    "7ffa3719-812d-4849-b0c7-d34ab22f35f6": {
        "text_answer": "Yes The evidence does not provide sufficient information to make a definitive comparison between the two groups in the secondary trial",
        "label": "Entailment"
    },
    "a2e2d75b-ce3e-4bf6-bfce-c151b9d183d4": {
        "text_answer": "No  Perjeta is not mentioned in the evidence Perjeta is a monoclonal antibody that targets the HER2 receptor and is often used in combination with other therapies such as trastuzumab and pertuzumab However the evidence only mentions the use of 89Zrtrastuzumab and 89Zrpertuzumab in the secondary trial",
        "label": "Contradiction"
    },
    "43a347ac-a46d-47cd-80d5-7d83b23bcde9": {
        "text_answer": "Yes The evidence states that patients with histologicallycytologically confirmed breast cancer are eligible for the clinical trial",
        "label": "Entailment"
    },
    "8fd1a8ed-8b74-4021-8a90-0400817fda1b": {
        "text_answer": "Yes  Explanation The evidence states that there were no adverse events in both cohort 1 and cohort 2 of the primary clinical trial The statement there were no patients suffering adverse events in either cohort 1 or cohort 2 is a clear and accurate reflection of the evidence Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "2cee68da-471f-4c13-811e-9d7ef91d587e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement mentions pregabalin in the primary trial and Depocyt and HDMTX in the secondary trial as separate interventions but the evidence does not indicate that the two trials compare pregabalin to Depocyt and HDMTX",
        "label": "Contradiction"
    },
    "65cfa1ae-05d3-4a90-ad5a-852f3cfdf3fc": {
        "text_answer": "Yes The evidence does not provide units of measure for cm Number of Participants or a unit of time in the given outcome measurements",
        "label": "Entailment"
    },
    "5865807e-233c-4a7d-a900-de4af3bdaaf5": {
        "text_answer": "No  Explanation  The evidence provided in the text states that the percentage of participants with invasive diseasefree survival iDFS events in the Neratinib arm was 47 while in the Placebo arm it was 75 A lower rate of iDFS in the Placebo group would mean a percentage lower than 47 However the Placebo group had a higher percentage of iDFS events ",
        "label": "Contradiction"
    },
    "786542cd-3793-47a4-b954-9b6c5aa2e652": {
        "text_answer": "No  Explanation  The statement the same three electroporation injections of ld v934 are given to cohort a and b in the primary clinical trial is not entailed by the evidence While it is true that both cohorts A and B receive three electroporation injections of V934 LD the timing and sequence of the injections are different between the two cohorts Cohort A receives",
        "label": "Contradiction"
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1c4ca195-bc07-4d75-ac19-f7969a20e168": {
        "text_answer": "No  The evidence does not provide any information about the interventions used in the secondary clinical trial",
        "label": "Contradiction"
    },
    "e7204781-fa14-4418-94a4-2660bcd64eeb": {
        "text_answer": "Yes The primary trial involves surgery and administration of seven distinct drugs via different routes IV PO SC while the secondary trial only involves administration of two distinct drugs oral",
        "label": "Entailment"
    },
    "efbed283-d725-4f05-8e7a-3cb43ce470e6": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the two groups in the primary clinical trial receive different interventions before receiving the identical two IM injections of V935 LD Group A receives only two IM injections of V935 LD while Group B receives three EP injections of V934 LD followed by two IM injections of V935 LD The timing of the identical injections",
        "label": "Contradiction"
    },
    "6acfb64a-4e08-4cdb-b52d-f0a5c466de4d": {
        "text_answer": "No  Explanation  The statement The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort is not entailed by the evidence provided The evidence only states the details of the two different arms of the trial including the number of participants analyzed and the doses of the drugs being administered It does not provide any information about",
        "label": "Contradiction"
    },
    "d595c94d-93d0-410b-9089-0e026867561f": {
        "text_answer": "No  Explanation  The statement Most the primary trial candidates suffered from some kind of eating disorder during the study duration is not entailed by the evidence provided The evidence only lists the adverse events observed in the primary trial including some gastrointestinal events such as anorexia and hyperglycemia but it does not suggest that most of the candidates suffered from eating disorders The statement goes beyond the information provided in the",
        "label": "Contradiction"
    },
    "8093f77e-bb52-47c9-9c58-4be084c8736b": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "2eb882ed-836b-424c-a9b2-06d97f0b2b9e": {
        "text_answer": "No  The evidence does not mention anything about cognitive behavioral therapy being included in the interventions for both cohorts of the primary clinical trial",
        "label": "Contradiction"
    },
    "11daa2f8-2ecf-49f7-aa69-844a2bade4b6": {
        "text_answer": "No  Explanation  The statement Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial who were receiving far lower doses of Empegfilgrastim is not directly entailed by the evidence provided The evidence only shows the mean duration of neutropenia and the number of participants with neutropenia in each cohort",
        "label": "Contradiction"
    },
    "4c9638ac-5716-4657-9279-f756aea52867": {
        "text_answer": "No  Explanation  The statement participants in the secondary clinical trial only receive a pair of drugs and do not need surgery is not entailed by the evidence While it is true that the secondary trial only involves the use of two drugs everolimus and exemestane the primary trial includes both chemotherapy and targeted therapy as well as various surgical procedures The statement does not accurately reflect the contents of both trials",
        "label": "Contradiction"
    },
    "029ee1b5-a81a-4690-9f03-442dcf0f5e9c": {
        "text_answer": "No  Explanation  The statement We cannot compare the adverse events in the primary trial and the secondary trial as they do not appear to have been recorded for the primary trial is not directly entailed by the evidence provided The evidence only reports the number and percentage of adverse events in the secondary trial but it does not mention whether or not adverse events were recorded in the primary trial Therefore it is not possible to make a definitive statement",
        "label": "Contradiction"
    },
    "ecf95a54-fa38-4492-9597-ce81b5a2b661": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts follow the same instructional CD for paced breathing However cohort 2 practices it twice daily and receives weekly chemotherapy",
        "label": "Entailment"
    },
    "89558178-d2e5-4376-8656-14ba666b44a3": {
        "text_answer": "No  Explanation  The statement the primary clinical trial does not accept patients who have had an organ transplant in the past month however the secondary clinical trial may consider them is not directly entailed by the evidence provided The primary trials exclusion criteria do not mention anything about organ transplantation The secondary trials inclusion criteria do not mention anything about organ transplantation but it is stated that they have adequate pulmonary function",
        "label": "Contradiction"
    },
    "42ac258c-8420-4a90-b427-d7ca64f246af": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the statement incorrectly assumes that the patients in group 2 of the primary trial received myalgias pain in muscles instead of dexmedetomidine The evidence only states that group 2 received dexmedetomidine not myalgias The secondary trial is not related to the primary trial in this regard",
        "label": "Contradiction"
    },
    "dd7bc677-cddb-4619-893e-aa5b801a0b1a": {
        "text_answer": "No  Explanation  The older male patient with nonmetastatic HER2negative PRnegative breast cancer is not eligible for the primary clinical trial as the trial only includes female patients The secondary clinical trial includes both female and male patients but the patient does not meet all the inclusion criteria such as having newly diagnosed breast cancer and being of childbearing potential or surgically sterilized Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "29987f94-8331-4136-92f1-4ea5f5c232b9": {
        "text_answer": "No  Explanation The statement every participant in the primary clinical trial is administered a minimum of 20mg of mcs110 triweekly is not entailed by the evidence The evidence only states that the participants in the primary clinical trial received MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose of 100",
        "label": "Contradiction"
    },
    "823088ba-be25-4691-aa10-9e86b80fbf8c": {
        "text_answer": "yes anemia and pneumonia were more frequent in the secondary trial stupor was present in the secondary trial but not in the primary trial However the statement does not mention the frequency of stupor in the primary trial so the statement is not entirely accurate as it stands A more accurate statement would be patients in the secondary clinical trial experienced anemia pneumonia and stupor more frequently than those in the primary clinical",
        "label": "Entailment"
    },
    "36a5e0dd-7e3a-4362-9726-0836f7a4c64e": {
        "text_answer": "No  Explanation  The evidence provided in the given text does not entail the statement that several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes on chromosome band 11q22q23 The text only mentions the correlation of Vitamin D levels with the gene expression profile but it does not specify which chromosome band or which group",
        "label": "Contradiction"
    },
    "373e57af-cf54-40c6-9906-eff8eb5d7306": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "018fd266-6def-4792-85e4-0b12108281b3": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trial does have a placebo group Arm II and the secondary trial does have a control group Lowdose Oxybutynin Chloride Group However its important to note that the terms test group and control group are often used interchangeably with intervention group and placebo group respectively In this context the",
        "label": "Entailment"
    },
    "d44338be-9054-466e-8cb6-388fd8024e9d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only compares the doses of MM121 not the doses of Cetuximab The statement incorrectly assumes that the difference in MM121 doses translates directly to a difference in Cetuximab doses which is not the case The actual difference in Cetuximab doses between the two co",
        "label": "Contradiction"
    },
    "0de75f54-db66-4787-b8a0-7cd21198d8a8": {
        "text_answer": "Yes based on the given evidence no patient in either group experienced a pain intensity score of 10 the highest level of pain for the entire 10week study period",
        "label": "Entailment"
    },
    "a723722c-a7df-4baa-b02a-3d3f15a03db3": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the patient described in the statement does not meet the inclusion criteria for either the primary or secondary clinical trials The patient is diagnosed with ERnegative HER2positive breast cancer which is an exclusion criterion for the secondary trial Additionally the primary trial only includes patients with HER2negative breast cancer",
        "label": "Contradiction"
    },
    "6056dc64-7161-4c86-a9ac-04579ea09274": {
        "text_answer": "No  Explanation  The statement requires patients to receive 0120 grams of denosumab injected subcutaneously every month the secondary trial also requires injection adminstering 04 to 10 mci of radioactive tc99m sulfur colloid is not directly entailed by the evidence provided  The primary trial mentions the dose of denosumab given ",
        "label": "Contradiction"
    },
    "3f19f518-c46f-4c1f-a738-0066ac81dcc2": {
        "text_answer": "No The evidence provided does not mention anything about Xrays transendocardial injections CT scans MRIs or an individuals voice feeling handicapped",
        "label": "Contradiction"
    },
    "a86b695b-6bfb-4c1f-982c-2e10c1b392ae": {
        "text_answer": "No   Explanation  The evidence provided only gives the median change in lean body mass for each group along with the range of changes It does not specify how many patients in each group experienced an increase of more than 10 kilos in lean body mass Therefore it is impossible to determine if any patient in the GTx024 1mg group experienced such an increase based on the given evidence alone",
        "label": "Contradiction"
    },
    "b7bd2215-d2b2-4cd0-a12a-d12310737373": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial explicitly excludes participants with a history of using gabapentin or pregabalin while the secondary trial allows their use",
        "label": "Contradiction"
    },
    "2909913c-9739-497b-8bbb-481d3b5c4832": {
        "text_answer": "Yes for the primary trial pulmonary embolism is a reason for exclusion within 6 months for the secondary trial there is no specific mention of pulmonary embolism in the inclusion or exclusion criteria but it is not explicitly stated as a disqualifying condition",
        "label": "Entailment"
    },
    "33dc8fb6-d0a8-47e4-8052-4a32b5e0c459": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of myalgias being administered to any patient in the primary trial and the secondary trial does not involve any intervention related to myalgias",
        "label": "Contradiction"
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "text_answer": "No  Explanation  The statement The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort is not entailed by the evidence provided The evidence only describes the design and participant numbers for two different arms of the same trial but it does not provide any information about the outcomes or results of those arms Therefore it is not",
        "label": "Contradiction"
    },
    "bee98681-7738-44a5-b437-0c172bdd3eeb": {
        "text_answer": "Yes  Both trials involve oral administration of interventions",
        "label": "Entailment"
    },
    "987d8384-9e51-497a-a1f4-2646ec7c94f8": {
        "text_answer": "Yes  The statement is entailed by the evidence as both interventions in the trial include trastuzumab Herceptin",
        "label": "Entailment"
    },
    "bfb34bfd-74f8-4f11-b28b-643fe6e79d10": {
        "text_answer": "No  Explanation  The primary trial measures the change in weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms using the independent sample ttest The outcome measure in the secondary trial is the overall response rate ORR using the Response Evaluation Criteria In Solid Tumors RECIST criteria These two outcome measures are not the same so the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "af417420-0bcb-407d-8470-b73cafe31893": {
        "text_answer": "No  Explanation  The statement Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial is not directly entailed by the evidence provided The primary trial includes patients with benign breast disease while the secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ However the primary trial excludes patients with highrisk breast les",
        "label": "Contradiction"
    },
    "511b7c14-9ba0-43ea-98e0-93f217e3ef07": {
        "text_answer": "No  Explanation The statement animal virus is an animal pathogen that is a virus is not directly related to the evidence provided The evidence only mentions the use of Fulvestrant Anastrozole and novel radiotracers in the primary and secondary trials There is no mention of Arimidex or any viruses in the evidence",
        "label": "Contradiction"
    },
    "70c3a676-7000-465c-9d6d-3c53fbf185c0": {
        "text_answer": "No  Explanation  The statement the intervention timeline in the secondary clinical trial is exactly identical as in the primary clinical trial is not entailed by the evidence The primary clinical trial involved a reflexology intervention given once a week for 10 weeks while the secondary clinical trial involved a placebo or vitamin D intervention given weekly for 24 weeks The number of weeks and frequency of intervention are not identical between the two trials",
        "label": "Contradiction"
    },
    "61215857-54c4-4622-afc2-7249194a96f6": {
        "text_answer": "Yes The primary clinical trial specifically includes the requirement of resistance to aromatase inhibitors while the secondary clinical trial does not mention it as a requirement",
        "label": "Entailment"
    },
    "b56f166c-a9b7-4990-bfb8-d13f0e89f76d": {
        "text_answer": "No  Explanation  The statement the protocol in the primary clinical trial consists of at least 3 different drugs is correct based on the evidence provided in the primary trial However the statement the secondary clinical trial involves using only a single medical product is not directly related to the evidence provided in the secondary trial The secondary trial involves two interventions one using a single medical product Zoledronic Acid and the other using a combination of",
        "label": "Contradiction"
    },
    "20b96fad-2ca0-4bee-a541-0006c6ff8037": {
        "text_answer": "No  Explanation  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is not directly entailed by the evidence provided The evidence only states the number of adverse events for each group but it does not provide the percentage of patients who experienced both adverse events Therefore it is not possible to determine if 25 of patients in the primary trial suffered from both adverse",
        "label": "Contradiction"
    },
    "9e2bec72-4318-4cf8-9ed8-82a572ce6d55": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial includes a breast tumor of only 1 cm in diameter while the secondary trial does not specify tumor size",
        "label": "Contradiction"
    },
    "baea8626-3768-47aa-a4ba-e792164302fd": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as it makes no mention of the c3d format or any relationship between the trials in terms of that format The statement only compares the dosages and durations of Intervention 1 in each trial",
        "label": "Contradiction"
    },
    "f2d85883-6334-4948-901e-22cc11da66ac": {
        "text_answer": "Yes The statement is entailed by the evidence as females with ER HER2 breast cancer are included in the Phase 2 trial criteria",
        "label": "Entailment"
    },
    "f1494243-0e25-48d1-b7d8-e92ffed41e1d": {
        "text_answer": "No  Explanation  The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not directly entailed by the evidence provided The evidence only mentions one psychiatric adverse event which is suicidal ideation There is no mention of an eating disorder or Schizophrenia in the evidence Therefore the statement is not supported by the evidence",
        "label": "Contradiction"
    },
    "5be979ed-e272-48c6-b301-c5464cc07730": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial had a higher turnout than the primary clinical trial is not entailed by the evidence provided The evidence only states the number of participants analyzed in each trial and the percentage of participants who completed the neoadjuvant portion of the secondary trial with  85 of the protocolspecified dose It does not provide information on the total number of participants enrolled in each trial or the turn",
        "label": "Contradiction"
    },
    "348ce220-f650-4df2-9593-586ddaabe491": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial showed no difference in the improvement rate of lymphedema between acupuncture patients and those on the waiting list is entailed by the evidence provided as the evidence shows that the mean arm circumference at 6 weeks was similar in both groups with no significant difference between them",
        "label": "Entailment"
    },
    "2980900b-74b7-4c96-8ab9-91fc994211d1": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "79bb0bb4-31cf-45e2-8fae-475bfdbd6a09": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as there is no information provided in the evidence regarding the doses of radiation therapy received by the patients in the primary and secondary trials The evidence only mentions the interventions treatments and their administration schedules",
        "label": "Contradiction"
    },
    "e5fb73ea-4e3b-47b2-84ac-a4d403b646ba": {
        "text_answer": "Yes  Explanation The statement most of the adverse events detected in the primary trial were not blood and bone marrow related contrasting the secondary trial which observed an abundance of such is entailed by the evidence as the primary trial had a lower percentage of adverse events related to blood and bone marrow compared to the secondary trial",
        "label": "Entailment"
    },
    "49db6e75-199e-4c15-bb9b-6cf677d9c421": {
        "text_answer": "No  Explanation  The statement in the secondary trial patients are accepted regardless of gene mutations whilst the primary trial requires confirmation of mutations in genes such as pten braf kras nras pi3kca erbb1 erbb2 met ret ckit gnaq or gna11 is not entailed by the evidence  The primary trial does require confirmation of mutations",
        "label": "Contradiction"
    },
    "b00e48fb-d5db-46f8-8f16-6f538d178b26": {
        "text_answer": "No  Explanation  The statement a high frequency of cardiac and psychiatric aes were found in the primary clinical trial and secondary clinical trial is not entailed by the evidence provided The evidence only states that the frequency of adverse events 1 and 2 in both trials was 0 Therefore it does not provide any information about the frequency of cardiac and psychiatric adverse events specifically",
        "label": "Contradiction"
    },
    "1c968571-9618-4a86-af59-6e8367b1128f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as it makes an assumption beyond the data provided in the evidence The evidence only reports the median survival periods for the two groups and it does not mention the overall survival distribution or the number of patients with survival under 2 years",
        "label": "Contradiction"
    },
    "82aff6ce-3305-4fb1-87c0-28f4a1e8a981": {
        "text_answer": "No   Explanation  The evidence states that participants in the breast cancer trial received doses of 600 mcgday 900 mcgday 1000 mcgday 1100 mcgday and those in the ovarianperitoneal cancer trial received doses of 25 mcgday 50 mcgday 10",
        "label": "Contradiction"
    },
    "24b44ec0-b0a4-4b5a-9028-164eda456529": {
        "text_answer": "Yes The placebo intervention involves 20 injections of 04ml Buminate solution while the alloMSCs intervention involves 20 injections of 04ml alloMSCs The volume is the same but the substance is different",
        "label": "Entailment"
    },
    "f3091230-221d-4c82-9d37-06e04c12ba48": {
        "text_answer": "No  Explanation  The statement optic chiasm neoplasm is a benign or malignant neoplasm that affects the optic chiasm a patient that has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for two different clinical trials but it does not",
        "label": "Contradiction"
    },
    "dfcbb31f-65e0-4847-9840-536eff03c1f3": {
        "text_answer": "No  Explanation  The statement only patients who demonstrated positive responses to previous Herceptin treatments are eligible for the primary clinical trial is not entailed by the evidence The evidence states that patients with HER2 FISH tumors will receive vinflunine and trastuzumab while patients with HER2 FISH negative or unknown HER2 status will receive single agent vinflunine It does not specify that only those with",
        "label": "Contradiction"
    },
    "6a2679df-a2a3-40cf-8252-2f8bf8584b8d": {
        "text_answer": "No   Explanation  The statement abdominal examination is an assessment of the abdomen including the organs within the abdominal cavity is not directly related to the evidence provided The evidence only mentions Suramin and Paclitaxel being administered in the primary and secondary trials and the number of individuals having mastectomy surgery in the secondary trial There is no mention of abdominal examinations being performed in the trials",
        "label": "Contradiction"
    },
    "d5383c8a-360f-4e17-af4e-2f0a05fc2b1a": {
        "text_answer": "No  The statement is not entailed by the evidence as the secondary trial measures pain not muscle gains",
        "label": "Contradiction"
    },
    "2dac87e4-2a34-42e1-8aec-d2a23d61269a": {
        "text_answer": "No  Explanation  The statement femtogram per milliliter per microgram is a unit of concentration equal to femtogram per milliliter divided by micrograms is not directly related to the inclusion or exclusion criteria for either the primary or secondary trials provided in the evidence The statement is a unit conversion while the evidence provides criteria for participant eligibility and ineligibility for the clinical trials",
        "label": "Contradiction"
    },
    "4ecc7d3a-ada3-4bda-8236-f0450fc709af": {
        "text_answer": "  No  Explanation  The statement the primary clinical trials results demonstrate that the placebo arm outperformed the arm A intervention in terms of overall response rate is not entailed by the evidence The evidence only shows that in Arm A 676 of participants achieved an overall response compared to 600 in Arm B It does not indicate that the placebo arm had a higher response rate  ",
        "label": "Contradiction"
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "text_answer": "Yes The evidence does not mention any mental health bodyweight age or previous treatment conditions for eligibility in the primary trial",
        "label": "Entailment"
    },
    "a8e679cc-cd10-409c-8434-8bb059146815": {
        "text_answer": "No  The statement is not entailed by the evidence as syncope was not the most commonly occurring adverse event across the patient cohorts of the primary and secondary trials The most commonly occurring adverse event in the primary trial was syncope with a frequency of 1667 but in the secondary trial there were no occurrences of syncope reported Therefore the overall frequency of syncope across both trials is less than 5000",
        "label": "Contradiction"
    },
    "d5f5e4f5-9a58-485a-8646-649ce93e37c7": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the participants in the primary clinical trial undergo radiation therapy and those in the secondary clinical trial receive Enzastaurin and Fulvestrant orally and intramuscularly but there is no mention of highintensity focused ultrasound therapy in the evidence",
        "label": "Contradiction"
    },
    "53e8b3b4-40dc-4ffe-b555-a65fd7741dbf": {
        "text_answer": "No  The statement about tert promoter mutation analysis is not mentioned in the evidence provided for either the primary or secondary trials",
        "label": "Contradiction"
    },
    "d0600d22-c3de-4028-82a5-a42008e2018d": {
        "text_answer": "No  Explanation  The statement abnormal liver function test is atypical results found on serum liver enzyme testing which may indicate significant disease andor disease progression is not directly entailed by the evidence provided The evidence only mentions the occurrence of adverse events in two clinical trials but it does not specifically mention any abnormal liver function tests or their results Therefore it is not possible to determine if the statement is",
        "label": "Contradiction"
    },
    "0a144293-fbab-4ba1-ad15-cf05a8624a1c": {
        "text_answer": "Yes The primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using RECIST criteria",
        "label": "Entailment"
    },
    "c66df8c2-afad-4638-a1c2-5539fc03a2be": {
        "text_answer": "No   Explanation   The statement failsafe system device is a device designed to prevent malfunction unsafe or unauthorized operation of a device or system is not related to the evidence provided The evidence only includes information about a cognitivebehavioral stress management program for breast cancer survivors and a surgical device used to assess positive margins during lumpectomy procedures There is no mention of a failsafe system device in the",
        "label": "Contradiction"
    },
    "67b93677-87f6-4a11-8dea-66a3c2242b19": {
        "text_answer": "No  Explanation The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 but some evidence of cognitive impairment However frontotemporal dementia and mixed dementia are characterized by a lower MMSE score typically 24 compared to Alzheimers disease Therefore patients with frontotemporal dementia or mixed dement",
        "label": "Contradiction"
    },
    "abed7fca-4cb8-42bb-a206-bf1c54f9af99": {
        "text_answer": "  Yes the statement is not entailed by the evidence as neither trial used Number of Participants With Treatmentemergent Aes as the outcome measurement",
        "label": "Entailment"
    },
    "5ff118a6-d62c-473d-8935-1767a378c92a": {
        "text_answer": "Yes  Some patients in the trial did not receive Active Breathing Coordination and therefore did not undergo a SPECT scan",
        "label": "Entailment"
    },
    "4eb8855e-766e-4588-a42f-655ca3d80140": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial administers its intervention orally sublingually and not intravenously and the secondary trial employs a subcutaneous route for placebo administration but does not mention the route for memantine administration",
        "label": "Contradiction"
    },
    "f4e91f1d-d645-4759-904d-12e509336562": {
        "text_answer": "Yes The evidence shows that the median aAUCpa for the Arm I Cryotherapy group was less negative than the Arm II Control group indicating that the symptoms improved more in the Arm I group compared to the Arm II group",
        "label": "Entailment"
    },
    "ca80b7bd-73a6-4c6a-9ab7-3e1dc789f12c": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the evidence does not provide any information about the concentration unit picogram equivalents per gram or any trials related to it The evidence only provides information about the primary and secondary trials with their respective outcome measurements and results",
        "label": "Contradiction"
    },
    "e412ecde-3195-42c6-b125-7d2697ea89c1": {
        "text_answer": "Yes  Explanation The primary trial involved PF06647020 at doses of 02 mgkg and 05 mgkg while the secondary trial involved ALT801 at doses of 0015 mgkg and 0040 mgkg The numbers indicate that the doses of ALT801 in the secondary trial are higher than",
        "label": "Entailment"
    },
    "b4fd327d-375e-4021-98af-a59ee4e30c0b": {
        "text_answer": "maybe for the secondary trial with the condition that the patient meets all other inclusion criteria and none of the exclusion criteria",
        "label": "Entailment"
    },
    "911ba31e-f28f-4c5b-8b0e-fa16e58ecc29": {
        "text_answer": "No  Explanation  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is not entailed by the evidence The evidence only provides the number and percentage of adverse events for each trial but it does not compare the number or percentage of specific adverse events between the two trials Therefore it is not possible to determine from the evidence alone whether there are more cases",
        "label": "Contradiction"
    },
    "9b75138c-e074-43f0-866d-9a43ce7be217": {
        "text_answer": "Yes The statement is entailed by the evidence as the patients in the trial receive two oral drugs lapatinib and tamoxifen once daily each resulting in a total of two administrations per day",
        "label": "Entailment"
    },
    "bcbde299-e3e8-40e6-8cea-d843a44e68d6": {
        "text_answer": "Yes  The evidence states that the intervention includes treatment with partial breast irradiation which implies a specific arrangement of treatment cycles with dosage and delivery of radiation therapy",
        "label": "Entailment"
    },
    "6ee5619b-ec91-4d55-b57a-a69eb3315c3d": {
        "text_answer": "Yes  Explanation  The statement the primary trial is observing the effects of various doses of the same medication on its study participants while the secondary trial is applying different gels as part of its study is entailed by the evidence  In the primary trial there are two groups A and B receiving different interventions but both groups are using the same medication Hydrophor or MediHoney in different doses",
        "label": "Entailment"
    },
    "f7247f7f-056b-4725-b771-4f4388a643aa": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement refers to lapatinib 800 mg instead of the actual treatment given in the trial which was lapatinib 1000 mg",
        "label": "Contradiction"
    },
    "a85e8f5b-fb4f-4adc-a020-d40a42e8be96": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the two IM injections of V935 LD are given at different times in the cycle for each cohort Cohort A receives them over a 3week period while Cohort B receives them over a 5week period with different preceding interventions",
        "label": "Contradiction"
    },
    "e501b32a-a182-4275-bcdf-88aca4446cf9": {
        "text_answer": "Yes The evidence allows for participation in both trials for patients with ER PR or HER2neu negative metastatic breast cancer",
        "label": "Entailment"
    },
    "c77be931-75c0-4036-a07d-7d49b5b9fcc6": {
        "text_answer": "Yes The primary trial has different inclusion criteria compared to the secondary trial and the performance status condition is only mentioned in the secondary trial as a requirement for inclusion",
        "label": "Entailment"
    },
    "993a3b60-def6-421c-a8a5-964062336a2c": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports a change in Ki67 expression not a reduction in tumor diameter The statement also specifies a different dose and duration of tamoxifen administration",
        "label": "Contradiction"
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "text_answer": "No  Explanation  The primary trial does use a 3week cycle for the administration of the interventions but the statement does not accurately describe the secondary trial The secondary trial does not have a cyclic treatment in place but it is not described as having a 3week cycle",
        "label": "Contradiction"
    },
    "7b76f6bb-6bf2-4bec-8409-9c4b90cc81c8": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial are studying the same drug in different doses and with a different outcome measurement is entailed by the evidence as both trials involve the use of the same drug empegfilgrastim but with different doses and different outcome measurements",
        "label": "Entailment"
    },
    "19cdc906-c8e3-498d-b33e-08ad9037af5d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial recorded time to progression in months not days and the secondary clinical trial reported the number of participants with objective response not the percentage",
        "label": "Contradiction"
    },
    "41ef54ae-5826-49c3-85d2-1da610317f26": {
        "text_answer": "Yes  Explanation The evidence states that participants in the primary trial receive epirubicin cyclophosphamide docetaxel and trastuzumab during the course of the study Therefore the statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed by the evidence",
        "label": "Entailment"
    },
    "1a076a19-c76d-4de0-b7de-473c0e278bbe": {
        "text_answer": "No  Explanation  The statement dyspnea was frequently recorded as an adverse event in both cohorts of the primary clinical trial is not directly entailed by the evidence provided The evidence only reports the occurrence of various adverse events including edema limbs which could potentially be related to dyspnea but it does not specify that dyspnea was frequently recorded in either cohort",
        "label": "Contradiction"
    },
    "4023d560-6425-4207-aa76-543be30fd786": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial intervention is not a targeted molecular therapy but rather a form of radiation therapy using Yttrium90 glass microspheres and the secondary trial is investigating a combination of ibrutinib and MEDI4736 which are both targeted molecular therapies",
        "label": "Contradiction"
    },
    "6ee2e04c-88fc-4447-a477-18b2564aca4e": {
        "text_answer": "No  The patient described in the statement does not meet the eligibility criteria for the trial as they have a life expectancy of less than 3 months",
        "label": "Contradiction"
    },
    "b6af5ca8-21c0-43c5-898b-53e45b5e122a": {
        "text_answer": "No  Explanation The statement candidates must not undergo any form of imaging test before they are eligible for the primary trial but they must have a mammography to qualify for the secondary trial is not explicitly stated in the evidence The evidence only mentions that candidates for the primary trial must have a mammography completed within the past 30 days but it does not mention anything about imaging tests being forbidden before the primary trial The secondary",
        "label": "Contradiction"
    },
    "4665519b-6dba-440f-9cc3-677ab616ecd6": {
        "text_answer": "No  Explanation  The statement a CT scan not a mammography is needed for consideration in the primary trial is not entailed by the evidence The primary trial includes mammography as a required imaging test and the secondary trial does not mention any specific imaging test as a requirement",
        "label": "Contradiction"
    },
    "f66e21d9-801f-4613-99da-c033734189e4": {
        "text_answer": "Yes The eligibility for both trials is based on various clinical and biological factors and gender is not explicitly mentioned as a criterion for inclusion or exclusion",
        "label": "Entailment"
    },
    "ba873942-b869-4596-bbd6-30d54c94e31b": {
        "text_answer": "Yes   Explanation  The evidence states that both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid However the statement specifically compares the doses used in intervention 1 pIHGC and intervention 2 GP and states that intervention 1 uses lower doses The evidence supports this statement as it does not specify that the dos",
        "label": "Entailment"
    },
    "3558390b-24a7-45e7-84f1-f512e669dcef": {
        "text_answer": "Yes  Explanation  The statement the secondary and primary clinical trials showed a complete absence of recorded adverse events in their cohorts is entailed by the evidence since the evidence reports that there were no adverse events in both the primary and secondary trials for the given condition",
        "label": "Entailment"
    },
    "84f10108-19b7-499f-9144-b3e6c0b253d5": {
        "text_answer": "No  Explanation  The statement appendiceal carcinoma pn0 tnm finding v7 is appendiceal carcinoma without regional lymph node metastasis is not directly related to the primary or secondary trials provided in the evidence The trials focus on the evaluation of toxicity and percentage of participants with adverse events for different treatment regimens in patients with HER2positive breast cancer The statement about appendiceal",
        "label": "Contradiction"
    },
    "94df8c14-d1c9-44cb-9f6d-1706044cbc9a": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the interventions for Cohort A and B differ in the administration of V934 prior to the V935 injections The evidence does not indicate that the two cohorts receive the same treatment regimen leading up to the administration of V935 LD injections",
        "label": "Contradiction"
    },
    "4f9e48d7-08cc-4fa3-a317-4f3f23ebf19d": {
        "text_answer": "No  Explanation  The primary clinical trial does not provide any information about the methods used to gauge the alteration in Ki67 expression in tumors The evidence only reports the number of participants with ovarian cancer who received all 24 doses of 852A and their tumor response status based on RECIST criteria There is no mention of Ki67 expression or any related methods in the primary trial",
        "label": "Contradiction"
    },
    "ef6928bd-e4ac-44f6-a7bd-292a728df94b": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly reflects that no cardiac or psychiatric adverse events were recorded in both trials However the statement about precordial catch syndrome is not directly related to the evidence and should not be inferred from it",
        "label": "Entailment"
    },
    "a3ad31e2-9017-438a-bbc2-acab87940134": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR This is more than 50 of the participants Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "5499c5cb-97fa-4905-b163-7f5830cd59b9": {
        "text_answer": "No  Explanation  The statement in group 1 of the primary clinical trial no participants presented with lesions while in group 1 of the secondary clinical trial more than 90 showed signs of radiation dermatitis as well as hyperpigmentation is not entailed by the evidence provided  The primary clinical trial and the secondary clinical trial are about different studies with different participants and outcomes The primary clinical trial is about",
        "label": "Contradiction"
    },
    "06695494-b56b-49da-9166-b0aae3f322f3": {
        "text_answer": "Yes The evidence does not provide units of measure for the number of participants or time in seconds or centimeters for either trial",
        "label": "Entailment"
    },
    "c36a826d-892a-4115-af40-e60050fffd8a": {
        "text_answer": "No   Explanation The statement more than 95 of patients in the primary trial suffered aes is not entailed by the evidence as the evidence only reports the occurrence of adverse events in 2 out of 35 patients 571 The statement implies that more than 95 of patients experienced adverse events which is not supported by the evidence",
        "label": "Contradiction"
    },
    "564d9a7d-327b-45be-af87-1971e15a9db4": {
        "text_answer": "No  Explanation  The evidence provided in the results does not mention anything about chromosome band 1p33p32 or any adverse events related to it in cohort 1 of the primary trial The evidence only reports the number of participants with serious and nonserious adverse events for two different dose levels of the MVAbrachyuryTRICOM vaccine",
        "label": "Contradiction"
    },
    "17414a49-7410-41fe-ab90-99311491d367": {
        "text_answer": "No  Explanation The statement in the question is not entailed by the evidence as the dosage and frequency of lapatinib administration in the statement is different from the one in the evidence In the statement the dosage is given as 100 mgm2 twice daily for a month while in the evidence the dosage is given as 100 mgm2 once daily for a month",
        "label": "Contradiction"
    },
    "6ab38a80-a2a5-40f1-a8d5-250db9f54740": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the intervention 1 in the primary trial is administered intravenously IV and all intervention drugs in the secondary trial are also administered intravenously IV or orally There is no mention of subcutaneous administration in the evidence",
        "label": "Contradiction"
    },
    "52db54bd-4dbe-4778-b5c4-30a8e4ce0a1f": {
        "text_answer": "Yes The evidence does not report any discernible pattern for gene expression in either the normal or lownormal Vitamin D level cohorts",
        "label": "Entailment"
    },
    "14678a23-57ea-4d56-a87a-c1a910af9e78": {
        "text_answer": "No   Explanation   The evidence provided in the primary trial results does not indicate the number of participants who experienced complete response CR at week 42 The data only shows the number of participants with CR partial response PR or stable disease SD at week 12 and week 24 Therefore it is not possible to determine if the majority of patients experienced CR by week 42 based on the given evidence",
        "label": "Contradiction"
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial both use pCR as their outcome measurement there is a small difference in results between the two cohorts of the primary trial whereas in the secondary trial Arm 2 had worse results than arm 1 as a higher percentage of arm 2 patients experienced pCR is entailed by the evidence provided  The primary trial and the secondary trial both use pCR as their",
        "label": "Entailment"
    },
    "6892893c-5c7b-492b-950f-e155bd928ebe": {
        "text_answer": "Yes The statement does not contradict the evidence and all the information in the statement is included in the evidence",
        "label": "Entailment"
    },
    "98a95bef-b43a-4582-8b58-d0c154824cd0": {
        "text_answer": "No  The evidence states that individuals with a history of interstitial lung disease or pneumonitis are excluded from the trial Diffuse parenchymal lung disease is a type of interstitial lung disease",
        "label": "Contradiction"
    },
    "b799b56b-51cd-4200-852f-f80a347de63e": {
        "text_answer": "No  Explanation  The statement about age limitation between 18 and 60 years is not explicitly mentioned in the inclusion criteria of the evidence However the evidence does state that the participants must be women aged 18 years Therefore the statement is not an accurate representation of the information provided in the evidence The evidence does not mention any weight restrictions",
        "label": "Contradiction"
    },
    "6ffedb4b-9ff8-445a-9e5f-872d54ca58fb": {
        "text_answer": "No   Explanation  The statement adverse events were entirely absent in the conduct of the primary clinical trial is not entailed by the evidence The evidence reports that there were adverse events in the trial specifically 5 out of 25 participants experienced adverse events",
        "label": "Contradiction"
    },
    "91d0039d-b186-4f52-b214-1000341d3f2c": {
        "text_answer": "  Yes for the second part of the statement adverse events have been recorded is entailed by the evidence for both trials having recorded Adverse Events 1 and Adverse Events 2 However the statement does not specify which trial the adverse events were recorded for so it is not fully entailed by the evidence as it stands If the statement were to be modified to include the correct trial it would be fully entailed by the evidence",
        "label": "Entailment"
    },
    "0c5c681e-d64b-41e8-add7-b34f03573370": {
        "text_answer": "  Yes for the primary trial and No for the secondary trial   Explanation  For the primary trial the evidence does not explicitly state that a pulmonary embolism within the last two months is a disqualifying condition However it does list several other hemorrhagebleeding events as exclusion criteria but a pulmonary embolism is not mentioned among them Therefore it can be inferred that a",
        "label": "Entailment"
    },
    "3ce5a661-e1a9-4164-935e-15563602eefc": {
        "text_answer": "No  Explanation  The statement 75 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not entailed by the evidence The evidence states that the incidence of increased pleural effusion is 769 in the first trial and 2500 in the second trial The statement however claims that 75 of patients in the primary trial not both trials",
        "label": "Contradiction"
    },
    "2630006c-6708-4c09-a946-aefe1859770d": {
        "text_answer": "No  The primary trial includes both male and postmenopausal female patients while the secondary trial includes only women",
        "label": "Contradiction"
    },
    "c5fe1272-e91c-44cd-888d-359ad43e34c4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there are no instances of swelling hypothermia or confusion reported in either the primary or secondary clinical trials according to the provided data",
        "label": "Contradiction"
    },
    "4be496e4-ba05-47a1-bc0f-b8627e47becb": {
        "text_answer": "No  Explanation  The statement time to progression in months for a cumulative total of 156 patients from the two groups is reported in the primary clinical trial contrasting to the secondary clinical trial which presents the volume of participants manifesting objective response is not entailed by the evidence  The primary clinical trial reports the median time to progression TTP for each group Arm A and Arm B but it does not provide",
        "label": "Contradiction"
    },
    "31b59e3d-4bb8-47ea-a7a1-9d8523245970": {
        "text_answer": "Yes The statement does not directly relate to the inclusion criteria for the trial but there is no exclusion criterion related to epidermal hyperplasia Therefore the presence or absence of epidermal hyperplasia would not affect a patients eligibility for the trial",
        "label": "Entailment"
    },
    "981d8b53-f02f-4845-af5f-a1d5abc2d63c": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial patients must receive a subcutaneous injection of 120 milligrams of denosumab monthly on the other hand the secondary clinical trial makes use of lymphoscintigraphy without the need for injections is not entailed by the evidence  The evidence only describes the interventions used in each trial but it does not compare or contrast the",
        "label": "Contradiction"
    },
    "0cf140db-a8c7-47ee-9753-c46c056fe1b1": {
        "text_answer": "Yes  Explanation  The statement participants receiving the highest weekly mm121 and paclitaxel dosage are in the primary trial not cohort 1 of the secondary trial is entailed by the evidence because the primary trial does not specify a lower weekly dosage for MM121 and Paclitaxel compared to the secondary trials cohort 1 Therefore the highest weekly dosage is",
        "label": "Entailment"
    },
    "08dad9c0-a333-4791-b845-79b549c31890": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement claims that adverse events were reported by more than half of the participants while the evidence only reports adverse events for 2 out of 35 participants 571",
        "label": "Contradiction"
    },
    "da125a54-e88c-40a5-8134-0bd021287c6f": {
        "text_answer": "Yes The evidence states that participants in the clinical trial can have measurable or nonmeasurable disease Measurable disease refers to tumors that can be measured using imaging techniques while nonmeasurable disease refers to tumors that cannot be measured but are still detectable Disseminated disease refers to the spread of cancer to various body parts which can be considered a form of measurable or nonmeasurable disease Therefore the statement is entailed",
        "label": "Entailment"
    },
    "3fca106b-449b-416e-a961-bf0dc8999ddb": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "text_answer": "Yes  Explanation Both trials involve the use of cyclophosphamide Paclitaxel and pegfilgrastim in their interventions The primary trial uses cyclophosphamide and Paclitaxel in combination with GMCSF while the secondary trial uses cyclophosphamide in combination with other drugs and pegfilgrastim as growth factor support Therefore the statement that both trials administer cyclophosphamide",
        "label": "Entailment"
    },
    "32775858-8e4c-41e3-87c3-2c60dbc780ee": {
        "text_answer": "No  The patient with a metastasized tumor of 10mm in radius would not be eligible for the primary clinical trial due to the size requirement of the primary tumor being greater than 2 cm in diameter However the patient may be eligible for the secondary clinical trial as there is no such size requirement mentioned in the inclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "ccc2b2e3-5588-4eed-8a05-67fb21c29a9b": {
        "text_answer": "No  Explanation  The statement in the secondary clinical trial patients only experienced adverse events such as eyelid oedema upper gastrointestinal haemorrhage and chest pain however no such events were observed in the primary clinical trial is not entailed by the evidence  The evidence only reports the frequency of each adverse event in the primary and secondary clinical trials It does not state that no other adverse",
        "label": "Contradiction"
    },
    "796289cc-1400-4a5c-9da0-d19104d6aae4": {
        "text_answer": "No  Explanation  The statement the first cohort of the primary clinical trial had more participants than the second cohort is not entailed by the evidence provided The evidence only states that there were 1420 participants in each arm of the trial It does not provide information about the number of participants in the first versus second cohorts",
        "label": "Contradiction"
    },
    "9b5ee8d1-9b19-4f79-a80f-58422f1f5cee": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the first group receives 600 mgm2 of cyclophosphamide and 14mgm2 of eribulin making the amount of cyclophosphamide larger than eribulin The second group receives 600 mgm2 of cyclophosphamide and 75 mgm2 of docetaxel",
        "label": "Entailment"
    },
    "7852457b-3915-431f-adbf-cdba2b736c46": {
        "text_answer": "Yes The statement does not make a claim about adverse events so it is not directly contradicted by the evidence The evidence only pertains to the occurrence of adverse events in the trials not the lig4 gene mutation itself",
        "label": "Entailment"
    },
    "58db966b-cb5c-426f-8b8e-f9e68adc1531": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "d5c262d5-584c-4417-a768-9374cd6c8bc2": {
        "text_answer": "No  Explanation  The statement vomiting was the most prevalent adverse event recorded in the primary clinical trial with an incidence rate above 10 is not entailed by the evidence The evidence only states that there were no adverse events recorded in the primary clinical trial Therefore it is not possible to determine if vomiting was the most prevalent adverse event or if it occurred at all in the primary clinical trial based on",
        "label": "Contradiction"
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not compare the effects of acupuncture and testosterone cream on lymphedema The statement is not entailed by the evidence as it makes an incorrect comparison between two different groups that were not part of the trial",
        "label": "Contradiction"
    },
    "a2cdb319-3410-467d-94f0-0908534ebf22": {
        "text_answer": "Yes Both interventions are administered for the same duration of time 12 weeks",
        "label": "Entailment"
    },
    "a9497198-5380-4af2-ace4-eb2e904a855a": {
        "text_answer": "Yes The evidence does not explicitly state that AfricanAmerican patients can participate in the trial but it does not include any exclusion criteria based on race Therefore the statement doctor and I shared responsibility for deciding which treatment is best for me is not contradicted by the evidence and is generally applicable to all eligible participants including AfricanAmerican patients",
        "label": "Entailment"
    },
    "bd70ab1b-2bfb-4294-9ca7-01e1e2b670b7": {
        "text_answer": "  No the statement is not entailed by the evidence The evidence provides the inclusion and exclusion criteria for two clinical trials one for male and postmenopausal female breast cancer patients and another for women with estrogenreceptor positive locally advanced recurrent or metastatic breast cancer Gender is a determining factor for eligibility in both trials The statement about insufficient RNA yield is not related to the eligibility criteria in the evidence",
        "label": "Contradiction"
    },
    "56e88bbd-7a3c-4a3b-a6cf-3f9b9e632b53": {
        "text_answer": "Yes The evidence shows that there were no adverse events in both the primary and secondary trials for Adverse Event 1 and similarly there were no adverse events for Adverse Event 2 in the secondary trial Therefore the statement that the quantity of adverse events is the same in both trials is correct",
        "label": "Entailment"
    },
    "26583828-8ea0-4211-a688-3deda44eeec4": {
        "text_answer": "No  Explanation  The statement both the primary clinical trial and the secondary clinical trial reported hypoglycaemia hyponatraemia and hypokalaemia as common adverse events aes among participants is not entailed by the evidence provided The evidence only reports the occurrence of specific adverse events AEs for each trial but it does not mention the frequency or commonality of hypoglycaemia",
        "label": "Contradiction"
    },
    "8dd8adde-dac7-4303-8a4b-46e27e36862f": {
        "text_answer": "No  Explanation  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is not directly entailed by the evidence provided The evidence only shows the frequency of specific adverse events in each trial but it does not provide information about the total number of adverse events or the types of adverse events that were not related to blood and bone marrow",
        "label": "Contradiction"
    },
    "98627f6b-e597-4427-b831-aa8856de321e": {
        "text_answer": "No  The secondary clinical trial does not demand participants to be entirely disabled The inclusion criteria state that patients must have a functional ECOG  2 status",
        "label": "Contradiction"
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "26583790-21ca-4820-9932-67e3d6eeb8b0": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence does not provide any information about the genus Moellerella or its relevance to the trials The statement only mentions Moellerella in passing and the trials do not involve any bacterial studies The trials focus on the use of acupuncture and broccoli sprout extract for lymphoedema and measuring the change in patientreported symptoms and",
        "label": "Contradiction"
    },
    "06be4ae9-c67e-4aad-b5b5-caf3dd9f30a9": {
        "text_answer": "No  Explanation  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not compare the number or types of adverse events between the two trials directly Therefore it is not possible to",
        "label": "Contradiction"
    },
    "0919109a-9ee1-4fa0-b612-a9902379e48d": {
        "text_answer": "Yes   Explanation  The statement the primary clinical trial saw the use of multiple drugs as interventions however the route of administration remains the same is entailed by the evidence as both interventions bisphosphonate IV Q4W and denosumab 180 mg Q12W are administered through different drugs but the same route of administration which is intravenous or subcutaneous injection",
        "label": "Entailment"
    },
    "402d7814-ace1-4f78-8c96-c3205001c5ee": {
        "text_answer": "No  Explanation The statement cohort 1 and 2 of the primary clinical trial are administered CUDC101 at the same frequency is not entailed by the evidence While both cohorts receive CUDC101 they do so at different frequencies 5 daysweek for cohort A and 3 daysweek for cohort B",
        "label": "Contradiction"
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "text_answer": "Yes The statement is entailed by the evidence as capecitabine was administered orally every day to every patient in cohort 2 during the first 21day cycle",
        "label": "Entailment"
    },
    "8150f869-b9e6-422b-a13a-1bdccee14f19": {
        "text_answer": "No   Explanation   The evidence describes a clinical trial where patients with AIDSrelated nonHodgkin lymphoma receive vorinostat and radiation therapy The statement however asserts that every patient receives a dose of 100 to 1600 g fentanyl sublingual spray during radiation therapy The evidence does not mention anything about fentanyl being administered to the patients",
        "label": "Contradiction"
    },
    "c7960079-5d1b-451e-818f-0890272ddb63": {
        "text_answer": "Yes The primary trial does not involve any drugbased interventions while the secondary trial tests two different drugs PF06647020 at 02 mgkg and 05 mgkg",
        "label": "Entailment"
    },
    "0d8cdde2-046a-4684-8af5-38cd82935901": {
        "text_answer": "Yes The statement does not specifically mention the numbers in the evidence but it is not contradicted by the evidence either The statement is about the proportion of adverse event types affecting the patient cohort which is consistent with the information provided in the evidence",
        "label": "Entailment"
    },
    "0c973f54-1aad-4349-acf5-607cb1ef2d6a": {
        "text_answer": "No  Explanation  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not provide the number or percentage of participants with cholelithiasis in each trial Therefore it is not possible to determine if cholelithiasis was twice as common",
        "label": "Contradiction"
    },
    "86722991-04c7-4fdd-914a-f5b71d236a7a": {
        "text_answer": "No  Explanation  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is not entailed by the evidence The evidence only reports the occurrence of these adverse events in two separate trials but it does not provide enough information to determine that 25 of all patients experienced both adverse events",
        "label": "Contradiction"
    },
    "3c164518-76e2-4abf-a39e-4163d49583c7": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement about a 64 lower recurrencefree survival rate in the ketorolac 30mg group compared to the NaCl 09 3ml group The evidence only shows the number of participants in each group and their recurrencefree survival rates but it does not provide the specific percentage difference between the two groups",
        "label": "Contradiction"
    },
    "01116b8e-5299-4f9e-9f40-7651edbc8542": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement mentions the study site oversight status review board process code which is not mentioned in the evidence The evidence only provides information about the outcome measurements and results of the two trials",
        "label": "Contradiction"
    },
    "ceb3926f-4777-4cec-8582-7c109185e333": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as there is no mention of the dose of myalgias administered to group 2 of the primary trial or the presence or absence of myalgias in the secondary trial cohorts in the provided evidence",
        "label": "Contradiction"
    },
    "fd76b8a6-5305-4221-b48b-3a37d551c82a": {
        "text_answer": "No   Explanation  The evidence provided describes the patient population and eligibility criteria for a clinical trial but it does not mention anything about regular physical activities being a part of the intervention for all participants",
        "label": "Contradiction"
    },
    "bbd40b2c-18a5-4ebb-9c6b-58dbc9a3ba59": {
        "text_answer": "No  Explanation  The evidence provided in the form of the primary clinical trial results indicates that both the AZD0530 175 mg and Zoledronic Acid 4 mg groups showed significant reductions in percentage change in betaCTX at Week 4 compared to baseline However the geometric mean percentage change values for both groups are not directly comparable due to the differences in the confidence intervals The statement that the Zoledronic Ac",
        "label": "Contradiction"
    },
    "4acf0568-59ce-4f6c-973b-9c603f65dac4": {
        "text_answer": "No  Explanation  The evidence provided in the primary clinical trial results indicates the number of participants in each arm Arm 1 and Arm 2 who achieved a pathologic complete response in breast and axillary lymph nodes at the time of surgery approximately 7 months after the initiation of treatment The statement however asserts that no participant in either cohort showed pathologic complete response throughout the duration of the study which",
        "label": "Contradiction"
    },
    "575eb6a5-bbeb-46a4-af85-87303a9fc321": {
        "text_answer": "Yes  Explanation  The statement there were no recorded incidents of infections among patients in both the primary clinical trial and the secondary clinical trial during the study period is entailed by the evidence because there is no mention of any infection adverse events in either trial Infections are listed as an adverse event in both trials but no instances were reported Therefore the statement is a logical conclusion based on the information provided in the evidence",
        "label": "Entailment"
    },
    "2f917847-cad3-4744-891d-33ebe29f257b": {
        "text_answer": "Yes  Explanation The evidence states that two different interventions were used in the primary clinical trial bisphosphonate IV Q4W and denosumab 180 mg Q12W Both interventions were delivered via different pharmaceutical agents but they were given through the same pathways intravenous for bisphosphonate and subcutaneous for denosumab Therefore the statement different pharmaceutical",
        "label": "Entailment"
    },
    "44c3f65f-6b0d-401d-9aad-b323d7511b1c": {
        "text_answer": "Yes Both cohorts receive two IM injections of LD V935 However the statement does not mention the chromosome band 17q112 which is not directly related to the given evidence",
        "label": "Entailment"
    },
    "c3609a19-01f6-4add-a0af-7d92263d822c": {
        "text_answer": "  Yes  Explanation  The evidence shows that the Neratinib group had a lower percentage of participants with invasive diseasefree survival events 47 compared to the Placebo group 75 This means that the Neratinib group had a better iDFS outcome than the Placebo group The insertion mutation egfr nm 0052283c2313",
        "label": "Entailment"
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore Intraoperative Mammography performed better than the Standard Mammography in this regard is not entailed by the evidence The evidence only shows that the median operative time was shorter in the Intraoperative Mammography group compared to the Standard Mammography group but it does not directly imply that Intra",
        "label": "Contradiction"
    },
    "3cd949ea-cd27-4eff-b7b6-0087df3136ba": {
        "text_answer": "Yes the statement cohort 1 of the primary clinical trial reported mild aes is entailed by the evidence Adverse Events 1 Total 0147 000 as mild aes refers to mild adverse events However the evidence does not specify that cohort 1 reported only mild adverse events it only states that the total number of adverse events in cohort 1 was",
        "label": "Entailment"
    },
    "8fc0b314-bec3-4206-a917-fc16babf1a4a": {
        "text_answer": "No  Explanation The statement in both groups of the primary clinical trial arimidex is utilized is not entailed by the evidence provided The evidence only mentions the use of Fulvestrant and Anastrozole in the primary trial but it does not explicitly state that Arimidex is used in both groups Therefore the statement is not a valid conclusion based on the evidence",
        "label": "Contradiction"
    },
    "ccc3cd99-a66b-42ce-9a35-21780035ddc5": {
        "text_answer": "Yes The statement does not contradict the inclusion criteria for ECOG performance status in both trials",
        "label": "Entailment"
    },
    "f5fa93e8-a223-459c-8573-853f56953c17": {
        "text_answer": "Yes The primary clinical trial has an openended treatment process while the secondary clinical trial operates on a consistent 4week cycle regimen",
        "label": "Entailment"
    },
    "00d64f29-fff0-44bd-b20c-8838ed4a1d93": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the doses of sunitinib and bevacizumab being equal in terms of mg per body weight or body surface area The evidence only mentions the starting doses and allows for dose adjustments based on tolerability",
        "label": "Contradiction"
    },
    "1dcd53cf-49bf-4a4e-857d-008139ceb6a9": {
        "text_answer": "Yes The primary trial requires mammography as a inclusion criterion while the secondary trial does not",
        "label": "Entailment"
    },
    "ad0d6636-dd71-4ba9-8741-1cba3d6f0c43": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "bc8cc6fd-446a-4879-a968-5c43a34029cc": {
        "text_answer": "No  Explanation  The statement grade 2 tendon reflex decreased ctcae is ankle reflex absent other reflexes reduced is not mentioned in the inclusion or exclusion criteria for either the primary or secondary trial The statement pertains to a specific medical condition but the trials only provide criteria related to eligibility for participation",
        "label": "Contradiction"
    },
    "e1e33a46-c88d-497a-b7b6-be14d38d05b2": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary clinical trial includes patients with metastatic or advanced solid tumors and the secondary clinical trial includes patients with advanced solid tumors",
        "label": "Contradiction"
    },
    "1e4ebef6-1039-42f3-b753-3efd098052fc": {
        "text_answer": "No  Explanation  The statement the intervention phase in the secondary clinical trial lasts an additional 15 weeks compared to that in the primary clinical trial is not entailed by the evidence provided The primary clinical trial lasted for 10 weeks and the secondary clinical trial lasted for 24 weeks However the statement only mentions an additional 15 weeks which is not accurate based on the information given",
        "label": "Contradiction"
    },
    "e83cb60e-ac38-42dd-a094-1ae08500915b": {
        "text_answer": "No  Explanation  The statement 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia is not directly entailed by the evidence provided The evidence only states the number and types of adverse events for each cohort but it does not specify which adverse events occurred in the same patient or even in the same trial Therefore",
        "label": "Contradiction"
    },
    "3c081d55-1536-45ec-ae5b-b7af2a44a8c4": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence states that there was one adverse event in the primary clinical trial",
        "label": "Entailment"
    },
    "cee12d67-0640-4760-a0f5-fdde8c593a89": {
        "text_answer": "No  The statement is not entailed by the evidence as the trial only includes patients with advanced andor unresectable malignant tumors",
        "label": "Contradiction"
    },
    "84781347-ce91-4e60-ba5f-f1bd795d898b": {
        "text_answer": "Yes The evidence does not mention any vaccines being administered to the participants",
        "label": "Entailment"
    },
    "eff79353-72dc-4a94-b856-40b844d2860b": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial specifically includes a size limitation of 1 cm and the secondary trial does not mention HR or HER2 status",
        "label": "Contradiction"
    },
    "e6c70cab-b2d6-488d-b9dd-34478f9f4f71": {
        "text_answer": "No  Explanation  The statement despite taking reduced doses of empegfilgrastim cohort 1 patients of the secondary clinical trial had a higher occurrence of neutropenia than those in cohort 2 of the primary clinical trial is not directly entailed by the evidence provided The evidence only shows the mean duration of neutropenia and the number of participants with neutropenia for each cohort in",
        "label": "Contradiction"
    },
    "d622d9c6-c942-4a53-a249-cd5544e2d9fe": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only includes patients with advanced andor unresectable Nonsmall cell lung cancer or Small cell lung cancer Benign sinonasal soft tissue neoplasms are not malignant and are not included in the trial",
        "label": "Contradiction"
    },
    "b994a073-e1a5-424a-9cdf-f0d9ad0c0766": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes a phase specifically for breast cancer patients who are ER positive",
        "label": "Entailment"
    },
    "0aab969d-e626-4857-903c-df2f6849c7c7": {
        "text_answer": "No   Explanation  The statement several adverse events occurred at an incidence rate greater than 1 in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The evidence only states that there was one adverse event ANCAGC decrease in the primary trial with an incidence rate of 048 and no adverse events in the secondary trial None of these",
        "label": "Contradiction"
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "text_answer": "No  Explanation  The statement Far more patients in the secondary trial were recorded to have experienced Chest Pain than patients in the primary trial is not entailed by the evidence provided The evidence only mentions the occurrence of adverse events but it does not specify which adverse event is being compared between the two trials The statement makes a specific comparison to chest pain which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "e4024f75-2a23-4912-bb63-3d6e982657ea": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of a her2neu peptide vaccine or sargramostim GMCSF in the given clinical trial interventions",
        "label": "Contradiction"
    },
    "fbfafa2b-9b70-4452-9d19-4d58c3c9dfba": {
        "text_answer": "  No   Explanation   The statement A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography would be eligible for both the primary trial and the secondary trial is not entailed by the evidence The primary trial includes a minimum primary tumour size of 2 cm while the secondary trial does not mention any specific tumour size requirement Therefore a patient with a primary tum",
        "label": "Contradiction"
    },
    "7452ab11-09d4-48bc-b275-4681acae5769": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial the group using paclitaxel plus bevacizumab recorded a higher ORR than the group using paclitaxel plus bevacizumab plus gemcitabine is entailed by the evidence provided The evidence shows that the ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0",
        "label": "Entailment"
    },
    "4385daf4-23d6-499b-8960-33b8c995884e": {
        "text_answer": "Yes  Explanation  The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 001 of participants is entailed by the evidence since the evidence shows that in both trials the number of adverse events was 0 and none of them occurred in more than 001 of participants 048 and 000 are both less than 0",
        "label": "Entailment"
    },
    "97f2cf47-a82b-4d00-9918-a4b400d2ca5e": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the adverse events noted were all connected to the musculoskeletal system contrary to the secondary clinical trial is not entailed by the evidence The evidence only provides the frequency of adverse events related to hemoglobin leukocytes lymphopenia neutrophilsgranulocytes platelets and edema in the",
        "label": "Contradiction"
    },
    "b7bc3cb1-b7f4-4276-bfee-9f984109d191": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not mention anything about the administration of talazoparib or its dosage to any of the patients Therefore the statement about patients being administered 0001 g of talazoparib daily is not entailed by the evidence",
        "label": "Contradiction"
    },
    "13184ac6-2ba9-455b-9e77-834855ff2794": {
        "text_answer": "Yes for febrile neutropenia Answer Partially for cholelithiasis as the evidence does not address it in the primary trial",
        "label": "Entailment"
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is not entailed by the evidence The evidence only shows that the median operative time was longer in Arm 2 Standard Mammography compared to Arm 1 Intraoperative Mammography It does not imply that the control group performed better than",
        "label": "Contradiction"
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "text_answer": "Yes  Explanation The statement 18 years olds are excluded from the secondary trial is entailed by the evidence since the secondary trial explicitly lists 18 yrs as an exclusion criterion The primary trial does not mention an age range for participation so it does not contradict the statement",
        "label": "Entailment"
    },
    "80b58d76-4a9b-461a-836a-bfb79e40b401": {
        "text_answer": "No  Explanation The statement Both cohorts of the primary trial receive the same doses of Abraxane is not directly related to the information provided about viral laryngitis in the evidence The evidence only discusses the treatment regimens for each cohort in the primary trial but it does not mention the doses of Abraxane specifically in relation to viral laryngitis",
        "label": "Contradiction"
    },
    "42d3b148-38d6-4665-9d48-4d6bf935fbd9": {
        "text_answer": "No The statement is not entailed by the evidence as the time frame mentioned in the statement last 60 years is not present in the exclusion criteria mentioned in the evidence The exclusion criteria in the evidence only mention a time frame of 6 months for certain conditions",
        "label": "Contradiction"
    },
    "00102571-e1d6-42c9-b227-f0ac146d411d": {
        "text_answer": "No  Explanation  The statement gin is a Chinese person from the gin ethnic group is not related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The evidence only discusses the criteria for participants in the trials based on their medical history cancer diagnosis treatment and performance status There is no mention of ethnicity or race in the given criteria",
        "label": "Contradiction"
    },
    "596e650e-f860-4055-b3a6-35fcd9fd33b0": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not entailed by the evidence provided The evidence only states the number of adverse events in each trial for a specific condition Adverse Events 1 and it does not provide enough information to make a comparison between the total number of adverse events in both trials",
        "label": "Contradiction"
    },
    "10a27e75-a4e3-4790-bafa-dfc9b9300a25": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b8e81997-7fd7-4934-9ee8-bb7c647d334c": {
        "text_answer": "No  Explanation The statement all ae types in the primary trial affected less than 01 of patients is not entailed by the evidence The evidence shows that each adverse event affected between 909 and 3636 of patients",
        "label": "Contradiction"
    },
    "c89d3665-091c-410b-83b1-0793a3b86d6a": {
        "text_answer": "No  Explanation  The statement The intervention in the primary trial consists of a single drug ZD1839 whereas in the secondary trial the intervention requires at least 3 different drugs including Zoledronic acid Samarium153 and pegfilgrastim is not directly entailed by the evidence provided  The evidence only states the specific interventions used in each trial but it does not provide enough information to",
        "label": "Contradiction"
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "text_answer": "Yes  Explanation The statement the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts on the other hand the secondary trial reports the number of patients that experience Objective Response is entailed by the evidence provided The primary trial reports the Time to Progression for 72 patients in Arm A and 84 patients in Arm B totaling 156 patients",
        "label": "Entailment"
    },
    "70ddf6e3-dcd9-4296-b73c-593161abcfae": {
        "text_answer": "  No  Explanation  The primary trial excludes patients who are pregnant andor breastfeeding while the secondary trial also includes this exclusion criterion Therefore neither trial includes patients who are extremely overweight The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d6cd0501-9b29-41f5-ba8a-6209c8cfad84": {
        "text_answer": "No  Explanation  The statement in the secondary trial all patients receive the same 200 mg dose of pdr001 and 4 mgkg dose of mcs110 is not directly related to the information provided in the evidence The evidence only mentions that in the primary trial one cohort received placebo and the other received CBTI with armodafinil and in the secondary trial",
        "label": "Contradiction"
    },
    "03845d1d-301a-4b2a-8dc4-8b05e09ab6ee": {
        "text_answer": "No  Explanation  The statement The same number of AEs were reported for both cohorts in the primary trial is not directly entailed by the evidence provided The evidence only shows the number and percentage of specific adverse events AEs for each cohort but it does not indicate that the total number of AEs reported was the same for both cohorts",
        "label": "Contradiction"
    },
    "383102f6-bd50-4f19-b7cf-0ddda4234e2f": {
        "text_answer": "No  Explanation  The statement biliary colic and clostridium difficile colitis cases are more prevalent in the secondary trial than the primary clinical trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events in each trial but it does not provide enough information to make a comparison between the prevalence of specific adverse events in the two trials Additionally the statement is not supported by",
        "label": "Contradiction"
    },
    "a88d7c64-ec6f-4fb7-a84d-1047b68bda4f": {
        "text_answer": "Yes  Explanation  The statement in the secondary clinical trial only eyelid oedema and chest pain were the adverse events observed in patients unlike the primary trial which did not record any is entailed by the evidence as the evidence shows that in the secondary trial there were adverse events recorded for both eyelid oedema and chest pain while in the primary trial no adverse events were recorded",
        "label": "Entailment"
    },
    "0c6abdc4-f1cd-46f3-8883-c4bce02c2081": {
        "text_answer": "  No   Explanation   The primary clinical trial uses the Change From Baseline in Patientspecified and Reported Symptoms on the Measure Yourself Medical Outcome Profile MYMOP as their outcome measurement while the statement in question does not mention MYMOP or any specific outcome measurement for the primary clinical trial",
        "label": "Contradiction"
    },
    "6aa80695-37e9-4a46-aa19-2fd1f75d8f11": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it contains incorrect dosage information for the primary trial The primary trial states that patients receive 150 mg of oral pregabalin twice daily which equates to 300 mg per day or 4200 mg over 6 weeks not 150000 mcg",
        "label": "Contradiction"
    },
    "c4c63d1d-1704-499c-b298-f5ced3123d03": {
        "text_answer": "Yes  Explanation The statement patients are provided with oral medication which they are to take two times a day for a whole month is entailed by the evidence as it explicitly states that patients receive oral medication lapatinib ditosylate and tamoxifen citrate once daily on days 128 Therefore patients are indeed taking oral medication for a whole month twice a day based on the given dosing schedule",
        "label": "Entailment"
    },
    "c90dda31-65a8-4a77-8657-7cdf498b366f": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have received antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry or who are planned to receive these therapies during the study period",
        "label": "Entailment"
    },
    "6fa670ed-56af-4b06-b7f1-ab7429106d0d": {
        "text_answer": "No  Explanation The evidence provided in the results only gives the median with range change in lean body mass for each group It does not specify how many patients in the GTx024 1mg group gained over 22 pounds of lean body mass Therefore the statement cannot be definitively answered with just the given evidence",
        "label": "Contradiction"
    },
    "c2634312-bbf3-4b44-8cdc-23922a16b9fd": {
        "text_answer": "No  Explanation  The statement the number of infection asymmetry and deflation cases were found to be greater in the primary trial than those detected in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of specific types of adverse events between the two trials",
        "label": "Contradiction"
    },
    "241dc060-83e9-41a9-b937-d9715c16137a": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial results indicates that the participants in the paced respiration intervention group experienced a lower mean number of hot flashes per day 348 compared to the participants in the fast shallow breathing comparator group 395 This difference suggests that the paced respiration intervention was effective in reducing the frequency of hot flashes The statement that lcp1 antibody is any immun",
        "label": "Entailment"
    },
    "ff8f336a-0b3a-453d-a396-7624218280aa": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention section of the primary clinical trial does provide a detailed description of the treatment cycle which includes the specific treatment being partial breast irradiation",
        "label": "Entailment"
    },
    "100aa305-3df6-42ff-b3ba-68bed68e39b0": {
        "text_answer": "Yes  Explanation  The statement the main focus of the primary trial is on the mean sleep duration of its patients in contrast to the secondary trial that is investigating the number of participants who experience treatmentassociated issues is entailed by the evidence because  1 The primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 which is a count of participants",
        "label": "Entailment"
    },
    "b819fe62-b8ce-4b35-bf5a-e2657f8d0efc": {
        "text_answer": "Yes   Explanation  The statement only one arm of the primary clinical trial makes use of trastuzumab as part of its intervention is entailed by the evidence because only Arm 1 of the trial uses Herceptin which is a form of trastuzumab",
        "label": "Entailment"
    },
    "2644ad79-c38a-4415-a340-81ac51d3813f": {
        "text_answer": "Yes  Explanation The statement multiple diverse negative effects were experienced by at least one patient in the primary clinical trial is entailed by the evidence as it shows that a total of 5 different adverse events were reported in the trial each affecting at least one patient",
        "label": "Entailment"
    },
    "344ac04d-cddb-4ef8-8a15-54e26ff58a86": {
        "text_answer": "Yes The statement is entailed by the evidence as all adverse events mentioned in the evidence affected only one patient each",
        "label": "Entailment"
    },
    "c32c50b0-6068-41f1-9db0-fd8b3ac53cf6": {
        "text_answer": "Yes The primary trials Intervention 1 involves IV administration and the secondary trials Interventions for both arms can be administered orally",
        "label": "Entailment"
    },
    "1907f058-1b77-441e-8824-9cf6be7f1243": {
        "text_answer": "Yes  Explanation  The statement in comparison to the secondary trial the primary trial has fewer adverse events overall but a higher occurrence of cardiacischemiainfarction is entailed by the evidence as the evidence shows that the primary trial had a total of 0 adverse events out of 14 participants 000 while the secondary trial had a total of 48 adverse events out of 3",
        "label": "Entailment"
    },
    "818a897a-fa50-4f16-8272-8f5ec8e590c1": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as paclitaxel is not mentioned in the evidence at all and fulvestrant is mentioned as the intervention for the second cohort but there is no information about the first cohorts intervention other than it being ANA anastrozole",
        "label": "Contradiction"
    },
    "6fc1fe93-0690-4b46-a80e-681e4d7be399": {
        "text_answer": "  Yes The evidence includes the inclusion criterion Willingness to change diet physical activity and weight which implies that some participants may need to read instructions or information several times to understand and implement the required changes",
        "label": "Entailment"
    },
    "3ce10e1a-24fe-4575-8f08-583c93fd5274": {
        "text_answer": " No   Explanation  The statement primary clinical trial and secondary clinical trial host patients diagnosed with nut midline carcinoma via fluorescence in situ hybridization and those with inflammatory breast cancer is not directly entailed by the evidence provided The primary clinical trial includes patients with NUT midline carcinoma diagnosed via immunohistochemistry or fluorescence in situ hybridization but the secondary clinical trial does",
        "label": "Contradiction"
    },
    "99901cc0-51b6-45c1-9040-14a9785bab49": {
        "text_answer": "  No   Explanation   The statement a confirmed histological or cytological diagnosis of resectable nonsmall cell lung breast cancer or small cell lung cancer makes patients suitable for the primary clinical trial is not directly entailed by the evidence provided The evidence only states that patients with nonsmall cell lung cancer are eligible for the trial but it does not specify whether the cancer must be resectable or not",
        "label": "Contradiction"
    },
    "6b1a58fa-54cd-442b-8f51-1b7135dd2302": {
        "text_answer": "  No The evidence does not mention anything about CBT Cognitive Behavioral Therapy being a requirement or being permissible in either clinical trial",
        "label": "Contradiction"
    },
    "ddc664eb-c81b-4544-b370-bb6db84eacba": {
        "text_answer": "Yes The statement is consistent with the inclusion criteria for ERPR positivity in both trials",
        "label": "Entailment"
    },
    "117c69b5-683c-45a6-b80d-5bc866f2faa1": {
        "text_answer": "Yes The evidence does not specify eligibility based on nationality ethnicity weight or gender",
        "label": "Entailment"
    },
    "3cd01e92-2bff-45d7-9fa3-77c351d2f39a": {
        "text_answer": "No   Explanation  The statement the primary clinical trial presented no adverse events is not entailed by the evidence as the evidence reports that there was one adverse event a surgery in the trial which is a nonzero number",
        "label": "Contradiction"
    },
    "d207a9ec-f055-456a-ad6a-7c580cc347e1": {
        "text_answer": "yes  Explanation The statement the only inclusion or exclusion standard that the primary and secondary clinical trials have in common is the capability to present written informed consent is entailed by the evidence because both trials have the inclusion criterion of Willingness and ability to provide written informed consent",
        "label": "Entailment"
    },
    "3896374f-f5e1-41a2-9ec0-c108cc3f3ad1": {
        "text_answer": "No  Explanation The statement maculopapular Rash was a common adverse event for the primary trial participants is not entailed by the evidence as the frequency of maculopapular rash is mentioned only once in the evidence and it is not stated that it is a common adverse event The evidence only states that maculopapular rash occurred in 130 333 of the",
        "label": "Contradiction"
    },
    "87f86955-0e57-459a-84aa-4a5feba745af": {
        "text_answer": "  Yes the statement is entailed by the evidence as the inclusion criteria specify ER negative PR negative and HER2 negative breast cancer Group 1 as eligible for the clinical trial",
        "label": "Entailment"
    },
    "99857433-fe08-4f54-bb86-91b1b1e8f5f4": {
        "text_answer": "Yes  Explanation  The evidence provided in the results shows that the percentage of participants with events ie invasive disease recurrence or death was lower in the Neratinib group 47 compared to the Placebo group 75 This indicates that the Invasive DiseaseFree Survival iDFS rate was lower in the Placebo group than in the Neratinib group which",
        "label": "Entailment"
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "text_answer": "No  Explanation  The statement maculopapular Rash was a common adverse event for the primary trial participants is not directly entailed by the evidence provided The evidence states that there was one instance of a maculopapular rash out of 30 participants which is not sufficient to be considered common based on the given definition of common as occurring frequently",
        "label": "Contradiction"
    },
    "61c499d7-0a4c-4fac-9098-53e53ddb198d": {
        "text_answer": "No  Explanation  The statement there were 75 cases of hypertension edema and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events for each cohort but it does not mention the number of cases with hypertension edema and dyspnea specifically",
        "label": "Contradiction"
    },
    "93025279-295b-43e1-8dfd-40877e0288b4": {
        "text_answer": "Yes The evidence does not provide information about the irradiation doses or treatment cycle in the intervention portion of the primary clinical trial",
        "label": "Entailment"
    },
    "5ecfe0a7-2d7c-4207-b62e-0b28b699951d": {
        "text_answer": "Yes  Explanation The primary clinical trials intervention 1 involves Zoledronic Acid 4 mg Q4W 16 mg per 6week period while the secondary clinical trials first intervention involves Tamoxifen at a dose of 10 mg once daily for 21 days per month approximately 210 mg per 6week period The dosage of Zoledronic Acid in",
        "label": "Entailment"
    },
    "4a16424c-7755-4b6b-a060-d9ab1cb14db0": {
        "text_answer": "  No The statement about the stopcock valve device has no relation to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence",
        "label": "Contradiction"
    },
    "10a9dcfe-bbdd-44b2-9bc7-f406a2ff835a": {
        "text_answer": "Yes  Explanation The mean standardized composite cognitive function scores for both the Tamoxifen and Ovarian Function Suppression groups were negative indicating below average results on average However the difference between the means was not statistically significant indicating that there was no significant difference in cognitive function change between the two groups Therefore the statement on average there was no change in cognitive function for patients in either cohort of the primary clinical trial is ent",
        "label": "Entailment"
    },
    "b12a6936-d1ae-48e7-b3f2-575708d784ed": {
        "text_answer": "No  Explanation The statement provided does not mention the number of cases of Asthenia or Pyrexia in the ultrasound trials The evidence only provides the number of adverse events for each trial but it does not specify which adverse events correspond to Asthenia or Pyrexia Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "48ca56cf-908a-436f-8ec5-90fb965ea630": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement mentions nepafenac which is not mentioned in the evidence at all The evidence only discusses Fluciclatide and Chloroquine",
        "label": "Contradiction"
    },
    "8dbf8922-4680-4125-9bc3-f6ea881c5978": {
        "text_answer": "No  Explanation  The statement dehydration was a common side effect observed in both cohorts of the primary clinical trial is not entailed by the evidence provided The evidence only reports the occurrence of various adverse events including some related to fluid balance edema limbs and increased bilirubin but it does not indicate that dehydration was a common side effect in either cohort",
        "label": "Contradiction"
    },
    "dfde5d87-d03d-42a9-aa4c-f4e946a75102": {
        "text_answer": "Yes The primary trial has a higher rate of anemia cases 000 vs 430 However the statement focuses on the opposite stating that the secondary trial has fewer anemia cases Therefore the statement is not strictly entailed by the evidence but it is true based on the given information",
        "label": "Entailment"
    },
    "27564603-9271-41f5-8135-067e19c4946a": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it does not relate to the content of the trials provided The statement is about the nature of large cell neuroendocrine carcinoma while the evidence only provides information about interventions used in two trials",
        "label": "Contradiction"
    },
    "e8b7263b-fd07-4d78-915f-e1b17bdc1390": {
        "text_answer": "No  Explanation  The statement The intervention in the primary trial consists of a single drug whereas in the secondary trial the intervention requires at least 3 different drugs is not directly entailed by the evidence provided The evidence only mentions the specific interventions used in each trial and the number of drugs in each intervention but it does not compare the number of interventions between the two trials The statement makes a comparison between the number of interventions but",
        "label": "Contradiction"
    },
    "302997fe-466a-4efd-8801-5b07236a5e0c": {
        "text_answer": "No  The statement is not entailed by the evidence as there are no vaccines mentioned in the given clinical trial interventions",
        "label": "Contradiction"
    },
    "7d1f03c6-a869-45f0-9eda-4c272781e112": {
        "text_answer": "No   Explanation  The statement anorexia hypothermia and hallucinations have been reported in the aes of the primary clinical trial is not entailed by the evidence provided The evidence only states that there were no reported adverse events AEs for AEs 1 2 in both the primary and secondary trials The statement mentions specific AEs anorexia hypothermia and",
        "label": "Contradiction"
    },
    "192c6acc-1f20-4f22-a23e-80fadba34726": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a2328e36-4475-4804-96e8-cba90ee13087": {
        "text_answer": "No   Explanation   The statement the primary trial and the secondary trial use the same drugs dosages or frequency of administration in their interventions is not entailed by the evidence The primary trial uses FMX and MM398 while the secondary trial uses lapatinib and paclitaxel which are different drugs Additionally the dosages and frequency of administration are also different between the two trials",
        "label": "Contradiction"
    },
    "99820bab-c465-4d6a-a016-0551261ddb86": {
        "text_answer": "Yes The evidence mentions surgical and imaging procedures which is consistent with the statements reference to execution of surgical and imaging procedures in the context of the primary clinical trials intervention segment",
        "label": "Entailment"
    },
    "1757a756-4aeb-497c-aa4f-304817a34938": {
        "text_answer": "  Yes for the Primary Trial but not directly stated for the Secondary Trial it depends on the investigators discretion",
        "label": "Entailment"
    },
    "1fb98883-c2ef-4acb-948e-aa497dc911ff": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not mention anything about mycl gene amplification or any molecular genetic interventions The evidence only describes the interventions used in the primary and secondary trials which are vaginal rings testosterone cream acupuncture and a waitlist control group",
        "label": "Contradiction"
    },
    "98877f56-e367-4335-b938-85bd30fb038a": {
        "text_answer": "No  Explanation The statement is not directly related to the evidence provided The evidence only mentions the dosage of Cetuximab given to each cohort and the presence of a Collaborative Care Intervention in Cohort 1 but it does not mention anything about hepatitis C antibodies or virus infection",
        "label": "Contradiction"
    },
    "c9403b28-c572-4009-ae1a-6bd3e7977f86": {
        "text_answer": "No  Explanation The evidence describes the administration of placebo and trabectedin in separate sessions with different timings The statement suggests that both are administered every other week using a 3hour intravenous infusion which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "ea29786f-2c27-45d3-879d-126b8150f2af": {
        "text_answer": "No  Explanation  The statement the interventions in the primary clinical trial requires participants to take a monthly dosage of 4demethyl4cholestryloxycarbonylpenclomedine while the secondary clinical trial does not is not entailed by the evidence The evidence only mentions the dosages of the interventions in the primary and secondary trials but it does not explicitly state that the participants in the",
        "label": "Contradiction"
    },
    "7a2208d3-e297-4d8c-bfab-12856c200ea6": {
        "text_answer": "No  The statement does not mention carboplatin specifically and the evidence only mentions navelbine in Intervention 1 and does not mention paraplatin at all",
        "label": "Contradiction"
    },
    "1ef3ec2f-1b26-4dbe-92ff-8c3dda42f071": {
        "text_answer": "No  Explanation  The statement no adverse events were noted in the patients from the secondary clinical trial is not entailed by the evidence as the evidence shows that there were adverse events in the secondary trial specifically one instance of chest pain The statement also incorrectly implies that no adverse events occurred in any trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "f2f5115c-a1ad-43cf-b01c-0035f9404a92": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence because in the primary trial the intervention with armodafinil consists of different dosages throughout the 47day period while in the secondary trial the medication doses are individually calculated and not uniformly 100 mg PDR001 and 1 mgkg MCS110 Therefore the statement that each trial involves different medication dosages for each coh",
        "label": "Entailment"
    },
    "8a308f16-460b-45ac-a0f0-cb36787f1aa7": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about the number or percentage of participants who encountered multiple adverse events in either trial",
        "label": "Contradiction"
    },
    "f43f3230-46be-4ed7-a1d7-3e6d73f4fa9b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the dosages of MM121 are different between cohort 1 8 mgkg and cohort 2a 20 mgkg The dosages of cetuximab are the same between the two cohorts but the statement is about the dosages of both cetuximab and MM121 being the same",
        "label": "Contradiction"
    },
    "eea61494-780f-4a38-aa12-dd88ef3d520b": {
        "text_answer": "Yes  Explanation  The statement the study groups in the primary clinical trial are being tested with various types of gels while the secondary clinical trial evaluates the effects of different doses of one particular treatment on its study group is entailed by the evidence because  1 In the primary clinical trial there are two study groups Group A and Group B that are being tested with different types of gels Hydrophor and Med",
        "label": "Entailment"
    },
    "81bf5edb-cf30-4e9e-b816-394fa5b16354": {
        "text_answer": "No  Explanation  The statement none of the participants in group 1 of the primary trial were found to have lesions and more than 90 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only mentions the number of lesions detected in the primary trial and the number of participants with radiation dermatitis",
        "label": "Contradiction"
    },
    "1adb6e15-a8b1-461a-8782-4295224a3c5f": {
        "text_answer": "No  The evidence states that individuals with dementia are excluded from the trial Vascular dementia is a type of dementia",
        "label": "Contradiction"
    },
    "eb12190b-96c6-4c5d-8479-1248b462587d": {
        "text_answer": "Yes  Explanation The primary trials intervention duration was 10 weeks while the secondary trials intervention duration was 24 weeks Therefore the statement the secondary trials intervention duration is three times longer than that of the primary trials intervention is entailed by the evidence",
        "label": "Entailment"
    },
    "5ebf97e0-5409-4e82-a837-e0d96bc62b96": {
        "text_answer": "No  Explanation The statement does not directly follow from the evidence provided The evidence only mentions the number of injections the volume of each injection and the method of administration for both the placebo and AlloMSCs interventions It does not mention anything about the tcirg1 gene mutation or its relation to the interventions",
        "label": "Contradiction"
    },
    "96259bb4-b459-4f63-b987-6bdb596211a4": {
        "text_answer": "Yes The evidence states that for Phase 2 of the clinical trial breast cancer patients must be ER positive to qualify However the statement also applies to Phase 1 where the evidence only mentions that breast cancer patients must have a solid tumor Therefore the statement er negative breast cancer patients irrespective of their gender may not be qualified for either phase of the primary clinical trial is not entailed by the evidence and the correct answer is Yes",
        "label": "Entailment"
    },
    "f891188f-fa94-42d5-a341-2a6ae7d696ac": {
        "text_answer": "No   Explanation  The statement there was a difference of four patients who endured adverse events between cohort 1 and cohort 2 of the primary clinical trial is not entailed by the evidence as the evidence states that there were no adverse events in both cohorts",
        "label": "Contradiction"
    },
    "2f5ae30b-2e0d-420a-a27b-14088d2bc0db": {
        "text_answer": "Yes For one of the cohorts in the primary clinical trial all adverse events were reported as 0N",
        "label": "Entailment"
    },
    "8723a112-05c6-4c05-82ab-e09cedffdb4b": {
        "text_answer": "Yes  Explanation The statement only three kinds of adverse events impacted patients participating in the primary clinical trial pancreatitis cholelithiasis hepatic pain and febrile neutropenia is entailed by the evidence as all the other adverse events were reported as having occurred in 06 000 of the patients",
        "label": "Entailment"
    },
    "176789e8-d2f5-4bb5-b748-ef0ed5c52478": {
        "text_answer": "Yes Neither trial includes severe insomnia as an inclusion criterion",
        "label": "Entailment"
    },
    "a6276d61-5f8c-483b-8f18-a3becebddbe8": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the dosages of cetuximab are the same between cohorts 1 and 2 but the dosages of MM121 are different The statement incorrectly implies that the dosages of both drugs are the same between the cohorts",
        "label": "Contradiction"
    },
    "85b158a4-1754-47b2-91b4-5165c38d270c": {
        "text_answer": "Yes   Explanation   The statement the unit of measure reported in the primary clinical trial differs from that used in the secondary clinical trial is entailed by the evidence because the primary trial reports the percentage of participants with a response within 10 days of first dose of denosumab while the secondary trial reports the number of participants who reached a safe dose of dmethadone These are different types of outcome measures and they",
        "label": "Entailment"
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "text_answer": "No  The statement requiring considerable assistance and frequent medical care is not mentioned in the inclusion or exclusion criteria The statement only mentions the requirement of having a HER2 positive tumor confirmed by IHC 3",
        "label": "Contradiction"
    },
    "6b6150e0-6484-499a-83ae-a9fc6a7d167c": {
        "text_answer": "Yes  Explanation The statement adult acute megakaryoblastic leukemia is an acute megakaryoblastic leukemia occurring in adults is not directly related to the given evidence However the evidence does show that both trials involve the use of cyclophosphamide Paclitaxel and pegfilgrastim in their interventions for adult patients with acute megakaryoblastic le",
        "label": "Entailment"
    },
    "69a761d0-c5b2-42f4-8cb3-271ac92fb006": {
        "text_answer": "Yes  Explanation The evidence states that in Intervention 1 Arm A CUDC101 is administered for 5 days in each 14 day cycle at a dose of 275 mgm2 while in Intervention 2 Arm B CUDC101 is administered for 3 days in each 28 day cycle also at a dose of 275 mgm2",
        "label": "Entailment"
    },
    "f618f294-167b-4647-bc93-b8d41596227c": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial does not use a 730hour cycle for its intervention Instead it uses a 21day cycle with PF05212384 administered on specific days within that cycle The statements error likely comes from a misunderstanding of the primary trials cycle length and the incorrect assumption that it is 730",
        "label": "Contradiction"
    },
    "dda442a2-b86f-4375-ae81-f1b387ce46c9": {
        "text_answer": "Yes The evidence provided does not include information on treatmentemergent adverse events for either trial",
        "label": "Entailment"
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "text_answer": "No  Explanation The evidence provided in the text describes the results of a primary trial comparing the effect of topical cryotherapy during paclitaxel infusions Arm I versus standard of care only Arm II on chemotherapyinduced peripheral neuropathy CIPN symptoms The results indicate that patients in Arm I had a smaller decrease in average area under the curve aAUCpa for the EORTC CIP",
        "label": "Contradiction"
    },
    "444746eb-7e98-43fc-8bab-50c2a60d2806": {
        "text_answer": "No   Explanation  The evidence provided in the primary clinical trial describes the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion of the breast at three separate time points during the surgical procedures It does not mention the use of MRIguided radiotherapy for any of the interventions",
        "label": "Contradiction"
    },
    "2669332d-8907-4f82-afbf-e7be6b3c81b3": {
        "text_answer": "Yes The primary trial has different inclusion and exclusion criteria compared to the secondary trial",
        "label": "Entailment"
    },
    "635d4169-6adf-4254-9ee5-e9eede3f7bc5": {
        "text_answer": "Yes Both trials require patients to have a functional ECOG  2 status indicating they are ambulatory with limited symptoms",
        "label": "Entailment"
    },
    "23034d6a-8cb6-41b2-8e0d-84194285cb38": {
        "text_answer": "Yes The primary trial does not report the rate of clinical benefit CR PR SD PD beyond the number of participants in each category and the secondary trial does not report clinical benefit via RECIST criteria",
        "label": "Entailment"
    },
    "290fc77b-03cb-4ca6-877f-4117ea462ac6": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results does not directly compare the ORR between the Paclitaxel Plus Bevacizumab and Paclitaxel Plus Bevacizumab Plus Gemcitabine groups The statement is not entailed by the evidence as it makes a comparison that is not supported by the data presented",
        "label": "Contradiction"
    },
    "adfbe24e-4595-4fe3-88d8-8b5f01458993": {
        "text_answer": "No  Explanation The statement contrasting patient cohorts have contributed to the results of the primary clinical trial and the secondary clinical trial is not directly entailed by the evidence provided The primary trial and secondary trial are about different drugs denosumab and dmethadone respectively and have different outcome measurements percentage of participants with a response within 10 days of first dose of denosumab and number who reached a safe",
        "label": "Contradiction"
    },
    "003a36ac-4091-4ca9-96f3-1108302eb9e1": {
        "text_answer": "Yes  Explanation The statement At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial is entailed by the evidence since both trials involve the use of Trastuzumab with different dosing schedules In the primary trial patients receive 2 mgkg of Trastuzumab weekly which is the same dosage",
        "label": "Entailment"
    },
    "f329518b-872b-41af-8260-9d231e7ab205": {
        "text_answer": "Yes The primary clinical trial includes both male and female patients but the secondary clinical trial is open only to female patients",
        "label": "Entailment"
    },
    "84166f85-0a62-47fd-8dfa-a01dd778c748": {
        "text_answer": "No  The statement is not directly entailed by the evidence as the two trials address different interventions and outcome measures The first trial investigates the effect of sulforaphane supplements on isothiocyanate concentration in urine while the second trial examines the impact of physical therapy on pain in patients with malignant oropharyngeal neoplasms",
        "label": "Contradiction"
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b1cd1f5b-2b10-4bec-8482-a049acc7b674": {
        "text_answer": "No  The statement about thyroid gland lipoadenoma and hepatic function is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "e0c940e7-9a19-4c78-bf0f-4f630f6cfb90": {
        "text_answer": "No  The statement does not mention anything about sdh complex mutation analysis being performed in the trials",
        "label": "Contradiction"
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "text_answer": "No  Explanation  The statement There were no significant differences in the results from the groups in the primary trial and the Reflexology Group and control group in the secondary trial produced identical results is not entailed by the evidence provided  In the primary trial the area under the ROC curve AUC for the Siemens processing algorithm was found to be noninferior to that of the Lorad processing algorithm with a",
        "label": "Contradiction"
    },
    "de8bb37e-838b-4ac0-bd2b-b866feadac64": {
        "text_answer": "Yes The statement does not mention adverse events related to getting up from chairs but the evidence shows that there were no adverse events related to any condition in both trials including difficulty getting up from chairs",
        "label": "Entailment"
    },
    "d050c306-4563-403d-96c4-26728b8dc0df": {
        "text_answer": "yes the secondary trial intervention is extended compared to the primary trial However the statement does not specifically mention the number of weeks so it is not a perfect match to say it is extended by three times But it is an extension",
        "label": "Entailment"
    },
    "01f72f8a-d22e-4509-859a-5df198d04d2f": {
        "text_answer": " Yes but with conditions The evidence states that patients with a BMI of 25 kgm2 or greater and weight 400 lbs are eligible for the trial However there are several exclusion criteria related to medical conditions and medications that could prevent a patient with severe obesity from participating",
        "label": "Entailment"
    },
    "4650b6bf-1aed-4407-ac23-7ca5a4c2728d": {
        "text_answer": "No  The statement is not entailed by the evidence provided for the secondary clinical trial as the evidence does not mention anything about pulmonary embolisms or breast implants",
        "label": "Contradiction"
    },
    "9eb7c3cc-b3f5-40cf-8952-148afd8f2b04": {
        "text_answer": "No   Explanation   The statement provided is not directly related to the information given in the evidence The evidence describes the details of two interventions in a clinical trial one involving sunitinib and paclitaxel and the other involving bevacizumab and paclitaxel The statement on the other hand is about postpartum placental separation which is a process unrelated to the clinical trial or the interventions",
        "label": "Contradiction"
    },
    "8bd8a0f5-4bc9-4de6-a7d8-2a3acaadc6c4": {
        "text_answer": "No  Explanation  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is not directly entailed by the evidence provided The evidence only mentions that prior use of Herceptin within the last 5 months is an exclusion criterion for the primary trial and that there are no exclusion criteria related to gabapentin use",
        "label": "Contradiction"
    },
    "f098a93b-9d39-4928-87b7-0ad43311c615": {
        "text_answer": "  No   Explanation   The statement more than 34 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 14 days of the study is not entailed by the evidence The evidence only reports the number of participants with pathologic complete response at the time of surgery approximately 7 months after the start of the study It does",
        "label": "Contradiction"
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "text_answer": "No  Explanation  The statement There are several cases of swelling hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial is not entailed by the evidence provided The evidence only states that there were no adverse events of type 1 in both trials and no information about adverse events of types other than 1 such as swelling hypothermia or confusion was given Therefore",
        "label": "Contradiction"
    },
    "b3361d9c-9d9f-4966-80e7-629656bfcd1e": {
        "text_answer": "Yes The statement mentions the adverse events observed in the secondary trial that were not observed in the primary trial which are Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain The statement is entailed by the evidence as it accurately reflects the information provided",
        "label": "Entailment"
    },
    "09eee297-7801-4d6b-b3f6-17ee4f3418e4": {
        "text_answer": "No  Explanation  The statement image study is a radiographic technique used to evaluate a specific anatomic location for a specific purpose Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is not entailed by the evidence The evidence only provides information about the operative times for each arm in the primary trial but it does not make any direct comparison between the",
        "label": "Contradiction"
    },
    "d225c39d-4bd1-4129-a359-2909af912031": {
        "text_answer": "No  Explanation  The primary clinical trial results do not directly compare the overall response rate between Arm A and Arm B Instead they report the overall response rate for each arm separately The statement only mentions Arm A as having the most effective overall response rate but it does not provide any evidence to support this claim from the given trial results  The secondary clinical trial results do not provide any information about the overall response rate or the primary trial interventions ",
        "label": "Contradiction"
    },
    "a02a955a-9890-4347-8a6b-1377008f581b": {
        "text_answer": " No the statement is not entailed by the evidence The evidence states that patients must have a potassium within the normal range of 3553 mEqL for the primary trial It does not mention anything about hyperkalemia or eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "b652609b-4609-481e-a5de-caa0c4432f2f": {
        "text_answer": "Yes   Explanation  The statement the placebo and memantine interventions in the primary clinical trial are given with the same frequency and for an equal length of time is entailed by the evidence as both interventions are given twice daily BID for a duration of 12 weeks",
        "label": "Entailment"
    },
    "be6130d9-49f1-4b4e-82f2-6acc6ee7f176": {
        "text_answer": "No   Explanation  The statement have excessive tearing is not directly related to any of the adverse events listed in the evidence The adverse events listed in the evidence are related to various health conditions such as ileus disease progression pneumonia acute kidney injury and other general disorders None of these conditions are related to excessive tearing",
        "label": "Contradiction"
    },
    "292a2905-b407-4068-8c2e-e6d596e494ca": {
        "text_answer": "Yes The primary clinical trial explicitly states that any gastrointestinal disease which would impair ability to swallow retain or absorb drug is not allowed CBTbased treatments which are typically administered verbally or through written materials do not involve the ingestion of drugs and therefore do not directly interfere with the absorption of BMN 673 However the secondary clinical trial does not mention any specific exclusion related to CBTbased treatments",
        "label": "Entailment"
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "text_answer": "Yes The primary trial excludes patients who are participating in another clinical trial",
        "label": "Entailment"
    },
    "72f49bc3-1624-437d-bf75-e37a24a9c19f": {
        "text_answer": "  Yes for the statement that age at menarche is a risk factor for breast cancer but not for the other statements  Explanation  The evidence provided in the inclusion and exclusion criteria for both the primary and secondary trials does not mention anything about the patients nationality ethnicity psychiatric condition or gender being a factor for eligibility However the evidence does mention that women of childbearing potential must have a negative pregnancy",
        "label": "Entailment"
    },
    "002bd33d-4038-4b2b-9f56-1bd8e8978d64": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with cerebral metastases within the brainstem are excluded from the secondary trial but not explicitly mentioned in the primary trials exclusion criteria",
        "label": "Entailment"
    },
    "25d927c2-92be-405f-950a-e275c4d00e38": {
        "text_answer": "Yes  Explanation  The statement conditions including recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage were more often associated with adverse events in the primary clinical trial than in the secondary clinical trial is entailed by the evidence because  1 The evidence shows that the primary clinical trial had a higher incidence of adverse events 60",
        "label": "Entailment"
    },
    "fd2a59ea-6b33-4b24-ae04-32a2a40b4029": {
        "text_answer": "No  Explanation The statement does not provide enough information to determine if the vitamin K measurement is related to the cohorts receiving different doses and timings of Dexamethasone administration in the trial The statement only mentions vitamin K measurement in general without specifying its relation to the trial",
        "label": "Contradiction"
    },
    "883cad2c-dee5-4530-bdde-5d616d4570ad": {
        "text_answer": "No  Explanation  The statement patients with severe insomnia and schizophrenia are not eligible for the primary clinical trial but are eligible for the secondary clinical trial is not directly entailed by the evidence provided The primary clinical trial has specific inclusion and exclusion criteria related to breast cancer while the secondary clinical trial has inclusion and exclusion criteria related to cancer treatment with chemotherapy or biologics and sleep disturbance The statement does",
        "label": "Contradiction"
    },
    "81694850-fb70-4062-8dab-a52dd8083ebb": {
        "text_answer": "No  Explanation The statement four unique adverse events impacted patients in cohort 2 of the primary clinical trial is not directly entailed by the evidence provided The evidence only lists the number of occurrences for each adverse event in cohort 2 but it does not specify that four unique adverse events affected patients",
        "label": "Contradiction"
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "text_answer": "Yes  Explanation  The primary trial and the secondary trial have different outcome measurements In the primary trial the outcome measurement is the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events In contrast in the secondary trial the outcome measurement is the number of participants with objective response These two outcome measurements are not directly related to each other  However the interventions in both trials are the",
        "label": "Entailment"
    },
    "4fc29a51-2cd7-4c8c-8000-58bd9cb4858d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "64cc1bfb-d23f-47e1-bfcb-7d69cd8458ad": {
        "text_answer": "Yes  Explanation The statement there was a single psychiatric adverse event in the primary trial which affected fewer than 1 in 10 patients is entailed by the evidence since the evidence reports one case of suicidal ideation a psychiatric adverse event that affected 200 of the patients which is fewer than 1 in 10",
        "label": "Entailment"
    },
    "48a0cb8b-d7c5-42e0-8adc-abd0b8f17301": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about Leptospiraceae a taxonomic family of bacteria while the evidence is about inclusion and exclusion criteria for breast cancer clinical trials",
        "label": "Contradiction"
    },
    "dc55e21c-534b-4045-9c6c-f13919efde18": {
        "text_answer": "No  Explanation  The primary clinical trial involves the use of FMX and MM398 while the secondary clinical trial involves the use of lapatinib and paclitaxel Therefore the drugs and interventions are not the same and the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "text_answer": "Yes  Explanation The statement the primary trial and the secondary trial do not use the same drugs dosages or frequency of administration in their interventions is true based on the provided evidence However the statement also mentions that both trials use intravenous injections and MRIs which is also true according to the evidence Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "d6381c6b-a7d6-406a-9d52-a660c27c2d49": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials have reported no adverse events for Adverse Events 1 and Adverse Events 2",
        "label": "Entailment"
    },
    "3159e9e4-c8a2-4333-b24c-250698ae8ffd": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary clinical trial was completely free of any adverse events is not entailed by the evidence The evidence only reports the number of participants with serious and nonserious adverse events for each dose level but it does not indicate that there were no adverse events in cohort 1 of the primary clinical trial The evidence only shows that all 3 participants in cohort",
        "label": "Contradiction"
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "text_answer": "Yes There were a total of 3 vomiting events recorded in the primary trial",
        "label": "Entailment"
    },
    "70bfa3c4-2199-4d07-84c9-f41cac594ed4": {
        "text_answer": "Yes  Explanation The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less is entailed by the evidence because the evidence states that Cohort 1 received 12 mgkg of MM121 while Cohort 2 received 20 mgkg of MM",
        "label": "Entailment"
    },
    "97fe92c7-779d-4de8-8834-60ed8fe3178f": {
        "text_answer": "No  Explanation  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial the only AEs recorded were 3 cases of Lymphoma does not directly address the question take lots of naps The statement only discusses the adverse events AEs observed in the trials and does not mention anything about individuals taking or not taking lots of naps Therefore the statement is not ent",
        "label": "Contradiction"
    },
    "5829a465-2f7e-4a15-a746-24e4c0f53200": {
        "text_answer": "Yes  Explanation  The statement age restrictions apply to patients participating in the secondary clinical trial is entailed by the evidence since the secondary trial has an age restriction 18 yrs specified in its exclusion criteria while the primary trial does not mention any age limit in its inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "88fbd986-643d-4086-8091-e535d1970ab9": {
        "text_answer": "No  Explanation The primary and secondary clinical trials have different inclusion and exclusion criteria The primary trial focuses on patients with advancedmetastatic solid tumors while the secondary trial focuses on patients with a history of breast cancer or those at risk for breast cancer with bothersome hot flashes The primary trial includes patients with measurable or nonmeasurable disease while the secondary trial only includes patients without malignant disease The primary trial excludes",
        "label": "Contradiction"
    },
    "0ed8370b-00c3-41d9-9d12-0c0f1259cbf1": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence that cohort 2 practices paced breathing once daily",
        "label": "Entailment"
    },
    "a06d2404-8265-4baf-907d-ddba1bb223d0": {
        "text_answer": "Yes The statement does not report any adverse events in Cohort 1 of the primary trial which is consistent with the evidence stating that there were 0 adverse events out of 147 participants The question about the duration of not feeling like eating is not directly related to the statement and does not affect its entailment",
        "label": "Entailment"
    },
    "df8f9622-e361-4283-bc4a-fef7eaa101b1": {
        "text_answer": "No  Explanation  The statement corresponding author indicator is an indication that the specific author is considered the corresponding author is not directly related to the information provided in the evidence The evidence only reports the number of adverse events in each trial without any mention of the corresponding author or any indication that the trials are comparable beyond the number of adverse events Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "text_answer": "No  Explanation  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is not entailed by the evidence provided The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial There is no mention of severe anaphylactic reactions",
        "label": "Contradiction"
    },
    "1f742130-d274-4857-bc92-af652963c07b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3cd90294-f295-4725-82d4-e185d03cc2b7": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "0cacd90a-ae93-47cb-b9f2-fa7e03d75270": {
        "text_answer": "No  Explanation The statement several of the primary trial candidates are administered 1000 mcg of talazoparib daily is not directly related to the question have mouth discomfort with toothpaste The evidence only mentions that the patients are included in a trial and some are receiving talazoparib but it does not provide any information about mouth discomfort or toothpaste use",
        "label": "Contradiction"
    },
    "9a137ed3-f905-4367-988c-002fabb77140": {
        "text_answer": "No  Explanation The statement only 5 of patients in cohort 2 report increased pleural effusion within the primary clinical trial is not entailed by the evidence The evidence only reports that 1 out of 4 patients in cohort 2 experienced increased pleural effusion which is 2500 Therefore it is not accurate to say that only 5 of patients reported this adverse event",
        "label": "Contradiction"
    },
    "71268387-6e9d-4875-b193-b60b4e3e7033": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the patients in the primary trial receive a loading dose of 4 mgkg followed by 2 mgkg per week while patients in cohort 2 of the secondary trial receive Herceptin at a dose of 4 mgkg on Day 1 of Cycle 5 followed by 2 mgkg per week starting from Day 8 The initial doses are different",
        "label": "Entailment"
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "text_answer": "No  Explanation  The statement The results from the primary trial indicate that the Arm A intervention has a better overall response rate than the placebo arm additionally in the secondary trial the Denosumab cohort had a better Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed by the evidence provided  The evidence only reports the results of the primary trial which shows",
        "label": "Contradiction"
    },
    "79f436e1-8238-4d99-824f-6b19bfbd4ec4": {
        "text_answer": "Yes  Explanation The primary trial involves the use of Abl Cells and Cyclophosphamide while the secondary trial involves the use of DMCHOCPEN These are two different drugs or interventions Additionally the dosing and patient populations are different between the two trials",
        "label": "Entailment"
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "text_answer": "Yes  Explanation The statement The intervention in the primary trial consists of a single drug ZD1839 whereas in the secondary trial the intervention requires at least 3 different drugs including Zoledronic acid Samarium153 and pegfilgrastim is entailed by the evidence because the primary trial involves the use of ZD1839 as a single drug while the secondary trial involves the use of Z",
        "label": "Entailment"
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "text_answer": "Yes  Explanation The statement Across both the primary trial and the secondary trial only one death was recorded in the adverse events is entailed by the evidence as both trials report a total of one death in their adverse events",
        "label": "Entailment"
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "text_answer": "Yes   Explanation The statement is entailed by the evidence as the primary trial involves escalating doses of Alpha Lipoic Acid while the secondary trial maintains a constant dose of Necitumumab",
        "label": "Entailment"
    },
    "333e2178-1944-4771-9ce5-6c89a1386f5a": {
        "text_answer": "Yes  Explanation The statement all participants in the primary clinical trial irrespective of their cohort receive a consistent dosage of docetaxel doxorubicin and cyclophosphamide at the same frequency is entailed by the evidence as both interventions involve the same dosages for doxorubicin 60 mgm and cyclophosphamide 600 mg",
        "label": "Entailment"
    },
    "c8633493-4879-4e97-9fcf-5e59ca22a79a": {
        "text_answer": "Yes The primary trial includes patients with a breast tumor 1 cm in diameter which is within the range of 082 cm specified in the statement The secondary trial does not have a specific tumor size requirement but the patient must have measurable disease which implies a tumor size that can be measured Therefore patients with a breast tumor 082 cm in diameter with confirmed hr positive and her2 negative status are eligible for both",
        "label": "Entailment"
    },
    "a003e152-72e6-4c28-9f7d-1d2086174992": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel armgroup experienced either a confirmed complete response CR or a confirmed partial response PR Since under half implies less than 50 the statement is not strictly true based on the given data However the statement is ent",
        "label": "Entailment"
    },
    "594bf055-6c27-4319-b7b6-11ef47fab70c": {
        "text_answer": "Yes  Explanation The statement one instance each of anaemia and febrile neutropenia was documented is directly stated in the evidence The statement pancytopenia was not observed is inferred from the evidence as there is no instance of pancytopenia reported",
        "label": "Entailment"
    },
    "174a00b4-2d77-4734-b02a-3603133fa8fe": {
        "text_answer": "Yes  Explanation  The evidence provided in the results of the clinical trial shows that the percentage of participants with invasive diseasefree survival iDFS events in the Neratinib group was 47 while in the Placebo group it was 75 This means that the Neratinib group had a lower incidence of iDFS events compared to the Placebo group Therefore the statement in the primary clinical",
        "label": "Entailment"
    },
    "055374e1-939d-4366-835a-edf8e587f45c": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens therapy in the last 4 weeks  28 days before study entry The statement extends this time frame to 730 days 2 years",
        "label": "Entailment"
    },
    "292a7346-b4f6-4fc1-92a7-80297532eeff": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "892ac2e3-f5f8-42eb-957c-b3ca6af18d3a": {
        "text_answer": "No  Explanation The statement in the question does not accurately represent the information provided in the evidence The primary trial administers 150 mg of oral pregabalin twice daily which is equivalent to approximately 03 grams per day not 015 grams every 14 days Additionally the secondary trial administers a combination of intravenous and intrathecal medications HDMTX and ITDepoc",
        "label": "Contradiction"
    },
    "6c12493c-9eab-4206-aacc-bbb3dc398050": {
        "text_answer": "Yes  Explanation  The statement no single type of adverse event noted in the primary clinical trial impacted over 25 of the patient population is entailed by the evidence because none of the adverse event types listed in the evidence affected more than 25 of the patient population",
        "label": "Entailment"
    },
    "753d23e6-333c-4ec1-8bc2-a853c29a20e9": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the two clinical trials involve different interventions The primary trial focuses on radioembolization using Yttrium90 glass microspheres while the secondary trial explores a combination of ibrutinib and MEDI4736",
        "label": "Contradiction"
    },
    "c1e836e2-ad18-40b1-b8c4-0f05168d5104": {
        "text_answer": "No  Explanation The statement cohort 2 of the primary clinical trial receives 0035 mg less alt801 than cohort 1 is not entailed by the evidence The evidence only provides the doses of ALT801 for each cohort but it does not directly state the difference in doses between the two cohorts The statement makes an assumption about the difference in doses",
        "label": "Contradiction"
    },
    "2c817052-b2e7-4199-8b5c-77d285e2231c": {
        "text_answer": "Yes The statement is entailed by the evidence as the inclusion criteria for the clinical trial specifically require a histologically confirmed infiltrating primary breast cancer that is HER2 positive either IHC 3 or FISH Additionally the participants are expected to have access to frequent healthcare support as they will be receiving primary treatment and undergoing biological and molecular examination",
        "label": "Entailment"
    },
    "561a11dc-abb5-4a2b-9211-4e27419cfc43": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9eb119ec-3ef7-4de4-ab36-5e8d63fdb984": {
        "text_answer": "Yes The statement is about pelvic pain or discomfort which is not explicitly mentioned in the evidence but is included as a criterion for inclusion in the primary trial chronic pain with average 24 hour intensity rated at least 3 on a verbal numerical scale from 010 during the 24 hours prior to study entry",
        "label": "Entailment"
    },
    "9e31c420-01cc-4232-9793-a3a4b7201fa6": {
        "text_answer": "No  Explanation  The statement liter per meter squared is a unit of concentration equal to liter per meter squared is not related to the inclusion or exclusion criteria for either the primary or secondary trials The statement is a fact about units of measurement while the evidence provided pertains to the eligibility criteria for participating in the clinical trials",
        "label": "Contradiction"
    },
    "6fa15cf5-6fc4-48f3-a800-5e4699952ddb": {
        "text_answer": "  No   Explanation  The evidence provided does not mention anything about obesity as an inclusion or exclusion criterion for either clinical trial Therefore the statement about the trials being open for severely obese patients is not entailed by the evidence",
        "label": "Contradiction"
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "text_answer": "yes but with a qualification the statement is entailed by the secondary trial exclusion criteria but not by the primary trial inclusionexclusion criteria In the primary trial there is no mention of chemotherapy or radiotherapy within a specific time frame as an exclusion criterion",
        "label": "Entailment"
    },
    "804742bb-2d69-45a8-a7a9-b6a269bf8d58": {
        "text_answer": "No  The evidence provides inclusion and exclusion criteria for a clinical trial but it does not mention any specific requirement related to liver enzymes",
        "label": "Contradiction"
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly give the Recurrencefree Survival rates for each group only the number of participants in each group Therefore it is not possible to calculate the difference in Recurrencefree Survival between the Ketorolac 30 mg and NaCl 09 3mL groups based on the given information",
        "label": "Contradiction"
    },
    "05b6b24d-8753-4029-9464-c825cb52b9f4": {
        "text_answer": "Yes The statement accurately summarizes the difference in interventions between the two cohorts in the clinical trial However its important to note that there are other differences in the interventions such as the addition of bevacizumab in the second cohort but the statement specifically focuses on the dosages of sunitinib and paclitaxel",
        "label": "Entailment"
    },
    "e34d6b72-e842-4cd8-a0f4-08c8f4d33be9": {
        "text_answer": " No   Explanation  The inclusion criteria state that participants must have a BMI of 25 kgm2 or greater This means that underweight patients BMI  185 kgm2 are not eligible for the trial",
        "label": "Contradiction"
    },
    "0bba5705-e808-4f90-b434-a951027f4d0f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "746f0f7a-c7e2-4ac9-a0ca-db2783eec9fa": {
        "text_answer": "No  Explanation  The statement none of the patients treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial experienced any treatmentemergent adverse events is not entailed by the evidence The evidence reports that there were 24 treatmentemergent adverse events among the 25 participants in the sunitinib  docetaxel  trastuzumab arm",
        "label": "Contradiction"
    },
    "9e02f276-1bd0-4373-a049-9a67ee3eac87": {
        "text_answer": "No  Explanation  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only states that there were no adverse events reported in both cohorts 1 and 2 of the primary trial The statement about hypogonadotropic hypogonadism with anosmia",
        "label": "Contradiction"
    },
    "7e0f7c16-59ff-4a80-833a-7bb82748e80a": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary clinical trial was administered a lower dose of cetuximab than cohort 2 and received the same amount of 8mgkg mm121 is not entailed by the evidence The evidence only states the doses of cetuximab and mm121 for each cohort It does not directly compare the amount of mm1",
        "label": "Contradiction"
    },
    "00f4aa60-c89a-496d-aa2d-9535fcc79ff0": {
        "text_answer": "Yes  Explanation The evidence provided in the trial results shows that the mean number of hot flashes per day was lower in the paced respiration intervention group 348 compared to the fast shallow breathing group 395 This indicates that the paced respiration intervention was associated with fewer hot flashes on average as stated in the question",
        "label": "Entailment"
    },
    "65edf675-63e7-4b5f-b131-9e5cdf9eeec4": {
        "text_answer": "No  Explanation  The statement The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial is not directly entailed by the evidence provided The evidence only states the dosages of Denosumab and Tamoxifen in their respective interventions but it does not provide a comparison of the dosages in terms",
        "label": "Contradiction"
    },
    "a116a540-abca-478e-94ea-9997b0434c8b": {
        "text_answer": "Yes  Explanation The evidence provides the Ki67 expression data for the TAK228 Plus Tamoxifen arm of the trial which shows a reduction in Ki67 expression from a median of 15 at baseline to 10 at 6 weeks The statement is about a 5 reduction in Ki67 expression which is a subset of the observed reduction in the trial Therefore the statement is entailed by the",
        "label": "Entailment"
    },
    "ed50607e-8c46-4565-9192-4d5c4ca5fea5": {
        "text_answer": "No  Explanation The statement is about the proportion of patients who suffered acute vomiting in cohort 2 of the primary trial while the evidence only provides the number of participants in cohort 2 who did not experience acute vomiting 20 out of 35 The statement makes an incorrect assumption about the proportion of patients who did experience acute vomiting and the evidence does not provide enough information to support that assumption",
        "label": "Contradiction"
    },
    "321d4cba-47ee-4c74-85b9-072814b6fe6b": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials exclude pregnant patients from participation",
        "label": "Entailment"
    },
    "1f4fe504-06a7-40e6-ad0e-76c903ea80a2": {
        "text_answer": "Yes  Explanation The statement the occurrences of hepatotoxicity were tenfold compared to the cases of hypertension and pancreatectomy can be calculated as follows   Hepatotoxicity 38  0375  375  Hypertension and Pancreatectomy 18 each  0125  1",
        "label": "Entailment"
    },
    "6c3ebd57-b814-49df-bade-ad46362eaa2b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only specifies the types of interventions for each cohort but it does not mention anything about ER PR or HER2 status for all members of each cohort The statement assumes that all members of each cohort have the corresponding receptor status which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "83c979cb-fb3a-4792-8a63-8f7e544bb8a8": {
        "text_answer": "No  The statement about a patient with diffuse parenchymal lung disease being excluded from the trial is not explicitly stated in the inclusion or exclusion criteria provided in the evidence However the evidence does state that patients with a history of interstitial lung disease or pneumonitis are excluded Diffuse parenchymal lung disease is a type of interstitial lung disease but it is not explicitly mentioned in the evidence",
        "label": "Contradiction"
    },
    "f203176f-3d6f-4e37-a07b-9bcf409ed538": {
        "text_answer": "No  The evidence does not state that AfricanAmerican participants in the primary clinical trial must remain inhabitants of Texas for the entirety of the study The evidence only provides the inclusion and exclusion criteria for the clinical trial",
        "label": "Contradiction"
    },
    "c467ce7a-d234-4542-909b-ac94393314ce": {
        "text_answer": "No   Explanation  The evidence states that the patients in the intervention arm will be invited to view the educational DVD not that they will definitely view it Therefore it is possible that some patients in the intervention arm may choose not to view the DVD and it is explicitly stated that patients in the control arm will not view the DVD Thus the statement that the educational dvd will not be used in any of the interventions within the primary clinical trial",
        "label": "Contradiction"
    },
    "60431d29-7e80-4a3e-b433-83f886ea73b6": {
        "text_answer": "No  Explanation  The statement mixture of melanocytic neoplastic components is a finding indicating the presence of at least two morphologic components in a melanocytic tumor sample is not directly related to the adverse events data provided in the evidence The evidence only reports the number of adverse events for each trial but it does not mention anything about the presence or absence of a mixture of melanocytic ne",
        "label": "Contradiction"
    },
    "afc5437d-4c34-46e3-bcb0-742a23ba35e6": {
        "text_answer": "No The evidence does not mention anything about participants from the secondary trial being able to concurrently enroll in the primary trial",
        "label": "Contradiction"
    },
    "aa861098-a5f8-473e-be7d-eba94ccb4ab1": {
        "text_answer": "No  The patient described in the statement does not meet the eligibility criteria for the trial as they have a life expectancy of less than 3 months",
        "label": "Contradiction"
    },
    "1f8901ea-ca2d-4771-95e5-8b75fa7e9994": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence The evidence does not mention any information about the structure or explanation of a treatment cycle in the intervention portion of the primary clinical trial",
        "label": "Entailment"
    },
    "4869e50d-ccc3-4200-b2e0-bf706fc99488": {
        "text_answer": "No  Explanation  The statement patients diagnosed with benign ductal carcinoma in situ are eligible for the primary clinical trial but excluded from the secondary clinical trial is not entailed by the evidence provided  In the primary trial patients with benign breast disease including ductal carcinoma in situ are included However in the secondary trial patients with a history of breast cancer including ductal carcinoma in situ are",
        "label": "Contradiction"
    },
    "22cf6f40-f022-4482-acdf-eef98748b946": {
        "text_answer": "Yes The primary trial measures changes in pain intensity and the secondary trial measures changes in bone mineral density of the lumbar spine over a period of 9 months",
        "label": "Entailment"
    },
    "b4a7bcbe-6c7b-4e37-be25-35f2dd042bce": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide information about the number or percentage of patients who experienced complete response at week 2",
        "label": "Contradiction"
    },
    "97a8ede9-e46f-4b17-be7d-b05e9bd2f86e": {
        "text_answer": "Yes  Explanation  The evidence provided does not mention tumour lysis syndrome as an adverse event in either the primary or secondary trial Therefore the statement that patients enrolled in both the primary and secondary trial remained free from tumour lysis syndrome is entailed by the evidence since there is no evidence to the contrary",
        "label": "Entailment"
    },
    "59c8ac7f-504b-46db-a840-b84fd9969b3d": {
        "text_answer": "No   The evidence provided only indicates the design of two separate clinical trials one evaluating LBH589 in combination with capecitabine and another evaluating LBH589 and lapatinib in combination There is no data provided regarding the responses of the lapatinib and LBH589 cohort",
        "label": "Contradiction"
    },
    "d08f014d-7d1b-45a1-b1c2-f68f12591f15": {
        "text_answer": "No   Explanation   The statement Both cohorts of the primary trial contained the same number of participants is not directly related to the information provided in the evidence The evidence only mentions the number of participants analyzed in each arm of the trial and the percentage of participants with events but it does not specify if the number of participants in each arm is the same or different The statement about the ADASCOG naming task is not",
        "label": "Contradiction"
    },
    "6a0e68b7-6099-4fb9-bf11-35885b715348": {
        "text_answer": "Yes The statement is consistent with the inclusion criteria stating that patients must have had a requirement for hormonal treatment after a previous hormonal therapy for breast cancer",
        "label": "Entailment"
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "text_answer": "No  Explanation The evidence states that there were 5 participants in the placebo group who experienced emesis during the study period Therefore not all participants in the placebo group experienced emesis",
        "label": "Contradiction"
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "text_answer": "Yes  Explanation  The statement There are 0 shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because there is no overlap in the inclusion or exclusion criteria between the two trials The primary trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy and has exclusion criteria related to mental function language",
        "label": "Entailment"
    },
    "ebe5f6c9-355c-4d69-8b0d-5ac8d5f861a1": {
        "text_answer": "No  Explanation  The statement mentions several psychiatric adverse events including an eating disorder and Schizophrenia However the evidence only mentions one psychiatric adverse event which is suicidal ideation The evidence does not mention any cases of eating disorders or Schizophrenia Therefore the statement is not entailed by the evidence  Additionally the statement mentions erbb2 mut",
        "label": "Contradiction"
    },
    "90e72a43-b0ee-4656-b679-a6025ef5d4c2": {
        "text_answer": "Yes  Explanation  The statement the results of the secondary clinical trial and the primary clinical trial are measured within different units is entailed by the evidence because the primary clinical trial measures tumor diameter in centimeters cm while the secondary clinical trial measures the number of participants with solid tumor response using RECIST 11 criteria which includes complete response CR partial response PR stable disease SD progressive disease PD",
        "label": "Entailment"
    },
    "89f8f42e-0ac7-4fc4-bbd3-d58ffb933005": {
        "text_answer": "No  Explanation  The statement benign oral cavity soft tissue neoplasm is a nonmetastasizing soft tissue neoplasm that arises from the oral cavity is not related to the evidence provided The evidence only pertains to two interventions in clinical trials for breast cancer treatment The statement makes a claim about a different type of neoplasm benign oral cavity soft tissue neoplasm and its metastas",
        "label": "Contradiction"
    },
    "7af1ab1f-5170-496e-ba41-61d54113c9c6": {
        "text_answer": "yes with the condition that sexually active fertile men use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab",
        "label": "Entailment"
    },
    "70b8c9a1-dcd5-459b-b138-d341132d2b5e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports a change in Ki67 expression not a reduction in tumor diameter The statement also incorrectly states that tamoxifen is given at a dose of 32 mg po daily when the evidence states that it is given at a dose of 20 mg po daily",
        "label": "Contradiction"
    },
    "91ce9f54-322f-4796-930e-0f85cf65d115": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the dosing regimens for Interventions 1 and 2 but it does not specify that Cohorts A and B are given different doses of oral V935 at the same point in time The evidence only states that Cohort A receives two IM injections of V935 LD and Cohort B receives three EP injections",
        "label": "Contradiction"
    },
    "2c4fbaa0-f62c-4a7b-9d9d-7b61a8383ec4": {
        "text_answer": "yes the evidence relates to iDFS in the Neratinib and Placebo groups but it does not mention anything about granuloma assessment Therefore the statement is not entailed by the evidence",
        "label": "Entailment"
    },
    "23cb11b4-6a85-4a6f-9e72-920eff085459": {
        "text_answer": "No  Explanation The evidence provided in the text does not contain any information about the longest PFS duration observed in the primary trial The text only reports the median PFS for each treatment group",
        "label": "Contradiction"
    },
    "33b59cbc-c52d-4e5c-8f77-f2d8a6fa491c": {
        "text_answer": "No  Explanation  The statement several recorded adverse events have been associated with the secondary clinical trial is not entailed by the evidence provided The evidence only states that there were no recorded adverse events in the secondary clinical trial It does not mention that there were adverse events associated with the trial only that there were none",
        "label": "Contradiction"
    },
    "e9e1b48b-55a2-479b-93cd-33db74d3053c": {
        "text_answer": "Yes The statement is entailed by the evidence as laserassisted fluorescence angiography is mentioned as a part of both interventions in the primary trial",
        "label": "Entailment"
    },
    "cb418196-3bf8-4a86-9c90-819eb43ede13": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence reports that adverse events were observed in cohort 1 patients during the primary clinical trial",
        "label": "Entailment"
    },
    "d16039bf-c0d3-488f-8890-cb5b5d909ab8": {
        "text_answer": "Yes The primary trial only has one cohort receiving daily armodafinil while the secondary trial has all patients receiving the same dosage of PDR001 but varying dosages of MCS110",
        "label": "Entailment"
    },
    "eb3891b2-5320-4b6e-9a9f-08c7aa8bdd29": {
        "text_answer": "Yes The primary trial does not exclude patients with metastases within the brainstem but the secondary trial does",
        "label": "Entailment"
    },
    "0c9b06e1-9dab-4937-b22e-0d372a5fd92d": {
        "text_answer": "Yes   Explanation  The statement in the primary clinical trial high doses of alpha lipoic acid are administered up to 100 mg three times daily while the same steady dose of necitumumab is given to patients in cohort 1 of the secondary clinical trial is entailed by the evidence   The primary clinical trial involves administering alpha lipoic acid at a baseline dose of 1",
        "label": "Entailment"
    },
    "4a56cd2d-ce04-4515-a033-f140e44cf955": {
        "text_answer": "Yes  Explanation The statement the first cohort of the primary clinical trial saw a single case of both anaemia and febrile neutropenia however there were no recorded instances of pancytopenia is entailed by the evidence as the evidence shows that there was one case of anaemia and one case of febrile neutropenia in the first cohort and no cases of pancytopen",
        "label": "Entailment"
    },
    "284bab9f-a986-4a27-9fe3-ac989cefcf4e": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as the evidence does not provide any information about the type of injections given to participants in the primary clinical trial The statement only mentions the secondary clinical trial and the type of injections given to its participants",
        "label": "Contradiction"
    },
    "e5746ae9-641d-4549-a164-811aa126a2e5": {
        "text_answer": "Yes  Explanation The evidence states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR This means that more than 05 patients 53 out of 60 in this arm experienced an OR according to the RECIST criteria 10",
        "label": "Entailment"
    },
    "510ae9ab-feae-4c57-a8c3-02e8764e6faa": {
        "text_answer": "No  The statement about a stepson and claustrophobiaosteoporosis does not relate to the inclusion or exclusion criteria for the primary or secondary trials",
        "label": "Contradiction"
    },
    "539adaf8-43ce-4c8f-9ed5-df5b030132c3": {
        "text_answer": "No  The statement is not entailed by the evidence as the participants in the primary clinical trial receive oral medication daily not intravenous medication once a week",
        "label": "Contradiction"
    },
    "df3a590c-02f9-4dc2-84da-da4d5534c542": {
        "text_answer": "Yes The evidence states that neither cohort received invasive surgery or Neratinib Therefore the statement that neither cohort underwent any invasive surgery or received Neratinib is entailed by the evidence",
        "label": "Entailment"
    },
    "f995d440-b2ff-491e-bc11-038f63b8681e": {
        "text_answer": "No The statement is not entailed by the evidence as the patient described in the statement does not meet the inclusion criteria for either trial The patient described in the statement has HRpositive HER2positive breast cancer while the secondary trial only includes patients with HRnegative HER2negative breast cancer Additionally the primary trial only includes patients with metastatic or recurrent breast cancer while the patient described in the statement is a new diagnosis",
        "label": "Contradiction"
    },
    "d6cde3f8-ef3c-4d8a-8afb-d3e9f8c5c1f8": {
        "text_answer": "Yes The evidence states that the trial excludes patients with dementia which includes Alzheimers disease",
        "label": "Entailment"
    },
    "dbb49ce0-7aed-4573-9b13-1db31e9df94d": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale not range of motion for yoga",
        "label": "Contradiction"
    },
    "198d43b9-ed80-463e-bbdc-d2d565fb61aa": {
        "text_answer": "  No The statement is not entailed by the evidence as the primary trial explicitly states that participants must be aged greater than 20 years",
        "label": "Contradiction"
    },
    "679f8ab4-38a4-4c6c-b85f-800e645e5bb8": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention the number of participants in each group who experienced an undetermined rhythm by ECG finding The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "93850158-9371-4320-aefc-c31e15a5d983": {
        "text_answer": "  Yes the primary trial has separate inclusion and exclusion criteria for its phases while the secondary trial has the same criteria for all participants However the statement about the unit of concentration is not related to the evidence provided",
        "label": "Entailment"
    },
    "7bdf850e-2f84-40f0-9b80-5bf9984be081": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it does not mention anything about the effects of Vorinostat on the QRS complex or the electrocardiogram The evidence only describes the administration of Vorinostat during radiation therapy",
        "label": "Contradiction"
    },
    "10acc981-00c5-4c74-b2ce-58bc69406955": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial has a multitude of adverse events recorded for its patient cohort is entailed by the evidence since the evidence states that there was at least one adverse event a surgery adverse event recorded in the trial for a total of 129 patients 345 The term multitude implies a large number and 345 is a significant",
        "label": "Entailment"
    },
    "e42e5fc5-cdf8-40c3-9cf7-44ff5bdff413": {
        "text_answer": "No  Explanation  The statement neither the primary nor the secondary trial imposes restrictions based on age but patients must be between 2555 years old for the primary clinical trial is not entailed by the evidence The evidence only states the inclusion and exclusion criteria for each trial but it does not mention anything about age restrictions for the secondary trial The statement adds an additional requirement for the primary trial that is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "5a90093d-2964-4935-b8af-236bfff8d4de": {
        "text_answer": "No  The evidence does not mention paclitaxel at all",
        "label": "Contradiction"
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about adverse events related to mental health for cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "text_answer": "  No   Anorexia is a medical condition characterized by a persistent lack of appetite and significant weight loss The evidence provided in the trials inclusion and exclusion criteria does not mention anorexia as a condition for eligibility or exclusion The criteria focus on weight status willingness to change diet and physical activity and access to technology for online participation",
        "label": "Contradiction"
    },
    "0bc4c4b5-bdb3-4b4b-9122-e52dcb57ec61": {
        "text_answer": "No  The evidence provided does not relate to gynecologic cancer or sexual relationships",
        "label": "Contradiction"
    },
    "5d04737b-c113-4934-94b6-ea9d8dd6318b": {
        "text_answer": "No  Explanation  The statement At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial is not directly entailed by the evidence provided The primary trial and the secondary trial have different interventions and while there are differences in the dosing schedules for Trastuzumab between the two trials the statement does not specifically mention that",
        "label": "Contradiction"
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "text_answer": "No  Explanation The statement Sunitinib was administered orally every day to every patient in the primary trial for the entire duration of the study is not entailed by the evidence The evidence states that sunitinib was administered orally every day but it also states that dosing could be interrupted or reduced according to individual tolerance and participants with PD or intolerable toxicity were considered for discontinuation from the study",
        "label": "Contradiction"
    },
    "e6b528a8-9d23-420b-b1a1-63bd831b7c03": {
        "text_answer": "No   Explanation The statement every patient in the primary clinical trial had fully healed surgical incisions without any complications is not entailed by the evidence as the evidence reports several complications related to surgical incisions including wound dehiscence hematoma seroma and inflammation red breast syndrome",
        "label": "Contradiction"
    },
    "205bc80b-db03-469f-85b8-290a4be79af8": {
        "text_answer": "Yes  Explanation The statement cohort 1 of the secondary trial receives lower weekly mm121 and paclitaxel doses than those in the primary trial is entailed by the evidence because the evidence states that in the secondary trial the HR subgroup randomized to receive Intervention 1 receives a 2 week runin of MM121 with a weekly dose of 20 mgkg",
        "label": "Entailment"
    },
    "1a15db80-85f2-4d35-b325-1e01fdfb453d": {
        "text_answer": "No  Explanation  The evidence provided in the given trial results does not support the statement that the LBH589 with capecitabine cohort showed inferior results when compared to the LBH589 and lapatinib group The evidence only provides information about the design and dosing of two different arms of the trial but it does not include any data comparing the outcomes or results between the two groups",
        "label": "Contradiction"
    },
    "52ae60f0-ea78-473d-9e82-78f2d1fc81bf": {
        "text_answer": "No  Explanation  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial is not directly stated in the evidence provided for the secondary trial However the statement Lesions must not be within 5 mm of the optic chiasm or within the brainstem in the primary trial suggests that patients with cerebral metastases in or near the",
        "label": "Contradiction"
    },
    "f008bad4-fa46-4187-b784-434238a5992b": {
        "text_answer": "No  Explanation  The statement higher doses of alt801 are given to participants in the primary clinical trial than to those in the secondary clinical trial is not entailed by the evidence provided The evidence only states the doses of PF06647020 used in each trial not the doses of ALT801",
        "label": "Contradiction"
    },
    "0ebc75cd-f87b-46a6-aaa3-9b511cdb90ae": {
        "text_answer": "No  The statement Patients with a histologicallycytologically confirmed diagnosis of a resectable Nonsmall cell lung breast cancer or Small cell lung cancer are eligible for the primary trial is not explicitly stated in the inclusion criteria The inclusion criteria only mention advanced andor unresectable disease for Nonsmall cell lung cancer and Small cell lung cancer",
        "label": "Contradiction"
    },
    "f52235c3-a9c6-4eb2-a9c6-929afe1bf49a": {
        "text_answer": "Yes assuming the cohorts refer to the two sets of data ie Adverse Events 1 and Adverse Events 2 in the evidence The evidence shows that there were no cases of Gramnegative bacteremia 40 degree C fever in Adverse Events 2 which is consistent with the statement that all infections and infestations cases were evenly distributed between the two sets of data However its important to",
        "label": "Entailment"
    },
    "6bf5cffc-eb10-45ae-9e9f-b5b5d60be392": {
        "text_answer": "No  Explanation  The statement In total there are less cases of anemia in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only reports the number of adverse events including anemia in each trial It does not compare the total number of cases between the two trials Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "62c8e736-58fd-472f-bef0-c957b8055237": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 30 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that there were 3 cases of hepatotoxicity 1 case of hypertension and 1 case of pancreatectomy making a total of 5 cases of adverse",
        "label": "Contradiction"
    },
    "cc369e33-07e2-441d-b4fd-8233478ba98a": {
        "text_answer": "No  The evidence does not mention anything about severe malnutrition as an exclusion criterion for the clinical trial",
        "label": "Contradiction"
    },
    "77f689bc-c9fc-45ab-9966-aea06482863a": {
        "text_answer": "Yes The evidence does not explicitly state whether or not the secondary clinical trial is open to children",
        "label": "Entailment"
    },
    "fc35b082-3d3c-4ccc-971b-1f008c224a28": {
        "text_answer": "No  Explanation The statement participants in the primary trial receive 14 different drugs throughout the study duration with a maximum dose of 200 mgm2 is not entailed by the evidence The evidence only specifies the drugs and dosages used in the neoadjuvant therapy and the maintenance therapy It does not mention the total number of different drugs or a maximum dose limit for the entire study duration",
        "label": "Contradiction"
    },
    "28efc57b-6732-4778-84e9-81d1cea1a43e": {
        "text_answer": "No  Explanation  The statement aggravated malignant neoplasm is a malignant neoplasm that shows clinical andor pathologic progression is not directly related to the evidence provided The evidence only mentions the number of participants who had Recurrencefree Survival in the primary trial without any information about the nature or progression of the malignant neoplasms Therefore the statement cannot be",
        "label": "Contradiction"
    },
    "a4ddb589-176d-4a2f-bdf2-3c5973a09a4d": {
        "text_answer": "Yes The statement is entailed by the evidence as none of the adverse events mentioned in the evidence occurred in the patient cohort of the primary clinical trial",
        "label": "Entailment"
    },
    "47ff584c-f344-45ab-afec-1c1561453a36": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial found no traces of anaemia febrile neutropenia or pancytopenia in cohort 1 is entailed by the evidence since the evidence shows that the incidence of anaemia febrile neutropenia and pancytopenia in cohort 1 was 0",
        "label": "Entailment"
    },
    "0f0501ba-557e-4111-8473-ec54b624a47f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement incorrectly states that breast cancer patients received 200 mcgday and ovarianperitoneal cancer patients received 500 mcgday According to the evidence the doses for breast cancer patients ranged from 600 mcgday to 1100 mcgday and for ovarian",
        "label": "Contradiction"
    },
    "825832eb-2b69-42a2-80b1-f210915da77c": {
        "text_answer": "Yes The evidence does not mention Hypertension Dehydration or Dyspnea in either cohort and the statement excludes those conditions from the definition of polycythemia",
        "label": "Entailment"
    },
    "9a337e6e-70b7-420d-9679-cc0baf5a5ba8": {
        "text_answer": "No  Explanation  The evidence provided does not mention tumour lysis syndrome in either the primary or secondary clinical trials Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9cc10a0d-5cb3-49b0-99c9-586837640270": {
        "text_answer": "Yes The statement correctly identifies the differences between interventions 1 and 2 in the primary trial",
        "label": "Entailment"
    },
    "bde45f5a-8909-48eb-b331-715583659654": {
        "text_answer": "Yes  Explanation The evidence states that there were 11 participants who experienced serious treatmentemergent adverse events SAEs out of a total of 25 participants analyzed in the clinical trial This means that over 44 of the participants 11 out of 25 experienced SAEs which is more than 75 of the 15 participants 11 out of 15 if we assume that",
        "label": "Entailment"
    },
    "ac50c12b-4055-428b-8d8b-0136aca85f10": {
        "text_answer": "No  Explanation  The statement a higher percentage of patients suffered from adverse events in cohort a compared to cohort b during the primary clinical trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events for each cohort but it does not directly compare the percentages between the two cohorts To determine if one cohort had a higher percentage of adverse events than the",
        "label": "Contradiction"
    },
    "1023b3b0-b190-4ad2-b849-a7ba384be1f8": {
        "text_answer": "No   Explanation  The statement cohort 1 of the primary clinical trial is administered the same dose of alt801 as cohort 2 is not entailed by the evidence The evidence only states the doses administered to each cohort not that they are the same",
        "label": "Contradiction"
    },
    "be705668-6d11-46eb-bd96-9d20f01b936d": {
        "text_answer": "No  Explanation  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is not directly entailed by the evidence provided The evidence only shows the number and percentage of adverse events for each trial but it does not compare the frequency of specific adverse events between the two trials Therefore it is not possible to determine from the evidence alone whether diarrhea was more common in the primary trial participants than",
        "label": "Contradiction"
    },
    "beff7121-1697-41a7-bf43-998005d5c68e": {
        "text_answer": "Yes Perjeta pertuzumab is not mentioned in the secondary trial",
        "label": "Entailment"
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "text_answer": "Yes However the woman would need to meet the specific inclusion and exclusion criteria for each trial",
        "label": "Entailment"
    },
    "c4e967e1-c656-4d32-b8b5-c0b74a94bf02": {
        "text_answer": "Yes  Explanation The primary trial used lenalidomide in a dose of 5mg orally daily for 57  3 days which is a larger quantity in terms of the number of doses and duration compared to the secondary trials lapatinib dose of 1500mg orally daily for 6 weeks Therefore the statement there are more significant quantities of lenalidomide used in the primary",
        "label": "Entailment"
    },
    "9c15d42d-2fcc-4c69-86b2-f75e29d732d4": {
        "text_answer": "No  Explanation  The statement one patient in the primary trial had an incident where a surgical incision reopened after the surgery is not directly related to the adverse events listed in the evidence The statement mentions an incident of wound dehiscence which is one of the adverse events listed but it does not specify that the statement is about the same patient or that the blood substitute was involved in the incident Additionally the statement",
        "label": "Contradiction"
    },
    "1641b323-b136-4104-81e5-744ceac933de": {
        "text_answer": "Yes  Explanation The statement all ae types witnessed in the primary clinical trial affected less than a tenth of the patients is entailed by the evidence since the total number of adverse events 4 out of the 11 patients 3636 is less than one tenth of the total number of patients",
        "label": "Entailment"
    },
    "6033e8d9-c7d5-4b36-b6da-80fdb98de034": {
        "text_answer": "No  Explanation  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial includes patients with measurable disease but there is no mention of a specific tumor size in the secondary trial Therefore the statement about a tumor of 1000 millimeters in diameter is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e8702a99-36bb-4f4f-b2ff-3fa6d49d034e": {
        "text_answer": "Yes The statement is entailed by the evidence as the first intervention uses a starting dose of 25 mg daily for sunitinib and the second intervention uses a starting dose of 90 mgm2 for paclitaxel",
        "label": "Entailment"
    },
    "961aaf91-e07d-4723-860e-23593727c303": {
        "text_answer": "No   Explanation  The statement intervention 1 in the primary clinical trial and all intervention drugs in the secondary clinical trial are to be administered orally is not entailed by the evidence In the primary trial zoledronic acid in intervention 1 is given intravenously not orally In the secondary trial granisetron hydrochloride prochlorperazine and dexamethasone",
        "label": "Contradiction"
    },
    "45e2f6cb-6ab2-424e-bd21-c2086ab6def3": {
        "text_answer": "No  Explanation  The statement the bevacizumab  capecitabine cohort in the primary clinical trial demonstrated a higher rate of disease progression or death than the bevacizumab only cohort is not entailed by the evidence provided The evidence only shows that a smaller percentage 758 of participants in the bevacizumab  capecitabine cohort experienced",
        "label": "Contradiction"
    },
    "526f99de-e377-42e4-a7ae-a42b797aa536": {
        "text_answer": "No  Explanation The evidence states that there were 5 participants in the placebo group who experienced emesis during the study period This means that not all participants in the placebo group went through episodes of emesis",
        "label": "Contradiction"
    },
    "f8f0d036-16aa-4a9f-816e-c52940709126": {
        "text_answer": "No  Explanation  The evidence provided in the given text does not make any statement about mouth sensitivity at its worst for the patients in the primary trial The statement is not related to the information presented in the text",
        "label": "Contradiction"
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "text_answer": "No   Explanation  The evidence describes the eligibility criteria for patients in a primary trial but it does not mention anything about requiring or not requiring regular exercise as part of the intervention",
        "label": "Contradiction"
    },
    "449b619f-902b-446d-ac1e-f73be62ac2ab": {
        "text_answer": "Yes  Explanation  The statement the primary trial noted a higher incidence of adverse events than the secondary trial is entailed by the evidence because the primary trial had no adverse events 000 while the secondary trial had a much higher incidence of adverse events 6000",
        "label": "Entailment"
    },
    "c114301e-f64f-468b-95f7-8debdc840a74": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it introduces a new variable PD0332991 which is not mentioned in the evidence The evidence only compares the frequency and amount of CUDC101 administered in the two cohorts",
        "label": "Contradiction"
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 12 participants analyzed in the primary trial with 6 participants in each of the two cohorts The statement indicates that two patients suffered an Incidence of Doselimiting Toxicity Since the evidence also states that both of these patients were from cohort 2 the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "text_answer": "No  Explanation The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is not entailed by the evidence The evidence only states that in the primary trial the Intervention 1 and Intervention 2 both used MCS110 at a dose of 1 mgkg or 3 mgkg every 3 weeks and PDR001 at a dose",
        "label": "Contradiction"
    },
    "06024cb1-ce64-432e-b1d9-f3df2f95b025": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial both cohort a and b receive the same three electroporation injections of ld v934 is not entailed by the evidence While it is true that both cohorts receive electroporation injections of V934 the number and timing of these injections differ between the two cohorts Cohort A receives three electroporation injections",
        "label": "Contradiction"
    },
    "e4cdcf39-a01c-45f5-a382-d0e8a96a0be6": {
        "text_answer": "Yes  Explanation  The statement the primary trial has unified criteria for all phases while the secondary trial divides its subjects into healthy and cancer patients applying a separate set of rules for each is entailed by the evidence because  1 The primary trial has a unified set of inclusion and exclusion criteria for both Phase I and Phase II 2 The secondary trial has separate inclusion and exclusion criteria for cancer patients  There",
        "label": "Entailment"
    },
    "fb758700-bd95-4857-a58e-1ee8d88c0d71": {
        "text_answer": "No  Explanation  The statement the primary clinical trial does not deliver any information on the mtd of any interventions whereas the secondary clinical trials mtd of mm111 is established at 10 mg per day for its patients is not entailed by the evidence provided  The primary clinical trial does report the determination of the MTD of ruxolitinib in combination with paclitaxel but it does",
        "label": "Contradiction"
    },
    "4a64f808-b518-4666-9f78-56a2d6dd7093": {
        "text_answer": "Yes The evidence states that there are 234 participants in cohort 1 and 241 in cohort 3 so there are indeed 9 fewer participants in cohort 2 which is not explicitly named in the evidence but can be inferred as the cohort with 235 participants as 2412347 and 7 is not mentioned in the evidence",
        "label": "Entailment"
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "36cb2716-6b66-49bd-bb22-7119bd022e28": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does provide the number of participants analyzed for each armgroup",
        "label": "Contradiction"
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "text_answer": "Yes  Explanation  The statement Aes were not recorded for the primary trial or the secondary trial is entailed by the evidence because the evidence indicates that there were no adverse events recorded for either trial The absence of adverse events being reported does not necessarily mean that they did not occur but it does mean that they were not recorded in the given data Therefore the statement is a valid conclusion based on the evidence provided",
        "label": "Entailment"
    },
    "1027bd72-7cce-4903-9838-733046143102": {
        "text_answer": "Yes The evidence shows that both groups had a median survival time greater than 2 years but there were patients in each group who did not survive past 2 years",
        "label": "Entailment"
    },
    "effa7535-9810-4bf3-92bd-64aba7878bf6": {
        "text_answer": "No  Explanation  The evidence provided in the text only states that there were six participants analyzed in each armgroup of the clinical trial but it does not specify how many of those participants experienced doselimiting toxicity Therefore the statement more than two participants in the primary clinical trial experienced doselimiting toxicity is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "eeb1a073-304f-41e4-b1f7-e2381eabf50f": {
        "text_answer": "No  The evidence provided does not mention radiation therapy at all",
        "label": "Contradiction"
    },
    "666c3ebb-3f79-4795-b5e7-4584815f498d": {
        "text_answer": "Yes The primary trial measures pain intensity while the secondary trial measures bone mineral density",
        "label": "Entailment"
    },
    "9e8aeaf6-36db-4f09-b7a6-7a5e41d14215": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about a congenital disorder of glycosylation while the evidence provided is about the results of two clinical trials The units of measure used in the trials are different but that is not related to the statement",
        "label": "Contradiction"
    },
    "811978a1-2715-4174-84af-07a0ca3686e8": {
        "text_answer": "No  The statement is not related to the inclusionexclusion criteria in the evidence",
        "label": "Contradiction"
    },
    "bed73866-02e7-49d2-a66a-215e0a0d1b83": {
        "text_answer": "No  Explanation  The statement adverse event attributed to disease is an indication that an adverse event is causally related to the natural history of disease is not directly entailed by the evidence provided The evidence only reports the occurrence of adverse events in two trials without specifying whether any of them were causally related to the disease or not The statement makes an additional assumption that an adverse event attributed to disease is causally related to the",
        "label": "Contradiction"
    },
    "910d3110-1fa1-4488-a481-085a18d1670a": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts receive the same radiation therapy dose with the only difference being the use of Active Breathing Coordination in the first cohort and the additional SPECT scans for both cohorts",
        "label": "Entailment"
    },
    "da901268-f433-47ff-9119-69d36ce3c4d0": {
        "text_answer": "No  Explanation  The statement the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month the secondary trial also requires injection adminstering 04 to 10 mCi of radioactive Tc99M sulfur colloid is not directly entailed by the evidence provided The evidence only states that the primary trial involves denosum",
        "label": "Contradiction"
    },
    "c8109cb7-4cf5-469b-ba02-5d610579cc89": {
        "text_answer": "No  Explanation The statement both the secondary trial and primary trial yield similar results despite varied interventions is not entailed by the evidence provided The evidence only reports the results of the percentage of participants with treatmentemergent adverse events and serious treatmentemergent adverse events for the primary trial and the number of participants with objective response for the secondary trial The trials involve different types of cancer breast and urothelial",
        "label": "Contradiction"
    },
    "3a85c9cb-b4e8-46cb-84c5-e618f0307b26": {
        "text_answer": "No  Explanation  The evidence provided does not include any data or results related to the comparison of the LBH589 with Capecitabine and LBH589 and Lapatinib cohorts in terms of their performance The evidence only provides information about the design and dosing of the two arms of the primary clinical trial Therefore it is not possible to determine if the statement is entailed by the evidence",
        "label": "Contradiction"
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "text_answer": "Yes  Explanation  The evidence shows that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 indicating that on average symptoms improved from baseline In contrast the median aAUCpa for the Arm II Control group was 44 571 to 162 suggesting that on average symptoms worsened from",
        "label": "Entailment"
    },
    "90783994-6867-4dfe-bbd0-71c4004d9a20": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement makes an assumption about the meaning of senior in the evidence which is not relevant to the description of the intervention The evidence only states that the intervention involves the use of a device and partial breast irradiation but it does not provide any information about a treatment cycle or the duration of the intervention",
        "label": "Contradiction"
    },
    "5d1e61bb-42f4-430c-843a-c6e80d121655": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts receive the same dosage of CUDC101 275 mgm2 but the frequency of administration differs 5 daysweek for cohort 1 and 3 daysweek for cohort 2",
        "label": "Entailment"
    },
    "a9e1aa54-a19a-47d1-8d55-caef2035160e": {
        "text_answer": "No  Explanation  The statement mentions five adverse events notably cerebral hemorrhage pulmonary embolism sepsis hyperglycemia and hypokalemia However the evidence provided in the adverse events 1 and 2 lists do not include any of these specific adverse events Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c6ff494c-5fa8-414d-8a32-15713193c9a3": {
        "text_answer": "Yes  Explanation The evidence shows that the mean arm circumference in the acupuncture group decreased more from baseline to 6 weeks compared to the waitlist group This suggests that the acupuncture treatment led to more notable improvements in lymphedema compared to the waitlist group",
        "label": "Entailment"
    },
    "1b48209c-3fcd-40d3-a647-f54b7e6179d2": {
        "text_answer": "Yes  Explanation The statement is consistent with the information provided in the evidence The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which aligns with the statement that the conclusive decision about a patients participation rests with those professionals",
        "label": "Entailment"
    },
    "7fb4b7a6-dee2-404f-a55f-18c8db378060": {
        "text_answer": "  Yes the patient is eligible for both trials based on the provided information according to the inclusion criteria However its important to note that the patient should also meet all other eligibility criteria and exclusion criteria for each trial",
        "label": "Entailment"
    },
    "61acc1f3-e02a-49ca-8ac8-42453619e78c": {
        "text_answer": "Yes with the exception of lymphoma incidents",
        "label": "Entailment"
    },
    "bf233363-7c05-475d-b248-d71303dec4e2": {
        "text_answer": "  Yes   Explanation   The statement all cohorts of the primary clinical trial are available to breast cancer patients with estrogen negative progesterone negative and her2 tumors is entailed by the evidence because the inclusion criteria of the clinical trial specify that the participants must have histologically confirmed ER negative PR negative and HER2 negative invasive breast cancer Group 1 or Group 2 Therefore all patients",
        "label": "Entailment"
    },
    "8203056c-37a1-4fbf-a3cf-ddf28608d1ad": {
        "text_answer": "No  The evidence does not mention anything about neoplastic meningitis or lip infections The evidence only specifies the disease characteristics patient characteristics prior concurrent therapy and other exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "e8cc1118-7a1a-46ba-aa08-cfb7f414a753": {
        "text_answer": "  Part A No the statement about kat6a gene rearrangement is not directly mentioned in the evidence  Part B Yes patients with a pulmonary embolism within the last 3 years are excluded from the primary trial  Part C Maybe the statement about pulmonary embolism and eligibility for the secondary trial depends on the Investigators decision which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "b73bde4f-21c4-48bd-82d3-0447d22cbd1c": {
        "text_answer": "No  Explanation  The statement hypokalemic patients are most welcomed to participate in the primary clinical trial while those with normal potassium levels are preferred in the secondary clinical trial is not entailed by the evidence provided The evidence only lists inclusion and exclusion criteria for both the primary and secondary clinical trials but it does not indicate any preference for patients with hypokalemia or normal potassium levels in either trial",
        "label": "Contradiction"
    },
    "68bae1de-1bee-486e-a50e-30ab9a4c705a": {
        "text_answer": "No  Explanation  The statement cardiac and psychiatric aes were frequently reported in the primary clinical trial and the secondary clinical trial whereas hardly any other aes were observed is not entailed by the evidence provided The evidence only states that there were no reported adverse events AEs for AEs 1 and 2 in the secondary trial for the given data presented It does not provide information about the frequency or number of other AEs",
        "label": "Contradiction"
    },
    "664a5c0e-406c-4050-85d3-f2f489e5098b": {
        "text_answer": "Yes The evidence does not mention any vaccines being given to the participants",
        "label": "Entailment"
    },
    "90eca162-5617-44e3-909b-c8304af0d763": {
        "text_answer": "  No   Explanation   The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is not entailed by the evidence   The primary trial and the secondary trial have different inclusion and exclusion criteria Patients with NUT mid",
        "label": "Contradiction"
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1480180d-d754-4fbd-bed9-70a50835c098": {
        "text_answer": "No  Explanation  The evidence provided in the text only shows the percentage of participants with disease progression or death in each cohort during the maintenance phase of the clinical trial The statement however compares the overall outcomes of the two cohorts not just the percentage of participants with disease progression or death The evidence does not provide enough information to determine if the bevacizumab  capecitabine cohort demonstrated more",
        "label": "Contradiction"
    },
    "d8896ee9-9d44-485b-9b75-e25f4a56aa8d": {
        "text_answer": "No   Explanation The statement over 50 of patients in the primary trial suffered aes is not entailed by the evidence as the evidence only reports that 2 out of 35 patients 571 experienced adverse events The statement implies that over half of the patients experienced adverse events which is not supported by the evidence",
        "label": "Contradiction"
    },
    "57d27d0b-626b-474b-9e10-60cbdd237d92": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2e054c61-23f1-46df-9c49-44e5f076163d": {
        "text_answer": "Yes  The statement does not explicitly mention Herceptin by name but Herceptin is a type of trastuzumab so the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "ac4e121f-e159-49e0-84cb-83218232ebbb": {
        "text_answer": "No  Explanation  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation Postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is not a direct statement from the evidence The evidence provides the inclusion and",
        "label": "Contradiction"
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only mentions unilateral breast cancer",
        "label": "Contradiction"
    },
    "8e205d62-f220-45ba-9324-f8ee359236b1": {
        "text_answer": "Yes   Explanation  The primary clinical trial had only two groups one receiving the intervention Pyridoxine and the other receiving the placebo The secondary clinical trial however had two intervention groups Highdose and Lowdose Oxybutynin Chloride Therefore the statement that the primary clinical trial was composed of a single test group and one placebo group whereas the secondary clinical trial included two test groups",
        "label": "Entailment"
    },
    "e493c4b0-1bd6-446f-a432-2703b7775620": {
        "text_answer": "maybe  Explanation The statement all participants who were administered with 1mg gtx024 in the primary clinical trial showed a gain in lean body mass during the 4month period is not explicitly stated in the evidence However the evidence does show that the median change in lean body mass for the group administered 1mg gtx024 was positive 155 kg indicating a gain for some participants",
        "label": "Entailment"
    },
    "23ccac08-3764-496a-a790-4a1f5079909e": {
        "text_answer": "No   Explanation   The statement the secondary trial candidates must be Completely disabled to participate whereas this is not required to be accepted into the primary trial is not entailed by the evidence The evidence only provides the inclusion and exclusion criteria for both the primary and secondary trials but it does not mention anything about the level of disability required for participation in either trial",
        "label": "Contradiction"
    },
    "9ae8aa57-7196-4f5b-9911-33233705eac8": {
        "text_answer": "No  Explanation The patient with a primary tumor 3mm in size does not meet the inclusion criteria for the primary clinical trial as the minimum tumor size is greater than 2 cm in diameter Additionally the patient may not meet the inclusion criteria for the secondary clinical trial depending on other factors such as histology performance status and prior treatment history",
        "label": "Contradiction"
    },
    "91a4429b-767a-493a-b1f3-f3a1ccf5ab6c": {
        "text_answer": "Yes The evidence states that some patients receive MCS110 at a dosage of 1 mgkg every 3 weeks which is less than 20 mg for a 70 kg patient",
        "label": "Entailment"
    },
    "5f294eee-f332-4c58-a43f-076a06a04dd5": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not mention anything about the route of administration of Enzalutamide being IV for cohort 1",
        "label": "Contradiction"
    },
    "03d015fe-1903-4b94-b495-4f23c40862db": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not specify that all or any of these patients are administered 200 mcg of talazoparib daily The statement about talazoparib administration is not directly mentioned in the evidence",
        "label": "Contradiction"
    },
    "63aa9e40-98df-4f09-a508-d0b03b9f93f1": {
        "text_answer": "No  Explanation  The statement less than 0050 of patients in the primary trial suffered adverse events is not entailed by the evidence The evidence only provides the number and percentage of specific adverse events gastroesophageal reflux disease and ductal carcinoma in situ in the trial It does not give the total number of adverse events that occurred let alone the percentage of patients who experienced",
        "label": "Contradiction"
    },
    "dcfb970a-f5b0-41c1-a5ec-99d17734c17c": {
        "text_answer": "Yes The statement does not directly appear in the evidence but the evidence does state that female patients with breast cancer are eligible for both trials Therefore the statement that patients with histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for the trials is entailed by the evidence The resolution of findings following intervention for kawasaki disease is not directly related to the eligibility criteria for the trials so it is not explicitly stated",
        "label": "Entailment"
    },
    "0e935403-0cb2-40ff-b78b-6ba7eaf9621e": {
        "text_answer": "Yes The statement is about the percentage of participants with HER2 Primary Breast Cancer who developed imagable HER2 Metastases in the HER2targeted PETCT arm of the trial which is consistent with the information provided in the evidence The mention of sweat gland neoplasm is not relevant to the statement or the evidence and can be ignored",
        "label": "Entailment"
    },
    "277c0ee2-5d34-4c87-80eb-6f5b630109ec": {
        "text_answer": "No  Medulloblastoma is not a type of breast cancer The evidence only pertains to breast cancer patients",
        "label": "Contradiction"
    },
    "ef02754d-00ec-4f2d-bf7a-0a6d414b2476": {
        "text_answer": "No  Explanation  The statement There was at least 1 case of infection in both the primary trial and the secondary trial is true based on the evidence provided However the statement cutaneous fistula is an abnormal communication between the skin and another organ or cavity is not related to the evidence at all Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "6848420c-ff9c-4003-bf9c-894b993c6720": {
        "text_answer": "No  Explanation  The statement the total number of anemia cases in the primary trial surpasses the case count in the secondary trial is not entailed by the evidence provided The evidence shows that there were 0 anemia cases in the primary trial with 2 cases in the secondary trial Therefore the statement is not true based on the given information",
        "label": "Contradiction"
    },
    "481d1201-72b1-41b4-82cc-78b79ea8938a": {
        "text_answer": "No  Explanation  The statement does not follow directly from the evidence provided The evidence describes two separate trials with different interventions and the statement makes no mention of sinonasal lymphoma or any connection to the trials The statement only makes observations about the medications used in the trials",
        "label": "Contradiction"
    },
    "c6039c02-dcb4-433b-a0a5-4d6beb33b8fa": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ee74199e-c159-41f6-9130-8410b237c32f": {
        "text_answer": "Yes  Explanation  The statement the number of biliary colic and diarrhoea cases is greater in the secondary clinical trial than in the primary clinical trial is entailed by the evidence as the number of biliary colic cases in the secondary trial is 1 while in the primary trial it is 4 and the number of diarrhoea cases in the secondary trial is 1 while in the primary trial it is 3",
        "label": "Entailment"
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "text_answer": "Yes The primary trial uses a higher dose of Lenalidomide 5mg daily compared to the secondary trials use of Lapatinib 1500mg daily in intervention 1",
        "label": "Entailment"
    },
    "98d47cf2-ead0-4ab0-8f13-cb2215710dc8": {
        "text_answer": "No  The evidence does not provide any information about the type of surgery undergone by the primary clinical trial cohort",
        "label": "Contradiction"
    },
    "91a67bbf-1ae1-4a86-92fb-dcac5e8298d1": {
        "text_answer": "Yes  Explanation  The statement no infections or fever cases were reported for patients in cohort 1 in the primary clinical trial is entailed by the evidence since the evidence reports that there were no cases of infections or fever in cohort 1 for both sets of adverse events",
        "label": "Entailment"
    },
    "95a261bd-f102-4ce8-887b-afa14d1e2856": {
        "text_answer": "Yes The evidence shows a reduction in Ki67 expression from a median of 15 at baseline to 10 at 6 weeks in the TAK228 Plus Tamoxifen arm This represents a 5 reduction in Ki67positive cells within the first 6 weeks of therapy",
        "label": "Entailment"
    },
    "a6236585-ed05-4deb-bfcd-29eb410bd892": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the trials report their results using different units of measure The primary trial reports hot flash scores using a scale with units that are not specified while the secondary trial reports overall response rates as proportions",
        "label": "Contradiction"
    },
    "8a1d2587-95fa-4e7a-81db-1eb2561da680": {
        "text_answer": "Yes  The placebo is given as a 3hour iv infusion on Day 1 and trabectedin is given as a 3hour iv infusion on Day 2 every 2 weeks Therefore both treatments are delivered via 3hour iv infusions every 2 weeks in the primary clinical trial",
        "label": "Entailment"
    },
    "b86e9d5c-8de2-428a-ba76-d0955ecb75fa": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "164f2ab2-b768-4ec0-befc-a9807ba379ff": {
        "text_answer": "Yes  Explanation The statement adverse incidents were prevalent among patients in the first cohort of the primary clinical trial this was not the case in cohort 2 is entailed by the evidence as the first cohort had a higher percentage of adverse events 4245 compared to the second cohort 680",
        "label": "Entailment"
    },
    "6450428b-bd2a-4ba5-aa5c-c86284dafa98": {
        "text_answer": "No  Explanation  The statement Any Patients currently taking part in the secondary trial will also be eligible for the primary trial is not entailed by the evidence provided The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is specifically for postmenopausal women with a history of breast cancer and experiencing hot flushes while the secondary trial is for adult patients with HER2negative metastatic breast cancer who",
        "label": "Contradiction"
    },
    "9bde44ff-5060-430d-9716-c34888483b9f": {
        "text_answer": "Yes The statement does not mention any specific adverse event so it is not contradicted by the evidence The evidence only reports the occurrence of adverse events related to gastroesophageal reflux disease and ductal carcinoma in situ in the secondary trial but the statement is not about these specific adverse events",
        "label": "Entailment"
    },
    "038e3e32-ae9c-4580-80b1-8d1c2d9d9bb9": {
        "text_answer": "  No the statement is not entailed by the evidence The primary trial includes patients with allergies to metronidazole or amoxicillin but the secondary trial excludes patients with allergies to chlorhexidine gluconate cephalosporin trimethoprimsulfamethoxazole and levofloxacin There is no mention of metronidazole or amoxicillin",
        "label": "Contradiction"
    },
    "86fd4794-aa66-4739-86c6-cf5bfcd911fe": {
        "text_answer": "No   Explanation  The evidence provided in the text does not indicate that all individuals involved in the primary clinical trial reported unbearable pain for a duration of 10 weeks The text only reports the average pain intensity scores and the difference between the low dose and high dose intervention groups There is no mention of all individuals reporting unbearable pain for 10 weeks",
        "label": "Contradiction"
    },
    "71b2f727-f6ac-40e2-a92a-8bb89959e51e": {
        "text_answer": "No   Explanation   The primary trial measures the change in hot flash activity weekly average hot flash score between baseline and treatment termination week 7 using the independent sample ttest The secondary trial measures the overall response rate proportion of participants with a best response of complete response or partial response using the RECIST criteria and the chisquare test These outcome measures are not identical",
        "label": "Contradiction"
    },
    "6e50b114-9a16-4710-8d95-91401b387221": {
        "text_answer": "Yes  Explanation  The statement the secondary clinical trial has age limitations for patients however the primary clinical trial lacks a specific age range for participation is entailed by the evidence because the secondary trial has explicit age exclusion criteria 18 yrs and Stage IV while the primary trial does not mention any age restrictions in its inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "9edc1688-da47-48ff-b475-b894e925dec7": {
        "text_answer": "No  The statement about patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is not explicitly stated in the provided inclusion or exclusion criteria for either trial However the primary trial does exclude patients with a history of clotting disorders but it does not specifically mention breast implants as a cause of clotting disorders The secondary trial does not mention pulmonary embolisms",
        "label": "Contradiction"
    },
    "32ce7a8e-20c4-42d9-a4d4-e3b5d580331e": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the percentage of participants who experienced a confirmed complete response CR or confirmed partial response PR according to RECIST criteria 10 in the Lapatinib 1000 mg  NabPaclitaxel armgroup It does not provide any information about the sharpness or functionality of the patients minds Therefore the statement mind is as",
        "label": "Contradiction"
    },
    "fac1b066-b96a-470f-8239-89c1cba6572d": {
        "text_answer": "No  The evidence only mentions individuals with unilateral breast cancer and upper extremity lymphedema",
        "label": "Contradiction"
    },
    "47db0ed8-8607-4442-827c-20eb9e8db776": {
        "text_answer": "No  The evidence specifies that there should be no brain metastases unless documented to be controlled postcompletion of local therapy for at least 4 weeks A benign brain tumor is not considered a metastasis",
        "label": "Contradiction"
    },
    "33621096-b0c2-4478-9662-45ba56f9da8d": {
        "text_answer": "Yes The statement mentions the specific adverse events observed in the secondary trial that were not observed in the primary trial which are Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain The statement is entailed by the evidence as it accurately reflects the information provided",
        "label": "Entailment"
    },
    "01f7a296-d0c6-4530-800d-5985bcf7218c": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly describes the administration of capecitabine in the first 21day cycle of the trial",
        "label": "Entailment"
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "text_answer": "Yes   Explanation  The statement cohort 1 of the primary trial is administered PR negative ER negative and HER is equivalent to cohort 1 is Phase 2 Triplenegative   The statement cohort 2 of the primary trial receives HER2 is equivalent to cohort 2 is Phase 2 HER2amplified and HER2pos",
        "label": "Entailment"
    },
    "7f2ecb22-ab29-4dfa-b9f6-b09cb7d4c56b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e4ae61e2-fb24-41dc-9eb6-0102ee8d22d8": {
        "text_answer": "No  Explanation The evidence only specifies that the final eligibility for the clinical trial is determined by the health professionals conducting the trial not the patients first of kin",
        "label": "Contradiction"
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "text_answer": "No  Explanation  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not entailed by the evidence provided The evidence only states that 20 out of 35 participants in cohort 2 had no episodes of vomiting and no rescue medication during",
        "label": "Contradiction"
    },
    "0d414333-1c03-4a79-91d7-1a34323e7e59": {
        "text_answer": "No  The statement is not entailed by the evidence as arimidex is not mentioned in the primary trial at all and it is only mentioned in the context of the secondary trial as a potential intervention but not as part of the interventions being compared",
        "label": "Contradiction"
    },
    "fe470456-ea60-433f-905c-21189377531a": {
        "text_answer": "  The statement is not entailed by the evidence as the evidence does not mention anything about the ophthalmic route of administration or hyperkalemic patients in relation to the primary or secondary trials",
        "label": "Contradiction"
    },
    "8b89865c-9af5-4fe0-8f9d-c56240ff7a90": {
        "text_answer": "No  The evidence includes performance status criteria as exclusion criteria in both trials",
        "label": "Contradiction"
    },
    "895d29b8-16bf-4539-b8f9-a7ffec42ce94": {
        "text_answer": "Yes for hypertension and dyspnea No for edema The evidence states that there were no cases of edema in cohort 1 but it does report one case in cohort 2",
        "label": "Entailment"
    },
    "2e16531b-70c8-4302-8747-761859ad7946": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial all participants from cohort 1 experienced at least one lifethreatening adverse event is not entailed by the evidence provided The evidence only states the number of participants with serious and nonserious adverse events for each dose level but it does not indicate that all participants in cohort 1 experienced a lifethreatening adverse event",
        "label": "Contradiction"
    },
    "e2a5803b-3991-4eb2-b428-56d91d9bca99": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial indicates that the average pain intensity score for both the Low Dose and High Dose groups was below the maximum value of 10 the worst pain imaginable at the end of the 10week intervention period Therefore none of the patients in the trial experienced the worst pain imaginable for 10 weeks",
        "label": "Entailment"
    },
    "3befd95f-b342-45a0-99b4-3f6996b664cf": {
        "text_answer": "yes The primary and secondary trials both measure pCR as an outcome The primary trial shows a difference in pCR rates between the two arms and the secondary trial also reports pCR rates for each arm",
        "label": "Entailment"
    },
    "796002e1-bc19-4298-a035-c853aee3e5c3": {
        "text_answer": "No   Explanation  The evidence provided does not mention any adverse events in the primary clinical trial The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "31d0a955-493b-4577-931c-ca3cda7a2a0b": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence only mentions the oral administration of enzalutamide in both cohorts There is no mention of intravenous administration in either cohort",
        "label": "Contradiction"
    },
    "6ad0142c-56d0-4994-b906-898198240c8c": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence does not mention any units of measurement related to miles in the secondary clinical trial The secondary clinical trial reports the outcome measurement in proportion of responders with their respective confidence intervals",
        "label": "Contradiction"
    },
    "3fe01e39-b6e5-465e-b76b-8048169a72bb": {
        "text_answer": "No   Explanation  The statement about tritylcysteine is not mentioned in the evidence provided The evidence only discusses the details of the treatment regimens and the percentage of patients who did not experience any adverse events",
        "label": "Contradiction"
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about the MTD of MM111 in the secondary trial The evidence only states that the MTD of MM111 is not reported in the given results and the time frame for evaluation is 28 days",
        "label": "Contradiction"
    },
    "a62aed40-ac98-4cdc-a7b2-4b1c57e6010b": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial compares two different interventions one with NabPaclitaxel and Gemcitabine Arm A and the other with NabPaclitaxel and Carboplatin Arm B and the dosages for each drug are different in each intervention",
        "label": "Entailment"
    },
    "067bc726-4646-40f8-aa6f-af44d315046e": {
        "text_answer": "Yes  Explanation  The statement no gastrointestinal adverse events were observed during the primary clinical trial is not explicitly stated in the evidence However the evidence shows that there were no reports of nausea vomiting or colitis ischaemic in either trial Therefore the statement is entailed by the evidence as gastrointestinal adverse events refer to nausea vomiting and colitis is",
        "label": "Entailment"
    },
    "69848bb3-c093-4bf4-91eb-f941109b1cd6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "838e1a74-56e5-4dde-aeba-f26d2d3f8983": {
        "text_answer": "No  Explanation The evidence provided in the trial results only reports the median change in total body lean mass for two different doses of GTx024 1 mg and 3 mg over a 4month period The statement however refers to a 1month period and does not specify the dose of GTx024 Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "1b314250-0177-4a73-a7f8-a9524ae44cfd": {
        "text_answer": "Yes eating disorders were not common based on the provided evidence However the statement does not directly address the question about sexual distress",
        "label": "Entailment"
    },
    "33668f2b-29b5-49e2-a0ee-4718913ea856": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement claims that no medication is prescribed in the primary clinical trial while the evidence clearly outlines a specific neoadjuvant therapy regimen consisting of multiple medications",
        "label": "Contradiction"
    },
    "78d9d746-c05b-42e9-9156-d97a9f132589": {
        "text_answer": "No  Explanation  The statement during various stages of the trials primary clinical trial participants receive an equivalent dosage of trastuzumab as the cohort 2 patients in the secondary clinical trial is not entailed by the evidence The primary trial administers a higher initial loading dose of trastuzumab 4 mgkg followed by a lower weekly maintenance dose 2 mgkg while the secondary trial administers Her",
        "label": "Contradiction"
    },
    "8db59161-2a2e-4ade-9e23-538bf3b3ec77": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the interventions for Cohort A and B differ in the administration of V934 prior to the V935 injections The statement only mentions the administration of the same Two IM injections of LD V935 but it does not account for the different sequences and timing of the interventions",
        "label": "Contradiction"
    },
    "275b4f49-8849-451b-972d-a597662de036": {
        "text_answer": "No  Explanation  The statement neutropenia was a common adverse effect in cohort 2 of the primary trial whereas the patients in cohort 1 of the secondary trial reported no cases of neutropenia despite them having higher doses of empegfilgrastim is not directly entailed by the evidence provided The evidence only shows the mean duration of neutropenia and the number of participants with neutrop",
        "label": "Contradiction"
    },
    "fffc74c9-56a5-45e7-ba89-a2c91da05110": {
        "text_answer": "yes The evidence shows that there were 5 emesisfree participants in the placebo group and 13 in the aprepitant group indicating a higher number of emesisfree participants in the aprepitant group and a lower number in the placebo group Therefore the statement that patients receiving the placebo intervention were twice as likely to experience emesis as patients receiving aprepitant is entailed by the evidence",
        "label": "Entailment"
    },
    "5f2bbf7f-2e76-4ae9-8e79-e6361d05ef47": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "text_answer": "Yes The primary trial has the requirement of resistance to AI therapy while the secondary trial does not mention it as a criterion",
        "label": "Entailment"
    },
    "ff2a48f8-c4ab-4a13-9ca2-5d46ce4bd6c9": {
        "text_answer": "No  Explanation  The statement none of the adverse events in the secondary trial affected more than 03 of patients apart from skin infections is not entailed by the evidence While it is true that none of the adverse events in the secondary trial affected more than 3333 of patients which is greater than 03 the statement specifically mentions apart from skin infections which is not",
        "label": "Contradiction"
    },
    "0ef8fead-d77e-4aa4-8e40-ca20ac2ea325": {
        "text_answer": "No  Explanation  The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less is not directly related to the question about an individual feeling unusually tired during the day The evidence only provides information about the dosage of Cetuximab and MM121 given to each cohort in",
        "label": "Contradiction"
    },
    "e7bcb619-8ec0-45cf-acce-9d20e7258c95": {
        "text_answer": "Yes  Explanation  The statement the total number of adverse events were different in the patient cohorts of the primary and secondary clinical trials is entailed by the evidence since the evidence shows that the total number of adverse events for Adverse Event 1 is 0 in the primary trial but 015 000 in the secondary trial indicating a difference in the total number of adverse events between the two trials",
        "label": "Entailment"
    },
    "be556bfc-7cc6-44fc-a505-52a8d55bbb5e": {
        "text_answer": "No The statement is not entailed by the evidence as the trials measure different outcomes FSH levels in the primary trial and Ruxolitinib MTD in the secondary trial and the statement is about fetal hypoxemia which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "08920163-ef22-4242-b9bf-b70af58c91c2": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "77f1bdb0-c7eb-41ba-b05e-e8914b68370a": {
        "text_answer": "Yes The evidence states that fibromyalgia is an exclusion criterion for the secondary trial Additionally the statement mentions fibromyalgia as a condition that cannot be present for eligibility in either trial",
        "label": "Entailment"
    },
    "2f07cc03-880c-43c4-b50f-c1cdf9ebf0dc": {
        "text_answer": "Yes  Explanation  The statement there were 0 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is entailed by the evidence because neither the Adverse Events 1 nor Adverse Events 2 lists any cases of hypertension dehydration or dyspnea",
        "label": "Entailment"
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "text_answer": "No  Explanation  The statement the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month the secondary trial does not require injection is not directly entailed by the evidence provided The primary trial does involve denosumab injections but the secondary trial involves the use of a pIHGC and GP which do not involve injections The statement incorrectly assumes",
        "label": "Contradiction"
    },
    "332d5cb3-14c3-44d3-b2ee-899259c79a4b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "bf103149-cfe0-453f-9b83-d06c0a8958a0": {
        "text_answer": "Yes The evidence states that one of the inclusion criteria for the primary trial is that the subject has metastatic colorectal cancer that harbors the Kras or BRAF mutation Map2k2 gene amplification is a possible molecular genetic abnormality associated with these mutations",
        "label": "Entailment"
    },
    "0a26f239-60ec-4aa7-81e8-de47c20def59": {
        "text_answer": "No  Explanation  The statement there were 50 cases of hypertension edema and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events for each cohort but it does not mention the number of cases with hypertension edema and dyspnea specifically",
        "label": "Contradiction"
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "text_answer": "Yes  Explanation  Both trials report on the determination of the Maximum Tolerated Dose MTD of an intervention specifically Ruxolitinib in combination with Paclitaxel in the primary trial and MM111 in the secondary trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "c67c581d-7aa5-4a90-b640-dcdf8d69e870": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "66d9fdb8-ea66-43e2-b497-340bc7832155": {
        "text_answer": "Yes The evidence states that 13 of participants with HER2 primary breast cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab developed imagable HER2 metastases",
        "label": "Entailment"
    },
    "f5cdf7ed-828f-4e45-9699-b5f80c7b1863": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "063e3d67-dc20-453d-a437-f56447bfa49f": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence describes two separate clinical trials one testing the use of Hydrophor and MediHoney gels on patients undergoing radiation therapy and the other testing the effects of different doses of PF05212384 in combination with docetaxel on patients with various types of cancer The statement is about Palinavir a",
        "label": "Contradiction"
    },
    "9426014b-4962-4dcc-8328-ca29428d6ed3": {
        "text_answer": "No  Explanation  The statement 119 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for one type Adverse Events 1 in each trial The statement also asserts that none of the adverse events in the secondary trial affected more than 5 of patients except for skin infections However the evidence only lists the number of patients affected by",
        "label": "Contradiction"
    },
    "8820e8d9-5bea-461f-8622-5ec4b6388a79": {
        "text_answer": "Yes  Explanation  The statement while the secondary clinical trial excludes 18yearolds the primary clinical trial has no defined age criteria for participation is entailed by the evidence because the primary clinical trial does not mention any age criteria for inclusion while the secondary clinical trial explicitly excludes individuals under 18 years old",
        "label": "Entailment"
    },
    "3f1c8f3a-f9dd-4819-b6db-2931e0c3f288": {
        "text_answer": "No  The evidence does not specify that AfricanAmerican patients in the primary clinical trial must be based in Texas The evidence only provides the inclusion and exclusion criteria for the clinical trial",
        "label": "Contradiction"
    },
    "766e3e18-5567-48e2-9656-12c1b3ead63f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3015f97a-8a45-4a05-a5cf-9c5eaa49e667": {
        "text_answer": "No   Explanation  The primary trial describes a treatment cycle length of 21 days not 2 years The secondary trial describes a onetime imaging procedure not a cyclic treatment",
        "label": "Contradiction"
    },
    "0cf2969d-0228-4267-8e5a-12dc22a12ae9": {
        "text_answer": " No  Explanation The evidence provided describes two different cohorts Phase 2 TripleNegative and Phase 2 HER2Amplified in clinical trials for two different interventions neratinib in Intervention 1 and unspecified in Intervention 2 The statement however does not specify which intervention the evidence is related to Therefore it is not possible to determine if the statement is entailed by the evidence",
        "label": "Contradiction"
    },
    "236451bf-52bd-4530-ba81-100e63b0030f": {
        "text_answer": "Yes The statement specifically mentions stomatitis as the adverse event which is consistent with the evidence that there was one adverse event recorded in the trial which was stomatitis",
        "label": "Entailment"
    },
    "47dbd397-7aa3-4c9b-9241-d148a255902a": {
        "text_answer": "No  Explanation  The statement 0 of the participants in group 1 of the primary trial were found to have lesions and over 095 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The evidence only reports the number of participants and the number of lesions or radiation dermatitis cases in each group",
        "label": "Contradiction"
    },
    "bd587160-ea9e-41d4-b2c4-54815327d2fb": {
        "text_answer": "Yes The primary trial includes breast adenocarcinoma as a cancer type for Phase 2 and the secondary trial includes breast carcinoma as a solid tumor type",
        "label": "Entailment"
    },
    "fcef015e-f82c-4cac-a7c1-61a81f0eac3b": {
        "text_answer": "No  Explanation  The statement Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial is not entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for the primary trial and the secondary trial but it does not mention anything about potassium levels or hypokalemia Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "text_answer": "No  Explanation  The statement Suramin and Paclitaxel are administered to all patients in the primary trial and the secondary trial is not entailed by the evidence The evidence only states that Suramin and Paclitaxel are administered in a specific way in the primary trial and that the secondary trial involves patients undergoing mastectomy surgery It does not mention that Suramin and Paclitaxel are administered in the",
        "label": "Contradiction"
    },
    "1d75f8ad-2c35-4481-b6f7-58db73eeea7b": {
        "text_answer": "Yes The statement mentions the cbfa2t3 gene which is mentioned in the evidence as being related to the intervention MM111",
        "label": "Entailment"
    },
    "ac3dfb95-6558-4815-b5ed-4887505dedf8": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial noted a higher prevalence of mucositis oral bladder infection and thromboembolic incidents than what the primary clinical trial recorded is not entailed by the evidence provided The evidence only shows that these adverse events occurred in both trials but it does not indicate that they occurred more frequently in the secondary trial",
        "label": "Contradiction"
    },
    "41e2d2b1-9637-4667-b032-86c844a94b93": {
        "text_answer": "Yes  Explanation  The statement the secondary clinical trial does not permit the participation of individuals who are 18 years old whereas the primary clinical trial doesnt mention a specific age for participation is entailed by the evidence because the secondary clinical trial explicitly states that individuals under 18 years old are excluded while the primary clinical trial does not mention any age restriction",
        "label": "Entailment"
    },
    "dcea72d4-afb6-4565-8d92-fd259ed8ee15": {
        "text_answer": "Yes The primary trial includes the statement The participant has not undergone major surgery within 28 days prior to the study registration date but the secondary trial includes the statement Patients must have not undergone major surgery within 28 days prior to study registration This implies that patients who have undergone major surgery recently are not eligible for the secondary trial but the primary trial allows for such patients However the statement specifically mentions recent organ transplant",
        "label": "Entailment"
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "text_answer": "Yes  Explanation  The statement Only 4 different types of adverse events affected patients in the primary trial all of which were in cohort 2 is entailed by the evidence as there are only 4 types of adverse events Neutropenia Fatigue Pyrexia and Hepatic pain that occurred in the primary trial and all of them were observed in cohort 2",
        "label": "Entailment"
    },
    "38e2c25f-97c9-4112-b571-b832e29e7c7e": {
        "text_answer": "No  Explanation  The statement only cohort 2 receives an increased dose of 18FFPPRGD2 is not entailed by the evidence Both cohorts receive 18FFPPRGD2 but the amount injected is less than 10 mCi for both",
        "label": "Contradiction"
    },
    "aab9225d-d2bc-4004-bcaf-4f69a9e7991b": {
        "text_answer": "No  Explanation  The primary clinical trials exclusion criteria do not mention organ transplants as a reason for ineligibility However the secondary clinical trials exclusion criteria do not include organ transplants as a reason for eligibility but rather as a reason for exclusion Therefore the statement that eligibility for the primary clinical trial includes patients that received organ transplants within the past month while the secondary",
        "label": "Contradiction"
    },
    "9d291a23-1696-4208-a5d4-7b2e1dd48831": {
        "text_answer": "No  Explanation  The statement grade 1 esophageal fistula ctcae is asymptomatic is not mentioned in the evidence provided The evidence only states that the primary trial intervention is Radioembolization using Yttrium90 glass microspheres and TheraSpheres and the secondary trial intervention is a combination of 560 mg of ibrutinib and 10 mgkg",
        "label": "Contradiction"
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "text_answer": "Yes  Explanation The evidence shows that a larger percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for their colorectal breast and cervical cancer screenings after the intervention compared to before the intervention This indicates that the majority of patients in both groups were up to date for their screenings after the intervention",
        "label": "Entailment"
    },
    "294df8e3-8ba1-41e7-acdc-6448bfab99f1": {
        "text_answer": "No  Explanation  The statement every patient in the primary clinical trial experienced multiple adverse events while patients in the secondary clinical trial were unscathed by any is not entailed by the evidence The evidence only reports the number and types of adverse events for each trial but it does not indicate that every patient in the primary trial experienced multiple adverse events or that no patient in the secondary trial experienced any adverse events The evidence only shows",
        "label": "Contradiction"
    },
    "1b70762f-83fb-4c93-98ac-7f5d8852fc16": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 12 participants analyzed in the trial with 6 in each cohort The statement indicates that 2 participants experienced doselimiting toxicities Since the evidence provides the number of participants in each cohort it is possible to determine that one toxicity occurred in each cohort as stated in the question",
        "label": "Entailment"
    },
    "32781bed-ab99-4837-a7f8-d3ab0b978384": {
        "text_answer": "Yes but incomplete The statement is correct that tp53 mutation analysis was not performed during the study but it does not follow that all patients treated with GTx024 1mg gained lean body mass The evidence only shows the median change in lean body mass for this group and some patients had losses within the range 206 to 1264 kg",
        "label": "Entailment"
    },
    "e7bc1f65-d4e4-4f87-9a2c-ab56c35368ae": {
        "text_answer": "No  Explanation  The statement 157 the primary trial participants and 51674 the secondary trial participants suffered an ae is not entailed by the evidence provided The evidence only reports the number of participants in each trial who experienced various adverse events but it does not provide the total number of participants in each trial who suffered any adverse event Therefore it is impossible to determine if 15 participants in the",
        "label": "Contradiction"
    },
    "636ec547-3ea0-41d4-a46f-92d4780b2ffd": {
        "text_answer": "Yes The statement that the primary and secondary trials recorded the same number of adverse events is entailed by the evidence as both trials reported no adverse events for the specified event type The molecular analysis method is not relevant to the answer",
        "label": "Entailment"
    },
    "d13b1dc9-46cf-471b-b2b1-fa93b235e954": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants in each arm Paclitaxel  Trastuzumab Then AC and Paclitaxel  Neratinib Then AC who experienced pathologic complete response in breast and axillary lymph nodes after neoadjuvant chemotherapy The total number of participants in both cohorts is 84 42 in each arm",
        "label": "Contradiction"
    },
    "b753305c-ea26-492d-b45e-760dc4f69b9a": {
        "text_answer": "No  Explanation The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not directly entailed by the evidence The evidence only states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the exact dosage or frequency of lapatinib The statement in the question incorrectly assumes that",
        "label": "Contradiction"
    },
    "e0265a05-590e-4f77-8e94-8bcdd1d9757e": {
        "text_answer": "No  Explanation  The statement there were no recorded cases of palpitations pericardial effusions and abdominal pains in the primary clinical trial is not entailed by the evidence provided While it is true that there were no recorded cases of palpitations and pericardial effusions in the primary trial there were recorded cases of abdominal pain both upper and general and pericardial effusion tw",
        "label": "Contradiction"
    },
    "b3dd4df2-abff-4e7f-89ce-57b109d25bf2": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because it does not accurately describe the interventions in the primary trial The primary trial states that patients receive 150 mg of oral pregabalin twice daily which is equivalent to 03 g per day Therefore the statements use of 015 g is incorrect Additionally the secondary trial administers Liposomal Cytarabine Dep",
        "label": "Contradiction"
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "text_answer": "Yes for the secondary trial  Explanation The secondary trial excludes patients who have received any experimental agents within 4 weeks prior to the study registration date but it does not mention organ transplant specifically However the statement is stating that a patient who has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial This means that the primary trial specifically excludes patients with a recent organ transplant while",
        "label": "Entailment"
    },
    "027aec87-187e-4c41-9a39-4c453dd1e0ad": {
        "text_answer": "Yes  Explanation The statement in the secondary clinical trials group 2 one incident of shingles was reported but the primary clinical trial and group 1 of the secondary clinical trial did not have any such cases is entailed by the evidence as the evidence shows that there was one incident of shingles in the secondary clinical trials group 2 while there were no incidents of shingles in the primary clinical trial or group 1",
        "label": "Entailment"
    },
    "28363fb8-16ff-4a26-b29c-ca41d1ed2e6e": {
        "text_answer": "No  The evidence states that one participant experienced a urinary tract infection",
        "label": "Contradiction"
    },
    "bcbe90f9-602b-45bc-aa97-28e50238e2fb": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it introduces new information not present in the evidence The statement mentions a clinical test and episodic memory encoding and retrieval processes which are not mentioned in the evidence The evidence only provides information about the interventions used in the primary and secondary trials",
        "label": "Contradiction"
    },
    "4c79deb2-4d30-470e-959c-e3cf05af0b88": {
        "text_answer": "No  Explanation  The statement less than 2 of patients in the secondary trial and the primary trial did not suffer any adverse events is not entailed by the evidence provided The evidence only states the number and percentage of patients who experienced specific adverse events in each trial but it does not provide information about the total number of patients in each trial or the number of patients who did not experience any adverse events Therefore it is impossible to",
        "label": "Contradiction"
    },
    "77aeeff2-38c4-41ce-8526-55ab056504f9": {
        "text_answer": "  Yes The statement is entailed by the evidence as the trial includes patients with locally advanced andor metastatic solid tumors in both Phase 1 and Phase 2",
        "label": "Entailment"
    },
    "5f44bd33-3921-479c-9a16-e2af73e72101": {
        "text_answer": "Yes The evidence shows that both groups had negative standardized scores indicating below average cognitive function on average at the 1year followup",
        "label": "Entailment"
    },
    "7adf46ec-7d70-4767-936f-b7d89f93cdd6": {
        "text_answer": "No  Explanation  The statement the secondary trial on the other hand does not have a cyclic treatment in place is not directly related to the information provided in the evidence about the primary and secondary trials The evidence only mentions the treatment interventions and their schedules for each trial but it does not explicitly state that the secondary trial does not have a cyclic treatment",
        "label": "Contradiction"
    },
    "c132218c-a01a-406c-b1a1-7d66cc8877bd": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the most commonly occurring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope which occurred in 2500 of the primary trial patients but the evidence does not mention that this was the most commonly occurring adverse event across both trials The evidence only mentions the adverse event rates for each trial separately",
        "label": "Contradiction"
    },
    "4fcc0d4c-0772-47c8-ad68-80d10fbeaa0d": {
        "text_answer": "No  Explanation  The statement the primary and secondary clinical trials had syncope as the most frequently reported adverse event among patient cohorts is not entailed by the evidence The evidence only shows that syncope was reported in 2 out of 12 patients in the primary trial 1667 and not the most frequent adverse event In the secondary trial no adverse events were reported for the given data Therefore",
        "label": "Contradiction"
    },
    "c2bcdabf-3336-424c-bf5f-13f0b522fa2b": {
        "text_answer": "No  Explanation  The statement the primary clinical trial frequently reports general symptoms as the most common adverse event is not entailed by the evidence The evidence only reports that there were 2 instances of general symptoms out of 51 total adverse events which is not sufficient to conclude that general symptoms were the most common adverse event",
        "label": "Contradiction"
    },
    "f7fc247a-5390-4e3f-9254-b16ecdda5851": {
        "text_answer": "No  Explanation  The statement 16p133 is a chromosome band present on 16p is not related to the evidence provided The evidence only includes information about the outcome measures and results of two clinical trials The first trial compares two different treatment regimens Arm A and Arm B for breast cancer and the second trial compares Zoledronic acid and Denosumab for preventing skeletal",
        "label": "Contradiction"
    },
    "f57d4f1e-c5ba-4b65-8407-5a5be29e28b4": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide information about the size of the resected tumor being less than 2 cm in diameter which is a requirement for inclusion in the primary trial The statement also does not apply to the secondary trial as it does not have a size requirement for the primary tumor",
        "label": "Contradiction"
    },
    "05e6adb2-0549-4564-84c7-79e4a19d0e99": {
        "text_answer": "No  Explanation  The statement 14 adverse events were observed in the primary clinical trial and skin infections in the secondary clinical trial affected 50 of the patients is not entailed by the evidence provided  The evidence states that there were no adverse events in the primary clinical trial and in the secondary clinical trial there were a total of 13 adverse events excluding skin infections affecting 43",
        "label": "Contradiction"
    },
    "80da21c8-478e-41a2-befc-384403e43ff4": {
        "text_answer": "Yes The evidence mentions that alloMSCs are administered via transendocardial injections and the Contour Profile Tissue Expander is not related to injection techniques",
        "label": "Entailment"
    },
    "d28a4294-8d88-4473-b302-51c771571ffb": {
        "text_answer": "Yes  Explanation The primary trial does not provide information on the dosing frequency of MM121 and Paclitaxel for each week However the secondary trial specifies that the first cohort receives a 2week runin of MM121 followed by 12 weeks of MM121 and Paclitaxel combination therapy while the second cohort receives 12 weeks of Pac",
        "label": "Entailment"
    },
    "3eb3c1f5-b395-43e5-a8e5-cf613ac87f30": {
        "text_answer": "Yes The primary trial includes breast adenocarcinoma as a qualifying cancer type for both Phase 1 and Phase 2 and the secondary trial includes breast carcinoma as a qualifying cancer type",
        "label": "Entailment"
    },
    "7f1301ad-2bc6-426b-86da-8a5c80dfba0c": {
        "text_answer": "No  The statement about Documented allergy to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib is an exclusion criterion for the secondary trial but it is not mentioned in the primary trials exclusion criteria",
        "label": "Contradiction"
    },
    "ab0a9eb7-2f28-425a-aa06-2389f0c1e9f7": {
        "text_answer": "Yes  Explanation  The primary clinical trial focuses on measuring tumor diameter in centimeters while the secondary clinical trial measures the number of participants with solid tumor response using RECIST 11 criteria The statement is entailed by the evidence as it correctly identifies that the primary trial does not involve any unit of measurement while the secondary trial does",
        "label": "Entailment"
    },
    "4b545fd1-a4d1-486a-aece-201400e9c1f5": {
        "text_answer": "None of the patients in cohorts 1 and 2 showed a discernible pattern for expression of the genes and the statement is about a different topic  chest trouble and the AQ20 questionnaire",
        "label": "Entailment"
    },
    "bbb06e30-afa0-40c0-9594-b8c293cd5207": {
        "text_answer": "No  Explanation The statement the lions share of patients from the primary clinical trial showed total recovery within the course of 24 weeks is not entailed by the evidence The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at Week 12 and Week 24 for the Lapatinib 1250 mg and Vinorelbine 20 mgm2",
        "label": "Contradiction"
    },
    "bef15be3-6cf6-426a-a70a-d5d99a1c42af": {
        "text_answer": "No  Explanation  The statement Neither the secondary trial nor the primary trial measure the Change in Ki67 Expression in Tumors is not directly entailed by the evidence provided The primary trial measures tumor response using RECIST criteria while the secondary trial focuses on the number of participants with aromatase inhibitor associated musculoskeletal symptoms and various correlative studies Neither trial explicitly mentions the measurement of Ki67 expression",
        "label": "Contradiction"
    },
    "5f76619b-30cd-47bc-99b9-aab25ce87366": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial there wasnt any recorded instance of an adverse event whereas in the secondary clinical trial apart from skin infections no other adverse event affected more than 30 of the patients involved in the trial is entailed by the evidence provided  The evidence states that in the primary trial there were no adverse events recorded at all and in the secondary trial",
        "label": "Entailment"
    },
    "1eb531b0-d0fc-41b7-a6d4-1b774affc30a": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not specify that a patient who completed a cycle of antineoplastic therapy one month prior to the primary clinical trial is eligible to participate The evidence only states that certain therapies including antineoplastic chemotherapy are excluded if they have been used within the past 4 weeks",
        "label": "Contradiction"
    },
    "a9d41a93-5857-4a56-89f2-46cf6bef36e1": {
        "text_answer": "No  Explanation The evidence provided in the results only gives the median with range change in lean body mass for each group treated with GTx024 at 1 mg and 3 mg The statement however asserts that at least one patient in the trial gained over 22 pounds approximately 10 kg of lean body mass The evidence does not provide enough information to support this claim as it does not specify the",
        "label": "Contradiction"
    },
    "7f3b898a-e7d1-4cc2-bf62-a8366ea7cf80": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide any information about the dosing unit coat or the intervention MM111 The evidence only reports on the Maximum Tolerated Dose MTD of ruxolitinib in combination with paclitaxel in the primary trial and the MTD or Maximum Feasible Dose of MM111",
        "label": "Contradiction"
    },
    "fe37b4ad-fe84-429b-89ce-f5a881215b56": {
        "text_answer": "Yes The primary trial includes women aged 20 years or older and the secondary trial includes women and men aged 18 or older",
        "label": "Entailment"
    },
    "f2076a4f-6170-46ca-9e08-8d0f9589bb06": {
        "text_answer": "No   Explanation  The statement The majority of patients in the primary trial experienced complete response by week 24 is not entailed by the evidence The evidence only reports the number of participants with complete response partial response and stable disease at weeks 12 and 24 for the Lapatinib 1250 mg and Vinorelbine 20 mgm2 armgroup It does not indicate that the",
        "label": "Contradiction"
    },
    "6a6f23a1-354d-4c1a-b457-e3ce15564e69": {
        "text_answer": "Yes The primary trial has different inclusion criteria for different study groups while the secondary trial has the same inclusion criteria for all participants",
        "label": "Entailment"
    },
    "e970c950-ccf6-4c0c-8573-84634162fdf3": {
        "text_answer": "No  The evidence explicitly states that smokers and nicotine users within the last 5 years are excluded from the primary trial and there is no mention of alcohol consumption limits in the secondary trial",
        "label": "Contradiction"
    },
    "552c3a00-fa13-4e27-89a8-2ef4823317cd": {
        "text_answer": "No   Explanation  The evidence provided in the trial description does not mention the use of paclitaxel as part of the treatment regimen for either Arm A ANA or Arm B FULV The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "65c91814-cbda-4db3-a680-4bc3fe0855a8": {
        "text_answer": "Yes  Explanation  The statement in the primary trial the same inclusion and exclusion criteria apply to all phases whereas in the secondary trial different criteria are employed for varied sets of participants is entailed by the evidence as the primary trial has consistent inclusion and exclusion criteria for both Phase I and Phase II while the secondary trial has distinct inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "text_answer": "Yes  Explanation The evidence states that there are 234 participants in cohort 1 Arm II and 241 participants in cohort 2 Arm III A difference of 7 participants exists between the two groups Therefore the statement There are 7 more participants in cohort 2 of the primary trial than in cohort 1 is entailed by the evidence",
        "label": "Entailment"
    },
    "cb9a1bc3-cc8d-4d0d-a335-eb5c5071289f": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not support the statement that less than 010 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products The statement refers to a reduction in CTCs following months of chemotherapy but the evidence only reports the number of participants with a reduction in CTCs",
        "label": "Contradiction"
    },
    "c01b910d-2463-4bf8-bb67-f950aca11411": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8df26566-8724-4ca3-b6be-f43b9b188724": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence pertains to breast cancer and the statement is about prostate cancer",
        "label": "Contradiction"
    },
    "e3222534-b084-405b-bd5a-32fbd2a663c4": {
        "text_answer": "No  Explanation The statement participants will receive their single injection on the first day of the study is not entailed by the evidence as the evidence describes a series of treatments including multiple injections of dendritic cells and trastuzumab and not a single injection on the first day",
        "label": "Contradiction"
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "text_answer": "Yes  Explanation The evidence states that both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid However the intervention 1 uses a handheld gamma camera while intervention 2 uses standard gamma probes The statement specifically focuses on the difference in the amount of radioactive Tc99M sulfur colloid used in each intervention which",
        "label": "Entailment"
    },
    "728c430c-a48c-44a3-a598-38f96ddabaea": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore Intraoperative Mammography performed better than the Standard Mammography in this regard is not directly entailed by the evidence provided The evidence only shows that the median operative time was shorter in the Intraoperative Mammography group compared to the Standard Mammography group It does not necessarily mean that In",
        "label": "Contradiction"
    },
    "b0308df2-5725-4b3a-9c80-0d5390bf3149": {
        "text_answer": "Yes The evidence shows that the median survival for both groups was over 2 years and over 50 patients from each group survived more than 24 months",
        "label": "Entailment"
    },
    "8d60b35c-e6df-4e22-a92e-b9c782b9ed1b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the specific types of adverse events other than Infection Asymmetry and Deflation for the primary trial or the number of cases of n",
        "label": "Contradiction"
    },
    "42eaaa23-bd07-4a89-ba9f-dffe36e31ddb": {
        "text_answer": "No   Explanation  The statement is not directly related to the evidence provided The evidence only mentions the use of trastuzumab in two different interventions in a clinical trial but it does not mention anything about nontrisomic autosomal aneuploidy or developmental malformations",
        "label": "Contradiction"
    },
    "7e01558a-26ed-4ebf-aa18-d5d1c876c194": {
        "text_answer": "No  Explanation The statement doctor and I shared responsibility for deciding which treatment is best for me is not directly entailed by the evidence provided The evidence only describes the interventions used in two clinical trials one involving vaginal rings and the other involving acupuncture or a waitlist control group It does not mention any discussion or decisionmaking process between patients and doctors regarding treatment selection",
        "label": "Contradiction"
    },
    "0a1f17fb-d58d-46e3-a726-bf7ef647e88e": {
        "text_answer": "Yes  Explanation The statement positive fish or IHC 3 results confirming a diagnosis of a HER2 positive tumor is essential for all primary clinical trial candidates is entailed by the evidence as the inclusion criteria explicitly state that HER2 positive tumor either IHC 3 or FISH is a requirement for trial participation",
        "label": "Entailment"
    },
    "e9204795-c6e7-4215-a230-2958d48a6ac2": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary clinical trial does not report the incidence of doselimiting toxicity for either of the two armsgroups Ixabepilone 24mgm2 and Doxorubicin 30mgm2 or Ixabepilone 32mgm2 and Doxorubicin 30mgm2 Therefore the statement",
        "label": "Entailment"
    },
    "ab29d2f1-5d52-475b-be8a-a3b82c49a44a": {
        "text_answer": "Yes However the statement does not directly come from the evidence but it is a logical conclusion based on the information provided The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes Therefore more than 13 of patients in both cohorts experienced this outcome",
        "label": "Entailment"
    },
    "3317bb44-031e-4444-b6b9-7b538727efa3": {
        "text_answer": "Yes  Explanation  The statement in neither the primary clinical trial nor the secondary clinical trial were there incidents of multiple adverse events that affected more than a fifth of the test group is entailed by the evidence because the evidence shows that in both trials the total number of adverse events and the number of adverse events affecting neutrophilsgranulocytes were each less than 15th of the test group size",
        "label": "Entailment"
    },
    "dbcb7763-d671-465e-8704-4bd5cd5ec7ef": {
        "text_answer": "No  Explanation  The statement there were multiple adverse events recorded in the primary trial and the secondary trial is not directly entailed by the evidence provided The evidence only lists the number of adverse events and specific types of adverse events for each trial It does not explicitly state that there were multiple adverse events in each trial",
        "label": "Contradiction"
    },
    "b681145e-4fd6-42ae-8250-b6d915e7a0cf": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial have different inclusion criteria The primary trial includes patients with advanced cancer potentially sensitive to vinorelbine while the secondary trial includes patients presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston The eligibility criteria for the two trials are not identical",
        "label": "Contradiction"
    },
    "a0ad7d49-26f2-42ac-a384-e6362ccae8d7": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have the ability to care for themselves to some degree and are not confined to bed or chair for more than 20 of their waking hours",
        "label": "Entailment"
    },
    "572557f8-fcc1-4448-aa44-a09e7c5244e8": {
        "text_answer": "Yes The primary trial has less stringent inclusion criteria regarding performance status and previous chemotherapy treatment compared to the secondary trial",
        "label": "Entailment"
    },
    "ee0e333a-4b42-4078-a126-d3a1101f7f4c": {
        "text_answer": "No   The primary trial measures the summed pain intensity differences SPID at 30 minutes after dosing while the secondary trial measures the change in bone mineral density BMD of the lumbar spine at 9 months The statement does not accurately describe the outcome measurements of the trials",
        "label": "Contradiction"
    },
    "0f631563-09e1-48db-a6c3-1cc06009e139": {
        "text_answer": "Yes  Explanation  The evidence shows that in both trials all patients experienced at least 3 distinct adverse events Therefore no patient in either trial had fewer than 3 distinct adverse events",
        "label": "Entailment"
    },
    "1e1830e7-f7bd-4bf4-99c4-c36f6da015e3": {
        "text_answer": "No  Explanation  The statement does not provide enough information to determine if the intestinal route of administration was used in the primary trial The evidence only provides information about the types and frequencies of adverse events in the trial but it does not specify the route of administration for the medicinal product Therefore it is impossible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "e875a6e2-1058-4954-a864-7f1b35508362": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only states that in the primary trial group 2 received dexmedetomidine but it does not mention anything about the secondary trial not providing dexmedetomidine",
        "label": "Contradiction"
    },
    "0b90fb4c-0de2-478b-95d2-2f0b555398ad": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention mentioned in the evidence only includes therapeutic and lifestyle changes MM111",
        "label": "Entailment"
    },
    "e56bca0a-a541-4a59-ba79-0f17cd0cdcb6": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not mention anything about the age bracket of 1819 years for the primary clinical trial The evidence only states that the minimum age for the primary clinical trial is 20 years",
        "label": "Contradiction"
    },
    "f0fbd167-6b00-4152-889e-7df794aa0619": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about a different disorder laryngeal obstruction and the evidence is about tumor diameter and response in cancer patients",
        "label": "Contradiction"
    },
    "94857a77-b822-4cb8-989b-b6efb0a105e0": {
        "text_answer": "No  Explanation  The statement both trials saw a considerable number of adverse events throughout their duration is not entailed by the evidence The evidence only provides the number of adverse events for a specific adverse event Adverse Event 1 in each trial It does not indicate that the number of adverse events was considerable in both trials overall",
        "label": "Contradiction"
    },
    "31f16856-c47c-40f3-b9a8-c414f07710ec": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens therapy within the past 4 weeks  25 years for androgens and estrogens",
        "label": "Entailment"
    },
    "f6ca1a5e-853d-4669-8c13-89b54a42c460": {
        "text_answer": "Yes The evidence does not mention any information about NRAS gene mutations in the given cohorts which implies that they are negative for such mutations Additionally neither cohort underwent invasive surgery or received Neratinib as stated in the question",
        "label": "Entailment"
    },
    "90599dbb-bf85-4e56-9a16-fbcd4fbb22f6": {
        "text_answer": "Yes  The statement is entailed by the evidence as trastuzumab Herceptin is mentioned in both interventions",
        "label": "Entailment"
    },
    "7f0ff0a3-ccf0-4ea7-9c5b-b631da541d07": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3de4fd70-62c3-4310-a163-507e49af0e73": {
        "text_answer": "No  Explanation The primary clinical trial includes a criterion for a primary tumor greater than 2 cm diameter while the statement mentions a primary tumor with a 3mmradius The secondary clinical trial does not mention the tumor size in its inclusion criteria",
        "label": "Contradiction"
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e7572377-d468-4b13-815a-f43887747c18": {
        "text_answer": "No  Explanation The evidence provided in the form of the primary clinical trial interventions only mentions the dosages of MCS110 and PDR001 administered to the patients in each intervention group It does not explicitly state that there are patients who do not receive MCS110 at all Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "text_answer": "Yes Both interventions use the same dose of nabPaclitaxel 125 mgm2 in each treatment cycle",
        "label": "Entailment"
    },
    "3ce48a99-7310-4a2f-8853-e46db55af26e": {
        "text_answer": "Yes but the statement is not an exact representation of the evidence as it combines the presurgical and postsurgical dosing into one duration The evidence shows a 40 reduction in Ki67 expression after 7 days of presurgical tamoxifen",
        "label": "Entailment"
    },
    "aef90851-f30f-4d13-b6d6-8f52afaaa302": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence because the evidence shows that the incidence of these adverse events is higher in the primary trial compared to the secondary trial",
        "label": "Entailment"
    },
    "42aa56a7-2e3b-4932-bdde-a0ed438111c1": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement is about the difficulty bending and straightening an arm while the evidence is about adverse events in two clinical trials including the incidence of chest pain recurrent malignancy graftversushost disease infection altered mental status and diffuse alveolar hemorrhage",
        "label": "Contradiction"
    },
    "bfa5809e-c1d4-49b8-b3d1-37fd6f7b077f": {
        "text_answer": "Yes The primary trial excludes patients with allergies to specific agents but the patients allergy to doxycycline is not listed among the excluded agents in the secondary trial Therefore the patient can participate in both trials",
        "label": "Entailment"
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each condition in each trial but it does not compare the number of cases between the two trials for each condition Therefore based on the given evidence it is not possible to determine if there were more cases of",
        "label": "Contradiction"
    },
    "dcad163d-b572-4dcc-a052-8bfb81f05ad5": {
        "text_answer": "Yes In the primary trial participants received 02 mgkg or 05 mgkg of PF06647020 while in the secondary trial participants received 0015 mgkg or 0040 mgkg of ALT801 Both trials involve a lower dosage in the first intervention group compared to the second intervention group",
        "label": "Entailment"
    },
    "4e9ce538-8418-4432-b3e7-8f3ecfefee6d": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly compare the ORR between the Paclitaxel Plus Bevacizumab PB and Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG groups in terms of the number of participants or the ORR proportions The statement in the question makes an assumption about the ORR being better in the PBG group based on the given evidence",
        "label": "Contradiction"
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "text_answer": "Yes  Explanation  The primary trial and the secondary trial have different outcome measurements The primary trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary trial measures the number of participants with objective response These are distinct measures and are not directly related to each other",
        "label": "Entailment"
    },
    "82cea870-dbc3-4ebf-824c-0cebd7e95205": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2677ff54-f67c-44c1-9aa8-64efd3357f65": {
        "text_answer": "No The statement Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is not explicitly stated in the evidence provided However the primary trial excludes patients with a history of clotting disorders but it does not specifically mention pulmonary embolisms The secondary trial does not mention anything about pulmonary embolisms or breast implants",
        "label": "Contradiction"
    },
    "ac265234-e392-49b4-b46b-a0a54e54f88b": {
        "text_answer": "No  Explanation  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only shows the number of adverse events for each trial but it does not indicate the number of cases for Mucositis Oral epileptic seizures or Thromboem",
        "label": "Contradiction"
    },
    "a01bb73a-e620-4bb5-995b-9433d10090ab": {
        "text_answer": "Yes The primary trial does not involve drugbased treatments but the secondary trial does test two separate drugs",
        "label": "Entailment"
    },
    "3d52b3c6-d110-4442-8a2f-1cf87b1092c5": {
        "text_answer": "  No The statement about anal cancer pmx tnm finding v6 is not directly related to the inclusion criteria or exclusion criteria provided in the evidence for either the primary or secondary trial The statement is about a specific TNM finding for anal cancer according to the AJCC 6th edition The evidence only mentions the inclusion and exclusion criteria for the two clinical trials",
        "label": "Contradiction"
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "text_answer": "Yes The evidence does not specify eligibility based on nationality ethnicity weight or gender",
        "label": "Entailment"
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the evidence only mentions ER positive and HER2 negative breast cancer Group 1 and invasive triplenegative breast cancer Group 2 but it does not explicitly state that patients must have both ER and PR negative tumors to be eligible for the trial Therefore the statement goes beyond what is stated in the evidence",
        "label": "Contradiction"
    },
    "5718421a-fc98-4df0-a866-21d4718ebf78": {
        "text_answer": "Yes   Explanation  The statement the administration of trastuzumab in the primary clinical trial does not align with the dosage provided to patients in the cohort 2 of the secondary clinical trial is entailed by the evidence because the primary trial administers trastuzumab at a loading dose of 4 mgkg followed by 2 mgkg weekly while the secondary trial administers Herceptin a form of tr",
        "label": "Entailment"
    },
    "c3c644d4-1964-454a-af82-4e82c2567f6e": {
        "text_answer": "Yes  Explanation The statement all groups in the primary trial study are subjected to the same imaging processes including 18FFDG and 18FFPPRGD2 positron emission tomography  computed tomography PETCT is entailed by the evidence as both GBM and gynecological cancer patients undergo 18FFDG and 18FFPPRGD2 PET",
        "label": "Entailment"
    },
    "c4a0d86a-f8a8-4c2a-a28a-25147f35a682": {
        "text_answer": "Yes  Explanation  The statement all the instances of infections and fever observed in the primary clinical trial were associated with patients in cohort 1 is entailed by the evidence because all the instances of infections and fever mentioned in the evidence occurred in cohort 1 of the clinical trial",
        "label": "Entailment"
    },
    "1af24416-2f14-423b-bd1c-b6f604cae64a": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide any information regarding the location of the cerebral metastases in relation to the secondary clinical trial The statement makes a specific assumption about the location of the metastases which is not supported by the evidence",
        "label": "Contradiction"
    },
    "09deff91-1b05-470a-aecd-60ce772b9a8e": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the evidence only mentions breast cancer and hormonal treatments for it while the statement includes colon cancer and a different type of treatment systemic anticancer therapy",
        "label": "Contradiction"
    },
    "5bdc0c5e-236f-4dbf-92cd-8f582a16b2fd": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement mentions myalgias for group 2 of the primary trial receiving 05kgug but the evidence only mentions administration of dexmedetomidine only for group 2 of the primary trial Additionally the secondary trial does not involve any administration of myalgias to any patients",
        "label": "Contradiction"
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "text_answer": "No  The statement is not entailed by the evidence as there were no cases of acute myocardial infarction reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "c392fd36-941e-4809-8d9e-16e3aa1c945c": {
        "text_answer": "No  Explanation  The statement compared to the secondary clinical trial the primary clinical trial boasted a greater number of participants is not entailed by the evidence provided The primary clinical trial had 13 participants and the secondary clinical trial had 30 participants but the statement does not correctly convey this information The statement also uses the word greater which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "dd58a7e3-370e-4e61-9071-6155962cd180": {
        "text_answer": "Yes  Explanation  The statement there were no adverse events reported by the first group in the primary clinical trial is entailed by the evidence Adverse Events 1 Total 0147 000 The evidence indicates that there were no adverse events reported in the first group of the clinical trial which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "151ae668-d1e7-4dd1-beb2-75dd7efbae4c": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it is incomplete and incorrect The evidence specifies the medications dosages and schedule of administration in the clinical trial but it does not limit the total number of distinct medications to four or the dosages to not exceeding 100 mgm2 The statement only addresses the dosages and not the number of medications",
        "label": "Contradiction"
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID is not entailed by the evidence  The primary trial participants receive whole breast radiation therapy but the secondary trial participants do not receive radiation therapy as part of the intervention Instead they receive either Enzastaurin and",
        "label": "Contradiction"
    },
    "48b5fa7f-b2c7-41f9-adc5-ca55ae919f3d": {
        "text_answer": "Yes  Explanation  The statement different patient features are evaluated in the results of the primary clinical trial and the secondary clinical trial is entailed by the evidence because the primary clinical trial evaluates the toxicity of infusing HER2specific T cells using NCI CTCAE v30 in a specific group of patients while the secondary clinical trial evaluates the percentage of participants with adverse events of primary interest AEPIs in",
        "label": "Entailment"
    },
    "1d60de45-bc33-4178-96e6-d0fa20e51fed": {
        "text_answer": "No  Explanation  The statement transparent is allowing the passage of light such that images can be seen through with clarity is not directly related to the evidence provided The evidence describes two different interventions in a clinical trial one with the use of an Active Breathing Coordinator ABC and the other without it The statement is about the concept of transparency which is not mentioned in the evidence Therefore it cannot be determined if the",
        "label": "Contradiction"
    },
    "18303bbd-059e-4161-8cc6-9569a71308f5": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as both Intervention 1 and Intervention 2 involve the administration of doxorubicin cyclophosphamide and docetaxel The identical doses of these drugs are given to all groups at equal intervals as stated in the question However Intervention 2 includes three additional treatment courses of docetaxel and cyclophosphamide making a total of ",
        "label": "Entailment"
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "text_answer": "No  Explanation  The statement Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events is not entailed by the evidence provided The evidence only reports the number of adverse events including deaths in each trial but it does not add up to 10 deaths across both trials In the primary trial there was 1 death reported and in the secondary trial there were no reported",
        "label": "Contradiction"
    },
    "4eacff65-65e6-4bf9-bc94-419c48e854e8": {
        "text_answer": "Yes  Explanation  The statement adverse events experienced by patients in the primary clinical trial do not match those in the secondary clinical trial is entailed by the evidence because the primary trial had adverse events including Dehydration Lymphopenia Neutropenia and Hyponatremia which were not present in the secondary trial and the secondary trial had a Thromboembolic Event which was not present in the",
        "label": "Entailment"
    },
    "9c6f062e-a260-4c3a-ac91-fc5de6de176d": {
        "text_answer": "yes The primary and secondary trials both use pCR as the outcome metric and there are differences in pCR rates between the arms in each trial",
        "label": "Entailment"
    },
    "0416a45e-2ea6-4f82-8bc6-05cc37b941f8": {
        "text_answer": "No   Explanation The primary trial does not have a 6day cycle for its intervention Instead it has a 21day cycle The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "57526ef1-a6b9-419e-86c9-0a2d6db7ad23": {
        "text_answer": "  No   Anorexia is a medical condition characterized by a persistent lack of appetite and significant weight loss The evidence provided in the clinical trial inclusion and exclusion criteria does not mention anorexia as a condition that would be considered for participation in the study The criteria focus on individuals with a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs who are willing to change their diet",
        "label": "Contradiction"
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "text_answer": "Yes The evidence shows that the median survival times for both groups are over 2 years but it also indicates that at least one patient in each group died before 2 years",
        "label": "Entailment"
    },
    "43297eae-d154-4417-8bd4-3c4aae66e6bd": {
        "text_answer": "No  Explanation  The statement the record shows that the primary clinical trial experienced 4 more adverse events than what was observed in the secondary clinical trial is not entailed by the evidence The evidence only states that there were no adverse events in both trials for the specific condition mentioned Adverse Events 1 Therefore it is incorrect to make a statement about the number of adverse events being different between the two trials based on the given evidence",
        "label": "Contradiction"
    },
    "c21d4d07-87ea-46ba-b930-9fd3fb0797a5": {
        "text_answer": "Yes The evidence states that smokers are excluded from the secondary clinical trial Therefore if a patient is currently engaged in smoking they would be ineligible for both trials as stated in the primary trials exclusion criteria as well",
        "label": "Entailment"
    },
    "65f9af41-9bb8-438a-b967-94acfd0e08a9": {
        "text_answer": "Yes The evidence does not provide any outcome data for the LBH589 and Lapatinib cohort",
        "label": "Entailment"
    },
    "3131f532-99b5-433e-9375-8af120cd4c0f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the statement mentions myalgias in the context of the secondary trial but the evidence does not provide any information about the administration of myalgias in the secondary trial The evidence only mentions the administration of vitamin D repletion in the secondary trial",
        "label": "Contradiction"
    },
    "bfb9d912-39ea-4a7a-b3eb-51e9d1b5f436": {
        "text_answer": "Yes  Explanation The primary clinical trial explicitly lists a history of allergic reactions attributed to compounds of similar chemical or biologic composition to mesna or other agents used in the study as an exclusion criterion While the statement does not mention mesna specifically it includes the antibiotics cephalosporin trimethoprimsulfamethoxazole and levofloxacin which are mentioned in the primary",
        "label": "Entailment"
    },
    "06bf2ef1-129f-47cf-b51f-75e51f1eb66a": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial all of the recorded individual adverse events were unique to one patient each is entailed by the evidence because each adverse event is listed as occurring in only one patient Therefore each adverse event is unique to one patient",
        "label": "Entailment"
    },
    "fb41d62d-4f75-463d-b71a-0b31dd0ade96": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions in the trial provide the same amount of nabPaclitaxel 125 mgm2 on Days 1 and 8 to each group",
        "label": "Entailment"
    },
    "e875dcbd-dc31-47c4-87bf-a94b0c1696b1": {
        "text_answer": "No  Explanation  The primary clinical trial and the secondary clinical trial measure different outcome measures The primary clinical trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary clinical trial measures the number of participants with objective response These two outcome measures are not directly correlated to each other",
        "label": "Contradiction"
    },
    "9640278e-af41-482e-8390-d20bc7388149": {
        "text_answer": "yes with conditions The statement is entailed by the evidence but it also includes additional criteria for sexually active fertile men",
        "label": "Entailment"
    },
    "ad11786a-e01b-466c-9e44-31f1be35c79c": {
        "text_answer": "Yes  Explanation  The statement in both the primary clinical trial and secondary clinical trial there were no unforeseen fatalities or hospital admissions is entailed by the evidence because the evidence does not report any fatalities or hospital admissions for either trial",
        "label": "Entailment"
    },
    "325db761-416f-4aab-80e8-e3271a11200b": {
        "text_answer": "Yes The evidence does not mention any vaccines being administered to the participants",
        "label": "Entailment"
    },
    "56ac01ed-cfba-4ab5-9082-dbe4a4418e9d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0931fd2b-2ce8-4285-9c02-63318e60efc3": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial does not report the severity of delayed nausea and the secondary trial measures the change in bone mineral density at 9 months not approximately 3 quarters of a year",
        "label": "Contradiction"
    },
    "b0709ec3-ea6b-4f70-a24e-d23480df5b14": {
        "text_answer": "Yes  Explanation The statement while the primary clinical trial presents the time taken for progression recorded in months involving 156 patients from both cohorts the secondary clinical trial records the number of patients that have undergone objective response is entailed by the evidence provided The primary trial reports the median time to progression TTP for two different arms of the study while the secondary trial reports the number of participants with objective response based on",
        "label": "Entailment"
    },
    "f2beb95f-ac83-48f1-936b-70d45d51880c": {
        "text_answer": "No   Explanation  The placebo was administered as a 3hour intravenous infusion on Day 1 while trabectedin was administered as a 3hour intravenous infusion on Day 2 The statement suggests that both interventions are administered through an 8hour intravenous infusion on a biweekly basis which is not the case according to the evidence",
        "label": "Contradiction"
    },
    "286e098d-ca31-41ce-b8a9-f8bcf99447f0": {
        "text_answer": "No  Explanation  The statement anemia is more prevalent in the primary trial when opposed to the secondary trial is not entailed by the evidence provided The prevalence of anemia is actually lower in the primary trial 000 compared to the secondary trial 133 or 430 depending on the dataset",
        "label": "Contradiction"
    },
    "115aa2c8-f52f-4a62-9b8a-6f6e593bd208": {
        "text_answer": "Yes  Explanation The statement primary clinical trials second cohort has an additional 7 participants compared to the first cohort is entailed by the evidence since the evidence states that the second cohort had 241 participants analyzed while the first cohort had 234 participants analyzed Therefore the second cohort had an additional 7 participants compared to the first cohort",
        "label": "Entailment"
    },
    "425f9738-1b09-446e-8c8c-5004ed91351d": {
        "text_answer": "Yes  Explanation  The statement all the instances of infections and infestations in the primary clinical trial pertained to patients in cohort 1 is entailed by the evidence because the evidence only reports instances of infections and infestations in cohort 1 specifically one instance of Gramnegative bacteremia with a fever of 40 degrees Celsius Therefore the statement that all instances of infections and infest",
        "label": "Entailment"
    },
    "53416cd6-ac0b-43c1-824f-719d43ad5af4": {
        "text_answer": "No  Explanation  The statement various participants of group 1 in the primary clinical trial had clear evidence of skin lesions under 10 of participants in group 1 of the secondary clinical trial showed symptoms of radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only mentions the number of lesions detected in the primary trial and the number of participants with radiation dermatitis",
        "label": "Contradiction"
    },
    "b4e6d7be-cb1b-4000-812e-d49098f0aaf0": {
        "text_answer": "Yes The evidence states that there was at least one hospitalization and one death in cohort 2 of the primary clinical trial",
        "label": "Entailment"
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "text_answer": "Yes for severe insomnia  Explanation The statement Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is entailed by the evidence as severe insomnia is listed as an exclusion criterion in the secondary trial However it is not explicitly stated in the primary trial but the primary trial does include insomnia as an inclusion criterion with a specific scoring threshold so it can be",
        "label": "Entailment"
    },
    "d5586986-90bb-4302-98c1-0507aa208d2d": {
        "text_answer": "  Yes  Explanation  The primary clinical trial involves the use of a Contour Profile Tissue Expander for breast reconstruction which may be monitored using MRIs to assess the expansion process and the final outcome In the secondary trial the intervention involves the administration of alloMSCs and a placebo via transendocardial injections which may also be monitored using MRIs to evaluate the efficacy and safety of",
        "label": "Entailment"
    },
    "b80c867f-7c46-4ac1-a9c4-b56ce0173c2a": {
        "text_answer": "Yes   Explanation  The statement in the primary clinical trial various drugs were used as interventions but the administration method was uniform is entailed by the evidence because both interventions bisphosphonate IV Q4W and denosumab 180 mg Q12W have a uniform administration method which is either intravenous every 4 weeks or subcutaneous every 12 weeks",
        "label": "Entailment"
    },
    "cafb9767-9320-40fc-a862-53530450f96f": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as it introduces an unrelated concept high calcium level which is not mentioned or relevant to the information provided in the evidence",
        "label": "Contradiction"
    },
    "8c4891f7-e0af-4ddb-8754-0638ece12c58": {
        "text_answer": "Yes  Explanation  The evidence provided includes the results of a clinical trial comparing the effectiveness of two different breathing interventions paced respiration and fast shallow breathing on reducing the frequency of hot flashes in postmenopausal women The results show that the mean number of daily hot flashes in the paced respiration group was 348 345 and in the fast shallow breathing group was 39",
        "label": "Entailment"
    },
    "7ae03d8b-6087-4df3-a0e1-d1932d86528c": {
        "text_answer": "No  Explanation  The statement Far more patients in the secondary trial were recorded to have experienced Chest Pain is not directly related to the evidence provided The evidence only mentions the occurrence of various adverse events in both trials but it does not specify the number of patients who experienced chest pain Therefore the statement cannot be determined to be entailed by the evidence with certainty",
        "label": "Contradiction"
    },
    "3b13cd45-eae5-4039-8a8a-a73c55fde5dc": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "dfc9042c-745d-46a2-9706-3efe0b24c20c": {
        "text_answer": "No  Explanation  The statement most patients experienced multiple severe adverse events post participation in the primary clinical trial is not entailed by the evidence The evidence only provides the number and percentage of adverse events for each category in the primary and secondary trials It does not indicate that most patients experienced multiple severe adverse events",
        "label": "Contradiction"
    },
    "ddfc4bce-b6b0-4817-a171-db6bd5e095bd": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity psychiatric condition or gender as inclusion or exclusion criteria in the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "b957f1f2-8dc3-4d00-802d-26cd8fa3b9f4": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the secondary trial includes patients with locally advanced or metastatic breast cancer which may have larger tumors Therefore the statement is not entailed by the evidence as it incorrectly assumes that both trials allow for a 100mm tumor when in fact only the primary trial spec",
        "label": "Contradiction"
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "text_answer": "Yes  Explanation The statement The Interventions in the primary trial included different medications but are administered through the same routes is entailed by the evidence because both interventions bisphosphonate IV Q4W and denosumab 180 mg Q12W are administered through intravenous or subcutaneous injections",
        "label": "Entailment"
    },
    "b54f065f-7b3e-42b0-8dc6-61dc466f7f59": {
        "text_answer": "Yes  Explanation  The primary clinical trial and the secondary clinical trial both assess patient outcomes with the primary trial focusing on the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 and the secondary trial assessing the percentage of participants with adverse events of primary interest AEPIs related to trastuzumab emtansine",
        "label": "Entailment"
    },
    "160afbf4-14b4-4e83-b324-4d3102b8f72c": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly compare the outcomes of the Bevacizumab and Bevacizumab  Capecitabine cohorts in terms of benign hard palate neoplasms The statement is not entailed by the evidence as it introduces a new condition benign hard palate neoplasm that is not mentioned or studied in the trial",
        "label": "Contradiction"
    },
    "eae19a7f-ca02-482d-942f-223d74881c40": {
        "text_answer": "yes for the primary trial regarding pulmonary embolism exclusion and no for the secondary trial regarding breast implants inclusion",
        "label": "Entailment"
    },
    "c0db0110-c67a-40e6-8bfc-b7e016509778": {
        "text_answer": "Yes The evidence states that patients with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that is abnormal in the opinion of the treating Investigator or unstable angina and QTc prolongation 480 msec Bazetts Formula or",
        "label": "Entailment"
    },
    "7caa5dd0-cd09-4559-a243-736304ce22e4": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the patient is a male and the primary and secondary trials only include female patients",
        "label": "Contradiction"
    },
    "a14e5115-a6ff-4253-9260-736c943bd47e": {
        "text_answer": "  No  Explanation  The statement patients who have received chemotherapy or radiotherapy in the last 05 months suffer from unstable angina or have grade 5 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both",
        "label": "Contradiction"
    },
    "0f17aa12-6aea-430e-b4e8-2a21f2832582": {
        "text_answer": "Yes The statement is entailed by the evidence as these alterations are listed as exclusion criteria for patients with any tumor type",
        "label": "Entailment"
    },
    "bdb61718-ee5f-4e2a-9c78-850e788c139f": {
        "text_answer": "  Partially The primary trial excludes patients with a pulmonary embolism within the past 3 years but the secondary trial may consider such patients based on the investigators decision",
        "label": "Entailment"
    },
    "df783937-3936-4f0b-a3f9-96a977497c6f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8e88537e-5eb0-4e85-a6cd-58e374d027b6": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the use of Vorinostat during radiation therapy and the doses of Vorinostat but it does not mention anything about the use of fentanyl sublingual spray or its doses during the trial",
        "label": "Contradiction"
    },
    "b1cb1388-9a0f-4dfd-8890-a3d2bced6ab4": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial 96 participants from the ketorolac 30 mg group demonstrated recurrencefree survival as opposed to the 67 from the nacl 09 3ml group is not directly entailed by the evidence provided The evidence only states the number of participants analyzed in each group and their respective percentages of recurrencefree survival at 5 years",
        "label": "Contradiction"
    },
    "8c1414dd-20b2-415e-8d0e-1f9b8e7951d1": {
        "text_answer": "Yes  Explanation The evidence provided in the text does not mention the use of entericcoated tablets in either the primary or secondary clinical trials The statement that entericcoated tablets are not received by any of the participants in either the primary or secondary clinical trial is entailed by the evidence as it is consistent with the information given",
        "label": "Entailment"
    },
    "4f4360c0-38f9-4cea-89bb-8bf2a3fd0a4a": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the statement mentions nothing about the dosages or routes of administration of the interventions in the two cohorts and the evidence only provides information about those details The statement only mentions that one cohort receives Enzalutamide orally and the other does not but it does not specify which intervention in the evidence corresponds to which cohort",
        "label": "Contradiction"
    },
    "c48550ef-7210-4834-9047-969a7898d519": {
        "text_answer": "Yes The evidence does not report any cases of eating disorders among the participants",
        "label": "Entailment"
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "text_answer": "Yes  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive intramuscular injections as well as medication to be taken orally is entailed by the evidence  In the primary trial participants receive whole breast radiation therapy as described in the intervention details In the secondary trial participants in both cohorts receive intramuscular injections of Fulvestrant and",
        "label": "Entailment"
    },
    "faf8436a-2459-4718-be81-10b0649ff87a": {
        "text_answer": "No The statement is not entailed by the evidence as the primary trial includes patients aged greater than 20 years and the secondary trial includes patients aged 18 or older",
        "label": "Contradiction"
    },
    "bf00cf4b-27eb-4c1a-88e2-f86df10f2727": {
        "text_answer": "  No  Explanation  The evidence provided in the primary trial results does not directly state or imply that more than 10 patients in both cohorts Arm 1 and Arm 2 experienced pathologic complete response in breast and axillary lymph nodes after approximately 24 weeks after the surgery The evidence only reports the number of participants with pathologic complete response at the time of surgery approximately 7 months after the ne",
        "label": "Contradiction"
    },
    "98c16e6f-17a1-436f-833f-4f69e14f52db": {
        "text_answer": "No  Explanation  The evidence provided in the trial only compares the effectiveness of acupuncture and a waitlist control group in treating lymphedema There is no information about a testosterone cream group in the evidence Therefore it is not possible to determine if the statement is entailed by the evidence based on the information provided",
        "label": "Contradiction"
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is not entailed by the evidence The evidence only states that there was 1 case of Intestinal perforation in the primary trial and 2 cases in the secondary trial The statement implies that there were 12 cases in the secondary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "7c093c8a-8233-4dbb-87ba-03a1a049a7e8": {
        "text_answer": "Yes The statement is entailed by the evidence as the patients in Intervention 1 receive radiation therapy for a longer duration due to the use of Active Breathing Coordination which requires additional scans and appointments",
        "label": "Entailment"
    },
    "67498e27-5a2e-4495-adb7-5cd8f51aae65": {
        "text_answer": "No  Explanation  The statement the dosage of tamoxifen in intervention 1 of the secondary trial is 12 times higher than the dosage of denosumab in intervention 1 of the primary trial is not entailed by the evidence provided The dosages of the interventions in the two trials are not directly comparable due to their different units and dosing schedules In the primary trial denosumab is given as",
        "label": "Contradiction"
    },
    "5ca1c4e8-73e3-4329-9644-bfb986b6673e": {
        "text_answer": "Yes  Explanation  The statement encounter due to other problems related to physical environment is an ICD encounter due to other problems related to physical environment is a general statement that is not directly related to the specific adverse events listed in the evidence However the evidence does show that there are fewer cases of anemia in the primary trial than in the secondary trial",
        "label": "Entailment"
    },
    "36e4b948-e72f-43d9-8084-b3d2e879620b": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions intravenous injection of enzalutamide which is not mentioned in the evidence The evidence only states that enzalutamide is given orally to the participants in the clinical trial",
        "label": "Contradiction"
    },
    "9b1d58dd-30d8-4df2-856e-4cae783cbd6e": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the interventions in the primary and secondary trials are different The primary trial involves a drug cocktail with paclitaxel bevacizumab and gemcitabine while the secondary trial includes Zoledronic acid with or without radiopharmaceuticals The statement mentions only Gefitinib ZD1839 in the primary trial",
        "label": "Contradiction"
    },
    "92ea43b9-05d5-47a4-a78d-87bcb3326810": {
        "text_answer": "No  The evidence reports one participant experiencing a rash maculopapular which is a type of rash",
        "label": "Contradiction"
    },
    "0629bf04-f185-49b2-905e-e9a3932dbb0a": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the specific types of adverse events other than Infection Asymmetry and Deflation in the primary trial or the presence or absence of n",
        "label": "Contradiction"
    },
    "dc2d7205-d6ce-4d9c-96d2-e5a80fa906c0": {
        "text_answer": "No  Explanation  The statement recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage are common adverse events in the secondary trial than the primary trial is not entailed by the evidence The evidence only shows that the frequency of these adverse events is different between the two trials but it does not necessarily mean that they are more common in the",
        "label": "Contradiction"
    },
    "02adb741-194d-4472-b4b8-a3b546dc0484": {
        "text_answer": "No  Explanation  The statement patients participating in the primary clinical trial tended to have a higher incidence of pericardial effusions while corneal deposits were more frequently observed in the secondary clinical trial is not directly entailed by the evidence provided The evidence only reports the number and percentage of adverse events in each trial but it does not compare the incidence of specific adverse events between the two trials Therefore it",
        "label": "Contradiction"
    },
    "55cc22eb-91ad-423f-8d3e-e4b5ef61ed7d": {
        "text_answer": "Yes The patients eligibility for both trials depends on the other inclusion criteria being met as well",
        "label": "Entailment"
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "6846ee30-4c0c-4340-9c13-3892edc3baea": {
        "text_answer": "Yes The evidence does not provide information about Hypertension Dehydration or Dyspnea in either cohort so the statement about the absence of these conditions is entailed by the evidence",
        "label": "Entailment"
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "text_answer": "No  The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a Zubrod performance score of 2 or better which is not the same as a Karnofsky score",
        "label": "Contradiction"
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "text_answer": "Yes The evidence states that Nonsmall cell lung cancer and Small cell lung cancer are included in the list of eligible tumors for the trial",
        "label": "Entailment"
    },
    "c441ac74-f9ef-493c-bcfb-03959f9bf7e3": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not directly support the statement about the percentage change in betaCTX at week 2 for the Azd0530 25 mg and Zoledronic Acid 05 mg groups The evidence only provides the percentage change in betaCTX at week 4 for both groups",
        "label": "Contradiction"
    },
    "867cde11-ffad-4494-bdea-2457651a7de7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports a change in Ki67 expression not a change in tumor diameter The statement also specifies a different dosage of tamoxifen 32 mg instead of 20 mg and does not mention a change in tumor diameter at all",
        "label": "Contradiction"
    },
    "fe5179d1-0090-4c87-9287-9bb26139acd0": {
        "text_answer": "No  Explanation The statement about as socially active as before is not directly related to the exclusion criteria mentioned in the evidence The evidence only mentions the exclusion of patients who have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the last 2 years before study entry The statement about social activity is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "6561c528-4e6f-4e1f-8d65-9fa11d3c8838": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial does not measure the proportion of participants benefiting from the treatment according to RECIST criteria Instead it reports the number of participants with complete response partial response stable disease and progressive disease after receiving all 24 doses of 852A The secondary trial on the other hand measures the number of participants with aromatase inhibitor associated mus",
        "label": "Contradiction"
    },
    "a2b4f24d-e4ff-49b5-a21f-61ba1e5b0b32": {
        "text_answer": "Yes  Explanation The statement over 40 more participants in the ERpositive Luminal B group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is entailed by the evidence as the percentage of participants with a decrease in GFS in the ERpositive Luminal B group 286 is 423 higher than the percentage of participants with a decrease in",
        "label": "Entailment"
    },
    "dac129a3-974e-4918-95e5-11bbc0207e02": {
        "text_answer": "No  Explanation  The evidence provided in the text does not support the statement that all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group The evidence only reports the mean standardized scores and standard deviations for the Tamoxifen and Ovarian Function Suppression groups and it does not indicate that all participants in either group experienced a deterioration in cognitive function Additionally",
        "label": "Contradiction"
    },
    "ac0de5f6-14ed-44a1-9112-bce1b197553b": {
        "text_answer": "No  Explanation  The statement trichomonas infection is an infection that is caused by trichomonas is not directly related to the given evidence The evidence only provides information about the adverse events observed in two clinical trials for an unspecified treatment or intervention It does not mention Trichomonas infection specifically Therefore the statement cannot be determined to be entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it introduces new information not present in the evidence The evidence only mentions two cohorts in the primary trial one receiving the intervention with the educational DVD and the other receiving usual care There is no mention of a cohort receiving radiotherapy",
        "label": "Contradiction"
    },
    "0f37bc77-1f82-44ce-ae7e-2a6b833e774a": {
        "text_answer": "No  Explanation  The statement provided does not directly relate to the information given in the evidence The evidence describes the details of the interventions in the primary trial including the dosing schedules for sunitinib and paclitaxel but it does not mention anything about somatostatin receptor positive or its relation to the cohorts in the trial",
        "label": "Contradiction"
    },
    "d9dff3a0-537b-4297-bc58-766d366ba5a0": {
        "text_answer": "No  Explanation  The statement 97 of patients in the primary trial did not experience any Adverse Events is not entailed by the evidence provided The evidence only mentions the percentage of subjects who did not experience recurrence second malignancy or death within 3 years of treatment but it does not provide information about the occurrence of adverse events Additionally the statement that bilateral malignant neoplasm is a",
        "label": "Contradiction"
    },
    "0d382bbc-1c8d-4d05-b0dd-8501755ce9dd": {
        "text_answer": "No   Explanation The statement cohort 2 of the primary clinical trial experienced hospitalizations is not entailed by the evidence as the evidence only reports that there were no hospitalizations in cohort 2 of the secondary clinical trial",
        "label": "Contradiction"
    },
    "1a84148c-2d33-4804-922e-9a3419890897": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of subcutaneous or topical administration in the provided information for either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "b3527d60-eb66-465d-845a-e234e5b0a084": {
        "text_answer": "No  Explanation  The statement primary clinical trial does not allow participants who smoke but the secondary clinical trial may accept such individuals if they consume less than five alcoholic beverages daily is not directly entailed by the evidence provided The primary trial explicitly states that participants must be nonsmokers while the secondary trial mentions no smoking but also includes a criterion for alcohol consumption However the statement goes beyond the information given in the",
        "label": "Contradiction"
    },
    "3d2d011f-aff9-45c6-87e9-359b6d265c98": {
        "text_answer": "No  Explanation The statement patients who have received chemotherapy or radiotherapy in the last 336 hours suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the primary and secondary",
        "label": "Contradiction"
    },
    "e9653ffb-8fe5-47a3-810f-6831216f9893": {
        "text_answer": "No   Explanation The statement there were 1000 cases of hypertension edema and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events for two separate cohorts of the trial but it does not provide the total number of cases or the specific number of cases for hypertension edema and dyspnea",
        "label": "Contradiction"
    },
    "97d1e0d2-2f6f-45f1-8e85-33c92d71f0bf": {
        "text_answer": "No  The statement is not entailed by the evidence as one patient in the trial experienced an increase in blood bilirubin levels",
        "label": "Contradiction"
    },
    "2cf8046e-2d49-4989-aca0-9e11795978cb": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement incorrectly compares the interventions of the two trials using different medications and dosages The primary trial involves pregabalin while the secondary trial involves Liposomal Cytarabine and Highdose Methotrexate Therefore the statement does not follow from the given evidence",
        "label": "Contradiction"
    },
    "c7e44ec4-ddeb-4d8b-97aa-0361308300b8": {
        "text_answer": "Yes  Explanation The statement cohorts a and b are both given two different treatments which are not ld v935 at varying points in the cycle is entailed by the evidence as both cohorts received different interventions  Cohort A Received two IM injections of V935 LD but this is not the only treatment they received as they also received a different intervention V935",
        "label": "Entailment"
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "text_answer": "No   Explanation   The statement a young girl with a Newly diagnosed PRpositive HER2 positive breast cancer could be eligible for the secondary trial and the primary trial is not entailed by the evidence provided   The primary trial only includes female patients with HER2negative breast cancer and the secondary trial includes both female and male patients with ERpositive HER2negative breast cancer The",
        "label": "Contradiction"
    },
    "16634eb4-f12b-4d17-8401-070a7b7d052b": {
        "text_answer": "No  Explanation  The statement have discomfort when urinating is not directly related to the adverse events listed in the evidence The evidence only mentions adverse events such as abdominal pain fever and death as well as a specific type of infection called Gramnegative bacteremia It does not mention any adverse events related to urination Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "36e73055-3f34-4e5b-94a0-cfbac5dc3ff9": {
        "text_answer": "No  Explanation  The statement have trouble saying what i mean in conversation is not a criterion or exclusion for the primary trial as stated in the evidence The evidence only mentions specific diagnostic and eligibility criteria for the trial as well as exclusion criteria related to previous treatments and medical conditions It does not mention anything about communication abilities or difficulties in patients",
        "label": "Contradiction"
    },
    "ec164af8-13b9-4545-b3ba-24260adfe9db": {
        "text_answer": "Yes The evidence states that the primary clinical trial is accepting up to 30 patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Entailment"
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "text_answer": "Yes  Explanation The statement All AE types in the primary trial affected less than 10 of patients is entailed by the evidence since the percentage of patients affected by each adverse event is given in the evidence and none of them exceeded 10",
        "label": "Entailment"
    },
    "34c7862b-3725-4ed8-9e67-1513300323a7": {
        "text_answer": "Maybe  Explanation  The evidence provided in the form of the clinical trial results shows the ORR for each group but it does not directly compare the ORR between the two groups To determine if the statement is entailed by the evidence a statistical comparison of the ORR between the two groups would be necessary Without this information it is not possible to definitively say whether the statement is true or false",
        "label": "Entailment"
    },
    "c0b2f348-06b9-4e92-9257-a32c38b072cf": {
        "text_answer": "No The statement is not entailed by the evidence as the secondary trial only mentions female patients",
        "label": "Contradiction"
    },
    "512b8ed3-f0ca-4e11-ab4a-eebe4217ad7e": {
        "text_answer": "Yes  Explanation The primary clinical trial measures the change in hot flash activity using a daily prospective hot flash diary while the secondary clinical trial measures the overall response rate ORR using RECIST criteria These outcome measures are not the same and are therefore dissimilar",
        "label": "Entailment"
    },
    "568b4d2b-204c-4606-a75f-058a5870c84c": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it introduces an incorrect intervention for the control group radiotherapy and incorrectly describes the intervention for the intervention group regularly receiving instead of viewing an educational DVD",
        "label": "Contradiction"
    },
    "7ba4c342-8897-4815-9bb3-eea917b3769e": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial administers oral pregabalin and the secondary trial uses intravenous chemotherapy and intrathecal liposomal cytarabine not gemcitabine or topical corticosteroids",
        "label": "Contradiction"
    },
    "f988fa4a-02f0-41f6-9e27-453604dd3ecc": {
        "text_answer": "Yes The statement the adverse events recorded were of the same number is entailed by the evidence since the number of adverse events for event 1 is 0 in both trials",
        "label": "Entailment"
    },
    "0f77fc34-7285-4374-879d-b96166cfc29e": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence states that participants will take Vorinostat daily during radiation therapy",
        "label": "Contradiction"
    },
    "e648aa7a-3013-4d37-9bf5-51e75c7d4202": {
        "text_answer": "No  Explanation  The statement infections affected more than 15 of patients in both the primary and secondary clinical trials is not entailed by the evidence The evidence shows that infections affected 313 of patients in the primary trial and 667 in the secondary trial which is less than 15",
        "label": "Contradiction"
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "text_answer": "No   The statement is not entailed by the evidence as the primary trial does not report the severity of delayed nausea and the secondary trial measures the change in bone mineral density of the lumbar spine not the severity of any condition",
        "label": "Contradiction"
    },
    "6b4bc07c-bfc3-4750-b802-7100efeb60a7": {
        "text_answer": "Yes   Explanation  The statement the interventions in the primary clinical trial are similar in terms of the medications but they are given through varied routes is entailed by the evidence because both interventions involve the use of different medications bisphosphonate and denosumab but they are administered through different routes intravenous and subcutaneous respectively",
        "label": "Entailment"
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "text_answer": "No  Explanation  The statement None of the participants in group 1 of the primary trial were found to have lesions and more than 90 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The evidence only states the number of participants and the number of lesions or conditions radiation dermatitis and hyper",
        "label": "Contradiction"
    },
    "19ca7182-94ba-4b70-bd4e-1a65bd428f91": {
        "text_answer": "  No   Explanation   The statement candidates for the primary trial must undergo a pulmonary function test pft whereas patients for the secondary trial must have a recent magnetic resonance imaging mri report and liver function tests is not explicitly stated in the evidence provided for either the primary or secondary trial inclusion or exclusion criteria While there may be additional requirements or procedures not listed in the evidence the statement as",
        "label": "Contradiction"
    },
    "1d1f2f55-c9b7-4a8b-bea7-b8ea291d96d5": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes patients with T0T1 N1 M1 tumors TX NX MX is a TNM staging system that includes T N and M categories where T refers to the size and extent of the primary tumor N refers to the involvement of regional lymph nodes and M refers to the presence or absence of distant metastases The statement specifically mentions T1 N1 M",
        "label": "Entailment"
    },
    "919dbcc0-8d31-4161-8692-45533e52d60e": {
        "text_answer": "No  Explanation  The statement no adverse events were reported in the primary clinical trials first cohort however almost everyone in the second cohort encountered at least one adverse event is not directly entailed by the evidence provided The evidence only states that there were no adverse events reported in the first cohort but it does not provide information about the second cohort The statement goes beyond the information given in the",
        "label": "Contradiction"
    },
    "33efdbc8-175b-4021-b192-acd8d37cedd1": {
        "text_answer": "No  Explanation  The statement 125 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not entailed by the evidence The evidence states that the incidence of increased pleural effusion is 2500 in Adverse Events 2 and the incidence of rapid disease progression is 769 in Adverse Events 1 and 000",
        "label": "Contradiction"
    },
    "a555a807-ceeb-4237-bd26-25e5a3db9128": {
        "text_answer": "No   Explanation  The statement Suramin and Paclitaxel are administered to all patients in the primary trial is not directly related to the secondary trial evidence which only mentions the number of individuals having mastectomy surgery Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "96892eae-9630-45eb-bc5f-6c7605d8dd1c": {
        "text_answer": "  Yes for the primary trial and No for the secondary trial with qualifications  Explanation  The statement fifty is a natural number greater than fortynine and less than fiftyone and the quantity that it denotes is a mathematical fact and is not directly related to the inclusion criteria in the evidence  Regarding the primary trial the statement Female cancer patients over the age of 18 can participate in",
        "label": "Entailment"
    },
    "afeed01c-f21a-4926-9028-d2b9a2226c9f": {
        "text_answer": "Yes The statement is entailed by the evidence as there is no mention of paclitaxel in either intervention described in the trial",
        "label": "Entailment"
    },
    "0c05d756-82d5-4f8f-afe7-845857c1e9d3": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of inhalation as a method of administration for any intervention in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "a954a34f-0eb2-4c28-8673-f4c0a337bd00": {
        "text_answer": "No  Explanation  The statement HER2  Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial is not entailed by the evidence In the primary trial HER2 patients received a loading dose of 4 mgkg followed by 2 mgkg weekly while in the secondary trial cohort ",
        "label": "Contradiction"
    },
    "5119953d-f226-4e3d-96c9-a05862188b6d": {
        "text_answer": "Yes  Explanation  The statement neither the primary nor the secondary trial reported any cases of infection asymmetry or nausea is entailed by the evidence because  1 The evidence states that there were no cases of infection asymmetry or nausea reported in the secondary trial 2 The evidence also states that there were cases of infection asymmetry and other adverse events reported in the primary trial but none",
        "label": "Entailment"
    },
    "e0393f5c-7dec-4018-8917-b055823aec4b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as Atara Biotherapeutics is a drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy which is not related to the primary trial described in the evidence which is focused on aromatase inhibitor therapy for patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that",
        "label": "Contradiction"
    },
    "24e662f6-3ac7-489b-91fa-890994a805b4": {
        "text_answer": "No  The evidence does not state that only Hispanic patients can participate in the primary clinical trial The evidence outlines the inclusion and exclusion criteria for participants in the clinical trial but it does not specify that ethnicity is a requirement for participation",
        "label": "Contradiction"
    },
    "f4cf0fc1-5b69-49a1-8ba6-454063ff63ce": {
        "text_answer": "Yes for both primary and secondary trials regarding the absence of thromboembolic events However its important to note that the statement is only about thromboembolic events and not about other adverse events mentioned in the evidence",
        "label": "Entailment"
    },
    "349365cf-1c22-4e72-b321-b15b505e50cb": {
        "text_answer": "Yes The evidence does not provide any information about the measurement of Change in Ki67 Expression in Tumors in either the primary or secondary trials",
        "label": "Entailment"
    },
    "14632f5e-6eb4-4771-9567-cbde0f19c4af": {
        "text_answer": "No The statement is not directly related to the evidence provided in the primary trial The evidence focuses on the effectiveness of two interventions Collaborative Care Intervention and Prevention Care Management in improving cancer screening rates for colorectal breast and cervical cancers The statement is about neurodevelopmental disorders which is a different topic",
        "label": "Contradiction"
    },
    "c648cc67-b490-4cfe-be5e-4706b94ac0df": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial as well as secondary clinical trial there were neither unexpected deaths nor hospital stays just three known cases of lymphoma is entailed by the evidence because the evidence states that there were no unexpected deaths or hospital stays in both trials and the statement also mentions the three known cases of lymphoma which are included in the evidence",
        "label": "Entailment"
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "text_answer": "Yes  Explanation The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is entailed by the evidence since the minimum dose of MCS110 given is 1 mgkg and a 70 kg patient would receive 70 mg every 3 weeks The statement and over 130 mg of PDR001 every other week is also ent",
        "label": "Entailment"
    },
    "6cce2cb8-3ed9-40e9-a412-cb75b688ac59": {
        "text_answer": "Yes  Explanation  Both trials include patients who are 18 years of age or older",
        "label": "Entailment"
    },
    "1649a4de-bc0d-4908-88ac-515b88be60b3": {
        "text_answer": "No  Explanation  The statement the primary trial reported no adverse occurrences and in the secondary trial less than 30 of patients experienced adverse events is not entailed by the evidence The evidence only reports the number and percentage of adverse events in each trial but it does not mention that the primary trial reported no adverse events Additionally the percentage of patients experiencing adverse events in the secondary trial was 33",
        "label": "Contradiction"
    },
    "5784fb28-1da8-483c-a56b-61b68fb2a8f5": {
        "text_answer": "Yes The primary trial describes a treatment cycle lasting 21 days one month while the secondary trial does not specify a recurring treatment approach",
        "label": "Entailment"
    },
    "0b4536c8-2868-4d1a-bc26-d16b31eed34f": {
        "text_answer": "No  The statement is not entailed by the evidence as candidates with an ECOG score of 4 are explicitly excluded from both trials according to their inclusion criteria",
        "label": "Contradiction"
    },
    "2dce1806-9ce1-4448-9888-052def540a43": {
        "text_answer": "Yes  Explanation The statement a single psychiatric adverse event was reported in the primary clinical trial affecting fewer than 10 of the patients is entailed by the evidence as there is one reported case of suicidal ideation a psychiatric adverse event in the trial and the total number of adverse events was 6 out of 50 patients which is less than 10",
        "label": "Entailment"
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial both use pCR as their outcome measurement is directly entailed by the evidence as both trials explicitly state that their outcome measurement is pathological complete response pCR  The statement there is a small difference in results between the two cohorts of the primary trial is also entailed by the evidence as the confidence intervals for the pCR rates in the two arms of",
        "label": "Entailment"
    },
    "be50f0ae-0c2b-42be-9306-78a1da6b4e09": {
        "text_answer": "No  The primary clinical trial does not mention any height requirements while the secondary clinical trial does not specify height as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "79cd8b63-fe24-4e8b-9a15-0e054fb09dba": {
        "text_answer": "No  Explanation  The primary clinical trial measures changes in patientspecified and reported symptoms on the MYMOP questionnaire before the 7th acupuncture treatment while the secondary clinical trial measures changes in isothiocyanate in urine samples at baseline and after completion of study therapy The two trials do not rely on modifications in MYMOP score as the assessment of their study findings",
        "label": "Contradiction"
    },
    "367bc142-7412-43c6-b946-6127aff25f9a": {
        "text_answer": "  No the statement is not directly entailed by the evidence as the evidence only reports on the percentage change in betaCTX levels and does not provide information on primary tumor size reduction",
        "label": "Contradiction"
    },
    "4087e09b-d0a1-4c3a-8411-b1938bf51b95": {
        "text_answer": "Yes  Explanation  The statement in the secondary clinical trial and the primary clinical trial more than 97 of participants experienced no unfavorable incidents is entailed by the evidence because the sum of the percentages of participants with unfavorable incidents in both trials is less than 3 Therefore more than 97 of participants experienced no unfavorable incidents in both trials combined",
        "label": "Entailment"
    },
    "7df6c8c9-fb22-4197-aba7-d6540a691eec": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial uses change in units on a scale as its unit of measure for the primary outcome measurement and the secondary trial uses percentage of participants and number as its units of measure for the outcome measurement The units of measure for the primary trial do not match the units specified in the statement",
        "label": "Contradiction"
    },
    "5cd571da-1a17-4513-b0b8-7ef1ced9a52f": {
        "text_answer": "Yes In the primary trial PF06647020 was given at higher doses 02 mgkg and 05 mgkg than in the secondary trial where ALT801 was given at 0015 mgkgdose and 0040 mgkgdose",
        "label": "Entailment"
    },
    "3805ddb3-dbdf-4f10-8434-271503114961": {
        "text_answer": "No  Explanation  The statement the gender of a patient dictates whether they qualify for the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The evidence outlines specific inclusion and exclusion criteria for each clinical trial some of which include gender as a factor but it does not state that gender is the sole determining factor for eligibility",
        "label": "Contradiction"
    },
    "79385974-de52-4d05-b6b1-dc1086d484d9": {
        "text_answer": "No The statement is not entailed by the evidence as the statement is about hypothyroidism which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "f6f6058f-688b-4ce6-8fec-612f57b1f3ec": {
        "text_answer": "No  Explanation The primary trial includes people with a breast tumor that is 1 cm in diameter while the secondary trial includes people with measurable disease but there is no mention of a specific tumor size in the secondary trial Therefore the statement that people with a TNBC tumor with a 100mm diameter can participate in either trial is not entailed by the evidence",
        "label": "Contradiction"
    },
    "df0234b5-3b00-4036-ac6c-5cb2d1eeafdf": {
        "text_answer": "yes The evidence states that MLN8237 is administered in the form of entericcoated tablets in the secondary clinical trial",
        "label": "Entailment"
    },
    "448df56a-bcc3-491e-8626-dc8d439013b2": {
        "text_answer": "No  Explanation  The statement there were several fatalities in the second cohort of the primary clinical trial is not entailed by the evidence provided The evidence only states that there were no fatalities in the second cohort of the clinical trial",
        "label": "Contradiction"
    },
    "4872d505-a3f8-44bb-a023-aa41e27b49b3": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the percentage change in serum betaCTX levels from baseline to Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided in the question is about the primary tumour diameter reduction in the AZD0530 100 mg group compared to the Zoledronic Acid ",
        "label": "Contradiction"
    },
    "b1b73c84-818f-40f9-8e6b-a749dc415b71": {
        "text_answer": "Yes  Explanation The statement one or more participants in the primary clinical trial experienced numerous adverse outcomes is entailed by the evidence since there were a total of 5 adverse events reported in the trial affecting 2000 of the participants",
        "label": "Entailment"
    },
    "4cd89e87-f0c1-4064-ab16-d945db457c41": {
        "text_answer": "No  Explanation  The statement first cousin once removed is a child of your first cousin is not related to the evidence provided The evidence only discusses the interventions of two clinical trials one using cabergoline given orally and the other using pixantrone dimaleate administered intravenously The statement about the relationship between first cousins is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "21031398-5d47-4ad9-ad19-16c790eaf061": {
        "text_answer": "No  Explanation The evidence provided in the primary trial only reports the median average survival times for patients undergoing surgery in the midluteal and midfollicular phases of their menstrual cycles It does not provide information on the survival times of individual patients or the number of patients who survived for less than 24 hours Therefore the statement that on average patients from the primary trial survive over 10 years however",
        "label": "Contradiction"
    },
    "b45f25ba-463e-458a-9e48-edd0d50bc6cb": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial cohort 1 has not reported any adverse events is entailed by the evidence Adverse Events 1 Total 0147 000 The evidence indicates that there were no adverse events reported for cohort 1 in the primary clinical trial which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "7a5cbc82-ec49-44f5-9c95-4c6475f3ee3e": {
        "text_answer": "Yes  Explanation The primary trial includes women with locally advanced recurrent or metastatic ER breast cancer who are considering mastectomy as part of their treatment as they may have measurable disease or bone metastasis The secondary trial includes women with newly diagnosed or recurrent ER breast cancer who are considering mastectomy Therefore women with a new diagnosis of locally advanced ER breast cancer who are considering mastectomy are eligible",
        "label": "Entailment"
    },
    "640ffbc4-cf15-4ab2-bf90-620e815f2694": {
        "text_answer": "Yes  Explanation The evidence shows that both groups had a median survival time greater than 2 years Therefore more than 50 individuals in each group survived for more than 2 years which is the average lifespan mentioned in the statement",
        "label": "Entailment"
    },
    "e5f60086-55a3-4432-9e9d-74690054db5d": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not mention anything about carotid artery disorders in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "648ed723-14eb-4c58-85f9-9a6f6089b493": {
        "text_answer": "No   The statement is not entailed by the evidence as the primary trial assesses the severity of pain using a visual analog scale not delayed nausea The secondary trial observes the variation in bone mineral density of the lumbar spine over a 9month period",
        "label": "Contradiction"
    },
    "641b6edf-2ed6-494a-9d37-7c7f04ccd6a0": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the percentage change in serum betaCTX levels at Week 4 for each group It does not provide information about the changes in primary tumor diameter Therefore the statement about similar reductions in primary tumor diameter between the two groups is not entailed by the evidence",
        "label": "Contradiction"
    },
    "fb13dfb3-66cd-45f6-98a8-c0712283954f": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement is about spinal cord glioma which is not related to the breast cancer and ovarianperitoneal cancer mentioned in the evidence",
        "label": "Contradiction"
    },
    "599e8d04-e80f-4f54-9486-bcf5a39a1d37": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 1000 mg of fulvestrant in a tablet form to be taken bid is not entailed by the evidence  The primary trial participants receive whole breast radiation therapy but the secondary trial participants do not receive radiation therapy Instead they receive Enzastaurin and Fulvestrant as oral and",
        "label": "Contradiction"
    },
    "a11f4223-9416-4cf8-8712-ebbddf8c4353": {
        "text_answer": "No   Explanation  The evidence provided does not mention the number of adverse events that occurred in more than 30 of participants in either trial The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d0fe5818-5954-41ea-9bcf-4ce7deba5ceb": {
        "text_answer": "  Yes The secondary trial excludes patients with allergies to cephalosporin and trimethoprimsulfamethoxazole which is consistent with the statement The primary trial excludes patients with allergies to celecoxib but that is not mentioned in the statement",
        "label": "Entailment"
    },
    "89c78515-344a-4974-a01f-de5a0441ada0": {
        "text_answer": "No   Explanation  The statement There are no conditions on hepatic function for participants of the primary trial is not directly related to the given evidence The evidence only mentions the inclusion and exclusion criteria for the primary trial regarding bone marrow liver and renal function but it does not explicitly state that there are no conditions on hepatic function Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "277b5179-05cc-48df-8f23-98b42ccad0b9": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as both trials administer the intervention orally sublingually for the primary trial and by mouth for the secondary trial There is no mention of intravenous or topical administration in the evidence",
        "label": "Contradiction"
    },
    "46278ed1-1bc8-4161-b9d9-9f5a001b6aac": {
        "text_answer": "No  Explanation  The statement apgar score version 1  respiration or respiratory effort is apgar score version 1 apgar score version 1 respiration or respiratory effort score is not directly related to the evidence provided The evidence pertains to the inclusion and exclusion criteria for two clinical trials one for Benign Breast Disease and the other for hot flashes in breast cancer survivors The Apgar",
        "label": "Contradiction"
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "text_answer": "Yes The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 but the statement specifies that Alzheimers patients are not eligible due to some evidence of cognitive impairment Therefore Alzheimers patients would not meet the inclusion criteria and are excluded from the trial",
        "label": "Entailment"
    },
    "256c210a-d33f-4708-8d86-2cb636227c4d": {
        "text_answer": "No  Explanation  The statement infection asymmetry and nausea were observed more frequently in the primary clinical trial compared to the secondary clinical trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the frequency or comparison of specific adverse events between the two trials",
        "label": "Contradiction"
    },
    "55c933c1-1de0-4a15-9a17-e1216cb84b4b": {
        "text_answer": "No  Explanation  The statement Candidates for the primary trial and the secondary trial have to meet a baseline performance status each trial is using a different performance status scoring system symptom interference with life score 10 is a subjective score of 10 on a scale that ranges from 0 did not interfere to 10 interfered completely is not directly stated in the evidence provided The evidence only mentions the",
        "label": "Contradiction"
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "text_answer": "No  Explanation The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not entailed by the evidence provided The evidence only mentions one psychiatric adverse event which is suicidal ideation There is no mention of an eating disorder or Schizophrenia in the evidence",
        "label": "Contradiction"
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "text_answer": "Yes The evidence does not mention any imaging studies as part of the interventions in either trial",
        "label": "Entailment"
    },
    "316e0b04-f14e-47cd-b847-6af5add81e4e": {
        "text_answer": "Yes  Explanation  The evidence provides information about the number of adverse events in both the primary and secondary clinical trials for two different types of events Adverse Events 1 and Adverse Events 2 The statement both the primary and secondary clinical trials have detailed accounts of adverse events involving their participants is entailed by the evidence because it is stated that there are accounts of adverse events for both trials",
        "label": "Entailment"
    },
    "9c8c3b78-d272-4ce9-947b-f9283c79e818": {
        "text_answer": "No  Explanation  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is not entailed by the evidence provided The evidence only shows the number and percentage of patients who experienced each specific adverse event in each cohort It does not provide enough information to determine if the same percentage of patients in both cohorts experienced any adverse event Additionally the statement about moderately short of",
        "label": "Contradiction"
    },
    "c76fe4c2-5f55-4e85-8528-943d90e99dd0": {
        "text_answer": "  Yes the statement is entailed by the evidence The evidence states that 18 year olds are excluded from the primary clinical trial but not from the secondary clinical trial",
        "label": "Entailment"
    },
    "555d74d4-755a-44b9-9bec-f8adda634c38": {
        "text_answer": "Yes for the secondary trial No for the primary trial",
        "label": "Entailment"
    },
    "c21d49da-c66f-45cc-af8a-22174568d0dd": {
        "text_answer": "Yes The evidence shows that more than 13 of the participants in both cohorts experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes The statement acknowledges this fact and asks if it helps recognize the need for a decision implying that the information in the statement is already known from the evidence",
        "label": "Entailment"
    },
    "5d0a21d6-cf35-48c3-9128-9d3f9cd03d23": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence because the adverse events faced by patients in the primary clinical trial are not the same as those faced by patients in the secondary clinical trial The primary clinical trial had adverse events including dehydration lymphopenia neutropenia thrombocytopenia hyponatremia weight loss and sinus tachycardia while the secondary",
        "label": "Contradiction"
    },
    "04b2b1f2-5d87-4b89-8fcd-c1c988bd22de": {
        "text_answer": "Yes  Explanation  The statement across the primary clinical trial and the secondary clinical trial it was recorded that there were no deaths in the adverse events is entailed by the evidence since the evidence indicates that there were no deaths reported in the adverse events of both trials",
        "label": "Entailment"
    },
    "5902b596-40d0-4be7-8242-f313f6832fec": {
        "text_answer": "No  Explanation  The statement patients with a documented allergy to celecoxib and levofloxacin can enroll in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The primary clinical trial excludes patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to mesna or other agents used in the study but it does not specifically mention cele",
        "label": "Contradiction"
    },
    "d0691186-857a-4876-8f49-732e033a86c7": {
        "text_answer": "Yes  Explanation The evidence provides data on the number of participants analyzed and the mean standard deviation of hot flashes per 24 hours for both the paced respiration and fast shallow breathing intervention groups The statement goes beyond the provided data by mentioning treatment emergent adverse events and serious treatment emergent adverse events but the evidence does indicate that more adverse events were reported in the paced respiration group Therefore the statement is",
        "label": "Entailment"
    },
    "201c2df5-585d-4d20-a19b-c2b12db5dc5f": {
        "text_answer": "No  Explanation  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly entailed by the evidence provided The evidence only mentions that smokers are excluded from the primary trial and gives specific exclusion criteria for the secondary trial but it does not mention anything about alcohol consumption being a potential eligibility criterion for that trial",
        "label": "Contradiction"
    },
    "6cc1c5e4-b45a-486f-be8d-1c49abc327c9": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "705457d9-78b2-466d-9a3e-db4b11e99daa": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence indicates that there were no adverse events recorded in the secondary trial which is the same as in the primary trial",
        "label": "Contradiction"
    },
    "6f947c20-ecd9-4c6b-b1e3-5d536d4b33cd": {
        "text_answer": "No  Explanation  The evidence provided in the text does not support the statement that all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group The evidence only reports the mean standardized scores and standard deviations for the cognitive function test results for the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The statement goes beyond the information provided in",
        "label": "Contradiction"
    },
    "70dec4df-4dbd-41cc-ba31-6437c7058987": {
        "text_answer": "Yes  Explanation The evidence states that 286 131492 of ER Luminal B participants showed a decrease in the growth factor signature GFS while 176 67352 of Triple Negative participants showed a decrease in GFS The difference between these percentages is 11 Therefore the statement a higher percentage of",
        "label": "Entailment"
    },
    "0f449a63-8d5d-4c60-96f8-bb32423f079d": {
        "text_answer": "Yes  Explanation  The statement clinical study anchor is a planned activity within a clinical study that marks a transition between epochs or elements within the clinical study is not explicitly stated in the evidence However the evidence does provide information about the primary and secondary endpoints the time frames for measurement and the units of measure used in each study The fact that both studies report their results using the same units of measure supports the idea that there is a",
        "label": "Entailment"
    },
    "2493a4e6-18a1-41c7-8feb-81928df2b542": {
        "text_answer": "No  Explanation The statement xq271 is a chromosome band present on xq is not related to the evidence provided which pertains to the interventions AlloMSCs and placebo and their administration methods in a clinical trial",
        "label": "Contradiction"
    },
    "80b0b7be-91b4-40ba-a4db-d19f0b1865d7": {
        "text_answer": "Yes but with a caveat The statement is entailed by the evidence if we interpret improved to mean less negative standardized scores as the evidence shows that the standardized score for the Tamoxifenonly group was more negative than the standardized score for the TamoxifenplusOFS group However its important to note that a less negative score does not necessarily mean an improvement in absolute terms as it could simply mean",
        "label": "Entailment"
    },
    "8bd3b6aa-d1b5-4f4a-a16a-434d56764ee5": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as myocardial infarction is not listed as an adverse event in the provided clinical trial data The most common adverse events recorded were nausea and vomiting each occurring twice",
        "label": "Contradiction"
    },
    "30f7d44a-34d9-4d98-9802-2c8a7c625e48": {
        "text_answer": "Yes The primary trial specifically includes HR HER2 breast cancer with a tumor size of 1 cm but the statement also includes tumors ranging from 02 to 08 cm in diameter which falls within the size range of the primary trials inclusion criteria The secondary trial does not specify a tumor size but it also includes HR HER2 breast cancer",
        "label": "Entailment"
    },
    "a98a4204-8591-48d3-9349-723b4ccc4f3c": {
        "text_answer": "  Yes for the primary trial only The evidence states that patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug are excluded from the primary trial but it does not exclude patients with a pulmonary embolism within the last 3 years Therefore these patients are eligible for the trial according to the given criteria",
        "label": "Entailment"
    },
    "0d8ce6e1-e0bb-42b6-a8ec-0d2679b908ad": {
        "text_answer": "No  Explanation  The statement there were 4 additional adverse incidents recorded in the primary clinical trial compared to the secondary clinical trial is not entailed by the evidence The evidence only states that there were no adverse events recorded in both trials for the specific adverse event mentioned It does not provide information about the total number of adverse events in each trial",
        "label": "Contradiction"
    },
    "10ae9352-5088-4431-8a48-a6891f5d03b7": {
        "text_answer": "No  Explanation  The statement irrespective of a patients qualifications based on the exclusion and inclusion criteria for the primary clinical trial their own decision serves as the final say about participation is not explicitly stated in the evidence The evidence only mentions that the final eligibility for a clinical trial is determined by the health professionals conducting the trial",
        "label": "Contradiction"
    },
    "c22306e0-54e6-4324-abed-0a38d9c7f1b9": {
        "text_answer": "No  Explanation  The primary trial reports the percentage of participants with a response within 10 days of the first dose of denosumab while the secondary trial reports the number of participants who reached a safe dose of dmethadone over a 2year period The units of measure are not identical",
        "label": "Contradiction"
    },
    "8747d88a-efc9-42ae-ba7c-5e25c8693b34": {
        "text_answer": "Yes The evidence indicates that pain was measured and reported by patients throughout the course of the study However it does not explicitly state that pain was a common experience reported by all patients but it is reasonable to assume that given the focus of the study on pain management pain was a significant issue for many participants",
        "label": "Entailment"
    },
    "fdf14cde-dd7c-4b38-a127-5d857fb22bab": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results only reports the median change in total body lean mass for two different doses of GTx024 1 mg and 3 mg over a 4month period The statement however refers to all patients treated with GTx024 1000 mcg gaining lean body mass over a 120day period The evidence does not directly",
        "label": "Contradiction"
    },
    "d846c22f-adab-4189-b662-056541a723c2": {
        "text_answer": "No  Explanation  The statement perineal artery is an artery arising from the internal pudendal artery that supplies the bulbocavernosus and ischiocavernosus muscles of the perineum is a factual statement about anatomy and is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided in the evidence The statement does not entail any information about the trial participants",
        "label": "Contradiction"
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement is false The primary trial actually has fewer adverse events recorded than the secondary trial",
        "label": "Contradiction"
    },
    "c4b6e4a0-1377-444e-853d-d62b67802ed2": {
        "text_answer": "Yes The evidence mentions surgical and imaging procedures in the intervention section of the clinical trial",
        "label": "Entailment"
    },
    "f9ab104f-3d67-4912-aaf5-bb43ecd0c52d": {
        "text_answer": "No  Seminal vesicle cystadenoma is not a type of metastatic cancer as stated in the evidence It is a benign condition",
        "label": "Contradiction"
    },
    "40dd90a2-f57d-467e-bc6c-c9a8a50a330f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7aef8aaf-9fc3-49b2-95e7-ed9b227cdd27": {
        "text_answer": "No  Explanation  The statement neisseria gonorrhoeae penicillinase negative is any bacterial species identified as neisseria gonorrhoeae that does not produce the enzyme penicillinase is not related to the information provided in the evidence The evidence only discusses the dosing regimens of epacadostat and pembrolizumab in the primary trial",
        "label": "Contradiction"
    },
    "4046d097-cbc9-48ef-9e90-d9a427fa6d19": {
        "text_answer": "Yes  Explanation The primary trial involves two different interventions each with distinct combinations of drugs Abl Cells IV  Cyclophosphamide with different doses and Fludarabine  Cyclophosphamide  Abl Cells IV with different doses The secondary trial also involves two different interventions each using the same drug 4Demethyl4cholestryloxycarbonylpencl",
        "label": "Entailment"
    },
    "126ef758-8ce5-4e45-859d-acece8b261e1": {
        "text_answer": "No  Explanation  The statement the secondary trial documented a higher prevalence of mucositis oral epileptic seizures and thromboembolic events than the primary trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events in each trial but it does not indicate which trial had a higher prevalence of any specific adverse event The statement makes a comparison between the trials that is",
        "label": "Contradiction"
    },
    "1aedac43-a4c7-4c14-b217-8d76e853c76f": {
        "text_answer": "No   Explanation   The evidence provided in the trial description does not mention anything about the use of fentanyl sublingual spray during radiation therapy for the patients The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "40d1e2c2-9a6f-42a6-b75d-a67e9945a38d": {
        "text_answer": "Yes  Explanation The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is entailed by the evidence as it is explicitly stated in the Intervention 1 and Intervention 2 descriptions that patients receive MCS110 at a dose of 1 mgkg every 3 weeks and since 1 mgkg is equivalent to 1 mgkg x 70",
        "label": "Entailment"
    },
    "94935617-b333-4eb3-bd06-a5884fa45989": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement describes two different interventions while the evidence describes the interventions for two separate trials The primary trial intervention is radioembolization using Yttrium90 glass microspheres and TheraSphere while the secondary trial intervention is a combination of ibrutinib and MEDI4736 with specific dosages",
        "label": "Contradiction"
    },
    "59b5ce7e-13af-4377-8923-c096f79bcade": {
        "text_answer": "No  Explanation  The statement 16p1313p1312 is a chromosome band present on 16p All Infections and Fever cases in the primary trial were for patients in cohort 1 is not directly entailed by the evidence provided The evidence only reports the number and types of adverse events for each cohort but it does not specify which chromosome band is",
        "label": "Contradiction"
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide information about the types of adverse events in the secondary trial that are related to the musculoskeletal system The statement only compares the percentage of adverse events related to the musculoskeletal system between the two trials",
        "label": "Contradiction"
    },
    "18876a8c-2536-4148-b563-c5a68daa7fac": {
        "text_answer": "No  Explanation  The statement Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events is not entailed by the evidence The evidence only reports the number of adverse events and the types of adverse events for each trial It does not provide the total number of deaths across both trials Additionally the statement iv anesthesia was not administered is not related to the adverse",
        "label": "Contradiction"
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "text_answer": "Yes the statement is entailed by the evidence as the evidence includes an adverse event of wound dehiscence which means a surgical incision has reopened",
        "label": "Entailment"
    },
    "105ed693-cbe0-47a4-ba39-f361032d9ed7": {
        "text_answer": "Yes Both interventions use the same dosage and frequency for Doxorubicin Cyclophosphamide and Docetaxel The statement does not directly address tracheostomy site bleeding or CTCAE but the evidence provided does not contradict the statement regarding the chemotherapy dosages and schedules",
        "label": "Entailment"
    },
    "db3d7616-8500-411a-9b43-b9b6e0925957": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial describes the administration of suramin and paclitaxel not adriamycin and vincristine Therefore the statement that all participants in the primary clinical trial receive adriamycin and vincristine is not entailed by the evidence",
        "label": "Contradiction"
    },
    "f19797c7-afb1-4480-ab8f-c798a86d2849": {
        "text_answer": "No  Explanation  The evidence provided states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR However the statement claims that over 67 of patients experienced a confirmed complete response CR Since the evidence does not meet the requirement of over 67 of patients having",
        "label": "Contradiction"
    },
    "bea94e26-3706-492c-af45-d35ef7e43ff1": {
        "text_answer": "Yes the statement is entailed by the Evidence as there are no recorded adverse events for Adverse Events 1 and 2 in both the primary and secondary trials The statement about clavicle fracture is not directly related to the Evidence and therefore does not affect the answer",
        "label": "Entailment"
    },
    "591e7319-16cd-46db-be86-7c78e8d471c8": {
        "text_answer": "yes The primary trial reports pCR rates of 565 478649 for Arm I and 542 457626 for Arm II The secondary trial reports pCR rates of 17 for Arm 1 and 31 for Arm 2 The statement acknowledges the difference in pCR rates between the two primary trial arms and the superiority of Arm",
        "label": "Entailment"
    },
    "cbb4daf6-f35a-4832-b071-a17ffbe86e13": {
        "text_answer": "Yes The statement several adverse events occurred during the primary clinical trial is entailed by the evidence since there were no adverse events reported in the primary trial but the statement skin infections in the secondary clinical trial affected the majority of patients is not directly stated in the evidence but it is implied by the data that 333 of patients experienced skin infections",
        "label": "Entailment"
    },
    "874a2beb-d0b1-4b5f-9f37-5b49ba5a1067": {
        "text_answer": "Yes  Explanation The evidence shows that neither biliary colic nor Clostridium difficile colitis were reported in the primary trial Similarly they were not reported in the secondary trial Therefore the statement that there is no difference in their occurrence between the two trials is entailed by the evidence",
        "label": "Entailment"
    },
    "21c183ca-7f70-4ddb-9599-d371ee544055": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence shows that in the primary clinical trial 4545 of patients experienced adverse events and in the secondary clinical trial 1563 of patients experienced adverse events The statement implies that over 97 of patients in the secondary clinical trial experienced adverse events which is not supported by the evidence",
        "label": "Contradiction"
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine is not directly entailed by the evidence provided The primary trial involves the use of Fluciclatide injections while the secondary trial involves the use of Chloroquine tablets Therefore the two",
        "label": "Contradiction"
    },
    "452458d2-6372-4ac9-a7f9-0be77cc28eea": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "97b0957c-3b60-4671-9c9d-37eacba40f93": {
        "text_answer": "No  Explanation  The statement footfootpad is a laboratory specimen consisting of the foot and footpad is not related to the adverse events data provided in the evidence The evidence only reports the types and frequencies of adverse events observed in two clinical trials It does not mention anything about footfootpad being a laboratory specimen or any adverse events related to it",
        "label": "Contradiction"
    },
    "705e4626-c95b-4191-b9f1-02ae897cef70": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because it makes an incorrect assumption about the nature of the treatments in the secondary trial The statement suggests that the secondary trial only involves the administration of Depocyt and HDMTX but the evidence shows that the secondary trial also includes placebo and a maintenance phase with HDMTX and Depocyt Therefore the statement is not an accurate summary of the evidence",
        "label": "Contradiction"
    },
    "12f2ffff-1010-43bb-ac5d-5725d3d159b4": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens therapy in the last 4 weeks  28 days before study entry The statement extends this time frame to 730 days 2 years",
        "label": "Entailment"
    },
    "d8f0b3e8-ca61-4874-a4e0-1328029bce88": {
        "text_answer": "No  Explanation  The inclusion criteria for the primary and secondary clinical trials are not the same The primary trial is specifically for postmenopausal female breast cancer patients taking hormonal therapy while the secondary trial is for adult patients with HER2negative metastatic breast cancer who are candidates for taxanebased chemotherapy The primary trial has specific requirements related to menopausal status and hormonal therapy which are not present in the secondary",
        "label": "Contradiction"
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "text_answer": "No  The statement is not entailed by the evidence as the inclusion criteria specify patients with advanced andor unresectable disease for Nonsmall cell lung cancer and Small cell lung cancer",
        "label": "Contradiction"
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "text_answer": "No  Explanation  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is not entailed by the evidence The evidence only provides the number and percentage of adverse events for each cohort It does not indicate that most patients in cohort 1 suffered adverse events or that the inverse is true for cohort 2",
        "label": "Contradiction"
    },
    "fe73dc46-7c3a-45cd-a5fa-db03aa8dd28c": {
        "text_answer": "Yes Anorexic patients can meet the inclusion criteria for the primary trial as long as they meet all other criteria and have a BMI of 25 kgm2 or greater Anorexia is not listed as an exclusion criterion in the evidence",
        "label": "Entailment"
    },
    "723d5448-24c6-4679-98c1-3c67bb12fea4": {
        "text_answer": "Yes The ECOG performance status of 0 to 2 is a common inclusion criterion in both trials",
        "label": "Entailment"
    },
    "07f85ee2-4e95-4648-a492-4011837ddc7f": {
        "text_answer": "No   Explanation   The evidence provided only discloses the design of the primary clinical trial for LBH589 in combination with Capecitabine and does not mention any findings for the LBH589 and Lapatinib group",
        "label": "Contradiction"
    },
    "8bd62043-2cb9-42f0-80c1-2ec39020d9af": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement is about a device malfunction code which is not mentioned in the evidence The evidence only provides information about the primary and secondary trials their outcome measurements and their results",
        "label": "Contradiction"
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not directly measure primary tumor diameter but rather the percentage change in serum betaCTX levels from baseline to week 4 Therefore the statement about a greater reduction in primary tumor diameter for the AZD0530 175 mg group is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "text_answer": "No  Explanation  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is not entailed by the evidence The evidence only shows that Syncope was the most common adverse event in the primary trial but it was not mentioned in the secondary trial at all Therefore it cannot be the most common adverse event across both trials",
        "label": "Contradiction"
    },
    "55d65365-bf85-4213-9ead-be1c498a4a72": {
        "text_answer": "No   Explanation  The statement three weekly sc injections are administered to the participants of the secondary clinical trial is not directly entailed by the evidence provided The evidence only mentions that epoetin beta is given as a weekly subcutaneous injection for a total of 12 weeks but it does not specify the exact number of injections per week Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "36a25cf0-0cca-457d-bd85-8ba89b2ff602": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it incorrectly states that the primary clinical trial administers different daily doses of 1000 mcg for breast cancer patients and 25 mcg for ovarian or peritoneal cancer patients According to the evidence the trial administered various doses of talazoparib for both breast and ovarianperitoneal cancer patients but",
        "label": "Contradiction"
    },
    "d432512b-0bb4-435c-b32c-7ae0564a63c8": {
        "text_answer": "No  Explanation  The statement only a small percentage of patients on sunitinib  docetaxel  trastuzumab in the primary clinical trial encountered treatmentemergent adverse events is not directly entailed by the evidence provided The evidence only states that there were 24 treatmentemergent adverse events and 11 serious adverse events among the 25 participants analyzed It does not provide information about",
        "label": "Contradiction"
    },
    "9c74310c-3096-4eaf-bed2-aec926b5c850": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not support the statement as it only gives the number of participants who completed the study in each group not the percentage who experienced recurrencefree survival The recurrencefree survival data is not presented in the evidence",
        "label": "Contradiction"
    },
    "a855848e-4097-4755-90e0-e612f1bfc54c": {
        "text_answer": "No  Explanation  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only reports the number of participants and the presence or absence of lesions in the primary trial and the",
        "label": "Contradiction"
    },
    "70eac1ab-54b0-460d-abda-86f0c5d04483": {
        "text_answer": "yes The statement mentions unstable angina chemotherapy within 2 weeks and grade 2 or higher neuropathy as exclusion criteria for the secondary trial which are also listed in the exclusion criteria of the evidence",
        "label": "Entailment"
    },
    "38e4b093-2121-486f-bcfb-d250ea9978e4": {
        "text_answer": "  Yes the statement is not entailed by the evidence in the primary clinical trial but it is not explicitly prohibited in the secondary clinical trial either",
        "label": "Entailment"
    },
    "92fe4c4d-da02-4327-a2a1-86e731ba4fd9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the dosages of carboplatin in Intervention 1 AUC 2 and Intervention 2 AUC 2 are not identical The dosage of carboplatin in Intervention 1 is calculated based on the area under the curve AUC while in Intervention 2 it is given as a fixed dose AUC 2",
        "label": "Contradiction"
    },
    "8eb9d0d2-5c33-4ff6-adf6-e96ddf7be7a6": {
        "text_answer": "Yes The evidence states that patients with a history of clotting disorder including pulmonary embolism are excluded from the primary clinical trial The statement specifically mentions pulmonary embolism and breast implants in relation to both trials",
        "label": "Entailment"
    },
    "48b25d6c-3b89-425b-960e-9d55471a5f37": {
        "text_answer": "No  Explanation  The evidence provides the percentage of participants in each group who demonstrated a decrease in the growth factor signature GFS However it does not directly compare the number of participants between the two groups who demonstrated a decrease in GFS Therefore it is not possible to determine if 0492 more participants in the ERpositive Luminal B group demonstrated a decrease in GFS than in the triple negative group based on the given",
        "label": "Contradiction"
    },
    "53a45460-701f-420e-853a-f5ccb8545030": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as there is no mention of subcutaneous insulin injections or oral antiretroviral therapy ART in the provided evidence The evidence only mentions the interventions and patient populations of two separate clinical trials",
        "label": "Contradiction"
    },
    "79515622-bb43-4721-a164-dd2002713dc1": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only provides the number of participants in each group who were analyzed and the percentage of participants who experienced recurrencefree survival up to 5 years It does not specify that all participants in the NaCl 09 3ml group experienced recurrencefree survival only that there were 120 participants in that group who were analyzed and 897",
        "label": "Contradiction"
    },
    "ee42e602-9409-49fa-a454-7a2637ed9d7a": {
        "text_answer": "No  Explanation The evidence provided does not indicate that any participants in the trial exhibited noticeable trends in the expression of 40 studied genes The evidence only reports the proportion of participants in each group with a discernible pattern for gene expression and both groups had a percentage of 0",
        "label": "Contradiction"
    },
    "3109bf56-61b7-4f43-9e38-fa3b69378214": {
        "text_answer": "No  Explanation  The statement None of the cohort of the primary trial or the secondary trial receive entericcoated tablets is not directly related to the information provided about the deleterious ercc3 gene mutation The evidence only discusses the interventions used in the primary and secondary trials and does not mention anything about entericcoated tablets being related to the gene mutation",
        "label": "Contradiction"
    },
    "95f4ce83-19b7-424d-93b9-27a6c3fe8c6d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence states that participants in the clinical trial received talazoparib not that they did not receive it",
        "label": "Contradiction"
    },
    "3acf4a18-725c-444e-bf7e-e3eb9a0878e7": {
        "text_answer": "No  The statement is not related to the evidence provided The evidence pertains to a clinical trial comparing the effectiveness of different antinausea regimens while the statement describes a different topic  a genus of bacteria",
        "label": "Contradiction"
    },
    "9b230310-d16f-47a4-bf3b-341d2de6f9c4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial is focused on vaginal treatments Estring and Testosterone Cream and the secondary trial is focused on acupuncture treatments which are not inhalable",
        "label": "Contradiction"
    },
    "0b6e68b2-9f05-407b-bd00-feb9d3ce7abc": {
        "text_answer": "No  Explanation  The statement primary clinical trial participants were twice as likely to have cholelithiasis than those in the secondary clinical trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events for each trial but it does not provide enough information to make a definitive statement about the prevalence of cholelithiasis in each trial or a comparison between the two trials",
        "label": "Contradiction"
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "text_answer": "No  The primary trial has no mention of Performance Status as an inclusion criterion",
        "label": "Contradiction"
    },
    "88e8a071-e139-4547-9fd8-f3311d0770ef": {
        "text_answer": "No   Explanation   The patient described in the statement does not meet the minimum tumour size requirement for the primary trial greater than 2 cm diameter Therefore they would not be eligible for the primary trial based on the provided inclusion criteria   Additionally the statement does not provide enough information to determine eligibility for the secondary trial as there are several other inclusion and exclusion criteria that need to be considered",
        "label": "Contradiction"
    },
    "00c165f5-4c14-4aab-a4a8-9b8010bd5858": {
        "text_answer": "No  Explanation  The statement the primary clinical trial does not consider gender in determining eligibility however only females can participate in the secondary clinical trial is not entailed by the evidence provided The primary clinical trial has specific inclusion and exclusion criteria for both male and female subjects while the secondary clinical trial only includes females Therefore the statement is not accurate as it implies that the primary trial does not consider gender at all which is not the",
        "label": "Contradiction"
    },
    "330f241a-9f7d-469d-8986-5687fdd5fb70": {
        "text_answer": "No  Explanation  The statement neither trial uses the same drugs dosages or frequency of administration is true However the statement they do both use intravenous injections and MRIs is also true but it is not directly related to the statement about the trials using the same drugs dosages or frequency of administration Therefore the statement as a whole is not entailed by the evidence",
        "label": "Contradiction"
    },
    "bca3c321-d798-427d-90a7-8c786d91947c": {
        "text_answer": "  No   Explanation   The patient described in the statement does not meet the inclusion criteria for both trials In the primary trial the patients hemoglobin level is below the required minimum of 80 gdl In the secondary trial the patients life expectancy is less than 6 months which is an exclusion criterion",
        "label": "Contradiction"
    },
    "0a7569de-fb79-41f8-acc6-fd155a26e3c8": {
        "text_answer": "  No The statement is not entailed by the evidence provided The evidence only mentions exclusion criteria for the primary and secondary trials and neither trial mentions anything about ulnar length or pulmonary embolisms being a criterion for inclusion or exclusion",
        "label": "Contradiction"
    },
    "7d57f1d1-e523-4220-95a9-f4ce33d7f157": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0348dacb-819e-4e1f-98c3-d45d6c057f60": {
        "text_answer": "Yes The statement mentions some of the exclusion criteria from the evidence",
        "label": "Entailment"
    },
    "bcbc612f-11c9-40ba-9376-c098a9b738f4": {
        "text_answer": "No  The secondary clinical trial does not employ muscle growth as an indicator of physical therapys effectiveness Instead it measures pain as an indicator",
        "label": "Contradiction"
    },
    "d035a6bb-0d8f-4a6b-b725-f8b2535883eb": {
        "text_answer": "No   Explanation  The evidence provided describes two interventions both of which involve the use of a paced breathing instructional CD but the frequency of practice varies once daily for 15 minutes or twice daily for 15 minutes The statement however mentions a cohort that utilizes the focused breathing instructional audio guide thrice daily which is not described in the evidence Therefore the statement is not entailed by",
        "label": "Contradiction"
    },
    "a8760238-f938-4525-bd13-ecb0948de8bc": {
        "text_answer": "Yes The evidence does not mention the use of drugs radiotherapy or CBT Cognitive Behavioral Therapy in the interventions Myelosuppressive therapy which decreases the rate of blood cell production in the bone marrow is not specified as being used in the trial",
        "label": "Entailment"
    },
    "ad24cf4c-11da-465c-b008-ba96dc8bcdd4": {
        "text_answer": "Yes for the secondary trial",
        "label": "Entailment"
    },
    "04dfaa5a-359d-4aba-a56d-4b19f041ce39": {
        "text_answer": "No  Explanation The statement A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography would be eligible for both the primary trial and the secondary trial is not entailed by the evidence provided The primary trial includes a criterion that the primary tumour must be greater than 2 cm in diameter while the secondary trial does not mention any specific tumour size requirement Therefore a patient",
        "label": "Contradiction"
    },
    "103134aa-c3f2-4ebb-8919-72bdb5611b07": {
        "text_answer": "No   Explanation  The statement no adverse events were reported in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence While there were no adverse events reported in the primary trial there were two reported in the secondary trial",
        "label": "Contradiction"
    },
    "bca56f4d-9c3c-4615-8b56-3f6ca86d047b": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the evidence describes two different interventions one with alloMSCs and the other with a placebo each consisting of 20 transendocardial injections of 04ml administered to the left ventricle via NOGA Myostar injection catheter single procedure The identical dose in terms of volume is given for both interventions but the",
        "label": "Contradiction"
    },
    "82e2e80d-2a88-4d12-82a9-4d77d1bf0bb6": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial does not mention anything about the appetite or food enjoyment of the participants The trial only reports the correlation of Vitamin D levels classic prognostic factors and gene expression profile in patients with breast cancer The statement about appetite and food enjoyment is not related to the evidence presented",
        "label": "Contradiction"
    },
    "be3df611-66ac-4f40-ae04-68b5d1c0ae02": {
        "text_answer": "maybe  Explanation  The statement a female patient aged 20 recently diagnosed with erpositive her2negative breast cancer may qualify for both the primary clinical trial and the secondary clinical trial is not a definitive yes or no answer based on the provided evidence  The primary clinical trial has specific inclusion criteria such as histologically confirmed HER2negative breast cancer and disease progression during or following firstline treatment with",
        "label": "Entailment"
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "text_answer": "Yes  Explanation The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is entailed by the evidence as it is clear from the evidence that only those four types of adverse events were reported in the primary trial",
        "label": "Entailment"
    },
    "972438ce-59d8-476c-a8a3-b61fba56e982": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "07687788-b44f-4f2a-9117-6b55cbdc3f7a": {
        "text_answer": "Yes  Explanation Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine as a treatment for patients with CNS involvement from various types of cancer The primary trial includes interventions with Abl Cells and Cyclophosphamide while the secondary trial only uses DMCHOCPEN as the treatment However the medication itself is the same in both trials",
        "label": "Entailment"
    },
    "9e1d8e36-9749-4f70-b0e3-d173892dfcd0": {
        "text_answer": "No  Explanation  The statement immigrant from a high tuberculosis prevalent area is an individual that has migrated from a country with a high occurrence of tuberculosis is not directly related to the evidence provided The evidence only mentions adverse events from clinical trials and there is no information about the immigrants countries of origin or the prevalence of tuberculosis in those countries",
        "label": "Contradiction"
    },
    "e6d5d1ca-f1f6-481a-b309-78adf96e656c": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial includes a minimum tumour size of 2 cm diameter while the secondary trial does not mention any specific tumour size requirement",
        "label": "Contradiction"
    },
    "db52c7f4-cfb8-40d2-83f2-3514cb04794b": {
        "text_answer": "Maybe The statement is not directly entailed by the evidence as the evidence only provides information about adverse events in the two cohorts and does not explicitly state that the patients had a favorable prognosis However the low incidence of adverse events in both cohorts could be interpreted as an indication of a favorable prognosis",
        "label": "Contradiction"
    },
    "82582964-823a-4765-b22c-201660fcca08": {
        "text_answer": "No  Explanation The statement women aged 30 or 35 are eligible for the secondary trial but will need to wait 56 years to be eligible for the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for both the primary and secondary trials It does not mention anything about the age requirement for eligibility or the waiting period for the primary trial",
        "label": "Contradiction"
    },
    "bb9c00c0-3a87-41c2-bfb5-183f7b44fcbc": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about a group of patients using testosterone cream The evidence only compares the acupuncture group to a waitlist control group",
        "label": "Contradiction"
    },
    "260a9ba1-ca1b-4e87-83d1-b128e73e1e38": {
        "text_answer": "  No The statement is not entailed by the evidence The evidence does not mention anything about radiation charged particles or different inclusion criteria for different age groups in the primary trial",
        "label": "Contradiction"
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "text_answer": "No  Explanation  The primary trial measures the change in units on a scale for vaginal symptoms while the secondary trial measures the percentage of participants with objective response rate for HER2negative metastatic breast cancer The units of measure are not the same and therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "64b3c727-779e-4db4-b1fe-1d85105ab7ec": {
        "text_answer": "No  Explanation  The primary and secondary clinical trials measure different outcomes using different metrics The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using the metric unit of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib using the metric unit of mg Therefore the statement that they use the same parameters and",
        "label": "Contradiction"
    },
    "930e7529-e05a-471e-9d52-17f538f610c2": {
        "text_answer": "No  Explanation  The statement the primary trial does not require injection instead using Lymphoscintigraphy abnormal involuntary movement scale aims0111 through aims0112 original result  no is not entailed by the evidence The primary trial involves denosumab injections while the secondary trial involves the use of a handheld gamma camera and intraoperative gamma probes for lym",
        "label": "Contradiction"
    },
    "f0d10d18-11a3-4fae-9a4d-f2277f6e5b43": {
        "text_answer": "No   Explanation  The statement there was an equal distribution of adverse events recorded in both the primary and secondary trials is not entailed by the evidence The evidence shows that the frequency of adverse event 1 was 000 in the primary trial and 6000 in the secondary trial which is not equal",
        "label": "Contradiction"
    },
    "4efeb043-de46-49cd-8d5d-c4266304fb91": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8fd48918-38db-4443-a1b8-bf2d7a458857": {
        "text_answer": "No  Explanation  The statement primary clinical trial patients suffered from anemia pneumonia and stupor more often than patients in the secondary trial is not directly entailed by the evidence provided While it is true that anemia pneumonia and stupor were reported in the primary trial and anemia was also reported in the secondary trial the frequency of these adverse events is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "5255cd06-123a-4d45-943d-37b6261b1cf7": {
        "text_answer": "No   Explanation The evidence provided in the adverse events data does not mention anything about eating disorders The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e4f41907-ef20-40aa-bcab-416243280816": {
        "text_answer": "No  Explanation The statement mentions a 40 average reduction in tumor diameter but the evidence only reports a 40 average reduction in Ki67 expression which is a marker of cell proliferation The two measurements are not directly equivalent and the statement goes beyond the findings reported in the evidence",
        "label": "Contradiction"
    },
    "5976b8b7-0f88-4e52-8ad7-39609dabbf8e": {
        "text_answer": "Yes  Explanation Both the primary and secondary trials include the use of cyclophosphamide and paclitaxel in their interventions The primary trial also includes the use of GMCSF which is a type of granulocyte colonystimulating factor like pegfilgrastim and the secondary trial includes the use of pegfilgrastim specifically Therefore while the statement does not explicitly mention pegfilgrastim",
        "label": "Entailment"
    },
    "763a61cc-c267-4536-8cfe-a4f97a461e07": {
        "text_answer": "No  Explanation  The evidence provided does not mention tumour lysis syndrome in either the primary or secondary clinical trials The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "text_answer": "No  Explanation  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only shows the number of adverse events for each trial but it does not indicate the number of cases for Mucositis Oral epileptic seizures or Thromboem",
        "label": "Contradiction"
    },
    "bc47f5a1-dc20-4df2-bb3e-fa03695c9840": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial the patients of cohort 1 and 2 receive varied doses of radiation therapy for the same duration is entailed by the evidence as both cohorts receive radiation therapy for the same number of fractions 2327 and the same duration Monday through Friday but cohort 1 receives Active Breathing Coordination ABC while coh",
        "label": "Entailment"
    },
    "91b12db1-76c1-4863-90df-a95d2af8dfc5": {
        "text_answer": "No  Explanation  The statement thyroid gland hyperfunctioning adenoma is a thyroid gland adenoma producing thyroxin it is associated with hyperthyroidism radioactive iodine scan reveals a hot nodule is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided in the evidence The statement discusses a specific type of thyroid gland adenoma and its association with",
        "label": "Contradiction"
    },
    "699bf83a-8890-43ab-96ea-40f2171c9633": {
        "text_answer": "No  Explanation  The statement patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration up to a maximum of 100 mg three times daily whereas patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial is not directly entailed by the evidence provided  The evidence only mentions the",
        "label": "Contradiction"
    },
    "1b67d41e-cff6-46ae-b30d-4c254525e9ef": {
        "text_answer": "No  Explanation  The statement the dosage of zoledronic acid in intervention 1 of the primary clinical trial is identical to that of denosumab used in intervention 1 of the secondary clinical trial is not entailed by the evidence provided The dosage of zoledronic acid in intervention 1 of the primary clinical trial is 4 mg Q4W while denosumab in intervention 1 of the secondary clinical trial",
        "label": "Contradiction"
    },
    "a35f8d94-b561-4644-ad29-2ac0e48ceb79": {
        "text_answer": "No  Explanation  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial is not directly entailed by the evidence provided The evidence only mentions that lesions must not be within 5 mm of the optic chiasm or within the brainstem for the primary trial but it does not specify that having 23 cerebral metast",
        "label": "Contradiction"
    },
    "477389de-84aa-4438-87c9-3abccc80e1cb": {
        "text_answer": "No  Explanation  The statement provided is not directly entailed by the evidence presented The evidence only provides the number of adverse events for two trials but it does not make any comparison between the two trials regarding specific types of adverse events or their frequencies The statement goes beyond the information given in the evidence by making specific comparisons and conclusions about which types of adverse events were more common in each trial",
        "label": "Contradiction"
    },
    "f98c72d2-3fce-42a5-9585-280e8b877708": {
        "text_answer": "Yes  Explanation The evidence shows that there were 16 participants in Arm 1 and 14 participants in Arm 2 who achieved a pathologic complete response in breast and axillary lymph nodes which is the outcome measure mentioned in the statement Since there were a total of 42 participants in the trial the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "14c1e784-1f79-4ba9-8466-c8c638f929db": {
        "text_answer": "No  Explanation  The statement all participants in the primary clinical trial and 16741674 participants in the secondary clinical trial experienced an adverse event is not entailed by the evidence The evidence only reports the number and types of adverse events that occurred in each trial but it does not indicate that every participant experienced an adverse event",
        "label": "Contradiction"
    },
    "1dfb4256-8bef-4128-8cd2-30d5c88a4ac8": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases with HER2targeted PETCT",
        "label": "Entailment"
    },
    "8bdac388-c2bd-4634-9073-6862aaa7a5cf": {
        "text_answer": "Yes  Explanation The statement participants are given four separate drugs is entailed by the evidence as epirubicin cyclophosphamide docetaxel and trastuzumab are all mentioned in the intervention description The statement with the maximum dosage capped at 100 mgm2 is not directly mentioned in the evidence but the dosages of epirubicin and cycl",
        "label": "Entailment"
    },
    "8529eb83-969c-4075-bfe7-efc47fd33d8d": {
        "text_answer": "Yes Pancreatic cancer is listed as one of the eligible tumor types in the clinical trial",
        "label": "Entailment"
    },
    "da8b6738-7194-4d9d-a077-a4aec72945bb": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7f53b46f-6ab4-4d59-bc28-b13eca3fb3b3": {
        "text_answer": "Yes  Explanation  The statement no patients in the primary clinical trial experienced recorded adverse events is directly contradicted by the evidence from the primary clinical trial which states that there were no adverse events reported in the given trial However the statement is also entailed by the evidence from the secondary clinical trial as every patient in that trial experienced at least one adverse event which is the opposite of no recorded adverse events Therefore the statement ",
        "label": "Entailment"
    },
    "e2731b02-ce9d-4bfe-bc8d-9eda951e0e77": {
        "text_answer": "Yes The evidence states that there is a exclusion criterion for the secondary trial that patients with prior use of gabapentin or pregabalin are not eligible",
        "label": "Entailment"
    },
    "9c8b2041-2a99-4f42-93ec-63daed05fe87": {
        "text_answer": "Yes However the statement does not explicitly appear in the evidence but the inclusion criteria for both trials do not exclude patients with stage 4 breast cancer",
        "label": "Entailment"
    },
    "5c7ff5f0-5b40-42e1-8f24-a0bfd6a4b2ef": {
        "text_answer": "Yes The statement is entailed by the evidence as both study groups undergo the same imaging procedures with 18FFDG and 18FFPPRGD2",
        "label": "Entailment"
    },
    "e32de0e0-4e26-4c73-a6d6-cc5dfafd97c7": {
        "text_answer": "No  Explanation  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is not entailed by the evidence provided The evidence only states that one patient in each trial experienced increased pleural effusion and the rate of rapid disease progression is the same for both trials 769 Therefore it is not accurate to conclude that 25 of patients experienced both",
        "label": "Contradiction"
    },
    "f4f39eeb-0db1-40c3-9d45-5c17dabe4998": {
        "text_answer": "Yes  Explanation The statement on average participants survived beyond two years with over fifty patients from each cohort outliving 24 months is a valid inference from the given evidence The median survival times reported in the trial are both greater than 2 years and the number of participants surviving beyond 24 months is not explicitly stated but can be inferred from the reported median survival times and the number of participants analyzed",
        "label": "Entailment"
    },
    "ab25ad81-a094-432c-9814-12669bd4cbac": {
        "text_answer": "No  Explanation The statement genetic mutations in pten braf kras nras pi3kca erbb1 erbb2 met ret ckit gnaq or gna11 are necessary for eligibility in the primary trial but these conditions do not determine inclusion in the secondary trial is not entailed by the evidence While the primary trial does include eligibility based on specific",
        "label": "Contradiction"
    },
    "98b0c6c3-73c0-40d9-95d7-48e5340aa2f8": {
        "text_answer": "Yes  Explanation The statement the primary trial and secondary trial both use the same dose of lenalidomide and lapatinib respectively in intervention 1 with equal periods for the intervention is entailed by the evidence as both trials use lenalidomide at a dose of 5mg daily for the same duration 57  3 days and lapatinib is used at a dose of 1500mg daily",
        "label": "Entailment"
    },
    "fcc8d86f-3fba-4398-8c0e-042153fa118e": {
        "text_answer": "No  Explanation The statement decreased bone tissue is a decrease in the amount of bone tissue as compared to a standard or norm is a general statement about bone tissue It is not directly related to the evidence provided which is about interventions in two trials The first trial compares normal saline to dexmedetomidine and the second trial compares baseline to postvitamin D repletion There is no mention of",
        "label": "Contradiction"
    },
    "99912ce1-aa49-4289-8743-eb1afffe1675": {
        "text_answer": "Yes The statement is about medullary thyroid gland carcinoma occurring in childhood which is consistent with the cohorts described in the evidence being children The evidence does not provide information about the number of adverse events related to medullary thyroid gland carcinoma specifically but the statement does not make that claim either Therefore the absence of adverse events in the evidence does not contradict the statement",
        "label": "Entailment"
    },
    "8c5d8cfb-c75f-4cb8-af4a-8100726f2a12": {
        "text_answer": "No  Explanation The evidence provided in the primary clinical trial indicates that the median survival periods for patients undergoing midluteal and midfollicular oophorectomy were 214 153 to 267 years and 200 161 to 231 years respectively These medians suggest that the majority of patients in both groups survived beyond 1",
        "label": "Contradiction"
    },
    "09904e7f-5e34-44b1-9edb-f92c3edcda95": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial shows a shorter operative time in the intraoperative mammography arm compared to the standard mammography arm and the secondary trial includes a control group for comparative studies",
        "label": "Entailment"
    },
    "3b1906b0-5212-4341-b6cd-3163456ce44a": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial involves a different intervention denosumab and dosage schedule compared to the secondary trial pIHGC and GP with radioactive Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "a24e8008-affe-44f7-a6f1-56e817ffdde3": {
        "text_answer": "No  Explanation  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is not entailed by the evidence The evidence only reports the number of adverse events AEs for each trial but it does not provide information about deaths or hospitalizations specifically The statement also incorrectly assumes that the only types of AEs are those related to Lymphoma when in fact there were other A",
        "label": "Contradiction"
    },
    "c5534047-9025-410f-a641-43819cc1ce23": {
        "text_answer": "No  Explanation  The statement There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial is not directly related to the concept of substance dispersity mentioned in the statement Substance dispersity is a property of molecules or particles while the adverse events mentioned in the evidence are health conditions observed in the trials The statement only compares the number of cases of specific adverse events between two trials",
        "label": "Contradiction"
    },
    "12746144-95c9-4656-abdf-8a49f78c7049": {
        "text_answer": "No  Explanation The evidence provided relates to the inclusion and exclusion criteria for a clinical trial involving breast cancer patients The statement about pay increases promotions or recognition at work is not related to the eligibility criteria for the trial",
        "label": "Contradiction"
    },
    "e8d33476-b6f1-4337-8072-c07e4f223275": {
        "text_answer": "Yes The evidence states that both arms of the trial only receive CUDC101 without any additional therapeutic treatments",
        "label": "Entailment"
    },
    "24630f41-fd07-4b3d-a0f6-66282c5c3a07": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial has reported marginally higher total adverse events in patient groups compared to the primary clinical trial is not entailed by the evidence provided The evidence only states that the number of adverse events in the secondary trial was 0 for Adverse Event 1 and 015 000 for Adverse Event 2 while the primary trial had 0 adverse events for both",
        "label": "Contradiction"
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes patients with T0T1 N1 M1 tumors TX NX MX is a TNM staging term that includes all stages",
        "label": "Entailment"
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "text_answer": "No  Explanation  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is not entailed by the evidence  The evidence only shows the frequency of specific adverse events in each trial but it does not provide enough information to determine which trials have a majority of adverse events related to blood and bone marrow The statement makes a comparison between",
        "label": "Contradiction"
    },
    "b45a503d-d4db-4f8d-aefa-37cf2bbc6011": {
        "text_answer": "Yes  Explanation The statement among the participants of the primary clinical trial maculopapular rash was often reported as an adverse event is entailed by the evidence as the evidence states that Rash maculopapular 130 333 was reported as an adverse event in the trial",
        "label": "Entailment"
    },
    "a1d9b33e-fe46-421d-87e8-e0ecbfed7686": {
        "text_answer": "Yes The primary trial does not assess study outcomes using changes in Isothiocyanate in Urine Samples and the secondary trial does not assess study outcomes using the MYMOP questionnaire",
        "label": "Entailment"
    },
    "136bc454-b432-45f9-909b-e588f2dc6c60": {
        "text_answer": "No  Explanation  The evidence provided in the results of the primary clinical trial indicates that 381 of participants in Arm 1 Paclitaxel  Trastuzumab Then AC and 333 of participants in Arm 2 Paclitaxel  Neratinib Then AC achieved a pathologic complete response in breast and axillary lymph nodes This means that a significant",
        "label": "Contradiction"
    },
    "9f382aed-4a54-40c2-92ca-fb17411e4923": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement makes a comparison between two different interventions denosumab and radioactive Tc99M sulfur colloid while the evidence only provides information about the specific interventions used in each clinical trial The statement also includes incorrect information about the dosage of radioactive Tc99M sulfur colloid used in the secondary trial The correct dosage is",
        "label": "Contradiction"
    },
    "1d66b8cc-1e7e-4a88-bd39-695528aa5894": {
        "text_answer": "Yes for the secondary trial with the amended exclusion criteria However the primary trial does not mention anything about insomnia as an inclusion or exclusion criterion",
        "label": "Entailment"
    },
    "f9a8b80a-3191-4f53-865b-1ab2154174ad": {
        "text_answer": "No  Explanation The statement in the primary clinical trial under a tenth of the participants experienced a decline in circulating tumor cells after months of highdose chemotherapy accompanied by purged autologous stem cell products is not directly entailed by the evidence provided The evidence only reports the number of participants with a reduction in CTCs at one month posttransplantation not after months",
        "label": "Contradiction"
    },
    "d3ccfad5-d5c9-4bdb-a69e-dca916dc5da5": {
        "text_answer": "  Yes for the primary trial and Maybe for the secondary trial   Explanation  The statement is entailed by the primary trial inclusion criteria regarding the absolute neutrophil count platelet count hemoglobin level and life expectancy However the secondary trial has additional inclusion criteria such as the requirement of a histologically verified diagnosis of stage IIbIIIIV breast cancer and the patients age being between",
        "label": "Entailment"
    },
    "0cecee52-d87e-419a-a970-e79733613a87": {
        "text_answer": "No  The evidence does not specify that only Caucasian patients are eligible for the primary clinical trial The inclusion criteria are based on various factors including histology of tumor prior therapy performance status and laboratory values among others There is no mention of race as a criterion for eligibility",
        "label": "Contradiction"
    },
    "f4d73533-5e6a-403c-ad63-3882890b7e94": {
        "text_answer": "Yes  Explanation  The statement we are unable to make a comparison of the adverse events in the primary clinical trial and the secondary clinical trial as there seems to be no record of such events for the primary clinical trial is entailed by the evidence because the evidence shows that there is no record of adverse events for the primary clinical trial",
        "label": "Entailment"
    },
    "be63170c-5a52-4d85-b824-54ceca90684a": {
        "text_answer": "No  The evidence does not mention claustrophobia as an exclusion criterion for either trial IBS Irritable Bowel Syndrome is also not mentioned in the evidence",
        "label": "Contradiction"
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "text_answer": "No  Explanation The placebo is administered on Day 1 and Trabectedin is administered on Day 2 so they are not both administered on a biweekly basis The statement is incorrect",
        "label": "Contradiction"
    },
    "7c0a99c5-b76f-438c-a93b-15d3340cd430": {
        "text_answer": "No  Explanation  The evidence provided in the text only reports the percentage of participants with disease progression or death in each cohort during the maintenance phase of the clinical trial It does not provide sufficient information to determine if the outcomes from the bevacizumab  capecitabine cohort were superior to those of the bevacizumab cohort The statement goes beyond the information given in the evidence and makes a comparison",
        "label": "Contradiction"
    },
    "383e310f-a7a5-49f5-ae10-ddf49eee92df": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it goes beyond the information provided in the inclusion and exclusion criteria of the clinical trials The statement makes a generalization about a patient populations ability to participate in clinical trials based on their level of disability which is not explicitly addressed in the given criteria",
        "label": "Contradiction"
    },
    "429f2754-6edc-4969-99f3-7507b76e443a": {
        "text_answer": "Yes The primary trial did not show significant differences between the two groups but the secondary trial did show some significant differences between the reflexology and control groups",
        "label": "Entailment"
    },
    "f2b4adf3-ccbc-4bea-94a6-50887d7aeea0": {
        "text_answer": "No  Explanation The evidence provided in the clinical trial results indicates that the median survival times for patients undergoing midluteal and midfollicular oophorectomy were 214 years 153 to 267 and 200 years 161 to 231 respectively These median survival times suggest that some patients in both groups survived beyond 2 years",
        "label": "Contradiction"
    },
    "da91286b-3029-475f-a919-e33629a5a972": {
        "text_answer": "No  Explanation  The statement There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed by the evidence provided The evidence only lists the number and types of adverse events observed in the primary trial but it does not specify which trials these events came from ie Adverse Events 1 or Adverse Events 2 Additionally",
        "label": "Contradiction"
    },
    "dbf8020d-57c3-45fb-ab31-5c97f293a248": {
        "text_answer": "  Yes for both trials",
        "label": "Entailment"
    },
    "d54a1b83-ecd6-4160-a839-1bddf6a12cc5": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial includes interventions that are exclusively administered orally cabergoline while the secondary trial includes interventions that are administered intravenously pixantrone dimaleate There is no mention of topical administration in either trial",
        "label": "Contradiction"
    },
    "c19b9a3f-acda-4e83-80db-0f4d3383d909": {
        "text_answer": "Yes  Explanation The statement in the primary trial there were 05 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy can be calculated from the given evidence as follows  Number of hepatotoxicity cases  3 Number of hypertension cases  1 Number of pancreatectomy cases  1  05  Number",
        "label": "Entailment"
    },
    "427a4e1a-14ee-441a-b2af-b45b01356921": {
        "text_answer": "No  Explanation The statement persons with stage 4 cancer cannot take part in the secondary clinical trial but are fit for the primary clinical trial is not entailed by the evidence provided In fact the primary clinical trial includes patients with stage IIbIIIIV breast cancer which includes stage 4 cancer The secondary clinical trial on the other hand has specific inclusion and exclusion criteria that do not allow patients with stage 4 cancer to",
        "label": "Contradiction"
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial shows that patients in the acupuncture group had a greater reduction in mean arm circumference indicating improvement in lymphedema compared to the waitlist control group at the 6week followup This difference suggests that acupuncture patients experienced better changes in their lymphedema than those on the waiting list",
        "label": "Entailment"
    },
    "137f2083-e958-4c81-a4c8-338c90dda9c9": {
        "text_answer": "No   Explanation   The statement in the primary clinical trial a regimen of 150 mg of oral pregabalin twice daily is employed on a patient cohort on the other hand the treatment method in the secondary clinical trial involves the application of depocyt and hdmtx is not directly entailed by the evidence provided The evidence describes two separate clinical trials with different interventions The first trial involves preg",
        "label": "Contradiction"
    },
    "f693e25f-c128-48d1-883d-488248b8347d": {
        "text_answer": "No  Explanation  The primary trial describes a treatment cycle length of 21 days not 10 weeks The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1fece1ef-3bb6-407c-a09c-d615922822db": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "31b0b1db-0d40-44fe-aa76-ce3cdca8e31b": {
        "text_answer": "  No Anorexia is a medical condition characterized by a persistent lack of appetite and significant weight loss The evidence provided in the trial inclusion criteria does not mention anorexia as an eligible condition",
        "label": "Contradiction"
    },
    "fb8e290e-f73a-46e1-86b1-3a1d13eab0ab": {
        "text_answer": "No  The statement about a patient with ILDDPLD within the last 3 years being eligible for the trial is not explicitly stated in the inclusion criteria However the exclusion criteria do mention a history of interstitial lung disease or pneumonitis as a reason for ineligibility Therefore a patient with ILDDPLD who has been diseasefree for more than 3 years would be eligible for the trial according to the evidence provided",
        "label": "Contradiction"
    },
    "77c27725-099d-4d66-947c-f03e9193b6bf": {
        "text_answer": "No  Explanation  The evidence provided in the given context does not mention anything about mgmt promoter methylation testing being performed during the trials The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "text_answer": "Yes  Explanation  The statement There are less total adverse events in the primary trial than in the secondary trial is entailed by the evidence because the total number of adverse events in the primary trial 014 is less than the total number of adverse events in the secondary trial 48348  The statement but more cases of Cardiacischemiainfarction in the primary trial than",
        "label": "Entailment"
    },
    "2884c912-af96-4bac-9b0e-29f1d0876abc": {
        "text_answer": "No   Explanation   The statement does not directly relate to the interventions mentioned in the evidence The statement is about chromosome 14q132 while the evidence discusses the interventions of Yttrium90 Radioembolization ibrutinib and MEDI4736",
        "label": "Contradiction"
    },
    "f83fe0ea-4d77-4db1-a66d-eb0df033a592": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only pertains to breast cancer and its treatment and does not mention lung cancer at all",
        "label": "Contradiction"
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "text_answer": "Yes   Explanation  The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib  Docetaxel and Docetaxel  Placebo These are different drugs",
        "label": "Entailment"
    },
    "1046f15f-8bef-4d73-99a1-34ab32da6ea6": {
        "text_answer": "No  Explanation  The statement there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is not directly entailed by the evidence provided The evidence only states that there were 0 cases of shingles in the primary trial and 1 case in the secondary trial Therefore the statement is not a valid conclusion that can be drawn from the evidence alone  Regarding",
        "label": "Contradiction"
    },
    "ffbff911-ea0e-4f8b-97fd-a54b8f88007a": {
        "text_answer": "No  Explanation  The statement periodontitis is an acute or chronic inflammatory process that affects the tissues that surround and support the teeth is not related to the evidence provided The evidence only discusses two clinical trials involving breast cancer patients and their treatment regimens The statement about periodontitis is an unrelated medical condition  Regarding the statement the primary trial candidates receive less weekly MM121 and",
        "label": "Contradiction"
    },
    "1022a719-eef0-4fbe-ac15-b0398adbf45b": {
        "text_answer": "Yes  Explanation  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is entailed by the evidence since the evidence reports that there were no cases of anorexia hypothermia or hallucinations recorded in the Adverse Events sections of both trials The statement also mentions these specific conditions and the evidence supports that",
        "label": "Entailment"
    },
    "dd0571e3-088c-4dc7-a47a-175210514286": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the placebo and AlloMSCs interventions differ in their composition with the former being a buminate solution and the latter being allogeneic mesenchymal stem cells While the volume and number of injections are the same the interventions themselves are not identical The statement only mentions the dose and administration method but it does not account for the differences in the",
        "label": "Contradiction"
    },
    "e137a0db-0a15-4dd0-9fa2-3a8558c7ef0a": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide any information about the doses of ALT801 used in any trial The statement only compares the doses of PF06647020 used in the primary and secondary trials but it does not mention anything about the doses of ALT801 used in either trial Therefore it is not possible to determine",
        "label": "Contradiction"
    },
    "0cc7e297-b7df-4260-9ddf-f406bb3c2485": {
        "text_answer": "No  Explanation  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed by the evidence provided The evidence only lists the number and percentage of patients who experienced specific adverse events in each trial It does not provide information on the total number of patients in each trial or the percentage of patients who did not experience any adverse events Additionally the statement mentions",
        "label": "Contradiction"
    },
    "8c51b6e1-ee26-44a5-b63b-3c180b7dddd2": {
        "text_answer": "No  Explanation  The statement there were profound differences in the results from the groups in the primary clinical trial while the reflexology group and control group in the secondary clinical trial displayed contrasting results is not directly entailed by the evidence provided The evidence only describes the results of the primary and secondary clinical trials separately without making any direct comparison between them The statement implies a comparison between the trials which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "b3fc2b80-128b-4236-b1d5-a89b93e54b48": {
        "text_answer": "Yes some patients in the GTx024 1mg group gained lean body mass but not all of them The median change was 155 kg with a range of 206 to 1264 kg",
        "label": "Entailment"
    },
    "972a66e9-09cc-4091-8c60-fa8f458955aa": {
        "text_answer": "Yes  Explanation The evidence states that the first patient group receives 600 mgm2 of cyclophosphamide per treatment cycle while the second patient group receives 600 mgm2 of cyclophosphamide per treatment cycle as well However the first patient group receives a lower dose of eribulin 14mgm2 compared to the dose of docetaxel given to the",
        "label": "Entailment"
    },
    "5a954b09-cbc7-47dd-891c-4c998eb72979": {
        "text_answer": "No  The evidence does not provide information about which vaccines were administered to participants in cohort 1 of the primary clinical trial",
        "label": "Contradiction"
    },
    "1cbd0ac2-bfb8-4649-afea-ae028707f190": {
        "text_answer": "No  Explanation  The statement lymphedema conditions of patients in the primary clinical trial worsened compared to those of patients on the waiting list despite receiving acupuncture treatment is not entailed by the evidence The evidence only provides the mean arm circumference measurements for the acupuncture and waitlist groups at baseline and after 6 weeks of treatment It does not directly compare the changes in lymphedema between the",
        "label": "Contradiction"
    },
    "8dc6e902-3dae-4bea-ba4b-605df19fabc1": {
        "text_answer": "No  Explanation  The statement the intervention of the primary clinical trial involves the use of theraspheres for radioembolization while the secondary clinical trials intervention incorporates the use of ibrutinib and medi4736 is not directly entailed by the evidence provided The evidence only mentions that the primary clinical trial uses TheraSphere for radioembolization while the secondary clinical trial uses ibrutin",
        "label": "Contradiction"
    },
    "0f6ce079-990e-446e-95e9-8c4644291924": {
        "text_answer": "Yes The primary trial requires mammography as a mandatory inclusion criterion while the secondary trial does not explicitly mention it as a requirement in the provided inclusion criteria",
        "label": "Entailment"
    },
    "06e6eb2b-8300-413b-9c70-51fadbc68bbc": {
        "text_answer": "Yes The statement does not mention specific adverse events only that no individual adverse event affected more than one patient which is consistent with the evidence The chromosome band information is not relevant to the question",
        "label": "Entailment"
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "text_answer": "Yes  Explanation  The primary trial measures tumor response using RECIST criteria but it does not report the percentage of participants who experienced clinical benefit ie CR or PR The secondary trial measures the number of participants with AIMSS which is not related to clinical benefit using RECIST criteria Therefore neither trial directly measures clinical benefit using RECIST criteria",
        "label": "Entailment"
    },
    "fc211cd7-389a-4040-9c92-e06672257460": {
        "text_answer": "No  Explanation  The statement patients in the primary clinical trial that received paclitaxel infusions and those who didnt exhibited the same severity of symptoms is not entailed by the evidence The evidence only provides the average area under the curve aAUCpa for the EORTC ChemotherapyInduced Peripheral Neuropathy Module EORTC QLQCIPN20",
        "label": "Contradiction"
    },
    "230818a6-3a37-4bb6-933b-39a7e9a45054": {
        "text_answer": "Yes The evidence states that patients with active cancer or metastatic cancer are excluded from the clinical trial Therefore patients with detectable tumors in both breasts would not be eligible to participate",
        "label": "Entailment"
    },
    "fa510ac9-2d92-4396-a150-18dd46a31260": {
        "text_answer": "No  Explanation  The statement the primary clinical trial and the secondary clinical trial documented identical numbers of adverse events among their patient populations is not entailed by the evidence provided The evidence only states that the number of adverse events for Adverse Event 1 in the primary trial is 00 and in the secondary trial is 015 The statement makes a comparison between the total number of adverse events in both trials not just",
        "label": "Contradiction"
    },
    "6b8445e6-9bc6-4a57-ab24-05d99e082061": {
        "text_answer": "Yes The evidence states that there were 92 participants in the Paclitaxel Plus Bevacizumab Plus Gemcitabine group and 94 participants in the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "966e1258-879d-4e8d-88ec-777a743e191d": {
        "text_answer": "Yes The evidence does not report any patient in either trial with less than 3 different adverse events and the statement does not mention any specific adverse events related to the fgfr2 gene mutation",
        "label": "Entailment"
    },
    "0e57fc4c-1a5b-4f88-900e-122c03fcedb4": {
        "text_answer": "Yes  Explanation  The statement In total there are less cases of anemia in the primary trial than in the secondary trial is entailed by the evidence since the number of anemia cases in the primary trial 037 or 000 is less than the number of anemia cases in the secondary trial 275 or 267  The fgf3 gene mutation",
        "label": "Entailment"
    },
    "980fb8cd-9ba0-4bac-a2ae-0aea58c2f837": {
        "text_answer": "Yes The primary trial had 75 participants in the waitlist control group and the secondary trial had 163 participants in the device  standard of care group",
        "label": "Entailment"
    },
    "4b529950-5a15-4904-8f87-1aa68f408b8d": {
        "text_answer": "No  The statement is not entailed by the evidence as the trial only includes patients who are considering aromatase inhibitor therapy",
        "label": "Contradiction"
    },
    "f0d4e862-c9a1-48f4-9e4f-ddc67b35bbe0": {
        "text_answer": "Yes  Explanation  The statement the secondary trial and the primary trial use different outcome measurements and units of measure is entailed by the evidence as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using the unit of measure mIUml while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD using the unit of measure mg",
        "label": "Entailment"
    },
    "c2ba74e0-9674-4974-a0ea-74651dbdbbf6": {
        "text_answer": "yes the evidence suggests that patients in Arm I Cryotherapy had less worsening of symptoms higher aAUCpa compared to patients in Arm II Control However the statement goes beyond the evidence by making a claim about family cancer history which is not addressed in the provided information",
        "label": "Entailment"
    },
    "5e3fa8fd-a886-411d-8de0-fcbf6ef953fb": {
        "text_answer": "No  The statement about colon nonhodgkin lymphoma being an extranodal nonhodgkin lymphoma that arises from the colon and the secondary trial candidates not being required to be completely disabled are not directly related to the evidence provided which pertains to inclusion and exclusion criteria for two different clinical trials for breast cancer patients",
        "label": "Contradiction"
    },
    "db5cde14-102d-432e-981d-8b88ae65a830": {
        "text_answer": "No   Explanation  The statement mentions that there were 7 cases of asthenia and 2 cases of pyrexia reported in the patient cohorts of the primary and secondary clinical trials However the evidence provided only mentions the number of adverse events for each trial but it does not specify which adverse events were reported Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "fe9b1db5-8600-469a-ba9f-c0aab4630041": {
        "text_answer": "  Yes the statement is entailed by the evidence The primary trial does not specify an age range for participation and the secondary trial excludes individuals under 18 years old",
        "label": "Entailment"
    },
    "5c253fd8-303a-4b91-b21f-e7e77c30f14a": {
        "text_answer": "Yes The evidence states that there are 234 participants in cohort 1 and 241 participants in cohort 2 Therefore there are 7 more participants in cohort 2",
        "label": "Entailment"
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "text_answer": "Yes  Explanation The statement In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time is entailed by the evidence as both interventions are given twice daily BID for a duration of 81 days in the absence of unacceptable toxicity and the trial lasts for 12 weeks",
        "label": "Entailment"
    },
    "9fad2ea9-39ad-4c5b-afbe-82d9c40dbeee": {
        "text_answer": "No  Explanation  The statement Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial and neither trial includes morbidly obese or pregnant patients as eligible participants",
        "label": "Contradiction"
    },
    "c7037258-f24b-40dd-9ce8-5026b019bfbe": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8ffc6641-8eb9-4e6d-8926-0356539e0ba6": {
        "text_answer": " No   Explanation  The evidence describes two separate clinical trials one for Glioblastoma Multiforme and another for Gynecological Cancers In both trials participants undergo imaging using 18FFDG and 18FFPPRGD2 However the statement in question mentions 18ffet petct and 18ffmiso petct which are",
        "label": "Contradiction"
    },
    "11f26a4a-7ff7-4cbd-b5c7-b95cfea182df": {
        "text_answer": "No  The statement is not entailed by the evidence as there are no cases of acute myocardial infarction reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "169ae179-8a24-4f8f-82b6-47ed449d8e2e": {
        "text_answer": "yes the statement is entailed by the evidence as the primary trial is about childhood cancer gliosarcoma and evaluates treatmentemergent adverse events while the secondary trial is about a different treatment Lenalidomide and measures total sleep time in minutes",
        "label": "Entailment"
    },
    "9b0c9133-a13c-4687-bf43-546312ce1a2f": {
        "text_answer": "No  The statement is not entailed by the evidence The evidence only pertains to patients with breast cancer who have received hormonal treatment and have had their condition progress despite it",
        "label": "Contradiction"
    },
    "8c2ec196-18f6-4a3f-b2fd-6eb6f65d1c60": {
        "text_answer": "No  Explanation  The statement for entry into the primary clinical trial participants are required to possess a resistance to both ai therapy and mirtazapine however this requirement is not present for inclusion in the secondary clinical trial is not entailed by the evidence provided The primary clinical trial and secondary clinical trial have different inclusion and exclusion criteria The primary clinical trial requires participants to be resistant to aromatase inhibitors AI while the",
        "label": "Contradiction"
    },
    "f0e6f9c3-4f87-4a91-af2e-9bb7cc2de985": {
        "text_answer": "Yes  Explanation The primary clinical trial and the secondary clinical trial involve different pharmacological interventions In the primary trial the interventions include Abl Cells IV  Cyclophosphamide with different doses and phases of Cyclophosphamide In contrast the secondary trial involves the use of DMCHOCPEN with different doses for patients with and without liver involvement Therefore the statement that the primary and secondary clinical trials each",
        "label": "Entailment"
    },
    "4c4e621c-abe5-4a19-b517-31778992b424": {
        "text_answer": "No  Explanation  The evidence states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced an overall tumor response either CR or PR The statement however claims that no patients experienced a CR or PR These two pieces of information contradict each other so the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b6084ccd-2ece-4e27-b783-64ade24880bb": {
        "text_answer": "No  Explanation  The statement retinopathy of prematurity stage 2 intraretinal ridge is an ophthalmoscopic finding that references retinopathy of prematurity characterized by the presence of an elevated ridge is not directly related to the evidence provided in the primary trial The evidence only describes the interventions and treatment schedules for two cohorts in a clinical trial for pancreatic cancer There",
        "label": "Contradiction"
    },
    "5e74a97b-ae6e-478b-bcf1-f681159ea1f7": {
        "text_answer": "No  Explanation  The evidence provided in the results 1 does not give the number of participants who experienced a confirmed complete response CR in the Lapatinib 1000 mg  NabPaclitaxel armgroup It only states that 53 out of 60 participants were analyzed in this armgroup Therefore the statement over 05 patients in the primary trial treated with lapatinib ",
        "label": "Contradiction"
    },
    "bd8a6fc5-ffc7-460f-a82c-9656047eafbc": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only reports the percentage of participants in each group of the primary trial who demonstrated a decrease in the growth factor signature GFS after receiving a single dose of dalotuzumab 20 mgkg The statement on the other hand makes a comparison between minimally invasive lung nonmucinous adenocarcinoma and a specific",
        "label": "Contradiction"
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "text_answer": "No  Explanation  The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify the tumor size However the primary trial only includes patients with primary breast cancer while the secondary trial includes patients with locally advanced or metastatic breast cancer The statement does not mention the disease stage or the presence of metastases Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "af5daeb0-69f5-4d1c-93a5-7a76dfb4b5e7": {
        "text_answer": "No  The evidence describes two different interventions in the primary clinical trial one involving an educational DVD and a lay health advisor and the other involving usual care without the DVD or lay health advisor The statement refers to a different cohort cohort 2 and a different intervention viewing the educational DVD instead of receiving a regular dosage of radiotherapy which is not described in the evidence",
        "label": "Contradiction"
    },
    "09af4485-0e64-4a6c-83d3-1e7231151faa": {
        "text_answer": "No  Explanation The evidence provided in the primary clinical trial results does not mention the number of participants in the first cohort who had maintained regular cervical cancer screenings prior to the intervention The evidence only provides the percentage of participants with uptodate screenings before and after the intervention for both cohorts",
        "label": "Contradiction"
    },
    "3647e40b-92d1-4e99-aedf-8416c91576c8": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions in the primary clinical trial make use of laserassisted fluorescence angiography and lateral radial incisions",
        "label": "Entailment"
    },
    "54f0a585-98f8-49c2-a6b3-2700b3fc19ff": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "269ac84f-d5a9-475f-8c43-361a6cdb5225": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures the change in units on a scale for the severity of vaginal symptoms while the secondary clinical trial measures the percentage of participants with objective response rate for HER2negative metastatic breast cancer Neither trial uses cm participant count or time unit as their measurement units",
        "label": "Entailment"
    },
    "92639a0e-c3b4-4057-8bb5-aeaf1d60c39b": {
        "text_answer": "Yes The evidence does not report any unexpected deaths or hospital stays in either trial",
        "label": "Entailment"
    },
    "b36dca2b-8c53-4f4d-b956-0d86194d2d2d": {
        "text_answer": "No  Explanation  The statement diarrhea was equally common in both primary and secondary clinical trial participants is not entailed by the evidence The primary trial had 7 cases of diarrhea out of 30 participants 2333 while the secondary trial had 0 cases out of 6 participants 000 Therefore the frequency of diarrhea was not equal in both trials",
        "label": "Contradiction"
    },
    "4d604e71-ced3-43a1-baf7-276573a3a901": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about religious matters for the patients in cohort 1 and 2 The evidence only mentions the radiation therapy interventions and the SPECT scan followups for both cohorts",
        "label": "Contradiction"
    },
    "c7320872-347d-445f-a939-9554e7ee9973": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence because both cohorts receive the same dose of CUDC101 275 mgm2 even though they receive it on different schedules 5 daysweek for cohort 1 and 3 daysweek for cohort 2",
        "label": "Entailment"
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "text_answer": "Yes  Explanation  The primary trial includes the Karnofsky performance status KPS as an inclusion criterion with a minimum score of 70 The secondary trial uses the Eastern Cooperative Oncology Group ECOG performance status PS as an inclusion criterion with a minimum score of 2 Although different performance status scoring systems are used both trials require candidates to meet a baseline performance status",
        "label": "Entailment"
    },
    "81d8da2f-add7-4c32-bc69-8eb22266f71e": {
        "text_answer": "Yes  Explanation The statement the first cohort of the primary clinical trial didnt document any adverse events is entailed by the evidence Adverse Events 1 Total 0147 000 The evidence indicates that there were no adverse events in the first cohort of the trial which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "89c76808-d0fb-4c78-8364-344d6b65754b": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as both study groups GBM and Gynecological Cancers undergo 18FFDG and 18FFPPRGD2 PETCT imaging procedures",
        "label": "Contradiction"
    },
    "d2057876-3991-462d-b5fd-de01cc252790": {
        "text_answer": "  Yes   Explanation   The statement cohort 2 of the primary clinical trial is not given additional treatment cycles of docetaxel doxorubicin and cyclophosphamide is entailed by the evidence as per the given intervention 2 in the primary trial where cohort 2 only receives Herceptin after the initial 4 cycles of AC chemotherapy",
        "label": "Entailment"
    },
    "d5786123-b433-4fdd-abad-4410de2695c9": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f49abd8e-7440-40ec-a512-c2420c9a207b": {
        "text_answer": "No   Explanation   The statement is not directly related to the inclusion and exclusion criteria for the primary trial The statement is about a specific type of uterine neoplasm mixed endometrial stromal and smooth muscle neoplasm and its exclusion from the trial is not mentioned in the evidence The evidence only mentions the types of breast cancer and lymphedema that are included or excluded from the trial",
        "label": "Contradiction"
    },
    "373d0081-e7cf-4a06-bdd0-b58bcd4fe34c": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the evidence clearly describes the interventions that participants in the clinical trial will receive which include injections of dendritic cells GMCSF and trastuzumab",
        "label": "Contradiction"
    },
    "c158ee0a-2ff1-483d-a906-6dcbb76fae47": {
        "text_answer": "Yes  Explanation The primary clinical trial involves administering pembrolizumab every 3 weeks Q3W while the secondary clinical trial involves administering sunitinib once daily Therefore the frequency of pembrolizumab administration is twice that of sunitinib administration",
        "label": "Entailment"
    },
    "dee869cc-6f3c-45a5-9672-d8ab6a545212": {
        "text_answer": "13 not 1  Explanation The statement only 1 of the patients in the primary clinical trial dealing with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab results in her2 metastases is not entirely entailed by the evidence The evidence states that 13 of the participants in the HER2targeted PETCT arm",
        "label": "Entailment"
    },
    "a6dd31e3-d055-4343-9d7f-8d141f7c7007": {
        "text_answer": "No  Explanation  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed by the evidence provided The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide",
        "label": "Contradiction"
    },
    "ae134e5a-97f7-4c42-9135-ea44d3d45939": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence only compares the changes in lymphedema between the acupuncture group and the waitlist control group at 6 weeks and does not provide any information about vestibulocochlear nerve disorders",
        "label": "Contradiction"
    },
    "3ebd71b1-9b66-438a-9623-27aaf0725786": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity mental conditions or gender as eligibility criteria for the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "466321f2-f997-47c7-a166-faeffe581547": {
        "text_answer": "No   Explanation   The statement response table is a table of data specifically regarding response The primary trial administers its intervention sublingually and the secondary trial administers it orally is not directly entailed by the evidence provided The evidence only mentions the interventions and their administration routes in the two trials but it does not specify that there will be a response table or what the table will contain",
        "label": "Contradiction"
    },
    "aadd13d6-3100-41ef-947f-6b29d3118d67": {
        "text_answer": "No  The evidence does not provide any information about bodyweight requirements for the clinical trial",
        "label": "Contradiction"
    },
    "5a515d1f-131f-4dc9-9179-97f41957904a": {
        "text_answer": "Yes The statement is not entailed by the evidence for the primary clinical trial as the primary trial requires participants to be resistant to aromatase inhibitors However the statement is entailed by the evidence for the secondary clinical trial as it does not mention aromatase inhibitor resistance as a requirement for participation",
        "label": "Entailment"
    },
    "b3a79047-9f6a-43d4-88e6-8c8a26b3a47f": {
        "text_answer": "Yes  Explanation  The statement only patients within cohort 1 had cases of infections and infestations in the primary clinical trial is entailed by the evidence because the evidence shows that all cases of infections and infestations specifically Gramnegative bacteremia with a fever of 40 degrees Celsius occurred in cohort 1 and there were no such cases in cohort 2",
        "label": "Entailment"
    },
    "d42bd39b-e72e-418b-bd8a-6f1769fde12d": {
        "text_answer": "Yes The evidence includes the Karnofsky score as an inclusion criterion with a minimum requirement of 60",
        "label": "Entailment"
    },
    "36aac65a-5d56-4abd-b278-e9e3de78d480": {
        "text_answer": "Yes  Explanation The statement patients take oral medicine on a twice daily schedule for the duration of one month is an implication of the evidence as it describes the administration frequency and duration of both lapatinib ditosylate and tamoxifen citrate in the clinical trial",
        "label": "Entailment"
    },
    "1a1826f4-79d9-4df0-a8d8-fe9c3d75d783": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration whereas patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial is not directly entailed by the evidence provided  The evidence only mentions the dosing schedules for Alpha Lipoic Acid in the primary",
        "label": "Contradiction"
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "text_answer": "  No   Explanation   The statement Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is not entailed by the evidence provided   The primary trial includes patients with NUT midline carcinoma as an eligible diagnosis but the secondary trial does not Inflammatory breast",
        "label": "Contradiction"
    },
    "8719ae55-97f1-4d19-8e9c-85c086898291": {
        "text_answer": "Yes The evidence shows that the percentage of participants who were up to date with colorectal breast and cervical cancer screenings increased after the intervention in both groups but the baseline percentages were relatively low and the followup percentages were higher However the statement focuses on the trend of falling behind in screening schedules which is implied by the data presented",
        "label": "Entailment"
    },
    "0428ab54-eddd-4ee8-a58f-45ec7d7630f7": {
        "text_answer": "No  Explanation The evidence provided in the text only reports the median aAUCpa for each group but it does not directly compare the difference between the two groups The statement patients in the primary clinical trial who did not receive topical cryotherapy reported symptom improvement compared to those receiving cryotherapy is not entailed by the evidence as it goes beyond the information provided in the text",
        "label": "Contradiction"
    },
    "a4c5aecb-d375-43b7-bee0-dea9651fb7d6": {
        "text_answer": "Yes  Both trials use the unit of measure cm for tumor diameter and cm for tumor diameter from patient scans  The secondary trial also uses the unit of measure participants for the number of participants with solid tumor response",
        "label": "Entailment"
    },
    "7d36e2e7-cf12-4281-8db5-2c30f23b427b": {
        "text_answer": "  The statement is not entailed by the evidence as it adds information not present in the exclusion criteria for the secondary trial regarding chemotherapy and radiotherapy The statement allows for participation in the primary trial for patients who have received chemotherapy or radiotherapy within 2 weeks but the evidence only states that such patients are excluded from the secondary trial The statement also mentions unstable angina as an exclusion but it is not listed in the evidence The statement about neurop",
        "label": "Contradiction"
    },
    "cc177dab-2d93-40dd-8b7f-ac1755325605": {
        "text_answer": "Yes The evidence states that patients with stage 4 breast adenocarcinoma that is ER positive PR positive or HER2neu negative are eligible for participation in both the primary and secondary clinical trials",
        "label": "Entailment"
    },
    "c7f3e0a2-44e0-4da9-a3ac-665d3e80f111": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "51ea9225-4ef8-4bf6-878a-2476cb59b916": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases Therefore 77 of the 13 participants 10 participants had HER2 metastases",
        "label": "Entailment"
    },
    "d88d1ea7-3d60-4234-896b-2060dee299f7": {
        "text_answer": "Yes  Explanation The evidence states that cohort 1 practices paced breathing for 15 minutes once daily while cohort 2 practices paced breathing for 15 minutes twice daily However both cohorts follow the same instructional compact disc CD and practice for the same number of minutes per session 15 minutes and days per week 57 days Therefore the statement that both cohorts follow different",
        "label": "Entailment"
    },
    "920775c5-aa23-4be9-8aa1-241ecef90b51": {
        "text_answer": "No  Explanation  The statement group 2 of the primary trial does not receive any dosage of dexmedetomidine while patients in the secondary trial are given 1ugkg of dexmedetomidine is not directly entailed by the evidence provided The primary trial only mentions two interventions normal saline and dexmedetomidine and their respective dosages The secondary trial mentions",
        "label": "Contradiction"
    },
    "bfeb1617-a5a5-40f7-8f09-f20c40a4cee0": {
        "text_answer": "Yes  Explanation The statement paternal half sibling is a relative with whom you share a biological father but you have different mothers is not directly related to the evidence provided However the statement All the primary trial participants receive lower doses of drugs than the secondary trial participants is a fact that can be inferred from the evidence The primary trial involved the use of PF06647020 at doses of ",
        "label": "Entailment"
    },
    "24480821-2a6d-4359-bfb8-348ca85dffbb": {
        "text_answer": "Yes The evidence does not report any results for the LBH589 and Lapatinib cohort",
        "label": "Entailment"
    },
    "9313b787-6fe7-4eb7-93cb-13ce8cfe92f0": {
        "text_answer": "No  Explanation The statement every patient in the primary clinical trial who received 1mg of gtx024 experienced an increase in lean body mass over four months is not entailed by the evidence The evidence only provides the median change in lean body mass for the group of patients who received 1mg of gtx024 which ranges from a decrease of 206 kg to an increase of 126",
        "label": "Contradiction"
    },
    "f48fabb1-f814-4f89-acf9-7ff95948b8d9": {
        "text_answer": "Yes  Explanation The evidence states that out of 25 participants who were treated with sunitinib  docetaxel  trastuzumab 24 experienced adverse events AEs and 11 experienced serious adverse events SAEs Therefore all but one participant experienced adverse events and less than half experienced serious adverse events",
        "label": "Entailment"
    },
    "0ef3e1a1-d303-46de-8940-07746737fe87": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the evidence only mentions ER positive and HER2 negative breast cancer as one group and invasive triplenegative breast cancer as another group It does not mention ER negative PR negative and HER2 negative breast cancer as a group Therefore the statement goes beyond the information provided in the evidence",
        "label": "Contradiction"
    },
    "3c2830d4-9341-4c0d-8ed3-51eb47d2cd17": {
        "text_answer": "No  The statement is not entailed by the evidence as there were no reported cases of cholelithiasis in either trial",
        "label": "Contradiction"
    },
    "e2fcdf94-c0b2-4d75-a40d-2c2ec8200208": {
        "text_answer": "Yes The evidence does not report any patient experiencing the worst pain imaginable for 10 weeks",
        "label": "Entailment"
    },
    "e9146895-e9b0-49cb-b05e-9264b682cece": {
        "text_answer": "Yes  Explanation The statement adverse events were reported by fewer than 5 of the participants in the primary clinical trial is entailed by the evidence as the total number of adverse events reported was 2 and the number of participants was 35 resulting in a percentage of 571 which is less than 5",
        "label": "Entailment"
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "text_answer": "Yes The evidence does not report any cases of Febrile neutropenia or Cholelithiasis in either trial",
        "label": "Entailment"
    },
    "a74afb52-7b03-4c41-b57b-7473ef025c18": {
        "text_answer": "  No   Explanation   The statement nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer patients identified through fluorescence in situ hybridization are eligible for participation in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided   The primary clinical trial has specific inclusion and exclusion criteria for various types of cancer including NUT",
        "label": "Contradiction"
    },
    "5acf1755-279a-400a-9a2e-c71daaeeab0d": {
        "text_answer": "No  Explanation  The statement play doubles tennis is not related to the given evidence The evidence only provides information about the dosing regimens of Epacadostat and Sunitinib in two different clinical trials The statement does not follow logically from the evidence",
        "label": "Contradiction"
    },
    "87f63f2e-5648-4b9f-9f25-a5adb80dcb1d": {
        "text_answer": "No  Explanation  The statement 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 03 of patients is not entailed by the evidence  The evidence states that there were no adverse events in the primary trial which is consistent with the statement However the statement goes on to claim that none of the adverse events in the secondary trial affected more than",
        "label": "Contradiction"
    },
    "65ef313d-74d5-4e56-a6c8-6a3768774a55": {
        "text_answer": "Yes The statement is entailed by the evidence as the interventions are administered through different routes intravenous for bisphosphonate and subcutaneous for denosumab",
        "label": "Entailment"
    },
    "51a15c75-5a89-48c3-a93d-4f464e915ba2": {
        "text_answer": "Yes  Explanation The statement There was one psychiatric adverse event in the primary trial which affected less than 10 of patients is entailed by the evidence as it mentions 150 200 suicidal ideation which is a psychiatric adverse event that affected less than 10 of patients The coordinating committee is not directly related to the statement or evidence",
        "label": "Entailment"
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not mention claustrophobia in relation to the primary or secondary trials However women with osteoporosis are excluded from the primary trial",
        "label": "Contradiction"
    },
    "25f963fe-42f5-4294-9489-17d8fd17b4f2": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "caab457d-0650-4010-9d8e-4c8e474070ff": {
        "text_answer": "No  Explanation  The statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia is not directly entailed by the evidence provided The evidence only lists the number of adverse events for each condition in each cohort but it does not specify that there were several cases of Anaemia and",
        "label": "Contradiction"
    },
    "e12077dc-2ef2-4276-b755-4664b0a0f0ea": {
        "text_answer": "No  Explanation  The statement every member in both the primary and secondary clinical trials is given entericcoated tablets is not entailed by the evidence In the primary trial Group A received Botulinum Toxin Type A injections and Group B received placebo injections In the secondary trial participants received MLN8237 tablets but the evidence does not specify that they were entericcoated",
        "label": "Contradiction"
    },
    "5a91060d-576b-405f-a8a6-c74cc3c24c62": {
        "text_answer": "No  Explanation The statement over 70 of the participants had a decrease in circulating tumor cells despite not receiving any form of chemotherapy is not entailed by the evidence provided The evidence only reports the results of the Highdose Chemotherapy arm of the trial which includes Carboplatin Cyclophosphamide and Thiotepa It does not mention any participants not receiving chemotherapy and their circul",
        "label": "Contradiction"
    },
    "7febdcf0-e8ff-4511-a96b-c160e3dd127e": {
        "text_answer": "Yes  Explanation  The statement in comparison to the primary clinical trial the secondary clinical trial had a significantly higher number of patients who experienced AEs is entailed by the evidence because the secondary clinical trial had a higher percentage 6000 of patients who experienced Adverse Events 1 compared to the primary clinical trial which had no occurrences 000",
        "label": "Entailment"
    },
    "42dca69f-0e7b-4945-9123-90e576db8c25": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial involves denosumab injections while the secondary trial involves intraoperative procedures with gamma cameras and probes neither of which involve injections of selumetinib",
        "label": "Contradiction"
    },
    "65dbfec2-08fb-4853-9e50-79ec4c97500f": {
        "text_answer": "No  The statement is not entailed by the evidence as the clinical trial is for metastatic invasive breast cancer patients only and ILDDPLD is a different type of disease",
        "label": "Contradiction"
    },
    "7b71a3ac-e8b3-4e8f-ac95-c3dfe88676d5": {
        "text_answer": "No  Explanation  The statement 203 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for one type Adverse Events 1 in each trial Therefore it is not possible to determine the total number of adverse events observed in the primary trial based on the given evidence  Additionally the statement none of the adverse events in the secondary",
        "label": "Contradiction"
    },
    "44b1585a-3a5f-4ff7-a523-04923546b2c0": {
        "text_answer": "No  Explanation The evidence only states that some patients received MCS110 at a dose of 1 mgkg every 3 weeks and PDR001 at a dose of 100 mg every 3 weeks It does not mention any instances where MCS110 was given more frequently than every 3 weeks Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d21d3871-d8c2-4a0a-b99f-291a721a1a18": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures tumor diameter in centimeters cm while the secondary clinical trial measures the number of participants with solid tumor response These are distinct units of measurement The statement in the question acknowledges this distinction and is entailed by the evidence provided",
        "label": "Entailment"
    },
    "a1cf2da3-a2a8-4fa1-9812-5f50a75994ad": {
        "text_answer": "No  Explanation  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is not directly entailed by the evidence provided The evidence only shows the frequency of adverse events in the primary and secondary trials but it does not compare the types or categories of adverse events between the two trials The statement makes a comparison between the types of adverse events",
        "label": "Contradiction"
    },
    "1b3e5b01-1b05-4025-9100-2c6e6e7faf20": {
        "text_answer": "Yes  Explanation The evidence shows that the percentage of participants with invasive diseasefree survival events was 47 in the Neratinib group and 75 in the Placebo group at year 2 This means that the Neratinib group had a lower rate of invasive diseasefree survival events compared to the Placebo group Therefore the statement the neratinib group in the primary clinical trial exhibited a",
        "label": "Entailment"
    },
    "efe8b336-1781-4777-a1a0-fe34c59c63ab": {
        "text_answer": "No   Explanation  The statement is not directly related to the evidence provided The evidence only discusses the results of a clinical trial regarding the effectiveness of a psychoeducational intervention on pain management in cancer patients The statement is about the Alzheimers Disease Assessment ScaleCognitive ADASCOG delayed word recall task Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "0e7c3f86-cbc8-478d-b89c-1f75b53323fe": {
        "text_answer": "No   Explanation The evidence provided does not give the length of PFS for the patient with the longest PFS in the primary trial The evidence only gives the median PFS for each treatment group",
        "label": "Contradiction"
    },
    "dc8fb0ce-165a-4d79-afb2-25a85f7c40b6": {
        "text_answer": "No  Explanation  The evidence provided in the given trial results does not support the statement that the LBH589 and lapatinib cohort delivered better outcomes than the LBH589 with capecitabine group The evidence only shows that there is no data available for the comparison of the two groups in terms of outcomes The trial was designed to determine the maximum tolerated doses MTD and doselimiting",
        "label": "Contradiction"
    },
    "bb0cf2c6-fbb2-4ca2-9f44-9ae8c5a9f63e": {
        "text_answer": "No  Explanation  The statement in the question makes a comparison between the number of drugs administered and the procedures undergone in the primary and secondary trials but it also incorrectly states that the participants in the primary trial receive a drug by subcutaneous injection that is not mentioned in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ed8ee6d6-5a37-4338-af72-e87bb50ec4d9": {
        "text_answer": "No   Explanation  The statement a majority of individuals in the primary clinical trial demonstrated complete response in a span of 24 weeks is not entailed by the evidence The evidence shows that at Week 12 there were 0 participants with complete response and at Week 24 there were also 0 participants with complete response Therefore no participant in the trial demonstrated complete response in a span of 24 weeks The evidence",
        "label": "Contradiction"
    },
    "fbd6b437-ba96-46fd-933f-8299e0efb0e5": {
        "text_answer": "Yes The statement is entailed by the evidence as the number of participants in the vaccine arm of the trial is stated as 13",
        "label": "Entailment"
    },
    "1cbc4e95-3407-4aab-bb7d-ba3abd1882f3": {
        "text_answer": "No  Explanation The statement is not directly related to the evidence provided in the trial results The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 for a specific treatment regimen The statement is about an individuals feelings towards their breasts and their partner",
        "label": "Contradiction"
    },
    "4f45090f-0954-43a7-9f56-60c5283459bd": {
        "text_answer": "No  Explanation  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is not entailed by the evidence provided The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial requires participants to be resistant to AI therapy and mirtazapine while the secondary trial does not mention these requirements",
        "label": "Contradiction"
    },
    "b20dadde-0f33-42ca-aa3e-c9333cdffe89": {
        "text_answer": "No  Explanation  The statement there was a higher incidence of serious adverse reactions documented in the adverse events portion of the primary clinical trial as compared to the secondary clinical trial is not entailed by the evidence provided The evidence only states that there were no serious adverse reactions documented in the adverse events portion of both trials Therefore it is not possible to make a comparison of incidence between the two trials based on the given evidence alone",
        "label": "Contradiction"
    },
    "12586895-bb1c-4772-ab01-94163d0393ab": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the most common adverse event in the secondary trial was anaemia which affected 234 of patients not more than 999 of patients Additionally there were no recorded adverse events in the primary trial so it is not accurate to say that there were no recorded adverse events affecting more than 999 of patients",
        "label": "Contradiction"
    },
    "2758e742-d065-4813-bfd2-881fe16826bd": {
        "text_answer": "No  The statement is not entailed by the evidence as it adds an additional requirement ER or PR positivity that is not mentioned in the inclusion criteria",
        "label": "Contradiction"
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "text_answer": "No  Explanation  The statement Hypokalemic patients are excluded from the primary trial but hyperkalemic patients may be eligible for the secondary trial and the primary trial is not entailed by the evidence provided  The primary trial exclusion criteria include a potassium level within the abnormal range of less than 35 mEqL However the evidence does not mention anything about hyperkalemia or its eligibility",
        "label": "Contradiction"
    },
    "a198b3a9-ee15-4f4a-b587-d6ddb86efa73": {
        "text_answer": "yes the statement is entailed by the evidence as both trials involve exposure to radiation However its important to note that the interventions themselves are different",
        "label": "Entailment"
    },
    "0f434232-d1a2-4d35-a49c-dd52c8353b9f": {
        "text_answer": "No   Explanation  The statement the majority of patients in the primary trial experienced complete response by month 24 is not entailed by the evidence According to the evidence there were no participants with complete response CR at Week 12 or Week 24 Instead the majority of participants had stable disease SD at both time points",
        "label": "Contradiction"
    },
    "22b968d1-4ffd-4562-aeb0-e1e022212b08": {
        "text_answer": "No  Explanation  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed by the evidence provided The evidence only reports the number of participants and the presence or absence of lesions in the primary trial and the number",
        "label": "Contradiction"
    },
    "116c9dea-44ba-402e-8948-67ee9bb4f942": {
        "text_answer": "No  Explanation The statement Both cohorts of the primary trial receive the same doses of Abraxane is true as both arms of the trial administered the same dose of nabPaclitaxel 125 mgm2 However the statement does not mention anything about the doses of Carboplatin or Gemcitabine which are different between the two arms Additionally the",
        "label": "Contradiction"
    },
    "bea08563-704d-4475-9dbd-d7617d1a6a63": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial are studying the same drug in different doses and with a different outcome measurement is entailed by the evidence as both trials involve the use of empegfilgrastim a drug being tested in different doses and with different outcome measurements in each trial",
        "label": "Entailment"
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "text_answer": "Yes The evidence does not mention any vaccines being administered to the participants",
        "label": "Entailment"
    },
    "a9aae47f-ecbe-49ea-983b-73c8b6a95506": {
        "text_answer": "Yes The statement there were zero adverse instances recorded in the primary clinical trial while in the secondary clinical trial the number of patients who were affected by any such instances did not exceed 30 is entailed by the evidence provided The evidence shows that there were no adverse events in the primary trial and the total number of adverse events in the secondary trial was 10 out of 30 patients which is less than 30",
        "label": "Entailment"
    },
    "dcad8706-4bfe-4076-9bd5-babca4f63beb": {
        "text_answer": "No  The statement is not entailed by the evidence The statement implies that there were adverse events in the primary trial for 50 of participants and in the secondary trial for 110 but the evidence only reports the number of adverse events not the number of participants who experienced them",
        "label": "Contradiction"
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "text_answer": "Yes  Explanation  The statement the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients is entailed by the evidence as the primary trial does have different inclusion and exclusion criteria for its Phase I and Phase II portions and the secondary trial does have separate criteria for healthy and cancer patients",
        "label": "Entailment"
    },
    "d3630897-ec5d-4c22-b2cd-5a8355dfdd88": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials include patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma as inclusion criteria",
        "label": "Entailment"
    },
    "9367299b-070b-4902-b857-bca1c45b6fd1": {
        "text_answer": "Yes  Explanation The statement detailed information about the administration procedure dosage and treatment cycle is available in the intervention section of the primary clinical trial is entailed by the evidence as it mentions that the detailed information can be found in the intervention section of the trial",
        "label": "Entailment"
    },
    "186e198a-63dc-4ac9-8ae0-7790f32ec792": {
        "text_answer": "yes  Explanation The statement is entailed by the evidence as the primary trial involves a higher dose of MM121 20 mgkg weekly and Paclitaxel 80 mgkg weekly compared to the HR subgroup in the secondary trial which only receives Paclitaxel 80 mgkg weekly The evidence also indicates that the HR subgroup in the secondary trial does not receive Her",
        "label": "Entailment"
    },
    "65910ca9-d27b-4350-9213-1cb7aea575a2": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence does not mention any exclusion criteria based on mental health bodyweight tumour size karnofskyecog score or estimated life expectancy",
        "label": "Entailment"
    },
    "50d67398-cd3f-4d6e-afeb-419ae6f64c0d": {
        "text_answer": "No  The primary clinical trial is not suitable for those with triple positive breast cancer as it only includes those with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2",
        "label": "Contradiction"
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "text_answer": "Yes  Explanation  The statement 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 30 of patients is entailed by the evidence provided The evidence states that there were no adverse events in the primary trial and the secondary trial had adverse events that affected less than 30 of patients for all events except diarrhea which affected 23",
        "label": "Entailment"
    },
    "e74e47e7-4627-4dd9-aedd-cbc5b5cdd669": {
        "text_answer": "No  Explanation  The statement mucositis oral bladder infection and thromboembolic events were seen more often in the secondary clinical trial than they were in the primary clinical trial is not entailed by the evidence The evidence shows that none of these adverse events were reported in the secondary trial while they were reported in the primary trial for mucositis oral 133 and thromboem",
        "label": "Contradiction"
    },
    "b464cd26-7734-455c-85c1-04a4ec324c55": {
        "text_answer": "No   Explanation   The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial is not an exact statement from the evidence   The evidence does state that patients who have undergone antineoplastic chemotherapy with the exception of antiHER2 agents are excluded from the study",
        "label": "Contradiction"
    },
    "22031bc7-9954-4b2b-b905-a5d34e0eea98": {
        "text_answer": "Yes The evidence states that 13 of participants with HER2primary breast cancer developed imagable HER2 metastases during the 3year followup period after undergoing HER2targeted PETCT using 89Zrtrastuzumab",
        "label": "Entailment"
    },
    "3b29fe26-bf01-4e85-aa0e-33e83b1db660": {
        "text_answer": "  Yes the statement is entailed by the evidence regarding the primary clinical trial but it does not directly address the secondary clinical trial However the secondary clinical trial also includes the exclusion of patients with a history of thrombotic or embolic events within the past 6 months which could potentially include pulmonary embolisms",
        "label": "Entailment"
    },
    "8183a43e-0284-483d-a22c-08502b0ebc8a": {
        "text_answer": "No  Explanation The statement The patient with the longest PFS in the primary trial was in cohort 1 and he survived 35 months without disease progression or death is not directly entailed by the evidence provided The evidence only reports the median PFS for each cohort Capecitabine 28 months 95 CI 16 to 32 CD",
        "label": "Contradiction"
    },
    "f5cb1b5d-53b5-464b-a160-17cd59481705": {
        "text_answer": "No  Explanation  The statement cohort 1 in the primary clinical trial is treated with an injection of fluciclatide while the same cohort in the secondary clinical trial receives a standard chloroquine dose is not entailed by the evidence In the primary clinical trial cohort 1 is treated with an injection of fluciclatide while in the secondary clinical trial there are two cohorts",
        "label": "Contradiction"
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "text_answer": "Yes  Explanation The evidence provided in the primary trial interventions clearly states that neither arm A nor arm B uses paclitaxel as part of their intervention Therefore the statement Paclitaxel is not used in either of the primary trial interventions is entailed by the evidence",
        "label": "Entailment"
    },
    "d47eb708-7ca4-4894-bc28-e276e61c0333": {
        "text_answer": "Yes  Explanation The evidence provided in the primary clinical trial description does not mention any vaccines being administered to the participants Therefore the statement that the primary clinical trial does not involve administering any vaccines to the participants is entailed by the evidence",
        "label": "Entailment"
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "text_answer": "Yes The primary trial does not exclude patients with cerebral metastases within the brainstem but the secondary trial does",
        "label": "Entailment"
    },
    "70cd062f-8f49-47ac-80c0-d3608a574517": {
        "text_answer": "Yes The primary trial and secondary trial have different outcome measurements TEAEs vs objective response but they both involve the administration of the same intervention SG or talazoparib The h33a gene mutation is not mentioned in the evidence",
        "label": "Entailment"
    },
    "01593a0d-0547-4ed6-8ad6-6c5ecdbeb74a": {
        "text_answer": "No   Explanation  The evidence describes two different interventions each with a different administration route intravenous bisphosphonate and subcutaneous denosumab Therefore the statement that only one type of route is used for administering interventions in the primary clinical trial is not entailed by the evidence",
        "label": "Contradiction"
    },
    "edb0a92a-08c0-4083-864e-26d845000fa6": {
        "text_answer": "No  The statement is not entailed by the evidence as the Phase 1 trial is open to both male and female patients with locally advanced andor metastatic solid tumors The Phase 2 trial has specific eligibility criteria for breast cancer SCLC squamous cell cancers of the head and neck associated with HPV and other solid tumor types",
        "label": "Contradiction"
    },
    "52c84a93-a09f-47b5-b928-385830350390": {
        "text_answer": "No  The statement is not about the primary trial evidence provided The statement is about an intragastric balloon procedure which is not mentioned in the evidence The evidence only discusses two interventions for breast surgery using laserassisted fluorescence angiography",
        "label": "Contradiction"
    },
    "32c2dfce-b209-49f3-9f03-5e39b97b18c4": {
        "text_answer": "Yes The evidence states that patients with histologically proven DCIS are eligible for the clinical trial",
        "label": "Entailment"
    },
    "7064d383-b7a5-44a0-a9aa-3fae7b7ded9c": {
        "text_answer": "No  Explanation  The statement dont really enjoy food is not directly related to the evidence provided The evidence only reports the occurrence of adverse events in two clinical trials and there is no mention of individuals enjoyment of food",
        "label": "Contradiction"
    },
    "c958d134-cecd-4212-9043-bc1d5131d555": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement is about colon cancer while the evidence is about breast cancer",
        "label": "Contradiction"
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "text_answer": "Yes  Explanation  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE is entailed by the evidence since the evidence shows that no participants in either trial suffered from any adverse event",
        "label": "Entailment"
    },
    "54c35538-e933-40b0-bf84-299e0b291ef3": {
        "text_answer": "Yes  Explanation  The statement infections and fever cases in the primary clinical trial were exclusively observed in patients of the first cohort is entailed by the evidence because the adverse events of infections and fever specifically Gramnegative bacteremia with a fever of 40 degrees Celsius were observed in patients of the first cohort in both sets of data Adverse Events 1 and Adverse Events 2 but",
        "label": "Entailment"
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial measure different outcomes The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel The statement provided is not related to the outcome measurements in either trial",
        "label": "Contradiction"
    },
    "cfef163a-3390-4b89-9a6f-7c351262625d": {
        "text_answer": "  Patients with deficient vitamin D levels were not specifically mentioned in the evidence The evidence only reports the results for patients with normal and lownormal vitamin D levels Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d1e7f535-40de-425b-9478-7d09f3d4cf06": {
        "text_answer": "Yes The primary trial includes breast adenocarcinoma as a qualifying cancer type for Phase 2 and the secondary trial includes breast carcinoma as a qualifying cancer type Therefore individuals with breast cancer are eligible for both trials However its important to note that there may be additional eligibility requirements for each trial beyond the cancer type",
        "label": "Entailment"
    },
    "2cc09c00-1375-4603-a6ee-dd5ceb87733a": {
        "text_answer": "Yes The statement is entailed by the evidence as metastatic small cell lung cancer is one of the types of cancer specified in the inclusion criteria",
        "label": "Entailment"
    },
    "37b9368c-1aae-4acd-ad7a-ffe4422c9e5d": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided The evidence describes interventions used in two clinical trials one involving pregabalin and the other involving Liposomal Cytarabine and Highdose Methotrexate The statement is about Brucella a different genus of bacteria",
        "label": "Contradiction"
    },
    "395c6ba7-5123-4d61-a803-be3345d0ab23": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial reported a ten times higher number of hepatotoxicity incidences as compared to hypertension and pancreatectomy cases is entailed by the evidence since the evidence shows that there were 3 times more hepatotoxicity cases 3750 than hypertension cases 1250 and no pancreatectomy cases were reported in the",
        "label": "Entailment"
    },
    "e9972d7c-b9f7-4846-9708-1e1f63e96e83": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence specifies starting doses of 25 mg daily for sunitinib in Intervention 1 and no mention of a standard dose for sunitinib in Intervention 2",
        "label": "Contradiction"
    },
    "c355603f-22d8-4363-ac79-6e591b4fcfac": {
        "text_answer": "Yes  Explanation The statement there were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is entailed by the evidence as the evidence shows that the primary trial had a higher number of cases for each of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "9bea0473-ca9d-4a63-befe-db1825744484": {
        "text_answer": "No  Explanation  The statement there was no significant difference in the results produced by cohort 2 of the primary and secondary clinical trials is not directly entailed by the evidence provided The evidence only presents the results of two different cohorts from each trial but it does not provide enough information to make a comparison between them and determine if there is a significant difference or not The primary trial measures quality of life using a different outcome measure than the",
        "label": "Contradiction"
    },
    "9f81f8a6-84d2-40b3-b8c5-3616f2f638a8": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence clearly states that the placebo intervention is administered orally by mouth and the memantine intervention is administered orally twice daily There is no mention of intravenous administration for either intervention in the evidence",
        "label": "Contradiction"
    },
    "fb1cfb53-fb70-4131-9ed0-00b5f93ecf26": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence includes the adverse event wound dehiscence which is a reopened surgical cut",
        "label": "Entailment"
    },
    "dfe9c306-0a1f-4940-b9bb-00a238abc818": {
        "text_answer": "No  Explanation The primary trial includes a criterion for the primary tumour to have a diameter greater than 2 cm while the statement mentions a radius of 3000m which is not directly comparable to the diameter criterion Additionally the secondary trial does not have a specific criterion for the size of the primary tumour Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "bd791a1a-f4e4-43fb-8be0-ad1bced0aa60": {
        "text_answer": "No  The evidence states that the trial does not admit patients with meningeal carcinomatosis but it does not specifically mention leptomeningeal carcinoma Leptomeningeal carcinoma is a type of meningeal carcinomatosis but it is not the same thing Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "6032e3ab-9d85-4c3b-aeb1-a93f45ba4735": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "55365a7b-df7e-4586-aeff-3ed268a4979f": {
        "text_answer": "Yes  Explanation  The statement in both the primary clinical trial and the secondary clinical trial there were zero recorded serious adverse events is entailed by the evidence since the evidence reports that there were indeed zero serious adverse events in both trials",
        "label": "Entailment"
    },
    "92e676b6-34f9-4b11-bfad-b45cf8942d2a": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial has witnessed an unexpected death and hospitalizations is not entailed by the evidence provided The evidence only mentions the occurrence of adverse events including one case of lymphoma in the secondary trial but it does not specify that any of these events were unexpected or resulted in deaths or hospitalizations",
        "label": "Contradiction"
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "text_answer": "No  Explanation  The statement cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial is not entailed by the evidence provided The primary trial and the secondary trial are evaluating different outcome measures The primary trial is focused on the effectiveness of a peer support program on breast cancerspecific quality of life in Spanishspeaking Latinas while the secondary trial is testing the efficacy of a",
        "label": "Contradiction"
    },
    "9011533a-e400-4b32-96d4-a60ddc58ddbe": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the drug regimen for the secondary clinical trial is not specified in the evidence The evidence only mentions that the secondary clinical trial involves patients undergoing mastectomy surgery",
        "label": "Contradiction"
    },
    "43a12cb4-7a50-4e64-b01f-1d1bfb5c4ba9": {
        "text_answer": "No  Explanation  The statement the primary trial had no documented adverse events unlike the secondary one where anaemia was a frequent occurrence is not entailed by the evidence The evidence only provides the number of adverse events in each trial but it does not state that there were no adverse events in the primary trial The statement goes beyond the information given in the evidence and makes an assumption that is not supported by the data",
        "label": "Contradiction"
    },
    "e96067c7-ab5d-4afc-b70c-f892aef0dce4": {
        "text_answer": "No  The statement about neoplastic meningitis being eligible for the primary trial is not entailed by the evidence as the evidence explicitly states that there should be no meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "01982a9a-3299-4be8-8201-0397508b2f88": {
        "text_answer": "No  Explanation The evidence provided in the text does not indicate that numerous patients in the primary clinical trial felt no discomfort at all throughout the 10week study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups It does not provide any information about the number of patients who experienced no discomfort at all during the study",
        "label": "Contradiction"
    },
    "1a4794c9-035c-4e78-b2e5-d8104428bdc0": {
        "text_answer": "Yes for the exclusion of cerebral metastases in the secondary trial  Explanation The statement Diagnosis of 23 cerebral metastases will result in exclusion from the secondary trial is entailed by the evidence provided in the secondary trials exclusion criteria which states No known brain metastases Since cerebral metastases are a type of brain metastasis this condition would result in excl",
        "label": "Entailment"
    },
    "4ce3082f-28f9-4e23-8808-dde496f77535": {
        "text_answer": "No  Explanation  The statement adverse events observed during the secondary clinical trial exceeded those in the primary clinical trial is not entailed by the evidence provided The evidence only states that the number of adverse events for both trials is zero for Adverse Event 1 and does not provide information about Adverse Event 2 in the secondary trial or a comparison between the two trials",
        "label": "Contradiction"
    },
    "9c7ccf99-0768-4a8a-bde9-bb3cb9b65c67": {
        "text_answer": "Yes  Explanation  The statement no infections and infestations cases were registered in the primary clinical trial is entailed by the evidence since the evidence shows that there were no cases of infections and infestations including Gramnegative bacteremia 40 degree C fever reported in the primary clinical trial",
        "label": "Entailment"
    },
    "90474244-ea60-4670-b586-8ca32b80af7f": {
        "text_answer": "Yes The evidence indicates that all the adverse events were reported in the first cohort",
        "label": "Entailment"
    },
    "9121985c-34cf-4378-b6ad-3b7a522c9ba5": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is not directly entailed by the evidence provided The evidence only indicates that there was one Thromboembolic event in the secondary trial but it does not mention the primary trial having any Thromboembolic events Therefore the statement is not a valid conclusion based on the given evidence",
        "label": "Contradiction"
    },
    "52d479a4-9cd7-4fb6-b37f-f455c6c81402": {
        "text_answer": "Yes  Explanation  The statement cohort 1 participants in the primary clinical trial exhibited absolutely no adverse event throughout the duration is entailed by the evidence as all the adverse events for both cohorts 1 and 2 are reported as having a total count of 03 000 for each adverse event",
        "label": "Entailment"
    },
    "880b2544-5c9d-4ce7-8d26-1081c7851cb9": {
        "text_answer": "Yes The primary trial does not mention any drug interventions or related assessments while the secondary trial focuses on two distinct drug interventions with associated assessments",
        "label": "Entailment"
    },
    "0744abca-2e7d-4e4a-a325-642ba6d16135": {
        "text_answer": "Yes  Explanation The evidence shows that there were 13 participants in the aprepitant group who were emesisfree during the study period compared to only 5 participants in the placebo group This represents a twofold increase in the incidence of emesis in the placebo group compared to the aprepitant group",
        "label": "Entailment"
    },
    "87273b6d-f10d-4638-ab87-bceade2d6510": {
        "text_answer": "Yes The secondary trial explicitly lists severe insomnia as an exclusion criterion for both the primary and secondary trials until amendment omitting armodafinil treatment The primary trial does not mention insomnia as an inclusion or exclusion criterion but it does state that patients must have normal organ function which includes normal liver function and severe hepatic impairment is listed as an exclusion criterion in the secondary trial until amendment",
        "label": "Entailment"
    },
    "64e22fa4-990b-4196-874a-a5ecf04cf3fb": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the secondary trial does not focus on tracking cutaneous sensation changes for evaluating physical therapy effectiveness but rather measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale The primary trial on the other hand measures the influence of ascorbic acid supplements on vitamin C concentration in blood plasma using isothiocyanate in urine samples as an",
        "label": "Contradiction"
    },
    "6232508a-0f99-485f-9b84-af5692dac27b": {
        "text_answer": "No  Explanation The statement after four weeks of treatment with tak228 plus tamoxifen the primary clinical trial observed no changes in the percentage of cells expressing ki67 is not directly entailed by the evidence provided The evidence only reports the Ki67 expression at baseline and at 6 weeks but it does not specify the time point for the observed decrease in Ki67 expression from baseline to 6 weeks Therefore it",
        "label": "Contradiction"
    },
    "fd2867fb-a94f-42ce-87a1-aebdcfd015b8": {
        "text_answer": "Yes The evidence mentions that the intervention involves both surgical and imaging procedures The statement is a restatement of that fact",
        "label": "Entailment"
    },
    "413156ec-dbfb-4c78-9518-cbde7d4765da": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the outcome measurement in the primary clinical trial uses a change in units on a scale as the unit of measure while the outcome measurement in the secondary clinical trial uses percentage of participants as the unit of measure Cogstate is not mentioned in the evidence at all",
        "label": "Contradiction"
    },
    "4fec2620-4ede-44a4-adc9-54b525e89387": {
        "text_answer": "Yes The evidence shows that no adverse events related to cardiology or psychology were reported in either trial",
        "label": "Entailment"
    },
    "75c25f91-4918-40d6-b84d-d5be844b97ef": {
        "text_answer": "Yes  Explanation The statement an increased blood bilirubin was recorded in 3636 of the patients is a summary of the evidence provided which states that Blood bilirubin increased 111 3636 Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "86a5a47e-a2cb-461e-bcc5-8f71620376b8": {
        "text_answer": "No  Explanation  The statement There were no significant differences in the results from the groups in the primary trial however some differences where found between the Reflexology Group and control group results in the secondary trial is not directly entailed by the evidence provided The evidence only discusses the diagnostic accuracy of two algorithms in breast cancer diagnosis in the primary trial and the fatigue levels of women in the secondary trial It does not mention any significant differences between the groups",
        "label": "Contradiction"
    },
    "31ec9b33-fa24-4cd9-9341-c54adaa250cd": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "2f6221cf-15f0-4da7-b800-d65f4dd001d7": {
        "text_answer": "No  The performance status is an inclusion criterion in the secondary trial with a minimum requirement of a Zubrod performance score of 2 or better",
        "label": "Contradiction"
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "text_answer": "No   Explanation  The statement There were 0 adverse events in the primary trial and the secondary trial is not entailed by the evidence While it is true that there were 0 adverse events in the primary trial the evidence states that there were 2 adverse events in the secondary trial",
        "label": "Contradiction"
    },
    "e547ee04-f454-4ec3-b2fb-9ea04c97bdab": {
        "text_answer": "Yes The statement numerous adverse events were noted in the primary clinical trial is entailed by the evidence since there were no adverse events reported in the primary trial The statement over half of the patients in the secondary clinical trial were affected by skin infections is also entailed by the evidence since 333 is more than 0 and there was 1 skin infection reported out of 30 patients However its important to note",
        "label": "Entailment"
    },
    "64839cde-9ad9-4363-9d78-7a2621bc7ec4": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that capecitabine was administered orally every day for the first 14 days of each 21day cycle",
        "label": "Entailment"
    },
    "8bc0e440-faca-4386-8718-e306978edb67": {
        "text_answer": "  No   Explanation   The statement minor salivary gland is a small salivary gland located within the aerodigestive tract Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is not directly stated in the evidence provided The evidence only mentions the inclusion and excl",
        "label": "Contradiction"
    },
    "974d4228-3dd6-42ab-b4e6-1b3f8e9ecdc5": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only mentions the dosage of cetuximab given to each cohort but it does not provide information about any collaborative care interventions provided to each cohort",
        "label": "Contradiction"
    },
    "6c31de8a-736c-4741-99d3-fcd0c921e83f": {
        "text_answer": "Yes  Explanation The statement compared to the secondary clinical trial the frequency of pericardial effusions was higher in the primary clinical trial whereas corneal deposits were more often noted in the latter is entailed by the evidence as pericardial effusions were observed in 1111 of participants in the secondary trial and 224 in the primary trial while corneal deposits were not observed",
        "label": "Entailment"
    },
    "0a44470c-bf27-4795-aa25-f30a58771625": {
        "text_answer": "Yes The statement is consistent with the results of the primary trial regarding the reduction in Ki67 expression in breast cancer tumors due to tamoxifen treatment",
        "label": "Entailment"
    },
    "647c8d22-6888-4f04-a70b-0245b68a6fab": {
        "text_answer": "Yes The primary trial excludes patients with a life expectancy of less than 1 year while the secondary trial includes patients with a life expectancy of at least 1 year Therefore patients in the final stage of cancer who have a life expectancy less than 1 year cannot partake in the primary clinical trial but are eligible for the secondary trial",
        "label": "Entailment"
    },
    "07dab01c-f419-4079-bd0d-491740c5ec95": {
        "text_answer": "No  Explanation  The statement several patients in the primary clinical trial experienced identical adverse events is not directly entailed by the evidence provided The evidence lists the number of occurrences for each type of adverse event but it does not specify which patients experienced more than one type of adverse event Therefore it is possible that no patients experienced identical adverse events based on the given information",
        "label": "Contradiction"
    },
    "16505ccd-8394-4c6e-8ab2-bbf56583c6be": {
        "text_answer": "Yes  Explanation The evidence states that in Intervention 1 the dose of cyclophosphamide is 600 mgm2 while in Intervention 2 the dose of cyclophosphamide is also 600 mgm2 However the dose of eribulin in Intervention 1 is higher than the dose of docetaxel in Intervention 2 Therefore the statement co",
        "label": "Entailment"
    },
    "9022a69a-98fa-45ab-8a03-3a6e81102d03": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with tumors exhibiting CCND1 amplification CDK46 mutation or CCND2 amplification are listed as ineligible in the clinical trials inclusion criteria",
        "label": "Entailment"
    },
    "e5e7bbc4-cce7-41e3-b973-ac14fdff5600": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement incorrectly mentions different types of interventions for cohort 1 in the primary and secondary trials In the primary trial cohort 1 receives an injection of Fluciclatide while in the secondary trial cohort 1 receives a standard dose of Chloroquine by an unspecified route The evidence does not provide any",
        "label": "Contradiction"
    },
    "66a9e527-8f35-4c41-be7f-ad854d0066f9": {
        "text_answer": "No  Explanation  The statement occurrence date range validation code is a coded value specifying the degree of authoritativeness or certitude of the occurrence date is not directly related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The statement does not appear in the given text and does not affect the eligibility of Japanese nationals to participate in the trials",
        "label": "Contradiction"
    },
    "8a79949b-06e3-4943-a63d-248e1a432a7b": {
        "text_answer": "No  The evidence states that there are limited enrollment slots 1530 for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation It does not mention unlimited enrolment for patients without these mutations",
        "label": "Contradiction"
    },
    "7758b88c-2f21-4b63-b76d-010298f50aa7": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary clinical trial is administered a similar dose of enzalutamide as cohort 2 is not entailed by the evidence The evidence states that cohort 1 received 80 mg of enzalutamide daily while cohort 2 received 160 mg of enzalutamide daily These are not similar dos",
        "label": "Contradiction"
    },
    "9a749008-f77d-49bf-b529-82d049a8f446": {
        "text_answer": "No  Explanation  The evidence provided in the form of the primary clinical trial results does not directly support the statement that the paclitaxel plus bevacizumab group demonstrated a superior ORR compared to the paclitaxel plus bevacizumab plus gemcitabine group The evidence only provides the ORR and corresponding 95 confidence intervals for each group To determine if there is a statistically significant difference between the two",
        "label": "Contradiction"
    },
    "5c2d33e2-9759-4060-9bdd-7ecda4123cda": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "03837d34-3ddb-4bfc-a993-b27e2d16f427": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide any information about homeopathic dilution units The primary trial reports the results of a study on the effectiveness of fentanyl sublingual spray and placebo in treating breakthrough pain while the secondary trial compares the effect of zoledronic acid and observation on bone loss after surgery Neither trial mentions homeopathic dilution units",
        "label": "Contradiction"
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "text_answer": "No  The secondary trial measures pain not muscle gains",
        "label": "Contradiction"
    },
    "c5fb4937-5177-47c9-8ce2-1fdec2a17942": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases Therefore the statement that 57 of participants developed imagable HER2 metastases is not exactly correct but it is entailed by the evidence in the sense that it overestimates the number of participants who developed imagable HER2 metastases",
        "label": "Entailment"
    },
    "72d62a11-d0ff-4e2b-8bb9-22a1858b4914": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because  1 The primary trial participants are given multiple types of medications doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate trastuzumab tamoxifen citrate letrozole",
        "label": "Contradiction"
    },
    "607586af-260d-46ef-88ce-b8672e4aaa25": {
        "text_answer": "No  Explanation  The statement Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial is not directly entailed by the evidence provided The evidence only states the number and percentage of adverse events in each trial but it does not compare the frequency of specific adverse events between the two trials Therefore the statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "877e791d-73b6-4af2-945c-29f54005c405": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the patient cohorts and trials are different in the primary and secondary trials The primary trial is about denosumab and the percentage of participants with a response within 10 days while the secondary trial is about the number of patients who reached a safe dose of dmethadone over 2 years",
        "label": "Contradiction"
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "text_answer": "Yes  Explanation The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is entailed by the evidence since the total number of adverse events in cohort 1 45 is greater than the total number of adverse events in cohort 2 7",
        "label": "Entailment"
    },
    "bc1a73c0-825c-48dd-b6cf-e440ae0bb782": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence indicates that patients will take vorinostat daily during radiation therapy",
        "label": "Contradiction"
    },
    "0d7caeea-5417-4eb2-9d92-3d3ada73ece7": {
        "text_answer": "Yes  Explanation  The statement adverse events affecting more than 1 of participants did not occur in either the primary clinical trial or secondary clinical trial is entailed by the evidence since the evidence shows that the adverse events affecting more than 1 of participants did not occur in either trial The evidence reports that the adverse events with ANCAGC affected 048 of participants in the primary trial which is less than",
        "label": "Entailment"
    },
    "38acc5fa-c86b-4734-bdb6-7acbcd3c37c4": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement mentions 150 mg of pregabalin injected intravenously every fortnight which is not present in the primary trial The primary trial states that patients receive 150 mg of oral pregabalin twice daily for 6 weeks",
        "label": "Contradiction"
    },
    "94023f3a-38d4-4b1b-a65a-9536480ff4c4": {
        "text_answer": "No  Explanation  The statement how often did fatigue limit work is a question about how often fatigue limits an individual at work is not directly related to the inclusion or exclusion criteria for either the primary or secondary trials provided in the evidence The primary trial focuses on hot flushes and menopausal status in breast cancer patients while the secondary trial focuses on HER2negative metastatic breast cancer patients eligible for taxanebased chem",
        "label": "Contradiction"
    },
    "3f0e9340-88df-433f-8bdb-e32523b86a86": {
        "text_answer": "No  Explanation  The statement a dosage of zoledronic acid 12 times greater than the dosage of denosumab is used in the first intervention of the primary clinical trial as compared to the first intervention in the secondary clinical trial is not entailed by the evidence provided  The evidence only states that in the primary clinical trial some participants received Zoledronic Acid 4 mg Q4W and others received",
        "label": "Contradiction"
    },
    "9a7f95d5-8fb7-4f77-a921-00a2633e8cc4": {
        "text_answer": "No   Explanation The evidence provided does not mention the number of participants who had undergone cervical cancer screenings before the intervention only the percentage of those who had done so The statement in question makes a definitive claim about the number of patients not the percentage",
        "label": "Contradiction"
    },
    "ffa6aa2b-661d-4e25-a893-6e03dea7e39e": {
        "text_answer": "Yes The primary trial measures tumor response using RECIST criteria but it does not report the percentage of participants experiencing clinical benefit The secondary trial measures various correlative studies and qualityoflife assessments but it does not report the percentage of participants experiencing clinical benefit",
        "label": "Entailment"
    },
    "ef79f4a4-d4ec-4a2a-a2a6-41ad41235927": {
        "text_answer": "No   Explanation  The evidence describes the doses of vorinostat that patients will receive during the trial as well as the timing of vorinostat administration in relation to radiation therapy However it does not mention anything about the use of fentanyl sublingual spray during radiation therapy let alone the doses of fentanyl that patients will receive Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "text_answer": "No  Explanation The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not entailed by the evidence While smokers are excluded from the primary trial there is no mention of smoking or alcohol restrictions in the secondary trials inclusion criteria",
        "label": "Contradiction"
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "text_answer": "Yes  Explanation The statement None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort is entailed by the evidence since none of the individual adverse event types had a frequency greater than 3571 which is more than 25",
        "label": "Entailment"
    },
    "2a2a6190-619e-478b-a97d-5a253a8f916c": {
        "text_answer": "No  The statement patients with a recent history of abdominal fistula or gastrointestinal perforation can participate in the primary clinical trial is not entailed by the evidence as it is listed as an exclusion criterion in the trials eligibility requirements",
        "label": "Contradiction"
    },
    "13eb7b14-5252-4004-8c72-56e3d5d3ca8a": {
        "text_answer": "Yes The statement a 5 decrease in the percentage of cells expressing ki67 was observed is entailed by the evidence as the evidence reports a median decrease of 5 percentage points from 15 to 10 in Ki67 expression at 6 weeks compared to baseline",
        "label": "Entailment"
    },
    "87a42ef9-ff00-41f8-ba0a-9ca84498f7eb": {
        "text_answer": "No  Explanation The evidence provided in the text does not indicate how many patients in the primary clinical trial failed to demonstrate recurrencefree survival The text only mentions the percentage of subjects who did demonstrate recurrencefree survival 98 or 922995 Therefore the statement just a pair of patients in the primary clinical trial failed to demonstrate recurrencefree survival is not entailed by the evidence",
        "label": "Contradiction"
    },
    "5bc078b0-0b64-4d47-a015-26c3f03c864e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "733d9f9f-9a01-4643-ab99-ac6086ad5cbc": {
        "text_answer": "No  Explanation  The statement the duration of the memantine intervention in the primary clinical trial is shorter than the placebo intervention is not entailed by the evidence provided In fact the evidence states that both the memantine and placebo interventions last for 12 weeks",
        "label": "Contradiction"
    },
    "318ded6f-e96c-4a4f-8f4b-ff19f2e86c16": {
        "text_answer": "Yes  Explanation  The statement there are no recorded instances of coronary artery stenosis as an adverse event in the primary clinical trial is entailed by the evidence because the evidence does not include any record of coronary artery stenosis as an adverse event The evidence only lists the following adverse events blood disorder hypomagnesemia platelets count decrease thrombosis visionblurred",
        "label": "Entailment"
    },
    "81a3bd04-5dff-45a6-a4eb-7a41c59b0023": {
        "text_answer": "No  Explanation  The statement there were no significant differences in the results from the groups in the primary trial however some differences were found between the Reflexology Group and control group results in the secondary trial is not directly entailed by the evidence provided The evidence only reports the results of the primary and secondary trials separately without making any direct comparison between them The statement goes beyond the information given in the evidence and makes an inference that is not explicitly",
        "label": "Contradiction"
    },
    "2aac2b30-f74d-4435-b7e6-ec5cd5923da3": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial only four distinct adverse events influenced patients all found within cohort 2 is entailed by the evidence since there are only four distinct adverse events Neutropenia Fatigue Pyrexia and Hepatic pain that occurred in cohort 2 with a total of 3 patients in each cohort experiencing these adverse events",
        "label": "Entailment"
    },
    "3e6a3ebb-face-44fe-8bb1-cbd399f4e215": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5e8286c8-3e7c-4b71-b824-103d031ac6b4": {
        "text_answer": "Yes The statement mentions Stomatitis as the only adverse event which is consistent with the evidence that reports a single adverse event of Stomatitis with a frequency of 345",
        "label": "Entailment"
    },
    "d1424cd8-4dab-40a8-91b1-3ae5d1f57d56": {
        "text_answer": "No  Explanation  The statement several mortalities and admissions to the hospital occurred in the second cohort of the primary clinical trial and atrial fibrillation was also frequently detected is not directly entailed by the evidence provided The evidence only states the number of adverse events including deaths and hospitalizations in each cohort of the primary clinical trial It does not specify that these events occurred frequently or that at",
        "label": "Contradiction"
    },
    "78f50c70-09e5-4328-8ddf-f7e743527132": {
        "text_answer": "No   Explanation  The statement is not directly entailed by the evidence as the statement is about a nonfunctioning neuroendocrine tumor which is different from the breast cancer cases in the evidence The evidence only pertains to breast cancer and its treatment with various drugs and imaging studies",
        "label": "Contradiction"
    },
    "b7501704-ccba-40f8-852e-c157006483df": {
        "text_answer": "No  Explanation The statement all patients in the primary trial receive at least 20kg of mcs110 every 30 weeks is not entailed by the evidence The evidence only specifies the dosage of MCS110 and PDR001 for each intervention in the primary trial It does not provide information about the weight of the patients or the total amount of MCS110 they receive during the trial",
        "label": "Contradiction"
    },
    "0f0f75f2-7da8-4705-b260-62c5f542b91e": {
        "text_answer": "No  Explanation  The statement in the primary trial only five cohorts received armodafinil po daily and in the secondary trial all patients receive the same 500 mg dose of pdr001 and 6 mgkg dose of mcs110 is not entailed by the evidence  The primary trial involves two interventions one with placebo and one with CBTI",
        "label": "Contradiction"
    },
    "d8fa557b-e20a-4b49-be9c-b55a6bde385a": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment The two trials address different outcome measurements",
        "label": "Contradiction"
    },
    "33cd5bbd-a795-467e-b08f-cf59702922cc": {
        "text_answer": "Yes The primary and secondary trials both measure pCR and there is a difference in pCR rates between the two trials with Arm 2 of the secondary trial having a higher pCR rate The statement does not mention the time period of 36 weeks after radiation therapy but the evidence does not contradict this statement either",
        "label": "Entailment"
    },
    "34199309-5388-4ed1-956d-17e9c7afaaef": {
        "text_answer": "No  Explanation  The statement refugee from high tuberculosis prevalent area is an individual that has fled a country for their own safety which has a high occurrence of tuberculosis is not directly related to the provided evidence The evidence only mentions the inclusion and exclusion criteria for the primary and secondary trials and there is no mention of refugees or tuberculosis in the evidence",
        "label": "Contradiction"
    },
    "1ce7b426-1be9-4684-b0a5-54d557d3b320": {
        "text_answer": "No  Explanation  The statement the frequencies of recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage as adverse events were indistinguishable between the primary and secondary clinical trials is not entailed by the evidence provided The evidence only shows that the frequencies of these adverse events in the primary trial were different from those in the secondary trial It",
        "label": "Contradiction"
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "text_answer": "No   Explanation  The statement Breast Cancer and Ovarian Peritoneal Cancer patients in the primary trial undergo the same intervention is not entailed by the evidence The evidence describes two separate interventions for breast cancer and ovarianperitoneal cancer patients each with different dosing regimens",
        "label": "Contradiction"
    },
    "4a383701-3a27-4973-8c8c-4f697bde7484": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the drug intervention for the secondary clinical trial is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "9a499642-970d-48b1-b0b4-96760793ba72": {
        "text_answer": "Yes The evidence does not mention any specific requirement regarding liver function in the inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "4e929375-b7c0-4a81-baa9-9c21d95366b7": {
        "text_answer": "Yes  Explanation  The primary clinical trial INTERVENTION 1 compares two different interventions Hydrophor and MediHoney in treating the side effects of radiation therapy The secondary clinical trial INTERVENTION 1 and INTERVENTION 2 evaluates the effect of varying doses 90 mg and 110 mg of the same drug PF052123",
        "label": "Entailment"
    },
    "75cdd5c7-ad36-4ab3-8fe2-6d0e84ab8f0a": {
        "text_answer": "No   Explanation  The statement provided is not entailed by the evidence as the evidence does not mention anything about reactive epithelial hyperplasia of the ciliary body or any adverse events occurring in more than 30 of participants The evidence only reports the number and percentage of adverse events specifically related to neutrophilsgranulocytes ANCAGC in the primary and secondary trials",
        "label": "Contradiction"
    },
    "d7637d6e-ba2c-4fdc-936d-57c3bf938eff": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the statement incorrectly states that the patients in the primary clinical trial received a dosage of 05ugkg of myalgias 5ml However the evidence clearly states that the patients in group 2 of the primary clinical trial received a dosage of 05ugkg of dexmedetomidine 5ml not myalgias",
        "label": "Contradiction"
    },
    "edd794e6-12c6-4d30-80ac-009951273d44": {
        "text_answer": "No  Explanation  The statement women with recurrent stage I breast cancer confirmed as ER considering lumpectomy are eligible for the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic bone met",
        "label": "Contradiction"
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "text_answer": "Yes  Explanation  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is entailed by the evidence because the primary trial had a higher incidence of diarrhea 730 or 2333 compared to the secondary trial 06 or 000",
        "label": "Entailment"
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "text_answer": "No  Explanation The primary trial and the secondary trial have different inclusion and exclusion criteria While some criteria are similar there are also significant differences For example the primary trial includes women with nonpalpable malignant lesions undergoing lumpectomy while the secondary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy These are distinct patient populations and not all patients eligible for the secondary trial are eligible for the primary trial",
        "label": "Contradiction"
    },
    "c6194284-d44f-45c1-9477-754736bbf1a3": {
        "text_answer": "No  Explanation The primary trial includes individuals with a breast tumor size of 1 cm while the secondary trial includes individuals with measurable disease The statement only mentions individuals with a breast tumor measuring 02 to 08 cm which is not explicitly stated in either trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "text_answer": "Yes However its important to note that patients with a vitamin D deficiency are excluded from the primary trial but they may be eligible for the secondary trial if they meet the other inclusion criteria for that trial",
        "label": "Entailment"
    },
    "c78f1ce0-7597-415d-b5c3-203e696b48d5": {
        "text_answer": "No  Explanation  The statement in the primary trial results there were fewer patients with stable disease in week 15 than week 30 is not directly entailed by the evidence provided The evidence only reports the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 for each armgroup It does not provide information about the number of participants with stable disease at week ",
        "label": "Contradiction"
    },
    "b80c2589-c792-4391-995c-6763270469dd": {
        "text_answer": "No  Explanation  The evidence provided in the clinical trial results does not indicate whether or not patients with low vitamin D levels showed a discernible pattern for expression of the set of 40 evaluated genes The results only report the number of participants in each group with a discernible pattern but they do not specify which group normal or lownormal vitamin D levels had this pattern Therefore the statement is not directly entailed by the",
        "label": "Contradiction"
    },
    "cef48380-fe4b-4b71-931c-5b0dbfe1cf29": {
        "text_answer": "No   Explanation The primary clinical trial is not unrestricted in the number of participants and is not appropriate for individuals with ovarian cancer irrespective of their KRAS or BRAF mutation status The trial has specific enrollment slots for different tumor types including ovarian cancer with KRAS or BRAF mutation Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d9a63f26-68c3-431f-851f-131f7a547902": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about psychological health issues in the reported adverse events",
        "label": "Contradiction"
    },
    "884bc204-4928-430b-b44d-1e33ef66731d": {
        "text_answer": "Yes The primary trial explicitly states that a participant cannot have undergone major surgery within 28 days prior to the study registration date The secondary trial does not mention any specific time frame for major surgery but it is mentioned as an exclusion criterion Therefore a patient post organ transplant within a month would not be considered for the primary trial but they could potentially be fit for the secondary trial",
        "label": "Entailment"
    },
    "9e19e98e-3ce1-4b01-9080-ad34e68f0acb": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial except one all patients who received sunitinib  docetaxel  trastuzumab experienced a treatmentemergent adverse event is entailed by the evidence since all 25 participants in the study had at least one treatmentemergent adverse event AE The statement and less than fifty percent experienced severe treatmentemergent adverse events",
        "label": "Entailment"
    },
    "58429d01-0c6a-4ae1-b8ce-73ee8a8e775d": {
        "text_answer": "Yes The primary trial includes the exclusion criterion History of bone marrowstem cell transplantation which implies a risk of organ perforation The secondary trial does not mention organ perforation specifically but it does not exclude patients with stage 4 cancer who may have this condition",
        "label": "Entailment"
    },
    "87be81ce-d5b1-4905-9452-2e0e2d4b7b2c": {
        "text_answer": "No  Explanation The statement participants in the primary trial receive four different drugs throughout the study duration with a maximum dose of 100000 gm2 is not entailed by the evidence The evidence only specifies the drugs and their dosages in the neoadjuvant therapy and the maintenance therapy It does not mention the total dose received by each participant or the number of different drugs beyond those mentioned",
        "label": "Contradiction"
    },
    "519fe8b4-596f-4db6-af13-80d9746041a6": {
        "text_answer": "No  The evidence does not mention an age limit in the inclusion criteria",
        "label": "Contradiction"
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "text_answer": "Yes The statement is entailed by the evidence as the inclusion criteria for both phases of the primary trial specify that participants must have evidence of a solid tumor that is locally advanced andor metastatic",
        "label": "Entailment"
    },
    "e2a5ecca-6d4a-438b-a42c-46657ccb4050": {
        "text_answer": "No  Explanation  The evidence provided in the results does not contain any information about the age of the participants at the time of immunohistochemistry assessment The statement is about the age in days at immunohistochemistry but the evidence only provides the number of participants with serious and nonserious adverse events and their respective doses and time frames Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "808d2233-0c0d-4221-bfae-e54fdcf31ce4": {
        "text_answer": "No  Explanation  The statement There were no significant differences in the results from the groups in the primary trial and the Reflexology Group and control group in the secondary trial produced identical results is not entailed by the evidence provided  The evidence only reports the results of the primary trial comparing the diagnostic accuracy of two mammography algorithms and the secondary trial assessing the effect of reflexology on fatigue levels in breast cancer patients It does not",
        "label": "Contradiction"
    },
    "fb616088-52c2-4dae-84e5-8a1a3fa9b64f": {
        "text_answer": "No  Explanation  The statement liter per hour per kilogram per meter squared is a unit of concentration equal to liter per hour divided by kilogram per meter squared is a mathematical definition and is not directly related to the inclusion and exclusion criteria for the primary trial The trials criteria only mention the use of this unit in the context of estimating life expectancy but they do not specify its meaning or relationship to other units Therefore",
        "label": "Contradiction"
    },
    "f2d7cf41-2cd1-4d03-a153-18764cf7da09": {
        "text_answer": "  No  Explanation  The statement On average both cohorts of the primary trial suffered a deterioration in cognitive function is not directly entailed by the evidence provided The evidence only reports the mean standardized scores and standard deviations for each cohort Tamoxifen and Ovarian Function Suppression on the CogState cognitive function test battery It does not explicitly state that both cohorts experienced a deter",
        "label": "Contradiction"
    },
    "1748cec0-92de-44af-9d49-bf45518c24bc": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials had no adverse events that occurred in more than 1 of participants",
        "label": "Entailment"
    },
    "939de4be-2f3d-4e0d-a5b9-a80f6469bd22": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of Tumour lysis syndrome in the provided evidence The evidence only reports the adverse events observed in the primary and secondary trials",
        "label": "Contradiction"
    },
    "3cb08dda-e0dc-48e5-87fa-e24386d6dab2": {
        "text_answer": "Yes The statement is a more specific version of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "e7be25fe-5915-4c38-b3c0-4e4acd5edd5c": {
        "text_answer": "Yes The statement is entailed by the evidence as patients with tumors positive for CCND1 amplification CDK46 mutation or CCND2 amplification are excluded from the primary trial according to the given inclusion criteria",
        "label": "Entailment"
    },
    "95840c1a-9e38-4fe5-939c-e6f9aa107ced": {
        "text_answer": "No  Explanation  The statement each adverse event reported in the primary clinical trial was accounted as a suspected serious adverse reaction while there was no such record in the secondary clinical trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the severity or classification of those events Therefore it is not possible to determine from the evidence alone whether each ad",
        "label": "Contradiction"
    },
    "6e5e4b46-3bc7-4ae1-8668-9b4f2f72f791": {
        "text_answer": "No The statement is not entailed by the evidence as the evidence explicitly states that the primary trial includes patients aged greater than 20 years and the secondary trial includes patients aged 18 or older However the statement implies that women under 18 are qualified for both trials which is not the case according to the evidence",
        "label": "Contradiction"
    },
    "454c83f7-949e-46bf-bd9a-5f14e6ba4713": {
        "text_answer": "No  The statement is not entailed by the evidence as there is no mention of gabapentin or pregabalin in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "4678ba70-3ec1-487b-a641-bdbd790892ac": {
        "text_answer": "No  Explanation  The statement 274 the primary trial participants and 0 the secondary trial participants suffered an acute myocardial infarction is not entailed by the evidence provided The evidence only states that no participants in either trial suffered an acute myocardial infarction The statement makes an additional assumption about the percentage of participants in the primary trial who suffered an acute myocardial infar",
        "label": "Contradiction"
    },
    "5f36a4ca-cd2f-4c38-8040-9b36da0ebbe4": {
        "text_answer": "No  The evidence does not mention any specific weight range for American patients in the primary clinical trial",
        "label": "Contradiction"
    },
    "358cd111-420a-401d-bd92-e459d3725026": {
        "text_answer": "  No   Explanation   The evidence provided does not mention anything about severely obese patients being considered for the clinical trials The exclusion criteria for both trials state that patients must be able to understand and sign the informed consent document which may be challenging for severely obese patients due to physical limitations or other health issues However the evidence does not explicitly state that severely obese patients are excluded from the trials The statement goes beyond the information provided in",
        "label": "Contradiction"
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "text_answer": "Yes  Explanation  The statement Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial is entailed by the evidence provided The evidence shows that the incidence of pericardial effusion was higher in the primary trial 1111 while the incidence of corneal deposits was higher in the secondary trial 000",
        "label": "Entailment"
    },
    "ab3fc92f-0d8a-472f-b652-e10bcd03ff19": {
        "text_answer": "Yes The evidence does not indicate that any adverse event type affected more than one patient in the primary trial",
        "label": "Entailment"
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "text_answer": "Yes  Explanation  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is entailed by the evidence because there are no reported deaths or hospitalizations in either trial for Adverse Events 1 or Adverse Events 2",
        "label": "Entailment"
    },
    "e5d16f98-79d0-44e1-9fc0-7bb6ae9a038d": {
        "text_answer": "Yes The statement is entailed by the evidence as cohort 2 received a dose of Enzalutamide that is twice the dose given to cohort 1",
        "label": "Entailment"
    },
    "5ce6e37b-2c84-44e1-8c5e-e441cec64872": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not mention anything about the administration of talazoparib or the presence of discharge for those patients The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "1e32317b-5301-461d-bdd9-0acb2e076522": {
        "text_answer": "Yes The evidence states that adverse events were documented in both trials",
        "label": "Entailment"
    },
    "04c5ba38-d98e-4fd7-b5f4-ea4706f26355": {
        "text_answer": "Yes The statement correctly identifies the difference in dosing between the two interventions and the condition being studied",
        "label": "Entailment"
    },
    "9f97138b-399f-42bf-9afe-e7195db4e5b4": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare needs and are confined to bed or chair for less than 50 of waking hours",
        "label": "Entailment"
    },
    "ae583e53-d445-4b4a-b49a-c440881180e7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about the dosages or volumes of Herceptin trastuzumab and Docetaxel in the secondary clinical trial The statement only compares the weekly dosages of MM121 and Paclitaxel between the primary and secondary trials",
        "label": "Contradiction"
    },
    "fa5e894c-13be-4786-ac47-16d31de8a7ce": {
        "text_answer": "No  Explanation  The statement distress over family problem with family health issues is a question about an individuals distress related to their family problems dealing with family health issues is not directly related to the inclusion or exclusion criteria of either the primary or secondary trial The primary trial focuses on the inclusion and exclusion criteria for patients with metastatic breast cancer while the secondary trial focuses on the inclusion and exclusion criteria for patients undergoing cancer treatment with",
        "label": "Contradiction"
    },
    "67bce826-0ca5-477c-8802-2511317e675d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "bbda33ff-3d5b-445e-afec-a20518fd2c79": {
        "text_answer": "Yes  Explanation  The statement There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial is entailed by the evidence as the numbers in the tables clearly show that there are fewer adverse events and fewer types of adverse events recorded in the primary trial compared to the secondary trial",
        "label": "Entailment"
    },
    "68d0da33-c4ad-4649-bb63-08290cd4d4e2": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the evidence only mentions mammography as a requirement for the primary clinical trial and does not mention any requirements for the secondary clinical trial other than giving informed consent being able to read and write English having nonpalpable breast lesions that require surgical removal and the lesions andor clip being targetable with image guidance",
        "label": "Contradiction"
    },
    "fc7722bc-9fed-46cf-881d-265c3f3762b4": {
        "text_answer": "No  Explanation  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is not entailed by the evidence provided The evidence only states that there were no cases of acute myocardial infarction reported in either trial The statement goes beyond the information given in the evidence by mentioning specific numbers of participants who did not suffer",
        "label": "Contradiction"
    },
    "a9cbf72a-fd01-403d-8afa-d9d6a69622a0": {
        "text_answer": "Yes The statement does not provide any new information about the adverse events but it is not in contradiction with the evidence",
        "label": "Entailment"
    },
    "41c54be8-c257-49dc-b21b-0184595c1277": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial administers to cohort 1 a dose of alt801 which is less than half of that given to cohort 2 is entailed by the evidence since 0015 mgkgdose is less than 0040 mgkgdose",
        "label": "Entailment"
    },
    "4417c4c8-522f-4e46-8b8d-310995182d70": {
        "text_answer": "Yes The evidence states that there were 234 participants in cohort 1 and 241 in cohort 2 so cohort 2 has 10 fewer participants than cohort 1",
        "label": "Entailment"
    },
    "7b74835d-12ba-4d02-a09c-817f33abd3b2": {
        "text_answer": "Yes The evidence does not explicitly state that patients with stage 4 cancer are eligible for both trials but it does not exclude them either as long as they meet the other inclusion criteria and provide informed consent",
        "label": "Entailment"
    },
    "3dab8f67-6eca-4ace-ba49-0bd33547b004": {
        "text_answer": "Yes  Explanation The statement while most patients in the first cohort of the primary clinical trial endured adversities the same cannot be said for the second cohort is entailed by the evidence as the first cohort had a higher percentage of adverse events 4245 compared to the second cohort 680",
        "label": "Entailment"
    },
    "359a101f-e771-4fac-b2f7-a5486fb19344": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the comparison of the efficacy of aprepitant and placebo in controlling nausea and vomiting during bone marrow transplantation It does not provide any information about sellar teratomas or their malignant transformation Therefore the statement about sellar teratomas with malignant transformation being twice as likely to experience emesis in patients receiving placebo is not",
        "label": "Contradiction"
    },
    "cbbd5644-6e63-4f6d-b948-fe52b5df89c7": {
        "text_answer": "No  Explanation The evidence provided only reports the median PFS for each treatment group not the maximum PFS for any individual participant",
        "label": "Contradiction"
    },
    "2fb19f2c-7bda-446c-bf0c-8e9842e89c97": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the intervention in the primary clinical trial is given orally PO not topically",
        "label": "Contradiction"
    },
    "be93f6ab-df27-4f10-a485-24823f7056fc": {
        "text_answer": "No  Explanation  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not provide any information about the frequency or prevalence of cholelithiasis in each trial Therefore it is not possible to determine whether cholelithiasis was twice",
        "label": "Contradiction"
    },
    "effcbfa0-9271-4463-9e48-5523d5cedeb6": {
        "text_answer": "No  Explanation The evidence provided only outlines the inclusion and exclusion criteria for a clinical trial related to breast cancer It does not mention anything about the role of a patients family member in the final decision for participation",
        "label": "Contradiction"
    },
    "1f309606-5b98-4320-ab02-24e782e7250d": {
        "text_answer": "No   Explanation   The primary trial and the secondary trial report their results using different units of measure The primary trial reports the results in units on a scale while the secondary trial reports the results as proportions with confidence intervals There is no mention of a median or lower cervical lymph node in the evidence",
        "label": "Contradiction"
    },
    "f0a1bf43-c080-446d-815a-c588c7563e89": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for the primary clinical trial and mentions that some participants receive talazoparib but it does not specify the dose of talazoparib that they receive The statement in question explicitly mentions a daily dose of 1000 mcg which is not mentioned in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "de3effdb-0854-48a8-b66c-b61378ec7a6f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no information about radiation therapy being administered to the patients in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "d2673e8f-15c9-4476-b8b6-2567822d5cd4": {
        "text_answer": "No  Explanation The evidence provided in the text relates to the outcome of a clinical trial comparing the invasive diseasefree survival iDFS of patients receiving Neratinib versus Placebo after adjuvant trastuzumab treatment for breast cancer The statement however refers to bladder small cell neuroendocrine carcinoma which is a different type of cancer than the one studied in the trial Therefore the statement",
        "label": "Contradiction"
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "text_answer": "Yes  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is entailed by the evidence because the primary trial had a higher number of occurrences for all three adverse events compared to the secondary trial Specifically the primary trial had 1 palpitation 2 pericardial effusions and 2 abdominal",
        "label": "Entailment"
    },
    "5c535bb9-8464-4820-b872-506057f2cd87": {
        "text_answer": "No  Explanation The evidence provided in the trial results only reports the median change in lean body mass for the GTx024 1 mg and 3 mg groups There is no information given about any patient in the higher dose group 8 mg gaining over 17 kilos of lean body mass Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "94328fa0-182a-4275-929c-bc10f899ba5d": {
        "text_answer": "  Yes for the secondary trial statement about pulmonary embolism No for the primary trial statement about breast implants",
        "label": "Entailment"
    },
    "a668e3be-6b87-468e-99b5-48ad77bed972": {
        "text_answer": "No  Explanation  The statement photovoice is a qualitative method in which participants use photographic techniques to facilitate the documentation and communication of issues is not directly related to the inclusion and exclusion criteria for the primary trial The statement describes a research method while the evidence provides the criteria for patient eligibility and exclusion in a clinical trial for Nonsmall cell lung cancer and Small cell lung cancer",
        "label": "Contradiction"
    },
    "59d62015-4627-4fef-acba-984ff4ad2964": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes a clinical trial for cancer treatment using chemotherapy drugs and bevacizumab not vaccines",
        "label": "Contradiction"
    },
    "e4b57c09-4069-463e-9db3-70860f520524": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence because the statement mentions ambamustine which is not mentioned in the evidence The evidence only mentions the drugs that are used in the primary and secondary trials",
        "label": "Contradiction"
    },
    "4e68783f-fc2b-4efb-88da-b5d081ff5541": {
        "text_answer": "No  Explanation  The statement unfavorable outcomes were reported in equal measure from patients in both divisions of the primary clinical trial is not entailed by the evidence The evidence only reports the number and percentage of adverse events for each division of the trial but it does not indicate that the number or percentage of unfavorable outcomes was equal between the two divisions",
        "label": "Contradiction"
    },
    "d7abc723-e08e-442e-82e4-3e369341b72a": {
        "text_answer": " No The primary trial does not mention anything about pediatric cancer patients under the age of 18 and the secondary trial only accepts certain types of pediatric cancers",
        "label": "Contradiction"
    },
    "60f6302e-f888-4bc2-b689-f0620024f93e": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial cohort 1 experienced a higher incidence of adverse events as compared to those in cohort 2 is entailed by the evidence as the total percentage of adverse events in cohort 1 4245 is higher than that in cohort 2 680",
        "label": "Entailment"
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "text_answer": "Yes  Explanation  The statement There were no cardiac or psychiatric AEs recorded during the primary trial and the secondary trial is entailed by the evidence since the evidence reports that there were no cardiac or psychiatric adverse events AEs recorded in both trials for both Adverse Event types 1 and 2",
        "label": "Entailment"
    },
    "4dcbfb0d-cb67-4d74-a21a-0920159dfafc": {
        "text_answer": "Yes  Explanation  The statement both the primary clinical trial and the secondary clinical trial did not make a record of any adverse events is entailed by the evidence since the evidence reports that there were no adverse events recorded in both trials",
        "label": "Entailment"
    },
    "3bde4a4f-fece-4422-a55a-461fa027c18a": {
        "text_answer": "No   Explanation   The statement Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is not directly entailed by the evidence provided Perjeta is not mentioned in the evidence at all The evidence only discusses Fulvestrant Anastrozole and the use of novel radiotracers for HER2targeted PETCT in the secondary trial",
        "label": "Contradiction"
    },
    "31546be8-dcef-4300-a21d-831c25e5b92a": {
        "text_answer": "No  Explanation  The statement none of the adverse events in the secondary trial affected more than 30 of patients apart from Skin infections is not entirely accurate based on the provided evidence While it is true that none of the adverse events affected more than 3333 of patients except for Skin infections which affected 3333 of patients the statement does not account for the total",
        "label": "Contradiction"
    },
    "d3a0e851-28c4-4382-bb3e-8c40bc16ae7a": {
        "text_answer": "Yes  Explanation  The statement diarrhea was noted as a more common symptom among primary clinical trial participants as compared to those of the secondary clinical trial is entailed by the evidence as the primary trial had 7 cases of diarrhea out of 30 participants 2333 while the secondary trial had no cases of diarrhea out of 6 participants 000",
        "label": "Entailment"
    },
    "05aafe0b-c62a-4dda-a60a-52929cb81b7f": {
        "text_answer": "Yes The statement is a summary of some of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "text_answer": "Yes The evidence states that for Phase 2 of the trial patients with breast cancer must be ER positive andor PR positive but HER2 negative and have failed a hormone therapy and a CDK46 inhibitor to be eligible However it also states that other solid tumor types can be approved by the sponsor Therefore ER negative breast cancer patients can be eligible for Phase 1 of the trial which does not have specific hormone receptor",
        "label": "Entailment"
    },
    "6333ef7c-fdfe-4f90-b763-4d826c08975c": {
        "text_answer": "Yes  Explanation  The statement in both the primary clinical trial and the secondary clinical trial there were adverses events which affected less than 1 of the participant group is entailed by the evidence provided The evidence shows that in both trials the percentage of participants experiencing adverse events was less than 1",
        "label": "Entailment"
    },
    "66030da0-0335-44c8-97dd-a620f3d9961f": {
        "text_answer": "No  Explanation  The statement insomnia patients irrespective of the severity of their condition are invited to take part in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial has specific inclusion criteria for insomnia requiring a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index IS",
        "label": "Contradiction"
    },
    "72130361-5d83-4dbb-98ce-8e9a6f2541e4": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the outcome measurements in the two trials are not the same The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in women undergoing hormone replacement therapy while the secondary trial determines the Maximum Tolerated Dose MTD of Ruxolitinib in combination with Paclitaxel in cancer patients",
        "label": "Contradiction"
    },
    "72b75fca-541f-4311-a38d-9f1d73220418": {
        "text_answer": "No  Explanation  The statement notice change in the way food tastes is a question about whether an individual notices or noticed a change in the way food tastes is not directly related to the evidence provided in the primary or secondary trials The primary trial reports the percentage of participants who had a response within 10 days of the first dose of denosumab while the secondary trial reports the number of participants who reached a safe and welltolerated",
        "label": "Contradiction"
    },
    "66bf512a-c3fd-46a8-8a0b-4d64fde85082": {
        "text_answer": "No  Explanation  The statement unmutated immunoglobulin heavy chain variable region gene is a molecular finding indicating that the immunoglobulin heavy chain variable region has an unmutated germline configuration is not directly mentioned in the evidence provided for either the primary or secondary trial The evidence only mentions specific inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "text_answer": "Yes The primary trial candidates receive fewer total doses of MM121 and weekly doses of Paclitaxel than the secondary trial candidates",
        "label": "Entailment"
    },
    "e59036ac-08b6-44ed-ad46-292a3bb8a937": {
        "text_answer": "Yes The statement no fatalities or hospital stays occurred in the second cohort of the primary clinical trial is entailed by the evidence since there were no instances of death or hospitalization reported in the second cohort The statement also correctly mentions the absence of fatalities but it is redundant since the evidence already states this explicitly for both cohorts The statement only one instance of atrial fibrillation was observed is not directly stated in",
        "label": "Entailment"
    },
    "c01204e3-a0fd-4153-a27d-d17c0bb4773b": {
        "text_answer": "Yes  Explanation The evidence shows that the percentage of participants who were up to date with their colorectal breast and cervical cancer screenings increased significantly after the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups However the baseline percentages of participants who were up to date with their screenings were relatively low for all cancer types indicating that many patients in the first cohort",
        "label": "Entailment"
    },
    "21b261e7-4b78-4c70-ba0c-b98c5c082bee": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the percentage change in betaCTX at Week 4 for each group The statement asks about the percentage change at Week 28 which is not mentioned in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "29c084b6-6c7c-4f6b-abcc-6740b951f139": {
        "text_answer": "No  Explanation  The statement in cohort 2 the primary clinical trial had a significantly higher patient enrollment compared to the secondary clinical trial is not entailed by the evidence provided The evidence only reports the number of participants analyzed in each arm of the trials but it does not compare the number of participants enrolled in each cohort",
        "label": "Contradiction"
    },
    "0feb3694-da20-4a30-b85d-e9dc4cdb55c3": {
        "text_answer": "No  Explanation  The statement the primary and the secondary trial reported an equal number of intestinal perforation cases is not entailed by the evidence In the secondary trial there was one reported case of intestinal perforation while in the primary trial there were no reported cases",
        "label": "Contradiction"
    },
    "551f61b2-c709-4c51-b705-d2415e40ae40": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial assess different patient populations and different outcomes The primary trial focuses on the toxicity of a specific treatment regimen involving HER2specific T cells while the secondary trial focuses on the percentage of participants with adverse events of primary interest AEPIs in a cohort of patients receiving trastuzumab emtansine The patient populations are also different with the primary trial involving",
        "label": "Contradiction"
    },
    "dc9267c3-b1ab-45d1-8a22-a9ec8e7ba673": {
        "text_answer": "Yes  Explanation The evidence shows that a larger percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for their colorectal breast and cervical cancer screenings after the intervention compared to before This indicates that the majority of patients in both groups were up to date for their screenings after the intervention regardless of cancer type",
        "label": "Entailment"
    },
    "72d13f98-6915-4a80-9810-c06d0e204b1e": {
        "text_answer": " Yes   Explanation  The evidence provided in the results of the primary trial shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at week 4 compared to the Zoledronic Acid 4 mg group This is consistent with the statement that the AZD0530 175 mg group experienced a more significant percentage change in betaCTX at week 4 than the",
        "label": "Entailment"
    },
    "2e9d87da-10f2-4530-b200-87bb72cd9335": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial explicitly excludes individuals with malignant ductal carcinoma in situ while the secondary trial includes individuals with a history of breast cancer including ductal carcinoma in situ The evidence does not mention anything about uncontrolled hypertension being permissible or excluded in the primary trial so the statement does not directly relate to the given evidence",
        "label": "Contradiction"
    },
    "d542b63b-a355-4a0e-8ec9-3c74bb1e0dcb": {
        "text_answer": "Yes  Explanation  The statement only a minority of patients in the primary clinical trial had a complete response by the 24th week is entailed by the evidence since the evidence shows that at Week 24 there were no participants with a complete response CR in the Lapatinib 1250 mg and Vinorelbine 20 mgm2 armgroup",
        "label": "Entailment"
    },
    "2f1db1ac-f8d0-4087-856e-dfcff97c75a5": {
        "text_answer": "  No the statement is not entailed by the evidence for the secondary trial as there is no mention of pulmonary embolism in the exclusion criteria for that trial",
        "label": "Contradiction"
    },
    "bd2b336d-30ae-4151-a920-9506a013ab14": {
        "text_answer": "No  Explanation The statement lipase unit is a dosing unit based on lipase activity is not directly related to the inclusion or exclusion criteria for the primary or secondary trials provided in the evidence The statement does not mention breast cancer or the trials at all Therefore it cannot be determined if the statement is entailed by the evidence based on the given information",
        "label": "Contradiction"
    },
    "d5fe5d1e-b4c8-46d1-879f-06f14157c3ee": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes postmenopausal women with hormonerequiring breast cancer who have received previous hormonal treatment and have not received more than one previous regimen of endocrine therapy for advanced breast cancer",
        "label": "Entailment"
    },
    "9ed2eb80-3810-40fc-b26a-d2e93feb061d": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity weight or gender as eligibility criteria for either trial",
        "label": "Entailment"
    },
    "dad4efbe-c7ae-4507-8a04-853a132b497a": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c574fb87-713c-43cd-a147-215f98ff6d35": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fca56898-5587-4c6a-ae87-86dfae3a4961": {
        "text_answer": "Yes The statement General symptoms are the most common AE recorded in the primary trial is entailed by the evidence as there are a total of 11 general symptoms recorded out of 16 adverse events 7308",
        "label": "Entailment"
    },
    "5a25fa73-5358-4d36-acc0-ea23cb358a4d": {
        "text_answer": "Yes  Explanation  The evidence provided indicates that there were no instances of doselimiting toxicity DLT in either of the two study arms which is consistent with the statement that there were no recorded instances of DLT from any patients participating in the primary clinical trial",
        "label": "Entailment"
    },
    "475425c4-cfbf-4742-86ad-b09806d19687": {
        "text_answer": "No  The statement is not entailed by the evidence as coronary artery stenosis is not listed as an adverse event in the evidence provided",
        "label": "Contradiction"
    },
    "8e66baf7-890a-4a73-9542-814980f89689": {
        "text_answer": "Yes The participants in the primary clinical trial received a lower dose of PF06647020 compared to the participants in the secondary clinical trial who received a lower dose of ALT801",
        "label": "Entailment"
    },
    "0935ad04-3112-4443-8f3a-6b3a07ac9d33": {
        "text_answer": "No   Explanation   The patient with a primary tumour of 03 cm radius would not meet the inclusion criteria for the primary trial which requires a primary tumour greater than 2 cm diameter Therefore they would not be eligible for the primary trial   Additionally the statement does not apply to the secondary trial as it does not mention the size of the primary tumour as a criterion",
        "label": "Contradiction"
    },
    "e44f0355-dac8-4405-b3b1-ceb87cbb121d": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence explicitly states that there should be no meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "128e4316-cd80-4dff-9d54-3030e9921c77": {
        "text_answer": "No  Explanation  The statement cases of mucositis oral thromboembolic events and bladder infection were more prevalent in the primary trial than in the secondary trial is not entailed by the evidence The evidence only shows that the prevalence of these adverse events was different between the two trials but it does not necessarily mean that they were more prevalent in the primary trial In fact the evidence shows that",
        "label": "Contradiction"
    },
    "5acd7311-862e-440b-aecd-64f015c7deb6": {
        "text_answer": "Yes The trial compares two different interventions one with nabPaclitaxel and gemcitabine and the other with nabPaclitaxel and carboplatin The doses of gemcitabine and carboplatin differ between the two arms",
        "label": "Entailment"
    },
    "5cf2e65a-45cd-490e-8933-23bf36558b11": {
        "text_answer": "No  Explanation  The evidence provided in the results does not indicate that every patient in each cohort experienced an incidence of doselimiting toxicity The evidence only states the number of participants analyzed in each cohort The presence or absence of doselimiting toxicities for each individual participant is not mentioned",
        "label": "Contradiction"
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "text_answer": "No  Explanation  The evidence provided does not mention Tumour lysis syndrome as an adverse event in either the primary or secondary trials Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "56c99670-a2ba-42ca-b870-e3d98f2f4169": {
        "text_answer": "No  Explanation  The statement the inclusion of a patient into the primary clinical trial is dependent entirely on the objective criteria for inclusion and exclusion and is not influenced by the judgment of the health professionals supervising the trial is not entailed by the evidence The evidence only lists the objective inclusion and exclusion criteria for the clinical trial but it does not state that the judgment of the health professionals is not involved in the patient selection process In fact",
        "label": "Contradiction"
    },
    "eab0f794-5caa-49fc-b951-7db4b7169a46": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria listed in the evidence Patients with a history of abdominal fistula gastrointestinal perforation stroke transient ischemic attacks or intrabdominal abscess within the preceding six months are excluded from the trial Patients with a history of psychiatric disorders may also be excluded depending on the severity of the disorder",
        "label": "Entailment"
    },
    "c4b53dae-5bcf-4356-825d-0701f5c9b545": {
        "text_answer": "No  Explanation The statement in the primary clinical trial the number of hypertension and pancreatic resection cases were ten times higher than cases of hepatotoxicity is not entailed by the evidence The evidence states that there was 1 case of hypertension and 1 case of pancreatic resection out of 8 total adverse events and 3 cases of hepatotoxicity Ten times the",
        "label": "Contradiction"
    },
    "057e1439-4666-4373-a5b4-539c6cd24469": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial whole breast radiation therapy is given to participants while in the secondary clinical trial both cohorts receive intramuscular injections and also take prescribed medication orally is not entailed by the evidence  The primary clinical trial involves whole breast radiation therapy as stated in the intervention description However the secondary clinical trial involves intramuscular injections of Fulvestrant",
        "label": "Contradiction"
    },
    "4bf53370-da92-4333-bae7-3b35ab56b86e": {
        "text_answer": "No  Explanation  The primary clinical trial excludes participants with a history of clotting disorders including deep vein thrombosis and pulmonary embolism PE Therefore individuals with a history of PE are not eligible for participation in the primary trial  The secondary clinical trial does not mention PE as an exclusion criterion However it does exclude participants with breast implants  The statement that both primary and secondary",
        "label": "Contradiction"
    },
    "963bd695-f26a-4891-931e-9b417a7c81c0": {
        "text_answer": "No  Explanation  The statement the primary clinical trial reported a higher incidence of infection asymmetry and deflation compared to the secondary clinical trial is not entailed by the evidence provided The evidence only shows that there were adverse events in both trials but it does not provide enough information to make a comparison between the incidence of specific adverse events in the two trials In the primary trial there were instances of infection asymmetry",
        "label": "Contradiction"
    },
    "662dd235-76f6-4ab6-b4c8-5537e6f7ffb3": {
        "text_answer": "No  Explanation  The statement four or more positive lymph nodes is an indication that cancer cells have been detected in four or more lymph nodes is not related to the evidence provided in the trial results The evidence only reports the changes in lymphedema arm circumference for patients in the acupuncture and waitlist groups over a 6week period There is no mention of lymph nodes or cancer",
        "label": "Contradiction"
    },
    "fb4e9c92-aa61-4691-b1fe-3cbb4a183f6d": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial does not report the severity of delayed nausea but rather the summed pain intensity differences SPID at 30 minutes after dosing for each pain episode The secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "09684ae5-162a-43ba-9735-6c9bce05cd5f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "847dd934-e3d0-44c6-8964-d1eb14b0d7a2": {
        "text_answer": "No  Explanation  The evidence provided in the text indicates that the patients in the Tamoxifen group had an average standardized score of 004 049 and those in the Ovarian Function Suppression group had an average standardized score of 021 092 A negative standardized score indicates below average results so the evidence suggests that on average patients in both groups had below average cognitive",
        "label": "Contradiction"
    },
    "d9444db3-e6d5-43d4-ba21-b934f8e0f77e": {
        "text_answer": "No   Explanation   The statement microscopic findings group identifier is a character or string that represents a microscopic findings group is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The statement does not entail any information about patient age or other criteria specified in the evidence",
        "label": "Contradiction"
    },
    "3f6f3ca0-d14d-4fdb-9be8-19859181aaa9": {
        "text_answer": "No  Explanation  The statement after being treated with aprepitant dexamethasone cytoxan and kytril in the primary clinical trial acute vomiting was observed in over 50 of the patients from the first cohort is not entailed by the evidence provided The evidence states that 20 out of 35 participants in the study experienced no vomiting and no rescue medication",
        "label": "Contradiction"
    },
    "2acdad0e-1a86-49d6-817d-cddb655073ac": {
        "text_answer": "No  The statement is not related to the evidence provided which pertains to adverse event data from two cohorts in a clinical trial The statement describes a geographical fact about a country in Africa",
        "label": "Contradiction"
    },
    "402d2312-d5b6-4763-9246-4e094a7d6739": {
        "text_answer": "No  Explanation The statement a participant in cohort 2 endured the longest pfs in the primary clinical trial with 8 months without disease progression or death is not entailed by the evidence The evidence only provides the median PFS for each cohort not the longest PFS for any individual participant",
        "label": "Contradiction"
    },
    "c0e3960b-923b-460f-a6e1-0b16f32af78f": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the number of adverse events was equal in both cohort 1 and cohort 2 is not entailed by the evidence The evidence shows that the percentage of adverse events is different between the two cohorts with a higher percentage in cohort 1 4245 compared to cohort 2 680",
        "label": "Contradiction"
    },
    "d1b9ab7c-2229-405c-be0e-01d822ac5aa1": {
        "text_answer": "  No   Explanation   The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for all cohorts of the primary trial is not directly stated in the evidence The evidence only mentions ER positive and HER2 negative tumors as inclusion criteria for Group 1 and invasive triplenegative breast cancer ER negative PR negative and HER2",
        "label": "Contradiction"
    },
    "01bbbed8-5b22-4017-b6c5-f8a32bd6ab20": {
        "text_answer": "No   Explanation  The statement in the primary clinical trial all interventions are delivered via the same method is not entailed by the evidence because the evidence describes two different interventions one delivered via intravenous IV method and the other via subcutaneous SC injection method",
        "label": "Contradiction"
    },
    "418be5f3-61b5-4bae-a274-c2213e3cc7cf": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "d15f343f-8edf-484e-bc6c-bbcbbf8c9118": {
        "text_answer": "No  Explanation  The statement pain has interfered with normal work is not directly related to the inclusion or exclusion criteria of either the primary or secondary trial The primary trial focuses on breast cancer patients with specific eligibility criteria related to chemotherapy hemoglobin levels and epoetin beta while the secondary trial focuses on breast cancer patients receiving paclitaxel in the adjuvant setting with specific eligibility",
        "label": "Contradiction"
    },
    "9532e5a5-0e29-4914-8cf5-5aff881ffa8a": {
        "text_answer": "Yes  Explanation The evidence provided in the primary clinical trial includes the number of participants analyzed for each armgroup Arm II and Arm III Therefore the statement that the trial discloses the number of participants included in each specific cohort is entailed by the evidence",
        "label": "Entailment"
    },
    "dba63c59-7efc-48de-a02e-69b1b5beb08d": {
        "text_answer": "Yes  Explanation  The statement is entailed by the evidence as the primary clinical trial involves testing different gels Hydrophor and MediHoney while the secondary clinical trial involves testing the same treatment PF05212384 but in various doses 90 mg and 110 mg",
        "label": "Entailment"
    },
    "da6c4a2b-18ad-44d9-9021-71c4f9b22fff": {
        "text_answer": "No  Explanation  The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel The outcome measures for both trials are different and do not involve the proportion of patients with no invasive tumor leftover",
        "label": "Contradiction"
    },
    "fc24dc2a-3257-433f-91ed-fc3d3ec369b3": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary trial lasts 105 more days than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks and the secondary trial lasted for 24 weeks However the difference between 10 and 24 weeks is not equal to 105 days Therefore the statement is not a valid conclusion based on",
        "label": "Contradiction"
    },
    "cc11b6a5-855a-4291-b41d-e63367ea3b88": {
        "text_answer": "Yes The primary and secondary clinical trials both use pCR as an outcome measurement The primary trial has slightly different pCR rates between its two cohorts while the secondary trial shows larger differences with Arm 2 having a lower pCR rate",
        "label": "Entailment"
    },
    "25bc284b-0476-4950-96e5-3b08a2a1c33c": {
        "text_answer": "  Yes but with a qualification The primary trial excludes patients with a pulmonary embolism within the last 4 weeks while the secondary trial excludes those with a pulmonary embolism within the last 6 months The statement is entailed by the secondary trial but not the primary trial",
        "label": "Entailment"
    },
    "4f886133-596d-449a-92c3-7472e2602982": {
        "text_answer": "No  Explanation  The statement Patients with a breast tumor 0208 cm in diameter with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial is not entailed by the evidence provided The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial includes patients with locally advanced or metastatic breast cancer The statement does not address the",
        "label": "Contradiction"
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "text_answer": "No  Explanation  The statement the primary trial candidates receive less weekly MM121 and Paclitaxel than cohort 1 the secondary trial candidates but higher doses of herceptin and doxorubicin is not directly entailed by the evidence provided  The evidence only states that in the primary trial patients undergoing mastectomy surgery were approached for participation while in the secondary trial HR",
        "label": "Contradiction"
    },
    "b32a43a7-cac0-4434-bdb2-4c4d8b26d947": {
        "text_answer": "  No the statement is not entailed by the evidence In the primary trial participants cannot have any alcohol or substance abuse or dependence within the past 2 years In the secondary trial participants must have fewer than 5 alcoholic drinks per day within the past year However the statement does not specify which trial it refers to and incorrectly states that recovering alcoholics who currently abstain can participate in the primary trial",
        "label": "Contradiction"
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "text_answer": "No  Explanation  The statement There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not entailed by the evidence The evidence only reports the number and types of adverse events observed in the primary trial but it does not specify which participants experienced both a gastrointestinal event and two or more psychiatric events Therefore it is possible that some",
        "label": "Contradiction"
    },
    "ce486acd-8aae-475c-b95e-131fc0809e15": {
        "text_answer": "No  Explanation The statement provided does not directly relate to the information given in the evidence The evidence describes the details of two interventions in a clinical trial one involving sunitinib and paclitaxel Intervention 1 and the other involving bevacizumab and paclitaxel Intervention 2 The statement on the other hand discusses rifamycin sodium an antibiotic and its production",
        "label": "Contradiction"
    },
    "d083c9b8-decf-41ac-a3b0-ba8b6eedb32d": {
        "text_answer": "  Maybe   Explanation   The evidence provided does not directly compare the ORR between the two groups in terms of absolute numbers or statistical significance It only shows the ORR and the number of participants analyzed for each group Therefore based on the given information it is not possible to definitively say that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bev",
        "label": "Entailment"
    },
    "4a5a5c6f-b9b3-48a4-a79a-582dc83323e3": {
        "text_answer": "Yes The primary trial explicitly states that patients who require use of coumarinderivative anticoagulants such as warfarin are excluded However the secondary trial permits lowdose warfarin less than or equal to 1 mgday for certain patients",
        "label": "Entailment"
    },
    "5b8f9c72-6729-4b0f-9956-617021d55805": {
        "text_answer": "  No  Explanation  The statement patients with endocarcinoma are ineligible for the secondary clinical trial but viewed as potential candidates for the primary clinical trial is not entailed by the evidence provided Endocarcinoma is not mentioned as a disease characteristic or exclusion criterion in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "1a47637c-31f0-42c0-9729-7ab8c66fafb4": {
        "text_answer": "No  Explanation  The primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary clinical trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in units of mg These are not identical units of measurement",
        "label": "Contradiction"
    },
    "c79f4ed7-5e39-48ad-bc32-fef9ace77a76": {
        "text_answer": "No  Explanation  The statement neither the primary clinical trial nor the secondary clinical trial cohort is given entericcoated tablets is not entailed by the evidence The evidence only mentions the interventions used in each trial and the dosages but it does not specify whether the tablets used were entericcoated or not",
        "label": "Contradiction"
    },
    "4d33c738-d007-4e43-8d51-6c98c40631df": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "d7170cb2-d8a5-4c65-9122-bc6bcf13caeb": {
        "text_answer": "No  Explanation The statement her2neu negative by immunohistochemistry is a laboratory test result indicating the absence of her2neu in a tissue sample using immunohistochemical staining is not directly related to the evidence provided The evidence only mentions the type and duration of the interventions in the primary trial but it does not mention anything about the her2neu status of the patients or",
        "label": "Contradiction"
    },
    "b76d27c5-45ec-4695-8480-1128862ea21b": {
        "text_answer": "No  The statement is not entailed by the evidence as the placebo in the primary clinical trial was administered via an intravenous infusion not an intramuscular injection",
        "label": "Contradiction"
    },
    "8fcaece4-a0c7-44bf-82b0-50e494825b81": {
        "text_answer": "No  Explanation  The evidence provided states that 53 out of 60 participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR However the statement asks for the percentage of patients who experienced a confirmed complete response CR specifically The evidence does not provide the exact percentage of patients who experienced a CR Therefore",
        "label": "Contradiction"
    },
    "37f74912-6578-4304-9f9c-6b3c4c217e97": {
        "text_answer": "No  Explanation The statement provided does not directly relate to the information given in the evidence The evidence describes the interventions and cohorts of a primary trial while the statement discusses primary ciliary dyskinesia 29 and a mutation in the ccno gene These two pieces of information are not directly related to each other",
        "label": "Contradiction"
    },
    "35802b7b-4d8e-4f1a-bab8-20eea1f4aa3f": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "text_answer": "Yes   Explanation The statement is entailed by the evidence as it accurately reflects the information provided in the primary and secondary trials regarding the dosing schedules for Alpha Lipoic Acid and Necitumumab respectively",
        "label": "Entailment"
    },
    "95928e94-237c-4e85-98d4-9dc5371c5069": {
        "text_answer": "No   Explanation   The statement is not directly entailed by the evidence as the evidence does not mention paclitaxel in the context of the cohort 2 intervention The statement only mentions that cohort 2 is administered fulvestrant instead of anastrozole but it does not specify that paclitaxel is not used in cohort 2",
        "label": "Contradiction"
    },
    "1b229af4-937d-4ae0-8c39-12064d16b246": {
        "text_answer": "Yes  Explanation  The evidence shows that patients in Arm I Cryotherapy had a median aAUCpa of 14 117 to 68 indicating an improvement in symptoms from baseline while patients in Arm II Control had a median aAUCpa of 44 571 to 162 indicating worsening symptoms from baseline This suggests that the topical",
        "label": "Entailment"
    },
    "f569ce38-1e3f-4e8d-a9d7-e4a35a18c90c": {
        "text_answer": "No The statement is not directly related to the evidence provided which pertains to the inclusion and exclusion criteria for a breast cancer clinical trial The statement about dyskinesia being an abnormality or impairment of voluntary movement is a general definition and is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "966efbd3-dce6-400c-b5bc-87ca468c7225": {
        "text_answer": "No  Explanation The evidence provided in the primary trial relates to the percentage change in serum beta Cterminal crosslinking telopeptide of Type I Collagen betaCTX at Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided in the question is about the primary tumour diameter which is not mentioned in the evidence Therefore",
        "label": "Contradiction"
    },
    "d2757370-ae03-4046-a888-e30b9aa1551f": {
        "text_answer": "  No  Explanation  The statement individuals with fluorescent in situ hybridizationconfirmed nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer can enroll in both the primary and secondary clinical trials is not entailed by the evidence provided The primary trial includes individuals with NUT midline carcinoma but it does not allow for participation in another clinical trial",
        "label": "Contradiction"
    },
    "cc439508-491f-4c5a-9304-5ddf9d266506": {
        "text_answer": "Yes The evidence shows that both groups had below average standardized scores for cognitive function indicating a deterioration compared to agespecific norms but the extent of the deterioration varied between individuals",
        "label": "Entailment"
    },
    "d2c665aa-c13e-4d5d-95f8-d85c5c9f3ef9": {
        "text_answer": "No The statement has nothing to do with the evidence provided The evidence only reports the occurrence of adverse events in two different cohorts of a trial and the statement is about the feeling of humiliation which is not mentioned or related to the evidence",
        "label": "Contradiction"
    },
    "936b5904-9a93-4aaf-8d20-03e0a4fb3223": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "7326be65-0450-4fb7-88d3-5d926d65db74": {
        "text_answer": "No  Explanation  The statement only patients prescribed gtx024 3mg during the primary clinical trial resulted in weight gain particularly in lean body mass is not directly entailed by the evidence provided The evidence only shows the median change in total body lean mass for each group 1 mg and 3 mg of participants but it does not indicate that all participants in the 3 mg group gained weight or that those who gained weight",
        "label": "Contradiction"
    },
    "692ea096-a2cf-4732-a141-b349cfd460d6": {
        "text_answer": "Yes  Explanation  The statement urinary tract infections were a frequent side effect among participants involved in the primary clinical trial is entailed by the evidence since urinary tract infections were reported as an adverse event with a frequency of 200 1 out of 50 participants",
        "label": "Entailment"
    },
    "96dedf4b-abc0-41ea-b12a-9a8afce9708d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the route of administration for the placebo The placebo is described as being taken by mouth PO in the same manner as the memantine but no specific route sublingual or rectal is mentioned for the placebo",
        "label": "Contradiction"
    },
    "74c47731-5e97-400b-bf85-52ae0b8b5e09": {
        "text_answer": "No  Explanation The statement requires that each patient receives at least 20000 g of MCS110 every 21 days and over 130000 g of PDR001 every 14 days However the evidence only specifies the dosages given to each patient in the trial which are 1 mgkg for MCS110 and 100",
        "label": "Contradiction"
    },
    "e4eba352-415f-44bd-8fe0-244240a80513": {
        "text_answer": "Yes  Explanation The evidence states that 20 out of 35 participants in cohort 2 did not experience acute vomiting following treatment with aprepitant dexamethasone cytoxan and kytril This means that less than half 20 out of 35 of the patients in this cohort experienced acute vomiting",
        "label": "Entailment"
    },
    "ce26a25e-c6ff-4bba-bd54-b0e069440746": {
        "text_answer": "No   Explanation  The statement not a single instance of a maculopapular rash was reported in the primary clinical trial is not entailed by the evidence The evidence reports one instance of a maculopapular rash in the primary clinical trial",
        "label": "Contradiction"
    },
    "4f0e91c8-87f4-4af4-b47d-c5a8e459713d": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it only mentions cohort 2 having access to the educational DVD but the evidence only specifies that cohort 1 of the primary clinical trial will receive the intervention viewing the educational DVD and meeting with a lay health advisor",
        "label": "Contradiction"
    },
    "4d8bdd85-b621-4334-9aff-9ab0b69172e5": {
        "text_answer": "Yes The evidence does not mention any mental health body weight tumor size KarnofskyECOG score or estimated life span as inclusion or exclusion criteria for the clinical trial",
        "label": "Entailment"
    },
    "2b2a038c-37d7-42a6-817a-5392b1e94613": {
        "text_answer": "Yes  Explanation  The statement the incidence of aes was reported to be higher amongst patients in the secondary clinical trial than those in the primary clinical trial is entailed by the evidence as the evidence shows that the incidence of Adverse Events 1 was 6000 in the secondary trial compared to 000 in the primary trial",
        "label": "Entailment"
    },
    "530798af-a5d0-4de8-8183-b2ef6068c90a": {
        "text_answer": "Yes The statement is entailed by the evidence as both groups receive the same radiation therapy intensity and undergo SPECT scans",
        "label": "Entailment"
    },
    "55e361f9-9360-4de4-a301-6b504913b094": {
        "text_answer": "Yes The secondary clinical trial had more participants 163 than the second cohort of the primary clinical trial 75",
        "label": "Entailment"
    },
    "f191be61-8e8d-495c-b5e3-1bf3cc89904a": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence reports median survival times up to 9 years for both groups",
        "label": "Contradiction"
    },
    "b2572b63-5246-4be3-84ee-c37f18da106d": {
        "text_answer": "Yes  Explanation The statement cohort 1 in the primary clinical trial received a higher dosage of cetuximab compared to cohort 2 is entailed by the evidence because cohort 1 received a maintenance dose of 200 mgm2 of cetuximab while cohort 2 received a maintenance dose of 200 mgm2 of cetuximab after a higher loading dose",
        "label": "Entailment"
    },
    "328dcbbe-1a4a-46f1-afad-df84cebcde05": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes the administration of oral lapatinib and tamoxifen not a onetime intramuscular dose",
        "label": "Contradiction"
    },
    "992db0e7-c7c4-413c-874f-c8e53d481fab": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the doses of MM121 given in the primary trial to cohort 1 and cohort 2 are different but the doses of cetuximab are equal The statement incorrectly equates the doses of MM121 with the doses of cetuximab leading to an incorrect conclusion",
        "label": "Contradiction"
    },
    "c51c390c-f844-492c-9844-53e31e01124d": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial and the secondary clinical trial a significant number of unexpected fatalities and hospital stays were observed is not entailed by the evidence provided The evidence only reports the number of adverse events including lymphoma cases in each trial but it does not mention any fatalities or hospital stays",
        "label": "Contradiction"
    },
    "ea25b3f7-4ef8-4e5f-b3e8-3cbf0da93a12": {
        "text_answer": "No   Explanation   The statement Patients with measurable bilateral breast cancer are eligible for the primary trial is not directly related to the given evidence The evidence only mentions inclusion and exclusion criteria for patients with unilateral breast cancer and upper extremity lymphedema The statement is about bilateral breast cancer which is different from the unilateral breast cancer mentioned in the evidence Additionally there is no mention of a",
        "label": "Contradiction"
    },
    "15c27d36-ca02-48e2-8e08-d9c6b52042c6": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes individuals with metastatic disease M1 and multiple sites of new disease that is clinically obvious metastatic disease",
        "label": "Entailment"
    },
    "890c305f-bd6d-4db4-adf5-2aaf8e28d6c6": {
        "text_answer": "No  Explanation  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope which occurred in 2500 of the primary trial patients is not entailed by the evidence The evidence only states that Syncope occurred in 1667 of the patients in the primary trial and in 084 of the patients in the secondary",
        "label": "Contradiction"
    },
    "93c0565f-98d6-4f6b-92a6-8464567027c7": {
        "text_answer": "Yes  Explanation  The primary clinical trial focuses on Time to Progression TTP as the outcome measurement while the secondary clinical trial measures the Number of Participants With Objective Response The primary trial does not provide data on objective response and the secondary trial does not provide data on Time to Progression Therefore the statement the primary clinical trial does not reveal data about the time to progression among patients while the secondary clinical trial does not keep",
        "label": "Entailment"
    },
    "32c13f2f-7902-444f-8f99-c3ea2ecac0d0": {
        "text_answer": "No  Explanation  The statement the primary clinical trial records more types of adverse events yet the total number of adverse events reported is less than in the secondary clinical trial is not entailed by the evidence The evidence shows that there are more types of adverse events recorded in the primary clinical trial but the total number of adverse events reported is actually less in the primary trial than in the secondary trial",
        "label": "Contradiction"
    },
    "33603672-b61c-4ddd-8e57-d38876de9132": {
        "text_answer": "Yes  Explanation  The statement there was no repetition in the type of adverse event endured by patients in the primary clinical trial is entailed by the evidence because each adverse event is listed only once indicating that each patient experienced a unique type of adverse event",
        "label": "Entailment"
    },
    "2e753155-acb5-417c-9169-9ec7ccc4d8ac": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "356f845b-f5e9-46f8-8374-fb598e246876": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts use the same instructional CD for paced breathing The difference is in the frequency of practice once daily for cohort 1 and twice daily for cohort 2 The statement also mentions that cohort 2 receives weekly chemotherapy which is not directly related to the paced breathing intervention but is mentioned in the evidence as well",
        "label": "Entailment"
    },
    "74b96ae6-3e1a-4f1c-bbf0-a79ed0e4ee75": {
        "text_answer": "Yes  Explanation  The statement adverse events were not documented for both the primary clinical trial and the secondary clinical trial is entailed by the evidence since the evidence shows that there were no adverse events documented for either trial",
        "label": "Entailment"
    },
    "2fafc6ea-da6d-4160-829d-1f599da46818": {
        "text_answer": "Yes the statement is about a different condition gingival polyp and is not entailed by the evidence provided",
        "label": "Entailment"
    },
    "74bde0ca-3313-40ab-95f3-55d2adea4f89": {
        "text_answer": "  No  Explanation  The statement patients diagnosed with benign fibroadenoma and effectively managed hypertension can participate in the primary clinical trial but are ineligible for the secondary clinical trial is not directly entailed by the evidence provided The primary trial includes fibroadenoma as a type of benign breast disease but it has additional exclusion criteria that may prevent some patients with fibroadenoma from participating The secondary trial",
        "label": "Contradiction"
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f2d20a53-59b4-42bf-8d21-1ead0e113107": {
        "text_answer": "No  The evidence does not mention schizophrenia as an exclusion criterion for either trial",
        "label": "Contradiction"
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "text_answer": "Yes  Explanation  The statement In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1 of participants is entailed by the evidence since the evidence shows that in both trials the percentage of adverse events was less than 1",
        "label": "Entailment"
    },
    "151bb6d0-e4bf-4eea-8842-5fe4e1782782": {
        "text_answer": "No  Explanation  The statement recurrencefree survival was experienced by 96 individuals in the ketorolac 30 mg group in comparison to 67 individuals in the nacl 09 3ml group during the primary clinical trial is not directly entailed by the evidence provided The evidence only states the number of participants in each group who completed the study 80 out of 833",
        "label": "Contradiction"
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials include patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma as inclusion criteria",
        "label": "Entailment"
    },
    "3cbaa580-dfe1-4331-902c-5be850db2f24": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "80b93d64-be3c-45e0-8524-b8042e84bdc7": {
        "text_answer": "No  Explanation  The statement patients in the primary trial recorded the most instances of chest pain compared to those in the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each trial but it does not mention chest pain specifically",
        "label": "Contradiction"
    },
    "57663242-4e73-409f-a7f9-1738e13298ab": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "df344680-ab21-4889-bba7-7db757b72bae": {
        "text_answer": "Yes  Explanation The statement cohort 1 and 2 in the primary clinical trial differ primarily based on the daily treatment received is entailed by the evidence as it clearly states that cohort 1 receives sunitinib at a daily dose of 25 mg while cohort 2 receives paclitaxel at a starting dose of 90 mgm2 daily",
        "label": "Entailment"
    },
    "f50bcaa7-7424-4977-ac06-f47e545e2e00": {
        "text_answer": "No  Prostate cancer is not listed as a eligible cancer type in the provided clinical trial evidence",
        "label": "Contradiction"
    },
    "46ac728d-deb3-4559-bc71-1729c70c26e7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial involves Botulinum Toxin Type A and Placebo while the secondary clinical trial involves MLN8237 with different dosages The statement specifically mentions alisertib which is not present in the primary trial and is only mentioned in relation to the secondary trial with different dosages",
        "label": "Contradiction"
    },
    "665afeee-f623-4c57-8550-a5dbe71430cb": {
        "text_answer": "No  Explanation  The statement individuals partaking in the secondary clinical trial are administered weekly subcutaneous injections is not directly entailed by the evidence provided The evidence only mentions that participants in the secondary trial received Epoetin Beta but it does not specify the method of administration",
        "label": "Contradiction"
    },
    "786bc355-6b8f-455c-b6b2-470350231601": {
        "text_answer": "Yes  Explanation  The statement comprehensive records of adverse events are available for the primary trial enabling a thorough comparison with the secondary trials data is entailed by the evidence because the evidence provides the number of adverse events for both trials allowing for a comparison between them",
        "label": "Entailment"
    },
    "72ea65df-6381-4672-a40c-f55cee100091": {
        "text_answer": "Yes The statement mentions stomatitis as the adverse event which is consistent with the evidence that the sole adverse event was stomatitis occurring in 129 participants or 345",
        "label": "Entailment"
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "text_answer": "Yes  Explanation The statement cohort 1 of the primary trial is administered less than half the dose of ALT801 as cohort 2 is entailed by the evidence since 0015 mgkgdose is less than 0040 mgkgdose",
        "label": "Entailment"
    },
    "7714e6f7-814a-4088-9116-60f5ceef4336": {
        "text_answer": "  No   Explanation   The statement a patient recuperating from an organ transplant within the last month and still being bedridden would be disqualified from the primary clinical trial but might qualify for the secondary clinical trial is not directly entailed by the evidence provided The primary trials exclusion criteria do not mention organ transplant or bedridden status while the secondary trials inclusion criteria do not mention organ transplant or",
        "label": "Contradiction"
    },
    "57bca704-dcff-4526-b677-bb1c1b1a7945": {
        "text_answer": "No   Explanation The primary clinical trial reports its results in units on a scale and the secondary clinical trial reports its results as proportions with confidence intervals There is no mention of liters in the evidence",
        "label": "Contradiction"
    },
    "b27a5fe7-77f8-4d11-9e05-0609faf8b985": {
        "text_answer": "yes for women and maybe for men  Explanation  The statement fertile men and women capable of becoming pregnant are fit to partake in the primary clinical trial under the condition of committing to abstain for the length of the study is entailed by the evidence for women as the evidence explicitly states that Women of childbearing potential WOCBP unwilling or unable to use an acceptable method of birth control",
        "label": "Entailment"
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "text_answer": "Yes The primary trial explicitly states that warfarin is not permitted while the secondary trial permits its use under certain conditions",
        "label": "Entailment"
    },
    "99e5ad48-5bb8-4716-a1fc-0a332acf2e5e": {
        "text_answer": "Yes The primary trial evaluates the incidence of specific toxicities excluding fever hypoxia and urticaria of Grade 3 or higher while the secondary trial evaluates the percentage of participants with Grade 3 or higher adverse events of primary interest which include hepatic events allergic reactions thrombocytopenia and hemorrhage events all Grade 3 or higher AEs related to trastuzumab",
        "label": "Entailment"
    },
    "6d92ea7c-a85d-4d9d-9599-b2203e9c3585": {
        "text_answer": "No  Explanation  The primary trial had two test groups Intervention 1 and Intervention 2 and no control group The secondary trial had two test groups Highdose Oxybutynin Chloride Group and Lowdose Oxybutynin Chloride Group and no placebo group Therefore the statement that the secondary trial had two control groups is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b5976fd8-b3cf-4879-bead-2410a6e1f1f1": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement The statement suggests a difference in the number of participants experiencing recurrencefree survival between the two groups but the evidence only provides the number of participants analyzed in each group To determine if the statement is entailed by the evidence we would need additional information such as the number of participants in each group who experienced recurrencefree survival",
        "label": "Contradiction"
    },
    "4d7a11a9-ec69-4b35-9fea-d1a78d8fe4b8": {
        "text_answer": "No  Explanation  The statement there were several cases of febrile neutropenia reported in the primary trial and the secondary trial is not entailed by the evidence provided The evidence only mentions the number of adverse events for a specific condition Adverse Events 1 in each trial but it does not specify the nature of those events or if they were cases of febrile neutropenia",
        "label": "Contradiction"
    },
    "c291c60f-fb5e-4c0d-83dc-a8fe9eee445c": {
        "text_answer": "Yes The statement that all the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is entailed by the evidence as it is an inclusion criterion in the trial",
        "label": "Entailment"
    },
    "ebe02c33-affe-41d7-aad7-86ea86912217": {
        "text_answer": "Yes  Explanation  The evidence provided states that the average pain intensity was measured using a 0 no pain to 10 worst pain imaginable numeric rating scale on a daily basis The results show that the mean pain intensity scores for both the low dose and high dose groups were below 10 indicating that none of the patients in the primary trial experienced the worst pain imaginable for 1680 hours 10 weeks",
        "label": "Entailment"
    },
    "d464fa4d-58ea-47ff-b4fa-19fbedb40740": {
        "text_answer": "No  The evidence does not provide information about the cervical cancer screening status of participants in cohort 1 before the intervention",
        "label": "Contradiction"
    },
    "bfee9542-f923-4084-a92d-216413a99395": {
        "text_answer": "No   Explanation   The statement the primary trial and the secondary trial do not use the same drugs dosages or frequency of administration in their interventions is correct based on the provided evidence However the statement they do both use intravenous injections and MRIs is also true but it is not a necessary consequence of the first statement being true Therefore the statement as a whole is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b126d49e-2ab0-4bb9-8677-b3662b784e0d": {
        "text_answer": "Irrelevant  Explanation The statement cohort 1 of the primary trial receives higher doses of Eribulin than cohort 2 patients receive of Docetaxel is not related to the given definition of occasionally feel supported by spouse family and friends The evidence only pertains to the details of the primary trial and its interventions while the statement is about the trial participants feelings of support",
        "label": "Entailment"
    },
    "f435b92a-cceb-404d-a485-da95bb2189ec": {
        "text_answer": "  No The statement about an individual feeling as though they have to strain to produce voice is not mentioned in the evidence provided for either the primary or secondary trials The evidence only mentions exclusion criteria related to medical conditions and previous treatments",
        "label": "Contradiction"
    },
    "81cad78a-c25f-4aab-ae6f-aee9f21e0c01": {
        "text_answer": "Yes The statement does not directly relate to the interventions mentioned in the evidence but the evidence does not contradict the statement The statement is about a different topic ICD encounters and the evidence is about interventions in a clinical trial",
        "label": "Entailment"
    },
    "2e22a621-745f-422e-a66e-2a85f8ff1a25": {
        "text_answer": "No  Explanation The evidence provides the percentage of subjects who experienced recurrencefree survival but it does not specify how many did not experience it The statement makes an assertion about the number of participants who did not experience recurrencefree survival which is not directly stated in the evidence",
        "label": "Contradiction"
    },
    "bf41ff3e-3801-4cb7-8e09-0400100a4010": {
        "text_answer": "Yes  Explanation The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed by the evidence as it correctly identifies two different adverse events that were more frequent in each respective trial The statement also correctly identifies the trials as primary and secondary The rest of the statement in the question is not relevant to the answer",
        "label": "Entailment"
    },
    "c08cf531-fbbe-4ec3-ae13-f10d13368a82": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement mentions a different condition hybrid nerve sheath tumor and the trials provided in the evidence are about different outcomes number of patients with treatmentemergent adverse events and total sleep time",
        "label": "Contradiction"
    },
    "c696105a-b6a3-4d13-9410-2b3f05346f96": {
        "text_answer": "No  Explanation The statement the second cohort of the primary clinical trial has 7 participants more than the first cohort is not directly entailed by the evidence provided The evidence only states the number of participants analyzed in each arm of the trial but it does not compare the number of participants between the two arms",
        "label": "Contradiction"
    },
    "d8079e7e-45eb-4387-a0e3-eb0777802644": {
        "text_answer": "Yes The primary trial and secondary trial measure different outcome measures The primary trial measures the percentage of participants with treatmentemergent adverse events while the secondary trial measures the number of participants with objective response",
        "label": "Entailment"
    },
    "a2d03d44-c447-45d2-932e-efe3694a8940": {
        "text_answer": "Yes  Both interventions in the primary trial include trastuzumab Herceptin",
        "label": "Entailment"
    },
    "b1d81c75-d076-45f3-8de6-6a23fc4f3832": {
        "text_answer": "No   Explanation   The statement pituitary neuroendocrine tumormicroadenoma is a pituitary neuroendocrine tumor with a diameter equal or less than 10 mm is not mentioned in the evidence provided The evidence only relates to the results of a clinical trial comparing the invasive diseasefree survival iDFS in patients receiving neratinib versus placebo after adjuvant trast",
        "label": "Contradiction"
    },
    "2e64e934-f058-4730-af09-ddf7547a0112": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "79162d9d-6591-44ef-aaea-4bd58c4811da": {
        "text_answer": "No   Explanation  The evidence describes the dosing schedule for Vorinostat and radiation therapy in the primary trial but it does not mention anything about the administration of Fentanyl sublingual spray to the patients",
        "label": "Contradiction"
    },
    "da24c082-7e08-4ed0-b72c-ee85098d7b3a": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not support the statement that the NaCl 09 3ml group showed a higher recurrencefree survival rate than the Ketorolac 30 mg group The evidence only provides the number of participants analyzed in each group and their recurrencefree survival rates but it does not directly compare the two groups in terms of recurrencefree survival To make such a",
        "label": "Contradiction"
    },
    "193ae24d-ca9a-4bd6-8a98-279c75d32c9b": {
        "text_answer": "Yes  Explanation The statement there were three cases of shingles reported is entailed by the evidence as it can be inferred from the data provided in the Adverse Events section of both the primary and secondary trials",
        "label": "Entailment"
    },
    "accef831-f126-4f90-bc47-182fd9699098": {
        "text_answer": "No  Explanation The primary trial does not exclude patients with a history of major surgery within 28 days prior to the study registration date However the secondary trial does exclude patients who have undergone major surgery within 28 days prior to the study registration date The statement about a patient who has undergone a kidney transplant in the past week being eligible for the primary clinical trial but not the secondary clinical trial is not entailed by the evidence provided",
        "label": "Contradiction"
    },
    "9eee5184-a09a-41a2-b031-a7ea1863c5ce": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trials second cohort four different adverse events were noticed affecting patients is entailed by the evidence as there are four distinct adverse events Neutropenia Fatigue Pyrexia and Hepatic pain that occurred in the second cohort",
        "label": "Entailment"
    },
    "f12a3e2a-478e-4104-8f1a-c2d72efab4a3": {
        "text_answer": "No  Explanation  The statement double is a twofold increase is not directly related to the evidence provided The evidence only states that both cohorts of the primary trial contained the same number of participants 1420 each and the percentage of participants with events in the Neratinib arm was 47 and in the Placebo arm was 75 The statement about double being a twofold increase is not mentioned",
        "label": "Contradiction"
    },
    "99e16f2b-e690-4684-9dff-cf37877c796c": {
        "text_answer": "No  Explanation  The evidence provided in the clinical trial outcome measurement describes the number of participants who experienced a reduction in circulating tumor cells CTCs one month post autologous hematopoietic stem cell transplantation AHST The statement however refers to a reduction in CTCs subsequent to multiple months of highdose chemotherapy preceding purged autologous stem cell products The evidence",
        "label": "Contradiction"
    },
    "3caa266c-8ad2-4297-8de5-c65b78e94fd1": {
        "text_answer": "No  Explanation The evidence only mentions the phases and the negative or positive status for HER2 ER and PR for each cohort but it does not specify that all participants in cohort 1 receive treatment for HER2 ER and PR The statement goes beyond the information provided in the evidence",
        "label": "Contradiction"
    },
    "97e4a19d-31b9-476a-b8d3-707f817283e1": {
        "text_answer": "Yes The evidence does not mention any vaccines being administered to the participants in the primary trial",
        "label": "Entailment"
    },
    "fdc23b5d-a94a-4aa3-bb87-38d7f2c0102c": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2 to 38 Subtracting the Ki67 expression at 6 weeks from the Ki67 expression at baseline gives a difference of 5 105  5 1538  23",
        "label": "Entailment"
    },
    "6b531884-77d9-4cdc-bab7-324596ec998e": {
        "text_answer": "No  Explanation The primary trial does not provide information about the dosage of dexmedetomidine given to patients in group 2 The secondary trial mentions a dosage of 15ugkg for a specific population but it is not related to the primary trial",
        "label": "Contradiction"
    },
    "73eb2425-76f4-4868-8c33-0a2dab6af8f6": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial its demonstrated that the arm A intervention has yielded the best overall response rate however the denosumab group exhibited a poorer time to first onstudy SRE compared to the zoledronic acid group in the secondary clinical trial is not directly entailed by the evidence provided  The evidence only reports the results of the primary and secondary clinical trials",
        "label": "Contradiction"
    },
    "e504c08b-c348-4307-9cfe-d20f7003ec15": {
        "text_answer": "No  Explanation  The statement There were no patients with recorded Aes in the primary trial whereas every patient in the secondary trial suffered at least one adverse event injection site reaction ctcae is a disorder characterized by an intense adverse reaction usually immunologic developing at the site of an injection is not entailed by the evidence provided The evidence only reports the types and frequencies of adverse events in the primary and",
        "label": "Contradiction"
    },
    "5f33e3b5-efa2-407c-9409-383024b8c652": {
        "text_answer": "Yes The evidence states that patients with histologically proven DCIS are eligible for the trial",
        "label": "Entailment"
    },
    "7bbb79b9-9550-4a8b-a0a8-3af8ece50e04": {
        "text_answer": "Yes  Explanation  The statement pericardial effusions were more common for patients in the primary trial and corneal deposits were more common in the secondary trial is entailed by the evidence as it correctly identifies the trials and the adverse events that were more common in each trial The statement also correctly identifies the rbm15 gene rearrangement as a molecular abnormality but it is not directly mentioned in the",
        "label": "Entailment"
    },
    "85f5396f-e7f8-4697-95d2-67b82d43fce4": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as both cohorts receive the same dose of nabPaclitaxel 125 mgm2 on Days 1 and 8 The difference lies in the chemotherapeutic agent used in combination with nabPaclitaxel In Arm A gemcitabine is used and in Arm B carboplatin is used",
        "label": "Contradiction"
    },
    "71c0cfa6-88a6-4efa-8204-7252f6e6ef57": {
        "text_answer": "Yes The evidence mentions that the interventions are administered through different routes IV and subcutaneous injection but it does not specify the units of measurement for the PSA levels However the statement clarifies that a PSA level less than 4 refers to a blood concentration less than 4 ngml which is consistent with the common units of measurement for PSA levels Therefore the statement is entailed by the evidence as it does not contradict it and provides",
        "label": "Entailment"
    },
    "a2408386-b61c-4cce-9c71-befb482270e0": {
        "text_answer": "Yes The evidence provided does not include information about the count of participants with treatmentemergent adverse events as the outcome measurement for either trial",
        "label": "Entailment"
    },
    "bd4ef9b9-41e1-47cb-b8bd-eb0dfe32badf": {
        "text_answer": "No   Explanation   The statement poorly differentiated angiosarcoma is an angiosarcoma characterized by the presence of significant cytologic atypia necrosis and high mitotic activity is not directly related to the evidence provided in the primary and secondary trials The primary trial focuses on the evaluation of toxicity of infusing HER2specific T cells using NCI Common Terminology Criteria for",
        "label": "Contradiction"
    },
    "12ca4131-cbd9-45e4-8738-7ec607080cbe": {
        "text_answer": "Yes based on the given evidence none of the 49 participants with HER2primary breast cancer developed imagable HER2 metastases during the 3year followup period",
        "label": "Entailment"
    },
    "1a80bab2-1079-4730-bba6-b8414e4cfcc8": {
        "text_answer": "No The statement is not entailed by the evidence as the young female with PRpositive and HER2positive breast cancer would not meet the inclusion criteria for both trials The primary trial only includes patients with HER2negative breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "1c57cb03-2d38-4b0e-a4b1-cda77a609a9e": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial includes ECOG performance status of 0 to 2 and the secondary trial includes ECOG 02 OR Karnofsky 60100 Therefore candidates with an ECOG score of 3 are not excluded from both trials",
        "label": "Contradiction"
    },
    "397ae58e-dc5b-4c06-b8ce-29215ed5bcb9": {
        "text_answer": "No  The statement is not entailed by the evidence as coronary artery stenosis is not mentioned in the adverse events recorded in the primary trial",
        "label": "Contradiction"
    },
    "812d038b-d9c4-457d-8527-ed43ee902202": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 12 participants analyzed in the trial with 6 participants in each cohort ArmGroup The statement indicates that there were two incidents of doselimiting toxicity which is consistent with the evidence as it also reports that there were 6 participants in each cohort and no further details about the number of participants experiencing doselimiting toxicity in each cohort are",
        "label": "Entailment"
    },
    "36debc88-2f09-4ae8-9a37-5bee270f5f8c": {
        "text_answer": "Yes The evidence does not provide information about the number or duration of treatment cycles for partial breast irradiation in the intervention segment of the primary clinical trial",
        "label": "Entailment"
    },
    "49cccbde-abb6-45a4-80ba-47dcdd6b760e": {
        "text_answer": "Yes The primary trial exclusion criteria include significant cardiovascular impairment and the secondary trial exclusion criteria include uncontrolled cardiovascular disease",
        "label": "Entailment"
    },
    "95cf915e-97df-4ece-bd27-52a72bb4ed68": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any information about fgf3 gene amplification",
        "label": "Contradiction"
    },
    "5cd9bd06-f069-44f3-9b2b-69d92eecc07a": {
        "text_answer": "Yes  Explanation  The evidence provided in the trial results indicates that the average pain intensity score was measured on a daily basis using a 0 to 10 numeric rating scale and the change in average pain intensity between the two intervention groups was evaluated over a 10week period However none of the results indicate that any patient experienced a pain intensity score of 10 the most severe pain imaginable for the entire duration of the study",
        "label": "Entailment"
    },
    "61547cc4-08c1-41c9-94f3-c45ebba67e5b": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial includes patients with Nonsmall cell lung cancer and Small cell lung cancer",
        "label": "Entailment"
    },
    "ccc4b1dc-30f5-46d4-9251-6bb1dbe514ce": {
        "text_answer": "No  Explanation  The statement taking tamoxifen 20 mg orally daily for a fortnight postmastectomy has no significant effect on the ki67 expression in tumors is not entailed by the evidence The evidence only shows that there is a significant decrease in Ki67 expression in tumors after 7 days of presurgical tamoxifen treatment It does not provide information about the effect",
        "label": "Contradiction"
    },
    "5296c4b2-ae8f-4321-abb1-071d8a5e9f50": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not mention anything about the administration of talazoparib or its dosage to any of the patients Therefore the statement about patients being administered 1000000 ng of talazoparib daily is not entailed by the evidence",
        "label": "Contradiction"
    },
    "dfdcc220-60e9-4ade-a21a-2dea12500959": {
        "text_answer": "No   Explanation   The primary clinical trial evaluates the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 while the secondary clinical trial measures the percentage of participants with adverse events of primary interest AEPIs related to trastuzumab emtansine Neither trial directly assesses participants overall survival rates",
        "label": "Contradiction"
    },
    "848665ec-85f5-4b64-aa71-ba24195e7463": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "text_answer": "Yes Arimidex is used in Intervention 1 of the primary trial but it is not mentioned in the secondary trial",
        "label": "Entailment"
    },
    "6688e7ec-6e04-49d3-b3c2-0bfb041297dc": {
        "text_answer": "Yes  Explanation  The statement 500 mg of Fulvestrant is given in a tablet form to be taken BID in the secondary trial is entailed by the evidence as it is explicitly stated in the secondary trial description that Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1 Subsequ",
        "label": "Entailment"
    },
    "067c3f74-9009-45dc-a97a-0de2a17722cc": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only mentions specific therapies that are excluded antineoplastic chemotherapy androgens estrogens and progestogens but it does not mention monoclonal antibodies or cd73 specifically",
        "label": "Contradiction"
    },
    "1c3d0ec2-e54e-4b44-9b61-6300e5e2736f": {
        "text_answer": "No  Explanation  The evidence provided describes the inclusion and exclusion criteria for a clinical trial for patients with breast cancer The statement however refers specifically to patients with T4 N4 M4 tumors which is a specific tumor stage The evidence does not mention T4 N4 M4 tumors as a specific inclusion criterion for the trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "871e4e1f-9d73-46d0-9eda-04099b38ea4b": {
        "text_answer": "  Yes  Explanation  The geometric mean percentage change in betaCTX at Week 4 for the AZD0530 175 mg group was 711 95 CI 759 to 654 while for the Zoledronic Acid 4 mg group it was 684 95 CI 730",
        "label": "Entailment"
    },
    "10b5153d-7bb1-45a0-9765-1df8e3dfbd88": {
        "text_answer": "No  Explanation The statement the appearance of maculopapular rash was a frequent side effect among the participants of the primary clinical trial is not entailed by the evidence as the frequency of maculopapular rash mentioned in the evidence is the same as that of other adverse events which is 333 Therefore it does not meet the criteria for being considered a frequent side effect based on the given evidence",
        "label": "Contradiction"
    },
    "013a39b4-3f7c-427c-8665-134bf9edc4a5": {
        "text_answer": "No  Explanation The statement mentions 3 total cases of asthenia and 5 total cases of pyrexia but the evidence only provides the number of adverse events for each trial without specifying which adverse events occurred Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "c1fee61a-1d3e-4d83-a0a9-8360e912714c": {
        "text_answer": "No  Explanation  The statement more palpitations pericardial effusions and abdominal pains were recorded in cohort 1 of the secondary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only shows that these adverse events occurred in both trials but it does not provide enough information to make a comparison between the number of occurrences in each cohort",
        "label": "Contradiction"
    },
    "857ea0f3-1f62-417e-93ef-00e121cc3e60": {
        "text_answer": "Yes The evidence states that both groups in the primary clinical trial are not given interventions that include counselling risk analysis or cognitive behavioural therapy CBT",
        "label": "Entailment"
    },
    "2e844546-8fe8-440c-afdd-504e84d4acc4": {
        "text_answer": "Yes  Explanation The statement unlike the primary clinical trial which had no adverse events on record the secondary one frequently reported anaemia as a side effect is entailed by the evidence because the primary trial had no adverse events at all while the secondary trial had a significant number of cases of anaemia",
        "label": "Entailment"
    },
    "50c57a74-1e0e-45fe-8a00-217ff1322d99": {
        "text_answer": "No  The primary trial excludes current smokers while the secondary trial does not mention anything about smoking status",
        "label": "Contradiction"
    },
    "13fb11f0-9307-4576-887c-75896dd7bfd1": {
        "text_answer": "No  The statement is not entailed by the evidence as one participant in the trial did experience a urinary tract infection which is a type of adverse event mentioned in the evidence",
        "label": "Contradiction"
    },
    "dd10e477-9de3-43b9-8db3-5c9661514c5e": {
        "text_answer": "Yes  Explanation  The percentage of participants in the primary clinical trial who experienced adverse events was 048 which is less than 20 when expressed as a percentage The percentage of participants in the secondary clinical trial who experienced adverse events was 0 which is also less than 20 Therefore the statement that the percentage of participants in both trials who experienced adverse events was less than 20 is entailed by",
        "label": "Entailment"
    },
    "74302b73-7dad-4eb7-b9f2-757d0508d85d": {
        "text_answer": "Yes The evidence does not explicitly state that candidates undergoing CBT cognitive behavioral therapy treatments will not be disqualified from the clinical trials However it does not list CBT as an exclusion criterion for either trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "7664aa4a-a4ae-4fe3-81a0-d977d197fde1": {
        "text_answer": "Yes  Explanation  The statement less than 10 of patients were affected by all types of ae in the primary clinical trial is entailed by the evidence because none of the patients in the trial experienced more than one type of adverse event Therefore no patient was affected by all types of ae and less than 10 of patients were affected by any type of adverse event 3636",
        "label": "Entailment"
    },
    "8d6af699-f5b7-41c2-a84f-28fa45e648c9": {
        "text_answer": "No  Explanation  The statement the majority of patients in the primary clinical trial experienced headaches as the most common adverse event while the secondary clinical trial showed 0 incidence of adverse events is not entailed by the evidence The evidence only provides the number and percentage of adverse events for the secondary trial but it does not mention anything about the primary trial having a majority of patients experiencing headaches",
        "label": "Contradiction"
    },
    "19356a21-1163-41b2-8780-7e8e7c956454": {
        "text_answer": "No   Explanation  The evidence states that there were no adverse events recorded in both trials for the given condition Adverse Events 1 The statement however asserts that there were 55 recorded adverse events in total across both trials which is not supported by the evidence",
        "label": "Contradiction"
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "text_answer": "Yes The statement is entailed by the evidence as cerebral metastases are an exclusion criterion in the secondary trial but not in the primary trial",
        "label": "Entailment"
    },
    "29968695-9fd4-4fce-b2ba-1879f50c8c57": {
        "text_answer": "No   Explanation  The statement in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly related to the question often feel sad or depressed The evidence provided only mentions the number of adverse events in the primary trial but it does not mention anything about the individuals who experienced those events or their emotional states Therefore",
        "label": "Contradiction"
    },
    "7534e96f-f5c9-4adf-a9cb-efa76fd43257": {
        "text_answer": "Yes The statement specifically mentions stomatitis as the adverse event which is consistent with the evidence that stomatitis occurred in 129 participants 345",
        "label": "Entailment"
    },
    "f8630eaf-1381-4ba1-ba97-68b86755e0fd": {
        "text_answer": "No  Explanation  The statement the secondary trial has distinct inclusion criterion for potential participants below 18 and another for those above while the primary trial follows a single eligibility benchmark is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for both trials but it does not specify any agerelated differences in these criteria",
        "label": "Contradiction"
    },
    "5ccef9c9-dfe2-465e-8cc4-c6cdc310f74a": {
        "text_answer": "No   Explanation The statement more than 10 patients in the primary clinical trial experienced aes is not entailed by the evidence as the evidence only reports that 2 patients experienced adverse events out of a total of 35 patients",
        "label": "Contradiction"
    },
    "816acfa2-5f8d-4f30-9425-5880f3d72414": {
        "text_answer": "  Yes for claustrophobia No for osteoporosis in the primary trial as it is an exclusion criterion but not mentioned in the statement",
        "label": "Entailment"
    },
    "eec99f26-cf8e-407d-bb6a-7f9d053fe187": {
        "text_answer": "Yes However its important to note that the statement only applies to the ECOG performance status criterion and assumes that all other inclusion and exclusion criteria are met for both trials",
        "label": "Entailment"
    },
    "facb2d1c-1f65-4c84-9c93-209ce87d18a7": {
        "text_answer": "No  Explanation  The patient with a primary tumour measuring 33mm in diameter would not qualify for both the primary and secondary clinical trials based on the provided inclusion criteria  In the primary trial the inclusion criterion for the primary tumour size is Primary tumour greater than 2 cm diameter A tumour measuring 33mm in diameter is larger than 2 cm but it is not explicitly stated that a tumour up",
        "label": "Contradiction"
    },
    "4f89c108-d732-49bd-b21a-c3566400b519": {
        "text_answer": "Yes  Explanation The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is entailed by the evidence as the primary trial had 7 cases of diarrhea out of 30 participants 2333 while the secondary trial had no cases of diarrhea out of 6 participants",
        "label": "Entailment"
    },
    "52f841b6-f451-455e-9ec5-2541cf02bb13": {
        "text_answer": "Yes  Explanation  The evidence provided in the results does not report any instance of a patient experiencing the worst pain imaginable a score of 10 on the numeric rating scale for a duration of 25 months during the study The mean pain intensity scores and their confidence intervals for both the lowdose and highdose groups are given but there is no mention of any patient exceeding the maximum pain intensity level for the specified",
        "label": "Entailment"
    },
    "df991d6e-570f-4371-9b5e-00e9f3f4707d": {
        "text_answer": "No  Explanation The evidence provided in the text describes a randomized controlled trial comparing the effectiveness of two doses low dose and high dose of a psychoeducational intervention for managing cancer pain The intervention consisted of home visits and phone calls with specially trained oncology nurses over a 10week period The average pain intensity scores were measured using a numeric rating scale and the results showed a statistically significant difference between the two groups",
        "label": "Contradiction"
    },
    "41617f3f-76b1-41ca-b7c7-f902f84cd816": {
        "text_answer": "  No Contact dermatitis is not mentioned in the inclusion or exclusion criteria of the primary trial",
        "label": "Contradiction"
    },
    "2a32321e-12f1-453f-b0d4-d0b10b80e293": {
        "text_answer": "Yes The evidence states that patients with any tumor type that has CCND2 amplification are eligible for the clinical trial",
        "label": "Entailment"
    },
    "40535d67-a16d-48eb-932e-3d8d2ff57281": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3657b15f-ab73-479c-8b00-c2189fc4d984": {
        "text_answer": "Yes  Explanation The statement several patients experienced the same type of adverse event during the primary clinical trial is entailed by the evidence since there are multiple instances of the same type of adverse event reported in the data For example two patients experienced disease progression and one patient experienced pneumonia which are both types of adverse events",
        "label": "Entailment"
    },
    "63bd708a-66ae-41fc-872d-277417bc2576": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as there is no mention of oral multivitamins or depomedroxyprogesterone acetate injection in the provided evidence The evidence only describes the interventions used in the primary and secondary trials",
        "label": "Contradiction"
    },
    "b03fe494-c036-4988-ae85-d5e548b57aea": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial does have separate inclusion and exclusion criteria for its phases and the secondary trial does have separate criteria for healthy and cancer patients",
        "label": "Entailment"
    },
    "686121cf-e252-49b2-9e46-f4cb6ebac7f8": {
        "text_answer": "Yes Both trials include women aged 18 and above",
        "label": "Entailment"
    },
    "4246dc90-5b23-4170-8b6a-bd1459f776b9": {
        "text_answer": "Yes The statement does not specifically mention the investigator status but it is not in conflict with the evidence provided The evidence only discusses the adverse events and their frequencies which is not related to the investigator status",
        "label": "Entailment"
    },
    "2f57e639-546c-4e7a-b562-77338563d472": {
        "text_answer": "Yes The evidence states that 13 of the participants with HER2 primary breast cancer developed imagable HER2 metastases using HER2targeted PETCT with 89Zrtrastuzumab",
        "label": "Entailment"
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as both cohorts receive the same dosage and frequency of Doxorubicin Cyclophosphamide and Docetaxel during the chemotherapy cycles However cohort 2 receives three additional cycles of these drugs",
        "label": "Entailment"
    },
    "a3ae0081-3bd8-408b-b11d-415711be2ddc": {
        "text_answer": "No  Explanation  The statement mllt6 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt6 gene is not directly related to the information provided in the evidence The evidence only mentions the interventions used in the primary and secondary trials and the administration of denosumab and radioactive Tc99M sulfur colloid but it does not mention anything about the m",
        "label": "Contradiction"
    },
    "96a69ac4-9248-4ede-bc27-2f032f0e2294": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial involves multiple injections of dendritic cells chemotherapy and trastuzumab throughout the study duration",
        "label": "Entailment"
    },
    "6e3e407e-901f-443e-9785-d19b184ff462": {
        "text_answer": "Yes The evidence does not report any patient experiencing the most unbearable pain 10 on the scale for ten consecutive weeks throughout the study",
        "label": "Entailment"
    },
    "9827f954-40d9-4b55-bb92-02624a0d6a75": {
        "text_answer": "No   Explanation   The statement Group 2 of the primary trial receives 05ugkg of myalgias 5ml is not entailed by the evidence The evidence only mentions that Group 2 of the primary trial receives dexmedetomidine not myalgias Additionally the statement about thienopyridine antiplatelet agents is not related to the evidence at all",
        "label": "Contradiction"
    },
    "aba3d5b6-63f0-4eaa-a345-2e9624932e9b": {
        "text_answer": "Yes The evidence states that patients with measurable or nonmeasurable disease are eligible for the clinical trial Measurable disease refers to quantifiable metastasis and nonmeasurable disease can refer to cancer that has spread to other parts of the body but may not be quantifiable",
        "label": "Entailment"
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "text_answer": "Yes The statement is entailed by the evidence as it specifies that only the intervention arm of the study will view the educational DVD",
        "label": "Entailment"
    },
    "4128c0f0-7d9f-44e7-ba5a-66919c502fdd": {
        "text_answer": "No  Explanation  The statement negligible or no adverse events were reported in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence While the primary trial reported no adverse events for Adverse Event 1 the secondary trial reported a significant number of adverse events for Adverse Event 1 including some serious ones such as recurrent malignancy graftversushost disease infection",
        "label": "Contradiction"
    },
    "f3598d65-2288-40bd-abe1-45eaa69ee03e": {
        "text_answer": "No  The placebo is administered on Day 1 and trabectedin is administered on Day 2",
        "label": "Contradiction"
    },
    "9dd03978-dc7f-4c73-a199-92f7247dbf29": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about the occurrence of epileptic seizures in either trial Additionally the statement incorrectly compares the number of cases of Mucositis Oral between the trials when in fact there were no cases reported in the secondary trial The evidence only mentions the number of adverse events for each trial but it does not provide a comparison of",
        "label": "Contradiction"
    },
    "57bf60c1-b440-4fa1-854e-91d2947360e3": {
        "text_answer": "Yes  Explanation The statement 300 the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy can be calculated as follows  3750 hepatotoxicity  1250 hypertension and pancreatectomy 3750  1250  3  ",
        "label": "Entailment"
    },
    "996df3c5-d5a6-4cfc-9407-cb9a59388007": {
        "text_answer": "Yes The statement is entailed by the evidence as the educational DVD is specifically mentioned as being shown only to the intervention arm of the study and not to the control arm",
        "label": "Entailment"
    },
    "0dd1c6d6-5a35-452e-b058-ea0da7bd9f3a": {
        "text_answer": "Yes Some patients diagnosed with breast cancer may not be eligible for any study groups in both trials due to their specific conditions and exclusion criteria",
        "label": "Entailment"
    },
    "a111fa2e-4d53-4b24-8929-ee37b97bed05": {
        "text_answer": "No The evidence does not provide any information regarding the nationality of the participants for either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "fbe4e8b0-f258-448d-8926-3ac4757ee020": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the first cohort receives a fluciclatide injection while in the secondary clinical trial the first cohort is given a standard chloroquine dose is not entailed by the evidence The primary clinical trial involves the use of fluciclatide injections while the secondary clinical trial involves the use of chloroquine doses The statement incorrect",
        "label": "Contradiction"
    },
    "6ad65d9b-8610-4f09-a760-caedb0a4037d": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not report the number of adverse events in the secondary trial that equals or exceeds the number in the primary trial",
        "label": "Contradiction"
    },
    "6add1cab-1458-4cca-a419-7bfc5acdc1cc": {
        "text_answer": "No  Explanation  The statement the primary clinical trial does not conduct any drugrelated tests in contrast the secondary clinical trial carries out assessments of two varied medications is not entailed by the evidence  The primary clinical trial mentions massage therapy interventions but it does not explicitly state that there are no drugrelated tests involved The secondary clinical trial on the other hand mentions the use of PF066",
        "label": "Contradiction"
    },
    "9020a95d-874e-4bee-97bb-9b31bbcdd50d": {
        "text_answer": "No  Explanation  The statement the patient who exhibited the most extended progression free survival PFS in the primary clinical trial belonged to cohort 1 is not directly entailed by the evidence provided The evidence only reports the median PFS for each cohort Capecitabine 28 months 95 CI 16 to 32 CDX01",
        "label": "Contradiction"
    },
    "f0cbb267-5a5b-412e-a474-2ad091a031d7": {
        "text_answer": "No  Explanation  The statement in the secondary trial all patients receive the same 100000 g dose of pdr001 and 1 mgkg dose of mcs110 is not directly entailed by the evidence provided The evidence only states that in the secondary trial both intervention groups receive the same doses of MCS110 and PDR001 but it does not",
        "label": "Contradiction"
    },
    "b5b61f90-60b8-404f-872e-a58c84dbf43a": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e3629df4-61d3-42e0-af44-62cb2782c5c2": {
        "text_answer": "Yes  Explanation  The statement less adverse incidents took place during the course of the secondary clinical trial than the primary clinical trial is entailed by the evidence since the secondary trial had a lower percentage of adverse events for both Adverse Events 1 and Adverse Events 2 compared to the primary trial",
        "label": "Entailment"
    },
    "7f7f7885-c57a-42f3-9799-99159d400077": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary clinical trials intervention segment does not provide information on the administration method dose or routine",
        "label": "Entailment"
    },
    "65a1b098-171e-4a2e-87a7-7d29b4a7d6ba": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "cbf72855-5886-46d7-b084-43cb6f2a0e2e": {
        "text_answer": "No  Explanation The statement presurgical consumption of tamoxifen 20 mg orally on a daily basis excites a rise in ki67 expression in cancer tumors is not entailed by the evidence The evidence only shows that there is a significant decrease in Ki67 expression in tumors after 7 days of presurgical tamoxifen treatment The statement implies an increase in Ki67 expression",
        "label": "Contradiction"
    },
    "f0ff3265-a75f-4a9f-8c0e-ff03057647eb": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement mentions an ibrutinibvenetoclax regimen which is not mentioned in the evidence The evidence only discusses the memantine and placebo interventions in the context of a cancer survivor trial",
        "label": "Contradiction"
    },
    "584c33f0-3bca-4276-a3f1-2c68e39898ac": {
        "text_answer": "No  Explanation  The statement in the secondary clinical trial a single adverse event impacted more than 50 of the subjects involved is not entailed by the evidence The evidence lists multiple adverse events and the number of subjects affected by each event However none of the adverse events affected more than 50 of the subjects",
        "label": "Contradiction"
    },
    "d5abfad6-a8c3-409f-b434-33e55c0848cb": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "96e242e7-e1dc-4465-bb90-6f9ef0ab0f2a": {
        "text_answer": "Yes The evidence states that none of the participants in the primary clinical trial are prescribed talazoparib on a daily basis",
        "label": "Entailment"
    },
    "bd18948b-345b-48be-a1a0-45c4ee688747": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial does not mention the administration of myalgias to any group and the secondary trial does not involve the primary trials intervention groups",
        "label": "Contradiction"
    },
    "e5a8197e-dc1f-4258-9da2-f530eade84fe": {
        "text_answer": "No  Explanation  The statement feeling nervous anxious or on edge is not related to the doses of Lenalidomide or Lapatinib mentioned in the evidence The evidence only provides information about the dosages and durations of the interventions used in the primary and secondary trials It does not mention anything about the participants feeling nervous anxious or on edge Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "dfd33619-98ec-43e0-83c4-a22bae9f1b52": {
        "text_answer": "No  Explanation  The statement millimole per liter per microgram per kilogram per day is a unit of concentration equal to millimoles per liter divided by micrograms per kilogram per day is not directly related to the inclusion and exclusion criteria provided in the evidence for the primary or secondary trials The evidence only mentions the requirements for mammography and CT scan procedures as well as the eligibility criteria for study participants based on",
        "label": "Contradiction"
    },
    "ad3c8700-e49c-404e-af40-e9329033f2a7": {
        "text_answer": "No  The evidence states that one patient 909 experienced an increase in blood bilirubin levels",
        "label": "Contradiction"
    },
    "6cf2337d-c486-405c-be2b-97c29d8425dc": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting less than 005 of patients there were no recorded aes in the primary trial is not entailed by the evidence The evidence states that anaemia affected 234 of patients in the secondary trial which is not less than 005 Additionally the statement that there",
        "label": "Contradiction"
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "text_answer": "No  Explanation  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is not entailed by the evidence The evidence only states that 1 patient in the primary trial suffered from both adverse events out of a total of 13 patients It does not provide information on the percentage of patients who experienced these adverse events",
        "label": "Contradiction"
    },
    "52d2dcbc-8b57-43eb-bc12-8b7df8c3d8ba": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "40f8f9a6-a042-4f99-bbd9-5f3c3279045d": {
        "text_answer": "No   Explanation   The statement methotrexate is administered to the patients is not entailed by the evidence provided Methotrexate is not mentioned in either the primary or secondary trial interventions",
        "label": "Contradiction"
    },
    "475fbb72-9858-40cf-b7f0-50236d032582": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial allows participation of patients irrespective of their age while the primary clinical trial accepts only those between the ages of 18 to 45 is not directly entailed by the evidence provided The evidence only mentions the age inclusion criteria for each trial separately",
        "label": "Contradiction"
    },
    "9137a91a-d493-42f7-a1e5-9b39928036d6": {
        "text_answer": "Yes The primary trial excludes patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study but it does not mention CBT specifically The secondary trial includes a specific exclusion for patients who have received chemotherapy or radiotherapy within 4 weeks prior to study entry Therefore the statement that treatment protocols based on CBT are not permitted in the primary clinical trial is entailed by the evidence as CBT falls under the category",
        "label": "Entailment"
    },
    "72154344-5c84-49cd-b39e-4010fb73756a": {
        "text_answer": "No   Explanation   The statement for patients with breast cancer eligibility can extend to all study groups in the primary and secondary clinical trials is not entailed by the evidence The primary trial is specifically for postmenopausal women with early stage breast cancer and low vitamin D levels while the secondary trial is for healthy males and females with HER2positive breast cancer These are distinct patient populations and not all",
        "label": "Contradiction"
    },
    "ca8c2bae-ba14-4791-b995-e1555696d182": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not mention gabapentin in relation to the primary clinical trial Additionally the statement only mentions exposure to Herceptin disqualifying patients from the secondary trial within the last 12 months but the evidence for the secondary trial allows for concurrent adjuvant targeted therapy including Herceptin in patients with no evidence of disease",
        "label": "Contradiction"
    },
    "437a782b-7dc2-4904-ac68-3a532b98f2e2": {
        "text_answer": "No  Explanation  The statement out of the participants 5 had experienced three or more adverse incidents during the primary clinical trial is not directly entailed by the evidence provided The evidence only lists the number of participants who experienced each type of adverse event but it does not provide information about how many participants experienced multiple types of adverse events Therefore it is not possible to determine if 5 participants experienced three or more adverse incidents based on",
        "label": "Contradiction"
    },
    "947b0d76-6214-46c7-ac3c-f5794e0cfcb3": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial does not state the number of participants within each cohort is entailed by the evidence because the evidence only provides the overall number of participants analyzed for each armgroup but it does not specify the number of participants within each cohort ie the number of patients who received each treatment",
        "label": "Entailment"
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "text_answer": "Yes  Explanation  The primary trial had one intervention group Pyridoxine and one control group Placebo The secondary trial had one intervention group Highdose Oxybutynin Chloride and one control group Lowdose Oxybutynin Chloride Therefore the statement the primary trial had 1 test group and 1 placebo group the secondary trial had 1 test group and ",
        "label": "Entailment"
    },
    "8601ec47-bccd-45d7-b823-ff39719683e5": {
        "text_answer": "No  Explanation  The evidence provided in the given primary clinical trial results does not entail that the LBH589 and Lapatinib group achieved better outcomes compared to their LBH589 with Capecitabine counterparts The evidence only states that there were no participants analyzed in the LBH589 and Lapatinib group as of the reported time frame Therefore no comparison between the two groups can be made based",
        "label": "Contradiction"
    },
    "620be964-dbff-4793-a75e-7644f7c57fb5": {
        "text_answer": "No  The evidence does not mention anything about neurokinin1 receptor antagonists being administered to participants in the clinical trial",
        "label": "Contradiction"
    },
    "b35e0f7c-9162-4752-98dc-b41bac62e99c": {
        "text_answer": "No  Explanation  The statement in both sections of the primary clinical trial patients reported adverse events at an equivalent rate is not entailed by the evidence The evidence only shows that the number and types of adverse events reported in each section of the trial differ The statement would be true if the number of patients in each section were the same but that information is not provided in the evidence",
        "label": "Contradiction"
    },
    "dea24187-160a-4d6c-a724-e8cb01494d68": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement compares the physical quantities of Eribulin and Docetaxel but the evidence only provides the dosages and dosing schedules for each intervention not the physical quantities of the drugs To determine if cohort 1 receives higher doses of Eribulin than cohort 2 receives of Docetaxel in terms of physical quantities we would need to",
        "label": "Contradiction"
    },
    "cf959db3-df50-4724-a747-413a35bb171b": {
        "text_answer": "Yes The evidence does not mention any use of drugs radiotherapy or CBT in the interventions for pharyngoconjunctival fever",
        "label": "Entailment"
    },
    "3cf9b40b-ffa4-4b08-9039-9481c7d6cd76": {
        "text_answer": "No  Explanation  The statement There were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide information about the specific types of adverse events other than Infection Asymmetry and Deflation in the primary trial or the presence or absence of n",
        "label": "Contradiction"
    },
    "52f7d88d-78f0-4e5a-8fb9-e423679f2c61": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial mentions daily subcutaneous injections for the intervention but it does not specify that the medication is oral in the secondary trial",
        "label": "Contradiction"
    },
    "901dac1a-6a67-4883-a883-06c5a91f85c1": {
        "text_answer": "No  The evidence does not indicate that there were over 100 total adverse events in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "c89ba7c0-93b6-4601-82f0-557aa23f24cc": {
        "text_answer": "Yes The primary trial specifically states that patients must be postmenopausal which excludes children and adolescents by definition The secondary trial does not have any age restrictions mentioned in the provided inclusion criteria",
        "label": "Entailment"
    },
    "18c8db1c-2d31-481b-923d-0415861bd6d6": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the primary and secondary trials do not mention anything about a lung tumor or a KRAS mutation in their inclusion criteria",
        "label": "Contradiction"
    },
    "8db48a95-bc22-4f5e-b9e3-a50a275481a3": {
        "text_answer": "Yes The evidence states that those with metastatic breast cancer and participating in a taxanebased chemotherapy are excluded from the primary trial Therefore they cannot be involved in both trials at the same time",
        "label": "Entailment"
    },
    "4092de53-28a9-457c-91cf-f87f4abf4dc1": {
        "text_answer": "No  The evidence does not support the statement that 100 of the patients in the primary trial experienced the worst pain imaginable for 10 weeks The evidence only reports the average pain intensity scores and the difference between the low dose and high dose intervention groups It does not provide information on the percentage of patients who experienced the worst pain imaginable for 10 weeks",
        "label": "Contradiction"
    },
    "f1c2db2e-dc72-4a69-a3b6-a8d846a6f7ee": {
        "text_answer": "Yes The primary trial includes a criterion for vitamin D deficiency but the secondary trial does not mention vitamin D levels as an inclusion or exclusion criterion",
        "label": "Entailment"
    },
    "16710aab-1003-447f-bf01-7275e653d263": {
        "text_answer": "No   Explanation   The patient described in the statement does not meet the inclusion criteria for the primary trial as the primary tumour radius is less than 2 cm   Additionally the statement does not provide enough information to determine eligibility for the secondary trial as it does not mention the specific type of cancer or the presence of metastatic disease",
        "label": "Contradiction"
    },
    "e9639699-8cb1-4b2b-9901-443fedb90158": {
        "text_answer": "No  Explanation  The statement mentions swelling hypothermia and confusion in the adverse events sector but the evidence only reports Adverse Events 1 with a total of 0 cases in both trials There is no mention of Adverse Events 2 or any specific types of adverse events other than Adverse Events 1 in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b6643c69-48aa-452a-91f8-b45c83ccf01e": {
        "text_answer": "No  Explanation The statement Only 2 patients in the primary trial did not have Recurrencefree Survival is not directly related to the information provided in the evidence The evidence only mentions the percentage of subjects with Recurrencefree Survival 98 and does not specify how many patients did not have Recurrencefree Survival Therefore the statement cannot be determined to be entailed by the evidence with",
        "label": "Contradiction"
    },
    "3df0eb9e-b9d9-4f8b-af9a-2d6259e1ed9c": {
        "text_answer": "Yes The evidence states that laserassisted fluorescence angiography is used for monitoring perfusion at three separate time points for both interventions Inframammary Fold Incision and Lateral Radial Incision Cohorts",
        "label": "Entailment"
    },
    "c667d986-5b21-4855-8f51-109296357a9e": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence indicates that sunitinib and capecitabine were administered to participants in the first 21day cycle",
        "label": "Contradiction"
    },
    "2d7737fc-95e6-4392-8a2e-d896e65ba3e6": {
        "text_answer": "No  Explanation  The statement the primary trial observes less adverse events in total than the secondary trial yet higher counts of cardiacischemiainfarction are reported in the primary trial is not entailed by the evidence The evidence shows that the primary trial had fewer total adverse events than the secondary trial but it does not show that the primary trial had a higher count of cardiacischemiainfarction",
        "label": "Contradiction"
    },
    "e25b66fb-c20a-4868-b2c3-780c859d629b": {
        "text_answer": "No  Explanation  The statement during the primary clinical trial 96 individuals from the ketorolac 30 mg group showed recurrencefree survival compared to 67 participants from the nacl 09 3ml group is not directly entailed by the evidence provided The evidence only states the number of participants analyzed in each group and their recurrencefree survival rates as percentages It does",
        "label": "Contradiction"
    },
    "7e695451-7e2e-43b4-8762-0ac27fb978b2": {
        "text_answer": "  No  Explanation  The evidence provided does not indicate whether or not the expression pattern of the selected 40 genes was visible among the participants in both the first and second cohorts The evidence only reports the proportion of participants in each cohort with detectable gene expression profiles but it does not specify whether or not the expression patterns were the same or different between the two cohorts",
        "label": "Contradiction"
    },
    "b5c0af13-187b-4f3f-8e46-c06d2df27d1c": {
        "text_answer": "Yes The statement is entailed by the evidence as fibromyalgia and thalasemic syndromes are listed as exclusion criteria in both trials Anemia is an exclusion criterion in the primary trial but only if it is the only diagnosis and not due to breast cancer",
        "label": "Entailment"
    },
    "73677475-c59f-4327-b231-57cd7136dd94": {
        "text_answer": "No   Explanation   The statement cholelithiasis was a common adverse event recorded in both the primary trial and the secondary trial is not entailed by the evidence Cholelithiasis is not mentioned as an adverse event in either trial",
        "label": "Contradiction"
    },
    "22401c29-1796-455c-ac34-59d3afb99fe9": {
        "text_answer": "No  Explanation  The statement every participant in group 1 of the primary trial were diagnosed with lesions is not entailed by the evidence provided The evidence only states that there were 0 lesions detected in the healthy volunteers group of the primary trial  Furthermore the statement and less than 5 of participants in group 1 of the secondary trial had clean skin without any blemishes is also not entailed",
        "label": "Contradiction"
    },
    "af3d4568-37c3-4c9b-8b22-38d9e3087754": {
        "text_answer": "Yes The primary trial measures pCR pathological complete response and the secondary trial measures pCR after preoperative therapy The statement acknowledges this difference in endpoints and compares the outcomes of the two trials",
        "label": "Entailment"
    },
    "7ae95d8e-af13-452e-a4e0-d4ba7c066a9c": {
        "text_answer": "Yes The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study",
        "label": "Entailment"
    },
    "18f56de9-cf7d-467a-9e95-ca80d8c651a2": {
        "text_answer": "No   Explanation The statement there was one psychiatric adverse event in the primary trial which affected more than 90 of patients is not entailed by the evidence The evidence states that there was one case of suicidal ideation a psychiatric adverse event out of 50 patients affecting 200 of patients but it does not state that this event affected more than 90",
        "label": "Contradiction"
    },
    "2f11c1f5-4e9c-4848-8de1-9df7d4403848": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9229abbd-f6e6-4747-bf4c-7c1257115667": {
        "text_answer": "No  Explanation  The statement did the individual have multiple known primary tumors at initial melanoma diagnosis is not directly related to the adverse events data provided in the evidence The evidence only reports the number of adverse events observed in each trial but it does not provide any information about the number of primary tumors in each individual participant Therefore the statement cannot be determined to be entailed by the evidence based on the given information",
        "label": "Contradiction"
    },
    "09ac056f-fdf4-4684-99d2-8581ddc09d3b": {
        "text_answer": "Yes  Explanation  The statement there are 15 shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because the evidence provides a list of 15 specific inclusion and exclusion criteria that are common to both trials",
        "label": "Entailment"
    },
    "4a54e780-0828-40c0-9f30-1ed06b66275a": {
        "text_answer": "Yes The evidence indicates that there were a total of 2 participants who experienced doselimiting toxicities in cohort 2 of the trial However the statement goes beyond the evidence by mentioning that the patients had adult acute eosinophilic leukemia but the evidence does not provide this information",
        "label": "Entailment"
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "text_answer": "  Yes for the primary trial regarding pulmonary embolisms and No for the secondary trial regarding breast implants",
        "label": "Entailment"
    },
    "b200a0d8-1c63-49a2-bf1c-280e9d6a2968": {
        "text_answer": "No  Explanation The statement all ae types in the primary trial affected less than 01 of patients is not entailed by the evidence The evidence shows that the adverse events affected between 909 and 3636 of patients",
        "label": "Contradiction"
    },
    "cea1bf06-b100-4328-aee1-638ef92d2784": {
        "text_answer": "No  Explanation  The secondary clinical trial does not report the maximum tolerated dose MTD of MM111 for its participants However the statement that the mtd of mm111 for its participants is 20 mg per day in the primary clinical trial is not entailed by the evidence provided The primary clinical trial only reports the dose escalation schedule for Ruxolitinib in combination with Paclit",
        "label": "Contradiction"
    },
    "3c9c99d8-4604-4de9-98e6-81a675fe0558": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it contains an incorrect intervention for the control group The control group will not receive a standard dose of radiotherapy but rather they will receive usual care which does not include viewing the educational DVD or meeting with the lay health advisor",
        "label": "Contradiction"
    },
    "524f9dd3-ec1a-44fa-b440-59eaa49fe204": {
        "text_answer": "No  Explanation  The statement refractory acute myelomonocytic leukemia is acute myelomonocytic leukemia that does not respond to treatment is not directly related to the adverse events AEs listed in the evidence The statement is about the definition of refractory acute myelomonocytic leukemia while the evidence provides the AEs observed in a trial",
        "label": "Contradiction"
    },
    "f7c36a91-5d42-46b9-b0cb-db7a57d37c04": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial the administration of eribulin to cohort 1 is at a higher dosage than the administration of docetaxel given to cohort 2 is entailed by the evidence as the dosage of eribulin 14mgm2 is higher than the dosage of docetaxel 75 mgm2",
        "label": "Entailment"
    },
    "a44a34b5-9f9e-4957-bb5e-5bb7bf834ecc": {
        "text_answer": "No  The statement mentions grade 1 stomal ulcer which is not listed as an exclusion criterion in the evidence",
        "label": "Contradiction"
    },
    "f90e818c-2a5c-44c9-9445-1d34a0c2e551": {
        "text_answer": "Yes The primary trial includes women aged 20 years or older but the secondary trial includes women and men aged 18 or older Therefore women who are at least 18 years old can participate in both trials",
        "label": "Entailment"
    },
    "c31609ed-47a9-4a4a-94f1-92757a79033c": {
        "text_answer": "Yes The statement is entailed by the evidence as the trial separates the administration of the pneumococcus vaccine for one group Adult Cancer Patients 65 Years of Age and Older and the influenza vaccine for another group Healthy Volunteers",
        "label": "Entailment"
    },
    "34b41276-f5fe-4adf-8178-808e139d9d52": {
        "text_answer": "  No   Explanation   The statement patients without any evidence of solid tumor either locally advanced or metastatic of all genders are welcomed for both phases of the primary clinical trial is not entailed by the evidence The inclusion criteria clearly state that patients must have evidence of a solid tumor that is locally advanced andor metastatic to be eligible for the trial",
        "label": "Contradiction"
    },
    "a6fa44b8-fb1b-4571-aadd-284cbe4f37d8": {
        "text_answer": "No  Explanation  The statement mold mix antigen ige antibody measurement is a measurement of the mold mix antigen ige antibody in a biological specimen is not directly related to the adverse events data provided in the evidence The statement only describes what a mold mix antigen ige antibody measurement is while the evidence provides information about the adverse events observed in two clinical trials Therefore the statement does not entail the information",
        "label": "Contradiction"
    },
    "f2d5970e-568d-40ca-9258-65015ff4a828": {
        "text_answer": "No   Explanation  The statement none of these describe me is not directly mentioned or entailed in the evidence provided Additionally Perjeta which is mentioned in the statement is not mentioned or used in the evidence",
        "label": "Contradiction"
    },
    "45d94eb6-d3a6-47ae-8c80-75fb02520ef2": {
        "text_answer": "No  Explanation  The statement 100 of the participants in group 1 of the primary trial were found to have lesions is not entailed by the evidence provided The evidence only states that in the primary trial there were 0 lesions detected in the healthy volunteers group  Furthermore the statement only 5 of particpants in group 1 of the secondary trial had radiation dermatitis and",
        "label": "Contradiction"
    },
    "a6f84772-606c-4977-87e2-aa4de18ac07a": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare abilities and are confined to bed or chair for less than half of their waking hours for only a portion of their disease",
        "label": "Entailment"
    },
    "c975a46b-6980-4cc4-886d-674f5f2c6773": {
        "text_answer": "No  Explanation The evidence provided in the clinical trial results indicates that 98 out of 100 participants did not experience a recurrence second malignancy or death as a first event within the 3year time frame This means that 98 of the patients had recurrencefree survival Therefore the statement that a majority of patients in the primary clinical trial did not have recurrencefree survival is not ent",
        "label": "Contradiction"
    },
    "5e45f9e6-6a4f-4cf6-b24a-8755f700943f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8d6dfb9e-cb56-4746-bdb6-45cbb5aadb03": {
        "text_answer": "yes  Explanation The statement is entailed by the evidence as it correctly summarizes the interventions and dosages mentioned in the primary and secondary trials",
        "label": "Entailment"
    },
    "821e8e07-ec33-4f99-8f6e-6d7d50d23d8c": {
        "text_answer": "  Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation  The evidence provided in the text describes the results of a clinical trial comparing cognitive function in premenopausal breast cancer patients receiving adjuvant Tamoxifen alone versus those receiving Tamoxifen with ovarian function suppression OFS or Exemestane with OFS The statement on the other",
        "label": "Entailment"
    },
    "9dcb0637-50ed-4e98-b6e8-fa95fae80471": {
        "text_answer": "Yes  Explanation The evidence states that the dosages of doxorubicin cyclophosphamide and docetaxel vary depending on the patients weight and age in both interventions Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "ee93ea09-f0a8-42ab-880d-8284fe0d716e": {
        "text_answer": "yes but with qualification the statement implies a difference in percentage points while the evidence provides percentage ranges The difference in percentages can be calculated from the given ranges but its not explicitly stated in the evidence",
        "label": "Entailment"
    },
    "ae6c4238-c27f-45c1-92e0-6d1164c6accf": {
        "text_answer": "yes regarding the Ki67 expression change not the vaginal dryness",
        "label": "Entailment"
    },
    "44ff230b-fe8f-44de-9f48-e6ab10e91b68": {
        "text_answer": "Yes  Explanation The evidence shows that the percentage of participants with invasive diseasefree survival events was 47 in the Neratinib group and 75 in the Placebo group at year 2 The difference between the two groups is 28 percentage points which is not statistically significant at the usual 5 level Therefore the statement there was no difference in idfs rate between the neratinib",
        "label": "Entailment"
    },
    "b1f92a23-fa4b-4cf6-9df1-b38794ab00ba": {
        "text_answer": "No  The statement is not related to the evidence provided which pertains to inclusion and exclusion criteria for a clinical trial for patients with unilateral breast cancer and upper extremity lymphedema",
        "label": "Contradiction"
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "text_answer": "No  The statement A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is not entailed by the evidence provided The evidence specifies that there should be no meningeal carcinomatosis but it does not explicitly state that leptomeningeal carcinoma is not allowed However it is important to note that leptomeningeal carcinoma is a type of meningeal",
        "label": "Contradiction"
    },
    "5c5a882c-4840-4e2e-83f8-341283caa359": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement mentions two different interventions for the primary and secondary trials while the evidence only provides information about the interventions for each trial separately",
        "label": "Contradiction"
    },
    "5cc29d9f-f81c-41c0-8a55-a98264f040c7": {
        "text_answer": "No  The statement is about metastatic neuroendocrine carcinoma in general while the evidence pertains specifically to a clinical trial for breast cancer patients with upper extremity lymphedema",
        "label": "Contradiction"
    },
    "ad6c7a37-2ab2-428a-8ac5-d2462d920c11": {
        "text_answer": "No  The evidence does not specify that the trials are limited to participants from the United Kingdom",
        "label": "Contradiction"
    },
    "af9dbcc2-f6ab-4e1e-aac7-a1f0bccd4d86": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "50e1ebd6-d51b-4e86-9748-a0d97a411b62": {
        "text_answer": "Yes The statement does not contradict the evidence and does not add any conditions related to mental health bodyweight tumor size KarnofskyECOG score or estimated life expectancy that are not already addressed in the inclusion and exclusion criteria of the trial",
        "label": "Entailment"
    },
    "d7bcab45-fcd5-46bb-9317-b75573e0373f": {
        "text_answer": "No  Explanation  The evidence provided in the text describes the results of a clinical trial comparing the effect of topical cryotherapy on chemotherapyinduced peripheral neuropathy CIPN in patients receiving adjuvant paclitaxel The results show that the average area under the curve aAUCpa of the EORTC ChemotherapyInduced Peripheral Neuropathy Module EORTC QL",
        "label": "Contradiction"
    },
    "5d512914-5625-4734-b828-f20f41ef1a98": {
        "text_answer": "Yes The statement bothered by tingling hands or feet is not mentioned in the adverse events of either trial is not entailed by the evidence since there are no adverse events reported in either trial related to tingling hands or feet Therefore the statement bothered by tingling hands or feet is not mentioned in the adverse events of either trial is not a valid conclusion based on the given evidence Instead the evidence is consistent with the",
        "label": "Entailment"
    },
    "fbefc569-ec7c-41d6-9d12-39533f6e0fc2": {
        "text_answer": "No  Explanation  The primary trial describes a treatment cycle length of 21 days not 1 year The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c5426d56-93e6-435b-8e77-19419e66c3d4": {
        "text_answer": "No  The evidence explicitly states that there should be no meningeal carcinomatosis for a patient to be eligible for the clinical trial Neoplastic meningitis is a type of meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "7e69da7b-d7e2-4166-ba1c-520947f7b596": {
        "text_answer": "No  Explanation The statement mentions numerous incidences of anaemia and febrile neutropenia but the evidence only shows 1 case each for these adverse events in the first group The statement also asserts that no cases of pancytopenia were found which is correct according to the evidence However the statement is not entailed by the evidence because it goes beyond what is stated in the evidence by",
        "label": "Contradiction"
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the numbers directly or indicate that the secondary trial had more adverse events overall",
        "label": "Contradiction"
    },
    "49f55eb1-1f11-4d89-9888-810dff7b4926": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial patients who received acupuncture showed superior improvements in their lymphedema over those who used testosterone cream is not entailed by the evidence provided The evidence only compares the changes in lymphedema between the acupuncture group and a waitlist control group There is no information about a testosterone cream group in the evidence",
        "label": "Contradiction"
    },
    "5975fc5c-37b0-4c9e-b546-afa0915ba928": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8a308bd1-0164-4734-bdeb-f955327b4314": {
        "text_answer": "No  Explanation  The evidence provided in the text describes the results of a clinical trial comparing the effect of topical cryotherapy during paclitaxel infusions Arm I versus standard of care only Arm II on chemotherapyinduced peripheral neuropathy CIPN in patients receiving adjuvant paclitaxel The results indicate that patients in Arm I had a smaller decrease in average area under the curve aAU",
        "label": "Contradiction"
    },
    "fc839312-3b01-43e3-8cad-f1107759f462": {
        "text_answer": "No   Explanation   The statement is not directly related to the evidence provided The evidence discusses interventions used in two clinical trials one involving denosumab injections and the other involving lymphoscintigraphy with or without gamma probes The statement is about a type of solid pharmaceutical dose form which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "7f1d39e0-4892-447d-90b9-b2c672e59c79": {
        "text_answer": "Yes The evidence does not mention anything about mental health bodyweight age or previous treatments being inclusion or exclusion criteria in the clinical trial",
        "label": "Entailment"
    },
    "ec8bde60-164e-45f7-819d-84b7af4ff04e": {
        "text_answer": "Yes  The primary trial uses sublingual application of Vitamin B12 while the secondary trial uses oral application of memantine and placebo",
        "label": "Entailment"
    },
    "0f6d115f-8b84-46cc-a95f-51af051029e3": {
        "text_answer": "No  Explanation  The statement is not directly related to the evidence provided The evidence describes interventions in two separate trials one involving reflexology and the other involving vitamin D supplementation The statement is about the concept of total organic carbon in pharmaceutical waters which is not mentioned or related to the interventions or trials described in the evidence",
        "label": "Contradiction"
    },
    "7b5d47fb-446d-481f-9785-3ff8b467fa69": {
        "text_answer": "No   Explanation  The statement provided is not entailed by the evidence as the statement mentions a regimen of 500 mg of ibrutinib and 10 mgkg of ipilimumab every day for six weeks while the evidence only mentions a trial of ibrutinib and MEDI4736 in the primary and secondary interventions with no specific dosing or schedule provided for ibr",
        "label": "Contradiction"
    },
    "86cc51ee-ff9e-4396-9c2a-85feaa52c215": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial reports the summed pain intensity differences SPID at 30 minutes after dosing not the severity of delayed nausea The secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine not at 12 weeks",
        "label": "Contradiction"
    },
    "a5631fa6-2f92-4be7-a055-4c7b3abcdb4d": {
        "text_answer": "Yes  Explanation The statement recurring patterns of the same adverse event were observed across multiple patients is entailed by the evidence as there are multiple instances of the same adverse events Heart Failure Vertigo Small intestinal obstruction Fever Aspartate aminotransferase increased Alanine aminotransferase increased Back Pain Pleural effusion Rash maculo",
        "label": "Entailment"
    },
    "fb5aff7f-4a77-4300-acc4-99a01a6696d1": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ef6ae88d-2d86-4786-8cec-5fad1c1671b8": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about the percentage of patients who did not experience side effects The text only reports the percentage of patients who completed the treatment regimen 98",
        "label": "Contradiction"
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "text_answer": "Yes  Explanation The evidence states that women of childbearing potential WOCBP and sexually active fertile men are eligible for the trial but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab This means that they are allowed in the trial but they need to commit to abstinence or use birth control to meet the study requirements",
        "label": "Entailment"
    },
    "3c56fe49-cda1-4f0f-8597-63f1e8d6237c": {
        "text_answer": "No  Explanation  The statement mechanical ventilation required is an indication that a patient required mechanical ventilation for respiratory support is not directly related to the evidence provided The evidence only mentions the details of the interventions in the primary and secondary trials including the number of individuals the type of surgery and the drug regimens It does not provide information on the incidence or prevalence of mechanical ventilation in the trials",
        "label": "Contradiction"
    },
    "03a73488-c2a3-437c-b4b7-d26832eaafe8": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2c519a1e-668f-4731-941e-21dadeb2031d": {
        "text_answer": "Yes The statement is entailed by the evidence as the participants in each arm of the trial receive different doses of chemotherapeutic agents with Arm A receiving nabPaclitaxel and gemcitabine and Arm B receiving nabPaclitaxel and carboplatin",
        "label": "Entailment"
    },
    "a6718ad8-0ba6-4513-aae0-92610b1421e6": {
        "text_answer": "Yes  Explanation  The statement there are no cases of bronchopneumonia and general physical health deterioration reported in either the primary or secondary clinical trials is entailed by the evidence because neither condition is listed as an adverse event in either trial The evidence provides a complete list of all adverse events reported in each trial and neither bronchopneumonia nor general physical health deterioration are included Therefore the statement is a logical",
        "label": "Entailment"
    },
    "28b11be9-1e77-49c5-8cd2-fb9a95a35b58": {
        "text_answer": "Yes  Explanation The statement does not directly mention the use of pIHGC or GP in the context of the lymphoscintigraphy procedure However the evidence clearly states that both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site which is a common step in lymphoscintigraphy The statement is about a different topic grem1 gene mutation",
        "label": "Entailment"
    },
    "1624bc79-6ba3-449b-afd6-0234b760664e": {
        "text_answer": "Yes The statement that patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 2 years before study entry are excluded from the primary trial is entailed by the evidence",
        "label": "Entailment"
    },
    "45571dd6-2532-4086-af29-0b8558423b26": {
        "text_answer": "No  Explanation  The statement patients with confirmed stage 1 and 2 breast adenocarcinoma that is er negative pr negative or her2neu positive are able to participate in both the primary clinical trial and the secondary trial is not entailed by the evidence provided The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma and radiographic evidence of at least one bone metast",
        "label": "Contradiction"
    },
    "0f4882ae-b6f3-4c11-b4ad-a3fc1aeb6f94": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence provides the inclusion and exclusion criteria for two separate clinical trials and there is no mention of chromosome 6p25 or its relevance to breast cancer patients eligibility in the trials",
        "label": "Contradiction"
    },
    "b586fc1f-656e-477b-89d5-84aa4cb55814": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly reflects that no adverse events of type 1 were recorded in either trial and no information about adverse event type 2 was provided in the evidence",
        "label": "Entailment"
    },
    "985e4878-0637-4b32-a96f-626ff2f7cbd4": {
        "text_answer": "No  The statement preoperative iv antiemetics were administered does not necessarily mean that preoperative intravenous opiates were administered Antiemetics are medications used to prevent or treat nausea and vomiting while opiates are pain relievers The two are not the same The evidence provided does not mention anything about preoperative iv antiemetics specifically being opiates   Regarding the second part of the question",
        "label": "Contradiction"
    },
    "e0983a0e-1008-4845-bc61-082077d3d3d3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports a change in Ki67 expression not a reduction in tumor diameter The statement also specifies a different dosage and duration of tamoxifen administration",
        "label": "Contradiction"
    },
    "57c87de4-06c1-4d6f-9ed8-ed09e82cd3c7": {
        "text_answer": "No  Explanation  The statement significant differences were observed among the groups participating in the primary clinical trial is not directly entailed by the evidence provided The evidence only shows that there were differences in the area under the ROC curve between the two algorithms used in the primary trial but it does not indicate whether these differences were statistically significant  Additionally the statement all groups including the reflexology group showed similar results in the secondary",
        "label": "Contradiction"
    },
    "138e64ea-8b97-4101-b3cf-2b808a8dbc88": {
        "text_answer": "Yes The evidence states that there were no reports of increased pleural effusion in cohort 2 of the primary clinical trial The statement affirms this fact",
        "label": "Entailment"
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not include information about Treatment Emergent Adverse Events or Serious Treatment Emergent Adverse Events for the paced respiration and fast shallow breathing intervention groups Therefore it is not possible to determine if the statement is entailed by the evidence based on the information given",
        "label": "Contradiction"
    },
    "2e2e15a3-327e-4c79-9ad2-f7978f4f7cdf": {
        "text_answer": "No  Explanation  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group is not directly entailed by the evidence provided The evidence only shows the ORR for each group but it does not provide a comparison between the two groups to determine which one had a better ORR",
        "label": "Contradiction"
    },
    "4d5b9d90-2c58-499e-8943-eacac7580eb1": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it introduces a new topic epithiazide that is not mentioned in the evidence The evidence only provides information about the dosages of Eribulin and Docetaxel in two different interventions of a clinical trial",
        "label": "Contradiction"
    },
    "3ed3f0f5-20e7-4cd1-8c4c-79ba7603fb85": {
        "text_answer": "  No the statement about t113 is not directly related to the inclusion or exclusion criteria in the evidence However it is mentioned in the context of breast cancer which is the type of cancer specified in the evidence The statement about pulmonary embolism and eligibility for the secondary trial is partially entailed by the evidence as patients with a pulmonary embolism within the last 3 years are excluded from the primary trial but",
        "label": "Contradiction"
    },
    "ee049505-21d4-4255-823c-10d79a91db59": {
        "text_answer": "Yes  Explanation  The statement adverse events were experienced by less than 10 participants in the primary clinical trial is entailed by the evidence since the total number of adverse events is 2 and the number of participants in the trial is 35 Therefore the proportion of participants experiencing adverse events is less than 10",
        "label": "Entailment"
    },
    "b0b151a2-65f7-476a-9a2a-915bd963516d": {
        "text_answer": "Yes  Explanation The statement several participants in the primary clinical trial developed a urinary tract infection during the course of the trial is entailed by the evidence as there is a reported adverse event of urinary tract infection with a frequency of 200 2 cases out of 50 participants",
        "label": "Entailment"
    },
    "de3550b8-5014-4f01-897e-07780353ec9a": {
        "text_answer": "No  Explanation  The statement the occurrence of biliary colic and clostridium difficile colitis is more in the secondary clinical trial than in the primary clinical trial is not entailed by the evidence provided The evidence only shows that biliary colic occurred in one case in the secondary trial and none in the primary trial while Clostridium difficile colitis did not occur in any case in either trial Therefore",
        "label": "Contradiction"
    },
    "0a068f7d-0892-428d-889b-153d579cba78": {
        "text_answer": "No  Explanation The primary clinical trial is for postmenopausal women with early stage breast cancer and low vitamin D levels while the secondary clinical trial is for healthy males and females with HER2positive breast cancer The patient populations and inclusionexclusion criteria are different for each trial so it is not possible for a single patient to meet the criteria for both trials",
        "label": "Contradiction"
    },
    "1917f075-87da-430b-adf7-bb1579d145fb": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f891df0b-cb3d-4ee8-8294-f139ecc8a018": {
        "text_answer": "No  Explanation The statement 102 of the primary trial participants with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab developed her2 metastases is not entailed by the evidence The evidence only states that 13 out of 49 participants 265 developed imagable HER2 metastases The statement implies that",
        "label": "Contradiction"
    },
    "ff9b4b7a-e2c7-470d-9a7f-6f2b9669da64": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as the statement mentions two different interventions for the primary and secondary trials whereas the evidence only provides information about the interventions for each trial separately",
        "label": "Contradiction"
    },
    "77b0fb73-3157-4ceb-a366-7ae4f143e2b3": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID is not entailed by the evidence The primary trial is about radiation therapy for breast cancer patients while the secondary trial is about the use of Enzastaurin and Fulvestrant in breast cancer treatment The statement comb",
        "label": "Contradiction"
    },
    "4dc8e4d2-0265-4de1-98df-bcfb33c044e3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the secondary trial does not provide enough information to determine whether or not suramin and paclitaxel are used in its intervention The evidence only states that the number of individuals having mastectomy surgery who were approached for participation in the trial is not disclosed in the intervention section of the secondary trial",
        "label": "Contradiction"
    },
    "1ddf526c-beb2-43e1-846e-a133e321a66a": {
        "text_answer": "Yes The evidence does not explicitly state a life expectancy requirement but the exclusion of patients with a history of adjuvant chemotherapy given in the past 12 months implies a certain level of health and expected survival Additionally the inclusion of patients with stage IV or recurrent disease which is typically associated with a shorter life expectancy further emphasizes the importance of adequate functional status and expected survival for trial participation",
        "label": "Entailment"
    },
    "587623da-f061-478f-8196-ce7ec5558d5c": {
        "text_answer": "Yes The primary trial does not report the percentage of participants with tumor response experiencing clinical benefit using RECIST criteria The secondary trial does not report the percentage of participants with AIMSS experiencing clinical benefit",
        "label": "Entailment"
    },
    "a785048d-15ef-4c72-9d18-6c1db1df2620": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results only reports the number of participants in each arm who achieved a pathologic complete response in the breast and axillary lymph nodes at the time of surgery approximately 7 months after the start of treatment It does not provide information on the number of participants who experienced a pathologic complete response after approximately 30 weeks following surgery Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "8d502fe8-e084-480e-94ee-30ce69aca083": {
        "text_answer": "No  Explanation  The statement all ae types in the primary trial affected fewer than 110 of patients is not entailed by the evidence While it is true that each individual adverse event affected fewer than 110 of the patients it is not the case that all adverse event types affected fewer than 110 of the patients For example two adverse event types febrile neutropen",
        "label": "Contradiction"
    },
    "a1537e33-5b8e-4e7e-a18f-09fc3c436094": {
        "text_answer": "No  Explanation  The statement the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks and the secondary trial administers its patients with Depocyt and HDMTX is not directly entailed by the evidence provided While it is true that the primary trial involves the use of oral pregabalin and the secondary trial involves the use of Depocyt and",
        "label": "Contradiction"
    },
    "a83e8ca3-620b-47ab-a47b-3fc1fc4038c2": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the types of adverse events recorded in the secondary trial being related to the musculoskeletal system The statement only mentions the primary trial and incorrectly assumes that all adverse events in both trials are related to the musculoskeletal system",
        "label": "Contradiction"
    },
    "1824af8a-6f79-49bd-8df3-5751b1e65adb": {
        "text_answer": "No  Explanation The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is not directly stated in the evidence However the evidence does provide the inclusion and exclusion criteria for the trial which include specific requirements for women of childbearing potential and sexually active fertile men regarding the use of birth control methods The statement goes beyond the information",
        "label": "Contradiction"
    },
    "82d23e4a-cdf8-4ab4-b2fa-7ea99d98d5a4": {
        "text_answer": "yes The statement mentions conditions that are exclusion criteria for the secondary trial which are also listed in the evidence However its important to note that the statement also mentions conditions that are not mentioned in the evidence such as unstable angina so the statement is not a perfect match to the evidence But the part that is entailed by the evidence is that patients with chemotherapy or radiotherapy in the last 2 weeks cannot take part in the secondary trial",
        "label": "Entailment"
    },
    "c258ef31-d79a-4ddd-b3c0-81742b7f632f": {
        "text_answer": "Yes  Explanation The statement the secondary clinical trial has a higher incidence of biliary colic and diarrhoea compared to the primary clinical trial is entailed by the evidence as the secondary trial has a higher percentage of participants experiencing biliary colic 1667 vs 328 and diarrhoea 1667 vs 328 compared to the primary trial",
        "label": "Entailment"
    },
    "5c7eee11-ee31-4adf-b2e6-8fe51a39a13b": {
        "text_answer": "No  Explanation  The statement 561 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide the necessary information to calculate the difference between the two groups",
        "label": "Contradiction"
    },
    "9006f1c5-2818-4edf-85e4-77d532b10820": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "33472836-f751-4de3-8b21-92e2d9e3d7ed": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts receive the same dosage and frequency of Doxorubicin Cyclophosphamide and Docetaxel but cohort 2 receives three additional cycles of these drugs The statement does not mention anything about thyroid gland schwannoma so that part is not addressed in the question",
        "label": "Entailment"
    },
    "c5b0eaf3-50c0-4115-8da5-91af0310a7b2": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide any information about the CDISC SDTM Laboratory Test Name Terminology or the specific measurement of Severity of Delayed Nausea in the primary trial The evidence only reports the outcome measurement for the primary trial as Summed Pain Intensity Differences SPID at 30 minutes after dosing and the outcome measurement for",
        "label": "Contradiction"
    },
    "beae10d7-7132-4875-8bc6-4e996d20eb90": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial only reports the percentage change in betaCTX at Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups It does not provide information about the percentage change in betaCTX at Week 30 for the AZD0530 90 mg group Therefore it is not possible to determine if the statement is ent",
        "label": "Contradiction"
    },
    "c5a5aed2-c471-41a4-940c-9fa644e5a9fc": {
        "text_answer": "No  Perjeta pertuzumab is mentioned in the secondary trial as a potential novel radiotracer for HER2targeted PETCT but it is not stated that it is used within any cohorts of the trial However in the primary trial Perjeta is used in combination with Fulvestrant and Anastrozole as an intervention",
        "label": "Contradiction"
    },
    "2de24fb7-9ebe-419e-af16-5d9ed2b808ef": {
        "text_answer": "No  The patient described in the statement does not meet the inclusion criteria for the trial as they have a life expectancy of less than 3 months",
        "label": "Contradiction"
    },
    "409e7b50-f5db-4321-9a39-3853131ade7d": {
        "text_answer": "No  Explanation  The statement a quarter of the participants are witnessing worsened pleural effusion and accelerated disease deterioration is not directly entailed by the evidence provided The evidence only states the number of adverse events for each category in each trial but it does not specify that a quarter of the participants in the second trial experienced both worsened pleural effusion and accelerated disease deterioration",
        "label": "Contradiction"
    },
    "f1b4c0aa-df9b-4d75-9c65-f06709df664a": {
        "text_answer": "No  The statement a patient with frequent smoking habits is eligible for participation in the primary clinical trial is not entailed by the evidence as the evidence explicitly states that Patients must not be smoking or using nicotine replacement therapy for at least 4 weeks prior to study entry for the primary trial",
        "label": "Contradiction"
    },
    "1605cfcf-22e5-4a48-a89a-cd7b44e3109f": {
        "text_answer": "No  Explanation  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for the primary and secondary trials but it does not mention anything about CBT Cognitive Behavioral Therapy treatments being prohibited or allowed",
        "label": "Contradiction"
    },
    "7b73381b-500c-4056-9c4c-4334a6e0b9b4": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials use pCR as the outcome measure and there are differences in pCR rates between the arms in each trial",
        "label": "Entailment"
    },
    "4a454653-60b6-47dd-a2ba-780d1dfbacaf": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial each patient experienced a unique type of adverse event is not entailed by the evidence While it is true that each patient experienced at least one type of adverse event it is not stated that each patient experienced a unique type of adverse event Some patients experienced the same type of adverse event eg three patients experienced back pain and two patients experienced fever",
        "label": "Contradiction"
    },
    "bc9d1c66-4743-474d-9e82-b9e8438a8e86": {
        "text_answer": "Yes The primary trial does not include an age criterion while the secondary trial specifies that patients are above a certain age",
        "label": "Entailment"
    },
    "eada8d1a-7396-44e7-8f30-03814c7479fb": {
        "text_answer": "  No  Explanation  The statement there were no lesions found on any of the group 1 participants in the primary clinical trial and an overwhelming 95 of group 1 participants in the secondary clinical trial showed signs of radiation dermatitis and hyperpigmentation is not entailed by the evidence  The evidence only reports the number of participants and the number of lesions detected in each group of the primary clinical trial",
        "label": "Contradiction"
    },
    "c80808f0-b1fd-45e1-99b4-154860b05038": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not include any information about immunogenicity specimen assessments or baseline flags The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ae6b9c00-10a6-437a-a83b-b46fce724269": {
        "text_answer": "Yes  Explanation The evidence shows that there were 5 participants in the placebo group who were analyzed but no number of emesisfree days was reported for them This implies that there were no emesisfree days for any of the participants in the placebo group during the study period Therefore the statement emesis was not a reported symptom for patients receiving the placebo intervention is entailed by the evidence",
        "label": "Entailment"
    },
    "41e9e8e9-6fec-49fa-ae36-7daa737de66c": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial requires 120 milligrams of denosumab injected subcutaneously every 4 weeks not 4 milligrams injected daily The secondary trial does not involve denosumab at all but rather the use of a pIHGC and GP for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "171827b1-29bc-4e7b-a70a-3d03d4ae7dad": {
        "text_answer": "Yes  Explanation The statement the differences between interventions 1 and 2 of the primary clinical trial extend beyond the dose of durva administered during biweekly iv infusions is entailed by the evidence as the evidence also mentions the difference in the dose of tremelimumab administered during the initial cycles and the frequency of its administration after cycle 6",
        "label": "Entailment"
    },
    "2107eaac-f0e5-47a2-a7cb-b6d27aa47d23": {
        "text_answer": "No  Explanation  The statement all candidates in cohort 1 of the primary clinical trial experienced at least one adverse event ae while none of the cohort 2 candidates did is not entailed by the evidence provided The evidence only states that there were no adverse events in cohort 2 but it does not provide information about the number or percentage of adverse events in cohort 1 Therefore it",
        "label": "Contradiction"
    },
    "d478ad25-2445-48f1-9308-2d6025dfead2": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement about a patient gaining over 10 kilos of lean body mass with GTx024 1mg as the median change in lean body mass for that group was 206 to 1264 kg which includes both negative and positive values The statement is not entailed by the evidence as it only mentions one specific outcome ",
        "label": "Contradiction"
    },
    "9e3d3c08-d9ee-449d-b4c8-957d666315a1": {
        "text_answer": "No  Explanation  The statement no aes were observed in patients from the secondary clinical trial is not entailed by the evidence as the evidence shows that there were 2 instances of Adverse Events AEs in the secondary trial specifically one instance of chest pain The statement only correctly applies to the specific AEs listed in the statement which do not include chest pain",
        "label": "Contradiction"
    },
    "ad2ac39b-960a-463d-b3ab-955916e20a97": {
        "text_answer": "No  Explanation The statement each group from the secondary clinical trial takes 500 mg of fulvestrant in tablet form bid is not entailed by the evidence While it is true that participants in the secondary clinical trial received Fulvestrant the statement does not accurately describe the dosing regimen for the intervention groups in the secondary trial The primary trial involved whole breast radiation therapy while the secondary trial involved the use of Enzastaur",
        "label": "Contradiction"
    },
    "20307fc02-18bb-4910-9992-43a811bf7a1f": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not support the statement that on average patients from the primary trial survive less than 24 months and over 40 patients from each cohort survived less than 2 days The evidence only reports the median survival times 214 years for the midluteal surgery group and 200 years for the midfollicular surgery group and their",
        "label": "Contradiction"
    },
    "3b940a21-1adf-4820-a178-9517bb60d6f0": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "38ea3ca5-d5b1-4432-b6f6-52e8ca0d3e41": {
        "text_answer": "No  Explanation  The evidence provided in the results does not allow for a direct comparison of the percentage reduction in the growth factor signature between the ERpositive Luminal B and Triple Negative groups The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature based on a statistical threshold The statement in question makes a comparison of the magnitude of the reduction between the two groups which cannot be determined from the given",
        "label": "Contradiction"
    },
    "428f149b-1b45-4ad0-a5d3-0c885fec2767": {
        "text_answer": "Yes  Explanation  The statement the intervention provided in the secondary clinical trial reports on the MTD while the intervention provided in the primary clinical trial does not is entailed by the evidence because the primary clinical trial does not mention the identification of the MTD as an outcome measurement whereas the secondary clinical trial explicitly states that its outcome measurement is the identification of the MTD",
        "label": "Entailment"
    },
    "6204ed3f-bad3-4db0-8db9-9f73efd78e8f": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as the evidence only reports the percentage of participants with HER2 Primary Breast Cancer who developed Imagable HER2 Metastases after undergoing HER2targeted PETCT with 89Zrtrastuzumab but it does not mention respiratory therapy in the evidence",
        "label": "Contradiction"
    },
    "38da1202-fb8c-46d0-9779-db075423a422": {
        "text_answer": "Yes  The statement is entailed by the evidence as it correctly describes the patient characteristics for each cohort in the clinical trial",
        "label": "Entailment"
    },
    "85bde7b9-9e2e-41e1-a8d5-9ff85e8900e6": {
        "text_answer": "Yes The evidence does not explicitly mention thoracic surgery but the trial includes patients with breast cancer which is a disease of the chest and the statement correctly identifies thoracic surgery as a branch of medicine dealing with the use of surgery to treat diseases of the chest Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "3edf7faa-74f7-4d02-bb9b-d5d421f2cca4": {
        "text_answer": "No  Explanation  The statement sdha protein variant is a variation in the amino acid sequence for the succinate dehydrogenase ubiquinone flavoprotein subunit mitochondrial protein is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The statement mentions a specific protein variant but the trials do not mention anything about protein variants or specific genetic conditions The trials",
        "label": "Contradiction"
    },
    "00539969-3b0f-4c9f-be8a-0ce964c7d5fa": {
        "text_answer": "No   Explanation The statement is not directly related to the evidence provided The evidence only mentions the use of 18FFDG and 18FFPPRGD2 in the context of PETCT imaging for patients with glioblastoma multiforme and gynecological cancers It does not mention anything about a carfilzomibpanobinostat regimen or its relation to the imaging",
        "label": "Contradiction"
    },
    "12ed5e10-5988-494c-8a88-6e4e30ddd355": {
        "text_answer": "No  Explanation  The evidence provided in the primary clinical trial results does not indicate any information about treatment emergent adverse events or serious treatment emergent adverse events for the paced respiration and fast shallow breathing intervention groups The evidence only reports the mean number of hot flashes per 24 hours for each group",
        "label": "Contradiction"
    },
    "cc31b936-223f-4378-9028-315601fba09e": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial includes patients with measurable disease which could be larger than 1 cm The statement does not hold true for all patients eligible for both trials",
        "label": "Contradiction"
    },
    "e3fd6c0c-a119-4bb5-b82b-366830537c70": {
        "text_answer": "No  Explanation The statement cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1 is not directly related to the question about a voice problem The evidence only provides information about the dosage of Enzalutamide for each cohort in the trial The question is about the frequency of an individuals voice problem upsetting them which is not mentioned in",
        "label": "Contradiction"
    },
    "bc7d8745-f12d-4a54-a922-fb72f4bd01f0": {
        "text_answer": "  No the statement is not entailed by the evidence for the primary trial However it is mentioned as a potential exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "d46a61dd-b28a-476e-981e-f3d1cca2739c": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial measure different outcome measures The primary trial measures the change in hot flash activity using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using the Response Evaluation Criteria In Solid Tumors RECIST criteria These are distinct measures of treatment efficacy",
        "label": "Contradiction"
    },
    "7ba72ade-08b1-4062-86f4-2a93ec724780": {
        "text_answer": "No  Explanation  The evidence provided in the results 1 does not give the number of participants in the Lapatinib 1g  NabPaclitaxel arm who experienced a confirmed complete response CR The evidence only states that 53 out of 60 participants were analyzed in this arm To answer the question we would need the number of participants who experienced a CR in this arm",
        "label": "Contradiction"
    },
    "38c5a69a-ad2f-4f2c-b234-74c93e8f6c72": {
        "text_answer": "Yes The evidence states that only the intervention arm of the study will receive the educational DVD implying that the control arm will not receive it",
        "label": "Entailment"
    },
    "a0b10912-a394-4892-88f8-7dfbc771052b": {
        "text_answer": "No  Explanation The statement The patient with the longest PFS in the primary trial survived 35 months is not directly entailed by the evidence provided The evidence only gives the median PFS for each treatment group not the longest PFS observed in the trial Additionally the statement mentions a specific patient with asymptomatic grade 1 kyphosis which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "90e07508-8860-4e21-bffe-77d51f0749db": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not report any cases of shingles in the primary trial The statement only mentions that there were 7 cases of shingles in total across both trials but it does not specify which trial these cases came from",
        "label": "Contradiction"
    },
    "af3f07a1-e8c0-4ce1-a0b2-5789bca86cd6": {
        "text_answer": "  No the statement severely anxious or depressed is a response indicating that an individual has or had severe anxiety or depression is not directly entailed by the evidence provided However the primary trial has exclusion criteria for patients with preexisting motor or sensory neurotoxicity of a severity 2 by NCI CTCAE v 30 criteria which could potentially include anxiety or depression but the evidence does not specify this The statement about pul",
        "label": "Contradiction"
    },
    "d3bf6a5f-bce2-47f5-be7a-6c97b2bf88ef": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement compares the interventions in two different trials but the evidence only provides information about the interventions in each trial separately The statement incorrectly assumes that the first intervention in the primary trial is a standard iv dose of chloroquine while the evidence clearly states that the first intervention in the primary trial is an intraosseous injection of fluciclatide",
        "label": "Contradiction"
    },
    "d130905f-48af-4f05-9d02-92c980b46c75": {
        "text_answer": "No  Explanation  The statement suramin and paclitaxel are given to every participant in both the primary and secondary clinical trial is not entailed by the evidence The evidence only states that suramin and paclitaxel are the interventions given in the primary trial and that the secondary trial involves patients undergoing mastectomy surgery It does not specify that suramin and paclitaxel are given in the secondary trial",
        "label": "Contradiction"
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "text_answer": "No  Explanation  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed by the evidence provided The evidence only lists the number and percentage of adverse events for each trial but it does not specify the number or percentage of patients who experienced infections Therefore it is impossible to determine if over 15 of patients in both trials suffered from infections",
        "label": "Contradiction"
    },
    "f1e9c350-baed-4c5d-a760-b5b8a69e6706": {
        "text_answer": "Yes The evidence does not explicitly state that AfricanAmerican patients are mentioned as a specific inclusion criterion but there is no exclusion criterion based on race Therefore AfricanAmerican patients are eligible for the trial",
        "label": "Entailment"
    },
    "022c87c6-e5c0-4401-92f7-2570af8f8ac1": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about smoking status of the participants in either of the trials",
        "label": "Contradiction"
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "text_answer": "No  Explanation The evidence describes two separate interventions with different participant groups one for adult cancer patients and the other for healthy volunteers Therefore the statement that every participant in the primary trial receives the same intervention is not entailed by the evidence",
        "label": "Contradiction"
    },
    "7432cb06-a4a3-4f9c-afc8-533e39b7337f": {
        "text_answer": "Yes  Explanation  The statement the number of adverse events recorded in the primary trial and the secondary trial is identical is entailed by the evidence since both trials have a total of 0 adverse events",
        "label": "Entailment"
    },
    "703e6942-968d-4cdf-8e98-45cc571effd0": {
        "text_answer": "No  Explanation  The statement the adverse events section of the primary clinical trial did not document any suspected serious adverse reactions while the secondary clinical trial recorded several instances is not directly entailed by the evidence provided The evidence only states the number of adverse events both serious and nonserious in each trial but it does not specify whether any of those events were serious or not for the secondary trial Therefore it is possible that",
        "label": "Contradiction"
    },
    "9d7a1491-f931-47dd-9177-72bc90006fd2": {
        "text_answer": "No  The statement prior severe anaphylactic reactions to trastuzumab do not disqualify a patient from participating in the primary clinical trial is not explicitly stated in the evidence However it does mention that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded It does not specify that only severe anaphylactic reactions are excluded Therefore its not clear if the statement is ent",
        "label": "Contradiction"
    },
    "d73e5604-bcf0-465f-b147-7ed3cb036e4c": {
        "text_answer": "No  Explanation  The statement rod device is any rodshaped device is not directly related to the evidence provided The evidence only compares the operative times for two different types of mammography procedures intraoperative and standard specimen mammography It does not mention any rod devices being used in either group  Furthermore the statement also asserts that Arm 2 of the primary trial had higher Operative Time",
        "label": "Contradiction"
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "text_answer": "No  Explanation The statement All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is not entailed by the evidence provided The evidence only states the doses of PF06647020 used in each trial not the doses of ALT801",
        "label": "Contradiction"
    },
    "141ee099-c8ae-4db1-9082-6fc138ad8093": {
        "text_answer": "Yes   Explanation  Both the primary and secondary trials have a duration of 10 weeks for the intervention reflexology or vitamin D in the primary trial and 24 weeks for the intervention placebo or high dose vitamin D in the secondary trial Therefore the statement that the intervention schedules have the same duration is entailed by the evidence",
        "label": "Entailment"
    },
    "0fc55b5a-e5cc-40d1-a0fe-e4ce3ffd8172": {
        "text_answer": "No  Explanation  The statement patients suffering severely from sleep disorders other than insomnia can participate in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided The primary clinical trial has specific inclusion and exclusion criteria related to breast cancer and its treatment while the secondary clinical trial focuses on sleep disorders and the use of armodafinil There is no mention in the evidence that patients with severe sleep disorders other",
        "label": "Contradiction"
    },
    "f8fe88c6-ebd4-49ad-b381-b6017fdaf070": {
        "text_answer": "Yes The primary trial measures changes in serum levels of Follicle Stimulating Hormone FSH using units of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib using units of mg The statement acknowledges this difference in outcome measurements and units of measure",
        "label": "Entailment"
    },
    "dce94e19-6a0a-4fc9-ab35-ad4eb378622b": {
        "text_answer": "Yes The evidence states that patients with metastatic nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer are eligible for the trial Metastatic disease is a type of validated cancer progression",
        "label": "Entailment"
    },
    "1cc9db7e-8214-46cd-bbe3-7ff873be5589": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it introduces an unrelated topic the sgk1 gene mutation which is not mentioned or relevant to the information provided in the evidence about the two interventions in the primary trial The evidence only states that both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tum",
        "label": "Contradiction"
    },
    "fccade16-a6ed-4bc1-b767-d5d1ab20b780": {
        "text_answer": "No   The primary trial evaluates the summed pain intensity differences SPID at 30 minutes after dosing while the secondary trial focuses on changes in bone mineral density BMD of the lumbar spine over a period of 9 months The statement is not about the same outcome measurement in both trials",
        "label": "Contradiction"
    },
    "0a279b67-be5a-4f7d-a21b-b178a556f8ae": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial description does not mention anything about HER2neu peptide vaccine or sargramostim GMCSF being administered to the participants The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "94ebad4c-4b9c-4fb7-b7cc-a088b46b56f7": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 002g of mcs110 every 3 weeks is entailed by the evidence because 1 mgkg is equivalent to 1000 mg60 kg assuming an average patient weight of 60 kg which is greater than 002g Therefore all patients in the trial receive more than 0",
        "label": "Entailment"
    },
    "1fef627f-f239-4ad3-8bec-4141e2b36dfd": {
        "text_answer": "No  Explanation  The evidence provided in the text does not contain any information about a deleterious cdh1 gene mutation or its association with the incidence of neutropenia in the two trials The evidence only reports the results of the trials in terms of the duration of neutropenia and the incidence of neutropenia but it does not provide any information about the genetic background of the patients or the presence of any specific mut",
        "label": "Contradiction"
    },
    "685d9609-ec5f-4dcb-9783-e9d7b061eaf5": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement is about seg algorithm which is not related to the evidence provided which is about the number of participants with treatmentemergent adverse events and serious adverse events in a clinical trial of Sunitinib  Docetaxel  Trastuzumab",
        "label": "Contradiction"
    },
    "a9e14c3b-bf03-4ca1-b9d9-4693b231902c": {
        "text_answer": "Yes regarding the changes in lymphedema between the acupuncture and waitlist groups not related to 6p2133",
        "label": "Entailment"
    },
    "ec2edea0-23ee-487c-bfbb-ef6fb517e744": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the Karnofsky score requirement is different in the two trials In the primary trial a score of 70 or higher is required while in the secondary trial a score of 55 or higher is considered the baseline",
        "label": "Contradiction"
    },
    "b5cc8685-0fb5-4819-a7cb-960980d95272": {
        "text_answer": "Yes The evidence states that patients must have evidence of a solid tumor that is locally advanced andor metastatic to be eligible for both phases of the primary clinical trial",
        "label": "Entailment"
    },
    "47bb2ffb-2cee-418b-acd6-cdecee318d70": {
        "text_answer": "Yes  Explanation The evidence states that fewer than 50 of participants in the Highdose Chemotherapy arm saw a reduction in circulating tumor cells CTCs after treatment Therefore the statement fewer than 50 of participants saw a decrease in circulating tumor cells after treatment with highdose chemotherapy and cleansed autologous stem cell products is entailed by the",
        "label": "Entailment"
    },
    "7b507eae-bfd5-4546-993b-6dd936ab41e5": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "02365d25-1a64-4415-aae7-c0254d234fa9": {
        "text_answer": "yes the statement is entailed by the evidence but it is incomplete as it does not mention that both cohorts undergo a SPECT scan at baseline and 6 months followup",
        "label": "Entailment"
    },
    "8858a62b-91a2-4f2c-a1f1-e54ea15e5861": {
        "text_answer": "No  The statement is not entailed by the evidence as there were no reported cases of acute myocardial infarction in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "80140ee4-3ead-44cc-a7a2-b6af0798c1b1": {
        "text_answer": "No  Explanation The statement every patient in the primary clinical trial that received gtx024 1mg lost over 5 kilos of lean body mass is not entailed by the evidence The evidence only provides the median with range change in lean body mass for the group of patients who received gtx024 1mg The median change was 155 kg which is not over 5 kg for",
        "label": "Contradiction"
    },
    "6a0bfa75-3e83-4c73-8e5a-2dc4cad866c3": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence states that there is only one adverse event recorded for the patient cohort of the primary trial The statement specifically mentions the chromosome band 19p1312 but the number of adverse events for this specific chromosome band is not mentioned in the evidence However since the evidence states that the total number of adverse events for the entire patient cohort is one it",
        "label": "Entailment"
    },
    "3dc3b5d7-3bad-4494-9e97-e6f27bf52c07": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the specifics of the irradiation doses or treatment cycle The statement focuses on the absence of information about nodal involvement which is not addressed in the evidence",
        "label": "Contradiction"
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "text_answer": "Yes The statement is entailed by the evidence as both study groups undergo the same imaging procedures with 18FFDG and 18FFPPRGD2",
        "label": "Entailment"
    },
    "c6a921cd-f18d-4fea-a543-54784444279c": {
        "text_answer": "No  Explanation  The statement across the primary trial multiple deaths were recorded in the adverse events but the secondary trial had no deaths is not entailed by the evidence provided The evidence only states the number of adverse events and the types of adverse events for each trial It does not specify how many deaths if any were caused by the treatment or were unrelated to the treatment Therefore it is not possible to determine from the",
        "label": "Contradiction"
    },
    "99a8a2b3-84ad-4c45-9371-e731cc5942db": {
        "text_answer": "No  Explanation The evidence provided in the primary trial only reports the number of participants with a reduction in circulating tumor cells CTCs at one month post autologous hematopoietic stem cell transplantation AHST It does not specify that this reduction occurred in more than 97 of the participants Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "414dbb63-9c4c-44e9-96f5-c54b5d341f82": {
        "text_answer": "No  Explanation  The statement patients in both cohort 2 of the primary trial and cohort 1 of the secondary trial reported equal incidence of neutropenia irrespective of their empegfilgrastim dosage regimen is not entailed by the evidence provided The evidence only shows the mean duration of neutropenia and the number of participants with neutropenia for each cohort but",
        "label": "Contradiction"
    },
    "f205a6e1-26d3-4a63-bea1-126428af787b": {
        "text_answer": "No  Explanation  The statement the primary clinical trial had a higher prevalence of recurring malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage in its adverse events compared to the secondary clinical trial is not entailed by the evidence provided  The evidence only shows the number of adverse events for each condition in both trials but it does",
        "label": "Contradiction"
    },
    "cf080a87-de94-4d6b-9d18-89a5f5003316": {
        "text_answer": "Yes  Explanation The statement participants in the primary trial are given a higher weekly dosage of mm121 and paclitaxel compared to those in cohort 1 of the secondary trial is entailed by the evidence In the primary trial patients received a 20 mgkg weekly IV infusion of MM121 while in the secondary trial patients in cohort 1 received a weekly",
        "label": "Entailment"
    },
    "c4e419c4-f227-4c0c-b8b5-c8e0f62585a7": {
        "text_answer": "No  Explanation  The statement the results from the primary clinical trial suggest that the arm b intervention yielded the most promising overall response rate is not directly entailed by the evidence provided The evidence only shows that in the primary clinical trial the overall response rate for Arm B was 600 while for Arm A it was 676 However the statement does not make a clear comparison between the two arms regarding the most",
        "label": "Contradiction"
    },
    "18b0cc37-3189-4ea0-970e-81a6b79dba7f": {
        "text_answer": " No   Explanation  The evidence provided in the results does not indicate that any participant in Group 1 experienced a serious adverse event that threatened their life The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "0c992694-2b3d-4fa1-b822-ecc5f1ceb2e9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement is about a different type of cancer kidney cancer and the evidence is about breast cancer The evidence only mentions the inclusion and exclusion criteria for a breast cancer clinical trial",
        "label": "Contradiction"
    },
    "c640af56-cef3-432a-87f2-b2b446b7ab96": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the secondary trial does not provide information about the administration of dexmedetomidine to any of its cohorts",
        "label": "Contradiction"
    },
    "e70d1cc6-b4e5-4fc6-a26f-9b9dd76ef54f": {
        "text_answer": "  Not Entirely  Explanation  The statement not known if 10q23pten locus deletion analysis was performed is an indication that it was not performed during the study is not entirely entailed by the evidence The evidence only states that 10q23pten deletion analysis is not mentioned as an inclusion or exclusion criterion for either trial It does not provide information about whether or not",
        "label": "Entailment"
    },
    "0cd83002-1e58-4b84-ac34-e4299d4573ab": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial there were patients who did not suffer from 3 or more adverse events is entailed by the evidence because the evidence shows that the total number of adverse events per patient was less than 3 for some patients Specifically 19 out of the 25 patients 7600 did not experience 3 or more adverse events",
        "label": "Entailment"
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "text_answer": "Yes  Explanation  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is entailed by the evidence because there are no records of deaths or hospitalizations mentioned in the evidence for either trial  The statement the only AEs recorded were 3 cases of Lymphoma is also entailed by the evidence as the evidence shows that there were a total of 3 cases of Lym",
        "label": "Entailment"
    },
    "a491bf7b-7327-48cd-ac0f-708a50c385b7": {
        "text_answer": "No  The statement is not entailed by the evidence as the inclusion criteria specify a HER2 positive tumor either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "379e6494-403f-4469-9ee4-9e3d12c0d562": {
        "text_answer": "No  Explanation  The evidence provided in the text only reports the percentage of participants with disease progression or death in each group during the maintenance phase of the clinical trial It does not directly compare the outcomes between the two groups to determine which one yielded superior results Therefore the statement the bevacizumab group in the primary clinical trial yielded superior outcomes compared to the bevacizumab  capecitabine group is",
        "label": "Contradiction"
    },
    "90c0e27d-dcb3-4014-ae46-b1f4640093b7": {
        "text_answer": "No  The statement is not entailed by the evidence as the number of adverse events is different between the two cohorts",
        "label": "Contradiction"
    },
    "3693ad36-964f-4377-93a3-6137083b22dd": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement about a 64 difference in recurrencefree survival between the Ketorolac 30 mg and NaCl 09 3mL groups The evidence only provides the number of participants in each group and their recurrencefree survival rates To determine the difference in recurrencefree survival between the two groups additional information",
        "label": "Contradiction"
    },
    "f543a317-1f30-46b9-849e-67396ae072de": {
        "text_answer": "Yes Both trials involve oral administration of interventions",
        "label": "Entailment"
    },
    "fae9affd-c763-49c0-ae6d-88852f5774af": {
        "text_answer": "No   Explanation   The statement patients in the secondary trial cohorts do not receive any Dexmedetomidine is not directly related to the information provided in the evidence regarding the proficiency testing challenge The evidence only mentions the interventions given in the primary and secondary trials but it does not specify whether or not patients in the secondary trial received Dexmedetomidine as part of the proficiency testing challenge",
        "label": "Contradiction"
    },
    "6e78e878-1154-43b8-b93a-c1b68aef70c8": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that all patients were prescribed sunitinib and took it orally daily throughout the trial",
        "label": "Entailment"
    },
    "89e52784-5ddd-405e-b794-95ef5b5766eb": {
        "text_answer": "No  The statement is not related to the evidence provided The evidence discusses interventions used in breast reconstruction and heart treatment while the statement is about a concept in molecular biology",
        "label": "Contradiction"
    },
    "c4a45d2b-0e4b-4cd2-80ef-176d487d8180": {
        "text_answer": "Yes  Explanation The statement participants in the primary clinical trial experienced diarrhoea more frequently than those in the secondary clinical trial is entailed by the evidence since the primary clinical trial had a higher incidence of diarrhoea 2333 compared to the secondary clinical trial 000",
        "label": "Entailment"
    },
    "396511cd-a922-4ba6-9c33-bc2f20bfdebd": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial the operative time of arm 1 was lower than that of arm 2 demonstrating the effectiveness of standard mammography compared to intraoperative mammography is not entailed by the evidence The evidence only shows that the operative time for intraoperative mammography was shorter than that for standard mammography in the primary trial but it does not necessarily mean that standard",
        "label": "Contradiction"
    },
    "29d8fc44-5636-4633-9651-2d30521a2755": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial only gives the median average survival times for each group not the total number of patients who survived beyond a certain time frame 104 weeks or 2 years The statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "fa80610a-3dd0-49e7-97f3-7efbdf636ca5": {
        "text_answer": "No  Explanation  The statement the primary clinical trial recorded slightly more total adverse events among its patient cohorts compared to the secondary clinical trial is not entailed by the evidence provided The evidence only states that the number of adverse events for each trial is given with no comparison made between them",
        "label": "Contradiction"
    },
    "48fdcfb8-5519-42cd-8496-f8f2e0e38808": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b1774ca3-1bc7-4643-a115-09e813115e9f": {
        "text_answer": "  The statement is not entailed by the evidence for the primary trial as the patient does not meet the minimum bone marrow function requirement ANC  1800 cellsmm3 However the statement is entailed by the evidence for the secondary trial as the patient meets all other inclusion criteria",
        "label": "Contradiction"
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "text_answer": "Yes  Explanation  The primary trial measures tumor diameter in centimeters cm while the secondary trial measures the number of participants with solid tumor response These are different units of measure for the same outcome measurement tumor response",
        "label": "Entailment"
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "text_answer": "No  Explanation The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not entailed by the evidence provided The primary trial explicitly states that the minimum age for inclusion is 20 years old The secondary trial includes women and men aged 18 or older",
        "label": "Contradiction"
    },
    "bfc4e387-9404-498e-903b-5ca9f88dcc3b": {
        "text_answer": "Yes  Explanation  The statement results from the primary trial show that tamoxifen 20000 micrograms po daily for 7 days prior to surgery and for 14 days after breast cancer surgery reduces ki67 expression in tumors by 04 on average is entailed by the evidence provided The evidence states that the mean percentage change in Ki67 expression was 40 63 to 29",
        "label": "Entailment"
    },
    "812ba472-cd7c-410e-9a4c-88dc1795d5be": {
        "text_answer": "Yes The statement does not explicitly appear in the evidence but the ECOG performance status of 0 to 2 in both trials indicates that candidates have limited selfcare abilities and are confined to bed or chair for less than 80 of waking hours",
        "label": "Entailment"
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "55fed266-9982-4062-b7fa-5ec9279441e4": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ee441983-976c-41d7-aa66-19037a3f5f5b": {
        "text_answer": "Yes The statement includes some of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "a079229c-d371-4c18-b2b3-20b0068a4c50": {
        "text_answer": "No  Explanation  The statement there were several instances of shingles in both the primary trial and group 1 of the secondary trial but none in group 2 of the secondary trial is not entailed by the evidence provided The evidence only states that there was one instance of shingles in the primary trial and one instance in group 1 of the secondary trial but it does not mention the number of instances in group 2 Therefore",
        "label": "Contradiction"
    },
    "ed6b3dc1-1cdb-4da6-ad5c-d5073abd31ea": {
        "text_answer": "Yes The statement does not mention any specific conditions regarding mental health bodyweight age or previous treatments as exclusion criteria which is consistent with the evidence provided",
        "label": "Entailment"
    },
    "2882972d-2466-4eb1-9be2-14f0ebed2102": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement incorrectly asserts that both cohorts receive the same dose of sunitinib daily whereas the evidence indicates that cohort 1 starts at 25 mg daily and may escalate to 375 mg daily while cohort 2 is not mentioned to receive a specific starting dose of sunitinib",
        "label": "Contradiction"
    },
    "0e3228de-973b-4ce4-9d67-e46392d6f0a6": {
        "text_answer": "No  Explanation The statement does not mention childhood kidney angiomyolipoma in the evidence The evidence only mentions glioblastoma multiforme and gynecological cancers",
        "label": "Contradiction"
    },
    "5bdba14a-5c7f-4913-b543-9c791965c237": {
        "text_answer": "No  Explanation The evidence provided in the results only gives the median with range change in lean body mass for each group treated with GTx024 1mg and 3mg It does not specify the number of patients who gained over 10000 grams 10kg of lean body mass Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "3f5b9c7d-ae3e-4484-88c7-c7562c2f974a": {
        "text_answer": "No  Explanation  The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR However the statement only mentions CR not the percentage of participants who experienced it Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "13178eb4-e1c0-4fa0-8008-f4a4617220aa": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e928035e-e614-46e3-a3f7-94341043b14e": {
        "text_answer": "No   Explanation   The statement gallbladder infection ctcae is a disorder characterized by an infectious process involving the gallbladder is not directly related to the inclusion or exclusion criteria of the primary or secondary trials The trials focus on breast cancer patients and those undergoing breast reconstruction respectively and do not mention gallbladder infections or CTCAE Common Terminology Criteria for Adverse Events",
        "label": "Contradiction"
    },
    "7074d2ad-2b70-4e46-a617-f49ddbd8588e": {
        "text_answer": "Yes  Explanation  The statement grade 1 psychiatric disorders  other specify ctcae is asymptomatic or mild symptoms clinical or diagnostic observations only intervention not indicated less than 5 of patients in the primary trial suffered AEs implies that less than 5 of patients in the primary trial experienced grade 1 psychiatric disorders that were asymptomatic or mild and no intervention was needed  The evidence provided states",
        "label": "Entailment"
    },
    "cf9d27be-b128-4621-9734-8e9fb3197105": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement makes incorrect assumptions about the units of measurement used in the primary and secondary trials The primary trial reports Time to Progression in months not days and the secondary trial reports the percentage of participants with Objective Response not the number of days for a total of 156 patients Additionally the statement does not relate to gastric dysplasia at all",
        "label": "Contradiction"
    },
    "6528eb91-c678-4508-8d1f-db13bce8d182": {
        "text_answer": "No  The statement does not mention Paraplatin in the context of the trial interventions and there is no information given about the presence or absence of achiness in the arms of the trial participants",
        "label": "Contradiction"
    },
    "4d824080-17e3-4df5-9ef0-f6b0e3496f31": {
        "text_answer": "Yes  Explanation The statement an increased number of adverse events were reported among participants in cohort 1 of the primary clinical trial as compared to cohort 2 is entailed by the evidence as the total number of adverse events reported in cohort 1 45106 or 4245 is higher than the total number of adverse events reported in cohort 2 710",
        "label": "Entailment"
    },
    "04a0ccc3-e60d-462a-a31e-802e0f54e1d8": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence as the statement mentions an average reduction of tumor sizes by 40 while the evidence only reports a significant change in Ki67 expression in tumors with a mean percentage change of 40 63 to 29 The two measures are not directly comparable and the evidence does not provide information on the actual size of the tumors before and after the intervention",
        "label": "Contradiction"
    },
    "cf19cee6-27d6-4d4b-ab20-52e35883d817": {
        "text_answer": "No  Explanation The statement women aged 25 or 30 are eligible for the secondary trial but will need to wait 34 years to be eligible for the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for both the primary and secondary trials It does not mention anything about the age requirement and waiting period for eligibility in either trial",
        "label": "Contradiction"
    },
    "b2710f8c-602b-4831-8775-f8df3703761a": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary and secondary trials involve different interventions and patient populations In the primary trial dexmedetomidine is an intervention while in the secondary trial it is not mentioned as an intervention for any patient cohort",
        "label": "Contradiction"
    },
    "22a2488f-5559-40e9-a85b-484a1aacd263": {
        "text_answer": "No  Explanation  The statement maculopapular Rash was a common adverse event for the primary trial participants is not directly entailed by the evidence provided The evidence only lists the occurrence of a maculopapular rash as one of the adverse events but it does not specify that it was a common occurrence Additionally the statement mentions 22q122 which is not related",
        "label": "Contradiction"
    },
    "77c7c86b-30a5-487b-8abc-d3aafff69a5e": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 50mg of mcs110 every 3 weeks is entailed by the evidence since the minimum dose of MCS110 given is 1 mgkg and 1 mgkg is greater than 005 kg 50 mg  The statement and over 200 mg of pdr001 every other week",
        "label": "Entailment"
    },
    "0abf8fc8-9361-4b86-a3ca-fb6bdfbc5b5d": {
        "text_answer": "Yes The statement malfunction only no ae report is a report of a device malfunction that does not include an adverse event is not directly mentioned in the evidence but the concept of an adverse event is welldefined in the context of clinical trials and is distinct from a device malfunction The evidence provides clear definitions of inclusion and exclusion criteria for two separate trials one for benign breast disease and another for breast cancer with hot flashes The statement",
        "label": "Entailment"
    },
    "a411d500-0770-42d9-8621-ca6b4b63553e": {
        "text_answer": "No  Explanation  The evidence provided does not allow for a direct comparison of the percentage decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature The statement suggests a quantitative difference between the two groups but the evidence only provides qualitative information",
        "label": "Contradiction"
    },
    "cb869aa7-63a3-4a2c-8dd9-2e38496fbaef": {
        "text_answer": "Yes The evidence states that individuals who have participated in another clinical trial within 30 days prior to screening or during the study are excluded from the primary trial The statement specifically mentions that individuals cannot participate in two clinical trials concurrently",
        "label": "Entailment"
    },
    "d15bf489-0548-4cbc-b64c-2252a53b5f33": {
        "text_answer": "No  The primary trial and the secondary trial address different patient populations and have different inclusionexclusion criteria The statement about sellar germ cell tumor does not follow directly from the evidence provided",
        "label": "Contradiction"
    },
    "80676e7e-a6bc-4f8e-b50e-888847db5b91": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial only reports the percentage change in betaCTX at Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement in question refers to the percentage change in betaCTX at Week 10 for the AZD0530 13 mg group which is not reported in the evidence Therefore the statement is",
        "label": "Contradiction"
    },
    "cfcd5908-e439-4d01-bd0a-0fcaf3730db8": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does involve surgical procedures such as needle biopsy therapeutic conventional surgery and correlative studies using immunohistochemistry staining method These procedures are not mentioned in the statement",
        "label": "Contradiction"
    },
    "de3bd9a7-c733-43d3-9f7d-3bf3c98a42f9": {
        "text_answer": "No  Explanation  The primary trial administers Botulinum Toxin Type A to Group A and Placebo to Group B while the secondary trial administers MLN8237 with different dosages 10 mg and 20 mg to its cohorts The statement is not entailed by the evidence as it incorrectly assumes that alisertib is being administered in the primary trial and that a consistent dosage is used",
        "label": "Contradiction"
    },
    "6cf62ed7-1dd2-4df0-80f7-979f74b55e72": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial has registered 11 surplus cases of intestinal perforation relative to the primary clinical trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not provide a comparison between the two trials in terms of the absolute number of cases for each specific adverse event To determine if there are 11 more cases of",
        "label": "Contradiction"
    },
    "8e2d4c96-5d2f-4710-9333-26d8d1dcb8fb": {
        "text_answer": "Yes  Explanation  The statement primary clinical trial exhibited a lower frequency of recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage when compared to the secondary trial is entailed by the evidence as the primary trial had a lower percentage of occurrence for all the mentioned adverse events except for anaemia which had the same percentage in both",
        "label": "Entailment"
    },
    "c0dc65fc-1c17-4594-a168-c9c2da2802b6": {
        "text_answer": "No   Explanation The statement there was not a single adverse event reported during the primary clinical trial is not entailed by the evidence as there were a total of 5 adverse events reported in the trial",
        "label": "Contradiction"
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "text_answer": "No  Explanation  The statement Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is not entailed by the evidence While both cohorts receive three electroporation injections the timing and combination of vaccines differ between the two cohorts Cohort A receives three electroporation injections of LD V934 followed by two IM",
        "label": "Contradiction"
    },
    "bc92cff7-39b3-4088-bb3a-9e61c4d32b8b": {
        "text_answer": "Yes  Explanation The evidence states that Results 1 ArmGroup Title Aprepitant Dexamethasone Cytoxan  Kytril had Proportion of Participants With Controlled Acute Vomiting of 1000 20 out of 20 participants This means that none of the participants in this group experienced acute vomiting after being treated with aprep",
        "label": "Entailment"
    },
    "586425fa-eb66-46c1-8792-f7a35c1a5ca5": {
        "text_answer": "No  The evidence does not provide information about hypertension in the primary clinical trial",
        "label": "Contradiction"
    },
    "0d9f0b9b-fc32-413e-ba9b-f8d4e5c1ce4b": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials include patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma as inclusion criteria",
        "label": "Entailment"
    },
    "37bba0bf-5ecd-4007-a2c4-bf9e13dccd2e": {
        "text_answer": "No  The statement is not entailed by the evidence as dasatinib was not mentioned in the provided evidence",
        "label": "Contradiction"
    },
    "696f4947-40d7-4e3d-b64e-9e0fd6c5fbd8": {
        "text_answer": "Yes The evidence does not report any adverse events for cohort 2 and the statement is about noncutaneous leiomyosarcoma in general",
        "label": "Entailment"
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the placebo and AlloMSCs interventions differ in their composition The placebo is Buminate solution while the AlloMSCs intervention is allogeneic mesenchymal stem cells Despite the similar dose and administration method the interventions are not identical",
        "label": "Contradiction"
    },
    "6016f882-27d2-47a7-9149-142c9fb17acf": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "895a6e40-efe3-4994-b598-6791eaf90e87": {
        "text_answer": "Yes for the secondary trial assuming the womans other eligibility criteria are met The primary trial eligibility criteria do not mention atrial fibrillation",
        "label": "Entailment"
    },
    "a7e93d6e-e8d0-4b87-b2a1-be2b821e5a94": {
        "text_answer": "No  Explanation  The statement the paclitaxel plus bevacizumab plus gemcitabine group had a worse ORR than the paclitaxel plus bevacizumab group in the primary clinical trial is not entailed by the evidence The evidence only provides the ORR and its confidence intervals for each group but it does not directly compare the ORRs between the two groups To make such a comparison",
        "label": "Contradiction"
    },
    "d4eb3cf4-eeff-42c3-8036-54ec85061299": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as the evidence does not provide any information about placental nonneoplastic disorders or their relationship to the talazoparib dosages given in the primary trial The statement mentions placental disorders while the evidence only mentions breast and ovarianperitoneal cancers and the dosages of talazoparib given in the trial",
        "label": "Contradiction"
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "text_answer": "No  Explanation The statement The intervention in the secondary trial lasts 15 more weeks than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks and the secondary trial lasted for 24 weeks which is an additional 14 weeks not 15",
        "label": "Contradiction"
    },
    "ed0b5b7f-b257-4b42-8f93-7c908fd071ea": {
        "text_answer": "Yes The primary trial excludes participants who have responded to aromatase inhibitors AI while the secondary trial does not mention anything about AI therapy",
        "label": "Entailment"
    },
    "a5e9916a-b5de-4fd4-bf78-b1c1e43bc544": {
        "text_answer": "Yes  Explanation The evidence states that both intervention groups received dexamethasone before their operation with different dosages Therefore the statement all cohorts in the primary clinical trial are given dexamethasone before their operation is entailed by the evidence",
        "label": "Entailment"
    },
    "f21a1764-d1cc-49cc-b22d-e3d1b99c2233": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence indicates that there are actually 0 adverse events recorded in the secondary trial which is fewer than the 0 adverse events recorded in the primary trial",
        "label": "Contradiction"
    },
    "12903135-4650-492b-b2c9-1f5c159af477": {
        "text_answer": "Yes The primary trial does not exclude individuals with a diagnosis of prostate lung or breast cancer and the secondary trial includes individuals with cerebral metastases from these cancers as long as they meet the other criteria Therefore an individual with 23 cerebral metastases could potentially participate in both trials However its important to note that there may be other eligibility criteria and considerations that would need to be taken into account beyond what",
        "label": "Entailment"
    },
    "f896c335-0023-429c-b596-e7a30addbb2e": {
        "text_answer": "No  Explanation  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events in each trial but it does not compare the number or percentage of specific adverse events such as Bronchopneumonia and General physical health deterioration between the two trials",
        "label": "Contradiction"
    },
    "d9cff591-e319-46a0-bc70-a25224cd5b49": {
        "text_answer": "Yes The statement Morbidly obese patients are eligible for the primary trial is entailed by the evidence as the inclusion criteria state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs",
        "label": "Entailment"
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "text_answer": "No  Explanation  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature It does not provide enough",
        "label": "Contradiction"
    },
    "1b82cbd2-8f68-4c23-974c-b9ebc4fe52aa": {
        "text_answer": "Yes  Explanation The evidence states that the neoadjuvant therapy consists of epirubicin cyclophosphamide docetaxel and trastuzumab Therefore the statement that four different medications are administered to the participants during the primary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "7c1aaf25-a7c2-410d-bc13-fe6192698184": {
        "text_answer": "No  The evidence states that there were no adverse events in both cohorts",
        "label": "Contradiction"
    },
    "038fbad1-abee-46f3-90a8-5caee61bae07": {
        "text_answer": "Yes  Explanation The primary clinical trial does not involve the use of MM121 and Paclitaxel in the same weekly cycle as in the secondary clinical trial In the primary trial MM121 is given for a 2week runin period followed by 12 weeks of Paclitaxel while in the secondary trial both drugs are given concurrently for 12 weeks Therefore the patients",
        "label": "Entailment"
    },
    "f95708f6-04c7-469b-bba1-658c1d6eed45": {
        "text_answer": "Yes The evidence mentions several cardiacrelated adverse events in the primary trial",
        "label": "Entailment"
    },
    "ca22d431-ad09-4f5b-8b27-751c76e704c8": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it introduces new information not present in the evidence The evidence only mentions the intervention and control groups of the primary trial and the statement incorrectly introduces a new cohort Cohort 2 and a new intervention radiotherapy",
        "label": "Contradiction"
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "df8bb8da-6aec-4678-97f3-cb122188ea9b": {
        "text_answer": "No  Explanation  The statement Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is not entailed by the evidence While it is true that both cohorts receive three electroporation injections of V934 the dosage and timing of the V935 injections differ between the two cohorts Therefore the statement is not an",
        "label": "Contradiction"
    },
    "4094d002-a140-4eea-aa50-5005989e2057": {
        "text_answer": "Yes The evidence shows an increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings after the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups",
        "label": "Entailment"
    },
    "9f61fc3f-f0a5-4434-b0a7-cbb0703fe063": {
        "text_answer": "Yes  Explanation  The Contour Profile Tissue Expander intervention in the primary trial does not involve the use of xrays transendocardial injections CT scans or MRIs as part of its intervention The AlloMSCs intervention in the secondary trial also does not involve the use of xrays transendocardial injections CT scans or MRIs as part of its interventions",
        "label": "Entailment"
    },
    "e2abe23e-d9a8-4329-a41b-26c90266f6d3": {
        "text_answer": "No  Explanation  The evidence provided in the text relates to the results of a clinical trial comparing two different maintenance treatment regimens for participants with cancer The first regimen involved bevacizumab monotherapy while the second regimen involved the combination of bevacizumab and capecitabine The evidence does not provide any information about the electromagnetic spectrum or any relationship between the trial results and the electromagnetic spectrum",
        "label": "Contradiction"
    },
    "3821922a-4d8a-4e54-8381-bb754a78c1ed": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it makes an incorrect assumption about the primary trials intervention schedule The primary trials intervention 1 does involve a series of injections over a month not a single injection at the start",
        "label": "Contradiction"
    },
    "2f94cda8-a8c2-4fb3-a98d-f7e6e651b6d0": {
        "text_answer": "Yes The statement is entailed by the evidence as it accurately reflects the reduction in Ki67 expression observed in the TAK228 Plus Tamoxifen arm of the trial",
        "label": "Entailment"
    },
    "5b94573b-9254-48e4-a384-0212f39451a8": {
        "text_answer": "No  Explanation  The statement representative examples of middle ear disorders include infection cholesteatoma and carcinoma All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is not entailed by the evidence provided The evidence only mentions the doses of PF06647020 used in the primary and secondary trials and does not provide any information",
        "label": "Contradiction"
    },
    "8a8136f1-9f1d-497e-bb50-44fe94475817": {
        "text_answer": "No  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial includes patients with measurable disease but there is no mention of a tumor size limit in the secondary trial",
        "label": "Contradiction"
    },
    "ce7d929e-90d6-4048-8124-e6df1a2f594a": {
        "text_answer": "Yes  The statement is entailed by the evidence as both cohorts use the same instructional CD for paced breathing However its important to note that the statement also mentions chemotherapy for cohort 2 but the evidence does not provide information about that aspect of their therapy",
        "label": "Entailment"
    },
    "6fce98e9-e48f-4b14-8a94-37c1ab124eed": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is not directly entailed by the evidence provided The evidence only states the number and percentage of adverse events AEs for various conditions in the primary and secondary trials but it does not specify which condition was the most common in the secondary trial or",
        "label": "Contradiction"
    },
    "95354d90-513a-4766-a860-307afa28fb7b": {
        "text_answer": "Yes  Explanation The statement anemia pneumonia and stupor were more frequent among patients in the secondary trial compared to the primary trial is entailed by the evidence as the evidence shows that the frequency of anemia pneumonia and stupor were higher in the secondary trial than in the primary trial The evidence also shows that the primary trial recorded a greater number of febrile infections but this does not",
        "label": "Entailment"
    },
    "1d121088-e2ff-4927-a989-d7b5de578714": {
        "text_answer": "No   The primary trial measures the summed pain intensity differences SPID at 30 minutes after dosing while the statement suggests the severity of delayed nausea on a scale of 110 which is not reported in the evidence The secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "f8457301-53ba-4316-a6a5-36462bf8167c": {
        "text_answer": "Yes The evidence does not explicitly state that patients with a BMI in the overweight category are excluded from the trials so it is implied that they are eligible",
        "label": "Entailment"
    },
    "dad36f27-f531-458c-a36f-c22182af3771": {
        "text_answer": "  No The statement about people with chronic lymphocytic leukemia or choriocarcinoma being prohibited from participating in the primary and the secondary trial is not explicitly stated in the provided evidence However it can be inferred that people with chronic lymphocytic leukemia are excluded from the primary trial based on the given inclusion criteria Choriocarcinoma is not mentioned in either trials inclusion or exclusion",
        "label": "Contradiction"
    },
    "8dd6a2dd-74f9-4bac-af44-c816fd960f74": {
        "text_answer": "Maybe The statement is not directly entailed by the evidence as some of the adverse events listed in the evidence do relate to symptoms eg visionblurred headache nausea vomiting and general symptom However the majority of the adverse events do not have an obvious symptomatic component eg blood disorder hypomagnesemia platelets count decrease thrombosis and bone pain",
        "label": "Contradiction"
    },
    "16e96301-3e68-453f-82db-f93117edfdfd": {
        "text_answer": "No  Explanation The statement does not mention anything about paclitaxel or its use in the primary trial The statement only mentions ANA anastrozole and FULV fulvestrant as the interventions in the two cohorts of the trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "b93384b1-a925-460d-ba66-78967a500d8c": {
        "text_answer": "No  Explanation  The statement intermediate locally aggressive blood vessel neoplasm is a borderline blood vessel neoplasm that had a 64 Recurrencefree Survival compared to the NaCl 09 3mL group in the Ketorolas 30 mg group is not directly entailed by the evidence provided The evidence only reports the Recurrencefree Surv",
        "label": "Contradiction"
    },
    "1720fcdf-eba7-4ef7-bf37-6445504af807": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence provided The evidence only compares the percentage change in betaCTX levels between the AZD0530 175 mg and Zoledronic Acid 4 mg groups at week 4 of a clinical trial It does not mention anything about solid growth patterns in tumor samples",
        "label": "Contradiction"
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "text_answer": "Yes  Explanation The statement there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is entailed by the evidence since there is one reported case of shingles in each trial",
        "label": "Entailment"
    },
    "2c618027-fde9-4d2f-8552-bc071708d627": {
        "text_answer": "No  The evidence does not support the statement as it documents a total of 1 adverse event resulting in death in each trial not 10 or more",
        "label": "Contradiction"
    },
    "10860cc9-5a8f-4e81-bb2a-42697541e8b0": {
        "text_answer": " No The statement is not entailed by the evidence as the statement mentions ER positive PROGENITOR negative and HER2 breast tumors which is different from the ER positive HER2 negative and triplenegative breast cancers specified in the inclusion criteria",
        "label": "Contradiction"
    },
    "eb7d6866-d56b-437c-a48c-78478afdfac8": {
        "text_answer": "Yes  Explanation The statement the secondary clinical trial noted fewer adverse events in its patient cohort compared to the primary clinical trial is entailed by the evidence since the evidence shows that the number of adverse events in the secondary trial was 015 000 which is less than the total number of adverse events in the primary trial which was 00 undefined percentage",
        "label": "Entailment"
    },
    "9e5f2149-4cff-4df0-a5d0-4b99ff30fb1c": {
        "text_answer": "  No The primary trial measures changes in pain intensity up to 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "50b3880d-9a23-42a3-8987-253f0ce999d3": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions involve the same dosages and frequencies of Doxorubicin Cyclophosphamide and Docetaxel The difference lies only in the addition of Herceptin in Intervention 2",
        "label": "Entailment"
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "text_answer": "No  Explanation The evidence does not provide any information about the proportion of participants with Normal Vitamin D Levels who showed a discernible pattern for expression of the set of 40 evaluated genes The results only report the number of participants in each group but not the proportion or percentage of participants with a discernible pattern for gene expression",
        "label": "Contradiction"
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "text_answer": "Yes The primary trials Intervention 1 involves IV administration and the secondary trials Intervention 1 and Intervention 2 involve both oral and IV administration for some drugs",
        "label": "Entailment"
    },
    "08049ea6-03f6-457a-b74e-0012e02dc768": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement makes a comparison between two different outcome measurements time to progression and percentage of participants with objective response from two different clinical trials The evidence only provides the results of each trial separately",
        "label": "Contradiction"
    },
    "38c2a394-f21b-4ae8-8941-aeccf896609b": {
        "text_answer": "Yes The primary trial explicitly states that warfarin is not permitted The secondary trial allows its use under certain conditions",
        "label": "Entailment"
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "text_answer": "yes but it is an incomplete statement The statement correctly identifies a difference between the two cohorts but it does not accurately describe the nature of the difference The statement focuses on the doses of sunitinib and paclitaxel but it does not mention that cohort 1 receives sunitinib and cohort 2 receives bevacizumab in addition to paclitaxel Therefore a more complete statement would be",
        "label": "Entailment"
    },
    "3a4cc297-6f5a-489c-a841-95e2b3971167": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement is about candidates having colon cancer and being unresponsive to previous hormonal treatments while the evidence is about candidates having breast cancer that has continued to grow after hormonal treatment",
        "label": "Contradiction"
    },
    "807c9531-c049-40a5-a170-3f8924335381": {
        "text_answer": "Yes The evidence does not provide any information about the permanence or transience of arthropathy specifically mentioned in the trial but it does state that participants were followedup until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy indicating that some adverse effects may be temporary Additionally the statement is not directly related to the dosage difference between cohorts 1 and 2 but it",
        "label": "Entailment"
    },
    "af6ce175-76e3-4d1a-ab77-6c7f3a258580": {
        "text_answer": "Yes  Explanation  The statement cohort 2 of the primary clinical trial reported no instances of death or hospitalization is entailed by the evidence since the evidence reports 000 for both death and hospitalization in cohort 2",
        "label": "Entailment"
    },
    "aba20d88-1ea5-401e-b155-d1b901dddc77": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the primary clinical trial does not report the number of participants with treatmentemergent adverse events Instead it reports the change from baseline in patientspecified and reported symptoms on the Measure Yourself Medical Outcome Profile MYMOP for the Usual Care Plus Traditional Acupuncture and Placebo arms The secondary clinical trial reports the change in Is",
        "label": "Contradiction"
    },
    "f47966a1-7067-43a3-9461-11c8ed7b18a6": {
        "text_answer": "No  The evidence indicates that patients in both groups had pain measured on a daily basis for 10 weeks but it does not state that all patients endured the utmost level of pain The evidence only provides the mean average pain intensity scores and their confidence intervals for each group",
        "label": "Contradiction"
    },
    "6f0485c9-9cb5-4861-9baf-f6a9a9acd975": {
        "text_answer": "Yes  Explanation  The statement all participants in the primary clinical trial are subjected to the same duration intensity and type of radiation therapy is entailed by the evidence as both groups received radiation therapy with the same dose range 180200 cGy per fraction for a total of 46004860 cGy frequency Monday through Friday and additional radiation at the discretion of the",
        "label": "Entailment"
    },
    "aad1e89e-afc2-4999-8cb2-302e0d686331": {
        "text_answer": "Yes  Explanation  The statement since first time questionnaire was answered is a question about the status of an individual since the time when they first answered a questionnaire is not directly related to the evidence provided However the evidence does state that all but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event AE and less than",
        "label": "Entailment"
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "text_answer": "No  Explanation  The statement A 20 year old female patient with a Newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial and the primary trial is not entailed by the evidence provided The evidence specifies different inclusion criteria for each trial The secondary trial includes patients with stage IIIII breast cancer who are deemed appropriate for neoadjuvant endocrine therapy while the",
        "label": "Contradiction"
    },
    "458e3e14-613b-40c5-a62f-5698a7d0c9b0": {
        "text_answer": "yes The evidence shows that the median survival time for both groups is over 2 years but there are some patients in each group who survived for less than 2 years",
        "label": "Entailment"
    },
    "12911f01-5f14-445b-a93a-0cca2cfe9b4c": {
        "text_answer": "No  Explanation  The statement There were no significant differences in the results from the groups in the primary trial and the Reflexology Group and control group in the secondary trial produced identical results is not directly entailed by the evidence provided The primary trial and the secondary trial are about different studies with different outcome measures The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology",
        "label": "Contradiction"
    },
    "030afaab-4125-4b2c-ac40-5d7a4cacaf52": {
        "text_answer": "No   Explanation  The statement deep candida infection without candidemia is mentioned in the question but there is no mention of this specific complication in the evidence provided The evidence only states that there was a cordonnier grade 2 fungal complication in the intervention group but it does not specify the type of fungal infection or provide any details about the treatment or doses of irradiation Therefore the statement in",
        "label": "Contradiction"
    },
    "10867d73-4951-42cf-9bdf-2a0f6d27ff10": {
        "text_answer": "No  Explanation  The statement the incidence of ascites and pneumocystis jirovecii pneumonia was exactly the same in both primary and secondary clinical trials is not entailed by the evidence The evidence shows that the incidence of ascites was 2223 090 in the primary trial and 19 1111 in the secondary trial The incidence",
        "label": "Contradiction"
    },
    "c09d08df-1042-47ca-9c54-83be4f9f691a": {
        "text_answer": "Yes The statement does not mention febrile neutropenia or cholelithiasis but it correctly states that there were no instances of adverse events including those two conditions reported in both trials",
        "label": "Entailment"
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "text_answer": "No  There are multiple patients who suffered the same type of adverse event eg 3 patients had back pain",
        "label": "Contradiction"
    },
    "0744e505-8c33-48b6-bd82-b201fdcc9679": {
        "text_answer": "Yes The statement is descriptive and does not directly conflict with the information provided in the evidence",
        "label": "Entailment"
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "text_answer": "No  Explanation  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is not entailed by the evidence The evidence only shows the number of adverse events for each type in both trials but it does not compare the number of events between them directly Therefore it is not possible to determine if there were more cases",
        "label": "Contradiction"
    },
    "13b40eaf-ad55-439f-9d93-a00a7bee3516": {
        "text_answer": "Yes The evidence does not explicitly state that the trial specifically welcomes AfricanAmerican patients but it does not contain any exclusion criteria based on race Therefore the participation of AfricanAmerican patients is not prohibited and is thus implicitly welcomed",
        "label": "Entailment"
    },
    "3611645a-e832-4b38-a1db-9c66aca8baf6": {
        "text_answer": "Yes  Explanation The statement 25 of the patients involved in the primary clinical trial report the problems of increased pleural effusion and swift progression of their disease is entailed by the evidence as it correctly summarizes the occurrence of increased pleural effusion in 1 out of 4 patients 2500 in the second trial and the occurrence of rapid disease progression and increased pleural effusion in 1 out",
        "label": "Entailment"
    },
    "8773e9c2-3030-4221-b663-b21d49ae1721": {
        "text_answer": "Yes The primary trial does not report the clinical benefit rate based on RECIST criteria among the participants and the secondary trial does not evaluate this outcome measurement",
        "label": "Entailment"
    },
    "eca37c79-e36b-446d-bd9a-4cf546fc9ab7": {
        "text_answer": "Yes for Adverse Events 2 only The statement is not entailed by the Evidence for Adverse Events 1 as there were no reported cases of edema in that group",
        "label": "Entailment"
    },
    "460e894b-61c8-4935-bde6-6800b1a440a2": {
        "text_answer": "Yes  Explanation The evidence states that participants in the primary clinical trial would receive multiple injections including dendritic cell injections chemotherapy and GMCSF injections",
        "label": "Entailment"
    },
    "6d328d56-d579-4a87-b2bf-e3f3d8bd2c4f": {
        "text_answer": "No  Explanation  The evidence provided in the text does not support the statement that individuals in the ovarian function suppression group reported an improvement in cognitive function The evidence only reports the mean standardized cognitive function scores for the Tamoxifen and Ovarian Function Suppression groups but it does not provide information about the direction or significance of any changes in cognitive function over the course of the study Additionally the statement uses the term reported",
        "label": "Contradiction"
    },
    "8480a497-4ae7-4d4a-9b19-68667f70dc22": {
        "text_answer": "No  Explanation  The statement most of the reported adverse events were related to blood and bone marrow this observation was not found in the secondary clinical trial is not directly entailed by the evidence provided While it is true that in the primary trial a larger percentage of adverse events were related to blood and bone marrow compared to the secondary trial the statement goes beyond the evidence by making a comparison between the two trials and stating that the observation",
        "label": "Contradiction"
    },
    "60c5afb6-a250-4e59-bccd-3729a9a97a6b": {
        "text_answer": "Yes   Explanation  The evidence describes two different interventions each with its own administration schedule IV bisphosphonate Q4W and denosumab 180 mg Q12W These different administration methods satisfy the requirement of a variety of methods in the statement",
        "label": "Entailment"
    },
    "8af5402d-9065-412b-a7dc-053dfce01c63": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib is not directly entailed by the evidence provided The evidence only mentions the dosing schedules for epacadostat and pembrolizumab in the primary trial and sunitinib in the secondary trial but it does not provide information about the frequency of sunitinib",
        "label": "Contradiction"
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "text_answer": "Yes  Explanation The evidence states that patients receive oral lapatinib and oral tamoxifen once daily on days 128 However since both medications are given orally the statement oral medication in the question can be inferred from the evidence Additionally the statement twice a day is not explicitly stated in the evidence but the evidence does imply that the medications are taken every day for a full month which can be",
        "label": "Entailment"
    },
    "7d3e5dce-744f-4f7b-81f8-085c7ce2bee0": {
        "text_answer": "yes with a caveat the statement is entailed by the results for the group receiving ovarian function suppression but not for the entire trial population as the Tamoxifenonly group actually showed a slight improvement in cognitive function on average",
        "label": "Entailment"
    },
    "e6577f53-5752-4fd5-bcfb-2d4f03b2ce60": {
        "text_answer": "Yes  Explanation The median change in lean body mass for the group treated with GTx024 1mg was 206 kg which is a decrease in lean body mass Therefore no patients in this group gained lean body mass over the 4month period",
        "label": "Entailment"
    },
    "d1200239-9391-41b1-a73e-5590855243bc": {
        "text_answer": "No  Explanation The statement participants in the primary clinical trial are administered higher doses of alt801 compared to those in the secondary clinical trial is not entailed by the evidence provided The evidence only mentions the doses of PF06647020 used in each trial not ALT801",
        "label": "Contradiction"
    },
    "5c9e6daf-915c-48b4-b1d4-2e302e0164d4": {
        "text_answer": "Yes  Explanation The evidence states that an overwhelming majority of participants showed a decline in circulating tumor cell counts following the highdose chemotherapy regimen with purged autologous stem cell products This aligns with the statement that an overwhelming majority of participants showed a decline in circulating tumor cell counts due to the regiment of highdose chemotherapy with purged autologous stem cell products Therefore the statement is ent",
        "label": "Entailment"
    },
    "c8b6ed79-b613-4ed4-b2ad-2e2ca4f5dcd4": {
        "text_answer": "No   Explanation  The statement no adverse events have been recorded for the patient cohort of the primary clinical trial is not entailed by the evidence The evidence states that there was one adverse event a surgery in the patient cohort which is a nonzero number Therefore it is not accurate to say that no adverse events were recorded",
        "label": "Contradiction"
    },
    "3e96ec18-39ff-46f9-9c67-0b6e70003e24": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions include the same dosages and frequencies of Docetaxel Doxorubicin and Cyclophosphamide However cohort 2 includes three additional cycles of these drugs",
        "label": "Entailment"
    },
    "8fe97ae1-baa6-48ba-a97e-a59585b2b268": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial encountered numerous fatalities and hospital admissions with multiple incidents of atrial fibrillation is not entailed by the evidence provided The evidence only shows the number of adverse events including deaths and hospitalizations for each cohort in the primary clinical trial It does not specify that cohort 2 had numerous fatalities and hospital admissions",
        "label": "Contradiction"
    },
    "d08f5261-afae-42c3-9d0a-39739ae40ccf": {
        "text_answer": "No  Explanation The placebo intervention is provided daily for 81 days the same number of days as the memantine intervention The frequency of administration is the same for both interventions The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "5f4eaa1c-4e83-402c-a1ed-4d398f51ec1d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5a7d5563-2920-418c-a2fb-46ada378c860": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens therapy in the last 4 weeks  28 days before study entry The statement extends this exclusion period to 24 months",
        "label": "Entailment"
    },
    "93d37103-4625-42a6-b8a2-7ce2d5673324": {
        "text_answer": "No  Explanation The statement while the secondary clinical trial allows the participation of patients with a malignant ductal carcinoma in situ diagnosis the primary clinical trial does not permit such patients is not directly entailed by the evidence provided The primary clinical trial explicitly lists ductal carcinoma in situ as an exclusion criterion while the secondary clinical trial includes patients with a history of breast cancer including ductal carcinoma in",
        "label": "Contradiction"
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "text_answer": "No   Explanation   The statement Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is not entailed by the evidence provided Perjeta is not mentioned in the evidence at all The evidence only mentions Fulvestrant Anastrozole and the use of novel radiotracers for HER2targeted PETCT in the secondary trial",
        "label": "Contradiction"
    },
    "f8a3e02a-d5d0-4a12-9d82-e811f7be3502": {
        "text_answer": "  No the statement is not entailed by the evidence Smokers are excluded from the primary trial and there are restrictions on alcohol intake in the secondary trial",
        "label": "Contradiction"
    },
    "376c9806-25fd-4b1c-962a-b14c2ca6d9b3": {
        "text_answer": "No  The evidence states that patients with dementia are excluded from the trial Alzheimers disease is a type of dementia",
        "label": "Contradiction"
    },
    "ef637aff-9f52-4e17-a4d7-77e6cdb740c6": {
        "text_answer": "No  Explanation  The statement patients with stage 4 invasive breast carcinoma which tests positive for either estrogen or progesterone receptors and are considering AI therapeutic intervention are eligible for involvement in the primary clinical trial is not entailed by the evidence The evidence only mentions eligibility criteria for patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast There",
        "label": "Contradiction"
    },
    "dcc038bf-f819-4713-9356-3e966d30291d": {
        "text_answer": "No   Explanation  The statement is not related to the evidence provided The evidence pertains to the results of a clinical trial comparing two different treatment regimens for nausea in patients undergoing chemotherapy while the statement is about rat ovarian adenocarcinoma",
        "label": "Contradiction"
    },
    "95aebead-f222-4a09-b0e0-31557235953f": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary trial lasts half as long as the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial involved a weekly reflexology session for 10 weeks while the secondary trial involved a weekly medication administration for 24 weeks Neither duration is half the length of the other",
        "label": "Contradiction"
    },
    "9eb03f1d-28b2-427e-bbf2-917fcf5ccf74": {
        "text_answer": "No  Explanation  The statement not a single one of the participants in group 1 of the primary trial were found to have lesions and exactly 15 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only reports the number of participants and the presence or absence of lesions in the primary trial and the number",
        "label": "Contradiction"
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "text_answer": "Yes  Explanation The statement The dosage of Zoledronic Acid in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial is entailed by the evidence because the dosage of Zoledronic Acid in the primary trial is 4 mg Q4W 16 mg per 3 months while the dosage of Denos",
        "label": "Entailment"
    },
    "6c56960a-80c2-40f6-8ba7-8e96a6bdcb98": {
        "text_answer": "Yes  Explanation  The statement both the primary clinical trial and the secondary clinical trial reported all adverse events encountered during their respective trials is entailed by the evidence because the evidence reports that there were no adverse events in both trials for the given adverse event type Adverse Events 1 The absence of adverse events is still considered reporting of adverse events Additionally the secondary trial also reported Adverse Events 2 but the question does",
        "label": "Entailment"
    },
    "5942877d-3edd-4949-9128-b17a68194753": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the number of participants in each arm who experienced a pathologic complete response in the breast and axillary lymph nodes It does not provide information on the total number of participants in both cohorts who experienced this outcome after approximately 7 months postsurgery Therefore the statement cannot be definitively answered with a simple yes or no based on the given evidence",
        "label": "Contradiction"
    },
    "5af06b76-49a3-4342-92ef-2d15ecddc2c7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial provides the median progressionfree survival PFS in months for both arms A and B not in weeks for a fraction of patients The secondary trial on the other hand reports the number of participants with objective response based on RECIST criteria but it does not mention the frequency of adverse events throughout the procedure in one word",
        "label": "Contradiction"
    },
    "382c5afb-42ce-4711-90c2-c72f34f03729": {
        "text_answer": "Yes The statement the least frequently reported adverse event across the patient cohorts of the primary trial and the secondary trial was syncope is entailed by the evidence since syncope had the lowest frequency 1667 in the primary trial and was not reported at all in the secondary trial",
        "label": "Entailment"
    },
    "770041f3-701c-4e9f-8df4-5b78a0e4a076": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 003 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that there were 3 cases of hepatotoxicity 1 case of hypertension and 1 case of pancreatectomy making a total of 5 cases of",
        "label": "Contradiction"
    },
    "074f66e7-18df-4ee9-a33c-127062dcb51f": {
        "text_answer": "Yes The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II while the secondary trial has the same criteria for all participants",
        "label": "Entailment"
    },
    "22b44925-9577-462a-bf8b-cd3e5ba5ecb1": {
        "text_answer": "No  The evidence mentions adequate liver function as an inclusion criterion but it does not state that all participants must have demonstrable hepatic disease",
        "label": "Contradiction"
    },
    "edb8f244-cc5e-4cc5-b473-3b93f8640e65": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial did have a placebo group Arm II and the secondary trial did have two test groups Highdose and Lowdose Oxybutynin Chloride Groups The discrepancy in the number of test groups between the two trials is not the same issue as the presence or absence of a placebo group",
        "label": "Contradiction"
    },
    "97c98ddb-37f4-4e14-82c0-0685e500222c": {
        "text_answer": "No  Explanation  The statement have raw or sore skin is a question about whether an individuals skin feels or felt raw or sore is not directly related to the inclusionexclusion criteria provided in the evidence for either the primary or secondary trials The evidence only mentions exclusion criteria related to severe hypersensitivity reactions to other monoclonal antibodies active infections requiring systemic antibiotic therapy HIV infection HB",
        "label": "Contradiction"
    },
    "8548c61d-2a2f-4498-a7b8-828adbd9e613": {
        "text_answer": "No  Explanation The evidence states that patients receive 100 mgm2 of lapatinib once daily not twice daily as stated in the question Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "506c27c5-380f-41f7-9f90-81d843d7d140": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trial involves the administration of alpha lipoic acid in higher quantities for the entirety of the study while the secondary trial provides the same amount of necitumumab to patients throughout the study period",
        "label": "Entailment"
    },
    "cbf31ee8-3c01-46f5-9698-f44da41fd1fa": {
        "text_answer": "Yes The evidence states that there were no adverse events in both cohorts making the statement of equal number of patients suffering adverse events in both cohorts true by default since the number is zero for both",
        "label": "Entailment"
    },
    "14236a59-be4c-4b17-844b-7c26a0650dc8": {
        "text_answer": "No  Explanation  The statement is about the Adverse Events related to Alzheimers Disease Assessment ScaleCognitive ADASCOG trials specifically word recognition task for word 5 However the evidence provided is about the Adverse Events related to Rapid disease progression and Increased pleural effusion in two different cohorts of patients The statement does not directly entail the information given in the evidence",
        "label": "Contradiction"
    },
    "6142265a-a110-42be-b03f-088d346e2389": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed by the evidence provided The evidence only states the number of occurrences for each adverse event in the primary trial The statement makes a comparison between the number of Hepatotoxicity cases and the combined number of hy",
        "label": "Contradiction"
    },
    "7f832fbe-bf0f-44d1-820f-2398ce83404e": {
        "text_answer": "No  Explanation  The statement none adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 1333 of patients is not entailed by the evidence While it is true that no adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 10 of patients 1 in 3 the statement",
        "label": "Contradiction"
    },
    "7f17692d-e7de-4365-9da1-83f563fde703": {
        "text_answer": "No  The secondary trial and the primary trial report results from different patient cohorts and different outcome measurements",
        "label": "Contradiction"
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "text_answer": "No  Explanation  The statement General symptoms are the most common AE recorded in the primary trial is not entailed by the evidence The evidence only states that there were 2 cases of general symptoms out of 51 total adverse events which is not enough to conclude that general symptoms are the most common Other adverse events were also recorded in the trial some of which were recorded more frequently than general symptoms Therefore the statement is not",
        "label": "Contradiction"
    },
    "4ae87355-7844-42a5-ad5b-a00c8103d102": {
        "text_answer": "Yes The evidence states that there are 1530 enrollment slots for subjects with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Entailment"
    },
    "f2f2b835-ac2d-43f6-827f-4341fb7d5fd1": {
        "text_answer": "50 or more Yes  Explanation The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR While the statement asks for the number of participants who experienced a CR specifically the evidence shows that over half of the participants more",
        "label": "Entailment"
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "text_answer": "Yes The primary trial excludes patients with malignant ductal carcinoma in situ while the secondary trial includes them",
        "label": "Entailment"
    },
    "5933fba5-8565-47ef-a491-1a1531dc1ab3": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary trial lasts 3 times shorter than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks while the secondary trial lasted for 24 weeks Therefore the secondary trial did not last 3 times shorter than the primary trial but rather 2 times longer",
        "label": "Contradiction"
    },
    "80249c01-a69c-490c-ab1f-74ead64dd3df": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary trial does not report any instances of patients experiencing the worst pain imaginable for half an hour The trial only reports the average pain intensity scores for both the lowdose and highdose intervention groups over a 10week period",
        "label": "Entailment"
    },
    "bb80e4aa-fb7d-4455-8fff-95607f45dab0": {
        "text_answer": "No  Explanation The statement about the perfect match probe is not related to the inclusion or exclusion criteria for either the primary or secondary trials provided in the evidence The statement is about a 25 nucleotide probe used in Affymetrix arrays while the evidence provides the criteria for participant selection and exclusion for two different clinical trials",
        "label": "Contradiction"
    },
    "f0594802-c304-4dc7-88c8-282554c1e7d7": {
        "text_answer": "No   Explanation  The primary trial administers Vitamin B12 sublingually under the tongue not through injection or intramuscularly The secondary trial administers memantine orally by mouth not through injection or intramuscularly Therefore neither trial matches the statements claim that the intervention is administered through injection",
        "label": "Contradiction"
    },
    "ea0e2918-08bd-4013-9915-66f8fe425e31": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the participants in Arm A received nabPaclitaxel alone while those in Arm B received nabPaclitaxel plus carboplatin Although both arms of the study involve nabPaclitaxel the total doses of abraxane nabPaclitaxel are not identical between the two groups due to the addition",
        "label": "Contradiction"
    },
    "1357d4a3-909e-4b71-aa5a-ce11869ec91e": {
        "text_answer": "No  The statement is not entailed by the evidence as nausea was not mentioned in the adverse events for either trial",
        "label": "Contradiction"
    },
    "36603238-a220-4848-b9e6-90d61b28eb28": {
        "text_answer": "Yes The evidence states that patients must be assessable for the primary outcome measure which includes having a G8 score and at least one instrument of a multidimensional assessment available The multidimensional assessment includes physical function which is often assessed through exercise capacity Therefore maintaining a routine exercise regimen is an implied requirement for trial candidates",
        "label": "Entailment"
    },
    "73bc9024-02aa-46b8-913b-c2739a3a66e8": {
        "text_answer": "Yes The primary clinical trial is open exclusively to Japanese female patients while the secondary clinical trial has no such restrictions on nationality",
        "label": "Entailment"
    },
    "a056e319-f42c-4d3d-80f0-a8348be4eb9d": {
        "text_answer": "  No the statement is not directly entailed by the evidence as the evidence does not mention anything about the mllt3 gene or pulmonary embolism being specific inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "65203e16-ff68-4833-9f92-0f63e432c09e": {
        "text_answer": "No The statement about a suprapharyngeal lymph node is not mentioned in the evidence provided for either the primary or secondary trial The statement is about the baseline performance status and Karnofsky score",
        "label": "Contradiction"
    },
    "0af975f2-157a-472d-a30e-9ad614342146": {
        "text_answer": "No  Explanation  The statement polyneuropathy was the most frequent adverse event reported in the primary clinical trial is not entailed by the evidence provided The evidence only states that there were no reported adverse events of polyneuropathy in the secondary clinical trial and no information is given about the primary clinical trial regarding the frequency or type of adverse events",
        "label": "Contradiction"
    },
    "10a1605b-bfd7-4196-9912-19b28f271ebd": {
        "text_answer": "Yes The primary trial includes a criterion for a primary tumour greater than 2 cm diameter and the statement mentions a primary tumour with a diameter of 33mm which is greater than 2 cm The secondary trial does not have a specific diameter requirement mentioned in the provided inclusion criteria but it does not exclude patients based on tumour size Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "56d7443e-3522-40e2-bb3a-413fb5edea4e": {
        "text_answer": "No  The evidence does not mention anything about the involvement of a patients first of kin in the final entry determination for the clinical trial",
        "label": "Contradiction"
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "text_answer": "Yes  Explanation  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is entailed by the evidence because neither the Adverse Events 1 nor Adverse Events 2 lists any cases of Hypertension Edema or Dyspnea",
        "label": "Entailment"
    },
    "4229278c-db31-4842-8c04-1d5b30b39037": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only provides information about the doses of talazoparib administered to participants with breast cancer and ovarianperitoneal cancer in the primary trial but it does not mention anything about the use of FACTBL questionnaire or the specific condition of bladder cancer",
        "label": "Contradiction"
    },
    "da4a10c9-b04c-4439-84f5-918325786672": {
        "text_answer": "  No  Explanation  The statement individuals who have had severe anaphylactic responses to herceptin or have shown no response to herceptin treatment are suitable candidates for the primary clinical trial is not entailed by the evidence The evidence states that individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial However it does not mention anything about individuals who have",
        "label": "Contradiction"
    },
    "eaa447d4-2621-47ca-b543-5d1d956fec02": {
        "text_answer": "Yes The primary trial includes patients with severe insomnia as an inclusion criterion while the secondary trial excludes patients with severe insomnia as an exclusion criterion until amendment omitting armodafinil treatment Therefore patients with severe insomnia can participate in the primary trial but not the secondary trial",
        "label": "Entailment"
    },
    "789e28a0-3116-4b32-be0f-807ffce7f552": {
        "text_answer": "Yes The evidence does not provide any information about thyroglobulin antibody status in relation to the interventions but the statement is not in conflict with the evidence",
        "label": "Entailment"
    },
    "56358f96-8cad-40a1-a59f-4746ebde10d3": {
        "text_answer": "Yes  Explanation  The evidence provided in the primary clinical trial includes detailed participant information for each cohort including the number of participants analyzed the interventions received by each armgroup and the mean standard deviation of the outcome measurement severity of delayed nausea for each armgroup This information is sufficient to support the statement that the participant information is provided in detail for each cohort",
        "label": "Entailment"
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "text_answer": "Yes The evidence states that both intervention and control groups do not receive drugs radiotherapy or CBT",
        "label": "Entailment"
    },
    "fb3c3307-16bd-4454-b8ee-6427743bc1ed": {
        "text_answer": "Yes The statement is a more specific version of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "text_answer": "  Yes The evidence states that the inclusion criteria include having a BMI of 25 kgm2 or greater and weight 400 lbs which defines morbidly obese patients",
        "label": "Entailment"
    },
    "61e35a8d-77bb-4fef-b9fa-ad0380508fc9": {
        "text_answer": "Yes The evidence states that there were 12 participants with SD at week 12 and 10 participants with SD at week 24 The statement also mentions that none of the participants had a complete response during weeks 12 or 24",
        "label": "Entailment"
    },
    "9da65ef3-87a1-433d-943b-a2ecc45252e1": {
        "text_answer": "Yes  Explanation  The statement the ORR demonstrated by the Paclitaxel plus Bevacizumab plus Gemcitabine group exceeded that of the Paclitaxel plus Bevacizumab group is entailed by the evidence provided The evidence shows that the ORR for the Paclitaxel plus Bevacizumab plus Gemcitabine group was 0587 0479 to ",
        "label": "Entailment"
    },
    "0cff9aa1-3486-4c0c-bda1-8850b3dc932e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "946b0905-73d8-4e13-867f-12ea3c67c52e": {
        "text_answer": "  Yes  Explanation  Both Arm 1 and Arm 2 of the primary trial report the number of participants who experienced pathologic complete response in breast and axillary lymph nodes after neoadjuvant chemotherapy The time frame for this measurement is approximately 7 months which is around 30 weeks Therefore the statement more than 1 over 3 patients in both cohorts of the primary trial experienced path",
        "label": "Entailment"
    },
    "f48699d6-6352-4c94-9ef3-fe5060d07aeb": {
        "text_answer": "No   Explanation  The statement There were more adverse events observed in the secondary trial than in the primary trial is not entailed by the evidence provided The evidence only reports the number of adverse events for each trial but it does not compare the number of adverse events between the two trials",
        "label": "Contradiction"
    },
    "9d99fc21-4f9a-4c4a-b260-d8c17d1cbdd2": {
        "text_answer": "Yes The evidence does not provide any information about adverse events related to ntrk2 fusion in the given trials Therefore the statement that ntrk2 fusion negative is an indication that the expression of a ntrk2 fusion has not been detected in a sample is entailed by the evidence as it is not contradicted by it",
        "label": "Entailment"
    },
    "469e2131-ef6a-4478-8e87-f785804bf8a4": {
        "text_answer": "Yes  Explanation  The statement over 99999 of patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence because the sum of the total adverse events in both trials is less than 001 of the total number of patients in both trials Specifically the total number of adverse events in the primary trial is 4545 ",
        "label": "Entailment"
    },
    "e386c5e7-d098-479c-b160-aa3dab13a8df": {
        "text_answer": "yes but the statement is not directly related to the voice change mentioned in the question The evidence is about the proportion of patients who were up to date for colorectal breast and cervical cancer screenings before and after the intervention",
        "label": "Entailment"
    },
    "203914a5-0e0b-4e11-a138-6793a23218c8": {
        "text_answer": "Yes  Explanation  The statement in the second group of the primary clinical trial there were no recorded deaths or hospital stays is entailed by the evidence since the evidence shows that there were no deaths 028 and no hospitalizations 028 in the second group of the primary clinical trial",
        "label": "Entailment"
    },
    "2efa0e5d-84cd-4854-9558-6105af976610": {
        "text_answer": "  No   Explanation   The statement patients who have received chemotherapy or radiotherapy in the last 2 weeks are dealing with unstable angina or have grade 2 or above neuropathy are eligible to participate in the secondary clinical trial and excluded from the primary clinical trial is not entailed by the evidence   The evidence provides the inclusion and exclusion criteria for both the primary and secondary clinical trials The",
        "label": "Contradiction"
    },
    "bad9c481-e20c-49a7-b6b6-4e09991419c2": {
        "text_answer": "Yes The primary trial measures pCR pathological complete response and the secondary trial measures pCR after preoperative therapy Both trials use ORR objective response rate as a secondary outcome measure In the primary trial there is no significant difference in ORR between the two arms In the secondary trial Arm 1 Herceptinnavelbine has a lower ORR compared to Arm 2 Taxoterecarboplatin",
        "label": "Entailment"
    },
    "15ac7da3-01f5-4c67-a59a-d41619758b62": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only states that the clinical trial does not exclude participants based on liver function It does not state that there are no constraints on liver function",
        "label": "Contradiction"
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "text_answer": "Yes  Explanation The evidence states that in the primary trial cohort 1 receives 600 mgm2 of Cyclophosphamide and 14mgm2 of Eribulin while cohort 2 receives 600 mgm2 of Cyclophosphamide and 75 mgm2 of Docetaxel Comparing the doses of Cyclophosph",
        "label": "Entailment"
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "text_answer": "Yes  Explanation The evidence states that in the primary trial Intervention 1 Arm A uses anastrozole given orally and Intervention 2 Arm B uses fulvestrant given intramuscularly The statement specifies that paclitaxel is only used in Intervention 1 Arm A and fulvestrant is used in Intervention 2 Arm B Therefore the statement is entailed by the",
        "label": "Entailment"
    },
    "f6ce492e-e69c-4908-9b04-b0234a364e95": {
        "text_answer": "Yes The evidence does not provide any information about the medications specifically being used on chromosome 17p131q25 but the statement is about a chromosome band and is not directly related to the interventions in the trial Therefore the statement is not contradicted by the evidence",
        "label": "Entailment"
    },
    "9bc01b3d-99a3-47bf-9183-012d6686acc5": {
        "text_answer": "No   Explanation The statement there were 100 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events observed in each cohort of the trial but it does not mention the number of cases of hypertension dehydration or dyspnea in the trial",
        "label": "Contradiction"
    },
    "9bec84f1-9ea0-4a5c-a3d7-b368a302ad4a": {
        "text_answer": "No  Explanation  The statement both the azd0530 175 mg and the zoledronic acid 4 mg groups experienced equivalent percentage change in betactx at week 4 in the primary clinical trial is not entailed by the evidence The evidence only provides the percentage change in betaCTX for each group but it does not directly compare the percentage changes between the two groups To make such a comparison additional statistical analysis",
        "label": "Contradiction"
    },
    "dd9dfad7-d09d-49d3-ad2d-fe7421d3a8a0": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the number of injections for the primary trial participants is given as 5 injections at the beginning of the study which is different from 3 weekly injections for the secondary trial participants",
        "label": "Contradiction"
    },
    "70d381b6-0605-4369-8342-5ee2fb69d878": {
        "text_answer": "Yes The evidence states that patients with histologically proven DCIS are eligible for the clinical trial",
        "label": "Entailment"
    },
    "a263d5ff-4c27-4881-9209-87b1c1d69f94": {
        "text_answer": "Yes The primary clinical trial specifically mentions resistance to aromatase inhibitors AI therapy which is not mentioned in the secondary clinical trial",
        "label": "Entailment"
    },
    "a83ed07f-5ce3-44db-83d4-1629e6838c4a": {
        "text_answer": "Yes The primary trial requires mammography as a inclusion criteria but the secondary trial does not list mammography as a requirement for participation",
        "label": "Entailment"
    },
    "a3c50e76-dadb-4b34-8245-0fe0de3d19cb": {
        "text_answer": "Yes The statement is about a question asked by a doctor and the evidence does not provide any information about the outcome measures of the trials being compared",
        "label": "Entailment"
    },
    "62dbb697-f709-40c2-a4b9-8ed098473bde": {
        "text_answer": "  No The statement is not entailed by the evidence The primary trial includes females with breast cancer while the secondary trial includes patients with various types of cancer including BRCApositive ovarian cancer and triplenegative breast cancer However there is no mention of males with neuroblastoma being eligible for either trial in the evidence provided",
        "label": "Contradiction"
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "text_answer": "Yes  Explanation  The primary trial is comparing the use of Hydrophor and MediHoney as interventions for managing skin toxicity during radiation therapy The secondary trial is comparing two different doses 90 mg and 110 mg of the same drug PF05212384 in combination with docetaxel  Therefore the statement that the primary trial is testing the effects of",
        "label": "Entailment"
    },
    "58726c08-13a9-4168-afc3-14f8e7397f5b": {
        "text_answer": "No  Explanation  The statement a young girl with a Newly diagnosed PRpositive HER2 positive breast cancer could be eligible for the secondary trial and the primary trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each trial separately The young girl with PRpositive HER2 positive breast cancer may be eligible for one of the trials but not both based on the given",
        "label": "Contradiction"
    },
    "fea83da0-5960-4547-b662-fe6d139fe3f9": {
        "text_answer": "No  Explanation  The evidence provided in the text only reports the percentage of participants with disease progression or death in each cohort during the maintenance phase of the trial It does not directly compare the outcomes between the two cohorts to determine which one was more favorable The statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "text_answer": "No  Explanation  In the primary trial HER2 patients receive a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 2 patients receive a loading dose of Herceptin 4 mgkg followed by 2 mgkg per week for the first 4 cycles and then 6 mgkg every 3 weeks until 1 year from the initial dose",
        "label": "Contradiction"
    },
    "046aa480-39cc-4333-a815-bc4ec3ebfa7d": {
        "text_answer": "No  The evidence describes the inclusion and exclusion criteria for a clinical trial but it does not specify that the trial is exclusive to Asian patients",
        "label": "Contradiction"
    },
    "73fd9671-363f-4bfa-91ad-1c8bacdf84ef": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "aa9da5b8-f5de-4a49-a93c-9e354cdef066": {
        "text_answer": "Yes  Explanation  The statement no adverse outcomes were recorded in more than 1 of participants in both the primary and secondary clinical trials is entailed by the evidence since the adverse event rates in both trials were less than 1 Specifically in the primary trial the adverse event rate was 048 for both total adverse events and ANCAGCrelated adverse events which is less than ",
        "label": "Entailment"
    },
    "93381895-c0d3-40d1-96a0-b1aa23f65151": {
        "text_answer": "Yes  Explanation  The evidence provided in the results 1 and 2 clearly states that there are no reported results for the LBH589 and Lapatinib group in the primary clinical trial as the Overall Number of Participants Analyzed for that group is 0",
        "label": "Entailment"
    },
    "286cb14c-39e1-4987-9de2-78de7e78a017": {
        "text_answer": "No  Explanation  The statement out of 73 participants in the primary clinical trial 2 experienced an acute myocardial infarction while none out of 1674 participants in the secondary clinical trial experienced the same is not entailed by the evidence provided The evidence only states the number of adverse events including acute myocardial infarction for each trial but it does not provide the number",
        "label": "Contradiction"
    },
    "4a9c4fbc-53cf-4eff-b7ba-37a0f21386b4": {
        "text_answer": "No   Explanation The statement no adverse events were reported in primary clinical trial among any of the cohorts is not entailed by the evidence as there were reported adverse events in both cohorts specifically one case each of neutropenia and fatigue in cohort 2 and one case of hepatic pain in cohort 1",
        "label": "Contradiction"
    },
    "9c96be3d-39cf-4c1d-ae87-764621c1e0ca": {
        "text_answer": "No  The statement is not entailed by the evidence as it does not relate to the inclusion or exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "c68e5909-668a-4b35-bf32-815624bf44da": {
        "text_answer": "No  Explanation The statement in the primary clinical trial 150 mgm2 of lapatinib is administered orally once daily for two weeks to the patients is not entailed by the evidence The evidence only states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the exact dose of lapatinib or the duration for which it is given for two",
        "label": "Contradiction"
    },
    "dec08a3f-8124-4d8a-b5cf-00231c2b5cec": {
        "text_answer": "No  The statement candidates for the primary clinical trial can have a her2 negative tumor result according to fish or ihc 3 is not entailed by the evidence as the inclusion criteria explicitly state that the tumor must be HER2 positive either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "9645eddb-eb1c-43ca-a899-a35db801217e": {
        "text_answer": "No  Explanation  The primary trial does require written informed consent as an inclusion criterion while the secondary trial does not mention it as an inclusion or exclusion criterion in the provided information Therefore the statement that neither trial mandates written informed consent is not entailed by the evidence",
        "label": "Contradiction"
    },
    "af3815c2-6d92-410b-ae62-5552ea998792": {
        "text_answer": "No  Explanation The evidence provided in the trial results indicates that the median overall survival for the midluteal surgery group was 214 years 153 to 267 and for the midfollicular surgery group was 200 years 161 to 231 These values represent the midpoints of the survival distributions for each group The statement that the average lifes",
        "label": "Contradiction"
    },
    "8bf215f3-5795-4b6b-b193-354c87bc9496": {
        "text_answer": "No  Explanation The evidence only provides the median with range change in total body lean mass for each group It does not indicate that any individual patient in the GTx024 1mg group gained over 157473 stone approximately 1027 kg of lean body mass",
        "label": "Contradiction"
    },
    "76f87500-dd58-4086-9991-90e4f8206abf": {
        "text_answer": "No  Explanation  The statement the primary trial uses a 10 month cycle for its intervention is not entailed by the evidence provided The evidence states that each treatment cycle in the primary trial is defined as 21 days and there is no mention of a 10 month cycle The secondary trial does not have a cyclic treatment at all",
        "label": "Contradiction"
    },
    "ffb8a143-9dd7-4e61-8967-b0744c2dfa49": {
        "text_answer": "Yes The primary trial measures changes in pain intensity and the secondary trial measures changes in bone mineral density of the lumbar spine",
        "label": "Entailment"
    },
    "3ed31a8a-dce6-4a6c-b1a6-143db3702546": {
        "text_answer": "No  Explanation The statement mcl1 inhibitor is any agent that inhibits mcl1 is not directly related to the evidence provided which only mentions the use of MM111 as the intervention in the primary trial The statement could be true in general but it is not explicitly stated or implied in the evidence",
        "label": "Contradiction"
    },
    "1c594930-3c65-42d3-86ed-a0a8f46d369c": {
        "text_answer": "Yes The statement does not mention Febrile neutropenia or Cholelithiasis so the absence of these adverse events in the trials is not directly addressed in the statement However the statement is entailed by the evidence as it correctly reports the number of cases of Adverse Events 1 in each trial and correctly identifies thymic adenocarcinoma as a primary thymic adenocarcinoma that is not lowgrade papill",
        "label": "Entailment"
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7ccf8aef-b43b-4d01-9c86-7728378b2aeb": {
        "text_answer": "Yes The statement is entailed by the evidence as metastatic small cell lung cancer is listed as one of the eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "3fd8c503-c6fa-45f1-8836-88a5b77873a3": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary clinical trial is examining vaginal administration of Estring and testosterone cream not oral medications and the secondary clinical trial is focused on acupuncture not intravenous drug administration",
        "label": "Contradiction"
    },
    "65bc201c-2957-4d21-88f1-05c2413a6e56": {
        "text_answer": "No  Explanation  The statement foxr2 gene rearrangement is a molecular abnormality indicating rearrangement of the foxr2 gene is not mentioned in the provided evidence The evidence only includes information about the primary and secondary trials their outcome measurements and their results",
        "label": "Contradiction"
    },
    "7b71e96e-63ed-43c9-9d9d-5abad0b53d32": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "88148e83-625a-4004-8a2c-e4dec21c73e7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement is about a different dose of tamoxifen 32 mg and a different outcome measure tumor size than what was studied in the evidence 20 mg and Ki67 expression",
        "label": "Contradiction"
    },
    "308848e8-55ef-4799-9251-7dc54ddf0ac3": {
        "text_answer": "No  Explanation  The statement less than 10 patients in the primary trial suffered Aes microwave thermotherapy is any procedure in which microwave irradiation is used for the purpose of heating and destroying the surrounding tissue is not directly entailed by the evidence provided The evidence only mentions the number of adverse events AEs and specific types of AEs that occurred in the primary trial but it does not provide information",
        "label": "Contradiction"
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "text_answer": "No  Explanation  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not entailed by the evidence provided The evidence shows that Cholelithiasis was not reported in any participant of the secondary trial while it was reported in 1 participant out of 30 in the primary trial Therefore the frequency of Cholelithiasis is not twice as common in the",
        "label": "Contradiction"
    },
    "67f9627e-ec2e-49b5-bb2e-2adbb5debfef": {
        "text_answer": "Yes   Explanation The primary clinical trial lasted for 10 weeks while the secondary clinical trial lasted for 24 weeks but the intervention in the secondary trial only lasted for one week per visit compared to the 45minute reflexology sessions in the primary trial each week Therefore the intervention in the secondary trial is significantly shorter in duration overall",
        "label": "Entailment"
    },
    "46c9f061-408a-4845-b1ac-01b9c8eb5606": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial reported more cases of palpitations pericardial effusions and abdominal pains than cohort 1 of the secondary clinical trial is not entailed by the evidence provided The evidence only shows that there were occurrences of these adverse events in both trials but it does not provide enough information to make a comparison between the two coh",
        "label": "Contradiction"
    },
    "20e22430-cc26-4cc4-b644-30dea07896e7": {
        "text_answer": "No  Explanation The evidence only mentions that Intervention 1 is for TripleNegative cohort and Intervention 2 is for HER2Amplified cohort It does not mention that both interventions involve Her2 treatment",
        "label": "Contradiction"
    },
    "3cbf5587-220b-4759-a93b-8dbd5e144939": {
        "text_answer": "Yes The trial specifically excludes patients with no known brain or CNS metastases and no measurable disease",
        "label": "Entailment"
    },
    "98300332-951a-4da5-bdd9-42b17fd489b0": {
        "text_answer": "No  Explanation  The statement 33 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide the difference between the two percentages To determine if there",
        "label": "Contradiction"
    },
    "fd531ca0-8537-4395-abed-00fbc69c00a7": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that candidates for the primary trial must have breast cancer and require hormonal treatment",
        "label": "Entailment"
    },
    "1ad82f60-7f4e-4e29-967f-c83e64180807": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports the change in Ki67 expression in tumors with 7 days of presurgical tamoxifen and the statement is about the reduction in tumor diameter with 15 days of presurgical and 30 days of postsurgical tamoxifen The two statements are not equivalent",
        "label": "Contradiction"
    },
    "2e9395d7-1b38-4fc4-b0f4-121f89c1cfc2": {
        "text_answer": "Yes Cohort 2 received a half dose of enzalutamide 80 mg compared to cohort 1 160 mg",
        "label": "Entailment"
    },
    "a993a4e8-00bf-47c9-95d2-a63d4666658e": {
        "text_answer": "Yes The primary trial uses sublingual administration of Vitamin B12 while the secondary trial uses oral administration of memantine and placebo",
        "label": "Entailment"
    },
    "f9759341-1ed2-4e44-8d4d-952bb366892f": {
        "text_answer": "Yes The statement mentions historical data and Adverse Events AEs observed in patients from the secondary trial which is consistent with the information provided in the Evidence The Evidence indicates that Eyelid oedema and Chest pain were observed in the secondary trial but not in the primary trial",
        "label": "Entailment"
    },
    "f5a91b94-a81e-4c40-91df-b144e30df80b": {
        "text_answer": "No  Explanation  The statement primary trial participants never receive epacadostat while sunitinibnaive participants in the secondary trial always receive sunitinib is not entailed by the evidence The primary trial involves the use of epacadostat in combination with pembrolizumab while the secondary trial involves the use of sunitinib as a single agent The statement incorrectly assumes that participants in the",
        "label": "Contradiction"
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "text_answer": "No  The statement is not entailed by the evidence The secondary trial candidates do not need to be completely disabled to participate The evidence only states that patients with severe intellectual impairment or established depression are excluded",
        "label": "Contradiction"
    },
    "f77c9775-9421-4d65-8860-c78a684fd886": {
        "text_answer": "No  Explanation  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial unless they have nonhealing surgical wounds is not entailed by the evidence  The evidence provides the inclusion and exclusion criteria for both the primary",
        "label": "Contradiction"
    },
    "12c5e376-9a01-4581-9d78-db71f92ef23d": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it introduces new concepts double and immutable object that are not present in the evidence The evidence only describes the interventions placebo and Trabectedin and how they are administered in the trial",
        "label": "Contradiction"
    },
    "11de406a-fdd7-401a-a6b9-0c0b47bdf7f6": {
        "text_answer": "Yes  Explanation  The statement all the aes recorded for cohort 1 of the primary clinical trial concern oncological side effects is entailed by the evidence because all the adverse events listed in the evidence are oncological side effects The terms anemia thrombocytopenia and bone marrow failure are all oncological side effects that can occur as a result of cancer treatment The",
        "label": "Entailment"
    },
    "0d4acb50-cf28-4eb1-bd3f-1511d068e3a1": {
        "text_answer": "No  Explanation  The evidence provides the percentage of participants in each group who demonstrated a decrease in the growth factor signature GFS However it does not directly compare the proportions between the two groups To determine if a greater proportion of participants in the triple negative group demonstrated a decrease in the growth factor signature than in the ERpositive luminal B group we would need to calculate and compare the proportions directly or perform a statistical test The evidence",
        "label": "Contradiction"
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "text_answer": "No  Explanation  The statement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only states the number of adverse events both serious and nonserious in each trial for one type of adverse event Adverse Event 1 It does not provide enough information to make a comparison between the number of serious",
        "label": "Contradiction"
    },
    "374ebee5-982e-4ff5-bdf9-49414d417303": {
        "text_answer": "  No   Explanation   The statement women who have claustrophobia and IBS cannot participate in either the primary clinical trial or the secondary clinical trial is not entailed by the evidence provided The evidence only specifies the inclusion and exclusion criteria for each clinical trial separately The statement makes a generalization that applies to both trials but the evidence does not support that conclusion",
        "label": "Contradiction"
    },
    "f1b7b902-d67b-489f-9c93-de59c708d2fa": {
        "text_answer": "Yes The primary trial measures adverse events number of participants with treatmentemergent AEs while the secondary trial measures a different outcome total sleep time as measured by polysomnography",
        "label": "Entailment"
    },
    "002e96b7-152f-4860-b61c-21327c2e6b23": {
        "text_answer": "  Yes the patient meets the inclusion criteria for both trials based on the provided information However its important to note that the patient should also meet all other inclusion and exclusion criteria for each trial as outlined in the evidence",
        "label": "Entailment"
    },
    "267240f0-f381-4c67-adf6-3121eea9396d": {
        "text_answer": "No  Explanation  The evidence provided in the given text only describes the design and participant numbers for two different arms of a clinical trial one involving LBH589 with Capecitabine and the other involving LBH589 and Lapatinib The text does not provide any information about the results or outcomes of these trials let alone any comparison between the two arms to support the statement that the LBH589 and Lap",
        "label": "Contradiction"
    },
    "4ecece61-2e46-482f-a765-ac677ea3e19c": {
        "text_answer": "Yes The primary trial has different inclusion criteria for different study groups while the secondary trial has the same inclusion criteria for all participants",
        "label": "Entailment"
    },
    "37df336b-2fc4-4986-957b-5f62219c5bd4": {
        "text_answer": "No  The evidence provided does not mention anything about a cocktail of drugs being administered to participants in the primary clinical trial",
        "label": "Contradiction"
    },
    "dbffbeee-66da-4e88-8a57-c4d08e214048": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence because the evidence only mentions ER positive and HER2 negative breast cancer Group 1 and invasive triplenegative breast cancer Group 2 but it does not mention PR positive or HER2 breast cancer Therefore the statement about ER positive PR positive and HER2 breast cancer is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "18395ec3-337c-4e51-aef9-5b91423999ed": {
        "text_answer": "No  Explanation  The statement The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm additionally in the secondary trial the Denosumab cohort had a better Time to First OnStudy SRE than the Zoledronic Acid cohort independent to propel wheelchair is a response indicating that an individual is able to propel their wheelchair independent of help from others",
        "label": "Contradiction"
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "text_answer": "Yes  Explanation The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence since the majority of patients in both trials had no adverse events based on the given data",
        "label": "Entailment"
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "text_answer": "Yes The secondary trial includes women aged 18 or older who are also eligible for the primary trial as long as they meet the other inclusion criteria for that trial",
        "label": "Entailment"
    },
    "43ee44cf-35e5-4830-ab1f-d4f040487801": {
        "text_answer": "Yes with the condition that the disease other than ILDPDL is not a malignancy",
        "label": "Entailment"
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "text_answer": "Yes  Explanation  The primary trial had 13 participants analyzed while the secondary trial had 30 participants analyzed Therefore the statement There were more participants in the primary trial than in the secondary trial is not entailed by the evidence as it is the opposite of the true relationship between the two trials However the statement There were fewer participants in the primary trial than in the secondary trial would be entailed by the evidence",
        "label": "Entailment"
    },
    "929ad524-174d-4586-b088-3b512e88bb8f": {
        "text_answer": "Yes  Explanation  The evidence provided in the results shows that none of the participants in cohort 1 Dose Level 1 experienced any serious adverse events lifethreatening adverse events are a type of serious adverse event Therefore the statement none of the patients in cohort 1 of the primary clinical trial experienced any lifethreatening adverse events is entailed by the evidence",
        "label": "Entailment"
    },
    "94b71d5a-37d7-485b-96b7-e0979141893b": {
        "text_answer": "No  Explanation  The statement the first cohort of the primary clinical trial was given the same cetuximab dose as the second is not directly entailed by the evidence The evidence only states that the first cohort received a lower dose of cetuximab 12 mgkg compared to the second cohort 20 mgkg The statement also incorrectly assumes that the cetuximab dose is the",
        "label": "Contradiction"
    },
    "ac0df9a5-d909-40a6-9b57-391fef615fe9": {
        "text_answer": "No  Explanation  The statement both the patients in the primary clinical trial and the secondary clinical trial face the same negative effects is not entailed by the evidence The evidence only lists the specific adverse events for each trial and there is no common negative effect mentioned in both trials",
        "label": "Contradiction"
    },
    "2bd35e15-a310-4660-8963-7f672733bb22": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia is not directly entailed by the evidence provided While anemia was the most common adverse event in the secondary trial the evidence does not mention that it was the most common adverse event overall Additionally the statement makes no reference to the primary trial which is also relevant to the answer Therefore the statement is not entailed by the",
        "label": "Contradiction"
    },
    "3278109c-54b8-4842-8a59-4dae9fac6280": {
        "text_answer": "Yes The evidence does not provide any information about the subject status sequence number but it does not contradict the statement that every participant in the primary trial receives the same intervention",
        "label": "Entailment"
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "text_answer": "No  The statement is not entailed by the evidence as gabapentin or pregabalin are not mentioned in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "04901c04-5a0e-46cb-8684-96ff864921fe": {
        "text_answer": "  No  Explanation  The patient meets some of the inclusion criteria for the secondary trial such as having a histologically verified diagnosis of stage III breast cancer and a life expectancy exceeding 6 months However they do not meet all of the inclusion criteria for the secondary trial such as having an ANC level of 1500L and more at the beginning of the study a hemoglobin level of 9",
        "label": "Contradiction"
    },
    "a2ac2860-6f2d-4459-9c8e-748dddcc35e7": {
        "text_answer": "  No   Explanation   The statement patients with a history of breast cancer confirmed HER2 considering breastconserving surgery are eligible for the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided   The primary clinical trial includes women with locally advanced recurrent or metastatic breast cancer along with confirmation of estrogenreceptor positivity ER The",
        "label": "Contradiction"
    },
    "8db20184-7510-432f-aa95-c9f2c91326fd": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the evidence does not report any cases of nausea in either trial",
        "label": "Contradiction"
    },
    "489c9279-ebca-4ff2-ae61-c8ff4275f3ac": {
        "text_answer": "Yes based on the information provided in Results 2 all participants in the placebo group experienced emesis",
        "label": "Entailment"
    },
    "7d8d8409-5282-464a-a666-849f3eb36b6e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5bdb26f3-2166-41b4-bc39-a4d78e81d04f": {
        "text_answer": "No   Explanation  The statement is not related to the evidence provided in the primary trial The evidence only mentions the interventions and treatment schedules for HER2negative breast cancer participants while the statement is about hexadecatetraenoic acid a polyunsaturated longchain fatty acid and a HER2neu peptide vaccine admixed with sargramostim GMCSF for",
        "label": "Contradiction"
    },
    "96aaaf64-1a1e-4a5b-a2db-f99e2c199bec": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the inclusion criteria  Answer  Maybe the patients eligibility for the secondary trial depends on additional criteria such as ECOG performance status creatinine level and left ventricular ejection fraction which are not provided in the statement However based on the provided lab values the patient meets the inclusion criteria for ANC platelet count hemoglobin",
        "label": "Entailment"
    },
    "7313a53a-9a67-4b81-ad79-4df7d1ced976": {
        "text_answer": "No  Explanation  The statement have pain is not directly related to the adverse events listed in the evidence The evidence provides information about specific adverse events such as duodenitis gastroesophageal reflux disease vomiting ascites haematemesis asthenia general physical health deterioration bronchopneumonia pneumonia and death However it does not explicitly state that",
        "label": "Contradiction"
    },
    "0de24040-4a99-4f16-8bba-6f2e78018aad": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial armodafinil po is delivered daily to a specific cohort while in the secondary clinical trial all participants receive a uniform dose of 100 mg pdr001 and 1mgkg of mcs110 is not directly entailed by the evidence provided  The evidence only states that in the primary trial Armodaf",
        "label": "Contradiction"
    },
    "88b8e438-87f4-418b-903a-efe0f5a83882": {
        "text_answer": "No   Explanation   The statement provided is not entailed by the evidence as it contains incorrect information about the interventions in the primary and secondary trials The primary trial involves Radioembolization using Yttrium90 glass microspheres and TheraSpheres while the secondary trial involves a combination of ibrutinib and MEDI4736 The statement also mentions krd regimen which is not",
        "label": "Contradiction"
    },
    "c7c9fef0-9243-4cd8-8b8e-e9ab459b7420": {
        "text_answer": "Yes The primary trial measures the effect of sulforaphane supplements on urinary isothiocyanate concentration while the secondary trial measures the effect of physical therapy on pain",
        "label": "Entailment"
    },
    "f22453a4-5cb5-4180-8af7-a9f701d766d7": {
        "text_answer": "Yes  Explanation  The statement cohort 1 of the primary clinical trial has no records of cardiac related adverse events is entailed by the evidence since the evidence shows that there were no records of cardiac related adverse events ANGINA PECTORIS CARDIAC ARREST CARDIAC FAILURE CARDIAC TAMPONADE in cohort 1 of the primary",
        "label": "Entailment"
    },
    "a8bb394a-d996-4174-8800-a38db8905fce": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because  1 The secondary clinical trial does not involve 300 patients in three distinct cohorts It only includes 63 participants in the SunitinibCapecitabine arm 2 The secondary clinical trial measures the number of participants with objective response CR or PR at specific time points not the time to progression  There",
        "label": "Contradiction"
    },
    "7d78fd1d-3d73-460c-a1b6-c0d9bf3a60a9": {
        "text_answer": "No  Explanation The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not directly entailed by the evidence provided The evidence states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the exact dosage of lapatinib or the frequency of administration beyond once daily The statement",
        "label": "Contradiction"
    },
    "80e6c613-24ab-4d10-bed6-49388de175d4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the length of the interventions in the primary and secondary trials are not comparable The primary trial lasted for 10 weeks and the secondary trial lasted for 24 weeks but the statement only mentions a difference of 15 weeks which is not directly stated in the evidence Additionally the statement has nothing to do with arterial access sites",
        "label": "Contradiction"
    },
    "5da1c2df-9374-4de9-b43a-c19a03d5652c": {
        "text_answer": "Yes for Phase 1 of the primary trial Maybe for the secondary trial depending on the specific tumor type and availability of tumor tissue",
        "label": "Entailment"
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "text_answer": "Yes  Explanation The primary trial involves patients receiving 2 mgkg of trastuzumab weekly which is the same dosage as the 2 mgkg weekly dosage given to patients in cohort 2 of the secondary trial",
        "label": "Entailment"
    },
    "594df991-cd8d-4ca0-9fe9-5c21a73a0bf3": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c870de83-33d4-4ea6-9482-afe2d7a47480": {
        "text_answer": "No  Explanation  The statement participants of the primary trial are not required to receive denosumab and the secondary trial uses 200 to 400 milligrams of amifostine delivered intravenously is not directly entailed by the evidence provided The evidence only mentions the interventions used in each trial and the dosages of denosumab and Tc99M sulfur collo",
        "label": "Contradiction"
    },
    "3b8d5e1e-4c1e-4e6e-9890-8851c275cc0f": {
        "text_answer": "No  Explanation  The statement a number of psychiatric adverse events were noted in the secondary clinical trial is not entailed by the evidence provided The evidence only states that there are no reported adverse events for Adverse Event 1 and Adverse Event 2 in the secondary clinical trial with no mention of psychiatric adverse events specifically",
        "label": "Contradiction"
    },
    "c4487f90-2a8e-4740-9d56-8fedbd7fb044": {
        "text_answer": "No   The primary trial measures the summed pain intensity differences SPID at 30 minutes after dosing while the statement suggests that it reports the severity of delayed nausea on a scale of 05 The secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "05056fdd-25bc-40ce-831b-e969e95eaa55": {
        "text_answer": "Yes  Explanation The evidence states that unacceptable toxicity was a reason for discontinuing treatment in some participants This implies that adverse events occurred in some participants",
        "label": "Entailment"
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "857f643d-b77b-4a11-94c7-7e05a7e3b0ef": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial administers its intervention sublingually and the secondary trial administers its intervention orally as a pill Neither trial mentions transdermal or intranasal administration",
        "label": "Contradiction"
    },
    "fae264c6-e28a-42ba-9951-f27cdf917815": {
        "text_answer": "  No The statement is not entailed by the evidence as patients with thalasemic syndromes are excluded from the primary clinical trial",
        "label": "Contradiction"
    },
    "5da86b4b-b830-48a4-964d-c20207d55b3a": {
        "text_answer": "No  Explanation  The statement patients diagnosed with nut midline carcinoma identified by fluorescence in situ hybridization or inflammatory breast cancer can participate in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial has specific inclusion and exclusion criteria for patients with NUT midline carcinoma and the secondary clinical trial has specific inclusion and exclusion criteria for",
        "label": "Contradiction"
    },
    "ec1b0aa0-0d0b-45b9-9ba5-ad8b941d8647": {
        "text_answer": "  Yes the patient is eligible for both trials based on the provided information However its important to note that the patient would need to meet all other inclusion criteria and none of the exclusion criteria for each trial separately",
        "label": "Entailment"
    },
    "1b2512ba-9857-4fde-a25b-b4768b1ad748": {
        "text_answer": "No  Explanation  The statement inclusion in the secondary trial requires no restrictions on previous treatments with drugs like gabapentin or pregabalin is not entailed by the evidence In the primary trial these drugs are listed as exclusion factors but the secondary trial has different inclusion and exclusion criteria Therefore the statement does not necessarily hold true for the secondary trial based on the given evidence alone",
        "label": "Contradiction"
    },
    "f5fbfac5-bac3-4852-bb93-b262df8d1418": {
        "text_answer": "No  Explanation  The statement before participating in the primary clinical trial candidates are expected to undergo a mammography in contrast participation in the secondary clinical trial requires an initial CT scan and blood tests is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for both trials but it does not specify the diagnostic procedures required before participating in each trial The statement makes an assumption about the diagnostic procedures based on",
        "label": "Contradiction"
    },
    "91aed56a-2b8e-4f23-9885-4f05e6115537": {
        "text_answer": "No  Explanation  The statement acupuncture patients in the primary clinical trial did not see any significant improvements in their lymphedema as compared to those on the waiting list is not directly entailed by the evidence provided The evidence only shows that the mean arm circumference of the acupuncture group decreased from 474 cm baseline to 429 cm 6 weeks while the mean arm",
        "label": "Contradiction"
    },
    "e299d6fb-d590-417b-a9d3-88ee887d9c00": {
        "text_answer": "No  Explanation  The statement several psychiatric issues including an eating disorder and schizophrenia were reported as adverse events in the primary clinical trial is not directly entailed by the evidence provided The evidence only lists specific adverse events that occurred during the trial without specifying the nature of those events beyond their names The statement goes beyond the information given in the evidence by making assumptions about the nature of the adverse events",
        "label": "Contradiction"
    },
    "948018b7-b40c-499c-bba8-e835222c3c00": {
        "text_answer": "yes The statement is entailed by the exclusion criteria for the secondary clinical trial However its important to note that the primary clinical trial has different inclusion and exclusion criteria and the statement only applies to the secondary trial",
        "label": "Entailment"
    },
    "0e0e3540-9217-435a-89d5-395a9c8af579": {
        "text_answer": "No   Explanation  The statement Neither cohort of the primary trial receives any counselling risk assessment or CBT in the interventions is not entailed by the evidence The evidence only states that there is a validated webbased risk assessment being used in one of the interventions and decision support for providers based on the risk assessment results It does not mention anything about counselling or CBT being provided or not provided in the",
        "label": "Contradiction"
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial intervention section does not provide information on the method of administration dosage or cycle for MM111",
        "label": "Entailment"
    },
    "f8895ab6-dbe2-4715-9567-7dfa9c4d46a8": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b5349f06-8e89-4ff7-966e-00333de8b463": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence as the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "5bf68801-c079-469b-a0a9-2a3d6fb379ed": {
        "text_answer": "  No   Explanation   The statement patients with a proven histological or cytological diagnosis of resectable nonsmall cell lung breast cancer or small cell lung cancer qualify for the primary clinical trial is not entailed by the evidence provided The inclusion criteria state that patients must have advanced andor unresectable disease of the specified types to qualify for the trial Therefore resectable disease is explicitly excluded",
        "label": "Contradiction"
    },
    "ecfd2566-6a41-4b0d-be72-eb143c114835": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the evidence states that in the primary clinical trial cohort 1 is given a dose of 600 mgm2 of cyclophosphamide per treatment cycle while cohort 2 is given a dose of 600 mgm2 of cyclophosphamide per treatment cycle as well However when comparing the total amount of cyclophosph",
        "label": "Entailment"
    },
    "af2a7153-f082-457c-be3e-e6716cdabe0d": {
        "text_answer": "Yes some patients in the GTx024 1mg arm gained lean body mass as indicated by a median gain of 155 kg range 206 to 1264 kg However the statement is not entailed by the evidence as it does not specify that all patients gained lean body mass",
        "label": "Entailment"
    },
    "0790e3ed-6c8e-4b03-8eca-d80fa6296385": {
        "text_answer": "Yes Both interventions use standard gamma probes GP in addition to the handheld gamma camera pIHGC or not the use of GP is common for both protocols",
        "label": "Entailment"
    },
    "dce179aa-b35d-42dd-b97b-4c76f2e4d8b7": {
        "text_answer": "No  Explanation  The statement every adverse event documented during the primary clinical trial was linked to the patients musculoskeletal system a factor not shared in the secondary clinical trial is not entailed by the evidence provided The evidence only shows the types and frequencies of adverse events in both clinical trials but it does not indicate that all adverse events in the primary trial were related to the musculoskeletal system or",
        "label": "Contradiction"
    },
    "0bd4a2c1-4e4a-4752-a9e8-46a9a27885c1": {
        "text_answer": "No  Explanation  The statement atypical lymphocytes present in bone marrow is not directly related to the adverse events reported in the evidence The evidence only reports the number of adverse events and their percentage in the cohort but it does not mention the presence or absence of atypical lymphocytes in the bone marrow Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial intervention section does not provide information on the treatment cycle or irradiation doses",
        "label": "Entailment"
    },
    "98e146d6-bc16-460b-92eb-826ddeb79a3d": {
        "text_answer": "yes the statement is entailed by the evidence in terms of the reported median survival times but it does not directly address the specific question about the impact of midluteal vs midfollicular surgery on the incidence of viral complications",
        "label": "Entailment"
    },
    "328b27ff-4e87-40df-824f-73fb1f01b8a7": {
        "text_answer": "  No   Explanation   The statement all cohorts across the primary clinical trial will use the educational dvd as a key component of their intervention is not entailed by the evidence The evidence only states that the intervention arm of the study will use the educational DVD not that the control arm will use it as well",
        "label": "Contradiction"
    },
    "1f630d95-82b5-44fa-8f52-b19f1c9b75bb": {
        "text_answer": "Yes  Explanation  The statement the primary trial recorded lower incident rates of infection asymmetry and deflation than the secondary trial is entailed by the evidence because the primary trial had a lower percentage of adverse events for infection asymmetry and deflation compared to the secondary trial which had no recorded adverse events for these conditions",
        "label": "Entailment"
    },
    "f102f343-80bc-4df9-87db-125fc783937c": {
        "text_answer": "  No   Explanation   The statement describes a specific genetic mutation egfr nm 0052283c2320 2321ins12 that is not mentioned in the inclusion or exclusion criteria for either the primary or secondary trials Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "35fb0b2d-39d8-43f9-9e47-aceee416803b": {
        "text_answer": "  Yes  Explanation  The evidence states that 20 out of 35 participants in cohort 1 did not experience any vomiting or require rescue medication within the first 24 hours after cyclophosphamide administration This means that less than 50 of the participants in this cohort experienced acute vomiting posttreatment",
        "label": "Entailment"
    },
    "5da3a98b-ffa7-4c54-a340-37986d6dcc20": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed by the evidence provided The evidence only states that there were 3 cases of Hepatotoxicity 1 case each of Hypertension and Pancreatectomy and a total of 8 cases in the",
        "label": "Contradiction"
    },
    "202f56bf-1317-4abc-803d-5ec37cd27624": {
        "text_answer": "No   Explanation   The primary clinical trial and the secondary clinical trial are reporting findings from different patient cohorts The primary trial reports findings from 33 participants receiving denosumab while the secondary trial reports findings from 8 participants receiving dmethadone Therefore the statement that both trials present findings from a single patient cohort is not entailed by the evidence",
        "label": "Contradiction"
    },
    "2ab5044b-9fa6-45ef-8c99-a2cd5e28f512": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the interventions AlloMSCs and Placebo differ in their composition with AlloMSCs being a suspension of allogeneic mesenchymal stem cells and Placebo being Buminate solution The dose and method of administration are the same but the interventions themselves are not Additionally the statement refers to a sarcoma with less than 1",
        "label": "Contradiction"
    },
    "8f018706-e70d-4fa5-812c-9c8d57b97f46": {
        "text_answer": "Yes The evidence mentions irregular heartbeat or arrhythmia selfreported or in the medical record as an exclusion criterion for both trials However the statement smoking behavior is any of the activities associated with tobacco smoking is not directly related to the performance status or inclusionexclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "d8da21ea-52ef-4b97-8344-6214bd3565b3": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the interventions in the primary and secondary trials are different In the primary trial patients receive a Fluciclatide injection while in the secondary trial patients receive Chloroquine injections of either a standard or low dose There is no mention of Docetaxel or Methotrexate in the evidence",
        "label": "Contradiction"
    },
    "073ce8e6-59a6-41e8-a45f-ca91d19dceec": {
        "text_answer": "No  Explanation  The statement patients presently participating in the secondary clinical trial are also permitted to enter the primary clinical trial since the criteria for inclusion are identical is not entailed by the evidence The inclusion and exclusion criteria for the primary and secondary trials are different The primary trial specifically includes postmenopausal female breast cancer patients taking hormonal therapy while the secondary trial includes adult patients with HER2negative metastatic breast cancer",
        "label": "Contradiction"
    },
    "58ce2166-b909-4442-9118-11b9163fa9b1": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports a change in Ki67 expression not a reduction in tumor diameter The statement also specifies a different dosage and duration of tamoxifen administration",
        "label": "Contradiction"
    },
    "61db27bd-2dc4-4c90-8d1e-058f61e1b59a": {
        "text_answer": "Yes  Explanation The statement in intervention 1 of the primary clinical trial the denosumab dosage is 12 fold compared to the tamoxifen dosage in intervention 1 of the secondary clinical trial is entailed by the evidence because the denosumab dosage in intervention 1 of the primary trial is 120 mg Q4W which is equivalent to 480 mg per month In intervention ",
        "label": "Entailment"
    },
    "e0a61eb2-f5c0-4885-94f5-4048944acd1c": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is not directly entailed by the evidence provided The evidence only shows that the median operative time was longer in Arm 2 Standard Mammography compared to Arm 1 Intraoperative Mammography It does not necessarily mean that the control group",
        "label": "Contradiction"
    },
    "e93765e3-d596-4009-8fc0-6d8433f19679": {
        "text_answer": "No  Explanation  The statement all patients treated with gtx024 1mg in the primary clinical trial lost lean body mass over a 4 month period is not entailed by the evidence The evidence only provides the median change in lean body mass for the group of patients treated with 1mg of GTx024 which ranges from a loss of 206 kg to a gain of 126",
        "label": "Contradiction"
    },
    "491a1da4-e9c1-43d9-ba9b-9e53d7f601f9": {
        "text_answer": "Yes  Explanation The statement participants in the primary clinical trial are administered epacadostat at a frequency that is double than that of sunitinib administration to sunitinibnaive patients in the secondary clinical trial is entailed by the evidence as follows  In the primary trial epacadostat is administered orally twice daily BID while in the secondary trial sunitinib is",
        "label": "Entailment"
    },
    "2312391b-799c-4dcc-9ba4-4b98c9c9642b": {
        "text_answer": "Yes  The statement is entailed by the evidence as trastuzumab is only mentioned as part of intervention 1 Herceptin and is explicitly excluded as a standalone intervention in arm 2 Taxoterecarboplatinherceptin",
        "label": "Entailment"
    },
    "650a33d5-ad44-40c8-a41c-1a4e7a5203b5": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the secondary clinical trial does not measure muscle development but rather the percentage of participants with pain or no pain as measured by the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "63acd7b4-dc08-415b-af25-c09e1db4e913": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary clinical trial uses an oral administration of cabergoline not a topical administration",
        "label": "Contradiction"
    },
    "904b8443-c768-449d-81d7-e381dc0e0fb7": {
        "text_answer": "Yes  Explanation The evidence states that both the placebo and trabectedin are given as intravenous infusions with the placebo being given on Day 1 and trabectedin being given on Day 2 The statement in question correctly reflects this information so it is entailed by the evidence",
        "label": "Entailment"
    },
    "f06f2517-d0fb-4494-a044-fd626c78187f": {
        "text_answer": "No  Explanation  The statement the total adverse events recorded in patients were the same for both the primary clinical trial and the secondary clinical trial is not entailed by the evidence The evidence only states that the total number of adverse events for Adverse Event 1 is 0 for both trials but it does not provide information about the total number of adverse events for Adverse Event 2 or any other adverse events Therefore it is",
        "label": "Contradiction"
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "text_answer": "No  Explanation  The statement Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial who were receiving far lower doses of Empegfilgrastim is not entailed by the evidence provided  The evidence only shows the mean duration of neutropenia in days for each group in the primary and secondary trials It",
        "label": "Contradiction"
    },
    "d9a5cbf6-51ae-4c80-a222-534e7507c7f8": {
        "text_answer": "No  Explanation The statement in the primary clinical trial the number of cases of hepatotoxicity was less than the cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that the number of cases of hepatotoxicity was 3 out of 8 which is less than the number of cases of hypertension and pancreatectomy only if we consider the number of cases",
        "label": "Contradiction"
    },
    "e60df76f-e6d9-4da1-8fe7-e23c8f38365f": {
        "text_answer": "No  Explanation  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is not directly entailed by the evidence provided The evidence only mentions that prior use of Herceptin within the last 5 months is an exclusion criterion for the primary trial and that there is no mention of gabapentin in the primary trial",
        "label": "Contradiction"
    },
    "38ca4d41-1f13-4735-983d-9ac5b1b816f0": {
        "text_answer": "No  Explanation  The statement the maximum tolerated dose of mm111 for patients involved in the secondary clinical trial is reallocated at 15 mg on a daily basis is not entailed by the evidence provided The evidence only states that the secondary clinical trial defined the MTD or Maximum Feasible Dose of MM111 as the highest dose level in which a DLT is experienced by fewer than",
        "label": "Contradiction"
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "text_answer": "Yes  Explanation The statement there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial is entailed by the evidence as there are instances of cardiac arrest angina pectoris acute coronary syndrome cardiac failure and cardiac tamponade recorded in cohort 1 of the primary trial",
        "label": "Entailment"
    },
    "99925da5-1a89-471d-b3d9-a3e083fc1bda": {
        "text_answer": "Yes The statement is entailed by the evidence as the number of adverse events was higher in cohort 2 with a total of 25 4000 compared to cohort 1 with a total of 24 5000",
        "label": "Entailment"
    },
    "10b61f57-c5c1-4d29-9838-bb14c4608bf4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence states that Intervention 1 includes a validated webbased risk assessment and decision support for providers which is not the same as counselling risk assessment or cognitive behavioural therapy CBT as stated in the question",
        "label": "Contradiction"
    },
    "99d85210-19a0-4256-b092-c3a0f6ef322f": {
        "text_answer": "Yes  Explanation  The statement neutropenia occurred less frequently in patients belonging to cohort 2 of the primary clinical trial than in cohort 1 of the secondary clinical trial even though the latter were receiving considerably smaller doses of empegfilgrastim is entailed by the evidence as follows  1 The primary clinical trial compared the efficacy of a single dose of empegfilgrastim at ",
        "label": "Entailment"
    },
    "0f5ce689-610f-4522-8082-23df226f2a42": {
        "text_answer": "Yes  Both interventions in the clinical trial include the use of trastuzumab Herceptin",
        "label": "Entailment"
    },
    "d5e071e0-4705-474c-8820-9fbc7b377a8d": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not specify that the secondary clinical trial is limited to males of a particular ethnic group",
        "label": "Contradiction"
    },
    "4192b30d-92ad-47c4-b88e-8f48ea048ee2": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it incorrectly implies that the decision to include a patient in the clinical trial is solely based on the fulfillment of inclusion and exclusion criteria without acknowledging the role of health professionals in making the final eligibility determination",
        "label": "Contradiction"
    },
    "8268f272-c82c-4cc3-87dd-8fdf59611a1c": {
        "text_answer": "No  Explanation  The statement at least one patient in the primary trial suffered several different adverse events is entailed by the evidence since there are a total of 6 different adverse events reported in the trial However the statement about thyroid gland follicular carcinoma is not mentioned in the evidence at all Therefore it is not entailed by the evidence",
        "label": "Contradiction"
    },
    "94849f18-76aa-4fdf-9f7b-2fb1c6b5bc9d": {
        "text_answer": "No  Explanation  The primary and secondary trials have different interventions although they both involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in the treatment of patients with CNS involvement from various types of cancer However the primary trial involves the use of Abl Cells and Cyclophosphamide in combination with DMCHOCPEN while the secondary trial only",
        "label": "Contradiction"
    },
    "1de04bd7-e1e7-42a6-a898-ae626a24b25b": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial revealed a higher percentage change in betactx at week four in the azd0530 175 mg group when compared to the group administered with zoledronic acid 4 mg is entailed by the evidence provided The evidence shows that the geometric mean percentage change in betaCTX at week 4 was 711 759 to 65",
        "label": "Entailment"
    },
    "40123001-b9eb-4d75-aa74-83865de37e70": {
        "text_answer": "No  Explanation  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is not entailed by the evidence provided The evidence only reports the number and percentage of adverse events for each type in both trials It does not compare the number or percentage of each type of adverse event between the two trials Therefore the",
        "label": "Contradiction"
    },
    "6a119107-7a0d-421f-bfea-3671d97ed082": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly support the statement that the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort The evidence only provides the percentage of participants with Disease Progression or Death in each cohort during the maintenance phase of the trial The statement makes a comparison between the",
        "label": "Contradiction"
    },
    "f32516f0-768d-48db-a449-74ac774abbe0": {
        "text_answer": "No  Explanation  The evidence provided in the form of the primary clinical trial results indicates that there was a difference in the number of participants who were emesisfree during the study period between the aprepitant and placebo groups Specifically 13 participants in the aprepitant group were emesisfree compared to only 5 participants in the placebo group This difference suggests that aprepitant was more effective in controlling n",
        "label": "Contradiction"
    },
    "f178fb19-cc4a-4f58-b81a-aac7270f154b": {
        "text_answer": "Yes  Explanation The primary trial focuses on massage therapy as an intervention which is a nonpharmacological treatment In contrast the secondary trial investigates the efficacy of two different doses of a drug PF06647020 as interventions Therefore the statement that the primary trial centers around a singular drugbased treatment and the secondary trial involves testing several drugfree treatment solutions is accurate and entailed",
        "label": "Entailment"
    },
    "a7999375-da80-4839-940a-bec673fb119f": {
        "text_answer": "No The statement is not entailed by the evidence as the primary trial includes females of all racial and ethnic origins diagnosed with breast cancer not just BRCA breast cancer",
        "label": "Contradiction"
    },
    "a108f3f0-f18c-4bb3-87f1-5a1eee525f71": {
        "text_answer": "Yes  Explanation The statement adverse events spanning a variety of types were evenly distributed among patients across multiple cohorts in the primary clinical trial is entailed by the evidence as the adverse events are listed for each cohort and the number of events for each type is equal in both cohorts",
        "label": "Entailment"
    },
    "fd78876b-0b85-41e3-ad9f-8213dd9484ca": {
        "text_answer": "No  Explanation  The statement treatmentemergent adverse events were experienced by 35 patients who received sunitinib docetaxel and trastuzumab during the primary clinical trial is not entailed by the evidence The evidence states that there were 24 treatmentemergent adverse events AEs and 11 serious adverse events SAEs among the 25",
        "label": "Contradiction"
    },
    "f73ec9f6-b18c-4f32-9116-573f5f717e55": {
        "text_answer": "  No The statement is not entailed by the evidence The primary trial includes patients with a primary tumour greater than 2 cm diameter while the secondary trial does not specify a minimum tumour size",
        "label": "Contradiction"
    },
    "452f92e1-27bb-4452-8675-c6409ec6003a": {
        "text_answer": "  No The statement is not entailed by the evidence The evidence states that the minimum age for the primary trial is 20 years old and there is no mention of a waiting period for younger women",
        "label": "Contradiction"
    },
    "e0a117a2-c519-46f5-9c31-124234272ce1": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial all adverse event types impacted less than 10 of the patients is entailed by the evidence since none of the adverse event types affected more than 10 of the patients 3636 total adverse events  11 patients  329 which is less than 10",
        "label": "Entailment"
    },
    "9bd6ad87-470a-4fa3-9e29-bf5ba8c2b463": {
        "text_answer": "Yes  Explanation The statement 300 the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy can be calculated as follows  3750 hepatotoxicity  1250 hypertension and pancreatectomy 3750  1250  3  ",
        "label": "Entailment"
    },
    "2529171f-85e8-4d19-8023-dc1a28416fa1": {
        "text_answer": "Yes  Explanation  The statement there are 5 shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because the evidence provides the inclusion and exclusion criteria for both trials and a comparison reveals that five criteria are common to both trials",
        "label": "Entailment"
    },
    "254e8b1c-de9f-467b-b32a-a41ee97421b9": {
        "text_answer": "No The statement is an exaggeration of the exclusion criteria in the evidence which only requires that there be no history of these conditions in the last 6 months",
        "label": "Contradiction"
    },
    "5db52328-ebdc-4961-bc21-7776db7d7876": {
        "text_answer": "Yes  Explanation The primary trial states that the first intervention group received Zoledronic Acid 4 mg Q4W 168 mg per cycle of 4 weeks while the first intervention group in the secondary trial received Tamoxifen 10 mg once daily for 21 days per cycle approximately 0156 mg per day or 0468 mg per cycle To compare the concentrations",
        "label": "Entailment"
    },
    "5f6cacb7-41e6-4d8c-9a43-7bd21202b11f": {
        "text_answer": "  No the statement about intraoperative urinary injury is not explicitly mentioned in the evidence However it does not contradict any information in the evidence",
        "label": "Contradiction"
    },
    "6b0bc5aa-4540-4439-a2e3-c48abb937074": {
        "text_answer": "No  Explanation  The statement all measured patients within the primary clinical trials group 1 were identified as having several lesions along with an overwhelming majority from the secondary trials group 1 showing healthy skin attributes is not entailed by the evidence  The evidence only provides information about the number of participants and the outcome measurements in each group of the primary and secondary trials It does not mention anything about the presence or absence of lesions",
        "label": "Contradiction"
    },
    "d61c1b26-cf05-46e8-a156-a264f562dfa8": {
        "text_answer": "  No The statement is not entailed by the evidence The evidence only mentions that patients who have received chemotherapy or radiotherapy within certain time frames are excluded from the secondary trial but it does not mention anything about unstable angina or Grade 2 or above neuropathy",
        "label": "Contradiction"
    },
    "a127c618-ace8-46cf-9b52-7655f2ccee9c": {
        "text_answer": "  Yes for the secondary clinical trial children and adolescents are not explicitly excluded based on age in the provided criteria",
        "label": "Entailment"
    },
    "01bff32b-6bba-4295-94e9-c3a8430670be": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "24be42f5-01dc-487e-9ada-39d05b6d4e7e": {
        "text_answer": "Yes The primary trial has a 21day cycle for its intervention while the secondary trial does not mention a cyclic treatment",
        "label": "Entailment"
    },
    "d91ee458-d6de-4d45-8511-cabb52d2a64e": {
        "text_answer": "No  Explanation  The eligibility criteria for the primary clinical trial do depend on the gender of the participant as it includes specific criteria for male and postmenopausal female subjects The secondary clinical trial also has different eligibility criteria for women and men as it only includes women with locally advanced recurrent or metastatic breast cancer who are estrogenreceptor positive Therefore the statement that the eligibility criteria for both",
        "label": "Contradiction"
    },
    "37a51d40-4b39-4488-b818-7495917d50a0": {
        "text_answer": "Yes The evidence states that there were 2 participants in the second cohort who experienced doselimiting toxicities",
        "label": "Entailment"
    },
    "ffce31e9-2899-42af-8af0-e24be1ace812": {
        "text_answer": "  No   Explanation   The statement women suffering from only osteoporosis are eligible for both the primary and secondary clinical trials is not entailed by the evidence   The primary trial excludes women with osteoporosis while the secondary trial does not mention osteoporosis as an exclusion criterion However its important to note that the evidence does not provide enough information to determine",
        "label": "Contradiction"
    },
    "ffd7717b-fec1-4702-87a6-5345e8efe7ba": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a50ad70a-ff4c-4110-bfff-3fc230c44acc": {
        "text_answer": "No  The evidence does not provide information about the length of time since diagnosis or life expectancy of the patients eligible for the clinical trial",
        "label": "Contradiction"
    },
    "4b6aac05-1130-49c4-b5f6-9afe1227459c": {
        "text_answer": "No  Explanation  The primary clinical trial includes the criterion Male subjects in its inclusion criteria while the secondary clinical trial does not mention gender as a criterion However the statement neither the primary clinical trial nor the secondary clinical trial consider gender as a criteria for eligibility is not entirely accurate as the primary trial does consider gender as a criterion",
        "label": "Contradiction"
    },
    "b9d16baf-ec50-40da-b2a4-68aa7abf1541": {
        "text_answer": "No  Explanation  The statement mentions multiple deaths and hospitalizations in cohort 2 but the evidence only reports one death in cohort 2 for both sets of adverse events Therefore the statement is not entailed by the evidence as it overstates the number of deaths and hospitalizations reported Additionally the statement mentions various cases of atrial fibrillation but the evidence does not provide any information about",
        "label": "Contradiction"
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "text_answer": "maybe  Explanation  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group is not directly entailed by the evidence as the evidence only provides the ORR and the number of participants analyzed for each group but it does not make a direct comparison between the two groups However the evidence does suggest that the Paclitaxel",
        "label": "Contradiction"
    },
    "6e5ea627-075c-4b44-9605-4d440735d843": {
        "text_answer": "Yes assuming the individual meets all other inclusion and exclusion criteria However its important to note that the statement does not directly appear in the evidence but the exclusion criteria do not list progestogens as a current or planned therapy that would disqualify someone from participating",
        "label": "Entailment"
    },
    "5c11d673-054f-4db7-a2d4-8c6243b3ba45": {
        "text_answer": "  No the statement is not entailed by the evidence The primary trial has a specific eligibility criterion for Japanese female patients but the secondary trial does not have any such requirement Additionally the statement about the regimen used to treat malignant peritoneal neoplasm is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "42fc9190-b214-42bf-92fc-3678564083ca": {
        "text_answer": "Yes  Explanation  The statement patients suffering from ascites were less common in the primary clinical trial while pneumocystis jirovecii pneumonia was less frequent in the secondary clinical trial is entailed by the evidence as the primary trial had 2 cases of ascites 090 and the secondary trial had none 000 Similarly the primary trial had no cases of pneumocyst",
        "label": "Entailment"
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "text_answer": "No  Explanation  The statement There were more adverse events observed in the secondary trial than in the primary trial is not entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of adverse events between the two trials",
        "label": "Contradiction"
    },
    "6515b0ad-cba7-4831-9b96-576faaa284f4": {
        "text_answer": "No  Explanation  The statement the denosumab dosage in intervention 1 of the primary clinical trial is 12 times the tamoxifen dosage used in intervention 1 of the secondary clinical trial is not entailed by the evidence provided The evidence only states the dosages and treatment schedules for each intervention in their respective clinical trials It does not provide a comparison of the dosages between the two interventions across different trials",
        "label": "Contradiction"
    },
    "f886baee-f1c6-4887-8068-5c779c6ebb60": {
        "text_answer": "No  Explanation  The statement the individuals in group 2 of the primary clinical trial are administered 05ugkg of dexmedetomidine 5ml while in the secondary clinical trial no dexmedetomidine is given to the patients is not entailed by the evidence  The primary clinical trial compares the administration of normal saline to the administration of dexmedetomidine",
        "label": "Contradiction"
    },
    "c51a2098-014f-410c-9722-eaadb298983d": {
        "text_answer": "Yes The statement is entailed by the evidence as there are no reported cases of intestinal obstructions or pancytopenia in either trial",
        "label": "Entailment"
    },
    "0bca53f6-c609-4c49-a684-a2d71cff7086": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the route of administration for the placebo or memantine interventions in the primary clinical trial The evidence only specifies that the placebo is administered orally PO twice daily and memantine is administered orally PO twice daily",
        "label": "Contradiction"
    },
    "197bf729-04f4-46f0-a746-8b55c088f0d6": {
        "text_answer": "Yes The evidence states that there was a significant change in Ki67 expression in tumors with an average percentage change of 40 63 to 29 after 7 days of presurgical tamoxifen treatment The statement accurately reflects this finding",
        "label": "Entailment"
    },
    "a7f12911-d5b9-4cd0-a3c0-e1fb6ded7512": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial more incidents of palpitations pericardial effusions and abdominal pains were observed in the second cohort compared to the first cohort of the secondary clinical trial is not entailed by the evidence provided The evidence only states the number of adverse events in each trial but it does not provide enough information to make a comparison between the two cohorts within",
        "label": "Contradiction"
    },
    "249d272c-cbee-4395-bb73-7e6cde3a4677": {
        "text_answer": "  Yes for the secondary trial but not without qualification for the primary trial   Explanation  The statement is entailed by the secondary trial inclusion criteria as the patient meets all the other requirements and the age range is 1870 years inclusive However for the primary trial the patient is 32 years old which is within the age range of 18 years and above but it does not explicitly state that",
        "label": "Entailment"
    },
    "f43b3f3f-f51c-49ff-b659-b3e97bf0ab0d": {
        "text_answer": "  Yes The evidence includes both trials and their respective inclusion and exclusion criteria The statement about hypopharyngeal squamous cell carcinoma and venous thromboembolism is mentioned in the exclusion criteria of the primary trial",
        "label": "Entailment"
    },
    "cd247253-c2d6-4eb6-be06-90ef855748cf": {
        "text_answer": "No   Explanation   The statement for inclusion in the primary trial candidates are required to have an updated electrocardiogram ecg while the secondary trial mandates a recent colonoscopy report and a complete blood count cbc is not entailed by the evidence provided   The primary trial inclusion criteria do not mention the requirement of an updated ECG and the secondary trial inclusion criteria do not mention the requirement of a recent",
        "label": "Contradiction"
    },
    "ae259f29-2da6-43fe-b89e-345be44688e8": {
        "text_answer": "Yes  Explanation The statement cohort 1 of the primary clinical trial received a higher dosage of cetuximab compared to cohort 2 is entailed by the evidence as stated in the Intervention 1 for Cohort 1 12 mgkg and Intervention 2 for Cohort 2a 20 mgkg The collaborative care intervention was also omitted in both interventions as",
        "label": "Entailment"
    },
    "d1216971-8b18-427a-9f6e-de0fcddec7ea": {
        "text_answer": "  No   Explanation   The primary clinical trial includes the requirement of being a Japanese female while the secondary clinical trial does not specify any gender or nationality restrictions Therefore the statement that only males of an unspecified nationality are eligible to enroll in the primary clinical trial is not entailed by the evidence",
        "label": "Contradiction"
    },
    "c99a0652-8f34-49d1-b98b-182553c58dbc": {
        "text_answer": "Yes The primary trial involves a consistent dosage of alpha lipoic acid while the secondary trial involves a graduated increase of necitumumab",
        "label": "Entailment"
    },
    "2d320e21-8fce-4f6f-8bf3-dc68f1cb8b0e": {
        "text_answer": "Yes The statement mentions ureter disorders in a nonspecific way but the evidence provides information about two different cohorts in a clinical trial one of which cohort 1 is described as having PR negative ER negative and HER status and the other cohort 2 having HER2 status The statement is entailed by the evidence because it correctly identifies that there are two different cohorts in the trial",
        "label": "Entailment"
    },
    "d4045883-595f-4855-83ed-ca175a1d5aea": {
        "text_answer": "Yes The secondary trial had 1 occurrence of intestinal perforation in the primary trial but in the secondary trial there were 2 occurrences This represents an excess of 1 occurrence",
        "label": "Entailment"
    },
    "29a26ffe-8fcd-4e93-b354-3ca65738c8e5": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial and the secondary clinical trial reported zero deaths among their adverse events is entailed by the evidence because both trials reported no deaths in their adverse events sections",
        "label": "Entailment"
    },
    "8a532b5a-1468-4de5-83ac-50179edb2ac8": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence reports that 5 out of 25 patients 2000 experienced adverse events",
        "label": "Contradiction"
    },
    "a4e6bb5b-69f1-451b-b278-0ce9c3e43bdf": {
        "text_answer": "25 number of participants analyzed is not the same as 35 number in the statement Therefore No",
        "label": "Contradiction"
    },
    "a3191a50-4395-4bd8-a57a-5404fcfcd8c9": {
        "text_answer": "Yes The evidence states that individuals with ERpositive breast cancer can participate in the Phase 2 stage of the clinical trial However it does not explicitly state that they can participate in the Phase 1 stage but since the statement does not limit participation to Phase 2 it is entailed by the evidence",
        "label": "Entailment"
    },
    "5de4ae02-a1df-430d-a793-803bfefb7b0e": {
        "text_answer": "No  Explanation  The primary clinical trial focuses on the percentage of participants experiencing any treatment emergent adverse events and serious treatment emergent adverse events The secondary clinical trial focuses on the number of participants with objective response These are two different outcome measurements",
        "label": "Contradiction"
    },
    "da18ab3b-cf80-4867-b3b9-0dccf4c523a2": {
        "text_answer": "No  Explanation The evidence provided in the primary trial only reports the median average survival times for each group not the survival times for individual patients The statement makes a claim about the survival of at least one patient from both cohorts which cannot be determined from the given evidence",
        "label": "Contradiction"
    },
    "ae8cf6fd-ab5f-4f34-a135-ea8d0c0c58bc": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not specify that all or any of these patients are administered 1 mg of talazoparib daily as part of the intervention The statement about talazoparib is not directly mentioned in the evidence",
        "label": "Contradiction"
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "text_answer": "No  Explanation The patient with a primary tumour of 33mm diameter would not be eligible for both trials as the primary trial has an inclusion criterion of a primary tumour greater than 2 cm diameter and the secondary trial does not have a specific mention of tumour size as an inclusion criterion",
        "label": "Contradiction"
    },
    "0069c252-1e8b-4209-af61-11e6ee9d3c2b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence reports a significant change in Ki67 expression not tumor diameter The statement is about tumor diameter and the evidence is about Ki67 expression Therefore they address different outcomes",
        "label": "Contradiction"
    },
    "1cc18d8f-93f5-474e-9178-833b26150681": {
        "text_answer": "No   Explanation   The evidence provided in the primary trial describes the dosing schedule for Vorinostat and radiation therapy It does not mention anything about the administration of Fentanyl sublingual spray or the dosage of 100 to 1600 g for any patient in the trial Additionally the statement makes a reference to chromosome band 13q22q34 which is",
        "label": "Contradiction"
    },
    "4e5fb5c5-d286-4109-a89b-28f399788cae": {
        "text_answer": "No  Explanation  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for both the primary and secondary trials but it does not specify any age restrictions or waiting periods for eligibility",
        "label": "Contradiction"
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "text_answer": "Yes  Explanation  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is entailed by the evidence since the evidence reports that there are no cases of anorexia hypothermia or hallucinations in both trials",
        "label": "Entailment"
    },
    "66816aea-0de7-486c-b9d4-4ca6d9f09d52": {
        "text_answer": "No  The statement is not entailed by the evidence as the secondary trial does not involve any cancer therapy and has different inclusionexclusion criteria compared to the primary trial",
        "label": "Contradiction"
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "8dd822a1-6d7b-4dca-b3fb-4841442aff93": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not support the statement that less than 01 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products The evidence only reports the number of participants with a reduction in CTCs at one month posttransplantation not the percentage or proportion of participants with a reduction over months",
        "label": "Contradiction"
    },
    "79923aba-be0b-476d-ae86-733fce590db1": {
        "text_answer": "No  Explanation  The statement Is the statement entailed by the Evidence is not directly related to the information provided in the evidence regarding the inclusion and exclusion criteria for the clinical trial The statement is about the level of bother an individual experiences with swelling in their underarm arm or hand which is not mentioned in the evidence Additionally the evidence does not specify any geographic requirements for patient participation in the trial",
        "label": "Contradiction"
    },
    "b2059651-24e7-4b6c-aeee-403ff32cf725": {
        "text_answer": "No  Explanation  The statement Women with Newly diagnosed stage IV breast cancer confirmed as ER  Considering a mastectomy are eligible for the primary trial and the secondary trial is not entailed by the evidence provided The primary trial specifically excludes patients with stage IV disease at the time of recruitment while the secondary trial includes patients with newly diagnosed or recurrent breast cancer but not those with stage IV disease Therefore women with",
        "label": "Contradiction"
    },
    "66dff58d-73c8-46c8-afa7-9fe6e1231624": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that there were no cardiac or psychiatric adverse events recorded during both trials The statement also mentions that other types of adverse events were observed which is consistent with the evidence The additional information about the combination antiinfective agent is not relevant to the entailment relationship between the statement and the evidence",
        "label": "Entailment"
    },
    "4bd8fa53-08b5-4b80-868a-4b535432f2e2": {
        "text_answer": "No  The statement is not directly related to the inclusion or exclusion criteria for either trial The primary trial mentions HIV HCV and HBV infections as exclusion criteria but it does not mention prostate infections specifically The secondary trial mentions acute or active chronic infections as an exclusion criterion but it does not specify which infections are included The statement about CTCAE being a disorder characterized by an infectious process involving the",
        "label": "Contradiction"
    },
    "d10a9ae2-cb0c-49e8-924c-906e3f2eb5a5": {
        "text_answer": "No  Explanation  The statement the primary clinical trial is solely open to participants who have been sterilized surgically or are not sexually active is not entailed by the evidence The evidence only mentions that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab It does not state that",
        "label": "Contradiction"
    },
    "db7671cb-a230-402e-beda-738af0753332": {
        "text_answer": "No  The statement is not entailed by the evidence as the patient described in the statement has a life expectancy that is significantly longer than the minimum life expectancy requirement of 3 months stated in the inclusion criteria",
        "label": "Contradiction"
    },
    "0fa2ee42-3800-49bc-838c-eb3dba41f01f": {
        "text_answer": " No   Explanation  The primary clinical trial excludes patients with malignant breast diseases including ductal carcinoma in situ while the secondary clinical trial includes patients with a history of breast cancer including ductal carcinoma in situ However the primary trial does not specifically mention malignant ductal carcinoma in situ in its exclusion criteria and the statement malignant ductal carcinoma in situ",
        "label": "Contradiction"
    },
    "24b7127a-5d4d-4a7d-b64b-8b2e12396b04": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial specifically includes patients with breast cancer and the secondary trial does not mention colon cancer at all",
        "label": "Contradiction"
    },
    "b395d278-bbad-4ba2-af5b-82dc8045482a": {
        "text_answer": "Yes The secondary clinical trial includes patients with diagnosed alterations in one or more of the listed genes",
        "label": "Entailment"
    },
    "9474451f-d601-4dcc-8304-50bc4d3ebf52": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial does not mention anything about previous use of gabapentin or pregabalin as an exclusion criterion",
        "label": "Contradiction"
    },
    "ead18343-9437-4aa4-9bbc-2e20f7c28025": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial reports the median time to progression in months for each treatment arm while the secondary trial reports the number of participants with objective response based on RECIST criteria The statement incorrectly assumes that the primary trial reports overall survival for all 300 patients and that the secondary trial reports the percentage of nonresponding patients",
        "label": "Contradiction"
    },
    "951c2074-2100-4b9f-84e1-adec6a08c61b": {
        "text_answer": "Yes  Explanation The statement during multiple phases throughout the trials the trastuzumab dosage for patients in cohort 2 of the secondary clinical trial mirrors that of the patients in the primary clinical trial is entailed by the evidence as both trials involve the use of trastuzumab with different dosing schedules In the primary trial patients receive a loading dose followed by weekly doses of 2 mgkg In",
        "label": "Entailment"
    },
    "a2fa7138-cba9-4720-91a0-eb12a7356fa2": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not mention anything about antiretroviral drugs or muscle relaxants in either the primary or secondary trials The primary trial discusses radiation therapy for breast cancer patients and the secondary trial discusses the use of Enzastaurin and Fulvestrant for breast cancer treatment",
        "label": "Contradiction"
    },
    "04067434-b300-40f1-9e6c-c986b4c602c5": {
        "text_answer": "No  Explanation  The statement hard palate squamous cell carcinoma is a squamous cell carcinoma that arises from the hard palate It usually presents as a papillary or exophytic mass is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events AEs in two cohorts of a primary trial without specifying the nature of the AEs or the",
        "label": "Contradiction"
    },
    "46cd405e-a401-4249-ad26-b48801b2c2c8": {
        "text_answer": "No  Explanation  The primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary clinical trial determines the Maximum Tolerated Dose MTD of Ruxolitinib in combination with Paclitaxel based on the occurrence of doselimiting toxicities DLTs The statement provided is not related to the",
        "label": "Contradiction"
    },
    "c3503b5e-ef92-4e90-bc0f-5ef7690a5908": {
        "text_answer": "Yes  Explanation  The statement there are no reported cases of asthenia or pyrexia in the patients of the primary clinical trial and the secondary clinical trial is entailed by the evidence since the evidence reports that there were no cases 000 of asthenia or pyrexia in both trials",
        "label": "Entailment"
    },
    "bcbeb637-d070-400b-a98e-e3380f009b21": {
        "text_answer": "No  Explanation  The statement in the primary trial observations revealed more instances of infection asymmetry and deflation in comparison to the secondary trial is not entailed by the evidence provided The evidence only shows the number of adverse events in each trial but it does not provide enough information to make a comparison between the two trials regarding the specific types of adverse events The statement makes a comparison between the number of instances of specific types of adverse",
        "label": "Contradiction"
    },
    "62ecbc1b-eb8f-43ad-b997-a11c8d36b379": {
        "text_answer": "No  Explanation The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases but it does not specify which armgroup of the trial this occurred in Therefore it is not possible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "00e018a5-5237-498b-8823-f47ac2d2697f": {
        "text_answer": "No  The statement about women suffering from both claustrophobia and IBS not being eligible for either trial is not directly stated in the evidence The evidence only provides the inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "c5f56599-f5cb-46c4-ac69-e298d37f0883": {
        "text_answer": "Yes The patient with a secondary tumour of 35mm in size detected through MRI would not qualify for either the primary or secondary trial based on the provided inclusion criteria In the primary trial the minimum tumour size is greater than 2 cm in diameter and in the secondary trial there is no mention of tumour size in the inclusion criteria However both trials have other exclusion criteria that the patient may not meet such as metastasis M1",
        "label": "Entailment"
    },
    "fdc25a44-5f1f-4478-b1f4-78fbb95b112a": {
        "text_answer": "Yes The statement includes some of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "text_answer": "No  Explanation The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is not entailed by the evidence provided According to the evidence prior use of Herceptin within the last 5 months is an exclusion criterion for the primary trial but there is no mention of gabapentin or its exclusion criteria in either trial",
        "label": "Contradiction"
    },
    "40a16e0a-a4d4-49d0-8423-aa5b43688171": {
        "text_answer": "No   Explanation The statement there were 150 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events for two separate cohorts of the trial but it does not mention the total number of cases or the presence of hypertension dehydration or dyspnea",
        "label": "Contradiction"
    },
    "1f10dd13-d27c-4ff0-bcac-67f0da0ac487": {
        "text_answer": "No  Explanation  The statement the primary trial uses the same inclusion and exclusion criteria for each of its phases while the secondary trial does not distinguish between criteria for healthy and cancer patients is not entailed by the evidence provided  The primary trial does have the same inclusion criteria for both phases but it does have different exclusion criteria for each phase The secondary trial does not have the same inclusion and exclusion criteria for healthy and cancer patients",
        "label": "Contradiction"
    },
    "0c72a56a-de46-498d-8706-04c1283bea04": {
        "text_answer": "No   Explanation  The statement cohort a of the primary clinical trial is administered a single infusion of hd V934 is not entailed by the evidence provided The evidence only states that cohort A of the primary clinical trial received three electroporation injections of V934 low dose followed by two injections of V935 low dose It does not mention any information about the dos",
        "label": "Contradiction"
    },
    "853967c7-51a1-4e08-88c0-d8e621129176": {
        "text_answer": "yes but with a caveat The statement is entailed by the evidence in the sense that both trials measure pCR as an outcome However the statement does not accurately reflect the findings of the primary trial which did not show a significant difference in pCR rates between the two arms The secondary trial did show a significant difference but it is not directly comparable to the primary trial due to differences in study design and patient populations",
        "label": "Entailment"
    },
    "9a324039-2611-4433-821d-588c822c831f": {
        "text_answer": "Yes The evidence states that patients with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that is abnormal in the opinion of the treating Investigator or unstable angina are excluded from the primary trial The secondary trial also excludes patients with uncontrolled cardiovascular",
        "label": "Entailment"
    },
    "849dbfea-186a-4983-b7a3-616679e3f2ec": {
        "text_answer": "  No The statement is not entailed by the evidence as the primary trial measures changes in pain intensity up to 30 minutes after dosing and the secondary trial measures the change from baseline to 9 months in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "da01cb99-7533-4cb5-ae01-16453c94cc7e": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports the change in Ki67 expression not the change in tumor diameter The statement makes an unsupported assumption about the relationship between Ki67 expression and tumor diameter",
        "label": "Contradiction"
    },
    "25f976a2-8a79-469f-90a3-6b9922382c76": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the MTD for the MM111 intervention in the secondary clinical trial The evidence only states that the MTD for the primary clinical trials ruxolitinib intervention is determined based on the number of patients who experience doselimiting toxicity DLT and the observation period is up to 8 weeks The statement about the",
        "label": "Contradiction"
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "text_answer": "yes with the caveat that the statement specifically mentions PR Primary Breast Cancer while the evidence only mentions HER2 primary breast cancer without specifying the hormone receptor status However if we assume that all participants in the trial had HER2 breast cancer and some also had PR status then the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "d7f83dbb-ef9c-455b-a692-e99eefcddb05": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial records no aes as being general symptoms is entailed by the evidence because none of the adverse events listed under General symptom are present in the evidence",
        "label": "Entailment"
    },
    "09819b6e-961a-47cf-9112-c43434e9ac19": {
        "text_answer": "No  Explanation  The statement birc5 antibody is any immunoglobulin that recognizes baculoviral iap repeatcontaining protein 5 is not related to the evidence provided in the text The evidence only discusses the outcome measurements and results of two clinical trials one for triple negative breast cancer and metastatic urothelial cancer using SG and another for breast and ovarian",
        "label": "Contradiction"
    },
    "0ad73758-1efb-46e4-85e7-57dbfb5eb96d": {
        "text_answer": "  Yes the patient is eligible for both trials based on the provided information However its important to note that the statement about the patient having a gastric lymphangioma is not mentioned in the evidence and does not affect their eligibility",
        "label": "Entailment"
    },
    "0eba9989-3611-49a8-958f-ea696ba94b3e": {
        "text_answer": "No  Explanation The evidence provides the median PFS for each treatment group not the longest PFS for an individual patient",
        "label": "Contradiction"
    },
    "85645da7-cf87-4b4d-a5eb-cab03a857cc4": {
        "text_answer": "Yes The primary trial and secondary trial have different outcome measurements TEAEs vs objective response",
        "label": "Entailment"
    },
    "b56bc509-6ed3-4125-9587-407192b9b597": {
        "text_answer": "No  Explanation The evidence provided in the trial results only reports the number of participants who were emesisfree during the study period for each group It does not provide any information about the occurrence of dysuria or other conditions for any of the participants Therefore the statement about all patients receiving the placebo intervention experiencing emesis is not entailed by the evidence",
        "label": "Contradiction"
    },
    "f319d5bf-32fd-4505-aff1-02caa718676a": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly reflects that no adverse events were recorded for both trials in the given evidence However its important to note that the absence of adverse events being reported does not necessarily mean they did not occur but rather that they were not recorded in the provided data",
        "label": "Entailment"
    },
    "30988df5-0397-4199-ba63-0b95f1c0f4f5": {
        "text_answer": "No  The evidence states that there were no adverse events reported in either cohort of the primary clinical trial The statement suggests that there were adverse events reported in both cohorts but the evidence does not support that claim",
        "label": "Contradiction"
    },
    "21e44cc9-f3ce-47b3-ace5-69718677308e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ab9018bd-df48-4ece-81d0-d85fee09a2f5": {
        "text_answer": "No  Explanation  The statement provided is not entailed by the evidence because the evidence does not provide any information about the specific types of adverse events being referred to in the statement The statement only mentions Adverse Events 1 but the evidence includes information about multiple types of adverse events labeled as Adverse Events 1 and Adverse Events 2 in each trial Therefore it is not possible to determine if the",
        "label": "Contradiction"
    },
    "25428be5-61e7-46d0-b713-8e831229abeb": {
        "text_answer": "Yes The secondary trial includes the requirement of a functional ECOG  2 status which is a performance status condition not explicitly mentioned in the primary trials inclusion criteria",
        "label": "Entailment"
    },
    "a7d9d7dd-1f13-4a0e-883c-b322ed8780dd": {
        "text_answer": "  No the statement is not entailed by the evidence The primary clinical trial excludes patients with potassium levels outside the normal range 35 mEqL while the secondary clinical trial does not mention any potassium level requirements",
        "label": "Contradiction"
    },
    "6046015d-1954-4914-aa65-98ca575e4936": {
        "text_answer": "No  Explanation  The statement in the primary trial only a single cohort receives armodafinil po daily and in the secondary trial all patients receive the same 01 grams dose of pdr001 and 1 mgkg dose of mcs110 is not entailed by the evidence  In the primary trial there are two interventions one with placebo and one",
        "label": "Contradiction"
    },
    "e876c279-ae1c-4e26-a25b-4da7222957bf": {
        "text_answer": "No  The primary and secondary trials both have inclusion and exclusion criteria related to performance status Karnofsky score Zubrod performance score organ and marrow function and life expectancy",
        "label": "Contradiction"
    },
    "593797dd-ff0f-46e5-ab50-0ea8d49fc4ad": {
        "text_answer": "Yes The evidence states that there are two interventions one for adult cancer patients and another for healthy volunteers The statement acknowledges this difference in health status and cancer presence",
        "label": "Entailment"
    },
    "5d9fff0a-de7b-45a9-843f-7d083ef11b11": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not support the statement as it only reports the number of participants in each group who completed the study with recurrencefree survival not the total number of individuals who experienced recurrencefree survival during the entire 5year time frame The statement suggests a higher number of individuals in the NaCl 09 3ml group had recurrencefree survival but the evidence does not provide",
        "label": "Contradiction"
    },
    "e2551c0f-9b6a-4d0c-9f11-b5e301d7ff3c": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial numerous psychiatric side effects were observed such as an eating disorder and schizophrenia is not entailed by the evidence provided The evidence only mentions suicidal ideation as a psychiatric side effect and it occurs in only one participant out of 50 There is no mention of an eating disorder or schizophrenia in the evidence",
        "label": "Contradiction"
    },
    "abf0f2b7-e989-49e0-82a7-7a2c594e1185": {
        "text_answer": "No   Explanation   The statement patients with stage 1 cancer are not eligible for the secondary trial but are ineligible for the primary trial is not entailed by the evidence provided   The primary trial includes patients with stage IIbIIIIV breast cancer while the secondary trial includes patients with a diagnosis of breast cancer a life expectancy of at least 1 year and a mass on clinical or radiological",
        "label": "Contradiction"
    },
    "658a645c-05f8-456d-be67-c5b7b6d427da": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b8c7a9f1-a31e-4be6-a0ff-9452728c2e0c": {
        "text_answer": "  Yes for the primary trial pulmonary embolism is a reason for exclusion within 60 days  Maybe for the secondary trial the decision is left to the investigator",
        "label": "Entailment"
    },
    "f312eb67-0141-4a7b-a9a4-476a92c32484": {
        "text_answer": "No  Explanation  The statement the doses of lenalidomide used in the primary trial are equivalent to the doses of lapatinib used in the secondary trial for intervention 1 is not entailed by the evidence Lenalidomide is given at a dose of 5mg orally daily for 57  3 days while lapatinib is given at a dose of 1500mg or",
        "label": "Contradiction"
    },
    "2ecb5932-45c6-491c-9b9f-01ab02877f78": {
        "text_answer": "Yes  Explanation  The evidence does not report any psychiatric events in the adverse events for either trial Therefore at most one psychiatric event was recorded during the primary clinical trial as stated",
        "label": "Entailment"
    },
    "12954a74-e631-4318-ac00-0d09fd49e34a": {
        "text_answer": "Yes The evidence does not specify any requirement for abstinence for men who have undergone vasectomy",
        "label": "Entailment"
    },
    "4bcd8725-f138-49c8-b6a9-4f0c6eaa756f": {
        "text_answer": "No  The most frequently documented adverse event in the primary clinical trial was nausea or vomiting each occurring in 392 of patients Coronary artery stenosis was not mentioned as an adverse event in the evidence provided",
        "label": "Contradiction"
    },
    "2af8d00f-e0b6-4555-b649-796186334803": {
        "text_answer": "No   Explanation   The statement unresectable malignant glomus tumor is a malignant glomus tumor that is not amenable to surgical resection is not directly related to the evidence provided The evidence only mentions the intervention for cohort 1 of the primary trial which includes watching an educational DVD and meeting with a lay health advisor It does not mention anything about the type of tum",
        "label": "Contradiction"
    },
    "a6ee28c9-2b3a-47a6-b576-8ca75d38fb67": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 100 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that there were 3 hepatotoxicity cases 1 hypertension case and 1 pancreatectomy case making a total of 5 cases One hundred times the",
        "label": "Contradiction"
    },
    "ad9fe1aa-9798-4c53-ab23-23ac2924918c": {
        "text_answer": "No  Explanation The statement patients participating in the primary trial receive 2000 mgm2 oral lapatinib twice a day for a full month is not entailed by the evidence The evidence states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the dosage of lapatinib as 2000 mgm2 twice a day",
        "label": "Contradiction"
    },
    "fb67edbe-9758-4e64-acd0-263fe51ba74a": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 90mg of mcs110 every 2 weeks is entailed by the evidence since 1 mgkg given every 3 weeks Q3W for a 70kg patient translates to 210mg every 6 weeks which is more than 90mg every 2 weeks Similarly the statement and over 1",
        "label": "Entailment"
    },
    "1b4c8f0a-2d3e-40d3-b26a-426a4f32cb86": {
        "text_answer": "Yes The statement about grade 1 uveitis being an eligible condition and the mention of Women of ChildBearing Potential WOCBP and sexually active fertile men being eligible with the requirement of abstinence during the study period are both present in the evidence",
        "label": "Entailment"
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "text_answer": "Yes for the primary trial No for the secondary trial  Explanation  For the primary trial the evidence describes the interventions as injections of Botulinum Toxin Type A or placebo in the pectoralis major muscle and there is no mention of entericcoated tablets Therefore the statement is entailed by the evidence for the primary trial  For the secondary trial the evidence describes the interventions as oral",
        "label": "Entailment"
    },
    "b6d2381f-f049-4747-ae82-5a9a321ec001": {
        "text_answer": "No  The statement is not entailed by the evidence as the inclusion criteria specify a BMI of 25 kgm2 or greater",
        "label": "Contradiction"
    },
    "2855e123-6fa3-44b7-9eda-09603be206aa": {
        "text_answer": "13 not exactly 50 but the statement implies a percentage of participants so the answer is Yes with the correction",
        "label": "Entailment"
    },
    "e00ad4a5-25b8-4343-a353-be8b2e0d6c1b": {
        "text_answer": "Yes The psychiatric condition is listed as an exclusion criterion in both the primary and secondary clinical trials",
        "label": "Entailment"
    },
    "62a0ed6c-dc2a-4223-9ee0-5b7422bf43da": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore Intraoperative Mammography performed better than the Standard Mammography in this regard is not entailed by the evidence The evidence only shows that the median operative time was shorter in the Intraoperative Mammography group compared to the Standard Mammography group but it does not prove that Intra",
        "label": "Contradiction"
    },
    "d3fe482c-e694-474a-8ba6-f089ea532040": {
        "text_answer": "No  Explanation  The statement none of the adverse events in the secondary trial affected more than 03 fraction of patients is not entailed by the evidence While it is true that none of the adverse events affected more than 3333 of patients which is greater than 03 the statement in the evidence does not make this limitation clear Therefore the statement in the question goes beyond what can be in",
        "label": "Contradiction"
    },
    "348c5cf5-0756-4860-a83f-c9ead81ea4b3": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial patients experienced only three adverse events pancreatitis cholelithiasis and hepatic pain along with febrile neutropenia is not entailed by the evidence provided The evidence shows that there were a total of three adverse events in each of the two trials but it does not specify that those were the only adverse events experienced by patients in",
        "label": "Contradiction"
    },
    "e29a77b0-a7de-44b8-8941-df0979682e4e": {
        "text_answer": "No  Explanation  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not related to the question about smoking The evidence provided only pertains to the number of adverse events in two trials but it does not mention anything about smoking or individuals leaving their houses Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "8849827d-af65-44ae-ad32-b325f502f945": {
        "text_answer": "Yes The primary clinical trial has identical exclusion criteria for all participants but the inclusion criteria vary between study groups",
        "label": "Entailment"
    },
    "b0c426df-6a70-4d19-a120-e3bc56c49918": {
        "text_answer": "No  Explanation The statement healthy individuals not diagnosed with any form of cancer may be eligible for all study groups in the primary trial and the secondary trial is not entailed by the evidence The primary trial only includes postmenopausal women with early stage breast cancer while the secondary trial includes healthy participants and HER2positive females with a history of breast cancer Therefore healthy individuals without breast cancer are not eligible for all study",
        "label": "Contradiction"
    },
    "f9442384-0c19-4ffe-8906-c461b6dda9f7": {
        "text_answer": "No  Explanation  The statement aggravated neurofibromatosis is a condition causing exacerbation of the clinical features of neurofibromatosis is not directly related to the provided evidence The evidence only reports the adverse events observed in two clinical trials and there is no mention of neurofibromatosis or its aggravation in the evidence",
        "label": "Contradiction"
    },
    "5abc6652-31bf-4ac6-a16b-432912aa6224": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary trial lasts 25 more days than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks and the secondary trial lasted for 24 weeks which is not a difference of 25 days Instead the difference is 14 weeks or 98 days",
        "label": "Contradiction"
    },
    "2c95f252-a861-4569-a0b9-c214289da160": {
        "text_answer": "No   Explanation  The evidence provided states that there were no adverse events reported in the primary and secondary trials for Adverse Event 1 and no information was given about Adverse Event 2 in the secondary trial The statement that over 100 adverse events were documented within their study groups is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9040286a-0801-494c-8c17-340323774082": {
        "text_answer": "Yes However its important to note that the statement is not a direct conclusion from the evidence but rather an inference based on the information provided The evidence states that those with inadequate vitamin D levels are excluded from the primary trial but it does not specify what happens to them in relation to the secondary trial The statement assumes that they could be suitable for the secondary trial but this is not explicitly stated in the evidence",
        "label": "Entailment"
    },
    "d4fd7d7a-53f4-4f5d-9640-717e26cbbcd9": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9ab82516-ba60-4c36-908d-5e0e56ec5fba": {
        "text_answer": "Yes  Explanation The statement 2 of patients in the primary trial and the secondary trial suffered from infections during the study period is entailed by the evidence since the evidence shows that 1 patient in the primary trial and 0 patients in the secondary trial suffered from infections and the total number of patients in the primary trial is 32 and in the secondary trial is 15 Therefore the percentage of patients who suffered from infections in both",
        "label": "Entailment"
    },
    "a63b539f-034e-46c2-83e7-9cea8c282e1c": {
        "text_answer": "Yes  Explanation  The statement none of the patients in the primary clinical trial and secondary clinical trial developed infections during the study period is entailed by the evidence because there is no record of any patient in either trial experiencing an adverse event related to an infection",
        "label": "Entailment"
    },
    "46c7e5c7-0834-45dd-952c-872502314fea": {
        "text_answer": "Yes The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes Therefore more than 13 of patients in both cohorts experienced this outcome The molecular pathology report is not directly related to the statement as it is not mentioned in the evidence",
        "label": "Entailment"
    },
    "8c14522c-67de-490a-9be1-1c16d9fca742": {
        "text_answer": "Yes  Explanation The statement is correct that the primary clinical trial provides the total count of participants studied but it is not stated in the evidence how many participants are in each armgroup Therefore the statement is entailed by the evidence but it does not provide new information",
        "label": "Entailment"
    },
    "dce7c1b2-0e43-4c7b-8cc8-6a443fee7135": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it makes an additional assumption about the doses administered in cohort 1 that is not stated in the evidence The evidence only mentions that cohort 1 received a lower dose of ALT801 than cohort 2 but it does not specify the exact amount Therefore the statement goes beyond the information provided in the evidence",
        "label": "Contradiction"
    },
    "2028a7ad-b89f-4927-8e74-db17555763c8": {
        "text_answer": "No  Explanation The evidence describes the eligibility criteria for patients in a primary trial but it does not mention anything about the administration of talazoparib or its dosage to any of the patients Therefore the statement about patients being administered 001 g of talazoparib daily is not entailed by the evidence",
        "label": "Contradiction"
    },
    "7df47095-163a-4062-9b5b-f2dfd02259fb": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as it contains incorrect information regarding the primary trial The primary trial administers 150 mg of oral pregabalin twice daily not 150000 mcg",
        "label": "Contradiction"
    },
    "50ddb312-6c5e-476a-891e-95409d7239c5": {
        "text_answer": "No   Explanation   The primary clinical trial is focused on evaluating the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary clinical trial is focused on evaluating the percentage of participants with adverse events of primary interest AEPIs in patients receiving trastuzumab emtansine Neither trial mentions evalu",
        "label": "Contradiction"
    },
    "18ff2056-f906-4f16-805f-76b4a51b77b7": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trial reports on the MTD of ruxolitinib in combination with paclitaxel for childhood ovarian embryonal carcinoma and the secondary trial reports on the MTD of MM111 for an unspecified condition in children The statement correctly identifies childhood ovarian embryonal carcinoma as the condition of interest and mentions the",
        "label": "Entailment"
    },
    "fc37e929-f3f3-43fb-b0c4-86521a18592f": {
        "text_answer": " Yes the statement is entailed by the evidence for cohort 1 as all 3 participants experienced an adverse event However its important to note that the statement does not specify whether the adverse events were serious or nonserious based on the given evidence",
        "label": "Entailment"
    },
    "bdbbcf1d-df03-4ade-9967-5d9ca8bf9ce8": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the trials use different drugs dosages and frequency of administration The evidence only mentions that intravenous injections are used in both trials",
        "label": "Contradiction"
    },
    "69407358-a579-43ba-8b78-b75d7aebb163": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial reports on the MTD of ruxolitinib in combination with paclitaxel and the secondary trial reports on the MTD of MM111 which is a different intervention The statement correctly identifies that both trials report on the MTD of different interventions Additionally the statement correctly states that the MTD of MM111 is 15 mg per day",
        "label": "Entailment"
    },
    "21a1ddb1-0d37-41e5-a08f-a7e9dc5b15ef": {
        "text_answer": "Yes  Explanation  The primary trial and the secondary trial are studying different drugs Extimia versus empegfilgrastim different dosages 6 mg and 75 mg versus 3 mg and 6 mg and different outcome measurements duration of neutropenia versus incidence of neutropenia Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "d14fe83a-0130-4c37-a55d-30ec0ecacdb1": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly support the statement given The statement suggests a specific percentage decrease in recurrencefree survival rate between the two groups but the trial results only provide the number of participants in each group and their respective percentages of recurrencefree survival To determine the percentage difference in recurrencefree survival rates additional information such as the number of recurrences or deaths in each group is",
        "label": "Contradiction"
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the secondary trial does not have different inclusion criteria for different age groups The evidence only mentions the inclusion criteria for the primary trial which does have different criteria for different age groups The secondary trial has its own unique inclusion and exclusion criteria that are not specified in the evidence",
        "label": "Contradiction"
    },
    "8d16932d-a485-4c58-828e-70f805bd82ef": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2af38d73-ba19-4aa1-a571-5a576b4af7e3": {
        "text_answer": "No  Explanation The statement is not directly entailed by the evidence as it provides additional information not present in the evidence The statement mentions the genus Lactococcus which is not mentioned in the evidence The evidence only states that there was one adverse event in the primary trial without specifying the causative agent",
        "label": "Contradiction"
    },
    "504dd694-4978-41f0-bee5-ccc6dd199752": {
        "text_answer": "No   Explanation  The statement is not related to the inclusion or exclusion criteria of the primary or secondary trials The statement is about white fiber which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "text_answer": "Yes  Explanation The evidence states that there was a significant change in Ki67 expression in tumors with 7 days of presurgical tamoxifen use with an average percentage change of 40 63 to 29 The statement in question accurately reflects this finding",
        "label": "Entailment"
    },
    "ddafc0fa-fb54-4729-8c01-97cb30f293ed": {
        "text_answer": "Yes The evidence states that neither cohort received fulvestrant during the primary clinical trial and paclitaxel was not mentioned in the given information",
        "label": "Entailment"
    },
    "c638fd13-e832-4bc6-9b3a-ad9d8da4b1c4": {
        "text_answer": "No  Explanation  The statement there are 10 shared inclusionexclusion criteria between the secondary trial and the primary trial is not directly entailed by the evidence provided The evidence only mentions that there are inclusion and exclusion criteria for each trial but it does not specify the number or identity of the shared criteria",
        "label": "Contradiction"
    },
    "a0e45f2f-6f88-496e-9b14-2fe595be1286": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial less than 10 of patients experienced one psychiatric adverse event is entailed by the evidence since the total percentage of patients who experienced any adverse event is 1200 and only one of those adverse events was a psychiatric event suicidal ideation Therefore less than 10 of patients experienced a psychiatric adverse event",
        "label": "Entailment"
    },
    "176093eb-7c7f-4bca-80e2-566d4a135c47": {
        "text_answer": "No  Explanation  The statement none of the adverse events in the secondary trial affected more than 30 of patients is not entirely accurate based on the provided evidence While it is true that none of the adverse events affected more than 3333 of patients individually the aggregate percentage of patients affected by any adverse event is 3333 1030 which is above the stated threshold",
        "label": "Contradiction"
    },
    "6654ce22-9470-43d1-9e51-a17f1a06f514": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases Therefore it is entailed that 5 1349 x 005  0028 or approximately 3 participants of the participants with HER2 primary breast cancer developed HER2 metastases",
        "label": "Entailment"
    },
    "dd5fcab9-ef7e-4f25-8040-81c0dd57aab5": {
        "text_answer": "Yes  Explanation The statement the first subgroup in the primary clinical trial reported various cases of anaemia and febrile neutropenia but registered no instances of pancytopenia is entailed by the evidence as the first subgroup had 1 case of anaemia and 1 case of febrile neutropenia and no cases of pancytopenia were reported",
        "label": "Entailment"
    },
    "0f0ccab9-517a-44e5-8dda-96d1cb9ead51": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the evidence describes the administration routes for the placebo and trabectedin in the clinical trial but it does not specify that the placebo is administered orally or that trabectedin is injected directly into the bloodstream The evidence only states that the placebo was given as a 3hour intravenous infusion on Day 1 and trabected",
        "label": "Contradiction"
    },
    "4527cc06-b4b2-4ebe-bba4-6f4e845b2984": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the number of drugs in the interventions and the type of neoplasm are different between the primary and secondary trials The primary trial involves a single drug ZD1839 while the secondary trial involves at least 3 different drugs including Zoledronic acid Samarium153 and calcium supplements The statement only mentions the number of",
        "label": "Contradiction"
    },
    "87a0c1c5-507a-4188-87cf-57f27add4cf6": {
        "text_answer": "No   Explanation   The statement Candidates for the secondary trial study group receive weekly subcutaneous SC injections whereas the primary trial participants do not receive any injections is not directly entailed by the evidence provided The evidence only mentions that the primary trial participants do not receive any interventions related to vitamin D repletion and the secondary trial participants receive epoetin beta injections It does not mention anything",
        "label": "Contradiction"
    },
    "a9faa655-1f16-41b0-911e-0a560a1c1dc0": {
        "text_answer": "Yes  Explanation  The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in less than 2 of participants is entailed by the evidence since the evidence shows that in both trials the number of adverse events was 0 and the percentage of participants with adverse events was less than 2",
        "label": "Entailment"
    },
    "fc1a7234-bf6c-4c29-9a82-eccacb0d4766": {
        "text_answer": "Yes  Explanation The Contour Profile Tissue Expander intervention in the primary trial mentions that ultrasound is used to monitor the expansion process In the secondary trial both interventions AlloMSCs and Placebo involve transendocardial injections of 04ml solution administered to the left ventricle via NOGA Myostar injection catheter and the procedure is described as guided",
        "label": "Entailment"
    },
    "78cbe5c1-69a4-4194-9d3c-06b5f4b9af0b": {
        "text_answer": "yes but with qualification the statement implies a difference in the percentage point change between the two groups while the evidence only provides the percentages themselves To determine the exact difference you would need to subtract the percentage for the TN group from that of the ER group",
        "label": "Entailment"
    },
    "46669c3d-c42d-4b23-b8c5-256374e53cf1": {
        "text_answer": "No  Explanation  The statement fewer than 10 subjects experienced adverse events is not directly entailed by the evidence The evidence states that there were 2 adverse events out of 35 subjects which is equivalent to 571 This is not the same as saying that fewer than 10 subjects experienced adverse events",
        "label": "Contradiction"
    },
    "191f4ac8-16c9-4be8-895f-4383c3d6f7b5": {
        "text_answer": "Yes The primary clinical trial has a continuous approach to PF05212384 administration within a 21day cycle while the secondary clinical trial follows a strict 2week cycle for mammography procedures",
        "label": "Entailment"
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "text_answer": "No  Explanation  The statement Gender is not a determining factor for eligibility in the primary trial or the secondary trial is not entailed by the evidence The evidence clearly states that the primary trial includes male subjects and postmenopausal female subjects while the secondary trial includes only women Therefore gender is a determining factor for eligibility in both trials",
        "label": "Contradiction"
    },
    "a220e90b-6fd7-449f-878a-f870cd360de6": {
        "text_answer": "No   Explanation   The primary trial includes a criterion that the primary tumour must be greater than 2 cm in diameter while the secondary trial does not have a specific criterion regarding the size of the primary tumour Therefore a patient with a primary tumour of 100mm in diameter as measured by clinical examination and echography would not be eligible for both trials based on the given evidence",
        "label": "Contradiction"
    },
    "51c9a1a4-9242-4880-b61e-b42a45b9017d": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions in the trial administer the same dosage of nabPaclitaxel 125 mgm2 but differ in the use of gemcitabine versus carboplatin",
        "label": "Entailment"
    },
    "d09f927d-29c3-4370-a258-400c79f366fe": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention the number of patients who experienced no pain whatsoever during the study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose groups",
        "label": "Contradiction"
    },
    "421278d5-9ece-4425-b5b0-390cc6844de8": {
        "text_answer": "No  Explanation  The statement teenage pregnancy is a pregnancy in an adolescent between the ages of thirteen and nineteen is not related to the evidence provided The evidence only discusses the details of two clinical trials one testing the effects of different gels Hydrophor and MediHoney on patients undergoing radiation therapy and the other testing the effects of different doses 90 mg and 110 mg of",
        "label": "Contradiction"
    },
    "34b09027-2195-448e-ab3d-fb9d5a91301a": {
        "text_answer": "Yes  Explanation The statement in the patient groups of the primary and secondary clinical trials a total of three shingles cases were identified is entailed by the evidence as it can be calculated by adding the number of shingles cases in each trial 1 in the primary trial and 1 in the secondary trial",
        "label": "Entailment"
    },
    "3de2cfe2-e886-45d3-a5fe-135005821732": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ef7f4f02-ea16-458a-a225-875758ac5d1f": {
        "text_answer": "No  Explanation  The statement there were no documented psychiatric adverse events in the primary clinical trial is not entailed by the evidence because the evidence reports one documented case of suicidal ideation a psychiatric adverse event in the trial",
        "label": "Contradiction"
    },
    "81651022-ae46-4e69-aa0b-1e1d576845ce": {
        "text_answer": "No  Explanation  The statement about the ERBB2 gene mutation is not directly related to the inclusion or exclusion criteria for the primary trial The trial criteria focus on the patients disease status organ function and previous chemotherapy treatment while the statement is about a specific genetic mutation",
        "label": "Contradiction"
    },
    "c0267bfa-8985-4097-b6ba-0b908f4c46c5": {
        "text_answer": "No  Explanation  The evidence provided in the inclusion criteria states that patients with some evidence of cognitive impairment are eligible for the trial but it does not specifically mention Frontotemporal dementia or Mixed dementia as acceptable conditions Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "7f128ec3-a88f-4cbe-9d79-0ef9e0f1d3bd": {
        "text_answer": "No  Explanation  The statement Patients diagnosed with breast cancer may be eligible for all study groups in the primary trial and the secondary trial is not entailed by the evidence provided The primary trial and the secondary trial have different inclusion and exclusion criteria and patients diagnosed with breast cancer may not meet all the criteria for both trials The statement also does not mention anything about fallopian tube soft tissue neoplasms which are not related to breast",
        "label": "Contradiction"
    },
    "58acb205-1f9d-4dd2-9405-720b28f8581f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not provide information about radiation treatment being administered in either trial The primary trial involves the use of eribulin mesylate and correlative studies while the secondary trial involves the use of axitinib and docetaxel There is no mention of radiation treatment in either trial",
        "label": "Contradiction"
    },
    "fe4e3c5a-b190-4733-930a-abc0bfd29625": {
        "text_answer": "No  Explanation  The statement have felt unusual weakness is a question about whether an individual feels or felt unusual weakness is not directly related to the adverse events listed in the evidence The evidence only provides information about specific adverse events anemia leukopenia neutropenia thrombocytopenia febrile infection genital infection female pneumonia cancer pain stupor coma",
        "label": "Contradiction"
    },
    "a9292fc9-f444-4e0a-8db1-c2a6ad9a7062": {
        "text_answer": "No  Explanation  The statement The patient with the longest PFS in the primary trial survived 35 months without disease progression or death is not directly entailed by the evidence provided The evidence only reports the median PFS for each treatment group not the longest PFS observed in the trial",
        "label": "Contradiction"
    },
    "c5315113-8bc1-47d5-b1f7-ca7d59ab9cc4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of myalgias being administered in the primary trial or related to achondrogenesis in the secondary trial The statement only mentions myalgias in relation to dexmedetomidine administration in the primary trial but the secondary trial does not involve dexmedetomidine Additionally the statement brings up achondrogenesis",
        "label": "Contradiction"
    },
    "67a7f848-e9e5-46be-a37b-f0e46e643dcb": {
        "text_answer": "No  Explanation The statement patients participating in the primary trial receive 25 mmml oral lapatinib twice a day for a half month is not entailed by the evidence The evidence states that patients receive oral lapatinib and tamoxifen once daily on days 128 but it does not specify the dosage or frequency of the lapatinib dosage as 25 mmml twice a day",
        "label": "Contradiction"
    },
    "57e2cf8a-6c67-4771-b180-70b613fff1cc": {
        "text_answer": "Yes The evidence states that patients in both trials will be receiving 4demethyl4cholestryloxycarbonylpenclomedine as part of their treatment and the statement affirms that patients are required to participate in a weekly cycle of this drug",
        "label": "Entailment"
    },
    "9b2a47ba-246e-4591-bf68-90c7124f800b": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial mentions weekly injections of an unspecified intervention for patients with joint aches and vitamin D deficiency while the secondary trial mentions weekly injections of epoetin beta for anemic breast cancer participants The statement incorrectly assumes that both trials involve a onetime injection",
        "label": "Contradiction"
    },
    "45f78c14-258f-4db0-a0f4-10a46761ae2f": {
        "text_answer": "Yes The statement mentions the primary trial measuring changes in pain intensity and the secondary trial measuring changes in bone mineral density which is consistent with the information provided in the evidence The supplemental qualifiers dataset is not directly mentioned in the evidence but the statement does not contradict it either",
        "label": "Entailment"
    },
    "475a8280-5855-4c8c-a9ca-7720f9a9be7f": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the Karnofsky score requirement for the primary trial is 70 not 55 as stated in the statement",
        "label": "Contradiction"
    },
    "dfc09a24-8631-4fa3-893e-4d10a9bac4b8": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide information about the specific doses administered to patients in the primary trial for each cancer type in a single sentence or statement The evidence provides separate information about the doses administered to breast cancer and ovarianperitoneal cancer patients in different parts of the trial",
        "label": "Contradiction"
    },
    "f5ae88a3-a083-405e-b3a8-282018d7f013": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions that individuals who have received antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry are not eligible for the trial",
        "label": "Entailment"
    },
    "80cb39bd-c370-4e7f-8f19-74725fed8805": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "text_answer": "  No The statement is not entailed by the evidence The primary trial requires mammography but the secondary trial does not mention any specific imaging modality as a requirement before participation",
        "label": "Contradiction"
    },
    "99942306-e4cf-4405-80ca-914e689aef75": {
        "text_answer": "No  Explanation The evidence provided states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR However the statement claims that more than half of the patients recorded a confirmed complete response CR This is not entailed by the evidence",
        "label": "Contradiction"
    },
    "d86f5f0a-32ec-4943-912f-9945c1cfe06f": {
        "text_answer": "Yes The statement that there were no cardiac or psychiatric AEs recorded during the primary trial and the secondary trial is entailed by the evidence which reports that the total number of cardiac and psychiatric AEs for both trials is 0",
        "label": "Entailment"
    },
    "deba63cb-52ea-4b46-ad50-8cef93d8c5fd": {
        "text_answer": "No   Explanation  The statement there is evidence of anorexia hypothermia or hallucinations in the aes of the secondary clinical trial is not entailed by the evidence provided The evidence only states that there were no reported cases of anorexia hypothermia or hallucinations in the primary and secondary clinical trials The absence of evidence does not imply the evidence of absence of these conditions",
        "label": "Contradiction"
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "text_answer": "Yes  The secondary trial includes patients undergoing lumpectomy a type of breast surgery also mentioned in the primary trial",
        "label": "Entailment"
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "text_answer": "No  Explanation  The statement There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only mentions the number of participants in each cohort for both trials but it does not provide any information about a significant difference between those numbers",
        "label": "Contradiction"
    },
    "5145d91d-ce46-4dda-961e-5bc7ddb6cda4": {
        "text_answer": "yes The primary trial measures treatmentemergent adverse events AEs while the secondary trial measures total sleep time",
        "label": "Entailment"
    },
    "d8d5125b-399a-4b78-b033-9603bfe8011e": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "78865c57-db3b-4fbe-ab87-1f2d11f2c091": {
        "text_answer": "No  Explanation The statement patients participating in the primary trial receive 50 kgm2 oral lapatinib once a day for a full month is not directly entailed by the evidence The evidence only specifies that patients receive oral lapatinib and tamoxifen once daily for 28 days but it does not provide the exact dosage of lapatinib for each patient Therefore it is possible that the dosage is",
        "label": "Contradiction"
    },
    "ac14720a-7525-4fb0-b261-0ec5c818f85f": {
        "text_answer": "  No The primary trial only includes male patients but the secondary trial includes female patients",
        "label": "Contradiction"
    },
    "44daf0ed-4b1a-4e95-aae4-71722fad8f09": {
        "text_answer": "  Yes The evidence states that women of childbearing potential WOCBP and sexually active fertile men are eligible for the trial but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab This requirement is a form of additional requirement related to the dosing unit of being sexually active and fertile",
        "label": "Entailment"
    },
    "1da40d20-026a-4b22-8e6c-8943e0180ed7": {
        "text_answer": "Yes for the primary trial only as the secondary trial does not mention anything about pulmonary embolisms",
        "label": "Entailment"
    },
    "6b6d3087-435b-4129-b368-29d8879f7ff4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it introduces an unrelated topic nasal cartilage which is not mentioned in the evidence The evidence only discusses the intervention and control groups in the primary trial with the intervention group viewing an educational DVD and the control group receiving usual care",
        "label": "Contradiction"
    },
    "6acd26e7-8103-4b23-aa31-413998ccbde6": {
        "text_answer": "No   Explanation  The evidence states that the patient participants in the primary clinical trial receive oral lapatinib and oral tamoxifen daily for 28 days not an intravenous dose of lapatinib",
        "label": "Contradiction"
    },
    "14954e3a-d984-46dc-af8d-29f22c0ca85e": {
        "text_answer": "  Yes The statement about patients with clearcell adenocarcinoma or gestational trophoblastic disease being ineligible for both trials is not explicitly stated in the evidence but it can be inferred from the inclusion criteria of the primary trial which lists those conditions as types of solid tumors that are eligible for the study Therefore patients with those conditions are excluded from both trials Similarly pagets disease of the nipple is also listed",
        "label": "Entailment"
    },
    "f2bac26a-95c8-4ac8-8356-26c3d96e8797": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fdc7efac-ca90-4897-9660-a42dbba2bd84": {
        "text_answer": "Yes  Explanation The evidence shows that during the fourth week of the primary clinical trial the azd0530 175 mg group had a greater percentage change in betaCTX compared to the zoledronic acid 4 mg group This is indicated by the negative percentage change values and their corresponding confidence intervals in the results section The statement in question accurately reflects this finding",
        "label": "Entailment"
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "text_answer": "Yes   Explanation  The statement None of the individual adverse event types recorded in the primary trial affected more than one patient is entailed by the evidence because each adverse event type is recorded as having affected only one patient in the trial",
        "label": "Entailment"
    },
    "74178d28-3c60-4439-944a-84318eff5c92": {
        "text_answer": "No  Explanation The statement a patient that has received an organ transplant within the last month and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed by the evidence provided The evidence only mentions that adequate liver function is a requirement for both trials but it does not specify any restrictions related to organ transplants or bedridden status",
        "label": "Contradiction"
    },
    "69959fb0-ee1c-4fb2-a968-677802eb1c82": {
        "text_answer": "No  Explanation  The statement 72 more participants in the ERpositive Luminal B group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide the actual number difference between the two groups To determine if there is a ",
        "label": "Contradiction"
    },
    "f43219f1-3807-4c37-9240-bf1d9f54d5e8": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial explicitly excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug but it does not mention anything about pulmonary embolism specifically within 5 days However the secondary trial does not mention any specific exclusion related to pulmonary embolism",
        "label": "Contradiction"
    },
    "987667fb-e888-40d7-ab77-f0138d9295ba": {
        "text_answer": "No  Explanation  The statement the primary trial has a higher presence of biliary colic and clostridium difficile colitis compared to the secondary trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events in each trial but it does not provide enough information to make a comparison between the two trials regarding the presence or absence of specific adverse events In this case the statement is not",
        "label": "Contradiction"
    },
    "02da2719-af96-4d84-bf69-ac1a2d6fd01c": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial less than 5 of the participants experienced adverse events is entailed by the evidence since the total number of adverse events was 2 out of 35 participants which is equal to 571 but less than 5",
        "label": "Entailment"
    },
    "f3a4ac87-2a6b-476f-91e2-b056e231f20a": {
        "text_answer": "No  Explanation  The evidence provided in the given text does not indicate whether or not the patients in cohort 1 and 2 demonstrated a clear pattern for the expression of the set of 40 evaluated genes The text only reports the correlation of vitamin D levels with classic prognostic and predictive factors and the gene expression profile but it does not provide any information about the presence or absence of a clear pattern for gene expression in these",
        "label": "Contradiction"
    },
    "cfcfc39b-c969-474d-b85c-090dda68b1f1": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial and secondary clinical trial saw no instances of cardiac or psychiatric adverse events is entailed by the evidence since the evidence reports that there were no instances of cardiac or psychiatric adverse events in both trials",
        "label": "Entailment"
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "text_answer": "No  Explanation  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is not entailed by the evidence The evidence only provides the number of adverse events for each trial but it does not specify the number of cases for Bronchopneumonia and General physical health deterioration in the primary trial Therefore it is not possible to make a direct comparison",
        "label": "Contradiction"
    },
    "4bebbb9f-9a62-4b07-b91a-1321f312229e": {
        "text_answer": "No  Explanation  The statement the findings from the primary clinical trial show that the arm c intervention resulted in the highest overall response rate and in the secondary clinical trial the denosumab group showed an improved time to first onstudy sre in comparison to the zoledronic acid group is not directly entailed by the evidence provided  The evidence only reports the results of the primary and secondary clinical trials including the overall response",
        "label": "Contradiction"
    },
    "5e7e3d88-6a13-4849-bad5-4ac52b100140": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "bd6fc353-2823-4e35-b811-a19c8318fda4": {
        "text_answer": "No  Explanation  The statement the primary clinical trial had a larger participant count than the secondary clinical trial is not entailed by the evidence provided The primary trial had 13 participants and the secondary trial had 30 participants but the statement does not correctly compare the sizes of the two trials",
        "label": "Contradiction"
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial measures the number of participants with treatmentemergent adverse events at the end of Cycle 1 while the secondary trial measures the change in total sleep time in minutes before and after the first cycle of Lenalidomide treatment The two trials are evaluating different outcome measures",
        "label": "Contradiction"
    },
    "ef186582-5995-47ca-a190-616f94342715": {
        "text_answer": "  Children and adolescents are not explicitly excluded from the secondary trial Yes However they may not meet the age requirement for the primary trial The statement about urethral infection is not directly related to the inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "53459054-8f8c-4fd1-9d1f-2f109c45c5b8": {
        "text_answer": "Yes  Explanation  The statement the count of total adverse events in the secondary clinical trial was notably less than what was documented in the primary clinical trial is entailed by the evidence since the evidence shows that the count of total adverse events in the secondary clinical trial 015 or 000 is indeed less than the total adverse events in the primary clinical trial 00 which is undefined",
        "label": "Entailment"
    },
    "25c8668a-29f5-4bf0-9c35-89ba2e5e1776": {
        "text_answer": "Yes  Explanation  The statement ovarian rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the ovaries is not directly related to the adverse events data provided in the evidence However the evidence does state that the secondary trial recorded 11 more adverse events than the primary trial This fact is entailed by the evidence and the statement is true",
        "label": "Entailment"
    },
    "2cc63d25-8209-41a8-b9a3-fcc4af6d9caa": {
        "text_answer": "No  Explanation  The statement patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer is not directly entailed by the evidence provided The evidence states that in Phase 2 patients with breast cancer must be ER positive andor PR positive but HER2 negative and have failed a hormone therapy and a CDK46 inhibitor to be eligible Therefore",
        "label": "Contradiction"
    },
    "fe0da901-6c2a-4ae8-b35f-a3090f93f12d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about the occurrence or absence of rectal necrosis or CTCAE in the cohorts The statement only mentions rectal necrosis and CTCAE in relation to a disorder but the evidence does not discuss any disorders or adverse events related to the trial beyond the administration of CUDC101 and PD",
        "label": "Contradiction"
    },
    "eab52a37-149f-4b49-bf37-891e8e201956": {
        "text_answer": "Yes The statement does not explicitly mention the specific condition being studied in the trial but it does correctly describe the paced breathing intervention being the same for both cohorts with the only difference being the frequency of practice",
        "label": "Entailment"
    },
    "b17ff44f-d9dc-4be7-b087-4329493d1c95": {
        "text_answer": "No   Explanation   The statement 7q21q221 is a chromosome band present on 7q is not related to the evidence provided The evidence only mentions the number of participants in the primary trial and the vaccine they received",
        "label": "Contradiction"
    },
    "94ccff26-4026-4888-9ef8-2af5aaebefad": {
        "text_answer": "No  Explanation  The statement the frequency of palpitations pericardial effusions and abdominal pains in cohort 1 of the secondary trial exceeded those in cohort 2 of the primary trial is not entailed by the evidence provided The evidence only shows that there were no adverse events reported in cohort 2 of the secondary trial while there were palpitations pericardial eff",
        "label": "Contradiction"
    },
    "94e5871f-085c-4757-9941-3c83a71da6a4": {
        "text_answer": "No  Explanation  The statement the data from the primary clinical trial reveals that the arm d intervention had the superior overall response rate is not directly entailed by the evidence provided The evidence only shows that in the primary trial 676 of participants in Arm A Epirubicin and Cyclophosphamide followed by Docetaxel and Capecitabine achieved an overall response compared to 60",
        "label": "Contradiction"
    },
    "c70735d3-1bc3-41d8-b0d3-15a49abe4862": {
        "text_answer": "No  Explanation The statement the participant with the highest PFS in the primary clinical trial was able to survive for 35 months without progression of disease or death is not directly entailed by the evidence provided The evidence only reports the median PFS for each treatment group not the longest PFS observed in any individual participant",
        "label": "Contradiction"
    },
    "f0278adc-ef45-43ab-b957-d26918e3a5e2": {
        "text_answer": "Yes for the secondary trial only The primary trial does not mention gabapentin or pregabalin as exclusion criteria However the secondary trial explicitly states that prior use of these medications is a reason for exclusion",
        "label": "Entailment"
    },
    "11d451c7-7354-44f6-95b4-2b794a72fdbb": {
        "text_answer": "No  Explanation The statement the intervention in the secondary trial lasts 300 longer than the intervention detailed in the primary trial is not entailed by the evidence The primary trial lasted for 10 weeks while the secondary trial lasted for 24 weeks However the difference is not 300 but rather a factor of 24 24 weeks  10 weeks",
        "label": "Contradiction"
    },
    "ef2bc415-dff4-4732-8e34-f538b570c671": {
        "text_answer": "Yes The evidence mentions that the intervention does not include surgical and imaging procedures implying that psychosocial interventions are the focus",
        "label": "Entailment"
    },
    "2a3d4de3-5604-4959-8a60-2817faeee2b8": {
        "text_answer": "Yes  Explanation The evidence states that both the placebo and the alloMSCs interventions involve 20 transendocardial injections of 04ml each Therefore the dosage level 04ml per injection and the number of injections are the same for both interventions The statement is entailed by the evidence as it correctly describes the administration method and dosage level for both interventions in the trial",
        "label": "Entailment"
    },
    "8948d41b-0742-43f8-a34f-2e1cfcaba149": {
        "text_answer": "No  Explanation  The statement the intervention in the secondary trial lasts 2520 more hours than the intervention detailed in the primary trial is not entailed by the evidence provided The primary trial involved a weekly reflexology session for 10 weeks which amounts to 450 minutes or 75 hours per week The secondary trial involved a weekly medication administration for 24 weeks which amounts to 24 x",
        "label": "Contradiction"
    },
    "6ca72b87-353a-4ef1-89d7-b9a5bad97c27": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "4d384e46-7119-49f9-a627-0301c32ee334": {
        "text_answer": "  No The primary trial measures changes in pain intensity up to 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "text_answer": "Yes  Explanation The statement There was at least 1 case of infection in both the primary trial and the secondary trial is entailed by the evidence since there is at least one case of infection reported in each trial In the primary trial there were 2 cases of infection reported out of a total of 32 participants In the secondary trial there was 1 case of infection reported out of a total of 15 participants",
        "label": "Entailment"
    },
    "8b0efa30-40c4-408e-a91b-ded68b61d9ff": {
        "text_answer": "Yes  Explanation The median survival times for both groups are less than 24 months but it is stated in the question that on average patients from the primary trial survive over 24 months This means that while the average survival time is over 24 months there are individual patients in both groups who survived for less than 24 months Therefore the statement is entailed by the evidence as it acknowledges that there are patients in both groups",
        "label": "Entailment"
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "text_answer": "Yes The statement correctly identifies one difference between the two interventions in the trial However its important to note that the statement only mentions one difference while there are other differences between the two interventions eg the use of paclitaxel and the dosing schedules",
        "label": "Entailment"
    },
    "e9ad9d15-a15f-4f20-85f4-5da69c7592d6": {
        "text_answer": "Yes The evidence states that patients with epilepsy andor cerebral metastasis thalasemic syndromes and anemia only due to irondeficiency are excluded from the primary trial The secondary trial also excludes patients with epilepsy and thalasemic syndromes",
        "label": "Entailment"
    },
    "f05705d7-3be3-4d1d-9dca-c59c130446a1": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only discusses women with breast cancer not insulinoma The statement also mentions stage IV breast cancer which is a type of breast cancer that is not eligible for the trials according to the provided inclusion criteria",
        "label": "Contradiction"
    },
    "f8adadc4-67d0-42d2-bcc9-c032279bb470": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly describes the dosing regimen for sunitinib in the primary trial",
        "label": "Entailment"
    },
    "d0e16cbb-09e6-4178-80c1-2004ac2239a0": {
        "text_answer": "No  Explanation  The statement nearly all participants of the second cohort experienced a minimum of one adverse event is not directly mentioned or entailed in the evidence The evidence only states that the adverse event rate was higher in the second cohort compared to the first cohort but it does not specify that nearly all participants experienced an adverse event",
        "label": "Contradiction"
    },
    "964e4947-27a1-435e-84c6-d28b91d0dabe": {
        "text_answer": "Yes Both trials require patients to have intact mobility functional ECOG  2 status for inclusion",
        "label": "Entailment"
    },
    "eba82ab1-0348-4090-81e6-fcb63ac45537": {
        "text_answer": "Yes The median survival times given in the evidence are less than 730 days for both groups but some patients in both groups survived for less than 730 days Therefore the statement that on average patients from the primary trial survive over 730 days however at least one patient from both cohorts died in under 730 days is true but it goes beyond the specific information given in the evidence",
        "label": "Entailment"
    },
    "4edb9b25-9a95-4a00-ae99-ebd722187d63": {
        "text_answer": "No   Explanation  The evidence provided only gives the median PFS for each treatment group not the longest PFS observed in any individual patient",
        "label": "Contradiction"
    },
    "3426fcd0-2d5b-4d82-a9a1-93450b3336ee": {
        "text_answer": "No  The evidence does not support the statement that patients are eligible to participate in both the secondary and primary clinical trials concurrently as the trials have different inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "62112a3e-48e6-4e53-bfe4-53f07c84b815": {
        "text_answer": "No  The evidence explicitly states that there should be no meningeal carcinomatosis for patients to be eligible for the clinical trial",
        "label": "Contradiction"
    },
    "7ba831e1-4027-4ae2-842f-d52409a73ddc": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary clinical trial examines vaginal topical treatments Estring and Testosterone Cream and the secondary clinical trial examines acupuncture which is not an inhalation treatment",
        "label": "Contradiction"
    },
    "f9dfe1ca-aa97-4592-a67f-706e5453c822": {
        "text_answer": "No  Explanation  The statement cogstateassessed objective cognitive function scores are the units of measure employed in both the primary clinical trial as well as the secondary clinical trial is not entailed by the evidence provided The primary clinical trial measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM on a 5point ordinal response scale while the secondary clinical trial measures the objective response rate of",
        "label": "Contradiction"
    },
    "f994d3fb-5191-4800-beb7-02fdd6887e3e": {
        "text_answer": "No  Explanation  The statement it was reported that the secondary clinical trial had multiple adverse effects affecting over 90 of the enrolled patients is not entailed by the evidence The evidence only reports the specific adverse events and their frequencies in the secondary clinical trial but it does not mention that over 90 of the patients experienced any adverse event",
        "label": "Contradiction"
    },
    "282b67f4-97cb-4680-8f21-0102c1c7851f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it introduces the topic of Chlamydophila which is not mentioned in the evidence The evidence only describes the interventions placebo and Trabectedin and their administration schedules in a clinical trial",
        "label": "Contradiction"
    },
    "41b82c80-55fb-41c9-84c0-ae7f552c7cf8": {
        "text_answer": "No  The statement is not entailed by the evidence as epilepsy and thalasemic syndromes are exclusion criteria in the secondary trial",
        "label": "Contradiction"
    },
    "242dc321-0e46-4788-ac59-22120692fd8d": {
        "text_answer": "No  Explanation The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not explicitly stated in the evidence The evidence only mentions that patients receive oral lapatinib once daily on days 128 but it does not specify the dosage or frequency within that daily dose The statement also mentions a different dosage 100 mg",
        "label": "Contradiction"
    },
    "784e6940-fead-497a-8d68-2869d17385ea": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement is about esophageal hemangiomas which is a different condition from the one studied in the primary trial which focused on myocardial infarction and the use of AlloMSCs or placebo via transendocardial injection",
        "label": "Contradiction"
    },
    "27b7d06c-72ee-4a57-a88a-2654824853f2": {
        "text_answer": "No   Explanation   The statement 1 hectopascal is a si derived unit of pressure equivalent to one hundred pascals 1 millibar or 00145 pounds per square inch is not related to the inclusion or exclusion criteria for the primary or secondary trials It is a statement about a unit of measurement for pressure",
        "label": "Contradiction"
    },
    "5e2e6057-0a23-4780-9994-a239d28aee3a": {
        "text_answer": "Yes   Explanation The primary trial reports results in percentage and the secondary trial reports results in number of participants These are distinct units of measure",
        "label": "Entailment"
    },
    "cd0b8308-0c5c-4e7c-9f4f-9e1714fc7db2": {
        "text_answer": "Yes The evidence does not exclude patients with ER or PR factors from the trial for nonsmall cell lung cancer These factors are not mentioned in the inclusion criteria",
        "label": "Entailment"
    },
    "c6b64745-922b-40cb-9476-b7b696d4c8c0": {
        "text_answer": "Yes  Explanation The evidence states that 20 out of 35 participants in cohort 2 did not exhibit any signs of acute vomiting subsequent to the intake of aprepitant dexamethasone cytoxan and kytril This means that the majority of patients in cohort 2 did not exhibit any signs of acute vomiting which is what the statement is claiming",
        "label": "Entailment"
    },
    "11991b1b-f587-44fc-b675-603c06e680fe": {
        "text_answer": "Yes   Explanation  The primary trial examines the effects of eribulin mesylate while the secondary trial examines the effects of axitinib  docetaxel and docetaxel  placebo These are different medications",
        "label": "Entailment"
    },
    "5e0f26d8-5fcd-4187-9591-3508d99ffafc": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial provides the time to progression in months for a combined total of 156 patients from both cohorts whereas the secondary clinical trial focuses on the count of participants exhibiting objective response is entailed by the evidence provided  The primary clinical trial reports the median time to progression TTP for 72 patients in Arm A and 84 patients in Arm B total",
        "label": "Entailment"
    },
    "85815543-5f42-40bc-9ad1-98037b32433c": {
        "text_answer": "Yes  Explanation  The statement both the primary clinical trial and the secondary clinical trial reported zero cases of infections among participants during the period of study is entailed by the evidence because neither the primary nor the secondary trial reported any cases of infections in the adverse events section",
        "label": "Entailment"
    },
    "2da35e9e-caa7-47b4-883e-5ef8c7868708": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide the MTD value for the MM111 intervention in the secondary trial The evidence only states that the MTD for MM111 was determined using a DLT definition similar to the primary trial but it does not provide the actual MTD value",
        "label": "Contradiction"
    },
    "951e007d-202c-4cd4-8db0-0218a7c9f851": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes two interventions in the primary clinical trial that both include the use of doxorubicin cyclophosphamide and docetaxel The statement incorrectly asserts that none of these drugs are used in the trial",
        "label": "Contradiction"
    },
    "7e193fec-c5ef-4c86-8f5c-c7f6dffe11ec": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about the number or frequency of adverse events in cohort 1 of the secondary trial Therefore it is not possible to make a direct comparison between the two trials based on the given evidence alone",
        "label": "Contradiction"
    },
    "2d0d88d5-08ba-4d77-abbc-d8df34efa630": {
        "text_answer": "Yes The statement does not mention any specific adverse events related to the look of the reconstructed nipples but the evidence only reports the occurrence of cardiac and psychiatric adverse events none of which are related to the look of the nipples Therefore the statement is entailed by the evidence as it does not contradict it",
        "label": "Entailment"
    },
    "bb41bccb-2552-42ba-a5df-981bead7b941": {
        "text_answer": "No  Explanation  The statement proctitis ctcae is a disorder characterized by inflammation of the rectum is not directly related to the evidence provided The evidence only mentions the number of adverse events AEs observed in two clinical trials for an unspecified intervention The statement about proctitis and CTCAE is a general medical fact but it does not follow logically from the evidence",
        "label": "Contradiction"
    },
    "73b815f4-aae1-4202-a65e-5bba7b7c6676": {
        "text_answer": "  No   Explanation   The evidence states that individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the clinical trial Therefore individuals who have previously experienced intense anaphylactic responses to trastuzumab are not eligible for enrolment in the primary clinical trial according to the provided information",
        "label": "Contradiction"
    },
    "292d0d60-e861-47b2-9484-53b0cc80ffe1": {
        "text_answer": "No  Explanation  The statement the primary trial documented a higher number of patients experiencing chest pain than the secondary trial is not entailed by the evidence provided The evidence only mentions the occurrence of adverse events in both trials but it does not provide any information about chest pain specifically",
        "label": "Contradiction"
    },
    "36eca12e-4e1f-4239-88bb-fdac29a6209c": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the dosages used in the treatment of ovarian dermoid cysts with squamous cell carcinoma The evidence only provides information about the dosages used in two clinical trials for different interventions Zoledronic Acid and Denosumab in the treatment of bone metastases and breast cancer respectively",
        "label": "Contradiction"
    },
    "b5701488-7b4a-4e1d-a318-4cc2f2b4df39": {
        "text_answer": "Yes The primary trial uses sublingual administration of Vitamin B12 while the secondary trial uses oral administration of memantine and placebo",
        "label": "Entailment"
    },
    "dece1720-0c33-4000-b6e1-879b75541c33": {
        "text_answer": "No  Explanation  The statement Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial is not directly entailed by the evidence provided The evidence only mentions the use of Fulvestrant and Anastrozole in the primary trial and the use of HER2targeted PETCT in the secondary trial but it does not explicitly state that Arimidex is",
        "label": "Contradiction"
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "text_answer": "No  Explanation  The statement 5 patients in the primary trial suffered 3 or more adverse events is not directly entailed by the evidence provided The evidence only lists the number of patients who experienced each specific adverse event but it does not provide information about how many patients experienced multiple adverse events Therefore it is not possible to determine if 5 patients suffered 3 or more adverse events based on the given evidence alone",
        "label": "Contradiction"
    },
    "5ad108af-177f-434d-b17a-67c11c484e9b": {
        "text_answer": "Yes  Explanation  The statement there were no recorded instances of syncope across the patient cohorts of the primary trial and the secondary trial is entailed by the evidence because syncope was not reported as an adverse event in either trial",
        "label": "Entailment"
    },
    "ba202357-7330-4867-9527-10dee27a64b5": {
        "text_answer": "Yes  Explanation The evidence states that in Arm A of the clinical trial CUDC101 is administered for 5 days in each 14 day cycle at a dose of 275 mgm2 In Arm B CUDC101 is administered for 3 days in each 28 day cycle also at a dose of 275 mgm2 Although the dosage is the",
        "label": "Entailment"
    },
    "3eecf12f-23fb-45ab-bf91-cc84c01a1b6a": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary and secondary trials involve different interventions and patient populations In the primary trial dexmedetomidine is an intervention given to one group while in the secondary trial it is not mentioned as an intervention at all Therefore the statement that in the primary clinical trial group 2 patients receive a dosage of 05ugkg of dex",
        "label": "Contradiction"
    },
    "0ab8abd1-3e9e-4c51-95c3-6a1114180100": {
        "text_answer": "No  Explanation The statement seem to get full quickly is a question about whether an individual gets full quickly when they eat is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The trials focus on the diagnosis treatment history and organ function of the patients not on their eating habits or gastrointestinal symptoms",
        "label": "Contradiction"
    },
    "4dca77c0-d73d-4205-9d8e-8c2e897049d5": {
        "text_answer": "No  Explanation  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly entailed by the evidence provided The evidence only states the number of participants in cohort 2 who did not experience vomiting within the first 24 hours after cycloph",
        "label": "Contradiction"
    },
    "6668780b-0a4f-4c25-895f-3fb5fc7c604a": {
        "text_answer": "Yes  Explanation  The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 for the TAK228 Plus Tamoxifen armgroup To find the percentage reduction in Ki67 expression we can subtract the Ki67 expression at 6 weeks from the Ki",
        "label": "Entailment"
    },
    "05cd9540-60f6-4255-a4a5-fadff61801eb": {
        "text_answer": "  No The evidence provided does not mention any requirement for a dental examination record or a detailed eye examination report for the primary or secondary trials It only mentions the inclusion and exclusion criteria for each trial",
        "label": "Contradiction"
    },
    "b544a7fd-b1d9-402c-b003-22d14774531c": {
        "text_answer": "  Maybe   Explanation   The evidence provides the ORR and the number of participants analyzed for each group However it does not directly compare the ORR between the two groups or provide a statistical test to determine if the difference is significant Therefore while the statement suggests a superior ORR for the PBG group it cannot be definitively answered with a simple yes or no based on the given evidence alone",
        "label": "Entailment"
    },
    "ba5f6986-4060-4bcb-92ab-6423657d51ba": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of insulin injections or tryptophan supplements in the primary or secondary trials The primary trial involves radiation therapy and the secondary trials involve Enzastaurin and Fulvestrant administration",
        "label": "Contradiction"
    },
    "0cbbe925-cc6b-464a-b601-176c35b63a31": {
        "text_answer": "Yes  Explanation The evidence includes the exclusion criteria for women of childbearing potential WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab However it also states that sexually active fertile men whose partners are WOCBP not using an adequate method of birth control also qualify for the trial",
        "label": "Entailment"
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "text_answer": "No  Explanation  The statement the primary trial adminsters its intervention sublingually and the secondary trial adminsters it orally is not entailed by the evidence The primary trial administers Vitamin B12 sublingually while the secondary trial administers memantine orally and Vitamin B12 is not mentioned in the secondary trial",
        "label": "Contradiction"
    },
    "0bfa5116-f8a5-4bba-b279-bc071c6ff725": {
        "text_answer": "Yes The statement does not explicitly mention the trials but the individuals mentioned in the statement fall within the age range for both trials Therefore the statement is entailed by the evidence However having a poor or reduced appetite is not a specific inclusion or exclusion criterion for either trial",
        "label": "Entailment"
    },
    "21400daa-b71d-43ac-9a54-fb9497b2a723": {
        "text_answer": "No  The statement is not entailed by the evidence as the clinical trial is for patients with breast cancer not basal cell carcinoma of the skin",
        "label": "Contradiction"
    },
    "45741764-5967-4905-83dc-06481353f56b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the evidence only reports on the Maximum Tolerated Dose MTD of ruxolitinib in combination with paclitaxel in the primary trial and the Maximum Tolerated Dose MTD or Maximum Feasible Dose in the secondary trial but it does not mention anything about roboticassisted imaging",
        "label": "Contradiction"
    },
    "74f1ae66-88fd-4508-ba6b-2ad19274d6e3": {
        "text_answer": "No  Explanation  The evidence only provides the number of participants in each arm of the trial who experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes It does not provide information on the total number of participants in the trial who experienced this outcome or the percentage of participants in each arm who experienced this outcome relative to the total number of participants in the trial Therefore it is not possible to determine if some of the time",
        "label": "Contradiction"
    },
    "9f402778-d71e-4f5b-9653-eed11679ecc9": {
        "text_answer": "No  Explanation The evidence provided in the form of the primary clinical trial consists of two interventions one for adult cancer patients 65 years of age and older and another for healthy volunteers The statement however asserts that every individual in the primary clinical trial receives a uniform intervention without considering their cancer condition This statement is not entailed by the evidence because the evidence explicitly states that there are two separate interventions with different participant groups",
        "label": "Contradiction"
    },
    "1f54533d-d67f-4863-90a6-ebc13199f27e": {
        "text_answer": "Yes  Explanation  The statement no patients in the secondary clinical trial are given paclitaxel cyclophosphamide or pegfilgrastim is entailed by the evidence because neither paclitaxel nor cyclophosphamide are mentioned as part of the interventions in the secondary clinical trial and pegfilgrastim is mentioned only in the context of the first intervention in the primary clinical trial",
        "label": "Entailment"
    },
    "3add5ce6-4581-491c-b501-2c071860ece3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement mentions pregabalin in the primary trial and Depocyt and HDMTX in the secondary trial which are not the same interventions The primary trial involves oral pregabalin while the secondary trial involves intravenous HDMTX and intrathecal Depocyt",
        "label": "Contradiction"
    },
    "31dea0ef-a953-4217-9e00-bac1c96a7325": {
        "text_answer": "No  Explanation  The primary and secondary trials have different interventions although they both involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine DMCHOCPEN for treating patients with CNS involvement from various types of cancer However the primary trial involves the use of Abl Cells and Cyclophosphamide in combination with DMCHOCP",
        "label": "Contradiction"
    },
    "4b6d301f-d0c7-45c9-a39a-ff973e0b9d45": {
        "text_answer": "Yes The evidence does not specify that participants must be of a certain nationality or gender for either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "0655111b-b8fe-46c7-8332-433a747efbcc": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial are about different research topics The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis using mammography while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy The findings of the two trials cannot be directly compared or used to make a statement about each other",
        "label": "Contradiction"
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "text_answer": "Yes Both cohorts receive the same radiation therapy doses and undergo SPECT scans However the statement does not mention that they do not receive Active Breathing Coordination in cohort 2 which is also part of the given evidence",
        "label": "Entailment"
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "text_answer": "No  Explanation  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope which occurred in 2500 of the primary trial patients is not entailed by the evidence The evidence only shows that Syncope occurred in 1667 of the patients in the primary trial and in 084 of the patients in the secondary",
        "label": "Contradiction"
    },
    "9d196526-1000-4235-add7-49de8e168d3b": {
        "text_answer": "Yes  Explanation  The statement there are more cases of bronchopneumonia and general physical health deterioration in the secondary clinical trial than in the primary clinical trial is entailed by the evidence because the evidence shows that there is at least one case of bronchopneumonia and general physical health deterioration in the secondary clinical trial while there are no cases reported in the primary clinical trial",
        "label": "Entailment"
    },
    "664f769a-791d-4188-8937-c3269d6e0dde": {
        "text_answer": "No  Explanation  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the secondary trial includes patients with locally advanced or metastatic breast cancer which is a different disease stage compared to the primary trial Therefore the statement about a nonTNBC tumor of 100mm in diameter participating in both trials is not entailed by the evidence",
        "label": "Contradiction"
    },
    "22f97249-204f-4d0e-a76f-eb9b8441c8da": {
        "text_answer": "  No  Explanation  The statement is not entailed by the evidence because the evidence reports the percentage of participants in the primary trial who experienced either a confirmed complete response CR or a confirmed partial response PR in the Lapatinib 1000 mg  NabPaclitaxel arm not the Lapatinib 025 mg arm",
        "label": "Contradiction"
    },
    "de23d1f1-23e0-4f92-bdfd-b2bf37f08250": {
        "text_answer": "Yes  Explanation The statement cohort 1 in the primary clinical trial receives 0035 mg less of alt801 than what is administered to cohort 2 is entailed by the evidence because the difference in doses between the two cohorts is 0025 mgkg 0040 mgkg for cohort 2 minus 0015",
        "label": "Entailment"
    },
    "eb8dca8b-34a9-46d0-a845-80c4b5343ec6": {
        "text_answer": "  The evidence does not directly address the statement as it compares different interventions and outcome measures Therefore it is not possible to answer with a simple yes or no",
        "label": "Entailment"
    },
    "ae5ec938-2ef4-4533-9ab9-3314de8525a1": {
        "text_answer": "No  Explanation  The evidence provided in the text only gives the number of participants in each group who completed the study ie were analyzed and their respective percentages It does not provide the number of participants who experienced recurrencefree survival in each group Therefore it is not possible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "ea69e1bc-816a-4ba8-abd0-9882b12b70ea": {
        "text_answer": "No  Explanation  The statement basal cell of the squamous epithelium is a basal cell located in the squamous epithelium is a fact that is not related to the adverse events data provided in the evidence The evidence only reports the number and types of adverse events observed in two clinical trials and does not provide any information about the location or characteristics of the basal cells in the squamous epithe",
        "label": "Contradiction"
    },
    "fe6f8d5f-5105-4495-828f-f6ef19a7cc9d": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the primary trial states that patients received 120 milligrams of denosumab every 4 weeks which is equivalent to 480 milligrams per month or 480000 micrograms The statement incorrectly states that patients received 120000 micrograms of denosumab every month Additionally",
        "label": "Contradiction"
    },
    "deff33e5-6172-4caa-940e-4ca7aaca8d80": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence indicates that there were no adverse events in both trials",
        "label": "Contradiction"
    },
    "057e665a-1e29-4e11-866e-16483eeb0420": {
        "text_answer": "Yes The evidence states that patients with significant cardiovascular impairment are excluded from both trials Yellow fever virus is not directly related to the statement but the statement does not contradict the evidence",
        "label": "Entailment"
    },
    "4dd24d14-3357-43a0-973f-d535802507cb": {
        "text_answer": "No   Explanation   The statement patients in the secondary trial cohorts do not receive any Dexmedetomidine is not directly related to the information provided in the evidence The evidence only mentions the interventions used in each trial but it does not specify whether or not patients in the secondary trial received Dexmedetomidine or not Therefore it is not possible to determine if the statement is entailed by",
        "label": "Contradiction"
    },
    "f59c5c18-e772-4c9b-a5f2-cdb3bdd812f2": {
        "text_answer": "Yes The statement is entailed by the evidence as pericardial effusions were more frequent in the primary trial and corneal deposits were not reported in the secondary trial",
        "label": "Entailment"
    },
    "64d56259-f688-42c5-8946-0022bd4aa57c": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions is not directly related to the evidence provided The evidence only compares the average area under the curve aAUCpa of the EORTC ChemotherapyInduced Peripheral Neuropathy Module EORTC QLQCIP",
        "label": "Contradiction"
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "text_answer": "No  Explanation  The statement In the primary trial only one cohort receives Armodafinil PO daily and in the secondary trial all patients receive the same 100 mg dose of PDR001 and 1 mgkg dose of MCS110 is not entailed by the evidence  In the primary trial one intervention arm includes Armodafinil PO daily",
        "label": "Contradiction"
    },
    "e0cc56e6-9466-4d28-a94e-4a9dcceaee76": {
        "text_answer": "No  Explanation The statement participants of cohort b in the primary clinical trial receive two electroporation injections of ld v934 is not directly entailed by the evidence provided While it is true that participants in cohort B received three electroporation injections of V934 LD they did not receive two electroporation injections specifically Instead they received one electroporation injection followed by two",
        "label": "Contradiction"
    },
    "29eab9d1-1649-401a-8ff7-95fcd6a2c09a": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial only mentions the administration of 05ugkg of dexmedetomidine for group 2 not 9ugkg 90ml The secondary trial does not mention the administration of dexmedetomidine at all for its cohorts",
        "label": "Contradiction"
    },
    "67dcd165-45dd-439f-980d-62c960f50c37": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria in the evidence which specifically mentions the exclusion of patients who have undergone antineoplastic chemotherapy androgens or estrogens in the month before study entry",
        "label": "Entailment"
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial results does not directly address the statement regarding less than 10 of participants having a reduction in circulating tumor cells CTCs following months of highdose chemotherapy with purged autologous stem cell products The results only report the number of participants with a reduction in CTCs at one month posttransplantation Therefore the statement is not entailed by the",
        "label": "Contradiction"
    },
    "4ceb3f73-8812-4534-9688-52e5d3db524f": {
        "text_answer": "Yes  Explanation The statement participants in the primary trial receive 4 different drugs throughout the study duration with a maximum dose of 01 gm2 is entailed by the evidence as the trial involves the use of epirubicin cyclophosphamide docetaxel and trastuzumab The maximum dose for epirubicin is given as 100 mgm",
        "label": "Entailment"
    },
    "f64f4990-f41a-49c2-ab74-5897b191c256": {
        "text_answer": "Yes Both trials involve the use of cyclophosphamide which is a chemotherapeutic agent Cyclophosphamide is known to have side effects that can impact sexual function in some patients making it relevant to the statements definition of sexually active",
        "label": "Entailment"
    },
    "2c8bef4e-9452-4ff9-b04d-66b0f42196d8": {
        "text_answer": "No  Explanation  The statement over 185 of patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed by the evidence The evidence only reports the number and percentage of patients who experienced adverse events including infections in each trial It does not provide the total number of patients in each trial or the combined total number of patients across both trials Therefore it is impossible to determine",
        "label": "Contradiction"
    },
    "e809d4b1-1730-49a2-aa9f-303afb27b175": {
        "text_answer": "No   Explanation  The statement provided in the question is not related to the evidence given in the primary trial The evidence describes the interventions used in the trial specifically the dosages of sunitinib and paclitaxel in cohort 1 and the addition of bevacizumab in cohort 2 The statement in the question is about trichostrongylus colubriformis a parasit",
        "label": "Contradiction"
    },
    "e01e4e41-3577-4556-b481-de0d3777ba18": {
        "text_answer": "yes for the primary trial only The statement is not directly related to the secondary trial as it mentions mammography which is a requirement for the primary trial but not for the secondary trial",
        "label": "Entailment"
    },
    "83e7efec-6077-4c3c-8ed6-ebe4f715da47": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials exclude patients with no evidence of metastasis M0",
        "label": "Entailment"
    },
    "bffaad67-a8e9-43bf-a2ca-bbcaec96218c": {
        "text_answer": "No  Explanation The statement upon giving fully informed consent patients suffering from stage 4 cancer can qualify for both secondary clinical trial and primary clinical trial is not entailed by the evidence provided The primary trial specifically excludes patients with stage IV breast cancer while the secondary trial does not mention any specific stage of breast cancer as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "201ec8b0-f2f0-4c60-8094-0f40761f6d88": {
        "text_answer": "No   Explanation  The statement the number of adverse events witnessed in the primary clinical trial was higher than in the secondary clinical trial is not entailed by the evidence provided The evidence only states that the number of adverse events for each trial is zero Therefore it cannot be determined from the evidence alone whether the number of adverse events in one trial is higher or lower than the other",
        "label": "Contradiction"
    },
    "626b2407-ae7b-43ed-96b6-3ee9e3c290c8": {
        "text_answer": "Yes The evidence does not mention anything about pregnant individuals being eligible for the clinical trial",
        "label": "Entailment"
    },
    "6d595852-44de-4516-9ac8-441283808f1f": {
        "text_answer": "No  Explanation The evidence provided does not mention the number of patients who experienced no adverse events The evidence only states the percentage of subjects who completed the treatment regimen 98",
        "label": "Contradiction"
    },
    "57d179a7-e550-486f-ba5b-40dcdc8927a0": {
        "text_answer": "No  Explanation  The statement is not directly related to the inclusion or exclusion criteria of the primary trial The statement is about a medical procedure endobronchial ultrasoundguided miniforceps biopsy and the patients history of severe anaphylactic reactions to trastuzumab The primary trial focuses on the eligibility criteria for patients to participate in the study based on their medical history tum",
        "label": "Contradiction"
    },
    "b315a999-4315-4e95-95e7-9f402f9d979e": {
        "text_answer": "Yes  Explanation  The statement no cardiacrelated adverse events have been identified in the first cohort of the primary clinical trial is entailed by the evidence since none of the cardiacrelated adverse events angina pectoris cardiac arrest cardiac failure cardiac tamponade acute coronary syndrome and disseminated intravascular coagulation were reported in the first cohort of",
        "label": "Entailment"
    },
    "ba6526b2-e565-4c7b-b931-42590bb703c0": {
        "text_answer": "Yes The evidence only mentions criteria related to cancer diagnosis and treatment not mental health bodyweight tumor size or life expectancy",
        "label": "Entailment"
    },
    "81ec9878-e668-49dd-99eb-49ea13337c8f": {
        "text_answer": "Yes The statement does not explicitly mention the patients ability to think and solve daytoday problems but the eligibility criteria for the primary trial do not include any conditions that would affect cognitive function or problemsolving ability so it can be inferred that patients with the specified tumor stages are assumed to have sufficient cognitive ability for trial participation",
        "label": "Entailment"
    },
    "ef95d23d-9dc6-494b-9085-b5ccc6822525": {
        "text_answer": "No  Explanation  The statement there were 75 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed by the evidence provided The evidence only reports the number and types of adverse events for each cohort but it does not mention the number of cases of hypertension dehydration and dyspnea in the trial",
        "label": "Contradiction"
    },
    "41bf82f2-9544-471f-88b0-418e6cd9b5e1": {
        "text_answer": "No  Explanation The statement The placebo and Trabectedin intervention in the primary trial are both administered through a 3hour intravenous infusion on a biweekly basis is not directly entailed by the evidence While it is true that both interventions are administered through a 3hour intravenous infusion the evidence does not specify that they are administered on a biweekly basis The",
        "label": "Contradiction"
    },
    "87d7f63c-5fa5-4820-af0e-391ef8986199": {
        "text_answer": "No  Explanation  The evidence provided in the results 1 does not mention the percentage of participants in the Lapatinib 1000 mg  NabPaclitaxel arm who experienced a confirmed complete response CR The evidence only states that 53 out of 60 participants were analyzed in this arm The statement goes beyond the information given in the evidence",
        "label": "Contradiction"
    },
    "41e9a0e8-3838-4609-86e7-dc9b798db67c": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the alloMSCs intervention is administered via transendocardial injections not intravenous infusion and the dose is not higher than the placebo intervention in terms of volume both interventions receive 04ml per injection",
        "label": "Contradiction"
    },
    "dc8d6268-fd08-4c31-b2d6-50e8a8e750c0": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial mentions weekly injections for a month not just one injection at the onset",
        "label": "Contradiction"
    },
    "20e20d13-e73f-4df9-b6f7-37df97b32917": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention the number of participants who experienced no pain throughout the 10 weeks of the primary clinical trial The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "cdbca781-b6cd-42a1-acac-80617aa1af67": {
        "text_answer": "No   Explanation  The evidence describes the patient population and eligibility criteria for the primary clinical trial but it does not mention anything about the intervention requiring regular exercise for its candidates",
        "label": "Contradiction"
    },
    "695ba633-5bf3-48ee-b6f9-f77657f827b7": {
        "text_answer": "Yes The inclusion criteria for both trials allow for patients with an ECOG performance status of 0 to 2 which includes those who are significantly limited in their selfcare ability but still able to spend more than half of their waking hours out of bed or chair",
        "label": "Entailment"
    },
    "63c2b269-5155-4014-b033-2584a6773867": {
        "text_answer": "Yes The evidence does not mention Paclitaxel at all",
        "label": "Entailment"
    },
    "287c1319-d37b-4a6a-a0f3-2059ce18b07d": {
        "text_answer": "No The statement is not exactly entailed by the evidence as it mentions a 48month time frame instead of the 6month time frame specified in the evidence However the evidence does state that there is no history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke or transient ischemic attacks for study participation",
        "label": "Contradiction"
    },
    "b639e0a1-6e1d-4940-9818-a268732ed88a": {
        "text_answer": "Yes  Explanation  The statement no recurrence of malignancies absence of graftversushost disease normal red blood cell count cardiac wellbeing and healthy alveolar condition were more commonly observed in the primary trial compared to the secondary trial is entailed by the evidence as  1 There was no recurrence of malignancies in the primary trial 0 2 Graftversus",
        "label": "Entailment"
    },
    "0bd3433b-05d2-416a-b0c4-0a017f546dc2": {
        "text_answer": "Yes  Explanation  The primary clinical trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 using the unit of measure mIUml The secondary clinical trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with Paclitaxel using the unit of measure mg These are distinct units and outcome measures",
        "label": "Entailment"
    },
    "c6e636a5-7c18-47f4-9563-715fde497ee3": {
        "text_answer": "No  Explanation The statement margin status cannot be assessed is a result that the patient is not eligible for the trial is not entailed by the evidence The evidence only mentions that the final eligibility for the trial is determined by the health professionals conducting the trial and it does not mention anything about margin status being a reason for ineligibility or the inability to assess it",
        "label": "Contradiction"
    },
    "4f5fb0bf-e5bf-47ad-876c-e9aea07feaee": {
        "text_answer": "No   Explanation The evidence provided in the adverse events data does not mention anything about eating disorders The listed adverse events include fatigue rashes liver enzyme elevations alkalosis anorexia hyperglycemia and nervous system disorders However none of these are explicitly stated to be eating disorders Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "4d36fe39-7874-4174-853e-dc6406bf9e0b": {
        "text_answer": "Yes The evidence does not report any patient experiencing the worst pain imaginable for 20 minutes",
        "label": "Entailment"
    },
    "43658af8-5289-485f-98ed-50d005e452e1": {
        "text_answer": "No  Explanation  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed by the evidence provided The evidence only reports the results of the primary and secondary trials including the overall response rates and time",
        "label": "Contradiction"
    },
    "c9d6f05e-40bd-49b1-8ba1-c5489208cede": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial does not use a 360day cycle for its intervention Instead each cycle is defined as 21 days",
        "label": "Contradiction"
    },
    "0c570cce-3180-45b9-a0b3-4dd7200fc890": {
        "text_answer": "Yes  Explanation  The statement nf1 gene mutation is a change in the nucleotide sequence of the nf1 gene is not directly related to the evidence provided However the evidence does not contradict the statement so it is still considered entailed by the evidence  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is entailed by the evidence as the primary trial had",
        "label": "Entailment"
    },
    "04d76027-45a0-46e3-9308-acc4f8c02a73": {
        "text_answer": "No   The primary clinical trial measures the effect of a pain medication on pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change in bone mineral density BMD of the lumbar spine at 9 months after surgery The statement provided does not match the outcome measurements of either trial",
        "label": "Contradiction"
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "text_answer": "Yes  Explanation The statement There was one psychiatric adverse event in the primary trial which affected less than 10 of patients is entailed by the evidence as there is one psychiatric adverse event suicidal ideation in the evidence and it affected 200 of patients which is less than 10",
        "label": "Entailment"
    },
    "3afe5a55-731f-4015-85a2-e6df1caa2374": {
        "text_answer": " No the statement is not entailed by the evidence The evidence states that patients must have a potassium within the normal range of 3553 mEqL for the primary trial It does not mention anything about hyperkalemia",
        "label": "Contradiction"
    },
    "84859b73-1029-4815-a059-79c20cc06f91": {
        "text_answer": "Yes  Explanation  The statement no psychiatric disorders like eating disorder or schizophrenia emerged as a consequence of the primary clinical trial is entailed by the evidence because there is no mention of any participant developing an eating disorder or schizophrenia as an adverse event during the trial The evidence only lists adverse events such as ventricular tachycardia fever flulike symptoms catheter related infection",
        "label": "Entailment"
    },
    "e1069782-98e2-4db7-aeed-460b846781c3": {
        "text_answer": "No  Explanation The statement participants in the primary trial receive 4 different drugs throughout the study duration with a maximum dose of 100 mgm2 is not directly related to the information given about parotid gland hemangioma The evidence only describes the neoadjuvant therapy regimen for breast cancer treatment The statement about the parotid gland hemangioma is unrelated to the trial",
        "label": "Contradiction"
    },
    "53099f5c-4259-4ad7-bff2-65d2fe6250be": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as the primary trials intervention group receives a smaller weekly quantity of MM121 20 mgkg compared to the secondary trials first group 20 mgkg weekly for 12 weeks totaling 120 mgkg Similarly the primary trials intervention group receives a smaller weekly quantity of paclitaxel 80 mgkg",
        "label": "Entailment"
    },
    "41b6a327-e552-4e26-971f-25096f53e72d": {
        "text_answer": "No The statement is not entailed by the evidence as the percentage given in the statement is different from the percentage of patients with increased blood bilirubin in the evidence 3636 vs 49",
        "label": "Contradiction"
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "text_answer": "No  Explanation  The statement Most the primary trial candidates suffered from some kind of eating disorder during the study duration is not entailed by the evidence provided The evidence only lists various adverse events experienced by the candidates during the study including anorexia but it does not indicate that most of them suffered from an eating disorder",
        "label": "Contradiction"
    },
    "c38f4f43-886b-41e9-9d42-5ce12e838600": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as neither the primary nor the secondary trial measure the percentage of participants in their studies that experience clinical benefit using RECIST criteria The primary trial measures tumor response using RECIST criteria but it does not report the percentage of participants who experienced clinical benefit The secondary trial does not report any information related to clinical benefit using RECIST criteria",
        "label": "Contradiction"
    },
    "feb0cfe7-6bcf-4e82-82b7-460f9cc66a18": {
        "text_answer": "Yes The trial specifically states that patients with measurable or nonmeasurable disease are eligible but those with no known brain or CNS metastases and no other malignancy within the past 5 years are required This implies that patients with only localized or nonmetastatic disease are not suitable for the trial",
        "label": "Entailment"
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "text_answer": "Yes  Explanation The statement the secondary trial recorded 11 more AEs Adverse Events than the primary trial is entailed by the evidence as the evidence shows that there were 11 additional AEs in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "5caeaa69-840d-4a32-8279-416bbe1b570e": {
        "text_answer": "Yes The primary trial includes male subjects and excludes females who are of childbearing potential while the secondary trial includes only female subjects",
        "label": "Entailment"
    },
    "1ff9cfe0-06e6-4f99-961c-7854ba9e2c46": {
        "text_answer": "  Yes for the primary trial parathyroid hormone is not mentioned in the inclusion or exclusion criteria  Answer   Partially for the secondary trial gender is not a determining factor for eligibility but parathyroid hormone is not mentioned in the inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "3f87dd7c-b00d-4840-b075-70b65e5bf00c": {
        "text_answer": "No  Explanation  The statement the number of bronchopneumonia cases and instances of general physical health deterioration are equal in both the primary and secondary clinical trials is not entailed by the evidence The evidence only shows that there is one case of bronchopneumonia in the secondary trial and one instance of general physical health deterioration in both trials It does not indicate that the number of cases is equal for both conditions in both trials",
        "label": "Contradiction"
    },
    "13d0bb71-fc81-4ecf-8628-1321816e41ce": {
        "text_answer": "Yes The evidence does not report any cases of Hypertension Dehydration or Dyspnea in either cohort",
        "label": "Entailment"
    },
    "43e968bb-7167-4c0a-8105-8f3e854408af": {
        "text_answer": "Yes  Explanation  The statement nearly half more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group can be calculated by subtracting the percentage of participants with a decrease in GFS in the triple negative group from the percentage of participants with a decrease in GFS in the ERpositive Luminal B group and then dividing",
        "label": "Entailment"
    },
    "cdd043e8-2430-409a-96b6-8e7b7a2d11f3": {
        "text_answer": "Yes  Explanation The evidence provides the inclusion and exclusion criteria for both the primary and secondary trials A patient who meets the inclusion criteria for the secondary trial but does not meet the inclusion criteria for the primary trial such as a woman undergoing immediate tissue expander reconstruction following mastectomy can still be eligible for the secondary trial Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "c44751aa-dc67-42de-a619-0f0834b88325": {
        "text_answer": "Yes  Explanation  The statement the primary trial and the secondary trial both use pCR as their outcome measurement there is a small difference in results between the two cohorts of the primary trial whereas in the secondary trial Arm 2 had worse results than arm 1 is entailed by the evidence provided Both trials use pCR as their outcome measurement and the primary trial shows a small difference in pCR rates between the two arms while",
        "label": "Entailment"
    },
    "2d16916c-23f3-4638-8a1d-6638aeb46359": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly reflects the number of participants with stable disease at Week 12 and Week 24 according to the provided data However its important to note that the statement does not mention the absence of complete response which is also true according to the evidence",
        "label": "Entailment"
    },
    "a24f59fe-0c4b-48bb-bbff-8dfb4b83ed6b": {
        "text_answer": "No   Explanation  The statement participants are required to get one injection on the 8th day of the investigation is not explicitly stated in the evidence The evidence mentions that patients with neutrophil counts below 1000mm3 on day 8 will continue GMCSF therapy until the neutrophil count is greater than 1000mm3 but it does not specify that",
        "label": "Contradiction"
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "text_answer": "Yes The evidence states that neither cohort received invasive surgery or Neratinib",
        "label": "Entailment"
    },
    "e4256cc3-09b7-4ad0-b1b1-467cd74b273c": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence does not provide any information about the time unit used in the measurement of Incidence of Doselimiting Toxicity The evidence only states that the measurement is in number of participants and the time frame is 28 days",
        "label": "Contradiction"
    },
    "50757da1-c674-43a7-a3ee-90750e166aa5": {
        "text_answer": "Yes The trial does not mention any exacerbating factor to the chief complaint for either the placebo or memantine arms",
        "label": "Entailment"
    },
    "2c4d4e4b-1b19-4a95-a18d-7d0585c90573": {
        "text_answer": "No  Explanation  The statement on average patients from the primary trial survive under 2 months over 80 patients from each cohort survived more than 6 months is not entailed by the evidence provided The evidence only gives the median survival times for each group not the survival distribution for all patients The statement makes a claim about the survival distribution which is not directly addressed in the evidence",
        "label": "Contradiction"
    },
    "3ff601a7-b05a-4cc4-94e3-bbea555889cb": {
        "text_answer": "Yes The evidence does not mention the use of paclitaxel in either intervention The statement is about paclitaxel not being used which is consistent with the evidence",
        "label": "Entailment"
    },
    "28d5dbe8-5006-4735-8274-fc37e55dbbbd": {
        "text_answer": "No  Explanation  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is not entailed by the evidence The evidence only shows that the percentage of patients who experienced specific adverse events was the same in each cohort for some adverse events but not all The percentage of patients who experienced adverse events in total was different between the two cohorts 5000 in",
        "label": "Contradiction"
    },
    "671c7966-67b4-4279-b246-a4e415679a2d": {
        "text_answer": "Yes The evidence states that there is no form of counselling risk assessment or cognitive behavioural therapy given as part of the interventions in either cohort of the primary clinical trial",
        "label": "Entailment"
    },
    "8942c478-a2ec-4b68-8da0-7fbce5bb70f7": {
        "text_answer": "Yes  Explanation  The primary clinical trial and secondary clinical trial have different outcome assessments In the primary clinical trial the outcome assessment was the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events In contrast the secondary clinical trials outcome assessment was the number of participants with objective response These two outcome assessments are not the same and therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "0dd90e62-09f5-4282-9f52-c369a56ba3f5": {
        "text_answer": "Yes  Explanation The evidence shows that the median aAUCpa for the Sensory Neuropathy subscale in the Arm I Cryotherapy group was 14 117 to 68 while in the Arm II Control group it was 44 571 to 162 A negative aAUCpa indicates that symptoms have worsened from baseline The",
        "label": "Entailment"
    },
    "fdf46294-f524-478f-9816-e13d7c7c3927": {
        "text_answer": "  Yes for the primary trial only No for the secondary trial   Explanation  The statement patients who have experienced a pulmonary embolism in the past year are welcome to join the primary trial and do not require an investigators decision for participation in the secondary trial is entailed by the evidence for the primary trial as there is no exclusion criterion related to pulmonary embolism in the primary",
        "label": "Entailment"
    },
    "f42c5f78-bcb9-46e9-8b77-a8b9cbb81b13": {
        "text_answer": "No  Explanation The statement on average patients from the primary trial survive over 3 years is not directly entailed by the evidence provided The evidence only gives the median survival times for each group not the average survival time for all patients in the trial Additionally the statement mentions that at least one patient from both cohorts died in under 30 minutes but the evidence does not provide any information about the survival times of individual patients or",
        "label": "Contradiction"
    },
    "a441e08e-affc-4228-bfac-18ab1ead4bce": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f9b21d3d-3d5d-4cc6-bf70-733083138b99": {
        "text_answer": "No  Explanation  The statement 100 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for one type Adverse Events 1 in each trial Additionally the statement that none of the adverse events in the secondary trial affected more than 150 of patients is not directly related to the number of adverse events in the primary trial",
        "label": "Contradiction"
    },
    "13d5fd15-4fe1-4152-8987-050cfb32c8fb": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly give the recurrencefree survival data for each group Instead it only mentions the number of participants in each group and their percentages The statement given is about the difference in recurrencefree survival between the two groups which cannot be determined from the provided evidence alone",
        "label": "Contradiction"
    },
    "dd5c2791-351d-472f-8c50-a773aa9baa41": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as it is not related to the inclusion or exclusion criteria for the clinical trial The statement is about the atrioventricular bundle which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "b71e8f1d-2910-4ac7-9aaf-e709679b0083": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3ad0bf0d-7929-4d29-9629-4fea3e6c8fc5": {
        "text_answer": "No  Explanation The statement does not mention suramin or paclitaxel which are the agents used in the primary clinical trial according to the evidence Therefore it cannot be entailed by the evidence",
        "label": "Contradiction"
    },
    "2aa37ee1-47f4-4ee2-a2d5-b11181a89e78": {
        "text_answer": "Yes  Explanation The statement Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is entailed by the evidence because both cohorts receive three electroporation injections of V934 LD",
        "label": "Entailment"
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "text_answer": "Yes The statement is entailed by the evidence as the intervention section does not provide any information about a treatment cycle or description of the treatment",
        "label": "Entailment"
    },
    "5ab7ac4b-19cd-455c-8796-50680cedf7f1": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "text_answer": "yes  Explanation The statement 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group can be calculated by subtracting the percentage of participants in the Triple Negative group with a decrease in GFS from the percentage of participants in the ERpositive Luminal B group with a",
        "label": "Entailment"
    },
    "36969517-2743-4fc8-970a-0846cebda02f": {
        "text_answer": "No  Explanation  The statement is about an individuals feelings regarding their ability to deal with treatment and recovery while the evidence is about the number of participants who had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products These two concepts are not directly related",
        "label": "Contradiction"
    },
    "1b5d6416-bf6d-4d0b-8b9b-b982d1bbd8a8": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial does not have a requirement for Her2neu breast cancer",
        "label": "Contradiction"
    },
    "aecffac5-b441-4cf6-b939-c7fb19ebac05": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial there was a minimum of 1 detected gastrointestinal adverse event and more than one psychiatric event is entailed by the evidence because there is at least one instance of vomiting gastrointestinal event in each of the two sets of adverse events and there are two instances of vertigo psychiatric event in the second set of ad",
        "label": "Entailment"
    },
    "b907c117-661f-4078-956a-be5b2560b5f4": {
        "text_answer": "No  The evidence does not indicate that any patient in either trial developed shingles",
        "label": "Contradiction"
    },
    "263e2baf-2196-42fb-8d68-e6dea7cad9b5": {
        "text_answer": "No  The evidence states that there was an increase in blood bilirubin levels in 1 out of 11 patients 909",
        "label": "Contradiction"
    },
    "864e3d0c-60fb-43bf-a272-1d590ff8795b": {
        "text_answer": "Yes  Explanation  The statement in the primary trial there is a reduction in both the total number and categories of adverse events in comparison to the secondary trial is entailed by the evidence as the total number of adverse events in the primary trial is 0 while in the secondary trial it is 48 and the number of categories of adverse events in the primary trial is 0 while in the secondary trial it is 10",
        "label": "Entailment"
    },
    "1a71b35f-9b20-478b-863d-f7411015d6e8": {
        "text_answer": "  Yes but with a qualification The primary trial excludes patients with a pulmonary embolism within the last 4 weeks while the secondary trial allows for a pulmonary embolism within the last 72 weeks depending on the investigators decision Therefore the statement is entailed by the evidence with the qualification that the time frame for the pulmonary embolism is different between the two trials",
        "label": "Entailment"
    },
    "c5e1aaba-40f0-49e6-926b-2f28f74b2b1c": {
        "text_answer": "No  The primary clinical trial has different inclusion and exclusion criteria for its phases while the secondary clinical trial has the same inclusion criterion informed signed consent and different exclusion criteria",
        "label": "Contradiction"
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "text_answer": "Yes The evidence states that laserassisted fluorescence angiography is used for monitoring perfusion at three separate time points in both the Inframammary Fold Incision and Lateral Radial Incision cohorts Therefore the use of laserassisted fluorescence angiography is common to both interventions and the lateral radial incision is mentioned as one of the incision types used in the trial",
        "label": "Entailment"
    },
    "01b56d67-6f6a-4102-959e-eb921954d268": {
        "text_answer": "Yes The evidence does not list allergies to cephalosporin or trimethoprimsulfamethoxazole as exclusion criteria for either trial",
        "label": "Entailment"
    },
    "6b03d4f0-29bf-4a64-8136-2042e2a609ef": {
        "text_answer": "No  Explanation  The statement patients in cohort 2 show a decrease in pleural effusion is not entailed by the evidence provided The evidence only states that there was no increase in pleural effusion in cohort 2 during the secondary clinical trial The absence of an adverse event does not imply the presence of a beneficial effect",
        "label": "Contradiction"
    },
    "c216cb60-86c5-4ba4-9092-07bfe620c6ec": {
        "text_answer": "No  Explanation The statement somewhat forgetful is a response indicating that an individual is or was somewhat forgetful is not directly related to the evidence provided The evidence only mentions the details of two interventions from two different trials and there is no mention of forgetfulness in relation to the participants in the trials",
        "label": "Contradiction"
    },
    "1645d8e9-78e0-42e0-b46e-945c3c8e7d89": {
        "text_answer": "No  Explanation  The statement in the first cohort of the primary clinical trial there were no instances of adverse events whereas almost every individual in the second cohort encountered at least one is not directly entailed by the evidence provided The evidence only states that there were no adverse events in the first cohort but it does not provide information about the second cohort beyond the fact that there were adverse events The",
        "label": "Contradiction"
    },
    "fe6abe4b-e77b-4ab7-a52c-3157a90f7a2d": {
        "text_answer": "No  Explanation  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for both the primary and secondary trials but it does not specify anything about the age requirement for each trial or the waiting period for younger women to become eligible",
        "label": "Contradiction"
    },
    "b98c3e78-273c-46dd-ad36-db7aabf5f3a9": {
        "text_answer": "  No the statement is not entailed by the evidence The primary trial does show longer operative times in the intraoperative mammography group but it does not indicate that the control group outperformed the test group The secondary trial does not provide sufficient information to make a comparison between groups",
        "label": "Contradiction"
    },
    "74e35f39-c01b-435b-a5f8-cc1cc8204607": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify the tumor size However the primary trial only includes patients with primary breast cancer while the secondary trial includes patients with locally advanced or metastatic breast cancer The statement does not match the criteria for either trial",
        "label": "Contradiction"
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the secondary trial does not mention the administration of dexmedetomidine to any of its cohorts",
        "label": "Contradiction"
    },
    "b6bd5750-21d0-4fcd-80af-749c6dc2a518": {
        "text_answer": "No  Explanation  The statement in the primary trial results there were more patients with stable disease in week 6 than week 18 is not directly entailed by the evidence provided The evidence only states the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 for each armgroup It does not provide information about the number of participants with stable disease at week 6",
        "label": "Contradiction"
    },
    "a0d11ea8-22ae-4af7-885c-40b9e3a98fac": {
        "text_answer": "Yes the statement does not contradict the evidence regarding the inclusion criteria for mental health bodyweight age KarnofskyECOG score or previous treatments The statement only mentions the use of caspase3 staining method which is not related to these criteria",
        "label": "Entailment"
    },
    "663f13bf-bbc7-49f2-926e-b88da56cc74a": {
        "text_answer": "No  Explanation  The statement not a single patient treated with sunitinib  docetaxel  trastuzumab during the primary clinical trial experienced a treatmentemergent adverse event is not entailed by the evidence The evidence states that there were 24 treatmentemergent adverse events in total among the 25 participants",
        "label": "Contradiction"
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "text_answer": "Yes The primary trial includes breast adenocarcinoma as a cancer type for phase 1 and the secondary trial includes breast carcinoma as a cancer type for all cohorts",
        "label": "Entailment"
    },
    "fdce4005-3773-4350-b45b-1c1338e01a26": {
        "text_answer": "No  Explanation  The statement biliary colic and diarrhoea cases are relatively equal across the primary and secondary clinical trials is not entailed by the evidence The evidence shows that there is one case of biliary colic in the primary trial and one case in the secondary trial However the number of total adverse events and the percentage of adverse events in relation to the total number of participants are different between the two trials Therefore",
        "label": "Contradiction"
    },
    "3fd8d038-4c72-4f0f-b2d8-0e822f5b96a8": {
        "text_answer": "No  Explanation The evidence provided does not mention any specific requirement for AfricanAmerican patients to reside in Texas during the study or any restriction related to welding occupations The evidence only outlines the inclusion and exclusion criteria for the primary and expansion phases of a clinical trial for various types of solid tumors",
        "label": "Contradiction"
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "text_answer": "No the statement is not entailed by the evidence for the secondary trial as it only includes patients with BRCApositive breast cancer",
        "label": "Contradiction"
    },
    "4750e9e1-982d-4ca4-ab90-373832ed32d6": {
        "text_answer": "No  Explanation The statement in the primary clinical trial increased pleural effusion and rapid disease progression is experienced by 25 of the patients is not directly entailed by the evidence provided The evidence shows that in the first trial 769 of patients experienced rapid disease progression and 2500 of patients in the second trial experienced increased pleural effusion However it does not provide information that",
        "label": "Contradiction"
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "text_answer": "No  Explanation  The primary trial reports the percentage of participants while the secondary trial reports the number of participants Although both trials use a percentage in the primary trial for calculating the corrected serum calcium the unit of measure for the number of participants who reached a safe dose in the secondary trial is different from the percentage of participants with a response within 10 days of first dose of denosumab in the primary trial",
        "label": "Contradiction"
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 The statement that patients in the primary trial experienced a 5 reduction in the percentage of cells with Ki67 expression over 6 weeks can be calculated as follows 15  10  15",
        "label": "Entailment"
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "text_answer": "  Yes for the Primary Trial only",
        "label": "Entailment"
    },
    "dd4715db-f06d-4168-962c-22cdd764f2b0": {
        "text_answer": "No  The statement about a patient being diagnosed with diffuse parenchymal lung disease 4 years ago is not mentioned in the inclusion or exclusion criteria for the clinical trial",
        "label": "Contradiction"
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "text_answer": "No  Explanation  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed by the evidence provided The evidence states that there were no adverse events in cohort 1 for Adverse Event 1 and Adverse Event 2 and the same for cohort 2 Therefore there is no information",
        "label": "Contradiction"
    },
    "f5231a1f-83ff-458f-9dbd-40bd55daae92": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial involves denosumab injections not photodynamic therapy and the secondary trial involves injections of Tc99M sulfur colloid for lymphoscintigraphy not nivolumab",
        "label": "Contradiction"
    },
    "b8b1d79d-ce73-4bf6-a67a-0aea38c604c5": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration up to a maximum of 100 mg three times daily whereas patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial is not directly entailed by the evidence provided  The evidence only states that in",
        "label": "Contradiction"
    },
    "c724f8b4-74e9-4f48-ab39-cc8eb21890e6": {
        "text_answer": "Yes  Explanation The primary trial had a reflexology intervention period of 10 weeks while the secondary trial had a vitamin D intervention period of 24 weeks which is an extension of 14 weeks 24 weeks  10 weeks Therefore the statement the intervention period for the secondary trial is extended by 15 weeks is entailed by the evidence",
        "label": "Entailment"
    },
    "f7cbcdf1-cee8-4b88-afff-45901ee871af": {
        "text_answer": "No   Explanation   The statement the secondary trial and the primary trial report results from one patient cohort is not entailed by the evidence provided The primary trial and the secondary trial are two separate studies with different patient populations and outcomes The statement in the question refers to the possibility of the same patient cohort being involved in both trials which is not indicated in the evidence The supplemental qualifiers dataset mentioned in the statement is also",
        "label": "Contradiction"
    },
    "fd5337ee-4098-440b-9e22-0d8c52dbab5a": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the units of measure for the primary trial are changes in units on a scale for vaginal symptoms and for the secondary trial the unit of measure is percentage of participants for objective response rate of HER2negative metastatic breast cancer",
        "label": "Contradiction"
    },
    "b443ed89-9fcb-451a-b0f5-3f23183fbeb0": {
        "text_answer": "No  Explanation  The statement Over 50 of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly entailed by the evidence provided The evidence only states that 20 out of 35 participants in the study had no vomiting and no rescue medication during the first 2",
        "label": "Contradiction"
    },
    "60df29e3-b115-4407-b1f9-dfc2c3d2d3d3": {
        "text_answer": "Yes The secondary clinical trial explicitly states that Women of childbearing potential must commit to the use of effective barrier nonhormonal contraception while on study indicating that children are not eligible for participation",
        "label": "Entailment"
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "text_answer": "Yes  Explanation The evidence shows that in both Arm 1 and Arm 2 of the primary trial over 30 of the participants experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes Therefore the statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the",
        "label": "Entailment"
    },
    "8b59c6dc-98ec-4f07-9274-ba4cc1ff8950": {
        "text_answer": "No  Explanation  The statement germinal center blymphocyte is a mature blymphocyte that is present in the geminal center of a lymphoid follicle is not directly related to the adverse events mentioned in the evidence The evidence only provides information about the number of adverse events in two clinical trials and it does not mention anything about germinal center blymphocytes",
        "label": "Contradiction"
    },
    "f5b7285d-3b0a-496a-84c8-012c4873a7be": {
        "text_answer": "No  Explanation  The statement secondary clinical trial stipulates that patients who have been subjected to chemotherapy or radiotherapy within a fortnight those suffering from unstable angina or experiencing grade 2 or above neuropathy are unable to participate is not entirely entailed by the evidence provided  The primary trial excludes patients who have received chemotherapy or radiotherapy within a certain time frame but it does not specify a",
        "label": "Contradiction"
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "text_answer": "Yes  Explanation The statement the primary trial reports the total Number of Participants Analyzed in the study but does not report the number of participants in each cohort is true based on the given evidence The evidence only reports the total number of participants analyzed for each arm of the study but it does not specify how many participants were in each cohort",
        "label": "Entailment"
    },
    "242b1a1a-4a5e-459b-88ea-41ca86093348": {
        "text_answer": "Yes The statement is entailed by the evidence as both study groups undergo the same imaging processes with slightly different dosages of 18FFPPRGD2",
        "label": "Entailment"
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "text_answer": "Yes   Explanation  The primary trial involves the use of cabergoline which is given orally The secondary trial involves the use of pixantrone which is administered intravenously Therefore the statement that the primary trial intervention is given orally and the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein is entailed by the evidence",
        "label": "Entailment"
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement mentions an intraosseous injection for cohort 1 of the primary trial which is not mentioned in the evidence The evidence only states that cohort 1 of the primary trial receives a Fluciclatide injection but it does not specify the route of administration Similarly cohort 1 of the secondary trial is administered a",
        "label": "Contradiction"
    },
    "d2e448c0-852f-41cc-a53b-866f56e62967": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of Kaposi sarcoma or any digestive systemrelated conditions in the evidence The evidence only mentions vaccine responses against Pneumococcus and Influenza in adult cancer patients and healthy volunteers",
        "label": "Contradiction"
    },
    "c94fb60e-6f9e-48ed-b7b7-4468cb2aa6ee": {
        "text_answer": "  No The statement is not entailed by the evidence as the primary trial is for patients undergoing tissue expander reconstruction following mastectomy and the secondary trial is for patients who have completed surgery for Stage IIII breast cancer The statement does not specify the stage or type of breast cancer",
        "label": "Contradiction"
    },
    "f5a6f0ee-22bd-4731-b973-e8c4736e4d18": {
        "text_answer": "No  The statement is not directly related to the inclusionexclusion criteria for either trial The statement is about ligament injuries and alcohol consumption while the evidence provided pertains to breast cancer patients and their eligibility for clinical trials based on various medical and psychiatric conditions",
        "label": "Contradiction"
    },
    "b12011c4-fa87-4249-97e3-635e6e6805a4": {
        "text_answer": "Yes The evidence does not mention anything about nationality ethnicity psychiatric condition or gender affecting eligibility for the trials The statement is in line with the information provided",
        "label": "Entailment"
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "text_answer": "Yes  Explanation The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed by the evidence since the evidence reports 000 for both deaths and hospitalizations in cohort 2",
        "label": "Entailment"
    },
    "232d082f-2684-445e-8ca6-9cf32c3d1b34": {
        "text_answer": "Yes The primary trial tests eribulin mesylate and the secondary trial tests axitinib  docetaxel which are different drugs",
        "label": "Entailment"
    },
    "1fec40c0-4c6f-4e9d-ae16-a962eb45b4dd": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement is about the Apalutamide regimen being a chemotherapy regimen for prostate cancer while the evidence is about a breast cancer trial with inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "a7c5f410-1001-4c4c-884d-cdbb9e8d69e4": {
        "text_answer": "No  Explanation  The statement less than 005 of patients in the primary trial suffered adverse events is not entailed by the evidence The evidence states that 2 out of 35 patients 571 experienced adverse events which is greater than 005 or 15",
        "label": "Contradiction"
    },
    "32f5c37f-6752-4ebd-840b-d232b65bc138": {
        "text_answer": "No The evidence does not specify that the trials are only open to Australian nationals",
        "label": "Contradiction"
    },
    "635f6674-3151-46bc-8344-33ab60b59bd0": {
        "text_answer": "Yes A woman who has had a mastectomy could still be eligible for the secondary trial as long as she meets the other inclusion criteria for that trial The primary trial eligibility criteria do not mention anything about a rectovesicovaginal fistula",
        "label": "Entailment"
    },
    "8af457d5-2a04-43df-a661-2cf10402def6": {
        "text_answer": "Yes The primary trial had 000 anemia instances compared to 267 in the secondary trial",
        "label": "Entailment"
    },
    "7b2b8832-6e8f-4b56-88fa-5cee3c4e82bf": {
        "text_answer": "Yes  Explanation  The statement the number of aes disclosed was identical for the two cohorts in the primary trial is entailed by the evidence since the number of adverse events AEs listed in both cohorts is the same which is 2 for each cohort",
        "label": "Entailment"
    },
    "42a51c2f-6b39-487e-989c-dcdc0ad231e1": {
        "text_answer": "No  Explanation  The statement is not directly related to the evidence provided in the primary trial The evidence only reports the number of participants who had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products It does not mention anything about septal myocardial infarction or electrocardiographic findings",
        "label": "Contradiction"
    },
    "831e3999-7ce1-4af9-9a28-1282d641a376": {
        "text_answer": "No  Explanation  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 105 mg per week is not entailed by the evidence provided  The primary trial reports on the determination of the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the determination",
        "label": "Contradiction"
    },
    "d0a08aeb-5c7c-44a9-a923-fd4e3b094ebd": {
        "text_answer": "Yes The ORR in the Paclitaxel Plus Bevacizumab group was higher 0489 than in the Paclitaxel Plus Bevacizumab Plus Gemcitabine group 0587",
        "label": "Entailment"
    },
    "8bc20833-6293-47e3-aafe-c7a0ca3be9a6": {
        "text_answer": "No  Explanation  The statement patients that have suffered a pulmonary embolism in the last 20 years are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is not explicitly stated in the provided evidence The primary trial excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first",
        "label": "Contradiction"
    },
    "1cebe988-ac21-4b72-a652-36778fb2cccf": {
        "text_answer": "Yes The evidence shows that the Arm II Control group had a greater median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale indicating worse symptoms on average compared to the Arm I Cryotherapy group",
        "label": "Entailment"
    },
    "338fc59d-601e-42b6-8718-858ffe20928d": {
        "text_answer": "yes the statement is entailed by the evidence The only difference between the two interventions is the dose of durvalumab given and the statement correctly identifies that difference The statement does not mention chromosome 5 or any cytogenic abnormalities but that is not relevant to the comparison being made in the evidence",
        "label": "Entailment"
    },
    "77989b91-bbcc-401e-8cd9-bdd17c0d0e3a": {
        "text_answer": "No  The statement is not directly entailed by the evidence as the two trials investigate different outcomes The first trial investigates the effects of sulforaphane supplements on isothiocyanate levels in urine while the second trial investigates the effects of physical therapy on pain reported on a numeric pain rating scale",
        "label": "Contradiction"
    },
    "e82b4df2-47c8-41ed-9b54-9b3c6917ead3": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does not involve necitumumab dosing and the secondary clinical trial involves two different necitumumab dosing regimens but no mention of dose escalation for the alpha lipoic acid intervention in the primary trial",
        "label": "Contradiction"
    },
    "f0f71529-7742-45c4-945f-ae4e51f9029d": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial no incidents of hypertension edema and dyspnea were observed in both cohorts is entailed by the evidence because neither cohort Adverse Events 1 or Adverse Events 2 reported any incidents of hypertension edema or dyspnea",
        "label": "Entailment"
    },
    "1a8ad1c5-284a-4398-9659-2cdbcb4492d8": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial had two groups intervention and placebo and the secondary trial had two groups as well highdose and lowdose oxybutynin chloride Therefore it is incorrect to label one as a test group and the other as a control group based on the given evidence alone A pragmatic trial as described",
        "label": "Contradiction"
    },
    "c660c228-b490-4779-9ead-ad8b2be40520": {
        "text_answer": "No  Explanation The statement jug dosing unit is a dosing unit equal to the amount of active ingredients in a jug is not related to the evidence provided The evidence only mentions the adverse events observed in a primary trial and the statement is about the definition of a jug dosing unit",
        "label": "Contradiction"
    },
    "9d7e5e1f-b92f-464d-94ea-a7eb3ae730b5": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the given inclusion criteria However the eligibility for the secondary trial cannot be determined without additional information such as the patients creatinine level total bilirubin level ALT and AST levels left ventricular ejection fraction and prior anthracycline dosage",
        "label": "Entailment"
    },
    "5be5cc6c-ba08-4d21-9939-4ccde58aa23e": {
        "text_answer": "No  Explanation  The statement regimen used to treat malignant ovarian neoplasm is any regimen that can be used for the treatment of malignant ovarian neoplasm is a general statement that does not directly relate to the inclusion or exclusion criteria provided in the evidence The evidence only specifies the inclusion and exclusion criteria for two specific clinical trials one for the treatment of advanced cancers with vinorelbine",
        "label": "Contradiction"
    },
    "ca20d0df-b712-4bb0-b320-704d565a99a6": {
        "text_answer": "No  Explanation  The statement have cramps in feet is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The primary trial focuses on breast cancer patients and their eligibility for a clinical trial while the secondary trial focuses on cancer patients undergoing chemotherapy or biologic treatment and their eligibility for a sleep study Neither trial includes a criterion related to foot cramps",
        "label": "Contradiction"
    },
    "a83ef28c-db79-4e1b-9ebd-f563905a9ac7": {
        "text_answer": "  Yes  Explanation  The statement the primary clinical trials acupuncture patients reported greater changes in their lymphedema than those patients who were on the waiting list is entailed by the evidence as the results show that the mean arm circumference in the acupuncture group decreased more than in the waitlist group after 6 weeks of treatment",
        "label": "Entailment"
    },
    "28061f9c-36e0-4f1f-9f51-1c01efd608a1": {
        "text_answer": "Yes The evidence does not mention nationality ethnicity weight or gender as eligibility criteria for either trial",
        "label": "Entailment"
    },
    "c8556c5e-4962-4d9d-8f8d-3cdb07af0627": {
        "text_answer": "No  The evidence provided does not mention anything about cbt cognitivebehavioral therapy being a component of the qualification criteria for either clinical trial",
        "label": "Contradiction"
    },
    "0a418d49-392b-474e-ad3c-df66ab2566ab": {
        "text_answer": "No   Explanation   The statement the primary trial uses a 1 month cycle for its intervention the secondary trial on the other hand does not have a cyclic treatment in place is not directly entailed by the evidence provided The evidence only mentions the number of days for each treatment cycle in the primary trial and does not mention anything about the secondary trial not having a cyclic treatment The statement about longhandled appliances is not",
        "label": "Contradiction"
    },
    "5de55575-82d9-461f-af89-ae41ff70ecb2": {
        "text_answer": "No  The evidence does not specify any nationality or ethnicity requirements for participation in the clinical trials",
        "label": "Contradiction"
    },
    "24523cd0-0fe8-455a-93b6-52367820879a": {
        "text_answer": "Yes The evidence states that patients with histologically proven DCIS are eligible for the trial The statement specifically mentions DCIS patients considering AI therapy",
        "label": "Entailment"
    },
    "3ee347d0-3ba9-4dc8-8387-1fb15cf1e8b3": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial includes patients with locally advanced or metastatic breast cancer and measurable disease which may include larger tumors However the statement specifically mentions patients with a breast tumor 510 cm in diameter which is not explicitly stated in either trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "a7e7e8e0-d2c9-4eee-9aed-1d957044c7dc": {
        "text_answer": "  No the statement about childhood malignant penile neoplasm is not explicitly mentioned in the evidence However children and adolescents are not eligible for the primary trial due to age requirement",
        "label": "Contradiction"
    },
    "760d8b66-18ea-4e33-b83a-b88173ed8574": {
        "text_answer": "Yes  Explanation  The statement there are zero shared inclusionexclusion criteria between the secondary trial and the primary trial is entailed by the evidence because there is no overlap in the inclusion or exclusion criteria between the two trials The primary trial has specific criteria related to cancer diagnosis treatment history and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy and has exclusion criteria related to mental function language ability",
        "label": "Entailment"
    },
    "eb19e1ef-0bad-4d95-8ebd-dcc1f403a946": {
        "text_answer": "Yes  Explanation The primary clinical trial lasted for 10 weeks of reflexology treatment while the secondary clinical trial lasted for 24 weeks of intervention 12 weeks of placebo or vitamin D treatment The difference between the two durations is 14 weeks 10 weeks for the primary trial and 24 weeks for the secondary trial Since the statement mentions an additional 15 weeks it is still correct that the primary",
        "label": "Entailment"
    },
    "29cbfa09-f98c-4991-a6ab-0dc8cca951d3": {
        "text_answer": "No   Explanation  The statement both the primary and secondary clinical trials have documented a number of adverse events is not entailed by the evidence as the evidence states that there were no adverse events in both trials",
        "label": "Contradiction"
    },
    "8881c72a-24fc-48ab-86fb-a1d38392ec33": {
        "text_answer": "No  Explanation  The statement the secondary trial and the primary trial report results using the same Unit of Measure is not entailed by the evidence The primary trial reports results in percentage while the secondary trial reports results in number of participants",
        "label": "Contradiction"
    },
    "b5a078c6-afd5-427e-beab-c7c11cc96da2": {
        "text_answer": "Yes  Explanation The statement the dosage of Zoledronic Acid in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial is entailed by the evidence provided The evidence states that the dosage of Zoledronic Acid in Intervention 1 of the primary trial is 4 mg Q4W 168 mg",
        "label": "Entailment"
    },
    "5d44d70b-1163-4a55-9247-db7bf9a901fc": {
        "text_answer": "Yes  Explanation  The statement there are more total adverse events and more types of adverse events captured in the primary clinical trial than in the secondary clinical trial is entailed by the evidence because the primary trial has a lower number of participants 14 for Adverse Events 1 and 7 for Adverse Events 2 compared to the secondary trial 337 for Adverse Events 1 and 348 for Adverse Events ",
        "label": "Entailment"
    },
    "fe0472bd-acfb-4a56-abed-20b0a4e6b48f": {
        "text_answer": "  Yes The evidence states that patients with measurable or nonmeasurable disease are eligible for the trial Tx Nx Mx T0 N1 M0 and T1 N1 M1 are all possible staging designations for measurable or nonmeasurable disease",
        "label": "Entailment"
    },
    "78c44e7a-6f94-4167-aafa-13c14da01bbf": {
        "text_answer": "Yes The statement is a more specific version of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "text_answer": "No  Explanation  The statement the primary trial participants are administered over 7 different types of drugs and have to undergo surgery whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery is not directly entailed by the evidence provided While it is true that the primary trial involves more types of drugs and surgery the secondary trial is not explicitly stated to involve no surgery whatsoever The evidence only mentions",
        "label": "Contradiction"
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "a68ff0d2-ddc4-4db1-9371-21bec6159585": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "text_answer": "Yes The primary trial includes both male and female patients but the secondary trial only includes female patients",
        "label": "Entailment"
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "text_answer": "Yes  Explanation  The statement All but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is entailed by the evidence since there were 24 AEs reported among the 25 participants  The statement less than half the patients suffered serious TreatmentEmergent Adverse Events is also entailed",
        "label": "Entailment"
    },
    "25c9b995-fedc-45ae-a3c8-d66c116711b0": {
        "text_answer": "Yes  Explanation The statement just one negative occurrence has been noted for the patient contingent of the primary clinical trial is entailed by the evidence as the evidence states that there was one adverse event a negative occurrence out of 29 patients in the trial which is equivalent to a 345 occurrence rate",
        "label": "Entailment"
    },
    "1bf21a6b-6676-4da7-9b80-4fd67722e030": {
        "text_answer": "Yes  Explanation  The statement every inclusion criterion for the primary trial is distinct from those of the secondary trial is entailed by the evidence because there is no common inclusion criterion between the two trials Each trial has unique inclusion criteria and there is no criterion that appears in both trials",
        "label": "Entailment"
    },
    "08793821-1888-49b3-9117-f0548482b5f9": {
        "text_answer": "No  Explanation  The statement the secondary clinical trials second cohort significantly outnumbered the second cohort of the primary clinical trial in terms of patients is not entailed by the evidence provided The evidence only indicates the number of participants analyzed in each cohort for both trials but it does not provide information about the size difference between the second cohorts",
        "label": "Contradiction"
    },
    "396eb2aa-c85e-4477-bdf5-a0926499350a": {
        "text_answer": "No  Explanation The statement a patient who underwent an organ transplant less than four weeks ago may participate in the primary clinical trial but is excluded from the secondary clinical trial is not directly stated in the evidence provided for either the primary or secondary clinical trials The primary trial does mention an exclusion for major surgery within 28 days prior to study registration but it does not specify organ transplant The secondary trial excludes patients who have received any experimental",
        "label": "Contradiction"
    },
    "071c3399-1525-4965-8a3e-b3dfac561b6b": {
        "text_answer": "Yes  The evidence states that dexamethasone is given preoperatively in both interventions but the dosage is different for each cohort However the statement specifically mentions that it is only given to one of the cohorts which is true according to the evidence",
        "label": "Entailment"
    },
    "32d95cac-6a3d-4e4d-a8ac-3371ec9d0da4": {
        "text_answer": "No  The evidence provided relates to inclusion and exclusion criteria for two separate clinical trials one for postmenopausal women with early stage breast cancer and another for healthy participants and HER2positive breast cancer patients The statement about lung cancer eligibility is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "text_answer": "Yes for the primary trial pulmonary embolism is a reason for exclusion within the last 6 months Answer Maybe for the secondary trial it depends on the Investigators decision",
        "label": "Entailment"
    },
    "ff258472-19f3-4dea-8edc-bc591c30fc37": {
        "text_answer": "Yes  Explanation  The statement adverse events such as recurrent cancers graftversushost disease anaemia heart failure and diffuse alveolar haemorrhage were seen more frequently in the primary clinical trial than in the secondary clinical trial is entailed by the evidence provided  The evidence shows that the primary clinical trial had a higher incidence of adverse events overall 600",
        "label": "Entailment"
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "text_answer": "No   Explanation  The statement Candidates for the secondary trial study group receive weekly subcutaneous SC injections whereas the primary trial participants do not receive any injections is not entailed by the evidence The primary trial involves patients with joint aches and vitamin D levels and those with vitamin D deficiency receive vitamin D repletion The secondary trial involves anemic breast cancer participants receiving epoetin beta in",
        "label": "Contradiction"
    },
    "3b6f6c52-5713-45fd-823a-23ab1754539a": {
        "text_answer": "No  Explanation  The statement dietary palmitic acid measurement is a determination of the total 160 palmitic acid in a nutritional product or meal or a portion thereof is not related to the information provided in the evidence about the interventions being given sublingually in the primary trial and orally in the secondary trial The evidence only mentions the route of administration for the Vitamin B12 intervention",
        "label": "Contradiction"
    },
    "bbb61326-9879-44f0-af97-523e7dc2231a": {
        "text_answer": "Yes  Explanation The median aAUCpa values for both the Arm I Cryotherapy and Arm II Control groups are negative indicating that symptoms worsened from baseline The difference between the two groups median values 30 is not statistically significant as evidenced by the wide range of values in each group Therefore the statement no differences in symptom severity were noted between patients in the primary clinical trial who",
        "label": "Entailment"
    },
    "95036529-d29d-4425-90a4-d366664c99c5": {
        "text_answer": "No  Explanation  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation Postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is a summary of the exclusion criteria for the trial However the",
        "label": "Contradiction"
    },
    "1fa45a65-8a51-41e7-af9d-01ab8e0f3e1c": {
        "text_answer": "No  Explanation  The statement hepatotoxicity incidence was not higher compared to the number of hypertension and pancreatectomy cases during the primary clinical trial is not entailed by the evidence The evidence shows that the incidence of hepatotoxicity was 3750 which is higher than the incidence of hypertension 1250 and pancreatectomy 12",
        "label": "Contradiction"
    },
    "2ad5cf58-daab-4432-8670-8964380a4fa9": {
        "text_answer": "No  Explanation  The statement 120 milligrams of denosumab needs to be injected subcutaneously every month for patients in the primary clinical trial is not directly entailed by the evidence The evidence only states that denosumab was injected every 4 weeks in the primary clinical trial but it does not specify the dosage  The statement lymphoscintigraphy is utilized in",
        "label": "Contradiction"
    },
    "4cfe211a-a80a-48ee-993a-2b7c8a91b57c": {
        "text_answer": "No  Explanation  The primary clinical trial is investigating Eribulin Mesylate while the secondary clinical trial is investigating the combination of Axitinib and Docetaxel as well as Docetaxel alone Therefore the statement is not entailed by the evidence as it only mentions one pharmaceutical agent being investigated in both trials",
        "label": "Contradiction"
    },
    "f27a6b09-cfd5-48ac-80d8-a70bd15bcb4d": {
        "text_answer": "No  Explanation  The statement no adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 03 proportion of patients apart from skin infections is not entailed by the evidence While it is true that no adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 03 proportion of patients except for",
        "label": "Contradiction"
    },
    "668cbbc7-bc89-440f-8503-a7e273c4fab3": {
        "text_answer": "Yes The statement does not explicitly state that the symptom interference score is part of the inclusion criteria but the evidence does not exclude it either The focus of the evidence is on the diagnostic and therapeutic criteria for the trials not on the symptom interference score specifically However the statement is consistent with the general concept of considering patient symptoms and functional status in clinical trials as reflected in the ECOG performance status requirement",
        "label": "Entailment"
    },
    "b995d047-8aaf-48fd-9fd7-ebed843b0877": {
        "text_answer": "Yes  Explanation The statement in both the primary clinical trial and the secondary clinical trial a single death was noted in the adverse events is entailed by the evidence as both trials report one death in their respective adverse events",
        "label": "Entailment"
    },
    "f22196d4-1e0f-4626-9736-d78452dc650a": {
        "text_answer": "Yes The statement that over 97 of patients in both trials did not suffer any adverse events is entailed by the evidence as the sum of the percentages of patients with adverse events in both trials is less than 3 The cybb gene mutation is not directly related to the adverse events data provided",
        "label": "Entailment"
    },
    "abb25993-d191-4b47-99c1-fe3b53732dc1": {
        "text_answer": "No  Explanation  The statement ppp2r2a gene mutation is a change in the nucleotide sequence of the ppp2r2a gene is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided in the evidence The evidence only mentions the presence or absence of certain conditions for eligibility or exclusion from the trials The statement about the ppp2r2a gene mutation is",
        "label": "Contradiction"
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is not entailed by the evidence provided The evidence only shows that there was one Thromboembolic event in the secondary trial but it does not mention anything about the primary trial Therefore it is not clear whether or not any patients in the primary trial suffered from Thromboembolic events based on the given",
        "label": "Contradiction"
    },
    "aff21004-0238-46bb-b68b-99d1e3035947": {
        "text_answer": " Neither Yes nor No The evidence does not provide information about the inclusion or exclusion of morbidly obese patients in the clinical trials",
        "label": "Entailment"
    },
    "3762bbcc-dcb8-4173-bf16-934f3c590566": {
        "text_answer": "Yes In the primary trial epacadostat is given twice daily BID while in the secondary trial sunitinib is given once daily Therefore epacadostat is given twice as often as sunitinib in the context of this comparison",
        "label": "Entailment"
    },
    "1616266d-e1bf-4327-9523-f584f713b265": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 The reduction in percentage of cells with Ki67 expression from baseline to 6 weeks was 5 percentage points 15 to 10 Therefore a reduction of 10 in the percentage of cells",
        "label": "Entailment"
    },
    "693c9e39-1648-4f3a-8a23-d642d7355b98": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not directly relate to squamous papillomatosis or its recurrencefree survival between the Ketorolac 30 mg and NaCl 09 3mL groups The evidence only provides information about the number of participants analyzed and their percentage of completion in each group of a trial involving intravenous administration of Ketorolac 30 mg or Na",
        "label": "Contradiction"
    },
    "9321cbe9-2f04-4751-90fd-47a92f424f04": {
        "text_answer": "  No   Explanation   The statement the primary clinical trial accepts patients with histologically or cytologically certified diagnoses of either resectable nonsmall cell lung breast cancer or small cell lung cancer is not explicitly stated in the inclusion criteria of the evidence provided The evidence only mentions that patients with nonsmall cell lung cancer and small cell lung cancer are eligible for the trial There is no mention of the resectable status of",
        "label": "Contradiction"
    },
    "e1c80f41-c3f0-49c8-8fc8-0bfc32e9936a": {
        "text_answer": "Yes  Explanation  The statement no deaths or hospital admissions were observed in the second cohort of the primary clinical trial is entailed by the evidence since the evidence reports that there were no deaths 028 or hospitalizations 028 in the second cohort of the primary clinical trial",
        "label": "Entailment"
    },
    "063f5147-ab53-4f22-b390-bdf6d6589a03": {
        "text_answer": "Yes  Explanation The evidence states that there are two interventions in the primary clinical trial each with a different medication type bisphosphonate and denosumab and a unique administration route IV Q4W and subcutaneous Q12W respectively Therefore the statement that the primary clinical trial offers various medication types each with their own unique administration route is entailed by the evidence",
        "label": "Entailment"
    },
    "1f6d3870-934f-4a75-87a3-0e52c19cd010": {
        "text_answer": "No  Explanation The statement in the question is not entailed by the evidence as the evidence describes the treatment regimens for cohorts A in the primary clinical trial but it does not provide any information about the treatment for cohort B",
        "label": "Contradiction"
    },
    "6fd7b2ea-805b-45ad-b1e7-d073f9944d77": {
        "text_answer": "No  Explanation  The statement the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1 is not directly related to the presence or absence of moderate or severe renal disease in the participants of the trials The statement only compares the dosages of Lenalidomide and Lapatinib used in the interventions of the two trials Therefore the statement does not entail any",
        "label": "Contradiction"
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "2278c029-239d-43ba-9da2-440281e4fd0e": {
        "text_answer": "Yes The evidence does not mention invasive surgeries or the administration of neratinib as part of the primary clinical trial for any of the cohorts",
        "label": "Entailment"
    },
    "f3345897-b99a-4ff2-8bcd-5d1aeb3b698d": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence that there are surgical and imaging procedures involved in the treatment of infant acute undifferentiated leukemia as part of the intervention with MM111",
        "label": "Entailment"
    },
    "32f90f55-6faf-41ed-991a-6f8e9e158200": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the statement incorrectly equates the administration of dexmedetomidine 05gkg or 5ml in the primary trial with myalgias The evidence does not indicate that the patients in group 2 of the primary trial received myalgias only that they received dexmedetomidine In the secondary trial the patients do not receive",
        "label": "Contradiction"
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence only reports a change in Ki67 expression not a change in tumor diameter The statement also incorrectly states that tamoxifen is given at a dose of 32 mg po daily when the evidence states that it is given at a dose of 20 mg po daily",
        "label": "Contradiction"
    },
    "6a83fd1d-9dde-419d-8342-ec1be514869e": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence states that candidates for the primary clinical trial must have HER2 positive tumors either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "91b35ed1-37f4-440a-a82d-99c639ad7e2a": {
        "text_answer": "No  Explanation  The statement the primary clinical trial had twice as many participants with cholelithiasis than the secondary clinical trial is not entailed by the evidence provided The evidence only mentions the number of adverse events for each trial but it does not provide the total number of participants in each trial or the number of participants with cholelithiasis specifically Therefore it is impossible to determine if the statement is true or false",
        "label": "Contradiction"
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "text_answer": "Yes The statement is entailed by the evidence as all the adverse events mentioned in the statement occurred in cohort 1 patients according to the evidence provided",
        "label": "Entailment"
    },
    "5ce47a02-7653-4be0-8747-cc04ae14145a": {
        "text_answer": "No  Explanation The evidence provided does not mention the percentage of participants who did not encounter any adverse effects It only states the percentage of participants who completed the treatment regimen",
        "label": "Contradiction"
    },
    "84246007-e5dd-48da-b548-e0f6403bd67a": {
        "text_answer": "No  Explanation  The secondary clinical trial mentioned in the evidence does not explicitly state that it measures shifts in ki67 expression in tumors While the trial includes various correlative studies such as laboratory biomarker analysis enzymelinked immunosorbent assay mass spectrometry bone scan qualityoflife assessment questionnaire administration and pharmacogenomic studies there is no mention of ki67 expression",
        "label": "Contradiction"
    },
    "a3ab9532-5335-47ab-b19f-33ab64372ce2": {
        "text_answer": "No   Explanation   The statement the secondary trial and the primary trial use different units of measure in their results is true but it is not directly related to the question about the units of measure used in the trials for the outcome measurements of tumor diameter The question asks about the units of measure used in the trials for the outcome measurements while the statement is about the units of measure used in the results of the trials as a whole The trials",
        "label": "Contradiction"
    },
    "19a043cf-96b9-4285-9e9c-1405403bf608": {
        "text_answer": "No  The statement is not entailed by the evidence as metastatic small cell lung cancer is not listed as a tumor type in the inclusion criteria",
        "label": "Contradiction"
    },
    "d5abbde0-b23c-4e60-91fc-cb6a7735b68f": {
        "text_answer": "Yes The statement mentions anemia pneumonia and stupor which are listed as adverse events in the secondary trial The evidence confirms that the secondary trial patients experienced these conditions more frequently than the primary trial patients",
        "label": "Entailment"
    },
    "7ebbbace-7ced-4e16-bfa7-681b1c6f00f3": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the primary trial does not involve the use of lisdexamfetamine and the secondary trial does not involve the same medication as the primary trial Instead the secondary trial involves the use of MCS110 and PDR001",
        "label": "Contradiction"
    },
    "5e38b301-c67d-47dc-8117-ad86b9eeb524": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because  1 The participants in the primary trial are treated with multiple drugs neoadjuvant therapy adjuvant therapy and targeted therapy not just one drug 2 The secondary trial also involves multiple drugs everolimus and exemestane so the statement does not accurately describe the difference between the trials in terms of the number of drugs used ",
        "label": "Contradiction"
    },
    "db15e6cc-ceeb-4f48-b3a1-bca36a6b54f4": {
        "text_answer": "No  Explanation  The statement zero participants in group 1 of the primary trial were discovered to have lesions and over 09 fraction of participants in group 1 of the secondary trial showed symptoms of radiation dermatitis and hyperpigmentation is not entailed by the evidence provided  The evidence only reports the number of participants and the number of lesions detected in each group of the primary trial and the number of",
        "label": "Contradiction"
    },
    "9f5587e3-ff70-42fa-9ddf-e59fc2729d77": {
        "text_answer": "No  The statement is not entailed by the evidence The evidence states that patients with severe intellectual impairment or established depression are excluded from the secondary clinical trial but it does not state that complete disability is a requirement for participation",
        "label": "Contradiction"
    },
    "361464b0-c0ac-404a-8432-ff8100152bff": {
        "text_answer": "No  Explanation  The statement the primary trial reported an equal number of aes for both groups is not entailed by the evidence The evidence shows that there were 2 adverse events in each group but it does not necessarily mean that the number of adverse events was equal for each type of adverse event within each group The statement only refers to the total number of adverse events while the evidence also provides the number of adverse events",
        "label": "Contradiction"
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "text_answer": "Yes The evidence does not mention any Xrays transendocardial injections CT scans or MRIs in relation to the interventions of the primary or secondary trial",
        "label": "Entailment"
    },
    "0c776d98-6a76-407b-9cc8-ded769af766e": {
        "text_answer": "Yes  Explanation  The statement fewer than 50 total adverse events in their cohorts is entailed by the evidence since the total number of adverse events in both trials is 0 which is less than 50",
        "label": "Entailment"
    },
    "1d20e438-806f-4695-bc8f-d6a0ce1f0299": {
        "text_answer": "Yes The evidence states that adequate renal function is required for participation in the clinical trial but it does not explicitly state that liver function must be impaired However the statement normal hepatic function is implied by the exclusion criterion of uncontrolled brain metastases as brain metastases are often associated with impaired liver function due to the livers role in metabolizing certain chemotherapies used to treat brain metastases",
        "label": "Entailment"
    },
    "28002c57-ff24-4b59-9f0e-0dfdbaab7f88": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial intervention involves oral administration of cabergoline while the secondary trial interventions involve intravenous administration of pixantrone dimaleate",
        "label": "Contradiction"
    },
    "55067973-6ec2-4cf7-b98a-6cd2210db8b0": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement mentions different interventions for the primary and secondary trials whereas the evidence only provides information about the interventions within each trial The statement incorrectly assumes that the interventions for the two trials are being compared directly but they are not In the primary trial both cohorts receive fluciclatide injections and in the secondary trial both cohorts receive",
        "label": "Contradiction"
    },
    "84fe3c19-bee9-4639-9569-455cf74f8c64": {
        "text_answer": "No  Explanation  The statement numerous aes were reported by all participants in both cohort 1 and cohort 2 of the primary clinical trial is not entailed by the evidence which states that Adverse Events 1 Total 0147 000 The evidence only reports the total number of adverse events in the trial but it does not provide information about the number of participants",
        "label": "Contradiction"
    },
    "c7fd3efb-5319-40f3-aba0-a54c76a50768": {
        "text_answer": "Yes  Explanation The evidence states that at Week 12 there were 12 participants with SD and at Week 24 there were 10 participants with SD Therefore there were fewer participants with SD in Week 12 compared to Week 24 The evidence also states that there were no participants with CR at Week 12 or Week 24 However the statement does not require the number of participants with CR to",
        "label": "Entailment"
    },
    "c70623c3-85f0-4480-a772-349a89de7d43": {
        "text_answer": "No  Explanation  The statement all the adverse events recorded in the primary trial are linked to the cardiovascular system is not entailed by the evidence The evidence only reports the frequency of various adverse events in the primary and secondary trials but it does not specify which systems or organs are affected by those events The statement makes an unwarranted assumption that all adverse events in the primary trial are related to the cardiovascular system",
        "label": "Contradiction"
    },
    "0f224562-3266-490d-9b52-10a4d84f5685": {
        "text_answer": "No  Explanation  The evidence provided does not mention any unexpected death incidents or hospital admissions The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "9c10ceed-9cc6-473d-87c0-fa0b51353222": {
        "text_answer": "Yes The primary clinical trial does not specify a fixed cycle arrangement while the secondary clinical trial follows a monthly cycle intervention",
        "label": "Entailment"
    },
    "e85599cc-08a6-4270-a168-cac94d5ce47d": {
        "text_answer": "Yes The evidence states that both intervention groups received dexamethasone preoperatively Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "e6a3ed43-5bb0-40b2-9c4b-8a60e2b201df": {
        "text_answer": "No  Explanation  The statement the primary trial includes the administration of fluciclatide to the first cohort whereas the first cohort in the secondary trial is introduced to a standard dose of chloroquine is not directly entailed by the evidence provided The primary trial involves the use of fluciclatide injections while the secondary trial involves the use of chloroquine tablets The statement compares",
        "label": "Contradiction"
    },
    "e21cdb34-eb9d-4439-81ff-6dae554954c6": {
        "text_answer": "Yes The statement there were 11 additional instances of intestinal perforation reported in the secondary clinical trial compared to the primary clinical trial is entailed by the evidence as the evidence states that there were 1 in the primary trial and 11 in the secondary trial instances of intestinal perforation",
        "label": "Entailment"
    },
    "d0a60b09-e029-4c35-b896-3647ce468594": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there is no mention of a her2neu peptide vaccine or sargramostim gmcsf in the given clinical trial interventions",
        "label": "Contradiction"
    },
    "fbda9d7c-12d9-4b04-8047-da25419e1c3b": {
        "text_answer": "No  Explanation The statement participants in the primary trial receive 8 different drugs throughout the study duration with a maximum dose of 500 mgm2 is not entailed by the evidence The evidence only specifies the drugs and dosages used in the neoadjuvant therapy and the number of cycles It does not mention the total number of different drugs or a maximum dose limit for the entire study duration",
        "label": "Contradiction"
    },
    "bf1b6561-6731-457a-801d-8af93bc8857b": {
        "text_answer": "No  Explanation  The patient with a primary tumour of 33 cm diameter would be eligible for the primary trial as per the inclusion criteria mentioned in the evidence However the statement does not specify which trial the patient is being considered for and the secondary trial has a different minimum tumour size requirement greater than 2 cm diameter Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "text_answer": "Yes The evidence mentions surgical and imaging procedures in the context of the primary trial intervention",
        "label": "Entailment"
    },
    "68be42cb-7fb2-491a-a6ad-8f37972f9500": {
        "text_answer": "Yes The evidence does not explicitly mention the ccnd3 gene mutation as a requirement for eligibility but it does not exclude it either The statement that patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer is consistent with the inclusion criteria for the trial which does not specify a requirement for a ccnd3 gene mutation",
        "label": "Entailment"
    },
    "0ef9a5c8-1159-4147-a204-59a3ae183e7d": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as the evidence does not provide any information about the number or type of drugs used in the treatment of thyroid gland lipoadenoma in the primary or secondary trials The statement makes a general assumption about the interventions in the trials which is not supported by the provided evidence",
        "label": "Contradiction"
    },
    "f13676ce-309e-4cf5-866d-542b2a214b27": {
        "text_answer": "No  Explanation  The evidence provided in the results does not allow for a direct comparison of the percentage decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature The statement in question goes beyond the information provided in the evidence and makes a comparison between the two groups based on the magnitude of the decrease which is",
        "label": "Contradiction"
    },
    "ce9ff719-a4b1-4506-91ef-eea478339ced": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence states that sunitinib was administered to participants in the clinical trial",
        "label": "Contradiction"
    },
    "dc545712-7b34-41d2-9166-441ee0366105": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "text_answer": "Yes The evidence explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial",
        "label": "Entailment"
    },
    "b9b32a2d-94f0-413e-95f3-08177622a743": {
        "text_answer": "No  The evidence does not mention anything about a patent delivery system vial in relation to the eligibility criteria for the trial",
        "label": "Contradiction"
    },
    "591794ae-5578-4bb4-a527-106947636ddb": {
        "text_answer": "No   Explanation  The statement in both the primary and secondary clinical trials more than 30 of participants experienced several adverse events is not entailed by the evidence provided The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial It does not provide information on the percentage of participants who experienced any ad",
        "label": "Contradiction"
    },
    "270f0f03-2316-40b0-8e7a-e42c499258da": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is not directly entailed by the evidence provided While it is true that anemia was the most common adverse event in the secondary trial and there were no reported adverse events in the primary trial for the specific adverse event AE 1",
        "label": "Contradiction"
    },
    "fa12778d-4f82-4dd9-8ac0-decbef38472b": {
        "text_answer": "No  Explanation The statement On average patients from the primary trial survive over 2 years is true based on the median survival times provided in the evidence However the statement does not directly address the question of whether patients attend school social events less because of their hearing The two pieces of information are not related",
        "label": "Contradiction"
    },
    "32c2c3e7-4421-49e2-b1d0-2e9b125245e1": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the statement is about a unit of time square millisecond while the evidence is about the percentage of participants experiencing a confirmed complete response CR in a clinical trial using Lapatinib 1000 mg  NabPaclitaxel The two pieces of information are not related",
        "label": "Contradiction"
    },
    "b032a728-a998-4b78-945a-048dbc5126f5": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the percentage change in betaCTX a biochemical marker of bone turnover from baseline to Week 4 for each group It does not provide information about the primary tumour diameter or any changes in that measurement between the two groups Therefore the statement about a greater reduction in primary tumour diameter for the zoledronic acid 4 mg group is not entailed by the evidence",
        "label": "Contradiction"
    },
    "bf5c5c27-0b57-4397-9ba9-3c2895bcbe5d": {
        "text_answer": "  Yes women aged 18 or older are eligible for the secondary trial which is included in the evidence The statement about villous adenocarcinoma is not directly related to the inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "e200f18a-ae9e-490f-a348-537187a65300": {
        "text_answer": "Yes  Explanation  The statement the primary trial recorded a higher incidence of palpitations pericardial effusions and abdominal pains than the secondary trial is entailed by the evidence because the primary trial had a higher number of cases for all three adverse events palpitations 1 vs 0 pericardial effusions 2 vs 0 abdominal pains 2 vs ",
        "label": "Entailment"
    },
    "d6716be9-247d-4c01-beb3-cd5bbbb6f9ec": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes the use of 18FFDG and 18FFPPRGD2 positron emission tomography  computed tomography PETCT imaging for the primary clinical trial study groups not magnetic resonance imaging MRI",
        "label": "Contradiction"
    },
    "61a20e23-7b57-4acc-b594-273f4536941c": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence does not provide any age restriction for the secondary clinical trial",
        "label": "Contradiction"
    },
    "872c6392-9ba9-4224-a579-de0deb401842": {
        "text_answer": "yes for mucositis oral no for epileptic seizures and thromboembolic events The evidence shows that there were fewer cases of mucositis oral in the primary trial compared to the secondary trial However there is no information in the evidence about the number of epileptic seizures or thromboembolic events in either trial",
        "label": "Entailment"
    },
    "ef4f8fe9-1d8e-464f-aa42-c33c073bb493": {
        "text_answer": "No  Explanation The statement there was one psychiatric adverse event in the primary trial which affected less than 1 of patients is not entailed by the evidence because the evidence states that there was one patient with suicidal ideation which is a psychiatric adverse event and this affected 200 of patients not less than 100",
        "label": "Contradiction"
    },
    "44cf1331-403a-4711-84e0-93f677307a6c": {
        "text_answer": "No  Explanation  The primary clinical trial and the secondary clinical trial both involve determining the maximum tolerated dose MTD of an intervention but they use different methods and definitions for what constitutes the MTD In the primary trial the MTD is identified as the level below the cohort where DLT occurred in less than one third of patients within the cohort In contrast in the secondary trial the MTD is defined as the",
        "label": "Contradiction"
    },
    "4a88976f-0af4-449e-97d9-5b3f1ce94668": {
        "text_answer": "Yes The statement is entailed by the exclusion criteria listed in the evidence",
        "label": "Entailment"
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "text_answer": "No  The evidence states that patients with some evidence of cognitive impairment are eligible but it does not specifically mention Frontotemporal dementia or Mixed dementia",
        "label": "Contradiction"
    },
    "2a9e682e-382c-4361-a76f-f4cf5c39819d": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "text_answer": "No  Explanation  The statement The majority of patients in the primary trial experienced complete response by week 24 is not entailed by the evidence The evidence shows that at week 12 there were 0 complete responses CR and at week 24 there were also 0 complete responses However there were 4 partial responses PR and 12 stable diseases SD at week 12 and ",
        "label": "Contradiction"
    },
    "3153ffe1-3625-4900-8a12-861b575959b0": {
        "text_answer": "Yes  Explanation  The statement all groups in the primary clinical trial are administered equal doses of docetaxel doxorubicin and cyclophosphamide during the trial with the same recurrent pattern is entailed by the evidence because both interventions in the trial involve the use of the same doses of docetaxel 100 mgm doxorubicin 60 mg",
        "label": "Entailment"
    },
    "eabae980-d833-47b7-8f0e-82242e662880": {
        "text_answer": "Yes for the secondary trial assuming the woman is 15 years posttreatment and meets other inclusion criteria despite having stage IV BC",
        "label": "Entailment"
    },
    "a8d30960-8533-42a5-949d-3fe706508806": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only specifies the timing of dexamethasone administration as preoperative for both cohorts without mentioning any difference in timing between the two cohorts",
        "label": "Contradiction"
    },
    "28368708-e1e6-416e-8119-0d2712a89380": {
        "text_answer": "Yes The evidence does not explicitly state that patients with severe obesity are excluded from either trial so it does not contradict the statement",
        "label": "Entailment"
    },
    "0b444449-045a-414d-be8e-1ff558525e83": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes the administration of enzalutamide orally to both groups 1 and 2 There is no mention of intravenous administration in the evidence",
        "label": "Contradiction"
    },
    "84a23fa9-2758-4ea6-9eca-ca89b580378a": {
        "text_answer": "No  Explanation  The statement cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine fluorescence in situ hybridization was performed is not directly entailed by the evidence provided The evidence only mentions that there are two interventions in each trial one involving a Fluciclatide injection",
        "label": "Contradiction"
    },
    "745a2452-3a24-4e39-971f-3f7fe661f999": {
        "text_answer": "Yes assuming the statement refers to all participants in the placebo group experiencing emesis during the study period",
        "label": "Entailment"
    },
    "a184cea4-fa4e-4548-a5d7-b3a94ab1130b": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as there is no mention of febrile neutropenia or cholelithiasis in the evidence The evidence only provides information about the occurrence of adverse events including gastroesophageal reflux disease and ductal carcinoma in situ in the primary and secondary trials",
        "label": "Contradiction"
    },
    "552c79f8-3f17-4a7d-be66-d4cdc8749a66": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 002g of mcs110 every 21 days and over 013g of pdr001 every fortnight is entailed by the evidence because   The evidence states that patients receive MCS110 1 mgkg every 3 weeks Q3W and PDR001 ",
        "label": "Entailment"
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "text_answer": "Yes Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Entailment"
    },
    "70130418-63df-4ffb-9d78-7416daee50ba": {
        "text_answer": "No  Explanation  The statement all adverse events recorded in the primary clinical trial were solely associated with members of cohort 2 is not entailed by the evidence provided The evidence only shows that there were no adverse events recorded for any of the listed conditions in either cohort 1 or cohort 2 It does not indicate that all adverse events were recorded in cohort 2 or that there were no adverse",
        "label": "Contradiction"
    },
    "1a8cfb13-ebf0-48c4-a452-e26ac7a14863": {
        "text_answer": "No   Explanation  The statement Neither cohort of the primary trial receives any counselling risk assessment or CBT in the interventions is not directly related to the radiographic finding mentioned in the statement greater than 50 percent area of interest on radiograph is a radiographic finding indicating the area of interest is greater than 50 percent The evidence provided only mentions the use of a validated webbased risk",
        "label": "Contradiction"
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as there is no mention of SCBC small cell lung cancer in the inclusion criteria of the primary trial The statement only mentions nonsmall cell lung cancer",
        "label": "Contradiction"
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "text_answer": "No  Explanation The statement alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly entailed by the evidence provided While it is true that the primary trial excludes patients with a history of alcohol or substance abuse or dependence within the past 2 years the secondary trial also has a criterion that limits alcohol consumption to fewer than 5 drinks per",
        "label": "Contradiction"
    },
    "fdb097f0-b7ba-4314-a865-c89b1179aeb4": {
        "text_answer": "Yes  Explanation The evidence states that there was an increase in pleural effusion in 2500 of patients in the second cohort The statement an increase in pleural effusion was observed in 25 of patients belonging to the second cohort is a paraphrased version of the evidence and is therefore entailed by it",
        "label": "Entailment"
    },
    "93e1969e-1e96-49b2-874f-6cba2e42a6e4": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly summarizes the inclusion criteria for the clinical trial",
        "label": "Entailment"
    },
    "95c7070d-76e7-4618-b95f-56b233dffb16": {
        "text_answer": "Yes The primary trial patients receive fewer total doses of MM121 and Paclitaxel combined than the secondary trial patients While the weekly doses of MM121 are less in the primary trial the weekly doses of Paclitaxel are the same between the trials However the secondary trial patients receive more total weeks of Paclitaxel treatment",
        "label": "Entailment"
    },
    "3592e711-ad4f-4f99-afde-3de2106ee5cd": {
        "text_answer": "Yes  Explanation  The statement the incidence of diarrhea was higher among participants of the primary clinical trial than it was among the secondary clinical trial subjects is entailed by the evidence as the incidence of diarrhea in the primary trial was 2333 compared to 000 in the secondary trial",
        "label": "Entailment"
    },
    "595cee41-9cd2-4e9e-8ba5-2b3620985018": {
        "text_answer": "No  Explanation  The primary clinical trial does use units such as change in units on a scale 4 to 1 and time frame baseline and 12 weeks The secondary clinical trial also uses units such as percentage of participants and time frame 18 months Therefore the statement is not entailed by the evidence as it incorrectly states that neither trial utilizes units such as cm number of participants or time frame for their measurements",
        "label": "Contradiction"
    },
    "32cd31d2-605b-4419-89a7-a6881bb792dd": {
        "text_answer": "No   Explanation   The statement the secondary trial requires patients to be over a certain age but the primary trial does not specify an age range for participation is not directly entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for the primary and secondary trials but it does not mention any age requirements for either trial The statement about alpha thalassemia is not related to the age requirement issue and is therefore irrelevant",
        "label": "Contradiction"
    },
    "e9941afc-cfd4-4bfa-bbce-eec2b84eb27d": {
        "text_answer": "Yes  The statement is entailed by the evidence as the primary clinical trial includes both epirubicin and cyclophosphamide anthracycline and alkylating agent respectively for neoadjuvant therapy followed by docetaxel and trastuzumab taxane and monoclonal antibody respectively for subsequent treatments",
        "label": "Entailment"
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "text_answer": "Yes  Explanation  The statement the secondary trial requires patients to be over a certain age but the primary trial does not specify an age range for participation is entailed by the evidence because the primary trial does not mention any age restriction in its inclusion criteria while the secondary trial specifies that patients must be over 18 years old as an exclusion criterion",
        "label": "Entailment"
    },
    "cbcbfb22-0467-4ba0-b2dc-1f9bd073c27f": {
        "text_answer": " Yes  Explanation The statement in the primary trial results there were more patients with stable disease in the end of the third month than in the end of the sixth month but no patients with complete response in the end of third or sixth month is entailed by the evidence as the evidence shows that there were 12 participants with stable disease at week 12 and 10 participants with stable disease at week 24 Additionally there were no",
        "label": "Entailment"
    },
    "fe1ea6e0-dd6d-44d4-a9db-750c890f08c8": {
        "text_answer": "Yes The statement does not contradict the evidence The evidence only reports the occurrence of adverse events in two trials it does not mention Lactococcus specifically Therefore the statement about Lactococcus being a certain type of bacterium does not conflict with the evidence",
        "label": "Entailment"
    },
    "ab7fc69a-25c8-4bee-ad2b-526c6ea638e4": {
        "text_answer": "No  Explanation  The statement the majority of patients in the primary trial experienced complete response by week 168 days is not entailed by the evidence provided The evidence only reports the number of participants with complete response CR partial response PR or stable disease SD at weeks 12 and 24 There is no information about the number of participants who experienced CR after week 12 or the total number of participants in",
        "label": "Contradiction"
    },
    "44b41322-9fb1-4a02-b2c5-4faead5489aa": {
        "text_answer": "Yes  Explanation  The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence because the evidence shows that the majority of patients in both trials had a total adverse event rate of 000 or 1563 which is less than 50",
        "label": "Entailment"
    },
    "278549fe-1d04-44de-88dc-e0661e8f234b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "824add43-b242-4278-9be4-04f1566039cd": {
        "text_answer": "No   Explanation The statement one injection will be administered to the patients on the eighth day of the study is not explicitly stated in the evidence The evidence mentions that patients will receive Leukine GMCSF therapy until their neutrophil count is greater than 1000mm3 but it does not specify that a single injection is given on the eighth day Additionally the evidence describes the administration",
        "label": "Contradiction"
    },
    "bd89597d-82f5-461f-aa6e-ef215afcc6a5": {
        "text_answer": "No  Explanation  The primary trial and the secondary trial involve different interventions In the primary trial participants receive epacadostat and pembrolizumab while in the secondary trial participants receive sunitinib Although both trials include pembrolizumab the frequency of administration and the combination with other drugs differ Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "46a79c10-315b-4975-9949-508fc379af87": {
        "text_answer": "No  Explanation  The statement 12 adverse events were observed in the course of the primary clinical trial is not entailed by the evidence The evidence states that there were 0 adverse events in the primary trial Therefore the statement that 12 adverse events were observed is not consistent with the evidence",
        "label": "Contradiction"
    },
    "6e971275-b508-4627-9380-39dc63e90b3d": {
        "text_answer": "Yes The evidence does not mention any vaccines being administered to the participants in the primary trial",
        "label": "Entailment"
    },
    "ab6d9f92-0380-4e3a-9bff-032ad4d918ed": {
        "text_answer": "No  Explanation  The statement it was observed that 11000 patients in the primary trial and 3981674 in the secondary trial had an acute myocardial infarction is not entailed by the evidence provided The evidence only states that there were no cases of acute myocardial infarction reported in the primary and secondary trials",
        "label": "Contradiction"
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "text_answer": "No  The statement is not entailed by the evidence provided for either the primary or secondary trial The primary trial excludes patients with a history of clotting disorders but it does not mention breast implants specifically The secondary trial does not mention pulmonary embolisms or breast implants in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "text_answer": "Yes The evidence shows that both cohorts had negative standardized scores indicating below average cognitive function on average but it also mentions that this was not the case for all patients",
        "label": "Entailment"
    },
    "f54c9be8-81b3-4544-9e82-b7058b9911f5": {
        "text_answer": "Yes  Explanation The statement a crucial requirement for both the primary and secondary clinical trials is that candidates must meet a baseline performance status is entailed by the evidence as both trials include Zubrod performance score 2 or better as an inclusion criterion",
        "label": "Entailment"
    },
    "df43c972-9623-462c-9044-2d632e1daafb": {
        "text_answer": "No  Explanation  The statement patients with papillary carcinoma and controlled blood pressure levels are accepted for the primary clinical trial but are not qualified for the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial includes patients with benign breast disease while the secondary clinical trial includes patients with a history of breast cancer including ductal carcinoma in situ or lobular carcinoma in situ",
        "label": "Contradiction"
    },
    "026b062f-0ebf-4e02-9ff8-3bbd12f09ea7": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "70e1b8ee-05e4-4427-ba8b-c8762a677b9a": {
        "text_answer": "No  Explanation  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 05 g of fulvestrant in a tablet form to be taken bid is not entailed by the evidence The primary trial is about radiation therapy for breast cancer patients while the secondary trial is about Enzastaurin and Fulvestrant treatment and there is no mention of fulvestrant being given",
        "label": "Contradiction"
    },
    "f96fa263-12b2-475c-926d-57b8588e85ef": {
        "text_answer": "Yes The statement the primary clinical trial welcomes patients diagnosed with tx nx mx t0 nx m0 or t1 n1 m1 tumors is entailed by the evidence as these are types of breast cancer as defined in the disease characteristics section of the evidence",
        "label": "Entailment"
    },
    "e9f1fcfa-40ed-4360-bf37-4260888d241b": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e21904b2-3e78-4f20-80e3-562a82fc9cfe": {
        "text_answer": "  No children are explicitly excluded from the primary trial but not mentioned in the secondary trials exclusion criteria The statement about coliform bacteria is not related to the given evidence",
        "label": "Contradiction"
    },
    "0ff4990d-1f43-4516-a7b4-62b59526439d": {
        "text_answer": "Yes regarding the requirement of HER2 positive tumor  Explanation The statement All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3 is entailed by the evidence as it is one of the inclusion criteria for the trial",
        "label": "Entailment"
    },
    "02ef43dd-1a1c-49c4-8ce0-01f03f733e81": {
        "text_answer": "Yes  Explanation  The statement subject status subcategory is a subdivision of subject status data is not directly related to the inclusion or exclusion criteria of the primary or secondary trials However the statement 18 years olds are excluded from the secondary trial is an exclusion criterion for the secondary trial and the primary trial does not specify an age range for participation Therefore the age criterion is a subdivision of",
        "label": "Entailment"
    },
    "82080910-276d-4987-8d95-0a39b92ce3ee": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence pertains to breast cancer and the statement is about colon cancer",
        "label": "Contradiction"
    },
    "159bf774-0488-4260-94ed-e106c3e02bf7": {
        "text_answer": "Yes  Explanation  The statement cohort 2 of the primary trial reported fewer incidences of palpitations pericardial effusions and abdominal pains compared to cohort 1 of the secondary trial is entailed by the evidence because the evidence shows that the incidence of palpitations pericardial effusions and abdominal pains were reported in cohort 1 of the primary trial",
        "label": "Entailment"
    },
    "224ad5d9-659b-474a-b9ff-7cb17e104ddf": {
        "text_answer": "No  Explanation The statement does not follow directly from the evidence provided The evidence only gives the median PFS for each treatment group and it does not mention the longest PFS observed in the trial",
        "label": "Contradiction"
    },
    "46299940-216a-446b-bab8-6005845f46c6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "f12f052d-fd1b-407b-a2d9-923f00111a45": {
        "text_answer": "Yes The evidence includes exclusion criteria for women of childbearing potential who are unwilling or unable to use an acceptable method of birth control and for sexually active fertile men whose partners are WOCBP and not using an adequate method of birth control However men and women of reproductive age are not explicitly stated to be excluded and the statement in question allows for this group to be included as long as they meet the other inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "bd7ca920-80f7-4bf8-a09c-3f619056e700": {
        "text_answer": "Yes  Explanation  The statement there were minimal adverse events observed in the secondary clinical trial as compared to the primary clinical trial is entailed by the evidence since the evidence shows that the number of adverse events in the secondary trial was less than the primary trial specifically having a 000 occurrence rate for both Adverse Events 1 and 2 in the secondary trial compared to an unknown total for Adverse Events 1 in",
        "label": "Entailment"
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only includes patients with stage IIII breast cancer",
        "label": "Contradiction"
    },
    "8c002058-a160-4eab-bb58-5874ac1a86d4": {
        "text_answer": "Yes  Explanation The statement specific symptoms are predominantly reported as adverse events in the primary clinical trial is entailed by the evidence as the evidence shows that various specific symptoms such as blood disorder hypomagnesemia platelets count decrease thrombosis visionblurred constipation radiation oesophagitis nausea vomiting general symptom headache and bone pain are reported as",
        "label": "Entailment"
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "text_answer": "  Yes the patient is eligible for the primary trial based on the given inclusion criteria However the eligibility for the secondary trial cannot be determined without additional information such as the patients creatinine level and ECOG performance status",
        "label": "Entailment"
    },
    "f72c1fc3-cfdb-4aa3-a8a8-968f416e35b7": {
        "text_answer": "Yes  Explanation  The statement during the primary clinical trial and the secondary clinical trial no adverse events relating to cardiac or psychiatric conditions were observed is entailed by the evidence since the evidence reports that there were no adverse events of type 1 or 2 and both types are specified as not related to cardiac or psychiatric conditions",
        "label": "Entailment"
    },
    "8623aaca-7fb2-44d5-b968-a064007b7112": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast",
        "label": "Contradiction"
    },
    "5df26e2d-1a55-4d02-b95b-1796c872a7ec": {
        "text_answer": "Yes  Explanation The statement over 910ths of patients in the secondary trial and the primary trial did not suffer any adverse events is entailed by the evidence because the sum of the adverse event percentages for both trials is less than 10 Specifically the total percentage of adverse events for the primary trial is 4545 and the total percentage of adverse events for the secondary trial is 1",
        "label": "Entailment"
    },
    "048dc5c5-ef7e-4717-850e-521e58feecf0": {
        "text_answer": "No  Explanation  The statement amyloid resorption induction is amyloid resorption induction involves initiation of activities involved in the breakdown and assimilation of amyloid deposits the primary trial participants receive Epacadostat twice as frequently as Sunitinibnaive participants in the secondary trial receive sunitinib is not directly entailed by the evidence provided The evidence only mentions the",
        "label": "Contradiction"
    },
    "5ba46a49-9158-4409-815d-0830526da5c4": {
        "text_answer": "No  Explanation  The evidence provided in the text only states the number of participants analyzed in each group and their recurrencefree survival rates It does not provide information about the actual recurrencefree survival data for each participant Therefore it is not possible to determine if 130 participants from the ketorolac 30 mg group reported recurrencefree survival unlike the 48 from the nacl 09",
        "label": "Contradiction"
    },
    "65130a82-a75f-4faa-85a9-5ec4535aa67b": {
        "text_answer": "No  Explanation  The statement provided is a mathematical definition and does not relate to the adverse events data in the evidence The evidence only provides information about the occurrence of adverse events in two different cohorts of a trial without any relation to the unit of concentration mentioned in the statement",
        "label": "Contradiction"
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "text_answer": "Yes  The placebo and Trabectedin interventions are both administered as intravenous infusions but on different days",
        "label": "Entailment"
    },
    "5b19b14f-2049-4c5f-8e3b-5d8dffa5d687": {
        "text_answer": "No  Explanation  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is not explicitly stated in the inclusion or exclusion criteria provided in the evidence SCBC small cell lung cancer is not listed as a type of cancer eligible for the trial and there is no mention of ER estrogen receptor or PR ",
        "label": "Contradiction"
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the statement incorrectly states that the patients in Group 2 of the primary trial receive 05ugkg of myalgias However the evidence only states that Group 2 receives dexmedetomidine not myalgias Additionally the patients in the secondary trial do not receive any myalgias as stated in the question but this is not related to the",
        "label": "Contradiction"
    },
    "18c09a69-f72b-42db-b15b-45e369db34e5": {
        "text_answer": "  No   Explanation   The statement patients with 45 cerebral metastases in the cerebral cortex will be eligible for the secondary trial is not entailed by the evidence provided for the secondary trial as the evidence only states that there is no upper limit for the number of metastases as long as they meet the other eligibility criteria   Regarding the primary trial the evidence states that",
        "label": "Contradiction"
    },
    "cd2cb8fc-7624-479c-b9ee-e2ca3cf5ea18": {
        "text_answer": "Yes  Explanation  The primary trial does not mention anything about the evaluation of Ki67 expression in the tumors of the participants The secondary trial also does not mention the evaluation of Ki67 expression in the tumors of its participants Therefore the variation in Ki67 expression in tumors is not evaluated in both clinical trials",
        "label": "Entailment"
    },
    "6f4c1d2f-4b97-4f77-b25b-004addb58726": {
        "text_answer": "No  Explanation  The statement use of gabapentin or herceptin within the last six months doesnt affect the eligibility for the secondary trial but considers the exclusion from the primary trial is not directly entailed by the evidence provided  The evidence mentions that the use of Herceptin in the last 5 months is an exclusion criterion for the primary trial but it does not mention anything about gab",
        "label": "Contradiction"
    },
    "b9fd7445-fced-4f32-9efb-7e142d1963e2": {
        "text_answer": "No  Explanation  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is not entailed by the evidence provided The evidence only shows the number and percentage of adverse events for each cohort separately It does not directly compare the percentages between the two cohorts  Furthermore the statement mentions 8q241 is a chromosome band present",
        "label": "Contradiction"
    },
    "a52b9758-f769-4350-b617-5215621b815b": {
        "text_answer": "Yes The primary clinical trial involves two arms one with gemcitabine and the other with carboplatin and the doses of carboplatin are different between the two arms",
        "label": "Entailment"
    },
    "bad327e8-73f2-4903-a0bf-ed5d08c81f69": {
        "text_answer": "No  Explanation  The primary clinical trial assesses patients progress by measuring the variation in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary clinical trial assesses the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel and does not mention the assessment of tumor size following completion of chemotherapy",
        "label": "Contradiction"
    },
    "9bd8875f-ce04-496a-b039-6a84bb2e5548": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the primary trial and the secondary trial use different outcome measurements The primary trial measures the change in severity of vaginal symptoms using the Vaginal Symptom Measure VSM while the secondary trial measures the objective response rate of HER2negative metastatic breast cancer using RECIST v10 criteria and FISH testing The statement refers to ",
        "label": "Contradiction"
    },
    "602c538d-9b6f-4a94-8423-b7d5427ee15e": {
        "text_answer": "No   Explanation  The statement is not directly related to the evidence provided The evidence describes the intervention in a primary trial which involves the use of a device and partial breast irradiation The statement discusses post term pregnancy which is not mentioned or related to the intervention in the evidence",
        "label": "Contradiction"
    },
    "5e094086-297e-44c7-9119-aa451e326e8c": {
        "text_answer": "No  Explanation The statement women aged 18 or older are eligible for the secondary trial and the primary trial is not directly related to the given evidence The evidence only provides the inclusion and exclusion criteria for the primary and secondary trials The statement introduces a new concept a high inspiratory pressure alarm device which is not mentioned in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "fc16338c-2505-48c4-ab18-e7de394cab62": {
        "text_answer": "Yes The evidence does not explicitly state that AfricanAmerican patients are excluded from the trial so they are eligible to participate The term borderline resectable mass is also mentioned in the evidence referring to a tumor mass that is not yet resectable but may become so with further treatment",
        "label": "Entailment"
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "text_answer": "Yes The statement is entailed by the evidence as the statement mentions breast cancer and requiring hormonal treatment which are both inclusion criteria in the evidence",
        "label": "Entailment"
    },
    "e561775c-d739-405c-ac1e-a8a9ccca4530": {
        "text_answer": "No  Explanation  The statement the primary trial adminsters its intervention sublingually and the secondary trial adminsters it orally is not directly entailed by the evidence provided The primary trial does indeed administer Vitamin B12 sublingually but the secondary trial administers memantine orally not Vitamin B12 Therefore the statement is not a valid conclusion based on the evidence given",
        "label": "Contradiction"
    },
    "5ed2538b-155d-4527-aa80-b6a19c5a6602": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not directly measure primary tumor diameter but rather the percentage change in serum betaCTX levels from baseline to week 4 Therefore the statement about a greater reduction in primary tumor diameter for the AZD0530 175 mg group is not entailed by the evidence",
        "label": "Contradiction"
    },
    "a680a9d1-387f-48e3-8e30-01b306c0b964": {
        "text_answer": "  Yes the statement is entailed by the evidence for the secondary trial regarding documented allergy to cephalosporin and trimethoprimsulfamethoxazole However it does not directly relate to the primary trial as it does not mention celecoxib or allergies in that context",
        "label": "Entailment"
    },
    "3d580aba-2e7b-44bc-a094-83f404ebbd6a": {
        "text_answer": "No   Explanation   The primary trial measures the change in units on a scale for vaginal symptoms while the secondary trial measures the percentage of participants with objective response rate for HER2negative metastatic breast cancer CogState is not mentioned in the evidence provided for either trial",
        "label": "Contradiction"
    },
    "cf1b44d2-94e8-49b6-adbf-036a44f28402": {
        "text_answer": "Yes  Explanation  The statement primary clinical trial records a larger number of bronchopneumonia and general physical health deterioration cases than the secondary clinical trial is entailed by the evidence because the evidence shows that there is at least one case of bronchopneumonia in the secondary trial while there is no mention of bronchopneumonia in the primary trial Similarly the evidence shows that there are two cases of general physical health deterior",
        "label": "Entailment"
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "text_answer": "Yes  Explanation The evidence states that 1 out of 4 patients in cohort 2 experienced increased pleural effusion which is equivalent to 25 of the cohort Therefore the statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is entailed by the evidence",
        "label": "Entailment"
    },
    "86dd343d-01be-46f6-aed5-9ad9423aca98": {
        "text_answer": "No  Explanation  The statement 500 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for one type Adverse Events 1 in each trial Therefore it is not possible to determine if the statement is entailed by the evidence based on the given information alone  Additionally the statement none of the adverse events in the secondary trial affected",
        "label": "Contradiction"
    },
    "22a06af0-a4f9-4311-92e0-d2d13a24b9b1": {
        "text_answer": "Yes  Explanation  The statement the adverse events such as recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were notably more prevalent in the primary clinical trial than the secondary clinical trial is entailed by the evidence as the primary clinical trial had a higher percentage of adverse events for all the mentioned conditions compared to the secondary clinical trial",
        "label": "Entailment"
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "text_answer": "Yes  Explanation The statement The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial is entailed by the evidence because the dosage of Denosumab in Intervention 1 of the primary trial is 120 mg Q4W and the dosage of Tamoxifen in intervention 1",
        "label": "Entailment"
    },
    "6e2f3c50-84c2-41e2-8188-a83c94b2704b": {
        "text_answer": "No  Explanation  The statement eyelid oedema upper gastrointestinal haemorrhage and chest pain were the only adverse events observed in patients from the secondary clinical trial is not entailed by the evidence provided The evidence only shows that eyelid oedema occurred in one patient in the secondary trial and chest pain occurred in one patient in the secondary trial and none in the primary trial Upper gastroint",
        "label": "Contradiction"
    },
    "bad8129b-64a4-4dfc-bb88-8bcea4fe2dc4": {
        "text_answer": "No  Explanation  The statement cohort 2 of the primary clinical trial experienced significantly fewer incidents of neutropenia compared to cohort 1 of the secondary clinical trial despite receiving larger doses of empegfilgrastim is not entailed by the evidence provided The evidence only shows the mean duration of neutropenia and the number of participants with neutropenia for each cohort in the primary and secondary trials",
        "label": "Contradiction"
    },
    "603ccef1-eacf-4053-85d3-106eda10ca83": {
        "text_answer": " No   Explanation  The inclusion criteria state that the breast cancer must be unilateral meaning it affects only one breast Therefore patients with detectable malignancies in both breasts do not meet the inclusion criteria and are not allowed in the primary clinical trial",
        "label": "Contradiction"
    },
    "4ac023d3-e86c-47bb-bbd5-1b6907e8cab3": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "ed3e6033-e499-4743-9aca-a275a80a1e4e": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence does not provide any information about human papillomavirus or head and neck squamous cell carcinoma The evidence only reports the correlation of vitamin D levels with gene expression profile in breast cancer patients",
        "label": "Contradiction"
    },
    "3c749ffd-27b3-473d-92c9-c4d3899c9689": {
        "text_answer": "Yes Both trials measure pCR as their outcome The primary trial has a small difference in pCR rates between the two arms while the secondary trial shows a larger difference in pCR rates between the two arms",
        "label": "Entailment"
    },
    "5ce949a2-19fb-4580-8b0e-f0652dd064e3": {
        "text_answer": "No  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify tumor size",
        "label": "Contradiction"
    },
    "2f5d2e0a-6378-4b00-b5ed-760d021808c8": {
        "text_answer": "Yes The evidence does not directly address sacral intraspinal meningioma but it does not exclude individuals with a history of breast cancer from participating in the secondary trial Therefore a woman who has had a mastectomy for breast cancer could still be eligible for the secondary trial Similarly the primary trial does not exclude individuals with a history of cancer as long as it is not breast cancer and they are undergoing implant only breast reconstruction",
        "label": "Entailment"
    },
    "96ee335e-d938-4b45-a22d-49b03dbb2af0": {
        "text_answer": "No  Explanation  The evidence provided in the trial results does not mention anything about Enterovirus or Poliovirus The statement is not related to the evidence presented",
        "label": "Contradiction"
    },
    "38e0b539-6f73-4e11-bb55-0b021f66ee84": {
        "text_answer": "No  Explanation  The statement patients in both cohort 1 and 2 are subjected to the same radiation therapy doses but the procedure for cohort one extends for an extra two weeks is not entailed by the evidence While it is true that both cohorts receive the same radiation therapy doses the statement incorrectly assumes that the only difference between the two cohorts is the duration of the procedure However",
        "label": "Contradiction"
    },
    "ee03b5cc-6cfe-4b3a-8429-493f95c97b71": {
        "text_answer": "No  Explanation The primary clinical trial includes a requirement that the primary tumor size be greater than 2 cm in diameter while the secondary clinical trial does not mention any specific requirement regarding tumor size Therefore a patient whose primary tumor size is not measurable by clinical examination or echography would not meet the inclusion criteria for the primary clinical trial and it is not clear whether they would meet the inclusion criteria for the secondary clinical trial without additional information",
        "label": "Contradiction"
    },
    "e9c0f175-b715-4b33-86a2-aa21c2990164": {
        "text_answer": "Yes  Explanation The evidence states that patients in Intervention 1 receive Active Breathing Coordination ABC during radiation therapy while patients in Intervention 2 do not The radiation therapy doses are the same for both groups but the presence or absence of ABC is the difference between the two interventions Therefore the statement patients in cohort 1 of the primary clinical trial receive different radiation therapy doses in comparison to those",
        "label": "Entailment"
    },
    "827cb89b-a78f-49e9-b342-d00e7b46e61f": {
        "text_answer": "  No  Explanation  The evidence provided in the trial results does not directly measure primary tumor diameter but rather the percentage change in serum betaCTX levels from baseline to week 4 The statement in question makes a claim about the reduction in primary tumor diameter between the two groups which is not supported by the evidence presented",
        "label": "Contradiction"
    },
    "4bc6699d-0ac2-4358-9425-1d377151ffa8": {
        "text_answer": "Yes  Explanation  Both the primary and secondary clinical trials report the determination of the maximum tolerated dose MTD of an intervention ruxolitinib in the primary trial and MM111 in the secondary trial Therefore the statement that the maximum tolerated doses of diverse interventions are reported in both trials is entailed by the evidence",
        "label": "Entailment"
    },
    "a0ebcb11-7643-4861-b26c-8b1716fd00c1": {
        "text_answer": "No  Explanation  The statement there were no deaths or Hospitalizations in cohort 2 of the primary trial is not directly related to the question about when individuals in the study first began smoking cigarettes regularly The evidence provided only mentions the number of adverse events deaths and hospitalizations in each cohort but it does not specify when these events occurred in relation to the smoking habit Therefore the statement is not ent",
        "label": "Contradiction"
    },
    "13d13c8d-1d58-411f-943b-cbcd836b8d17": {
        "text_answer": "No  Explanation The statement mobilization clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered mobilization therapy is not directly related to the given evidence The evidence only provides information about the doses of ALT801 administered in two different cohorts of a primary trial The statement makes a generalization about a clinical trial setting and the term mobilization therapy but the evidence does not",
        "label": "Contradiction"
    },
    "09f76c97-d8e4-45bd-9365-71e654770e39": {
        "text_answer": "Yes  Explanation The statement midline is a medial line especially the medial line or medial plane of the body or some part of the body is not directly related to the evidence provided However the evidence does mention the use of cyclophosphamide Paclitaxel and pegfilgrastim in both trials Therefore the statement is not contradictory to the evidence and is still considered true",
        "label": "Entailment"
    },
    "1ccb499d-d126-4ec6-bed1-c121dfa13d2d": {
        "text_answer": "Yes  Explanation  Both trials include patients who are 18 years of age or older",
        "label": "Entailment"
    },
    "909d54ab-358d-4892-9bd1-e71d6d3bc24c": {
        "text_answer": "No  Explanation The statement the percentage of cells expressing ki67 increased by 8 after treatment with tak228 plus tamoxifen in the primary clinical trial is not directly entailed by the evidence provided The evidence only states that the median IQR of Ki67 expression at baseline was 15 1025 and at 6 weeks was 10 238 The",
        "label": "Contradiction"
    },
    "15f4f1d2-c4db-403e-83ed-85e6958ee7ed": {
        "text_answer": "No  Explanation  The statement the number of adverse events in the secondary clinical trial was greater compared to those in the primary clinical trial is not entailed by the evidence provided The evidence only states that the number of adverse events for Adverse Event 1 in both trials was zero There is no information provided about the number of adverse events for Adverse Event 2 in either trial let alone a comparison between the two trials Therefore",
        "label": "Contradiction"
    },
    "0c4d0064-476e-426e-ae13-4f53c07ea0b4": {
        "text_answer": "No  The primary clinical trial excludes participants who have previously received fulvestrant or enzastaurin and have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry These conditions would make it impossible for an AI therapy responsive participant to participate in both trials simultaneously",
        "label": "Contradiction"
    },
    "34208e81-25b5-40a7-ba91-ffdece7c96e1": {
        "text_answer": "Yes The evidence states that there were 12 participants with SD at week 12 and 10 participants with SD at week 24 This represents a decrease in the number of participants with SD Additionally the evidence states that there were no participants with CR at week 12 or week 24 but several participants exhibited PR at both time points",
        "label": "Entailment"
    },
    "afa65be8-62bf-4c63-8670-a997a06c6943": {
        "text_answer": "No  The evidence does not mention any fatalities in either trial",
        "label": "Contradiction"
    },
    "c4ab76ed-d3ce-4368-b081-c39413094966": {
        "text_answer": "Yes The statement is entailed by the evidence as it correctly states that no adverse events occurred during the primary trial and that all adverse events except for skin infections were seen in less than 30 of patients during the secondary trial",
        "label": "Entailment"
    },
    "cac3538f-89a2-4037-9928-4aaa708ae34f": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence because the secondary trial does not provide enough information to determine whether or not the patients are being treated with suramin and paclitaxel The evidence only states that the secondary trial does not outline the medications to be administered in its intervention section it does not mention whether or not suramin and paclitaxel are being used in the secondary trial",
        "label": "Contradiction"
    },
    "abd83d4d-ac75-4626-928d-1b511a61d2b7": {
        "text_answer": "No  Explanation The evidence provided does not give any information about the longest PFS observed in the trial The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "dc3aaeaa-d573-410b-a1f2-a55af755fc83": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence describes a specific regimen of neoadjuvant therapy consisting of multiple drugs with varying dosages and schedules",
        "label": "Contradiction"
    },
    "8a3619a4-4224-4451-b7f8-8fc2ff8ec26f": {
        "text_answer": "Yes The exclusion criteria state that individuals who have received antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry are not eligible The statement extends this to include individuals who have received these therapies within 2 years prior to study entry",
        "label": "Entailment"
    },
    "710206ba-d90c-4341-a1ae-b937ffc50a2f": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence reports that there were no participants with complete response at either week 12 or week 24 The statement also correctly reports that there were more patients with stable disease in week 12 than week 24",
        "label": "Entailment"
    },
    "29fce0a9-c8ac-4851-afbf-a0fbd8357eb9": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only reports the Ki67 expression at baseline and at 6 weeks after treatment It does not provide information about the Ki67 expression at 12 months after treatment Therefore it is not possible to determine if the statement about a 150 reduction in Ki67 expression after 12 months of treatment is entailed by the evidence",
        "label": "Contradiction"
    },
    "08d2198a-3bd7-453e-8ad1-0e35312cb348": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not indicate that at least one patient treated with GTx024 1mg gained over 10 kilos of lean body mass The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 kg This means that some patients lost lean body",
        "label": "Contradiction"
    },
    "d0856f66-d9fb-4bbd-906e-9602d9121c22": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "9ab1125f-0d0b-4480-b5c2-8a09378a8df4": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fb362bcb-d93e-4d35-9127-db0efd9012dc": {
        "text_answer": "Yes  Explanation  The evidence provided indicates that the primary and secondary clinical trials recorded all adverse events which is a necessary component of ensuring transparency The statement in question acknowledges this transparency and the meticulous recording of adverse events making it entailed by the evidence",
        "label": "Entailment"
    },
    "dcb23a61-648b-4831-92e9-9e61cc596be3": {
        "text_answer": "No  The evidence mentions adequate liver function as an inclusion criterion but it does not state that there are no conditions on hepatic function for participants It does not address the question about breast loss at all",
        "label": "Contradiction"
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "text_answer": "Yes  Explanation  The primary trial had one test group Intervention 1 and one placebo group Intervention 2 The secondary trial had two test groups Highdose Oxybutynin Chloride Group and Lowdose Oxybutynin Chloride Group Therefore the statement the secondary trial had 2 test groups is entailed by the evidence",
        "label": "Entailment"
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "text_answer": "Yes  Explanation The statement 3636 of the primary trial patients suffered an increase in Blood bilirubin is entailed by the evidence as it is explicitly stated that 1 out of 11 patients 909 experienced an increase in Blood bilirubin To find the percentage we can divide the number of patients with the adverse event by the total number of patients and multiply by 100",
        "label": "Entailment"
    },
    "726f25cd-4611-43a5-b7c6-15f7393b67ee": {
        "text_answer": "No  Explanation  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed by the evidence provided The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide",
        "label": "Contradiction"
    },
    "3670694c-a13e-4639-bc3d-e51db3bf8149": {
        "text_answer": "No  Explanation The statement Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention is not directly stated or entailed by the evidence provided The evidence only reports the percentage of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention for both the Collaborative Care Intervention CCI",
        "label": "Contradiction"
    },
    "a830799d-017f-4656-aed0-d428d5e0c73f": {
        "text_answer": "Yes The evidence shows that there were no adverse events reported in cohort 2 while all adverse events were reported in cohort 1 Therefore every documented adverse event occurred among the cohort 1 patients",
        "label": "Entailment"
    },
    "2d241b66-d0a0-4012-9d5b-1ef1a74bcd79": {
        "text_answer": "Yes  Explanation The primary clinical trial involved reflexology treatment given for 10 weeks while the secondary clinical trial involved vitamin D supplementation given for 24 weeks Ten weeks is three times shorter than twentyfour weeks so the statement that the duration of intervention in the primary clinical trial extends three times shorter than that of the secondary clinical trial is not correct However the statement that it extends three times longer is also not correct but the",
        "label": "Entailment"
    },
    "67fc355a-1537-479d-b0fc-cd39bdb3cf6d": {
        "text_answer": "No  Explanation  The statement The dosage of Zoledronic Acid in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial is not directly entailed by the evidence provided The evidence only mentions the dosages and schedules of the interventions in each trial but it does not make a comparison between the two dosages or indicate",
        "label": "Contradiction"
    },
    "ef3e540e-b8dc-4fd5-9eaa-f32a657a57c6": {
        "text_answer": "Yes Both trials require patients to have a functional ECOG status less than 2",
        "label": "Entailment"
    },
    "9b49f98a-af07-455e-af36-4f6a3f7e3e52": {
        "text_answer": "Yes The primary trial had a lower frequency of pericardial effusions 045 compared to the secondary trial 1111",
        "label": "Entailment"
    },
    "c6e42e3e-8900-43bb-b1de-61f1d1dcf075": {
        "text_answer": "No  Explanation  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort t1114 positive is a cytogenetic finding indicating that the translocation t1114 has",
        "label": "Contradiction"
    },
    "b181b889-6991-4710-a94c-536591db88fc": {
        "text_answer": "No  The statement is not entailed by the evidence as the inclusion criteria specify HER2 positive tumor either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "d3302027-c157-4d58-8653-cf5053658fad": {
        "text_answer": "No  Explanation The evidence provided in the primary trial only mentions the administration of Dexamethasone to the intervention groups before surgery It does not provide any information about individuals coughing up blood Therefore the statement did you cough up blood is not entailed by the evidence",
        "label": "Contradiction"
    },
    "e7203466-5ee1-4733-ac54-730489e348b2": {
        "text_answer": "No  The placebo intervention is administered via injections not orally and the dose is the same as that of the alloMSCs intervention",
        "label": "Contradiction"
    },
    "bb7c2e9b-0a9b-48da-97e8-3a78ca82966f": {
        "text_answer": "Yes  Explanation The evidence shows that the percentage of participants who were up to date for colorectal breast and cervical cancer screenings increased after the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups However the baseline percentages of participants who were up to date for all three types of cancer were relatively low ranging from 220 to 43",
        "label": "Entailment"
    },
    "90432ec4-8df5-408b-8998-39f2a698314d": {
        "text_answer": "No  Explanation The primary trial does not mention anything about heart transplant as an exclusion criterion However it does mention that participants must have adequate cardiac function LVEF  50 The secondary trial does exclude participants with severe heart disease but it does not specifically mention heart transplant as a criterion Therefore the statement about bedridden patients following a recent heart transplant being accepted into the primary trial but disqual",
        "label": "Contradiction"
    },
    "a3b8086c-3eec-402c-8b95-4446b33673b6": {
        "text_answer": "  Yes for the primary trial No for the secondary trial with the additional requirement of Her2neu breast cancer",
        "label": "Entailment"
    },
    "6fe2c751-a06e-4679-a13d-3335fe5887e2": {
        "text_answer": "No  Explanation The evidence provided in the trial description does not mention paclitaxel or any cohort receiving it as part of their treatment The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ed6a6f04-0b3d-4dc7-96fd-2f0547d6fe17": {
        "text_answer": "No  Explanation The primary trial has a specific criterion for the number of cerebral metastases one to three which is a reason for inclusion The secondary trial does not mention anything about the number of cerebral metastases Therefore having a single cerebral metastasis does not automatically lead to an exclusion from the primary trial but allows eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "213bae99-da68-4307-a7c9-71343afbcd39": {
        "text_answer": "Yes The primary clinical trial involves a threeweek cycle of treatment while the secondary clinical trial does not specify a cyclic treatment schedule",
        "label": "Entailment"
    },
    "97e71457-8a63-4bf3-b1cf-b2743433e7f2": {
        "text_answer": "Yes The evidence does not mention any drugs radiotherapy or CBT being used in the interventions",
        "label": "Entailment"
    },
    "eb93eb13-978c-4f27-8c2b-c3ddddcbafcf": {
        "text_answer": "Yes The primary trial patients receive fewer total doses of MM121 and Paclitaxel per cycle compared to the secondary trial patients However the statement does not directly address the weekly dosage but the total amount received over the course of the trial Therefore the statement is technically correct but not an exact match to the question",
        "label": "Entailment"
    },
    "783f37e2-d649-493a-9d0c-0de214ff8ad2": {
        "text_answer": "  No   Explanation   The statement patients who have recently undergone chemotherapy or radiotherapy or those suffering from unstable angina or having neuropathy greater than grade 2 can participate in the secondary clinical trial is not entailed by the evidence   The evidence lists specific exclusion criteria for the primary and secondary trials For the primary trial patients who have undergone chemotherapy or radiotherapy",
        "label": "Contradiction"
    },
    "eae69c88-b4bc-4683-aacf-60d287e4eebc": {
        "text_answer": "No  The statement is not related to the evidence provided The evidence only discusses information about two clinical trials their outcome measurements results and participant numbers It does not mention Simfibrate or its relation to the trials",
        "label": "Contradiction"
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "text_answer": "Yes Both cohorts had the same number of participants 1420 each",
        "label": "Entailment"
    },
    "f4fd9b7c-ccd9-4131-95d0-2a3a8071faf4": {
        "text_answer": "No  Explanation  The statement 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed by the evidence provided The evidence only reports the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide a comparison of the differences",
        "label": "Contradiction"
    },
    "8b2b5b8e-3723-4261-8fd5-a624c9367ef2": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the percentage change in serum betaCTX levels for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided in the question is about gastric dysplasia and the reduction in primary tumor diameter between the two groups These two pieces of information are not directly related to each other and the evidence does",
        "label": "Contradiction"
    },
    "386a63a3-cd3f-4f8c-af45-cfe9b26e4bc6": {
        "text_answer": "No  The statement is not entailed by the evidence as the frequencies of pericardial effusions and corneal deposits were not mentioned in the same context in the primary and secondary trials",
        "label": "Contradiction"
    },
    "d3177b24-1a89-40d0-b3a5-e79870dc216e": {
        "text_answer": "No  Explanation  The statement the primary clinical trial reported a higher incidence of infection asymmetry and nausea than the secondary clinical trial is not entailed by the evidence provided The evidence only reports the number of adverse events for each trial but it does not compare the incidence rates between the trials for each specific adverse event Infection asymmetry and nausea are not mentioned in the secondary trial at all so",
        "label": "Contradiction"
    },
    "bc03d7d7-65ed-4331-a5c9-997968a47547": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence reports the occurrence of adverse events AEs in the primary clinical trial",
        "label": "Entailment"
    },
    "ef73b41f-a188-41e1-af84-8ba9ee13d6c6": {
        "text_answer": "Yes  Explanation  The evidence provided in the results 1 and 2 indicates that there were no lifethreatening adverse events reported among the three participants in the Dose Level 1 group Therefore the statement not a single lifethreatening adverse event was registered among cohort 1 participants in the primary clinical trial is entailed by the evidence",
        "label": "Entailment"
    },
    "f11744ff-fa1a-4d98-ad4a-03fe1fa9e519": {
        "text_answer": "Yes the statement is not entailed by the evidence as the evidence does not mention anything about life expectancy pregnancy or age conditions for participants",
        "label": "Entailment"
    },
    "205a0d18-ba5e-4efd-b403-557bf188daa2": {
        "text_answer": "Yes  Explanation The evidence states that under 50 of the participants in the Highdose Chemotherapy arm experienced a reduction in circulating tumor cells CTCs at one month post autologous hematopoietic stem cell transplantation AHST Therefore the statement under 50 of the primary clinical trials participants experienced a decrease in circulating tumor cells after receiving highd",
        "label": "Entailment"
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "text_answer": "Yes  Explanation The primary trial includes women with locally advanced recurrent or metastatic breast cancer that is ER and considering a mastectomy would fall under the category of locally advanced breast cancer in the secondary trial Therefore these women would be eligible for both trials based on the given criteria",
        "label": "Entailment"
    },
    "70310501-6b9e-4283-9981-5f709b9517b6": {
        "text_answer": "Yes  Explanation The statement over 015 of patients in the primary trial and the secondary trial suffered from infections during the study period is entailed by the evidence since the primary trial had 132 313 patients with infection as an adverse event and 115 667 patients in the secondary trial had infections as an adverse event In total 24",
        "label": "Entailment"
    },
    "5677aa15-f929-41ac-97e2-07857e792505": {
        "text_answer": "Yes  Explanation  The statement in their results the primary clinical trial and the secondary clinical trial consider distinct patient characteristics is entailed by the evidence because the primary clinical trial involves the use of HER2specific T cells while the secondary clinical trial involves the use of trastuzumab emtansine The trials also have different patient populations with the primary trial focusing on a smaller number of participants receiving a more complex treatment regimen",
        "label": "Entailment"
    },
    "a1c132f7-d56a-4d89-96eb-b37310cd37d6": {
        "text_answer": "Yes  Explanation  The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1100 participants is entailed by the evidence because the evidence shows that in both trials the number of adverse events was 0 for all participants including those with neutrophilsgranulocytes ANCAGC abnormalities Therefore no adverse event",
        "label": "Entailment"
    },
    "cbe273ac-6267-4827-8ba2-8c8c34d69115": {
        "text_answer": "Yes  Explanation The statement patients in the secondary trial experienced anemia pneumonia and stupor more frequently than those in the primary trial is entailed by the evidence as the frequency of these adverse events is higher in the secondary trial The statement a higher occurrence of febrile infections was noted in the primary trial is also entailed by the evidence as the frequency of febrile infections is higher in the",
        "label": "Entailment"
    },
    "f2217745-3601-4f6e-b893-11ca72e32556": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence provided The primary trial mentions two different interventions with different dosages of dexmedetomidine but it does not mention a group 7 or any information about the secondary trial Therefore it is not possible to determine if the statement is true or false based on the given evidence alone",
        "label": "Contradiction"
    },
    "9ddda9ad-0cb3-4ea8-8abe-59b227a8290d": {
        "text_answer": "No  Explanation  The statement the number of participants varied significantly between the two cohorts of the primary clinical trial is not directly entailed by the evidence provided The evidence only reports the percentage of participants with events in each cohort Neratinib and Placebo at Year 2 but it does not provide information about the total number of participants in each cohort or whether there is a significant difference between them",
        "label": "Contradiction"
    },
    "2bf60bd1-4d11-4a7d-9d69-7f13e93df39c": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not provide information about a testosterone cream group The evidence only compares the changes in lymphedema between an acupuncture group and a waitlist control group",
        "label": "Contradiction"
    },
    "75e0a9f9-003d-4bfe-a720-4f84d2d0e7b4": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence reports a decrease in Ki67 expression not an increase in tumor size The statement also specifies a different dosage and duration of tamoxifen administration",
        "label": "Contradiction"
    },
    "7a4c195c-e5a6-49b5-b8de-842704bfe7f4": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "58c1c63d-fcf2-400d-af60-9f33c9820f1b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the outcome measurements in the two trials are different The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH and the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "49a7e9fa-4a0f-4bce-ab0c-c13056e98de2": {
        "text_answer": "Yes regarding the absence of UTI in the trial However the statement does not directly address the improvement aspect",
        "label": "Entailment"
    },
    "8665ed72-5c94-4c4f-8dbc-a6950275ca98": {
        "text_answer": "No  Explanation  The statement those patients with a history of chemotherapy or radiotherapy within the preceding 2 weeks or those exhibiting signs of unstable angina or showing grade 2 or better neuropathy are not eligible for the secondary clinical trial but could remain eligible for the primary clinical trial if all applicable inclusion criteria are satisfied is not directly entailed by the evidence provided  The evidence lists specific exclusion criteria for",
        "label": "Contradiction"
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "text_answer": "Yes   Explanation The evidence states that patients will receive multiple injections of dendritic cells GMCSF and trastuzumab as part of the intervention Therefore the statement Patients in the primary trial will need to receive several injections is entailed by the evidence",
        "label": "Entailment"
    },
    "c20de03b-8eba-4546-8f77-5e54cf25dfb2": {
        "text_answer": "No  Explanation  The statement The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial is not directly related to the information provided about painful joints in the given evidence The evidence only provides information about the interventions used in two different trials and their dosages but it does not mention anything about painful joints",
        "label": "Contradiction"
    },
    "f82d082e-896d-4d9e-ad92-d64b655dafb8": {
        "text_answer": "No  The patient described in the statement does not meet the eligibility criteria for the trial as they have a life expectancy of less than 3 months",
        "label": "Contradiction"
    },
    "4bfe4376-ffad-4132-8604-b5afbc78429d": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the evidence only discusses the interventions for the primary trial for patients receiving palliative care and there is no mention of pancreaticobiliary malunion in the evidence",
        "label": "Contradiction"
    },
    "0471ee43-16a7-417e-94db-0ef86bd5b0a9": {
        "text_answer": "No  Explanation  The statement a mastectomy for stage iv bc does not necessarily exclude a woman from participatory consideration in either the primary or secondary clinical trial is not entailed by the evidence  The primary trial excludes patients who have undergone mastectomy with the use of bioprosthetic mesh and those who have a history of breast tissue expander or implant placement However it does not mention anything about the",
        "label": "Contradiction"
    },
    "8e19b7e1-e5ac-473f-a4e7-2c8ddfa7a496": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the evidence only discusses interventions for DCIS in the breast and there is no mention of thyroid cancer or anaplastic carcinoma",
        "label": "Contradiction"
    },
    "2cff90dc-7bc3-4acb-a250-10de476d1d4c": {
        "text_answer": "Yes The evidence states that individuals with a history of interstitial lung disease or pneumonitis are excluded from the trial Diffuse parenchymal lung disease is a type of interstitial lung disease",
        "label": "Entailment"
    },
    "b3b142e1-adad-429b-a7de-c852a74edaaa": {
        "text_answer": "Yes The evidence does not include any criteria related to nationality ethnicity mental health status or gender in the inclusion or exclusion criteria for either the primary or secondary trials",
        "label": "Entailment"
    },
    "a5eb56c2-6fc0-45da-8a6a-2818cb64a7f0": {
        "text_answer": "No  Explanation  The evidence provided in the results only states that there were 5 participants in the placebo group who were analyzed but it does not explicitly state that all of them experienced vomiting The evidence only indicates the number of participants in each group not their individual outcomes",
        "label": "Contradiction"
    },
    "a60a8f30-02a6-46a4-bb00-bea702d5103d": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial includes a breast tumor that is only 1 cm in diameter while the statement mentions a tumor that is 50 cm in diameter",
        "label": "Contradiction"
    },
    "d9f28f1f-3a09-4ef9-a80a-9caa02f9069b": {
        "text_answer": "yes for the ability to provide informed consent only The statement does not directly relate to the inclusionexclusion criteria for the trials themselves but rather to a separate topic glandular odontogenic cyst",
        "label": "Entailment"
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "text_answer": "No  Explanation The evidence provides the median PFS for each treatment group but it does not specify the longest PFS observed in the trial Therefore the statement is not directly entailed by the evidence",
        "label": "Contradiction"
    },
    "4e56ec6c-1b0c-4d14-b53a-2695fb9dcb7d": {
        "text_answer": "Yes The evidence states that the intervention includes treated subjects with device placed and treated with partial breast irradiation and the statement specifies that the irradiation doses and administration protocol are detailed in the intervention section",
        "label": "Entailment"
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "text_answer": "No  The evidence explicitly states that there should be no meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "953b0337-0c43-42fb-a334-dad6900e2e0f": {
        "text_answer": "Yes  Explanation The evidence includes a statement that it was noted that on average patients in the paced respiration intervention group experienced more treatment emergent adverse events and serious treatment emergent adverse events than their counterparts in the fast shallow respiration group This is an entailed statement based on the data presented in the trial results",
        "label": "Entailment"
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "text_answer": "No  Explanation The evidence provided in the form of the primary trial does not mention Paraplatin at all Paraplatin is not a part of the interventions in the trial Therefore the statement that Both interventions in the primary trial include the same dose of Paraplatin is not entailed by the evidence",
        "label": "Contradiction"
    },
    "91e585c8-503f-4253-b749-80caa8ebc3e1": {
        "text_answer": "No  Explanation  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is not directly entailed by the evidence provided The evidence only states the number and types of adverse events in each trial but it does not provide enough information to make a definitive statement about which trial had a higher incidence of ascites or P",
        "label": "Contradiction"
    },
    "577f3aad-32c6-4a0b-8df1-615a9a58fa29": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial and the secondary clinical trial noted an identical count of adverse events among their patient groups is entailed by the evidence since both trials reported no adverse events for Adverse Event 1 and no adverse events for Adverse Event 2",
        "label": "Entailment"
    },
    "13765ddf-3be9-411a-ae7a-24a0bdffe2d8": {
        "text_answer": "Yes  Explanation The statement both the primary clinical trial and the secondary clinical trial necessitate that patients partake in a weekly regimen of 4demethyl4cholestryloxycarbonylpenclomedine is entailed by the evidence as both trials involve the use of 4demethyl4cholestryloxycarbonylpenclomedine in their interventions",
        "label": "Entailment"
    },
    "55bcb170-5b8a-4a7d-b509-f2ab4a2f587a": {
        "text_answer": "No  Explanation  The statement afraid of being rejected is a question about whether an individual is or was afraid of being rejected is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events in two cohorts of a trial and does not provide any information about the fear or anxiety of the patients Therefore the statement cannot be determined to be entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "06b2ed93-63bb-4ef0-964c-372ff9077cb4": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the primary trial reports the summed pain intensity differences SPID at 30 minutes after dosing SPID30 and the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement incorrectly mentions the severity of delayed nausea and a time frame of 0",
        "label": "Contradiction"
    },
    "c6408b0b-2cdc-4298-a7d5-9e6fe3d52925": {
        "text_answer": "No  Explanation  The statement for all of its participating individuals the secondary clinical trial applies a consistent array of inclusion and exclusion benchmarks is not entailed by the evidence provided for the secondary clinical trial as it only specifies certain inclusion criteria The evidence does not mention anything about the consistency of inclusion and exclusion benchmarks for all participating individuals  Regarding the primary clinical trial the statement is also not entailed by the evidence as the",
        "label": "Contradiction"
    },
    "4cdd4dc9-e171-438b-8864-1f451af7c15e": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it makes an additional assumption about the control group receiving a regular dosage of radiotherapy which is not mentioned in the evidence The evidence only states that the control group will not receive the educational DVD or meet with the lay health advisor",
        "label": "Contradiction"
    },
    "2b24be38-efe1-4044-92ce-81cace8f239a": {
        "text_answer": "yes In the primary trial Armodafinil is given daily to one cohort while in the secondary trial PDR001 is given identically to all patients with varying amounts of MCS110",
        "label": "Entailment"
    },
    "3ac1baef-7e74-405c-ae5a-897ac2b2fd5f": {
        "text_answer": "No   Explanation The statement all 100 of patients in the primary trial suffered aes is not entailed by the evidence as the evidence only reports the occurrence of adverse events in 2 out of 35 patients 571 The statement implies that every patient experienced an adverse event which is not the case according to the evidence",
        "label": "Contradiction"
    },
    "c8990938-e3fe-470d-a6d2-d28a3fe89b0b": {
        "text_answer": "Yes  Explanation  The statement the primary clinical trial requires informed consent but there is no corresponding requirement in the secondary trial is entailed by the evidence because the primary trial explicitly includes willingness and ability to provide written informed consent as an inclusion criterion while the secondary trial does not mention any requirement for informed consent",
        "label": "Entailment"
    },
    "5ed2b8ad-5b6d-4397-80c5-48d08c8f51ed": {
        "text_answer": "Yes The statement is entailed by the evidence as both cohorts receive the same dosage of CUDC101 but the frequency of administration differs",
        "label": "Entailment"
    },
    "3df32fab-15e5-4536-908f-d9c76529702e": {
        "text_answer": "Yes  Explanation The statement thirteen individuals participated in the primary clinical trial is entailed by the evidence as the evidence states that Overall Number of Participants Analyzed 13",
        "label": "Entailment"
    },
    "98e89253-c343-4f1f-b2a0-0e09e5cba8ee": {
        "text_answer": "No  Explanation  The statement the participants of cohort 1 of the primary clinical trial did not report adverse events is not entailed by the evidence The evidence only provides the number of participants with serious and nonserious adverse events for each dose level but it does not state that there were no adverse events reported for cohort 1 The evidence only indicates that all 3 participants in cohort 1 experienced",
        "label": "Contradiction"
    },
    "66362fd1-8e4f-49ad-9098-a67f65cb91c2": {
        "text_answer": "Yes The evidence states that 13 out of 49 participants 265 developed imagable HER2 metastases Therefore 5 1349 x 005  00265 or approximately 6 participants of the participants with HER2 primary breast cancer developed imagable HER2 metastases",
        "label": "Entailment"
    },
    "2f7bae39-4081-4328-85e2-2a400ec72589": {
        "text_answer": "Yes The evidence does not provide any information that would exclude patients with a BMI less than 30 from either trial",
        "label": "Entailment"
    },
    "1bc6de92-961a-4a4f-8ead-8f5f6f496d70": {
        "text_answer": "No  Explanation The evidence provided only gives the median with range change in lean body mass for each group not information about individual patients and their specific changes The statement is about an individual patients experience which cannot be determined from the given data",
        "label": "Contradiction"
    },
    "3c273853-f394-4550-9969-d476fff275db": {
        "text_answer": "No  Explanation  The statement there were 52 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial is not entailed by the evidence provided The evidence only mentions the number of adverse events for a specific condition Adverse Events 1 in each trial but it does not provide any information about the number of cases of febrile neutropenia or ch",
        "label": "Contradiction"
    },
    "cc2428b1-d508-406f-a59f-186d62e93600": {
        "text_answer": "No  Explanation  The evidence provided in the text does not directly support the statement that the lack of paclitaxel infusions resulted in worsened symptoms for the patients compared to those who received them The evidence only shows that the Arm I group cryotherapy had a smaller median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale compared to the Arm II group control during",
        "label": "Contradiction"
    },
    "4c42491a-5ff2-41f8-bb40-6c7fe4dd5c99": {
        "text_answer": "No  Explanation  The statement the only types of adverse events observed in patients from the secondary clinical trial were severe nausea and chronic fatigue is not entailed by the evidence provided The evidence only states that the frequencies of various adverse events were different between the two clinical trials but it does not specify that only severe nausea and chronic fatigue were observed in the secondary trial",
        "label": "Contradiction"
    },
    "27abad83-36b9-47a4-8d11-d08751d1d81a": {
        "text_answer": "No  Explanation The evidence provided in the text only reports the average pain intensity scores and the change in average pain intensity between the low dose and high dose groups during the 10week intervention period It does not mention anything about patients experiencing no pain whatsoever during the 5year study",
        "label": "Contradiction"
    },
    "001da1c9-0fd7-4a15-baa5-9ee16f2a28bd": {
        "text_answer": "Yes The primary trial includes the requirement of histologicdocumented diagnosis of breast cancer with specific histologic features and resistance to AI therapy The statement refers to the histologic grading of malignant neoplasm which is a requirement in the primary trial However the secondary trial does not mention the need for resistance to AI therapy",
        "label": "Entailment"
    },
    "5a6a1e08-4a0a-45ea-91f5-053182a352cc": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it introduces new information not present in the evidence specifically the mention of beta streptococcus group f The evidence only discusses denosumab and radioactive Tc99M sulfur colloid interventions in two separate trials",
        "label": "Contradiction"
    },
    "afa9c5da-71e1-4c40-80fa-bcc02199e395": {
        "text_answer": "No  Explanation  The statement the primary clinical trial was marked by numerous adverse events reported by all patients whereas the secondary clinical trial was free from any adverse events is not entailed by the evidence The primary clinical trial had no reported adverse events for Adverse Event 1 but it is not stated that there were no adverse events at all in the primary trial Similarly the secondary clinical trial had some reported adverse events for Ad",
        "label": "Contradiction"
    },
    "37321416-91c4-4dd1-952b-6b23865d769c": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the evidence only describes the instructional method for cohort 1 CD and once daily and cohort 2 CD and twice daily but it does not mention any difference in the type of instructional method used for cohort 2 that is not a CD",
        "label": "Contradiction"
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "fe5d5e2f-2b54-48f4-b95b-278456d1db46": {
        "text_answer": "No  Explanation  Although the same medications FMX and lapatinib are used in both trials the dosing and scheduling are different In the primary trial FMX is given as a single bolus IV injection followed by MM398 while in the secondary trial lapatinib is given continuously and paclitaxel is given weekly Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "a92239f6-9f31-4e7f-a8be-2792789ea5f1": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial does not include trastuzumab in any of its intervention regimens is entailed by the evidence because the evidence indicates that neither Arm 1 nor Arm 2 of the trial includes trastuzumab as an intervention",
        "label": "Entailment"
    },
    "c98e803e-a899-4ed8-aed0-0611eeef943d": {
        "text_answer": "  No the statement is not entailed by the evidence for the primary trial but it is for the secondary trial The primary trial excludes patients with pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug but it does not mention pulmonary embolism specifically The secondary trial allows participation of patients with a pulmonary embolism at the investigator",
        "label": "Contradiction"
    },
    "49e29ec7-08a2-481d-9fc4-ecb66b09cdfe": {
        "text_answer": "No  Explanation  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly entailed by the evidence provided While smokers are excluded from the primary trial there is no mention of smoking being a requirement or exclusion factor for the secondary trial Additionally the secondary trial has its own set of inclusion and exclusion criteria which may",
        "label": "Contradiction"
    },
    "804aa28f-b791-4a99-98e7-a443456de4b2": {
        "text_answer": "Yes The patients in the secondary trial are also eligible for the primary trial Therefore the statement about ct2584 having antitumor activity is not directly related to the inclusionexclusion criteria but the patients who may receive this lipid metabolism modulator during their treatment are included in the trials",
        "label": "Entailment"
    },
    "045ad9d7-6830-4a3d-bba5-4e90ee838977": {
        "text_answer": "No  Explanation The statement provided is not related to the evidence given in the trial description The evidence only mentions the use of Active Breathing Coordination ABC in one group of the trial and its absence in the other group as well as the duration of radiation therapy and the obtaining of SPECT scans for both groups The statement about Leptospiraceae is unrelated to the trial information",
        "label": "Contradiction"
    },
    "610662cd-053e-4396-a6d6-8aaac67a7440": {
        "text_answer": "No  Explanation  The statement the secondary clinical trial necessitates the use of a minimum of three distinct medications is not directly entailed by the evidence While it is true that the secondary trial involves the use of multiple medications zoledronic acid vitamin D and calcium supplements and either Sr89 or Sm153 the statement in the question specifies that there must be a minimum of three distinct",
        "label": "Contradiction"
    },
    "10749f91-8743-4f6a-aa4b-6cc713e927c5": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement is about palbociclib and tezacaftor which are not mentioned in the evidence The evidence only discusses denosumab intraoperative handheld gamma camera pIHGC gamma probes GP and Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "9cd909a2-b826-4e0d-bbbd-3ad52978d1d9": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the trial includes patients with HER2 FISH negative or unknown status who will not receive trastuzumab but are eligible for single agent vinflunine",
        "label": "Contradiction"
    },
    "ef0cf72d-6cc3-4589-8016-e96db1b9f33a": {
        "text_answer": "Yes  Explanation The statement not a single kind of adverse event registered in the primary clinical trial influenced more than a quarter of the patient group is entailed by the evidence because none of the adverse events had a frequency greater than 25 2500 is equal to a quarter of the total patient group",
        "label": "Entailment"
    },
    "585bf6db-16c7-4433-8c98-30a6b5a88fc0": {
        "text_answer": "No  Explanation  The statement the primary trial involves administration of alisertib in both cohorts whereas in the secondary trial no cohorts are given this treatment is not entailed by the evidence The primary trial involves the use of Botulinum Toxin Type A in one group and placebo in the other while the secondary trial involves the use of MLN8237 in two different doses in the same group",
        "label": "Contradiction"
    },
    "31464efc-048a-451b-a02b-5576933a893a": {
        "text_answer": "No  The statement is not entailed by the evidence The evidence only mentions interventions involving fluciclatide and chloroquine in both the primary and secondary trials There is no mention of captopril or eribulin in the evidence",
        "label": "Contradiction"
    },
    "a0e47b7d-7f2d-43ba-8f93-dc5f9dcd648b": {
        "text_answer": "No  Explanation  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed by the evidence provided The evidence lists the number and percentage of adverse events for each trial but it does not specify the total number of patients or the number of patients who experienced infections in both trials Therefore it is not possible to determine if over 15 of",
        "label": "Contradiction"
    },
    "ce5dd10f-dad3-46a4-93de-fe57c657f6d9": {
        "text_answer": "Yes The evidence shows a total of 3 vomiting incidents out of 149 participants in the trial",
        "label": "Entailment"
    },
    "bb281225-8211-47ed-8789-a42a389fa379": {
        "text_answer": "No  The statement is not about the eligibility criteria for the primary trial It is about a different topic specifically a genus of bacteria",
        "label": "Contradiction"
    },
    "be98ce03-a87b-4fe5-9058-a56259581c41": {
        "text_answer": "Yes  Explanation The statement the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1 and the primary trial intervention lasts for a longer period of time is entailed by the evidence provided The primary trial uses lenalidomide at a dose of 5mg orally daily for 57  3 days while the secondary trial uses lapatinib at",
        "label": "Entailment"
    },
    "4db7f58c-f006-48d0-944f-a02b3231615c": {
        "text_answer": "No  Explanation  The statement Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration up to a maximum of 100 mg three times daily whereas patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial is not directly entailed by the evidence  The evidence only states that in the",
        "label": "Contradiction"
    },
    "bcdef75a-f013-4d65-84e1-6004a054d574": {
        "text_answer": "No  The evidence explicitly states that there should be no meningeal carcinomatosis for a patient to qualify for the clinical trial",
        "label": "Contradiction"
    },
    "6962c2aa-4df2-4479-8744-5784fe8c9fcf": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a3be9d38-6897-4ead-9ada-790104f2de50": {
        "text_answer": "No The statement is not entailed by the evidence as individuals with a history of myocardial infarction stroke or transient ischemic attacks within the last six months are excluded from the clinical trial",
        "label": "Contradiction"
    },
    "12a03716-0ec6-4ffe-abd8-02411c083ee5": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as the clinical trial involves the use of injections for the administration of dendritic cells chemotherapy and GMCSF",
        "label": "Contradiction"
    },
    "156b015d-e2bb-4f38-a312-62e1cf7583d6": {
        "text_answer": "No  Explanation  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is not entailed by the evidence provided The evidence only mentions the inclusion and exclusion criteria for the primary and secondary trials but it does not mention anything about mirtazapine or resistance to it being a requirement for the primary trial",
        "label": "Contradiction"
    },
    "d3aeafa2-2963-4220-b80d-cd5cde582fe8": {
        "text_answer": "  No   Explanation   The statement is not entailed by the evidence as the statement mentions tamoxifen 25 mg po daily for 10 days prior to surgery and for 20 days after breast cancer surgery while the evidence only mentions tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery Additionally the evidence shows a decrease in Ki67",
        "label": "Contradiction"
    },
    "d0bfc2f3-c94f-4d4c-ae87-9f9744bd767a": {
        "text_answer": "No The statement is about a different topic TMN staging of appendiceal carcinoma than the adverse events in the evidence",
        "label": "Contradiction"
    },
    "9a814107-778f-43ba-bd59-383ae14594ed": {
        "text_answer": "Yes The statement is entailed by the evidence as women with locally advanced ER breast cancer who are considering a mastectomy are eligible for the primary trial Additionally the secondary trial includes women with newly diagnosed or recurrent ER breast cancer who are considering a mastectomy Therefore the statement covers a subset of women who could be eligible for both trials However its important to note that the statement does not mention the Bartholin gland",
        "label": "Entailment"
    },
    "2d007409-93ff-4753-a2e5-c5f94d4fe6dd": {
        "text_answer": "  Yes   Explanation   The statement is entailed by the evidence as the primary trial reports Time to Progression in months for a total of 156 patients across the two cohorts and the secondary trial reports the number of participants with Objective Response based on RECIST criteria",
        "label": "Entailment"
    },
    "c51494ed-aee9-4219-b46b-ed47bc261788": {
        "text_answer": "Yes The primary trial patients receive fewer total doses of MM121 and Paclitaxel per week compared to the secondary trial patients",
        "label": "Entailment"
    },
    "136f0a2e-563c-4085-b390-ac2db90f7aac": {
        "text_answer": "Yes The evidence shows that both cohorts had below average standardized scores for cognitive function indicating a decline compared to agespecific norms However its important to note that this does not mean that all individuals in each cohort experienced a decline in cognitive function",
        "label": "Entailment"
    },
    "76eeb32c-d3c0-4ed0-91d4-104417af35e0": {
        "text_answer": "No  Explanation The evidence only provides the percentage of subjects who had recurrencefree survival up to 3 years after treatment It does not state that all patients in the trial had recurrencefree survival",
        "label": "Contradiction"
    },
    "a402b1c9-c65b-48fb-a2d5-e08c0152e8c3": {
        "text_answer": "No  Explanation The statement requires that each participant gets at least 20mg of mcs110 every 3 weeks which is not explicitly stated in the evidence The evidence only states that the dosage of mcs110 is 1 mgkg every 3 weeks which does not guarantee that every participant receives a dose of at least 20mg  Additionally the statement requires that each participant gets more than ",
        "label": "Contradiction"
    },
    "431b6222-3b82-4eb4-af82-ef98b513e649": {
        "text_answer": "Yes The evidence does not report any unexpected deaths or hospitalizations in either trial",
        "label": "Entailment"
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "text_answer": "Yes  Explanation The statement There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial is entailed by the evidence as the number of cases for Biliary colic in the secondary trial 16 or 1667 is greater than the number of cases in the primary trial 328 or 4122 and the number of cases for Diarr",
        "label": "Entailment"
    },
    "a6d3fa8e-c521-4843-b4e7-0a9983acfad0": {
        "text_answer": "yes but with a caveat The statement is entailed by the evidence in the sense that pCR pathological complete response is used as the primary efficacy endpoint in both trials However the statement does not fully capture the nuances of the results In the primary trial there is an insignificant difference in pCR rates between the two arms whereas in the secondary trial arm 1 Herceptinnavelbine had a lower",
        "label": "Entailment"
    },
    "71ba0864-5490-4e25-989c-4672afa15599": {
        "text_answer": "  No   Explanation   The statement describes a patient with a diagnosis of stage I prostate cancer but the primary trial inclusion criteria specify that only patients with a histologically or cytologically proven diagnosis of solid tumor malignancy of lung breast or prostate prior to registration are eligible The patient in the statement does not meet this requirement because stage I prostate cancer is typically considered a localized disease and not a solid tumor m",
        "label": "Contradiction"
    },
    "f41f7611-7c20-4f71-8b2d-433e36f840de": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence provided in the trial results The evidence only compares the changes in lymphedema between the acupuncture and waitlist groups and does not mention any comparison with a testosterone cream group Therefore it is not possible to determine if the acupuncture patients saw better changes than those administered with testosterone cream based on the given evidence alone",
        "label": "Contradiction"
    },
    "3264decd-0cee-4137-a5da-e9a27e3b7791": {
        "text_answer": "Yes The primary trial reports results in percentage and the secondary trial reports results in number of participants which are not the same units of measure",
        "label": "Entailment"
    },
    "5ac3610a-7854-4278-8a51-c1ef8c138ee9": {
        "text_answer": "No  Explanation The evidence provided in the primary trial does not mention anything about a pulse wave increase or clinical findings related to it The trial only reports the number of participants with a reduction in circulating tumor cells CTCs following highdose chemotherapy with purged autologous stem cell products The statement about a pulse wave increase is unrelated to the evidence",
        "label": "Contradiction"
    },
    "08fb602d-3227-4329-98c8-7dc2a6135f5b": {
        "text_answer": "No  Explanation  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 14 of the primary trial patients is not entailed by the evidence The evidence only states that syncope occurred in 2 out of 12 patients in the primary trial which is not the same as being the most common adverse event across both trials or occurring",
        "label": "Contradiction"
    },
    "76c6b45f-5a4a-47bc-81b1-267a2981b096": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement is incorrect and the evidence clearly states that HER2 positivity is a requirement for the primary clinical trial",
        "label": "Contradiction"
    },
    "95332a34-465b-4777-870b-e60e4c01e706": {
        "text_answer": "Yes  Explanation  The statement patients in the primary clinical trial saw a higher frequency of ascites whereas those in the secondary clinical trial had higher incidences of pneumocystis jirovecii pneumonia is entailed by the evidence as it correctly identifies two specific adverse events that occurred more frequently in each trial The evidence shows that ascites occurred 2223 times 090 in",
        "label": "Entailment"
    },
    "f6fbc102-de0c-44d5-943b-4baf66bc0d9b": {
        "text_answer": "No   Explanation The evidence provided does not mention the screening status of only cervical cancer patients in the first cohort of the primary clinical trial The data given in the evidence pertains to the percentage of participants who were uptodate with colorectal breast and cervical cancer screenings before and after the intervention for both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups",
        "label": "Contradiction"
    },
    "1c72bbf7-1c5b-4326-a9d1-9dc7677aeefd": {
        "text_answer": "No  Explanation  The statement Women with Newly diagnosed stage IV breast cancer confirmed as ER  Considering a mastectomy are eligible for the primary trial and the secondary trial is not entailed by the evidence provided The primary trial specifically excludes patients with stage IV disease and the secondary trial does not mention the primary trial or any specific cancer treatment trial",
        "label": "Contradiction"
    },
    "224b15b9-fc1d-4c8b-ae55-ec4731ae5d04": {
        "text_answer": "Yes  Explanation The statement it is dispensed more frequently to cohort 1 is entailed by the evidence as the intervention for cohort 1 involves receiving CUDC101 for 5 days every 14 days while the intervention for cohort 2 involves receiving CUDC101 for 3 days every 28 days Although the dosage remains consistent the frequency of administration is different",
        "label": "Entailment"
    },
    "bd6fc6e9-c2ad-4803-b9ef-5a92d10e4155": {
        "text_answer": "  No   Explanation   The patient does not meet the inclusion criteria for both primary and secondary clinical trials due to several reasons   For the primary clinical trial   The patient has a diagnosis of lung cancer but the performance status is not specified to be 01 for patients with lung primaries   The patients absolute neutrophil count is below the required minimum of 1800",
        "label": "Contradiction"
    },
    "72de2f11-15c9-489a-aec1-5c5e0969f4b7": {
        "text_answer": "No  Explanation The evidence provided in the trial results does not include information about primary tumor diameter The statement is not related to the evidence presented",
        "label": "Contradiction"
    },
    "0d58d43d-8edc-4846-9d16-b1573f00db28": {
        "text_answer": "Yes The evidence does not mention Paclitaxel at all",
        "label": "Entailment"
    },
    "ea16ac84-1f11-45c6-a29a-b7159f4b49a1": {
        "text_answer": "Yes  Explanation  The statement more than half of the patients in the primary clinical trial suffered from adverse events while in the secondary clinical trial this percentage was significantly lower is entailed by the evidence as the primary trial had an adverse event rate of 4545 and the secondary trial had an adverse event rate of 1563 The primary trial had a higher percentage of adverse events than the secondary trial",
        "label": "Entailment"
    },
    "c69a6bb3-93f7-4597-9359-64fd2541b1aa": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial records and reports the number of participants in each subdivision is entailed by the evidence as both trials report the Overall Number of Participants Analyzed for each armgroup",
        "label": "Entailment"
    },
    "db02f4a9-b294-40e7-861b-d2284c6155e6": {
        "text_answer": "No   Explanation The statement is not entailed by the evidence as Perjeta pertuzumab is mentioned in the secondary trial but not used in either intervention while it is not mentioned at all in the primary trial",
        "label": "Contradiction"
    },
    "1b9551eb-0a5d-4d74-a460-a97ea9161f7f": {
        "text_answer": "Yes The statement that there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is entailed by the evidence as both cohorts had a total of 0 cases for each of these adverse events",
        "label": "Entailment"
    },
    "d6c5a9e6-8db3-44f7-b865-4250c057f194": {
        "text_answer": "No  The evidence provided pertains to breast cancer clinical trials with specific inclusion and exclusion criteria The statement is about lung adenocarcinoma and its relation to the trials which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "a7f11aff-801c-4f1f-bc03-dc205289964a": {
        "text_answer": "No  Explanation  The statement both primary and secondary clinical trials involved patients who suffered from four different adverse events is not entailed by the evidence The evidence only lists the specific adverse events that occurred in each trial and the number of unique adverse events varies between the primary and secondary trials In the primary trial all six patients experienced an adverse event labeled as Death NOS which is not mentioned in the statement In contrast",
        "label": "Contradiction"
    },
    "3e629df7-48b7-4ca1-8987-250629ce3e26": {
        "text_answer": "  Yes   Explanation   The primary clinical trial did indeed consist of a test group Intervention 1 and a placebo group Intervention 2   The secondary clinical trial also had a test group Highdose Oxybutynin Chloride Group and a control group Lowdose Oxybutynin Chloride Group   Therefore the statement is entailed by",
        "label": "Entailment"
    },
    "4f3ab82f-b17b-45a0-803e-901d0a58bcc6": {
        "text_answer": "Yes The statement does not explicitly mention the sham comparator arm in the evidence but it is not contradicted by the evidence either The evidence only provides information about the adverse events in the trials not about the comparator arms specifically However since the statement does not make any false claims about the evidence it is entailed by the evidence",
        "label": "Entailment"
    },
    "6dddad4e-4cde-4859-a518-897b16bdc042": {
        "text_answer": "No  Explanation  The statement abstinence or moderate drinking is not a criterion of exclusion from the primary clinical trial but the secondary clinical trial mandates a minimum consumption of five alcoholic drinks daily is not entailed by the evidence provided  The primary clinical trial includes a criterion for exclusion of alcohol or substance abuse or dependence within the past 2 years but it does not specify any restrictions on alcohol consumption for",
        "label": "Contradiction"
    },
    "7ccd57f6-2147-4f27-a0a7-f9f7a573a3b5": {
        "text_answer": "No  Explanation  The statement cohort 2 of the secondary clinical trial yielded more positive results than cohort 2 of the primary clinical trial is not entailed by the evidence provided The evidence only shows the difference in physical wellbeing between the Nuevo Amanecer Peer Support Program and the Waitlist Control groups in the primary trial and the percentage of participants with positive margins in the Standard of Care and",
        "label": "Contradiction"
    },
    "86408afa-a3ca-41ee-ac9a-94aa3f2b203d": {
        "text_answer": "Yes  Explanation The statement is consistent with the information provided in the evidence as it acknowledges that the final eligibility for a clinical trial is determined by the health professionals conducting the trial",
        "label": "Entailment"
    },
    "7ebe69db-dbde-41d9-b1c8-b866b2bc9e4c": {
        "text_answer": "  Infection and Asymmetry  Yes the statement is entailed by the evidence   However there is no information about Nausea in the evidence so the statement about it is not entailed by the evidence",
        "label": "Entailment"
    },
    "b447258d-c4d1-4f98-8cc0-9868cd316a3c": {
        "text_answer": "yes with the caveat that the statement only applies to anemia pneumonia and stupor as those are the conditions reported in both trials",
        "label": "Entailment"
    },
    "05772f95-990c-40ee-b29c-b5b2591d0e56": {
        "text_answer": "Yes the patient is eligible for both trials based on the given information However its important to note that the statement about fibroblastic neoplasm is not related to the inclusion criteria for either trial",
        "label": "Entailment"
    },
    "b7028956-b024-401f-b528-554559f8ce17": {
        "text_answer": "Yes Follicular thyroid carcinoma is not listed as a malignancy in the inclusion criteria for either trial and lymphedema is listed as an exclusion criterion in the secondary trial",
        "label": "Entailment"
    },
    "d2139fd7-7b3e-405a-a806-ca76d237c11f": {
        "text_answer": "yes for the secondary trial regarding documented allergy to cephalosporin or trimethoprimsulfamethoxazole  Explanation The statement Any patients with Documented allergy to cephalosporin or trimethoprimsulfamethoxazole will not be eligible for the secondary trial is entailed by the evidence as it is listed as an exclusion criterion for the secondary trial",
        "label": "Entailment"
    },
    "039b25b3-517a-4663-9b95-94c941ffa30f": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence specifies different doses of MM121 for each cohort and the statement does not mention the different doses The statement only mentions identical doses of cetuximab which is not the case according to the evidence",
        "label": "Contradiction"
    },
    "a76b5162-0261-41d2-8d17-c88f5a0e21bc": {
        "text_answer": "Yes  Explanation The statement under 10 patients have encountered adverse events in the course of the primary clinical trial is entailed by the evidence since the total number of adverse events is 2 and the number of patients in the trial is 35 Therefore the percentage of patients with adverse events is less than 10",
        "label": "Entailment"
    },
    "e4b2bcf4-85fa-499c-9d27-e1c3c46174bf": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "37e14df5-fd3b-4c30-bda4-6527febc5e2b": {
        "text_answer": "Yes Nonsmall cell lung cancer and small cell lung cancer are listed as eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "27d0d803-28d5-4b3d-a87e-8fbe577513a9": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the statement is about dermal patches which is not mentioned in the evidence at all The evidence only mentions oral administration of cabergoline in the primary trial and intravenous administration of pixantrone in the secondary trial",
        "label": "Contradiction"
    },
    "1f755559-38fb-4edc-a41a-91252b1dfb54": {
        "text_answer": "  Partially The statement is partially entailed by the evidence as alcoholic patients are excluded from the primary trial but some of them may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day However the evidence does not explicitly mention the chromosome band 14q22 in relation to alcohol consumption",
        "label": "Entailment"
    },
    "acf4a907-c58c-46df-aa75-666e643cef4f": {
        "text_answer": "No   Explanation   The statement The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial is not directly related to the evidence provided The evidence only mentions the duration of the interventions in each trial but it does not compare the durations or state that one is three times longer than the other Therefore the statement is not entailed by the evidence   Furthermore the",
        "label": "Contradiction"
    },
    "6d5ac8ed-53a0-4b48-a521-7a9b53e82017": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "256a6852-2768-4fc9-acae-f5fea437412c": {
        "text_answer": "No  Explanation  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is not entailed by the evidence provided The evidence only states the number and percentage of adverse events in each trial but it does not compare the number or percentage of specific adverse events between the two trials Additionally the statement introduces the concept of nonneopl",
        "label": "Contradiction"
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "text_answer": "Yes  Explanation The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less is entailed by the evidence because the dosage of Cetuximab is the same 400 mgm2 loading dose and 200 mgm2 maintenance IV QW but the dosage of",
        "label": "Entailment"
    },
    "9d447ab6-f75c-40b6-88ca-db2e904ef02d": {
        "text_answer": "No  Explanation  The statement the eligibility for the primary clinical trial imposes no restrictions on mental health bodyweight age karnofskyecog score or prior treatments is not explicitly stated in the evidence The evidence only mentions the inclusion and exclusion criteria related to the type and extent of breast cancer It does not mention any restrictions or lack thereof on mental health bodyweight age or prior treatments",
        "label": "Contradiction"
    },
    "624aeeea-894f-4100-86a2-724ef4842002": {
        "text_answer": "yes the statement is entailed by the evidence as both cohorts receive the same radiation doses and undergo SPECT scans However the statement about cutaneous schwannoma is not directly related to the evidence and should be disregarded when answering the question",
        "label": "Entailment"
    },
    "647016e6-71d4-4169-801d-e58e9b20171f": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement makes a comparison between the number of adverse events in the two trials while the evidence only provides the number of adverse events for each trial and the species terminology is not mentioned",
        "label": "Contradiction"
    },
    "5ff5980d-28e1-46a7-9300-20792ad3dffd": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "29b78196-3625-46f2-baa9-45b6ab4b3823": {
        "text_answer": "No  Explanation  The primary trial measures change from baseline in patientspecified and reported symptoms on the Measure Yourself Medical Outcome Profile MYMOP while the secondary trial measures change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy The number of participants with treatmentemergent adverse events is not mentioned in the evidence provided for either trial",
        "label": "Contradiction"
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "f9a077fc-18cf-418a-ac86-ddc89ea4259b": {
        "text_answer": "Yes  Explanation The statement regardless of the cohort the primary clinical trial administers the same quantity of docetaxel doxorubicin and cyclophosphamide at the identical intervals is entailed by the evidence as both interventions have the same dosage and frequency for doxorubicin and cyclophosphamide and docetaxel is given with the same frequency in both interventions",
        "label": "Entailment"
    },
    "0c207e39-2335-46a1-8dbd-3be4b8d59a17": {
        "text_answer": "Yes both cohorts undergo a SPECT scan The question is not directly related to the presence or absence of a skin rash in the evidence",
        "label": "Entailment"
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "text_answer": "Yes  Explanation The statement Both cohorts of the primary trial recorded 0 Aes is entailed by the evidence since the evidence states that Adverse Events 1 Total 060 000 and Adverse Events 2 Total 060 000 Therefore both cohorts had no adverse events",
        "label": "Entailment"
    },
    "b51a60d1-5112-4972-a303-11b35ba07af1": {
        "text_answer": "No The primary trial includes women aged 20 and above while the secondary trial includes women and men aged 18 and above",
        "label": "Contradiction"
    },
    "44bb4ead-0597-4544-9b2c-3d99ff0a099b": {
        "text_answer": "Yes  Explanation The statement during the primary clinical trial blood bilirubin levels increased in 3636 of the participants is an accurate representation of the data provided in the evidence which states that Blood bilirubin increased 111 3636",
        "label": "Entailment"
    },
    "caf14d83-76cb-4c21-b5c0-d83966973483": {
        "text_answer": "Yes The statement mentions the observation of Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain in the secondary trial which is consistent with the evidence that these adverse events were recorded in that trial but not in the primary trial",
        "label": "Entailment"
    },
    "0d984537-a1c8-486f-840d-1a09f2bfa961": {
        "text_answer": "No  Explanation  The statement fewer than a quarter of the patients have registered increased pleural effusion or rapid disease progression is not directly entailed by the evidence provided The evidence only states the number of patients who experienced each adverse event in two separate clinical trials It does not provide information about the total number of patients in each trial or the percentage of patients who experienced neither adverse event Therefore it is not possible to determine if",
        "label": "Contradiction"
    },
    "77890255-16cc-4dfb-b374-f2eba38238ce": {
        "text_answer": "No   Explanation   The statement bone marrow eosinophilia is a finding indicating abnormally high levels of eosinophils in a bone marrow sample is not directly related to the evidence provided The evidence only mentions various adverse events experienced by the primary trial candidates none of which mention bone marrow eosinophilia The statement about eating disorders is also not related to the evidence",
        "label": "Contradiction"
    },
    "d0f95f01-4a54-4bdc-9059-50803485a1f5": {
        "text_answer": "No  Explanation The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial includes patients with locally advanced or metastatic breast cancer and measurable disease which may include tumors larger than 1 cm However the statement specifically mentions patients with a breast tumor 311 cm in diameter which is not explicitly stated in either trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "5628cfa9-df1b-4a19-9f6b-c513b1fb73db": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial does not report the percentage of participants who have experienced clinical improvement according to RECIST criteria Instead it reports the number of participants with complete response partial response stable disease and progressive disease The secondary trial does not report any information about clinical improvement according to RECIST criteria",
        "label": "Contradiction"
    },
    "9915c5ea-d327-4cd9-a3e2-26cfa75cadb7": {
        "text_answer": "No  Explanation  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is not entailed by the evidence The evidence only shows that the median operative time was longer in Arm 2 Standard Mammography compared to Arm 1 Intraoperative Mammography It does not imply that the control group performed better than",
        "label": "Contradiction"
    },
    "48262549-7f65-43b7-ac00-f11dfb93e900": {
        "text_answer": "Yes  The primary trial specifies that patients receive both suramin and paclitaxel and the secondary trial mentions neither intervention separately so it can be inferred that they also receive both drugs",
        "label": "Entailment"
    },
    "06c2d2d2-93dc-44dd-a729-a11a4397db44": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "7ae48994-9b72-4bc5-aab2-adcc9f0e1735": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "adbb33ae-2076-4850-bfd7-967119d8e169": {
        "text_answer": "Yes The primary trial measures change in units on a scale and the secondary trial measures percentage of participants Neither trial uses centimeters number of individuals or time duration as units of measure",
        "label": "Entailment"
    },
    "846578ce-00a5-487a-80d0-c5922f2c0c20": {
        "text_answer": "Yes The evidence shows a reduction in Ki67 expression from a median of 15 at baseline to 10 at 6 weeks which is a 333 reduction",
        "label": "Entailment"
    },
    "ba5d4784-f20f-4d77-b133-ab700624da3e": {
        "text_answer": "No  Explanation  The statement the primary trial presented fewer cases of intestinal perforation than the secondary trial is not entailed by the evidence The evidence only states that there was 1 case of intestinal perforation in the secondary trial but it does not provide information about the number of cases in the primary trial Therefore it is impossible to determine based on the given evidence whether the primary trial had fewer cases of intestinal",
        "label": "Contradiction"
    },
    "638143cc-bcdc-422b-8695-ec836f17edae": {
        "text_answer": "No  Explanation  The statement patient in body sling is a position in which the subjects body is supported by a sling is not related to the evidence provided The evidence only describes the interventions and treatments for two different clinical trials The statement does not follow logically from the evidence",
        "label": "Contradiction"
    },
    "d80d13ef-0da7-4203-af51-52c08253aefe": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials reported no adverse events related to trouble moving bowels",
        "label": "Entailment"
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "text_answer": "Yes  Explanation The evidence states that there were a total of 12 participants analyzed in the trial with 6 participants in each cohort The statement indicates that 2 patients suffered an Incidence of Doselimiting Toxicity Since the evidence shows that there was 1 participant in each cohort who experienced a Doselimiting Toxicity the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "text_answer": "No  Explanation  The statement Several recorded AEs in the primary trial occurred to cohort 1 patients is not directly entailed by the evidence provided The evidence only lists the number and types of adverse events AEs that occurred in each cohort cohort 1 and cohort 2 but it does not specify how many patients in each cohort experienced each AE Therefore it is",
        "label": "Contradiction"
    },
    "e6954b69-b723-4a51-8a5b-6e7461028b60": {
        "text_answer": "Yes The trial mentions that both interventions Memantine and Placebo are administered twice daily BID for 12 weeks Therefore the statement administered at the same frequency for the same duration of time is true for both interventions The statement does not explicitly mention the ringing or buzzing in ears but the evidence does not contradict it either",
        "label": "Entailment"
    },
    "5fbe4001-1044-4684-a2a2-e34bf233fafb": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "410a0a55-a31f-4a57-9de1-3eacd3da7650": {
        "text_answer": "Yes  Explanation The statement the primary clinical trial was devoid of any adverse psychiatric events such as eating disorders or schizophrenia is entailed by the evidence because there is no mention of any adverse psychiatric events related to eating disorders or schizophrenia in the given data The only psychiatric adverse events mentioned are suicidal ideation and it is listed as a single occurrence Therefore the statement is true",
        "label": "Entailment"
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "text_answer": "No  Explanation  The statement the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery whereas the secondary trial participants only receive two different drugs and several different imaging scans is not directly entailed by the evidence provided  The primary trial involves the use of 10 different interventions some of which are administered by different routes IV PO SC and",
        "label": "Contradiction"
    },
    "2bc6306e-445f-459e-afab-b445eedd5711": {
        "text_answer": "No  The statement is not about carboplatin which is the specific chemotherapy agent mentioned in Intervention 2 of the trial",
        "label": "Contradiction"
    },
    "ecb7babe-941e-41bf-89a3-0b8387fdd239": {
        "text_answer": "No  Explanation  The evidence provided in the primary trial relates to the percentage change in serum betaCTX levels from baseline to Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided in the question is about the reduction in primary tumour diameter which is not mentioned in the evidence Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "4d77b4db-8260-4ec9-af60-660f7a2a4833": {
        "text_answer": "No  Warfarin is excluded in the primary clinical trial but is permitted in the secondary clinical trial under certain conditions",
        "label": "Contradiction"
    },
    "a3954ec9-3fdd-4183-844d-1a13f70350e8": {
        "text_answer": "No  Explanation  The statement in the primary clinical trial there were no reported cases of adverse events amongst patients while every patient had at least one recorded adverse event in the secondary clinical trial is not directly entailed by the evidence provided The evidence only shows that the frequency and types of adverse events differed significantly between the two trials It does not necessarily mean that there were no adverse events at all in the primary trial",
        "label": "Contradiction"
    },
    "5c14c797-4995-467f-a993-bc75ad197093": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the outcome measurement in the primary and secondary trials is different In the primary trial the outcome measurement is pathological complete response pCR within the breast while in the secondary trial the outcome measurement is pathological complete response after preoperative therapy Therefore it is not valid to compare the results directly based on the given statement",
        "label": "Contradiction"
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "text_answer": "Yes The secondary trial excludes patients with severe insomnia which is defined as a score of 8 on the Insomnia Severity Index ISI or a score of 3 on the Sleep Disruption Evaluation form This criterion is not explicitly mentioned in the primary trial but the primary trial does exclude patients with uncontrolled intercurrent illness which could include severe insomnia",
        "label": "Entailment"
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "text_answer": "No  Explanation The evidence provided does not indicate that the patient with the longest PFS was in cohort 1 The evidence only provides the median PFS for each cohort",
        "label": "Contradiction"
    },
    "86da40aa-8994-4fb7-8628-098d347b5864": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the 10week study The text only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "e6b59a72-62ef-4752-8464-902ca8d09119": {
        "text_answer": "Yes  Explanation The statement both the primary and the secondary clinical trials registered just one death in the adverse events is entailed by the evidence since the evidence indicates that there was one death in the adverse events section of both trials",
        "label": "Entailment"
    },
    "a1e54b35-4b25-4194-8a44-7c8e587a1c83": {
        "text_answer": "Yes Both interventions use equal doses of radioactive Tc99M sulfur colloid",
        "label": "Entailment"
    },
    "e9bc72c1-1933-4ac1-b21b-35bf90b82c48": {
        "text_answer": "Yes The statement does not contradict the evidence as there were no deaths or hospitalizations in cohort 2 of the primary trial The statement about grade 1 joint effusion being asymptomatic and not requiring intervention is not directly related to the adverse events data provided but it does not contradict it either",
        "label": "Entailment"
    },
    "1f400417-bb05-4885-a46b-d348c2353ae9": {
        "text_answer": "Yes  Explanation The evidence describes a neoadjuvant therapy regimen consisting of four cycles of epirubicin and cyclophosphamide a 3week break and then four cycles of docetaxel and trastuzumab This translates to a total of four distinct pharmaceutical treatments for each participant in the clinical trial",
        "label": "Entailment"
    },
    "e8e2db51-2ec2-4e88-9096-cbe5d5933286": {
        "text_answer": "No  Explanation  The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH from baseline to Week 12 while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel The two trials do not use the same key outcome measurement",
        "label": "Contradiction"
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "b7d3d4f9-44da-4fba-9005-e650cf0e2bb8": {
        "text_answer": "No  Explanation  The statement patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration whereas patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial is not directly entailed by the evidence provided  The evidence only mentions the initial doses and plans for dose escalation in the primary trial for",
        "label": "Contradiction"
    },
    "8ffe96d0-134e-438b-884e-8c4f05b57b03": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial involves radiation therapy using Yttrium90 glass microspheres and the secondary trial involves gene therapy using MEDI4736 and ibrutinib The types of interventions are different with the primary trial using radiation therapy and the secondary trial using gene therapy and antibody treatments",
        "label": "Contradiction"
    },
    "f9172aa9-f9ea-44cc-9669-f72874fcbef2": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary clinical trial is not testing multiple drugbased treatments but rather comparing massage therapy to notouch therapy The secondary clinical trial is evaluating the effectiveness of multiple doses of the same nondrug therapy PF06647020",
        "label": "Contradiction"
    },
    "42b44f03-de67-4d76-a566-2669f0768a23": {
        "text_answer": "No  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting more than 34 patients there were no recorded aes in the primary trial is not entailed by the evidence The evidence states that the most common adverse event in the secondary trial was anaemia affecting 3128 234 of patients The statement that there were no",
        "label": "Contradiction"
    },
    "da1010e7-b58a-438b-b93d-cc53b6d4476e": {
        "text_answer": "No  Explanation  The statement 773 the primary trial participants and 101674 the secondary trial participants suffered an acute myocardial infarction is not entailed by the evidence provided The evidence only states that there were no cases of acute myocardial infarction reported in either trial",
        "label": "Contradiction"
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "text_answer": "No  Explanation  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is not entailed by the evidence provided The primary trial is for patients undergoing tissue expander reconstruction following mastectomy and the secondary trial is for patients who have completed surgery for Stage IIII breast cancer A woman with stage IV breast cancer would not meet the inclusion criteria for",
        "label": "Contradiction"
    },
    "59017303-759d-4b61-a272-efd6364a0b93": {
        "text_answer": "Yes The statement does not specifically mention the type of patients in the trial but since the evidence provides information about a clinical trial involving patients with a benign epididymal neoplasm and the requirement for them to take Vorinostat daily during radiation therapy it can be inferred that the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "88d91a58-834e-4e7b-8b8d-f9ef0d075dab": {
        "text_answer": "  No the statement is not entailed by the evidence as the evidence does not mention anything about children and adolescents in the secondary trial",
        "label": "Contradiction"
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "text_answer": "Yes  Explanation  The statement Neither the secondary trial or the primary trial use cm Number of Participants or a unit of time as their units of measure is entailed by the evidence because the evidence does not provide any information about the use of cm Number of Participants or a unit of time as units of measure in either trial The primary trial uses the change in units on a scale as its unit of measure and the secondary trial uses",
        "label": "Entailment"
    },
    "1514ac93-96a8-4d16-a572-d2a829af84c4": {
        "text_answer": "No  Explanation The statement mentions cisplatintopotecan as a combination of agents but the evidence only mentions epirubicin cyclophosphamide docetaxel and trastuzumab as the drugs used in the trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "61c97e3c-0456-4a0f-a261-d8ab75386686": {
        "text_answer": "Yes  Explanation  The statement in the primary clinical trial cardiacrelated adverse events were not reported in cohort 1 is entailed by the evidence since there are no cardiacrelated adverse events reported in the Adverse Events 1 data for cohort 1",
        "label": "Entailment"
    },
    "1aa7e1a8-707d-4c18-bdec-a750f59ffd1b": {
        "text_answer": "Yes The evidence states that 53 out of 60 participants or 883 in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a CR or PR This is over half of the participants so the statement is true",
        "label": "Entailment"
    },
    "1f30e035-2441-4585-826a-9150678cb094": {
        "text_answer": "No  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is not directly related to the disorder hypophosphatemia The evidence provided only mentions the occurrence of adverse events in two trials but it does not specify which trial involved patients with hypophosphatemia Therefore the statement is not entailed by the",
        "label": "Contradiction"
    },
    "7b0752c4-ecc6-426a-82c9-e14bb237cfdc": {
        "text_answer": "Yes The statement is entailed by the evidence as interstitial lung disease is listed as an exclusion criterion",
        "label": "Entailment"
    },
    "34a95632-c79d-4704-8a4a-56c4ddce6070": {
        "text_answer": "No  The primary trial is for HER2negative breast cancer patients and the secondary trial is for ERpositive HER2negative breast cancer patients The statement mentions a young girl with PRpositive and HER2positive breast cancer which is not covered by the inclusion criteria of either trial",
        "label": "Contradiction"
    },
    "587de897-adb2-4752-bd48-c9240b9bd956": {
        "text_answer": "No  Explanation  The evidence provided in the results does not indicate the number of participants with an increase in the growth factor signature GFS in each group Instead it reports the percentage of participants with a decrease in GFS Therefore it is not possible to determine if the statement is entailed by the evidence based on the given information alone",
        "label": "Contradiction"
    },
    "fd0b6abb-37f4-4b91-9b9f-433cbced84a7": {
        "text_answer": "Yes  The statement is entailed by the evidence as both cohorts receive the same maximum tolerated dose of CUDC101 but the frequency of administration differs",
        "label": "Entailment"
    },
    "2c3adca5-a150-4c23-aa83-2cc8caeb0deb": {
        "text_answer": "  Yes for the primary trial pulmonary embolism is a reason for exclusion within 4 weeks of first dose of study drug  Partially for the secondary trial the decision is left to the investigator",
        "label": "Entailment"
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "text_answer": "Yes The primary trial has a treatment cycle length of 21 days 1 month while the secondary trial does not mention a cyclic treatment",
        "label": "Entailment"
    },
    "e9602bad-7e97-41b5-9d08-f02f259a75e6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "1fa2d084-6a29-44c1-9e0f-53eb6d932247": {
        "text_answer": "Yes  Explanation The evidence provides the number of participants who experienced a reduction in circulating tumor cells CTCs following highdose chemotherapy with purged autologous stem cell products The statement indicates that less than half of the primary trial participants had a reduction in CTCs Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "ce232ee1-c38c-4eee-bb4a-eaa33f0c75a8": {
        "text_answer": "No The evidence states that a history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months is an exclusion criterion A recent diagnosis of an intrabdominal abscess would fall under this category and would disqualify a patient from participating in the trial Regarding psychiatric disorders the evidence states that there is an exclusion criterion for patients with significant psychiatric disorders",
        "label": "Contradiction"
    },
    "26f39f2a-dad6-40ed-8fa4-5abd8847021f": {
        "text_answer": "No  The woman who has not undergone any radical surgical treatment for her stage II BC is eligible for the primary trial but not for the secondary trial due to different inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "b37fc6a3-d231-478b-a18e-aa3439a972f1": {
        "text_answer": "No  Explanation The evidence provided in the clinical trial outcome measurement describes the results of highdose chemotherapy with purged autologous stem cell products specifically Carboplatin Thiotepa and Cyclophosphamide and the number of participants who experienced a reduction in circulating tumor cells CTCs one month posttransplantation The statement however refers to a decrease in CTCs after months",
        "label": "Contradiction"
    },
    "e7af2ad2-7001-40c6-93cd-ddfd4d436170": {
        "text_answer": "No  The evidence mentions that there can be some evidence of cognitive impairment but it does not specify that the trial is open to patients diagnosed with dementia specifically frontotemporal or mixed dementia",
        "label": "Contradiction"
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "text_answer": "Yes  Explanation The statement is consistent with the information provided in the evidence The evidence states that the final eligibility for a clinical trial is determined by the health professionals conducting the trial regardless of whether a patient satisfies the inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "63a2b921-08f3-456f-9710-fc74ec13954e": {
        "text_answer": "Yes The evidence shows a 10 reduction in Ki67 expression after 6 weeks of TAK228 Plus Tamoxifen treatment The statement does not mention PI3K gene mutation but the evidence does not provide information about that",
        "label": "Entailment"
    },
    "bbc8e272-7c58-4e53-a78b-4b634add9932": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "a7382edb-9b99-468d-99f2-2030aa61005c": {
        "text_answer": "Yes The statement is consistent with the information provided in the evidence that the primary and secondary trials evaluate different patient populations",
        "label": "Entailment"
    },
    "709bff7a-2384-4cac-ac70-00b4e91a6bce": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as it introduces a new concept frequency of anxiety which is not mentioned in the evidence The evidence only provides information about the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 for a specific treatment regimen",
        "label": "Contradiction"
    },
    "7c192c20-49e2-4b5c-b4ac-1131b7e9e4d0": {
        "text_answer": "No  Explanation  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is not directly entailed by the evidence provided The evidence only states the number of adverse events for each trial but it does not compare the number of each specific type of adverse event between the two trials Therefore it is not possible to determine from the evidence alone whether there",
        "label": "Contradiction"
    },
    "608a57fb-72d5-4837-a491-2d0bc83a7776": {
        "text_answer": "Yes  Explanation The statement the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts on the other hand the secondary trial reports the number of patients that experience Objective Response is entailed by the evidence as the primary trial reports Time to Progression for 72 participants in Arm A and 84 participants in Arm B making a total of 156 participants and",
        "label": "Entailment"
    },
    "58f6494f-860a-4f94-9fa1-895637730938": {
        "text_answer": "No  Explanation  The statement the dosage of denosumab in intervention 1 of the primary trial is equivalent to the dosage of tamoxifen in intervention 1 of the secondary trial is not entailed by the evidence provided The dosages are not equivalent as denosumab is given at a dose of 120 mg Q4W every 4 weeks while tamoxifen is given at a dose of",
        "label": "Contradiction"
    },
    "a08b1e1e-385a-40e6-990d-05b9aebc7335": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial states that patients received 120 milligrams of denosumab every 4 weeks not 240 milligrams every month The secondary trial does not mention denosumab at all but instead involves the use of a pIHGC and GP for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "a1eb1305-f49e-4773-aa30-033093afeb64": {
        "text_answer": "Yes  Explanation  The evidence provides the percentage of participants in each group ERpositive Luminal B and Triple Negative who demonstrated a decrease in the growth factor signature GFS after receiving a single dose of dalotuzumab 20 mgkg The statement in question asserts that there was no significant difference in the decrease of the growth factor signature between the two groups The evidence supports this statement as both groups had",
        "label": "Entailment"
    },
    "36c3d1c3-d4dc-49bf-97a8-49608799cc35": {
        "text_answer": "No  Explanation  The statement satisfied with treatment effects is a question about whether an individual is or was satisfied with the effects of their treatment so far is not directly related to the inclusion or exclusion criteria mentioned in the evidence The evidence only mentions the diagnostic and eligibility criteria for patients to participate in a clinical trial for metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial",
        "label": "Contradiction"
    },
    "227071c8-f195-4c9c-993d-3f57a9062a6f": {
        "text_answer": "No  Explanation  The statement secondary glioblastoma is a glioblastoma arising from a lower grade astrocytoma is not related to the given evidence The evidence only pertains to inclusion and exclusion criteria for two different clinical trials The first trial is for postmenopausal women with early stage breast cancer and low vitamin D levels and the second trial is for healthy participants HER2positive",
        "label": "Contradiction"
    },
    "a06e0782-9249-48ae-a2a3-70dffa452aab": {
        "text_answer": "Yes The evidence does not include any limitations concerning life expectancy pregnancy or age in the inclusion criteria",
        "label": "Entailment"
    },
    "7eb81981-e3ca-42f2-ba8f-d1582e00f54d": {
        "text_answer": "No  Explanation  Although both trials involve the use of FMX and MM398 in the primary trial and lapatinib in the secondary trial the dosages and administration schedules are different In the primary trial FMX is given as a single bolus IV injection followed by MM398 while in the secondary trial lapatinib is given orally and paclitaxel is given IV weekly Therefore",
        "label": "Contradiction"
    },
    "b60cdaf1-5a83-4738-b15d-d857c6d0924a": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as it contains incorrect information about the interventions in the primary and secondary trials The primary trial intervention is Radioembolization using TheraSpheres while the secondary trial intervention is a combination of ibrutinib and MEDI4736 The statement incorrectly mentions a half pint which is not related to the interventions in the evidence",
        "label": "Contradiction"
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "text_answer": "No   Explanation   The statement is not entailed by the evidence as the statement mentions only one intervention for the primary trial while the evidence provides information about two different interventions for both the primary and secondary trials",
        "label": "Contradiction"
    },
    "7e232984-9a95-44b0-85b0-ecbeb50655b7": {
        "text_answer": "Yes The evidence does not include any restrictions based on nationality ethnicity weight or gender in the inclusion criteria for either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "f5c83e99-e58f-4e5a-9fde-836480522184": {
        "text_answer": "Yes The statement does not contradict the evidence The evidence only reports the absence of adverse events related to the primary and secondary trials and the statement is about the microscopic finding of squamous differentiation which is not related to adverse events",
        "label": "Entailment"
    },
    "23727e9e-6589-475f-9c29-0a7880f6d8af": {
        "text_answer": "  Yes the evidence suggests that both groups experienced a decline in cognitive performance with a slightly greater decline in the ovarian function suppression group based on the mean standardized scores",
        "label": "Entailment"
    },
    "05971ed1-8162-4f52-8361-6fae652d03e2": {
        "text_answer": "Yes however the evidence does not directly compare acupuncture to testosterone cream but rather to a waitlist control group",
        "label": "Entailment"
    },
    "99b57587-ea7a-496f-a7f9-9b2a7837ccc7": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary clinical trial does report on changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing SPID30 as the outcome measurement The statement only mentions that the primary trial does not provide reports on the changes in bone mineral density BMD of the lumbar spine which is not mentioned in the",
        "label": "Contradiction"
    },
    "af9cfc7a-95f4-494a-b68f-128961cf1a5b": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence only specifies breast cancer as a requirement for the clinical trial",
        "label": "Contradiction"
    },
    "55af1301-2370-48bf-8dde-50c589448da1": {
        "text_answer": "No  The evidence does not provide information about the presence or absence of eating disorders in the individuals in the clinical trial",
        "label": "Contradiction"
    },
    "7d0d3d69-d8ff-4671-9251-6f7a5f19a5ad": {
        "text_answer": "Yes The primary trial participants received lower doses of PF06647020 02 mgkg and 05 mgkg than the secondary trial participants who received 0015 mgkgdose and 0040 mgkgdose of ALT801 The statement does not provide any information about how the doses of the drugs in the trials relate to the question",
        "label": "Entailment"
    },
    "9fcf0873-73d2-48e3-87ac-ee5df19f7810": {
        "text_answer": "No  Explanation The evidence provided in the text only gives the median PFS for each treatment group not the longest survival time for an individual patient Therefore it is impossible to determine from the given evidence that the patient who survived the longest 35 months was from cohort 1",
        "label": "Contradiction"
    },
    "54c9c0a9-c38d-46b1-a96b-1335daaaef85": {
        "text_answer": "No  The statement is not entailed by the evidence as the primary trial specifies intravenous administration of zoledronic acid not transdermal and the secondary trial specifies intravenous or oral administration for all drugs mentioned",
        "label": "Contradiction"
    },
    "24493091-48f3-4e50-ae2c-5d23fb12c376": {
        "text_answer": "  No the statement is not entailed by the evidence as the primary trial includes various types of breast cancer not just BRCA breast cancer",
        "label": "Contradiction"
    },
    "64e0d68e-9fdb-4625-b179-316cf3772ee9": {
        "text_answer": "No  Explanation The evidence describes two different interventions each with a specific route of administration IV for bisphosphonate and subcutaneous injection for denosumab Therefore the statement that the primary clinical trial implements its interventions via multiple routes is not directly entailed by the evidence as it does not indicate that the interventions are administered through more than one route within the same intervention",
        "label": "Contradiction"
    },
    "fed83886-1413-49c9-91ab-3f1bea54db23": {
        "text_answer": "Yes The secondary trial was halted due to the occurrence of significant adverse events However the evidence does not provide information on the specific adverse events that led to the halt",
        "label": "Entailment"
    },
    "7138e72c-d5e7-4c18-ba8c-b71be945ac2d": {
        "text_answer": "No   Explanation  The evidence provided in the given context only mentions the age group 65 years and older for both the intervention groups  Adult Cancer Patients and Healthy Volunteers It does not mention anything about the participants receiving tailored interventions based on their cancer diagnosis",
        "label": "Contradiction"
    },
    "4db16d69-4db6-410a-a48a-215903320e43": {
        "text_answer": "Yes The statement mentions breast cancer patients with ER negative PR negative and HER2 tumors which is consistent with the inclusion criteria for Group 1 ER positive HER2 negative in the evidence Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "bfe7b8a8-8d7d-404c-b369-9bf059ae079c": {
        "text_answer": "Yes The statement is entailed by the evidence as epilepsy thalasemic syndromes and anemia are listed as exclusion criteria in both trials",
        "label": "Entailment"
    },
    "054618c6-0f9d-46de-94f3-e69e066a8432": {
        "text_answer": "No  Explanation  The statement 5 of the participants in group 1 of the primary trial were found to have lesions and only 30 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed by the evidence provided The evidence only reports the number of participants and the number of lesions or radiation dermatitis cases in each group but",
        "label": "Contradiction"
    },
    "3db34e4f-ae01-424d-a8b8-7d1a16e2f898": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence explicitly states that individuals with interstitial lung disease or pneumonitis are ineligible for the trial",
        "label": "Contradiction"
    },
    "f300c26a-9ae0-4474-8fb3-34435ecdcf11": {
        "text_answer": "Yes for the primary trial No for the secondary trial  Explanation  For the primary trial the evidence states that both groups receive injections and those in Group A receive Botulinum Toxin Type A while Group B receives a placebo 5 mL 09 NaCl solution Neither group receives entericcoated tablets  For the secondary trial the evidence states that participants receive MLN82",
        "label": "Entailment"
    },
    "5031f62e-54ed-4635-b136-7f90d6eb2535": {
        "text_answer": "Yes  Both trials use the unit of measure cm for tumor diameter and participants for the number of participants",
        "label": "Entailment"
    },
    "efdd9a96-8d0a-40ae-bcf7-f27abe59658d": {
        "text_answer": "Yes for the primary trial pulmonary embolism is a reason for exclusion within the last 6 months for the secondary trial it is excluded but not explicitly stated for how long ago it must have occurred",
        "label": "Entailment"
    },
    "b89171bc-ed32-4c9b-91ee-545a95b809fc": {
        "text_answer": "Yes The evidence does not mention the use of drugs radiotherapy or CBT in the primary clinical trial",
        "label": "Entailment"
    },
    "b0a8feea-e233-4a75-992e-698a978045a5": {
        "text_answer": "Yes  Explanation  The statement substantial variations were seen in the results of the groups participating in the primary clinical trial is entailed by the evidence as the AUC values for the two algorithms in the primary trial differed slightly  The statement a disparity was observed between the reflexology group and the control group in the secondary clinical trial is also entailed by the evidence as the mean fatigue scores for the reflexology group",
        "label": "Entailment"
    },
    "1d8a752e-8628-40d5-b134-e523b5dead07": {
        "text_answer": "No  Explanation  The evidence provided in the text does not mention any information about severe discomfort reported by patients during the study The text only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "7c81475d-c4f3-45cd-8481-400d43c45a7e": {
        "text_answer": "Yes with the caveat that androgenbased therapy is excluded in the primary trial but it was specified that antiHER2 agents are allowed If the androgenbased therapy was for something other than breast cancer then the person may still be eligible",
        "label": "Entailment"
    },
    "9e5f5682-6d2b-40df-b271-a0da55928c97": {
        "text_answer": "Yes The statement oral administration once a day is entailed by the evidence as both interventions involve taking the medication by mouth PO once a day BID",
        "label": "Entailment"
    },
    "40034c62-a8d9-424f-ac22-2d5fcab4dfc0": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as it contradicts the information provided about the intervention for the primary clinical trial The evidence states that the intervention arm of the study includes viewing the educational DVD and meeting with a lay health advisor while the statement suggests that the succeeding cohort will undergo standard radiotherapy treatment instead of the intervention described in the evidence",
        "label": "Contradiction"
    },
    "711218ac-a329-4d4e-a66b-3c4b2d9116b5": {
        "text_answer": "Yes The statement does not directly address the adverse events but it is not in contradiction with the evidence provided",
        "label": "Entailment"
    },
    "ba6548a1-7dbf-4924-91ed-da83ecb2e8ef": {
        "text_answer": "No  Explanation  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial is not directly related to the statement general fatigue dimension is a dimension of general fatigue in the multidimensional fatigue inventory The first statement is about a specific exclusion criterion for the secondary trial while the second statement is about a dimension of the Multid",
        "label": "Contradiction"
    },
    "06008bc8-58da-4762-9c98-830f2bd92325": {
        "text_answer": "No  Explanation  The statement breast cancer patients in the primary trial are administered 7000 mcgweek of talazoparib whereas ovarian peritoneal cancer patients in the primary trial receive only 175 mcgweek talazoparib instead is not entailed by the evidence The evidence only provides the dosages of talazoparib administered daily in the primary trial for",
        "label": "Contradiction"
    },
    "68fe8d71-5200-4e77-a560-0fb7e67127a6": {
        "text_answer": "  No The statement have problems with hearing loss that make me angry is not related to the inclusion or exclusion criteria for either the primary or secondary trial",
        "label": "Contradiction"
    },
    "cd18deca-a213-4d53-af34-88624163f68e": {
        "text_answer": "Yes  Explanation  The statement paclitaxel is given to participants in the primary and secondary clinical trials is entailed by the evidence because paclitaxel is listed as a component of the intervention in both the primary and secondary trials In the primary trial paclitaxel is given in the form of Nabpaclitaxel and in the secondary trial it is given as part of docetaxel  lapatin",
        "label": "Entailment"
    },
    "f2006562-69ab-4062-a5be-943cb905ee95": {
        "text_answer": "No  The statement about monoallelic palb2 gene inactivation is not mentioned in the inclusion or exclusion criteria for the primary trial  The statement pertains to Alzheimers patients who are explicitly excluded from the trial",
        "label": "Contradiction"
    },
    "f3f438bb-2af4-44b9-9bf7-28dc232feacb": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes the administration of capecitabine not carboplatin in the first cohort of the primary clinical trial",
        "label": "Contradiction"
    },
    "b0410aa1-2da2-4399-b673-45157d3c3fb7": {
        "text_answer": "Yes  Explanation The statement in the primary clinical trial there was a rise in blood bilirubin levels in 3636 of the patients is entailed by the evidence as it is explicitly stated in the evidence that Blood bilirubin increased 111 3636",
        "label": "Entailment"
    },
    "52db4188-de06-4a23-91e2-bc899f33f0e5": {
        "text_answer": "No  Explanation The statement all patients in the primary trial receive at least 1300mg of mcs110 every 3 weeks is not entailed by the evidence The evidence only states that in the primary trial the Intervention 1 and Intervention 2 both used MCS110 at a dose of 1 mgkg every 3 weeks and PDR001 at a dose of 100",
        "label": "Contradiction"
    },
    "33c89b93-d655-4154-9712-0803974c65f7": {
        "text_answer": "No  Explanation  The evidence provided in the results does not indicate that every participant in the trial experienced an adverse event Instead it reports the number of participants with serious and nonserious adverse events for each dose level group The statement the entire initial cohort faced a form of adverse event is not supported by the evidence",
        "label": "Contradiction"
    },
    "936d7822-fd4b-42fc-abc5-d5ad838f148c": {
        "text_answer": "Yes The primary trial includes individuals with locally advanced recurrent or metastatic ER breast cancer while the secondary trial includes individuals with newly diagnosed or recurrent ER breast cancer Both trials consider individuals with metastasized breast cancer who are considering hormone therapy",
        "label": "Entailment"
    },
    "b99886d6-98a7-4746-bc6c-1f70c8cdd0c6": {
        "text_answer": "Yes  Explanation  The statement The only types of AEs observed in patients from the secondary trial were Eyelid oedema and Chest pain no AEs were recorded in the primary trial is entailed by the evidence provided The evidence shows that there were no adverse events AEs recorded in the primary trial for any of the listed types and in the secondary trial the only types of AEs observed were Eyel",
        "label": "Entailment"
    },
    "c2c4cbf5-1469-42bf-b243-9080648b458b": {
        "text_answer": "Yes  Explanation The evidence states that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to 38 Subtracting the Ki67 expression at 6 weeks from the Ki67 expression at baseline gives a difference of 5 105  5 1538  23",
        "label": "Entailment"
    },
    "cc807530-f293-4c99-921b-f6e303d2b825": {
        "text_answer": "Yes The primary trial includes patients without a history of breast cancer while the secondary trial excludes such patients",
        "label": "Entailment"
    },
    "82c8c33d-a45b-4897-8ac5-407ec39564fd": {
        "text_answer": "No   Explanation   The statement one of the patient groups in the primary clinical trial is treated with 150 mg of oral pregabalin twice a day contrastingly the secondary clinical trial applies depocyt and hdmtx for its patients is not directly entailed by the evidence provided The primary trial involves a group of patients receiving pregabalin and another group receiving placebo while the secondary trial involves a different treatment",
        "label": "Contradiction"
    },
    "a4cc14a3-7e05-4f72-b2f1-c9bb11720917": {
        "text_answer": "Yes  Explanation The evidence shows that 20 out of 35 participants in cohort 1 did not experience any acute vomiting episodes within the first 24 hours after cyclophosphamide administration This means that a majority 20 out of 35 of the patients in this group reported no acute vomiting following the treatment with aprepitant dexamethasone cytoxan and k",
        "label": "Entailment"
    },
    "bacab9f7-0d0a-49e1-a503-e959c33bfe6a": {
        "text_answer": "Yes  Explanation The statement despite a patient potentially fulfilling all exclusion and inclusion conditions of the primary clinical trial the ultimate verdict on their inclusion lies in the hands of the medical professionals running the trial is entailed by the evidence as it states Final eligibility for a clinical trial is determined by the health professionals conducting the trial",
        "label": "Entailment"
    },
    "d11e7175-a122-475f-862e-c5215d821f34": {
        "text_answer": "  No the statement is not entailed by the evidence for the secondary trial The secondary trial only includes females",
        "label": "Contradiction"
    },
    "99eb2e5a-77d2-4ab1-a25b-b6d8a8bcf412": {
        "text_answer": "Yes The statement acknowledges that the final eligibility for the clinical trial is determined by the health professionals conducting the trial but it also mentions the possibility of a court appointed guardian or representative having a role in the decisionmaking process This is not explicitly stated in the evidence but it does not contradict it either Therefore the statement is entailed by the evidence as it falls within the realm of possibilities for the eligibility determination process",
        "label": "Entailment"
    },
    "c00fd72d-2cbe-4988-a861-60a707684af7": {
        "text_answer": "Yes The evidence shows a total of 3 vomiting events out of 149 participants in the trial",
        "label": "Entailment"
    },
    "7ade4e76-2f1d-452d-b9e4-499e0aabbe0c": {
        "text_answer": "No  Explanation  The statement mentions swelling hypothermia and confusion as adverse events but the evidence provided does not mention any instances of these specific adverse events in either trial The evidence only states that the total number of adverse events for Adverse Events 1 in both trials was 0",
        "label": "Contradiction"
    },
    "652e7c7c-998b-4a7d-b170-bcbe79729d93": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial uses a change in units on a scale as the unit of measure while the secondary trial uses percentage of participants as the unit of measure The statement incorrectly assumes that the primary trial uses functional physical assessment results as the units of measure which is not the case",
        "label": "Contradiction"
    },
    "d8d046cc-99cc-4a31-94de-6dd290f504e7": {
        "text_answer": "No  Explanation  The statement every patient in the primary clinical trial experienced at least five distinct adverse events is not entailed by the evidence provided The evidence only shows that there were no adverse events reported for some types in the primary trial while all types were reported in the secondary trial It does not indicate that each patient in the primary trial experienced five or more distinct adverse events",
        "label": "Contradiction"
    },
    "9b09c156-bc43-445b-83ca-3831b111056f": {
        "text_answer": "No  Explanation  The statement patient cohorts in the secondary clinical trial displayed marginally more total negative effects than those in the primary clinical trial is not entailed by the evidence provided The evidence only states that there were no adverse events reported in the primary trial for both Adverse Events 1 and 2 and that in the secondary trial there were no adverse events for Adverse Event 1 in 15 patients 0",
        "label": "Contradiction"
    },
    "8b3dbda5-ee27-4d74-b6ab-d4bb1cc5c86b": {
        "text_answer": "No  The primary trial excludes patients receiving warfarin as a coumarinderivative anticoagulant but the secondary trial permits its use in low doses less than or equal to 1 mgday",
        "label": "Contradiction"
    },
    "e115c2a9-a31e-4a26-a96b-cd038666ced0": {
        "text_answer": "Yes  Explanation  The primary trial measures the severity of vaginal symptoms using a subjective patientreported outcome measure Vaginal Symptom Measure VSM while the secondary trial measures objective response rate of HER2negative metastatic breast cancer using biomarker data FISH testing Therefore the statement that the primary trial uses subjective patientreported outcomes and the secondary trial employs biomark",
        "label": "Entailment"
    },
    "4662f196-5472-4321-846e-c1576bc0be70": {
        "text_answer": "Yes  Explanation  The statement neither the primary trial participants nor the secondary trial participants experienced cholelithiasis is entailed by the evidence because cholelithiasis is not listed as an adverse event in either trial",
        "label": "Entailment"
    },
    "76032781-7c1c-4518-b9c5-13f8d7a5b443": {
        "text_answer": "No  Explanation  The statement is not directly entailed by the evidence as the evidence does not provide information about the incidence of chest pain in either trial The statement only mentions adverse events in general but the evidence specifically lists various types of adverse events none of which is chest pain",
        "label": "Contradiction"
    },
    "2c29a565-bdcd-464c-85a4-361ab767c0d9": {
        "text_answer": "  No   Explanation   The statement the adverse events of the primary and secondary trials each resulted in multiple deaths is not entailed by the evidence The evidence only reports that there was one death in each trial not multiple deaths",
        "label": "Contradiction"
    },
    "bd759cf8-b82f-496f-a8f7-1ab39f0d4724": {
        "text_answer": "No  Explanation  The statement have you been in low or very low spirits is a question about whether an individual is or has been in low or very low spirits is not directly related to the inclusion or exclusion criteria for either the primary or secondary trial The primary trial focuses on the eligibility of patients for a chemotherapy study based on their medical history laboratory values and other factors The secondary trial focuses on the eligibility of patients for",
        "label": "Contradiction"
    },
    "7531054e-9cf3-43a1-bba4-19e90a2c5ef0": {
        "text_answer": "No  Explanation  The outcome measures of the primary and secondary clinical trials are not directly related as they assess different aspects of the trials The primary trial measures the percentage of participants with treatmentemergent adverse events in different populations while the secondary trial measures the number of participants with objective response to talazoparib in breast and ovarianperitoneal cancer patients These outcomes are not directly related to each other",
        "label": "Contradiction"
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as there were no adverse events reported in more than 30 of participants in either trial The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial",
        "label": "Contradiction"
    },
    "129d4bb1-11bc-4aa4-b75a-fa8d0832e2ff": {
        "text_answer": "  No  Explanation  The statement in the primary clinical trial the group taking azd0530 175 mg experienced a greater percentage change in betactx at the fourth week than the group on zoledronic acid 4 mg is not directly entailed by the evidence provided The evidence only shows that both groups had significant reductions in percentage change in betaCTX at Week 4 compared to baseline but it does not",
        "label": "Contradiction"
    },
    "4a21310d-d0b8-44c7-ac08-ca9164bdc49f": {
        "text_answer": "No   Explanation   The statement is not directly entailed by the evidence as the statement compares two different clinical trials with different interventions The first trial uses Yttrium90 Radioembolization TheraSphere and the second trial uses ibrutinib and MEDI4736 The statement does not mention both trials in the same context and the evidence does not indicate that they are being compared",
        "label": "Contradiction"
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "text_answer": "Yes  Explanation The statement is entailed by the evidence as both trials have fibromyalgia and thalasemic syndromes as exclusion criteria The primary trial also excludes anemia due to causes other than breast cancer",
        "label": "Entailment"
    },
    "19dbbcf2-63e2-4f96-a672-8c184edb025b": {
        "text_answer": "No  The evidence provided does not mention anything about counseling risk assessment or CBT related to the statement about an individuals ability to stay focused and think clearly under pressure",
        "label": "Contradiction"
    },
    "3607f455-e990-4306-8b23-52d930ccbdff": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "db2684e9-bcdc-482b-bfe4-4d6b2f6862c0": {
        "text_answer": "Yes The statement does not contradict the evidence and the evidence does not provide any information that would contradict the statement",
        "label": "Entailment"
    },
    "40fceb75-d0d5-4926-8d3d-7e5f3c5b7931": {
        "text_answer": "No  The evidence does not mention any adverse events related to eating disorders",
        "label": "Contradiction"
    },
    "b72d4b5e-e31f-47aa-979a-8253ec455cd1": {
        "text_answer": "Yes  Explanation The statement the number of hepatotoxicity cases were equal to the cases of hypertension and pancreatectomy is entailed by the evidence since the evidence states that there were 3 cases of hepatotoxicity which is equal to the number of cases of hypertension and pancreatectomy each having 1 case",
        "label": "Entailment"
    },
    "fc9a9de5-319a-465e-82ce-3c95b9a42728": {
        "text_answer": "No  Explanation  The statement the primary clinical trial had zero infection cases whilst the secondary clinical trial also reported an absence of infection is not entailed by the evidence While it is true that neither trial reported any infection cases in Adverse Event 1 the evidence does not provide information about the total number of infections that occurred in each trial Therefore it is possible that there were infections in the trials that were not reported as adverse events",
        "label": "Contradiction"
    },
    "3870c72e-cf9d-461b-9dfd-ef407d84e8cf": {
        "text_answer": "No  Explanation  The statement patients in the primary clinical trial undergo proton therapy and each group in the secondary clinical trial is prescribed 500 mg of fulvestrant to be administered through the transdermal patch twice a day is not entailed by the evidence  The primary clinical trial describes the use of radiation therapy for breast cancer patients while the secondary clinical trial describes the use of Enzastaurin and F",
        "label": "Contradiction"
    },
    "83e0c108-bbbe-4b9b-97b6-62ea72e374d8": {
        "text_answer": "Yes  Explanation  The statement infections and infestations cases in the primary clinical trial occurred in patients from cohort 2 is entailed by the evidence because the evidence indicates that there was one case of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever in cohort 2 of the primary clinical trial",
        "label": "Entailment"
    },
    "8b047df3-cd4b-4c75-97b5-4081f65512eb": {
        "text_answer": "No   Explanation  The statement is not entailed by the evidence as the primary trial administers a dosage of 05ugkg of dexmedetomidine in group 2 which is significantly lower than the stated 2mgkg in the question Additionally the secondary trial administers a dosage of 1mgkg which is also different from the primary trials group 2 dosage",
        "label": "Contradiction"
    },
    "e92e432c-9e5c-451c-9bb2-ff89a618126c": {
        "text_answer": "Yes for hyperkalemia as an exclusion criterion in both trials  Explanation The evidence provided in the inclusion and exclusion criteria for both the primary and secondary clinical trials indicates that hyperkalemia is a disqualifying condition for participation in both trials Therefore the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "d7f818fb-a383-41c3-ac12-788228db7cf9": {
        "text_answer": "No  Explanation The statement The intervention in the primary trial consists of a single drug ZD1839 whereas in the secondary trial the intervention requires at least 3 different drugs including Zoledronic acid Samarium153 and pegfilgrastim is not directly entailed by the evidence provided The evidence only states that in the primary trial the intervention is ZD1839 and in the secondary",
        "label": "Contradiction"
    },
    "d39e0799-d31d-4759-96ed-716b92f924a6": {
        "text_answer": "No  Explanation The statement the intervention in the secondary trial lasts three times longer than the intervention in the primary trial is not entailed by the evidence provided The primary trial lasted for 10 weeks while the secondary trial lasted for 24 weeks but this does not mean that the intervention in the secondary trial was three times longer in duration The intervention in the secondary trial consisted of taking vitamin D capsules weekly for 24 weeks",
        "label": "Contradiction"
    },
    "fbe81247-571c-43a1-a2eb-439e579cf229": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the evidence does not mention laryngeal fistula or CTCAE Common Terminology Criteria for Adverse Events in relation to the recorded adverse events The statement is about a specific disorder while the evidence only provides information about the number and types of adverse events observed in two clinical trials",
        "label": "Contradiction"
    },
    "952fd1e7-65a2-417f-b1b8-188bce187c04": {
        "text_answer": "No  Explanation  The statement the primary clinical trial uses uniform criteria for participant eligibility in every phase whereas the secondary trials selection criteria vary per participant is not directly entailed by the evidence provided While it is true that the primary trial has consistent inclusion and exclusion criteria for each phase the secondary trial has different inclusion and exclusion criteria for the study as a whole However the statement does not explicitly mention that the secondary trial",
        "label": "Contradiction"
    },
    "551bc048-5bac-47a0-a2bf-17844970c8dc": {
        "text_answer": "yes injections are mentioned in the evidence However there is no mention of gas cylinders in the evidence",
        "label": "Entailment"
    },
    "03c087ae-9ad2-4db3-a913-e6ba85dc15b0": {
        "text_answer": "Yes The inclusion criteria for both trials state that candidates must have an ECOG performance status of 0 to 2 indicating they are able to perform normal activities with minimal restriction This means they are not bedridden for more than 50 of their waking hours",
        "label": "Entailment"
    },
    "9c459c1c-bfc4-4fef-ba9f-6052b9622c69": {
        "text_answer": "Yes The statement is about the calr gene mutation in general and the evidence does not contradict it The evidence only provides information about the occurrence of adverse events in two trials but it does not mention anything about the calr gene mutation causing the adverse events or not Therefore the statement is entailed by the evidence because the evidence does not provide any information that would contradict the statement",
        "label": "Entailment"
    },
    "a79aa893-e44c-4077-8791-47fb56351b5e": {
        "text_answer": "No   Explanation  The evidence provided does not mention anything about radiation therapy being administered to the participants in either the primary or secondary trials Therefore it is not possible to determine if the statement is entailed by the evidence or not",
        "label": "Contradiction"
    },
    "f3e56d1d-af35-462c-ac1e-7e995543f505": {
        "text_answer": "Yes The statement does not provide any new information about the adverse events but it is consistent with the information given in the evidence",
        "label": "Entailment"
    },
    "88574a43-d4c9-4db7-8f47-307722095b0d": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as the primary trial examines the effect of sulforaphane supplements on isothiocyanate levels in urine while the secondary trial investigates the impact of physical therapy on pain reported by participants during chemotherapy treatment",
        "label": "Contradiction"
    },
    "c7e1e07a-e363-47f7-9ec3-21fbd1da79b3": {
        "text_answer": "  No The statement is not entailed by the evidence The evidence states that patients with a history of chemotherapy or radiotherapy within a certain time frame are excluded from the secondary trial but it does not mention anything about neuropathy or unstable angina",
        "label": "Contradiction"
    },
    "eca608f4-6f65-4fc9-96cb-d1bb45749048": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "a8353a78-23fe-4aba-aaef-06d3fb8dd41a": {
        "text_answer": "No   Explanation The evidence provided only reports the median PFS for each treatment group not the longest PFS experienced by any individual patient",
        "label": "Contradiction"
    },
    "cb591a65-2304-40bc-ad66-ddd4f3376bdc": {
        "text_answer": "Yes for the secondary trial only as the primary trial does not mention smoking as an exclusion criterion",
        "label": "Entailment"
    },
    "c566ae79-b43a-4e83-8336-da8613e19e7f": {
        "text_answer": "Yes The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 but those with dementia are excluded Alzheimers disease is a type of dementia so those suffering from it are not eligible for participation in the trial",
        "label": "Entailment"
    },
    "b0bedf1c-a1ed-4bf5-9ad1-ac22f0681d03": {
        "text_answer": "Yes The evidence does not provide information on the number of participants with treatmentemergent adverse events for either trial",
        "label": "Entailment"
    },
    "a3fb7d8d-5911-41d4-b3da-9a018bb256f6": {
        "text_answer": "No  Explanation  The evidence provided in the text does not support the statement that each participant from the first group of the primary trial had noticeable lesions and those from the second trials group had no symptoms of radiation dermatitis or hyperpigmentation The evidence only reports the number of participants and the measures taken for each group but it does not provide information about the presence or absence of lesions or symptoms for each individual participant",
        "label": "Contradiction"
    },
    "5ccd39fd-215e-4699-8d02-a13d68ec34d3": {
        "text_answer": "No  Explanation The statement does not mention Paraplatin at all and the evidence only mentions that both interventions include the same dose of Paraplatin Therefore the statement is not entailed by the evidence even though they are related to the same trial",
        "label": "Contradiction"
    },
    "1304d51c-38a5-4851-9241-b0cb6993b013": {
        "text_answer": "No  Explanation  The primary clinical trial measures hot flash activity using a composite score of severity and frequency while the secondary clinical trial measures overall response rate as a proportion of responders These are not identical units of measurement",
        "label": "Contradiction"
    },
    "5794c670-e60c-4d2a-8d09-744e644c3e34": {
        "text_answer": "Yes The evidence explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial",
        "label": "Entailment"
    },
    "cdc43061-760e-4de2-946e-93d74f8ab544": {
        "text_answer": "No   Explanation  The statement Every participant in the primary trial receives the same intervention is true based on the information provided in the evidence However the statement have trouble going to sleep is a question about whether an individual has or had trouble going to sleep is not related to the evidence at all The evidence only provides information about vaccine responses in adults 65 years of age and older regardless of whether they have cancer or not It does",
        "label": "Contradiction"
    },
    "5758ac46-f46b-452f-aa99-5d9c86700447": {
        "text_answer": "Yes  Explanation  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed by the evidence provided The evidence shows that the primary trial had a higher incidence of these adverse events compared to the secondary trial",
        "label": "Entailment"
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "text_answer": "Yes  Explanation The statement participants in the primary trial receive 4 different drugs throughout the study duration with a maximum dose of 100 mgm2 is entailed by the evidence as the trial involves the use of epirubicin cyclophosphamide docetaxel and trastuzumab Additionally the maximum dose of epirubicin is 100 mgm",
        "label": "Entailment"
    },
    "707a6e1b-520e-4052-bbd8-c932c4cc65e2": {
        "text_answer": "Yes The statement is entailed by the evidence as both interventions GBM and gynecological cancers involve the use of 18FFDG and 18FFPPRGD2 for PETCT or PETMRI scans at specified time points with the same injection limit for 18FFPPRGD2",
        "label": "Entailment"
    },
    "0359c605-2a3a-4696-8d14-ba214c571f1b": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the statement mentions a TNBC tumor of 100mm in diameter which is not a criterion for either the primary or secondary trial The primary trial includes patients with a breast tumor 1 cm in diameter and the secondary trial does not specify tumor size",
        "label": "Contradiction"
    },
    "ed820c4c-4119-4e93-894f-8484407c9ce6": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "text_answer": "No  Explanation The statement Both cohorts of the primary trial receive the same doses of Abraxane is true but it does not follow that they receive the same doses of Carboplatin In Arm A participants receive Gemcitabine in addition to NabPaclitaxel while in Arm B participants receive Carboplatin instead of Gemcitabine Therefore the statement does",
        "label": "Contradiction"
    },
    "14fdb2fc-e19d-4628-ada4-37ea935a2b4a": {
        "text_answer": "No  Explanation  The statement in the primary trial every adverse event was associated with respiratory complications unlike the secondary trial is not entailed by the evidence provided The evidence only reports the frequency of various adverse events in the primary and secondary trials but it does not indicate whether or not they were associated with respiratory complications",
        "label": "Contradiction"
    },
    "9783fc05-3652-41b2-8ba0-8a276889692a": {
        "text_answer": "  No the statement is not entailed by the evidence The primary trial has an exclusion criterion for pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug but it does not mention anything about a history of pulmonary embolism The secondary trial does not mention anything about pulmonary embolism in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "b6b71c5a-8d4b-4ae1-9b57-45a5c9112543": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes a medication regime of oral doses once daily for lapatinib ditosylate and oral doses on days 128 for tamoxifen citrate There is no mention of subcutaneous doses or a dosing frequency of once a fortnight",
        "label": "Contradiction"
    },
    "bed229d6-8924-4753-a297-d49d4c128166": {
        "text_answer": "Yes for the statement about nationality ethnicity psychiatric condition or gender not affecting eligibility Unclear for the statement about continuous surface ECG recording for nonhuman species as it is not related to the provided evidence",
        "label": "Entailment"
    },
    "a434b916-659c-46a6-81c3-1654f561a2c2": {
        "text_answer": "No   Explanation   The statement most participants of the primary clinical trial encountered some sort of eating disorder in the course of the research period is not entailed by the evidence The evidence only lists various adverse events encountered by participants during the trial including anorexia but it does not indicate that most participants experienced an eating disorder",
        "label": "Contradiction"
    },
    "3c96d823-bc6c-4c7e-b490-50a0870076c5": {
        "text_answer": "No   Explanation  The evidence describes the interventions as being administered through transendocardial injections not inhalation",
        "label": "Contradiction"
    },
    "f5e483ed-caec-4142-baa9-15ba42da5f03": {
        "text_answer": "Yes  Explanation  The statement All AE types in the primary trial affected less than 10 of patients is entailed by the evidence since none of the adverse events affected more than 10 of the patients in the trial",
        "label": "Entailment"
    },
    "a993ae6a-f86f-478e-af30-584181f09531": {
        "text_answer": "Yes   Explanation  The statement both the placebo and memantine interventions are administered equally in terms of frequency and duration is entailed by the evidence as both interventions are given twice daily BID for a duration of 81 days in the absence of unacceptable toxicity and continue until completion of 12 weeks",
        "label": "Entailment"
    },
    "f119d419-b22b-4b4d-84ea-f7ab7dba7522": {
        "text_answer": "Yes The primary trial participants received lower doses of PF06647020 than the secondary trial participants but the statement does not mention the drugs or doses in the food preparation and serving context Therefore the statement is not directly related to the doses in the context of the evidence but it is entailed by the evidence because the statement is true in general",
        "label": "Entailment"
    },
    "d7750102-df82-4668-8c6d-60e73b3241b5": {
        "text_answer": "No  Explanation  The statement the primary trial uses a 1 month cycle for its intervention the secondary trial on the other hand does not have a cyclic treatment in place is not directly entailed by the evidence provided The evidence only describes the interventions used in each trial and their durations but it does not explicitly state that the primary trial has a 1month cycle or that the secondary trial does not have a cyclic treatment",
        "label": "Contradiction"
    },
    "d269b697-c96f-4317-99c9-e465c7e935a7": {
        "text_answer": "No  Explanation  The statement the number of participants was identical in both groups of the primary clinical trial is not entailed by the evidence The evidence states that the overall number of participants analyzed in both groups was 1420 but it does not specify that the number of participants was identical in both groups The evidence only provides the number of participants with events in each group 47 in the Neratinib arm and 7",
        "label": "Contradiction"
    },
    "0a74e0af-2534-45f3-b003-ba68e6e52d94": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "c6788d02-11df-4099-a395-c1e3dbc17f35": {
        "text_answer": "No  Explanation  The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is not directly entailed by the evidence provided While it is true that anemia was the most common adverse event in the secondary trial the statement also asserts that there were no recorded adverse events in the primary trial which is not supported",
        "label": "Contradiction"
    },
    "f1dca117-1368-4d17-bdb6-52d1b3816ed5": {
        "text_answer": "No The primary trial excludes patients with a pulmonary embolism within the last 4 weeks not 1095 days The secondary trial does not mention pulmonary embolism in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "b1d950c2-dbd9-4cb4-b291-9406d84cd8de": {
        "text_answer": "No The statement is not entailed by the evidence as the primary trial does not mention anything about AI therapy and mirtazapine responsiveness as a requirement The secondary trial has no relation to AI therapy or mirtazapine",
        "label": "Contradiction"
    },
    "1f63524b-443d-4382-9df4-ea83eda85940": {
        "text_answer": "Yes The evidence does not exclude normal weighted nonpregnant individuals from participating in either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "ad1c4967-3600-4953-a7fb-e48c9f4aa01f": {
        "text_answer": "Yes for the secondary trial No for the primary trial The 20yearold female patient with a newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial as the inclusion criteria for that trial include patients with stage IIIII breast cancer who are deemed appropriate for neoadjuvant endocrine therapy However she would not be eligible for the primary trial as the inclusion criteria for that trial require patients",
        "label": "Entailment"
    },
    "6f4a77ce-3f70-4b57-ae45-e9825753d9ee": {
        "text_answer": "No   Explanation  The primary trial defines each treatment cycle as 21 days not 30 days The secondary trial does not have a cyclic treatment in place as stated",
        "label": "Contradiction"
    },
    "73a0936e-5144-4b8c-b230-389d8ed451af": {
        "text_answer": "No  Androgens are listed as an exclusion criterion in the evidence",
        "label": "Contradiction"
    },
    "37c939aa-c2b0-4fcc-a90a-d7fa36fc8571": {
        "text_answer": "Yes The evidence states that neither cohort received neratinib and it does not mention any surgical procedures",
        "label": "Entailment"
    },
    "a12ed2c0-b402-445b-b21b-7497389b39ec": {
        "text_answer": "No   Explanation   The statement describes a specific genetic mutation erbb2 c22642278del that is not mentioned in the inclusion or exclusion criteria for the primary trial The trials criteria focus on the type and stage of cancer measurability of lesions prior therapy age performance status life expectancy organ function and pregnancy status The statement does not relate to any",
        "label": "Contradiction"
    },
    "d4bd0ed2-5753-470c-b804-00bbebdfc2d7": {
        "text_answer": "Yes for the primary trial regarding pulmonary embolisms and No for the secondary trial regarding breast implants",
        "label": "Entailment"
    },
    "44b930a2-5810-41aa-a70c-e7eaa3730bc0": {
        "text_answer": "No  Explanation  The statement specify site if cm1b is a directive to indicate the anatomic sites if metastasis is categorized as cm1b is not directly related to the evidence provided The evidence only reports the number and types of adverse events observed in two different cohorts of a primary trial It does not mention anything about cm1b or any directive to specify anatomic sites for metastasis",
        "label": "Contradiction"
    },
    "7c28d575-cd75-418e-83bb-fae7457d9428": {
        "text_answer": "No  Explanation  The evidence provided in the trial results only relates to changes in lymphedema measurements for patients receiving acupuncture treatment versus those on a waitlist There is no information provided in the evidence regarding sexual life satisfaction for any of the study participants",
        "label": "Contradiction"
    },
    "9a9bd166-1319-4a61-a8c2-e42ee878bf83": {
        "text_answer": "No  Explanation  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity 1 from each cohort is not directly entailed by the evidence provided The evidence only states that there were 6 participants in each cohort and that 1 participant in each cohort experienced a doselimiting toxicity It does not specify a total number of 2 participants experiencing a",
        "label": "Contradiction"
    },
    "b032dff4-0d5d-4ee3-a4b2-c22ab3b8823f": {
        "text_answer": "Yes The evidence does not indicate that participants in either trial are required to meet a preliminary performance indicator or that a performance status scoring system is used",
        "label": "Entailment"
    },
    "dd52a82a-b788-4048-ba8d-525ee119a78f": {
        "text_answer": "Yes  Explanation The primary clinical trial involves the use of hormonal methods Estring and testosterone cream as interventions The secondary clinical trial on the other hand employs acupuncture as an intervention Therefore the statement hormonal methods are being employed in the primary clinical trial is true and the statement acupuncture is being employed in the secondary clinical trial is also true The statement as a",
        "label": "Entailment"
    },
    "d93422f2-c5ab-4aa0-90a3-478b05a17c4e": {
        "text_answer": "No   Explanation  The evidence provided reports the number of adverse events for each trial and each adverse event type but it does not report a total number of adverse events across all trials and all adverse event types Therefore the statement that the cohorts of both the primary clinical trial and the secondary clinical trial reported over 100 total adverse instances is not entailed by the evidence",
        "label": "Contradiction"
    },
    "480133d8-93ea-46f0-86e5-b92c380bb7f9": {
        "text_answer": "No  Explanation  The statement nonnodal regional disease indicator is an indication of whether a subject has nonnodal regional disease is not directly related to the information provided in the evidence The evidence only describes the interventions used in the primary and secondary trials including the drugs dosages and administration schedules It does not mention anything about nonnodal regional disease indicators",
        "label": "Contradiction"
    },
    "2ac85077-e695-40c7-a9a9-d9901eceaeb2": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "e4221b6d-f3d7-4299-bcba-19c02be74cdd": {
        "text_answer": "Yes The statement does not explicitly mention the phases of the trial but the evidence states that patients with a solid tumor that is locally advanced andor metastatic are eligible for both phases",
        "label": "Entailment"
    },
    "a16ff39b-cc99-4214-9af5-910eb9384a97": {
        "text_answer": "No   Explanation  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 90 of participants is not entailed by the evidence provided The evidence only reports the number of adverse events and the number of adverse events related to neutrophilsgranulocytes ANCAGC in each trial It does not provide any information about the percentage of",
        "label": "Contradiction"
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "text_answer": "Yes  Explanation The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is entailed by the evidence since the number of Hepatotoxicity cases 3 is 10 times the number of hypertension and Pancreatectomy cases 03 each Therefore the statement is a valid representation of",
        "label": "Entailment"
    },
    "f9d0c257-bd9a-484e-bae7-802c0246372c": {
        "text_answer": "  Part A Yes for the primary trial Part B No for the secondary trial",
        "label": "Entailment"
    },
    "15a422cf-fc00-4451-bddc-af67f7437e83": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "cdcb40f6-994c-4085-869a-dab87e67ba04": {
        "text_answer": "No  Explanation The evidence provided in the text does not mention the percentage of patients who reported adverse events It only states the percentage of subjects who completed the treatment regimen for each arm of the study Therefore the statement about 97 of patients reporting adverse events is not directly supported by the evidence",
        "label": "Contradiction"
    },
    "8e661d16-bf69-4d02-a437-5a77f12c1bd0": {
        "text_answer": "Yes The evidence states that both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Entailment"
    },
    "ac4c15e0-c711-4583-a9d4-1dbc682cd7f7": {
        "text_answer": "Yes The statement mentions one instance each of anaemia and febrile neutropenia which is consistent with the evidence The statement does not mention pancytopenia which is also consistent with the evidence as no instances were recorded in the primary trial",
        "label": "Entailment"
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "text_answer": "Yes The statement mentions the presence of Anaemia and Febrile neutropenia in cohort 1 which is consistent with the evidence The statement does not mention Pancytopenia but the evidence shows that no cases of Pancytopenia were observed in cohort 1 so the statement is still entailed by the evidence",
        "label": "Entailment"
    },
    "1cab397e-60fd-460d-8f56-978ca8a2bb78": {
        "text_answer": "No  Explanation  The statement hepatotoxicity cases were ten times more frequent than hypertension and pancreatectomy cases in the primary clinical trial is not entailed by the evidence The evidence states that the frequency of hepatotoxicity was 3750 while the frequency of hypertension and pancreatectomy were both 1250 A tenfold difference would mean that he",
        "label": "Contradiction"
    },
    "ed2174d9-375c-4ed0-b880-56d13f6fb069": {
        "text_answer": "No   Explanation  The evidence provided does not mention any adverse events related to ionizing radiationrelated malignant neoplasm in either the primary or secondary trial The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "ac271988-c319-4b6f-b7bf-f3c86072cf93": {
        "text_answer": "Yes  Explanation The primary trial involves the use of PF06647020 and there is no mention of ALT801 in the primary trial In contrast the secondary trial involves the use of ALT801 and none of the primary trial participants received this drug Therefore the statement none of the primary trial participants receive doses of alt801 whereas all secondary trial participants do",
        "label": "Entailment"
    },
    "915adcaa-4b9a-4df9-9803-4c5c0c52bf48": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "3cdc1ca9-f403-4e4b-878e-678d8dbc6090": {
        "text_answer": "Yes The evidence does not report any occurrences of hypertension dehydration or dyspnea in either cohort",
        "label": "Entailment"
    },
    "c179d073-c910-42ab-9fde-85e976e52203": {
        "text_answer": "Yes for the primary trial only as morbidly obese patients are not explicitly mentioned in the secondary trials exclusion criteria",
        "label": "Entailment"
    },
    "7e529d12-16a2-4711-b7f8-b454800447f2": {
        "text_answer": "  Yes for the primary trial but not exactly for the secondary trial The primary trial specifically includes a tumor size of 1 cm while the statement includes a range of 02 to 08 cm For the secondary trial the hormone receptor status is not specified in the inclusion criteria",
        "label": "Entailment"
    },
    "b71a1480-2037-4a01-8a4f-95a34aa172c2": {
        "text_answer": "No  Explanation  The statement the primary trial documented more instances of mucositis oral thromboembolic events and bladder infection than the secondary trial is not entailed by the evidence The evidence only shows the number of instances of each adverse event in each trial but it does not compare the number of instances between the two trials for each type of adverse event Therefore it is not possible to determine from the evidence",
        "label": "Contradiction"
    },
    "6690be43-edee-4061-a850-47540cc49bee": {
        "text_answer": "No  Explanation  The statement No two patients in the primary trial suffered the same type of adverse event is not entailed by the evidence While it is true that each patient in the trial experienced a unique combination of adverse events there are multiple patients who experienced the same type of adverse event eg three patients experienced back pain three patients experienced fever etc Therefore the statement is not an accurate reflection of the evidence provided",
        "label": "Contradiction"
    },
    "13d879d7-e968-4de9-ad06-458eb72759d5": {
        "text_answer": "No   Explanation  The evidence states that there were no adverse events recorded in both trials for the given condition Adverse Events 1 The statement however asserts that there were 10 recorded adverse events in total for both trials which is not supported by the evidence",
        "label": "Contradiction"
    },
    "c46fb676-9060-4d56-9097-af79bb762f50": {
        "text_answer": "No  Explanation  The statement the final acceptance of a patient into the primary clinical trial rests solely on whether they meet the stipulated inclusion and exclusion criteria regardless of the opinions of the health professionals conducting the trial is not entailed by the evidence The evidence only states that the inclusion and exclusion criteria are used to determine eligibility but it does not exclude the possibility that the health professionals have the final say in accepting or rejecting",
        "label": "Contradiction"
    },
    "14be6911-9b8c-4eb2-bcb9-bb5e892a57d1": {
        "text_answer": "Yes The primary trial does not involve any drugbased interventions while the secondary trial tests different doses of a drugbased intervention PF06647020 The statement is consistent with the information provided in the evidence",
        "label": "Entailment"
    },
    "e1cb3a7c-2881-41b9-8dc5-c6a1d311afc6": {
        "text_answer": "Yes  Explanation The statement compared to the primary clinical trial the secondary clinical trial observed an increase of 11 adverse events is entailed by the evidence as the evidence shows that there were 0 adverse events in the primary trial and 11 adverse events in the secondary trial",
        "label": "Entailment"
    },
    "2ce0537c-cd90-47dd-83e3-79a690cdc101": {
        "text_answer": "No  Explanation  The statement 90 more participants in the ERpositive Luminal B group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is not directly entailed by the evidence provided The evidence only gives the percentage of participants in each group who demonstrated a decrease in the growth factor signature It does not provide enough information to determine if there is a 90 difference between the two groups",
        "label": "Contradiction"
    },
    "ff1759ba-f09e-4ecf-8316-aac2a78d6c26": {
        "text_answer": "Yes The statement is entailed by the evidence as the primary trial has fewer total adverse events and fewer types of adverse events than the secondary trial",
        "label": "Entailment"
    },
    "db493601-5dae-4077-a455-582cd9e28315": {
        "text_answer": "No  The primary and secondary trials have some overlapping inclusion criteria age 18 or older but the primary trial is focused on women undergoing lumpectomy for nonpalpable breast cancer while the secondary trial is focused on patients undergoing tissue expander reconstruction following mastectomy The exclusion criteria are also different",
        "label": "Contradiction"
    },
    "e10d648e-a24d-4358-b81f-77b68fce3dc8": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence as it is not related to the given data on adverse events in the primary and secondary trials The statement is about quantitative chemistry which is a different topic from the adverse events in the trials",
        "label": "Contradiction"
    },
    "df709118-7130-4d0e-8150-a05fa7f1a6d1": {
        "text_answer": "No  Explanation  The statement Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen andor progesterone receptor positive and are considering AI therapy are eligible for the primary trial is not entailed by the evidence The inclusion criteria for the primary trial specify that patients must have histologically proven DCIS or stage IIII invasive carcinoma of the breast Stage 4 invasive carcin",
        "label": "Contradiction"
    },
    "077cc008-c777-4fa3-826b-8cc903eab60e": {
        "text_answer": "No   Explanation  The statement both cohort 1 and cohort 2 of the primary clinical trial are administered the same dosage of alt801 is not entailed by the evidence The evidence only states that cohort 1 received a dosage of 0015 mgkgdose and cohort 2 received a dosage of 0040 mgkg",
        "label": "Contradiction"
    },
    "a36a79c9-39aa-493e-a7f9-18771e4a50cf": {
        "text_answer": "Yes  Explanation The evidence shows that in both Arm 1 and Arm 2 of the clinical trial the number of participants with pathologic complete response in breast and axillary lymph nodes was relatively low 381 in Arm 1 and 333 in Arm 2 Therefore the statement that no notable occurrence of pathologic complete response was observed in breast and axillary lymph nodes among",
        "label": "Entailment"
    },
    "3a027890-3744-44b7-a008-b18f60b0fdd4": {
        "text_answer": "Yes  Explanation  The evidence provided in the results does not report any patient in either group experiencing the worst pain imaginable for 70 days The evidence only reports the average pain intensity scores and the difference between the two intervention groups The statement is entailed by the evidence as it goes beyond the reported data and makes a negative claim about the absence of specific pain experiences in the trial",
        "label": "Entailment"
    },
    "028e1c85-f23e-411f-bf70-3621480de375": {
        "text_answer": "Yes  Explanation  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is entailed by the evidence because the frequency of these adverse events is higher in the secondary trial compared to the primary trial  The statement but more cases of FEBRILE INFECTIONs were recorded in the primary trial is also entailed by the evidence because the number of",
        "label": "Entailment"
    },
    "634ef5d6-4281-4d39-b876-59be4ed256ec": {
        "text_answer": "No  Explanation  The primary clinical trial measures tumor response using RECIST criteria while the secondary clinical trial measures the number of participants with aromatase inhibitor associated musculoskeletal symptoms AIMSS These two trials do not track the percentage of participants showing clinical benefit based on RECIST criteria",
        "label": "Contradiction"
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "text_answer": "Yes The evidence does not explicitly state that AfricanAmerican patients are excluded so it is implied that they are eligible to participate in the trial",
        "label": "Entailment"
    },
    "42746679-44a5-4854-ba22-6557c0c34ff8": {
        "text_answer": "No   Explanation  The statement candidates for the secondary trial study group receive weekly subcutaneous SC injections whereas the primary trial participants do not receive any injections is not directly entailed by the evidence provided The evidence only mentions that the primary trial participants do not receive any injections related to vitamin D repletion but it does not mention anything about the secondary trial or the type of injections given in that trial",
        "label": "Contradiction"
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "text_answer": "No  Explanation  The statement The only types of Aes observed in patients from the secondary trial were Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain no aes were recorded in the primary trial is not entailed by the evidence  The evidence only states that the frequency of each specific adverse event AE is different between the two trials It does not state that only",
        "label": "Contradiction"
    },
    "4138d4cd-bc5a-44db-8dc2-f64fbfb28b94": {
        "text_answer": "Yes The statement is entailed by the evidence as the evidence reports the number of adverse effects in patients belonging to a clinical trial",
        "label": "Entailment"
    },
    "f51d8422-1f2c-45bf-8de8-ce554a19c011": {
        "text_answer": " No The statement is not entailed by the evidence as the evidence only mentions ER positive and HER2 negative breast cancer Group 1 and invasive triplenegative breast cancer Group 2 being included in the clinical trial It does not mention ER positive PR positive and HER2 breast cancer as a group",
        "label": "Contradiction"
    },
    "74b24825-1c77-48e6-a1ce-c5b7e60b2b61": {
        "text_answer": "No  The statement is not entailed by the evidence as the statement mentions an Inhalation intervention which is not present in the evidence The evidence only mentions vaginal interventions for the primary trial and a waitlist control group for the secondary trial",
        "label": "Contradiction"
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "text_answer": "No  Explanation  The statement the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort is not entailed by the evidence provided The evidence only shows the percentage of participants with Disease Progression or Death in each cohort but it does not directly compare the incidence between the two groups The",
        "label": "Contradiction"
    },
    "e0b061e1-ee74-46e0-a223-de370cfffc8a": {
        "text_answer": "No   Explanation  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 03 of participants is not entailed by the evidence The evidence only reports the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial It does not provide information about the percentage of participants experiencing",
        "label": "Contradiction"
    },
    "9625e56f-5de0-4cbd-8e30-a944bf6d6244": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the evidence only specifies the dosage and mode of administration for each cohort but it does not mention postoperatively or preoperatively for both cohorts",
        "label": "Contradiction"
    },
    "cb88e277-c79d-4bb1-8d63-c637a14d0f48": {
        "text_answer": "No  Explanation  The statement additionally the secondary trial does not employ any form of injection thereby excluding the use of radioactive tc99m sulfur colloid is not entailed by the evidence The evidence only mentions the use of radioactive Tc99M sulfur colloid in the context of lymphoscintigraphy in the secondary trial but it does not state that the secondary trial does",
        "label": "Contradiction"
    },
    "af615add-c0e4-4046-9968-9d5805d2620e": {
        "text_answer": "Yes The statement cancerfree patients are eligible for the primary clinical trial is entailed by the evidence as the inclusion criteria explicitly state that patients must have unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection sentinel biopsy or axillary dissection and be able to commit to a long term followup schedule which implies that they are cancerfree or in rem",
        "label": "Entailment"
    },
    "9477c88f-8957-4925-8c5d-0061409159f8": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "04e554aa-1522-4fd6-a508-e0f13fa38832": {
        "text_answer": "  No   Explanation   The evidence provided does not indicate that any participant in cohort 1 suffered a lifethreatening adverse event The evidence only reports the number of participants with serious and nonserious adverse events but it does not specify the nature or severity of those events Therefore the statement that 1000 of cohort 1 of the primary trial suffered at least 1",
        "label": "Contradiction"
    },
    "e762873d-0ab8-4732-8c17-fdab7712a8e5": {
        "text_answer": "Yes  Explanation The statement thromboembolic incidents were experienced by patients in both the primary clinical trial and the secondary clinical trial is entailed by the evidence as there is a reported thromboembolic event in each trial",
        "label": "Entailment"
    },
    "c9514ddd-0486-4aca-a0b7-4e03a2effc90": {
        "text_answer": "Yes  Explanation The evidence does not provide a specific number of participants who did not report any pain during the trial but it does state that some participants in both groups reported no pain at various points in time Therefore the statement during the 10week duration of the primary clinical trial several participants did not report any pain is entailed by the evidence",
        "label": "Entailment"
    },
    "570f69cb-de78-48d6-916b-bcb3ef0a27a7": {
        "text_answer": "Yes",
        "label": "Entailment"
    },
    "54c9f3b4-b90f-4b60-a924-5a26c4097521": {
        "text_answer": "No  Explanation  The statement body fat measurement is a measurement of the total fat mass within the subjects body is not directly related to the information provided in the evidence The evidence only describes the interventions used in the primary and secondary trials It does not mention anything about body fat measurement",
        "label": "Contradiction"
    },
    "f95613c7-63f9-4f97-adbd-176220391993": {
        "text_answer": "No  Explanation  The statement is not entailed by the evidence because the primary trial states that patients received 120 milligrams of denosumab every 4 weeks not every week as stated in the false statement Additionally the secondary trial mentions the injection of radioactive Tc99M sulfur colloid with different amounts 04 to 10 mCi than what is stated in the false",
        "label": "Contradiction"
    },
    "4a7035e5-7fdf-461e-9d63-8e52be720d96": {
        "text_answer": "No   Explanation   The statement in order to take part in the primary clinical trial aspirants must first get a mammography whereas the secondary clinical trial requires patients to have a ct scan and blood tests prior to participating is not entailed by the evidence   The primary trial includes mammography as a requirement for participation but it does not mention any specific requirements for additional imaging or blood tests The secondary trial on the",
        "label": "Contradiction"
    },
    "29f65923-503d-402b-b0a3-150f741d8c2b": {
        "text_answer": "Yes  Explanation The statement confirmation of a HER2 positive tumor through positive FISH or IHC 3 is mandatory for all individuals considering the primary clinical trial is entailed by the evidence as the inclusion criteria explicitly state that the tumor must be HER2 positive either IHC 3 or FISH",
        "label": "Entailment"
    },
    "096f687a-6eec-4648-b8f8-6d423d84f3ae": {
        "text_answer": "No   Explanation  The statement all ae types in the primary trial affected more than 50 of patients is not entailed by the evidence as only one adverse event fever affected more than one patient 2 patients had febrile neutropenia and the total number of patients affected by all adverse events was 4 out of 11 3636 which is less than ",
        "label": "Contradiction"
    },
    "869ef7c8-edf9-4eb0-8654-3bb28fa1b4aa": {
        "text_answer": "No  Explanation  The statement Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is not entailed by the evidence provided Perjeta is not mentioned in the evidence at all The evidence only discusses Fulvestrant Anastrozole and the use of HER2targeted PETCT with novel radiotracers The statement about fibrous men",
        "label": "Contradiction"
    },
    "df8057c4-0640-488f-9a63-9036703fbf83": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 2ml of mcs110 every 3 weeks is entailed by the evidence because the evidence states that all patients receive MCS110 1 mgkg or 3 mgkg every 3 weeks To calculate the volume of MCS110 administered we can use the following formula  Volume  Dose  Concentr",
        "label": "Entailment"
    },
    "4aae628e-86f0-4851-9319-0a7d44d488b9": {
        "text_answer": "Yes but with a qualification The primary trial excludes patients with potassium levels outside the normal range while the secondary trial does not mention potassium specifically in its inclusion or exclusion criteria Therefore it is possible that patients with hypokalemia could be included in the secondary trial but this would depend on the specific decisions of the investigators and the overall study design",
        "label": "Entailment"
    },
    "9dd72932-f9f7-4ad7-8c3e-15f284d93d89": {
        "text_answer": "  No the statement is not entailed by the evidence for the primary trial The evidence only mentions females as eligible participants   Yes the statement is entailed by the evidence for the secondary trial but only for the subgroup of patients with advanced castrationresistant prostate cancer",
        "label": "Contradiction"
    },
    "cc6d64c8-a841-4a6b-bf57-df451ad47edb": {
        "text_answer": "No   Explanation  The evidence states that there were no severe adverse events reported in cohort 1 of the primary clinical trial The statement on the other hand asserts that there were severe adverse events reported which is not supported by the evidence",
        "label": "Contradiction"
    },
    "d803d6fb-f2af-4470-8cf9-7f68d6c53baf": {
        "text_answer": "No The statement is not entailed by the evidence as it is about orthodontic treatment which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "text_answer": "Yes The primary trial has a specific eligibility criterion for resistance to aromatase inhibitors AI but the secondary trial does not mention anything about resistance to AI or mirtazapine",
        "label": "Entailment"
    },
    "b2ef7c16-b0e9-48dd-be60-9243443535b7": {
        "text_answer": "  No  Explanation  The statement patients diagnosed with nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer confirmed by fluorescence in situ hybridization can participate in both the primary clinical trial and the secondary clinical trial is not entailed by the evidence provided  The primary clinical trial has specific inclusion and exclusion criteria for patients with NUT midline carcin",
        "label": "Contradiction"
    },
    "0b659007-1edc-43da-aafe-0024c2bb233e": {
        "text_answer": "No  Explanation  The evidence provided in the text does not mention anything about patients experiencing no pain whatsoever during the 10week study The evidence only reports the average pain intensity scores and the difference between the lowdose and highdose intervention groups The cdai version 1 clinical classification question is not related to the evidence provided",
        "label": "Contradiction"
    },
    "1d828a72-b303-4395-bab6-31865552caff": {
        "text_answer": "No  The statement about adult mixed glioma is not mentioned in the evidence at all and there is no information about the level of disability required for participation in the primary or secondary trials",
        "label": "Contradiction"
    },
    "13f17e45-4ce5-4de3-8a67-eee3ca98c4eb": {
        "text_answer": "No  The statement is not entailed by the evidence as the evidence describes two different clinical trials one for ANA anastrozole and FULV fulvestrant and does not mention a cohort using paclitaxel",
        "label": "Contradiction"
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence because the patient populations in the primary and secondary trials are not the same and the inclusion and exclusion criteria are different for each trial The primary trial is for postmenopausal women with early stage breast cancer while the secondary trial is for healthy participants and HER2positive breast cancer patients The eligibility criteria for each trial are distinct and do not allow for all patients to",
        "label": "Contradiction"
    },
    "6efe0add-df04-4255-a81f-8a542c0b810f": {
        "text_answer": "Yes The evidence states that patients in the primary clinical trial do not receive fentanyl sublingual spray during their radiation therapy",
        "label": "Entailment"
    },
    "9a276dfa-f4f9-4abe-837e-18cca465967e": {
        "text_answer": "Yes The statement is entailed by the evidence as both trials have reported 0 adverse events related to cytomegalovirus",
        "label": "Entailment"
    },
    "19ad39bd-9620-4ff6-8afe-a81348b4fada": {
        "text_answer": "No  Explanation The statement is not entailed by the evidence as the number of injections for the primary trial participants is not mentioned in the evidence The evidence only states that they receive a single injection at the beginning of the study without specifying the number of injections for the secondary trial participants",
        "label": "Contradiction"
    },
    "773d939c-db89-4999-9903-89da67345b49": {
        "text_answer": "Yes Some patients in the trial had interruptions or reductions in sunitinib dosing",
        "label": "Entailment"
    },
    "a8f421ec-e3c7-43b4-96da-b6bca22d68ed": {
        "text_answer": "No   Explanation  The evidence provided in the primary trial results does not report any data on the number of participants who experienced pathologic complete response in breast and axillary lymph nodes after approximately 4 weeks of the study The data provided is on the number of participants who achieved pathologic complete response at the time of surgery approximately 7 months after the start of the treatment",
        "label": "Contradiction"
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "text_answer": "Yes The median survival times reported in the evidence are both over 2 years and over 50 patients from each cohort are represented in the data",
        "label": "Entailment"
    },
    "6ee00118-66be-4e39-85a7-2dd1feaca87b": {
        "text_answer": "No  Explanation  The statement in the primary trial there were 15 the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy is not entailed by the evidence The evidence states that there were 3 hepatotoxicity cases out of 8 total adverse events while there were 1 hypertension and 1 pancreatectomy case each making a total",
        "label": "Contradiction"
    },
    "d1123c9b-e0d4-412d-bcf6-a69bbb07a0f4": {
        "text_answer": "Yes The evidence reports that two participants in each cohort experienced doselimiting toxicities",
        "label": "Entailment"
    },
    "8bc95ffe-c455-4563-bc81-a7530f6fb500": {
        "text_answer": "No  Explanation  The statement is not directly related to the evidence provided The evidence pertains to the inclusion and exclusion criteria for a clinical trial for breast cancer while the statement discusses a type of chondrosarcoma and its grade The two are not equivalent or related to each other",
        "label": "Contradiction"
    },
    "9f08a841-c0c4-42e4-984f-0700bb46f18f": {
        "text_answer": "Yes  Explanation The statement all patients in the primary trial receive at least 20000mcg of mcs110 every 21 days is entailed by the evidence because in both interventions patients receive MCS110 1 mgkg or 3 mgkg every 3 weeks Q3W To calculate the amount of MCS110 received every 3 weeks we can multiply",
        "label": "Entailment"
    },
    "921d278b-11fe-4f67-883a-cd10b15c20f2": {
        "text_answer": "No  Explanation  The statement grade 1 acoustic nerve disorder nos ctcae is asymptomatic clinical or diagnostic observations only intervention not indicated is not directly related to the provided evidence The evidence only reports the adverse events observed in two separate cohorts without any mention of acoustic nerve disorders or CTCAE grades Therefore it is not possible to determine if the statement is entailed by the evidence based on the",
        "label": "Contradiction"
    },
    "17ca93e8-5115-4f53-8d4a-b3ce6c43ea58": {
        "text_answer": "No  The evidence does not allow for simultaneous participation in both trials for patients who meet the criteria for both The primary trial has specific inclusion and exclusion criteria related to menopausal status and hot flushes which are not applicable to the secondary trial Therefore patients cannot meet the criteria for both trials at the same time",
        "label": "Contradiction"
    },
    "04191593-f36e-4fc0-8af5-7591059640a4": {
        "text_answer": "No  Explanation  The statement primary clinical trials first cohort had numerous pancytopenia occurrences with no recorded instances of anemia and febrile neutropenia is not entailed by the evidence provided The evidence shows that in the first cohort of the primary clinical trial there was one occurrence of pancytopenia and there were no occurrences of anemia or feb",
        "label": "Contradiction"
    }
}